<mediawiki xmlns="http://www.mediawiki.org/xml/export-0.8/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.mediawiki.org/xml/export-0.8/ http://www.mediawiki.org/xml/export-0.8.xsd" version="0.8" xml:lang="en">
  <siteinfo>
    <sitename>Wikipedia</sitename>
    <base>http://en.wikipedia.org/wiki/Main_Page</base>
    <generator>MediaWiki 1.24wmf4</generator>
    <case>first-letter</case>
    <namespaces>
      <namespace key="-2" case="first-letter">Media</namespace>
      <namespace key="-1" case="first-letter">Special</namespace>
      <namespace key="0" case="first-letter" />
      <namespace key="1" case="first-letter">Talk</namespace>
      <namespace key="2" case="first-letter">User</namespace>
      <namespace key="3" case="first-letter">User talk</namespace>
      <namespace key="4" case="first-letter">Wikipedia</namespace>
      <namespace key="5" case="first-letter">Wikipedia talk</namespace>
      <namespace key="6" case="first-letter">File</namespace>
      <namespace key="7" case="first-letter">File talk</namespace>
      <namespace key="8" case="first-letter">MediaWiki</namespace>
      <namespace key="9" case="first-letter">MediaWiki talk</namespace>
      <namespace key="10" case="first-letter">Template</namespace>
      <namespace key="11" case="first-letter">Template talk</namespace>
      <namespace key="12" case="first-letter">Help</namespace>
      <namespace key="13" case="first-letter">Help talk</namespace>
      <namespace key="14" case="first-letter">Category</namespace>
      <namespace key="15" case="first-letter">Category talk</namespace>
      <namespace key="100" case="first-letter">Portal</namespace>
      <namespace key="101" case="first-letter">Portal talk</namespace>
      <namespace key="108" case="first-letter">Book</namespace>
      <namespace key="109" case="first-letter">Book talk</namespace>
      <namespace key="118" case="first-letter">Draft</namespace>
      <namespace key="119" case="first-letter">Draft talk</namespace>
      <namespace key="446" case="first-letter">Education Program</namespace>
      <namespace key="447" case="first-letter">Education Program talk</namespace>
      <namespace key="710" case="first-letter">TimedText</namespace>
      <namespace key="711" case="first-letter">TimedText talk</namespace>
      <namespace key="828" case="first-letter">Module</namespace>
      <namespace key="829" case="first-letter">Module talk</namespace>
    </namespaces>
  </siteinfo>
  <page>
    <title>Category:Combination antibiotics</title>
    <ns>14</ns>
    <id>995674</id>
    <revision>
      <id>548747374</id>
      <parentid>478009948</parentid>
      <timestamp>2013-04-04T23:36:02Z</timestamp>
      <contributor>
        <username>Addbot</username>
        <id>6569922</id>
      </contributor>
      <minor/>
      <comment>[[User:Addbot|Bot:]] Migrating 2 interwiki links, now provided by [[Wikipedia:Wikidata|Wikidata]] on [[d:q9463788]]</comment>
      <text xml:space="preserve" bytes="317">Combination antibiotics contain more than one [[antibiotic]] agent in the preparation. They are designed to either improve efficacy through synergistic action of the agents (e.g. [[co-trimoxazole]]), or to overcome bacterial resistance (e.g. [[co-amoxiclav]]).

[[Category:Antibiotics]]
[[Category:Combination drugs]]</text>
      <sha1>d8kx4mkuyzm63444m6it8v7asip1rxs</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Trimethoprim</title>
    <ns>0</ns>
    <id>102695</id>
    <revision>
      <id>608556407</id>
      <parentid>608058596</parentid>
      <timestamp>2014-05-14T15:23:04Z</timestamp>
      <contributor>
        <username>JustAGal</username>
        <id>1499324</id>
      </contributor>
      <comment>Disambiguated: [[Morganella]] → [[Morganella (bacterium)]], [[Providencia]] → [[Providencia (bacterium)]], [[trimester]] → [[Pregnancy]]</comment>
      <text xml:space="preserve" bytes="13711">{{drugbox
| Watchedfields = changed
| verifiedrevid = 470615131
| IUPAC_name = 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine
| image = Trimethoprim2DACS.svg
| width = 160
| image2 = Trimethoprim3Dan.gif
| width2 = 200

&lt;!--Clinical data--&gt;
| Drugs.com = {{drugs.com|monograph|trimethoprim}}
| MedlinePlus = a684025
| licence_US = Trimethoprim
| pregnancy_AU = B3
| pregnancy_US = C
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = Oral

&lt;!--Pharmacokinetic data--&gt;
| bioavailability = 90–100%
| protein_bound = 44%
| metabolism = [[hepatic]]
| elimination_half-life = 8-12 hours
| excretion = Urine (50–60%), faeces (4%)

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 738-70-5
| ATC_prefix = J01
| ATC_suffix = EA01
| ATC_supplemental = {{ATCvet|J51|EA01}}
| PubChem = 5578
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00440
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5376
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = AN164J8Y0X
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00145
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 45924
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 22
| PDB_ligand = TOP

&lt;!--Chemical data--&gt;
| C=14 | H=18 | N=4 | O=3 
| molecular_weight = 290.32 g/mol
| smiles = COc1cc(cc(c1OC)OC)Cc2cnc(nc2N)N
| InChI = 1/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IEDVJHCEMCRBQM-UHFFFAOYSA-N
}}
'''Trimethoprim''' ([[International Nonproprietary Name|INN]]) {{IPAc-en|t|r|aɪ|ˈ|m|ɛ|θ|ə|p|r|ɪ|m}} is a [[bacteriostatic]] [[antibiotic]] used mainly in the prevention and treatment of [[urinary tract infection]]s.

It belongs to the class of [[chemotherapy|chemotherapeutic]] agents known as [[dihydrofolate reductase inhibitor]]s. Trimethoprim was formerly marketed by [[GlaxoSmithKline]] under [[trade name]]s including '''Proloprim''', '''Monotrim''', and '''Triprim'''; but these trade names have been licensed to various [[generic drug|generic pharmaceutical]] manufacturers. In clinical use it is often abbreviated '''TRI''' or '''TMP'''; its common laboratory abbreviation is '''W'''.

&lt;!-- Society and culture --&gt;
It is on the [[World Health Organization's List of Essential Medicines]], a list of the most important medication needed in a basic [[health system]].&lt;ref&gt;{{cite web|title=WHO Model List of EssentialMedicines|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|work=World Health Organization|accessdate=22 April 2014|date=October 2013}}&lt;/ref&gt;

==Medical uses==
It is primarily used in the treatment of [[urinary tract infections]], although it may be used against any susceptible aerobic bacterial species (see table).&lt;ref name = AMH&gt;{{cite isbn|9780980579093}}&lt;/ref&gt; It may also be used to treat and prevent ''[[Pneumocystis jiroveci]]'' pneumonia.&lt;ref name = AMH/&gt; It is generally not recommended for the treatment of anaerobic infections like [[pseudomembranous colitis]] (the leading cause for antibiotic-induced diarrhoea).&lt;ref name = AMH/&gt;

{| class = wikitable
! Micro-organism name !! Susceptible  to trimethoprim?&lt;ref name = AMH/&gt;
|-
| colspan = 2 align = center | '''&lt;big&gt;Aerobic bacteria&lt;/big&gt;'''
|-
| ''[[Acinetobacter]]'' sp. || {{No}}

|-
| ''[[Aeromonas]]'' sp. || {{Yes}}
|-
| ''[[Burkholderia cepacia]]'' || {{Yes}}
|-
| ''[[Burkholderia pseudomallei]]'' || {{No}}
|-
| ''[[Campylobacter coli]]'' || {{No}}
|-
| ''[[Campylobacter jejuni]]'' || {{No}}
|-
| ''[[Citrobacter freundii]]'' || {{Yes}}
|-
| ''[[Corynebacterium jeikeium]]'' || {{No}}
|-
| ''[[Enterobacter]]'' sp. || {{Yes}}
|-
| ''[[Enterococcus]]'' sp. || {{No}}
|-
| ''[[Escherichia coli]]'' sp. || {{Yes}}
|-
| ''[[Haemophilus influenzae]]'' || {{Yes}}
|-
| ''[[Klebsiella]]'' sp. || {{Yes}}
|-
| ''[[Moraxella catarrhalis]]'' || {{No}}
|-
| ''[[Morganella (bacterium)|Morganella]]'' sp. || {{Yes}}
|-
| ''[[Neisseria meningitidis]]'' || {{No}}
|-
| ''[[Proteus mirabilis]]'' || {{Yes}}
|-
| ''[[Proteus vulgaris]]'' || {{Yes}}
|-
| ''[[Providencia (bacterium)|Providencia]]'' sp. || {{Yes}}
|-
| ''[[Pseudomonas aeruginosa]]'' || {{No}}
|-
| ''[[Salmonella]]'' sp. || {{Yes}}
|-
| ''[[Serratia]]'' sp. || {{Yes}}
|-
| ''[[Shigella]]'' sp. || {{No}}
|-
| ''[[Staphylococcus aureus]]'' || {{Yes}}
|-
| ''[[Staphylococcus saprophyticus]]'' || {{Yes}}
|-
| ''[[Stenotrophomonas maltophilia]]'' || {{No}}
|-
| ''[[Streptococcus]]'' - group A, B, C, G || {{Yes}}
|-
| ''[[Streptococcus pneumoniae]]'' || {{No}}
|-
| ''[[Streptococcus viridans]]'' group || {{No}}
|-
| ''[[Yersinia]]'' sp. || {{Yes}}
|-

|}


==Mechanism of action==
[[Image:THFsynthesispathway.png|frame|right|[[Tetrahydrofolate]] synthesis pathway]]
Trimethoprim binds to dihydrofolate reductase and inhibits the reduction of dihydrofolic acid (DHF) to tetrahydrofolic acid (THF).&lt;ref name = drugs82/&gt; THF is an essential precursor in the thymidine synthesis pathway and interference with this pathway inhibits bacterial DNA synthesis.&lt;ref name = drugs82/&gt; Trimethoprim's affinity for bacterial dihydrofolate reductase is several thousand times greater than its affinity for human dihydrofolate reductase.&lt;ref name = drugs82/&gt; [[Sulfamethoxazole]] inhibits dihydropteroate synthetase, an enzyme involved further upstream in the same pathway.&lt;ref name = drugs82/&gt; [[Trimethoprim/sulfamethoxazole|Trimethoprim and sulfamethoxazole]] are commonly used in combination due to their synergistic effects.&lt;ref name = drugs82/&gt; This drug combination also reduces the development of resistance that is seen when either drug is used alone.&lt;ref name = drugs82&gt;{{cite journal|last=Brogden|first=RN|coauthors=Carmine, AA; Heel, RC; Speight, TM; Avery, GS|title=Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections.|journal=Drugs|date=June 1982|volume=23|issue=6|pages=405-30|doi=10.2165/00003495-198223060-00001|pmid=7049657}}&lt;/ref&gt;

[[File:Wild-type_staphylococcus_aureus_DHFR_in_complex_with_NADPH_and_trimethoprim.gif|thumb|right|400px|''Staphylococcus aureus'' DHFR in complex with NADPH and trimethoprim PDB entry {{PDBe|2W9G}} &lt;ref&gt;{{cite pmid|19280600}}&lt;/ref&gt;]]
{{stack end}}

==Co-trimoxazole==
Trimethoprim was commonly (from 1969 to 1980 in the UK) used in a 1:5 combination with [[sulfamethoxazole]], a [[Sulfonamide (medicine)|sulfonamide]] antibiotic, which inhibits an earlier step in the folate synthesis pathway (see diagram below). This combination, also known as [[co-trimoxazole]], TMP-sulfa, or TMP-SMX, results in an [[in vitro]] [[synergistic]] antibacterial effect by inhibiting successive steps in folate synthesis. This claimed benefit was not seen in general clinical use.&lt;ref&gt;{{cite journal |author=Brumfitt W, Hamilton-Miller JM |title=Reassessment of the rationale for the combinations of sulphonamides with diaminopyrimidines | journal=J Chemother |date=December 1993 |volume=5 |issue=6 |pages=465–9 |pmid=8195839}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |author=Brumfitt W, Hamilton-Miller JM |title=Limitations of and indications for the use of co-trimoxazole | journal=J Chemother |date=February 1993 |volume=6 |issue=1 |pages=3–11 |pmid=8071675}}&lt;/ref&gt;

The combination's use has been declining due to reports of sulfamethoxazole [[bone marrow]] toxicity, resistance and lack of greater efficacy in treating common urine and chest infections,&lt;ref&gt;{{cite journal |author=Bean DC, Livermore DM, Papa I, Hall LM |title=Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man |journal=J Antimicrob Chemother |date=November 2005 | volume=56 |issue=5 |pages=962–4 |pmid=16150859 |url=http://jac.oxfordjournals.org/cgi/content/full/56/5/962 |doi=10.1093/jac/dki332}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |author=Felmingham D, Reinert RR, Hirakata Y, Rodloff A |title=Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin |journal=J Antimicrob Chemother |date=September 2002 | volume=50 |issue=Suppl S1 |pages=25–37 |pmid=12239226 |url=http://jac.oxfordjournals.org/cgi/reprint/50/suppl_2/25 |doi=10.1093/jac/dkf808}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |author=Johnson JR, Manges AR, O'Bryan TT, Riley LW |title=A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis |journal=Lancet |date=June 29, 2002 | volume=359 |issue=9325 |pages=2249–51 |pmid=12103291 |url= |doi=10.1016/S0140-6736(02)09264-4}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |author=Lawrenson RA, Logie JW |title=Antibiotic failure in the treatment of urinary tract infections in young women |journal=J Antimicrob Chemother |date=December 2001 | volume=48 |issue=6 |pages=895–901 |pmid=11733475  |url= |doi=10.1093/jac/48.6.895}} - suggest some small advantage in UTIs&lt;/ref&gt; and [[Sulfonamide (medicine)#Side effects|side effects of antibacterial sulfonamides]]. As a consequence, the use of co-trimoxazole was restricted in 1995 &lt;ref&gt;{{cite journal |author= |title=Co-trimoxazole use restricted |journal=Drug Ther Bull |date=December 1995 | volume=33 |issue=12 |pages=92–3 |pmid=8777892 |url=|doi=10.1136/dtb.1995.331292}}&lt;/ref&gt; following the availability of trimethoprim (not in combination) in 1980.

With its greater efficacy against a limited number of bacteria, Co-trimoxazole remains indicated for some infections; for example, it is used as prophylaxis in patients at risk for [[Pneumocystis pneumonia|''Pneumocystis jirovecii'' pneumonia]] (e.g. [[AIDS]] patients and those with some [[hematological malignancy|hematological malignancies]]) and as therapy in [[Whipple's disease]]. Gram-positive bacteria are generally or moderately susceptible.

==Contraindications and reactions==
Trimethoprim can cause [[thrombocytopenia]] (low levels of [[platelets]]) by lowering [[folic acid]] levels; this may also cause [[megaloblastic anemia]].
Trimethoprim antagonises the [[epithelial sodium channel]] (ENaC) in the [[distal tubule]], thup acting like [[amiloride]].  This can cause [[hyperkalemia]]. Trimethoprim also competes with [[creatinine]] for secretion into the renal tubule.  This can cause an artefactual rise in the serum creatinine. 
Use in [[EHEC]] infections may lead to an increase in expression of [[Shiga toxin]].&lt;ref&gt;{{ cite journal | author = Kimmitt PT, Harwood CR, Barer MR | title = Toxin Gene Expression by Shiga Toxin-producing ''Escherichia coli'': The Role of Antibiotics and the Bacterial SOS Response | journal = Emerg Infect Dis | year = 2000 | volume = 6 | issue = 5 | pages = 458–465 | pmid = 10998375 | pmc = 2627954 | url = http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627954/pdf/10998375.pdf | format = pdf | doi=10.3201/eid0605.000503}}&lt;/ref&gt; Due to the fact that it crosses the [[placenta]] and can affect folate metabolism, trimethoprim is relatively contraindicated during pregnancy, especially the first [[Pregnancy|trimester]].&lt;ref&gt;{{cite web | title = Trimethoprim | publisher = netdoctor.co.uk | title = Use extra precautions when taking the contraceptive pill | url = http://www.netdoctor.co.uk/medicines/100002648.html }}&lt;/ref&gt;  It may be involved in a reaction similar to [[disulfiram]] when alcohol is consumed after it is used, in particular when used in combination with [[sulfamethoxazole]].&lt;ref&gt;{{cite journal | author = Edwards DL, Fink PC, van Dyke PO | title = Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole | journal = J Clinical pharmacy | year = 1986 | volume = 5 | issue = 12 | pages = 999–1000 | pmid = 3492326 |
url = http://cat.inist.fr/?aModele=afficheN&amp;cpsidt=8287529 }}&lt;/ref&gt;&lt;ref&gt;{{ cite journal | author = Heelon MW; White M | title = Disulfiram cotrimoxazole reaction | journal = J Pharmacotherapy | year = 1998 | volume = 18 | issue = 4 | pages = 869–870 | pmid = 9692665 | url = http://cat.inist.fr/?aModele=afficheN&amp;cpsidt=2340043 }}&lt;/ref&gt;
The trophoblasts in the early fetus are sensitive to changes in the folate cycle. A recent study has found a doubling in the risk of miscarriage in women exposed to trimethoprim in the early pregnancy.&lt;ref&gt;{{ cite journal | author = Andersen JT, Petersen M, Jimenez-Solem E, Broedbaek K, Andersen EW, Andersen NL, Afzal S, Torp-Pedersen C, Keiding N, Poulsen HE | title = Trimethoprim use in early pregnancy and the risk of miscarriage: a register-based nationwide cohort study | journal = Epidemiology and Infection | year = 2013 | volume = 141 | issue = 8 | pages = 1749–1755 | doi = 10.1017/S0950268812002178 | pmid = 23010291 | url = http://journals.cambridge.org/action/displayAbstract?fromPage=online&amp;aid=8953186 }}&lt;/ref&gt;

==Chemistry==
Trimethoprim can be prepared from [[3,4,5-trimethoxybenzaldehyde]], 3-ethoxypropionitrile, and [[guanidine]]:&lt;ref&gt;Stenbuck, P.; Hood, H. M.; 1962, {{US Patent|3,049,544}}&lt;/ref&gt;

:[[File:Trimethoprim syn.png|600px]]

== References ==
{{reflist|2}}

==External links==
* [http://www.med.sc.edu:96/Biopharm/PDFs/NucleicAcidInhibitors.pdf Nucleic acid inhibitors] (PDF file).
{{Sulfonamides and trimethoprim}}

[[Category:Antibiotics]]
[[Category:Bacterial dihydrofolate reductase inhibitors]]
[[Category:Protozoal dihydrofolate reductase inhibitors]]
[[Category:Pyrimidines]]
[[Category:World Health Organization essential medicines]]
[[Category:Phenol ethers]]
[[Category:Aromatic amines]]</text>
      <sha1>dv0g8w93tond6140au0oa7046wf4omh</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Phytoalexin</title>
    <ns>0</ns>
    <id>1023906</id>
    <revision>
      <id>593446627</id>
      <parentid>566234552</parentid>
      <timestamp>2014-02-01T16:24:33Z</timestamp>
      <contributor>
        <username>Yikrazuul</username>
        <id>5113168</id>
      </contributor>
      <minor/>
      <comment>svg</comment>
      <text xml:space="preserve" bytes="12803">[[Image:Capsidiol.svg|thumb|[[Capsidiol]] is a phytoalexin produced by certain plants in response to pathogenic attack]]
'''Phytoalexins''' are [[antimicrobial]] and often [[antioxidative]] substances synthesized ''de novo'' by [[plant]]s that accumulate rapidly at areas of pathogen infection.  They are broad spectrum inhibitors and are chemically diverse with different types characteristic of particular plant species. Phytoalexins tend to fall into several classes including [[terpenoid]]s, [[glycomics|glyco]][[steroid]]s and [[alkaloid]]s; however, researchers often find it convenient to extend the definition to include all [[phytochemicals]] that are part of the plant's defensive arsenal.

== Function ==
Phytoalexins produced in plants act as toxins to the attacking organism.  They may puncture the [[cell wall]], delay maturation, disrupt metabolism or prevent reproduction of the pathogen in question. Their importance in plant defense is indicated by an increase in susceptibility of plant tissue to infection when phytoalexin biosynthesis is inhibited. Mutants incapable of phytoalexin production exhibit more extensive pathogen colonization as compared to wild type. As such, host-specific pathogens capable of degrading phytoalexins are more virulent than those unable to do so.&lt;ref&gt;{{cite journal | doi = 10.1073/pnas.91.19.8955 | author = Glazebrook and Ausbel | last2 = Ausubel | first2 = FM | title = Isolation of phytoalexin-deficient mutants of Arabidopsis thaliana and characterization of their interactions with bacterial pathogens | journal = PNAS | volume = 91 | issue = 19 | pages = 8955–8959 | year = 1994 | pmid = 8090752 | pmc = 44725}}&lt;/ref&gt;

When a plant cell recognizes particles from damaged [[cell (biology)|cell]]s or particles from the pathogen, the plant launches a two-pronged resistance: a general short-term response and a delayed long-term specific response. 

As part of the induced resistance, the short-term response, the plant deploys [[reactive oxygen species]] such as [[superoxide]] and [[hydrogen peroxide]] to kill invading cells. In pathogen interactions, the common short-term response is the [[hypersensitive response]], in which cells surrounding the site of infection are signaled to undergo [[apoptosis]], or  programmed cell death, in order to prevent the spread of the pathogen to the rest of the plant.

Long-term resistance, or systemic acquired resistance (SAR), involves communication of the damaged tissue with the rest of the plant using plant hormones such as [[jasmonic acid]], [[ethylene]], [[abscisic acid]] or [[salicylic acid]]. The reception of the signal leads to global changes within the plant, which induce genes that protect from further pathogen intrusion, including enzymes involved in the production of phytoalexins.  Often, if jasmonates or ethylene (both gaseous hormones) is released from the wounded tissue, neighboring plants also manufacture phytoalexins in response.  For herbivores, common [[Vector (epidemiology)|vector]]s for disease, these and other wound response aromatics seem to act as a warning that the plant is no longer edible.  Also, in accordance with the old adage, &quot;an enemy of my enemy is my friend,&quot; the aromatics may alert natural enemies of the plant invaders to the presence thereof.

== Recent research ==

[[Allixin]] (3-hydroxy-5-methoxy-6-methyl-2-pentyl-4''H''-pyran-4-one), a non-sulfur-containing compound having a [[pyrone|γ-pyrone]] skeleton structure, was the first compound isolated from [[garlic]] as a phytoalexin, a product induced in plants by continuous [[stress (mechanics)|stress]].&lt;ref name=Kodera&gt;{{cite journal | author = Kodera Y., Matuura H., Yoshida S., Sumida T., Itakura Y., Fuwa T., Nishino H. | journal = Chem. Pharm. Bull. | volume = 37 | pages = 1656–1658 | year = 1989 | doi = 10.1248/cpb.37.1656 | title = Allixin, a stress compound from garlic | issue = 6}}&lt;/ref&gt; This compound has been shown to have unique biological properties, such as anti-oxidative effects,&lt;ref name=Kodera/&gt; anti-microbial effects,&lt;ref name=Kodera/&gt; anti-tumor promoting effects,&lt;ref name=Nishino&gt;{{cite journal | author = Nishino H., Nishino A., Takayama J., Iwashima A., Itakura Y., Kodera Y., Matsuura H., Fuwa T. | journal = Cancer J. | volume = 3 | pages = 20–21 | year = 1990}}&lt;/ref&gt; inhibition of [[aflatoxin]] B2 [[DNA]] binding,&lt;ref name=Yamasaki&gt;{{cite journal | doi = 10.1016/0304-3835(91)90171-D | author = Yamasaki T., Teel R. W., Lau B. H. S. | title = Effect of allixin, a phytoalexin produced by garlic, on mutagenesis, DNA-binding and metabolism of aflatoxin B1 | journal = Cancer Lett. | volume = 59 | issue = 2 | pages = 89–94 | year = 1991 | pmid = 1909211}}&lt;/ref&gt; and neurotrophic effects.&lt;ref name=Yamasaki/&gt;  Allixin showed an anti-tumor promoting effect in vivo, inhibiting skin [[tumor]] formation by [[12-O-Tetradecanoylphorbol-13-acetate|TPA]] in [[7,12-Dimethylbenz(a)anthracene|DMBA]] initiated mice.&lt;ref name=Nishino/&gt;  Herein, allixin and/or its analogs may be expected useful compounds for cancer prevention or chemotherapy agents for other diseases.

== Role of natural phenols in the plant defense against fungal pathogens ==
[[Polyphenol]]s, especially [[isoflavonoids]] and related substances, play a role in the plant defense against fungal and other microbial pathogens.

In ''[[Vitis vinifera]]'' grape, ''trans''-[[resveratrol]] is a phytoalexin produced against the growth of fungal pathogens such as ''[[Botrytis cinerea]]''&lt;ref&gt;{{cite web|url=http://www.sipav.org/main/jpp/volumes/0309/030909.pdf |title=The role of grape polyphenols on trans-resveratrol activity against Botrytis cinerea and of fungal laccase on the solubility of putative grape PR proteins, F. Favaron, M. Lucchetta, S. Odorizzi, A.T. Pais da Cunha and L. Sella, Journal of Plant Pathology (2009), 91 (3), pages 579–588, 2009 579 |format=PDF |date= |accessdate=2011-01-22}}&lt;/ref&gt; and [[delta-viniferin]] is another grapevine phytoalexin produced following [[Fungal infection in plants|fungal infection]] by ''[[Plasmopara viticola]]''.&lt;ref&gt;{{cite journal | pmid=21821423|doi=10.1016/j.plaphy.2011.07.008 | title=Production of the phytoalexins trans-resveratrol and delta-viniferin in two economy-relevant grape cultivars upon infection with Botrytis cinerea in field conditions | year=2012 | last1=Timperio | first1=Anna Maria | last2=d’Alessandro | first2=Angelo | last3=Fagioni | first3=Marco | last4=Magro | first4=Paolo | last5=Zolla | first5=Lello | journal=Plant Physiology and Biochemistry | volume=50 | pages=65–71 | issue=1}}&lt;/ref&gt; [[Pinosylvin]] is a pre-infectious [[stilbenoid]] toxin (i.e. synthesized prior to infection), contrary to phytoalexins which are synthesized during infection. It is present in the [[heartwood]] of ''[[Pinaceae]]''.&lt;ref&gt;{{cite journal | doi=10.3390/11010103 | title=Screening Analyses of Pinosylvin Stilbenes, Resin Acids and Lignans in Norwegian Conifers | year=2006 | last1=Hovelstad | first1=Hanne | last2=Leirset | first2=Ingebjorg | last3=Oyaas | first3=Karin | last4=Fiksdahl | first4=Anne | journal=Molecules | volume=11 | pages=103–14 | pmid=17962750 | issue=1}}&lt;/ref&gt; It is a fungitoxin protecting the wood from [[Fungal infection in plants|fungal infection]].&lt;ref&gt;{{cite journal | doi=10.1016/j.fitote.2004.12.004 | title=Antibacterial and antifungal activity of pinosylvin, a constituent of pine | year=2005 | last1=Lee | first1=S.K. | last2=Lee | first2=H.J. | last3=Min | first3=H.Y. | last4=Park | first4=E.J. | last5=Lee | first5=K.M. | last6=Ahn | first6=Y.H. | last7=Cho | first7=Y.J. | last8=Pyee | first8=J.H. | journal=Fitoterapia | volume=76 | issue=2 | pages=258–60 | pmid=15752644}}&lt;/ref&gt;

[[Sakuranetin]] is a [[flavanone]], a type of flavonoid. It can be found in ''[[Polymnia fruticosa]]''&lt;ref&gt;[http://home.ncifcrf.gov/mtdp/Catalog/compounds/407228.html Sakuranetin on home.ncifcrf.gov]&lt;/ref&gt; and [[rice]], where it acts as a phytoalexin against spore germination of ''[[Magnaporthe grisea|Pyricularia oryzae]]''.&lt;ref&gt;[http://cat.inist.fr/?aModele=afficheN&amp;cpsidt=4682303 Sakuranetin, a flavonone phytoalexin from ultraviolet-irradiated rice leaves, Kodama O., Miyakawa J., Akatsuka T., Kiyosawa S, 1992]&lt;/ref&gt; In ''[[Sorghum]]'', the ''SbF3'H2'' gene, encoding a [[flavonoid 3'-hydroxylase]], seems to be expressed in [[Plant pathology|pathogen]]-specific [[3-deoxyanthocyanidin]] phytoalexins synthesis,&lt;ref&gt;[http://pcp.oxfordjournals.org/cgi/content/abstract/47/10/1412 Differential Expression of Two Flavonoid 3'-Hydroxylase cDNAs Involved in Biosynthesis of Anthocyanin Pigments and 3-Deoxyanthocyanidin Phytoalexins in Sorghum, Chun-Hat Shih, Ivan K. Chu, Wing Kin Yip and Clive Lo, 2006]&lt;/ref&gt; for example in ''Sorghum-[[Colletotrichum]]'' interactions.&lt;ref&gt;[http://abstracts.aspb.org/pb2009/public/P48/P48067.html Biosynthesis and regulation of 3-deoxyanthocyanidin phytoalexins induced during Sorghum-Colletotrichum interaction: Heterologous expression in maize. Chopra, Surinder  Gaffoor, Iffa Ibraheem, Farag]&lt;/ref&gt;

[[6-Methoxymellein]] is a [[dihydroisocoumarin]] and a phytoalexin induced in carrot slices by [[Ultraviolet C|UV-C]],&lt;ref&gt;{{cite journal | doi=10.1111/j.1439-0434.1993.tb01324.x | title=Induction of 6-Methoxymellein and Resistance to Storage Pathogens in Carrot Slices by UV-C | year=1993 | last1=Mercier | first1=J. | last2=Arul | first2=J. | last3=Ponnampalam | first3=R. | last4=Boulet | first4=M. | journal=Journal of Phytopathology | volume=137 | pages=44}}&lt;/ref&gt; that allows resistance to ''[[Botrytis cinerea]]''&lt;ref&gt;{{cite journal | doi=10.1016/0885-5765(87)90083-X | title=Cell death, 6-methoxymellein accumulation, and induced resistance to Botrytis cinerea in carrot root slices | year=1987 | last1=Hoffman | first1=R. | last2=Heale | first2=J.B. | journal=Physiological and Molecular Plant Pathology | volume=30 | pages=67}}&lt;/ref&gt; and other [[microorganism]]s.&lt;ref&gt;{{cite journal | doi=10.1016/S0031-9422(00)86959-9 | title=Isolation and antimicrobial activity of the phytoalexin 6-methoxymellein from cultured carrot cells | year=1983 | last1=Kurosaki | first1=Fumiya | last2=Nishi | first2=Arasuke | journal=Phytochemistry | volume=22 | issue=3 | pages=669}}&lt;/ref&gt;

[[Danielone]] is a phytoalexin found in the [[papaya]] fruit. This compound showed high antifungal activity against ''[[Colletotrichum gloesporioides]]'', a pathogenic fungus of papaya.&lt;ref&gt;Danielone, a phytoalexin from papaya fruit. Echeverri F., Torres F., Quinones W., Cardona G., Archbold R., Roldan J., Brito I., Luis J.G., and LahlouU E.-H., Phytochemistry, 1997, vol. 44, no2, pp. 255-256, {{INIST|2558881}}&lt;/ref&gt;

[[Stilbenoid|Stilbene]]s are produced in ''[[Eucalyptus sideroxylon]]'' in case of pathogens attacks. Such compounds can be implied in the [[hypersensitive response]] of plants. High levels of [[polyphenol]]s in some woods can explain their natural [[wood preservation|preservation]] against rot.&lt;ref&gt;{{cite journal |title=Inhibition of wood-rotting fungi by stilbenes and other polyphenols in Eucalyptus sideroxylon |first1=John H. |last1=Hart |first2=W. E. |last2=Hillis |journal=Phytopathology |volume=64 |pages=939–48 |year=1974 |doi=10.1094/Phyto-64-939 |issue=7}}&lt;/ref&gt;

== See also ==
* [[Allicin]]
* [[Garlic]]
* [[Pterostilbene]]
* [[Plant defense against herbivory]]
* [[Salvestrols]]

== References ==
{{reflist}}

&lt;!-- unused references
Moriguchi T., Matsuura H., Itakura Y., Katsuki H., Saito H., Nishiyama N., Life Sci., 61, 1413—1420 (1997).

Yukihiro Kodera, Makoto Ichikawa, Jiro Yoshida, Naoki Kashimoto, Naoto Uda, Isao Sumioka, Nagatoshi Ide and Kazuhisa Ono, &quot;Pharmacokinetic Study of Allixin, a Phytoalexin Produced by Garlic&quot;, Chem. Pharm. Bull., Vol. 50, 354-363 (2002) {{doi|10.1248/cpb.50.354}} [http://www.jstage.jst.go.jp/article/cpb/50/3/354/_pdf]
--&gt;

==External links==
*[http://www.lancs.ac.uk/staff/robertmr/downloads/mrr-crips.pdf Signals Regulating Multiple Responses to Wounding and Herbivores] Guy L. de Bruxelles and Michael R  Roberts
*[http://www.cepceb.ucr.edu/resources/pdf/walling/Walling-2000-JPGR.pdf The Myriad Plant Responses to Herbivores] Linda L. Walling
*[http://www.uky.edu/~garose/link100.htm THE CHEMICAL DEFENSES OF HIGHER PLANTS] GERALD A. ROSENTHAL
*[http://aob.oupjournals.org/cgi/content/full/89/5/503 Induced Systemic Resistance (ISR) Against Pathogens in the Context of Induced Plant Defences] MARTIN HEIL
*[http://www.plantphysiol.org/cgi/content/full/127/3/727 Notes from the Underground] Donald R. Strong and Donald A. Phillips
*[http://www.colostate.edu/Depts/Entomology/courses/en570/papers_2000/mannix.html Relationships Among Plants, Insect Herbivores, Pathogens, and Parasitoids Expressed by Secondary Metabolites] Loretta L. Mannix

[[Category:Antibiotics]]
[[Category:Phytoalexins]]</text>
      <sha1>l9tecirzmy0hzc6wtwvhbcu2vjnt49r</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Alliance for the Prudent Use of Antibiotics</title>
    <ns>0</ns>
    <id>1560804</id>
    <revision>
      <id>574661179</id>
      <parentid>565630871</parentid>
      <timestamp>2013-09-26T21:48:42Z</timestamp>
      <contributor>
        <username>Legoktm</username>
        <id>3855926</id>
      </contributor>
      <minor/>
      <comment>Robot - Speedily moving category Microbiology related organisations to [[:Category:Microbiology organisations]] per [[WP:CFDS|CFDS]].</comment>
      <text xml:space="preserve" bytes="3972">The '''Alliance for the Prudent Use of Antibiotics''' (APUA) is a non-profit organization founded in 1981 by Dr. [[Stuart B. Levy]], Professor of Medicine at [[Tufts University]] and headquartered in [[Boston, Massachusetts]].&lt;ref&gt;{{Cite book
 | last = Levy
 | first = Stuart
 | authorlink = 
 | coauthors = 
 | year = 2002
 | title = The Antibiotic Paradox
 | publisher = Perseus Publishing
 | location = Cambridge, MA
 | id =ISBN 0-7382-0440-4 
}}&lt;/ref&gt;
APUA’s mission is to strengthen society’s defenses against [[infectious disease]] by promoting appropriate access and use to [[antimicrobial]]  agents ([[antibiotic]]s, [[Antiviral drug|antivirals]], anti[[malaria]]ls etc.) and controlling [[antibiotic resistance|antimicrobial resistance]] on a worldwide basis. APUA has a network of affiliated chapters in over 50 countries, and conducts applied antimicrobial resistance research, education, capacity building and advocacy at the global and grassroots levels.

Wide-scale misuse of antibiotics and other antimicrobials and related resistance to these drugs is challenging [[infectious disease]] treatment and health care budgets worldwide. Antimicrobials are uniquely societal drugs because each individual patient use can propagate resistant organisms. APUA’s provides information to individuals, doctors and policy makers aimed at preserving the power of these agents by preventing infection, reducing drug resistance and increasing the effectiveness of treatment for infectious diseases, including acute [[bacteria]]l diseases, [[tuberculosis]], [[AIDS]] and [[malaria]].

==APUA Leadership Award==
Each year, APUA presents its Leadership Award in recognition of outstanding global contributions and 
commitment to preserve the power of antibiotics. Past recipients include:

*2012 Roman S. Kozlov M.D. and APUA-Russia&lt;ref&gt;http://www.tufts.edu/med/apua/news/leadership_award.shtml&lt;/ref&gt;

*2011 Giuseppe Cornaglia, M.D. of the European Society of Clinical Microbiology and Infectious Diseases

*2010 Otto Cars, M.D., chairman of [http://www.reactgroup.org ReAct – Action on Antibiotic Resistance], based in Uppsala, Sweden[http://www.tufts.edu/med/apua/news/press_release_9-14-10.shtml]

*2009 [[Infectious Diseases Society of America]] [http://www.tufts.edu/med/apua/2009_leadership_award_recipients.pdf]

*2008 [http://www.swab.nl/swab/swabcms.nsf/showfs/foreign|Dutch Working Party on Antibiotic Policy (SWAB)] and [http://www.wip.nl/UK/Default.htm Dutch Working Party on Infection Prevention (WIP)] [http://www.tufts.edu/med/apua/2008_leadership_award_recipients.pdf]

*2007 [[International Centre for Diarrhoeal Disease Research, Bangladesh]] (ICDDR,B),  [http://www.icddrb.org/activity/index.jsp?activityObjectID=3463]

*2006 Herman Goossens and Anna Lönnroth, [[European Commission]]  [https://www.grace-lrti.org/NR/rdonlyres/009F5B34-4B49-443E-B72E-1F847A2B9EFD/194/GRACENewsletterOctober2006.pdf]

*2005 Dr. Richard Besser - the U.S. [[Centers for Disease Control and Prevention]] [http://www.tufts.edu/med/apua/News/ICAAC.html]

*2004  Dr. Gabriel Schmunis - the [[Pan American Health Organization]] 

*2003 
**Robert L. Langer - [[McDonald's Corporation]]    
**Drs. Frank M. Aarestrup and Henrik C. Wegener - [[Danish Veterinary Institute]] [http://www.tufts.edu/med/apua/News/finalawards3FE2.pdf]

*2002 
**Dr. Murray Lumpkin - [[U.S. Food and Drug Administration]]  
**Dr. David Bell - U.S. Centers for Disease Control and Prevention  
**Dr. Marissa Miller - [[National Institute of Allergy and Infectious Diseases]]

*2001  Dr. Rosamund Williams - [[World Health Organization]]

==See also==
*[[Use of antimicrobial agents in the food industry]]

== Trivia ==
*The union's acronym means &quot;help&quot; in [[Finnish language|Finnish]].

==References==
{{Reflist}}

==External links==
*[http://www.apua.org APUA web site]

[[Category:Antibiotics]]
[[Category:Microbiology organisations]]
[[Category:Non-profit organizations based in Massachusetts]]</text>
      <sha1>n6dsu1e4vr43qyfg7l3xdkw7aycl1ta</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Daptomycin</title>
    <ns>0</ns>
    <id>1758235</id>
    <revision>
      <id>605690212</id>
      <parentid>597053352</parentid>
      <timestamp>2014-04-25T01:51:27Z</timestamp>
      <contributor>
        <username>Beland</username>
        <id>57939</id>
      </contributor>
      <minor/>
      <comment>/* History */ capitalization</comment>
      <text xml:space="preserve" bytes="31150">{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 457630808
| IUPAC_name = ''N''-decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-&lt;BR&gt;L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-''threo'' -3-methyl-L-glutamyl-3-anthraniloyl-L-alanine[egr]&lt;sub&gt;1&lt;/sub&gt;-lactone
| image = Daptomycin Ball et al.svg
| width = 300px

&lt;!--Clinical data--&gt;
| tradename = Cubicin
| Drugs.com = {{drugs.com|monograph|daptomycin}}
| pregnancy_US = B
| legal_US = Rx-only
| routes_of_administration = [[Intravenous]]

&lt;!--Pharmacokinetic data--&gt;
| bioavailability = n/a
| protein_bound = 90–95%
| metabolism = Renal (speculative)&lt;ref&gt;{{cite journal | author = Woodworth JR, Nyhart EH, Brier GL, Wolny JD, Black HR | title = Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers | journal = Antimicrob Agents Chemother. | volume = 36 | issue = 2 | pages = 318–25 |date=February 1992 | pmid = 1318678 | pmc = 188435 | url = http://aac.asm.org/cgi/pmidlookup?view = long&amp;pmid = 1318678 | doi = }}&lt;/ref&gt;
| elimination_half-life = 7–11 hours (up to 28 hours in renal impairment)
| excretion = [[Kidney|Renal]] (78%; primarily as unchanged drug); Faeces (5.7%)

&lt;!--Identifiers--&gt;
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 103060-53-3
| ATC_prefix = J01
| ATC_suffix = XX09
| PubChem = 16129629
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00080
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10482098
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = NWQ5N31VKK
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D01080
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 508162

&lt;!--Chemical data--&gt;
| C=72 | H=101 | N=17 | O=26 
| molecular_weight = 1619.7086 g/mol
&lt;!-- | InChI = 1/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1 --&gt;
| InChIKey = DOAKLVKFURWEDJ-RWDRXURGBK
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
&lt;!-- | StdInChI = 1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1 --&gt;
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DOAKLVKFURWEDJ-RWDRXURGSA-N
}}
{{Infobox protein family
| Symbol = 
| Name = 
| image = 
| width = 
| caption = 
| Pfam = 
| Pfam_clan =  
| InterPro = 
| SMART = 
| PROSITE = 
| MEROPS = 
| SCOP = 
| TCDB = 1.D.15
| OPM family = 172
| OPM protein = 1t5n
| CAZy = 
| CDD = 
}}

'''Daptomycin''' is a [[lipopeptide]] [[antibiotic]] used in the treatment of systemic and life-threatening infections caused by [[Gram-positive]] organisms. It is a naturally occurring compound found in the soil [[saprotroph]] ''[[Streptomyces roseosporus]]''. Its distinct mechanism of action makes it useful in treating infections caused by multi-resistant bacteria. It is marketed in the United States under the trade name '''Cubicin''' by [[Cubist Pharmaceuticals]].

== History ==
The compound '''LY 146032''' was discovered by researchers at [[Eli Lilly and Company]] in the late 1980s. LY 146032 showed promise in Phase I/II [[clinical trial]]s for treatment of infection caused by [[Gram-positive]] organisms. Lilly ceased development because high-dose therapy was associated with adverse effects on skeletal muscle, including [[myalgia]] and potential [[myositis]]. 

The rights to LY 146032 were acquired by [[Cubist Pharmaceuticals]] in 1997, which following U.S. [[Food and Drug Administration]] (FDA) approval in September 2003 for use in people older than 18 years began marketing the drug under the trade name Cubicin. Cubicin is marketed in the EU and in several other countries by [[Novartis]] following its purchase of [[Chiron Corporation]], previous licensee.&lt;ref name=Tally2000&gt;{{cite journal |author=Tally FP, DeBruin MF |title=Development of daptomycin for gram-positive infections |journal=[[J Antimicrob Chemother]]. |volume=46 |issue=4 |pages=523–6 |date=October 2000|pmid=11020247 |url=http://jac.oxfordjournals.org/cgi/pmidlookup?view=long&amp;pmid=11020247 |doi=10.1093/jac/46.4.523}}&lt;/ref&gt;&lt;ref name=&quot;Charles 2004&quot;&gt;{{cite journal |author=Charles PG, Grayson ML |title=The dearth of new antibiotic development: why we should be worried and what we can do about it |journal=Med J Aust. |volume=181 |issue=10 |pages=549–53 |date=November 2004|pmid=15540967 |url=http://www.mja.com.au/public/issues/181_10_151104/cha10412_fm.html}}&lt;/ref&gt;

==Mechanism of action==
Daptomycin has a distinct mechanism of action, disrupting multiple aspects of bacterial [[cell membrane]] function. It inserts into the cell membrane in a [[phosphatidylglycerol]] dependent fashion, where it then aggregates. The aggregation of daptomycin alters the curvature of the membrane, which creates holes that leak ions. This causes rapid [[depolarization]], resulting in a loss of membrane potential leading to inhibition of [[protein]], [[DNA]] and [[RNA]] synthesis, which results in bacterial cell death.&lt;ref name=&quot;Pogliano 2012&quot;&gt;{{cite journal |author=Pogliano J, Pogliano, N, Silverman, JA |title=Daptomycin-Mediated Reorganization of Membrane Architecture Causes Mislocalization of Essential Cell Division Proteins |journal=Journal of Bacteriology |volume=194 |issue=17 |pages=4494–4504 |date=September 2012|pmid=22661688 |url=http://www.ncbi.nlm.nih.gov/pubmed/22661688 |doi=10.1128/JB.00011-12}}&lt;/ref&gt;

== Microbiology ==
Daptomycin is bactericidal against Gram-positive bacteria only. It has proven ''in vitro'' activity against [[Enterococcus|enterococci]] (including [[glycopeptide]]-resistant Enterococci (GRE)), [[Staphylococcus|staphylococci]] (including [[methicillin-resistant Staphylococcus aureus|methicillin-resistant ''Staphylococcus aureus'']]), [[Streptococcus|streptococci]] and [[Corynebacterium|corynebacteria]].

== Daptomycin resistance ==
Daptomycin resistance is still uncommon but has been increasingly reported in GRE, starting in Korea in 2005, in Europe in 2010, in Taiwan 2011, and in the USA, where 9 cases have been reported from 2007 to 2011.&lt;ref&gt;Infect Dis Clin Pract 2013;21: 79-84.&lt;/ref&gt; Daptomycin resistance emerged in 5 of the 6 cases, while they were treated. 
The mechanism of resistance is unknown.

== Clinical use ==

===Indications===
Daptomycin is approved for use in adults in the United States for [[skin and skin structure infection]]s caused by [[Gram-positive]] infections, ''[[Staphylococcus aureus]]'' bacteraemia and right-sided ''S. aureus'' [[endocarditis]].  It binds avidly to [[pulmonary surfactant]], and therefore cannot be used in the treatment of pneumonia.&lt;ref&gt;{{cite journal
|author=Baltz RH.
|title=Daptomycin: mechanisms of action and resistance, and biosynthetic engineering.
|journal=Current Opinion in Chemical Biology
|volume=13
|issue=2
|pages=144–151
|date=Apr 2009
|pmid=19303806
|doi=10.1016/j.cbpa.2009.02.031
 }}&lt;/ref&gt; There seems to be a difference in working daptomycin on hematogenous pneumonia.&lt;ref&gt;{{cite journal
|author=Henken S, Bohling J, et al.
|title=Efficacy Profiles of Daptomycin for Treatment of Invasive and Noninvasive Pulmonary Infections with Streptococcus pneumoniae
|journal=Antimicrob Agents Chemother
|volume=54
|issue=2
|pages=707–717
|date=Feb 2010
|pmid=19917756
|doi=10.1128/AAC.00943-09 }}&lt;/ref&gt;

=== Efficacy ===
Daptomycin has been shown to be better than standard therapies ([[nafcillin]], [[oxacillin]], [[flucloxacillin]] or [[vancomycin]]) in the treatment of [[bacteraemia]] and right-sided [[endocarditis]] caused by ''Staphylococcus aureus''.&lt;ref&gt;{{cite journal
|author=Fowler VG, Boucher HW, Corey GR
|title=Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
|journal=N Engl J Med
|volume=355
|issue=7
|pages=653–65
|date=Aug 2006
|pmid=16914701
|doi=10.1056/NEJMoa053783 }}&lt;/ref&gt;  A study in [[Detroit, Michigan]] compared 53 patients treated suspected [[Methicillin-resistant Staphylococcus aureus|MRSA]] skin or soft tissue infection with daptomycin against [[vancomycin]],  has been shown to result in faster recovery from skin and soft tissue infections (4 days versus 7 days).&lt;ref&gt;{{cite journal
|author=Davis SL, McKinnon PS, Hall LM
|journal=Pharmacotherapy
|year=2007
|volume=27
|issue=12
|pages=1611&amp;ndash;1618
|url=http://www.medscape.com/viewarticle/569439
|pmid=18041881
|doi=10.1592/phco.27.12.1611
|title=Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.}}&lt;/ref&gt;  The main problems with this study were that vancomycin controls were historical (which means that the improved outcomes observed in the daptomycin treated patients could be due to improvements in practice over time that were unrelated to daptomycin use), and the target drug levels were low (lower limit 5&amp;nbsp;mg/dl, compared to the 10&amp;nbsp;mg/dl or 15&amp;nbsp;mg/dl currently recommended).

In Phase III clinical trials, limited data showed that daptomycin was associated with poor outcomes in patients with left-sided endocarditis{{Citation needed|date=September 2012}}. It is inactivated by pulmonary [[surfactant]]s and is not indicated for the treatment of [[pneumonia]]. Daptomycin has not been studied in patients with [[prosthetic heart valve|prosthetic valve]] endocarditis or [[meningitis]].&lt;ref name=Cubist2005&gt;Cubicin (daptomycin for injection) [homepage on the Internet]. Lexington (MA): Cubist Pharmaceuticals; c2003–06 [updated 2006 May 27; cited 2006 Aug 20]. Available from: http://www.cubicin.com/home.htm&lt;/ref&gt;

=== Dosage and presentation ===
In skin and soft tissue infections, 4&amp;nbsp;mg/kg daptomycin is given intravenously once daily.  For ''S. aureus'' bacteraemia or right-sided endocarditis, the approved dose is 6&amp;nbsp;mg/kg given intravenously once daily.

Daptomycin is given every 48 hours in patients with renal impairment, clearance &lt; 30 ml/min.  There is no information available on dosing in people less than 18 years of age.

Daptomycin is supplied as a sterile preservative-free pale yellow to light brown lyophilised 500&amp;nbsp;mg and 350&amp;nbsp;mg cake that must be reconstituted with 0.9% saline prior to use.

Daptomycin is applicable as 30-min-infusion or 2-min-injection.

=== Adverse effects ===
Adverse drug reactions associated with daptomycin therapy include:&lt;ref name=&quot;MicromedexDrugdex&quot;&gt;Daptomycin. In: Klasco RK, editor. Drugdex system, vol. 129. Greenwood Village (CO): Thomson Micromedex; 2006.&lt;/ref&gt;
*Cardiovascular: [[hypotension]] (2.4%), [[hypertension]] (1.1%), [[edema]], cardiac failure, [[supraventricular tachycardia]]
*Central nervous system: headache (5.4%), insomnia (4.5%), dizziness (2.2%), anxiety, confusion, [[Vertigo (medical)|vertigo]], [[paraesthesia]]
*Dermatological: rash (4.3%), [[pruritus]] (2.8%), [[eczema]]
*Endocrine: [[hypokalaemia]], [[hyperglycemia]], [[hypomagnesemia]], increased serum [[bicarbonate]], other [[electrolyte]] disturbances
*Gastrointestinal: constipation (6.2%), nausea (5.8%), diarrhea (5.2%), vomiting (3.2%), dyspepsia (0.9%), abdominal pain, decreased appetite, [[stomatitis]], flatulence
*Hematological: [[anemia]] (2.1%), [[leukocytosis]], [[thrombocytopenia]], [[thrombocytosis]], [[eosinophilia]], increased [[international normalised ratio]] (INR)
*Hepatic: abnormal [[liver function test]]s (3%) (including [[alkaline phosphatase]] and [[lactate dehydrogenase]]), [[jaundice]]
*Musculoskeletal: elevated [[creatine kinase]] (CK) levels (2.8–10.5%), limb pain (1.5%), [[arthralgia]] (0.9%), [[myalgia]], muscle cramps, muscle weakness, [[osteomyelitis]]
*Renal: acute [[renal failure]] (2.2%)
*Respiratory: [[dyspnea]] (2.1%)
*Other: injection site reactions (5.8%), fever (1.9%), [[hypersensitivity]]

There are also reports of [[myopathy]] and [[rhabdomyolysis]] occurring in patients simultaneously taking [[statin]]s&lt;ref&gt;Journal of Antimicrobial Chemotherapy. 63(6):1299-300, 2009 Jun.&lt;/ref&gt; but whether this is due entirely to the statin or whether daptomycin potentiates this effect is unknown. Due to the limited data available, the manufacturer recommends that statins be temporarily discontinued while the patient is receiving daptomycin therapy. [[Creatine kinase]] levels are usually checked regularly while individuals undergo daptomycin therapy.

In July 2010, the FDA issued a warning that Daptomycin could cause life-threatening [[eosinophilic pneumonia]]. The FDA said that it had identified seven confirmed cases of eosinophilic pneumonia  between 2004 and 2010 and an additional 36 possible cases. The seven confirmed victims were all older than 60 and symptoms appeared within two weeks of initiation of therapy.

== Biosynthesis ==
[[File:dap.52.gif|thumb|'''Figures 1-7.''' Biosynthesis of Daptomycin]]

[[File:nbt1265-F2.png|thumb|'''Figure 8.''' Structures of lipopeptide antibiotics.
Colors highlight the positions in daptomycin that have been modified by genetic engineering, as well as the origins of modules or subunits from A54145 or calcium-dependent antibiotic (CDA).&lt;ref name=Nguyen&gt;{{cite journal |author=Nguyen KT, Kau D, Gu JQ |title=A glutamic acid 3-methyltransferase encoded by an accessory gene locus important for daptomycin biosynthesis in Streptomyces roseosporus |journal=Mol Microbiol. |volume=61 |issue=5 |pages=1294–307 |date=September 2006|pmid=16879412 |doi=10.1111/j.1365-2958.2006.05305.x }}&lt;/ref&gt; 
]]

[[File:Nbt1265-F3.png|thumb|'''Figure 9.''' Combinatorial biosynthesis of lipopeptide antibiotics related to daptomycin. Position 8, which typically has D-Ala in daptomycin, was modified by module exchanges to contain D-Ser, D-Asn or D-Lys; position 11, which naturally has D-Ser, was modified by module exchanges to consist of D-Ala or D-Asn; position 12, which normally has 3-methyl-L-Glu, was modified by deletion of the methyltransferase gene to possess L-Glu; position 13, which normally has L-kynurenine (L-Kyn), was modified by subunit exchanges to contain L-Trp, L-Ile or L-Val; position 1 usually includes the anteiso-undecanoyl, isododecanoyl and anteiso-tridecanoyl fatty acyl groups. All of these alterations have been combinatorialized.
&lt;ref name=Nguyen/&gt;]]

{{essay|date=September 2009}}

Daptomycin is a cyclic lipopeptide antibiotic produced by the organism ''Streptomyces roseosporus''.&lt;ref&gt;{{cite journal |author=Miao V, Coëffet-Legal MF, Brian P |title=Daptomycin biosynthesis in Streptomyces roseosporus: cloning and analysis of the gene cluster and revision of peptide stereochemistry |journal=Microbiology (Reading, Engl.) |volume=151 |issue=Pt 5 |pages=1507–23 |date=May 2005 |pmid=15870461 |doi=10.1099/mic.0.27757-0 }}&lt;/ref&gt;&lt;ref name=Steenbergen&gt;{{cite journal |author=Steenbergen JN, Alder J, Thorne GM, Tally FP |title=Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections |journal=J Antimicrob. Chemother. |volume=55 |issue=3 |pages=283–8 |date=March 2005|pmid=15705644 |doi=10.1093/jac/dkh546 }}&lt;/ref&gt;  Daptomycin consists of thirteen amino acids, ten of which are arranged in a cyclic fashion, and three that adorn an exocyclic tail. Two non-proteinogenic amino acids exist in the lipopeptide, the unusual amino acid L-kynurenine (Kyn), only known to Daptomycin, and L-3-methylglutamic acid (mGlu). The N-terminus of the exocyclic tryptophan residue is coupled to decanoic acid, a medium chain (C10) fatty acid. Biosynthesis is initiated by the coupling of decanoic acid to the N-terminal [[tryptophan]], followed by the coupling of the remaining amino acids by nonribosomal peptide synthetase (NRPS) mechanisms.  Finally, a cyclization event occurs, which is catalyzed by a thioesterase enzyme, and subsequent release of the lipopeptide is granted.  
   
The non-ribosomal peptide synthetase (NRPS) responsible for the synthesis of Daptomycin is encoded by three overlapping genes, dptA, dptBC and dptD. The dptE and dptF genes, immediately upstream of dptA, are likely to be involved in the initiation of daptomycin biosynthesis by coupling decanoic acid to the N-terminal Trp.&lt;ref name=Mchenney&gt;{{cite journal |author=Mchenney MA, Hosted TJ, Dehoff BS, Rosteck PR, Baltz RH |title=Molecular cloning and physical mapping of the daptomycin gene cluster from Streptomyces roseosporus |journal=J Bacteriol. |volume=180 |issue=1 |pages=143–51 |date=1 January 1998|pmid=9422604 |pmc=106860 |url=http://jb.asm.org/cgi/pmidlookup?view=long&amp;pmid=9422604 }}&lt;/ref&gt; These novel genes (dptE, dptF ) correspond to products that most likely work in conjunction with a unique [[condensation domain]] to acylate the first amino acid (tryptophan).  These and other novel genes (dptI, dptJ) are believed to be involved in supplying the non-proteinogenic amino acids L-3-methylglutamic acid and Kyn; they are located next to the NRPS genes.&lt;ref name=Mchenney/&gt;

The decanoic acid portion of Daptomycin is synthesized by fatty acid synthase machinery (Figure 2).  Posttranslational modification of the apo-acyl carrier protein (ACP, thiolation, or T domain) by a phosphopantetheinyltransferase (PPTase) enzyme catalyzes the transfer of a flexible phosphopantetheine arm from coenzyme A to a conserved serine in the ACP domain through a phosphodiester linkage.  The holo-ACP can now provide a thiol on which the substrate and acyl chains are covalently tethered during chain elongations.  The two core catalytic domains are an acyltransferase (AT) and a ketosynthase (KS).  The AT acts upon a malonyl CoA substrate and transfers an acyl group to the thiol of the ACP domain.  This net transthiolation is an energy neutral step.  Next, the acyl-S-ACP gets transthiolated to a conserved cysteine on the KS; the KS decarboxylates the downstream malonyl-S-ACP and forms a β-ketoacyl-S-ACP.  This serves as the substrate for the next cycle of elongation. Before the next cycle begins, however, the β-keto group undergoes reduction to the corresponding alcohol catalyzed by a ketoreductase (KR) domain, followed by dehydration to the olefin catalyzed by a dehydratase (DH) domain, and finally reduction to the methylene catalyzed by an enoylreductase (ER) domain.  Each KS catalytic cycle results in the net addition of two carbons.  After three more iterations of elongation, a thioesterase enzyme catalyzes the hydrolysis, and thus release, of the free C-10 fatty acid.
   
To synthesize the peptide portion of Daptomycin, the mechanism of a non-ribosomal peptide synthetase (NRPS) is employed.  The biosynthetic machinery of an NRPS system is composed of multimodular enzymatic assembly lines that contain one module for each amino acid monomer incorporated.&lt;ref name=Fischbach&gt;{{cite journal |author=Fischbach MA, Walsh CT |title=Assembly-line enzymology for polyketide and nonribosomal Peptide antibiotics: logic, machinery, and mechanisms |journal=Chem Rev. |volume=106 |issue=8 |pages=3468–96 |date=August 2006|pmid=16895337 |doi=10.1021/cr0503097 }}&lt;/ref&gt;   Within each module, there are catalytic domains that carry out the elongation of the growing peptidyl chain.  The growing peptide is covalently tethered to a thiolation (T) domain; here it is termed the peptidyl carrier protein (PCP), as it carries the growing peptide from one catalytic domain to the next.  Again, the apo-T domain must be primed to the holo-T domain via a PPTase, attaching a flexible phosphopantetheine arm to a conserved serine residue.  An adenylation (A) domain selects the amino acid monomer to be incorporated and activates the carboxylate with ATP to make the aminoacyl-AMP.  Next, the A domain installs an aminoacyl group on the thiolate of the adjacent T domain (PCP).  The condensation (C) domain catalyzes the peptide bond forming reaction, which elicits chain elongation. It joins an upstream peptidyl-S-T to the downstream aminoacyl-S-T (Figure 7).  Chain elongation by one aminoacyl residue and chain translocation to the next T domain occurs in concert. The order of these domains is C-A-T.  In some instances, an epimerization (E) domain is necessary in those modules where L-amino acid monomers are to be incorporated and epimerized to D-amino acids.  The domain organization in such modules is C-A-T-E.&lt;ref name=Fischbach/&gt;

The first module has a three-domain C-A-T organization; these often occur in assembly lines that make N-acylated peptides.&lt;ref name=Fischbach/&gt; The first C domain catalyzes N-acylation of the initiating amino acid (tryptophan) while it is installed on T.  An adenylating enzyme (Ad) catalyzes the condensation of decanoic acid and the N-terminal tryptophan, which incorporates decanoic acid into the growing peptide (Figure 3). The genes responsible for this coupling event are dptE and dptF, which are located upstream of dptA, the first gene of the Daptomycin NRPS biosynthetic gene cluster.  Once the coupling of decanoic acid to the N-terminal tryptophan residue occurs, the condensation of amino acids begins, catalyzed by the NRPS.  

The first five modules of the NRPS are encoded by the dptA gene and catalyze the condensation of L-tryptophan, D-aspartate, L-aspartate, L-threonine, and glycine, respectively (Figure 4).  Modules 6-11, which catalyze the condensation of L-ornithine, L-aspartate, D-alanine, L-aspartate, glycine, and D-serine are encoded for the dptBC gene (Figure 5). DptD catalyzes the incorporation of two non-proteinogenic amino acids, L-3-methylglutamic acid (mGlu) and the unusual amino acid L-kynurenine (Kyn), which is only known thus far to Daptomycin, into the growing peptide (Figure 6).&lt;ref name=Steenbergen/&gt;  Elongation by these NRPS modules ultimately leads to macrocyclization and release in which an α-amino group, namely threonine, acts as an internal nucleophile during cyclization to yield the 10 amino acid ring (Figure 6).  The termination module in the NRPS assembly line has a C-A-T-TE organization.  The thioesterase (TE) domain catalyzes chain termination and release of the mature lipopeptide.&lt;ref name=Fischbach/&gt;

With the recent advances in molecular engineering over the past 25 years, new approaches in the production of novel antibiotics have emerged. Innovations in cloning and the subsequent analysis of antibiotic gene clusters, the engineering of biosynthetic pathways in ''Escherichia coli'', the transfer of engineered pathways from ''E. coli'' into ''Streptomyces'' expression hosts, and finally the stable maintenance and expression of cloned genes are all processes that have streamlined the process. More comprehensive understanding and knowledge of the mechanisms, as well as the substrate specificities during their assembly by polyketide synthases, nonribosomal peptide synthetases, glycosyltransferases and other enzymes have made molecular engineering design and outcomes more predictable.&lt;ref name=Baltz17160059&gt;{{cite journal |author=Baltz RH |title=Molecular engineering approaches to peptide, polyketide and other antibiotics |journal=Nat Biotechnol. |volume=24 |issue=12 |pages=1533–40 |date=December 2006|pmid=17160059 |doi=10.1038/nbt1265 }}&lt;/ref&gt;

The molecular engineering of Daptomycin, the only marketed acidic lipopeptide antibiotic up to date (Figure 8), has seen many advances since its inception into clinical medicine in 2003.&lt;ref&gt;{{cite journal |author=Baltz RH |title=Genetic manipulation of antibiotic-producing Streptomyces |journal=Trends Microbiol. |volume=6 |issue=2 |pages=76–83 |date=February 1998|pmid=9507643 |doi=10.1016/S0966-842X(97)01161-X }}&lt;/ref&gt;   It is an attractive target for combinatorial biosynthesis for many reasons: second generation derivatives are currently in the clinic for development;&lt;ref name=Baltz16311632&gt;{{cite journal |author=Baltz RH, Miao V, Wrigley SK |title=Natural products to drugs: daptomycin and related lipopeptide antibiotics |journal=Nat Prod Rep |volume=22 |issue=6 |pages=717–41 |date=December 2005|pmid=16311632 |doi=10.1039/b416648p }}&lt;/ref&gt;
Streptomyces roseosporus, the producer organism of daptomycin, is amenable to genetic manipulation;&lt;ref name=Baltz16193281&gt;{{cite journal |author=Baltz RH, Brian P, Miao V, Wrigley SK |title=Combinatorial biosynthesis of lipopeptide antibiotics in Streptomyces roseosporus |journal=J Ind Microbiol Biotechnol. |volume=33 |issue=2 |pages=66–74 |date=February 2006|pmid=16193281 |doi=10.1007/s10295-005-0030-y }}&lt;/ref&gt; the daptomycin biosynthetic gene cluster has been cloned, sequenced and expressed in a S. lividans;&lt;ref name=Baltz16311632/&gt; the lipopeptide biosynthetic machinery has the potential to be interrupted by variations of natural precursors, as well as precursor-directed biosynthesis, gene deletion, genetic exchange, and module exchange;&lt;ref name=Baltz16193281/&gt; the molecular engineering tools have been developed to facilitate the expression of the three individual NRPS genes from three different sites in the chromosome, using ermEp* for expression of two genes from ectopic loci;&lt;ref&gt;{{cite journal |author=Nguyen KT, Ritz D, Gu JQ |title=Combinatorial biosynthesis of novel antibiotics related to daptomycin |journal=Proc Natl Acad Sci USA. |volume=103 |issue=46 |pages=17462–7 |date=November 2006|pmid=17090667 |pmc=1859951 |doi=10.1073/pnas.0608589103 }}&lt;/ref&gt; other lipopeptide gene clusters, both related and unrelated to daptomycin, have been cloned and sequenced,&lt;ref name=Nguyen/&gt; thus providing genes and modules to allow the generation of hybrid molecules;&lt;ref name=Baltz16193281/&gt; derivatives can be afforded via chemoenzymatic synthesis;&lt;ref&gt;{{cite journal |author=Kopp F, Grünewald J, Mahlert C, Marahiel MA |title=Chemoenzymatic design of acidic lipopeptide hybrids: new insights into the structure-activity relationship of daptomycin and A54145 |journal=Biochemistry |volume=45 |issue=35 |pages=10474–81 |date=September 2006|pmid=16939199 |doi=10.1021/bi0609422 }}&lt;/ref&gt; and lastly, efforts in medicinal chemistry are able to further modify these products of molecular engineering.&lt;ref name=Baltz16311632/&gt;

New derivatives of daptomycin (Figure 9) were originally generated by exchanging the third NRPS subunit (DptD) with the terminal subunits from the A54145 (Factor B1) or calcium-dependent antibiotic (CDA) pathways to create molecules containing Trp13, Ile13, or Val13.&lt;ref name=Miao/&gt; Dpt D is responsible for incorporating the penultimate amino acid, 3-methyl-glutamic acid (3mGlu12), and the last amino acid, kynurenine (Kyn13), into the growing chain.  This exchange was achieved without engineering the interpeptide dockingsites. These whole-subunit exchanges have been coupled combinatorially with the deletion of the Glu12-methyltransferase gene, with module exchanges at intradomain linker sites at Ala8 and Ser11, and with variations of natural fatty acid side chains to generate over seventy novel lipopeptides in significant quantities; most of these resultant lipopeptides have potent antibacterial activities.&lt;ref name=Nguyen/&gt;&lt;ref name=Miao&gt;{{cite journal |author=Miao V, Coëffet-Le Gal MF, Nguyen K |title=Genetic engineering in Streptomyces roseosporus to produce hybrid lipopeptide antibiotics |journal=Chem Biol. |volume=13 |issue=3 |pages=269–76 |date=March 2006|pmid=16638532 |doi=10.1016/j.chembiol.2005.12.012 }}&lt;/ref&gt; Some of these compounds have in vitro antibacterial activities analogous to daptomycin. Further, one displayed ameliorated activity against an ''E. coli'' imp mutant that was defective in its ability to assemble its inherent lipopolysaccharide. A number of these compounds were produced in yields that spanned from 100 to 250&amp;nbsp;mg/liter; this, of course, opens up the possibility for successful scale-ups by means of fermentation techniques. Only a small percentage of the possible combinations of amino acids within the peptide core have been investigated thus far.&lt;ref name=Baltz17160059/&gt;

Thus, the biosynthetic genes for daptomycin, a calcium-dependent antibiotic, have been cloned, sequenced, analyzed bioinformatically, genetically, and biochemically.  The resultant information on the organization and expression of NRPS genes, among others, has been exploited and utilized to create combinatorial libraries of hybrid lipopeptide antibiotics related to daptomycin that have proven as effective antibiotics thus far in clinical trials .&lt;ref&gt;{{cite journal |author=Baltz RH |title=Biosynthesis and genetic engineering of lipopeptide antibiotics related to daptomycin |journal=Curr Top Med Chem |volume=8 |issue=8 |pages=618–38 |year=2008 |pmid=18473888 |url=http://www.bentham-direct.org/pages/content.php?CTMC/2008/00000008/00000008/0002R.SGM |doi=10.2174/156802608784221497}}&lt;/ref&gt;

== References ==
{{Reflist|2}}

== External links ==
*{{cite journal  | author=Giuliani A, Pirri G, Nicoletto S |title=Antimicrobial peptides: an overview of a promising class of therapeutics  |journal=Cent. Eur. J. Biol. |volume=2 |issue= 1 |pages= 1–33 |year= 2007 |doi=10.2478/s11535-007-0010-5  }}
*{{cite journal  | author=Pirri G, Giuliani A, Nicoletto S, Pizutto L, Rinaldi A |title=Lipopeptides as anti-infectives: a practical perspective |journal=Cent. Eur. J. Biol. |volume=4 |issue= 3 |pages= 258–273 |year= 2009 |doi=10.2478/s11535-009-0031-3  }}
*{{cite journal |author=Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI |title=The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections |journal=Clin Infect Dis. |volume=38 |issue=12 |pages=1673–81 |date=June 2004|pmid=15227611 |doi=10.1086/420818 |author6=Daptomycin 98-01 and 99-01 Investigators }}
*[http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=14171 PubChem Substance ID]
*[http://www.whocc.no/atcddd/new_atc_ddd.html New ATC Codes] (from [[WHO]])
* {{UMichOPM|families|superfamily|172}} - Orientations of daptomycin and tsushimycin in membrane

{{Cell wall disruptive antibiotics |Other}}

[[Category:Antibiotics]]
[[Category:Eli Lilly and Company]]
[[Category:Depsipeptides]]
[[Category:Lipopeptides]]
[[Category:Cyclic peptides]]
[[Category:Peripheral membrane proteins]]</text>
      <sha1>5s61v2mzxhpujpej0rn3m6e0acjfets</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Nitrofurantoin</title>
    <ns>0</ns>
    <id>714824</id>
    <revision>
      <id>605931986</id>
      <parentid>605598693</parentid>
      <timestamp>2014-04-26T19:14:01Z</timestamp>
      <contributor>
        <username>BattyBot</username>
        <id>15996738</id>
      </contributor>
      <minor/>
      <comment>fixed [[Help:CS1 errors#bad_date|CS1 errors: dates]] to meet [[MOS:DATEFORMAT]] (also [[WP:AWB/GF|General fixes]]) using [[Project:AWB|AWB]] (10083)</comment>
      <text xml:space="preserve" bytes="25731">{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 462261865
| IUPAC_name = (''E'')-1-[(5-nitro-2-furyl)methylideneamino]imidazolidine-2,4-dione
| image = nitrofurantoin.png

&lt;!--Clinical data--&gt;
| tradename = Macrobid, Macrodantin, others
| Drugs.com = {{drugs.com|monograph|nitrofurantoin}}
| MedlinePlus = a682291
| pregnancy_AU = A
| pregnancy_US = B
| legal_AU = S4
| legal_CA = Rx-only

| legal_US = Rx-only
| legal_UK = POM
| routes_of_administration = oral, rectal&lt;ref name=&quot;parrott1976&quot;&gt;{{Cite doi | 10.1002/jps.2600660713}}&lt;/ref&gt;

&lt;!--Pharmacokinetic data--&gt;
| bioavailability = 40%
| metabolism = [[liver]] (75%)
| elimination_half-life = 20 minutes
| excretion = [[urine]] and [[bile]]

&lt;!--Identifiers--&gt;
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 67-20-9
| ATC_prefix = J01
| ATC_suffix = XE01
| PubChem = 6604200
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00698
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 71415
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5036498
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 927AH8112L
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00439
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 572

&lt;!--Chemical data--&gt;
 | C=8 | H=6 | N=4 | O=5 
| molecular_weight = 238.16
| smiles = O=[N+]([O-])c2oc(/C=N/N1C(=O)NC(=O)C1)cc2
| InChI = 1/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+
| InChIKey = NXFQHRVNIOXGAQ-YCRREMRBBU
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NXFQHRVNIOXGAQ-YCRREMRBSA-N
}}

'''Nitrofurantoin''' (trade name '''Macrobid''' among others) is an [[antibiotic]] usually used to treat [[urinary tract infection]].

&lt;!-- Society and culture --&gt;
It is on the [[World Health Organization's List of Essential Medicines]], a list of the most important medication needed in a basic [[health system]].&lt;ref&gt;{{cite web|title=WHO Model List of EssentialMedicines|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|work=World Health Organization|accessdate=22 April 2014|date=October 2013}}&lt;/ref&gt;

==Medical use==
Nitrofurantoin has been available for the treatment of urinary tract infections (UTIs) since 1953.  Its current uses include the treatment of uncomplicated urinary tract infections and prophylaxis against urinary tract infections in people prone to recurrent UTIs.&lt;ref name=&quot;Macrobid Drug Label1&quot;&gt;{{cite web|title=Macrobid Drug Label|url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020064s021lbl.pdf|publisher=FDA|accessdate=21 April 2014}}&lt;/ref&gt;  Increasing bacterial antibiotic resistance to other commonly used agents, such as [[fluoroquinolones]] and [[trimethoprim/sulfamethoxazole]], has led to increased interest in using nitrofurantoin.&lt;ref name=&quot;pmid18154548&quot;&gt;{{cite journal |author=Garau J |title=Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline |journal=Clin. Microbiol. Infect. |volume=14 Suppl 1 |issue= |pages=198–202 |date=January 2008 |pmid= 18154548|doi=10.1111/j.1469-0691.2007.01852.x |url=http://www3.interscience.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=1198-743X&amp;date=2008&amp;volume=14&amp;issue=&amp;spage=198}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=McKinnell|first=JA|coauthors=Stollenwerk, NS; Jung, CW; Miller, LG|title=Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis.|journal=Mayo Clinic proceedings|date=Jun 2011|volume=86|issue=6|pages=480–8|pmid=21576512}}&lt;/ref&gt; Several trials comparing nirofurantoin to other commonly used agents have shown that this drug results in similar cure rates for uncomplicated urinary tract infections.&lt;ref&gt;{{cite journal|last=Christiaens|first=TC|coauthors=De Meyere, M; Verschraegen, G; Peersman, W; Heytens, S; De Maeseneer, JM|title=Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women.|journal=The British journal of general practice : the journal of the Royal College of General Practitioners|date=Sep 2002|volume=52|issue=482|pages=729–34|pmid=12236276}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=Gupta|first=K|coauthors=Hooton, TM; Roberts, PL; Stamm, WE|title=Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women.|journal=Archives of internal medicine|date=Nov 12, 2007|volume=167|issue=20|pages=2207–12|pmid=17998493}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=Iravani|first=A|coauthors=Klimberg, I; Briefer, C; Munera, C; Kowalsky, SF; Echols, RM|title=A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection.|journal=The Journal of antimicrobial chemotherapy|date=Mar 1999|volume=43 Suppl A|pages=67–75|pmid=10225575}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=Stein|first=GE|title=Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection.|journal=Clinical therapeutics|date=Nov 1999|volume=21|issue=11|pages=1864–72|pmid=10890258}}&lt;/ref&gt; The efficacy of nitrofurantoin in treating urinary tract infections combined with a low rate of bacterial resistance to this agent makes it one of the first-line agents for treating uncomplicated urinary tract infections as recommended by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.&lt;ref name=&quot;IDSA UTI Guidelines&quot;&gt;{{cite journal|last=Gupta|first=K.|coauthors=Hooton, T. M.; Naber, K. G.; Wullt, B.; Colgan, R.; Miller, L. G.; Moran, G. J.; Nicolle, L. E.; Raz, R.; Schaeffer, A. J.; Soper, D. E.|title=International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases|journal=Clinical Infectious Diseases|date=2011|volume=52|issue=5|pages=e103–e120|doi=10.1093/cid/ciq257|accessdate=20 April 2014}}&lt;/ref&gt;

Nitrofurantoin is not recommended for the treatment of [[pyelonephritis]],&lt;ref name=&quot;IDSA UTI Guidelines&quot; /&gt; [[prostatitis]]&lt;ref&gt;{{cite journal|last=Lipsky|first=Benjamin A.|coauthors=Byren, Ivor; Hoey, Christopher T.|title=Treatment of Bacterial Prostatitis|journal=Clinical Infectious Diseases|volume=50|issue=12|pages=1641–1652|doi=10.1086/652861}}&lt;/ref&gt; and intra-abdominal [[abscess]],&lt;ref&gt;{{cite journal|last=Solomkin|first=Joseph S.|coauthors=Mazuski, John E.; Bradley, John S.; Rodvold, Keith A.; Goldstein, Ellie J. C.; Baron, Ellen J.; O’Neill, Patrick J.; Chow, Anthony W.; Dellinger, E. Patchen; Eachempati, Soumitra R.; Gorbach, Sherwood; Hilfiker, Mary; May, Addison K.; Nathens, Avery B.; Sawyer, Robert G.; Bartlett, John G.|title=Diagnosis and Management of Complicated Intra‐abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America|journal=Clinical Infectious Diseases|volume=50|issue=2|pages=133–164|doi=10.1086/649554}}&lt;/ref&gt; because of extremely poor tissue penetration and low blood levels.

===Dosing===
Treatment is for five to seven days.  Shortened courses of 3 days are not recommended.&lt;ref name=&quot;IDSA UTI Guidelines&quot; /&gt; Nitrofurantoin should be taken with food, as this improves the absorption and [[bioavailability]] of the drug as well as lessening the common side effects of nausea and vomiting.&lt;ref&gt;{{cite journal|last=Gleckman|first=R|coauthors=Alvarez, S; Joubert, DW|title=Drug therapy reviews: nitrofurantoin.|journal=American journal of hospital pharmacy|date=Mar 1979|volume=36|issue=3|pages=342–51|pmid=369367}}&lt;/ref&gt;

===Antibacterial activity===
Nitrofurantoin has been shown to have good activity against the following organisms:
*''[[Escherichia coli|E. coli]]'',
*''[[Staphylococcus saprophyticus|Staph. saprophyticus]]'',
*[[Coagulase negative staphylococci]],
*''[[Enterococcus faecalis]]'',
*''[[Staphylococcus aureus]]'',
*''[[Streptococcus agalactiae]]'',
*''[[Citrobacter]]'' species, and
*''[[Klebsiella]]'' species,
and is used in the treatment of infections caused by these organisms.&lt;ref name=&quot;JAMA Abx Resistance&quot;&gt;{{cite journal|last=Gupta|first=K|coauthors=Scholes, D; Stamm, WE|title=Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women.|journal=JAMA : the journal of the American Medical Association|date=Feb 24, 1999|volume=281|issue=8|pages=736–8|pmid=10052444|accessdate=20 April 2014}}&lt;/ref&gt;

Many or all strains of the following are resistant to nitrofurantoin:&lt;ref name=&quot;JAMA Abx Resistance&quot; /&gt;
*''[[Enterobacter]]'' species,  
*''[[Klebsiella]]'' species,  
*''[[Proteus (bacterium)|Proteus]]'' species, 
*''[[Pseudomonas]]'' species.

[[Antibiotic susceptibility testing]] should always be performed to further elucidate the resistance profile of the particular strain of bacteria causing infection.

===Pregnancy===
Nitrofurantoin is [[Pregnancy Category]] B.&lt;ref name=&quot;Macrobid Drug Label1&quot; /&gt;  It is one of the few drugs that is commonly used in pregnancy to treat urinary tract infections.&lt;ref name=&quot;pmid18556490&quot;&gt;{{cite journal |author=Lee M, Bozzo P, Einarson A, Koren G |title=Urinary tract infections in pregnancy |journal=Can Fam Physician |volume=54 |issue=6 |pages=853–4 |date=June 2008 |pmid= 18556490|pmc= 2426978|doi= |url=http://www.cfp.ca/cgi/pmidlookup?view=long&amp;pmid=18556490}}&lt;/ref&gt; Other drugs used for urinary tract infections in pregnancy include [[cephalexin]], [[amoxicillin]], and [[pivmecillinam]].  The drug should not be given to women in late pregnancy due to the potential risk of [[hemolytic anemia]] in the newborn, as the newborn has not yet developed the enzymatic pathways necessary for [[glutathione]] metabolism and the drug may cause oxidative damage to the [[red blood cells]].  It has been shown that newborns of women given this drug late in pregnancy had a higher risk of developing neonatal [[jaundice]].&lt;ref name=Pregnancy&gt;{{cite journal|last=Nordeng|first=H|coauthors=Lupattelli, A; Romøren, M; Koren, G|title=Neonatal outcomes after gestational exposure to nitrofurantoin.|journal=Obstetrics and gynecology|date=Feb 2013|volume=121|issue=2 Pt 1|pages=306–13|pmid=23344280|accessdate=20 April 2014}}&lt;/ref&gt;

Several trials on the safety and [[teratogenicity]] of nitrofurantoin in pregnancy have shown mixed results.  A [[retrospective study]] in 2009 claimed that several birth defects, such as [[hypoplastic left heart syndrome]], [[ophthalmic]] malformations, [[cleft lip]] and [[cleft palate]], and [[atrial septal defect]] were more common in neonates exposed to nitrofurantoin during pregnancy.&lt;ref&gt;{{cite journal|last=Crider|first=KS|coauthors=Cleves, MA; Reefhuis, J; Berry, RJ; Hobbs, CA; Hu, DJ|title=Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.|journal=Archives of pediatrics &amp; adolescent medicine|date=Nov 2009|volume=163|issue=11|pages=978–85|pmid=19884587|accessdate=20 April 2014}}&lt;/ref&gt; A [[meta analysis]] of four out of twenty-two available studies on the safety of nitrofurantoin found no increased risk.&lt;ref&gt;{{cite journal|last=Ben David|first=S|coauthors=Einarson, T; Ben David, Y; Nulman, I; Pastuszak, A; Koren, G|title=The safety of nitrofurantoin during the first trimester of pregnancy: meta-analysis.|journal=Fundamental &amp; clinical pharmacology|date=1995|volume=9|issue=5|pages=503–7|pmid=8617414|accessdate=20 April 2014}}&lt;/ref&gt; A [[case-control study]] in 1998 found an increased risk of [[craniosynostosis]] after exposure to &quot;nitrosatable&quot; drugs.&lt;ref&gt;{{cite journal|last=Gardner|first=JS|coauthors=Guyard-Boileau, B; Alderman, BW; Fernbach, SK; Greene, C; Mangione, EJ|title=Maternal exposure to prescription and non-prescription pharmaceuticals or drugs of abuse and risk of craniosynostosis.|journal=International journal of epidemiology|date=Feb 1998|volume=27|issue=1|pages=64–7|pmid=9563695|accessdate=20 April 2014}}&lt;/ref&gt; A more recent 2013 population-based [[cohort study]] which used women registered in the Norwegian Prescription Database and linked the subjects to a birth outcomes database, however, found no increased risk of major malformations in neonates born to women who took nitrofurantoin in early pregnancy.&lt;ref name=&quot;Pregnancy&quot; /&gt; Many of the studies showing increased risk of nitrofurantoin had limitations and relied on patients' recall of the antibiotics they took during pregnancy rather than objective data, which may have led to [[recall bias]].  Nevertheless, in light of this conflicting data, the American College of Obstetrics and Gynecology (ACOG) recommends using antibiotics only for appropriate indications and for the shortest effective duration.&lt;ref&gt;{{cite journal|last=American College of Obstetricians and Gynecologists Committee on Obstetric Practice|title=ACOG Committee Opinion No. 494: Sulfonamides, nitrofurantoin, and risk of birth defects.|journal=Obstetrics and gynecology|date=Jun 2011|volume=117|issue=6|pages=1484–5|pmid=21606771|accessdate=20 April 2014}}&lt;/ref&gt;

==Pharmacology==
Organisms are said to be susceptible to nitrofurantoin if their [[minimum inhibitory concentration]] (MIC) is 32 [[Wiktionary:microgram|μg]]/mL or less.  The peak blood concentration of nitrofurantoin following an oral dose of nitrofurantoin 100&amp;nbsp;mg, is less than 1 [[microgram|μg]]/mL and may be undetectable; tissue penetration is negligible; the drug is well concentrated in the urine: 75% of the dose is rapidly metabolised by the liver, but 25% of the dose is excreted in the urine unchanged, reliably achieving levels of 200 μg/ml or more.  For this reason, nitrofurantoin cannot be used to treat anything other than simple [[cystitis]].

At the concentrations achieved in urine (&gt;100 microgm/mL), nitrofurantoin is [[bacteriocidal]].  It is [[bacteriostatic]] against most susceptible organisms at concentrations less than 32 micrograms per milliliter.&lt;ref name=&quot;Macrobid Drug Label1&quot; /&gt;

Nitrofurantoin and the [[quinolone]] antibiotics are mutually antagonistic ''in vitro''.  It is not known whether this is of clinical significance, but the combination should be avoided.&lt;ref name=&quot;Macrobid Drug Label1&quot; /&gt;

Resistance to nitrofurantoin may be chromosomal or plasmid mediated and involves inhibition of nitrofuran reductase.&lt;ref&gt;{{cite journal | author=McCalla DR, Kaiser C, Green MHL | title=Genetics of nitrofurazone resistance in ''Escherichia coli'' | journal=J Bacteriol | year=1978 | volume=133 | pages=10&amp;ndash;16 }}&lt;/ref&gt;  Acquired resistance in ''E. coli'' continues to be rare.

Nitrofurantoin and its metabolites are excreted mainly by the kidneys.  In renal impairment, the concentration achieved in urine may be subtherapeutic.  Nitrofurantoin should not be used in patients with a [[creatinine clearance]] of 60 mL/min or less. However a retrospective chart review may suggest that nitrofurantoin is not contraindicated in this population.&lt;ref name=&quot;Bains A, Buna D, Hoag NA 2009 248–252&quot;&gt;{{cite journal | author=Bains A, Buna D, Hoag NA | title=A retrospective review assessing the efficacy and safety of nitrofurantoin in renal impairment | journal=Canadian Pharmacists Journal| year=2009| volume=142| pages=248&amp;ndash;252|url=http://www.cpjournal.ca/perlserv/?request=get-document&amp;doi=10.3821%2F1913-701X-142.5.248 | doi=10.3821/1913-701X-142.5.248 | issue=5 }}&lt;/ref&gt;

==Mechanism==
The mechanism of action of nitrofurantoin is unique and complex.  The drug works by damaging bacterial [[DNA]], since its reduced form is highly reactive.&lt;ref name=&quot;Macrobid Drug Label1&quot; /&gt; This is made possible by the rapid reduction of nitrofurantoin inside the bacterial cell by [[flavoprotein]]s (nitrofuran reductase) to multiple reactive intermediates that attack [[ribosome|ribosomal]] proteins, DNA,&lt;ref&gt;{{cite journal | author=Tu Y, McCalla DR | title=Effect of activated nitrofurans on DNA, | year=1975 | journal=Biochem Biophys Acta | volume=402 | pages=142&amp;ndash;49 }}&lt;/ref&gt; respiration, [[pyruvate]] metabolism and other macromolecules within the cell.  Nitrofurantoin exerts greater effects on bacterial cells than mammalian cells because bacterial cells activate the drug more rapidly. It is not known which of the actions of nitrofurantoin is primarily responsible for its [[bactericide|bactericidal]] activity. It is likely that the broad mechanism of action for this drug is responsible for the low development of resistance to its effects, as the drug affects many different processes important to the bacterial cell.&lt;ref name=&quot;Macrobid Drug Label1&quot; /&gt;

==Adverse effects==
The most common side effects with nitrofurantoin are nausea, headache, and flatulence.  Less common adverse events (occurring in less than 1% of those taking the drug) include:&lt;ref name=&quot;Macrobid Drug Label1&quot; /&gt;

*Gastrointestinal: Diarrhea, [[dyspepsia]], abdominal pain, constipation, emesis 
*Neurologic: Dizziness, drowsiness, [[amblyopia]] 
*Respiratory: Acute pulmonary hypersensitivity reaction 
*Allergic: [[Pruritus]], [[urticaria]]
*Dermatologic: [[Alopecia]] 
*Miscellaneous: Fever, chills, malaise

Patients should be informed that nitrofurantoin colours urine brown; this is completely harmless.&lt;ref name=&quot;Macrobid Drug Label1&quot; /&gt;

Some of the more serious but rare side effects of nitrofurantoin have been a cause of concern.  These include pulmonary reactions, hepatotoxicity, and neuropathy.

===Pulmonary toxicity===
The pulmonary toxicity caused by nitrofurantoin can be categorized into acute, subacute, and chronic pulmonary reactions.  The acute and subacute reactions are thought to be due to a hypersensitivity reaction and often resolve when the drug is discontinued.  Acute reactions occur in about 1/5000 women who take the drug and are independent of dose.  These reactions usually develop 3–8 days after the first dose of nitrofurantoin, but may occur from a few hours to a few weeks after starting the drug.  Symptoms include fever, [[dyspnea]], chills, cough, [[pleuritic]] chest pain, headache, back pain, and [[epigastric]] pain.  Chest radiograph will often show unilateral or bilateral infiltrates similar to [[pulmonary edema]].  Treatment includes discontinuation of the nitrofurantoin, which should result in symptom improvement within 24 hours.&lt;ref&gt;{{cite journal|last=Williams|first=EM|coauthors=Triller, DM|title=Recurrent acute nitrofurantoin-induced pulmonary toxicity.|journal=Pharmacotherapy|date=May 2006|volume=26|issue=5|pages=713–8|pmid=16718946|accessdate=21 April 2014}}&lt;/ref&gt;

Chronic pulmonary reactions caused by nitrofurantoin include diffuse [[interstitial pneumonitis]], [[pulmonary fibrosis]], or both.&lt;ref name=&quot;Macrobid Drug Label1&quot; /&gt; This uncommon reaction may occur 1 month to 6 years after starting the drug and is usually related to the total lifetime dose of nitrofurantoin.  This reaction manifests with progressive shortness of breath.&lt;ref&gt;{{cite journal|last=Goemaere|first=Natascha NT|coauthors=Grijm, Karin; van Hal, Peter; den Bakker, Michael A|title=Nitrofurantoin-induced pulmonary fibrosis: a case report|journal=Journal of Medical Case Reports|date=2008|volume=2|issue=1|pages=169|doi=10.1186/1752-1947-2-169|accessdate=21 April 2014}}&lt;/ref&gt;  It is important to recognize nitrofurantoin as possible cause of symptoms and discontinue the drug when the suspicion of pulmonary side effects arises.  
   
===Hepatotoxicity===
Hepatic reactions, including [[hepatitis]], cholestatic [[jaundice]], chronic active hepatitis, and hepatic [[necrosis]], occur rarely. The onset of chronic active hepatitis may be insidious, and patients should be monitored periodically for changes in biochemical tests that would indicate liver injury.&lt;ref name=&quot;Macrobid Drug Label1&quot; /&gt; These reactions usually occur after exposure to the drug for more than 6 weeks.  If signs of liver failure are observed in a patient taking nitrofurantoin, the drug should be discontinued.  Re-challenge with the drug at a later date is not recommended, as the reaction may have a hypersensitivity component and recur when the drug is resumed.&lt;ref&gt;{{cite journal|last=Amit|first=G|coauthors=Cohen, P; Ackerman, Z|title=Nitrofurantoin-induced chronic active hepatitis.|journal=The Israel Medical Association journal : IMAJ|date=Mar 2002|volume=4|issue=3|pages=184–6|pmid=11908259|accessdate=21 April 2014}}&lt;/ref&gt;

===Neuropathy===
[[Neuropathy]] is a rare side effect of taking nitrofurantoin.  Patients may experience numbness and tingling in a stocking-glove pattern, which may or may not improve upon discontinuation of the drug.&lt;ref&gt;{{cite journal|last=Tan|first=IL|coauthors=Polydefkis, MJ; Ebenezer, GJ; Hauer, P; McArthur, JC|title=Peripheral nerve toxic effects of nitrofurantoin.|journal=Archives of neurology|date=Feb 2012|volume=69|issue=2|pages=265–8|pmid=22332195|accessdate=21 April 2014}}&lt;/ref&gt;

===Contraindications===
Nitrofurantoin is contraindicated in patients with decreased renal function (CrCl &lt; 60mL/min) due to systemic accumulation and subtherapeutic levels reached in the urinary tract.&lt;ref name=&quot;Macrobid Drug Label1&quot; /&gt;  However, a retrospective chart review suggests that the data for this cutoff is slim and that a cutoff of CrCl &lt; 40mL/min would be more appropriate.&lt;ref&gt;{{cite journal|last=Oplinger|first=M|coauthors=Andrews, CO|title=Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence.|journal=The Annals of pharmacotherapy|date=Jan 2013|volume=47|issue=1|pages=106–11|pmid=23341159|accessdate=21 April 2014}}&lt;/ref&gt;   Many of the severe side effects of this drug are more common in the elderly and those with renal impairment, as this causes the drug to be retained in the body and reach higher systemic levels.  Thus, the drug is not recommended for the elderly population according to 2012 AGS Beers Criteria.&lt;ref&gt;{{cite journal|last=American Geriatrics Society 2012 Beers Criteria Update Expert Panel|title=American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults.|journal=Journal of the American Geriatrics Society|date=Apr 2012|volume=60|issue=4|pages=616–31|pmid=22376048|accessdate=21 April 2014}}&lt;/ref&gt;

Nitrofurantoin is also contraindicated in neonates (babies up to the age of one month), as they have immature enzyme systems in their [[erythrocyte|red blood cell]]s ([[glutathione]] instability) and nitrofurantoin must therefore not be used because it can cause [[haemolytic anaemia]].  For the same reason, nitrofurantoin should not be given to pregnant women after 38 weeks of pregnancy, or who are about to give birth. Nitrofurantoin is contraindicated in patients with [[glucose-6-phosphate dehydrogenase deficiency]] because of risk of [[intravascular]] [[hemolysis]] resulting in [[anemia]].&lt;ref name=&quot;Macrobid Drug Label1&quot; /&gt;

==Use in animal feed==
Residues from the breakdown of [[nitrofuran]] veterinary antibiotics, including nitrofurantoin, have been found in chicken in [[Vietnam]], [[China]], [[Brazil]], and [[Thailand]].&lt;ref name=&quot;fao&quot;&gt;[http://www.fao.org/docrep/008/y5723e/y5723e0u.htm FAO: Nitrofuran study]&lt;/ref&gt; The European Union banned the use of nitrofurans in food producing animals by classifying it in ANNEX IV (list of pharmacologically active substances for which no maximum residue limits can be fixed) of the Council Regulation 2377/90.  The [[Food and Drug Administration]] (FDA) of the United States has prohibited furaltadone since February 1985 and withdrew the approval for the other nitrofuran drugs (except some topical uses) in January 1992.  The topical use of [[furazolidone]] and [[nitrofurazone]] was prohibited in 2002.  Australia prohibited the use of nitrofurans in food production in 1992.  Japan did not allocate MRLs for nitrofurans leading to the implementation of a &quot;zero tolerance or no residue standard&quot;.  In Thailand, the [[Ministry of Public Health (Thailand)|Ministry of Health]] issued in 2001 Proclamation No. 231 MRL of veterinary drug in food which did not allocate MRL for nitrofurans. The Ministry of Agriculture and Cooperatives had already prohibited importation and use of furazolidone and nitrofurazone in animal feed in 1999 which was extended to all nitrofurans in 2002.  Several metabolites of nitrofurans, such as furazolidone, furaltadone and nitrofurazone cause cancer or genetic damage in rats.&lt;ref name=&quot;fao&quot;/&gt;

==Precautions==
Nitrofurantoin should be taken with food to improve its absorption.

==Trade names==
*Furadantin  (U.S., UK)
*Macrobid (long acting preparation for twice daily dosing available in U.S., Canada, and UK)
*Macrodantin (U.S., UK)
*Uro-Tablinen, Furadantin, Nifuretten, Nifurantin, Urodin (GER, A, CH)
*Macrodantina (Mexico)
*Furatin, Niftran(by Ranbaxy), Niftas(by Intas Pharmaceuticals) (India)
*Furanit
*Uvamin (Middle East)

==References==
{{reflist|2}}

==External links==
*[http://www.drugs.com/pdr/Macrodantin_Capsules.html drugs.com for Macrodantin]
*[http://www.meds-help.com/nitrofurantoin/ Meds-Help.com for nitrofurantoin side effects, interactions and information]
*[http://www.drugs.com/pdr/macrodantin.html RxList for Macrobid (Nitrofurantoin)]

{{Nucleic acid inhibitors}}

[[Category:Antibiotics]]
[[Category:Hydantoins]]
[[Category:World Health Organization essential medicines]]
[[Category:Nitrofurans]]</text>
      <sha1>eijn2ono3q8976uo1g1argo1lxqfaku</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Cycloheximide</title>
    <ns>0</ns>
    <id>2109062</id>
    <revision>
      <id>609029678</id>
      <parentid>609029641</parentid>
      <timestamp>2014-05-18T00:34:42Z</timestamp>
      <contributor>
        <username>Andromeas</username>
        <id>8824767</id>
      </contributor>
      <comment>/* References */</comment>
      <text xml:space="preserve" bytes="5382">{{chembox
| Verifiedfields = changed
| verifiedrevid = 460110426
|   Name = Cycloheximide
|   ImageFile_Ref = {{chemboximage|correct|??}}
| ImageFile = Cycloheximide.png
|   ImageName = Cycloheximide
|   IUPACName = 4-[(2''R'')-2-[(1''S'',3''S'',5''S'')-3,5-Dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]piperidine-2,6-dione
|   OtherNames = naramycin a, hizarocin&lt;br /&gt;actidione, actispray&lt;br /&gt;kaken, U-4527
| Section1 = {{Chembox Identifiers
|   UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 98600C0908
| SMILES = O=C2NC(=O)CC(C[C@@H](O)[C@H]1C(=O)[C@@H](C)C[C@H](C)C1)C2
|   ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 27641
| ChemSpiderID = 5962
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 123292
| InChI = 1/C15H23NO4/c1-8-3-9(2)15(20)11(4-8)12(17)5-10-6-13(18)16-14(19)7-10/h8-12,17H,3-7H2,1-2H3,(H,16,18,19)/t8-,9-,11-,12+/m0/s1
| InChIKey = YPHMISFOHDHNIV-FSZOTQKABD
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C15H23NO4/c1-8-3-9(2)15(20)11(4-8)12(17)5-10-6-13(18)16-14(19)7-10/h8-12,17H,3-7H2,1-2H3,(H,16,18,19)/t8-,9-,11-,12+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YPHMISFOHDHNIV-FSZOTQKASA-N
| CASNo = 66-81-9
|    CASNo_Ref = {{cascite|correct|CAS}}
|   PubChem=6197
|   RTECS = MA4375000
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = C06685
  }}
| Section2 = {{Chembox Properties
| Formula      = C&lt;sub&gt;15&lt;/sub&gt;H&lt;sub&gt;23&lt;/sub&gt;NO&lt;sub&gt;4&lt;/sub&gt;
| MolarMass    = 281.35 g/mol
| Appearance   = colourless crystals
| Solvent      = 
| MeltingPt    = 119.5–121 °C
| SolubleOther = 
}}
| Section7 = {{Chembox Hazards
|   EUClass = Toxic (T)
|   ExternalMSDS = [http://msds.chem.ox.ac.uk/CY/cycloheximide.html Oxford MSDS]
|   RPhrases = {{R26}} {{R27}} {{R28}}
  }}
}}

'''Cycloheximide''' is an [[Enzyme inhibitor|inhibitor]] of [[protein biosynthesis]] in [[Eukaryote|eukaryotic]] organisms, produced by the bacterium ''[[Streptomyces griseus]]''.  Cycloheximide exerts its effect by interfering with the translocation step in protein synthesis (movement of two tRNA molecules and mRNA in relation to the ribosome) thus blocking [[Translation (genetics)|translational elongation]]. Cycloheximide is widely used in biomedical research to inhibit protein synthesis in eukaryotic cells studied ''in vitro'' (''i.e.'' outside of organisms).  It is inexpensive and works rapidly. Its effects are rapidly reversed by simply removing it from the culture medium.

Due to significant toxic side effects, including [[DNA damage]], [[teratogenesis]], and other [[reproduction|reproductive]] effects (including [[birth defect]]s and toxicity to [[spermatozoon|sperm]]&lt;ref&gt;[http://toxnet.nlm.nih.gov/index.html TOXNET&lt;!-- Bot generated title --&gt;]&lt;/ref&gt;), cycloheximide is generally used only in ''in vitro'' research applications, and is not suitable for human use as a therapeutic compound.  Although it has been used as a [[fungicide]] in agricultural applications, this application is now decreasing as the health risks have become better understood.

Cycloheximide is degraded by [[alkali]] (pH &gt; 7), decontamination of work surfaces and containers can be achieved by washing with a non-harmful alkali solution such as soap.

Since cycloheximide is an effective inhibitor of protein biosynthesis in eukaryotes only, it may be used to distinguish between proteins translated in the mitochondria and proteins translated in the cytosol. mRNA translated in cytosol or ER from mRNA derived from the nucleus will not be expressed in the presence of cycloheximide. Conversely, translation using mitochondrial ribosomes is unaffected by cycloheximide, and mitochondrial genes will continue to be expressed.

==Experimental applications==

Cycloheximide can be used as an experimental tool in molecular biology to determine the half-life of a [[protein]]. Treating cells with cycloheximide in a time-course experiment followed by [[Western blotting]] of the cell lysates for the protein of interest can show differences in protein half-life.  Cycloheximide treatment provides the ability to observe the half-life of a protein without confounding contributions from transcription or translation.

It is used as a plant growth regulator to stimulate ethylene production. It is used as a rodenticide and other animal pesticide. It is also used in media to detect unwanted bacteria by suppressing yeasts and molds in beer fermentation.

The translational elongation freezing properties of Cycloheximide are also used for ribosome profiling / translational profiling. Translation is halted via the addition of cycloheximide, and the DNA/RNA in the cell is then nuclease treated. The ribosome-bound parts of RNA can then be sequenced.

==Spectrum of fungal susceptibility==
Cycloheximide has been used to isolate dermatophytes and inhibit the growth of fungi in brewing applications. The following represents susceptibility data for a few commonly targeted fungi.
* ''Candida albicans'': 12.5 μg/ml
* ''Mycosphaerella graminicola'': 47.2 μg/ml - 85.4 μg/ml
* ''Saccharomyces cerevisiae'': 0.05 μg/ml - 1.6 μg/ml
&lt;ref&gt;http://antibiotics.toku-e.com/antimicrobial_548.html&lt;/ref&gt;


==See Also==
* [[Acetoxycycloheximide]]

==References==
{{reflist|2}}

[[Category:Antibiotics]]
[[Category:Fungicides]]
[[Category:Ketones]]
[[Category:Glutarimides]]
[[Category:Alcohols]]</text>
      <sha1>bhp4k4qmnwh4kju2hm91ky8apc77fql</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Allicin</title>
    <ns>0</ns>
    <id>311596</id>
    <revision>
      <id>608402789</id>
      <parentid>606646581</parentid>
      <timestamp>2014-05-13T16:10:16Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>/* Potential health benefits */Task 5: Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated coauthor parameter errors]]</comment>
      <text xml:space="preserve" bytes="17188">{{Chembox
| Verifiedfields = changed
| verifiedrevid = 477317730
| ImageFile1 = R-allicin-2D-skeletal.png
|  ImageName1 = Structural formula of R-allicin
| ImageFile2 =R-allicin-3D-balls.png
|  ImageName2 = Ball and stick model of R-allicin
| PIN = 2-Propene-1-sulfinothioic acid S-2-propenyl ester
| SystematicName = 3-[(Prop-2-ene-1-sulfinyl)sulfanyl]prop-1-ene
| Section1 = {{Chembox Identifiers
|  CASNo = 539-86-6
|   CASNo_Ref = {{cascite|changed|??}}
|  PubChem = 65036
|   PubChem_Ref = {{Pubchemcite|correct|PubChem}}
|  ChemSpiderID = 58548
|   ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
|  EINECS = 208-727-7
|  KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = C07600
|  MeSHName = Allicin
|  ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 28411
|  IUPHAR_ligand = 2419
|  Beilstein = 1752823
|  UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 3C39BY17Y6
| SMILES = O=S(SC\C=C)C\C=C
|  SMILES1 = C=CCSS(=O)CC=C
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 359965
| StdInChI = 1S/C6H10OS2/c1-3-5-8-9(7)6-4-2/h3-4H,1-2,5-6H2
|   StdInChI_Ref = {{stdinchicite|correct|chemspider}}
|  InChI = 1/C6H10OS2/c1-3-5-8-9(7)6-4-2/h3-4H,1-2,5-6H2
|  StdInChIKey = JDLKFOPOAOFWQN-UHFFFAOYSA-N
|   StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
|  InChIKey = JDLKFOPOAOFWQN-UHFFFAOYAO}}
| Section2 = {{Chembox Properties
|  C = 6
|  H = 10
|  O = 1
|  S = 2
|  ExactMass = 162.017306322 g mol&lt;sup&gt;−1&lt;/sup&gt;
|  Appearance = Colourless liquid
|  Density = 1.112 g cm&lt;sup&gt;−3&lt;/sup&gt;
|  MeltingPt = &lt;25 °C
|  BoilingPt = decomposes}}
}}

'''Allicin''' is an [[organosulfur compound]] obtained from [[garlic]], a species in the family [[Alliaceae]].&lt;ref name=&quot;Eric Block 1985 114–119&quot;&gt;{{cite journal|doi=10.1038/scientificamerican0385-114|author=Eric Block|title= The chemistry of garlic and onions|journal=Scientific American|volume=252|issue=March|year=1985|pages=114–9 | pmid = 3975593 }}&lt;/ref&gt; It was first isolated and studied in the laboratory by [[Chester J. Cavallito]] and John Hays Bailey in 1944.&lt;ref name=j1&gt;{{cite journal|doi=10.1021/ja01239a048|year=1944|last1=Cavallito|first1=Chester J.|last2=Bailey|first2=John Hays|journal=Journal of the American Chemical Society|volume=66|page=1950|issue=11}}&lt;/ref&gt;&lt;ref name=eric/&gt; When fresh garlic is chopped or crushed, the enzyme [[alliinase]] converts [[alliin]] into allicin, which is responsible for the aroma of fresh garlic.&lt;ref&gt;{{cite journal
   | author = Kourounakis, PN; Rekka, EA
   | title = Effect on active oxygen species of alliin and Allium sativum (garlic) powder
   | journal = Res Commun Chem Pathol Pharmacol.
   | volume = 74
   | issue = 2
   | pages = 249–252
   |date=November 1991
   | pmid = 1667340
 }}&lt;/ref&gt; The allicin generated is very unstable and quickly changes into a series of other sulfur containing compounds such as [[diallyl disulfide]].&lt;ref&gt;{{cite journal | title = Allicin and related compounds: Biosynthesis, synthesis and pharmacological activity | journal = Facta universitatis | date = 2011 | volume = 9 | issue = 1 | pages= 9–20 | doi = 10.2298/FUPCT1101009I | url = http://facta.junis.ni.ac.rs/phat/pcat2011/pcat2011-02.pdf}}&lt;/ref&gt; It exhibits [[antibacterial]], [[antifungal]], [[antiviral]], and [[antiprotozoal]] activity.&lt;ref&gt;{{cite pmid|24173810}}&lt;/ref&gt; Allicin is garlic's defense mechanism against attacks by pests.&lt;ref&gt;[http://www.phytochemicals.info/phytochemicals/allicin.php What is Allicin?]. Phytochemicals.info. Retrieved on 2012-12-26.&lt;/ref&gt;

==Structure and occurrence==
Allicin features the [[thiosulfinate]] functional group, R-S(O)-S-R. The compound is not present in garlic unless tissue damage occurs,&lt;ref name=&quot;Eric Block 1985 114–119&quot;/&gt; and is formed by the action of the enzyme [[alliinase]] on [[alliin]].&lt;ref name=&quot;Eric Block 1985 114–119&quot;/&gt; Allicin is [[Chirality (chemistry)|chiral]] but occurs naturally only as a [[racemate]].&lt;ref name=eric&gt;{{cite book | author = Eric Block | title = Garlic and Other Alliums: The Lore and the Science | location = Cambridge | publisher = Royal Society of Chemistry | date = 2010}}&lt;/ref&gt; The [[racemic]] form can also be generated by oxidation of [[diallyl disulfide]]:&lt;ref&gt;{{cite book |author=Cremlyn, R. J. W. |title=An introduction to organosulfur chemistry |publisher=Wiley |year=1996 |isbn=0-471-95512-4 }}&lt;/ref&gt;
:(SCH&lt;sub&gt;2&lt;/sub&gt;CH=CH&lt;sub&gt;2&lt;/sub&gt;)&lt;sub&gt;2&lt;/sub&gt; + [[meta-Chloroperoxybenzoic acid|RCO&lt;sub&gt;3&lt;/sub&gt;H]] → CH&lt;sub&gt;2&lt;/sub&gt;=CHCH&lt;sub&gt;2&lt;/sub&gt;S(O)SCH&lt;sub&gt;2&lt;/sub&gt;CH=CH&lt;sub&gt;2&lt;/sub&gt; + RCO&lt;sub&gt;2&lt;/sub&gt;H

Alliinase is irreversibly deactivated below pH 3; as such, allicin is generally not produced in the body from the consumption of fresh or powdered garlic.&lt;ref&gt;{{cite journal |author=Brodnitz, M.H., Pascale, J.V., Derslice, L.V. |title=Flavor components of garlic extract |journal=Journal of Agricultural and Food Chemistry |volume=19 |issue=2 |pages=273–5 |year=1971 |doi= 10.1021/jf60174a007|url=}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|doi=10.1111/j.1365-2621.1989.tb07926.x|title=Stability of Allicin in Garlic Juice|year=1989|last1=Yu|first1=Tung-HSI|last2=Wu|first2=Chung-MAY|journal=Journal of Food Science|volume=54|page=977|issue=4}}&lt;/ref&gt; Furthermore, allicin can be unstable, breaking down within 16 h at 23 °C.&lt;ref&gt;{{cite book |title= Garlic: the science and therapeutic application of ''Allium sativum'' L and related species |edition=2nd |last= Hahn |first= G |coauthors= in Koch HP, Lawson LD, eds. |year= 1996 |publisher= Williams and Wilkins |location= Baltimore |isbn=0-683-18147-5 |pages= 1–24}}&lt;/ref&gt;

==Potential health benefits==
{{medref|section|date=September 2013}}
Several animal studies published between 1995 and 2005 indicate that allicin may reduce [[atherosclerosis]] and fat deposition,&lt;ref&gt;{{cite journal|author= S. Eilat, Y. Oestraicher, A. Rabinkov, D. Ohad, D. Mirelman, A. Battler, M. Eldar and Z. Vered|title= Alteration of lipid profile in hyperlipidemic rabbits by allicin, an active constituent of garlic|journal= Coron. Artery Dis. |volume=6| year=1995| pages=985–990|pmid= 8723021|issue= 12}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|author= D. Abramovitz, S. Gavri, D. Harats, H. Levkovitz, D. Mirelman, T. Miron, S. Eilat-Adar, A. Rabinkov, M. [[Meir Wilchek|Wilchek]], M. Eldar and Z. Vered,|title= Allicin-induced decrease in formation of fatty streaks (atherosclerosis) in mice fed a cholesterol-rich diet|journal= Coron. Artery Dis. |volume=10|year=1999| pages=515–9|doi= 10.1097/00019501-199910000-00012|pmid= 10562920|issue= 7}}&lt;/ref&gt; normalize the [[lipoprotein]] balance, decrease [[blood pressure]],&lt;ref&gt;{{cite journal|author= Silagy CA, Neil HA|title= A meta-analysis of the effect of garlic on blood pressure|journal= J Hypertens|volume=12|year=1994| pages=463–8|pmid= 8064171|issue= 4}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|author= A. Elkayam, D. Mirelman, E. Peleg, M. [[Meir Wilchek|Wilchek]], T. Miron, A. Rabinkov, M. Oron-Herman and T. Rosenthal|title= The effects of allicin on weight in fructose-induced hyperinsulinemic, hyperlipidemic, hypertensive rats|journal= Am. J. Hypertens|volume=16|year=2003| pages=1053–6|doi= 10.1016/j.amjhyper.2003.07.011|pmid= 14643581|issue= 12}}&lt;/ref&gt; have anti-[[thrombosis|thrombotic]]&lt;ref&gt;{{cite journal|author= Srivastava KC|title= Evidence for the mechanism by which garlic inhibits platelet aggregation|journal= Prostaglandins Leukot Med|volume=22|year=1986|pages=313–321|doi= 10.1016/0262-1746(86)90142-3|pmid= 3088604|issue= 3}}&lt;/ref&gt; and anti-[[inflammation|inflammatory]] activities, and function as an [[antioxidant]] to some extent.&lt;ref&gt;{{cite journal|author= U. Sela, S. Ganor, I. Hecht, A. Brill, T. Miron, A. Rabinkov, M. [[Meir Wilchek|Wilchek]], D. Mirelman, O. Lider and R. Hershkoviz|title= Allicin inhibits SDF-1alpha-induced T cell interactions with fibronectin and endothelial cells by down-regulating cytoskeleton rearrangement, Pyk-2 phosphorylation and VLA-4 expression|journal= Immunology|volume=111|year=2004| pages=391–399|doi= 10.1111/j.0019-2805.2004.01841.x|pmid= 15056375|issue= 4|pmc= 1782446}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|author=Lindsey J. Macpherson, Bernhard H. Geierstanger, Veena Viswanath, Michael Bandell, Samer R. Eid, SunWook Hwang, and Ardem Patapoutian|title=The pungency of garlic: Activation of TRPA1 and TRPV1 in response to allicin]|journal=Current Biology|doi=10.1016/j.cub.2005.04.018|volume=15|year=2005|pages=929–934|pmid=15916949|issue=10}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|author=Bautista DM, Movahed P, Hinman A, Axelsson HE, Sterner O, Hogestatt ED, Julius D, Jordt SE and Zygmunt PM|title=Pungent products from garlic activate the sensory ion channel TRPA1| journal=Proceedings of the National Academy of Sciences of the United States of America|volume=102|issue=34|year=2005|pages=12248–52|doi=10.1073/pnas.0505356102|pmid=16103371|pmc=1189336}}&lt;/ref&gt; Other animal studies have shown a strong oxidative effect in the gut that can damage intestinal cells, though many of these results were obtained by excessive amounts of allicin, which has been clearly shown to have some toxicity at high amounts, or by physically injecting the lumen itself with allicin, which may not be indicative of what would happen via oral ingestion of allicin or garlic supplements.&lt;ref&gt;{{cite journal|doi=10.1002/ptr.1281|pmid=12601669|year=2001|last1=Banerjee|first1=SK|last2=Mukherjee|first2=PK|last3=Maulik|first3=SK|title=Garlic as an Antioxidant: The Good, The Bad and The Ugly|volume=17|issue=2|pages=97–106|journal=Phytotherapy Research}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|pmid=11238796|year=2003|last1=Amagase|first1=H|last2=Petesch|first2=BL|last3=Matsuura|first3=H|last4=Kasuga|first4=S|last5=Itakura|first5=Y|title=Intake of garlic and its bioactive components|volume=131|issue=3s|pages=955S–62S|journal=J Nutr}}&lt;/ref&gt; A [[randomized clinical trial]] funded by the [[National Institutes of Health]] (NIH) in the United States and published in the ''[[Archives of Internal Medicine]]'' in 2007 found that the consumption of garlic in any form did not reduce blood cholesterol levels in patients with moderately high baseline cholesterol levels.&lt;ref&gt;{{cite journal |author=Gardner CD, Lawson LD, Block E, et al. |title=Effect of raw garlic vs commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: a randomized clinical trial |journal=Arch. Intern. Med. |volume=167 |issue=4 |pages=346–53 |year=2007 |pmid=17325296 |doi=10.1001/archinte.167.4.346}}&lt;/ref&gt; The fresh garlic used in this study contained substantial levels of allicin, so the study casts doubt on the ability of allicin when taken orally to reduce blood cholesterol levels in human subjects.

In 2009, Vaidya, Ingold and Pratt clarified the mechanism of the antioxidant activity of garlic, such as trapping damaging free [[Radical (chemistry)|radicals]]. When allicin decomposes, it forms 2-propenesulfenic acid, and this compound is what binds to the free-radicals.&lt;ref&gt;{{cite journal |last= Vaidya|first= Vipraja|author2=Keith U. Ingold |author3=Derek A. Pratt |year= 2009|title= Garlic: Source of the Ultimate Antioxidants – Sulfenic Acids|journal= Angewandte Chemie|volume= 121|issue= 1|pages= 163–6|doi=10.1002/ange.200804560 | pmid = 19040240 }}&lt;/ref&gt; The 2-propenesulfenic formed when garlic is cut or crushed has a lifetime of less than one second.&lt;ref&gt;{{cite journal |author=Block E, Dane AJ, Thomas S, Cody RB|year=2010|title=Applications of Direct Analysis in Real Time–Mass Spectrometry (DART-MS) in ''Allium'' Chemistry. 2-Propenesulfenic and 2-Propenesulfinic Acids, Diallyl Trisulfane ''S''-Oxide and Other Reactive Sulfur Compounds from Crushed Garlic and Other Alliums|journal= Journal of Agricultural and Food Chemistry|volume= 58|pages= 4617–25|doi =10.1021/jf1000106 |pmid=20225897 |issue=8}}&lt;/ref&gt;

===Antibacterial activity===
{{medref|section|date=September 2013}}
Allicin has been found to have numerous antimicrobial properties, and has been studied in relation to both its effects and its biochemical interactions.&lt;ref&gt;{{cite journal |last= Ankri |first= S|author2=Mirelman D|year= 1999|title= Antimicrobial properties of allicin from garlic |pmid=10594976|journal= Microbes Infect|volume= 2|pages= 125–9 |issue= 2 |doi=10.1016/S1286-4579(99)80003-3}}&lt;/ref&gt; One potential application is in the treatment of [[methicillin-resistant Staphylococcus aureus|methicillin-resistant ''Staphylococcus aureus'']] (MRSA), an increasingly prevalent concern in hospitals. A screening of allicin against 30 strains of MRSA found high level of antimicrobial activity, including against strains that are resistant to other chemical agents.&lt;ref name=&quot;Cutler 2004 71-4&quot;&gt;{{cite journal |last= Cutler|first= RR|author2=P Wilson|year= 2004|title= Antibacterial activity of a new, stable, aqueous extract of allicin against methicillan-resistant ''Staphylococcus aureus'' |format=PDF |journal= British Journal of Biomedical Science|volume= 61|issue= 2|pages= 71–4|url= http://www.allimax.us/Cutler.pdf |pmid= 15250668}}&lt;/ref&gt; Of the strains tested, 88% had [[minimum inhibitory concentration]]s for allicin liquids of 16&amp;nbsp;mg/L, and all strains were inhibited at 32&amp;nbsp;mg/L. Furthermore, 88% of clinical isolates had [[Minimum Bactericidal Concentration|minimum bactericidal concentration]]s of 128&amp;nbsp;mg/L, and all were killed at 256&amp;nbsp;mg/L. Of these strains, 82% showed intermediate or full resistance to mupirocin. This same study examined use of an [[aqueous cream]] of allicin, and found it somewhat less effective than allicin liquid. At 500&amp;nbsp;mg/L, however, the cream was still active against all the organisms tested—which compares well with the 20&amp;nbsp;g/L mupirocin currently used for topical application.&lt;ref name=&quot;Cutler 2004 71-4&quot;/&gt;

A water-based formulation of purified allicin was found to be more chemically stable than other preparations of garlic extracts.&lt;ref name=&quot;Cutler 2004 71-4&quot;/&gt; They proposed that the stability may be due to the hydrogen bonding of water to the reactive oxygen atom in allicin and also to the absence of other components in crushed garlic that destabilize the molecule.&lt;ref&gt;{{cite book |title= The composition and chemistry of garlic cloves and processed garlic; ''in'' Garlic: the science and therapeutic application of ''Allium sativum'' L and related species |edition=2nd |editor= Lawson, LD; Koch HP |isbn=0-683-18147-5 |year= 1996 |publisher= Williams and Wilkins |location= Baltimore |pages= 37–107}}&lt;/ref&gt;

===Antiviral activity===
Allicin has  antiviral activity both in vitro and in vivo. Among the  viruses susceptible to allicin are Herpes simplex type 1  and 2, Parainfluenza virus type 3, human Cytomegalo  virus, Influenza B, Vaccinia virus, Vesicular stomatitis  virus and Human rhinovirus type 2.&lt;ref&gt;{{cite journal |journal= Journal of Medicinal Plants Research |volume= 6 |issue= 1 |pages= 59–65 |date= 9 January 2012 |doi= 10.5897/JMPR11.917 |title= Cytotoxicity and antimicrobial activity of allicin and its transformation products |first1= Dušica |last1= Ilić |first2= Vesna |last2= Nikolić |first3= Ana |last3= Ćirić |first4= Marina |last4= Soković |first5= Tatjana |last5= Stanojković |first6= Tatjana |last6= Kundaković |first7= Mihajlo |last7= Stanković |first8= Ljubiša |last8= Nikolić }}&lt;/ref&gt;

A small&lt;ref&gt;{{cite pmid|21322286}}&lt;/ref&gt; (146 healthy adults) double-blind, placebo-controlled study found that a daily supplement containing purified allicin, had dramatic results&lt;ref&gt;[http://www.cfp.ca/content/57/1/31.long Complementary and alternative medicine for prevention and treatment of the common cold]. Cfp.ca. Retrieved on 2012-12-26.&lt;/ref&gt; by reducing the risk of catching a cold by 64%, the symptom duration was reduced by 70% and those in the treatment group were much less likely to develop more than 1 cold.&lt;ref&gt;[http://news.bbc.co.uk/2/hi/health/1575505.stm HEALTH | Garlic 'prevents common cold']. BBC News (2001-10-03). Retrieved on 2012-12-26.&lt;/ref&gt;&lt;ref&gt;{{cite pmid|11697022}}&lt;/ref&gt;

==See also==
{{commons category|allicin}}
*[[Allyl isothiocyanate]], the active piquant chemical in [[mustard plant|mustard]], [[radish]]es, [[horseradish]] and [[wasabi]]
*[[Capsaicin]], the active piquant chemical in [[chili pepper]]s
*[[Piperine]], the active piquant chemical in [[black pepper]]&lt;!--why is this here?--&gt;
*[[syn-Propanethial-S-oxide|''syn''-Propanethial-''S''-oxide]], the chemical found in [[onion]]s
*[[List of phytochemicals in food]]

==References==
{{reflist|35em}}

==External links==
*{{cite journal |author=Johnston, Nicole |title=News in Brief: Garlic: A natural antibiotic |journal=Mdd modern drug discovery |volume=5 |issue=4 |year=2002 |url=http://pubs.acs.org/subscribe/journals/mdd/v05/i04/html/04news4.html |quote=Allicin, the major component of garlic, is one such agent, and it was recently shown to be potent against VRE and MRSA in two studies presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago in December.}}

{{Allium}}

[[Category:Thiosulfinates]]
[[Category:Alkenes]]
[[Category:Anti-inflammatory agents]]
[[Category:Antibiotics]]
[[Category:Dietary antioxidants]]
[[Category:Pungent flavors]]
[[Category:Allium]]
[[Category:Garlic]]
[[Category:Antifungals]]</text>
      <sha1>3r5g9isjxkqrnbw1w8bqyaj2eisvr2k</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Triclosan</title>
    <ns>0</ns>
    <id>349842</id>
    <revision>
      <id>607382616</id>
      <parentid>607255362</parentid>
      <timestamp>2014-05-06T20:34:29Z</timestamp>
      <contributor>
        <username>Leyo</username>
        <id>2320974</id>
      </contributor>
      <comment>Reverted 1 edit by [[Special:Contributions/Tigah Dude|Tigah Dude]] ([[User talk:Tigah Dude|talk]]): No comments/personal view please. ([[WP:TW|TW]])</comment>
      <text xml:space="preserve" bytes="41507">{{distinguish|triclocarban}}
{{unbalanced|reason=The article devotes a disproportionate amount of text to negative aspects: health concerns, environmental concerns, resistance concerns, and alternatives|date=May 2014}}
{{chembox
| Watchedfields = changed
| verifiedrevid = 470613750
|ImageFile=Triclosan.svg
|ImageSize=200
|ImageFile1=Triclosan-3D-vdW.png
|IUPACName=5-chloro-2-(2,4-dichlorophenoxy)phenol
|OtherNames= 2,4,4'-trichloro-2'-hydroxydiphenyl ether, 5-chloro-(2,4-dichlorophenoxy)phenol, trichloro-2'-hydroxydiphenyl ether, CH-3565, Lexol 300, Irgasan DP 300
|Section1= {{Chembox Identifiers
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5363
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4NM5039Y5X
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06226
| InChI = 1/C12H7Cl3O2/c13-7-1-3-11(9(15)5-7)17-12-4-2-8(14)6-10(12)16/h1-6,16H
| InChIKey = XEFQLINVKFYRCS-UHFFFAOYAS
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 849
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H7Cl3O2/c13-7-1-3-11(9(15)5-7)17-12-4-2-8(14)6-10(12)16/h1-6,16H
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XEFQLINVKFYRCS-UHFFFAOYSA-N
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo=3380-34-5
| PubChem=5564
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 164200
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB08604
| SMILES = Clc2cc(Cl)ccc2Oc1ccc(Cl)cc1O
| ATCCode_prefix = D08
| ATCCode_suffix = AE04
| ATC_Supplemental = &lt;br /&gt;{{ATC|D09|AA06}} (medicated dressing)
}}
|Section2= {{Chembox Properties
|  C=12|H=7|Cl=3|O=2
|  Appearance=White solid
|  Density=1.49 g/cm&lt;sup&gt;3&lt;/sup&gt; 
|  MeltingPt=55-57 °C
|  BoilingPtC=120
|  Solubility=
  }}
|Section3= {{Chembox Hazards
| ExternalMSDS = [http://www.glenmartinlimited.com/MSDS/gmmsds1154.pdf MSDS]
|  MainHazards=
|  FlashPtC = 162.2
|  AutoignitionC =
| NFPA-H = 2
| NFPA-F = 1
| NFPA-R = 0
  }}
}}
{{copy edit|date=December 2013}}
'''Triclosan,''' similar in its uses and mechanism of action to [[triclocarban]], is an [[antibiotic|antibacterial]] and [[fungus|antifungal]] agent found in numerous consumer products, including soaps, detergents, toys, and surgical cleaning treatments. Its efficacy as an antimicrobial agent and the risk of antibacterial resistance remains controversial. Additional research seeks to understand its potential effects on organism and environmental health. 

== Uses ==
Triclosan initially was used as hospital scrub in the 1970s. Since then, it has expanded commercially and now is prevalent in soaps (0.10-1.00%), [[shampoo]]s, [[deodorant]]s, [[toothpaste]]s, [[mouth wash]]es, and cleaning supplies.&lt;ref name=tri&gt;{{cite journal |author=Thompson A, Griffin P, Stuetz R, Cartmell E |title=The fate and removal of triclosan during wastewater treatment |journal=Water Environ. Res. |volume=77 |issue=1 |pages=63–7 |year=2005 |pmid=15765937 |doi=10.2175/106143005X41636 |jstor=25045839}}&lt;/ref&gt; It is also incorporated into an increasing number of consumer products, such as kitchen utensils, toys, bedding, socks, and trash bags.&lt;ref&gt;{{HPD|75}}&lt;/ref&gt;&lt;ref name=&quot;CDC&quot;&gt;{{cite journal|last1=Crinnion|first1=WJ |title=The CDC Fourth National Report on Human Exposure to Environmental Chemicals: what it Tells Us about our Toxic Burden and How it Assists Environmental Medicine Physicians|journal=Water Environ. Res. |volume=77 |issue=1 |pages=63–7 |year=2005 |pmid=15765937 |doi=10.2175/106143005X41636 |jstor=25045839|last2=Griffin|first2=P.|last3=Stuetz|first3=R.|last4=Cartmell|first4=E.}}&lt;/ref&gt; 

In healthcare, triclosan is used in surgical scrubs and personnel hand washes.&lt;ref name=FDA1994&gt;{{cite web|title=Federal Register Notice: Tentative Final Monograph for OTC Healthcare Antiseptic Drug Products - June 17, 1994|url=http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4098B1_02_03-FDA-TAB1.pdf|author=Food and Drug Administration|date=17 June 1994}}&lt;/ref&gt; Use in surgical units is effective with a minimum contact time of approximately two minutes.&lt;ref name=&quot;pmid2255283&quot;&gt;{{cite journal |author=Brady LM, Thomson M, Palmer MA, Harkness JL |title=Successful control of endemic MRSA in a cardiothoracic surgical unit |journal=Med. J. Aust. |volume=152 |issue=5 |pages=240–5 |date=March 1990 |pmid=2255283}}&lt;/ref&gt;&lt;ref name=&quot;pmid7677266&quot;&gt;{{cite journal |author=Zafar AB, Butler RC, Reese DJ, Gaydos LA, Mennonna PA |title=Use of 0.3% triclosan (Bacti-Stat) to eradicate an outbreak of methicillin-resistant Staphylococcus aureus in a neonatal nursery |journal=Am J Infect Control |volume=23 |issue=3 |pages=200–8 |date=June 1995 |pmid=7677266 |doi=10.1016/0196-6553(95)90042-X}}&lt;/ref&gt; More recently, showering with 2% triclosan has become a recommended regimen in surgical units for the decolonization of patients whose skin carries [[Methicillin-resistant Staphylococcus aureus|methicillin-resistant ''Staphylococcus aureus'']] (MRSA).&lt;ref name=&quot;pmid16581155&quot;&gt;{{cite journal |author=Coia JE, Duckworth GJ, Edwards DI, ''et al.'' |title=Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities |journal=J. Hosp. Infect. |volume=63 Suppl 1 |issue= |pages=S1–44 |date=May 2006 |pmid=16581155 |doi=10.1016/j.jhin.2006.01.001}}&lt;/ref&gt;

Triclosan also has been employed as an effective selective agent in molecular cloning. Bacteria host transformed by [[plasmid]]s harboring a triclosan resistant mutant ''FabI'' gene (mFabI) as a selectable marker can grow in presence of high dose of triclosan in the culture media.&lt;ref&gt;{{cite journal |author=Jang CW, Magnuson T |title=A novel selection marker for efficient DNA cloning and recombineering in E. coli |journal=PLoS ONE |volume=8 |issue=2 |pages=e57075 |year=2013 |pmid=23437314 |pmc=3577784 |doi=10.1371/journal.pone.0057075 |editor1-last=Poteete |editor1-first=Anthony R|bibcode = 2013PLoSO...857075J }}&lt;/ref&gt;

== Chemical structure and properties ==
This [[organic compound]] is a white powdered [[solid]] with a slight aromatic, phenolic odor. Categorized as a [[polychloro phenoxy phenol]], triclosan is a [[chlorine|chlorinated]] [[Simple aromatic ring|aromatic compound]] that has [[functional group]]s representative of both [[ether]]s and [[phenol]]s. Phenols often demonstrate antibacterial properties. Triclosan is only slightly soluble in water, but it is soluble in [[ethanol]], [[methanol]], [[diethyl ether]], and strongly [[basic (chemistry)|basic]] [[solution]]s such as a 1[[Concentration#Molarity|M]] [[sodium hydroxide]] solution. Triclosan can be synthesized from [[2,4-dichlorophenol]].

Common impurities include [[2,4-dichlorophenol]], [[chlorophenol|3-chlorophenol]], [[4-chlorophenol]], [[2,3,7,8-tetrachlorodibenzo-p-dioxin]], 2,3,7,8-tetrachlorodibenzo-p-furan, 2,8-dichlorobenzo-furan, 2,8-dichlorobenzo-p-dioxin, 1,3,7-trichlorodibenzo-p-dioxin, and 2,4,8-trichlorodibenzo-furan.&lt;ref&gt;Triclosan and its impurities - Quantex Labs www.quantexlabs.com/Portals/159220/docs/triclosan-impurities.pdf&lt;/ref&gt;

=== Synthesis ===
Under a reflux process, 2,4,4'-trichloro-2'-methoxydiphenyl ether is treated with [[aluminium chloride]]. &lt;ref&gt;Commonwealth of Australia. Department of Health and Ageing. National Industrial Chemicals Notification and Assessment Scheme. Priority Existing Chemical Assessment Report No. 30. National Industrial Chemicals Notification and Assessment Scheme, Jan. 2009. Web. Apr. 2014. &lt;http://oehha.ca.gov/prop65/public_meetings/052909coms/triclosan/ciba1.pdf&gt;.&lt;/ref&gt;

Triclosan can be synthesized through a three-step process starting with 1-(2-hydroxyethyl)pyrrolidin-2-one. The 1-(2-hydroxyethyl)pyrrolidin-2-one is to be dehydrated with either zinc or calcium oxide into 1-vinylpyrrolidin-2-one.&lt;ref&gt;Kahn, A.P. Production of N-Vinyl Pyrrolidone. US Patent 63970, Apr 1, 2004.&lt;/ref&gt; Then, 1-vinylpyrrolidin-2-one can be reacted with 5-chloro-2-(2,4-dichlorophenoxy)phenyl acrylate in n-heptane to form triclosan.&lt;ref&gt;Plochocka, K. Polymeric Delivery and Release Systems for Oral Care Actives. US Patent 6,315,987, Nov 13, 2001.&lt;/ref&gt;

== Mechanism of action ==
At high concentrations, triclosan acts as a [[biocide]] with multiple [[cytoplasm|cytoplasmic]] and [[Cell membrane|membrane]] targets.&lt;ref name=&quot;pmid15073159&quot;&gt;{{cite journal |author=Russell AD |title=Whither triclosan? |journal=J. Antimicrob. Chemother. |volume=53 |issue=5 |pages=693–5 |date=May 2004 |pmid=15073159 |doi=10.1093/jac/dkh171}}&lt;/ref&gt; However, at the lower concentrations seen in commercial products, triclosan appears [[bacteriostatic]], and it is seen to target bacteria primarily by inhibiting [[Fatty acid metabolism#Synthesis|fatty acid synthesis]].

Triclosan binds to bacterial ENR ([[enoyl-acyl carrier protein reductase]] enzyme), which is encoded by the gene ''FabI''. This binding increases the enzyme's affinity for NAD&lt;sup&gt;+&lt;/sup&gt; ([[nicotinamide adenine dinucleotide]]). This results in the formation of a stable, ternary complex of ENR-NAD&lt;sup&gt;+&lt;/sup&gt;-triclosan, which is unable to participate in fatty acid synthesis. Fatty acids are necessary for building and reproducing cell membranes. Humans do not have an ENR enzyme and thus are not affected.

==Effectiveness==

There is controversy over the effectiveness of triclosan. Some studies show that antimicrobial hand soaps containing triclosan provide a slightly greater bacterial reduction on the hands compared to plain soap, but other studies show there is no difference.&lt;ref name=&quot;Montville&quot;&gt;{{cite journal|last=Montville|first=Rebecca|coauthors=Schaffner, Donald W.|title=A Meta-Analysis of the Published Literature on the Effectiveness of Antimicrobial Soaps|journal=Journal of Food Protection|date=1 November 2011|volume=74|issue=11|pages=1875–1882|doi=10.4315/0362-028X.JFP-11-122|url=http://www.ingentaconnect.com/content/iafp/jfp/2011/00000074/00000011/art00011?token=00541e92af256202767fe06720297d7634777b557b5f7a5a3876382b6d3f6a4b4b6e6e42576b642738a4|pmid=22054188}}&lt;/ref&gt; In addition, researchers at Dial found that the transfer of bacteria to objects was reduced following washing with antimicrobial hand soap containing triclosan compared to regular soap.&lt;ref name=&quot;Fuls&quot;&gt;{{cite journal|last=Fuls|first=Janice L.|coauthors=Rodgers ND, et al.|title=Alternative Hand Contamination Technique To Compare the Activities of Antimicrobial and Nonantimicrobial Soaps under Different Test Conditions|journal=Applied and Environmental Microbiology|date=April 2008|month=25|volume=74|issue=12|pages=3739–3744|doi=10.1128/AEM.02405-07|url=http://aem.asm.org/content/74/12/3739|pmid=18441107|pmc=2446551}}&lt;/ref&gt; According to the FDA, antimicrobial soaps containing triclosan have not been shown to possess additional benefits over conventional soap and water. &lt;ref&gt;http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm205999.htm&lt;/ref&gt;

== Health concerns ==

Triclosan is a chlorinated aromatic compound with antibacterial, antifungal, and antiviral properties (sold under several trade names, including  UltraFresh, Amicor, and BioFresh). Triclosan penetrates the skin on contact and enters the bloodstream.&lt;ref&gt;{{cite web |first=Alexandra |last=Sifferlin |date=Aug 15, 2012 |title=Freaky Clean: Chemical in Antibacterial Soap Weakens Muscle Function |url=http://healthland.time.com/2012/08/15/freaky-clean-chemical-in-antibacterial-soap-weakens-muscle-function |work=Time}}&lt;/ref&gt; According to the United States [[Food and Drug Administration]] (FDA), at the present time, there is no evidence that triclosan in personal care products provides extra benefits to health beyond its anti-gingivitis effect in [[toothpaste]].&lt;ref name=&quot;fda&quot;&gt;{{cite web|url=http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm205999.htm|title=Triclosan: What Consumers Should Know|date=8 April 2010|publisher=U S Food and Drug Administration|accessdate=13 April 2010}}&lt;/ref&gt; Triclosan safety is currently under review by the FDA&lt;ref name=&quot;fda&quot;/&gt; and [[Health Canada]].&lt;ref name=&quot;CBC&quot;&gt;{{cite web|url=http://www.cbc.ca/news/health/story/2011/10/03/toxic-chemicals-monitor.html|title=Toxic chemical monitoring program gets $500M|date=4 October 2011|publisher=CBC}}&lt;/ref&gt; A [[systematic review]] of [[randomized controlled trial]]s found that triclosan-containing toothpastes are marginally beneficial in reduction of [[Dental caries|tooth cavities]] and reduces [[dental plaque]], [[Gingivitis|gingival inflammation]], and gingival bleeding.&lt;ref&gt;{{cite journal | author=Philip Riley and Thomas Lamont. | title= Triclosan/copolymer containing toothpastes for oral health| journal=Cochrane Database of Systematic Reviews | date= December 2013 | volume=12|issue=CD010514|pmid=24310847| doi= 10.1002/14651858.CD010514.pub2}}&lt;/ref&gt;

=== Allergy ===
A 2010 study found that children who had higher exposure to triclosan had a higher incidence of hay fever.&lt;ref name=&quot;Clayton-2010&quot;/&gt; Triclosan has also been associated with a higher risk of food allergy.&lt;ref&gt;{{cite journal |last1=Sicherer|first1=SH|last2=Leung|first2=DY |title=Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2012 |journal= Journal of Allergy and Clinical Immunology|volume=131 |issue=1 |pages=55–66 |date=January 2013 |pmid=23199604|doi=10.1016/j.jaci.2012.11.007}}&lt;/ref&gt; This may be because exposure to bacteria reduces allergies, as predicted by the [[hygiene hypothesis]] and not toxicology of the triclosan itself. This would also occur with [[chlorhexidine gluconate]] and [[PCMX]], among other antibacterial agents.&lt;ref name=&quot;Clayton-2010&quot;&gt;{{cite journal |author=Clayton EM, Todd M, Dowd JB, Aiello AE |title=The impact of bisphenol A and triclosan on immune parameters in the U.S. population, NHANES 2003-2006 |journal=Environ. Health Perspect. |volume=119 |issue=3 |pages=390–6 |date=March 2011 |pmid=21062687 |pmc=3060004 |doi=10.1289/ehp.1002883 |laysummary=http://www.sciencedaily.com/releases/2010/11/101129101920.htm |laysource=ScienceDaily |laydate=Nov. 30, 2010}}&lt;/ref&gt;&lt;ref&gt;{{cite web |url=http://www.npr.org/blogs/health/2010/11/29/131670317/new-questions-raised-on-chemicals-in-soaps-plastics?ft=1&amp;f=1007 |title=New Questions Raised On Chemicals In Soaps, Plastics : Shots - Health News Blog : NPR |publisher=npr.org |accessdate=2010-11-30 }}&lt;/ref&gt; Other studies have linked triclosan to allergic contact dermatitis in some individuals.&lt;ref name=&quot;Bhutani-2009&quot;&gt;{{cite journal |author=Bhutani T, Jacob SE |title=Triclosan: a potential allergen in suture-line allergic contact dermatitis |journal=Dermatol Surg |volume=35 |issue=5 |pages=888–9 |date=May 2009 |pmid=19389086 |doi=10.1111/j.1524-4725.2009.01151.x}}&lt;/ref&gt;&lt;ref name=&quot;Campbell-2006&quot;&gt;{{cite journal |author=Campbell L, Zirwas MJ |title=Triclosan |journal=Dermatitis |volume=17 |issue=4 |pages=204–7 |date=December 2006 |pmid=17150172 |doi=10.2310/6620.2006.06014}}&lt;/ref&gt;

=== By-products ===
In August 2009, the [[Canadian Medical Association]] asked the Canadian government to ban triclosan use in household products under concerns of creating bacterial resistance and producing dangerous side products ([[chloroform]]).&lt;ref name=&quot;ecadoap&quot;&gt;{{cite news|url=http://www.theglobeandmail.com/life/health/experts-concerned-about-dangers-of-antibacterial-products/article1259471/|title=Experts concerned about dangers of antibacterial products|last=Yang|first=Jeniffer|date=2009-08-21|work=Globe and Mail|accessdate=2009-08-25}}&lt;/ref&gt;

Triclosan can also react with the free chlorine in tap water to produce lesser amounts of other compounds, like [[2,4-dichlorophenol]].&lt;ref name=&quot;pmid15926568&quot;&gt;{{cite journal |author=Rule KL, Ebbett VR, Vikesland PJ |title=Formation of chloroform and chlorinated organics by free-chlorine-mediated oxidation of triclosan |journal=Environ. Sci. Technol. |volume=39 |issue=9 |pages=3176–85 |date=May 2005 |pmid=15926568 |doi=10.1021/es048943}}&lt;/ref&gt; Most of these intermediates convert into [[Polychlorinated dibenzodioxins|dioxins]] upon exposure to [[UV]] radiation (from the sun or other sources). Although small amounts of dioxins are produced, some dioxins are extremely toxic and are very potent [[endocrine disruptor]]s. They are also chemically stable, so that they are eliminated from the body slowly (they can [[bioaccumulate]] to dangerous levels), and they persist in the environment for a long time.&lt;ref&gt;[http://www.epa.gov/pbt/pubs/dioxins.htm Dioxins]&lt;/ref&gt; The dioxins which can be formed from triclosan are not considered to be those congeners of toxicologic concern for mammals, birds, and fish.&lt;ref name=EPA2013&gt;{{cite web|title=Environmental Protection Agency|url=http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPP-2012-0811-0002|work=Docket|date=27 March 2013}}&lt;/ref&gt;&lt;ref name=WHO&gt;{{cite journal|title=Consultation on assessment of the health risk of dioxins; re-evaluation of the tolerable daily intake (TDI): Executive Summary|journal=Food Additives and Contaminants|year=2000|volume=17|issue=4|pages=223–240|doi=10.1080/713810655|url=http://www.tandfonline.com/doi/abs/10.1080/713810655#preview|pmid=10912238}}&lt;/ref&gt;

The United States Pharmacopeia has established a monograph for triclosan that sets purity standards (&gt;97%).&lt;ref name=USP&gt;{{cite book|title=US Pharmacopoeia National Formulary|year=2012|publisher=United States Pharmacopeial|isbn=1936424126|url=http://www.usp.org/}}&lt;/ref&gt;

The [[American Dental Association]] published a response to the concerns stemming from the Virginia Tech study stating that the study is not relevant to toothpaste.&lt;ref name=&quot;pmid15926568&quot; /&gt;&lt;ref&gt;{{Cite web|url=http://www.ada.org/prof/resources/pubs/adanews/adanewsarticle.asp?articleid=1375 |title=ADA.org: ADA News: Triclosan study not relevant to toothpaste |publisher=ada.org |accessdate=2010-08-16 |archiveurl = http://web.archive.org/web/20071024144101/http://www.ada.org/prof/resources/pubs/adanews/adanewsarticle.asp?articleid=1375 |archivedate = 2007-10-24}}&lt;/ref&gt;

=== Environment ===
Triclosan is toxic to aquatic bacteria at levels found in the environment. Triclosan inhibits [[photosynthesis]] in [[diatom]] algae, which are responsible for a large part of the photosynthesis on Earth.&lt;ref&gt;{{cite journal |author=Ricart M, Guasch H, Alberch M, ''et al.'' |title=Triclosan persistence through wastewater treatment plants and its potential toxic effects on river biofilms |journal=Aquat. Toxicol. |volume=100 |issue=4 |pages=346–53 |date=November 2010 |pmid=20855117 |doi=10.1016/j.aquatox.2010.08.010}}&lt;/ref&gt;

=== Endocrine disruption ===
Triclosan has been associated with lower levels of thyroid hormone and testosterone. Specifically, triclosan decreases circulating levels of thyroxine hormone (T4) by increasing glucuronidase enzyme activity, which catabolizes T4 and other thyroid hormones.&lt;ref&gt;Crofton, Kevin M., et al. &quot;Short-term&lt; i&gt; in vivo&lt;/i&gt; exposure to the water contaminant triclosan: Evidence for disruption of thyroxine.&quot; Environmental Toxicology and Pharmacology 24.2 (2007): 194-197.http://www.sciencedirect.com/science/article/pii/S1382668907000683&lt;/ref&gt; This may lead to altered behavior, learning disabilities, and/or infertility. Very low doses of triclosan have been shown to act as an estrogen mimic and increase proliferation rates of breast cancer tumors.&lt;ref&gt;http://www.breastcancerfund.org/clear-science/radiation-chemicals-and-breast-cancer/triclosan.html&lt;/ref&gt; It may also chemically mimic [[thyroid hormone]] and bind to the hormone receptor sites, blocking them, so that normal hormones cannot be used. A study between 2003 and 2006 concluded that triclosan (as an endocrine disruptor) affects the immune system and showed a positive association with allergy or hay fever diagnosis.&lt;ref&gt;{{cite journal |author=Clayton EM, Todd M, Dowd JB, Aiello AE |title=The impact of bisphenol A and triclosan on immune parameters in the U.S. population, NHANES 2003-2006 |journal=Environ. Health Perspect. |volume=119 |issue=3 |pages=390–6 |date=March 2011 |pmid=21062687 |pmc=3060004 |doi=10.1289/ehp.1002883}}&lt;/ref&gt; Another study in 2000 offered the result that low amounts of triclosan can be absorbed through skin and can enter the bloodstream.&lt;ref&gt;{{cite journal |author=Moss T, Howes D, Williams FM |title=Percutaneous penetration and dermal metabolism of triclosan (2,4, 4'-trichloro-2'-hydroxydiphenyl ether) |journal=Food Chem. Toxicol. |volume=38 |issue=4 |pages=361–70 |date=April 2000 |pmid=10722890 |doi=10.1016/S0278-6915(99)00164-7}}&lt;/ref&gt;

Triclosan has also been found both in the bile of fish living downstream from wastewater processing facilities and in human milk.&lt;ref&gt;{{cite journal |author=Adolfsson-Erici M, Pettersson M, Parkkonen J, Sturve J |title=Triclosan, a commonly used bactericide found in human milk and in the aquatic environment in Sweden |journal=Chemosphere |volume=46 |issue=9–10 |pages=1485–9 |date=March 2002 |pmid=12002480 |doi=10.1016/S0045-6535(01)00255-7}}&lt;/ref&gt; The adverse effects of triclosan on the environment and its questionable benefits in toothpastes&lt;ref&gt;{{cite journal |author=Edvardsson S, Burman LG, Adolfsson-Erici M, Bäckman N |title=Risker och nytta med triklosan i tandkräm |trans_title=Risks and benefits of triclosan in toothpaste |language=German |journal=Tandläkartidningen |volume=97 |issue=10 |pages=58–64 |url=http://www.tandlakartidningen.se/media/1542/Edwardsson10_2005.pdf}}&lt;/ref&gt; have led to the Swedish Naturskyddsföreningen to recommend not using triclosan in toothpaste.&lt;ref&gt;[http://www.snf.se/pdf/rap-triclosan.pdf Start ~ Naturskyddsföreningen&lt;!-- Bot generated title --&gt;]&lt;/ref&gt; Another 2009 study demonstrated that triclosan exposure significantly impacts thyroid hormone concentrations in male juvenile rats.&lt;ref&gt;{{cite journal |author=Zorrilla LM, Gibson EK, Jeffay SC, ''et al.'' |title=The effects of triclosan on puberty and thyroid hormones in male Wistar rats |journal=Toxicol. Sci. |volume=107 |issue=1 |pages=56–64 |date=January 2009 |pmid=18940961 |doi=10.1093/toxsci/kfn225}}&lt;/ref&gt; However, a four-year study of possible effects of triclosan (0.3%) in toothpaste on thyroid hormone function found no effect of triclosan on thyroid hormone concentration in sera of adult human subjects.
&lt;ref&gt;{{cite journal |author=Cullinan MP, Palmer JE, Carle AD, West MJ, Seymour GJ |title=Long term use of triclosan toothpaste and thyroid function |journal=Sci. Total Environ. |volume=416 |issue= |pages=75–9 |date=February 2012 |pmid=22197412 |doi=10.1016/j.scitotenv.2011.11.063}}&lt;/ref&gt;

=== Muscle contraction ===
Triclosan has been reported to impair [[excitation-contraction coupling]] in cardiac and skeletal muscle function in mice.&lt;ref&gt;{{cite journal |author=Cherednichenko G, Zhang R, Bannister RA, ''et al.'' |title=Triclosan impairs excitation-contraction coupling and Ca&lt;sup&gt;2+&lt;/sup&gt; dynamics in striated muscle |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=109 |issue=35 |pages=14158–63 |date=August 2012 |pmid=22891308 |pmc=3435154 |doi=10.1073/pnas.1211314109 |bibcode=2012PNAS..10914158C}}&lt;/ref&gt;

== Environmental concerns ==
===Treatment and disposal of triclosan ===
The duration of triclosan in personal product use is relatively short. Upon disposal, triclosan is washed down the drain to municipal wastewater treatment plants, where about 97-98% of triclosan is removed from the water.&lt;ref&gt;Halden, Rolf U. &quot;On the Need and Speed of Regulating Triclosan and Triclocarban in the United States.&quot; Environmental science &amp; technology (2014). http://pubs.acs.org/doi/abs/10.1021/es500495p&lt;/ref&gt; Studies show that substantial quantities of triclosan (170,000 – 970,000 kg/yr) can break through wastewater treatment plants and damage algae on surface waters.&lt;ref&gt;Halden, Rolf U. &quot;On the Need and Speed of Regulating Triclosan and Triclocarban in the United States.&quot; Environmental science &amp; technology (2014). http://pubs.acs.org/doi/abs/10.1021/es500495p&lt;/ref&gt; In a study on effluent from wastewater treatment facilities, approximately 75% of triclocarban was present in sludge.&lt;ref&gt;Clarke, Bradley O., and Stephen R. Smith. &quot;Review of ‘emerging’organic contaminants in biosolids and assessment of international research priorities for the agricultural use of biosolids.&quot; Environment international 37.1 (2011): 226-247. http://www.sciencedirect.com/science/article/pii/S0160412010001224&lt;/ref&gt; This poses a potential environmental and ecological hazard, particularly for aquatic systems. The volume of triclosan re-entering the environment in sewage sludge after initial successful capture from wastewater is 44,000 ± 60,000 kg/yr.&lt;ref&gt;Halden, Rolf U. &quot;On the Need and Speed of Regulating Triclosan and Triclocarban in the United States.&quot; Environmental science &amp; technology (2014). http://pubs.acs.org/doi/abs/10.1021/es500495p&lt;/ref&gt; Triclosan can attach to other substances suspended in aquatic environments, which potentially endangers marine organisms and may lead to further bioaccumulation.&lt;ref&gt;&quot;Triclosan Facts.&quot; EPA. Environmental Protection Agency, Web. 17 Feb. 2014. &lt;http://www.epa.gov/oppsrrd1/REDs/factsheets/triclosan_fs.htm&lt;/ref&gt; Ozone is considered to be a tool for removing triclosan during sewage treatment. As little triclosan is released through plastic and textile household consumer products, these are not considered to be major sources of triclosan contamination.&lt;ref&gt;&quot;Triclosan Facts.&quot; EPA. Environmental Protection Agency, Web. 17 Feb. 2014. &lt;http://www.epa.gov/oppsrrd1/REDs/factsheets/triclosan_fs.htm&lt;/ref&gt;

During [[wastewater]] treatment, a portion of triclosan is degraded, while the remaining adsorbs to sewage [[sludge]] or exits the plant as effluent.&lt;ref name=&quot;pmid12523412&quot;&gt;{{cite journal |author=Singer H, Müller S, Tixier C, Pillonel L |title=Triclosan: occurrence and fate of a widely used biocide in the aquatic environment: field measurements in wastewater treatment plants, surface waters, and lake sediments |journal=Environ. Sci. Technol. |volume=36 |issue=23 |pages=4998–5004 |date=December 2002 |pmid=12523412 |doi=10.1021/es025750i|bibcode = 2002EnST...36.4998S }}&lt;/ref&gt;&lt;ref name=&quot;pmid16766013&quot;&gt;{{cite journal |author=Heidler J, Halden RU |title=Mass balance assessment of triclosan removal during conventional sewage treatment |journal=Chemosphere |volume=66 |issue=2 |pages=362–9 |date=January 2007 |pmid=16766013 |doi=10.1016/j.chemosphere.2006.04.066}}&lt;/ref&gt; In the environment, triclosan may be degraded by microorganisms or react with sunlight, forming other compounds, which include between 3 and 12% of chlorophenols and [[Polychlorinated dibenzodioxins|dioxins]] (In particular, 2,8-dichlorodibenzo-p-dioxin&lt;ref&gt;http://www.chemicalbook.com/ChemicalProductProperty_EN_CB5316744.htm{{full|date=July 2013}}&lt;/ref&gt; (2,8-DCDD) and [[2,4-dichlorophenol]] (2,4-DCP) are produced. Both also are photolabile and, thus, are intermediates).  As a result, triclosan was the target of a UK cancer alert, even though the study showed that the amount of chloroform generated was less than amounts often present in [[chlorinated]] [[drinking water]].

===Bioaccumulation===
While studies using semi-permeable membrane devices have found that triclosan does not strongly bioaccumulate, methyl-triclosan is comparatively more stable and [[lipophilicity|lipophilic]] and thus poses a higher risk of bioaccumulation in organisms. The ability of triclosan to bioaccumulate is affected by its ionization state in different environmental conditions. At a higher pH, triclosan is expected to bioaccumulate more significantly, while at a lower pH, methyl-triclosan is much more likely to bioaccumulate.&lt;ref&gt;Brausch, John, and Gary Rand. &quot;A review of personal care products in the aquatic environment: Environmental concentrations and toxicity.&quot; Chemosphere 82.11 (2011): 1518-1532. ScienceDirect. Web. 17 Feb. 2014. http://ac.els-cdn.com/S0045653510013007/1-s2.0-S0045653510013007-main.pdf?_tid=c685833c-9812-11e3-87db-00000aab0f6c&amp;acdnat=1392669395_a731b9c664c4e98737d93755500c43dd&lt;/ref&gt; Analysis of human autopsies have shown that triclosan can bioaccumulate in the liver and adipose tissues, but not in brain tissues.&lt;ref&gt;http://www.breastcancerfund.org/clear-science/radiation-chemicals-and-breast-cancer/triclosan.html&lt;/ref&gt;

===Ecotoxicity===
Triclosan and [[triclocarban]] (TCC) could have adverse repercussions on agriculture. Studies have indicated that TCC and TCS are absorbed through shoot systems in vegetables, at higher levels in roots than in tubers. While the levels of TCC and TCS in the vegetables are largely insufficient to cause major health damage, the levels of these chemicals are higher than in the drinking water supply.&lt;ref&gt;Mathews, Shiny, Shannon Henderson, and Dawn Reinhold. &quot;Uptake and accumulation of antimicrobials, triclocarban and triclosan, by food crops in a hydroponic system.&quot; Environmental Science and Pollution Research (2014): 1-9. http://www.ncbi.nlm.nih.gov.proxy.bc.edu/pubmed/24464075&lt;/ref&gt; Crops shown to take up antimicrobials from soil include barley, meadow fescue, carrots and pinto beans. Triclosan may also affect animal wildlife behavior.&lt;ref&gt;http://www.nrdc.org/living/chemicalindex/triclosan.asp&lt;/ref&gt; For example, TCS and TCC are 100-1,000 times more effective in inhibiting and killing algae, crustaceans and fish than they are in killing microbes. TCS have been observed in multiple organisms, including algae aquatic blackworms, fish and dolphins.  Earth dwelling species include earth worms, and species higher up the food chain. &lt;ref&gt;Halden, Rolf U. &quot;On the Need and Speed of Regulating Triclosan and Triclocarban in the United States.&quot; Environmental science &amp; technology (2014). http://pubs.acs.org/doi/abs/10.1021/es500495p&lt;/ref&gt;

== Resistance concerns ==

An article coauthored by Stuart Levy in the August 6, 1998 issue of ''[[Nature (journal)|Nature]]''&lt;ref name=&quot;pmid9707111&quot;&gt;{{cite journal |author=McMurry LM, Oethinger M, Levy SB |title=Triclosan targets lipid synthesis |journal=Nature |volume=394 |issue=6693 |pages=531–2 |date=August 1998 |pmid=9707111 |doi=10.1038/28970|bibcode = 1998Natur.394..531M }}&lt;/ref&gt; warned that triclosan's overuse could cause resistant strains of [[bacteria]] to develop, in much the same way that [[Antibiotic resistance|antibiotic-resistant]] bacterial strains are emerging. In 2003, the Scottish ''[[Sunday Herald]]'' newspaper reported that some UK supermarkets and other retailers were considering phasing out products containing triclosan.&lt;ref&gt;[http://web.archive.org/web/20050507110108/http://www.sundayherald.com/37782 Supermarkets to ban toxic detergent] Rob Edwards, Sunday Herald, 02 November  2003&lt;/ref&gt;

There continues to be much controversy on this subject. It has since been shown that while the laboratory method used by Levy was not effective in predicting bacterial resistance for [[biocide]]s like triclosan, triclosan does reduce species diversity, eradicate efficient TCS degrader species (see citation Table 4), and manipulate ecological relations.&lt;ref name=&quot;pmid12957932&quot;&gt;{{cite journal |author=McBain AJ, Bartolo RG, Catrenich CE, ''et al.'' |title=Exposure of sink drain microcosms to triclosan: population dynamics and antimicrobial susceptibility |journal=Appl. Environ. Microbiol. |volume=69 |issue=9 |pages=5433–42 |date=September 2003 |pmid=12957932 |pmc=194980 |doi=10.1128/AEM.69.9.5433-5442.2003}}&lt;/ref&gt; At least seven [[peer-review]]ed and published studies have been conducted demonstrating that triclosan is not significantly associated with bacterial resistance over the short term, including one study coauthored by Levy.&lt;ref name=&quot;pmid15273108&quot;&gt;{{cite journal |author=Aiello AE, Marshall B, Levy SB, Della-Latta P, Larson E |title=Relationship between triclosan and susceptibilities of bacteria isolated from hands in the community |journal=Antimicrob. Agents Chemother. |volume=48 |issue=8 |pages=2973–9 |date=August 2004 |pmid=15273108 |pmc=478530 |doi=10.1128/AAC.48.8.2973-2979.2004}}&lt;/ref&gt; 

Other studies have shown that some bacterial species can develop low-level resistance to triclosan at its lower bacteriostatic concentrations because of ''FabI'' mutations, which results in a decrease of triclosan's effect on ENR-NAD&lt;sup&gt;+&lt;/sup&gt; binding, as shown in ''[[Escherichia coli]]'' and ''[[Staphylococcus aureus]]''.&lt;ref name=&quot;pmid10196195&quot;&gt;{{cite journal |author=Heath RJ, Rubin JR, Holland DR, Zhang E, Snow ME, Rock CO |title=Mechanism of triclosan inhibition of bacterial fatty acid synthesis |journal=J. Biol. Chem. |volume=274 |issue=16 |pages=11110–4 |date=April 1999 |pmid=10196195 |doi=10.1074/jbc.274.16.11110}}&lt;/ref&gt;&lt;ref name=&quot;pmid12384334&quot;&gt;{{cite journal |author=Fan F, Yan K, Wallis NG, ''et al.'' |title=Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus |journal=Antimicrob. Agents Chemother. |volume=46 |issue=11 |pages=3343–7 |date=November 2002 |pmid=12384334 |pmc=128739 |doi=10.1128/AAC.46.11.3343-3347.2002 }}&lt;/ref&gt; Another way for these bacteria to gain low-level resistance to triclosan is to [[overexpress]] ''FabI''.&lt;ref name=&quot;pmid11418506&quot;&gt;{{cite journal |author=Slater-Radosti C, Van Aller G, Greenwood R, ''et al.'' |title=Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus |journal=J. Antimicrob. Chemother. |volume=48 |issue=1 |pages=1–6 |year=2001 |pmid=11418506|doi=10.1093/jac/48.1.1}}&lt;/ref&gt; Some bacteria have innate resistance to triclosan at low, bacteriostatic levels, such as ''[[Pseudomonas aeruginosa]]'', which possesses multi-drug efflux pumps that &quot;pump&quot; triclosan out of the cell.&lt;ref name=&quot;pmid12665747&quot;&gt;{{cite journal |author=Chuanchuen R, Karkhoff-Schweizer RR, Schweizer HP |title=High-level triclosan resistance in Pseudomonas aeruginosa is solely a result of efflux |journal=Am J Infect Control |volume=31 |issue=2 |pages=124–7 |date=April 2003 |pmid=12665747 |doi=10.1067/mic.2003.11}}&lt;/ref&gt; Other bacteria, such as some of the ''[[Bacillus]]'' genus, have alternative ''FabI'' genes (''FabK'') to which triclosan does not bind and hence are less susceptible.

A larger concern pertains to the potential for cross-resistance or co-resistance to other antimicrobials. Even if short term resistance does not develop, many believe that a larger issue is that superbugs will evolve against which no bactericide can be used. Studies investigating this possibility have been limited.&lt;ref name=&quot;pmid16922622&quot;&gt;{{cite journal |author=Yazdankhah SP, Scheie AA, Høiby EA, ''et al.'' |title=Triclosan and antimicrobial resistance in bacteria: an overview |journal=Microb. Drug Resist. |volume=12 |issue=2 |pages=83–90 |year=2006 |pmid=16922622 |doi=10.1089/mdr.2006.12.83}}&lt;/ref&gt;

The European Commission Scientific Committee on Consumer Safety (SCCS) concludes that to date, there exists no evidence that using triclosan leads to an increase in antibiotic resistance. However, it is difficult to say that triclosan exposure never leads to microbial resistance, as there is too much conflicting information to make a full risk analysis.&lt;ref&gt;[http://copublications.greenfacts.org/en/triclosan/index.htm Triclosan and Antibiotics resistance] summary by GreenFacts of an opion by the European Commission Scientific Committee on Consumer Safety (March 2010)&lt;/ref&gt;

== Alternatives ==
A comprehensive analysis from the University of Michigan School of Public Health indicated that plain soaps are just as effective as consumer-grade antibacterial soaps with triclosan in preventing illness and removing bacteria from the hands.&lt;ref&gt;{{cite web |url=http://www.physorg.com/news106418144.html |title=Plain soap as effective as antibacterial but without the risk |accessdate=2007-08-17 |work=}}&lt;/ref&gt;

Nonorganic antibiotics and organic biocides are effective alternatives to triclosan, such as silver and copper ions and [[nanoparticle]]s.&lt;ref&gt;{{cite journal |author=Kim JS, Kuk E, Yu KN, ''et al.'' |title=Antimicrobial effects of silver nanoparticles |journal=Nanomedicine |volume=3 |issue=1 |pages=95–101 |date=March 2007 |pmid=17379174 |doi=10.1016/j.nano.2006.12.001}}&lt;/ref&gt;

==Policy==
The U.S. [[Food and Drug Administration]], the [[Environmental Protection Agency]], and the [[European Union]] are regulatory bodies for triclosan. In the United States, manufacturers of products containing triclosan must indicate it on the label. In Europe, triclosan is regulated as a cosmetic preservative and must be listed on the label.&lt;ref&gt;{{cite web|title=REGULATION (EC) No 1223 /2009 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 30 November 2009 on cosmetic products|url=http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:342:0059:0209:en:PDF|work=Official Journal of the European Union|year=2009}}&lt;/ref&gt; The authorization of the inclusion of triclosan as an additive for plastic production for use in food packages is a legally contentious issue, as noted in the ''Microban International and Microban (Europe) v Commission'' case.&lt;ref&gt;[http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:075:0025:0026:EN:PDF COMMISSION DECISION of 19 March 2010 concerning the non-inclusion of 2,4,4’-trichloro-2’-hydroxydiphenyl ether in the Union list of additives which may be used in the manufacture of plastic materials and articles intended to come into contact with foodstuffs under Directive 2002/72/EC] 23.3.2010 Official Journal of the European Union&lt;/ref&gt;

In light of the health concerns, the [[Food and Drug Administration]] began in the 1970s to review the safety of [[triclocarban]] and triclosan, but did not implement any policies.&lt;ref&gt;Halden, Rolf U. &quot;On the Need and Speed of Regulating Triclosan and Triclocarban in the United States.&quot; Environmental science &amp; technology (2014). http://pubs.acs.org/doi/abs/10.1021/es500495p&lt;/ref&gt; In 2010, the Natural Resources Defense Council forced the FDA to review triclosan after suing them for their inaction.&lt;ref&gt;Halden, Rolf U. &quot;On the Need and Speed of Regulating Triclosan and Triclocarban in the United States.&quot; Environmental science &amp; technology (2014). http://pubs.acs.org/doi/abs/10.1021/es500495p&lt;/ref&gt; Since the FDA prohibited [[hexachlorophene]],a compound similar to TCS, scientists argue the FDA should also ban TCS.&lt;ref&gt;Halden, Rolf U. &quot;On the Need and Speed of Regulating Triclosan and Triclocarban in the United States.&quot; Environmental science &amp; technology (2014). http://pubs.acs.org/doi/abs/10.1021/es500495p&lt;/ref&gt;

==Current and future research==
The future of TCC is unknown, but scientists are searching for more sustainable antimicrobials that maintain their antibacterial properties while also being minimally toxic to the environment, humans, and wildlife. This entails low degrees of bioaccumulation and rapid, clean biodegredation in existing wastewater treatment facilities. A lowered potential or no potential for resistance is also preferable.&lt;ref&gt;Halden, Rolf U. &quot;On the Need and Speed of Regulating Triclosan and Triclocarban in the United States.&quot; Environmental science &amp; technology (2014). http://pubs.acs.org/doi/abs/10.1021/es500495p&lt;/ref&gt; These next generation chemicals should aim to act on a broad spectrum of microbes and pathogens while also being minimally toxic and bioaccumulating in non-target species. 

Synthesis of these compounds could be improved upon by finding renewable sources for their production that lack occupational hazards.&lt;ref&gt;Halden, Rolf U. &quot;On the Need and Speed of Regulating Triclosan and Triclocarban in the United States.&quot; Environmental science &amp; technology (2014). http://pubs.acs.org/doi/abs/10.1021/es500495p&lt;/ref&gt; Research regarding the sustainability of chemical production is currently being used to help formulate green pharmaceuticals. These same principles may be applied to the development of improved antimicrobials.&lt;ref&gt;Halden, Rolf U. &quot;On the Need and Speed of Regulating Triclosan and Triclocarban in the United States.&quot; Environmental science &amp; technology (2014). http://pubs.acs.org/doi/abs/10.1021/es500495p&lt;/ref&gt; Development in this area would benefit both people and the environment.&lt;ref&gt;Halden, Rolf U. &quot;On the Need and Speed of Regulating Triclosan and Triclocarban in the United States.&quot; Environmental science &amp; technology (2014). http://pubs.acs.org/doi/abs/10.1021/es500495p&lt;/ref&gt;

== See also ==
* [[Chlorhexidine gluconate]]
* [[Chlorine]]
* [[Chloroform]]
* [[Chloroxylenol]]
* [[Hygiene hypothesis]]
* [[Triclocarban]]
* [[Antibacterial soap]]
* [[Dial (soap)]]
* [[Simple aromatic ring|aromatic compound]]
* [[Bioaccumulation]]
* [[Breast Cancer]]
* [[Hand Sanitizer]]
* [[Deodorant]]

== References ==
{{Reflist|2}}

== Further reading ==
* Toxicological Sciences, 2009, 107 (1): 56-64, &quot;The Effects of Triclosan on Puberty and Thyroid Hormones in Male Wistar Rats&quot;
* Reproductive Toxicology, Apr 2009, 27(2):177-185, &quot;Alteration of testicular steroidogenesis and histopathology of reproductive system in male rats treated with triclosan&quot;

== External links ==
* ''[http://www.quantexlabs.com/Portals/159220/docs/triclosan-impurities.pdf Triclosan and Its Impurities]''
* ''[http://www.worldwatch.org/system/files/Soap.pdf Antibacterials? Here's the Rub]'' &amp;ndash; campaign site.
* [http://www.nytimes.com/2011/08/20/business/triclosan-an-antibacterial-chemical-in-consumer-products-raises-safety-issues.html?pagewanted=1&amp;_r=1&amp;emc=eta1/ ''Antibacterial Chemical Raises Safety Issues''] New York Times Aug 19, 2011

{{Antiseptics and disinfectants}}
{{Medicated dressings}}

[[Category:Antibiotics]]
[[Category:Antifungals]]
[[Category:Endocrine disruptors]]
[[Category:Organochlorides]]
[[Category:Phenol ethers]]</text>
      <sha1>p4deg38jbf2jev0k3xqou5o0zzdyipr</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Pristinamycin</title>
    <ns>0</ns>
    <id>3675099</id>
    <revision>
      <id>586718129</id>
      <parentid>554463430</parentid>
      <timestamp>2013-12-19T00:34:58Z</timestamp>
      <contributor>
        <username>Brainiacal</username>
        <id>19461952</id>
      </contributor>
      <comment>minor corrections for clarification</comment>
      <text xml:space="preserve" bytes="6828">{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464214518
| image = Pristinamycin IA.png
| image2 = Streptogramin A.svg

&lt;!--Combo data--&gt;
| type = combo
| component1 = Pristinamycin IA
| class1 = [[antibiotic]]
| component2 = Pristinamycin IIA
| class2 = [[antibiotic]]

&lt;!--Clinical data--&gt;
| tradename =  
| Drugs.com = {{drugs.com|international|pristinamycin}}
| MedlinePlus = a603007
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category =  
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, or Class A, B, C --&gt;
| legal_US = &lt;!-- OTC / Rx-only / Schedule I, II, III, IV, V --&gt;
| legal_status =  
| routes_of_administration =  

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 270076-60-3
| ATCvet =  
| ATC_prefix = J01
| ATC_suffix = FG01
| PubChem = 11979535
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10152812
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1256399

&lt;!--Chemical data--&gt;
| smiles = CCC1C(=O)N2CCCC2C(=O)N(C(C(=O)N3CCC(=O)CC3C(=O)NC(C(=O)OC(C(C(=O)N1)NC(=O)c4c(cccn4)O)C)c5ccccc5)Cc6ccccc6)C.CC1/C=C\C(=O)NC/C=C\C(=C/C(CC(=O)Cc2nc(co2)C(=O)N3CCC=C3C(=O)OC1C(C)C)O)\C
| InChI = 1/C43H49N7O10.C28H35N3O7/c1-4-29-40(56)49-21-12-17-30(49)41(57)48(3)32(23-26-13-7-5-8-14-26)42(58)50-22-19-28(51)24-31(50)37(53)47-35(27-15-9-6-10-16-27)43(59)60-25(2)34(38(54)45-29)46-39(55)36-33(52)18-11-20-44-36;1-17(2)26-19(4)9-10-24(34)29-11-5-7-18(3)13-20(32)14-21(33)15-25-30-22(16-37-25)27(35)31-12-6-8-23(31)28(36)38-26/h5-11,13-16,18,20,25,29-32,34-35,52H,4,12,17,19,21-24H2,1-3H3,(H,45,54)(H,46,55)(H,47,53);5,7-10,13,16-17,19-20,26,32H,6,11-12,14-15H2,1-4H3,(H,29,34)/b;7-5-,10-9-,18-13-
| InChIKey = MVTQIFVKRXBCHS-FHWPYUEJBW
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C43H49N7O10.C28H35N3O7/c1-4-29-40(56)49-21-12-17-30(49)41(57)48(3)32(23-26-13-7-5-8-14-26)42(58)50-22-19-28(51)24-31(50)37(53)47-35(27-15-9-6-10-16-27)43(59)60-25(2)34(38(54)45-29)46-39(55)36-33(52)18-11-20-44-36;1-17(2)26-19(4)9-10-24(34)29-11-5-7-18(3)13-20(32)14-21(33)15-25-30-22(16-37-25)27(35)31-12-6-8-23(31)28(36)38-26/h5-11,13-16,18,20,25,29-32,34-35,52H,4,12,17,19,21-24H2,1-3H3,(H,45,54)(H,46,55)(H,47,53);5,7-10,13,16-17,19-20,26,32H,6,11-12,14-15H2,1-4H3,(H,29,34)/b;7-5-,10-9-,18-13-
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MVTQIFVKRXBCHS-FHWPYUEJSA-N
}}

'''Pristinamycin''' ([[International Nonproprietary Name|INN]]), also spelled '''pristinamycine''', is an [[antibiotic]] used primarily in the treatment of [[Staphylococcus|staphylococcal]] infections, and to a lesser extent [[Streptococcus|streptococcal]] infections. It is a [[streptogramin]] group antibiotic, similar to [[virginiamycin]], derived from the bacterium ''[[Streptomyces|Streptomyces pristinaespiralis]]''. It is marketed in Europe by [[Sanofi-Aventis]] under the trade name '''Synercid''' and '''Pyostacine'''.

Pristinamycin is a mixture of two components that have a synergistic antibacterial action. [[Pristinamycin IA]] is a [[macrolide]], and results in pristinamycin's having a similar spectrum of action to [[erythromycin]]. [[Pristinamycin IIA]] (streptogramin A) is a [[depsipeptide]].&lt;ref name=&quot;Hamilton-Miller1991&quot;&gt;{{cite journal | author = Hamilton-Miller J | title = From foreign pharmacopoeias: 'new' antibiotics from old? | journal = J Antimicrob Chemother | volume = 27 | issue = 6 | pages = 702–5 | year = 1991 | pmid = 1938680 | doi = 10.1093/jac/27.6.702}}&lt;/ref&gt; PI and PII are coproduced by ''S. pristinaespiralis'' in a ratio of 30:70. Each compound binds to the bacterial 50 S ribosomal subunit and inhibits the elongation process of the protein synthesis, thereby exhibiting only a moderate bacteriostatic activity. However, the combination of both substances acts synergistically and  leads to a potent bactericidal activity that can reach up to 100 times that of the separate components.

The pristinamycin biosynthetic gene cluster is the largest antibiotic supercluster known so far, with a size of ~210 kb, wherein the PI and PII biosynthetic genes are not clustered individually but are scattered across the complete sequence region.&lt;ref&gt;Mast Y, Weber T, Gölz M, Ort-Winklbauer R, Gondran A, Wohlleben W, Schinko E (2010) Characterization of the ‘pristinamycin supercluster’ of Streptomyces pristinaespiralis. Microbial Biotechnology. {{doi|10.1111/j.1751-7915.2010.00213.x}}&lt;/ref&gt; Furthermore, this biosynthetic gene region is interrupted by a cryptic type II PKS gene cluster.  

==Clinical use==
Despite the macrolide component, it is effective against erythromycin-resistant staphylococci and strepcococci.&lt;ref name=&quot;Weber2001&quot;&gt;{{cite journal | author = Weber P | title = [Streptococcus pneumoniae: lack of emergence of pristinamycin resistance] | journal = Pathol Biol (Paris) | volume = 49 | issue = 10 | pages = 840–5 | year = 2001 | pmid = 11776696 | doi = 10.1016/S0369-8114(01)00255-3}}&lt;/ref&gt;&lt;ref name=&quot;Leclercq2003&quot;&gt;{{cite journal | author = Leclercq R, Soussy C, Weber P, Moniot-Ville N, Dib C | title = [In vitro activity of the pristinamycin against the isolated staphylococci in the french hospitals in 1999-2000] | journal = Pathol Biol (Paris) | volume = 51 | issue = 7 | pages = 400–4 | year = 2003 | pmid = 12948760 | doi = 10.1016/S0369-8114(03)00054-3}}&lt;/ref&gt;  It is active against [[Methicillin-resistant Staphylococcus aureus|methicillin-resistant ''Staphylococcus aureus'']] (MRSA). Its usefulness for severe infections, however, may be limited by the lack of an [[intravenous]] formulation owing to its poor solubility.&lt;ref name=&quot;Martindale34&quot;&gt;{{cite book | editor= Edited by Sean C. Sweetman | title=[[Martindale: The complete drug reference]] | edition=34th | date=November 30, 2004 | publisher=Pharmaceutical Press | location=London | isbn= 0-85369-550-4}}&lt;/ref&gt; Nevertheless it is sometimes used as an alternative to [[rifampicin]]+[[fusidic acid]] or [[linezolid]] for the treatment of MRSA.

The lack of an intravenous formulation led to the development of the pristinamycin-derivative [[quinupristin/dalfopristin]] (i.e., [[Synercid]]), which may be administered intravenously for more severe MRSA infections.

== See also ==
* [[Methicillin-resistant Staphylococcus aureus|Methicillin-resistant ''Staphylococcus aureus'']] (MRSA)
* [[Quinupristin/dalfopristin]]

== Footnotes ==
&lt;div class=&quot;references-small&quot;&gt;&lt;references /&gt;&lt;/div&gt;

{{Macrolides, lincosamides and streptogramins}}

[[Category:Antibiotics]]
[[Category:Combination antibiotics]]
[[Category:Depsipeptides]]
[[Category:Cyclic peptides]]</text>
      <sha1>9y41vb59umfhsligt21xogzid8mudjv</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Arsphenamine</title>
    <ns>0</ns>
    <id>99714</id>
    <revision>
      <id>595839385</id>
      <parentid>595839359</parentid>
      <timestamp>2014-02-17T06:47:26Z</timestamp>
      <contributor>
        <username>J M Rice</username>
        <id>182338</id>
      </contributor>
      <minor/>
      <text xml:space="preserve" bytes="5762">[[Image:Salvarsan-montage.png|thumb|right|300px|right|The structure of '''Arsphenamine''' has been proposed to be akin to the [[azobenzene]] ('''A'''), but mass spectral studies published in 2005 suggest&lt;ref name=&quot;pmid15624113&quot;/&gt; it is actually a mixture of the trimer '''B''' and the pentamer '''C'''.]]
'''Arsphenamine''', also known as '''Salvarsan''' and '''compound 606''', is a [[medication|drug]] that was introduced at the beginning of the 1910s as the first effective treatment for [[syphilis]], and was also used to treat [[African trypanosomiasis|trypanosomiasis]].&lt;ref name='ITOM'&gt;{{Cite journal |last1=Gibaud |first1=Stéphane |last2=Jaouen |first2=Gérard |title=Arsenic - based drugs: from Fowler's solution to modern anticancer chemotherapy |url=http://link.springer.com/chapter/10.1007%2F978-3-642-13185-1_1 |journal=[http://www.springer.com/series/3418 Topics in Organometallic Chemistry] |year=2010 |volume=32 |pages=1–20  |doi= 10.1007/978-3-642-13185-1_1 |series=Topics in Organometallic Chemistry |isbn=978-3-642-13184-4}}&lt;/ref&gt; 
It is an [[Organoarsenic chemistry|organoarsenic molecule]], and was the first modern [[Chemotherapy|chemotherapeutic agent]].

==History==
[[Sahachiro Hata]] and [[Paul Ehrlich]] discovered the antisyphilitic activity of this compound in 1909 in Erlich's laboratory, during a survey of hundreds of newly synthesized organic [[arsenic]]al compounds. Ehrlich had theorized that by screening many compounds, a drug could be discovered with antimicrobial activity without killing the human. Ehrlich's team began their search for such a &quot;[[magic bullet]]&quot; among chemical derivatives of the dangerously toxic drug [[atoxyl]]. This was the first organized team effort to optimize the biological activity of a [[lead compound]] through systematic chemical modifications, the basis for nearly all modern pharmaceutical research.

Arsphenamine was originally called &quot;606&quot; because it was the sixth in the sixth group of compounds synthesized for testing; it was marketed by [[Hoechst AG]] under the [[trade name]] '''Salvarsan''' in 1910.&lt;ref name=acs&gt;{{cite web |url=http://pubs.acs.org/cen/coverstory/83/8325/8325salvarsan.html |title=Salvarsan |accessdate=2010-02-01 |quote= |publisher=[[Chemical &amp; Engineering News]] }}&lt;/ref&gt;&lt;ref&gt;In Germany, it was the practice to designate compounds by their development number. Another compound known commonly in Germany by its number is [[parathion]], which was the 605th compound to be developed in search for insecticide. It is commonly known as [[E605]] (E stands for ''Entwicklungsnummer'' (German for &quot;development number&quot;))&lt;/ref&gt; Salvarsan was the first organic antisyphilitic, and a great improvement over the inorganic [[Mercury (element)|mercury]] compounds that had been used previously. It was distributed as a yellow, crystalline, [[hygroscopy|hygroscopic]] powder that was highly unstable in air.&lt;ref&gt;{{cite web |url=http://chestofbooks.com/health/materia-medica-drugs/American-Medical-Association/A-Handbook-of-Useful-Drugs/Salvarsan-Salvarsan-N-N-R.html |title=A Handbook of Useful Drugs |accessdate=2010-08-17 |quote= |publisher=[[American Medical Association]] |year=1913}}&lt;/ref&gt; This significantly complicated administration, as the drug had to be dissolved in several hundred milliliters of distilled, sterile water with minimal exposure to air to produce a solution suitable for injection. Some of the side effects{{which|date=November 2013}} attributed to Salvarsan were thought to be caused by improper handling and administration, causing Ehrlich, who worked assiduously to standardize practices, to observe, &quot;the step from the laboratory to the patient's bedside ... is extraordinarily arduous and fraught with danger.&quot; &lt;ref name=acs /&gt;

Ehrlich's laboratory developed a more soluble (but slightly less effective) arsenical compound, [[Neosalvarsan]] (neoarsphenamine), which was easier to prepare, and it became available in 1912. These arsenical compounds came with considerable risk of side effects, and they were supplanted as treatments for syphilis in the 1940s by [[penicillin]].

After leaving Erlich's laboratory, Hata continued parallel investigation of the new medicines in [[Japan]].&lt;ref&gt;{{cite journal|author=Izumi, Yoshio; and Isozumi, Kazuo|year=2001|url=http://www.kjm.keio.ac.jp/past/50/2/91.pdf|format=free download pdf|title=Modern Japanese medical history and the European influence|journal=Keio Journal of Medicine|volume=50|pages=91–99|pmid=11450598|issue=2|doi=10.2302/kjm.50.91}}&lt;/ref&gt;

==Mechanism==
The [[bacterium]] that causes syphilis is a [[spirochete]], ''[[Treponema pallidum]]''. Arsphenamine is not toxic to spirochetes until it has been converted to an active form by the body.

==Structure==
From Salvarsan's discovery until recently, it was believed that the structure featured an As=As [[double bond]]. However, in 2005, an extensive [[mass spectrometry|mass spectral analysis]] showed the actual structure is most likely to be a mixture of the [[cyclic compound|cyclic]] [[trimer (chemistry)|trimer]] and a [[pentamer]].&lt;ref name=&quot;pmid15624113&quot;&gt;{{cite journal |author=Lloyd NC, Morgan HW, Nicholson BK, Ronimus RS |title=The composition of Ehrlich's salvarsan: resolution of a century-old debate |journal=Angew. Chem. Int. Ed. Engl. |volume=44 |issue=6 |pages=941–4 |year=2005 |pmid=15624113 |doi=10.1002/anie.200461471}}&lt;/ref&gt;&lt;ref name=acs/&gt; The revised structure features As-As single bonds, not double bonds.

==See also==
* ''[[Dr. Ehrlich's Magic Bullet]]'', 1940 film about Ehrlich's quest to find a cure for syphilis.

==References==
{{reflist|2}}

[[Category:Antibiotics]]
[[Category:Organoarsenic compounds]]
[[Category:Phenols]]
[[Category:Amines]]
[[Category:German inventions]]
[[Category:Syphilis]]</text>
      <sha1>82i819toxfd2qt80u18edjn2tf2gkhi</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Glycyrrhizol</title>
    <ns>0</ns>
    <id>4075126</id>
    <revision>
      <id>544293633</id>
      <parentid>542789236</parentid>
      <timestamp>2013-03-15T06:11:05Z</timestamp>
      <contributor>
        <username>Addbot</username>
        <id>6569922</id>
      </contributor>
      <minor/>
      <comment>[[User:Addbot|Bot:]] Migrating 1 interwiki links, now provided by [[Wikipedia:Wikidata|Wikidata]] on [[d:q5572791]]</comment>
      <text xml:space="preserve" bytes="2308">{{chembox
| Watchedfields = changed
| verifiedrevid = 408565402
| Name=Glycyrrhizol A
| ImageFile = Glycyrrhizol A.png
| ImageSize = 200px
| IUPACName = 1-Methoxy-2,8-bis-(3-methyl-but-2-enyl)-6''H''-[1]benzofuro[3,2-c]chromene-3,9-diol
| OtherNames = 
| Section1 = {{Chembox Identifiers
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 9721048
| InChI = 1/C26H28O5/c1-14(2)6-8-16-10-18-19-13-30-23-12-21(28)17(9-7-15(3)4)25(29-5)24(23)26(19)31-22(18)11-20(16)27/h6-7,10-12,27-28H,8-9,13H2,1-5H3
| InChIKey = CBPFOSMNDISZLV-UHFFFAOYAJ
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 65976
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 522282
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C26H28O5/c1-14(2)6-8-16-10-18-19-13-30-23-12-21(28)17(9-7-15(3)4)25(29-5)24(23)26(19)31-22(18)11-20(16)27/h6-7,10-12,27-28H,8-9,13H2,1-5H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = CBPFOSMNDISZLV-UHFFFAOYSA-N
| CASNo = 877373-00-7
| PubChem = 11546269
| SMILES = o2c1c(cc(c(O)c1)C\C=C(/C)C)c3c2c4c(OC)c(c(O)cc4OC3)C\C=C(/C)C
}}
| Section2 = {{Chembox Properties
| Formula = C&lt;sub&gt;26&lt;/sub&gt;H&lt;sub&gt;28&lt;/sub&gt;O&lt;sub&gt;5&lt;/sub&gt;
| MolarMass = 420.50 g/mol
| ExactMass = 420.193674 u
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility = }}
| Section3 = {{Chembox Hazards
| MainHazards = 
| FlashPt = 
| Autoignition = }}
}}

'''Glycyrrhizol A''' is a [[prenylated]] [[pterocarpan]], a derivative of [[isoflavonoid]]s. It is a compound isolated from the root of the Chinese [[Licorice]] plant (''[[Glycyrrhiza uralensis]]'').

Recent studies by scientists from [[University of California, Los Angeles|UCLA]] have suggested that these compounds have [[antibacterial]] properties.&lt;ref&gt;{{cite journal | author= He J, Chen L, Shi W, Lu, Q-Y | title=Antibacterial Compounds from ''Glycyrrhiza uralensis'' | journal=[[Journal of Natural Products]] | volume=69| issue=1 | year=2006 | pages=121–124 | id= | doi=10.1021/np058069d | pmid= 16441081}}&lt;/ref&gt; The strongest antibacterial activity was observed against ''[[Streptococcus mutans]]'', an organism known to cause tooth decay in humans.

==References==
{{reflist}}

{{Pterocarpan}}

[[Category:Pterocarpans]]
[[Category:Antibiotics]]
[[Category:Chromenes]]

{{Natural-phenol-stub}}</text>
      <sha1>sfokm4pnnbva2p6zkeby33dd5kwup8b</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Hitachimycin</title>
    <ns>0</ns>
    <id>4166701</id>
    <revision>
      <id>568814042</id>
      <parentid>568812849</parentid>
      <timestamp>2013-08-16T16:06:34Z</timestamp>
      <contributor>
        <username>CheMoBot</username>
        <id>7377957</id>
      </contributor>
      <comment>Updating {{drugbox}} (changes to verified and watched fields - added verified revid - updated 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'CAS_number_Ref', 'Verifiedfields', 'Watchedfields', 'verifiedrevid') per [[WP:CHEMVALID|Chem/Drugbox v...</comment>
      <text xml:space="preserve" bytes="2797">{{Orphan|date=February 2009}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 447552583
| IUPAC_name = (2''Z'',4''E'',6''E'',12''E'')-16,20-dihydroxy-21-methoxy-&lt;br&gt;3-methyl-10-phenyl-9-azabicyclo[17.3.0]&lt;br&gt;docosa-2,4,6,12,19-pentaene-8,18-dione
| image = Hitachimycin.svg

&lt;!--Clinical data--&gt;
| tradename =  
| pregnancy_category =  
| legal_status =  
| routes_of_administration =  

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| metabolism =  
| excretion =  

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 77642-19-4
| ATC_prefix = none
| PubChem = 5384563
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 21106324

&lt;!--Chemical data--&gt;
| C=29 | H=35 | N=1 | O=5 
| molecular_weight = 477.592 [[Gram|g]]/[[Mole (unit)|mol]]
|  ChemSpiderID = 10306390
|  smiles = O[C@H]1CC\C=C\C[C@H](NC(=O)\C=C\C=C\C(\C)=C/[C@H]2C[C@H](OC)C(\O)=C2\C(=O)C1)c3ccccc3
|  InChI = 1/C29H35NO5/c1-20-11-9-10-16-27(33)30-24(21-12-5-3-6-13-21)15-8-4-7-14-23(31)19-25(32)28-22(17-20)18-26(35-2)29(28)34/h3-6,8-13,16-17,22-24,26,31,34H,7,14-15,18-19H2,1-2H3,(H,30,33)/b8-4+,11-9+,16-10+,20-17-/t22-,23-,24-,26-/m0/s1
|  InChIKey = PLQKHNPZPRTISL-QSQNXQFYBV
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C29H35NO5/c1-20-11-9-10-16-27(33)30-24(21-12-5-3-6-13-21)15-8-4-7-14-23(31)19-25(32)28-22(17-20)18-26(35-2)29(28)34/h3-6,8-13,16-17,22-24,26,31,34H,7,14-15,18-19H2,1-2H3,(H,30,33)/b8-4+,11-9+,16-10+,20-17-/t22-,23-,24-,26-/m0/s1
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = PLQKHNPZPRTISL-QSQNXQFYSA-N
}}
'''Hitachimycin''', also known as '''stubomycin''', is a [[Cyclic compound|cyclic]] [[polypeptide]] produced by ''[[Streptomyces]]'' that acts as an [[antibiotic]]. It exhibits cytotoxic activity against mammalian cells, [[Gram-positive]] bacteria, [[yeast]], and [[fungi]], as well as [[hemolysis|hemolytic]] activity; this is mediated by changes at the [[cell membrane]] and subsequent [[lysis]].&lt;ref&gt;{{cite journal |author=Komiyama K, Edanami K, Tanoh A, Yamamoto H, Umezawa I |title=Studies on the biological activity of stubomycin |journal=J. Antibiot. |volume=36 |issue=3 |pages=301–11 |year=1983 |pmid=6833150 |doi=}}&lt;/ref&gt; Owing to its cytotoxic activity against mammalian cells and [[tumor]]s, it was first proposed as an [[Antineoplastic|antitumor antibiotic]].&lt;ref&gt;{{cite journal |author=Umezawa I, Takeshima H, Komiyama K, Koh Y, Yamamoto H, Kawaguchi M |title=A new antitumor antibiotic, stubomycin |journal=J. Antibiot. |volume=34 |issue=3 |pages=259–65 |year=1981 |pmid=7275806 |doi=}}&lt;/ref&gt;

As of 2007, it has not been used in a clinical setting.

==References==
&lt;references/&gt;

{{Cell wall disruptive antibiotics}}

[[Category:Antibiotics]]</text>
      <sha1>oi444krkndio7swgtnn2l5suk2yx0hm</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Gramicidin S</title>
    <ns>0</ns>
    <id>2747566</id>
    <revision>
      <id>601502086</id>
      <parentid>600043004</parentid>
      <timestamp>2014-03-27T13:23:19Z</timestamp>
      <contributor>
        <ip>37.24.254.109</ip>
      </contributor>
      <text xml:space="preserve" bytes="9901">{{Drugbox
| verifiedrevid = 443848998
| IUPAC_name = Gramicidin S
| image = Gramicidin S.svg

&lt;!--Clinical data--&gt;
| tradename =  
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B / C / D / X --&gt;
| legal_AU = &lt;!-- Unscheduled / S2 / S4 / S8 --&gt;
| legal_UK = &lt;!-- GSL / P / POM / CD --&gt;
| legal_US = &lt;!-- OTC / Rx-only --&gt;
| routes_of_administration = Topical

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 113-73-5
| PubChem = 73357
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 66085
| NIAID_ChemDB = 002002
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 5530
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 373496

&lt;!--Chemical data--&gt;
| C=60 | H=92 | N=12 | O=10 
| molecular_weight = 1140.7059 g/mol
| smiles = CC(C)C[C@H]1C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN)C(C)C)Cc4ccccc4)CC(C)C)CCCN)C(C)C)Cc5ccccc5
| InChI = 1/C60H92N12O10/c1-35(2)31-43-53(75)67-45(33-39-19-11-9-12-20-39)59(81)71-29-17-25-47(71)55(77)70-50(38(7)8)58(80)64-42(24-16-28-62)52(74)66-44(32-36(3)4)54(76)68-46(34-40-21-13-10-14-22-40)60(82)72-30-18-26-48(72)56(78)69-49(37(5)6)57(79)63-41(23-15-27-61)51(73)65-43/h9-14,19-22,35-38,41-50H,15-18,23-34,61-62H2,1-8H3,(H,63,79)(H,64,80)(H,65,73)(H,66,74)(H,67,75)(H,68,76)(H,69,78)(H,70,77)/t41-,42-,43-,44-,45+,46+,47-,48-,49-,50-/m0/s1
| InChIKey = IUAYMJGZBVDSGL-XNNAEKOYBH
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C60H92N12O10/c1-35(2)31-43-53(75)67-45(33-39-19-11-9-12-20-39)59(81)71-29-17-25-47(71)55(77)70-50(38(7)8)58(80)64-42(24-16-28-62)52(74)66-44(32-36(3)4)54(76)68-46(34-40-21-13-10-14-22-40)60(82)72-30-18-26-48(72)56(78)69-49(37(5)6)57(79)63-41(23-15-27-61)51(73)65-43/h9-14,19-22,35-38,41-50H,15-18,23-34,61-62H2,1-8H3,(H,63,79)(H,64,80)(H,65,73)(H,66,74)(H,67,75)(H,68,76)(H,69,78)(H,70,77)/t41-,42-,43-,44-,45+,46+,47-,48-,49-,50-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IUAYMJGZBVDSGL-XNNAEKOYSA-N
}}
 
'''Gramicidin S''' or '''Gramicidin Soviet'''&lt;ref&gt;{{Citation | last1 = Gause | first1 = G. F. | last2 = Brazhnikova | first2 = M. G. | doi = 10.1038/154703a0 | title = Gramicidin S and its use in the Treatment of Infected Wounds | year = 1944 | pages = 703–703 | volume = 154 | journal = [[Nature (journal)|Nature]] | postscript = . | issue=3918}}&lt;/ref&gt; is an antibiotic effective against some [[Gram positive]] and [[Gram negative]] bacteria as well as some fungi. It is a derivative of [[gramicidin]], produced by the [[Gram positive]] bacterium ''Bacillus brevis''. Gramicidin S is a [[cyclodecapeptide]], constructed as two identical [[pentapeptide]]s joined head to tail, formally written as ''cyclo''(-[[valine|Val]]-[[ornithine|Orn]]-[[leucine|Leu]]-D-[[phenylalanine|Phe]]-[[proline|Pro]]-)&lt;sub&gt;2&lt;/sub&gt;. That is to say, it forms a ring structure composed of five different amino acids, each one used twice within the structure.&lt;ref&gt;

{{Citation | last=Llamas-Saiz | first = Antonio | title= Double-stranded helical twisted b-sheet channels in crystals of gramicidin S grown in the presence of trifluoroacetic and hydrochloric acids | journal = [[Acta Crystallographica Section D]] | volume = D63 | pages = 401–407 | year = 2007 | doi = 10.1107/S0907444906056435 | pmid=17327677 | last2=Grotenbreg | first2=GM | last3=Overhand | first3=M | last4=Van Raaij | first4=MJ | issue=Pt 3}}

&lt;/ref&gt; Another interesting point is that it utilizes two amino acids uncommon in [[peptide]]s: [[ornithine]] as well as the atypical [[stereoisomer]] of [[phenylalanine]]. It is synthesized by gramicidin S synthetase.&lt;ref&gt;{{Citation | last = Conti  | first = E  | title = Structural basis for the activation of phenylalanine in the non-ribosomal biosynthesis of gramicidin S  | journal = The EMBO Journal  | volume = 16  | pages = 4174–4183  | year = 1997  | doi = 10.1093/emboj/16.14.4174 | pmid = 9250661 | last2 = Stachelhaus | first2 = T | last3 = Marahiel | first3 = MA | last4 = Brick | first4 = P | issue = 14 | pmc = 1170043 }}&lt;/ref&gt;

== History ==
Gramicidin S was discovered by Russian microbiologist [[Georgyi Frantsevitch Gause]] and his wife [[Maria Brazhnikova]] in 1942. Within the year Gramicidin S was being used in Soviet military hospitals to treat infection and eventually found usage at the front lines of combat by 1946.&lt;ref name=&quot;pmid12212443&quot;&gt;{{Citation | pmid=12212443 | last1=Gall | first1=YM | last2=Konashev | first2=MB | title= The discovery of Gramicidin S: the Intellectual Transformation of G.F. Gause from Biologist to Researcher of Antibiotics and on its Meaning for the Fate of Russian Genetics | journal = [[Hist. Phil. Life Sci.]] | volume = 23 | issue=1 | pages = 137–50 | year = 2001}}&lt;/ref&gt; Gause was awarded the [[Stalin Prize]] for Medicine for his discovery in 1946. In 1944, Gramicidin S was sent by the [[Ministry of Health (Soviet Union)|Ministry of Health of the USSR]] to [[Great Britain]] via the [[International Red Cross]] in a collaborative effort to establish the exact structure. English chemist [[Richard Synge]] proved that the compound was an original antibiotic and a polypeptide using paper chromatography.&lt;ref&gt;[http://www.britannica.com/eb/article-9070753/RLM-Synge R.L.M. Synge - Britannica Online Encyclopedia&lt;!-- Bot generated title --&gt;]&lt;/ref&gt; He would later go on to receive the [[Nobel Prize]] for his work in chromatography. The crystal structure was finally established by [[Dorothy Hodgkin]] and [[Gerhard Schmidt (biologist)|Gerhard Schmidt]]; [[Margaret Thatcher]] who worked for a term in 1947 with Gerhard Schmidt on the antibiotic Gramicidin S, as an undergraduate research project.  The importance of Gramicidin S and antibiotic research in general was so great that Gause was not persecuted during the period of [[Lysenkoism]] in the USSR, while many of his colleagues were being executed. Indeed, it was his need for developing new strains to mass-produce antibiotics that allowed politically sanctioned collaborations with [[geneticist]]s like [[Joseph Rapoport]] and [[Alexander Malinovsky]], who would both actively participate in the downfall of Lysenkoism.&lt;ref name=&quot;pmid12212443&quot; /&gt;

== Structure and pharmacological effect ==
[[Image:Crystal structure of modified Gramicidin S.png|thumb|200px|left|Crystal structure of modified Gramicidin S. Modification includes [[Tert-butyloxycarbonyl protecting group|Boc groups]] on the [[ornithine]] as well as [[methylation]] of select amide nitrogens to force cyclic conformation.&lt;ref&gt;{{citation |title=Stereochemistry of Protected Ornithine Side Chains of Gramicidin S Derivatives: X-ray Crystal Structure of the Bis-Boc-tetra-N-methyl Derivative of Gramicidin S |journal=[[Journal of the American Chemical Society]] |year=2002 |issue=43 |pages=12684–12688 |doi=10.1021/ja020307t |last1=Yamada |first1=Keiichi |last2=Unno |first2=Masafumi |last3=Kobayashi |first3=Kyoko |last4=Oku |first4=Hiroyuki |last5=Yamamura |first5=Hatsuo |last6=Araki |first6=Shuki |last7=Matsumoto |first7=Hideyuki |last8=Katakai |first8=Ryoichi |last9=Kawai |first9=Masao |displayauthors=9 |volume=124 |pmid=12392415}}&lt;/ref&gt;]]
Structurally, Gramicidin S differs from [[Gramicidin|Gramicidin D]], which is a linear [[peptide]] and forms a beta helix in [[Cell membrane|cellular membrane]]s. The mode of action is not entirely agreed upon, but it is generally accepted that it is the disruption of the barrier properties of [[cellular membrane]]s which causes cell death. Recent research reveals that Gramicidin S interacts more so with [[Ion|anionic]] membranes (such as those of bacteria) vs. [[zwitterion]]ic membranes and more fluid membranes.&lt;ref&gt;{{Citation | last1 = Prenner | first1 = E. J. | last2 = Kiricsi | first2 = M | last3 = Jelokhani-Niaraki | first3 = M | last4 = Lewis | first4 = RN | last5 = Hodges | first5 = RS | last6 = McElhaney | first6 = RN | title = Structure-Activity Relationships of Diastereomeric Lysine Ring Size Analogs of the Antimicrobial Peptide Gramicidin S: MECHANISM OF ACTION AND DISCRIMINATION BETWEEN BACTERIAL AND ANIMAL CELL MEMBRANES | journal = Journal of Biological Chemistry | volume = 280 | issue = 3 | pages = 2002–2011 | year = 2004 | pmid = 15542606 | doi = 10.1074/jbc.M406509200 | postscript = . }}&lt;/ref&gt; It has a [[molecular mass]] of ca. 1,140 and is a solid, usually encapsulated in two-percent sterile spirit solution. ''[[In vitro]]'' assays show it has a [[Minimum inhibitory concentration|MIC]] of 5-15 μg/mL.&lt;ref&gt;{{Citation | last1=Xiao | first1=Jingbo | last2=Weisblum | first2=Bernard | last3=Wipf | first3=Peter | title=Electrostatic versus Steric Effects in Peptidomimicry:  Synthesis and Secondary Structure Analysis of Gramicidin S Analogues with (E)-Alkene Peptide Isosteres | journal=Journal of the American Chemical Society | volume=127 | issue=16 | pages=5742–5743 | year=2005 | pmid=15839644 | doi = 10.1021/ja051002s | postscript=. }}&lt;/ref&gt;

== Use ==
Gramicidin S has historically been employed as a topical antibiotic for the treatment of infections from superficial wounds. It exhibits strong antibiotic activity against a broad spectrum of Gram negative and Gram-positive bacteria and against several pathogenic
fungi. Like [[Gramicidin D]], Gramicidin S causes [[hemolysis]] at low concentrations, thus is not an effective drug for the treatment of systemic infections. Additionally, Gramicidin S has been employed as a spermicide and therapeutic for genital ulcers caused by [[sexually transmitted disease]].&lt;ref&gt;Krylov YuF (1993) Compendium of medicinal products of Russia. Inpharmchem Press,
Moscow, p 343 [in Russian]&lt;/ref&gt;

== References ==
{{reflist|2}}

{{Membrane proteins}}

[[Category:Antibiotics]]
[[Category:Cyclic peptides]]
[[Category:Russian inventions]]</text>
      <sha1>garirifpuz20pjbp421hn8sk3ni38c8</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Hexamethylenetetramine</title>
    <ns>0</ns>
    <id>397175</id>
    <revision>
      <id>605453145</id>
      <parentid>605376185</parentid>
      <timestamp>2014-04-23T13:39:54Z</timestamp>
      <contributor>
        <ip>139.30.123.212</ip>
      </contributor>
      <text xml:space="preserve" bytes="10981">{{chembox
| Verifiedfields = changed
| verifiedrevid = 457472844
|   ImageFileL1 = Hexamine.svg
|   ImageFileR1 = Hexamine-3D-balls.png
|IUPACName=1,3,5,7-Tetraazatricyclo[3.3.1.1&lt;sup&gt;3,7&lt;/sup&gt;]decane
|OtherNames=Hexamine; Methenamine; &lt;BR&gt;Urotropine; 1,3,5,7-
tetraazaadamantane, Formin, Aminoform
|Section1= {{Chembox Identifiers
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3959
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = J50OIX95QV
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201270
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00393
| InChI = 1/C6H12N4/c1-7-2-9-4-8(1)5-10(3-7)6-9/h1-6H2
| InChIKey = VKYKSIONXSXAKP-UHFFFAOYAW
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C6H12N4/c1-7-2-9-4-8(1)5-10(3-7)6-9/h1-6H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VKYKSIONXSXAKP-UHFFFAOYSA-N
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo=100-97-0
| EINECS=202-905-8
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 6824
| PubChem=4101
| SMILES=C1N2CN3CN1CN(C2)C3
| MeSHName=Methenamine
| ATCCode_prefix = J01
| ATCCode_suffix = XX05
  }}
|Section2= {{Chembox Properties
|  Formula=C&lt;sub&gt;6&lt;/sub&gt;H&lt;sub&gt;12&lt;/sub&gt;N&lt;sub&gt;4&lt;/sub&gt;
|  MolarMass=140.186 g/mol
|  Appearance=White crystalline solid
|  MeltingPt=
|  BoilingPt=280&amp;nbsp;°C ([[Sublimation (chemistry)|sublimes]])
|  Solubility=85.3&amp;nbsp;g/100&amp;nbsp;mL
|  Density =1.33&amp;nbsp;g/cm³ (at 20&amp;nbsp;°C)
|  pKa = 4.89&lt;ref&gt;{{cite journal|last=Cooney|first=Aidan P.|coauthors=Crampton, Michael R.; Golding, Peter|title=The acid-base behaviour of hexamine and its N-acetyl derivatives|journal=Journal of the Chemical Society, Perkin Transactions 2|year=1986|issue=6|pages=835|doi=10.1039/P29860000835}}&lt;/ref&gt; 
  }}
|Section3= {{Chembox Hazards
|  MainHazards=Highly flammable, harmful
|  FlashPtC = 250
|  AutoignitionC = 410
  }}
}}

'''Hexamethylenetetramine''' or methenamine is a [[heterocycle|heterocyclic organic compound]] with the formula (CH&lt;sub&gt;2&lt;/sub&gt;)&lt;sub&gt;6&lt;/sub&gt;N&lt;sub&gt;4&lt;/sub&gt;.  This white [[crystal]]line compound is highly soluble in water and polar organic solvents.  It has a cage-like structure similar to [[adamantane]].  It is useful in the synthesis of other chemical compounds, e.g. plastics, pharmaceuticals, rubber additives.  It [[Sublimation (chemistry)|sublimes]] in a vacuum at 280&amp;nbsp;°C. 

==Synthesis, structure, reactivity==
The compound was discovered by [[Aleksandr Butlerov]] in 1859.&lt;ref&gt;A. Butlerow (1859) [http://books.google.com/books?id=NYs8AAAAIAAJ&amp;pg=PA242#v=onepage&amp;q&amp;f=false &quot;Ueber einige Derivate des Jodmethylens&quot;] (On some derivatives of methylene iodide), ''Annalen der Chemie und Pharmacie'', vol . 111, pages 242 - 252.  In this paper, Butlerov  discovered formaldehyde, which he called &quot;Dioxymethylen&quot; (methylene dioxide) [page 247] because his empirical formula for it was incorrect (C&lt;sub&gt;4&lt;/sub&gt;H&lt;sub&gt;4&lt;/sub&gt;O&lt;sub&gt;4&lt;/sub&gt;).  On pages 249-250, he describes treating formaldehyde with ammonia gas, creating hexamine.&lt;/ref&gt;&lt;ref&gt;See also:  A. Butlerow (1860) [http://books.google.com/books?id=14lKAAAAYAAJ&amp;pg=PA322#v=onepage&amp;q&amp;f=false &quot;Ueber ein neues Methylenderivat&quot;] (On a new methylene derivative), ''Annalen der Chemie und Pharmacie'', vol. 115, no. 3, pages 322-327.&lt;/ref&gt;&lt;ref&gt;http://library.istu.edu/hoe/books/ruschem.pdf&lt;/ref&gt;

Hexamethylenetetramine is prepared industrially by combining [[formaldehyde]] and [[ammonia]].&lt;ref name=Ullmann&gt;Karsten Eller, Erhard Henkes, Roland Rossbacher, Hartmut Höke &quot;Amines, Aliphatic&quot; in ''Ullmann's Encyclopedia of Industrial Chemistry'', 2005, Wiley-VCH Verlag, Weinheim. {{DOI|10.1002/14356007.a02_001}}&lt;/ref&gt;  The reaction can be conducted in gas-phase and in solution.

The molecule has a symmetric [[tetrahedron|tetrahedral]] cage-like structure, similar to [[adamantane]], whose four &quot;corners&quot; are [[nitrogen]] atoms and &quot;edges&quot; are [[methylene bridge]]s. Although the molecular shape defines a cage, no void space is available at the interior for binding other atoms or molecules, unlike [[crown ether]]s or larger [[cryptand]] structures.

The molecule behaves like an amine base, undergoing protonation and ''N''-[[alkylation]].

===Oxidation===
When treated with [[nitric acid]], hexamine forms the explosive [[RDX]] (known chemically as cyclotrimethylenetrinitramine).&lt;ref name=Ullmann&gt;Karsten Eller, Erhard Henkes, Roland Rossbacher, Hartmut Höke &quot;Amines, Aliphatic&quot; Ullmann's Encyclopedia of Industrial Chemistry, 2000, Wiley-VCH, Weinheim. {{DOI|10.1002/14356007.a02_001}}&lt;/ref&gt;  Hexamine reacts with [[hydrogen peroxide]] to form [[hexamethylene triperoxide diamine]].&lt;ref&gt;{{cite journal|last=Schaefer|first=William P.|coauthors=Fourkas, John T.; Tiemann, Bruce G.|title=Structure of hexamethylene triperoxide diamine|journal=Journal of the American Chemical Society|date=April 1985|volume=107|issue=8|pages=2461–2463|doi=10.1021/ja00294a043}}&lt;/ref&gt; or dilute [[sulfuric acid]].{{cn|date=May 2013}}

==Applications==
The dominant use of hexamethylenetetramine is in the production of powdery or liquid preparations of [[phenolic resin]]s and phenolic [[resin]] moulding compounds, where it is added as a hardening component. These products are used as binders, e.g. in brake and clutch linings, abrasive products, non-woven textiles, formed parts produced by moulding processes, and fireproof materials.&lt;ref name=Ullmann/&gt;

===Medical uses===
As the [[mandelic acid]] salt (generic methenamine mandelate, USP&lt;ref&gt;{{cite web | url = http://www.methenaminemandelate.com/ | title = Methenamine mandelate, USP | publisher = Edenbridge Pharmaceuticals}}&lt;/ref&gt;) it is used for the treatment of urinary tract infection.  It decomposes at an acidic pH to form [[formaldehyde]] and [[ammonia]], and the formaldehyde is bactericidal; the mandelic acid adds to this effect. Urinary acidity is typically ensured by co-administering vitamin C ([[ascorbic acid]]) or [[ammonium chloride]]. Its use had temporarily been reduced in the late 1990s, due to adverse effects, particularly chemically-induced [[hemorrhagic cystitis]] in overdose,&lt;ref&gt;{{cite journal | pmid = 5410299 | year = 1970 | last1 = Ross Jr | first1 = RR | last2 = Conway | first2 = GF | title = Hemorrhagic cystitis following accidental overdose of methenamine mandelate | volume = 119 | issue = 1 | pages = 86–7 | journal = American journal of diseases of children (1960)}}&lt;/ref&gt; but its use has now been re-approved because of the prevalence of [[antibiotic resistance]] to more commonly used drugs. This drug is particularly suitable for long-term prophylactic treatment of urinary tract infection, because bacteria do not develop resistance to formaldehyde. It should not be used in the presence of renal insufficiency.{{medcn|date=May 2013}}

===Histological stains===
[[Methenamine silver stain]]s are used for [[staining]] in [[histology]], including the following types:
*[[Grocott's methenamine silver stain]], used widely as a screen for [[fungi|fungal]] [[microorganisms|organism]]s.
*[[Jones' stain]], a methenamine silver-[[Periodic acid-Schiff]] that stains for [[basement membrane]], availing to view the &quot;spiked&quot; [[Glomerular basement membrane]] associated with [[membranous glomerulonephritis]].

===Solid fuel===
Together with [[1,3,5-trioxane]], hexamethylenetetramine is a component of [[hexamine fuel tablet]]s used by campers, hobbyists, the military and relief organizations for heating camping food or military rations.  It burns smokelessly, has a high energy density (30.0&amp;nbsp;MJ/kg), does not liquify while burning, and leaves no ashes.

Standardized 0.149&amp;nbsp;g tablets of methenamine (hexamine) are used by fire-protection laboratories as a clean and reproducible fire source to test the flammability of carpets and rugs.&lt;ref name=&quot;schon&quot;/&gt;

===Food additive===
Hexamethylene tetramine or hexamine is also used as a [[food additive]] as a preservative (INS number 239). It is approved for usage for this purpose in the EU,&lt;ref&gt;UK Food Standards Agency: {{cite web |url=http://www.food.gov.uk/safereating/chemsafe/additivesbranch/enumberlist |title=Current EU approved additives and their E Numbers |accessdate=2011-10-27}}&lt;/ref&gt; where it is listed under [[E number]] E239, however it is not approved in the USA, Australia, or New Zealand.&lt;ref&gt;Australia New Zealand Food Standards Code{{cite web |url=http://www.comlaw.gov.au/Details/F2011C00827 |title=Standard 1.2.4 - Labelling of ingredients |accessdate=2011-10-27}}&lt;/ref&gt;

===Reagent in organic chemistry===
Hexamethylenetetramine is a versatile [[reagent]] in [[organic synthesis]].&lt;ref&gt;Nikola Blažzević, D. Kolbah, Branka Belin, Vitomir Šunjić, Franjo Kajfež Synthesis &quot;Hexamethylenetetramine, A Versatile Reagent in Organic Synthesis&quot; 1979; 1979(3): 161-176. {{DOI|10.1055/s-1979-28602}}&lt;/ref&gt; It is used in the [[Duff reaction]] (formylation of arenes),&lt;ref&gt;{{OrgSynth | author = A. T. Bottini, Vasu Dev, and Jane Klinck | title = Syringic Aldehyde| collvol = 4 | collvolpages = 866| year = 1963 | prep = CV4P0866}}&lt;/ref&gt; the [[Sommelet reaction]] (converting benzyl halides to aldehydes),&lt;ref&gt;{{OrgSynth | author = Kenneth B. Wiberg | title = 2-Thiophenaldehyde| collvol = 3 | collvolpages = 811| year = 1963 | prep = CV3P0811}}&lt;/ref&gt; and in the [[Delepine reaction]] (synthesis of amines from alkyl halides).&lt;ref&gt;{{OrgSynth | author = A. T. Bottini, Vasu Dev, and Jane Klinck | title = 2-Bromoallylamine| collvol = 5 | collvolpages = 121| year = 1963 | prep = CV5P0121}}&lt;/ref&gt;

===Explosives===
Hexamethylenetetramine is the base component to  produce [[RDX]] and consequently, [[C-4_(explosive)|C-4]]&lt;ref name=Ullmann/&gt; as well as Hexogen, Oktogen, hexamine dinitrate and [[Hexamethylene triperoxide diamine|HMTD]].

==Producers==
Since 1990 the number of European producers has been declining. The French SNPE factory closed in 1990; in 1993, the production of hexamethylenetetramine in [[Leuna]], Germany ceased; in 1996, the Italian facility of Agrolinz closed down; in 2001, the UK producer [[Borden (company)|Borden]] closed;  in 2006, production at Chemko, Slovak Republic, was closed. Remaining producers include INEOS in Germany, Caldic in the Netherlands, and [[Hexion]] in Italy. In the US, [[Eli Lilly and Company]] stopped producing methenamine tablets in 2002.&lt;ref name=&quot;schon&quot;&gt;Alan H. Schoen (2004), [http://www.cpsc.gov/BUSINFO/methtabs.pdf ''Re: Equialence of methenamine Tablets Standard for Flammability of Carpets and Rugs'']. U.S. Consumer product Safety Commission, Washington, DC, July 29, 2004. Many other countries who still produce this include Russia, Saudi Arabia, China and Australia.&lt;/ref&gt; In Australia, Hexamine Tablets for fuel are made by Thales Australia Ltd.

==References==
{{reflist}}

{{Other antibacterials}}

[[Category:Nitrogen heterocycles]]
[[Category:Preservatives]]
[[Category:Antibiotics]]
[[Category:Fuels]]
[[Category:Reagents for organic chemistry]]
[[Category:Corrosion inhibitors]]
[[Category:Polycyclic organic compounds]]</text>
      <sha1>0alizdm6nazw28m6le0nten0gf4z3y0</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Ethambutol</title>
    <ns>0</ns>
    <id>2702931</id>
    <revision>
      <id>606959930</id>
      <parentid>606261199</parentid>
      <timestamp>2014-05-03T23:31:20Z</timestamp>
      <contributor>
        <ip>147.126.10.148</ip>
      </contributor>
      <text xml:space="preserve" bytes="5998">{{chembox
| ImageFile = Ethambutol.svg
| ImageFile_Ref = {{chemboximage|correct|??}}
| ImageFile_Comment = Stereo, skeletal formula of ethambutol
| ImageFile2 = Ethambutol substance photo.jpg
| ImageFile3 = Ethambutol ball-and-stick.png
| OtherNames = (2''S'',2’''S'')-2,2’-(Ethane-1,2-diyldiimino)dibutan-1-ol&lt;ref&gt;{{cite web|title=ethambutol (CHEBI:4877)|url=https://www.ebi.ac.uk/chebi/searchId.do?chebiId=4877|work=Chemical Entities of Biological Interest|publisher=European Bioinformatics Institute|accessdate=26 April 2012|location=UK|date=18 August 2010|at=Main}}&lt;/ref&gt;
| Section1 = {{chembox Identifiers
|  CASNo = 74-55-5
|  CASNo_Ref = {{cascite|correct|??}}
|  PubChem = 14052
|  PubChem_Ref = {{pubchemcite|correct|pubchem}}
|  ChemSpiderID = 13433
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
|  UNII = 8G167061QZ
|  UNII_Ref = {{fdacite|correct|FDA}}
|  EINECS = 200-810-26
|  DrugBank = DB00330
|  DrugBank_Ref = {{drugbankcite|correct|drugbank}}
|  KEGG = D07925
|  KEGG_Ref = {{keggcite|correct|kegg}}
|  MeSHName = Ethambutol
|  ChEBI = 4877
|  ChEBI_Ref = {{ebicite|correct|EBI}}
|  ChEMBL = 44884
|  ChEMBL_Ref = {{ebicite|correct|EBI}}
|  ATCCode_prefix = J04
|  ATCCode_suffix = AK02
|  SMILES = CC[C@@H](CO)NCCN[C@@H](CC)CO
|  StdInChI = 1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1
|  StdInChI_Ref = {{stdinchicite|correct|chemspider}}
|  StdInChIKey = AEUTYOVWOVBAKS-UWVGGRQHSA-N
|  StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
}}
| Section2 = {{chembox Properties
|  C = 10
|  H = 24
|  N = 2
|  O = 2
|  Appearance = White crystals
|  Odor = Odourless
|  LogP = −0.291
}}
| Section3 = {{chembox Pharmacology
|  AdminRoutes = Oral
|  Metabolism = Hepatic
|  HalfLife = 3–4 hours
|  ProteinBound = 20–30%
|  Excretion = Renal
|  PregCat = B
}}
| Section4 = {{chembox Related
|  OtherCpds = {{unbulleted list|[[ethylenediamine]]|[[TMEDA]]}}
}}
}}

'''Ethambutol''' (commonly abbreviated '''EMB''' or simply '''E''') is a [[bacteriostatic]] [[antimycobacterial]] [[drug]] prescribed to treat [[tuberculosis]].&lt;ref name=&quot;pmid18242089&quot;&gt;{{cite journal |author=Yendapally R, Lee RE |title=Design, synthesis, and evaluation of novel ethambutol analogues |journal=Bioorg. Med. Chem. Lett. |volume=18 |issue=5 |pages=1607–11 |date=March 2008 |pmid=18242089 |pmc=2276401 |doi=10.1016/j.bmcl.2008.01.065 |url=http://linkinghub.elsevier.com/retrieve/pii/S0960-894X(08)00082-6}}&lt;/ref&gt;  It is usually given in combination with other [[Tuberculosis treatment|tuberculosis drugs]], such as [[isoniazid]], [[rifampicin]] and [[pyrazinamide]].

&lt;!-- Medical uses --&gt;
Ethambutol is used along with other medications to treat a number of infections including: [[tuberculosis]], ''[[Mycobacterium avium complex]]'', and ''[[Mycobacterium kansasii]]''.&lt;ref name=AHFS2014&gt;{{cite web | title = Ethambutol Hydrochloride
 | url = http://www.drugs.com/monograph/ethambutol-hydrochloride.html | work = The American Society of Health-System Pharmacists | accessdate = 24 April 2014 }}&lt;/ref&gt;

&lt;!-- Adverse effects --&gt;
It can cause problems with vision, liver problems and allergies among other side effects.&lt;ref name=AHFS2014/&gt; It is [[pregnancy category]] C  in the United States due to concerns with eye issues and category A in Australia meaning that they did not find evidence of harm after being taken by many pregnant women.&lt;ref name=AHFS2014/&gt;&lt;ref&gt;{{cite web|title=Prescribing medicines in pregnancy database|url=http://www.tga.gov.au/hp/medicines-pregnancy.htm#.U1Yw8Bc3tqw|work=Australian Goverment|accessdate=22 April 2014|date=3 March 2014}}&lt;/ref&gt; It is reasonable to use during breast feeding if required.&lt;ref name=AHFS2014/&gt;

&lt;!-- Society and culture --&gt;
It is sold under the trade names '''Myambutol''' and '''Servambutol'''. It is on the [[World Health Organization's List of Essential Medicines]], a list of the most important medication needed in a basic [[health system]].&lt;ref&gt;{{cite web|title=WHO Model List of EssentialMedicines|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|work=World Health Organization|accessdate=22 April 2014|date=October 2013}}&lt;/ref&gt;

==Medical uses==
Ethambutol is used along with other medications to treat a number of infections including: [[tuberculosis]], ''[[Mycobacterium avium complex]]'', and ''[[Mycobacterium kansasii]]''.&lt;ref name=AHFS2014/&gt;

==Adverse effects==
* [[Optic neuritis]]&lt;ref name=&quot;pmid16710500&quot;&gt;{{cite journal |author=Lim SA |title=Ethambutol-associated optic neuropathy |journal=Ann. Acad. Med. Singap. |volume=35 |issue=4 |pages=274–8 |date=April 2006 |pmid=16710500 |doi= |url=http://www.annals.edu.sg/pdf/35VolNo4200605/V35N4p274.pdf}}&lt;/ref&gt; (hence contraindicated in children below six years of age)
* [[Red-green colour blindness]]
* [[Peripheral neuropathy]]
* [[Arthralgia]]
* [[Hepatotoxicity]]
* Hyperuricaemia
* Vertical [[pathologic nystagmus|nystagmus]]
* Milk skin reaction

==Mechanism of action==
Ethambutol is [[bacteriostatic]] against actively growing TB bacilli. It works by obstructing the formation of [[cell wall]]. [[Mycolic acid]]s attach to the 5'-hydroxyl groups of [[arabinose|&lt;small&gt;D&lt;/small&gt;-arabinose]] residues of [[arabinogalactan]] and form mycolyl-arabinogalactan-peptidoglycan complex in the cell wall. It disrupts arabinogalactan synthesis by inhibiting the enzyme [[arabinosyl transferase]]. Disruption of the arabinogalactan synthesis inhibits the formation of this complex and leads to increased permeability of the cell wall.

==Pharmacokinetics==
It is well absorbed from the [[gastrointestinal tract]] and well distributed in body tissues and fluids.  50% is excreted unchanged in urine.

==References==
{{reflist}}

==External links==
*[http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682550.html Medline Plus drug information]

{{antimycobacterials}}

[[Category:Antibiotics]]
[[Category:Tuberculosis]]
[[Category:World Health Organization essential medicines]]
[[Category:Alcohols]]</text>
      <sha1>hvyguiuxrs2pizq6ilgfinn1kfkn20m</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Nonribosomal peptide</title>
    <ns>0</ns>
    <id>1118963</id>
    <revision>
      <id>540633847</id>
      <parentid>535567622</parentid>
      <timestamp>2013-02-26T14:22:57Z</timestamp>
      <contributor>
        <username>Addbot</username>
        <id>6569922</id>
      </contributor>
      <minor/>
      <comment>[[User:Addbot|Bot:]] Migrating 7 interwiki links, now provided by [[Wikipedia:Wikidata|Wikidata]] on [[d:q1443801]] ([[User talk:Addbot|Report Errors]])</comment>
      <text xml:space="preserve" bytes="10982">'''Nonribosomal peptide'''s (NRP) are a class of [[peptide]] [[secondary metabolites]], usually produced by [[microorganism]]s like [[bacterium|bacteria]] and [[fungi]]. Nonribosomal peptides are also found in higher organisms, such as [[nudibranch]]s, but are thought to be made by bacteria [[commensalism|inside]] these organisms.{{Citation needed|date=December 2007}}  While there exist a wide range of peptides that are not synthesized by [[ribosome]]s, the term ''nonribosomal peptide'' typically refers to a very specific set of these as discussed in this article.

Nonribosomal peptides are synthesized by '''nonribosomal peptide synthetases''', which, unlike the [[ribosome]]s, are independent of [[messenger RNA]]. Each nonribosomal peptide synthetase can synthesize only one type of peptide. Nonribosomal peptides often have a [[cyclic compound|cyclic]] and/or branched structures, can contain non-[[proteinogenic]] [[amino acid]]s including &lt;small&gt;D&lt;/small&gt;-amino acids, carry modifications like ''[[Nitrogen|N]]''-methyl and ''N''-formyl groups, or are [[Glycosylation|glycosylated]], [[Acylation|acylated]], [[Halogenation|halogenated]], or [[Hydroxylation|hydroxylated]].  Cyclization of amino acids against the peptide &quot;backbone&quot; is often performed, resulting in [[oxazoline]]s and [[thiazoline]]s; these can be further oxidized or reduced.  On occasion, dehydration is performed on [[serine]]s, resulting in [[dehydroalanine]].  This is just a sampling of the various manipulations and variations that nonribosomal peptides can perform. Nonribosomal peptides are often [[protein dimer|dimer]]s or [[protein trimer|trimer]]s of identical sequences chained together or cyclized, or even branched.

Nonribosomal peptides are a very diverse family of natural products with an extremely broad range of biological activities and pharmacological properties. They are often toxins, [[siderophore]]s, or [[pigment]]s. Nonribosomal peptide [[antibiotic]]s, [[cytostatic]]s, and [[immunosuppressant]]s are in commercial use.

==Examples==

* [[Antibiotic]]s
** [[Actinomycin]]
** [[Bacitracin]]
** [[Calcium dependent antibiotic]]
** [[Daptomycin]]
** [[Vancomycin]]
** [[Tyrocidine]]
** [[Gramicidin]]
** [[Zwittermicin A]]
* [[Antibiotic]] precursors
** [[Penicillin|ACV-Tripeptide]]
* [[Cytostatic]]s
** [[Epothilone]]
** [[Bleomycin]]
* [[Immunosuppressant]]s
** [[Ciclosporin]] (Cyclosporine A)
* [[Siderophore]]s
** [[Enterobactin]]
** [[Myxochelin A]]
* [[Pigment]]s
** [[Indigoidine]]
* [[Toxin]]s
** [[Microcystin]]s and
** [[Nodularin]]s, [[cyanotoxin]]s from [[cyanobacteria]].
* Nitrogen storage polymers
** [[Cyanophycin]] - produced by some [[cyanobacteria]]
* Phytotoxins
** HC-toxin - a virulence factor made by the plant pathogenic fungus ''[[Cochliobolus]] (Helminthosporium) carbonum''&lt;ref&gt;{{cite journal | author = J.D. Walton | year = 2006 | journal = Phytochemistry | volume = 67 | pages = 1406–1413 | url = http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TH7-4KCXJJD-2&amp;_user=1111158&amp;_rdoc=1&amp;_fmt=&amp;_orig=search&amp;_sort=d&amp;view=c&amp;_acct=C000051676&amp;_version=1&amp;_urlVersion=0&amp;_userid=1111158&amp;md5=7140334d685f86282facf3886a203c33 | pmid = 16839576 | doi = 10.1016/j.phytochem.2006.05.033 | title = HC-toxin | issue = 14}}&lt;/ref&gt;
** AM-toxin - made by the plant pathogenic fungus ''[[Alternaria]] alternata'' pv. ''Mali''&lt;ref&gt;{{cite journal | author = R.D. Johnson, L. Johnson, Y. Itoh, M. Kodama, H. Otani, and K. Kohmoto | year = 2000 | journal = Molecular Plant-Microbe Interactions | volume = 13 | pages = 742–753 | url = http://apsjournals.apsnet.org/doi/abs/10.1094/MPMI.2000.13.7.742?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dncbi.nlm.nih.gov | pmid = 10875335 | doi = 10.1094/MPMI.2000.13.7.742 | title = Cloning and Characterization of a Cyclic Peptide Synthetase Gene from Alternaria alternata Apple Pathotype Whose Product Is Involved in AM-Toxin Synthesis and Pathogenicity | issue = 7}}&lt;/ref&gt;
** victorin - a chlorinated cyclic pentapeptide made by the pathogenic fungus ''[[Cochliobolus]] victoriae''. Its nonribosomal synthesis has not been established.

== Biosynthesis ==

Nonribosomal peptides are synthesized by one or more specialized nonribosomal peptide-synthetase (NRPS) [[enzyme]]s. The NRPS genes for a certain peptide are usually organized in one [[operon]] in bacteria and in [[gene cluster]]s in [[eukaryote]]s. However the first fungal NRP to be found was [[ciclosporin]]. It is synthesized by a single 1.6MDa NRPS.&lt;ref&gt;K. Turgay, M. Krause and M. A. Marahiel, Mol. Microbiol., 1992, 6, 529.&lt;/ref&gt; The enzymes are organized in modules that are responsible for the introduction of one additional amino acid. Each module consists of several domains with defined functions, separated by short spacer regions of about 15 amino acids. 

The [[biosynthesis]] of nonribosomal peptides shares characteristics with the [[polyketide]] and [[fatty acid]] biosynthesis. Due to these structural and mechanistic similarities, some nonribosomal peptide synthetases contain [[polyketide|polyketide synthase]] modules for the insertion of [[acetate]] or [[propionic acid|propionate]]-derived subunits into the peptide chain.

=== Modules ===

The order of modules and domains of a complete nonribosomal peptide synthetase is as follows:

* ''Initiation'' or ''Starting'' module: [F/NMT]-A-PCP-
* ''Elongation'' or ''Extending'' modules: -(C/Cy)-[NMT]-A-PCP-[E]-
* ''Termination'' or ''Releasing'' module: -(TE/R)

(Order: [[N-terminus]] to [[C-terminus]]; ''[]'': optionally; ''()'': alternatively)

=== Domains ===

* F: Formylation (optional)
* A: Adenylation (required in a module)
* [[Peptidyl carrier protein|PCP]]: Thiolation and Peptide Carrier Protein with attached 4'-phospho-pantetheine (required in a module)
* C: Condensation forming the amide bond (required in a module)
* Cy: Cylization into thiazoline or oxazolines (optional)
* Ox: Oxidation of thiazolines or oxazolines to thiazoles or oxazoles (optional)
* Red: Reduction of thiazolines or oxazolines to thiazolidines or oxazolidines (optional)
* E: Epimerization into D-amino acids (optional)
* NMT: ''N''-methylation (optional)
* TE: Termination by a thio-esterase (only found once in a NRPS)
* R: Reduction to terminal aldehyde or alcohol (optional)

=== Starting stage ===

* Loading: The first amino acid is activated with [[adenosine triphosphate|ATP]] as a mixed [[acyl]]-[[phosphoric acid]] [[anhydride]] with [[adenosine monophosphate|AMP]] by the A-domain and loaded onto the [[serine]]-attached 4'-phospho-[[pantethine]] (4'PP) sidechain of the PCP-domain catalyzed by the PCP-domain (thiolation) .

* Sometimes the amino group of the bound amino acid is [[Formylation|formylated]] by an F-domain or [[Methylation|methylated]] by an NMT-domain.

===Elongation stages===

* Loading: Analogous to the starting stage, each module loads its specific amino acid onto its PCP-domain.

* [[Condensation]]: The C-domain catalyzes the [[amide]] [[Chemical bond|bond]] formation between the [[thioester]] group of the growing peptide chain from the previous module with the amino group of the current module. The extended peptide is now attached to the current PCP-domain.

* [[Condensation]]-[[Cyclization]]: Sometimes the C-domain is replaced by a Cy-domain, which, in addition to the amide bond formation, catalyzes the reaction of the [[serine]], [[threonine]], or [[cysteine]] sidechain with the amide-''[[Nitrogen|N]]'', thereby forming [[oxazolidine]]s and [[thiazolidine]], respectively.

* [[Epimerization]]: Sometimes an E-domain epimerizes the innermost amino acid of the peptide chain into the [[D-configuration]].

* This cycle is repeated for each elongation module.

=== Termination stage ===

* Termination: The TE-domain (thio-esterase domain) [[Hydrolysis|hydrolyzes]] the completed polypeptide chain from the ACP-domain of the previous module, thereby often forming cyclic amides ([[lactam]]s) or cyclic [[ester]]s ([[lactone]]s).

* Also, the peptide can be released by an R-domain that [[Redox|reduces]] the thioester bond to terminal [[aldehyde]] or [[alcohol]].

=== Processing===

The final peptide is often modified, e.g., by [[glycosylation]], [[acylation]], [[halogenation]], or [[hydroxylation]]. The responsible enzymes are usually associated to the synthetase complex and their genes are organized in the same [[operon]]s or [[gene cluster]]s.

===Priming and Deblocking===

To become functional, the 4'-phospho-pantetheine sidechain of [[coenzyme A|acyl-CoA]] molecules has to be attached to the PCP-domain by 4'PP transferases (Priming) and the [[Sulfur|S]]-attached [[acyl]] group has to be removed by specialized associated thioesterases (TE-II) (Deblocking).

=== Substrate specificities ===

Most domains have a very broad [[substrate (biochemistry)|substrate]] [[Specificity (tests)|specificity]] and usually only the A-domain determines which amino acid is incorporated in a module. Ten amino acids that control substrate specificity and can be considered the '[[codons]]' of nonribosomal peptide synthesis have been identified.  The [[condensation domain|condensation C-domain]] is also believed to have substrate specificity, especially if located behind an epimerase E-domain-containing module where it functions as a 'filter' for the epimerized [[isomer]].

== Mixed with Polyketides ==

Due to the similarity with polyketide synthetases (PKS), many secondary metabolites are, in fact, fusions of NRPs and polyketides.  In essence, this occurs when PK modules follow NRP modules, and vice versa.  Although there is high degree of similarity between the PCP domains of both types of sythetases, the mechanism of condensation is different from a chemical standpoint (claisen vs. transamidation).

* [[Epothilone]]

== See also ==

* [[Esterase]]
* [[Polyketide]]

== Literature ==

* {{cite journal | author = Dirk Schwarzer, Robert Finking, and Mohamed A. Marahiel | journal = [[Nat. Prod. Rep.]] | doi = 10.1039/b111145k | title = Nonribosomal peptides: from genes to products | year = 2003 | volume = 20 | pages = 275–87 | pmid=12828367 | issue = 3}}

* {{cite journal | author = Mohamed A. Marahiel, Torsten Stachelhaus, and Henning D. Mootz | doi = 10.1021/cr960029e | title = Modular Peptide Synthetases Involved in Nonribosomal Peptide Synthesis | year = 1997 | journal = [[Chem. Rev.]] | volume = 97 | pages = 2651–2674 | pmid=11851476 | issue = 7}}

* {{cite journal | author = Segolene Caboche, Maude Pupin, Valerie Leclere, Arnaud Fontaine, Philippe Jacques and Gregory Kucherov | doi = 10.1093/nar/gkm792 | title = NORINE: a database of nonribosomal peptides | year = 2008 | journal = [[Nucleic Acids Research]] | volume = 36(Database issue) | pages = D326–31 | pmid = 17913739 | issue = Database issue | pmc = 2238963}}

==References==

{{reflist|2}}

[[Category:Molecular biology]]
[[Category:Enzymes]]
[[Category:Glycopeptide antibiotics]]
[[Category:Antibiotics]]
[[Category:Peptides]]</text>
      <sha1>1hbi605phbzv1d6jlxcv8s9m58qttot</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Tyrocidine</title>
    <ns>0</ns>
    <id>5606788</id>
    <revision>
      <id>598427713</id>
      <parentid>598426199</parentid>
      <timestamp>2014-03-06T17:55:53Z</timestamp>
      <contributor>
        <username>CheMoBot</username>
        <id>7377957</id>
      </contributor>
      <comment>Updating {{chembox}} (no changed fields - added verified revid - updated 'CASNo_Ref', 'Watchedfields', 'verifiedrevid') per [[WP:CHEMVALID|Chem/Drugbox validation]] (report [[Wikipedia_talk:WikiProject_Chemicals|errors]] or [[user talk:CheMoBot|bugs]])</comment>
      <text xml:space="preserve" bytes="11495">{{chembox
| verifiedrevid = 451504941
|ImageFile= Tyrocidine A.svg
|ImageSize= 300px
|IUPACName= 3-((3''S'',6''R'',9''S'',12''S'',15''S'',
18''S'',21''S'',24''S'',27''R'',32a''S'')
-9-(2-amino-2-oxoethyl)-
21-(3-aminopropyl)-
3,6,27-tribenzyl-15-
(4-hydroxybenzyl)-24-isobutyl-
18-isopropyl-
1,4,7,10,13,16,19,22,25,28-
decaoxodotriacontahydropyrrolo[1,2-a]
[1,4,7,10,13,16,19,22,25,28]
decaazacyclotriacontin-
12-yl)propanamide
|Section1={{Chembox Identifiers
|  CASNo_Ref = {{cascite|correct|??}}
| CASNo= 8011-61-8
|  PubChem= 16129635
  }}
|Section2={{Chembox Properties
|  Formula=C&lt;sub&gt;66&lt;/sub&gt;H&lt;sub&gt;87&lt;/sub&gt;N&lt;sub&gt;13&lt;/sub&gt;O&lt;sub&gt;13&lt;/sub&gt;
|  MolarMass=1270.47628
  }}
}}

'''Tyrocidine''' is a mixture of cyclic decapeptides produced by the bacteria ''[[Bacillus brevis]]'' found in soil.  It can be composed of 4 different amino acid sequences, giving tyrocidine A–D (See figure 1).    Tyrocidine is the major constituent of [[tyrothricin]], which also contains [[gramicidin]].&lt;ref name= &quot;pcid16129635&quot;&gt;Pubchem: Tyrocidine and Tyrothricin.{{cite web |url=http://www.ncbi.nlm.nih.gov/sites/entrez?term=16129635%5Buid%5D&amp;cmd=search&amp;db=pccompound |title=PubChem Compound Result |format= |work= |accessdate=}}&lt;/ref&gt;  Tyrocidine was the first commercially available antibiotic, but has been found to be toxic toward human blood and reproductive cells.  The function of tyrocidine within its host ''B. brevis'' is thought to be regulation of [[sporulation]].&lt;ref name=&quot;pmid9352938&quot;&gt;{{cite journal |author=Mootz HD, Marahiel MA |title=The tyrocidine biosynthesis operon of Bacillus brevis: complete nucleotide sequence and biochemical characterization of functional internal adenylation domains |journal=J. Bacteriol. |volume=179 |issue=21 |pages=6843–50 |date=November 1997 |pmid=9352938 |doi= |url=http://jb.asm.org/cgi/pmidlookup?view=long&amp;pmid=9352938 |pmc=179617}}&lt;/ref&gt;
[[Image:TyrocidineA-D.png|450px|thumb|left|Figure 1: a) Amino acid sequence of tyrocidine A. b) Sequence changes for the 4 types of tyrocidine.]]

Tyrocidines A, B, and C are cyclic decapeptides. The biosynthesis of tyrocidine involves three enzymes. Parts of its sequence are identical to [[gramicidin]] S.

==History==

In 1939, the American microbiologist [[René Dubos]] discovered the soil microbe ''Bacillus brevis''.  He observed the ability of the microbe to decompose the capsule of [[pneumococcus]] bacterium, rendering it harmless.  From the soil microbe ''B. brevis'', he isolated [[tyrothricin]], which had a high toxicity to a large range of bacteria.  Tyrothricin was later found to be a mixture of the peptides gramicidin and tyrocidine.  These were observed to have toxic effects in red blood cells and reproductive cells in humans, however, if applied externally as an ointment tyrocidine could also be used as a potent antimicrobial agent.&lt;ref&gt;{{cite encyclopedia
  | title =Antibiotics
  | encyclopedia = The Columbia Electronic Encyclopedia
  | volume = 6th ed.
  | pages = online
  | publisher = Columbia University Press
  | year = 2007
  | id =
  | accessdate = May 2008}}&lt;/ref&gt;
Dubos's discovery helped revive interest in research on [[penicillin]].

==Mechanism of action==

Tyrocidine has a unique mode of action in which it disrupts the cell membrane function, making it a favorable target for engineering derivatives.&lt;ref name=&quot;pmid12857101&quot;&gt;{{cite journal |author=Qin C, Bu X, Wu X, Guo Z |title=A chemical approach to generate molecular diversity based on the scaffold of cyclic decapeptide antibiotic tyrocidine A |journal=J Comb Chem |volume=5 |issue=4 |pages=353–5 |year=2003 |pmid=12857101 |doi=10.1021/cc0300255 |url=}}&lt;/ref&gt;  Tyrocidine appears to perturb the lipid bilayer of a microbe’s inner membrane by permeating the lipid phase of the membrane.  The exact affinity and location of tyrocidine within the phospholipid bilayer is not yet known.&lt;ref&gt;{{cite journal |author=Prenner EJ, Lewis RN, McElhaney RN |title=The interaction of the antimicrobial peptide gramicidin S with lipid bilayer model and biological membranes |journal=Biochim. Biophys. Acta |volume=1462 |issue=1–2 |pages=201–21 |date=December 1999 |pmid=10590309 |doi= 10.1016/S0005-2736(99)00207-2|url=http://linkinghub.elsevier.com/retrieve/pii/S0005-2736(99)00207-2}}&lt;/ref&gt;

==Biosynthesis==

The biosynthesis of Tyrocidine is similar to Gramicidin S, and is achieved through the use of [[Nonribosomal_peptide|nonribosomal protein]] synthetases (NRPSs).&lt;ref name=&quot;pmid17653357&quot;&gt;{{cite journal |author=Kopp F, Marahiel MA |title=Macrocyclization strategies in polyketide and nonribosomal peptide biosynthesis |journal=Nat Prod Rep |volume=24 |issue=4 |pages=735–49 |date=August 2007 |pmid=17653357 |doi=10.1039/b613652b |url=}}&lt;/ref&gt;   Its biosynthesis is via an enzymatic assembly consisting of 3 peptide synthetase proteins, TycA, TycB, and TycC, which contain 10 modules.  The different tyrocidine analogues (A–D) are not produced by different enzymes, but rather by an enzyme system that is capable of incorporating different amino acids of structural similarity at specified sites.  The amino acid sequence is determined by the organization of the enzyme and not by any RNA template.&lt;ref&gt;{{cite journal |author=Roskoski R, Gevers W, Kleinkauf H, Lipmann F |title=Tyrocidine biosynthesis by three complementary fractions from Bacillus brevis (ATCC 8185) |journal=Biochemistry |volume=9 |issue=25 |pages=4839–45 |date=December 1970 |pmid=4320358 |doi= 10.1021/bi00827a002|url=}}&lt;/ref&gt;
[[Image:Tyrocidine operon.png|300px|thumb|left|Figure 2: The tyrocidine operon]]
The tyrocine synthetases TycA, TycB, and TycC are encoded on the tyrocine operon.  This consists of the three genes encoding for the three synthetases as well as three additional [[open reading frames]] (ORFs).  These ORFs, labeled as TycD, TycE, and TycF are downstream of the three synthetase genes (see figure 2).  TycD &amp;TycE have the highest similarity to members of the [[ATP-binding cassette]] (ABC) transporter family which aid in the transport of substrates across a membrane.  It has been suggested that the tandem transporters play a role in conferring resistance in the producer cell through tyrocidine secretion.   TycF has been identified as a thioesterase (TE) and is similar to other TEs in bacterial operons used for encoding peptide synthetases.  However, the precise function of these TEs remains unknown.&lt;ref name=&quot;pmid9352938&quot;/&gt;  The size of the peptide synthetases corresponds to the amount of activation they carry out.   TycA is the smallest and activates a single amino acid from one module, TycB is intermediate in size and activates 3 amino acids with 3 modules, and TycC is the largest and activates 6 amino acids with 6 modules (See figure 3).&lt;ref name=&quot;pmid9352938&quot;/&gt;
[[Image:Tyrocidine domain organization.png|200px|center|frame|Figure 3: Modules and Domains for Tyrocidine biosynthesis]]
Each module performs all the catalytic reactions necessary to incorporate a single amino acid onto the peptide chain.  This is accomplished through the subdomains for adenylation (A), peptityl carrier protein (PCP), condensation (C), and depending on the amino acid position, an [[epimerization]] (E). The adenylation subdomain is used in activating the specific amino acid.  Each module uses one molecule of the selected substrate amino acid with one molecule of [[Adenosine triphosphate|ATP]] to give an aminoacyl adenylate enzyme complex and pyrophosphate.  The activated amino acid can then be transferred to the enzyme bound 4'-[[phosphopantetheine]] of the carrier protein with the expulsion of [[Adenosine monophosphate|AMP]] from the system.  The carrier protein uses the 4'-phosphopantetheine prosthetic group for loading of the growing peptide and their monomer precursors.&lt;ref name=&quot;pmid12167866&quot;&gt;{{cite journal |author=Kohli RM, Walsh CT, Burkart MD |title=Biomimetic synthesis and optimization of cyclic peptide antibiotics |journal=Nature |volume=418 |issue=6898 |pages=658–61 |date=August 2002 |pmid=12167866 |doi=10.1038/nature00907 |url=}}&lt;/ref&gt; Elongation of the peptide chain is achieved through condensation of the upstream PCP onto an adjacent downstream PCP-bound monomer. In certain domains you will find modification subdomains, such as the E subdomain seen in domains 1 and 4 in tyrocidine, which will generate the D-configured amino acid.  On the final module is the TE domain used as a catalyst for cyclization or product release.  The release of the product from the carrier protein is achieved through acylation of the active site serine of TE in which the decapeptide is transferred from the thiol ether to the serine residue.  Deacylation can then occur through intramolecular cyclization or through hydrolysis to give the cyclic or linear product respectively (See figure 4). [[Image:Tyrocidine cyclization.png|500px|thumb|right|Figure 4: Proposed cyclization reaction catalyzed by thioesterase]]
In the case of tyrocidine, ring closure has been shown to be highly favorable due to 4 H-bonds helping the decapeptide backbone to adopt a stable conformation (See figure 5).&lt;ref name=&quot;pmid12857101&quot;/&gt;&lt;ref name=&quot;pmid12167866&quot;/&gt;  This intramolecular cyclization occurs in a head-to-tail fashion involving the N-terminus of the &lt;small&gt;D&lt;/small&gt;-Phe1 and the C-terminus of the &lt;small&gt;L&lt;/small&gt;-Leu10 (See figure 4).&lt;ref name=&quot;pmid17653357&quot;/&gt;&lt;ref&gt;{{cite journal |author=Trauger JW, Kohli RM, Mootz HD, Marahiel MA, Walsh CT |title=Peptide cyclization catalysed by the thioesterase domain of tyrocidine synthetase |journal=Nature |volume=407 |issue=6801 |pages=215–8 |date=September 2000 |pmid=11001063 |doi=10.1038/35025116 |url=}}&lt;/ref&gt;
[[Image:Tyrocidine H-bonding.png|300px|center|thumb|Figure 5: Hydrogen-bonding illustrating stabilizing effects of cyclization]]

==Chemoenzymatic strategies==
There is no chemical solution for macrocyclization of a peptide chain.  Isolated tyrocidine (Tyc) TE domains can be used to cyclize chemically derived peptidyl-thioester substrates, providing a powerful route to new cyclic compounds.  In order for this macrocyclization to occur, the peptide chain must be activated at its C-terminus with an ''N''-acethylcysteamine (SNAC) [[leaving group]].&lt;ref name=&quot;pmid17653357&quot;/&gt;  An [[alanine scan]] through the 10 positions of tyrocidine shows that only the &lt;small&gt;D&lt;/small&gt;-Phe and &lt;small&gt;L&lt;/small&gt;-Orn are required for sufficient cyclization.
Tyc TE can also be used biomimetically in which it mimics the environment created by the TE domain with the substrate’s PCP through use of a synthetic tether linked to a [[polyethylene glycol]] (PEG) amide resin.&lt;ref name=&quot;pmid12167866&quot;/&gt;  Use of this resin bound to a desired substrate with isolated TE can allow for catalytic release of the resin as well as macrocyclization of the substrate (See figure 6 &lt;ref name=&quot;pmid12167866&quot;/&gt;).  Use of [[solid phase peptide synthesis]] (SPPS) allowed the incorporation of a diverse array of monomers into the peptide chain.  Later studies used the high tolerance of Tyc TE in order to modify the peptide backbone post-synthetically.  This also allowed for glycosylation of the tyrosine or serine residues to be incorporated.&lt;ref name=&quot;pmid17653357&quot;/&gt;  Use of these methods has led to many promising new therapeutic agents.{{Citation needed|date=September 2011}}[[Image:Tyrocidine syn.png|600px|thumb|center|Figure 6: Biomimetic macrocyle synthesis.]]

==References==

&lt;references/&gt;

==External links==
* {{MeshName|Tyrocidine}}

[[Category:Antibiotics]]</text>
      <sha1>dgr820rvocp8jvaocppqg7251paw39h</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Ceragenin</title>
    <ns>0</ns>
    <id>4001307</id>
    <revision>
      <id>607376826</id>
      <parentid>607376607</parentid>
      <timestamp>2014-05-06T19:53:08Z</timestamp>
      <contributor>
        <username>Gogo Dodo</username>
        <id>1257855</id>
      </contributor>
      <comment>Rm, per [[WP:EL]]</comment>
      <text xml:space="preserve" bytes="3179">{{Update |date=January 2014}}
'''Ceragenins''', or '''cationic selective antimicrobials''' (CSAs), are synthetically produced small molecule chemical compounds consisting of a [[sterol]] backbone with [[amino acids]] and other chemical groups attached to them. These compounds have a net positive charge that is electrostatically attracted to the negatively charged cell membranes of certain viruses, fungi and bacteria. CSAs have a high binding affinity for such membranes (including [[Lipid A]]&lt;ref&gt;Ding B., Yin N., Liu Y., Cardenas-Garcia J., Evanson R., Orsak T., Fan M., Turin G., and Savage P.B.: [http://dx.doi.org/10.1021/ja046909p Origins of Cell Selectivity of Cationic Steroid Antibiotics] ''J. Am. Chem. Soc.'', 126(42), 13642 -13648, 2004.&lt;/ref&gt;) and are able to rapidly disrupt the target membranes leading to rapid cell death. While CSAs have a mechanism of action that is also seen in antimicrobial peptides, which form part of the body's innate immune system, they avoid many of the difficulties associated with their use as medicines.&lt;ref name=&quot;press&quot;&gt;{{cite web |url=http://www.csa54.info/ceragenix-pharmaceuticals/article1.html |title=Vanderbilt University, Brigham Young University, and Ceragenix Pharmaceuticals Report Novel Drug Compound Kills Multiple HIV Strains; Synthetic Small Molecule Acts Through Unique Strain-Independent Virucidal Mechanism |publisher=Ceragenix Pharmaceuticals |date=2006-02-06 |accessdate=2006-03-24 }}&lt;/ref&gt;

[[Image:CSA-8.png|right|frame|CSA-8, member of Ceragenin family]]
Ceragenins were invented by Dr. [[Paul B. Savage]] of [[Brigham Young University]]'s Department of Chemistry and Biochemistry. In data previously presented by Dr. Savage and other researchers, CSAs have been shown to have broad spectrum antibacterial activity.&lt;ref&gt;{{cite journal |url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12445638&amp;dopt=Abstract |title=Antibacterial properties of cationic steroid antibiotics |authors=Savage PB, Li C, Taotafa U, Ding B, Guan Q |date=2002-11-19 |journal=FEMS microbiology letters |accessdate=2006-03-24 }}&lt;/ref&gt;  Dr. Derya Unutmaz, Associate Professor of Microbiology and Immunology at the Vanderbilt University School of Medicine, tested several CSAs in his laboratory for their ability to kill [[HIV]] directly.  According to Unutmaz, &quot;We have some preliminary but very exciting results.  But we would like to formally show this before making any claims that would cause unwanted hype.&quot;&lt;ref&gt;{{cite news |url=http://news.bbc.co.uk/1/hi/health/4696496.stm |title=Chemical 'blocks HIV infection' |date=2006-09-26 |work=[[BBC News Online]] |accessdate=2006-03-24 |date=2006-02-09 }}&lt;/ref&gt;

On February 6, 2006, researchers (including Dr. Paul B. Savage) announced that a Ceragenin compound, CSA-54, appears to inactivate HIV. This conclusion seems to still be awaiting peer review.&lt;ref&gt;{{cite web |url=http://www.sltrib.com/business/ci_3482712 |title=Has BYU prof found AIDS cure? |date=2006-03-01 |work=[[The Salt Lake Tribune]] |author=Mims, Bob |accessdate=2006-03-24 }}&lt;/ref&gt;

==References==
{{Reflist}}

{{Antiretroviral drug}}

[[Category:Antibiotics]]
[[Category:Steroids]]</text>
      <sha1>a46xwjkjz93q4epjb3mddbznfu9nwl2</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Puromycin</title>
    <ns>0</ns>
    <id>614572</id>
    <revision>
      <id>608540667</id>
      <parentid>607446800</parentid>
      <timestamp>2014-05-14T13:09:39Z</timestamp>
      <contributor>
        <username>Louisajb</username>
        <id>13226235</id>
      </contributor>
      <comment>changed chemblid</comment>
      <text xml:space="preserve" bytes="6290">{{chembox
| Verifiedfields = changed
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4A6ZS6Q2CL
| verifiedrevid = 464376480
|ImageFile=Puromycin skeletal.svg
|ImageSize=
|IUPACName=3'-deoxy-''N,N''-dimethyl-3'-[(''O''-methyl-&lt;small&gt;L&lt;/small&gt;-tyrosyl)amino]adenosine
|OtherNames=
|Section1={{Chembox Identifiers
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 388623
| InChI = 1/C22H29N7O5/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32)/t14-,15+,16+,18+,22+/m0/s1
| InChIKey = RXWNCPJZOCPEPQ-NVWDDTSBBO
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H29N7O5/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32)/t14-,15+,16+,18+,22+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RXWNCPJZOCPEPQ-NVWDDTSBSA-N
| CASNo_Ref = {{cascite|changed|??}}
| CASNo=53-79-2
|  PubChem = 439530
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 469912
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05653
|  DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB08437
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 17939
| SMILES = O=C(N[C@@H]3[C@H](O[C@@H](n2cnc1c2ncnc1N(C)C)[C@@H]3O)CO)[C@@H](N)Cc4ccc(OC)cc4
|  MeSHName=Puromycin
  }}
|Section2={{Chembox Properties
|C=22|H=29|N=7|O=5
|  MolarMass=471.50956
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3={{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}

'''Puromycin''' is an [[antibiotic]] that is a [[protein synthesis inhibitor]] by inhibiting translation.

== Inhibition of translation ==

Puromycin is an [[aminonucleoside]] [[antibiotic]], derived from the ''[[Streptomyces alboniger]]'' bacterium,&lt;ref&gt;[http://www.fermentek.co.il/puromycin.htm Puromycin ] from [[Fermentek]]&lt;/ref&gt; that causes premature chain termination during translation taking place in the [[ribosome]]. Part of the molecule resembles the 3' end of the aminoacylated [[tRNA]]. It enters the A site and transfers to the growing chain, causing the formation of a puromycylated nascent chain and premature chain release.&lt;ref&gt;{{cite journal | author = Pestka, S. | year = 1971 | title =  Inhibitors of ribosome functions | journal = Annu. Rev. Microbiol. | volume = 25 | pages = 487–562 | doi = 10.1146/annurev.mi.25.100171.002415 | pmid = 4949424}}&lt;/ref&gt; The exact mechanism of action is unknown at this time but the 3' position contains an [[amide]] linkage instead of the normal [[ester]] linkage of [[tRNA]]. That makes the molecule much more resistant to [[hydrolysis]] and stops the [[ribosome]].

Puromycin is not selective for either [[prokaryotes]] or [[eukaryotes]].

Also of note, puromycin is critical in [[mRNA display]]. In this reaction, a puromycin molecule is chemically attached to the end of an [[mRNA]] template, which is then translated into protein. The puromycin can then form a covalent link to the growing [[peptide]] chain allowing the mRNA to be physically linked to its translational product.

Antibodies that recognize puromycylated nascent chains can also be used to purify newly synthesized polypeptides&lt;ref&gt;{{cite journal | author = Eggers, D.K., Welch, W.J., and Hansen W.J. | year = 1997 | journal =  Mol Biol Cell | volume = 8 | pages = 1559–1573 | pmid = 9285825 | title = Complexes between nascent polypeptides and their molecular chaperones in the cytosol of mammalian cells | issue = 8 | pmc = 276176 | doi=10.1091/mbc.8.8.1559}}&lt;/ref&gt; and to visualize the distribution of actively translating ribosomes by [[immunofluorescence]].&lt;ref&gt;{{cite journal | author = Starck, S.R., Green, H.M., Alberola-Ila, J. and Roberts R.W. | year = 2004 | title = A general approach to detect protein expression in vivo using fluorescent puromycin conjugates | journal = Chem. Biol. | volume = 11 | pages = 999–1008 | doi = 10.1016/j.chembiol.2004.05.011 | pmid = 15271358 | issue = 7}}&lt;/ref&gt;

== Peptidase Inhibitor ==
Puromycin is a reversible inhibitor of dipeptidyl-peptidase II ([[Serine protease|serine peptidase]]) and cytosol alanyl aminopeptidase ([[metallopeptidase]]).&lt;ref&gt;{{cite journal | author = Dando, P.M, Young, N.E &amp; Barrett, A.J | year = 1997 | journal = Biomed Health Res | volume = 13 | pages = 88–95}}&lt;/ref&gt;&lt;ref&gt;{{cite journal | author = McDonald, J. K., Reilly, T. J., Zeitman, B.B., and Ellis, S. | year = 1968 | journal =  J Bio Chem | volume = 243 | pages = 2028–2037}}&lt;/ref&gt; The mechanism of inhibition is not well understood, however puromycin can be used to distinguish between aminopeptidase M (active) and cytosol alanyl aminopeptidase (inhibited by puromycin).

== Cell culture ==
Puromycin is used in cell biology as selective agent in cell culture systems. It is toxic to prokaryotic and eukaryotic cells. Resistance to puromycin is conferred by the Pac gene encoding a puromycin ''N''-acetyl-transferase (PAC) that was found in a Streptomyces producer strain. Puromycin is soluble in water (50&amp;nbsp;mg/ml) as colorless solution at 10&amp;nbsp;mg/ml. Puromycin is stable for one year as solution when stored at -20 °C. The recommended dose as a selection agent in cell cultures is within a range of 1-10 μg/ml, although it can be toxic to eukaryotic cells at concentrations as low as 1 μg/ml. Puromycin acts quickly and can kill up to 99% of nonresistant cells within 2 days.

== Selection of ''Escherichia coli'' ==

Puromycin is poorly active on ''E. coli''. Puromycin-resistant transformants are selected in LB agar medium supplemented with 125&amp;nbsp;µg/ml of puromycin. But use of puromycin for ''E. coli'' selection requires precise pH adjustment and also depends on which strain is selected. For hassle–free selection and optimum results the use of special modified puromycin is possible. Plates containing puromycin are stable for 1 month when stored at 4 °C.

== References ==
{{reflist}}

== External links ==
* The [[MEROPS]] online database for peptidases and their inhibitors: [http://meropstest.sanger.ac.uk/cgi-bin/smi_summary?mid=J00019 Puromycin]

{{Protein synthesis inhibitor antibiotics}}

[[Category:Antibiotics]]</text>
      <sha1>crowsv6weulb3tihc34sns7yriyxe2h</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Monensin</title>
    <ns>0</ns>
    <id>6335141</id>
    <revision>
      <id>602929175</id>
      <parentid>602927195</parentid>
      <timestamp>2014-04-05T22:49:08Z</timestamp>
      <contributor>
        <ip>23.255.238.238</ip>
      </contributor>
      <comment>/* Mechanism of action */  Corrected a capitalization error (TI—Ti)</comment>
      <text xml:space="preserve" bytes="7965">{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 408764013
|   Name = Monensin A
|   ImageFile = Monensin A.svg
|   ImageSize = 
|   IUPACName = 4-[2-[5-ethyl-5-[5-[6-hydroxy-6-
(hydroxymethyl)-3,5-dimethyl-oxan-2-yl]-
3-methyl-oxolan-2-yl]oxolan-2-yl]-
9-hydroxy-2,8-dimethyl-1,6-dioxasp
iro[4.5]dec-7-yl]-3-methoxy-2-methyl-
pentanoic acid
| OtherNames = monensic acid
| Section1 = {{Chembox Identifiers
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 906O0YJ6ZP
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 27617
| SMILES = O=C(O)[C@@H](C)[C@H](OC)[C@H](C)[C@H]5O[C@]1(O[C@@](C)(CC1)[C@@H]2O[C@@](CC)(CC2)[C@@H]4O[C@@H]([C@H]3O[C@@](O)(CO)[C@@H](C[C@@H]3C)C)C[C@@H]4C)C[C@H](O)[C@H]5C
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 389937
| PubChem = 441145
| InChI = 1/C36H62O11/c1-10-34(31-20(3)16-26(43-31)28-19(2)15-21(4)36(41,18-37)46-28)12-11-27(44-34)33(8)13-14-35(47-33)17-25(38)22(5)30(45-35)23(6)29(42-9)24(7)32(39)40/h19-31,37-38,41H,10-18H2,1-9H3,(H,39,40)/t19-,20-,21+,22+,23-,24-,25-,26+,27+,28-,29+,30-,31+,33-,34-,35+,36-/m0/s1
| InChIKey = GAOZTHIDHYLHMS-KEOBGNEYBF
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 256105
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C36H62O11/c1-10-34(31-20(3)16-26(43-31)28-19(2)15-21(4)36(41,18-37)46-28)12-11-27(44-34)33(8)13-14-35(47-33)17-25(38)22(5)30(45-35)23(6)29(42-9)24(7)32(39)40/h19-31,37-38,41H,10-18H2,1-9H3,(H,39,40)/t19-,20-,21+,22+,23-,24-,25-,26+,27+,28-,29+,30-,31+,33-,34-,35+,36-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = GAOZTHIDHYLHMS-KEOBGNEYSA-N
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo = 17090-79-8
| ATCvet = yes
| ATCCode_prefix = A16
| ATCCode_suffix = QA06
| ATC_Supplemental = {{ATCvet|P51|AH03}}
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08228
| RTECS = 
  }}
| Section2 = {{Chembox Properties
|   Formula = C&lt;sub&gt;36&lt;/sub&gt;H&lt;sub&gt;62&lt;/sub&gt;O&lt;sub&gt;11&lt;/sub&gt;
|   MolarMass = 670.871g/mol
|   Appearance = solid state, white crystals
|   Density = 
|   Solubility = 3x10&lt;sup&gt;-6&lt;/sup&gt; g/dm&lt;sup&gt;3&lt;/sup&gt; (20&amp;nbsp;°C)
|   Solvent = 
|   SolubleOther = [[ethanol]], [[acetone]], [[diethyl ether]], [[benzene]]
|   MeltingPt = 104&amp;nbsp;°C 
|   BoilingPt = 
|   Viscosity = 
|   RefractIndex = 
  }}
| Section8 = {{Chembox Related
|   Function =  
|   OtherFunctn = [[antibiotics]], [[ionophores]]
|   OtherCpds = [[Monensin A methyl ester]],
  }} }}
'''Monensin''' is a [[polyether]] [[antibiotic]] isolated from ''[[Streptomyces]] cinnamonensis''.&lt;ref&gt;{{cite journal |author= Daniel Łowicki and Adam Huczyński|year= 2013|title= Structure and Antimicrobial Properties of Monensin A and Its Derivatives: Summary of the Achievements|journal= BioMed Research International|volume= 2013|issue= |pages=1–14|doi=10.1155/2013/742149}}&lt;/ref&gt;  It is widely used in ruminant animal feeds.&lt;ref&gt;Patrick Butaye, Luc A. Devriese, Freddy Haesebrouck &quot;Antimicrobial Growth Promoters Used in Animal Feed: Effects of Less Well Known Antibiotics on Gram-Positive Bacteria&quot; Clinical Microbiology Reviews, 2003, p. 175-188, Vol. 16.  {{DOI|10.1128/CMR.16.2.175-188.2003}}&lt;/ref&gt; 

The structure of monensin was first described by Agtarap ''et al.'' in 1967, and was the first polyether antibiotic to have its structure elucidated in this way. The first [[total synthesis]] of monensin was reported in 1979 by Kishi ''et al.''&lt;ref name=&quot;Nicolaou&quot;&gt;{{cite book |title= Classics in Total Synthesis|last= Nicolaou|first= K. C.|authorlink=K. C. Nicolaou |coauthors= E. J. Sorensen|year= 1996|publisher= VCH|location= Weinheim, Germany|isbn= 3-527-29284-5|page= |pages=185–187 |url= |accessdate= }}&lt;/ref&gt;

==Mechanism of action==
Monensin A is an [[ionophore]] related to the [[crown ether]]s with a preference to form complexes with monovalent [[cation]]s such as: Li&lt;sup&gt;+&lt;/sup&gt;, Na&lt;sup&gt;+&lt;/sup&gt;, K&lt;sup&gt;+&lt;/sup&gt;, Rb&lt;sup&gt;+&lt;/sup&gt;, Ag&lt;sup&gt;+&lt;/sup&gt;, and Ti&lt;sup&gt;+&lt;/sup&gt;.&lt;ref&gt;A. Huczyński, M. Ratajczak-Sitarz, A. Katrusiak, [[Bogumił Brzezinski|B. Brzezinski]], &quot;Molecular structure of the 1:1 inclusion complex of Monensin A lithium salt with acetonitrile&quot;, ''[[Journal of Molecular Structure|J. Mol. Struct.]]'', 2007, 871, 92-97, {{doi|10.1016/j.molstruc.2006.07.046}}&lt;/ref&gt;&lt;ref&gt;M. Pinkerton, L. K. Steinrauf, &quot;Molecular structure of monovalent metal cation complexes of monensin&quot;, ''[[Journal of Molecular Biology|J. Mol. Biol.]]'', 1970 49(3), 533-546&lt;/ref&gt; Monensin A is able to transport these cations across lipid membranes of cells in an electroneutral (i.e. non-depolarizing) exchange, playing an important role as an Na&lt;sup&gt;+&lt;/sup&gt;/H&lt;sup&gt;+&lt;/sup&gt; [[antiporter]]. Recent studies have shown that monensin may transport sodium ion through the membrane in both electrogenic and electroneutral manner.&lt;ref&gt;{{cite journal|last=Huczyński|first=Adam|coauthors=Jan Janczak, Daniel Łowicki, Bogumil Brzezinski|title=Monensin A acid complexes as a model of electrogenic transport of sodium cation|journal=[[Biochimica et biophysica acta{{!}}Biochim. Biophys. Acta]]|date=2012|volume=1818|pages=2108–2119|doi=10.1016/j.bbamem.2012.04.017}}&lt;/ref&gt; This approach explains ionophoric ability and in consequence antibacterial properties of not only parental monensin, but also its derivatives that not possess carboxylic group. It blocks [[intracellular]] protein transport, and exhibits [[antibiotic]], [[malaria|antimalarial]], and other biological activities.&lt;ref&gt;H. H. Mollenhauer, D. J. Morre,  L. D. Rowe, &quot;Alteration of intracellular traffic by monensin; mechanism, specificity and relationship to toxicity&quot;, ''[[Biochimica et Biophysica Acta|Biochim. Biophys. Acta]]'', 1990, 1031(2), 225-246, {{doi|10.1016/0304-4157(90)90008-Z}}&lt;/ref&gt; The [[antibacterial]] properties of monensin and its derivatives are a result of their ability to transport metal cations through cellular and subcellular [[Biological membrane|membranes]].&lt;ref&gt;A. Huczyński, J. Stefańska, P. Przybylski, B. Brzezinski and F. Bartl, &quot;Synthesis and antimicrobial properties of Monensin A esters&quot;, ''[[Bioorganic &amp; Medicinal Chemistry Letters|Bioorg. Med. Chem. Lett.]]'', 2008, 18, 2585-2589, {{doi|10.1016/j.bmcl.2008.03.038}}&lt;/ref&gt;
[[Image:Monensin2.png|300 px|thumb|left|The structure of the sodium (Na&lt;sup&gt;+&lt;/sup&gt;) complex of monensin A.]]

==Uses==
Monensin is used extensively in the beef and dairy industries to prevent [[coccidiosis]], increase the production of propionic acid and prevent bloat.&lt;ref&gt;T. Matsuoka, M.N. Novilla, T.D. Thomson and A.L. Donoho, &quot;Review of monensin toxicosis in horses&quot;, ''[[Journal of Equine Veterinary Science]]'' 16, 1996, 8-15,  {{doi|10.1016/S0737-0806(96)80059-1}}&lt;/ref&gt; Furthermore monensin, but also its derivatives monensin methyl [[ester]] (MME), and particularly monensin decyl ester (MDE) are widely used in [[ion-selective electrode]]s.&lt;ref&gt;K. Tohda, K. Suzuki, N. Kosuge, H. Nagashima, H. Inoue K. Watanabe, &quot;A Sodium Ion Selective Electrode Based on a Highly Lipophilic Monensin Derivative and Its Application to the Measurement of Sodium Ion Concentrations in Serum&quot;, ''[[Analytical Sciences|Anal. Sci.]]'' 6, 1990, 227-232, {{doi|10.2116/analsci.6.227}}&lt;/ref&gt;&lt;ref&gt;
N. Kim, K. Park, I. Park, Y. Cho, Y. Bae, &quot;Application of a taste evaluation system to the monitoring of Kimchi fermentation&quot;, ''[[Biosensors and Bioelectronics]]'' 20, 2005, 2283-2291,{{doi|10.1016/j.bios.2004.10.007}}&lt;/ref&gt;&lt;ref&gt;K. Toko, &quot;Taste Sensor&quot;, ''[[Sensors and Actuators B: Chemical]]'' 64, 2000, 205-215, {{doi|10.1016/S0925-4005(99)00508-0}}&lt;/ref&gt;

==Toxicity==
Monensin has some degree of activity on mammalian cells and thus toxicity is common. This is especially pronounced in horses, where monensin has an LD&lt;sub&gt;50&lt;/sub&gt; 1/100th that of ruminants. Accidental poisoning of equines with monensin is a well-documented occurrence.

==References==
{{reflist}}
{{Nonribosomally synthesized porters}}

[[Category:Antibiotics]]
[[Category:Ionophores]]
[[Category:Carboxylic acids]]</text>
      <sha1>f6cslmydtvkgfzxowk3n8aq44j418pm</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Broad-spectrum antibiotic</title>
    <ns>0</ns>
    <id>541592</id>
    <revision>
      <id>597045370</id>
      <parentid>597042896</parentid>
      <timestamp>2014-02-25T09:09:52Z</timestamp>
      <contributor>
        <username>Materialscientist</username>
        <id>7852030</id>
      </contributor>
      <minor/>
      <comment>[[Help:Reverting|Reverted]] edits by [[Special:Contributions/175.139.181.169|175.139.181.169]] ([[User talk:175.139.181.169|talk]]) to last version by 203.74.120.93</comment>
      <text xml:space="preserve" bytes="3440">The term '''broad-spectrum antibiotic''' refers to an [[antibiotic]] that acts against a wide range of disease-causing [[bacteria]].&lt;ref&gt;Clayton L. Thomas Editor, Taber's Cyclopedic Medical Dictionary 17th ed., 1993 (ISBN 0-8036-8313-8)&lt;/ref&gt; A broad-spectrum antibiotic acts against both [[Gram-positive]] and [[Gram-negative]] bacteria, in contrast to a [[narrow-spectrum antibiotic]], which is effective against specific families of [[bacteria]].&lt;ref&gt;S.J. Hopkins, Drugs and Pharmacology for Nurses 12th ed., 1997 (ISBN 0-443-05249 2)&lt;/ref&gt; An example of a commonly used broad-spectrum antibiotic is [[ampicillin]].&lt;ref&gt;S.J. Hopkins, Drugs and Pharmacology for Nurses 12th ed., 1997 (ISBN 0-443-05249 2)&lt;/ref&gt;

== Uses ==
Broad-spectrum antibiotics are properly used in the following [[medicine|medical]] situations:

* Empirically (i.e., based on the experience of the practitioner), prior to the formal identification of the causative bacteria, when there is a wide range of possible illnesses and a potentially serious illness would result if treatment is delayed.  This occurs, for example, in [[meningitis]], where the patient can become fatally ill within hours if broad-spectrum antibiotics are not initiated.

* For drug resistant bacteria that do not respond to other, more [[narrow-spectrum antibiotic]]s.

* In the case of [[superinfection]]s, where there are multiple types of bacteria causing illness, thus warranting either a broad-spectrum antibiotic or combination antibiotic therapy.

* For [[prophylaxis]] after an operation, in order to prevent bacterial infections occurring.

== Risks ==
As a side-effect, antibiotics can change the body's normal microbial content by attacking indiscriminately both the pathological and naturally occurring, beneficial or harmless bacteria found in the intestines, lungs and bladder.&lt;ref&gt;E.A. Martin, Oxford Concise Medical Dictionary 6th ed., 2003 (ISBN 0-19-860753-9)&lt;/ref&gt; The destruction of the body's normal bacterial [[flora]] provides an opportunity for drug-resistant microorganisms to grow vigorously and can lead to a secondary infection such as ''[[Clostridium difficile]]''&lt;ref&gt;S.J. Hopkins, Drugs and Pharmacology for Nurses 12th ed., 1997 (ISBN 0-443-05249 2)&lt;/ref&gt; (also known as &quot;[[C. diff]]&quot;) or [[Candidiasis]] (also known as &quot;thrush&quot;) in females. This side-effect is more likely with the use of broad-spectrum antibiotics.&lt;ref&gt;E.A. Martin, Oxford Concise Medical Dictionary 6th ed., 2003 (ISBN 0-19-860753-9)&lt;/ref&gt;

==Examples==
In [[medicine]]: 
*[[Amoxicillin]]
*[[Carbapenems]], including [[Imipenem]], [[Meropenem]], [[Ertapenem]]
*[[Piperacillin/tazobactam]]
*[[Levofloxacin]], [[gatifloxacin]], [[moxifloxacin]], Ciprofloxacin
*[[Streptomycin]]
*[[Tetracycline antibiotics|Tetracycline]]
*[[Chloramphenicol]]
*[[Ticarcillin]]
In [[veterinary medicine]], [[Co-amoxiclav]], (in small animals); [[penicillin]] &amp; [[streptomycin]] and [[oxytetracycline]] (in farm animals); [[penicillin]] and [[sulfonamide (medicine)|potentiated sulfonamides]] (in horses).

==See also==
* [[Empiric therapy]]
* [[Narrow-spectrum antibiotic]]

==References==
{{reflist|2}}

* Clayton L. Thomas Editor, Taber's Cyclopedic Medical Dictionary 17th ed., 1993 (ISBN 0-8036-8313-8)
* S.J. Hopkins, Drugs and Pharmacology for Nurses 12th ed., 1997 (ISBN 0-443-05249 2)
* Ibid
* E.A. Martin, Oxford Concise Medical Dictionary 6th ed., 2003 (ISBN 0-19-860753-9)

[[Category:Antibiotics]]</text>
      <sha1>4iwb3i2jtlznq7ebftekxta155eobn9</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Neosalvarsan</title>
    <ns>0</ns>
    <id>1963552</id>
    <revision>
      <id>592627362</id>
      <parentid>574281621</parentid>
      <timestamp>2014-01-27T12:29:04Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="2562">{{chembox
| verifiedrevid = 444024073
|ImageFile=Neosalvarsan.svg
|ImageSize=
|ImageFile2=Neosalvarsan-3D-vdW.png
|IUPACName=
|OtherNames= Sodium 3,3'-diamino-4,4'-dihydroxyarsenobenzene-N-formaldehydesulfoxylate; Neoarsphenamine;914
|Section1= {{Chembox Identifiers
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 9586
| InChI = 1/C13H14As2N2O4S.Na/c16-10-5-8(1-3-12(10)18)14-15-9-2-4-13(19)11(6-9)17-7-22(20)21;/h1-6,17-19H,7,16H2,(H,20,21);/q;+1/p-1
| InChIKey = BGYSJUFVJUJSOL-REWHXWOFAO
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C13H14As2N2O4S.Na/c16-10-5-8(1-3-12(10)18)14-15-9-2-4-13(19)11(6-9)17-7-22(20)21;/h1-6,17-19H,7,16H2,(H,20,21);/q;+1/p-1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BGYSJUFVJUJSOL-UHFFFAOYSA-M
| CASNo_Ref = {{cascite|correct|??}}
| CASNo=457-60-3
|  PubChem=9980
|  UNII_Ref = {{fdacite|correct|FDA}}
| UNII = O7K7R0O4BG
| SMILES = [Na+].[O-]S(=O)CNc2cc(/[As]=[As]/c1ccc(O)c(N)c1)ccc2O
}}
|Section2= {{Chembox Properties
|  Formula=C&lt;sub&gt;13&lt;/sub&gt;H&lt;sub&gt;13&lt;/sub&gt;As&lt;sub&gt;2&lt;/sub&gt;N&lt;sub&gt;2&lt;/sub&gt;NaO&lt;sub&gt;4&lt;/sub&gt;S
|  MolarMass=466.15 g/mol
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3= {{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}

'''Neosalvarsan''' is a synthetic [[chemotherapeutic]] that is an [[organoarsenic compound]].  It became available in 1912 and superseded the more toxic and less water-soluble [[salvarsan]] as an effective treatment for [[syphilis]].    Because both of these arsenicals carried considerable risk of side effects, they were replaced for this indication by [[penicillin]] in the 1940s. 

Both salvarsan and neosalvarsan were developed in the laboratory of [[Paul Ehrlich]] in [[Frankfurt]], [[Germany]].  Their discoveries were the result of the first organized team effort to optimize the biological activity of a [[lead compound]] through systematic chemical modifications.&lt;ref&gt;{{cite journal |author=Strebhardt K, Ullrich A |title=Paul Ehrlich's magic bullet concept: 100 years of progress |journal=Nat. Rev. Cancer |volume= 8|issue= 6|pages= 473–80|date=May 2008 |pmid=18469827 |doi=10.1038/nrc2394 |url=}}&lt;/ref&gt; This scheme is the basis for most modern [[pharmaceutical]] research. Both salvarsan and neosalvarsan are [[prodrug]]s — that is, they are [[metabolism|metabolised]] into the active drug in the body.

==References==
&lt;references/&gt;

[[Category:Sulfinates]]
[[Category:Antibiotics]]
[[Category:Organoarsenic compounds]]
[[Category:Phenols]]</text>
      <sha1>i4j1iavihz3eimlgt3rxio1nc2vejqp</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Geldanamycin</title>
    <ns>0</ns>
    <id>4041200</id>
    <revision>
      <id>586280554</id>
      <parentid>586220748</parentid>
      <timestamp>2013-12-16T02:36:07Z</timestamp>
      <contributor>
        <username>AManWithNoPlan</username>
        <id>12416903</id>
      </contributor>
      <comment>use consistent cite format</comment>
      <text xml:space="preserve" bytes="5543">{{chembox
| verifiedrevid = 443833298
| ImageFile = Geldanamycin.svg
| ImageSize = 
| IUPACName = (4''E'',6''Z'',8''S'',9''S'',10''E'',12''S'',13''R'',14''S'',16''R'')-13-hydroxy&lt;br/&gt;
-8,14,19-trimethoxy-4,10,12,16-tetramethyl&lt;br/&gt;
-3,20,22-trioxo-2-azabicyclo[16.3.1]&lt;br/&gt;
docosa-1(21),4,6,10,18-pentaen-9-yl carbamate
| OtherNames = 
| Section1 = {{Chembox Identifiers
| Abbreviations = 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10272739
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 278315
| InChI = 1S/C29H40N2O9/c1-15-11-19-25(34)20(14-21(32)27(19)39-7)31-28(35)16(2)9-8-10-22(37-5)26(40-29(30)36)18(4)13-17(3)24(33)23(12-15)38-6/h8-10,13-15,17,22-24,26,33H,11-12H2,1-7H3,(H2,30,36)(H,31,35)/b10-8-,16-9+,18-13+/t15-,17+,22+,23+,24-,26+/m1/s1
| InChIKey = QTQAWLPCGQOSGP-KSRBKZBZBP
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C29H40N2O9/c1-15-11-19-25(34)20(14-21(32)27(19)39-7)31-28(35)16(2)9-8-10-22(37-5)26(40-29(30)36)18(4)13-17(3)24(33)23(12-15)38-6/h8-10,13-15,17,22-24,26,33H,11-12H2,1-7H3,(H2,30,36)(H,31,35)/b10-8-,16-9+,18-13+/t15-,17+,22+,23+,24-,26+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = QTQAWLPCGQOSGP-KSRBKZBZSA-N
| InChIKey1 = QTQAWLPCGQOSGP-KSRBKZBZSA-N
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 30562-34-6
| EINECS = 
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB02424
| SMILES = NC(=O)O[C@H]1C(/C)=C/[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)C\C2=C(/OC)C(=O)\C=C(\NC(=O)C(\C)=C\C=C/[C@@H]1OC)C2=O
| InChI = 
| RTECS =
| MeSHName =
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI =
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = 
| ATCCode = }}
| Section2 = {{Chembox Properties
| Formula = C&lt;sub&gt;29&lt;/sub&gt;H&lt;sub&gt;40&lt;/sub&gt;N&lt;sub&gt;2&lt;/sub&gt;O&lt;sub&gt;9&lt;/sub&gt;
| MolarMass = 560.64 g/mol
| Appearance = Gold-yellow fine crystalline powder
| Density = 
| MeltingPt = 
| Melting_notes =
| BoilingPt = 
| Boiling_notes = 
| Solubility = 
| SolubleOther = 
| Solvent = 
| pKa = 
| pKb = 
| IsoelectricPt = 
| SpecRotation = 
| RefractIndex = 
| Viscosity = 
| Dipole = }}
| Section3 = {{Chembox Structure
| CrystalStruct = 
| Coordination = 
| MolShape = 
| Dipole = }}
| Section4 = {{Chembox Thermochemistry
| DeltaHf = 
| DeltaHc = 
| Entropy = 
| HeatCapacity = }}
| Section5 = {{Chembox Pharmacology
| AdminRoutes =
| Bioavail = 
| Metabolism = 
| HalfLife = 
| ProteinBound
| Excretion = 
| Legal_status =
| Legal_US =
| Legal_UK =
| Legal_AU =
| Legal_CA =
| PregCat = 
| PregCat_AU = 
| PregCat_US = }}
| Section6 = {{Chembox Explosive
| ShockSens = 
| FrictionSens = 
| ExplosiveV = 
| REFactor = }}
| Section7 = {{Chembox Hazards
| ExternalMSDS = 
| EUClass = 
| EUIndex = 
| MainHazards = 
| NFPA-H = 
| NFPA-F = 
| NFPA-R = 
| NFPA-O =  
| RPhrases = 
| SPhrases = 
| RSPhrases =
| FlashPt = 
| Autoignition = 
| ExploLimits = 
| PEL = }}
| Section8 = {{Chembox Related
| OtherAnions = 
| OtherCations = 
| OtherFunctn = 
| Function = 
| OtherCpds = }}
}}
'''Geldanamycin''' is a [[benzoquinone]] [[ansamycin]] [[antibiotic]] that inhibits the function of [[Hsp90]] (Heat Shock Protein 90) by binding to the unusual ADP/ATP-binding pocket of the protein.&lt;ref&gt;{{cite pmid|9672245}}&lt;/ref&gt; HSP90 client proteins play important roles in the regulation of the cell cycle, cell growth, cell survival, [[apoptosis]], [[angiogenesis]] and [[oncogenesis]].

[[File:1yetgdm.png|thumb|Hsp90-geldanamycin complex. PDB {{PDBe|1yet}}&lt;ref&gt;{{cite pmid|9108479}}&lt;/ref&gt;]]Geldanamycin induces the degradation of proteins that are mutated in [[tumor]] cells such as [[v-Src]], [[Bcr-Abl]] and [[p53]] preferentially over their normal cellular counterparts. This effect is mediated via HSP90. Despite its potent antitumor potential, geldanamycin presents several major drawbacks as a drug candidate such as [[hepatotoxicity]], further, Jilani ''et al''. reported that geldanamycin induces eryptosis ([[apoptosis]] of [[erythrocytes]]) under physiological concentrations.&lt;ref&gt;{{cite doi|10.1159/000356596}}&lt;/ref&gt; These side effects have led to the development of geldanamycin analogues, in particular analogues containing a derivatisation at the 17 position:

* [[17-AAG]]
* [[17-DMAG]]

== Biosynthesis ==

Geldanamycin was originally discovered in the organism ''[[Streptomyces hygroscopicus]]''.&lt;ref&gt;{{Cite pmid|16502293}}&lt;/ref&gt; It is a macrocyclic polyketide that is synthesized by a Type I [[polyketide synthase]]. The genes gelA, gelB, and gelC encode for the polyketide synthase. The PKS is first loaded with 3-amino-5-hydroxybenzoic acid (AHBA). It then utilizes [[malonyl-CoA]], [[methylmalonyl-CoA]], and methoxymalonyl-CoA to synthesize the precursor molecule Progeldanamycin.&lt;ref&gt;{{Cite pmid|19308924}}&lt;/ref&gt; This precursor is subjected to several enzymatic and non-enzymatic tailoring steps to produce the active molecule Geldanamycin, which include hydroxylation, o-methylation, carbamoylation, and oxidation.&lt;ref&gt;{{Cite pmid|16381049}}&lt;/ref&gt;

== Notes ==
{{reflist}}

== References ==
* {{cite pmid|14999769}}

== External links ==
*[http://geldanamycin.info/index.htm A comprehensive  review about Geldanamycin, 17AAG and 17DMAG]
*[http://www.fermentek.co.il/geldanamycin.htm Geldanamycin from ] [[Fermentek]]
* [http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=GDM Geldanamycin bound to proteins] in the [[Protein Data Bank|PDB]]

[[Category:Antibiotics]]
[[Category:Quinones]]
[[Category:Carbamates]]
[[Category:Lactams]]
[[Category:Phenol ethers]]
[[Category:Ethers]]
[[Category:Alcohols]]</text>
      <sha1>rgwlc8maa0922nttnu5v1dzamr0biri</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Topoisomerase inhibitor</title>
    <ns>0</ns>
    <id>6688255</id>
    <revision>
      <id>592686947</id>
      <parentid>561108292</parentid>
      <timestamp>2014-01-27T20:23:35Z</timestamp>
      <contributor>
        <username>Citation bot 4</username>
        <id>9540159</id>
      </contributor>
      <minor/>
      <comment>[Cat511-dev]Misc citation tidying. You can [[WP:UCB|use this bot]] yourself. [[WP:DBUG|Report bugs here]].</comment>
      <text xml:space="preserve" bytes="23248">{{Refimprove|date=June 2011}}
'''Topoisomerase inhibitors''' are agents designed to interfere with the action of [[topoisomerase]] enzymes&lt;ref name=&quot;urlDefinition of topoisomerase inhibitor - NCI Dictionary of Cancer Terms&quot;&gt;{{cite web |url=&lt;nowiki&gt;http://www.cancer.gov/dictionary?CdrID=46665&lt;/nowiki&gt;{{dead link|date=June 2011}} |title=Definition of topoisomerase inhibitor - NCI Dictionary of Cancer Terms |format= |work= |accessdate=}}&lt;/ref&gt; (topoisomerase I and II), which are [[enzymes]] that control the changes in [[DNA]] structure&lt;ref name=&quot;urlDorlands Medical Dictionary:topoisomerase inhibitor&quot;&gt;{{cite web |url=&lt;nowiki&gt;http://www.mercksource.com/pp/us/cns/cns_hl_dorlands_split.jsp?pg=/ppdocs/us/common/dorlands/dorland/nine/14181948.htm&lt;/nowiki&gt;{{dead link|date=June 2011}} |title=Dorlands Medical Dictionary:topoisomerase inhibitor |work= |accessdate=}}&lt;/ref&gt; by [[enzyme catalysis|catalyzing]] the breaking and rejoining of the [[phosphodiester]] backbone of DNA strands during the normal [[cell cycle]].

In recent years, topoisomerases have become popular targets for [[cancer]] chemotherapy treatments. It is thought that topoisomerase inhibitors block the [[DNA ligase|ligation]] step of the cell cycle, generating single and double stranded breaks that harm the integrity of the genome. Introduction of these breaks subsequently leads to apoptosis and cell death.

Topoisomerase inhibitors can also function as [[antibacterial]] agents.&lt;ref name=&quot;pmid15700957&quot;&gt;{{cite journal |pages=559–92 |doi=10.1021/cr030101q |title=Bacterial Topoisomerase Inhibitors:  Quinolone and Pyridone Antibacterial Agents |year=2005 |last1=Mitscher |first1=Lester A. |journal=Chemical Reviews |volume=105 |issue=2 |pmid=15700957}}&lt;/ref&gt; [[Quinolone]]s have this function.&lt;ref name=&quot;pmid18437302&quot;&gt;{{cite journal |pages=11–23 |doi=10.1007/978-1-59745-246-5_2 |chapter=Methods to Assay Inhibitors of DNA Gyrase and Topoisomerase IV Activities |title=New Antibiotic Targets |series=Methods In Molecular Medicine™ |year=2008 |last1=Fisher |first1=L. Mark |last2=Pan |first2=Xiao-Su |isbn=978-1-58829-915-4 |volume=142}}&lt;/ref&gt;

==Classification==
Topoisomerase inhibitors are often divided according to which type of enzyme it inhibits.
* [[Topoisomerase I]] inhibitors:  [[irinotecan]], [[topotecan]], [[camptothecin]] and [[lamellarin D]] all target type IB topoisomerases, 
* [[Topoisomerase II]] inhibitors: [[etoposide]] ([[VP-16]]), [[teniposide]], [[doxorubicin]], [[daunorubicin]], [[mitoxantrone]], [[amsacrine]], [[ellipticines]], [[aurintricarboxylic acid]],&lt;ref name=pmid7857317&gt;{{cite journal |pmid=7857317 |year=1995 |last1=Benchokroun |first1=Y |last2=Couprie |first2=J |last3=Larsen |first3=AK |title=Aurintricarboxylic acid, a putative inhibitor of apoptosis, is a potent inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells |volume=49 |issue=3 |pages=305–13 |journal=[[Biochemical pharmacology]] |doi=10.1016/0006-2952(94)00465-X}}&lt;/ref&gt; and [[HU-331]], a quinolone synthesized from [[cannabidiol]].

Numerous plant derived [[natural phenol]]s (ex. [[Epigallocatechin gallate|EGCG]],&lt;ref name=&quot;Neukam-2008&quot;&gt;{{cite journal |pages=8–12 |doi=10.1016/j.mrgentox.2008.03.013 |title=Tea flavanols inhibit cell growth and DNA topoisomerase II activity and induce endoreduplication in cultured Chinese hamster cells |year=2008 |last1=Neukam |first1=Karin |last2=Pastor |first2=Nuria |last3=Cortés |first3=Felipe |journal=Mutation Research/Genetic Toxicology and Environmental Mutagenesis |volume=654 |pmid=18541453 |issue=1}}&lt;/ref&gt;&lt;ref name=&quot;Berger-2001&quot;&gt;{{cite journal |pages=101–5 |doi=10.1006/bbrc.2001.5736 |title=Green Tea Constituent (−)-Epigallocatechin-3-gallate Inhibits Topoisomerase I Activity in Human Colon Carcinoma Cells |year=2001 |last1=Berger |first1=S |journal=Biochemical and Biophysical Research Communications |volume=288 |pmid=11594758 |last2=Gupta |first2=S |last3=Belfi |first3=CA |last4=Gosky |first4=DM |last5=Mukhtar |first5=H |issue=1}}&lt;/ref&gt;&lt;ref name=&quot;Suzuki-2001&quot;&gt;{{cite journal |pmid=11558576 |year=2001 |last1=Suzuki |first1=K |last2=Yahara |first2=S |last3=Hashimoto |first3=F |last4=Uyeda |first4=M |title=Inhibitory activities of (-)-epigallocatechin-3-O-gallate against topoisomerases I and II |volume=24 |issue=9 |pages=1088–90 |journal=Biological &amp; Pharmaceutical Bulletin |doi=10.1248/bpb.24.1088}}&lt;/ref&gt;&lt;ref name=&quot;Bandele-2008&quot;&gt;{{cite journal |pages=936–43 |doi=10.1021/tx700434v |title=(−)-Epigallocatechin Gallate, A Major Constituent of Green Tea, Poisons Human Type II Topoisomerases |year=2008 |last1=Bandele |first1=Omari J. |last2=Osheroff |first2=Neil |journal=[[Chemical Research in Toxicology]] |volume=21 |issue=4 |pmid=18293940 |pmc=2893035}}&lt;/ref&gt;&lt;ref name=&quot;Bandele-2007&quot;&gt;{{cite journal |pages=6097–108 |doi=10.1021/bi7000664 |title=Bioflavonoids as Poisons of Human Topoisomerase IIα and IIβ |year=2007 |last1=Bandele |first1=Omari J. |last2=Osheroff |first2=Neil |journal=Biochemistry |volume=46 |issue=20 |pmid=17458941 |pmc=2893030}}&lt;/ref&gt; [[genistein]], [[quercetin]], [[resveratrol]]) possess strong topoisomerase inhibitory properties affecting both types of enzymes. They may  express function of [[phytoalexin]]s - compounds produced by plants to combat vermin and pests.

Use of topoisomerase inhibitors for antineoplastic treatments may lead to [[secondary neoplasm]]s because of DNA damaging properties of the compounds.  Also plant derived polyphenols shows signs of carcinogenity, especially in fetuses and neonates who do not detoxify the compounds sufficiently.&lt;ref name=&quot;Paolini-2003&quot;&gt;{{cite journal |pmid=12787918 |year=2003 |last1=Paolini |first1=M |last2=Sapone |first2=A |last3=Valgimigli |first3=L |title=Avoidance of bioflavonoid supplements during pregnancy: a pathway to infant leukemia? |volume=527 |issue=1–2 |pages=99–101 |journal=Mutation research |doi=10.1016/S0027-5107(03)00057-5}}&lt;/ref&gt;&lt;ref name=&quot;Strick-2000&quot;&gt;{{cite journal |pages=4790–5 |doi=10.1073/pnas.070061297 |title=Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia |year=2000 |last1=Strick |first1=R. |journal=Proceedings of the National Academy of Sciences |volume=97 |issue=9 |pmid=10758153 |pmc=18311 |last2=Strissel |first2=PL |last3=Borgers |first3=S |last4=Smith |first4=SL |last5=Rowley |first5=JD}}&lt;/ref&gt;&lt;ref name=&quot;Ross-2000&quot;&gt;{{cite journal |pmid=10781030 |year=2000 |last1=Ross |first1=JA |title=Dietary flavonoids and the MLL gene: A pathway to infant leukemia? |volume=97 |issue=9 |pages=4411–3 |pmc=34309 |journal=Proceedings of the National Academy of Sciences of the United States of America |doi=10.1073/pnas.97.9.4411}}&lt;/ref&gt; An association between high intake of [[tea]] (containing [[polyphenol]]s) during pregnancy and  elevated risk of childhood malignant central nervous system (CNS) tumours has been found.&lt;ref name=pmid18361498&gt;{{cite journal |pmid=18361498 |year=2008 |last1=Wang |first1=R |last2=Zhou |first2=W |last3=Jiang |first3=X |title=Reaction kinetics of degradation and epimerization of epigallocatechin gallate (EGCG) in aqueous system over a wide temperature range |volume=56 |issue=8 |pages=2694–701 |doi=10.1021/jf0730338 |journal=Journal of Agricultural and Food Chemistry}}&lt;/ref&gt;&lt;ref name=&quot;Plichart-2008&quot;&gt;{{cite journal |pages=376–83 |doi=10.1097/CEJ.0b013e3282f75e6f |title=Parental smoking, maternal alcohol, coffee and tea consumption during pregnancy and childhood malignant central nervous system tumours: the ESCALE study (SFCE) |year=2008 |last1=Plichart |first1=Matthieu |last2=Menegaux |first2=Florence |last3=Lacour |first3=Brigitte |last4=Hartmann |first4=Olivier |last5=Frappaz |first5=Didier |last6=Doz |first6=François |last7=Bertozzi |first7=Anne-Isabelle |last8=Defaschelles |first8=Anne-Sophie |last9=Pierre-Kahn |first9=Alain |journal=European Journal of Cancer Prevention |volume=17 |issue=4 |pmid=18562965 |pmc=2746823|display-authors=9 }}&lt;/ref&gt;

==Compounds that target Type I topoisomerase==
Human DNA topoisomerase I (Top1) is an essential enzyme that relaxes DNA supercoiling during replication and transcription. Top1 generates DNA single-strand breaks that allow rotation of the cleaved strand around the double helix axis. Top1 also religates the cleaved strand to reestablish intact duplex DNA.
The Top1-DNA intermediates, known as cleavage complexes, are transient and at low levels under normal circumstances. However, treatment with Top1 inhibitors, such as the camptothecins, stabilize the cleavable complexes, prevent DNA religation and induce lethal DNA strand breaks. Cancer cells are selectively sensitive to the generation of these DNA lesions.

Top1 is a validated target for the treatment of human cancers.  Camptothecins are among the most effective anticancer agents recently introduced into clinical practice.  In this regard, the camptothecin derivative topotecan (Hycamtin) is approved by the U.S. FDA for the treatment of ovarian and lung cancer.  Another camptothecin derivative irinotecan (CPT11) is approved for the treatment of colon cancer.

There are, however, certain clinical limitations of the camptothecin derivatives.  These include: 1) spontaneous inactivation to a lactone form in blood, 2) rapid reversal of the trapped cleavable complex after drug removal, requiring prolonged infusions, 3) resistance of cancer cells overexpressing membrane transporters, and 4) dose-limiting side effects of diarrhea and neutropenia.

To circumvent these limitations, Dr. Mark Cushman at Purdue University and Dr. Yves Pommier at the National Cancer Institute developed the non-camptothecin family of indenoisoquinoline inhibitors of Top1.  In contrast to the camptothecins, the indenoisoquinolines are: 1) chemically stable in blood, 2) inhibitors of Top1 cleavable complexes at distinct sites, 3) not substrates of membrane transporters, and 4) more effective as anti-tumor agents in animal models.  The preclinical and IND package filed with the US Food and Drug Administration along with complete GMP production supporting the lead molecule are components of the published and non-published information covered by the license agreement with Purdue Research Foundation the National Cancer Center and Linus Oncology, Inc.

Linus Oncology has licensed the intellectual property that covers the development of these and related indenoisoquinoline derivatives.   Phase I Study in Adults With Relapsed Solid Tumors and Lymphomas is ongoing (2012).

Indenoisoquinolines (green) form a ternary complexes of Top1 (brown) and DNA (blue) (Pommier et al.) and act as interfacial inhibitors.

There are several advantages of these novel non-camptothecin Top1 inhibitors as compared to the FDA-approved camptothecin analogs:

*   They are synthetic and chemically stable compounds
*   The Top1 cleavage sites trapped by the indenoisoquinolines have different genomic locations, implying differential targeting of cancer cell genomes
*   The Top1 cleavage complexes trapped by indenoisoquinolines are more stable, indicative of prolonged drug action
*   The indenoisoquinolines are seldom or not used as substrates for the multidrug resistance efflux pumps (ABCG2 and MDR-1)

Based on these highly favorable characteristics, two indenoisoquinoline derivatives (from a series of &gt; 400 molecules), indotecan (LMP400; NSC 743400) and indimitecan (LMP776; NSC 725776) are presently under evaluation in a Phase I clinical trial being conducted at the National Cancer Institute for patients with relapsed solid tumors and lymphomas. http://clinicaltrials.gov/ct2/show/NCT01051635 

==Compounds that target Type II topoisomerase==
These inhibitors are split into two main classes: topoisomerase ''poisons'', which target the topoisomerase-DNA complex, and topoisomerase ''inhibitors'', which disrupt catalytic turnover.

===Topo II poisons===
Examples of topoisomerase poisons include the following:
*''eukaryotic'' type II topoisomerase inhibitors (topo II): [[amsacrine]], [[etoposide]], etoposide phosphate, [[teniposide]] and [[doxorubicin]].  These drugs are anti-cancer therapies.
*''bacterial'' type II topoisomerase inhibitors ([[gyrase]] and topo IV): [[fluoroquinolones]].  These are antibacterials and include such fluoroquinolones as ciprofloxacin.

Some of these poisons encourage the forward cleavage reaction (fluoroquinolones), while other poisons prevent the re-ligation of DNA (etoposide and teniposide).

Interestingly, poisons of type IIA topoisomerases can target prokaryotic and eukaryotic enzymes preferentially, making them attractive drug candidates.  [[Ciprofloxacin]] targets prokaryotes in excess of a thousandfold more than it targets eukaryotic topo IIs.  The mechanism for this specificity is unknown, but drug-resistant mutants cluster in regions around the active site.

===Topo II inhibitors===
These inhibitors target the N-terminal ATPase domain of topo II and prevent topo II from turning over.

Examples of topoisomerase inhibitors include :
*[[ICRF-193]].&lt;ref name=&quot;pmid17495539&quot;&gt;{{cite journal |pages=1265–7 |doi=10.4161/cc.6.10.4225 |title=Chk1 is required for G2/M Checkpoint Response Induced by the Catalytic Topoisomerase II Inhibitor ICRF-193 |year=2007 |last1=Robinson |first1=Helen |last2=Bratlie-Thoresen |first2=Sigrid |last3=Brown |first3=Robert |last4=Gillespie |first4=David A.F. |journal=Cell Cycle |volume=6 |issue=10 |pmid=17495539}}&lt;/ref&gt; The structure of this compound bound to the ATPase domain was solved by Classen (Proceedings of the National Academy of Science, 2004) showing that the drug binds in a non-competitive manner and locks down the dimerization of the ATPase domain.&lt;ref name=&quot;Baird&quot;&gt;{{cite journal |pages=27893–8 |doi=10.1074/jbc.M102544200 |title=The ATPase Reaction Cycle of Yeast DNA Topoisomerase II. SLOW RATES OF ATP RESYNTHESIS AND Pi RELEASE |year=2001 |last1=Baird |first1=C. L. |journal=Journal of Biological Chemistry |volume=276 |issue=30 |pmid=11353771 |last2=Gordon |first2=MS |last3=Andrenyak |first3=DM |last4=Marecek |first4=JF |last5=Lindsley |first5=JE}}&lt;/ref&gt;

* [[genistein]].

==References==
{{reflist}}


18.	Antony S, Agama KK, Miao ZH, Takagi K, Wright MH, Robles AI, Varticovski L, Nagarajan M, Morrell A, Cushman M, Pommier Y. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res. 2007 Nov 1;67(21):10397-405. 

19.	Antony S, Agama KK, Miao ZH, Hollingshead M, Holbeck SL, Wright MH, Varticovski L, Nagarajan M, Morrell A, Cushman M, Pommier Y. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity. Mol Pharmacol. 70:1109-1120, 2006.

20.	Antony S, Kohlhagen G, Agama K, Jayaraman M, Cao S, Durrani FA, Rustum YM, Cushman M, Pommier Y. Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Mol Pharmacol. 2005 Feb;67(2):523-30. 

21.	Antony S, Jayaraman M, Laco G, Kohlhagen G, Kohn KW, Cushman M, Pommier Y. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Cancer Res. 2003 Nov 1;63(21):7428-35.

22.	Bakshi RP, Sang D, Morrell A, Cushman M, Shapiro TA. Activity of indenoisoquinolines against African trypanosomes. Antimicrob Agents Chemother. 2009 Jan;53(1):123-8.

23.	Baxter J, Diffley JFX. Topoisomerase II inactivation prevents the completion of DNA replication in budding yeast. Molecular Cell. 2008 Jun 20;30(6):790-802.

24.	Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT. Topoisomerase levels determine chemotherapy response ''in vitro'' and ''in vivo''. Proc Natl Acad Sci USA. 2008 Jul 1;105(26):9053-8.

25.	Cho WJ, Le QM, My Van HT, Youl Lee K, Kang BY, Lee ES, Lee SK, Kwon Y. Design, docking, and synthesis of novel indeno[1,2-c]isoquinolines for the development of antitumor agents as topoisomerase I inhibitors. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3531-4.

26.	Cinelli MA, Cordero B, Dexheimer TS, Pommier Y, Cushman M. Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships. Bioorg Med Chem. 2009 Oct 15;17(20):7145-55. Epub 2009 Sep 6.

27.	Cinelli MA, Morrell AE, Dexheimer TS, Agama K, Agrawal S, Pommier Y, Cushman M. The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode. Bioorg Med Chem. 2010 Aug 1;18(15):5535-52. Epub 2010 Jun 20.

28.	Cinelli MA, Morrell A, Dexheimer TS, Scher ES, Pommier Y, Cushman C. Design, synthesis, and biological evaluation of 14-substituted aromathecins as Topoisomerase I inhibitors. J Med Chem. 2008 Aug 14;51(15):4609-19.

29.	Cushman M, Jayaraman M, Vroman JA, Fukunaga AK, Fox BM, Kohlhagen G, Strumberg D, Pommier Y. Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors. J Med Chem. 2000 Oct 5;43(20):3688-98.

30.	Holleran JL, Parise RA, Yellow-Duke AE, Egorin MJ, Eiseman JL, Covey JM, Beumer JH. Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776. J Pharm Biomed Anal. 2010 Sep 5;52(5):714-20.

31.	Ioanoviciu A, Antony S, Pommier Y, Staker BL, Stewart L, Cushman M. Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. J Med Chem. 2005;48:4803–14.

32.	Kinders RJ, Hollingshead M, Lawrence S, Ji J, Tabb B, Bonner WM, Pommier Y, Rubinstein L, Evrard YA, Parchment RE, Tomaszewski J, Doroshow JH; Development of a validated immunofluorescence assay for yH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. Clin Cancer Res. 2010 Nov 15;16(22):5447-57. Epub 2010 Oct 5.

33.	Kiselev E, Dexheimer TS, Pommier Y, Cushman M. Design, synthesis, and evaluation of dibenzo[c,h][1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents. J Med Chem. 2010 Dec 23;53(24):8716-26. Epub 2010 Nov 23.

34.	Marchand C, Antony S, Kohn KW, Cushman M, Ioanoviciu A, Staker BL, Burgin AB, Stewart L, Pommier Y. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trappingof topoisomerase I-DNA covalent complexes. Mol Cancer Ther. 2006 Feb;5(2):287-95.

35.	Morrell A, Placzek M, Parmley S, Grella B, Antony S, Pommier Y, Cushman M. Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors. J Med Chem. 2007 Sep 6;50(18):4388-404.

36.	Morrell A, Placzek M, Parmley S, Antony S, Dexheimer TS, Pommier Y, Cushman M. Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization. J Med Chem. 2007 Sep 6;50(18):4419-30.

37.	Morrell A, Jayaraman M, Nagarajan M, Fox BM, Meckley MR, Ioanoviciu A, Pommier Y, Antony S, Hollingshead M, Cushman M. Evaluation of indenoisoquinoline topoisomerase I inhibitors usinga hollow fiber assay. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4395-9.

38.	Nagarajan M, Morrell A, Antony S, Kohlhagen G, Agama K, Pommier Y, Ragazzon PA, Garbett NC, Chaires JB, Hollingshead M, Cushman M. Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors. J Med Chem. 2006 Aug 24;49(17):5129-40.

39.	Nagarajan M, Xiao X, Antony S, Kohlhagen G, Pommier Y, Cushman M. Design, synthesis, and biological evaluation of indenoisoquinoline topoisomerase I inhibitors featuring polyamine side chains on the lactam nitrogen. J Med Chem. 2003;46:5712–24.

40.	Pfister TD, Reinhold WC, Agama K, Gupta S, Khin SA, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH, Pommier Y. Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol Cancer Ther. 2009 Jul;8(7):1878-84. Epub 2009 Jul 7.

41.	Pommier Y, Cushman M. The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.Mol Cancer Ther. 2009 May;8(5):1008-14. Epub 2009 Apr 21.

42.	Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010 May 28;17(5):421-33.

43.	Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev. 2009 Jul;109(7):2894-902.

44.	Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789–802.

45.	Pommier Y. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. Curr Med Chem Anticancer Agents 2004;4:429-34.

46.	Song Y, Shao Z, Dexheimer TS, Scher ES, Pommier Y, Cushman M. Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors. J Med Chem. 2010 Mar 11;53(5):1979-89.

47.	Sordet O, Goldman A, Redon C, Solier S, Rao VA, Pommier Y Topoisomerase I requirement for death receptor-induced apoptotic nuclear fission. J Biol Chem. 2008 Aug 22;283(34):23200-8. Epub 2008 Jun 13.

48.	Staker BL, Feese MD, Cushman M, Pommier Y, Zembower D, Stewart L, Burgin AB. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem. 2005 Apr 7;48(7):2336-45.
49.	Teicher BA. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol. 2008;75:1262–71.

50.	seng CH, Chen YL, Lu PJ, Yang CN, Tzeng CC. Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Bioorg Med Chem. 2008;16:3153–62.

51.	Tuduri S, Crabbé L, Conti C, Tourrière H, Holtgreve-Grez H, Jauch A, Pantesco V, DeVos J, Thomas A, Theillet C, Pommier Y, Tazi J, Coquelle A, Pasero P. Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol. 2009 Nov;11(11):1315-24. Epub 2009 Oct 18.
52.	Van HT, Le QM, Lee KY, Lee ES, Kwon Y, Kim TS, Le TN, Lee SH, Cho WJ. Convenient synthesis of indeno[1,2-c]isoquinolines as constrained forms of 3-arylisoquinolines and docking study of a topoisomerase I inhibitor into DNA-topoisomerase I complex. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5763-7.

53.	M. Nagarajan, A. Morrell, A. Ioanoviciu, S. Antony, G. Kohlhagen. M. Hollingshead, Y. Pommier, and M. Cushman, &quot;Synthesis and Evaluation of Indenoisoquinoline Topoisomerase I Inhibitors Substituted with Nitrogen Heterocycles,&quot; J. Med. Chem. 49, 6283  (2006).


{{QuinoloneAntiBiotics}}
{{Chemotherapeutic agents}}

[[Category:Antibiotics]]
[[Category:Topoisomerase inhibitors]]</text>
      <sha1>8gb5pzgd6n8c4fis85wevr7kpfgc3im</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Surfactin</title>
    <ns>0</ns>
    <id>7136636</id>
    <revision>
      <id>584000154</id>
      <parentid>567085187</parentid>
      <timestamp>2013-12-01T03:15:21Z</timestamp>
      <contributor>
        <ip>173.28.189.33</ip>
      </contributor>
      <text xml:space="preserve" bytes="11613">{{Chembox
| ImageFile = Surfactin.png
|  ImageSize =
|  ImageAlt =
| IUPACName =
| OtherNames =
| Section1 = {{Chembox Identifiers
|  CASNo =
|  PubChem =
| ChEMBL = 508272
|  SMILES = CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O1}}
| Section2 = {{Chembox Properties
|  Formula = C53H93N7O13
|  MolarMass = 1036.3 g/mol
|  Appearance =
|  Density =
|  MeltingPt =
|  BoilingPt =
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards =
|  FlashPt =
|  Autoignition = }}
}}
{{Infobox protein family
| Symbol = 
| Name = 
| image = 
| width = 
| caption = 
| Pfam = 
| Pfam_clan =  
| InterPro = 
| SMART = 
| PROSITE = 
| MEROPS = 
| SCOP = 
| TCDB = 1.D.11
| OPM family = 172
| OPM protein = 2npv
| CAZy = 
| CDD = 
}}

'''Surfactin''' is a very powerful [[surfactant]] commonly used as an [[antibiotic]]. It is a [[bacteria]]l [[Cyclic compound|cyclic]] [[lipopeptide]], largely prominent for its exceptional surfactant power.&lt;ref&gt;Mor, A. Peptide-based antibiotics: A potential answer to raging antimicrobial resistance. ''Drug Develop. Res. (2000) 50'': 440–447.&lt;/ref&gt; Its [[amphiphilic]] properties help this substance to survive in both [[hydrophilic]] and [[hydrophobic]] environments. It is an antibiotic produced by the [[Gram-positive]] [[endospore]]-forming bacteria ''[[Bacillus subtilis]]''.&lt;ref&gt;Peypoux F, Bonmatin JM, Wallach J. Recent trends in the [[biochemistry]] of Surfactin; ''Applied Microbiol Biotechnol. (1999)'' 51:553–63&lt;/ref&gt; In the course of various studies of its properties, surfactin was found to exhibit effective characteristics like [[antibacterial]], [[Antiviral drug|antiviral]], [[Fungicide|antifungal]], anti-[[mycoplasma]] and [[hemolytic]] activities.&lt;ref&gt;Pooja Singh and Swaranjit Singh Cameotra; Potential applications of microbial surfactants in [[biomedical sciences]]; ''Institute of Microbial Technology'', Sector 39 A, [[Chandigarh]] 160036, [[India]].&lt;/ref&gt;

==Structure and Synthesis ==
Surfactin's structure consists of a [[peptide]] loop of seven [[amino acids]] (L-[[asparagine]], L-[[leucine]], [[glutamic acid]], L-leucine, L-[[valine]] and two D-leucines), and a hydrophobic [[fatty acid]] chain thirteen to fifteen [[carbon]]s long which allows it to penetrate [[cell membrane|cellular membranes]]. Glutamic acid and aspartic acid residues at positions 1 and 5 respectively, constituting a minor polar domain. On the opposite side, valine residue at position 4 extends down facing the fatty acid chain, making up a major hydrophobic domain. Below critical [[micella]]r concentrations (CMCs) the fatty acid tail can extend freely into [[solution]], and then participate in hydrophobic interactions within [[micelles]].&lt;ref&gt;Grau, A, J C. Gomez Fernandez, and R Peypoux. A Study on the Interactions of Surfactin With Phospholipid Vesicles. ''BBA (1999)'' 1418: 307–319.&lt;/ref&gt; This antibiotic is synthesized by a linear [[nonribosomal peptide]] [[synthetase]], [[surfactin synthetase]], and has, in solution, a characteristic &quot;horse saddle&quot; [[Chemical structure|conformation]] that explains its large spectrum of biological activity.&lt;ref&gt;Nathalie Hue, Laurent Serani, Olivier Laprévote; Structural investigation of cyclic peptidolipids from ''Bacillus subtilis'' by high-energy tandem [[mass spectrometry]]; ''Institut de Chimie des Substances Naturelles'', CNRS, avenue de la Terrasse, 91198 Gif-sur-Yvette, France.&lt;/ref&gt;

==Physical properties==

===Surface tension===
Surfactin, like other surfactants, affects the surface tension of liquids in which it is dissolved. It can lower the [[water]]'s [[surface tension]] from 72 m[[Newton (unit)|N]]/m to 27&amp;nbsp;mN/m at a concentration as low as 20 µ[[Concentration#Molarity|M]].&lt;ref&gt;Yeh MS, Wei YH, Chang JS. Enhanced Production of surfactin from ''Bacillus subtilis'' by addition of solid carriers (2005) ''Biotechnol Prog. 4'':1329–34&lt;/ref&gt; Surfactin accomplishes this effect as it occupies the intermolecular space between water [[molecule]]s, decreasing the attractive forces between adjacent water molecules, mainly [[hydrogen bond]]s, creating a more [[fluid]] solution that can go into tighter regions of space increasing water’s wetting ability.&lt;ref&gt;Dufour S, Deleu M, Nott K, Wathelet B, Thonart P, Paquot M. Hemolytic activity of new linear surfactin analogs in relation to their physico-chemical properties. (2005) ''BBAGEN 25949'':1–9&lt;/ref&gt; Overall, this property is significant not only for surfactin but for surfactants as a whole, as they are primarily used as detergents and [[soap]]s.

===Molecular mechanisms===
There are three prevailing [[hypotheses]] for how surfactin works.&lt;ref&gt;Deleu, M, O Bouffioux, H Razafindralambo, and M Paquot. Interaction of Surfactin with Membranes: A Computational Approach. ''(2003) Langmuir 19'': 3377–3385.&lt;/ref&gt; These are described below.

====Cation-carrier effect====
The cation-carrier effect is characterized by surfactin’s ability to drive [[Valence (chemistry)|monovalent]] and [[divalent]] cations through an [[Organic compound|organic]] barrier. The two [[acid]]ic residues aspartate and glutamate form a &quot;claw&quot; of sorts which easily stabilizes divalent [[cation]]s. [[Calcium]] ions make for the best-fitting cations stabilizing the surfactin conformation and functioning as an assembly template for the formation of [[micelles]]. When surfactin penetrates the outer sheet, its fatty acid chain interacts with the [[acyl]] chains of the [[phospholipid]]s, with its headgroup in proximity to the phospholipids polar heads. Attachment of a cation to causes the complex to cross the bilipidic layer undergoing a [[Flippase|flip-flop]]. The headgroup aligns itself with the phospholipids of the inner sheet and the fatty acid chain interacts with the phospholipids acyl chains.&lt;ref&gt;Heerklotz, H, T Wieprecht, and J Seelig. Membrane Perturbation oby the Lipopeptide Surfactin and Detergents as Studied by Deuterium NMR. ''J. Phys. Chem. (2004)108'': 4909–4915&lt;/ref&gt; The cation is then delivered into the intracellular medium.

====Pore-forming effect====
The pore-forming ([[ion channel]]) effect is characterized by the formation of cationic channels.  It would require surfactin to self-associate inside the membrane, since it cannot span across the cellular membrane. Supramolecular-like structures by successive [[molecular self-assembly|self-association]] could then form a channel. This hypothesis for the most part applies only to uncharged membranes where there is a minimal energy barrier between outer and inner membrane leaflets.&lt;ref&gt;Deleu, M, O Bouffioux, H Razafindralambo, and M Paquot. Interaction of Surfactin with Membranes: A Computational Approach. (2003) ''Langmuir 19'': 3377–3385.&lt;/ref&gt;

====Detergent effect====
The detergent effect draws on surfactin's ability to insert its fatty acid chain into the bilipidic layer causing disorganization leading to membrane permeability.&lt;ref&gt;Kragh-Hansen, U, M Maire, and J Moller. The Mechanism of Detergent Solubilization of Liposomes and Protein-Containing Membranes. ''Biophys. J. (1998) 75'': 2932–2946.&lt;/ref&gt; Insertion of several surfactin molecules into the membrane can lead to the formation of mixed micelles by self-association and bilayer influenced by fatty chain hydrophobicity ultimately leading to bilayer solubilization.&lt;ref&gt;Maire, M, P Champeil, and J V. Moller. Interaction of Membrane Proteins and lipids with Solubilizing Detergents. ''BBA  (2000) 1508'': 86–111.&lt;/ref&gt;

==Biological properties==
Surfactin has a nonspecific mode of action, which originates both benefits and disadvantages. It’s advantageous in the sense that surfactin can act on many kinds of cell membranes, both Gram-positive and Gram-negative. Its non-specificity also has bearing on its tendency to not produce [[Antibiotic resistance|resistant strains of bacteria]]. Consequently, this efficient mode of cell destruction is indiscriminate, and attacks [[red blood cells]] with deadly efficiency.

===Antibacterial and antiviral properties===
Surfactin, true to its antibiotic nature, has a very significant antibacterial property, as it is capable of penetrating the cell membranes of all types of bacteria. There are two main types of bacteria and they are [[Gram-negative]] and Gram-positive. The two bacteria types differ in the composition of their membrane. The Gram-negative bacteria have an outer [[lipopolysaccharide]] membrane and a thin peptidoglycan layer followed by a phospholipids bilayer, whereas the Gram-positive bacteria lack the outer membrane and carry a thicker [[peptidoglycan]] layer as well as a phospholipids bilayer.&lt;ref&gt;Bergey, John G. Holt, Noel R. Krieg, Peter H.A. Sneath (1994). ''Bergey's Manual of Determinative Bacteriology'', 9th ed., Lippincott Williams &amp; Wilkins. ISBN 0-683-00603-7.&lt;/ref&gt; This is an essential factor that contributes to surfactin’s detergent-like activity as it is able to create a permeable environment for the lipid bilayer and causes disruption that solubilizes the membrane.&lt;br&gt;
For surfactin to carry out its antibacterial property successfully, the bacterium needs to be treated with a high concentration. In fact, surfactin needs to be in concentrations between 12–50 µ[[gram|g]]/m[[Liter|l]] in order for it to carry out minimal antibacterial effects.&lt;ref&gt;Heerklotz H, Seelig J. Detergent-like action of the antibiotic peptide surfactin on lipid membranes. (2001) ''Biophysical J 81(3):''1547–54&lt;/ref&gt; This is also known as the minimum inhibitory concentration (MIC).&lt;br&gt;
The antiviral effects of surfactin distinguish this antibiotic from others. This property is such because surfactin has been found to disintegrate enveloped [[virus]]es. Surfactin not only disintegrates the viral lipid enveloped, but also the [[capsid]] of the virus through ion channel formations. This process has been proven through test on several envelop viruses such as [[HIV]] and [[Herpes simplex virus|HSV]].&lt;ref&gt;Jung M, Lee S, Kim H, Kim H. Recent Studies on Natural Products as Anti-HIV Agents. (2000). ''Current Medicinal Chemistry 7'':000-000&lt;/ref&gt; Also, the [[isoform]]s of the fatty acid chain containing 14 or 15 carbon atoms exhibited an improvement in inactivation of the viral envelops. Unfortunately, surfactin only affected cell-free viruses and those that had penetrated the cell were unaffected. Concurrently, if surfactin were exposed to a high medium of protein or lipid concentrations, its antiviral activity would be limited. This is also known as the buffer effect and is a significant drawback in surfactin’s antiviral activity.

===Toxicity===
Surfactin has only one drawback: its non specific cytotoxicity. This is seen as surfactin has the ability to [[lysis|lyse]] a cell. The hemolytic effect has been the result of surfactin having the ability to lyse red blood cells that is enough to warrant caution if used [[intravascular]]ly. Fortunately, these results were seen at high concentrations of about 40 µM to 60 µM. These concentrations also exhibited the effect of proliferating cells in vitro though it also was the {{LD50}} for this type of cells.&lt;ref&gt;[http://www.cibasc.com/index/ind-index/ind-per_car/ind-pc-ah/ind-pc-triclosan.htm Triclosan Information @ Ciba Specialty Chemicals.]&lt;/ref&gt; At concentrations below 25 µM, toxicity effects of surfactin are not significant.

==References==
{{Reflist|2}}

[[Category:Colloidal chemistry]]
[[Category:Cleaning product components]]
[[Category:Surfactants]]
[[Category:Antibiotics]]
[[Category:Lipopeptides]]</text>
      <sha1>fpfe0577gpnxidz3ivztfh0bq9c6610</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Aphidicolin</title>
    <ns>0</ns>
    <id>4149080</id>
    <revision>
      <id>575374857</id>
      <parentid>575373684</parentid>
      <timestamp>2013-10-02T01:47:49Z</timestamp>
      <contributor>
        <username>CheMoBot</username>
        <id>7377957</id>
      </contributor>
      <comment>Updating {{chembox}} (no changed fields - updated 'CASNo_Ref') per [[WP:CHEMVALID|Chem/Drugbox validation]] (report [[Wikipedia_talk:WikiProject_Chemicals|errors]] or [[user talk:CheMoBot|bugs]])</comment>
      <text xml:space="preserve" bytes="2537">{{chembox
| verifiedrevid = 441877939
|ImageFile=Aphidicolin structure.png
|ImageSize=200px
|IUPACName= (3''R'',4''R'',4a''R'',6a''S'',8''R'',9''R'',11a''S'',11b''S'')-4,9-bis(hydroxymethyl)-4,11b-dimethyltetradecahydro-8,11a-methanocyclohepta[''a'']naphthalene-3,9-diol
|OtherNames=
|Section1={{Chembox Identifiers
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10280269
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 29711
| InChI = 1/C20H34O4/c1-17(11-21)15-4-3-13-9-14-10-19(13,7-8-20(14,24)12-22)18(15,2)6-5-16(17)23/h13-16,21-24H,3-12H2,1-2H3/t13-,14+,15-,16+,17-,18-,19-,20-/m0/s1
| InChIKey = NOFOAYPPHIUXJR-APNQCZIXBU
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H34O4/c1-17(11-21)15-4-3-13-9-14-10-19(13,7-8-20(14,24)12-22)18(15,2)6-5-16(17)23/h13-16,21-24H,3-12H2,1-2H3/t13-,14+,15-,16+,17-,18-,19-,20-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NOFOAYPPHIUXJR-APNQCZIXSA-N
| CASNo_Ref = {{cascite|correct|??}}
| CASNo=38966-21-1
|  PubChem=457964
|  SMILES = OC[C@@]4(O)CC[C@]31C[C@H]4C[C@@H]3CC[C@H]2[C@](C)(CO)[C@H](O)CC[C@]12C
}}
|Section2={{Chembox Properties
|C=20|H=34|O=4
|  MolarMass=338.48 g/mol
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3={{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}

'''Aphidicolin''' is defined as a tetracyclic [[diterpene]] [[antibiotic]] with antiviral and antimitotical properties.  Aphidicolin is a reversible [[Enzyme inhibitor|inhibitor]] of [[eukaryote|eukaryotic]] nuclear [[DNA]] replication. It blocks the cell cycle at early [[S phase]]. It is a specific inhibitor of [[DNA polymerase]] A,D in eukaryotic cells and in some viruses and an [[apoptosis]] inducer in [[HeLa]] cells.
&lt;br&gt;Natural aphidicolin is a secondary metabolite of the fungus ''[[Nigrospora oryzae]]''.&lt;ref&gt;[http://www.fermentek.co.il/aphidicolin.htm Aphidicolin product page] from [[Fermentek]]&lt;/ref&gt;

== References ==
* {{cite journal |author=Dhillon VS, Husain SA, Ray GN |title=Expression of aphidicolin-induced fragile sites and their relationship between genetic susceptibility in breast cancer, ovarian cancer, and non-small-cell lung cancer patients |journal=Teratog., Carcinog. Mutagen. |volume=Suppl 1 |issue= |pages=35–45 |year=2003 |pmid=12616595 |doi=10.1002/tcm.10068 |url=}}

&lt;references/&gt;

[[Category:Antibiotics]]
[[Category:Transferase inhibitors]]
[[Category:Diterpenes]]
[[Category:Cycloheptanaphthalenes]]

{{organic-compound-stub}}</text>
      <sha1>lk6pe45y3i880wqli9pe0dyuk4h42vl</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Antibiotic sensitivity</title>
    <ns>0</ns>
    <id>2943640</id>
    <revision>
      <id>582676383</id>
      <parentid>578589022</parentid>
      <timestamp>2013-11-21T14:43:06Z</timestamp>
      <contributor>
        <username>Ashwin Bhosle</username>
        <id>18571707</id>
      </contributor>
      <minor/>
      <comment>2 citations added</comment>
      <text xml:space="preserve" bytes="2351">{{Unreferenced|date=January 2013}}
[[Image:KB test.jpg|right|thumb|'''Antibiotic sensitivity''' Thin wafers containing [[antibiotic]] have been placed on an agar plate growing bacteria. Bacteria are not able to grow around antibiotics to which they are sensitive]]
'''Antibiotic sensitivity''' is the susceptibility of [[bacteria]] to [[antibiotic]]s. Antibiotic susceptibility testing (AST) is usually carried out to determine which antibiotic will be most successful in treating a bacterial infection ''in vivo''. Testing for antibiotic sensitivity is often done by the [[Kirby-Bauer antibiotic testing|Kirby-Bauer method]]. Small wafers containing antibiotics are placed onto a plate upon which bacteria are growing. If the bacteria are sensitive to the antibiotic, a clear ring, or zone of inhibition, is seen around the wafer indicating poor growth. Other methods to test antimicrobial susceptibility include the Stokes method, [[E-test]] (also based on antibiotic diffusion). Agar and Broth dilution methods for [[Minimum inhibitory concentration|Minimum Inhibitory Concentration]] determination.&lt;ref&gt;http://www.slideshare.net/doctorrao/antibiotic-sensitivity-testing-presentation&lt;/ref&gt;

Ideal antibiotic therapy is based on determination of the aetiological agent and its relevant antibiotic sensitivity. Empiric treatment is often started before laboratory microbiological reports are available when treatment should not be delayed due to the seriousness of the disease. The effectiveness of individual antibiotics varies with the location of the infection, the ability of the antibiotic to reach the site of infection, and the ability of the bacteria to resist or inactivate the antibiotic. Some antibiotics actually kill the bacteria ([[bactericidal]]), whereas others merely prevent the bacteria from multiplying ([[bacteriostatic]]) so that the host's immune system can overcome them. [[Mueller-Hinton agar|Müeller-Hinton agar]] is most frequently used in this antibiotic susceptibility test.
&lt;ref&gt;http://www.microrao.com/micronotes/antibiotic.pdf&lt;/ref&gt;
== See also ==
* [[Antibiotic resistance]]
* [[Miles and Misra method|Miles-Misra method]]

== References ==
{{reflist}}

==External links==
* [http://www.drkoop.com/ency/93/003741.html Research Data]
* [http://people.ku.edu/~jbrown/antibiotic.html Raw Data]

[[Category:Antibiotics]]</text>
      <sha1>p3y9naq0pow6ah831m0c58y31o50rmo</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Antimycin A</title>
    <ns>0</ns>
    <id>3163120</id>
    <revision>
      <id>603294156</id>
      <parentid>590596544</parentid>
      <timestamp>2014-04-08T12:20:18Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>/* Mechanism of action */Task 4: Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated coauthor parameter errors]] ([[Wikipedia:Bots/Requests for approval/Monkbot 4|bot trial]])</comment>
      <text xml:space="preserve" bytes="5055">{{Chembox
| Verifiedfields = changed
| verifiedrevid = 457132775
|ImageFile=Antimycin A.svg
|ImageSize=
|IUPACName= (2{R},3{S},6{S},7{R},8{R})-3-[(3-formamido-
2-hydroxybenzoyl)amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-
1,5-dioxonan-7-yl 3-methylbutanoate
|OtherNames=
|Section1= {{Chembox Identifiers
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 14246
| InChI1 = 1/C28H40N2O9/c1-6-7-8-9-11-20-25(39-22(32)14-16(2)3)18(5)38-28(36)23(17(4)37-27(20)35)30-26(34)19-12-10-13-21(24(19)33)29-15-31/h10,12-13,15-18,20,23,25,33H,6-9,11,14H2,1-5H3,(H,29,31)(H,30,34)/t17-,18+,20-,23+,25+/m1/s1
| InChIKey1 = UIFFUZWRFRDZJC-SBOOETFBBB
| CASNo_Ref = {{cascite|changed|??}}
| CASNo=642-15-9
|  ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 211501
| PubChem = 14957
|  ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 22584
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C28H40N2O9/c1-6-7-8-9-11-20-25(39-22(32)14-16(2)3)18(5)38-28(36)23(17(4)37-27(20)35)30-26(34)19-12-10-13-21(24(19)33)29-15-31/h10,12-13,15-18,20,23,25,33H,6-9,11,14H2,1-5H3,(H,29,31)(H,30,34)/t17-,18+,20-,23+,25+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UIFFUZWRFRDZJC-SBOOETFBSA-N
| SMILES = O=CNc1cccc(c1O)C(=O)N[C@@H]2C(=O)O[C@H]([C@H](OC(=O)CC(C)C)[C@H](C(=O)O[C@@H]2C)CCCCCC)C
|  MeSHName=Antimycin+A
  }}
|Section2= {{Chembox Properties
|  Formula=C&lt;sub&gt;28&lt;/sub&gt;H&lt;sub&gt;40&lt;/sub&gt;N&lt;sub&gt;2&lt;/sub&gt;O&lt;sub&gt;9&lt;/sub&gt;
|  MolarMass=548.63 g/mol
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3= {{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}
'''Antimycins''' are a group of secondary metabolites produced by ''[[Streptomyces]]'' bacteria.&lt;ref name=&quot;pmid4558141&quot;&gt;{{cite journal |author=Neft N, Farley TM |title=Conditions influencing antimycin production by a Streptomyces species grown in chemically defined medium |journal=Antimicrob. Agents Chemother. |volume=1 |issue=3 |pages=274–6 |date=March 1972 |pmid=4558141 |pmc=444205 |doi= |url=http://aac.asm.org/cgi/pmidlookup?view=long&amp;pmid=4558141}}&lt;/ref&gt;

== Uses ==
It is the active ingredient in Fintrol, a chemical [[piscicide]] ([[fish]] [[poison]]) used in [[fisheries]] management and in the [[catfish]] industry.&lt;ref name=&quot;pest&quot;&gt;{{cite web|url=http://www.pesticideinfo.org/Detail_Product.jsp?REG_NR=03909600002&amp;DIST_NR=039096|title=Fintrol concentrate|publisher=PAN Pesticides Database - Pesticide Products|accessdate=9 February 2010}}&lt;/ref&gt;

== Mechanism of action ==
Antimycin A binds to the Qi site of [[Coenzyme Q – cytochrome c reductase|cytochrome c reductase]], thereby inhibiting the [[oxidation]] of [[ubiquinol]] in the [[electron transport chain]] of oxidative phosphorylation. The inhibition of this reaction disrupts the formation of the [[Electrochemical gradient|proton gradient]] across the [[Inner mitochondrial membrane|inner membrane]]. The production of ATP is subsequently inhibited, as protons are unable to flow through the ATP synthase complex in the absence of a proton gradient. This inhibition also results in the formation of quantities of the toxic free radical [[superoxide]].&lt;ref name=&quot;pmid15007303&quot;&gt;{{cite journal |author=Dairaku N, Kato K, Honda K, et al.
|title = Oligomycin and antimycin A prevent nitric oxide–induced apoptosis by blocking cytochrome C leakage  |journal=J. Lab. Clin. Med. |volume=143 |issue=3 |pages=143–51 |date=March 2004 |pmid=15007303 |doi=10.1016/j.lab.2003.11.003 |url=http://linkinghub.elsevier.com/retrieve/pii/S0022214303002385}}&lt;/ref&gt;

It has also been found to inhibit the cyclic electron flow within [[photosynthesis|photosynthetic]] systems along the proposed [[ferredoxin]] quinone reductase pathway.{{Citation needed|date=February 2010}}

Fungus-growing attine ants have been shown to use antimycins - produced by symbiotic Streptomyces bacteria - in their fungiculture, to inhibit non-cultivar (i.e. pathogenic) fungi.&lt;ref&gt;{{cite journal|last=Schoenian|author2=et al|journal=Proc Natl Acad Sci USA|year=2011|volume=108|issue=5|doi=10.1073/pnas.1008441108|url=http://www.pnas.org/content/108/5/1955.long|title=Chemical basis of the synergism and antagonism in microbial communities in the nests of leaf-cutting ants|first1=I.|pages=1955–1960|pmid=21245311|pmc=3033269}}&lt;/ref&gt; One research group studying these symbiotic Streptomyces bacteria recently identified the biosynthetic gene cluster for antimycins, which was unknown despite the compounds themselves being identified 60 years ago. Antimycins are synthesised by a hybrid polyketide synthase (PKS)/non-ribosomal peptide synthase (NRPS).&lt;ref&gt;Seipke, R.F., Barke, J., Brearley, C., Hill, L., Yu, D.W., Goss, R.G. and Hutchings, M.I. (2011). A single Streptomyces mutualist makes multiple antifungals to support the fungus farming ant Acromyrmex octospinosus. PLoS ONE. In Press&lt;/ref&gt;

== References ==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Toxicology]]
[[Category:Salicylamides]]
[[Category:Lactones]]
[[Category:Carboxylate esters]]
[[Category:Isobutyrates]]</text>
      <sha1>pdmgv1qzft77puj99xxtbshg0fypsbv</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Gliotoxin</title>
    <ns>0</ns>
    <id>8016328</id>
    <revision>
      <id>604384655</id>
      <parentid>575374172</parentid>
      <timestamp>2014-04-16T01:07:55Z</timestamp>
      <contributor>
        <username>BattyBot</username>
        <id>15996738</id>
      </contributor>
      <minor/>
      <comment>fixed [[Help:CS1 errors#bad_date|CS1 errors: dates]] to meet [[MOS:DATEFORMAT]] (also [[WP:AWB/GF|General fixes]]) using [[Project:AWB|AWB]] (10069)</comment>
      <text xml:space="preserve" bytes="7012">{{chembox
| Watchedfields = changed
| verifiedrevid = 441932116
| ImageFile = Gliotoxin.png
| ImageSize = 
| IUPACName = (3''R'',6''S'',10a''R'')-6-hydroxy-3-(hydroxymethyl)-2-methyl-2,3,6,10-tetrahydro-5a''H''-3,10a-epidithiopyrazino[1,2-''a'']indole-1,4-dione
| OtherNames = 
|C=13|H=14|N=2|O=4|S=2
| Section1 = {{Chembox Identifiers
| Abbreviations = 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5988
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 331627
| ChEMBL2 = 145588
| InChI = 1S/C13H14N2O4S2/c1-14-10(18)12-5-7-3-2-4-8(17)9(7)15(12)11(19)13(14,6-16)21-20-12/h2-4,8-9,16-17H,5-6H2,1H3/t8-,9-,12+,13+/m0/s1
| InChIKey = FIVPIPIDMRVLAY-RBJBARPLBT
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C13H14N2O4S2/c1-14-10(18)12-5-7-3-2-4-8(17)9(7)15(12)11(19)13(14,6-16)21-20-12/h2-4,8-9,16-17H,5-6H2,1H3/t8-,9-,12+,13+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = FIVPIPIDMRVLAY-RBJBARPLSA-N
| InChIKey1 = FIVPIPIDMRVLAY-RBJBARPLSA-N
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 67-99-2
| EINECS = 
| PubChem = 6223
| SMILES = O=C1N([C@@]2(SS[C@@]14N(C2=O)[C@H]3C(=C\C=C/[C@@H]3O)/C4)CO)C
| InChI = 
| RTECS =
| MeSHName =
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI =
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = 
| ATCCode = }}
| Section2 = {{Chembox Properties
| Formula = C&lt;sub&gt;13&lt;/sub&gt;H&lt;sub&gt;14&lt;/sub&gt;N&lt;sub&gt;2&lt;/sub&gt;O&lt;sub&gt;4&lt;/sub&gt;S&lt;sub&gt;2&lt;/sub&gt;
| MolarMass = 326.4 g/mol
| Appearance = white to light yellow solid
| Density = 1.75 g/ml
| MeltingPt = 
| Melting_notes =
| BoilingPt = 
| Boiling_notes = 
| Solubility = 
| SolubleOther = soluble
| Solvent = DMSO
| pKa = 
| pKb = 
| IsoelectricPt = 
| SpecRotation = 
| RefractIndex = 
| Viscosity = 
| Dipole = }}
| Section3 = {{Chembox Structure
| CrystalStruct = 
| Coordination = 
| MolShape = 
| Dipole = }}
| Section4 = {{Chembox Thermochemistry
| DeltaHf = 
| DeltaHc = 
| Entropy = 
| HeatCapacity = }}
| Section5 = {{Chembox Pharmacology
| AdminRoutes =
| Bioavail = 
| Metabolism = 
| HalfLife = 
| ProteinBound
| Excretion = 
| Legal_status =
| Legal_US =
| Legal_UK =
| Legal_AU =
| Legal_CA =
| PregCat = 
| PregCat_AU = 
| PregCat_US = }}
| Section6 = {{Chembox Explosive
| ShockSens = 
| FrictionSens = 
| ExplosiveV = 
| REFactor = }}
| Section7 = {{Chembox Hazards
| ExternalMSDS = [http://www.fermentek.co.il/MSDS/Gliotoxin-MSDS.htm MSDS] from [[Fermentek]]
| EUClass = 
| EUIndex = 
| MainHazards = 
| NFPA-H = 
| NFPA-F = 
| NFPA-R = 
| NFPA-O =  
| RPhrases = 
| SPhrases = 
| RSPhrases =
| FlashPt = 
| Autoignition = 
| ExploLimits = 
| PEL = }}
| Section8 = {{Chembox Related
| OtherAnions = 
| OtherCations = 
| OtherFunctn = 
| Function = 
| OtherCpds = }}
}}
'''Gliotoxin''' is a [[sulfur|sulfur-containing]] [[mycotoxin]] produced by several species of  [[fungus|fungi]], including [[human pathogen|pathogens of humans]] such as ''[[Aspergillus fumigatus]]'',&lt;ref name=&quot;Scharf&quot;&gt;{{cite journal|author=Scharf DH, Heinekamp T, Remme N, Hortschansky P, Brakhage AA, Hertweck C.|year= 2012|title=Biosynthesis and function of gliotoxin in Aspergillus fumigatus|journal=Appl Microbiol Biotechnol.|volume=93|pages=467–72|pmid=22094977|doi=10.1007/s00253-011-3689-1}}&lt;/ref&gt;  and also by species of ''[[Trichoderma]]'', and ''[[Penicillium]]''. Gliotoxin has also been reported from [[yeast]]s of the genus ''[[Candida (genus)|Candida]]'',&lt;ref&gt;Larsen, B,Shah, D, 1991 &quot;Candida isolates of yeast produce a gliotoxin-like substance&quot; Mycopathologia 116:203-208, 1991.&lt;/ref&gt; but results from other studies have cast doubt on the production of this metabolite by ''Candida'' fungi.&lt;ref name=&quot;Kupfahl&quot;&gt;{{cite journal|author=Kupfahl C, Ruppert T, Dietz A, Geginat G, Hof H.|year= 2007|title=Candida species fail to produce the immunosuppressive secondary metabolite gliotoxin in vitro|journal=FEMS Yeast Res|volume=7|pages=986–92|pmid=17537180|doi=10.1111/j.1567-1364.2007.00256.x|issue=6}}&lt;/ref&gt;&lt;ref name=&quot;Kosalec&quot;&gt;{{cite journal|author=Kosalec I, Puel O, Delaforge M, Kopjar N, Antolovic R, Jelic D, Matica B, Galtier P, Pepeljnjak S.|year= 2010|title=Isolation and cytotoxicity of low-molecular-weight metabolites of Candida albicans|journal=Front Biosci|volume=13|pages=6893–904|pmid=18508703|doi=10.2741/3197}}&lt;/ref&gt; Gliotoxin was originally isolated from ''Gliocladium fimbriatum'', and was named accordingly. It is an epipolythiodioxopiperazine metabolite.

Gliotoxin possesses [[immunosuppressive]] properties as it may suppress and cause [[apoptosis]] in certain types of cells of the [[immune system]], including [[neutrophil]]s, [[eosinophil]]s,  [[granulocytes]], [[macrophage]]s, and [[thymocyte]]s. It also acts as an inhibitor of [[farnesyl transferase]]. It noncompetitively inhibits the [[chymotrypsin]]-like activity of the 20S [[proteasome]]. [[In vivo]] it displays [[anti-inflammatory]] activity.&lt;ref&gt;http://www.biomol.com/SiteData/docs/productdata/pi129.pdf&lt;/ref&gt; It acts by blocking [[thiol]] groups in the [[cell membrane]]s. It was investigated as an [[antibiotic]] and [[Antifungal medication|antifungal]] in the 1940s and recently as an [[Antiviral drug|antiviral]] agent.&lt;ref name=v45n02&gt;{{citation|url=http://kb.osu.edu/dspace/bitstream/1811/3460/1/V45N02_045.pdf|title=Effects of Gliotoxin on Trichophyton Gypseum|work=The Ohio Journal of Science|date=March 1945|last=Herrick|first=J. Arthur}}&lt;/ref&gt;&lt;ref name=ArV&gt;{{citation|url=http://www.springerlink.com/content/xu77512357275320/|title=Antiviral action of gliotoxin |work=Archives of Virology|date=March 2, 2005|last=McDougall|first=J. K.}}&lt;/ref&gt;

==Biosynthesis==
&lt;gallery&gt;
File:Glitoxin.png
&lt;/gallery&gt;

== References ==
&lt;references /&gt;
*''Identification of an agent in cultures of ''Aspergillus fumigatus'' displaying anti-phagocytic and immunomodulating activity in vitro'': A. Müllbacher, et al.; J. Gen. Microbiol. 131, 1251 (1985)

* ''Clinical Isolates of yeast produce a gliotoxin-like substance&quot;. D. Shah and B. Larsen; Mycopatholgia 116: 203-208,(1991)
 
*&quot;Mechanism of gliotoxin action and factors mediating gliotoxin sensitivity&quot;. R.W. Jones &amp; J.G. Hancock; J. Gen. Microbiol. 134: 2067-2075 (1988)

* ''Gliotoxin stimulates Ca&lt;sup&gt;2+&lt;/sup&gt; release from intact rat liver mitochondria'': M. Schweizer &amp; C. Richter; Biochemistry 33, 13401 (1994)
 
*''Extracellular calcium is not required for gliotoxin or dexamethasone- induced DNA fragmentation: a reappraisal of the use of EGTA'': P. Waring &amp; A. Sjaarda; Int. J. Immunopharmacol. 17, 403 (1995)

== External links ==
Puri, A., Ahmad, A. and Panda, B. P. (2010), Development of an HPTLC-based diagnostic method for invasive aspergillosis. Biomed. Chromatogr., 24: 887–892. doi: 10.1002/bmc.1382 [http://onlinelibrary.wiley.com/doi/10.1002/bmc.1382/abstract]
* [http://www.fermentek.co.il/gliotoxin.htm Gliotoxin] product page from [[Fermentek]]

{{Toxins}}

[[Category:Antibiotics]]
[[Category:Mycotoxins]]
[[Category:Immunosuppressants]]
[[Category:Indoles]]
[[Category:Lactams]]
[[Category:Alcohols]]</text>
      <sha1>8qxhozctzb9jqxn1l42dgs75ia5gep0</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Clofazimine</title>
    <ns>0</ns>
    <id>3321174</id>
    <revision>
      <id>607397259</id>
      <parentid>605283999</parentid>
      <timestamp>2014-05-06T22:29:17Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>/* Metabolism */Task 3: Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated coauthor parameter errors]]</comment>
      <text xml:space="preserve" bytes="14445">{{Drugbox
| verifiedrevid = 460042943
| IUPAC_name = ''N'',5-''bis''(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine
| image = Clofazimine.svg
| width = 150

&lt;!--Clinical data--&gt;
| tradename = Lamprene
| Drugs.com = {{drugs.com|monograph|clofazimine}}
| MedlinePlus = a682128
| pregnancy_category =  
| legal_status =  
| routes_of_administration =  

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life = 70 days

&lt;!--Identifiers--&gt;
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 2030-63-9
| ATC_prefix = J04
| ATC_suffix = BA01
| ATC_supplemental =  
| PubChem = 2794
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00845
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2692
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = D959AE5USF
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00278
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1292

&lt;!--Chemical data--&gt;
| C=27 | H=22 | Cl=2 | N=4 
| molecular_weight = 473.396 g/mol
| smiles = Clc1ccc(cc1)NC=3/C(=N/C(C)C)/C=C2/N(c4c(\N=C2C=3)cccc4)c5ccc(Cl)cc5
| InChI = 1/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3/b30-24+
| InChIKey = WDQPAMHFFCXSNU-BGABXYSRBX
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3/b30-24+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WDQPAMHFFCXSNU-BGABXYSRSA-N
| synonyms = &lt;small&gt;''N'',5-''bis''(4-chlorophenyl)-3-(1-methylethylimino)-5''H''-phenazin-2-amine &lt;/small&gt;
}}
'''Clofazimine''' is a fat-soluble riminophenazine dye used in combination with [[rifampicin]] and [[dapsone]] as multidrug therapy (MDT) for the treatment of [[leprosy]]. It has been used investigationally in combination with other antimycobacterial drugs to treat ''[[Mycobacterium avium]]'' infections in [[AIDS]] patients and ''[[Mycobacterium avium paratuberculosis]]'' infection in [[Crohn's disease]] patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, [[erythema]] nodosum leprosum (ENL). (From AMA Drug Evaluations Annual, 1993, p1619). The drug is given as an alternative to patients who can not tolerate the effects of [[dapsone]] for tuberculosis.&lt;ref name=&quot;ReferenceA&quot;&gt;Clinical Microbiology Made Ridiculously Simple&lt;/ref&gt;

&lt;!-- Society and culture --&gt;
It is on the [[World Health Organization's List of Essential Medicines]], a list of the most important medication needed in a basic [[health system]].&lt;ref&gt;{{cite web|title=WHO Model List of EssentialMedicines|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|work=World Health Organization|accessdate=22 April 2014|date=October 2013}}&lt;/ref&gt;

==Side effects==

Eosinophilic enteritis, GI irritation, and discoloration of the skin upon exposure to the sun are the major reported side effects.&lt;ref name=&quot;ReferenceA&quot;/&gt;

Clofazimine produces pink to brownish skin pigmentation in 75-100% of patients within a few weeks, as well as similar discoloration of most bodily fluids and secretions. These discolorations are reversible but may take months to years to disappear. The prescribing information indicates that several patients have developed [[Depression (mood)|depression]] as a result of this chronic skin discoloration, resulting in two [[suicide]]s.

Cases of [[icthyosis]] and skin dryness are also reported in response to this drug (8%-28%), as well as rash and pruritis (1-5%).

40-50% of patients develop gastrointestinal intolerance. Rarely, patients have died from bowel obstructions and intestinal bleeding, or required abdominal surgery to correct the same.

==Mechanism==
Clofazimine works by binding to the guanine bases of bacterial DNA, thereby blocking the template function of the DNA and inhibiting bacterial proliferation.&lt;ref name=&quot;Arbiser&quot;&gt;{{cite journal | author = Arbiser JL, Moschella SL |date=Feb 1995 | title = Clofazimine: a review of its medical uses and mechanisms of action | url = | journal = J Am Acad Dermatol | volume = 32 | issue = 2  Pt 1 | pages = 241–7 }}&lt;/ref&gt;&lt;ref name=&quot;Morrison&quot;&gt;{{cite journal | author = Morrison N. E., Morley G. M. | year = 1976 | title = The mode of action of clofazimine: DNA binding studies | url = | journal = Int. J. Lepr. | volume = 44 | issue = | pages = 133–135 }}&lt;/ref&gt; It also increases activity of bacterial phospholipase A2, leading to release and accumulation of lysophospholipids,&lt;ref name=&quot;Arbiser&quot;/&gt;&lt;ref name=&quot;Morrison&quot;/&gt; which are toxic and inhibit bacterial proliferation.&lt;ref&gt;Dennis, E. A. 1983. Phospholipases, p. 307-353. In P. D. Boyer
(ed.), The enzymes, 3rd ed., vol. 16. Lipid enzymology. Academic Press, Inc., New York.&lt;/ref&gt;&lt;ref&gt;{{cite journal | doi = 10.1111/j.1749-6632.1989.tb14913.x | author = Kagan V. E. | year = 1989 | title = Tocopherol stabilizes membrane against phospholipase A, free fatty acids and lysophospholipids | url = | journal = Ann. N.Y. Acad. Sci. | volume = 570 | issue = | pages = 121–135 | pmid = 2698101 }}&lt;/ref&gt;

Clofazimine does also act as [[FIASMA]] (functional inhibitor of [[Sphingomyelin phosphodiesterase|acid sphingomyelinase]]).&lt;ref name=&quot;pmid18504571&quot;&gt;{{cite journal |author=Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, Mühle C, Terfloth L, Groemer T, Spitzer G, Liedl K, Gulbins E, Tripal P|title=Identification of novel functional inhibitors of acid sphingomyelinase|journal=PLOS ONE|volume=6|issue=8|pages=e23852|year=2011|doi=10.1371/journal.pone.0023852|pmid=21909365|pmc=3166082}}&lt;/ref&gt;

==Supply==
Clofazimine is marketed under the trade name '''Lamprene''' by [[Novartis]]. One of the only suppliers of clofazimine's active pharmaceutical ingredient in the world is Sangrose Laboratories, located at [[Mavelikara]] in the southern Indian state of [[Kerala]].

==Metabolism==
Clofazimine has a very long half life of about 70 days. [[Autopsy|Autopsies]] performed on clofazimine patients have found [[crystal]]-like drug-membrane aggregates in the intestinal mucosa, [[liver]], [[spleen]], and [[lymph nodes]].&lt;ref name = &quot;Baik&quot;&gt;{{cite journal
  | last = Baik | first = J. | authorlink =  |author2=Rosania, G. R.
  | title = Molecular Imaging of Intracellular Drug–Membrane Aggregate Formation
  | journal = [[Molecular Pharmaceutics]]
  | volume = 8 | issue = 5 | pages = 1742–1749
  | publisher =  | location =  | date = 2011-07-29
  | language =  | url = http://pubs.acs.org/doi/abs/10.1021/mp200101b
  | doi = 10.1021/mp200101b
  | pmid = 21800872 | accessdate = 2012-02-01}}&lt;/ref&gt;

==Immunosuppressive effects==
The immunosuppressive effects of clofazimine were immediately noticed when applied in animal model. Macrophages were first reported to be inhibited due to the stabilization of lysosomal membrane by clofazimine.&lt;ref name=&quot;pmid4948088&quot;&gt;{{cite journal |author=Conalty ML, Barry VC, Jina A |title=The antileprosy agent B.663 (Clofazimine) and the reticuloendothelial system. |journal=Int J Lepr Other Mycobact Dis. |volume=39 |issue=2 |pages=479–92 |date=Apr 1971 |pmid=4948088 |doi= |url=}}&lt;/ref&gt; Clofazimine also showed a dosage-dependent inhibition of neutrophil motility, lymphocyte transformation,&lt;ref name=&quot;pmid7098757&quot;&gt;{{cite journal |author=Gatner EM, Anderson R, van Remsburg CE, Imkamp FM. |title=The in vitro and in vivo effects of clofazimine on the motility of neutrophils and transformation of lymphocytes from normal individuals. |journal=Lepr Rev. |volume=53 |issue=2 |pages=85–90 |date=Jun 1982 |pmid=7098757 |doi= |url=}}&lt;/ref&gt; mitogen-induced [[PBMC]] proliferation &lt;ref name=&quot;pmid7049077&quot;&gt;{{cite journal |author=van Rensburg CE, Gatner EM, Imkamp FM, Anderson R. |title=Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. |journal=Antimicrob Agents Chemother. |volume=21 |issue=5 |pages=693–7 |date=May 1982 |pmid=7049077 |doi= |url= |pmc=181995}}&lt;/ref&gt; and complement-mediated solubilization of pre-formed immune complexes in vitro.&lt;ref name=&quot;pmid1624226&quot;&gt;{{cite journal |author=Kashyap A, Sehgal VN, Sahu A, Saha K. |title=Anti-leprosy drugs inhibit the complement-mediated solubilization of pre-formed immune complexes in vitro. |journal=Int J Immunopharmacol. |volume=14 |issue=2 |pages=269–73 |date=Feb 1992 |pmid=1624226 |doi= 10.1016/0192-0561(92)90039-N|url=}}&lt;/ref&gt; A mechanistic studying of clofazimine in human [[T cells]] revealed that this drug is a Kv1.3 ([[KCNA3]]) channel blocker.&lt;ref name=&quot;pmid19104661&quot;&gt;{{cite journal |author=Ren YR, Pan F, Parvez S, Fleig A, Chong CR, Xu J, Dang Y, Zhang J, Jiang H, Penner R, Liu JO. |editor1-last=Alberola-Ila |editor1-first=Jose |title=Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. |journal=PLOS ONE |volume=3 |issue=12 |pages=e4009 |date=Dec 2008 |pmid=19104661 |doi= 10.1371/journal.pone.0004009|url= |pmc=2602975}}&lt;/ref&gt; This indicates that clofazimine will be potentially used for treatment of [[multiple sclerosis]], [[rheumatoid arthritis]] and [[type 1 diabetes]]. Because the Kv1.3-high effector memory T cells (T&lt;sub&gt;EM&lt;/sub&gt;) are actively involved in the development of these diseases,&lt;ref name=&quot;pmid17088564&quot;&gt;{{cite journal |author=Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, Knaus HG, Nepom GT, Gutman GA, Calabresi PA, Chandy KG. |title=Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. |journal=Proc Natl Acad Sci U S A. |volume=103 |issue=46 |pages=17414–9 |date=Nov 2006 |pmid=17088564 |doi= 10.1073/pnas.0605136103|url= |pmc=1859943}}&lt;/ref&gt; and Kv1.3 activity is essential for stimulation and proliferation of T&lt;sub&gt;EM&lt;/sub&gt; by regulating calcium influx in the T cells.&lt;ref name=&quot;pmid12782673&quot;&gt;{{cite journal |author=Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG. |title=The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. |journal=J Clin Invest. |volume=111 |issue=11 |pages=1703–13 |date=Jun 2003 |pmid=12782673 | doi = 10.1172/JCI16921 |pmc=156104}}&lt;/ref&gt; 

Several clinical trials were also conducted looking for its immunosuppressive activity even before it was approved for leprosy by FDA. It was first reported to be effective in treating chronic discoid lupus erythematosus with 17 out of 26 patients got remission.&lt;ref name=&quot;pmid4851057&quot;&gt;{{cite journal |author=Mackey JP, Barnes J. |title=Clofazimine in the treatment of discoid lupus erythematosus. |journal=Br J Dermatol. |volume=91 |issue=1 |pages=93–6 |date=Jul 1974 |pmid=4851057 |doi= 10.1111/j.1365-2133.1974.tb06723.x|url=}}&lt;/ref&gt; But later another group found it was ineffective in treating diffuse, photosensitive, systemic lupus erythematosus.&lt;ref name=&quot;pmid7137755&quot;&gt;{{cite journal |author=Jakes JT, Dubois EL, Quismorio FP Jr. |title=Antileprosy drugs and lupus erythematosus. |journal=Ann Intern Med. |volume=97 |issue=5 |pages=788 |date=Nov 1982 |pmid=7137755 |doi= |url=}}&lt;/ref&gt; Clofazimine also has been sporadically reported with some success in other autoimmune diseases such as psoriasis,&lt;ref name=&quot;pmid708598&quot;&gt;{{cite journal |author=Chuaprapaisilp T, Piamphongsant T. |title=Treatment of pustular psoriasis with clofazimine. |journal=Br J Dermatol. |volume=99 |issue=3 |pages=303–5 |date=Sep 1978 |pmid=708598 |doi= 10.1111/j.1365-2133.1978.tb02001.x|url=}}&lt;/ref&gt; Miescher’s granulomatous cheilitis,&lt;ref name=&quot;pmid3720016&quot;&gt;{{cite journal |author=Podmore P, Burrows D. |title=Clofazimine--an effective treatment for Melkersson-Rosenthal syndrome or Miescher's cheilitis. |journal=Clin Exp Dermatol. |volume=11 |issue=2 |pages=173–8 |date=Mar 1986 |pmid=3720016 |doi= 10.1111/j.1365-2230.1986.tb00443.x|url=}}&lt;/ref&gt; Crohn’s disease and ulcerative colitis.&lt;ref name=&quot;PMC1419688&quot;&gt;{{cite journal |author=Kelleher D, O'Brien S, Weir DG |title=Preliminary trial of clofazimine in chronic inflammatory bowel disease |journal=Gut |volume=23 |issue= |pages=A432–A463 |year=1982 |doi=10.1136/gut.23.5.A432 |pmc=1419688}}&lt;/ref&gt;
A recent clinical study of clofazimine was done in post-bone marrow transplantation patients &lt;ref name=&quot;pmid9116272&quot;&gt;{{cite journal |author=Lee SJ, Wegner SA, McGarigle CJ, Bierer BE, Antin JH. |title=Treatment of chronic graft-versus-host disease with clofazimine. |journal=Blood. |volume=89 |issue=7 |pages=2298–302 |date=Apr 1997 |pmid=9116272 |doi= |url=}}&lt;/ref&gt; with over 50% of them having skin involvement, flexion contractures or oral manifestations achieved complete or partial responses. 7 out of 22 patients were able to reduce other immunosuppressants such as cyclosporine A.

==History==
Clofazimine, initially known as B663, was first synthesised in 1954 by a team with the scientists J.G. Belton, M.L. Conalty, Seán O'Sullivan and Dermot Twomey led by Dr Vincent Barry, from Sunday's Well in Cork at [[Trinity College, Dublin]] as an anti-tuberculosis drug. The drug proved ineffective against tuberculosis but in 1959 a researcher named Chang identified its effectiveness against leprosy. After clinical trials in Nigeria and elsewhere during the 1960s, some sponsored by the Swiss pharmaceutical company [[Geigy]] (today member of the [[Novartis]] group of drug producers), the product was launched in 1969 as Lamprene.

The U.S. government named clofazimine an [[orphan drug]] in June 1986. Geigy gained FDA approval for the drug in December 1986.

== References ==
{{reflist|2}}

==External links==
*[http://www.fda.gov/cder/foi/label/2003/19500slr010_lamprene_lbl.pdf Official FDA Drug Label]
*[http://www.rxlist.com/cgi/generic3/clofazimine.htm RxList Clofazimine (most information taken from FDA)]
* [http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Clofazimine U.S. National Library of Medicine: Drug Information Portal - Clofazimine]

{{Antimycobacterials}}

[[Category:Antibiotics]]
[[Category:Orphan drugs]]
[[Category:World Health Organization essential medicines]]
[[Category:Phenazines]]
[[Category:Organochlorides]]</text>
      <sha1>qmqer0cuia8rmmbkpqyb2jxppd11jku</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Chromomycin A3</title>
    <ns>0</ns>
    <id>4454120</id>
    <revision>
      <id>578616304</id>
      <parentid>578615052</parentid>
      <timestamp>2013-10-24T22:52:54Z</timestamp>
      <contributor>
        <username>CheMoBot</username>
        <id>7377957</id>
      </contributor>
      <comment>Updating {{chembox}} (changes to verified and watched fields - updated 'ChEMBL_Ref', 'Verifiedfields', 'Watchedfields') per [[WP:CHEMVALID|Chem/Drugbox validation]] (report [[Wikipedia_talk:WikiProject_Chemicals|errors]] or [[user talk:CheMoBot|bugs]])</comment>
      <text xml:space="preserve" bytes="4152">{{Unreferenced|date=December 2009}}
{{Chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 414067478
| ImageFile = Chromomycin A3.png
| ImageSize = 300px
| IUPACName = (1''S'')-1-''C''-((2''S'',3''S'')-7-{[4-''O''-acetyl-2,6-dideoxy-3-''O''-(2,6-dideoxy-4-''O''-methyl-α-&lt;small&gt;D&lt;/small&gt;-''lyxo''-hexopyranosyl)-β-&lt;small&gt;D&lt;/small&gt;-''lyxo''-hexopyranosyl]oxy}-3-{[4-''O''-acetyl-2,6-dideoxy-3-''C''-methyl-α-&lt;small&gt;L&lt;/small&gt;-''arabino''-hexopyranosyl-(1&amp;rarr;3)-2,6-dideoxy-β-&lt;small&gt;D&lt;/small&gt;-''arabino''-hexopyranosyl-(1&amp;rarr;3)-2,6-dideoxy-β-&lt;small&gt;D&lt;/small&gt;-''arabino''-hexopyranosyl]oxy}-5,10-dihydroxy-6-methyl-4-oxo-1,2,3,4-tetrahydroanthracen-2-yl)-5-deoxy-1-''O''-methyl-&lt;small&gt;D&lt;/small&gt;-xylulose
| IUPACName_hidden = yes
| OtherNames = Chromomycin A3&lt;br&gt;Toyomycin
| Section1 = {{Chembox Identifiers
| Abbreviations =
| InChI = 1S/C56H80O27/c1-20-32(78-38-18-35(51(25(6)75-38)83-55(67)68)81-36-15-31(59)50(70-10)24(5)74-36)14-29-12-28-13-30(52(71-11)49(66)44(61)21(2)57)53(48(65)42(28)47(64)41(29)43(20)60)82-39-17-33(45(62)23(4)73-39)79-37-16-34(46(63)22(3)72-37)80-40-19-56(9,69)54(26(7)76-40)77-27(8)58/h12,14,21-26,30-31,33-40,44-46,50-54,57,59-64,69H,13,15-19H2,1-11H3,(H,67,68)/t21-,22-,23-,24-,25-,26+,30+,31-,33-,34-,35-,36-,37+,38+,39+,40+,44+,45-,46-,50+,51+,52+,53+,54+,56+/m1/s1
| InChIKey = VWUDFIOZFAFOMW-QUOOOCNJBW
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C56H80O27/c1-20-32(78-38-18-35(51(25(6)75-38)83-55(67)68)81-36-15-31(59)50(70-10)24(5)74-36)14-29-12-28-13-30(52(71-11)49(66)44(61)21(2)57)53(48(65)42(28)47(64)41(29)43(20)60)82-39-17-33(45(62)23(4)73-39)79-37-16-34(46(63)22(3)72-37)80-40-19-56(9,69)54(26(7)76-40)77-27(8)58/h12,14,21-26,30-31,33-40,44-46,50-54,57,59-64,69H,13,15-19H2,1-11H3,(H,67,68)/t21-,22-,23-,24-,25-,26+,30+,31-,33-,34-,35-,36-,37+,38+,39+,40+,44+,45-,46-,50+,51+,52+,53+,54+,56+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VWUDFIOZFAFOMW-QUOOOCNJSA-N
| InChIKey1 = VWUDFIOZFAFOMW-QUOOOCNJSA-N
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 7059-24-7
| EINECS =
| PubChem = 656673
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID=16735739
| SMILES =
| InChI =
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 216639
| RTECS =
| MeSHName =
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI =
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG =
| ATCCode = }}
| Section2 = {{Chembox Properties
| C=57|H=82|O=26
| Appearance =
| Density =
| MeltingPt =
| Melting_notes =
| BoilingPt =
| Boiling_notes =
| Solubility =
| SolubleOther =
| Solvent =
| pKa =
| pKb =
| IsoelectricPt =
| SpecRotation =
| RefractIndex =
| Viscosity =
| Dipole = }}
| Section3 = {{Chembox Structure
| CrystalStruct =
| Coordination =
| MolShape =
| Dipole = }}
| Section4 = {{Chembox Thermochemistry
| DeltaHf =
| DeltaHc =
| Entropy =
| HeatCapacity = }}
| Section5 = {{Chembox Pharmacology
| AdminRoutes =
| Bioavail =
| Metabolism =
| HalfLife =
| ProteinBound
| Excretion =
| Legal_status =
| Legal_US =
| Legal_UK =
| Legal_AU =
| Legal_CA =
| PregCat =
| PregCat_AU =
| PregCat_US = }}
| Section6 = {{Chembox Explosive
| ShockSens =
| FrictionSens =
| ExplosiveV =
| REFactor = }}
| Section7 = {{Chembox Hazards
| ExternalMSDS =
| EUClass = 
| EUIndex =
| MainHazards =
| NFPA-H =
| NFPA-F =
| NFPA-R =
| NFPA-O =
| RPhrases =
| SPhrases =
| RSPhrases =
| FlashPt =
| Autoignition =
| ExploLimits =
| PEL = }}
| Section8 = {{Chembox Related
| OtherAnions =
| OtherCations =
| OtherFunctn =
| Function =
| OtherCpds = }}
}}

'''Chromomycin A3''' is an [[Natural anthraquinone|anthraquinone]]. It is a glycosidic [[antibiotic]] produced at the [[Industrial fermentation|fermentation]] of a strain of ''[[Streptomyces|Streptomyces griseus]]''. It is also called toyomycin.

== Uses ==
*Membrane-impermeant G/C-specific fluorescent DNA-binding dye.
*Antibacterial antibiotic.
*Antitumor antibiotic that inhibits RNA synthesis, especially in solid tumors
*''Attention:'' actual medical use is unknown.

== References ==
{{reflist}}

{{Anthraquinone}}

[[Category:Antibiotics]]
[[Category:Anthraquinone glycosides]]</text>
      <sha1>7bjc8w73f8f24dadidsaixe39wlxzzp</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Cathelicidin</title>
    <ns>0</ns>
    <id>9022604</id>
    <revision>
      <id>605682445</id>
      <parentid>604548907</parentid>
      <timestamp>2014-04-25T00:31:04Z</timestamp>
      <contributor>
        <ip>137.110.136.67</ip>
      </contributor>
      <comment>/* See also */</comment>
      <text xml:space="preserve" bytes="14930">{{Infobox protein family
| Symbol = Cathelicidin
| Name = Cathelicidin
| image = PDB_1kwi_EBI.jpg
| width = 
| caption = Crystal Structure Analysis of the Cathelicidin Motif of Protegrins
| Pfam = PF00666
| Pfam_clan = CL0121
| InterPro =  IPR001894
| SMART = 
| PROSITE = PDOC00729
| SCOP = 1lyp
| TCDB = 
| OPM family = 236
| OPM protein = 2k6o
}}
{{PBB|geneid=820}}
'''Cathelicidin'''-related antimicrobial peptides are a family of [[polypeptides]] found in [[lysosomes]] of [[macrophage]]s and [[Granulocyte|polymorphonuclear leukocytes]] (PMNs).&lt;ref&gt;{{cite web | title = Entrez Gene: CAMP cathelicidin antimicrobial peptide| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&amp;Cmd=ShowDetailView&amp;TermToSearch=820| accessdate = }}&lt;/ref&gt; Cathelicidins serve a critical role in mammalian innate immune defense against invasive bacterial infection.&lt;ref name=&quot;Zanetti_2004&quot;/&gt;

Members of the cathelicidin family of antimicrobial polypeptides are characterized by a highly conserved region (cathelin domain) and a highly variable cathelicidin peptide domain.&lt;ref name=&quot;Zanetti_2004&quot;&gt;{{cite journal | author = Zanetti M | title = Cathelicidins, multifunctional peptides of the innate immunity | journal = J. Leukoc. Biol. | volume = 75 | issue = 1 | pages = 39–48 | date = January 2004 | pmid = 12960280 | doi = 10.1189/jlb.0403147 }}&lt;/ref&gt;

Cathelicidin peptides have been isolated from many different species of [[mammals]].  Cathelicidins were originally found in [[neutrophils]] but have since been found in many other cells including [[Epithelium|epithelial]] cells and [[macrophage]]s after activation by bacteria, viruses, fungi, or the hormone [[1,25-D]], which is the hormonally active form of [[vitamin D]].&lt;ref name=&quot;pmid16497887&quot;&gt;{{cite journal | author = Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin R | title = Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response | journal = Science | volume = 311 | issue = 5768 | pages = 1770–3 |date=March 2006 | pmid = 16497887 | doi = 10.1126/science.1123933 }}&lt;/ref&gt;

The cathelicidin family shares primary sequence homology with the [[cystatin]]&lt;ref name=&quot;pmid12713586&quot;&gt;{{cite journal | author = Zaiou M, Nizet V, Gallo RL. | title = Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence | journal = J Invest Dermatol. | volume = 5 | issue = 120 | pages = 810–6 |date=May 2003 | pmid = 12713586 | doi = 10.1046/j.1523-1747.2003.12132.x3 }}&lt;/ref&gt; family of cysteine proteinase inhibitors, although amino acid residues thought to be important in such protease inhibition are usually lacking.

==Characteristics==
Cathelicidins range in size from 12 to 80 amino acid residues and have a wide range of structures.&lt;ref name=&quot;pmid10931440&quot;&gt;{{cite journal | author = Gennaro R, Zanetti M | title = Structural features and biological activities of the cathelicidin-derived antimicrobial peptides | journal = Biopolymers | volume = 55 | issue = 1 | pages = 31–49 | year = 2000 | pmid = 10931440 | doi = 10.1002/1097-0282(2000)55:1&lt;31::AID-BIP40&gt;3.0.CO;2-9 }}&lt;/ref&gt;  Most cathelicidins are linear peptides with 23-37 amino acid residues, and fold into amphiphatic [[α-helices]]. Additionally cathelicidins may also be small-sized molecules (12-18 residues) with beta-hairpin structures, stabilized by one or two disulphide bonds. Even larger cathelicidin peptides (39-80 amino acid residues) are also present. These larger cathelicidins display repetitive [[proline motifs]] forming extended polyproline-type structures.&lt;ref name=&quot;Zanetti_2004&quot;/&gt;

==Family members==
Cathelicidin family components have been found in: humans, monkeys, mice, rats, rabbits, guinea pigs, pandas, pigs, cattle, frogs, sheep, goats, and horses.

Currently identified cathelicidins include the following:&lt;ref name=&quot;Zanetti_2004&quot;/&gt;
*Human:[[hCAP-18]]/[[LL-37]]
*Rhesus Monkey: RL-37
*Mice:[[CRAMP-1]]/2, (Cathelicidin-related Antimicrobial Peptide&lt;ref name=&quot;pmid9148921&quot;&gt;{{cite journal | author = Gallo RL, Kim KJ, Bernfield M, Kozak CA, Zanetti M, Merluzzi L, Gennaro R | title = Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse | journal = J. Biol. Chem. | volume = 272 | issue = 20 | pages = 13088–93 |date=May 1997 | pmid = 9148921 | doi = 10.1074/jbc.272.20.13088 }}&lt;/ref&gt;
*Rats: rCRAMP
*Rabbits: CAP-18
*Guinea Pig: CAP-11
*Pigs: [[PR-39]], Prophenin, PMAP-23,36,37
*Cattle: BMAP-27,28,34 (Bovine Myeloid Antimicrobial Peptides); Bac5, Bac7
*Frogs: cathelicidin-AL (found in ''[[Amolops loloensis]]'')&lt;ref name=&quot;pmid22009138&quot;&gt;{{cite journal | author = Hao X, Yang H, Wei L, Yang S, Zhu W, Ma D, Yu H, Lai R | title = Amphibian cathelicidin fills the evolutionary gap of cathelicidin in vertebrate | journal = Amino Acids | volume = 43 | issue = 2 | pages = 677–85 |date=August 2012 | pmid = 22009138 | doi = 10.1007/s00726-011-1116-7 }}&lt;/ref&gt;
*Sheep:
*Goats:
*Horses:
*Pandas:

==Clinical significance==
Patients with [[rosacea]] have elevated levels of cathelicidin and elevated levels of stratum corneum tryptic enzymes (SCTEs). Antibiotics have been used in the past to treat rosacea, but antibiotics may only work because they inhibit some SCTEs.&lt;ref name=&quot;pmid17676051&quot;&gt;{{cite journal | author = Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, Dorschner RA, Bonnart C, Descargues P, Hovnanian A, Morhenn VB, Gallo RL | title = Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea | journal = Nat. Med. | volume = 13 | issue = 8 | pages = 975–80 |date=August 2007 | pmid = 17676051 | doi = 10.1038/nm1616   }}&lt;/ref&gt;

Higher levels of human cathelicidin antimicrobial protein (hCAP18), which are up-regulated by [[vitamin D]], appear to significantly reduce the risk of death from infection in [[dialysis]] patients. Patients with a high level of this protein were 3.7 times more likely to survive kidney dialysis for a year without a fatal infection.&lt;ref name=&quot;pmid19133797&quot;&gt;{{cite journal | author = Gombart AF, Bhan I, Borregaard N, Tamez H, Camargo CA, Koeffler HP, Thadhani R | title = Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis | journal = Clin. Infect. Dis. | volume = 48 | issue = 4 | pages = 418–24 |date=February 2009 | pmid = 19133797 | doi = 10.1086/596314 | last5 = Camargo }}&lt;/ref&gt;

Vitamin D up-regulates genetic expression of cathelicidin, which exhibits broad-spectrum microbicidal activity against bacteria, fungi, and viruses.&lt;ref name=&quot;pmid11807545&quot;&gt;{{cite journal | author = Zasloff M | title = Antimicrobial peptides of multicellular organisms | journal = Nature | volume = 415 | issue = 6870 | pages = 389–95 |date=January 2002 | pmid = 11807545 | doi = 10.1038/415389a }}&lt;/ref&gt;&lt;ref name=&quot;pmid20119827&quot;&gt;{{cite journal | author = Kamen DL, Tangpricha V | title = Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity | journal = J. Mol. Med. | volume = 88 | issue = 5 | pages = 441–50 |date=May 2010 | pmid = 20119827 | pmc = 2861286 | doi = 10.1007/s00109-010-0590-9 }}&lt;/ref&gt; Cathelicidin rapidly destroys the lipoprotein membranes of microbes enveloped in [[phagosome]]s after fusion with [[lysosome]]s in [[macrophage]]s.

==See also==
* [[Antimicrobial peptides]]
* [[Innate immune system]]
* [[Richard Gallo]]

==References==
{{Reflist|2}}

==Further reading==
{{refbegin | 2}}
* {{cite journal | author = Dürr UH, Sudheendra US, Ramamoorthy A | title = LL-37, the only human member of the cathelicidin family of antimicrobial peptides | journal = Biochim. Biophys. Acta | volume = 1758 | issue = 9 | pages = 1408–25 |date=September 2006 | pmid = 16716248 | doi = 10.1016/j.bbamem.2006.03.030 | url =  }}
* {{cite journal | author = Chromek M, Slamová Z, Bergman P, Kovács L, Podracká L, Ehrén I, Hökfelt T, Gudmundsson GH, Gallo RL, Agerberth B, Brauner A | title = The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection | journal = Nat. Med. | volume = 12 | issue = 6 | pages = 636–41 |date=June 2006 | pmid = 16751768 | doi = 10.1038/nm1407 | url =  }}
* {{cite journal | author = Gombart AF, Borregaard N, Koeffler HP | title = Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3 | journal = FASEB J. | volume = 19 | issue = 9 | pages = 1067–77 |date=July 2005 | pmid = 15985530 | doi = 10.1096/fj.04-3284com | url =  }}
* {{cite journal | author = López-García B, Lee PH, Gallo RL | title = Expression and potential function of cathelicidin antimicrobial peptides in dermatophytosis and tinea versicolor | journal = J. Antimicrob. Chemother. | volume = 57 | issue = 5 | pages = 877–82 |date=May 2006 | pmid = 16556635 | doi = 10.1093/jac/dkl078 | url =  }}
*{{cite journal  | author=Lehrer RI, Ganz T |title=Cathelicidins: a family of endogenous antimicrobial peptides |journal=Curr. Opin. Hematol. |volume=9 |issue= 1 |pages= 18–22 |year= 2002 |pmid= 11753073 |doi=10.1097/00062752-200201000-00004  }}
*{{cite journal  | author=Niyonsaba F, Hirata M, Ogawa H, Nagaoka I |title=Epithelial cell-derived antibacterial peptides human beta-defensins and cathelicidin: multifunctional activities on mast cells |journal=Current drug targets. Inflammation and allergy |volume=2 |issue= 3 |pages= 224–31 |year= 2003 |pmid= 14561157 |doi=10.2174/1568010033484115  }}
*{{cite journal  | author=van Wetering S, Tjabringa GS, Hiemstra PS |title=Interactions between neutrophil-derived antimicrobial peptides and airway epithelial cells |journal=J. Leukoc. Biol. |volume=77 |issue= 4 |pages= 444–50 |year= 2005 |pmid= 15591123 |doi= 10.1189/jlb.0604367 }}
*{{cite journal  | author=Agerberth B, Gunne H, Odeberg J, ''et al.'' |title=FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=92 |issue= 1 |pages= 195–9 |year= 1995 |pmid= 7529412 |doi=10.1073/pnas.92.1.195  | pmc=42844  }}
*{{cite journal  | author=Cowland JB, Johnsen AH, Borregaard N |title=hCAP-18, a cathelin/pro-bactenecin-like protein of human neutrophil specific granules |journal=FEBS Lett. |volume=368 |issue= 1 |pages= 173–6 |year= 1995 |pmid= 7615076 |doi=10.1016/0014-5793(95)00634-L  }}
*{{cite journal  | author=Gudmundsson GH, Magnusson KP, Chowdhary BP, ''et al.'' |title=Structure of the gene for porcine peptide antibiotic PR-39, a cathelin gene family member: comparative mapping of the locus for the human peptide antibiotic FALL-39 |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=92 |issue= 15 |pages= 7085–9 |year= 1995 |pmid= 7624374 |doi=10.1073/pnas.92.15.7085  | pmc=41476  }}
*{{cite journal  | author=Larrick JW, Hirata M, Balint RF, ''et al.'' |title=Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein |journal=Infect. Immun. |volume=63 |issue= 4 |pages= 1291–7 |year= 1995 |pmid= 7890387 |doi=  | pmc=173149  }}
*{{cite journal  | author=Gudmundsson GH, Agerberth B, Odeberg J, ''et al.'' |title=The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes |journal=Eur. J. Biochem. |volume=238 |issue= 2 |pages= 325–32 |year= 1996 |pmid= 8681941 |doi=10.1111/j.1432-1033.1996.0325z.x  }}
*{{cite journal  | author=Larrick JW, Lee J, Ma S, ''et al.'' |title=Structural, functional analysis and localization of the human CAP18 gene |journal=FEBS Lett. |volume=398 |issue= 1 |pages= 74–80 |year= 1997 |pmid= 8946956 |doi=10.1016/S0014-5793(96)01199-4  }}
*{{cite journal  | author=Frohm M, Agerberth B, Ahangari G, ''et al.'' |title=The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders |journal=J. Biol. Chem. |volume=272 |issue= 24 |pages= 15258–63 |year= 1997 |pmid= 9182550 |doi=10.1074/jbc.272.24.15258  }}
*{{cite journal  | author=Bals R, Wang X, Zasloff M, Wilson JM |title=The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=95 |issue= 16 |pages= 9541–6 |year= 1998 |pmid= 9689116 |doi=10.1073/pnas.95.16.9541  | pmc=21374  }}
*{{cite journal  | author=De Yang , Chen Q, Schmidt AP, ''et al.'' |title=LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells |journal=J. Exp. Med. |volume=192 |issue= 7 |pages= 1069–74 |year= 2000 |pmid= 11015447 |doi=10.1084/jem.192.7.1069  | pmc=2193321  }}
*{{cite journal  | author=Agerberth B, Charo J, Werr J, ''et al.'' |title=The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations |journal=Blood |volume=96 |issue= 9 |pages= 3086–93 |year= 2000 |pmid= 11049988 |doi=  }}
*{{cite journal  | author=Bals R, Lang C, Weiner DJ, ''et al.'' |title=Rhesus monkey (Macaca mulatta) mucosal antimicrobial peptides are close homologues of human molecules |journal=Clin. Diagn. Lab. Immunol. |volume=8 |issue= 2 |pages= 370–5 |year= 2001 |pmid= 11238224 |doi= 10.1128/CDLI.8.2.370-375.2001  | pmc=96065 }}
*{{cite journal  | author=Nagaoka I, Hirota S, Niyonsaba F, ''et al.'' |title=Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14(+) cells |journal=J. Immunol. |volume=167 |issue= 6 |pages= 3329–38 |year= 2001 |pmid= 11544322 |doi=  }}
*{{cite journal  | author=Hase K, Eckmann L, Leopard JD, ''et al.'' |title=Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium |journal=Infect. Immun. |volume=70 |issue= 2 |pages= 953–63 |year= 2002 |pmid= 11796631 |doi=10.1128/IAI.70.2.953-963.2002  | pmc=127717  }}
*{{cite journal  | author=Giuliani A, Pirri G, Nicoletto S |title=Antimicrobial peptides: an overview of a promising class of therapeutics |journal=Cent. Eur. J. Biol. |volume=2 |issue= 1 |pages= 1–33 |year= 2007 |doi=10.2478/s11535-007-0010-5  }}
*{{cite journal  | author=Burton MF, Steel PG |title=Chemistry and Biology of LL-37 |journal= Natural Product Reports, |volume=26 |issue= 12|pages= 1572–1584 |year= 2009| doi= 10.1039/b912533g }}
{{refend}}

[[Category:Immune system]]
[[Category:Antibiotics]]
[[Category:Leukocytes]]
[[Category:Vitamin D]]{{Granule contents}}
{{Pore-forming toxins}}</text>
      <sha1>2eoti16rwk8502ph9ecn41yf2q6h3tq</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Pyocyanase</title>
    <ns>0</ns>
    <id>9075585</id>
    <revision>
      <id>535002674</id>
      <parentid>532206441</parentid>
      <timestamp>2013-01-26T16:29:18Z</timestamp>
      <contributor>
        <username>Magioladitis</username>
        <id>1862829</id>
      </contributor>
      <minor/>
      <comment>fixed header names + [[WP:GENFIXES|general fixes]] using [[Project:AWB|AWB]] (8863)</comment>
      <text xml:space="preserve" bytes="1916">'''Pyocyanase''' was the first [[antibiotic]] drug to be used in hospitals. It is no longer used today.
[[Rudolph Emmerich]] and [[Oscar Löw]], two [[Germany|German]] physicians who were the first to make an effective medication from microbes, conducted experiments in the 1890s, roughly 30 years after [[Louis Pasteur]] showed that many diseases were caused by bacteria and nearly 40 years before the effective prescription of [[penicillin]]. They proved that the germs that caused one disease may be the cure for another.

Emmerich and Löw isolated germs from infected bandages that caused green infections in open wounds. The germ was a bacterium then called ''Bacillus pycyaneus'' (now called ''[[Pseudomonas aeruginosa]]'', it produces [[pyocyanin]], a characteristic green-blue phenazine pigment). They then mixed the isolate with other bacteria and showed that ''B. pycyaneus'' and extracts from its cultures were able to destroy other strains of bacteria. Among the bacteria that it killed were those that caused [[cholera]], [[typhoid]], [[diphtheria]], and [[anthrax]].&lt;ref name=&quot;Emmerich_Low1899&quot;&gt;{{cite journal | author=Emmerich R. and Löw O. | title=Bakteriolytische Enzyme als Ursache der erworbenen Immunität und die Heilung von Infectionskrankheiten durch dieselben | journal=Zeitschr. F. Hygiene | year=1899 | volume=31 | pages=1–65 | doi=10.1007/BF02206499}}&lt;/ref&gt;

From these experiments Emmerich and Löw created a medication based on extracts of ''B. pycyaneus'' that they called pyocyanase. It was the first antibiotic to be used in hospitals. Unfortunately, its effectiveness was sporadic, did not work equally on all patients, and the presence of large amounts of phenazines such as pyocyanin made it quite toxic to humans. As a result, the drug was eventually abandoned.

==See also==
[[Prontosil]]

==References==
{{Reflist}}

[[Category:Antibiotics]]
[[Category:History of medicine]]</text>
      <sha1>lx3vu105mc415oysh4v7ql8kavl21rc</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Nitrofural</title>
    <ns>0</ns>
    <id>1448897</id>
    <revision>
      <id>540833585</id>
      <parentid>524243213</parentid>
      <timestamp>2013-02-27T04:02:10Z</timestamp>
      <contributor>
        <username>Addbot</username>
        <id>6569922</id>
      </contributor>
      <minor/>
      <comment>[[User:Addbot|Bot:]] Migrating 6 interwiki links, now provided by [[Wikipedia:Wikidata|Wikidata]] on [[d:q425502]] ([[User talk:Addbot|Report Errors]])</comment>
      <text xml:space="preserve" bytes="3018">{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462261893
| IUPAC_name = 5-nitro-2-furaldehyde semicarbazone
| image = Nitrofurazone.png

&lt;!--Clinical data--&gt;
| tradename =  
| Drugs.com = {{drugs.com|CONS|nitrofurazone}}
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = C
| pregnancy_category =  
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, or Class A, B, C --&gt;
| legal_US = &lt;!-- OTC / Rx-only / Schedule I, II, III, IV, V --&gt;
| legal_status =  
| routes_of_administration =  

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 59-87-0
| CAS_supplemental =  
| ATC_prefix = B05
| ATC_suffix = CA03
| ATC_supplemental =  {{ATC|D08|AF01}} {{ATC|D09|AA03}} (dressing) {{ATC|P01|CC02}} {{ATC|S01|AX04}} {{ATC|S02|AA02}} {{ATCvet|G01|AX90}} {{ATCvet|P51|AC02}}
| PubChem = 5447130
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00336
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4566720
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = X8XI70B5Z6
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = C08042
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 869

&lt;!--Chemical data--&gt;
| chemical_formula =  
| C=6 | H=6 | N=4 | O=4 
| molecular_weight = 198.14 g/mol
| smiles = O=[N+]([O-])c1oc(/C=N/NC(=O)N)cc1
| InChI = 1/C6H6N4O4/c7-6(11)9-8-3-4-1-2-5(14-4)10(12)13/h1-3H,(H3,7,9,11)/b8-3+
| InChIKey = IAIWVQXQOWNYOU-FPYGCLRLBW
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C6H6N4O4/c7-6(11)9-8-3-4-1-2-5(14-4)10(12)13/h1-3H,(H3,7,9,11)/b8-3+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IAIWVQXQOWNYOU-FPYGCLRLSA-N
}}
 [[File:Раствор Фурацилина.JPG|thumb|left]]
'''Nitrofural''' ([[International Nonproprietary Name|INN]], trade name '''Furacin''') is a [[bactericidal]] compound used as an [[antibiotic]] most commonly in the form of ointments. Its use in medicine has become less frequent as safer and more effective products have become available{{cn|date=May 2011}}, and it has been discontinued in the US.&lt;ref&gt;Drugs.com: [http://www.drugs.com/cons/nitrofurazone-topical.html Nitrofurazone (Topical route)]&lt;/ref&gt; The substance is pale yellow and crystalline.

Other names include '''nitrofurazone''' and '''furacilin'''.

==Synthesis==
Synthesis:&lt;ref&gt;Stillman, W. B.; Scott, A. B.; 1947, {{US Patent|241664}}.&lt;/ref&gt;
[[File:Nitrofurazone synthesis.png|500px]]

==References==
{{reflist}}

{{Agents against leishmaniasis and trypanosomiasis}}
{{Otologicals}}

[[Category:Antibiotics]]
[[Category:Nitrofurans]]
[[Category:Antiprotozoal agents]]
[[Category:Otologicals]]
[[Category:Semicarbazones]]

{{Blood-drug-stub}}
{{Dermatologic-drug-stub}}
{{Antiinfective-drug-stub}}</text>
      <sha1>8hf20967oxf7uqpliwgqo67w18dpgsz</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Thioacetazone</title>
    <ns>0</ns>
    <id>4837630</id>
    <revision>
      <id>602155091</id>
      <parentid>470606810</parentid>
      <timestamp>2014-03-31T19:33:27Z</timestamp>
      <contributor>
        <username>NickPenguin</username>
        <id>703140</id>
      </contributor>
      <comment>no consensus to merge</comment>
      <text xml:space="preserve" bytes="2974">{{Drugbox
| verifiedrevid = 443222189
| IUPAC_name = ''N''-{4-[(ethanethioamidoimino)methyl]phenyl}acetamide
| image = Thioacetazone.svg

&lt;!--Clinical data--&gt;
| tradename =  
| Drugs.com = {{drugs.com|international|thioacetazone}}
| routes_of_administration = Oral

&lt;!--Identifiers--&gt;
| CAS_number = 104-06-3
| ATC_prefix = J04
| ATC_suffix = AM04
| ChEMBL = 375492
| PubChem = 9568512
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 7843221
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = MMG78X7SSR
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08584

&lt;!--Chemical data--&gt;
| C=10 | H=12 | N=4 | O=1 | S=1 
| molecular_weight = 236.3
| smiles = O=C(Nc1ccc(cc1)\C=N\NC(=S)N)C
| InChI = 1/C10H12N4OS/c1-7(15)13-9-4-2-8(3-5-9)6-12-14-10(11)16/h2-6H,1H3,(H,13,15)(H3,11,14,16)/b12-6+
| InChIKey = SRVJKTDHMYAMHA-WUXMJOGZBW
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H12N4OS/c1-7(15)13-9-4-2-8(3-5-9)6-12-14-10(11)16/h2-6H,1H3,(H,13,15)(H3,11,14,16)/b12-6+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SRVJKTDHMYAMHA-WUXMJOGZSA-N
| synonyms = &lt;small&gt;''N''-[4-[(carbamothioylhydrazinylidene)methyl]phenyl]acetamide&lt;/small&gt;
}}
'''Thioacetazone'''([[International Nonproprietary Name|INN]] and [[British Approved Name|BAN]]) is also called '''thiocetazone''', '''thiacetazone''', '''thiosemicarbazone''', '''benzothiozane''' or '''amithiozone'''([[United States Adopted Name|USAN]]); abbreviated '''T.'''

Thioacetazone is used in the treatment of [[tuberculosis]]; it has only weak activity against ''[[Mycobacterium tuberculosis]]'' and is only useful in preventing resistance to more powerful drugs like [[isoniazid]] and [[rifampicin]].  It is never used on its own to treat [[tuberculosis]];  it is used in a similar way to [[ethambutol]].  Thioacetazone is the only anti-TB drug that is ineffective when given intermittently.

There is no advantage to using thioacetazone if the regimen used already contains ethambutol, but many countries in sub-Saharan Africa still use thioacetazone because it is extremely cheap.  Use of thioacetazone is declining because it can cause severe (sometimes fatal) skin reactions in HIV positive patients.&lt;ref name=&quot;Rieder2001&quot;&gt;{{cite journal
| author=Rieder HL, Arnadottir T, Trebucq A, Enarson DA
| title=Tuberculosis treatment: dangerous regimens?
| journal=Int J Tuberc Lung Dis
| year=2001
| volume=5
| issue=1
| pages=1&amp;ndash;3
| pmid=11263509 }}&lt;/ref&gt;&lt;!--
--&gt;&lt;ref name=&quot;Nunn1993&quot;&gt;{{cite journal
| author=Nunn P, Porter J, Winstanley P
| title=Thiacetazone&amp;mdash;avoid like poison or use with care?
| journal=Trans R Soc Trop Med Hyg
| year=1993
| volume=87
| issue=5
| pages=578&amp;ndash;82
| pmid=7505496
| doi=10.1016/0035-9203(93)90096-9 }}&lt;/ref&gt;

==References==
&lt;references/&gt;

[[Category:Antibiotics]]
[[Category:Tuberculosis]]
[[Category:Acetanilides]]
[[Category:Thioureas]]


{{antibiotic-stub}}</text>
      <sha1>g2uqiytgb0z3qlla0jwy3fwxickccvl</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Avenanthramide</title>
    <ns>0</ns>
    <id>4083808</id>
    <revision>
      <id>597567410</id>
      <parentid>591855718</parentid>
      <timestamp>2014-02-28T20:10:37Z</timestamp>
      <contributor>
        <username>Path2k6</username>
        <id>1642729</id>
      </contributor>
      <minor/>
      <comment>/* Anti-inflammatory and anti-itch properties */ removing suspected ad</comment>
      <text xml:space="preserve" bytes="4797">'''Avenanthramides''' are a type of [[oats|oat]] [[phytoalexin]]s that exist predominantly in the [[groats]] of oat seeds.&lt;ref&gt;[http://www.aaccnet.org/FuncFood/pdfs/1006-01R.pdf Emmons, C. L. &amp; Peterson, D. M. (1999) Antioxidant activity and phenolic contents of oat groats and hulls. Cereal Chem. 76:902-906.]&lt;/ref&gt;

Among a group of at least 25 avenanthramides&lt;ref&gt;[http://pubs.acs.org/cgi-bin/searchRedirect.cgi/jafcau/1989/37/i01/pdf/jf00085a015.pdf 2. Collins, F. W. (1989) Oat phenolics: avenanthramides, novel substituted N-cinnamoylanthranilate alkaloids from oat groats and hulls. J. Agric. Food Chem. 37:60-66.]&lt;/ref&gt; that differ in the substituents on the [[cinnamic acid]] and [[anthranilic acid]] rings, three are predominant in oat grain: Bc (also called avenanthramide C), Bf (also called avenanthramide B) and Bp (also called avenanthramide A).  

''[[In vitro]]'' experiments indicate they have significant [[antioxidant]] activities, with Bc &gt; Bf &gt; Bp.&lt;ref&gt;[http://www.ars.usda.gov/research/publications/publications.htm?seq_no_115=129118 Peterson D.M.1; Hahn M.J.; Emmons C.L.(2002)  Oat Avenanthramides Exhibit Antioxidant Activities In Vitro. Food Chem. 79:4:473-478]&lt;/ref&gt; In human and animal tests, this antioxidant capacity provides health benefits ranging from reduced rate of [[LDL]] oxidation&lt;ref&gt;[http://jn.nutrition.org/cgi/content/full/134/6/1459  Chen, C.Y &amp; Blumberg , J. B. (2004) Vitamin C to Enhance Hamster and Human LDL Resistance to Oxidation J. Nutr. 134:1459-1466]&lt;/ref&gt; to protecting against [[cancers]] and [[heart disease]].&lt;ref&gt;Bailey, G.S. &amp; Williams, D.E.(1993) Potential Mechanisms for Food-Related Carcinogens and Anticarcinogens. Food Technol. 47:105-118&lt;/ref&gt;  Because of its antioxidant properties, high levels of avenanthramide are desirable in oat grain.    Researchers at the [[Agricultural Research Service]] (ARS) currently are trying to understand what environmental factors regulate the amount of avenanthramide produced in oat grain. [http://www.ars.usda.gov/is/pr/2010/100201.htm] Past studies have found an increase in avenanthramide production in plants that are infected by a fungus, leading researchers to believe that avenanthramide is used as a chemical defense in helping the oat grain fight off the fungus.  ARS researchers found that cultivars with the strongest resistance to crown rust, a fungus that affects oat grains, had the highest concentration of avenanthramide.  However, because not all cultivars with high crown rust resistance had high levels of avenanthramide, researchers suspect other environmental factors play a role in avenanthramide production.  Nevertheless, scientists suggest farmers can still select for highly resistant cultivars to increase the production of avenanthramide in their grain.&lt;ref&gt;{{cite web
|url= http://www.ars.usda.gov/is/pr/2010/100201.htm
|title= Studies Provide Insight into Key Oat Chemical 
|publisher=USDA Agricultural Research Service
|date=February 1, 2010}}&lt;/ref&gt;
 
They are [[tranilast]] analogues and have anti-inflammatory and anti[[fibrotic]] properties, probably due to TGF-beta inhibitory effects.

==Anti-inflammatory and anti-itch properties==

Ancient literature describes the [[anti-inflammatory]] and [[antipruritic]] properties of [[oatmeal]]. In 1978 the U.S. [[Food and Drug Administration]] (FDA) external review panel noted that colloidal oatmeal was safe and effective for the symptomatic relief of dry skin and itching.

Recent studies were conducted to verify whether avenanthramides are also responsible for the antipruritic activity of oat extracts. The results of human ''in vivo'' skin prick tests combined with an ''in vitro'' model, investigating the inhibitory activity of avenanthramides on the [[histamine]] net release from rat peritoneal [[mast cells]] stimulated by [[substance P]] showed a clear indication that avenanthramides found in oat extract play a major role in the reduction of itching and redness in skin. Because of the fundamental role of histamine in itch sensation, these results can be considered as a clear indication that oat extracts with a standardized content of avenanthramides are useful materials to reduce histamine related itch sensation and redness in skin.&lt;ref&gt;J. Vollhardt, D.A. Fielder and M. Redmond (2000)  Identification and Cosmetic Application of Powerful Anti-irritant Constituents of Oat Grain; Proceedings of the 21st IFSCC International Congress. 395&lt;/ref&gt; 

Most recently, extracts containing avenanthramides have been used in [[veterinary medicine]] in various topical forms, such as [[shampoos]], sprays and ear cleansing solutions for the relief of adverse skin conditions, including [[atopic dermatitis]].

== Notes ==
&lt;references/&gt;

[[Category:Antibiotics]]
[[Category:Phytoalexins]]
[[Category:Oats]]</text>
      <sha1>lysv9fqarhrdr5rzprrr1ncmcn1lfw2</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Herbimycin</title>
    <ns>0</ns>
    <id>10792481</id>
    <revision>
      <id>456832742</id>
      <parentid>443409987</parentid>
      <timestamp>2011-10-22T14:39:09Z</timestamp>
      <contributor>
        <username>CheMoBot</username>
        <id>7377957</id>
      </contributor>
      <comment>Updating {{chembox}} (changes to verified fields - updated 'DrugBank_Ref', 'UNII_Ref', 'CASNo_Ref') per [[WP:CHEMVALID|Chem/Drugbox validation]] (report [[Wikipedia_talk:WikiProject_Chemicals|errors]] or [[user talk:CheMoBot|bugs]])</comment>
      <text xml:space="preserve" bytes="3813">{{chembox
| Verifiedfields = changed
| verifiedrevid = 400103814
| ImageFile = Herbimycin.svg
| ImageSize = 250px
| IUPACName = [(2''R'',3''S'',5''S'',6''R'',7''S'',8''E'',10''R'',11''S'',12''E'',14''E'')-&lt;br&gt;2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-&lt;br&gt;16,20,22-trioxo-17-azabicyclo[16.3.1]&lt;br&gt;docosa-8,12,14,18,21-pentaen-10-yl] carbamate
| OtherNames = 
| Section1 = {{Chembox Identifiers
| Abbreviations = 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10272738
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1159659
| InChI = 1S/C30H42N2O9/c1-16-10-9-11-23(37-5)28(41-30(31)36)18(3)12-17(2)27(40-8)24(38-6)13-19(4)26(39-7)21-14-20(33)15-22(25(21)34)32-29(16)35/h9-12,14-15,17,19,23-24,26-28H,13H2,1-8H3,(H2,31,36)(H,32,35)/b11-9-,16-10+,18-12+/t17-,19-,23-,24-,26+,27+,28-/m0/s1
| InChIKey = MCAHMSDENAOJFZ-BVXDHVRPBC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C30H42N2O9/c1-16-10-9-11-23(37-5)28(41-30(31)36)18(3)12-17(2)27(40-8)24(38-6)13-19(4)26(39-7)21-14-20(33)15-22(25(21)34)32-29(16)35/h9-12,14-15,17,19,23-24,26-28H,13H2,1-8H3,(H2,31,36)(H,32,35)/b11-9-,16-10+,18-12+/t17-,19-,23-,24-,26+,27+,28-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MCAHMSDENAOJFZ-BVXDHVRPSA-N
| InChIKey1 = MCAHMSDENAOJFZ-BVXDHVRPSA-N
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 70563-58-5
| EINECS = 
| PubChem = 6436247
| SMILES = NC(=O)O[C@H]1C(/C)=C/[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C\2=C\C(=O)\C=C(\NC(=O)C(\C)=C\C=C/[C@@H]1OC)C/2=O
| InChI = 
| RTECS =
| MeSHName =
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI =
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = 
| ATCCode = }}
| Section2 = {{Chembox Properties
| Formula = C&lt;sub&gt;30&lt;/sub&gt;H&lt;sub&gt;42&lt;/sub&gt;N&lt;sub&gt;2&lt;/sub&gt;O&lt;sub&gt;9&lt;/sub&gt;
| MolarMass = 574.66 g/mol
| Appearance = 
| Density = 
| MeltingPt = 
| Melting_notes =
| BoilingPt = 
| Boiling_notes = 
| Solubility = 
| SolubleOther = [[hygroscopic]]
| Solvent = 
| pKa = 
| pKb = 
| IsoelectricPt = 
| SpecRotation = 
| RefractIndex = 
| Viscosity = 
| Dipole = }}
| Section3 = {{Chembox Structure
| CrystalStruct = 
| Coordination = 
| MolShape = 
| Dipole = }}
| Section4 = {{Chembox Thermochemistry
| DeltaHf = 
| DeltaHc = 
| Entropy = 
| HeatCapacity = }}
| Section5 = {{Chembox Pharmacology
| AdminRoutes =
| Bioavail = 
| Metabolism = 
| HalfLife = 
| ProteinBound
| Excretion = 
| Legal_status =
| Legal_US =
| Legal_UK =
| Legal_AU =
| Legal_CA =
| PregCat = 
| PregCat_AU = 
| PregCat_US = }}
| Section6 = {{Chembox Explosive
| ShockSens = 
| FrictionSens = 
| ExplosiveV = 
| REFactor = }}
| Section7 = {{Chembox Hazards
| ExternalMSDS = 
| EUClass = 
| EUIndex = 
| MainHazards = toxic 
| NFPA-H = 
| NFPA-F = 
| NFPA-R = 
| NFPA-O =  
| RPhrases = 
| SPhrases = 
| RSPhrases =
| FlashPt = 
| Autoignition = 
| ExploLimits = 
| PEL = }}
| Section8 = {{Chembox Related
| OtherAnions = 
| OtherCations = 
| OtherFunctn = 
| Function = 
| OtherCpds = }}
}}
'''Herbimycin''' is a [[benzoquinone]] [[ansamycin]] [[antibiotic]] that binds to [[Hsp90]] (Heat Shock Protein 90) and alters its function. HSP90 client proteins play important roles in the regulation of the cell cycle, cell growth, cell survival, [[apoptosis]], [[angiogenesis]] and [[oncogenesis]].

It was originally found by its [[herbicide|herbicidal]] activity, and thus named.

==Synonyms==
*Antibiotic Tan 420F
*Herbimycin A

==Biological activity==
Herbimycin induces the degradation of proteins that are mutated in [[tumor]] cells such as [[v-Src]], [[Bcr-Abl]] and [[p53]] preferentially over their normal cellular counterparts. This effect is mediated via HSP90.

==See also==
*[[Geldanamycin]]

[[Category:Antibiotics]]
[[Category:Quinones]]
[[Category:Carbamates]]
[[Category:Lactams]]
[[Category:Ethers]]


{{biochem-stub}}</text>
      <sha1>cq15ssto7dgksm6jhkd3ks0as6xkiec</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Staurosporine</title>
    <ns>0</ns>
    <id>10020042</id>
    <revision>
      <id>585168027</id>
      <parentid>579010941</parentid>
      <timestamp>2013-12-08T19:42:49Z</timestamp>
      <contributor>
        <username>Ginger Maine Coon</username>
        <id>15611063</id>
      </contributor>
      <minor/>
      <comment>Preview is too long, reorganized contents into sections for better flow and easier read.</comment>
      <text xml:space="preserve" bytes="11586">{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470470622
| IUPAC_name = (''9S,10R,11R,13R'')-2,3,10,11,12,13-Hexahydro-&lt;br&gt;10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-&lt;br&gt;1''H'',9''H''-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]&lt;br&gt;benzodiazonin-1-one
| image = Staurosporine.svg
| width = 150px

&lt;!--Clinical data--&gt;
| tradename =  
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category =  
| legal_AU = &lt;!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --&gt;
| legal_CA = &lt;!--             / Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL         / P       / POM / CD / Class A, B, C --&gt;
| legal_US = &lt;!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V --&gt;
| legal_status =  
| routes_of_administration =

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

&lt;!--Identifiers--&gt;
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 62996-74-1
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 44259
| IUPHAR_ligand = 346
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB02010
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 40272
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 15738
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 162

&lt;!--Chemical data--&gt;
| C=28 | H=26 | N=4 | O=3 
| molecular_weight = 466.53 g/mol
| smiles = C[C@@]12[C@@H]([C@@H](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)NC)OC
| InChI = 1/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1
| InChIKey = HKSZLNNOFSGOKW-FYTWVXJKBZ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HKSZLNNOFSGOKW-FYTWVXJKSA-N
}}

'''Staurosporine''' (antibiotic AM-2282 or STS) is a [[natural product]] originally isolated in 1977 from the bacterium ''[[Streptomyces]] staurosporeus''.&lt;ref name=&quot;omura&quot;&gt;{{cite journal |author= Omura S, Iwai Y, Hirano A, Nakagawa A, Awaya J, Tsuchiya H, Takahashi Y, Masuma R |title= A new alkaloid AM-2282 of Streptomyces origin taxonomy, fermentation, isolation and preliminary characterization |journal= J. Antibiot. |volume= 30 |issue= 4 |pages= 275–282 |year=1977 |pmid= 863788}}&lt;/ref&gt;
It was the first of over 50 [[alkaloid]]s to be isolated with this type of bis-indole chemical structure. The chemical structure of staurosporine was elucidated by X-ray analysis of a single crystal and the absolute stereochemical configuration by the same method in 1994.&lt;ref name=funato&gt;{{cite journal |author= Funato N, Takayanagi H, Konda Y, Toda Y, Harigaya Y, Omura S |title= Absolute configuration of staurosporine by X-ray analysis |journal= Tetrahedron Lett. |volume= 35 |issue= 8 |pages= 1251–1254 |year= 1994 |doi= 10.1016/0040-4039(94)88036-0}}&lt;/ref&gt;

Staurosporine was discovered to have biological activities ranging from anti-fungal to anti-hypertensive.&lt;ref&gt;[http://www.nature.com/nbt/journal/v8/n8/abs/nbt0890-732.html] Rüegg UT, Burgess GM. (1989) Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases.'' Trends in Pharmacological Science'' 10 (6): 218-220.&lt;/ref&gt;
The interest in these activities resulted in a large investigative effort in chemistry and biology and the discovery of the potential for anti-cancer treatment.

==Biological activities==
The main biological activity of staurosporine is the [[enzyme inhibition|inhibition]] of [[protein kinase]]s through the prevention of ATP binding to the kinase. This is achieved through the stronger affinity of staurosporine to the ATP-binding site on the kinase. Staurosporine is a prototypical ATP-competitive kinase inhibitor in that it binds to many kinases with high affinity, though with little selectivity.&lt;ref name=&quot;ambit&quot;&gt;{{cite journal |author= Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP |title= A quantitative analysis of kinase inhibitor selectivity |journal= Nat. Biotechnol. |volume= 26 |issue= 1 |pages= 127–132 |year=2008 |doi= 10.1038/nbt1358 |pmid= 18183025}}&lt;/ref&gt; Structural analysis of kinase pockets demonstrated that main chain atoms which are conserved in their relative positions to staurosporine contributes to staurosporine promiscuity.&lt;ref name=&quot;tanramluk&quot;&gt;{{cite journal |author= Tanramluk D, Schreyer A, Pitt WR, Blundell TL |title= On the origins of enzyme inhibitor selectivity and promiscuity: a case study of protein kinase binding to staurosporine |journal= Chem Biol Drug Des. |volume= 74 |issue= 1 |pages= 16–24 |year=2009 |doi= 10.1111/j.1747-0285.2009.00832.x |pmid= 19519740}}&lt;/ref&gt; This lack of specificity has precluded its clinical use, but has made it a valuable research tool. In research, staurosporine is used to induce [[apoptosis]]. The mechanism of how it mediates this is not well understood. It has been found that one way in which staurosporine induces apoptosis is by activating [[caspase-3]].&lt;ref name=&quot;Chae&quot;&gt;{{cite journal |author= Chae HJ, Kang JS, Byun JO, Han KS, Kim DU, Oh SM, Kim HM, Chae SW, Kim HR|title= Molecular mechanism of staurosporine-induced apoptosis in osteoblasts|journal= Pharmacological Research. |volume= 42|issue= 4|pages= 373–381|year= 2000 |doi= 10.1006/phrs.2000.0700 |pmid= 10987998}}&lt;/ref&gt;

==Chemistry family==
Staurosporine is the precursor of the novel [[protein kinase inhibitor]] [[midostaurin]] (PKC412).&lt;ref&gt;[http://www.fermentek.co.il/pkc412.htm Midostaurin] product page, [[Fermentek]]&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=Wang|first=Y|year=2008 |title=Dose- and Time-Dependent Pharmacokinetics of Midostaurin in Patients With Diabetes Mellitus|journal=J Clin Pharmacol|volume=48|pages=763–775|pmid=18508951|last2=Yin|first2=OQ|last3=Graf|first3=P|last4=Kisicki|first4=JC|last5=Schran|first5=H|issue=6|doi=10.1177/0091270008318006}}&lt;/ref&gt; Besides midostaurin, staurosporine is also used as a starting material in the commercial synthesis of [[K252c]] (also called staurosporine aglycone). In the natural biosynthetic pathway, K252c is a precursor of staurosporine.

[[Indolocarbazole]]s belong to the [[alkaloid]] sub-class of bisindoles. Of these [[carbazole]]s the Indolo(2,3-a)carbazoles are the most frequently isolated; the most common subgroup of the Indolo(2,3-a)carbazoles are the Indolo(2,3-a)pyrrole(3,4-c)carbazoles which can be divided into two major classes - halogenated (chlorinated) with a fully oxidized C-7 carbon with only one indole nitrogen containing a β-glycosidic bond and the second class consists of both indole nitrogen glycosilated, non-halogenated, and a fully reduced C-7 carbon.{{clarify|date=January 2012}} Staurosporine is part of the second non-halogenated class.&lt;ref name=&quot;urldspace.mit.edu&quot;&gt;{{cite web | url = http://dspace.mit.edu/bitstream/handle/1721.1/45151/314357162.pdf?sequence=1 | title = Structural studies of rebeccamycin, staurosporine, and violacein biosynthetic enzymes | author = Ryan KS | authorlink = | coauthors = | year = 2008 | format = | work =  Ph.D. Thesis| publisher = Massachusetts Institute of Technology | pages = | language = | archiveurl = | archivedate = | quote = | accessdate = }}&lt;/ref&gt;

[[File:Structure of aIndolo(2,3-a)pyrrole(3,4-c)carbazol.svg|thumb|300px|Structure of an Indolo[2,3-a]pyrrole[3,4-c]carbazol]]

[[File:Synthesis of Staurosporine.png|500px|Synthesis of Staurosporine]]

== Biosynthesis ==
The biosynthesis of staurosporine starts with the amino acid [[L-tryptophan]] in its [[zwitterion]]ic form. Tryptophan is converted to an [[imine]] by enzyme StaO which is an L-amino acid oxidase (that may be FAD dependent). The imine is acted upon by StaD to form an uncharacterized intermediate proposed to be the dimerization product between 2 imine molecules. Chromopyrrolic acid is the molecule formed from this intermediate after the loss of VioE (used in the biosynthesis of violacein – a natural product formed from a branch point in this pathway that also diverges to form [[rebeccamycin]]. An aryl aryl coupling thought to be catalyzed by a [[cytochrome P450|cytochrome P&lt;sub&gt;450&lt;/sub&gt;]] enzyme to form an aromatic ring system occurs.&lt;ref name=&quot;urldspace.mit.edu&quot;/&gt;

[[File:Staurosporine 2.png|500px|Staurosporine 2]]

This is followed by a [[nucleophile|nucleophilic attack]] between the indole nitrogens resulting in cyclization and then [[decarboxylation]] assisted by StaC exclusively forming staurosporine aglycone or K252c. [[Glucose]] is transformed to NTP-L-ristoamine by StaA/B/E/J/I/K which is then added on to the staurosporine aglycone at 1 indole N by StaG. The StaN enzyme reorients the sugar by attaching it to the 2nd indole nitrogen into an unfavored conformation to form intermediated O-demethyl-N-demethyl-staurosporine. Lastly, O-methylation of the 4'amine by StaMA and N-methylation of the 3'-hydroxy by StaMB leads to the formation of staurosporine.&lt;ref name=&quot;urldspace.mit.edu&quot;/&gt;

== Research in clinical use ==
Encapsulated in [[liposome]] [[nanoparticle]], staurosporine is showed to suppress tumors ''in vivo'' in a mouse model without the toxic side effects which have prohibited its use as anti-cancer drugs despite its high potency of causing apotosis.  Researchers in [[UC San Diego Health System|UC San Diego Moores Cancer Center]] develop a platform technology of high drug-loading efficiency by manipulating the pH environment of the cells.  When injected into the mouse [[glioblastoma]] model, staurosporine is found to accumulate primarily in the tumor via [[fluorescence in the life sciences|fluorescence]] confirmation, and the mice did not suffer weight loss compared to the control mice administered with the free compound, an indicator of reduced toxicity.&lt;ref&gt;{{cite web|url= http://health.ucsd.edu/news/releases/Pages/2013-10-21-potent-anti-cancer-drug-delivered-in-liposomes.aspx|title=Study Identifies Safe Delivery System for Tricky Yet Highly Potent Anti-Cancer Compounds|author=News Release|publisher=UC San Diego Health System|date=21 October 2013|accessdate=27 October 2013}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|displayauthors=8|last1=Mukthavaram|first1=Rajesh|last2=Jiang|first2=Pengei|last3=Saklecha|first3=Rohit|last4=Simbery|first4=Dmitri|last5=Bharati|first5=Ila|last6=Nomura|first6=Natsuko|last7=Chao|first7=Ying|last8=Pastorino|first8=Sandra|title=High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile|journal=[[International Journal of Nanomedicine]]|volume=8|issue=1|pages=3991-4006|year=2013|publisher=Dovepress|doi=10.2147/IJN.S51949|url= http://www.dovepress.com/high-efficiency-liposomal-encapsulation-of-a-tyrosine-kinase-inhibitor-peer-reviewed-article-IJN}}&lt;/ref&gt;

== List of compounds closely related to Staurosporine ==
* [[K252a]]
* [[Stauprimide]]
* [[Midostaurin]]

== References ==
&lt;references/&gt;

[[Category:Alkaloids]]
[[Category:Antibiotics]]
[[Category:Lactams]]
[[Category:Protein kinase inhibitors]]
[[Category:Indolocarbazoles]]</text>
      <sha1>5tqmq8c0iqghvktqwe0i30k8hl5mets</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Ascofuranone</title>
    <ns>0</ns>
    <id>11093946</id>
    <revision>
      <id>567920368</id>
      <parentid>567920334</parentid>
      <timestamp>2013-08-10T08:01:39Z</timestamp>
      <contributor>
        <username>حسن علي البط</username>
        <id>8350238</id>
      </contributor>
      <comment>added [[Category:Tetrahydrofurans]] using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="3535">{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457819837
|   Name = Ascofuranone
|   ImageFile = Ascofuranone structure.png
|   ImageSize = 200px
|   ImageName = Chemical structure of ascofuranone
|   IUPACName = 5-chloro-3-[(2''E'',6''E'')-7-[(2''S'')-5,5-dimethyl-4-oxo-tetrahydrofuran-2-yl]-3-methyl-octa-2,6-dienyl]-2,4-dihydroxy-6-methyl-benzaldehyde
|   IUPACName_hidden = yes
|   OtherNames = Ascofuranon
| Section1 = {{Chembox Identifiers
|   SMILES = O=Cc1c(O)c(c(O)c(Cl)c1C)C/C=C(/CC/C=C(\C)[C@H]2OC(C(=O)C2)(C)C)C
|   ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4939184
|   ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 133046
| PubChem = 6434242
|   InChI = 1/C23H29ClO5/c1-13(7-6-8-14(2)18-11-19(26)23(4,5)29-18)9-10-16-21(27)17(12-25)15(3)20(24)22(16)28/h8-9,12,18,27-28H,6-7,10-11H2,1-5H3/b13-9+,14-8+/t18-/m0/s1
|   InChIKey = VGYPZLGWVQQOST-JUERRSSIBJ
|   StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C23H29ClO5/c1-13(7-6-8-14(2)18-11-19(26)23(4,5)29-18)9-10-16-21(27)17(12-25)15(3)20(24)22(16)28/h8-9,12,18,27-28H,6-7,10-11H2,1-5H3/b13-9+,14-8+/t18-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VGYPZLGWVQQOST-JUERRSSISA-N
| CASNo_Ref = {{cascite|changed|??}}
| CASNo =38462-04-3
  }}
| Section2 = {{Chembox Properties
|   C=23|H=29|Cl=1|O=5
|   MeltingPt = 
|   Density = 1.207 g/mL
|   BoilingPtC = 581.2
  }}
}}
'''Ascofuranone''' is an [[antibiotic]] produced by the fungus ''[[Ascochyta viciae]]''.&lt;ref name=&quot;dead mice&quot;&gt;{{cite journal |author=Yabu Y, Yoshida A, Suzuki T, Nihei C, Kawai K, Minagawa N, Hosokawa T, Nagai K, Kita K, Ohta N |title=The efficacy of ascofuranone in a consecutive treatment on Trypanosoma brucei brucei in mice |journal=Parasitol. Int. |volume=52 |issue=2 |pages=155–64 |year=2003 |pmid=12798927 |doi=10.1016/S1383-5769(03)00012-6}}&lt;/ref&gt; that inhibits the ''[[Trypanosoma brucei]]'' [[alternative oxidase]] and is a lead compound in efforts to produce other drugs targeting this enzyme for the treatment of [[African trypanosomiasis|sleeping sickness]].&lt;ref&gt;{{cite journal |author=Minagawa N, Yabu Y, Kita K, Nagai K, Ohta N, Meguro K, Sakajo S, Yoshimoto A |title=An antibiotic, ascofuranone, specifically inhibits respiration and in vitro growth of long slender bloodstream forms of Trypanosoma brucei brucei |journal=Mol. Biochem. Parasitol. |volume=84 |issue=2 |pages=271–80 |year=1997 |pmid=9084049 |doi=10.1016/S0166-6851(96)02797-1}}&lt;/ref&gt; The compound is effective both in vitro [[cell culture]] and in infections in mice.&lt;ref name=&quot;dead mice&quot;/&gt;

Ascofuranone has also been reported to have anti-tumor activity,&lt;ref&gt;{{cite journal |author=Magae J, Hayasaki J, Matsuda Y, Hotta M, Hosokawa T, Suzuki S, Nagai K, Ando K, Tamura G |title=Antitumor and antimetastatic activity of an antibiotic, ascofuranone, and activation of phagocytes |journal=J. Antibiot. |volume=41 |issue=7 |pages=959–65 |year=1988 |pmid=3417568}}&lt;/ref&gt; and modulate the [[immune system]].&lt;ref&gt;{{cite journal |author=Magae J, Suzuki S, Nagai K, Yamasaki M, Ando K, Tamura G |title=In vitro effects of an antitumor antibiotic, ascofuranone, on the murine immune system |journal=Cancer Res. |volume=46 |issue=3 |pages=1073–8 |year=1986 |pmid=3080231}}&lt;/ref&gt;

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Natural phenols]]
[[Category:Terpenes and terpenoids]]
[[Category:Aldehydes]]
[[Category:Ketones]]
[[Category:Organochlorides]]
[[Category:Tetrahydrofurans]]</text>
      <sha1>hd4jhuerw2jtst9qzwskjdpf1hq8mvo</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Ethionamide</title>
    <ns>0</ns>
    <id>5211259</id>
    <revision>
      <id>600271814</id>
      <parentid>600271788</parentid>
      <timestamp>2014-03-19T07:01:22Z</timestamp>
      <contributor>
        <username>Chaupharm</username>
        <id>529395</id>
      </contributor>
      <comment>/* References */</comment>
      <text xml:space="preserve" bytes="9121">{{Drugbox
| verifiedrevid = 461096398
| IUPAC_name = 2-ethylpyridine-4-carbothioamide
| image = Ethionamide.png
| width = 150
| image2 = Ethionamide ball-and-stick.png

&lt;!--Clinical data--&gt;
| tradename = Trecator (Pfizer) 
| Drugs.com = {{drugs.com|monograph|ethionamide}}
| MedlinePlus = a682402
| pregnancy_category = C (US) 
| legal_status = Rx only (US) &lt;ref&gt;[http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04a413fe-95f4-47a7-42ac-283a9e78297d  Trecator (ethionamide) tablet, film coated (Wyeth Pharmaceuticals Company, a subsidiary of Pfizer Inc.)] on DailyMed&lt;/ref&gt; 
| routes_of_administration = [[oral administration]]

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound = Approximately 30% bound to proteins.
| metabolism =  
| elimination_half-life = 2 to 3 hours

&lt;!--Identifiers--&gt;
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 536-33-4
| ATC_prefix = J04
| ATC_suffix = AD03
| ATC_supplemental =  
| PubChem = 2761171
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00609
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2041901
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = OAY8ORS3CQ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00591
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4885
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1441

&lt;!--Chemical data--&gt;
| C=8 | H=10 | N=2 | S=1 
| molecular_weight = 166.244 g/mol
| smiles = S=C(c1ccnc(c1)CC)N
| InChI = 1/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11)
| InChIKey = AEOCXXJPGCBFJA-UHFFFAOYAA
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = AEOCXXJPGCBFJA-UHFFFAOYSA-N
}}

'''Ethionamide''' ([[International Nonproprietary Name|INN]]; chemical name 2-ethylpyridine-4-carbothioamide) is an [[antibiotic]] used in the treatment of [[tuberculosis]].  It was [[1956 in science#Medicine|discovered in 1956]].&lt;ref name=&quot;GTCABoard&quot;&gt;{{cite web| publisher= Global Tuberculosis Community Advisory Board | url= http://www.tbonline.info/posts/2011/8/24/ethionamide/ | title= Ethionamide | work= TB Online | quote= | accessdate=2012-08-18}}&lt;/ref&gt; It is sold under the brand name Trecator or Trecator SC &lt;ref&gt; &quot;Trecator and Trecator SC tablet by Wyeth&quot; |http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM164879.pdf &lt;/ref&gt; by [[Wyeth Pharmaceuticals]] which was purchased by  [[Pfizer]] in 2009.

Ethionamide is part of a group of drugs used in the treatment of drug resistant TB called thioamides. It is used as part of treatment regimens, generally involving 5 medicines, to treat [[Multi-drug-resistant tuberculosis|MDR]] and [[Extensively drug-resistant tuberculosis|XDR TB]].&lt;ref name=&quot;GTCABoard&quot;/&gt; Ethionamide is used as part of a South Africa’s standard regimen to treat MDR TB. It has been proposed for use in combination with [[gatifloxacin]].&lt;ref name=&quot;pmid12878502&quot;&gt;{{cite journal |author=Cynamon MH, Sklaney M |title=Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis |journal=Antimicrob. Agents Chemother. |volume=47 |issue=8 |pages=2442–4 |date=August 2003 |pmid=12878502 |pmc=166105 |doi= 10.1128/AAC.47.8.2442-2444.2003|url=http://aac.asm.org/cgi/pmidlookup?view=long&amp;pmid=12878502}}&lt;/ref&gt;

== Chemical synthesis &lt;ref&gt;[http://aevnmont.free.fr/SACH-BOOKS/Organic%20Chemistry/The%20Organic%20Chemistry%20of%20Drug%20Synthesis,%20Volume%201%20%28D.%20Lednicer%20&amp;%20L.%20A.%20Mitscher%29.pdf The Organic Chemistry of Drug Synthesis], Volume 1.   Daniel Lednicer, Lester A. Mitscher. ISBN 978-0-471-52141-9, 496 pages, February 1977&lt;/ref&gt; ==
[[File:Ethionamide synthesis chemme.png|thumb|center|500px|alt= Ethionamide synthesis chemme]]

==Physicochemical properties==

===Pharmacopoeial properties===
Ethionamide was described in an official monograph in several pharmacopoeia, e.g.[[The International Pharmacopoeia]], [[United States Pharmacopeia|USP]] and [[European Pharmacopoeia|Ph.Eur.]]

===Solubility===
Very sparingly soluble in water, ether ; sparingly soluble in methanol, ethanol, propylene glycol ;
soluble in hot acetone,	dichloroethane ; freely soluble in pyridine.&lt;ref&gt;Merck Index&lt;/ref&gt;

==Basic biology information==

===''In vitro'' potency against ''Mycobacterium tuberculosis''===
[[Minimum inhibitory concentration]] (MIC) against ''[[Mycobacterium tuberculosis|M.tuberculosis]]'' (H37Rv): 0.25 microgram/ml &lt;ref&gt;Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol. 1996 Sep;33(3):167-75.&lt;/ref&gt;

===Spectrum of activity===
Antimicrobial spectrum of ethionamide comprises [[Mycobacterium tuberculosis|''M. tuberculosis'']], ''M. bovis'' and ''M. segmatis''.&lt;ref&gt;http://link.springer.com/article/10.1007%2Fs002849900095# Current Microbiology September 1996, Volume 33, Issue 3, pp 167-175 DOI: 10.1007/s002849900095&lt;/ref&gt;

===Mechanism of action===
Ethionamide is a [[prodrug]]&lt;ref name=&quot;pmid11823459&quot;&gt;{{cite journal |author=Vannelli TA, Dykman A, Ortiz de Montellano PR |title=The anti-tuberculosis drug ethionamide is activated by a flavoprotein monooxygenase |journal=J. Biol. Chem. |volume=277 |issue=15 |pages=12824–9 |date=April 2002 |pmid=11823459 |doi=10.1074/jbc.M110751200 |url=http://www.jbc.org/cgi/pmidlookup?view=long&amp;pmid=11823459}}&lt;/ref&gt;  It is activated by the enzyme EthA, a mono-oxygenase in ''[[Mycobacterium tuberculosis]]'', and binds NAD+ to form an [[adduct]] which inhibits InhA in the same way as [[isoniazid]]. Expression of the ethA gene is controlled by EthR, a [[transcriptional repressor]]. It is understood that improving ethA expression will increase the efficacy of ethionamide and so EthR inhibitors are of great interest to co-drug developers.
The action may be through disruption of [[mycolic acid]].&lt;ref name=&quot;GTCABoard&quot;/&gt;&lt;ref name=&quot;pmid1416831&quot;&gt;{{cite journal |author=Quémard A, Lanéelle G, Lacave C |title=Mycolic acid synthesis: a target for ethionamide in mycobacteria? |journal=Antimicrob. Agents Chemother. |volume=36 |issue=6 |pages=1316–21 |date=June 1992 |pmid=1416831 |pmc=190338 |doi= |url=http://aac.asm.org/cgi/pmidlookup?view=long&amp;pmid=1416831}}&lt;/ref&gt;

===Efficacy in humans===
Ethionamide is indicated in combination with other antituberculosis agents for the treatment of all forms of tuberculosis caused by ''Mycobacterium tuberculosis''. However, ethionamide is only indicated as a second-line antimycobacterial drug when resistance to or 
toxicity from first-line drugs has developed.&lt;ref&gt;http://apps.who.int/prequal/whopar/whoparproducts/TB133part4v1.pdf&lt;/ref&gt;

===ADME data===
Ethionamide (ETA) pharmacokinetic parameters differed between TB patients and healthy volunteers, possibly due to differences in the completeness of absorption. Doses of at least 500&amp;nbsp;mg appear to be required to achieve serum concentrations above the typical ETA MIC.&lt;ref&gt;Zhu M, Namdar R, Stambaugh JJ, Starke JR, Bulpitt AE, Berning SE, Peloquin CA. Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis (Edinb). 2002;82(2-3):91-6. http://www.ncbi.nlm.nih.gov/pubmed/12356460&lt;/ref&gt;

ETA can be administered with food if tolerance is an issue.&lt;ref&gt;Barbara Auclair, David E. Nix, Rodney D. Adam, Gordon T. James, and Charles A. Peloquin. Pharmacokinetics of Ethionamide Administered under Fasting Conditions or with Orange Juice, Food, or Antacids. Antimicrob Agents Chemother. 2001 March; 45(3): 810–814. doi:10.1128/AAC.45.3.810-814.2001 PMCID:PMC90379&lt;/ref&gt;

==Safety and Tolerability==

===Human drug-drug interaction===
Trecator has been found to temporarily raise serum concentrations of isoniazid. Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly. In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs. Excessive ethanol ingestion should be avoided because a psychotic reaction has been reported. &lt;ref&gt;http://labeling.pfizer.com/showlabeling.aspx?id=473&lt;/ref&gt;

===Human potential toxicity and adverse reactions===

Ethionamide is structurally similar to [[methimazole]], has been shown to inhibit thyroid hormone synthesis, and was reported to cause
hypothyroidism in several TB patients.&lt;ref&gt;http://www.nejm.org/doi/pdf/10.1056/NEJM200506303522621&lt;/ref&gt;

==References==
{{Reflist|colonnes=2}}

==External links==
1. http://livertox.nih.gov/Ethionamide.htm

2. http://www.inchem.org/documents/pims/pharm/ethionam.htm

3. http://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+7473
{{Antimycobacterials}}

[[Category:Antibiotics]]
[[Category:Antitubercular agents]]
[[Category:Pyridines]]
[[Category:World Health Organization essential medicines]]</text>
      <sha1>3an9p2l11u1z07f5ckfj7beh45cbyhk</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Plectasin</title>
    <ns>0</ns>
    <id>2902438</id>
    <revision>
      <id>550144346</id>
      <parentid>544159203</parentid>
      <timestamp>2013-04-13T12:12:27Z</timestamp>
      <contributor>
        <username>John of Reading</username>
        <id>11308236</id>
      </contributor>
      <minor/>
      <comment>Typo/[[WP:AWB/GF|general]] fixing, replaced: a [[antibiotic]] → an [[antibiotic]] using [[Project:AWB|AWB]]</comment>
      <text xml:space="preserve" bytes="2017">'''Plectasin''' is an [[antibiotic]] found by [[Novozymes]]&lt;ref name=&quot;novozymes_press_release&quot;&gt;{{cite web|title=Novozymes reveals knowledge on new antibiotic against resistant bacteria|url=http://www.novozymes.com/en/MainStructure/PressAndPublications/PressRelease/2010/Plectasin+in+Science.htm|date=2010-05-28|accessdate=2010-05-28|work=Novozymes}}&lt;/ref&gt; in the [[Pezizales|Pezizalean]] fungus ''[[Pseudoplectania nigrella]]''. Plectasin belongs to the [[antimicrobial]] [[peptide]] class called [[Defensin]]s, which is also present in [[invertebrates]] such as flies and mussels. Pre-clinical tests in mice have shown promising results in that [[multiresistant]] [[bacteria]] have problems [[Mutation|mutating]] resistance against plectasin,&lt;ref&gt;{{cite web|title=Plectasin NZ2114 - Novel Microbial Agent|url=http://www.drugdevelopment-technology.com/projects/plectasin/|accessdate=2010-05-28|work=Drug Development Technology}}&lt;/ref&gt; which acts by directly binding the bacterial cell-wall precursor Lipid II.&lt;ref&gt;{{cite journal|title=Plectasin, a Fungal Defensin, Targets the Bacterial Cell Wall Precursor Lipid II|work=Science|authors=Kristensen, HH ''et al''|doi=10.1126/science.1185723|year=2010|volume=328|issue=5982|pages=1168–1172}}&lt;/ref&gt; At the end of 2008, Novozymes signed a global licensing agreement with [[Sanofi-Aventis]] for the further development and marketing of NZ2114, a derivative of plectasin, as a treatment for [[gram-positive]] bacterial infections, e.g. [[Streptococcus]] and [[Staphylococcus]] which are resistant to all existing antibiotics.&lt;ref name=&quot;novozymes_press_release&quot; /&gt;&lt;ref&gt;{{cite journal|pmc=2704636|title=In Vivo Pharmacodynamic Characterization of a Novel Plectasin Antibiotic, NZ2114, in a Murine Infection Model|authors=Kristensen, HH ''et al''|journal=Antimicrob Agents Chemother.|year=2009|volume=53|issue=7|pages=3003–3009|doi=10.1128/AAC.01584-08|pmid=19414576}}&lt;/ref&gt;

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Peptides]]


{{antibiotic-stub}}</text>
      <sha1>firc4iuzbovefsekphd33xz9q6usf79</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Ristocetin</title>
    <ns>0</ns>
    <id>4323503</id>
    <revision>
      <id>558330050</id>
      <parentid>558328505</parentid>
      <timestamp>2013-06-04T18:59:02Z</timestamp>
      <contributor>
        <username>Inferior Olive</username>
        <id>10577809</id>
      </contributor>
      <text xml:space="preserve" bytes="5627">{{chembox
| Verifiedfields = changed
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = ZP3E6S00IL
| verifiedrevid = 464382786
|ImageFile=Ristocetin.png
|ImageSize=200px
|IUPACName=
|OtherNames=
|Section1={{Chembox Identifiers
|  InChI = 1/C98H113N7O43/c1-30-50(111)20-39-22-54(30)138-55-21-33(5-12-49(55)110)63(100)88(127)105-67-70(115)35-7-13-52-37(15-35)18-44-62-45-19-38-16-36(8-14-53(38)140-84(45)87(83(44)139-52)148-98-86(78(123)74(119)59(144-98)29-135-94-80(125)75(120)69(114)32(3)137-94)147-97-85(77(122)73(118)58(27-107)143-97)146-95-79(124)71(116)51(112)28-134-95)82(145-60-25-46(99)68(113)31(2)136-60)47-10-9-41(93(132)133-4)42-23-40(108)24-56(141-96-81(126)76(121)72(117)57(26-106)142-96)61(42)43-17-34(6-11-48(43)109)64(89(128)101-47)102-91(130)66(62)104-90(129)65(39)103-92(67)131/h5-8,11-17,20-24,31-32,41,46-47,51,57-60,63-82,85-86,94-98,106-126H,9-10,18-19,25-29,99-100H2,1-4H3,(H,101,128)(H,102,130)(H,103,131)(H,104,129)(H,105,127)/t31-,32+,41-,46+,47?,51-,57+,58-,59-,60+,63?,64?,65?,66?,67+,68-,69+,70+,71-,72+,73-,74-,75-,76-,77+,78+,79+,80-,81-,82+,85+,86-,94-,95+,96+,97-,98+/m0/s1
| InChIKey = SGAHMTIMAXYJKX-JWVHJGEPBW
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C98H113N7O43/c1-30-50(111)20-39-22-54(30)138-55-21-33(5-12-49(55)110)63(100)88(127)105-67-70(115)35-7-13-52-37(15-35)18-44-62-45-19-38-16-36(8-14-53(38)140-84(45)87(83(44)139-52)148-98-86(78(123)74(119)59(144-98)29-135-94-80(125)75(120)69(114)32(3)137-94)147-97-85(77(122)73(118)58(27-107)143-97)146-95-79(124)71(116)51(112)28-134-95)82(145-60-25-46(99)68(113)31(2)136-60)47-10-9-41(93(132)133-4)42-23-40(108)24-56(141-96-81(126)76(121)72(117)57(26-106)142-96)61(42)43-17-34(6-11-48(43)109)64(89(128)101-47)102-91(130)66(62)104-90(129)65(39)103-92(67)131/h5-8,11-17,20-24,31-32,41,46-47,51,57-60,63-82,85-86,94-98,106-126H,9-10,18-19,25-29,99-100H2,1-4H3,(H,101,128)(H,102,130)(H,103,131)(H,104,129)(H,105,127)/t31-,32+,41-,46+,47?,51-,57+,58-,59-,60+,63?,64?,65?,66?,67+,68-,69+,70+,71-,72+,73-,74-,75-,76-,77+,78+,79+,80-,81-,82+,85+,86-,94-,95+,96+,97-,98+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SGAHMTIMAXYJKX-JWVHJGEPSA-N
| CASNo_Ref = {{cascite|changed|??}}
| CASNo=1404-55-3
|  PubChem=24846002
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 21106475
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1095986
|  SMILES=CC1C(C(CC(O1)OC2C3C(=O)NC(C4=CC(=CC(=C4C5=C(C=CC(=C5)C(C(=O)N3)NC(=O)C6C7=CC(=C(C(=C7)OC8=CC=C2C=C8)OC9C(C(C(C(O9)COC1C(C(C(C(O1)C)O)O)O)O)O)OC1C(C(C(C(O1)CO)O)O)OC1C(C(C(CO1)O)O)O)OC1=CC=C(C=C1)C(C1C(=O)NC(C2=CC(=C(C(=C2)O)C)OC2=C(C=CC(=C2)C(C(=O)N1)N)O)C(=O)N6)O)O)OC1C(C(C(C(O1)CO)O)O)O)O)C(=O)O)N)O
  }}
|Section2={{Chembox Properties
|  Formula=C&lt;sub&gt;94&lt;/sub&gt;H&lt;sub&gt;108&lt;/sub&gt;N&lt;sub&gt;8&lt;/sub&gt;O&lt;sub&gt;44&lt;/sub&gt;
|  MolarMass=2053.89052
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3={{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}

'''Ristocetin''' is an antibiotic, obtained from ''[[Amycolatopsis]] lurida'', previously used to treat [[staphylococcal infection]]s. It is no longer used clinically because it caused [[thrombocytopenia]] and [[platelet]] [[agglutination (biology)|agglutination]].  It is now used solely to assay those functions ''in vitro'' in the diagnosis of conditions such as [[von Willebrand disease]] (vWD) and [[Bernard-Soulier syndrome]].  Platelet agglutination caused by ristocetin can occur only in the presence of [[von Willebrand factor]] multimers, so if ristocetin is added to blood lacking the factor (or its receptor -- see below), the platelets will not clump.

In an unknown fashion, the antibiotic ristocetin causes von Willebrand factor to bind the platelet receptor glycoprotein Ib (GpIb), so when ristocetin is added to normal blood, it causes agglutination.

In some types of vWD (types 2B and platelet-type), even very small amounts of ristocetin cause platelet aggregation when the patient's platelet-rich [[Blood plasma|plasma]] is used.&lt;ref&gt;{{cite book |last=McPherson |first=Richard A. |coauthors=Matthew R. Pincus |title=Henry's Clinical Diagnosis and Management by Laboratory Methods |publisher=W. B. Saunders|location=Philadelphia |year=2006 |pages=760–2 |isbn=978-1-4160-0287-1}}&lt;/ref&gt;  This paradox is explained by these types having [[gain-of-function]] [[mutations]] which cause the vWD high molecular-weight multimers to bind more tightly to their receptors on platelets (the alpha chains of [[glycoprotein Ib (GPIb)]] receptors).  In the case of type 2B vWD, the gain-of-function mutation involves von Willebrand's factor (VWF gene), and in platelet-type vWD, the receptor is the object of the mutation (GPIb).  This increased binding causes vWD because the high-molecular weight multimers are removed from circulation in plasma since they remain attached to the patient's platelets.  Thus, if the patient's platelet-poor plasma is used, the ristocetin cofactor assay will not agglutinate standardized platelets (ie., pooled platelets from normal donors that are fixed in formalin), similar to the other types of vWD.

In all forms of the ristocetin assay, the platelets are fixed in [[formalin]] prior to the assay to prevent von Willebrand's factor stored in platelet granules from being released and participating in platelet aggregation.  Thus, the ristocetin cofactor activity depends only upon high-molecular multimers of the factor present in circulating plasma.

{{See also|Ristocetin-induced platelet aggregation}}

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Chemical pathology]]</text>
      <sha1>4d60f47uk5aq3sf7xl6su55c7g0vre7</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Spectinomycin</title>
    <ns>0</ns>
    <id>5120442</id>
    <revision>
      <id>605599023</id>
      <parentid>605598814</parentid>
      <timestamp>2014-04-24T12:35:31Z</timestamp>
      <contributor>
        <username>Jmh649</username>
        <id>3810835</id>
      </contributor>
      <text xml:space="preserve" bytes="5500">{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464405974
| IUPAC_name = (1''R'',3''S'',5''R'',8''R'',10''R'',11''S'',12''S'',13''R'',14''S'')-8,12,14-trihydroxy-5-methyl-11,13-''bis''(methylamino)-2,4,9-trioxatricyclo[8.4.0.0&lt;sup&gt;3,8&lt;/sup&gt;]tetradecan-7-one
| image = Spectinomycin.svg

&lt;!--Clinical data--&gt;
| tradename = Trobicin
| Drugs.com = {{drugs.com|monograph|spectinomycin-hydrochloride}}
| pregnancy_US = B
| legal_status = not available in US
| routes_of_administration =  

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 1695-77-8
| ATC_prefix = J01
| ATC_suffix = XX04
| ATC_supplemental =  
| PubChem = 15541
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00919
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 14785
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 93AKI1U6QF
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08526
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 9215
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1167

&lt;!--Chemical data--&gt;
| C=14 | H=24 | N=2 | O=7 
| molecular_weight = 332.35 g/mol
| smiles = O=C1[C@@]2(O[C@@H]3[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@H]3O[C@@H]2O[C@@H](C1)C)O
| InChI = 1/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1
| InChIKey = UNFWWIHTNXNPBV-WXKVUWSEBO
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UNFWWIHTNXNPBV-WXKVUWSESA-N
| synonyms = &lt;small&gt;(2''R'',4a''R'',5a''R'',6''S'',7''S'',8''R'',9''S'',9a''R'',10a''S'')-4a,7,9-trihydroxy-2-methyl-6,8-''bis''(methylamino)decahydro-4''H''-pyrano[2,3-''b''][1,4]benzodioxin-4-one&lt;/small&gt;
}}
'''Spectinomycin''' is an [[antibiotic]] useful for the treatment of the [[bacterial]] infection, [[gonorrhea]].&lt;ref name=AHFS2014&gt;{{cite web|title=Spectinomycin Hydrochloride
|url=http://www.drugs.com/monograph/spectinomycin-hydrochloride.html|publisher=The American Society of Health-System Pharmacists|accessdate=Apr 24, 2014}}&lt;/ref&gt;

It is marketed as the [[hydrochloride]] salt '''spectinomycin hydrochloride''' under the trade name '''Trobicin'''. It is in [[aminocyclitol]] class, closely related to the [[aminoglycosides]], produced by the [[bacteria|bacterium]] ''[[Streptomyces spectabilis]]''. Spectinomycin is produced in nature by many organisms including cyanobacteria and various plant species. It is present in the [[genome]] or plastome of many plastids as the spc [[operon]], which is usually 2–10 amino acids long (this has been known to vary). The difference in size may be due to the elimination of obsolete genes or the takeover of its function by nuclear genes. Spectinomycin is mainly produced by organisms as a [[antipredator adaptation|defence mechanism]] against predators.

&lt;!-- Society and culture --&gt;
It is on the [[World Health Organization's List of Essential Medicines]], a list of the most important medication needed in a basic [[health system]].&lt;ref&gt;{{cite web|title=WHO Model List of EssentialMedicines|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|work=World Health Organization|accessdate=22 April 2014|date=October 2013}}&lt;/ref&gt;

==Medical uses==
It is given by [[Injection (medicine)|injection]] to treat [[gonorrhea]], especially in patients who are allergic to [[penicillin]]s.

This antibiotic is no longer available in the United States. A resistance-conferring gene for spectinomycin can also be used as a selection marker in bacteria for molecular cloning purposes. Furthermore, Spectinomycin is used as a selection agent for transformed plant cells that contain the selectable marker gene Spcr.&lt;ref&gt;{{ cite web | title = Spectinomycin Hydrochloride | url = http://www.toku-e.com/Upload/Products/PDS/20120518003891.pdf | format = pdf | publisher = Toku-E | date = 2010-10-10 | accessdate = 2012-06-11 }}&lt;/ref&gt;

==Side effects==
Side effects include [[pruritus|itching]], [[chills]], stomach-ache, and [[erythema|red rash]].

==Mechanism of action==
Spectinomycin binds to the [[30S]] subunit of the bacterial [[ribosome]] and interrupts protein synthesis.

One form of resistance has emerged in the [[16S ribosomal RNA]] in [[Pasteurella multocida]].&lt;ref name=&quot;pmid17371823&quot;&gt;{{cite journal |author=Kehrenberg C, Schwarz S |title=Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida |journal=Antimicrob. Agents Chemother. |volume=51 |issue=6 |pages=2244–6 |date=June 2007 |pmid=17371823 |pmc=1891365 |doi=10.1128/AAC.00229-07 |url=}}&lt;/ref&gt;

==History==
There was a disruption in the supply in 2001.&lt;ref name=&quot;pmid11575327&quot;&gt;{{cite journal |author= |title=From the Centers for Disease Control and Prevention. Update on spectinomycin availability in the United States |journal=JAMA |volume=286 |issue=11 |pages=1308–9 |date=September 2001 |pmid=11575327 |doi= 10.1001/jama.286.11.1308|url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&amp;pmid=11575327}}&lt;/ref&gt;

==References==
{{reflist}}

{{AminoglycosideAntiBiotics}}

[[Category:Antibiotics]]
[[Category:World Health Organization essential medicines]]
[[Category:Pyrones]]</text>
      <sha1>8wvnz8mysx2auuos86o23eo31h5hyhj</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Fosmidomycin</title>
    <ns>0</ns>
    <id>2214885</id>
    <revision>
      <id>608268936</id>
      <parentid>607569794</parentid>
      <timestamp>2014-05-12T19:35:42Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Task 4: Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated coauthor parameter errors]]</comment>
      <text xml:space="preserve" bytes="5190">{{distinguish|Fosfomycin}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 461113697
| IUPAC_name = 3-[Formyl(hydroxy)amino]propylphosphonic acid
| image = Fosmidomycin.svg

&lt;!--Clinical data--&gt;
| tradename =  
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B / C / D / X --&gt;
| legal_AU = &lt;!-- Unscheduled / S2 / S4 / S8 --&gt;
| legal_UK = &lt;!-- GSL / P / POM / CD --&gt;
| legal_US = &lt;!-- OTC / Rx-only --&gt;

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 66508-53-0
| ATC_prefix = none
| PubChem = 572
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB02948
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 555
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5829E3D9I9
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 443725
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 203125

&lt;!--Chemical data--&gt;
| C=4 | H=10 | N=1 | O=5 | P=1 
| molecular_weight = 183.100 g/mol
| smiles = O=P(O)(O)CCCN(O)C=O
| InChI = 1/C4H10NO5P/c6-4-5(7)2-1-3-11(8,9)10/h4,7H,1-3H2,(H2,8,9,10)
| InChIKey = GJXWDTUCERCKIX-UHFFFAOYAD
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C4H10NO5P/c6-4-5(7)2-1-3-11(8,9)10/h4,7H,1-3H2,(H2,8,9,10)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = GJXWDTUCERCKIX-UHFFFAOYSA-N
}}
'''Fosmidomycin''' is an [[antibiotic]] that was originally isolated from culture broths of bacteria of the genus ''[[Streptomyces]]''.&lt;ref&gt;{{cite journal|last=Iguchi|first=E|author2=Okuhara, M |author3=Kohsaka, M |author4=Aoki, H |author5=Imanaka, H |title=Studies on new phosphonic acid antibiotics. II. Taxonomic studies on producing organisms of the phosphonic acid and related compounds.|journal=The Journal of antibiotics|year=1980|volume=33|issue=1|pages=19–23|pmid=7372546|url=http://www.journalarchive.jst.go.jp/japanese/jnlabstract_ja.php?cdjournal=antibiotics1968&amp;cdvol=33&amp;noissue=1&amp;startpage=18}}&lt;/ref&gt; It specifically inhibits [[DXP reductoisomerase]], a key enzyme in the [[non-mevalonate pathway]] of [[isoprenoid]] biosynthesis. It is a structural analogue of [[2-C-methyl-D-erythrose 4-phosphate]]. It inhibits the ''[[E. coli]]'' enzyme with a KI value of 38 nM (4), [[MTB]] at 80 nM, and the ''[[Francisella]]'' enzyme at 99 nM.&lt;ref&gt;Jawaid, S., Seidle, H., Zhou W, Abdirahman, H., Abadeer, M, Hix, JH, van Hoek, ML and RD Couch.  Kinetic Characterization and Phosphoregulation of the Francisella tularensis 1-Deoxy-D-Xylulose 5-Phosphoate Reductoisomerase (MEP Synthase), PLOS One, 4(12): e8288. {{doi|10.1371/journal.pone.0008288}}&lt;/ref&gt;

==Use in malaria==

The discovery of the non-mevalonate pathway in [[malaria parasites]] has indicated the use of fosmidomycin and other such inhibitors as [[Antimalarial drug|antimalarial]] drugs.&lt;ref name=&quot;Jomaa1999&quot;&gt;{{cite journal |last=Jomaa |first=H |authorlink= |author2=et al. |year=1999 |title=Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs |journal=Science |volume=285 |issue=5433 |pages=1573–6 |doi=10.1126/science.285.5433.1573 |url= |accessdate= |quote= |pmid=10477522 }}&lt;/ref&gt; Indeed, fosmidomycin has been tested in combination treatment with [[clindamycin]] for treatment of [[malaria]] with favorable results.&lt;ref name=&quot;Borrmann2004&quot;&gt;{{cite journal |last=Borrmann |first=S |authorlink= |author2=et al. |year=2004 |title=Fosmidomycin-clindamycin for ''Plasmodium falciparum'' infections in African children |journal=J Infect Dis |volume=189 |issue=5 |pages=901–8 |doi=10.1086/381785 |url= |accessdate= |quote= |pmid=14976608 }}&lt;/ref&gt;&lt;ref name=&quot;Borrmann2006&quot;&gt;{{cite journal |last=Borrmann |first=S |authorlink= |author2=et al. |year=2006 |title=Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with ''Plasmodium falciparum'' malaria |journal=Antimicrob Agents Chemother |volume=50 |issue=8 |pages=2713–8 |doi=10.1128/AAC.00392-06 |url= |accessdate= |quote= |pmid=16870763 |pmc=1538678 }}&lt;/ref&gt;&lt;ref name=&quot;Ruangweerayut2008&quot;&gt;{{cite journal |last=Ruangweerayut |first=R |authorlink= |author2=et al. |year=2008 |title=Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria |journal=Malaria J |volume=7 |issue= 1|pages=225 |doi=10.1186/1475-2875-7-225 |url= |accessdate= |quote= |pmid=18973702 |pmc=2600645 }}&lt;/ref&gt; It has been shown that an increase in copy number of the target enzyme ([[DXP reductoisomerase]]) correlates with ''[[in vitro]]'' fosmidomycin resistance in the lethal [[malaria]] parasite, ''[[Plasmodium falciparum]]''.&lt;ref name=&quot;Dharia2009&quot;&gt;{{cite journal |last=Dharia |first=NV |authorlink= |author2=et al. |year=2009 |title=Use of high-density tiling microarrays to globally identify mutations and elucidate mechanisms of drug resistance in ''Plasmodium falciparum'' |journal=Genome Biology |volume=10 |issue= 2|pages=R21 |doi=10.1186/gb-2009-10-2-r21 |url= |accessdate= |quote= |pmid=19216790 |pmc=2688282 }}&lt;/ref&gt;

== References ==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Oxidoreductase inhibitors]]
[[Category:Phosphonic acids]]

{{antibiotic-stub}}</text>
      <sha1>cm7e816pj92oyzzp0qbesqbf9btvpzl</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Resistome</title>
    <ns>0</ns>
    <id>11187650</id>
    <revision>
      <id>594949991</id>
      <parentid>544796793</parentid>
      <timestamp>2014-02-11T08:33:33Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="2324">The '''resistome''' is a proposed expression by Gerard D. Wright&lt;ref&gt;{{cite journal |author=Wright GD |title=The antibiotic resistome: the nexus of chemical and genetic diversity |journal=[[Nature Reviews Microbiology]] |volume=5 |pages=175–186 |date=March 2007 |doi=10.1038/nrmicro1614 |issue=3}}&lt;/ref&gt; for the collection of all the [[antibiotic resistance]] [[genes]] and their precursors in both pathogenic and non-pathogenic [[bacteria]].

This complete set of antibiotic resistance genes is composed of four different types of genes:
# Resistance genes found on '''pathogenic bacteria'''. These are the fewest but also the most problematic ones at present.
# Resistance genes found on '''antibiotic producers'''. The microorganisms such as soil-dwelling bacteria and fungi that naturally produce [[antibiotics]] have their own protection mechanisms&lt;ref&gt;{{cite journal |author=Cundliffe E |title=How antibiotic-producing organisms avoid suicide |journal=Annu. Rev. Microbiol. |volume=43 |pages=207–233 |year=1989 |doi=10.1146/annurev.mi.43.100189.001231 |pmid=2679354}}&lt;/ref&gt; to avoid the adverse effects of the antibiotics on themselves. The genes which code for these resistances are a strong source&lt;ref&gt;{{cite journal |author=Benveniste R, Davies J |title=Aminoglycoside antibioticinactivating enzymes in actinomycetes similar to those present in clinical isolates of antibiotic-resistant bacteria |journal=Proc. Natl Acad. Sci. USA |volume=70 |pages=2276–2280 |year=1973 |doi=10.1073/pnas.70.8.2276 |pmid=4209515 |issue=8 |pmc=433717}}&lt;/ref&gt; for the pathogenic bacteria.
# '''Cryptic resistance genes'''. These genes are embedded in the bacterial [[chromosome]] but do not obviously confer resistance, because their level of expression is usually low or they are not expressed.
# '''Precursor genes'''. These genes do not confer antibiotic resistance. However they encode proteins that confer to some kind of basal level activity against the antibiotic molecule or have affinity to the molecule. In both cases this interaction may evolve to a full resistance gene given the appropriate selection pressure.

Note that these groups are not independent, and some overlapping is expected between them.

== References ==
{{Reflist}}

[[Category:Antibiotics]]
[[Category:Antibiotic resistance]]
[[Category:Genomics]]</text>
      <sha1>m1ry59b0ioemdpyy3r3jhy3uih4vf7m</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Beauvericin</title>
    <ns>0</ns>
    <id>4554727</id>
    <revision>
      <id>575373698</id>
      <parentid>557393318</parentid>
      <timestamp>2013-10-02T01:37:31Z</timestamp>
      <contributor>
        <username>ArmbrustBot</username>
        <id>18663209</id>
      </contributor>
      <minor/>
      <comment>/* References */removing category per [[Wikipedia:Categories for discussion/Log/2013 September 21]], removed: Category:Chemical compounds found in Ascomycota using [[Project:AWB|AWB]]</comment>
      <text xml:space="preserve" bytes="3988">{{chembox
| Verifiedfields = changed
| verifiedrevid = 459526464
|ImageFile=Beauvericin.svg
|ImageSize=280px
|ImageFile2=Beauvericin_3d_structure.png
|ImageSize=280px
| IUPACName=(3''S'',6''R'',9''S'',12''R'',15''S'',18''R'')-3,9,15-tribenzyl-6,12,18-triisopropyl-4,10,16-trimethyl-1,7,13-trioxa-4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexone
| OtherNames=
| Section1= {{Chembox Identifiers
|  InChIKey = GYSCAQFHASJXRS-FFCOJMSVBB
|  StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C45H57N3O9/c1-28(2)37-40(49)46(7)35(26-32-21-15-11-16-22-32)44(53)56-39(30(5)6)42(51)48(9)36(27-33-23-17-12-18-24-33)45(54)57-38(29(3)4)41(50)47(8)34(43(52)55-37)25-31-19-13-10-14-20-31/h10-24,28-30,34-39H,25-27H2,1-9H3/t34-,35-,36-,37+,38+,39+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = GYSCAQFHASJXRS-FFCOJMSVSA-N
| CASNo_Ref = {{cascite|changed|??}}
|  CASNo = 26048-05-5
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 373872
|  PubChem = 3007984
|  ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 3000
|  KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = C11590
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2277520
|  SMILES = O=C1N(C)[C@H](C(=O)O[C@@H](C(=O)N([C@H](C(=O)O[C@@H](C(=O)N([C@H](C(=O)O[C@@H]1C(C)C)Cc2ccccc2)C)C(C)C)Cc3ccccc3)C)C(C)C)Cc4ccccc4
|  InChI = 1/C45H57N3O9/c1-28(2)37-40(49)46(7)35(26-32-21-15-11-16-22-32)44(53)56-39(30(5)6)42(51)48(9)36(27-33-23-17-12-18-24-33)45(54)57-38(29(3)4)41(50)47(8)34(43(52)55-37)25-31-19-13-10-14-20-31/h10-24,28-30,34-39H,25-27H2,1-9H3/t34-,35-,36-,37+,38+,39+/m0/s1
}}
|Section2= {{Chembox Properties
|C=45|H=57|N=3|O=9
|  MolarMass=783.95 g/mol
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3= {{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}
'''Beauvericin''' is a [[depsipeptide]] with [[antibiotic]] and [[insecticide|insecticidal]] effects belonging to the [[enniatin]] family. It was isolated from the [[fungus]] ''[[Beauveria bassiana]]'', but is also produced by several other fungi, including several ''[[Fusarium]]'' species;&lt;ref name=&quot;PMID 9687479&quot;&gt;{{cite journal |author=Logrieco A |title=Beauvericin Production by Fusarium Species |journal=Appl Environ Microbiol |volume=64 |issue=8 |pages=3084–8 |year=1998 |pmid=9687479 |doi= |pmc=106821 |author-separator=, |author2=Moretti A |author3=Castella G |display-authors=3 |last4=Kostecki |first4=M |last5=Golinski |first5=P |last6=Ritieni |first6=A |last7=Chelkowski |first7=J}}&lt;/ref&gt; it may therefore occur in [[grain]] (such as [[Maize|corn]], [[wheat]] and [[barley]]) contaminated with these fungi.&lt;ref name=&quot;PMID 9687479&quot;/&gt;&lt;ref&gt;{{cite journal |author=Logrieco A, Rizzo A, Ferracane R, Ritieni A |title=Occurrence of Beauvericin and Enniatins in Wheat Affected by Fusarium avenaceum Head Blight |journal=Appl Environ Microbiol |volume=68 |issue=1 |pages=82–5 |year=2002 |pmid=11772612 |doi=10.1128/AEM.68.1.82-85.2002 |pmc=126553}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |author=Jestoi M, Rokka M, Yli-Mattila T, Parikka P, Rizzo A, Peltonen K |title=Presence and concentrations of the Fusarium-related mycotoxins beauvericin, enniatins and moniliformin in finnish grain samples |journal=Food additives and contaminants |volume=21 |issue=8 |pages=794–802 |year=2004 |pmid=15370831 |doi=10.1080/02652030410001713906}}&lt;/ref&gt; Beauvericin is active against [[Gram-positive]] [[bacteria]] and [[mycobacteria]], and is also capable of inducing [[programmed cell death]] in [[mammal]]s.&lt;ref name=&quot;PMID 9687479&quot;/&gt;

Chemically, beauvericin is a cyclic hexadepsipeptide with alternating methyl-[[phenylalanine|phenylalanyl]] and hydroxy-iso-valeryl residues. Its [[ion]]-complexing capability allows beauvericin to transport [[alkaline earth metal]] and [[alkali metal]] ions across [[cell membrane]]s.

== References ==
{{Reflist}}

[[Category:Antibiotics]]
[[Category:Mycotoxins]]
[[Category:Ionophores]]
[[Category:Depsipeptides]]

{{antibiotic-stub}}</text>
      <sha1>n94hmok5df26zf1oxsp5k1xbbv7auj8</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Nigericin</title>
    <ns>0</ns>
    <id>4768528</id>
    <revision>
      <id>578615261</id>
      <parentid>556240737</parentid>
      <timestamp>2013-10-24T22:44:17Z</timestamp>
      <contributor>
        <username>Cydebot</username>
        <id>1215485</id>
      </contributor>
      <minor/>
      <comment>Robot - Removing category Chemical compounds found in Streptomyces species per [[WP:CFD|CFD]] at [[Wikipedia:Categories for discussion/Log/2013 October 8]].</comment>
      <text xml:space="preserve" bytes="3772">{{chembox
| Verifiedfields = changed
| verifiedrevid = 462260648
|ImageFile=Nigericin.svg
|ImageSize=350
|IUPACName=&lt;nowiki&gt;(2R)-2-[(2R,3S,6R)-6-[[(2S,4R,5R,7R,9R,10R)-
2-[(2R,5S)-5-[(2R,3S,5R)-5-[(2S,3S,5R,6R)-6-hydroxy-
6-(hydroxymethyl)-3,5-dimethyl-2-tetrahydropyranyl]-3-methyl-
2-tetrahydrofuranyl]-5-methyl-2-tetrahydrofuranyl]-9-methoxy-
2,4,10-trimethyl-1,6-dioxaspiro[4.5]decan-7-yl]methyl]-3-methyl-
2-tetrahydropyranyl]propanoic acid&lt;/nowiki&gt;
|OtherNames=Polyetherin A, Azalomycin M, Helixin C, Helix C
|Section1= {{Chembox Identifiers
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10196461
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 405862
| InChI1 = 1/C40H68O11/c1-21-11-12-28(46-33(21)26(6)36(42)43)17-29-18-30(45-10)27(7)40(48-29)25(5)19-38(9,51-40)32-13-14-37(8,49-32)35-23(3)16-31(47-35)34-22(2)15-24(4)39(44,20-41)50-34/h21-35,41,44H,11-20H2,1-10H3,(H,42,43)/t21-,22-,23-,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34-,35+,37-,38-,39-,40+/m0/s1
| InChIKey1 = DANUORFCFTYTSZ-SJSJOXFOBS
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C40H68O11/c1-21-11-12-28(46-33(21)26(6)36(42)43)17-29-18-30(45-10)27(7)40(48-29)25(5)19-38(9,51-40)32-13-14-37(8,49-32)35-23(3)16-31(47-35)34-22(2)15-24(4)39(44,20-41)50-34/h21-35,41,44H,11-20H2,1-10H3,(H,42,43)/t21-,22-,23-,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34-,35+,37-,38-,39-,40+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DANUORFCFTYTSZ-SJSJOXFOSA-N
| CASNo_Ref = {{cascite|changed|??}}
| CASNo=28380-24-7
|  PubChem= 34230
|  ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 7569
| SMILES = OC(=O)[C@H](C)[C@@H]1O[C@H](CC[C@@H]1C)C[C@H]6O[C@]2(O[C@@](C)(C[C@H]2C)[C@H]3CC[C@](C)(O3)[C@@H]4O[C@H](C[C@@H]4C)[C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)[C@H](C)[C@H](OC)C6
}}
|Section2= {{Chembox Properties
|  Formula=C&lt;sub&gt;40&lt;/sub&gt;H&lt;sub&gt;68&lt;/sub&gt;O&lt;sub&gt;11&lt;/sub&gt;
|  MolarMass=724.96132
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3= {{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}

'''Nigericin''' is an [[antibiotic]] derived from ''[[Streptomyces hygroscopicus]]''. Its isolation was described in the 1950s,&lt;ref name=&quot;pmid5229984&quot;&gt;{{cite journal |author=Graven SN, Estrada-O S, Lardy HA |title=Alkali metal cation release and respiratory inhibition induced by nigericin in rat liver mitochondria |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=56 |issue=2 |pages=654–8 |year=1966 |pmid=5229984 |doi=10.1073/pnas.56.2.654 |pmc=224422}}&lt;/ref&gt; and in 1968 the structure could be elucidated by [[X-ray crystallography]].&lt;ref name=&quot;pmid5696503&quot;&gt;{{cite journal |author=Steinrauf LK, Pinkerton M, Chamberlin JW |title=The structure of nigericin |journal=Biochem. Biophys. Res. Commun. |volume=33 |issue=1 |pages=29–31 |year=1968 |pmid=5696503 |doi=10.1016/0006-291X(68)90249-0 }}&lt;/ref&gt; The structure and properties of nigericin are similar to the [[antibiotic]] [[monensin]]. Commercially it is obtained as a byproduct, or contaminant, at the fermentation of [[Geldanamycin]]. It is also called Polyetherin A, Azalomycin M, Helixin C, Antibiotic K178, Antibiotic X-464.

Nigericin acts as an H&lt;sup&gt;+&lt;/sup&gt;, K&lt;sup&gt;+&lt;/sup&gt;, Pb&lt;sup&gt;2+&lt;/sup&gt; [[ionophore]].  Most commonly it is an [[antiporter]] of H&lt;sup&gt;+&lt;/sup&gt; and K&lt;sup&gt;+&lt;/sup&gt;.  

In the past nigericin was used as an antibiotic active against [[gram positive]] [[bacteria]]. It inhibits the  [[Golgi apparatus|Golgi]] functions in Eukaryotic cells. Nigericin exhibits anti-[[HIV]] activity.

== References ==
{{Reflist}}

== External references ==

[http://www.fermentek.co.il/nigericin.htm Commercial supplier of nigericin sodium]

{{Nonribosomally synthesized porters}}

[[Category:Antibiotics]]
[[Category:Ionophores]]</text>
      <sha1>6s2kjzje8lk4362s8wfujza3pia4qoi</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Leptomycin</title>
    <ns>0</ns>
    <id>4282370</id>
    <revision>
      <id>606358603</id>
      <parentid>592177282</parentid>
      <timestamp>2014-04-29T17:32:02Z</timestamp>
      <contributor>
        <username>Rjwilmsi</username>
        <id>203434</id>
      </contributor>
      <minor/>
      <comment>Added 1 dois to journal cites using [[Project:AWB|AWB]] (10081)</comment>
      <text xml:space="preserve" bytes="5728">{{chembox
| Watchedfields = changed
| verifiedrevid = 450847443
|ImageFile=Leptomycin B.svg
|ImageSize=
|IUPACName=(2''E'',5''S'',6''R'',7''S'',9''R'',10''E'',12''E'',15''R'',16''Z'',18''E'')-&lt;br&gt;17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-&lt;br&gt;19-[(2''S'',3''S'')-3-methyl-6-oxo-2,3-dihydropyran-&lt;br&gt;2-yl]-8-oxononadeca-2,10,12,16,18-pentaenoic acid
|OtherNames=
|Section1= {{Chembox Identifiers
|  InChI = 1/C33H48O6/c1-9-28(14-15-29-24(5)13-16-31(36)39-29)19-22(3)12-10-11-21(2)17-25(6)32(37)27(8)33(38)26(7)18-23(4)20-30(34)35/h10-11,13-17,19-20,22,24-27,29,33,38H,9,12,18H2,1-8H3,(H,34,35)/b11-10+,15-14+,21-17+,23-20+,28-19+/t22-,24+,25-,26+,27-,29+,33-/m1/s1
| InChIKey = YACHGFWEQXFSBS-RJXCBBHPBE
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C33H48O6/c1-9-28(14-15-29-24(5)13-16-31(36)39-29)19-22(3)12-10-11-21(2)17-25(6)32(37)27(8)33(38)26(7)18-23(4)20-30(34)35/h10-11,13-17,19-20,22,24-27,29,33,38H,9,12,18H2,1-8H3,(H,34,35)/b11-10+,15-14+,21-17+,23-20+,28-19+/t22-,24+,25-,26+,27-,29+,33-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YACHGFWEQXFSBS-RJXCBBHPSA-N
| CASNo_Ref = {{cascite|correct|??}}
| CASNo=87081-35-4
|  PubChem=6917907
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID=21106330
|  SMILES = OC(=O)\C=C(/C)C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)/C=C\[C@@H]1C
}}
|Section2= {{Chembox Properties
|  C=33|H=48|O=6
|  MolarMass=
|  Appearance=
|  Density=1.072 g/mL
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3= {{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}
'''Leptomycin''' B is a secondary [[metabolite]] produced by [[Streptomyces]] spp.

Leptomycin B (LMB) was originally discovered as a potent [[anti-fungal]] [[antibiotic]].&lt;ref&gt;{{cite journal |author=Hamamoto T, Seto H, Beppu T |title=Leptomycins A and B, new antifungal antibiotics. II. Structure elucidation |journal=J. Antibiot. |volume=36 |issue=6 |pages=646–50 |year=1983 |pmid=6874586 |doi=10.7164/antibiotics.36.646}}&lt;/ref&gt; Leptomycin B was found to cause cell elongation of the fission yeast ''[[Schizosaccharomyces pombe]]''. Since then this elongation effect has been used for the [[bioassay]] of leptomycin. However, recent data shows that Leptomycin causes G1 cell cycle arrest in mammalian cells&lt;ref&gt;{{cite journal |last=Lu |first=Chuanwen |authorlink= |coauthors=Changxia Shao, Everardo Cobos, Kamaleshwar P. Singh, Weimin Gao |date=March 2012 |title=Chemotherapeutic Sensitization of Leptomycin B Resistant Lung Cancer Cells by Pretreatment with Doxorubicin |journal=PLoS ONE |volume=7 |issue=3 |publisher= |location = United States| issn = 1932-6203 | pmid =22412944 |pmc=3296751 |doi = 10.1371/journal.pone.0032895 | bibcode = | oclc =| id = | url = | language = | format = | accessdate = | laysummary = | laysource = | laydate = | quote = }}&lt;/ref&gt; and is a potent anti-tumor agent against murine experimental tumors in combination therapy {{Citation needed|date=November 2010}}.

Leptomycin B has been shown to be a potent and specific nuclear export inhibitor in human&lt;ref&gt;{{cite journal |author=Kudo N, Wolff B, Sekimoto T, ''et al.'' |title=Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1 |journal=Exp. Cell Res. |volume=242 |issue=2 |pages=540–7 |date=August 1998 |pmid=9683540 |doi=10.1006/excr.1998.4136 |url=}}&lt;/ref&gt; and the fission yeast [[Schizosaccharomyces pombe]].&lt;ref&gt;{{cite journal |author=Nishi K, Yoshida M, Fujiwara D, Nishikawa M, Horinouchi S, Beppu T |title=Leptomycin B targets a regulatory cascade of crm1, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression |journal=J. Biol. Chem. |volume=269 |issue=9 |pages=6320–4 |date=March 1994 |pmid=8119981 |doi= |url=http://www.jbc.org/content/269/9/6320.abstract}}&lt;/ref&gt; Leptomycin B alkylates and inhibits ''CRM1'' (chromosomal region maintenance)/[[exportin]] 1 ({{Gene|XPO1}}), a protein required for nuclear export of proteins containing a [[nuclear export sequence]] (NES), by glycosylating a [[cysteine]] residue (cysteine 529 in ''S. pombe'').&lt;ref&gt;{{cite journal |author=Kudo N, Matsumori N, Taoka H, ''et al.'' |title=Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=96 |issue=16 |pages=9112–7 |date=August 1999 |pmid=10430904 |pmc=17741 |doi= 10.1073/pnas.96.16.9112|url=}}&lt;/ref&gt; In addition to antifungal and [[antibacterial]] activities, Leptomycin B blocks the cell cycle and is a potent [[anti-tumor]] agent. At low nM concentrations, Leptomycin B blocks the nuclear export of many proteins including [[HIV-1 Rev]], [[MAPK/ERK]], and [[NF-κB]]/IκB, and it inhibits the inactivation of [[p53]].&lt;ref name=&quot;pmid10900010&quot;&gt;{{cite journal| author=Hietanen S, Lain S, Krausz E, Blattner C, Lane DP| title=Activation of p53 in cervical carcinoma cells by small molecules. | journal=Proc Natl Acad Sci U S A | year= 2000 | volume= 97 | issue= 15 | pages= 8501–6 | pmid=10900010 | doi= 10.1073/pnas.97.15.8501| pmc=26977   }}&lt;/ref&gt; Leptomycin B also inhibits the export and translation of many [[RNA]]s, including [[COX-2]] and [[c-Fos]] mRNAs, by inhibiting export of [[ribonucleoprotein]]s{{Citation needed|date=November 2010}}.

Leptomycin A (LPA) was discovered together with LMB. LMB is twice as potent as LPA.

== References ==
&lt;references /&gt;

== External links ==
* {{MeshName|leptomycin+B}}

Original data copied with permission from [http://www.fermentek.co.il/leptomycin_B.htm Leptomycin B manufacturer product page] ([[Fermentek]])

[[Category:Antibiotics]]</text>
      <sha1>9myfq29a1u69512uvsw7x54z8eocbrh</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Trichostatin A</title>
    <ns>0</ns>
    <id>3181579</id>
    <revision>
      <id>593215820</id>
      <parentid>565590295</parentid>
      <timestamp>2014-01-31T02:21:13Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>/* See also */Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="5379">{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470613588
| IUPAC_name = 7-[4-(dimethylamino)phenyl]-''N''-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide
| image = Trichostatin A.svg
| image2 = Trichostatin A 3D 1t64.png

&lt;!--Clinical data--&gt;
| tradename =  
| pregnancy_category = D—[[teratogenic]]
| legal_status =  
| routes_of_administration =  

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 58880-19-6
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 444732
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB04297
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 392575
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 46024
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 99

&lt;!--Chemical data--&gt;
| C=17 | H=22 | N=2 | O=3 
| molecular_weight = 302.37 g/mol
| smiles = O=C(NO)\C=C\C(=C\[C@H](C(=O)c1ccc(N(C)C)cc1)C)C
| InChI = 1/C17H22N2O3/c1-12(5-10-16(20)18-22)11-13(2)17(21)14-6-8-15(9-7-14)19(3)4/h5-11,13,22H,1-4H3,(H,18,20)/b10-5+,12-11+/t13-/m1/s1
| InChIKey = RTKIYFITIVXBLE-QEQCGCAPBF
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H22N2O3/c1-12(5-10-16(20)18-22)11-13(2)17(21)14-6-8-15(9-7-14)19(3)4/h5-11,13,22H,1-4H3,(H,18,20)/b10-5+,12-11+/t13-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RTKIYFITIVXBLE-QEQCGCAPSA-N
}}

'''Trichostatin A''' (TSA) is an organic compound that serves as an antifungal antibiotic and selectively [[Enzyme inhibitor|inhibits]] the class I and II mammalian [[histone deacetylase]] (HDAC) families of [[enzyme]]s, but not class III HDACs (i.e., [[Sirtuin]]s).&lt;ref name=&quot;pmid15180568&quot;&gt;{{cite journal | author = Vanhaecke T, Papeleu P, Elaut G, Rogiers V | title = Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view | journal = Curr Med Chem | volume = 11 | issue = 12 | pages = 1629–43 | year = 2004 | pmid = 15180568| doi = | url =  }}&lt;/ref&gt;  TSA inhibits the [[eukaryote|eukaryotic]] [[cell cycle]] during the beginning of the growth stage. TSA can be used to alter [[gene expression]] by interfering with the removal of [[acetyl]] groups from [[histones]] ([[histone deacetylases]], HDAC) and therefore altering the ability of [[DNA]] [[transcription factors]] to access the DNA molecules inside [[chromatin]]. It is a member of a larger class of [[histone deacetylase inhibitor]]s (HDIs or HDACIs) that have a broad spectrum of epigenetic activities.  Thus, TSA has some potential as an anti-[[cancer]] drug.&lt;ref name=&quot;pmid15822187 &quot;&gt;{{cite journal | author = Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC | title = Clinical development of histone deacetylase inhibitors as anticancer agents | journal = Annu Rev Pharmacol Toxicol | volume = 45 | issue = | pages = 495–528 | year = 2005 | pmid = 15822187 | doi =10.1146/annurev.pharmtox.45.120403.095825 }}&lt;/ref&gt;  One suggested mechanism is that TSA promotes the expression of [[apoptosis]]-related [[gene]]s, leading to cancerous cells surviving at lower rates, thus slowing the progression of cancer.&lt;ref name=&quot;pmid18437899&quot;&gt;{{cite journal | author = Shankar S, Srivastava RK | title = Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis | journal = Adv Exp Med Biol | volume = 615 | issue = | pages = 261–98 | year = 2008 | pmid = 18437899 | doi = 10.1007/978-1-4020-6554-5_13| url = | series = Advances in Experimental Medicine and Biology | isbn = 978-1-4020-6553-8  }}&lt;/ref&gt;  Other mechanisms may include the activity of HDIs to induce cell differentiation, thus acting to &quot;mature&quot; some of the de-differentiated cells found in tumors. HDIs have multiple effects on non-histone effector molecules, so the anti-cancer mechanisms are truly not understood at this time.

TSA inhibits HDACs 1, 3, 4, 6 and 10 with [[IC50]] values around 20 nM.&lt;ref&gt;http://www.freepatentsonline.com/y2009/0263353.html&lt;/ref&gt;

TSA represses [[IL1B|IL (interleukin)-1β]]/LPS ([[lipopolysaccharide]])/IFNγ ([[interferon γ]])-induced [[nitric oxide synthase]] (NOS)2 expression in murine macrophage-like cells but ''increases'' LPS-stimulated NOS2 expression in murine N9 and primary rat microglial cells.&lt;ref name=Adcock2007&gt;{{cite web |url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2013887/ |title=HDAC inhibitors as anti-inflammatory agents |author=Adcock |year=2007 }}&lt;/ref&gt;

However, there TSA has not been tested in clinical trials as of 2013-05-27.&lt;ref&gt;http://clinicaltrials.gov/ct2/results?term=Trichostatin+A&lt;/ref&gt;

==See also==
*[[Histone deacetylase inhibitor]]
*[[Vorinostat|Vorinostat (SAHA)]]
*{{cite journal |author=Moon C, Kim SH |title=Use of epigenetic modification to induce FOXP3 expression in naïve T cells |journal=Transplant Proc. |volume=41 |issue=5 |pages=1848–54 |date=June 2009 |pmid=19545742 |doi=10.1016/j.transproceed.2009.02.101 }}

==References==
{{reflist}}

==External links==
* [http://www.fermentek.co.il/MSDS/trichostatin_A-MSDS.htm  Trichostatin_A Safety data sheet] by [[Fermentek]]

[[Category:Anilines]]
[[Category:Aromatic ketones]]
[[Category:Hydroxamic acids]]
[[Category:Histone deacetylase inhibitors]]
[[Category:Antibiotics]]</text>
      <sha1>acofaqlrajdr3quourira3gcvb3qj9k</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Salinosporamide A</title>
    <ns>0</ns>
    <id>11776982</id>
    <revision>
      <id>598776326</id>
      <parentid>587535925</parentid>
      <timestamp>2014-03-09T01:12:48Z</timestamp>
      <contributor>
        <ip>98.115.169.20</ip>
      </contributor>
      <text xml:space="preserve" bytes="10476">{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464386343
| ImageFile = Salinosporamide_A.svg
| ImageSize = 150px
| IUPACName = (4''R'',5''S'')-4-(2-chloroethyl)-1-((1''S'')-cyclohex-2-enyl(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
| OtherNames = Marizomib; NPI-0052
| Section1 = {{Chembox Identifiers
|  PubChem = 11347535
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 9522473
|  SMILES = O=C1O[C@@]3(C)[C@H](C(=O)N[C@@]13[C@@H](O)[C@@H]2/C=C\CCC2)CCCl
|  InChI = 1/C15H20ClNO4/c1-14-10(7-8-16)12(19)17-15(14,13(20)21-14)11(18)9-5-3-2-4-6-9/h3,5,9-11,18H,2,4,6-8H2,1H3,(H,17,19)/t9-,10+,11+,14+,15+/m1/s1
|  InChIKey = NGWSFRIPKNWYAO-SHTIJGAHBB
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C15H20ClNO4/c1-14-10(7-8-16)12(19)17-15(14,13(20)21-14)11(18)9-5-3-2-4-6-9/h3,5,9-11,18H,2,4,6-8H2,1H3,(H,17,19)/t9-,10+,11+,14+,15+/m1/s1
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = NGWSFRIPKNWYAO-SHTIJGAHSA-N
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 
|   PubChem = 
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 371405
|   SMILES = C[C@]13OC(=O)C3(NC(=O)[C@@H]1CCCl)[C@@H](O)C2/C=C\CCC2
}}
| Section2 = {{Chembox Properties
|   Formula = C&lt;sub&gt;15&lt;/sub&gt;H&lt;sub&gt;20&lt;/sub&gt;ClNO&lt;sub&gt;4&lt;/sub&gt;
|   MolarMass = 313.781 g/mol
|   Appearance = 
|   Density = 
|   MeltingPt = 
|   BoilingPt = 
|   Solubility = 
  }}
| Section3 = {{Chembox Hazards
|   MainHazards = 
|   FlashPt = 
|   Autoignition = 
  }}
}}

'''Salinosporamide A''' is a potent [[proteasome inhibitor]] being studied as a potential [[Anticancer agents|anticancer agent]].  It entered phase I human [[clinical trial]]s for the treatment of [[multiple myeloma]], only three years after its discovery in 2003.&lt;ref name=&quot;pmid12548698&quot;&gt;{{cite journal |author=Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W |title=Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora |journal=Angew. Chem. Int. Ed. Engl. |volume=42 |issue=3 |pages=355–7 |year=2003 |pmid=12548698 |doi=10.1002/anie.200390115}}&lt;/ref&gt;&lt;ref name=&quot;pmid16286248&quot;&gt;{{cite journal |author=Chauhan D |title=A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib |journal=Cancer Cell |volume=8 |issue=5 |pages=407–19 |year=2005 |pmid=16286248 |doi=10.1016/j.ccr.2005.10.013 |author-separator=, |author2=Catley L |author3=Li G |display-authors=3 |last4=Podar |first4=Klaus |last5=Hideshima |first5=Teru |last6=Velankar |first6=Mugdha |last7=Mitsiades |first7=Constantine |last8=Mitsiades |first8=Nicolas |last9=Yasui |first9=Hiroshi}}&lt;/ref&gt; This marine natural product is produced by the obligate marine bacteria ''[[Salinispora tropica]]'' and ''[[Salinispora arenicola]]'', which are found in ocean sediment. Salinosporamide A belongs to a family of compounds, known collectively as [[salinosporamide]]s, which possess a densely functionalized γ-lactam-β-lactone [[Bicyclic molecule|bicyclic core]].

==History==
Salinosporamide A was discovered by William Fenical and Paul Jensen from Scripps Institution of Oceanography in La Jolla, CA. In preliminary screening, a high percentage of the organic extracts of cultured ''Salinospora'' strains possessed antibiotic and anticancer activities, which suggests that these bacteria are an excellent resource for drug discovery. ''Salinospora'' strain CNB-392 was isolated from a heat-treated marine sediment sample and cytotoxicity-guided fractionation of the crude extract led to the isolation of salinosporamide A. Although salinosporamide A shares an identical bicyclic ring structure with [[omuralide]], it is uniquely functionalized. Salinosporamide A displayed potent in vitro cytotoxicity against HCT-116 human colon carcinoma with an IC50 value of 11&amp;nbsp;ng mL-1. This compound also displayed potent and highly selective activity in the NCI's 60-cell-line panel with a mean GI50 value (the concentration required to achieve 50% growth inhibition) of less than 10 nM and a greater than 4 log LC50 differential between resistant and susceptible cell lines. The greatest potency was observed against NCI-H226 non-small cell lung cancer, SF-539 CNS cancer, SK-MEL-28 melanoma, and MDA-MB-435 breast cancer (all with LC50 values less than 10 nM). Salinosporamide A was tested for its effects on proteasome function because of its structural relationship to omuralide. When tested against purified 20S proteasome, salinosporamide A inhibited proteasomal chymotrypsin-like proteolytic activity with an IC50 value of 1.3 nM.&lt;ref&gt;K. Lloyd, S. Glaser, B. Miller, Nereus Pharmaceuticals Inc.&lt;/ref&gt; This compound is approximately 35 times more potent than omuralide which was tested as a positive control in the same assay. Thus, the unique functionalization of the core bicyclic ring structure of salinosporamide A appears to have resulted in a molecule that is a significantly more potent proteasome inhibitor than omuralide.&lt;ref name=&quot;pmid12548698&quot;/&gt;

==Mechanism of action==
Salinosporamide A inhibits proteasome activity by covalently modifying the active site threonine residues of the 20S proteasome.

==Biosynthesis==
[[Image:Salinosporamide A and B.svg|thumb|400px|Salinosporamide A and B building blocks]]
[[Image:Biosynthesis of nonproteinogenic amino acid.png|thumb|400px|Proposed biosynthesis of the nonproteinogenic amino-acid beta-hydroxycyclohex-2'-enylanine (3) (R = H or S~PCP) via a shunt in the phenylalanine biosynthetic pathway]] 
[[Image:Salinosporamide A Biosynthesis.png|thumb|400px|Biosynthesis]]

It was originally hypothesized that salinosporamide B was a biosynthetic precursor to salinosporamide A due to their structural similarities.

It was thought that the halogenation of the unactivated methyl group was catalyzed by a non-heme iron halogenase.&lt;ref name=&quot;pmid17274624&quot;&gt;{{cite journal |author=Beer LL, Moore BS |title=Biosynthetic convergence of salinosporamides A and B in the marine actinomycete Salinispora tropica |journal=Org. Lett. |volume=9 |issue=5 |pages=845–8 |year=2007 |pmid=17274624 |doi=10.1021/ol063102o}}&lt;/ref&gt;&lt;ref name=&quot;pmid16895332&quot;&gt;{{cite journal |author=Vaillancourt FH, Yeh E, Vosburg DA, Garneau-Tsodikova S, Walsh CT |title=Nature's inventory of halogenation catalysts: oxidative strategies predominate |journal=Chem. Rev. |volume=106 |issue=8 |pages=3364–78 |year=2006 |pmid=16895332 |doi=10.1021/cr050313i}}&lt;/ref&gt; Recent work using [[Carbon 13|&lt;sup&gt;13&lt;/sup&gt;C]]-labeled feeding experiments reveal distinct biosynthetic origins of salinosporamide A and B.&lt;ref name=&quot;pmid17274624&quot;/&gt;&lt;ref name=&quot;pmid17340108&quot;&gt;{{cite journal |author=Tsueng G, McArthur KA, Potts BC, Lam KS |title=Unique butyric acid incorporation patterns for salinosporamides A and B reveal distinct biosynthetic origins |journal= Applied Microbiology and Biotechnology|volume= 75|issue= 5|pages= 999–1005|year=2007 |pmid=17340108 |doi=10.1007/s00253-007-0899-7}}&lt;/ref&gt;

While they share the biosynthetic precursors [[acetate]] and presumed β-hydroxycyclohex-2'-enylalanine ('''3'''), they differ in the origin of the four-carbon building block that gives rise to their structural differences involving the [[halogen]] atom. A hybrid [[polyketide synthase]]-nonribosomal peptide synthetase (PKS-NRPS) pathway is most likely the biosynthetic mechanism in which [[acetyl-CoA]] and butyrate-derived ethylmalonyl-CoA condense to yield the β-ketothioester ('''4'''), which then reacts with ('''3''') to generate the linear precursor ('''5''').

==Total synthesis==
The first stereoselective synthesis was reported by Rajender Reddy Leleti and E. J.Corey.&lt;ref name=&quot;pmid15149210&quot;&gt;{{cite journal |author=Reddy LR, Saravanan P, Corey EJ |title=A simple stereocontrolled synthesis of salinosporamide A |journal=J. Am. Chem. Soc. |volume=126 |issue=20 |pages=6230–1 |year=2004 |pmid=15149210 |doi=10.1021/ja048613p}}&lt;/ref&gt;  Later several routes to the total synthesis of salinosporamide A have been reported.&lt;ref name=&quot;pmid15149210&quot;/&gt;&lt;ref name=&quot;pmid17497868&quot;&gt;{{cite journal |author=Ling T, Macherla VR, Manam RR, McArthur KA, Potts BC |title=Enantioselective Total Synthesis of (-)-Salinosporamide A (NPI-0052) |journal=Org. Lett. |volume=9 |issue=12 |pages=2289–92 |year=2007 |pmid=17497868 |doi=10.1021/ol0706051}}&lt;/ref&gt;&lt;ref name=&quot;pmid17477539&quot;&gt;{{cite journal |author=Ma G, Nguyen H, Romo D |title=Concise Total Synthesis of (±)-Salinosporamide A, (±)-Cinnabaramide A, and Derivatives via a Bis-Cyclization Process: Implications for a Biosynthetic Pathway? |journal=Org. Lett. |volume=9 |issue=11 |pages=2143–6 |year=2007 |pmid=17477539 |doi=10.1021/ol070616u |pmc=2518687}}&lt;/ref&gt;&lt;ref name=&quot;pmid15941259&quot;&gt;{{cite journal |author=Endo A, Danishefsky SJ |title=Total synthesis of salinosporamide A |journal=J. Am. Chem. Soc. |volume=127 |issue=23 |pages=8298–9 |year=2005 |pmid=15941259 |doi=10.1021/ja0522783}}&lt;/ref&gt;

==Clinical study==
''[[In vitro]]'' studies using purified 20S proteasomes showed that salinosporamide A has lower [[EC50]] for trypsin-like (T-L) activity than does [[bortezomib]]. ''In vivo'' animal model studies show marked inhibition of T-L activity in response to salinosporamide A, whereas bortezomib enhances T-L proteasome activity.

Initial results from early-stage clinical trials of salinosporamide A in relapsed/refractory multiple myeloma patients were presented at the 2011 [[American Society of Hematology]] annual meeting.&lt;ref&gt;{{cite web|url=http://www.myelomabeacon.com/news/2012/01/23/marizomib-npi0052-may-be-effective-in-relapsedrefractory-multiple-myeloma-ash-2011/ |title=Marizomib May Be Effective In Relapsed/Refractory Multiple Myeloma (ASH 2011) |publisher=The Myeloma Beacon |date=2012-01-23 |accessdate=2012-06-10}}&lt;/ref&gt;  Further early-stage trials of the drug in a number of different cancers are ongoing.&lt;ref&gt;[http://clinicaltrials.gov/ct2/results?term=marizomib&amp;recr=Open&amp;rslt=&amp;type=&amp;cond=&amp;intr=&amp;outc=&amp;spons=&amp;lead=&amp;id=&amp;state1=&amp;cntry1=&amp;state2=&amp;cntry2=&amp;state3=&amp;cntry3=&amp;locn=&amp;gndr=&amp;rcv_s=&amp;rcv_e=&amp;lup_s=&amp;lup_e= ClinicalTrials.gov: Marizomib]&lt;/ref&gt;

==See also==
*[[Salinosporamide B]]

==References==
{{reflist}}

==External links==
*{{Commons category-inline|Salinosporamides}}

[[Category:Lactams]]
[[Category:Lactones]]
[[Category:Antibiotics]]
[[Category:Proteasome inhibitors]]
[[Category:Experimental cancer drugs]]</text>
      <sha1>6c52dv7uavoq5tonn9ldjuwuchel0kq</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Ansamycin</title>
    <ns>0</ns>
    <id>11788703</id>
    <revision>
      <id>608018463</id>
      <parentid>606200052</parentid>
      <timestamp>2014-05-11T07:19:20Z</timestamp>
      <contributor>
        <username>WolfmanSF</username>
        <id>1866741</id>
      </contributor>
      <minor/>
      <comment>-&gt; lower case; add links</comment>
      <text xml:space="preserve" bytes="2616">{{distinguish|Annamycin}}
[[File:Geldanamycin.svg|thumb|Structure of [[geldanamycin]], one of the benzoquinone ansamycins.]]
'''Ansamycins''' is a family of secondary metabolites that show [[antimicrobial]] activity against many [[gram-positive]] and some [[gram-negative]] bacteria and includes various compounds, among which: [[streptovaricins]] and [[rifamycins]].&lt;ref&gt;{{cite journal |author=Wehrli, W.; Staehelin, M. |journal=Bacteriol. Rev. |title=Actions of the rifamycins |volume=35 |issue=3 |pages=290 |year=1971 |pmid=5001420 |pmc=378391}}&lt;/ref&gt;  In addition, these compounds demonstrate antiviral activity towards bacteriophages and [[poxviruses]].

==Structure==
They are named ansamycins (from the Latin '''ansa''', ''handle'') because of their unique structure, which comprises an aromatic moiety bridged by an aliphatic chain.&lt;ref&gt;{{cite journal |author=Prelog, V.; Oppolzer, W. |journal=Helv. Chim. Acta. |title=Rifamycins. 4. Ansamycins, a novel class of microbial metabolism products |volume=56 |pages=2279 |year=1973}}&lt;/ref&gt; The main difference between various derivatives of ansamycins is the aromatic moiety, which can be a [[naphthalene]] ring or a [[naphthoquinone]] ring as in [[rifamycin]] and the [[naphthomycin]]s.&lt;ref&gt;{{cite journal |author=Balerna, M.; Keller-Schierlein, W.; Martius, C.; Wolf, H.; Zähner, H. |journal=Arch. Mikrobiol. |title=Metabolic products of microorganisms. 72. Naphthomycin, an antimetabolite of vitamin K |volume=65 |pages=303 |year=1969 |pmid=4988744 |issue=4}}&lt;/ref&gt;  Another variation comprises benzene or a benzoquinone ring system as in [[geldanamycin]] or [[ansamitocin]].  Ansamycins were first discovered in 1959 by Sensi et al. from ''[[Amycolatopsis]] mediterranei'', an [[actinomycete]].&lt;ref&gt;{{cite journal |author=Sensi, P.; Margalith, P.; Timbal, M. T. |journal=Ed. Sci. |title=Rifomycin, a new antibiotic; preliminary report |volume=14 |pages=146 |year=1959}}&lt;/ref&gt;

==Examples==
Rifamycins are a subclass of ansamycins with high potency against mycobacteria.  This resulted in their widespread use in the treatment of [[tuberculosis]], [[leprosy]], and AIDS-related mycobacterial infections.&lt;ref&gt;{{cite journal |author=Floss, H. G.; Yu, T. |journal=Curr. Opin. Chem. Biol. |title=Lessons from the rifamycin biosynthetic gene cluster |volume=3 |pages=592 |year=1999 |doi=10.1016/S1367-5931(99)00014-9 |pmid=10508670 |issue=5}}&lt;/ref&gt;  Since then various analogues have been isolated from other prokaryotes.

==References==
{{reflist|2}}

[[Category:Antibiotics]]
[[Category:Carbamates]]
[[Category:Lactams]]
[[Category:Quinones]]
[[Category:Ethers]]</text>
      <sha1>44m8epqo077wgngqn3y3w33p46nf1zg</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Thiolutin</title>
    <ns>0</ns>
    <id>12083623</id>
    <revision>
      <id>593180609</id>
      <parentid>578615482</parentid>
      <timestamp>2014-01-30T21:40:25Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="3310">{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470607244
| IUPAC_name = ''N''-(4-methyl-5-oxo-4,5-dihydro[1,2]dithiolo[4,3-''b'']pyrrol-6-yl)acetamide
| image = Thiolutin.png

&lt;!--Clinical data--&gt;
| tradename =  
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category =  
| legal_AU = &lt;!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --&gt;
| legal_CA = &lt;!--             / Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL         / P       / POM / CD / Class A, B, C --&gt;
| legal_US = &lt;!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V --&gt;
| legal_status =  
| routes_of_administration =  

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 87-11-6
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 6870
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 6608
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 507026

&lt;!--Chemical data--&gt;
| C=8 | H=8 | N=2 | O=2 | S=2 
| molecular_weight = 228.293 g/mol
| smiles = O=C(NC/2=C/1\SS\C=C\1N(C\2=O)C)C
| InChI = 1/C8H8N2O2S2/c1-4(11)9-6-7-5(3-13-14-7)10(2)8(6)12/h3H,1-2H3,(H,9,11)
| InChIKey = MHMRAFONCSQAIA-UHFFFAOYAX
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C8H8N2O2S2/c1-4(11)9-6-7-5(3-13-14-7)10(2)8(6)12/h3H,1-2H3,(H,9,11)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MHMRAFONCSQAIA-UHFFFAOYSA-N
| synonyms = &lt;small&gt;''N''-(8-methyl-7-oxo-3,4-dithia-8-azabicyclo[3.3.0]octa-1,5-dien-6-yl)acetamide, farcinicin, propiopyvothine, acetopyrrothine&lt;/small&gt;
}}

'''Thiolutin''' is a sulfur-containing antibiotic, which is a potent inhibitor of bacterial and yeast RNA polymerases.&lt;ref&gt;{{cite journal |author=Kebaara BW, Nielsen LE, Nickerson KW, Atkin AL |title=Determination of mRNA half-lives in Candida albicans using thiolutin as a transcription inhibitor |journal=Genome |volume=49 |issue=8 |pages=894–9 |date=Aug 2006 |pmid=17036064 |doi=10.1139/g06-046 }}&lt;/ref&gt; It was found to inhibit ''in vitro'' RNA synthesis directed by all three yeast RNA polymerases (I, II, and III). Thiolutin is also an inhibitor of [[mannan]] and [[glucan]] formation in ''[[Saccharomyces cerevisiae]]'' and used for the analysis of mRNA stability. Studies have shown that thiolutin inhibits adhesion of human umbilical vein endothelial cells ([[Human umbilical vein endothelial cell|HUVECs]]) to [[vitronectin]] and thus suppresses tumor cell-induced angiogenesis in vivo.

Thiolutin is formed in submerged [[Industrial fermentation|fermentation]] by several strains of ''[[Streptomyces|Streptomycetes luteosporeus]]''. Some sources erroneously specify &quot;aureothricin&quot; as a synonym of thiolutin. Aureothricin is an antibiotic very similar to thiolutin, and is created as a by-product during the thiolutin fermentation.&lt;ref&gt;[[Fermentek]] [http://www.fermentek.co.il/thiolutin.htm product page]&lt;/ref&gt;

== References ==
&lt;references /&gt;

[[Category:Antibiotics]]
[[Category:Organic disulfides]]
[[Category:Lactams]]
[[Category:Acetamides]]

{{pharma-stub}}</text>
      <sha1>ttht8t334i3dqvbrzch6z19mtcme7gb</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Guanacastepene A</title>
    <ns>0</ns>
    <id>2683423</id>
    <revision>
      <id>525863737</id>
      <parentid>450347572</parentid>
      <timestamp>2012-12-01T14:37:41Z</timestamp>
      <contributor>
        <username>Yobot</username>
        <id>7328338</id>
      </contributor>
      <minor/>
      <comment>clean up /fixed checkwiki error 18 using [[Project:AWB|AWB]] (8717)</comment>
      <text xml:space="preserve" bytes="2197">{{redirect|C22H30O5|another chemical with the same chemical formula|Methylprednisolone}}
{{chembox
| verifiedrevid = 418284282
| ImageFile = Guanacastepene A.png
| ImageSize = 200px
| IUPACName = (1''R'',2''R'',6''S'',8a''R'',10a''R'')-5-Formyl-6-hydroxy-1-isopropyl-8a,10a-dimethyl-3-oxo-1,2,3,6,7,8,8a,9,10,10a-decahydrobenzo[''f'']azulen-2-yl acetate
| OtherNames = 
| Section1 = {{Chembox Identifiers
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 8560244
| InChI = 1/C22H30O5/c1-12(2)18-20(27-13(3)24)19(26)16-10-15-14(11-23)17(25)6-7-21(15,4)8-9-22(16,18)5/h10-12,17-18,20,25H,6-9H2,1-5H3/t17-,18-,20+,21-,22-/m0/s1
| InChIKey = KCPNSIPCHJTGHJ-MYHSIESUBP
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H30O5/c1-12(2)18-20(27-13(3)24)19(26)16-10-15-14(11-23)17(25)6-7-21(15,4)8-9-22(16,18)5/h10-12,17-18,20,25H,6-9H2,1-5H3/t17-,18-,20+,21-,22-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KCPNSIPCHJTGHJ-MYHSIESUSA-N
| CASNo = 263357-41-1
| PubChem = 
| SMILES = O=C\C3=C2/C=C1/C(=O)[C@H](OC(=O)C)[C@@H]([C@]1(CC[C@@]2(CC[C@@H]3O)C)C)C(C)C
}}
| Section2 = {{Chembox Properties
| C=22 | H=30 | O=5
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility = }}
| Section3 = {{Chembox Hazards
| MainHazards = 
| FlashPt = 
| Autoignition = }}
}}

'''Guanacastepene A''' is a compound showing promising [[antibiotic]] activity. It is a [[diterpene]] that was extracted with [[hexane]] from a [[Costa Rica]]n [[fungus]] (CR115), found on the branches of the ''[[Daphnopsis Americana]]'' tree and purified by [[chromatography]].&lt;ref&gt;{{cite journal | author = Brady, Sean F.; Singh, Maya P.; Janso, Jeff E.; Clardy, Jon | title = Guanacastepene, a Fungal-Derived Diterpene Antibiotic with a New Carbon Skeleton | journal = Journal of the American Chemical Society | year = 2000 | volume = 122 | issue = 9 | pages = 2116–2117 | doi = 10.1021/ja993835m}}&lt;/ref&gt;

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Diterpenes]]
[[Category:Aldehydes]]
[[Category:Alcohols]]
[[Category:Ketones]]
[[Category:Benzoazulenes]]
[[Category:Acetate esters]]


{{antibiotic-stub}}
{{ketone-stub}}</text>
      <sha1>hnzavxub949op8m5d7gujgzpgddw8s7</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Roseophilin</title>
    <ns>0</ns>
    <id>10853181</id>
    <revision>
      <id>544776503</id>
      <parentid>506049813</parentid>
      <timestamp>2013-03-16T23:09:12Z</timestamp>
      <contributor>
        <username>Addbot</username>
        <id>6569922</id>
      </contributor>
      <minor/>
      <comment>[[User:Addbot|Bot:]] Migrating 1 interwiki links, now provided by [[Wikipedia:Wikidata|Wikidata]] on [[d:q7368629]]</comment>
      <text xml:space="preserve" bytes="2134">{{chembox
| verifiedrevid = 401044261
|ImageFile=Roseophilin.png
|ImageSize=150px
|IUPACName=15-[5-(3-Chloro-1''H''-pyrrol-2-yl)-3-methoxy-furan-2-yl]-13-isopropyl-2-aza-tricyclo[10.2.1.13,14]hexadeca-1(15),2-triene
|OtherNames=
|Section1={{Chembox Identifiers
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4578301
| InChI = 1/C27H33ClN2O2/c1-16(2)23-18-11-9-7-5-4-6-8-10-17-14-19(23)25(30-17)24(18)27-22(31-3)15-21(32-27)26-20(28)12-13-29-26/h12-16,18,23,30H,4-11H2,1-3H3/b26-21-,27-24-
| InChIKey = XEQIXGXEBJYNMG-OLPWBVPVBQ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C27H33ClN2O2/c1-16(2)23-18-11-9-7-5-4-6-8-10-17-14-19(23)25(30-17)24(18)27-22(31-3)15-21(32-27)26-20(28)12-13-29-26/h12-16,18,23,30H,4-11H2,1-3H3/b26-21-,27-24-
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XEQIXGXEBJYNMG-OLPWBVPVSA-N
| CASNo=142386-38-7
|  PubChem=5467324
| ChEMBL = 1945189
|  SMILES = Cl\C\5=C\C=N/C/5=C4\O/C(=C2\c1nc3cc1C(C(C)C)C2CCCCCCCC3)/C(/OC)=C4
}}
|Section2={{Chembox Properties
|  Formula=C&lt;sub&gt;27&lt;/sub&gt;H&lt;sub&gt;33&lt;/sub&gt;ClN&lt;sub&gt;2&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt;
|  MolarMass=453.02 g/mol
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3={{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}

'''Roseophilin''' is an [[antibiotic]] isolated from ''[[Streptomyces]] griscovirides'' shown to have antitumor activity.&lt;ref&gt;{{cite journal | author = Furstner, A. | journal = Angew. Chem., Int. Ed. | year = 2003 | volume = 42 | issue = 3582-3603}}&lt;/ref&gt; The chemical structure can be considered in terms of two components, a [[macrocyclic compound|macrotricyclic]] segment and a [[heterocyclic]] side-chain.  Several laboratory syntheses of roseophilin (e.g., those of [[Barry Trost|Trost]], Furstner, Salamone) are based upon the [[Paal-Knorr synthesis]], and two others are based on the [[Nazarov cyclization reaction]] (those of Tius, Frontier).

==References==
{{reflist}}


{{antibiotic-stub}}

[[Category:Antibiotics]]
[[Category:Pyrroles]]
[[Category:Furans]]
[[Category:Organochlorides]]
[[Category:Phenol ethers]]</text>
      <sha1>anmkpd2fi2sj116csstyv7kztup1rq5</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Streptolydigin</title>
    <ns>0</ns>
    <id>12480323</id>
    <revision>
      <id>606801615</id>
      <parentid>601773439</parentid>
      <timestamp>2014-05-02T18:24:43Z</timestamp>
      <contributor>
        <username>Barton1234</username>
        <id>15475713</id>
      </contributor>
      <text xml:space="preserve" bytes="2333">{{Orphan|date=February 2009}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470471049
| IUPAC_name = 2-[4-[6-(1,6-dimethylspiro[8,9-dioxabicyclo[3.3.1]non-3-ene-2,2'-oxirane]-7
| image = Streptolydigin.png

&lt;!--Clinical data--&gt;
| tradename =  
| pregnancy_category =  
| legal_status =  
| routes_of_administration =

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 7229-50-7
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 220508
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB04785
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 16736035
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1236068

&lt;!--Chemical data--&gt;
| C=32 | H=44 | N=2 | O=9 
| molecular_weight = 600.708 g/mol
| smiles = CNC(=O)C(C)C2C(=O)/C(C(=O)N2C1CCC(O)C(C)O1)=C(\O)/C=C/C(/C)=C/C(C)C5OC4(C)OC(\C=C/C34CO3)C5C
| InChI = 1/C32H44N2O9/c1-16(14-17(2)28-18(3)23-12-13-32(15-40-32)31(6,42-23)43-28)8-9-22(36)25-27(37)26(19(4)29(38)33-7)34(30(25)39)24-11-10-21(35)20(5)41-24/h8-9,12-14,17-21,23-24,26,28,35-36H,10-11,15H2,1-7H3,(H,33,38)/b9-8+,16-14+,25-22+
| InChIKey = KVTPRMVXYZKLIG-NCFIBNQNBP
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C32H44N2O9/c1-16(14-17(2)28-18(3)23-12-13-32(15-40-32)31(6,42-23)43-28)8-9-22(36)25-27(37)26(19(4)29(38)33-7)34(30(25)39)24-11-10-21(35)20(5)41-24/h8-9,12-14,17-21,23-24,26,28,35-36H,10-11,15H2,1-7H3,(H,33,38)/b9-8+,16-14+,25-22+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KVTPRMVXYZKLIG-NCFIBNQNSA-N
}}

'''Streptolydigin''' (Stl) is an [[antibiotic]] that works by inhibiting [[nucleic acid]] chain elongation by binding to [[RNA polymerase]], thus inhibiting [[RNA]] synthesis inside a [[cell (biology)|cell]].&lt;ref&gt;{{cite PMID |16122422}}&lt;/ref&gt;&lt;ref&gt;{{cite PMID |16167380}}&lt;/ref&gt;&lt;ref&gt;{{cite PMID |17581591}}&lt;/ref&gt; Streptolydigin inhibits bacterial RNA polymerase and eukaryotic [[RNA polymerase III]]. It has antibacterial activity against a number of [[Gram positive]] [[bacteria]].

== References ==
{{Reflist}}

[[Category:Antibiotics]]
[[Category:Spiro compounds]]
[[Category:Pyrrolidones]]
[[Category:Propionamides]]


{{antibiotic-stub}}</text>
      <sha1>6cegescaymj0c125hju1aeh3acl0wmz</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Clofoctol</title>
    <ns>0</ns>
    <id>12671952</id>
    <revision>
      <id>609236666</id>
      <parentid>569130336</parentid>
      <timestamp>2014-05-19T13:34:55Z</timestamp>
      <contributor>
        <username>Louisajb</username>
        <id>13226235</id>
      </contributor>
      <comment>added chembl id</comment>
      <text xml:space="preserve" bytes="3398">{{Drugbox
| Watchedfields = changed
| verifiedrevid = 443553734
| IUPAC_name = 2-[(2,4-dichlorophenyl)methyl]-&lt;br&gt;4-(2,4,4-trimethylpentan-2-yl)phenol
| image = Clofoctol.svg

&lt;!--Clinical data--&gt;
| tradename =  
| Drugs.com = {{drugs.com|international|clofoctol}}
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category =  
| legal_AU = &lt;!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --&gt;
| legal_CA = &lt;!--             / Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL         / P       / POM / CD / Class A, B, C --&gt;
| legal_US = &lt;!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V --&gt;
| legal_status =  
| routes_of_administration = Rectal ([[suppository]])&lt;ref name=Gramplus/&gt;

&lt;!--Pharmacokinetic data--&gt;
| bioavailability = 98%&lt;ref name=Gramplus/&gt;
| protein_bound =  
| metabolism = [[Hepatic]] [[glucuronidation]]&lt;ref name=Gramplus/&gt;
| elimination_half-life =  
| excretion = Biliary&lt;ref name=Gramplus/&gt;

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 37693-01-9
| ATC_prefix = J01
| ATC_suffix = XX03
| PubChem = 2799
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChEMBL = 1476605
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2697
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 704083NI0R
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07244

&lt;!--Chemical data--&gt;
| C=21 | H=26 | Cl=2 | O=1 
| molecular_weight = 365.336 g/mol
| smiles = Clc1cc(Cl)ccc1Cc2cc(ccc2O)C(C)(C)CC(C)(C)C
| InChI = 1/C21H26Cl2O/c1-20(2,3)13-21(4,5)16-7-9-19(24)15(11-16)10-14-6-8-17(22)12-18(14)23/h6-9,11-12,24H,10,13H2,1-5H3
| InChIKey = HQVZOORKDNCGCK-UHFFFAOYAB
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H26Cl2O/c1-20(2,3)13-21(4,5)16-7-9-19(24)15(11-16)10-14-6-8-17(22)12-18(14)23/h6-9,11-12,24H,10,13H2,1-5H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HQVZOORKDNCGCK-UHFFFAOYSA-N
}}
'''Clofoctol''' is a [[bacteriostatic]] [[antibiotic]]. It is used in the treatment of [[respiratory tract]] and ear, nose and throat infections caused by [[Gram-positive]] [[bacteria]].&lt;ref name=Gramplus&gt;{{cite web | url = http://www.torrinomedica.it/studio/schedefarmaci/GRAMPLUS.htm | title = Gramplus | date = July 25, 2007 | accessdate = 2007-08-10 | publisher = Studio Medico Torrino | language = Italian}}&lt;/ref&gt;
It is marketed in [[France]] under the trade name '''Octoplus''' and in [[Italy]] as '''Gramplus'''.

It is only functional against [[Gram-positive bacteria]].&lt;ref name=&quot;pmid6782374&quot;&gt;{{cite journal |author=Combe J, Simonnet F, Yablonsky F, Simonnet G |title=[Clofoctol binding by the bacteria (author's transl)] |language=French |journal=J Pharmacol |volume=11 |issue=4 |pages=411–25 |year=1980 |pmid=6782374 |doi=}}&lt;/ref&gt;

It penetrates into human lung tissue.&lt;ref name=&quot;pmid3391105&quot;&gt;{{cite journal |author=Danesi R, Gasperini M, Senesi S, Freer G, Angeletti CA, Del Tacca M |title=A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay |journal=Drugs Exp Clin Res |volume=14 |issue=1 |pages=39–43 |year=1988 |pmid=3391105 |doi= |url=}}&lt;/ref&gt;

==References==
{{Reflist}}


{{Antibiotic-stub}}
{{Other antibacterials}}

[[Category:Antibiotics]]
[[Category:Phenols]]
[[Category:Organochlorides]]</text>
      <sha1>nbd6b7wl7g827yv4yt2rb77rooxhg9v</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Fosfomycin</title>
    <ns>0</ns>
    <id>12671975</id>
    <revision>
      <id>591353251</id>
      <parentid>582395405</parentid>
      <timestamp>2014-01-19T01:33:49Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="11877">{{distinguish|Fosmidomycin}}
{{Drugbox
| verifiedrevid = 461113563
| IUPAC_name = [(2''R'',3''S'')-3-methyloxiran-2-yl]phosphonic acid
| image = FosfomycinImage.svg

&lt;!--Clinical data--&gt;
| tradename = Monurol
| Drugs.com = {{drugs.com|monograph|monurol}}
| MedlinePlus = a697008
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = B
| pregnancy_category =  
| legal_AU = &lt;!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --&gt;
| legal_CA = &lt;!--             / Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL         / P       / POM / CD / Class A, B, C --&gt;
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = Oral

&lt;!--Pharmacokinetic data--&gt;
| bioavailability = 30–37% (oral, fosfomycin [[Tris|tromethamine]]); varies with food intake
| protein_bound = Nil
| metabolism = Nil
| elimination_half-life = 5.7 hours (mean)
| excretion = [[Kidney|Renal]] and fecal, unchanged

&lt;!--Identifiers--&gt;
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 23155-02-4
| CAS_supplemental = {{CAS|78964-85-9}}
| ATC_prefix = J01
| ATC_suffix = XX01
| PubChem = 446987
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00828
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 394204
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2N81MY12TE
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04253
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 28915
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1757

&lt;!--Chemical data--&gt;
| C=3 | H=7 | O=4 | P=1 
| molecular_weight = 138.059 g/mol
| smiles = C[C@H]1[C@H](O1)P(=O)(O)O
| InChI = 1/C3H7O4P/c1-2-3(7-2)8(4,5)6/h2-3H,1H3,(H2,4,5,6)/t2-,3+/m0/s1
| InChIKey = YMDXZJFXQJVXBF-STHAYSLIBG
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C3H7O4P/c1-2-3(7-2)8(4,5)6/h2-3H,1H3,(H2,4,5,6)/t2-,3+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YMDXZJFXQJVXBF-STHAYSLISA-N
}}
'''Fosfomycin''' (also known as phosphomycin, phosphonomycin and the trade name '''Monurol''') is a [[broad-spectrum antibiotic]]&lt;ref name=&quot;pmid11481290&quot;&gt;{{cite journal |author=Grif K, Dierich MP, Pfaller K, Miglioli PA, Allerberger F |title=In vitro activity of fosfomycin in combination with various antistaphylococcal substances |journal=[[The Journal of antimicrobial chemotherapy]] |volume=48 |issue=2 |pages=209–17 |date=August 2001 |pmid=11481290 |doi= 10.1093/jac/48.2.209|url=http://jac.oxfordjournals.org/cgi/pmidlookup?view=long&amp;pmid=11481290}}&lt;/ref&gt; produced by certain ''[[Streptomyces]]'' species. It can now be made by chemical synthesis.

==History==
Fosfomycin (originally known as phosphonomycin) was discovered in a joint effort of [[Merck and Co.]] and Spain's Compañía Española de Penicilina y Antibióticos (Cepa).  It was first isolated by screening broth cultures of ''[[Streptomyces fradiae]]'' isolated from soil samples for the ability to cause formation of [[spheroplasts]] by growing bacteria.  The discovery was described in a series of papers published in 1969.&lt;ref&gt;Silver, L.L. Rational approaches to antibiotic discovery: pre-genomic directed and phenotypic screening, 2.4.2 Screens for spheroplast formation. In:  Thomas Dougherty, Michael J. Pucci, ''Antibiotic Discovery and Development.'' Chap. 2, p. 46.&lt;/ref&gt; Cepa began producing fosfomycin on an industrial scale in 1971 at its [[Aranjuez]] facility.&lt;ref&gt;Encros [http://www.ercros.es/eng/internas.asp?arxiu=qh_aranjuezh About us: Our history.]&lt;/ref&gt;

==Uses==
Fosfomycin is indicated in the treatment of [[urinary tract infection]]s, where it is usually administered as a single oral megadose.&lt;ref name=&quot;pmid9098664&quot;&gt;{{cite journal |author=Patel SS, Balfour JA, Bryson HM |title=Fosfomycin tromethamine: A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections |journal=Drugs |volume=53 |pages=637–656 |year=1997 |pmid=9098664 |issue=4 |doi=10.2165/00003495-199753040-00007}}&lt;/ref&gt; Its use in combination with [[Fosfomycin/tobramycin|tobramycin]] to treat lung infections in patients with [[cystic fibrosis]] was also explored.&lt;ref name=&quot;pmid22095545&quot;&gt;{{cite journal| author=Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M et al.| title=Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients with Pseudomonas Airway Infection. | journal=Am J Respir Crit Care Med | year= 2011 | volume=  185| issue=  2| pages=  171–8| pmid=22095545 | doi=10.1164/rccm.201105-0924OC | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=22095545  }}&lt;/ref&gt;&lt;ref name=&quot;NLM&quot;&gt;{{cite web|url=http://clinicaltrials.gov/ct2/show/NCT00794586|title=Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection|publisher=US National Library of Medicine|accessdate=3 May 2012}}&lt;/ref&gt;

The drug is well tolerated and has a low incidence of harmful side-effects.&lt;ref name=&quot;pmid9098664&quot;/&gt; However, development of bacterial resistance under therapy is a frequent occurrence and makes fosfomycin unsuitable for sustained therapy of severe infections.

Additional uses have been proposed.&lt;ref name=&quot;pmid18444827&quot;&gt;{{cite journal |author=Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI |title=Fosfomycin: use beyond urinary tract and gastrointestinal infections |journal=Clin. Infect. Dis. |volume=46 |issue=7 |pages=1069–77 |date=April 2008 |pmid=18444827 |doi=10.1086/527442 |url=http://www.journals.uchicago.edu/doi/abs/10.1086/527442?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dncbi.nlm.nih.gov}}&lt;/ref&gt; The global problem of advancing antimicrobial resistance has led to a renewed interest in its use more recently.&lt;ref&gt;Falagas ME, Grammatikos AP, Michalopoulos A. Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther. 2008; 6(5):593-600 PMID 18847400&lt;/ref&gt;

==Mechanism of action==

Fosfomycin is bactericidal and inhibits bacterial cell wall biogenesis by inactivating the enzyme [[UDP-N-acetylglucosamine enolpyruvyl transferase|UDP-''N''-acetylglucosamine-3-enolpyruvyltransferase]], also known as MurA.&lt;ref name=&quot;Brown&quot;&gt;{{cite journal |author=Brown ED, Vivas EI, Walsh CT, Kolter R |title=MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli |journal=J. Bacteriol. |volume=177 |issue=14 |pages=4194–7 |date=July 1995 |pmid=7608103 |pmc=177162 }}&lt;/ref&gt; This enzyme catalyzes the [[committed step]] in [[peptidoglycan]] biosynthesis, namely the ligation of [[phosphoenolpyruvate]] (PEP) to the 3'-hydroxyl group of [[Uridine diphosphate N-acetylglucosamine|UDP-''N''-acetylglucosamine]]. This pyruvate moiety provides the linker that bridges the glycan and peptide portion of peptidoglycan. Fosfomycin is a PEP analog that inhibits MurA by [[alkylation|alkylating]] an active site [[cysteine]] residue (Cys 115 in the ''[[Escherichia coli]]'' enzyme).&lt;ref name=&quot;urlCell Envelope.1995&quot;&gt;{{cite web |url=http://www.micro.siu.edu/micr425/425Notes/02-CellEnv.html |title=Cell Envelope.1995 |work= |accessdate=2008-11-08}}&lt;/ref&gt;

Fosfomycin enters the bacterial cell through the glycerophosphate transporter.

==Antibacterial spectrum and susceptibility==
Fosfomycin has broad antibacterial activity against both Gram-positive and Gram-negative pathogens, with useful activity against ''E. faecalis'', ''E. coli'', and various Gram-negatives like Citrobacter and Proteus.  Given a greater activity in a low pH milieu, and predominant excretion in active form into the urine, fosfomycin has found use for the prophylaxis and treatment of urinary tract infections caused by these uropathogens.  Of note, activity against ''S. saprophyticus'', Klebsiella and Enterobacter is variable and should be confirmed by MIC testing. 
Activity against ESBL-producing pathogens, notably ESBL-producing ''E. coli'' is good to excellent, due to the fact that the drug is not affected by cross-resistance issues.
Existing clinical data support use in uncomplicated UTI, caused by susceptible organisms.  However, susceptibility break-points of 64 mg/L should not be applied for systemic infections.    

==Biosynthetic gene cluster==
The complete fosfomycin biosynthetic [[gene cluster]] from ''[[Streptomyces]] fradiae'' has been cloned and sequenced and the heterologous production of fosfomycin in ''[[Streptomyces]] lividans'' has been achieved by Ryan Woodyer of the [[Huimin Zhao]] and Wilfred van der Donk research groups.&lt;ref name=&quot;pmid17113999&quot;&gt;{{cite journal |author=Woodyer RD, Shao Z, Thomas PM, ''et al'' |title=Heterologous production of fosfomycin and identification of the minimal biosynthetic gene cluster |journal=Chemistry &amp; biology |volume=13 |issue=11 |pages=1171–82 |date=November 2006 |pmid=17113999 |doi=10.1016/j.chembiol.2006.09.007 |url=http://linkinghub.elsevier.com/retrieve/pii/S1074-5521(06)00340-1}}&lt;/ref&gt;

==Resistance==
Mutations that inactivate the non-essential glycerophosphate transporter render bacteria resistant to fosfomycin.&lt;ref name=&quot;navas&quot;&gt;{{cite pmid|1963292}}&lt;/ref&gt;&lt;ref&gt;{{cite pmid|4605290}}&lt;/ref&gt;

===Fosfomycin resistance enzymes===
[[Enzyme]]s conferring resistance to fosfomycin have also been identified and are encoded both [[chromosome|chromosomally]] and on [[plasmid]]s.&lt;ref name=&quot;rigsby&quot;&gt;{{cite pmid|16399398}}&lt;/ref&gt;

Three related fosfomycin resistance enzymes (named FosA, FosB, and FosX) are members of the [[Lactoylglutathione_lyase#Structure|glyoxalase]] superfamily. These enzymes function by nucleophilic attack on carbon 1 of fosfomycin, which opens the epoxide ring and renders the drug ineffective. The enzymes differ by the identity of the nucleophile utilized in the reaction: [[glutathione]] for FosA, [[bacillithiol]] for FosB,&lt;ref name=&quot;pmid21751306&quot;&gt;{{cite journal |author=S. V. Sharma, V. K. Jothivasan, G. L. Newton, H. Upton, J. I.Wakabayashi, M. G. Kane, A. A. Roberts, M. Rawat, J. J. La Clair, and C. J. Hamilton. |title=Chemical and Chemoenzymatic Syntheses of Bacillithiol: A Unique Low-Molecular-Weight Thiol amongst Low G + C Gram-Positive Bacteria|journal=Angew. Chem. Int. Ed. |volume=50 |issue=31 |pages=7101–7104 |date=July 2011 |pmid=21751306 |doi=10.1002/anie.201100196}}&lt;/ref&gt; &lt;ref name=&quot;pmid23256780&quot;&gt;{{cite journal |author=A. A. Roberts, S. V. Sharma, A. W. Strankman, S. R. Duran, M. Rawat, and C. J. Hamilton. |title=Mechanistic studies of FosB: a divalent-metal-dependent bacillithiol-S-transferase that mediates fosfomycin resistance in Staphylococcus aureus|journal=Biochem. J. |volume=451 |issue=1 |pages=69–79 |date=July 2013 |pmid=23256780 |doi=10.1042/BJ20121541}}&lt;/ref&gt; and water for FosX.&lt;ref name=&quot;rigsby&quot; /&gt; In general, FosA and FosX enzymes are produced by Gram-negative bacteria, whereas FosB is produced by Gram-positive bacteria.&lt;ref name=&quot;rigsby&quot; /&gt;

FosC utilizes [[Adenosine triphosphate|ATP]] and adds a [[phosphate]] group to fosfomycin, thus altering its properties and making the drug ineffective.&lt;ref name=&quot;pmid7492106&quot;&gt;{{cite journal |author=García P, Arca P, Evaristo Suárez J |title=Product of fosC, a gene from Pseudomonas syringae, mediates fosfomycin resistance by using ATP as cosubstrate |journal=Antimicrob. Agents Chemother. |volume=39 |issue=7 |pages=1569–73 |date=July 1995 |pmid=7492106 |pmc=162783 |doi= |url=http://aac.asm.org/cgi/pmidlookup?view=long&amp;pmid=7492106}}&lt;/ref&gt;

== References ==
{{reflist|2}}

== External links ==
*[http://www.rxlist.com/cgi/generic/fosfomycin.htm Fosfomycin information at RxList]

{{Cell wall disruptive antibiotics}}

[[Category:Antibiotics]]
[[Category:Phosphonic acids]]
[[Category:Epoxides]]</text>
      <sha1>fogbqf64srj31upsx539fuxdd63atkt</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Xibornol</title>
    <ns>0</ns>
    <id>12671968</id>
    <revision>
      <id>585444631</id>
      <parentid>544903932</parentid>
      <timestamp>2013-12-10T15:39:34Z</timestamp>
      <contributor>
        <username>Louisajb</username>
        <id>13226235</id>
      </contributor>
      <comment>added chemblid</comment>
      <text xml:space="preserve" bytes="4051">{{Drugbox
| verifiedrevid = 447818390
| IUPAC_name = 4,5-dimethyl-2-[(1S,4R,6R)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl]phenol
| image = xibornol.png
| width = 120px

&lt;!--Clinical data--&gt;
| tradename =  
| Drugs.com = {{drugs.com|international|xibornol}}
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category =  
| legal_AU = &lt;!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --&gt;
| legal_CA = &lt;!--             / Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL         / P       / POM / CD / Class A, B, C --&gt;
| legal_US = &lt;!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V --&gt;
| legal_status =  
| routes_of_administration =  

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 13741-18-9
| ATC_prefix = J01
| ATC_suffix = XX02
| PubChem = 11777299
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChEMBL = 2104519
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 9951982
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = RQ12GMY0FZ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07433

&lt;!--Chemical data--&gt;
| C=18 | H=26 | O=1 
| molecular_weight = 258.398 g/mol
| smiles = Oc1cc(c(cc1C2CC3CCC2(C)C3(C)C)C)C
| InChI = 1/C18H26O/c1-11-8-14(16(19)9-12(11)2)15-10-13-6-7-18(15,5)17(13,3)4/h8-9,13,15,19H,6-7,10H2,1-5H3
| InChIKey = RNRHMQWZFJXKLZ-UHFFFAOYAB
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H26O/c1-11-8-14(16(19)9-12(11)2)15-10-13-6-7-18(15,5)17(13,3)4/h8-9,13,15,19H,6-7,10H2,1-5H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RNRHMQWZFJXKLZ-UHFFFAOYSA-N
}}
'''Xibornol''' is an [[antibiotic]].

It is primarily administered to the [[throat]].&lt;ref name=&quot;pmid17531411&quot;&gt;{{cite journal |author=Cirri M, Mura P, Mora PC |title=Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems |journal=Int J Pharm |volume=340 |issue=1–2 |pages=84–91 |year=2007 |pmid=17531411 |doi=10.1016/j.ijpharm.2007.03.021 |url=http://linkinghub.elsevier.com/retrieve/pii/S0378-5173(07)00267-0}}&lt;/ref&gt;

Xibornol is a lipophilic drug mainly used in Italy and Spain in spray dosage forms for the local treatment of infection and inflammation of the throat. Its poor water solubility makes difficult the development of aqueous formulations of the drug, thus giving rise to a limited number of stable and pharmaceutically accepted preparations. In fact, xibornol is actually marketed only as spray aqueous suspension. The aim of this work was to evaluate the possibility of developing a stable liquid formulation of the drug intended for oral spray administration using a self-microemulsifying drug delivery system (SMEDDS). These systems are able to adequately improve the drug solubility, allowing the introduction of relatively high concentration of drugs in the form of solution. Labrafil M1944, Labrafil M2125 and Labrafac CC were screened as oil phases, Labrasol and Labrafac PG as surfactants and Transcutol as co-surfactant. Pseudo-ternary phase diagrams were constructed, by titration with the aqueous phase of different oil phases and surfactant/co-surfactant mixtures in order to identify the self-microemulsification region and the optimal micro-emulsion composition. Then, complete pharmaceutical formulations were prepared and evaluated for stability and viscosity properties. The final selected formulations, containing Labrafil M1944, Transcutol, Labrafac PG and a hydrophilic co-solvent (propylene glycol or PEG 200) allowed complete solubilization of the required xibornol concentration (3%, w/v) and showed physical good stability up to 2 months at 25 and 4 °C, suitable viscosity and organoleptic properties.

==References==
{{reflist}}


{{Other antibacterials}}

[[Category:Antibiotics]]
[[Category:Phenols]]


{{antibiotic-stub}}</text>
      <sha1>0rnnegpzy6ao9usihpoca9ohpqems4q</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Prothionamide</title>
    <ns>0</ns>
    <id>12819536</id>
    <revision>
      <id>592864647</id>
      <parentid>566409287</parentid>
      <timestamp>2014-01-28T22:21:28Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="2329">{{Drugbox
| verifiedrevid = 447906208
| IUPAC_name = 2-propylpyridine-4-carbothioamide
| image = protionamide.png
| image2 = Prothionamide ball-and-stick.png

&lt;!--Clinical data--&gt;
| tradename =  
| Drugs.com = {{drugs.com|international|prothionamide}}
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category =  
| legal_AU = &lt;!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --&gt;
| legal_CA = &lt;!--             / Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL         / P       / POM / CD / Class A, B, C --&gt;
| legal_US = &lt;!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V --&gt;
| legal_status =  
| routes_of_administration =  

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 14222-60-7
| ATC_prefix = J04
| ATC_suffix = AD01
| PubChem = 666418
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 76YOO33643

&lt;!--Chemical data--&gt;
| C=9 | H=12 | N=2 | S=1 
| molecular_weight = 180.271 g/mol
}}
'''Protionamide''' (or '''prothionamide''') is a drug used in the treatment of [[tuberculosis]].&lt;ref name=&quot;pmid17227913&quot;&gt;{{cite journal |author=Wang F, Langley R, Gulten G, ''et al'' |title=Mechanism of thioamide drug action against tuberculosis and leprosy |journal=J. Exp. Med. |volume=204 |issue=1 |pages=73–8 |date=January 2007 |pmid=17227913 |pmc=2118422 |doi=10.1084/jem.20062100 |url=http://www.jem.org/cgi/pmidlookup?view=long&amp;pmid=17227913}}&lt;/ref&gt;

It has also been tested for use in the treatment of [[leprosy]].&lt;ref name=&quot;pmid16525107&quot;&gt;{{cite journal |author=Fajardo TT, Guinto RS, Cellona RV, Abalos RM, Dela Cruz EC, Gelber RH |title=A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy |journal=Am. J. Trop. Med. Hyg. |volume=74 |issue=3 |pages=457–61 |date=March 2006 |pmid=16525107 |doi= |url=http://www.ajtmh.org/cgi/pmidlookup?view=long&amp;pmid=16525107}}&lt;/ref&gt;

==See also==
* [[Thioamide]]

==References==
{{reflist}}

{{Antimycobacterials}}

[[Category:Antibiotics]]
[[Category:Pyridines]]
[[Category:Thioamides]]

{{antiinfective-drug-stub}}</text>
      <sha1>5jnt56l0rfw78ntlshw75qqhqhqnbkx</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Nifuroxazide</title>
    <ns>0</ns>
    <id>12158344</id>
    <revision>
      <id>587948400</id>
      <parentid>582108474</parentid>
      <timestamp>2013-12-27T18:23:29Z</timestamp>
      <contributor>
        <username>BattyBot</username>
        <id>15996738</id>
      </contributor>
      <minor/>
      <comment>fixed [[:Category:CS1 errors: dates|CS1 errors: dates]] &amp; [[WP:AWB/GF|General fixes]] using [[Project:AWB|AWB]] (9816)</comment>
      <text xml:space="preserve" bytes="4720">{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 462260501
| IUPAC_name = 4-Hydroxy-''N'''-[(5-nitrofuran-2-yl)methylene]benzohydrazide
| image = Nifuroxazide.svg

&lt;!--Clinical data--&gt;
| tradename =  
| Drugs.com = {{drugs.com|international|nifuroxazide}}
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category =  
| legal_AU = &lt;!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --&gt;
| legal_CA = &lt;!--             / Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL         / P       / POM / CD / Class A, B, C --&gt;
| legal_US = &lt;!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V --&gt;
| legal_status =  
| routes_of_administration = Oral

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 965-52-6
| ATC_prefix = A07
| ATC_suffix = AX03
| PubChem = 5337997
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4495115
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = PM5LI0P38J
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07111
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 244888

&lt;!--Chemical data--&gt;
| C=12 | H=9 | N=3 | O=5
| molecular_weight = 275.2 g/mol
| smiles = O=[N+]([O-])c2oc(/C=N/NC(=O)c1ccc(O)cc1)cc2
| InChI = 1/C12H9N3O5/c16-9-3-1-8(2-4-9)12(17)14-13-7-10-5-6-11(20-10)15(18)19/h1-7,16H,(H,14,17)/b13-7+
| InChIKey = YCWSUKQGVSGXJO-NTUHNPAUBE
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H9N3O5/c16-9-3-1-8(2-4-9)12(17)14-13-7-10-5-6-11(20-10)15(18)19/h1-7,16H,(H,14,17)/b13-7+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YCWSUKQGVSGXJO-NTUHNPAUSA-N
}}
'''Nifuroxazide''' ([[International Nonproprietary Name|INN]]) is an oral [[nitrofuran]] [[antibiotic]], patented since 1966&lt;ref name=&quot;patent1966&quot; /&gt; and used to treat [[colitis]] and [[diarrhea]] in humans and non-humans.&lt;ref name=&quot;patent_nonhumans&quot; /&gt;  It is sold under the brand names Ambatrol, Antinal, Bacifurane, Diafuryl (France), Diax (Egypt), Nifrozid, Ercefuryl (Romania, Czech Republic), Erfuzide (Thailand), Endiex (Slovakia), Nifuroksazyd (Poland), Pérabacticel (France), Pentofuryl (Germany), Topron (Latin America), Antinal (Egypt), Apazid (Morocco) and Septidiaryl. It is sold in capsule form and also as a suspension. The pharmaceutical group [[GlaxoSmithKline plc]] (Previously known as SmithKline Beecham) claims that nifuroxazide is highly effective and the consumers' group [[Healthy Skepticism]] says that GlaxoSmithKline's claims have no scientific support.&lt;ref name=&quot;healthy_skep_nifuroxazide&quot; /&gt;

==History==
Maurice Claude Ernest Carron patented the drug in the United States in 1966.&lt;ref name=&quot;patent1966&quot;&gt;USPTO No. 3290213 |http://www.google.com/patents?id=f2dwAAAAEBAJ&lt;/ref&gt; Subsequent patents issued to Germano Cagliero of Marxer S.p.A describe the use of nifuroxazide as an antibiotic used to treat livestock.&lt;ref name=&quot;patent_nonhumans&quot;&gt;USPTO No 4093746 |http://www.google.com/patents?vid=USPAT4093746&lt;/ref&gt;

==Effectiveness in humans==
In 1997, in an [[Ivory Coast]] promotional leaflet, [[GlaxoSmithKline]] claimed that nifuroxazide (under the brand name &quot;Ambatrol&quot;) is an anti-dehydration treatment, &quot;neutralise[s] microbacterials&quot; in diarrhoea, and has &quot;a spectrum which covers most enteropathogenic microbacterials, Shigella, [[Escherichia coli]], [[Salmonella]], [[staphylococcus|Staphylococci]], Klebsiella, [[Yersinia]]&quot;.&lt;ref name=&quot;healthy_skep_nifuroxazide&quot;&gt;{{cite web| last =| first =| authorlink =| coauthors =| title =SmithKline Beecham Ambatrol (nifuroxazide)| work =| publisher =[[Healthy Skepticism]]| date =June 1997| url =http://www.healthyskepticism.org/global/malam/int/mi1997-05_06/ |format =| doi =| accessdate =2010-12-21 |archiveurl=http://www.webcitation.org/5v94v2FtL |archivedate=2010-12-21  |deadurl=no}}&lt;/ref&gt; The international [[non-profit organisation]] [[Healthy Skepticism]], at the time using their former name, Medical Lobby for Appropriate Marketing (MaLAM), disagreed, stating &quot;We have not found any scientific evidence to support these claims.&quot;&lt;ref name=&quot;healthy_skep_nifuroxazide&quot; /&gt;

==Notes==
{{Reflist}}

{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}}

==External links==
* [http://www.essentialdrugs.org/edrug/archive/199802/msg00049.php point of view critical of nifuroxazide]

[[Category:Antibiotics]]
[[Category:Hydrazides]]
[[Category:Phenols]]
[[Category:Nitrofurans]]


{{antibiotic-stub}}
{{gastrointestinal-drug-stub}}</text>
      <sha1>57p3vap03cpdaq3owc0t68z9ezcoonq</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Neocarzinostatin</title>
    <ns>0</ns>
    <id>7031301</id>
    <revision>
      <id>571274847</id>
      <parentid>571273102</parentid>
      <timestamp>2013-09-02T19:59:43Z</timestamp>
      <contributor>
        <username>CheMoBot</username>
        <id>7377957</id>
      </contributor>
      <comment>Updating {{chembox}} (no changed fields - added verified revid - updated 'CASNo_Ref', 'verifiedrevid') per [[WP:CHEMVALID|Chem/Drugbox validation]] (report [[Wikipedia_talk:WikiProject_Chemicals|errors]] or [[user talk:CheMoBot|bugs]])</comment>
      <text xml:space="preserve" bytes="3734">{{Chembox
| verifiedrevid = 441386715
| Reference = &lt;ref&gt;{{cite journal|journal=[[Journal of Organic Chemistry|J. Org. Chem.]]|volume=71|issue=2|pages=636–644|year=2006|doi= 10.1021/jo052031o+S0022-3263(05)02031-1|title=Formal Total Synthesis of Neocarzinostatin Chromophore|author=Shoji Kobayashi, Makiko Hori, Guang Xing Wang, and Masahiro Hirama|pmid=16408974}} &lt;/ref&gt;
| Name = Neocarzinostatin chromophore
| ImageFile = Neocarzinostatin.png
| ImageSize = 200px
| IUPACName = &lt;small&gt;(1a''S'',5''R'',6''R'',6a''E'')-6-{[(2''R'',3''R'',4''R'',5''R'',6''R'')-4,5-Dihydroxy-6-methyl-3-(methylamino)tetrahydro-2''H''-pyran-2-yl]oxy}-1a-(2-oxo-1,3-dioxolan-4-yl)-2,3,8,9-tetradehydro-1a,5,6,9a-tetrahydrocyclopenta[5,6]cyclonona[1,2-b]oxiren-5-yl 2-hydroxy-7-methoxy-5-methyl-1-naphthoate&lt;/small&gt;
| OtherNames =
| Section1 = {{Chembox Identifiers
|  InChI = 1/C35H35NO12/c1-16-12-19(42-4)14-22-20(16)8-9-23(37)27(22)32(40)45-24-13-18-10-11-35(26-15-43-34(41)46-26)25(48-35)7-5-6-21(18)31(24)47-33-28(36-3)30(39)29(38)17(2)44-33/h8-9,12-14,17,21,24-26,28-31,33,36-39H,6,15H2,1-4H3/t17-,21?,24-,25?,26?,28-,29+,30-,31-,33-,35+/m1/s1
| InChIKey = BLXZMHNVKCEIJX-LTZUVELHBD
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C35H35NO12/c1-16-12-19(42-4)14-22-20(16)8-9-23(37)27(22)32(40)45-24-13-18-10-11-35(26-15-43-34(41)46-26)25(48-35)7-5-6-21(18)31(24)47-33-28(36-3)30(39)29(38)17(2)44-33/h8-9,12-14,17,21,24-26,28-31,33,36-39H,6,15H2,1-4H3/t17-,21?,24-,25?,26?,28-,29+,30-,31-,33-,35+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BLXZMHNVKCEIJX-LTZUVELHSA-N
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = [79633-18-4]
|   CASOther = &amp;nbsp;Neocarzinostatin chromophore&lt;br&gt;[9014-02-2], Neocarzinostatin
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID=21106457
|   PubChem =
|   SMILES = COc7cc1c(ccc(O)c1C(=O)O[C@@H]3\C=C4\C#C[C@@]5(OC5C#CCC4[C@H]3O[C@H]2O[C@H](C)[C@H](O)[C@H](O)[C@H]2NC)C6COC(=O)O6)c(C)c7
}}
| Section2 = {{Chembox Properties
|   Formula = C&lt;sub&gt;35&lt;/sub&gt;H&lt;sub&gt;33&lt;/sub&gt;NO&lt;sub&gt;12&lt;/sub&gt;
|   MolarMass = 659.64 g/mol
|   Appearance =
|   Density =
|   MeltingPt =
|   BoilingPt =
|   Solubility =
  }}
| Section3 = {{Chembox Hazards
|   MainHazards =
|   FlashPt =
|   Autoignition =
  }}
| Section5 = {{Chembox Pharmacology
| AdminRoutes =
| Bioavail =
| Metabolism =
| HalfLife =
| ProteinBound =
| Excretion = Renal
| Legal_status =
| Legal_US =
| Legal_UK =
| Legal_AU =
| Legal_CA =
| PregCat =
| PregCat_AU =
| PregCat_US =
   }}
}}

'''Neocarzinostatin'''  is a [[macromolecular]] [[chromoprotein]] [[enediyne]] [[antibiotic]] with anti-[[tumor]]al activity secreted by ''Streptomyces macromomyceticus''.

It consists of two parts, a labile [[chromophore]] (bicyclic dienediyne structure shown at right) and a 113 amino acid [[Apoenzyme#Cofactors|apoprotein]] to which the chromophore is tightly and non-[[covalent bond|covalently bound]] with high affinity (K&lt;sub&gt;d&lt;/sub&gt; ~ 10&lt;sup&gt;-10&lt;/sup&gt; M). The chromophore is a very potent [[DNA]]-damaging agent; it is very labile and the role of the apoprotein is to protect it and release it to the target DNA.  Opening of the epoxide under reductive conditions present in cells creates favorable conditions for a [[Bergman cyclization]], leading to a diradical intermediate and eventually double DNA strand cleavage.   Other members of the neocarzinostatin group of antibiotics are [[Macromomycin B|macromomycin]], [[actinoxanthin]], [[kedarcidin]] and [[maduropeptin]].

As a medicine it is among the most potent, and in Japan only it has been used against [[liver cancer]] clinically.

==References==
&lt;references/&gt;

[[Category:Antibiotics]]
[[Category:Cancer research]]
[[Category:Enediynes]]</text>
      <sha1>m4lafa7a3guwn9x1lcz764gtc6s2eqz</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Aminocoumarin</title>
    <ns>0</ns>
    <id>13459707</id>
    <revision>
      <id>544977089</id>
      <parentid>514339235</parentid>
      <timestamp>2013-03-17T15:35:30Z</timestamp>
      <contributor>
        <username>Addbot</username>
        <id>6569922</id>
      </contributor>
      <minor/>
      <comment>[[User:Addbot|Bot:]] Migrating 2 interwiki links, now provided by [[Wikipedia:Wikidata|Wikidata]] on [[d:q471668]]</comment>
      <text xml:space="preserve" bytes="4134">[[Image:Novobiocin.png|thumb|[[Skeletal formula]] of [[novobiocin]]]]
''' Aminocoumarin ''' is a class of  [[antibiotics]] that act by an inhibition of the [[DNA Gyrase]] enzyme involved in the cell division in [[bacteria]]. They are derived from '' [[Streptomyces]] '' species,&lt;ref&gt;{{cite pmid|19362650}}&lt;/ref&gt; whose best-known representative - '' [[Streptomyces coelicolor]]'' - was completely [[sequenced]] in 2002.&lt;ref&gt;Bentley SD, ''et al.''. Complete genome sequence of the model actinomycete &quot;Streptomyces coelicolor&quot; A3(2). ''Nature''. 2002 (417)141&amp;ndash;147 http://www.nature.com/nature/journal/v417/n6885/abs/417141a.html&lt;/ref&gt; 
The Aminocoumarin antibiotics include:

* [[Novobiocin]], Albamycin ([[Pharmacia]] And [[Upjohn]])
* [[Coumermycin]]
* [[Clorobiocin]]

==Structure==
The core of aminocoumarin antibiotics is made up of a 3-Amino-4,7-dihydroxycumarin ring, which is linked, e.g., with a sugar in 7-Position and a benzoic acid derivative in 3-Position.

Clorobiocin is a natural antibiotic isolated from several ''[[Streptomyces]]'' strains and differs from [[novobiocin]] in that the methyl group at the 8 position in the coumarin ring of [[novobiocin]] is replaced by a chlorine atom, and the carbamoyl at the 3' position of the noviose sugar is substituted by a 5-methyl-2-pyrrolylcarbonyl group.&lt;ref name=Tsai/&gt;

==Mechanism of action==
The ''' Aminocoumarin ''' antibiotics are known inhibitors of [[DNA gyrase]]. [[Antibiotic]]s of the aminocoumarin family exert their therapeutic activity by binding tightly to the B subunit of bacterial [[DNA gyrase]], thereby inhibiting this essential enzyme.&lt;ref&gt;Galm, Ute, Heller, Stefanie, Shapiro, Stuart, Page, Malcolm, Li, Shu-Ming, Heide, Lutz
Antimicrobial and DNA Gyrase-Inhibitory Activities of Novel Clorobiocin Derivatives Produced by Mutasynthesis Antimicrob. ''Agents Chemother''. 2004 48: 1307&amp;ndash;1312&lt;/ref&gt; They compete with ATP
for binding to the B subunit of this enzyme and inhibit the ATP-dependent DNA supercoiling catalysed by gyrase.&lt;ref name=M&gt;Maxwell, A., and Lawson, D. M. (2003). The ATP-binding site of type II topoisomerases as a target for antibacterial drugs. ''Curr Top Med Chem'', 3, 283-303.&lt;/ref&gt; X-ray crystallography studies have confirmed binding at the ATP-binding site located on the gyrB subunit of [[DNA gyrase]].&lt;ref name=Tsai&gt;F.T.F. Tsai, O.M. Singh, T.Skarzynski, A.J. Wonacott, S. Weston, A. Tucker, R.A. Pauptit, A.L. Breeze, J.P. Poyser, R. O'Brien et al., The high-resolution crystal structure of a 24-kDa gyrase B fragment from E. coli complexed with one of the most potent coumarin inhibitors, clorobiocin.'' Proteins'' 28 (1997), pp. 41–52
&lt;/ref&gt; Their [[Dissociation constant#Protein-ligand binding|affinity]] for gyrase is considerably higher than that of modern [[quinolone|fluoroquinolones]], which also target DNA gyrase but at the gyrA subunit.&lt;ref name=s&gt;Schmutz E, Mühlenweg A, Li SM, Heide L. (2003) Resistance genes of aminocoumarin producers: two type II topoisomerase genes confer resistance against coumermycin A1 and clorobiocin. ''Antimicrob Agents Chemother.'' Mar;47(3):869-77.&lt;/ref&gt;

==Resistance==

Resistance to this class of antibiotics usually results from genetic mutation in the gyrB subunit.&lt;ref&gt;M. Fujimoto-Nakamura, H. Ito, Y. Oyamada, T. Nishino, and J.-i. Yamagishi
Accumulation of Mutations in both gyrB and parE Genes Is Associated with High-Level Resistance to Novobiocin in Staphylococcus aureus
''Antimicrob. Agents Chemother''., September 1, 2005; 49(9): 3810 - 3815.&lt;/ref&gt; Other mechanisms include de novo synthesis of a coumarin-resistant gyrase B subunit by the novobiocin producer ''S. sphaeroides ''.&lt;ref name=s/&gt;

==Clinical use==
The clinical use of this antibiotic class has been restricted due to the low water solubility, low activity against gram-negative bacteria,&lt;ref name=M/&gt; and toxiciy ''in vivo'' of this class of antibiotics.&lt;ref&gt;A. Maxwell, The interaction between coumarin drugs and DNA gyrase. ''Mol. Microbiol''. 9 (1993), pp. 681–686.&lt;/ref&gt;

==References==
{{reflist|2}}

{{Nucleic acid inhibitors}}

[[Category:Antibiotics]]
[[Category:Coumarin drugs]]</text>
      <sha1>739mrj2yjpbgk23hprer4rgghm6g5e6</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Antimicrobial pharmacodynamics</title>
    <ns>0</ns>
    <id>14248130</id>
    <revision>
      <id>606618907</id>
      <parentid>590596480</parentid>
      <timestamp>2014-05-01T12:48:45Z</timestamp>
      <contributor>
        <username>Rjwilmsi</username>
        <id>203434</id>
      </contributor>
      <minor/>
      <comment>/* Post Antibiotic Effect */Added 1 dois to journal cites using [[Project:AWB|AWB]] (10081)</comment>
      <text xml:space="preserve" bytes="2845">'''Antimicrobial pharmacodynamics''' is the relationship between concentration of antibiotic and its ability to inhibit vital processes of endo- or ectoparasites and microbial organisms.&lt;ref name=nightingale&gt;C.H. Nightingale, T. Murakawa, P.G. Ambrose (2002) Antimicrobial Pharmacodynamics in Theory and Clinical Practice Informa Health Care ISBN 0-8247-0561-0&lt;/ref&gt; This branch of pharmacodynamics relates concentration of an anti-infective agent to effect, but specifically to its antimicrobial effect.&lt;ref name=&quot;pmid15031728&quot;&gt;{{cite journal |author=Drusano GL |title=Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' |journal=Nat. Rev. Microbiol. |volume=2 |issue=4 |pages=289–300 |year=2004 |pmid=15031728 |doi=10.1038/nrmicro862}}&lt;/ref&gt;

==Concentration-dependent effects==
The [[minimum inhibitory concentration]] and [[Minimum Bactericidal Concentration|minimum bactericidal concentration]] are used to measure ''in vitro'' activity antimicrobial and is an excellent indicator of antimicrobial potency. They don't give any information relating to time-dependent antimicrobial killing the so-called post antibiotic effect.&lt;ref name=nightingale/&gt;

==Post Antibiotic Effect==
The post antibiotic effect (PAE) is defined as persistent suppression of bacterial growth after a brief exposure (1 or 2 hours) of bacteria to an antibiotic even in the absence of [[Immune response|host defense mechanisms]].&lt;ref name=&quot;SHARMA2002&quot;&gt;http://medind.nic.in/ibi/t02/i6/ibit02i6p390.pdf&lt;/ref&gt; Factors that affect the duration of the post antibiotic effect include duration of antibiotic exposure, bacterial species, culture medium and class of antibiotic. It has been suggested that an alteration of DNA function is possibly responsible for post antibiotic effect following the observation that  most inhibitors of protein and nucleic acid synthesis (aminoglycosides, fluoroquinolones, tetracyclines, clindamycin, certain newer macrolides/ketolides, and rifampicin and rifabutin) induce long-term PAE against susceptible bacteria. &lt;ref&gt;{{cite journal |author=Guan L, Blumenthal RM, Burnham JC |title=Analysis of macromolecular biosynthesis to define the quinolone-induced postantibiotic effect in Escherichia coli |journal=Antimicrob. Agents Chemother. |volume=36 |issue=10 |pages=2118–24 |date=October 1992 |pmid=1280055 |pmc=245465 |doi= 10.1128/aac.36.10.2118|url=http://aac.asm.org/cgi/pmidlookup?view=long&amp;pmid=1280055}}&lt;/ref&gt;&lt;ref name=&quot;SHARMA2002&quot;/&gt; Theoretically, the ability of an antibiotic to induce a PAE is an attractive property of an antibiotic since antibiotic concentrations could fall below the MIC for the bacterium yet retain their effectiveness in their ability to suppress the growth.&lt;ref name=&quot;SHARMA2002&quot;/&gt;

==References==
{{Reflist}}

{{Pharmacology}}
[[Category:Antibiotics]]
[[Category:Pharmacodynamics]]</text>
      <sha1>7h0rdc4jrkkilsogt48dqqsnk8b85hs</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Katanosin</title>
    <ns>0</ns>
    <id>14398725</id>
    <revision>
      <id>606695079</id>
      <parentid>600976030</parentid>
      <timestamp>2014-05-01T22:35:12Z</timestamp>
      <contributor>
        <username>Rjwilmsi</username>
        <id>203434</id>
      </contributor>
      <minor/>
      <comment>Added 2 dois to journal cites using [[Project:AWB|AWB]] (10090)</comment>
      <text xml:space="preserve" bytes="6301">{{chembox
|Name = Katanosin B
| verifiedrevid = 400126831
|ImageFile= lysobactin.png
|ImageSize=
|IUPACName=''N''-[6-(2-amino-1-hydroxy-2-oxoethyl)-15-butan-2-yl-18-[3-(diaminomethylideneamino)propyl]-
12-(1-hydroxyethyl)-3-(hydroxymethyl)-24-(1-hydroxy-2-methylpropyl)-21-(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-28-phenyl-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]-
2-[(2-amino-4-methylpentanoyl)amino]-4-methylpentanamide
|IUPACName_hidden=yes
|OtherNames=Lysobactin
|Section1= {{Chembox Identifiers
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 170823
| InChI = 1/C58H97N15O17/c1-12-30(10)39-53(85)71-40(31(11)75)52(84)64-24-38(76)69-42(45(78)47(60)79)55(87)68-37(25-74)57(89)90-46(32-17-14-13-15-18-32)43(73-51(83)36(23-28(6)7)66-48(80)33(59)21-26(2)3)56(88)72-41(44(77)29(8)9)54(86)67-35(22-27(4)5)50(82)65-34(49(81)70-39)19-16-20-63-58(61)62/h13-15,17-18,26-31,33-37,39-46,74-75,77-78H,12,16,19-25,59H2,1-11H3,(H2,60,79)(H,64,84)(H,65,82)(H,66,80)(H,67,86)(H,68,87)(H,69,76)(H,70,81)(H,71,85)(H,72,88)(H,73,83)(H4,61,62,63)
| InChIKey = KQMKBWMQSNKASI-UHFFFAOYAZ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C58H97N15O17/c1-12-30(10)39-53(85)71-40(31(11)75)52(84)64-24-38(76)69-42(45(78)47(60)79)55(87)68-37(25-74)57(89)90-46(32-17-14-13-15-18-32)43(73-51(83)36(23-28(6)7)66-48(80)33(59)21-26(2)3)56(88)72-41(44(77)29(8)9)54(86)67-35(22-27(4)5)50(82)65-34(49(81)70-39)19-16-20-63-58(61)62/h13-15,17-18,26-31,33-37,39-46,74-75,77-78H,12,16,19-25,59H2,1-11H3,(H2,60,79)(H,64,84)(H,65,82)(H,66,80)(H,67,86)(H,68,87)(H,69,76)(H,70,81)(H,71,85)(H,72,88)(H,73,83)(H4,61,62,63)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KQMKBWMQSNKASI-UHFFFAOYSA-N
| CASNo=116340-02-4
|  PubChem=197270
|  SMILES = O=C(N)C(O)C2C(=O)NC(C(=O)OC(c1ccccc1)C(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)N2)C(O)C)C(C)CC)CCC/N=C(\N)N)CC(C)C)C(O)C(C)C)NC(=O)C(NC(=O)C(N)CC(C)C)CC(C)C)CO
|  MeSHName=Katanosin B
  }}
|Section2= {{Chembox Properties
|  C=58|H=97|N=15|O=17
|  Appearance=Solid
|  Density=1.42 g/cm&lt;sup&gt;3&lt;/sup&gt;
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3= {{Chembox Hazards
|  MainHazards=Xn
|  FlashPt=
|  Autoignition=
  }}
}}

'''Katanosins''' are a group of [[antibiotics]] (also known as '''lysobactins'''). They are [[natural product]]s with strong antibacterial potency.&lt;ref&gt;{{cite journal | pmid = 3209466 | year = 1988 | last1 = Bonner | first1 = DP | last2 = O'Sullivan | first2 = J | last3 = Tanaka | first3 = SK | last4 = Clark | first4 = JM | last5 = Whitney | first5 = RR | title = Lysobactin, a novel antibacterial agent produced by Lysobacter sp. II. Biological properties | volume = 41 | issue = 12 | pages = 1745–51 | journal = The Journal of antibiotics | doi=10.7164/antibiotics.41.1745}}&lt;/ref&gt; So far,  katanosin A and katanosin B (lysobactin) have been described.

==Sources==
Katanosins have been isolated from the fermentation broth of  [[microorganism]]s, such as ''[[Cytophaga]]''.&lt;ref&gt;{{cite journal | pmid = 3209465 | year = 1988 | last1 = O'Sullivan | first1 = J | last2 = McCullough | first2 = JE | last3 = Tymiak | first3 = AA | last4 = Kirsch | first4 = DR | last5 = Trejo | first5 = WH | last6 = Principe | first6 = PA | title = Lysobactin, a novel antibacterial agent produced by Lysobacter sp. I. Taxonomy, isolation and partial characterization | volume = 41 | issue = 12 | pages = 1740–4 | journal = The Journal of antibiotics}}&lt;/ref&gt; or the  Gram-negative bacterium ''[[Lysobacter]] sp.''&lt;ref&gt;{{cite journal | pmid = 3403364 | year = 1988 | last1 = Shoji | first1 = J | last2 = Hinoo | first2 = H | last3 = Matsumoto | first3 = K | last4 = Hattori | first4 = T | last5 = Yoshida | first5 = T | last6 = Matsuura | first6 = S | last7 = Kondo | first7 = E | title = Isolation and characterization of katanosins a and B | volume = 41 | issue = 6 | pages = 713–8 | journal = The Journal of antibiotics | doi=10.7164/antibiotics.41.713}}&lt;/ref&gt;

==Structure==
Katanosins are cyclic [[depsipeptide]]s ([[acylcyclodepsipeptide]]s). These proteinogenic structures are not regular [[protein]]s from [[primary metabolism]]. They origin from the bacterial [[secondary metabolism]]. Accordingly, various non-proteinogenic (non-ribosomal) [[amino acid]]s are found in katanosins, such as 3-hydroxy[[leucine]], 3-hydroxy[[asparagine]], allo-[[threonine]] and 3-hydroxy[[phenylalanine]]. All katanosins have a cyclic and a linear segment (“lariat structure”). The peptidic ring is closed with an ester bond (lactone).

Katanosin A and B differ in the amino acid position 7. The minor metabolite katanosin A has a [[valine]] in this position, whereas the main metabolite katanosin B carries an [[isoleucine]].

==Biological activity==
Katanosin antibiotics target the bacterial [[cell wall]] biosynthesis. They are highly potent against problematic [[Gram-positive]] hospital pathogens such as [[staphylococci]] and [[enterococci]]. Their promising biological activity attracted various biological and chemical research groups. Their in-vitro potency is comparable with the current “last defence” antibiotic [[vancomycin]].

==Chemical synthesis==
The first total syntheses of katanosin B (lysobactin) have been described in 2007.&lt;ref&gt;{{cite journal | pmid = 17211904 | year = 2007 | last1 = Von Nussbaum | first1 = F | last2 = Anlauf | first2 = S | last3 = Benet-Buchholz | first3 = J | last4 = Häbich | first4 = D | last5 = Köbberling | first5 = J | last6 = Musza | first6 = L | last7 = Telser | first7 = J | last8 = Rübsamen-Waigmann | first8 = H | last9 = Brunner | first9 = NA | title = Structure and total synthesis of lysobactin (katanosin B) | volume = 46 | issue = 12 | pages = 2039–42 | doi = 10.1002/anie.200604232 | journal = Angewandte Chemie (International ed. in English)| display-authors = 9 }}&lt;/ref&gt;&lt;ref&gt;{{cite journal | pmid = 17432854 | year = 2007 | last1 = Guzman-Martinez | first1 = A | last2 = Lamer | first2 = R | last3 = Vannieuwenhze | first3 = MS | title = Total synthesis of lysobactin | volume = 129 | issue = 18 | pages = 6017–21 | doi = 10.1021/ja067648h | pmc = 2151959 | journal = Journal of the American Chemical Society}}&lt;/ref&gt; 

==References==
&lt;references/&gt;

[[Category:Antibiotics]]
[[Category:Depsipeptides]]</text>
      <sha1>eshbd1jwa8e7xtsbv0lrw2dfr5krlyk</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>A23187</title>
    <ns>0</ns>
    <id>4149039</id>
    <revision>
      <id>596705759</id>
      <parentid>586905978</parentid>
      <timestamp>2014-02-23T00:33:29Z</timestamp>
      <contributor>
        <username>Trappist the monk</username>
        <id>10289486</id>
      </contributor>
      <minor/>
      <comment>/* Actions and uses */Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated coauthor parameter errors]] using [[Project:AWB|AWB]]</comment>
      <text xml:space="preserve" bytes="6614">{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 461749035
| IUPAC_name = 5-(methylamino)-2-({(2''R'',3''R'',6''S'',8''S'',9''R'',11''R'')-3,9,11-trimethyl-8-[(1''S'')-1-methyl-2-oxo-2-(1''H''-pyrrol-2-yl)ethyl]-1,7-dioxaspiro[5.5]undec-2-yl}methyl)-1,3-benzoxazole-4-carboxylic acid
| image = A23187.png

&lt;!--Clinical data--&gt;
| tradename =

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 52665-69-7
| ATC_prefix =  
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 11957499
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1256686
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10131749
|  smiles = O=C(O)c1c(NC)ccc2oc(nc12)C[C@H]5O[C@]3(O[C@@H]([C@H](C)C[C@H]3C)[C@@H](C(=O)c4cccn4)C)CC[C@H]5C
|  InChI = 1/C29H37N3O6/c1-15-10-11-29(17(3)13-16(2)27(38-29)18(4)26(33)20-7-6-12-31-20)37-22(15)14-23-32-25-21(36-23)9-8-19(30-5)24(25)28(34)35/h6-9,12,15-18,22,27,30-31H,10-11,13-14H2,1-5H3,(H,34,35)/t15-,16-,17-,18-,22-,27+,29+/m1/s1
|  InChIKey = HIYAVKIYRIFSCZ-CYEMHPAKBV
|  StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C29H37N3O6/c1-15-10-11-29(17(3)13-16(2)27(38-29)18(4)26(33)20-7-6-12-31-20)37-22(15)14-23-32-25-21(36-23)9-8-19(30-5)24(25)28(34)35/h6-9,12,15-18,22,27,30-31H,10-11,13-14H2,1-5H3,(H,34,35)/t15-,16-,17-,18-,22-,27+,29+/m1/s1
|  StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HIYAVKIYRIFSCZ-CYEMHPAKSA-N

&lt;!--Chemical data--&gt;
| C=29 | H=37 | N=3 | O=6 
| molecular_weight = 523.62 g/mol
}}
'''A23187''' is a mobile [[ion-carrier]] that forms stable complexes with divalent cations ([[ion]]s with a charge of +2). A23187 is also known as '''Calcimycin''', '''Calcium [[Ionophore]]''', '''Antibiotic A23187''' and '''Calcium [[Ionophore]] A23187'''. It is produced at [[Fermentation (biochemistry)|fermentation]] of [[Streptomyces]] [[Streptomyces chartreusensis|chartreusensis]].

== Actions and uses ==
A23187 has [[antibiotic]] properties against [[gram positive]] [[bacteria]] and [[fungus|fungi]].  It also acts as a divalent cation [[ionophore]], allowing these ions to cross [[cell membrane]]s, which are usually impermeable to them.&lt;ref&gt;{{cite web | url= http://www.online-medical-dictionary.org/A23187.asp?q=A23187| title=A23187| year=2006| publisher=Medical Dictionary Online| accessdate=2006-11-01| archiveurl= http://web.archive.org/web/20061210155944/http://www.online-medical-dictionary.org/A23187.asp?q=A23187| archivedate= 10 December 2006 &lt;!--DASHBot--&gt;| deadurl= no}}&lt;/ref&gt; A23187 is most selective for Mn&lt;sup&gt;2+&lt;/sup&gt;, somewhat less selective for [[calcium|Ca&lt;sup&gt;2+&lt;/sup&gt;]] and [[magnesium|Mg&lt;sup&gt;2+&lt;/sup&gt;]], much less selective for [[strontium|Sr&lt;sup&gt;2+&lt;/sup&gt;]], and even less selective for [[barium|Ba&lt;sup&gt;2+&lt;/sup&gt;]].&lt;ref&gt;{{cite journal | last =Abbott | first = Bernard| authorlink = BJ Abbott|author2=D S Fukuda|author3=D E Dorman|author4=J L Occolowitz|author5=M Debono|author6= L Farhner| title =Microbial transformation of A23187, a divalent cation ionophore antibiotic | journal =Antimicrobial Agents and Chemotherapy | volume = 16| issue =6 | pages = 808–812| publisher = | year = 1979| doi = | id = | accessdate = | pmid =119484 | pmc =352958 }}&lt;/ref&gt;  The ionophore is used in laboratories  to increase intracellular Ca&lt;sup&gt;2+&lt;/sup&gt; levels in intact [[cell (biology)|cell]]s. It also uncouples [[oxidative phosphorylation]], the process cells use to synthesize [[Adenosine triphosphate]] which they use for energy.  In addition, A23187 inhibits mitochondrial [[ATPase]] activity.  A23187  also induces apoptosis in some cells (e.g. mouse [[lymphoma]] cell line, or S49, and [[Jurkat cells]]) and prevents it in others (e.g. cells dependent on [[interleukin 3]] that have had the factor withdrawn).&lt;ref name=&quot;A23&quot;&gt;{{cite web | url= http://a23187.4mg.com/| title=A23187| accessdate=2006-11-01| archiveurl= http://web.archive.org/web/20061103171331/http://a23187.4mg.com/| archivedate= 3 November 2006 &lt;!--DASHBot--&gt;| deadurl= no}}&lt;/ref&gt;

[[Inex Pharmaceuticals Corporation]] (Canada) reported an innovative application of A23187. Inex used A23187 as a molecular tool in order to make artificial [[liposomes]] loaded with anti-[[cancer]] drugs such as [[Topotecan]].&lt;ref&gt;[http://cancerres.aacrjournals.org/cgi/content/full/60/13/3389 Liposomal Encapsulation of Topotecan Enhances Anticancer Efficacy in Murine and Human Xenograft Models]&lt;/ref&gt;

In [[IVF]] field, Ca Ionophore can be used in case of low fertilization rate after ICSI procedure, particularly with [[Globozoospermia]] (Round Head sperm syndrome), Ca Ionophore will replace absence of sperm acrosom, and plays role in oocyte activation after ICSI. Recommended use is 0.5 microgram/ml twice for 10 min interrupted with fresh media with 30 min incubation, followed with regular injected eggs culture for IVF.&lt;ref&gt;Effect of calcium ionophore on unfertilized oocytes after ICSI cycles; Iran J Reprod Med Vol. 10. No. 2. pp: 83-86, March 2012.&lt;/ref&gt;

==Biosynthesis==
The core biosynthetic enzymes are thought to include 3 proteins for the biosynthesis of the α-ketopyrrole moiety, 5 for modular type I polyketide synthases for the spiroketal ring, 4 for the biosynthesis of 3-hydroxyanthranilic acid, an N-methyltransferase tailoring enzyme, and a type II thioesterase.&lt;ref&gt;{{cite journal| journal=Antimicrob Agents Chemother. |date=March 2011 |volume=55| issue=3|pages=974–82 |title= Characterization of the biosynthesis gene cluster for the pyrrole polyether antibiotic calcimycin (A23187) in Streptomyces chartreusis NRRL 3882 |author=Wu Q, Liang J, Lin S, Zhou X, Bai L, Deng Z, Wang Z | PMID= 21173184 | doi=10.1128/AAC.01130-10 | pmc=3067094}}&lt;/ref&gt;

== Commercial availability ==
Commercially, A23187 is available as free [[acid]], Ca&lt;sup&gt;2+&lt;/sup&gt; salt, and 4-brominated analog.&lt;ref&gt;[http://www.fermentek.co.il/a23187FA.htm A23187 ] product page from [[Fermentek]]&lt;/ref&gt;

== References ==
&lt;references/&gt;

== External links ==
*[http://www.agscientific.com/Virtual/VirtualPages/Item_Page_ALL_TYPES.asp?ItemCode=A1020&amp;Item_Process_Mode=ADD A23187] from [[AG Scientific]], another vendor
*[http://www.biomol.com/Online_Catalog/Online_Catalog/Products/Product_Detail/38/?categoryID=42&amp;productID=133 A21387] from BIOMOL, a vendor's product page
*[http://www.bioaustralis.com/productorder.php?prodid=BIA-C1236&amp;name=Calcimycin&amp;searchtermf=Ionophore Calcimycin] from Bioaustralis, a vendor's product page

[[Category:Antibiotics]]
[[Category:Ionophores]]
[[Category:Benzoxazoles]]
[[Category:Pyrroles]]</text>
      <sha1>tpcq04khtj2x34vtzyadye52a6o5xyg</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Blasticidin S</title>
    <ns>0</ns>
    <id>15470327</id>
    <revision>
      <id>586821914</id>
      <parentid>545125309</parentid>
      <timestamp>2013-12-19T18:48:21Z</timestamp>
      <contributor>
        <ip>146.189.161.225</ip>
      </contributor>
      <comment>/* Mechanism of action */</comment>
      <text xml:space="preserve" bytes="3313">{{chembox
| verifiedrevid = 462805586
|ImageFile=Blasticidin S.png
|ImageSize=200px
|IUPACName=4-amino-1-[4-({('''3''S''''')-3-amino-5-&lt;nowiki&gt;[[&lt;/nowiki&gt;amino(imino)methyl](methyl)amino]pentanoyl}amino)-2,3,4-trideoxy-β-&lt;small&gt;D&lt;/small&gt;-''erythro''-hex-2-enopyranuronosyl]pyrimidin-2(1''H'')-one
|OtherNames=
|Section1={{Chembox Identifiers
|  CASNo_Ref = {{cascite|correct|??}}
| CASNo=2079-00-7
|  PubChem=258
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 476894
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = C02010
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 148673
|  SMILES = O=C1\N=C(\N)/C=C\N1[C@@H]\2O[C@H](C(=O)O)[C@H](/C=C/2)NC(=O)C[C@@H](N)CCN(C(=[N@H])N)C
|  InChI = 1/C17H26N8O5/c1-24(16(20)21)6-4-9(18)8-12(26)22-10-2-3-13(30-14(10)15(27)28)25-7-5-11(19)23-17(25)29/h2-3,5,7,9-10,13-14H,4,6,8,18H2,1H3,(H3,20,21)(H,22,26)(H,27,28)(H2,19,23,29)/t9-,10-,13+,14-/m0/s1
|  InChIKey = CXNPLSGKWMLZPZ-ZNIXKSQXBS
|  StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H26N8O5/c1-24(16(20)21)6-4-9(18)8-12(26)22-10-2-3-13(30-14(10)15(27)28)25-7-5-11(19)23-17(25)29/h2-3,5,7,9-10,13-14H,4,6,8,18H2,1H3,(H3,20,21)(H,22,26)(H,27,28)(H2,19,23,29)/t9-,10-,13+,14-/m0/s1
|  StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = CXNPLSGKWMLZPZ-ZNIXKSQXSA-N
  }}
|Section2={{Chembox Properties
|  C=17|H=26|N=8|O=5
|  MolarMass=422.44 g/mol
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3={{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}

'''Blasticidin S''' is an [[antibiotic]] that is produced by ''Streptomyces griseochromogenes''.  In biological research, specifically [[genetic engineering]], it is used to select transformed cells which have been engineered to carry a resistance gene for blasticidin.  In short, [[DNA]] of interest is fused to DNA encoding a resistance gene, and then is transformed into cells.  After allowing time for recovery and for cells to begin transcribing and translating their new DNA, blasticidin is added.  Now only the cells that have the new DNA can grow.

== Resistance genes ==
Three resistance genes have been cloned:

*  bls (an [[acetyl transferase]]) from ''Streptoverticillum sp.'' which itself produces blasticidin in a natural example of biological warfare
* bsr (a [[blasticidin-S deaminase]]) from ''Bacillus cereus'' (other bsr genes are known as well, see listings in [[Genbank]])
* BSD (another [[deaminase]]) from ''Aspergillus terreus''

bsr and BSD are the most commonly used resistance genes.  The proteins produced from these genes enable the cells carrying them to produce protein in the presence of blasticidin.

== Mechanism of action ==
Blasticidin prevents the growth of both [[eukaryotic]] and [[prokaryotic]] cells.  It works by inhibiting termination step of translation and peptide bond formation (to lesser extent) by the [[ribosome]].  This means that cells can no longer produce new proteins through [[translation_(genetics)| translation]] of [[mRNA]].

== References ==
* [http://www.blasticidin.com/ blasticidin.com]
* [http://www.uniprot.org/taxonomy/68214 Taxonomy of Streptomyces griseochromogenes]

[[Category:Antibiotics]]
[[Category:Genetic engineering]]
[[Category:Pyrimidones]]
[[Category:Guanidines]]</text>
      <sha1>k6j9o4pt8mx3ng2te6hm37b5zxtz1it</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Tunicamycin</title>
    <ns>0</ns>
    <id>13939854</id>
    <revision>
      <id>589789527</id>
      <parentid>584302800</parentid>
      <timestamp>2014-01-08T16:44:08Z</timestamp>
      <contributor>
        <ip>144.92.10.85</ip>
      </contributor>
      <comment>It does NOT block synthesis. It blocks glycosylation.</comment>
      <text xml:space="preserve" bytes="3998">{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 373567696
| ImageFile = Tunicamycin.svg
| ImageSize = 250px
| IUPACName = (E)-N-[(2S,3R,4R,5R,6R)-2-[(2R,3R,4R,5S,6R)-
3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-
6-[2-[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-
3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-
3-yl]-5-methylhex-2-enamide
| SystematicName = 
| OtherNames = NSC 177382
| Section1 = {{Chembox Identifiers
| Abbreviations = 
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 
11089-65-9 
| EINECS = 
| EINECSCASNO = 
| PubChem = 6433557
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 505513
| SMILES = CC(C)C\C=C\C(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)NC(=O)C)CC([C@@H]3[C@H]([C@H]
([C@@H](O3)N4C=CC(=O)NC4=O)O)O)O)O)O
| InChI = 
| RTECS = 
| MeSHName = Tunicamycin
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI =
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = 
| ATCCode_prefix = 
| ATCCode_suffix = 
| ATC_Supplemental =}}
| Section2 = {{Chembox Properties
| Formula = C&lt;sub&gt;39&lt;/sub&gt;H&lt;sub&gt;64&lt;/sub&gt;N&lt;sub&gt;4&lt;/sub&gt;O&lt;sub&gt;16&lt;/sub&gt;
| MolarMass = N/A
| Appearance = 
| Density = 
| MeltingPt = 
| Melting_notes = 
| BoilingPt = 
| Boiling_notes = 
| Solubility = 
| SolubleOther = 
| Solvent = 
| LogP = 
| VaporPressure = 
| HenryConstant = 
| AtmosphericOHRateConstant = 
| pKa = 
| pKb = }}
| Section3 = {{Chembox Structure
| CrystalStruct = 
| Coordination = 
| MolShape = }}
| Section4 = {{Chembox Thermochemistry
| DeltaHf = 
| DeltaHc = 
| Entropy = 
| HeatCapacity = }}
| Section5 = {{Chembox Pharmacology
| AdminRoutes = 
| Bioavail = 
| Metabolism = 
| HalfLife = 
| ProteinBound =
| Excretion = 
| Legal_status = 
| Legal_US = 
| Legal_UK = 
| Legal_AU = 
| Legal_CA = 
| PregCat = 
| PregCat_AU = 
| PregCat_US = }}
| Section6 = {{Chembox Explosive
| ShockSens = 
| FrictionSens = 
| ExplosiveV = 
| REFactor = }}
| Section7 = {{Chembox Hazards
| ExternalMSDS = 
| EUClass = 
| EUIndex = 
| MainHazards = 
| NFPA-H = 
| NFPA-F = 
| NFPA-R = 
| NFPA-O = 
| RPhrases = 28
| SPhrases = 28-37/39-45
| RSPhrases = 
| FlashPt = 
| Autoignition = 
| ExploLimits = 
| LD50 =
| PEL = }}
| Section8 = {{Chembox Related
| OtherAnions = 
| OtherCations = 
| OtherFunctn = 
| Function = 
| OtherCpds = }}
}}
'''Tunicamycin''' is a mixture of [[Homology (biology)|homologous]] [[nucleoside]] [[antibiotic]]s that inhibits the UDP-HexNAc: polyprenol-P HexNAc-1-P family of enzymes. In eukaryotes, this includes the enzyme GlcNAc phosphotransferase (GPT), which catalyzes the transfer of N-acetylglucosamine-1-phosphate from [[UDP-N-acetylglucosamine]] to [[dolichol phosphate]] in the first step of [[glycoprotein]] synthesis.  Tunicamycin blocks [[Glycosylation#N-linked glycosylation|N-linked glycosylation (N-glycans)]] and causes [[cell cycle]] arrest in [[G1 phase]]. It is used as an experimental tool in [[biology]], e.g. to induce [[unfolded protein response]].&lt;ref&gt;[http://www.fasebj.org/cgi/content/full/19/11/1510 Hepatitis C virus envelope proteins regulate CHOP via induction of ...]&lt;/ref&gt; Tunicamycin is produced by several [[bacteria]], including Streptomyces clavuligerus and Streptomyces Iysosuperficus. 

Tunicamycin homologues have varying molecular weights owing to the variability in fatty acids side chain conjugates.&lt;ref&gt;[http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Product_Information_Sheet/1/t7765pis.Par.0001.File.tmp/t7765pis.pdf] Tunicamycin product details]&lt;/ref&gt;

== See also ==

* [[Glycosylation]] - tunicamycin blocks all N-glycosylation of proteins
* [[Glycoprotein]]
* [[Streptomyces]] the genus

==References==
{{reflist}}

== External links ==

* Book section of Essentials in Glycobiology (1999) [http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=glyco.section.3051 Tunicamycin: Inhibition of DOL-PP-GlcNAc Assembly]
* [http://tunicamycin.noneto.com/ Tunicamycin data sheet] prepared by a student of the Open University, UK


[[Category:Antibiotics]]</text>
      <sha1>ewyd2w2vavkm5ibj0cdqlvkb5i856x9</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Dapsone</title>
    <ns>0</ns>
    <id>660116</id>
    <revision>
      <id>607486519</id>
      <parentid>605284263</parentid>
      <timestamp>2014-05-07T14:58:56Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Task 3: Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated coauthor parameter errors]]</comment>
      <text xml:space="preserve" bytes="21406">{{Drugbox
| verifiedrevid = 460773489
| IUPAC_name = 4-[(4-aminobenzene)sulfonyl]aniline
| image = Dapsone.svg
| image2 = Dapsone3d.png

&lt;!--Clinical data--&gt;
| tradename = Aczone
| Drugs.com = {{drugs.com|monograph|dapsone}}
| MedlinePlus = a682128
| pregnancy_AU = B2
| pregnancy_US = C
| legal_status = ℞-only &lt;small&gt;(U.S.)&lt;/small&gt;, [[Prescription drug|POM]] &lt;small&gt;(UK)&lt;/small&gt;
| routes_of_administration = Oral

&lt;!--Pharmacokinetic data--&gt;
| bioavailability = 70 to 80%
| protein_bound = 70 to 90%
| metabolism = [[Liver|Hepatic]] (mostly [[CYP2E1]]-mediated)
| elimination_half-life = 20 to 30 hours
| excretion = [[Kidney|Renal]]

&lt;!--Identifiers--&gt;
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 80-08-0
| ATC_prefix = D10
| ATC_suffix = AX05
| ATC_supplemental = {{ATC|J04|BA02}}
| PubChem = 2955
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00250
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2849
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 8W5C518302
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00592
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4325
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1043

&lt;!--Chemical data--&gt;
 | C=12 | H=12 | N=2 | O=2 | S=1 
| molecular_weight = 248.302 [[Gram|g]][[Mole (unit)|mol]]&lt;sup&gt;-1&lt;/sup&gt;
| smiles = O=S(=O)(c1ccc(N)cc1)c2ccc(N)cc2
| InChI = 1/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2
| InChIKey = MQJKPEGWNLWLTK-UHFFFAOYAJ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MQJKPEGWNLWLTK-UHFFFAOYSA-N
}}
'''Dapsone''' (diamino-diphenyl sulfone) is an [[antibacterial]] most commonly used in combination with [[rifampicin]] and [[clofazimine]] as multidrug therapy (MDT) for the treatment of ''[[Mycobacterium leprae]]'' infections ([[leprosy]]).  It is also second-line treatment for prophylaxis (prevention) against [[Pneumocystis pneumonia]] (PCP) caused by ''[[Pneumocystis jirovecii]]'' (formerly ''P. carinii'') in HIV patients in whom CD4 counts are below 200/mm&lt;sup&gt;3&lt;/sup&gt;.&lt;ref&gt;Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine, by Sabatine, 3rd Edition&lt;/ref&gt;

Dapsone is an odorless white to creamy-white crystalline powder with a slightly bitter taste, used in combination with [[pyrimethamine]] in the treatment of [[malaria]].&lt;ref&gt;{{cite pmid|19450348}}&lt;/ref&gt;&lt;ref&gt;{{cite pmid|17934257}}&lt;/ref&gt; Dapsone is commercially available in both topical and oral formulations.  Topical dapsone is available in a 5% gel formulation that is sold under the brand name Aczone and is produced by Allergan.  Oral dapsone is also available but is less commonly used than other sulfonamide antibiotics, many of which have a lower incidence of adverse effects.&lt;ref&gt;{{cite journal | pmid=11511841 |title=Dapsone and sulfones in dermatology: overview and update |year=2001 |last1=Zhu, et al. |journal=Journal of the American Academy of Dermatology | doi=10.1067/mjd.2001.114733 | first1=YI | last2=Stiller | first2=MJ | volume=45 | issue=3 | pages=420–34 }}&lt;/ref&gt;

&lt;!-- Society and culture --&gt;
It is on the [[World Health Organization's List of Essential Medicines]], a list of the most important medication needed in a basic [[health system]].&lt;ref&gt;{{cite web|title=WHO Model List of EssentialMedicines|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|work=World Health Organization|accessdate=22 April 2014|date=October 2013}}&lt;/ref&gt;

== Medical uses ==
As well as being used in leprosy, dapsone can also be used to treat mucous membrane [[pemphigoid]],&lt;ref name=&quot;pmid7037880&quot;&gt;{{cite journal |author=Rogers RS, Seehafer JR, Perry HO |title=Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone |journal=J. Am. Acad. Dermatol. |volume=6 |issue=2 |pages=215– |date=February 1982 |pmid=7037880 |doi= 10.1016/S0190-9622(82)70014-3|url=}}&lt;/ref&gt; (an autoimmune blistering disease of skin and mucous membranes), [[dermatitis herpetiformis]] and [[Linear immunoglobulin A dermatosis]], (both blistering skin diseases that are effectively treated with a long-time treatment with dapsone), and other skin conditions including [[lichen planus]].  Dapsone is also used in the treatment of [[pyostomatitis vegetans]], an oral manifestation of inflammatory bowel disease, commonly seen in patients with [[ulcerative colitis]].

It is also sometimes used to prevent [[Pneumocystis pneumonia]] (PCP) in immunosuppressed patients and to treat [[idiopathic thrombocytopenic purpura]].

It is used [[prophylaxis|prophylactically]] to prevent Pneumocystis pneumonia and [[toxoplasmosis]] in patients unable to tolerate [[trimethoprim]] with [[sulfamethoxazole]].&lt;ref name=&quot;AMH&quot;&gt;{{cite book | editor = Rossi S | title = [[Australian Medicines Handbook]]  | year = 2006 | location = Adelaide | isbn = 0-9757919-2-3}}&lt;/ref&gt;

Dapsone is also used to treat [[Brown recluse spider]] bites.&lt;ref name=&quot;pmid4051613&quot;&gt;{{cite journal |author=Rees RS, Altenbern DP, Lynch JB, King LE |title=Brown recluse spider bites. A comparison of early surgical excision versus dapsone and delayed surgical excision |journal=Ann. Surg. |volume=202 |issue=5 |pages=659–63 |date=November 1985 |pmid=4051613 |pmc=1250983 |doi= 10.1097/00000658-198511000-00020|url=}}&lt;/ref&gt; In presumed cases of [[brown recluse]] spider bites, dapsone is often used effectively, but clinical trials do not demonstrate similar effectiveness;&lt;ref&gt;{{cite journal | pmid = 15897381 | year = 2005 | last1 = Elston | first1 = DM | last2 = Miller | first2 = SD | last3 = Young Rj | first3 = 3rd | last4 = Eggers | first4 = J | last5 = McGlasson | first5 = D | last6 = Schmidt | first6 = WH | last7 = Bush | first7 = A | title = Comparison of colchicine, dapsone, triamcinolone, and diphenhydramine therapy for the treatment of brown recluse spider envenomation: A double-blind, controlled study in a rabbit model | volume = 141 | issue = 5 | pages = 595–7 | doi = 10.1001/archderm.141.5.595 | journal = Archives of dermatology}}&lt;/ref&gt; however, dapsone may be effective at treating many &quot;spider bites&quot; because many such cases are actually misdiagnosed microbial infections.&lt;ref name=&quot;AnnEmergMed2002-Vetter&quot;&gt;{{cite journal | author = Vetter R, Bush S | title = The diagnosis of brown recluse spider bite is overused for dermonecrotic wounds of uncertain etiology | journal = Ann Emerg Med | volume = 39 | issue = 5 | pages = 544–6 | year = 2002 | pmid = 11973562 | doi = 10.1067/mem.2002.123594}}&lt;/ref&gt;

Oral dapsone was one of the first medications used to treat moderate to severe acne vulgaris, and is still occasionally prescribed for the treatment of severe and abnormal acne (e.g. [[acne conglobata]] and [[acne fulminans]]).&lt;ref&gt;{{cite journal | pmid=14494150 |title=The treatment of acne vulgaris with dapsone |year=1961 |last1=Ross, et al. |journal=British Journal of Dermatology | doi=10.1111/j.1365-2133.1961.tb14398.x | first1=CM | volume=73 | pages=367–70 | issue=10 }}&lt;/ref&gt; Oral dapsone is generally reserved for cases where conventional treatments for severe acne, such as [[isotretinoin]] and first-line [[antibiotics]], are found to be ineffective.&lt;ref&gt;{{cite web|url=http://scienceofacne.com/dapsone-aczone/|title=Dapsone and Acne Vulgaris |publisher=ScienceOfAcne.com |date=2012-10-10 |accessdate=2012-08-17}}&lt;/ref&gt; In December 2008, a 5% dapsone gel called Aczone was introduced to the prescription market as a topical treatment for moderate to severe [[acne]].[http://www.aczone.com].  Preliminary reports suggest that topical dapsone is a safe and moderately effective acne treatment.&lt;ref&gt;{{cite journal | pmid=17208334 |title=Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris |year=2007 |last1=Draelos, et al. |journal=Journal of the American Academy of Dermatology | doi=10.1016/j.jaad.2006.10.005 | first1=ZD | last2=Carter | first2=E | last3=Maloney | first3=JM | last4=Elewski | first4=B | last5=Poulin | first5=Y | last6=Lynde | first6=C | last7=Garrett | first7=S | author8=United States/Canada Dapsone Gel Study Group | volume=56 | issue=3 | pages=439.e1–10 }}&lt;/ref&gt;

== Adverse effects ==
The dapsone hypersensitivity syndrome develops in 0.5-3.6% of persons treated with the drug, and is associated with a mortality of 9.9%.&lt;ref name=&quot;Zhang2013&quot;&gt;{{cite journal
| title =HLA-B*13:01 and the dapsone hypersensitivity syndrome.
| journal =N Engl J Med. 
| date =Oct 24, 2013
| author =
| authors =Zhang FR, Liu, H; Irwanto, A; et al. 
| volume =369
| issue =17
| pages =1620–8
| url =http://www.nejm.org/doi/full/10.1056/NEJMoa1213096
| doi =10.1056/NEJMoa1213096 
| pmid =24152261
| pmc =
}}&lt;/ref&gt;

=== Effects on the blood ===

The most prominent side-effects of this drug are dose-related [[hemolysis]] (which may lead to [[hemolytic anemia]]) and [[methemoglobinemia]].&lt;ref&gt;Jopling WH. Side-effects of antileprosy drugs in common use. Lepr Rev 1983; 54: 261–70.&lt;/ref&gt; About 20% of patients treated with dapsone suffer hemolysis &lt;ref&gt;{{cite journal |author=Puavilai S, Chutha S, Polnikorn N, et al. |title=Incidence of anemia in leprosy patients treated with dapsone |journal=J Med Assoc Thai |volume=67 |issue=7 |pages=404–7 |date=July 1984 |pmid=6512448 |doi= |url=}}&lt;/ref&gt; and the side-effect is more common and severe in those with [[glucose-6-phosphate dehydrogenase deficiency]], leading to the dapsone-containing antimalarial combination Lapdap being withdrawn from clinical use.&lt;ref&gt;http://www.who.int/medicines/publications/drugalerts/Alert_117_LapDap.pdf&lt;/ref&gt;&lt;ref&gt;{{cite journal |author=Luzzatto L |title=The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics |journal=Lancet |volume=376 |issue=9742 |pages=739–41 |date=August 2010 |pmid=20599264 |doi=10.1016/S0140-6736(10)60396-0 |url=}}&lt;/ref&gt; [[Agranulocytosis]] occurs rarely when dapsone is used alone but more frequently in combination regimens for malaria prophylaxis.&lt;ref&gt;Firkin FC, Mariani AF. Agranulocytosis due to dapsone. Med J Aust 1977; 2: 247–51.&lt;/ref&gt; Abnormalities in [[white blood cell]] formation, including [[aplastic anemia]], are rare, yet are the cause of the majority of deaths attributable to dapsone therapy.&lt;ref&gt;Foucauld J, et al. Dapsone and aplastic anemia. Ann Intern Med 1985; 102: 139.&lt;/ref&gt;&lt;ref&gt;Meyerson MA, Cohen PR. Dapsone-induced aplastic anaemia in a woman with bullous systemic lupus erythematosus. Mayo Clin Proc 1994; 69: 1159–62.&lt;/ref&gt;&lt;ref&gt;Björkman A, Phillips-Howard PA. Adverse reactions to sulfa drugs: implications for malaria chemotherapy. Bull WHO 1991; 69: 297–304.&lt;/ref&gt;

=== Effects on the liver ===

Toxic [[hepatitis]] and [[cholestatic jaundice]] have been reported by the manufacturer. [[Jaundice]] may also occur as part of the '''dapsone reaction''' or '''dapsone syndrome''' (see below). Dapsone is metabolized by the Cytochrome P450 system, specifically isozymes CYP2D6, CYP2B6, CYP3A4, and CYP2C19.&lt;ref&gt;{{cite journal|last=Ganesan|first=S|coauthors=Sahu, R; Walker, LA; Tekwani, BL|title=Cytochrome P450-dependent toxicity of dapsone in human erythrocytes|journal=J Appl Toxicol|date=April 2010|year=2010|volume=30|issue=3|pages=271–5|doi=10.1002/jat.1493|pmid=19998329|url=http://www.ncbi.nlm.nih.gov/pubmed/19998329|accessdate=7 March 2013}}&lt;/ref&gt; Dapsone metabolites produced by the cytochrome P450 2C19 isozyme are associated with the '''[[methemoglobinemia]]''' side effect of the drug.

=== Dermatologic ===

When used topically, dapsone can cause mild skin irritation, redness, dry skin, burning and itching. When used together with benzoyl peroxide products, temporary yellow or orange skin discolorations can occur.&lt;ref&gt;Aczone(Dapsone) Package insert. Irvine CA: Allergan Inc; September 2008&lt;/ref&gt;&lt;ref&gt;http://pharmacistanswers.com/medications-for-acne-guide.html&lt;/ref&gt;

=== Other adverse effects ===

Other adverse effects include [[nausea]], [[headache]], and [[rash]] (which are common), and [[insomnia]], [[psychosis]], and [[peripheral neuropathy]]. Effects on the [[lung]] occur rarely and may be serious, though are generally reversible.&lt;ref&gt;Jaffuel D, et al. Eosinophilic pneumonia induced by dapsone. BMJ 1998; 317: 181.&lt;/ref&gt;

=== Dapsone reaction ===

[[Hypersensitivity]] reactions occur in some patients. This reaction may be more frequent in patients receiving multiple-drug therapy.&lt;ref&gt;Richardus JH, Smith TC. Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy. Lepr Rev 1989; 60: 267–73.&lt;/ref&gt;&lt;ref&gt;Kumar RH, et al. Dapsone syndrome—a five year retrospective analysis. Indian J Lepr 1998; 70: 271–6.&lt;/ref&gt;&lt;ref&gt;Rao PN, Lakshmi TSS. Increase in the incidence of dapsone hypersensitivity syndrome—an appraisal. Lepr Rev 2001; 72: 57–62.&lt;/ref&gt;

The reaction always involves a [[rash]] and may also include [[fever]], jaundice, and [[eosinophilia]].&lt;ref&gt;Joseph MS. Hypersensitivity reaction to dapsone. Lepr Rev 1985; 56: 315–20.&lt;/ref&gt;&lt;ref&gt;Jamrozik K. Dapsone syndrome occurring in two brothers. Lepr Rev 1986; 57: 57–62.&lt;/ref&gt;&lt;ref&gt;Hortaleza AR, et al. Dapsone syndrome in a Filipino man. Lepr Rev 1995; 66: 307–13.&lt;/ref&gt;&lt;ref&gt;Tomecki KJ, Catalano CJ. Dapsone hypersensitivity: the sulfone syndrome revisited. Arch Dermatol 1981; 117: 38–9.&lt;/ref&gt;&lt;ref&gt;Kromann NP, et al. The dapsone syndrome. Arch Dermatol 1982; 118: 531–2.&lt;/ref&gt; In general, these symptoms will occur within the first six weeks of therapy or not at all, and may be ameliorated by [[corticosteroid]] therapy.&lt;ref name=&quot;AMH&quot; /&gt;

==Mechanism==
As an [[antibacterial]], dapsone inhibits [[bacteria]]l synthesis of [[dihydrofolic acid]], via competition with [[4-Aminobenzoic acid|para-aminobenzoate]] for the active site of dihydropteroate synthetase.&lt;ref&gt;{{cite web |url=http://www.medscape.com/viewarticle/440403_5 |title=Medscape.com |format= |work= |accessdate=2009-02-24}}&lt;/ref&gt; Though structurally distinct from dapsone, the sulfonamide group of antibacterial drugs also work in this way.

When used for the treatment of skin conditions in which bacteria do not have a role, the mechanism or action of dapsone is not well understood. Dapsone has [[anti-inflammatory]] and immunomodulatory effects,&lt;ref&gt;{{cite journal |author=Begon E, Chosidow O, Wolkenstein P |title=[Disulone] |language=French |journal=Ann Dermatol Venereol |volume=131 |issue=12 |pages=1062–73 |date=December 2004 |pmid=15692440 |doi= 10.1016/S0151-9638(04)93842-2|url=}}&lt;/ref&gt; which are thought to come from the drug's blockade of [[myeloperoxidase]]. This is thought to be its mechanism of action in treating [[dermatitis herpetiformis]].&lt;ref&gt;{{cite journal |author=Uetrecht JP |title=Myeloperoxidase as a generator of drug free radicals |journal=Biochem. Soc. Symp. |volume=61 |issue= |pages=163–70 |year=1995 |pmid=8660393 |doi= |url=}}&lt;/ref&gt;

As part of the [[respiratory burst]] that [[neutrophil]]s use to kill bacteria, myeloperoxidase converts hydrogen peroxide (H&lt;sub&gt;2&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt;) into hypochlorous acid (HOCl). HOCl is the most potent oxidant generated by neutrophils, and can cause significant tissue damage during inflammation.&lt;!-- The respiratory burst uses large quantities of oxygen, and a single neutrophil may produce enough HOCl in one second to destroy 150 bacteria.&lt;ref&gt;Weiss S. Tissue destruction by neutrophil. N Engl J Med 1989; 320:365-392.&lt;/ref&gt; In the absence of chloride ions or when there is excess hydrogen peroxide, the myeloperoxidase is converted to its inactive form. - SEEMS EXCESSIVE IN THIS CONTEXT--&gt; Dapsone arrests myeloperoxidase in an inactive intermediate form, reversibly inhibiting the enzyme.  This prevents accumulation of hypochlorous acid, and reduces tissue damage during inflammation.&lt;ref&gt;Bozeman P, Learn D, Thomas E. Assay of the human leukocyte encymes myeloperoxidase and eosinophil peroxidase. J Immunol Methods 1990; 126:125-133.&lt;/ref&gt;&lt;ref&gt;Bozeman P, Learn D, Thomas E. Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Biochem Pharmacol 1992; 44:553-563.&lt;/ref&gt;&lt;ref&gt;Stendahl O, Molin L, Lindroth M. Granulocyte-mediated release of histamine from mast cells. Effect of myeloperoxidase and its inhibition by antiinflammatory sulfone compounds. Int Arch Allergy Appl Immunol 1983; 70:277-284.&lt;/ref&gt;&lt;ref&gt;Kettle A, Gedye C, Winterbourn C. Superoxide is an antagonist of antiinflammatory drugs that inhibit hypochlorous acid production by myeloperoxidase. Biochem Pharmacol 1993; 45:2003-2010.&lt;/ref&gt;&lt;ref&gt;Kettle A, Winterbourn C. Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs. Biochem Pharmacol 1991; 41:1485-1492.&lt;/ref&gt;

Myeloperoxidase inhibition has also been suggested as a neuron-sparing mechanism for reducing inflammation in neurodegenerative diseases such as [[Alzheimer's disease]] and stroke.&lt;ref&gt;{{cite journal |author=Diaz-Ruiz A, Zavala C, Montes S, et al. |title=Antioxidant, antiinflammatory and antiapoptotic effects of dapsone in a model of brain ischemia/reperfusion in rats |journal=J. Neurosci. Res. |volume=86 |issue=15 |pages=3410–9 |date=November 2008 |pmid=18615706 |doi=10.1002/jnr.21775 |url=}}&lt;/ref&gt;

Though dapsone is an anti-inflammatory agent and not a steroid, it does not fit the usual definition of an [[NSAID]]. By definition, NSAIDs block [[cyclo-oxygenase]] as their primary mechanism of action, which dapsone does not do.

==Synthesis==
Dapsone was first synthesized by Fromm and Wittmann in 1908. 4,4'-Dinitrodiphenyl sulfide was oxidized to the sulfone in a solution of [[potassium dichromate]], [[glacial acetic acid]], and [[sulfuric acid]]. The nitro- groups on the sulfone were reduced with tin and concentrated hydrochloric acid, and the free base obtained by treatment with an alkali:&lt;ref&gt;{{cite journal | doi = 10.1002/cber.190804102131 | journal = [[Chemische Berichte|Ber.]] | author = E. Fromm, J. Wittmann | title = Derivate des p-Nitrothiophenols | year = 1908 | volume = 41 | issue = 2 | pages = 2264}}&lt;/ref&gt;

:[[Image:Synthesis of dapsone.png|600px]]

== Administration ==
To deal with dapsone-resistant leprosy cases, multidrug therapy was introduced by WHO in 1981; dapsone is administered along with rifampin and clofazimine or other antileprotic drugs.

== Specific considerations ==

Certain patients are at higher risks of adverse effects when using dapsone. Some specific issues that should be considered are:&lt;ref name=&quot;AMH&quot; /&gt;

* Related to the blood (a [[full blood count]] should be obtained prior to initiating therapy):
** [[Porphyria]]
** [[Anemia]]
** [[Cardiac disease]]
** [[Pulmonary disease]]
** [[HIV]] infection
** [[G6PD deficiency]]

* Related to the liver (obtain [[liver function test]]s before starting therapy):
** Liver impairment

* Related to [[allergy]]:
** Sulfonamide allergy is associated with dapsone allergy

Patients with [[Diabetes mellitus]] have been seen to exhibit unexpectedly low [[HbA1c]] results when taking Dapsone, and HbA1c i an unreliable test in states of increased red cell turnover, e.g. a drug induced haemolytic anaemia.

== History ==
In the early 20th century, the German chemist [[Paul Ehrlich]] was developing theories of [[selective toxicity]] based largely on the ability of certain [[dye]]s to kill [[microbe]]s. [[Gerhard Domagk]], who would later win a [[Nobel Prize]] for his efforts, made a major breakthrough in 1932 with the discovery of the antibacterial [[prontosil|prontosil red]] (sulfonamidochrysoidine). Further investigation into the involved chemicals opened the way to [[sulfa drug]] and [[sulfone|sulfone therapy]], first with the discovery of [[sulfanilamide]], the active agent of prontosil, by [[Daniel Bovet]] and his team at [[Pasteur Institute]] (1935),&lt;ref&gt;J. et T. Tréfouël, F. Nitti et D. Bovet, « Activité du p.aminophénylsulfamide sur l’infection streptococcique expérimentale de la souris et du lapin », ''C. R. Soc. Biol.'', 120, 23 novembre 1935, p. 756.&lt;/ref&gt; then with of dapsone independently by [[Ernest Fourneau]]&lt;ref&gt;E. Fourneau, Th. et J. Tréfouël, F. Nitti, D. Bovet, « Action antistreptococcique des dérivés sulfurés organiques », ''C. R. Acad. Sci.'', vol. 204, 1937, p. 1763.&lt;/ref&gt; in France and Gladwin Buttle&lt;ref&gt;G. Buttle, Y. Smith, G. Foster, « Treatment of streptococcal infections in mice with 4:4'diamino-dipheni-sulphone », ''Lancet'', vol. 1, 1937, p. 133.&lt;/ref&gt; in United-Kingdom.&lt;ref name=&quot;urlLeprosy | 14 History of dapsone and dyes&quot;&gt;{{cite web |url=http://www.itg.be/itg/DistanceLearning/LectureNotesVandenEndenE/22_Leprosyp14.htm |title=Leprosy &amp;#124; 14 History of dapsone and dyes |work= |accessdate=2009-02-24}} (1937)&lt;/ref&gt;

== References ==

{{reflist|2}}

== External links ==
*[http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682128.html MedlinePlus Drug Information]
* [http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Dapsone U.S. National Library of Medicine: Drug Information Portal - Dapsone]

{{Antimycobacterials}}
{{Nucleic acid inhibitors}}
{{Acne Agents}}

[[Category:Anilines]]
[[Category:Sulfones]]
[[Category:Dihydropteroate synthetase inhibitors]]
[[Category:Antibiotics]]
[[Category:Anti-acne preparations]]
[[Category:Leprosy]]
[[Category:World Health Organization essential medicines]]</text>
      <sha1>c9w0gcpnmmp02ecem9vz02hpdywpw42</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Telavancin</title>
    <ns>0</ns>
    <id>15929035</id>
    <revision>
      <id>600743143</id>
      <parentid>588675854</parentid>
      <timestamp>2014-03-22T15:31:17Z</timestamp>
      <contributor>
        <username>Citation bot</username>
        <id>7903804</id>
      </contributor>
      <minor/>
      <comment>[Cat543-dev]Add: year, pmid, display-authors, author pars. 2-15. You can [[WP:UCB|use this bot]] yourself. [[WP:DBUG|Report bugs here]].</comment>
      <text xml:space="preserve" bytes="9193">{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477861289
| image = Telavancin.png
| width = 200px
| IUPAC_name = (1''S'',2''R'',18''R'',19''R'',22''S'',25''R'',28''R'',40''S'')-22-(2-Amino-2-oxoethyl)-5,15-dichloro-48-{[2-''O''-(3-{[2-(decylamino)ethyl]amino}-2,3,6-trideoxy-3-methyl-α-&lt;small&gt;L&lt;/small&gt;-lyxo-hexopyranosyl)-β-&lt;small&gt;D&lt;/small&gt;-glucopyranosyl]oxy}-2,18,32,35,37-pentahydroxy-19-[(''N''-methyl-&lt;small&gt;D&lt;/small&gt;-leucyl)amino]-20,23,26,42,44-pentaoxo-36-{[(phosphonomethyl)amino]methyl}-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2&lt;sup&gt;3,6&lt;/sup&gt;.2&lt;sup&gt;14,17&lt;/sup&gt;.1&lt;sup&gt;8,12&lt;/sup&gt;.1&lt;sup&gt;29,33&lt;/sup&gt;.0&lt;sup&gt;10,25&lt;/sup&gt;.0&lt;sup&gt;34,39&lt;/sup&gt;]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid

&lt;!--Clinical data--&gt;
| tradename = Vibativ
| Drugs.com = {{drugs.com|monograph|telavancin-hydrochloride}}
| MedlinePlus = a610004
| licence_US = Telavancin
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = C
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, or Class A, B, C --&gt;
| legal_US = Rx-only
| routes_of_administration = intravenous

&lt;!--Pharmacokinetic data--&gt;
| bioavailability = N/A
| protein_bound     = 90%, mostly to [[albumin]]
| metabolism        = 
| elimination_half-life = 9 hours
| excretion         = 76% in urine, &lt;1% in feces

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 372151-71-8
| ATC_prefix = J01
| ATC_suffix = XA03
| PubChem = 3081362
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 71229
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2338980
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = XK134822Z0
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 607993

&lt;!--Chemical data--&gt;
| C=80 | H=106 | Cl=2 | N=11 | O=27 | P=1 
| molecular_weight = 1755.63 g/mol
| smiles = CCCCCCCCCCNCCN[C@]1(C[C@@H](O[C@H]([C@H]1O)C)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C(=C(C=C9[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)O)CNCP(=O)(O)O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C80H106Cl2N11O27P/c1-7-8-9-10-11-12-13-14-21-85-22-23-87-80(5)32-57(115-37(4)71(80)103)119-70-68(102)67(101)55(34-94)118-79(70)120-69-53-28-41-29-54(69)117-52-20-17-40(27-46(52)82)65(99)63-77(109)91-61(78(110)111)43-30-50(96)44(33-86-35-121(112,113)114)66(100)58(43)42-25-38(15-18-49(42)95)59(74(106)93-63)90-75(107)60(41)89-73(105)48(31-56(83)97)88-76(108)62(92-72(104)47(84-6)24-36(2)3)64(98)39-16-19-51(116-53)45(81)26-39/h15-20,25-30,36-37,47-48,55,57,59-65,67-68,70-71,79,84-87,94-96,98-103H,7-14,21-24,31-35H2,1-6H3,(H2,83,97)(H,88,108)(H,89,105)(H,90,107)(H,91,109)(H,92,104)(H,93,106)(H,110,111)(H2,112,113,114)/t37-,47+,48-,55+,57-,59+,60+,61-,62+,63-,64+,65+,67+,68-,70+,71+,79-,80-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ONUMZHGUFYIKPM-MXNFEBESSA-N
}}

'''Telavancin''' (trade name '''Vibativ''') is a [[bactericidal]] [[lipoglycopeptide]] for use in [[Methicillin-resistant Staphylococcus aureus|MRSA]] or other [[Gram-positive]] infections. Telavancin is a semi-synthetic derivative of [[vancomycin]].&lt;ref&gt;Astellas, Inc. ''VIBATIV prescribing information'', 9/2009.&lt;/ref&gt;&lt;ref name=HIG2005/&gt;

The FDA approved the drug in September 2009 for [[complicated skin and skin structure infection]]s (cSSSI),&lt;ref name=TA-FDA/&gt; and in June 2013 for [[Hospital-acquired pneumonia|hospital-acquired]] and ventilator-associated bacterial pneumonia caused by [[Staphylococcus aureus]].&lt;ref&gt;http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm358209.htm&lt;/ref&gt;

==History==
On 19 October 2007, the [[United States|US]] [[Food and Drug Administration]] (FDA) issued an [[approvable letter]] for telavancin. Its developer, [[Theravance]], submitted a complete response to the letter, and the FDA has assigned a [[Prescription Drug User Fee Act]] (PDUFA) target date of 21 July 2008.&lt;ref&gt;{{Cite web|url=http://www.drugs.com/nda/telavancin_080306.html |title=Drugs.com, FDA Accepts for Review Response to Approvable Letter for Telavancin |accessdate=2008-03-08 |work= }}&lt;/ref&gt;

On 19 November 2008, an FDA antiinfective drug advisory committee concluded that they would recommend telavancin be approved by the FDA.

The FDA approved the drug on 11 September 2009 for complicated skin and skin structure infections ([[cSSSI]]).&lt;ref name=TA-FDA&gt;{{cite press release
  | title = Theravance and Astellas Announce FDA Approval of Vibativ (telavancin) for the Treatment of Complicated Skin and Skin Structure Infections
  | publisher = Theravance, Inc. and Astellas Pharma US, Inc.
  | date = 2009-09-11
  | url = http://www.drugs.com/newdrugs/theravance-astellas-announce-fda-approval-vibativ-telavancin-complicated-skin-skin-structure-1629.html
  | accessdate = 16 September 2009
}}&lt;/ref&gt;

Theravance has also submitted telavancin to the FDA in a second indication, [[nosocomial pneumonia]], sometimes referred to as hospital-acquired pneumonia, or HAP. On 30 November 2012, an FDA advisory panel endorsed approval of a once-daily formulation of telavancin for nosocomial pneumonia when other alternatives are not suitable. However, telavancin did not win the advisory committee's recommendation as first-line therapy for this indication. The committee indicated that the trial data did not prove &quot;substantial evidence&quot; of telavancin's safety and efficacy in hospital-acquired pneumonia, including ventilator-associated pneumonia caused by Gram-positive organisms ''Staphylococcus aureus'' and ''Streptococcus pneumoniae''.&lt;ref&gt;[http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/11/theravance-vibativ-pneumonia.html FDA advisory group gives mixed review of Theravance pneumonia treatment. 30 Nov 2012] American City Business Journals/San Francisco/BiotechSF blog&lt;/ref&gt; On 21 June 2013 FDA gave approval for telavancin to treat patients with hospital-acquired pneumonia, but indicated it should be used only when alternative treatments are not suitable. FDA staff had indicated telavancin has a &quot;substantially higher risk for death&quot; for patients with kidney problems or diabetes compared to vancomycin.&lt;ref&gt;Leuty, Ron. [http://www.bizjournals.com/sanfrancisco/blog/biotech/2013/06/theravance-mrsa-vibativ-pneumonia.html Theravance gets FDA OK for antibiotic against pneumonia, with limits.] San Francisco Business Times. Jun 21, 2013.&lt;/ref&gt;

==Mechanism of action==
Like vancomycin, telavancin inhibits bacterial [[cell wall]] synthesis by binding to the &lt;small&gt;D&lt;/small&gt;-[[Alanine|Ala]]-&lt;small&gt;D&lt;/small&gt;-Ala terminus of the peptidoglycan in the growing cell wall (see [[Vancomycin#Pharmacology and chemistry|Pharmacology and chemistry of vancomycin]]). In addition, it disrupts bacterial [[Biological membrane|membranes]] by [[depolarization]].&lt;ref name=HIG2005&gt;{{Cite journal| url=http://aac.asm.org/cgi/content/full/49/3/1127| title=Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus| journal=Antimicrobial Agents and Chemotherapy| pages=1127–1134| volume=49| issue=3| year=2005| doi=10.1128/AAC.49.3.1127-1134.2005| pmid=15728913| last1=Higgins| first1=DL| last2=Chang| first2=R| last3=Debabov| first3=DV| last4=Leung| first4=J| last5=Wu| first5=T| last6=Krause| first6=KM| last7=Sandvik| first7=E| last8=Hubbard| first8=JM| last9=Kaniga| first9=K| last10=Schmidt| first10=D. E.| last11=Gao| first11=Q.| last12=Cass| first12=R. T.| last13=Karr| first13=D. E.| last14=Benton| first14=B. M.| last15=Humphrey| first15=P. P.| pmc=549257| display-authors=8}}&lt;/ref&gt;&lt;ref&gt;{{Cite journal
 | author = H. Spreitzer
 | date = 2 February 2009
 | title = Neue Wirkstoffe - Telavancin
 | journal = Österreichische Apothekerzeitung
 | issue = 3/2009
 | language = German
 }}&lt;/ref&gt;

==Adverse effects==
Common but harmless adverse effects include nausea, vomiting, constipation, and headache.&lt;ref name=&quot;Drugs.com&quot;&gt;Telavancin hydrochloride {{drugs.com|monograph|telavancin-hydrochloride}}&lt;/ref&gt;

Telavancin has a higher rate of kidney failure than [[vancomycin]] in two clinical trials.&lt;ref&gt;{{cite journal
| author = Saravolatz LD, Stein GE, Leonard B. Johnson LB
| title = Telavancin: a novel lipoglycopeptide
| journal = Clinical Infectious Diseases
| volume = 49
| issue = 12
| pages = 1908–1914
| doi = 10.1086/648438
| pmid = 19911938
| year = 2009
| last2 = Stein
| last3 = Johnson
}}&lt;/ref&gt; It showed [[teratogenic]] effects in animal studies.&lt;ref name=&quot;Drugs.com&quot; /&gt;

==Interactions==
Telavancin inhibits the liver enzymes [[CYP3A4]] and [[CYP3A5]]. No data regarding the clinical relevance are available.&lt;ref name=&quot;Drugs.com&quot; /&gt;

==References==
{{Reflist}}

==External links==
* [http://www.theravance.com Theravance, Inc.]
* [http://www.vibativ.com/ Vibativ information]

{{Cell wall disruptive antibiotics}}

[[Category:Antibiotics]]
[[Category:Halogen-containing natural products]]</text>
      <sha1>hub5g9u5tc87jn7tha823xwt7imil42</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Thiostrepton</title>
    <ns>0</ns>
    <id>16860881</id>
    <revision>
      <id>601710212</id>
      <parentid>593180810</parentid>
      <timestamp>2014-03-28T20:55:29Z</timestamp>
      <contributor>
        <ip>129.89.179.69</ip>
      </contributor>
      <comment>Corrected one typo.</comment>
      <text xml:space="preserve" bytes="7926">{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 386192575
|Reference=&lt;ref&gt;''[[Merck Index]]'', 11th Edition, '''9295'''.&lt;/ref&gt;
|ImageFile=Thiostrepton.png
|ImageSize=250px
|IUPACName=
|OtherNames=Alaninamide, Bryamycin, Thiactin 
|Section1={{Chembox Identifiers
|  CASNo_Ref = {{cascite|correct|??}}
| CASNo=1393-48-2
|  PubChem=16130278
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 468719
|  SMILES=C[C@@H](O)[C@@](C)(O)[C@@H](C2=NC6=CS2)NC(C1CSC(/C(NC([C@@H](NC(C3=CS[C@]([C@]4(NC([C@@H](NC(C(NC([C@H](C)NC%10=O)=O)=C)=O)C)=O)C(C5=CSC([C@H]([C@@H](C)OC(C8=CC([C@H](C)O)=C(C=CC(N[C@]([H])%10[C@H](CC)C)[C@@H]9O)C9=N8)=O)NC6=O)=N5)N=C(C7=NC(C(NC(C(NC(C(N)=O)=C)=O)=C)=O)=CS7)CC4)=N3)=O)[C@@H](C)O)=O)=C/C)=N1)=O
  }}
|Section2={{Chembox Properties
|  Formula=C&lt;sub&gt;72&lt;/sub&gt;H&lt;sub&gt;85&lt;/sub&gt;N&lt;sub&gt;19&lt;/sub&gt;O&lt;sub&gt;18&lt;/sub&gt;S&lt;sub&gt;5&lt;/sub&gt;
|  MolarMass=1664.83 g/mol
|  Appearance=White to off-white powder 
|  Density=
|  MeltingPt=246−256&amp;nbsp;°C 
|  BoilingPt=
|  Solubility= Insoluble
| SolubleOther = Soluble in CHCl&lt;sub&gt;3&lt;/sub&gt;, CH&lt;sub&gt;2&lt;/sub&gt;Cl&lt;sub&gt;2&lt;/sub&gt;, dioxane, pyridine, glacial acetic acid, DMF. Practically insoluble in the lower alcohols, nonpolar organic solvents, diluted aqueous acids or bases. May be dissolved by methanolic acid or base, but with decomposition.&lt;ref&gt;[http://www.fermentek.co.il/Thiostrepton.htm Thiostrepton product page] at [[Fermentek]]&lt;/ref&gt;
| Solvent = other solvents
  }}
|Section3={{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}

'''Thiostrepton''' is a natural cyclic [[oligopeptide]] [[antibiotic]], derived from several strains of [[Streptomyces|streptomycetes]], such as ''[[Streptomyces azureus]]'' and ''[[Streptomyces laurentii]]''.

== History ==

Thiostrepton was discovered by Donovick ''et al.'' who described its antibacterial properties in 1955.&lt;ref&gt;{{cite journal | author = Donovick R, Pagano JF, Stout HA, Weinstein MJ | journal = [[Antibiot Annu]] | year = 1955 | volume = 3 | pages =554–9}}&lt;/ref&gt;  [[Dorothy Crowfoot Hodgkin]] solved the structure of thiostrepton in 1970.&lt;ref&gt;{{cite journal | author = Anderson B, Crowfoot Hodgkin D, Viswamitra MA | journal = [[Nature (journal)|Nature]] | year = 1970 | volume = 225 | pages = 223–235 | doi = 10.1038/225233a0 | title = The Structure of Thiostrepton | issue=5229}}&lt;/ref&gt;
Early in 1978, Bycroft and Gowland&lt;ref&gt;B. W. Bycroft, M. S. Gowland, J. Chem. Soc. Chem. Commun. 1978, 256-258&lt;/ref&gt; proposed the biosynthesis of thiostrepton, which was still unclear until 2009. Several studies of thiopeptide biosynthesis&lt;ref&gt;L.C Wieland Brown, M. G. Acker, J. Clardy, C. T. Walsh, M. A. Fischbach, Proc. Natl. Acad. Sci. USA 2009, 106, 2549-2553&lt;/ref&gt;&lt;ref&gt;R. P. Morris, J. A. Leeds, H.-U. Nageli, L. Oberer, K. Memmert, E. Weber, M. J. LaMarche, C. N. Parker, N. Burrer, S. Esterow, A. E. Hein, E. K. Schmitt, P. Krastel, J. Am. Chem. Soc. 2009, 131, 5946-5955.&lt;/ref&gt;&lt;ref&gt;R. Liao, L. Duan, C. Lei, H. Pan, Y. Ding, Q. Zhang, D. Chen, B. Shen, Y. Yu, W. Liu_, Chem. Biol_. 2009, 16, 141-147.&lt;/ref&gt;&lt;ref&gt;W. L. Kelly, L. Pan, C. Li, J. Am. Chem. Soc. 2009, 131, 4327-4334&lt;/ref&gt; have been contemporarily published in 2009 and two of them (Liao ''et al.'' and Kelly ''et al.'') included the similar biosynthesis of thiostrepton: it's ribosomally synthesized from thiostrepton biosynthetic genes (tsr genes) and posttranslational modification is needed.

A total synthesis of Thiostrepton was completed by [[K.C. Nicolaou]], ''et al.'' in 2005.&lt;ref&gt;K. C. Nicolaou, B. S. Safina, M. Zak, S. H. Lee, M. Nevalainen, M. Bella, A. A. Estrada, C. Funke, F. J. Zecri, S. Bulat, J. Am. Chem. Soc. 2005, 127, 11176-11183&lt;/ref&gt;&lt;ref&gt;K. C. Nicolaou, M. Zak, B. S. Safina, A. A. Estrada, S. H. Lee, M. Nevalainen, J. Am. Chem. Soc. 2005, 127, 11159-11175&lt;/ref&gt;

== Applications ==

Thiostrepton  has been used in veterinary medicine in [[mastitis]] caused by [[gram-negative]] organisms and in dermatologic disorders. It is mostly used in complex ointments containing [[neomycin]], [[nystatin]], Thiostrepton and topical [[steroid]]s. It is also active against gram-positive bacteria. It is notable that ointments for human usage contain [[neomycin]], [[nystatin]], and topical [[steroid]]s, but no Thiostrepton.

Thiostrepton was reported (in 2008) to exhibit activity against breast cancer cells through targeting the transcription factor [[FOXM1|forkhead box M1]] ([[FOXM1]]).,&lt;ref&gt;{{cite journal |author=Kwok JM, Myatt SS, Marson CM, Coombes RC, Constantinidou D, Lam EW |title=Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression |journal=Mol. Cancer Ther. |volume=7 |issue=7 |pages=2022–32 |date=July 2008 |pmid=18645012 |doi=10.1158/1535-7163.MCT-08-0188 |url=}}&lt;/ref&gt; also in 2011.&lt;ref&gt;http://www.news-medical.net/news/20110822/Scientists-reveal-how-thiostrepton-blocks-FOXM1-protein-prevents-breast-cancer-development.aspx Scientists reveal how thiostrepton blocks FOXM1 protein, prevents breast cancer development. 2011&lt;/ref&gt;
It has also been shown to circumvent acquired cisplatin resistance in breast cancer cells under in invitro conditions.&lt;ref&gt;{{cite journal
 | journal=[[Molecular Cancer Research]]
 |date=January 2010
 | volume = 8
 | issue = 1
 | pages = 24–34
 | pmid = 20068070
 | title=FOXM1 confers acquired cisplatin resistance in breast cancer cells
 | author=Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, Coombes RC, Myatt SS, Lam EW.
 | doi=10.1158/1541-7786.MCR-09-0432
 | pmc=2809047
 }}&lt;/ref&gt;

Thiostrepton is used in molecular biology as a reagent for both positive and negative selection of genes involved in nucleotide metabolism.

== Biosynthesis ==

There are total 21 genes (tsrA~tsrU) in the biosynthetic gene cluster. The precursor of thiostrepton contains 58 amino acids in the peptide chain, which includes 41-aa leading peptide (LP) and 17-aa structural peptide (IASASCTTCICTCSCSS). Once the precursor is synthesized, cyclodehydratase tsrO and dehydrogenase tsrM catalyze the formation of thiazole or thiazoline from every cysteine residues in the peptide chain. After thiazole/thiazoline formation, dehydratases tsrJ, K and S then convert all the serine residues into dehydroalanines. A hetero Diels-Alder cyclization of the central dehydropiperidine (at S5, C13, and S14) has been suggested by Bycroft back to 1978 and been employed in the chemical synthesis of this core structure by Nicolaou ''et al.'' in 2005. An alternative mechanism of the dehydropiperidine formation has also been suggested by Kelly ''et al''. in 2009. Nevertheless, based on experimental evidence, tsrN and L are suggested to be responsible for the hetero Diels-Alder cyclization. The quinaldic acid moiety is suggested to be synthesized by the nine genes tsrFAEBDUPQI from tryptophan and then results in the closure of quinaldic acid macrocycle. At last, tsrR serves as a candidate for the oxidation of the Ile residue to afford thiostrepton.

[[File:Biosynthesis of Thiostrepton.png|thumb|900px|left]]{{clear}}

=== Alternative mechanism for the formation of the dehydropiperidine core ===

[[File:Alternative Mechanism for the dehydropiperidine thiopeptides biosynthesis.png|thumb|500px|left]]{{clear}}

== Total Synthesis ==
In 2005, Nicolaou ''et al.'' published the total synthesis of thiostrepton. At first, they constructed the key building blocks of thiostrepton (1): dehydropiperidine core (2), thiazoline macrocycle (3), bis-dehydroalanine tail (4), and quinaldic acid macrocycle (5). Then they assembled the building blocks sequentially as shown in the synthetic scheme (compound numbers are from the reference).

=== Building blocks for Thiostrepton ===

[[File:Thiostrepton buliding block.png|thumb|700px|left]]{{clear}}

=== Synthetic scheme ===

[[File:Total synthesis of thiostrepton.png|thumb|900px|left]]{{clear}}

== References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Peptides]]</text>
      <sha1>1rm6t03scay7mjjswqi3o5dzzugy0v3</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Allistatin</title>
    <ns>0</ns>
    <id>15969110</id>
    <revision>
      <id>463617775</id>
      <parentid>454239704</parentid>
      <timestamp>2011-12-02T05:11:22Z</timestamp>
      <contributor>
        <username>Geo g guy</username>
        <id>7149194</id>
      </contributor>
      <comment>cleanup provided (best I can get it)</comment>
      <text xml:space="preserve" bytes="1567">{{Unreferenced|date=July 2009}}

'''Allistatin''' (or '''Allistatine''') is an [[antibiotic]] that is found naturally in plants that belong to the [[Allium]] group, which includes [[garlic]] and [[onions]].
It is recognized as being a strong broad-spectrum [[fungicide]] and an antibiotic against a number of serious [[microorganism]]s (such as [[bacteria]]). The name &quot;allistatin&quot; refers to two very similar recognized compounds; allistatin I and II.

Studies have established that the most active factors in garlic (including allistatin I and allistatin II) are sulphur-containing compounds which are effective agents against [[staphylococcus]] and Escherichia coli ([[E. coli]]), which are bacteria that can cause serious infections that can lead to death. For this reason, Russia and other countries, use garlic routinely and extensively to treat numerous infections and diseases such as [[whooping cough]], [[grippe]] (Flu) and a host of infectious diseases of [[virus|viral]] and bacterial origin. {{Citation needed|date=July 2009}}

Apart from allistatin, garlic has many other substances (including [[vitamin]]s and minerals), but allistatin I, allistatin II, [[alliin]], [[allicin]], [[garlicin]] and [[ajoine]] are the strongest antibacterial, antifungal, antiviral, immune-enhancing and anti-[[platelet]] compounds found in large quantities in garlic.

==See also==
*[[Herbalism]]
*[[Traditional Korean medicine]]

{{Allium}}

[[Category:Antibiotics]]
[[Category:Allium]]
[[Category:Garlic]]
[[Category:Organosulfur compounds]]
[[Category:Pungent flavors]]</text>
      <sha1>fcn75vjbwp8n1ails2pqkxfsrjumtov</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Mupirocin</title>
    <ns>0</ns>
    <id>887234</id>
    <revision>
      <id>609063382</id>
      <parentid>605293254</parentid>
      <timestamp>2014-05-18T07:45:45Z</timestamp>
      <contributor>
        <username>Rjwilmsi</username>
        <id>203434</id>
      </contributor>
      <minor/>
      <comment>Added 3 dois to journal cites using [[Project:AWB|AWB]] (10193)</comment>
      <text xml:space="preserve" bytes="20065">{{distinguish|Miprocin|}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 408766144
| IUPAC_name = 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-&lt;nowiki&gt;[[&lt;/nowiki&gt;(2S,3S)-3- [(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl] oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
| image = Mupirocin structure.png
| width = 400

&lt;!--Clinical data--&gt;
| tradename = Bactroban
| Drugs.com = {{drugs.com|monograph|mupirocin}}
| MedlinePlus = a688004
| pregnancy_US = B
| pregnancy_category =
| legal_status = Rx Only (US)
| routes_of_administration = topical,nasal
| licence_US = Bactroban

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =
| protein_bound = 97%
| metabolism =
| elimination_half-life = 20 to 40 minutes

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 12650-69-0
| ATC_prefix = D06
| ATC_suffix = AX09
| ATC_supplemental = {{ATC|R01|AX06}}
| PubChem = 446596
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00410
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 393914
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = D0GX863OA5
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01076
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 719

&lt;!--Chemical data--&gt;
| C=26 | H=44 | O=9
| molecular_weight = 500.622 g/mol
| smiles = O=C(O)CCCCCCCCOC(=O)\C=C(/C)C[C@@H]2OC[C@H](C[C@@H]1O[C@H]1[C@@H](C)[C@@H](O)C)[C@@H](O)[C@H]2O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MINDHVHHQZYEEK-HBBNESRFSA-N
}}

'''Mupirocin''' ('''Bactroban''' or '''Centany''') is an [[antibiotic]] of the [[monoxycarbolic acid]] class.&lt;ref&gt;[http://www.antimicrobe.org/drugpopup/Mupirocin.pdf Mupirocin] by [http://www.antimicrobe.org/editorial-board.htm antimicrobe.org Editorial Board]. Retrieved June 2012&lt;/ref&gt; It was originally isolated from ''[[Pseudomonas fluorescens]]'' NCIMB 10586,&lt;ref name=&quot;pmid5003547&quot;&gt;{{cite journal |author=Fuller AT, Mellows G, Woolford M, Banks GT, Barrow KD, Chain EB |title=Pseudomonic acid: an antibiotic produced by Pseudomonas fluorescens |journal=Nature |volume=234 |issue=5329 |pages=416–7 |date=December 1971 |pmid=5003547 |doi= 10.1038/234416a0 }}&lt;/ref&gt; developed by [[Beecham (pharmaceutical company)|Beecham]]. 

Mupirocin is [[bacteriostatic]] at low concentrations and [[bactericidal]] at high concentrations.&lt;ref&gt;{{cite news | first=Kate | last=Moodabe | coauthors= Linda Bryant | title=Topical antibiotics - more harm than good? | publisher= | url =http://www.rnzcgp.org.nz/news/nzfp/Oct2000/moodabe.htm | work =Focus | pages =1 | accessdate = 2007-04-20 | language = |archiveurl = http://web.archive.org/web/20070716134428/http://www.rnzcgp.org.nz/news/nzfp/Oct2000/moodabe.htm &lt;!-- Bot retrieved archive --&gt; |archivedate = 2007-07-16}}&lt;/ref&gt; It is used topically and is effective against [[Gram-positive]] [[bacterium|bacteria]], including [[Methicillin-resistant Staphylococcus aureus|MRSA]].&lt;ref name=&quot;pmid365175&quot;&gt;{{cite journal |author=Hughes J, Mellows G |title=Inhibition of isoleucyl-transfer ribonucleic acid synthetase in Echerichia coli by pseudomonic acid |journal=Biochem. J. |volume=176 |issue=1 |pages=305–18 |date=October 1978 |pmid=365175 |doi= |pmc=1186229}}&lt;/ref&gt; Mupirocin is a mixture of several pseudomonic acids, with pseudomonic acid A (PA-A) constituting greater than 90% of the mixture. Also present in mupirocin are pseudomonic acid B with an additional hydroxyl group at C8,&lt;ref name=&quot;pmid402373&quot;&gt;{{cite journal |author=Chain EB, Mellows G |title=Pseudomonic acid. Part 3. Structure of pseudomonic acid B |journal=J. Chem. Soc. Perkin Trans. I |volume= |issue=3 |pages=318–24 |year=1977 |pmid=402373 |doi= 10.1039/p19770000318 }}&lt;/ref&gt; pseudomonic acid C with a double bond between C10 and C11, instead of the epoxide of PA-A,&lt;ref name=&quot;urlScienceDirect - Tetrahedron Letters: The structure and configuration of pseudomonic acid C&quot;&gt;{{cite journal |doi=10.1016/S0040-4039(00)71533-4 |title=ScienceDirect - Tetrahedron Letters: The structure and configuration of pseudomonic acid C |format= |work= |accessdate= |year=1980 |author=Clayton, J |journal=Tetrahedron Letters |volume=21 |pages=881 |issue=9 |last2=O'Hanlon |first2=Peter J. |last3=Rogers |first3=Norman H.}}&lt;/ref&gt; and pseudomonic acid D with a double bond at C4` and C5` in the 9-hydroxy-nonanoic acid portion of mupirocin.&lt;ref&gt;{{cite journal
| last1 = O'Hanlon | first1 = PJ
| last2 = Rogers | first2 = NH
| last3 = Tyler | first3 = JW
| title = The chemistry of pseudomonic acid. Part 6. Structure and preparation of pseudomonic acid D
| doi = 10.1039/P19830002655
| journal = Journal of the Chemical Society, Perkin Transactions 1
| pages = 2655–2657
| year = 1983
}}&lt;/ref&gt;

&lt;!-- Society and culture --&gt;
It is on the [[World Health Organization's List of Essential Medicines]], a list of the most important medication needed in a basic [[health system]].&lt;ref&gt;{{cite web|title=WHO Model List of EssentialMedicines|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|work=World Health Organization|accessdate=22 April 2014|date=October 2013}}&lt;/ref&gt;

==Medical uses==
Mupirocin is used as a topical treatment for bacterial skin infections, for example, [[furuncle]], [[impetigo]], open wounds, etc. It is also useful in the treatment of [[Methicillin-resistant Staphylococcus aureus|methicillin-resistant ''Staphylococcus aureus'']] (MRSA), which is a significant cause of death in hospitalized patients having received systemic antibiotic therapy. It is suggested, however, that mupirocin cannot be used for extended periods of time, or indiscriminately, as resistance does develop, and could, if it becomes widespread, destroy mupirocin's value as a treatment for MRSA. It may also result in overgrowth of non-susceptible organisms.

===Resistance===
Shortly after the clinical use of mupirocin began, strains of ''Staphylococcus aureus'' that were [[drug resistance|resistant]] to mupirocin emerged, with [[nares]] clearance rates of less than 30% success.&lt;ref name=&quot;pmid9511032&quot;&gt;{{cite journal |author=Cookson BD |title=The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice |journal=J. Antimicrob. Chemother. |volume=41 |issue=1 |pages=11–8 |date=January 1998 |pmid=9511032 |doi= 10.1093/jac/41.1.11 }}&lt;/ref&gt;&lt;ref&gt;{{cite web |url=http://www.acep.org/Clinical---Practice-Management/Topical-MRSA-Decolonization-Is-Warranted-During-Outbreaks/ |title=Topical MRSA Decolonization Is Warranted During Outbreaks |last1=Worcester |first1=Sharon |last2= |first2= |date=March 2008 |website=American College of Emergency Physicians |publisher=Elsevier Global Medical News |accessdate=18 November 2013}}&lt;/ref&gt; Two distinct populations of mupirocin-resistant ''S. aureus'' were isolated. One strain possessed low-level resistance, MuL, (MIC = 8–256&amp;nbsp;mg/L) and another possessed high-level resistance, MuH, (MIC &amp;gt; 256&amp;nbsp;mg/L).&lt;ref name=&quot;pmid9511032&quot;/&gt; Resistance in the MuL strains is probably due to [[mutation]]s in the organism's wild-type isoleucinyl-tRNA synthetase. In ''E. coli'' IleRS, a single amino acid mutation was shown to alter mupirocin resistance.&lt;ref name=&quot;pmid7929087&quot;&gt;{{cite journal |author=Yanagisawa T, Lee JT, Wu HC, Kawakami M |title=Relationship of protein structure of isoleucyl-tRNA synthetase with pseudomonic acid resistance of Escherichia coli. A proposed mode of action of pseudomonic acid as an inhibitor of isoleucyl-tRNA synthetase |journal=J. Biol. Chem. |volume=269 |issue=39 |pages=24304–9 |date=September 1994 |pmid=7929087 }}&lt;/ref&gt; MuH is linked to the acquisition of a separate Ile synthetase gene, mupA.&lt;ref name=&quot;pmid8431015&quot;&gt;{{cite journal |author=Gilbart J, Perry CR, Slocombe B |title=High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases |journal=Antimicrob. Agents Chemother. |volume=37 |issue=1 |pages=32–8 |date=January 1993 |pmid=8431015 |pmc=187600 |doi=10.1128/aac.37.1.32}}&lt;/ref&gt; Mupirocin is not a viable antibiotic against MuH strains. Other antibiotic agents such as [[azelaic acid]], [[nitrofurazone]], [[silver sulfadiazine]], and [[ramoplanin]] have been shown to be effective against MuH strains.&lt;ref name=&quot;pmid9511032&quot;/&gt;

Most strains of ''[[Propionibacterium acnes]]'', a causative agent of the skin disease [[acne vulgaris]], are naturally resistant to mupirocin.&lt;ref&gt;{{cite web|url=http://scienceofacne.com/antibiotic-susceptibility-of-propionibacterium-acnes/|title=Antibiotic Susceptibility of Propionibacterium acnes. |publisher=ScienceOfAcne.com |date=2011-06-11 |accessdate=2012-08-27}}&lt;/ref&gt;

The mechanism of mupirocin differs from other clinical antibiotics, rendering cross-resistance to other antibiotics unlikely.&lt;ref name=&quot;pmid9511032&quot;/&gt; However, the MupA gene may co-transfer with other antibacterial resistance genes. This has been observed already with resistance genes for [[triclosan]], [[tetracycline]], and [[trimethoprim]].&lt;ref name=&quot;pmid9511032&quot;/&gt;


==Mechanism==
Mupirocin reversibly binds to the isoleucyl t-RNA synthetase in ''[[Staphylococcus aureus]]'' and ''Streptococcus'', resulting in inhibition of protein synthesis.  [[DNA]] and cell wall formation are also negatively impacted to a lesser degree.&lt;ref name=&quot;pmid659331&quot;&gt;{{cite journal |author=Hughes J, Mellows G |title=On the mode of action of pseudomonic acid: inhibition of protein synthesis in Staphylococcus aureus |journal=J. Antibiot. |volume=31 |issue=4 |pages=330–5 |date=April 1978 |pmid=659331 |doi=10.7164/antibiotics.31.330}}&lt;/ref&gt; The inhibition of RNA synthesis was shown to be a protective mechanism in response to a lack of one [[amino acid]], [[isoleucine]].&lt;ref name=&quot;pmid4576025&quot;&gt;{{cite journal |author=Haseltine WA, Block R |title=Synthesis of Guanosine Tetra- and Pentaphosphate Requires the Presence of a Codon-Specific, Uncharged Transfer Ribonucleic Acid in the Acceptor Site of Ribosomes |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=70 |issue=5 |pages=1564–8 |date=May 1973 |pmid=4576025 |doi= 10.1073/pnas.70.5.1564|pmc=433543}}&lt;/ref&gt; In vivo studies in ''[[Escherichia coli]]'' demonstrated that pseudomonic acid inhibits isoleucine [[Isoleucyl-tRNA synthetase|t-RNA synthetase]] (IleRS).&lt;ref name=&quot;pmid365175&quot;/&gt; This mechanism of action is shared with [[furanomycin]], an analog of isoleucine.&lt;ref name=&quot;pmid4982424&quot;&gt;{{cite journal |author=Tanaka K, Tamaki M, Watanabe S |title=Effect of furanomycin on the synthesis of isoleucyl-tRNA |journal=Biochim. Biophys. Acta |volume=195 |issue=1 |pages=244–5 |date=November 1969 |pmid=4982424 |doi=10.1016/0005-2787(69)90621-2}}&lt;/ref&gt;

==Biosynthesis==
[[Image:Mupirocin Cluster chart.png|thumb|left|Table 1. The biosynthetic gene cluster of mupirocin]]

[[Image:Monic acid4.png|thumb|550px|Figure 1. The domain structure of MmpA, MmpC, and MmpD for the synthesis of monic acid. The biosynthesis of monic acid is not colinear but has been rearranged in this diagram. The protein name is displayed inside of the arrow with module and domain structure listed below. ACP=[[acyl carrier protein]], AT=acyl transferase, DH=[[dehydratase]], ER=enoyl reductase, HMG=[[3-hydroxy-3-methylglutaric acid]], MeT=methyl transferase, KR=ketoreductase, KS=ketosynthase, TE=[[thioesterase]].]]

[[Image:Pseudomonic acid A-D.png|400px|thumb|Figure 2. The structure of pseudomonic acid A-D, labeled A-D, respectively.]]

[[Image:Mupirocin C15 methylation.png|thumb|550px|Figure 3. The C15 methyl group of monic acid is attached to C3 by the following reaction scheme. MupH is an 3-hydroxy-3-methylglutarate-Coenzyme A synthase, MupJ and MupK are Enoyl-CoA hydratases.&lt;ref name=&quot;pmid12770824&quot;/&gt;]]

[[Image:Mupirocin pyran2.png|thumb|500px|Figure 4. The pyran ring of mupirocin is generated in this proposed multistep reaction [15]. Gene knockouts of mupO, mupU, mupV and macpE abolish PA-A production but not PA-B production, demonstrating that PA-B is a precursor to PA-A.&lt;ref name=&quot;pmid16039529&quot;/&gt;]]

[[Image:9-HNA.png|thumb|400px|Figure 5. MmpB is proposed to synthesize 9-HN with a 3-hydroxy-propionate starter unit and three malonyl-CoA extenter units. The domain structure of MmpB is shown below alongside MupE, the proposed enoyl reductase required for complete saturation of 9-HN. ACP=acyl carrier protein, DH=dehydratase, ER=enoyl reductase, KR=ketoreductase, KS=ketosynthase, TE=thioesterase.]]

===Biosynthesis of Pseudomonic Acid A===
The 74 kb mupirocin [[gene cluster]] contains six [[protein domain|multi-domain]] [[enzymes]] and twenty-six other peptides (Table 1).&lt;ref name=&quot;pmid12770824&quot;&gt;{{cite journal |author=El-Sayed AK, Hothersall J, Cooper SM, Stephens E, Simpson TJ, Thomas CM |title=Characterization of the mupirocin biosynthesis gene cluster from Pseudomonas fluorescens NCIMB 10586 |journal=Chem. Biol. |volume=10 |issue=5 |pages=419–30 |date=May 2003 |pmid=12770824 |doi= 10.1016/S1074-5521(03)00091-7 }}&lt;/ref&gt; Four large multi-domain type I [[polyketide synthase]] (PKS) proteins are encoded, as well as several single function enzymes with sequence similarity to type II PKSs.&lt;ref name=&quot;pmid12770824&quot;/&gt; Therefore, it is believed that mupirocin is constructed by a mixed type I and type II PKS system. The mupirocin cluster exhibits an atypical [[acyltransferase]] (AT) organization, in that there are only two AT domains, and both are found on the same protein, MmpC. These AT domains are the only domains present on MmpC, while the other three type I PKS proteins contain no AT domains.&lt;ref name=&quot;pmid12770824&quot;/&gt; The mupirocin pathway also contains several tandem [[acyl carrier protein]] doublets or triplets. This may be an adaptation to increase the throughput rate or to bind multiple substrates simultaneously.&lt;ref name=&quot;pmid12770824&quot;/&gt;

Pseudomonic acid A is the product of an [[esterification]] between the 17C polyketide monic acid and the 9C [[fatty acid]] 9-hydroxy-nonanoic acid. The possibility that the entire molecule is assembled as a single polyketide with a [[Baeyer-Villiger]] [[oxidation]] inserting an [[oxygen]] into the carbon backbone has been ruled out because C1 of monic acid and C9' of 9-hydroxy-nonanoic acid are both derived from C1 of acetate.&lt;ref name=&quot;pmid402372&quot;&gt;{{cite journal |author=Feline TC, Jones RB, Mellows G, Phillips L |title=Pseudomonic acid. Part 2. Biosynthesis of pseudomonic acid A |journal=J. Chem. Soc. Perkin Trans. I |volume= |issue=3 |pages=309–18 |year=1977 |pmid=402372 |doi= 10.1039/p19770000309 }}&lt;/ref&gt;

===Monic acid biosynthesis===
Biosynthesis of the 17C monic acid unit begins on MmpD (Figure 1).&lt;ref name=&quot;pmid12770824&quot;/&gt; One of the AT domains from MmpC may transfer an activated acetyl group from acetyl-Coenzyme A (CoA) to the first ACP domain. The chain is extended by malonyl-CoA, followed by a SAM-dependent methylation at C12 (see Figure 2 for PA-A numbering) and reduction of the B-keto group to an alcohol. The dehydration (DH) domain in module 1 is predicted to be non-functional due to a mutation in the conserved active site region. Module 2 adds another two carbons by malonyl-CoA extender unit, followed by ketoreduction (KR) and dehydration. Module three adds a malonyl-CoA extender unit, followed by SAM-dependent methylation at C8, ketoreduction, and dehydration. Module 4 extends the molecule with a malonyl-CoA unit followed by ketoreduction.

Assembly of monic acid is continued by the transfer of the 12C product of MmpD to MmpA.&lt;ref name=&quot;pmid12770824&quot;/&gt; Two more rounds of extension with malonyl-CoA units are achieved by module 5 and 6. Module 5 also contains a KR domain.

===Post-PKS tailoring===

The keto group at C3 is replaced with a methyl group in a multi-step reaction (Figure 3). MupG begins by decarboxylating a malonyl-ACP. The alpha carbon of the resulting acetyl-ACP is linked to C3 of the polyketide chain by MupH. This intermediate is dehydrated and decarboxylated by MupJ and MupK, respectively.&lt;ref name=&quot;pmid12770824&quot;/&gt;

The formation of the [[pyran]] ring requires many enzyme-mediated steps (Figure 4). The double bond between C8 and C9 is proposed to migrate to between C8 and C16.&lt;ref name=&quot;pmid16039529&quot;&gt;{{cite journal |author=Cooper SM |title=Shift to Pseudomonic acid B production in P. fluorescens NCIMB10586 by mutation of mupirocin tailoring genes mupO, mupU, mupV, and macpE |journal=Chem. Biol. |volume=12 |issue=7 |pages=825–33 |date=July 2005 |pmid=16039529 |doi=10.1016/j.chembiol.2005.05.015 |author-separator=, |author2=Laosripaiboon W |author3=Rahman AS |display-authors=3 |last4=Hothersall |first4=J |last5=Elsayed |first5=A |last6=Winfield |first6=C |last7=Crosby |first7=J |last8=Cox |first8=R |last9=Simpson |first9=T}}&lt;/ref&gt; [[Gene knockout]] experiments of mupO, mupU, mupV, and macpE have eliminated PA-A production.&lt;ref name=&quot;pmid16039529&quot;/&gt; PA-B production is not removed by these knockouts, demonstrating that PA-B is not created by hydroxylating PA-A. A knockout of mupW eliminated the pyran ring, identifying MupW as being involved in ring formation.&lt;ref name=&quot;pmid16039529&quot;/&gt; It is not known whether this occurs before or after the esterification of monic acid to 9-hydroxy-nonanoic acid.

The [[epoxide]] of PA-A at C10-11 is believed to be inserted after pyran formation by a [[cytochrome P450]] such as MupO.&lt;ref name=&quot;pmid12770824&quot;/&gt; A gene knockout of mupO abolished PA-A production but PA-B, which also conatins the C10-C11 epoxide, remained.&lt;ref name=&quot;pmid16039529&quot;/&gt; This indicates that MupO is either not involved or is not essential for this epoxidation step.

===9-Hydroxy-nonanoic acid biosynthesis===

The nine-carbon fatty acid 9-hydroxy-nonanoic acid (9-HN) is derived as a separate compound and later esterified to monic acid to form pseudomonic acid. &lt;sup&gt;13&lt;/sup&gt;C labeled [[acetate]] feeding has shown that C1-C6 are constructed with acetate in the canonical fashion of [[fatty acid synthesis]]. C7' shows only C1 labeling of acetate, while C8' and C9' show a reversed pattern of 13C labeled acetate.&lt;ref name=&quot;pmid402372&quot;/&gt; It is speculated that C7-C9 arises from a 3-hydroxypropionate starter unit, which is extended three times with malonyl-CoA and fully reduced to yield 9-HN. It has also been suggested that 9-HN is initiated by 3-hydroxy-3-methylglutaric acid (HMG). This latter theory was not supported by feeding of [3-&lt;sup&gt;14&lt;/sup&gt;C] or [3,6-&lt;sup&gt;13&lt;/sup&gt;C&lt;sub&gt;2&lt;/sub&gt;]-HMG.&lt;ref&gt;{{cite journal
| last1 = Martin | first1 = FM
| last2 = Simpson | first2 = TJ
| doi = 10.1039/P19890000207
| title = Biosynthetic studies on pseudomonic acid (mupirocin), a novel antibiotic metabolite of Pseudomonas fluorescens
| journal = Journal of the Chemical Society, Perkin Transactions 1
| pages = 207–209
| year = 1989
}}&lt;/ref&gt;

It is proposed that MmpB to catalyzes the synthesis of 9-HN (Figure 5). MmpB contains a KS, KR, DH, 3 ACPs, and a thioesterase (TE) domain.&lt;ref name=&quot;pmid12770824&quot;/&gt; It does not contain an enoyl reductase (ER) domain, which would be required for the complete reduction to the nine-carbon fatty acid. MupE is a single-domain protein that shows sequence similarity to known ER domains and may complete the reaction.&lt;ref name=&quot;pmid12770824&quot;/&gt; It also remains possible that 9-hydroxy-nonanoic acid is derived partially or entirely from outside of the mupirocin cluster.

{{clear}}

==References==
{{Reflist|30em}}

== External links ==
* [http://us.gsk.com/products/assets/us_bactroban_ointment.pdf Bactroban Prescribing Information] GlaxoSmithKline
* [http://us.gsk.com/products/assets/us_bactroban_nasal.pdf Bactroban Nasal Prescribing Information] GlaxoSmithKline

{{Antibiotics and chemotherapeutics for dermatological use}}
{{Nasal preparations}}
{{Other antibacterials}}

[[Category:Antibiotics]]
[[Category:Carboxylate esters]]
[[Category:Epoxides]]
[[Category:Fatty acids]]
[[Category:GlaxoSmithKline]]</text>
      <sha1>pp80w2jvma38dkc6ssa3jw47d1brjd4</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Bafilomycin</title>
    <ns>0</ns>
    <id>4128733</id>
    <revision>
      <id>579335324</id>
      <parentid>579315871</parentid>
      <timestamp>2013-10-29T19:53:03Z</timestamp>
      <contributor>
        <username>AnomieBOT</username>
        <id>7611264</id>
      </contributor>
      <minor/>
      <comment>Dating maintenance tags: {{Cn}}</comment>
      <text xml:space="preserve" bytes="3520">{{chembox
| Verifiedfields = changed
| verifiedrevid = 459513071
|Reference=&lt;ref&gt;[http://www.fermentek.co.il/bafilomycin_A1.htm Bafilomycin A1 product page] from [[Fermentek]]&lt;/ref&gt;
|Name = Bafilomycin A1
|ImageFile=Bafilomycin A1.svg
|ImageSize=250px
|IUPACName= &lt;small&gt;(3''Z'',5''E'',7''R'',8''S'',9''S'',11''E'',13''E'',15''S'',16''R'')-16- [(1''S'',2''R'',3''S'')-3-[(2''R'',4''R'',5''S'',6''R'')-2,4-dihydroxy-6- isopropyl-5-methyl-2-tetrahydropyranyl]-2- hydroxy-1-methylbutyl]-8-hydroxy-3,15- dimethoxy-5,7,9,11-tetramethyl-1- oxacyclohexadeca-3,5,11,13-tetraen-2-one&lt;/small&gt;
|OtherNames=
|Section1={{Chembox Identifiers
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10251049
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 290814
| InChI = 1/C35H58O9/c1-19(2)32-24(7)27(36)18-35(40,44-32)26(9)31(38)25(8)33-28(41-10)14-12-13-20(3)15-22(5)30(37)23(6)16-21(4)17-29(42-11)34(39)43-33/h12-14,16-17,19,22-28,30-33,36-38,40H,15,18H2,1-11H3/b14-12+,20-13+,21-16+,29-17-/t22-,23-,24+,25+,26+,27-,28+,30+,31-,32-,33-,35-/m1/s1
| InChIKey = XDHNQDDQEHDUTM-XJKSCTEHBD
| SMILES1 = O[C@@]1(C[C@@H](O)[C@H](C)[C@H](O1)C(C)C)[C@@H](C)[C@H](O)[C@H](C)[C@H]2OC(=O)C(\OC)=C\C(\C)=C\[C@@H](C)[C@@H](O)[C@H](C)CC(\C)=C\C=C\[C@@H]2OC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C35H58O9/c1-19(2)32-24(7)27(36)18-35(40,44-32)26(9)31(38)25(8)33-28(41-10)14-12-13-20(3)15-22(5)30(37)23(6)16-21(4)17-29(42-11)34(39)43-33/h12-14,16-17,19,22-28,30-33,36-38,40H,15,18H2,1-11H3/b14-12+,20-13+,21-16+,29-17-/t22-,23-,24+,25+,26+,27-,28+,30+,31-,32-,33-,35-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XDHNQDDQEHDUTM-XJKSCTEHSA-N
| CASNo_Ref = {{cascite|changed|??}}
| CASNo=88899-55-2
|  PubChem=6436223
|  DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB06733
| SMILES=C[C@H]1C/C(=C/C=C/[C@@H]([C@H](OC(=O)/C(=C/C(=C/[C@H]([C@H]1O)C)/C)/OC)[C@@H](C)[C@H]([C@H](C)[C@]2(C[C@H]([C@@H]([C@H](O2)C(C)C)C)O)O)O)OC)/C
  }}
|Section2={{Chembox Properties
|  Formula=C&lt;sub&gt;35&lt;/sub&gt;H&lt;sub&gt;58&lt;/sub&gt;O&lt;sub&gt;9&lt;/sub&gt;
|  MolarMass=622.83 g/mol
|  Appearance=Yellow powder
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3={{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}

The '''bafilomycins''' are a family of toxic [[macrolide]] [[antibiotics|antibiotic]] derived from ''[[Streptomyces griseus]]''. These compounds all appear in the same [[Industrial fermentation|fermentation]] and have quite similar biological activity. Bafilomycins are specific inhibitors of [[V-ATPase|vacuolar-type H+-ATPase]]. 

The most used bafilomycin is bafilomycin A1. This is a useful tool as it can prevent the re-acidification of [[Synapse|synaptic]] vesicles once they have undergone exocytosis.

Bafilomycin has [[antibacterial]], [[Antifungal medication|antifungal]], [[antineoplastic]], [[immunosuppressive]] activities.In addition, bafilomycin A1 has antimalarial activity &lt;ref&gt;van Schalkwyk DA, Chan XW, Misiano P, Gagliardi S, Farina C, Saliba KJ. &quot;Inhibition of Plasmodium falciparum pH regulation by small molecule indole derivatives results in rapid parasite death&quot; Biochem Pharmacol. 2010 May 1;79(9):1291-9. PMID 20067768&lt;/ref&gt; It has been shown to decrease multi-drug resistance.{{Cn|date=October 2013}}

Bafilomycin B1 has been mentioned as a potential [[osteoporosis|antiosteoporotic agent]] in treating bone lytic diseases.

== References ==
{{reflist}}

[[Category:Neurophysiology]]
[[Category:Antibiotics]]</text>
      <sha1>mc74owooba5lhi8evptjc652begg1sr</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Pulvinone</title>
    <ns>0</ns>
    <id>17589963</id>
    <revision>
      <id>575374235</id>
      <parentid>554422656</parentid>
      <timestamp>2013-10-02T01:42:30Z</timestamp>
      <contributor>
        <username>ArmbrustBot</username>
        <id>18663209</id>
      </contributor>
      <minor/>
      <comment>/* Sources */removing category per [[Wikipedia:Categories for discussion/Log/2013 September 21]], removed: Category:Chemical compounds found in Aspergillus species, Category:Chemical compounds found in Basidiomycota using [[Project:AWB|AWB]]</comment>
      <text xml:space="preserve" bytes="13992">{{chembox
| Watchedfields = changed
| verifiedrevid = 445548490
|   Name = Pulvinone
|   ImageFile = (EZ)-Pulvinone Structural Formulae.png
| imagename = mixture of ''cis''- and ''trans''-isomers
| ImageSize = 300px
|   IUPACName = (''E''/''Z'')-5-Phenylmethylene-4-hydroxy-3-phenylfuran-2(5''H'')-one
|   OtherNames = 
| Section1 = {{Chembox Identifiers
|   SMILES = 
|   CASNo_Ref = {{cascite|correct|??}}
|   CASNo = 4941-88-2
|   CASNo_Comment = (''E''/''Z'')
|   CASNo1 = 78376-10-0 
|   CASNo1_Comment = (''Z'')
|   CASNo2 = 100074-80-4
|   CASNo2_Comment = (''E'')
  }}
| Section2 = {{Chembox Properties
|   C=17|H=12|O=3
|   Appearance = Yellow needles
|   Density = 
|   Solubility = Insoluble 
|   MeltingPt = 243–247&amp;nbsp;°C &lt;ref name=&quot;Ramage&quot;&gt;{{cite journal | doi = 10.1039/P19840001539 | title = Dioxolanones as synthetic intermediates. Part 2. Synthesis of tetronic acids and pulvinones | year = 1984 | last1 = Ramage | first1 = Robert | last2 = Griffiths | first2 = Gareth J. | last3 = Shutt | first3 = Fiona E. | last4 = Sweeney | first4 = John N. A. | journal = Journal of the Chemical Society, Perkin Transactions 1 | pages = 1539}}&lt;/ref&gt;
|   BoilingPt = 
  }}
| Section3 = {{Chembox Structure
|   CrystalStruct = 
|   Dipole =
  }}
| Section7 = {{Chembox Hazards
|   ExternalMSDS = 
|   MainHazards = 
  }}
| Section8 = {{Chembox Related
|   Function = 
|   OtherFunctn =
|   OtherCpds = [[Pulvinic acid]], [[Vulpinic acid]]
  }}
}}

'''Pulvinone''', an [[organic compound]] belonging to the [[ester]]s, [[lactone]]s, [[alcohol]]s and [[butenolide]]s classes, is a yellow crystalline [[solid]]. Although the pulvinone is not a [[natural product]], several naturally occurring hydroxylated [[derivative (chemistry)|derivative]]s are known. These hydroxylated pulvinones are produced by [[fungi|fungal]] species, such as the in Europe common [[Larch Bolete]] (''Boletus elegans'', also known as ''[[Suillus]] grevillei''), or by [[mould]]s such as ''[[Aspergillus]] Terreus''.

==History==
[[Fungus|Fungi]] - such as [[boletus|boleti]] -, [[mould]]s and [[lichen]]s produce a wide range of pigments made up of one ([[monomer]]) or several ([[oligomers]]) units of [[pulvinic acid]]. In 1831, in the course of a study of the constituents of lichens (''Cetraria Vulpina''), the French chemist and pharmacist Antoine Bebert discovered a compound named ''vulpinic acid'', the first known naturally occurring methyl ester of pulvinic acid. More details about the structure of this pigment were disclosed in 1860 by the German chemists [[Franz Möller]] and [[Adolph Strecker]].&lt;ref name=&quot;canstatt&quot;&gt;''Canstatt's Jahresbericht über die Fortschritte in der Pharmacie und verwandte Wissenschaften in allen Ländern'', Harvard Universität, Jahrgang 10 (1861).&lt;/ref&gt; While trying to elucidate the structure of vulpinic acid, the German chemist [[Adolf Spiegel]] &lt;ref name=&quot;Spiegel1&quot;&gt;A. Spiegel, ''Ber. Dtsch. Chem. Ges.'' '''1880''', ''13'', 2, 1629-1635 {{doi|10.1002/cber.18800130293}}.&lt;/ref&gt;&lt;ref name=&quot;Spiegel2&quot;&gt;A. Spiegel, ''Ber. Dtsch. Chem. Ges.'' '''1880''', ''13'', 2, 2219-2221 {{doi|10.1002/cber.188001302237}}.&lt;/ref&gt;&lt;ref name=&quot;Spiegel3&quot;&gt;A. Spiegel, ''Ber. Dtsch. Chem. Ges.'' '''1881''', ''14'', 1, 873-874 {{doi|10.1002/cber.188101401183}}.&lt;/ref&gt;&lt;ref name=&quot;Spiegel4&quot;&gt;A. Spiegel, ''Ber. Dtsch. Chem. Ges.'' '''1881''', ''14'', 2, 1686-1696 {{doi|10.1002/cber.18810140230}}.&lt;/ref&gt; found in 1880 that the [[vulpinic acid]] could be [[saponification|saponified]] to a diacid. He named the resulting diacid [[pulvinic acid]]. The German chemist [[Jacob Volhard]]&lt;ref name=&quot;Volhard&quot;&gt;J. Volhard, ''Annal. Chem.'' '''1894''', ''282'', 1-21 {{doi|10.1002/jlac.18942820102}}.&lt;/ref&gt; elucidated the constitution of pulvinic acid by synthesizing it through the basic hydrolysis of a corresponding dicyanocompound. In the process, he also obtained small amounts of a side-product. One year later [[Ludwig Claisen]] and Th. Ewan&lt;ref name=&quot;Claisen_Ewan&quot;&gt;L. Claisen, Th. Ewan, ''Annal. Chem.'', '''1895''', ''284'', 245-299 {{doi|10.1002/jlac.18952840302}}.&lt;/ref&gt; achieved the synthesis of this side-product and characterized it as the 5-benzylidene-4-hydroxy-3-phenylfuran-2(5H)-one. [[Image:Pulvinone-FirstSyntheses.png|thumb|center|400px|Synthesis of pulvinone from vulpinic acid (Spiegel,&lt;ref name=&quot;Spiegel4&quot;/&gt; top) and from a corresponding dicyanide (Volhard,&lt;ref name=&quot;Volhard&quot;/&gt; below)]] Claisen and Ewan described it as ''das der Pulvinsäure zu Grunde liegende Lacton'' (the lactone underlying the structure of pulvinic acid): that was the origin of the name pulvinone.

==Natural occurrence==
Interestingly, it is only a century after the synthesis of the first pulvinone that the word ''Pulvinone'' turned into a collective term. In 1973, Edwards and Gill isolated the first naturally occurring hydroxylated pulvinone derivative.&lt;ref name=&quot;Gill_Edwards&quot;&gt;R. L. Edwards, M. Gill, ''J. Chem. Soc., Perkin Trans. 1'' '''1973''', 1921-1929. {{doi|10.1039/P19730001921}}.&lt;/ref&gt; This trihydroxylated pulvinone was found as one of the main pigments responsible for the yellow colour of the stem and caps of the European mushroom [[Larch Bolete]] (''Boletus elegans'', also known as ''[[Suillus grevillei]]'').
In the very same year 1973, Seto and coworkers also found hydroxylated pulvinones in cultures of the [[mould]] [[Aspergillus|Aspergillus terreus]].&lt;ref name=&quot;Seto1&quot;&gt;N. Ojima, S. Takenaka, S. Seto, ''Phytochemistry ([[Elsevier]])'' '''1973''', ''12'', 2527-2529.&lt;/ref&gt;&lt;ref name=&quot;Seto2&quot;&gt;N. Ojima, K. Ogura, S. Seto, ''J. Chem. Soc., Chem. Commun.'' '''1975''', 717-718.&lt;/ref&gt;&lt;ref name=&quot;Seto3&quot;&gt;N. Ojima, S. Takenaka, S. Seto, ''Phytochemistry ([[Elsevier]])'' '''1975''', ''14'', 573-576.&lt;/ref&gt; To insist on their origin - and thereby differentiate them from the hydroxylated pulvinones found in ''[[Suillus grevillei]]'' - Seto and coworkers named these compounds ''Aspulvinones''.&lt;ref name=&quot;Seto4&quot;&gt;N. Ojima, I. Takahashi, K. Ogura, S. Seto, ''Tetrahedron Lett.'' '''1976''', ''17'', 1013-1014.&lt;/ref&gt;&lt;ref name=&quot;Seto5&quot;&gt;I. Takahashi, N. Ojima, K. Ogura, S. Seto, ''Biochemistry'' '''1978''', ''17'', 2696-2702.&lt;/ref&gt;&lt;ref name=&quot;Seto6&quot;&gt;M. Kobayashi, N. Ojima, K. Ogura, S. Seto, ''Chem. Lett.'' '''1979''', 579-582.&lt;/ref&gt;&lt;ref name=&quot;Seto7&quot;&gt;H. Sugiyama, N. Ojima, M. Kobayashi, Y. Senda, J. Ishiyama, S. Seto, ''Agric. Biol. Chem.'' '''1979''', ''43'', 403-4.&lt;/ref&gt; The ''aspulvinone'' terminology also incorporates a letter, indicating the order of chromatographic elution of these compounds (hence, the least polar aspulvinone was named Aspulvinone A, the one eluting next Aspulvinone B, etc...).  

Like many other yellow pigments in fungi and lichens, pulvinones can be traced back from the pulvinic acid pathway. The ''pulvinone'' structural unit is found in a number of natural products. All monomeric (such as ''pulvinic acid'' itself, ''vulpinic acid'', ''comphidic acid'', the ''aspulvinones'' and the ''Kodaistatins''&lt;ref name=&quot;Kodaistatin&quot;&gt;L. Vértesy, H.-J. Burger, J. Kenja, M. Knauf, H. Kogler, E. F. Paulus, N. V. S. Ramakrishna, K. H. S. Swamy, E. K. S. Vijayakumar, P. Hammann, ''J. Antibiot.'' '''2000''', ''53'', 677-686.&lt;/ref&gt;) or oligomeric (''Badiones'',&lt;ref name=&quot;Steffan_Steglich&quot;&gt;B. Steffan, W. Steglich, ''Angew. Chem., Int. Ed.'' '''1984''', 23, 6, 445-447. {{doi|10.1002/anie.198404451}}.&lt;/ref&gt; ''Norbadione'',&lt;ref name=&quot;Gill_Lally&quot;&gt;M. Gill, D. A. Lally, ''Phytochemistry'' '''1985''', ''24'', 1351-1354. {{doi|10.1016/S0031-9422(00)81131-0}}.&lt;/ref&gt;&lt;ref name=&quot;LeGall_Mioskowski&quot;&gt;T. Le Gall, C. Mioskowski, B. Amekraz ''et al.'' ''Angew. Chem., Int. Ed.'' '''2003''', 42, 11, 1289-1293. {{doi|10.1002/anie.198404451}}.&lt;/ref&gt; ''Aurantricholon''&lt;ref name=&quot;&quot;&gt;D. Klostermeyer, L. Knops, T. Sindlinger, K. Polborn, W. Steglich ''Eur. J. Org. Chem.'' '''2000''', 4, 603-609. {{doi|10.1002/anie.200390332}}.&lt;/ref&gt;) derivatives of the pulvinic acid contain the ''pulvinone'' structural element.
So far, all naturally occurring pulvinone derivatives were found to be ''Z''-configured.

[[Image:PulvinoneDerivatives.png|thumb|center|550px|Natural products containing the ''pulvinone'' structural unit.]]
&lt;br style=&quot;clear:left;&quot; /&gt;

==Pharmacological properties==
* Rehse ''et al.''&lt;ref name=&quot;Rehse1&quot;&gt;K. Rehse, J. Wagenknecht, N. Rietbrock, ''Arch. Pharm. (Weinheim, Ger.)'' '''1978''', ''311'', 986-991.&lt;/ref&gt;&lt;ref name=&quot;Rehse2&quot;&gt;K. Rehse, U. Emisch, ''Arch. Pharm. (Weinheim, Ger.)'' '''1982''', ''315'', 1020-1025.&lt;/ref&gt;&lt;ref name=&quot;Rehse3&quot;&gt;K. Rehse, J. Schinke, G. Bochert, ''Arch. Pharm. (Weinheim, Ger.)'' '''1979''', ''312'', 390-394.&lt;/ref&gt;&lt;ref name=&quot;Rehse4&quot;&gt;K. Rehse, J. Lehmke, ''Arch. Pharm. (Weinheim, Ger.)'' '''1985''', ''318'', 11-14.&lt;/ref&gt; showed the anti-coagulant activity of some pulvinones in rats.
* At the beginning of the 80s, the companies [[Imperial Chemical Industries|ICI]] and [[SmithKline &amp; French|Smith Kline &amp; French]] patented a large number of derivatives of the vulpinic acid because of their anti-inflammatory, anti-fever and pain-killing properties. Yet vulpinic acid - as well as many of its derivatives - is a [[cytotoxicity|cytotoxic]] compound. Since pulvinones exhibit a lower cytotoxicity compared to vlupinic acid and its derivatives, [[Organon]] investigated the pharmaceutical potential of more than 100 pulvinones.&lt;ref name=&quot;Campbell&quot;&gt;A. C. Campbell, M. S. Maidment, J. H. Pick, D. F. M. Stevenson, ''J. Chem. Soc., Perkin Trans. 1'' '''1985''', 1567-1576. {{doi|10.1039/P19850001567}}.&lt;/ref&gt; To date, the results of these studies were not fully disclosed.
* In 2005, the [[Wyeth]] company patented biphenyl-substituted pulvinones&lt;ref name=&quot;Caufield&quot;&gt;C. E. Caufield, S. A. Antane, K. M. Morris, S. M. Naughton, D. A. Quagliato, P. M. Andrae, A. Enos, J. F. Chiarello, J. (Wyeth, and Brother Ltd., USA), ''WO 2005019196'', ''US 2005054721'', '''2005'''.&lt;/ref&gt;&lt;ref name=&quot;Antane&quot;&gt;S. A. Antane, C. E. Caufield, W. Hu, D. Keeney, P. Labthavikul, K. M. Morris, S. M. Naughton, P. J. Petersen, B. A. Rasmussen, G. Singh, Y. Yang, ''Bioorg. Med. Chem. Lett.'' '''2006''', 176-180. {{doi|10.1016/j.bmcl.2005.09.021}}.&lt;/ref&gt; due to their promising activity against Gram-positive bacteria, including otherwise [[Antibiotic resistance|resistant bacteria]]. However, pulvinone-based antibiotics were so far only patented for animal use.

==Chemical properties==
Pulvinone is a [[lactone]], more precisely an [[intramolecular]] ester of the ''trans-1,4-diphenyl-2,3-dihydroxy-1,3-butadiene-1-carboxylic acid'', from which it can be prepared through removal of one [[equivalent (chemistry)|equivalent]] of water:
[[Image:Pulvinone-lactone.png|thumb|center|450px|Preparation of pulvinone (lactone) from the corresponding carboxylic acid]]
&lt;br style=&quot;clear:left;&quot; /&gt;
The central 5-membered ring core of pulvinone reveals a 4-hydroxy-[[butenolide]] structure. They are essentially found in their [[enol]] form, which exhibits acidic properties due to the relative lability of the hydroxylic proton. 4-hydroxy-[[butenolide]]s such as pulvinones are therefore referred to as [[tetronic acid]]s, and belong to the larger category of [[vinylogous]] acids.

==Biosynthesis==
The fungal biosynthesis starts from aromatic aminoacids such as [[phenylalanine]] and [[tyrosine]]; after oxydeamination to the corresponding arylpyruvic acid, the pulvinone skeleton is formed by a sequence of dimerisation, oxidative ring-cleavage and decarboxylation.&lt;ref name=&quot;Gill_Steglich&quot;&gt;M. Gill, W. Steglich, ''Prog. Chem. Org. Nat. Prod.'', '''1987''', ''51'', 1-317. [[Springer-Verlag]].&lt;/ref&gt;

[[Image:Pulvinone Biosynthesis.png|thumb|center|550px|Suggested biogenetic relationship between the aromatic aminoacids phenylalanine and tyrosine, the corresponding arylpyruvic acids, and the fungal pigments Grevillines, Terphenylquinones, Pulvinic acids and Pulvinones.&lt;ref name=&quot;Gill_Steglich&quot;/&gt;]]
&lt;br style=&quot;clear:left;&quot; /&gt;

==Total synthesis==
[[Jacob Volhard]] was the first to synthesise vulpinic acid, pulvinic acid and pulvinone.&lt;ref name=&quot;Volhard&quot;/&gt;
To date, 11 [[total synthesis|total syntheses]] of pulvinones were reported:
* 1895 by Claisen and Ewan,&lt;ref name=&quot;Claisen_Ewan&quot;/&gt;
* 1975 and 1979 by Knight and Pattenden,&lt;ref name=&quot;Knight_Pattenden1&quot;&gt;D. W. Knight, G. Pattenden, ''J. Chem. Soc., Chem. Commun.'' '''1975''', 876-877 {{doi|10.1039/C39750000876}}.&lt;/ref&gt;&lt;ref name=&quot;Knight_Pattenden2&quot;&gt;D. W. Knight, G. Pattenden, ''J. Chem. Soc., Perkin Trans. 1'' '''1979''', 70-76 {{doi|10.1039/P19790000070}}.&lt;/ref&gt;
* 1979 by Jerris, Wovkulich and Amos B. Smith III,&lt;ref name=&quot;Smith&quot;&gt;P. J. Jerris, P. M. Wovkulich, A. B. Smith III, ''Tetrahedron Lett.'' '''1979''', 20, 4517-20 {{doi|10.1016/S0040-4039(01)86637-5}}.&lt;/ref&gt;
* 1984 by Ramage ''et al.'',&lt;ref name=&quot;Ramage&quot;/&gt;
* 1985 by Campbell ''et al.'',&lt;ref name=&quot;Campbell&quot;/&gt;
* 1990 by Gill ''et al.'',&lt;ref name=&quot;Gill2&quot;&gt;M. Gill, M. J. Kiefel, D. A. Lally, A. Ten, ''Aust. J. Chem.'' '''1990''', ''43'', 1497-518.&lt;/ref&gt;
* 1991 by Pattenden, Turvill and Chorlton,&lt;ref name=&quot;Pattenden&quot;&gt;G. Pattenden, M. W. Turvill, A. P. Chorlton, ''J. Chem. Soc., Perkin Trans. 1'' '''1991''', ''10'', 2357-2361.
{{doi|10.1039/P19910002357}}.&lt;/ref&gt;  
* 2005 by Caufield ''et al.'',&lt;ref name=&quot;Caufield&quot;/&gt;
* 2006 by Antane ''et al.'',&lt;ref name=&quot;Antane&quot;/&gt;
* 2007 by Kaczybura and Brückner,&lt;ref name=&quot;Brückner1&quot;&gt;N. Kaczybura, R. Brückner ''Synthesis'' '''2007''', 118-130. {{doi|10.1055/s-2006-950378}}.&lt;/ref&gt;
* 2007 by Bernier, Moser and Brückner.&lt;ref name=&quot;Brückner2&quot;&gt;D. Bernier, F. Moser, R. Brückner ''Synthesis'' '''2007''', 15, 2240-2248. {{doi|10.1055/s-2007-983800}}.&lt;/ref&gt;&lt;ref name=&quot;Brückner3&quot;&gt;D. Bernier, R. Brückner ''Synthesis'' '''2007''', 15, 2249-2272. {{doi|10.1055/s-2007-983803}}.&lt;/ref&gt;

== See also ==
* [[Pulvinic acid]]
* [[Variegatic acid]]
* [[Vulpinic acid]]

== Sources ==
{{reflist|2}}

{{Organic chemistry}}
{{Pharmacology}}
{{NSAIDs}}
{{Analgesics}}

[[Category:Enols]]
[[Category:Anticoagulants]]
[[Category:Antibiotics]]
[[Category:Analgesics]]
[[Category:Furones]]
[[Category:2,5-Dihydrofurans]]</text>
      <sha1>5koyckee262umya9742e8svohnh4hjo</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Zwittermicin A</title>
    <ns>0</ns>
    <id>17928523</id>
    <revision>
      <id>601524884</id>
      <parentid>593353798</parentid>
      <timestamp>2014-03-27T16:30:33Z</timestamp>
      <contributor>
        <username>Ellis O'Neill</username>
        <id>2513822</id>
      </contributor>
      <text xml:space="preserve" bytes="6073">
{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 366432625
|ImageFile= Zwastereo.png
|ImageSize= 300px
|IUPACName= 4,8-diamino-N-[1-amino-3-(carbamoylamino)-1-oxopropan-2-yl]-
2,3,5,7,9-pentahydroxynonanamide
| Section1 = {{Chembox Identifiers
|  CASNo_Ref = {{cascite|correct|??}}
| CASNo= 155547-95-8
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 24669086
|  SMILES = C([C@H]([C@H](CO)N)O)[C@H]([C@H]([C@H]([C@@H](C(=O)N[C@@H](CNC(=O)N)C(=O)N)O)O)N)O
|  InChI = 1/C13H28N6O8/c14-4(3-20)6(21)1-7(22)8(15)9(23)10(24)12(26)19-5(11(16)25)2-18-13(17)27/h4-10,20-24H,1-3,14-15H2,(H2,16,25)(H,19,26)(H3,17,18,27)/t4-,5-,6+,7+,8+,9+,10-/m0/s1
|  InChIKey = FYIPKJHNWFVEIR-VTAUKWRXBI
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C13H28N6O8/c14-4(3-20)6(21)1-7(22)8(15)9(23)10(24)12(26)19-5(11(16)25)2-18-13(17)27/h4-10,20-24H,1-3,14-15H2,(H2,16,25)(H,19,26)(H3,17,18,27)/t4-,5-,6+,7+,8+,9+,10-/m0/s1
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = FYIPKJHNWFVEIR-VTAUKWRXSA-N
  }}
| Section2 = {{Chembox Properties
|  Formula=C&lt;sub&gt;13&lt;/sub&gt;H&lt;sub&gt;28&lt;/sub&gt;N&lt;sub&gt;6&lt;/sub&gt;O&lt;sub&gt;8&lt;/sub&gt;
|  MolarMass=396.396820
  }}
}}

'''Zwittermicin A''' is an antibiotic that has been identified from the bacterium [[Bacillus cereus]] UW85.&lt;ref name=&quot;Zwittermicin&quot;&gt;Haiyin, He (April, 1994) &quot;Zwittermicin A, an Antifungal and Plant Protection Agent from Bacillus cereus&quot;, Tetrahedron Letters 35 (16) 2499-2502 doi=10.1016/S0040-4039(00)77154-1&lt;/ref&gt; It is a molecule of interest to agricultural industry because it has the potential to suppress plant disease due to its broad spectrum activity against certain gram positive and gram negative [[eukaryotic]] micro-organisms. The molecule is also of interest from a metabolic perspective because it represents a new structural class of antibiotic and suggests a crossover between [[polyketide]] and non-ribosomal peptide biosynthetic pathways. Zwittermicin A is linear aminopolyol.&lt;ref name=&quot;Synthesis&quot;&gt;{{cite journal |author=Rogers EW, Molinski TF |title=Asymmetric synthesis of diastereomeric diaminoheptanetetraols. A proposal for the configuration of (+)-zwittermicin a |journal=Org. Lett. |volume=9 |issue=3 |pages=437–40 |date=February 2007 |pmid=17249781 |doi=10.1021/ol062804a |url= |pmc=2729442}}&lt;/ref&gt;

==Biosynthesis==
Zwittermycin A [[biosynthesis]] is a hybrid of polyketide and non-ribosomal peptide synthetic pathways. Most likely, all of the synthases are located on one megasynthase much like a type I ketosynthase. Based on mutant studies, the biosynthetic cluster involved in zwittermicin production have been identified and the pathway proposed. The [[gene]]s responsible for the production of zwittermicin A are located on a 16 kb cluster containing nine orfs and a self resistant gene zmaR, a [[gene]] that encodes an [[acylation]] [[enzyme]] that deactivate zwittermicin A.&lt;ref name=&quot;Cluster&quot;&gt;{{cite journal |author=Stohl EA, Milner JL, Handelsman J |title=Zwittermicin A biosynthetic cluster |journal=Gene |volume=237 |issue=2 |pages=403–11 |date=September 1999 |pmid=10521664 |doi= 10.1016/S0378-1119(99)00315-7|url=http://linkinghub.elsevier.com/retrieve/pii/S0378111999003157}}&lt;/ref&gt; The hybrid [[synthase]] used in zwittermicin A production utilizes modified extender units such as hydroxymalonyl-ACP, aminomalonyl-ACP and [[2,3-diaminopropionate]]. Therefore, many of the genes in the biosynthetic cluster encode for [[enzyme]]s responsible for the synthesis of these extender units used in the hybrid synthase. For example, orf5 encodes ZWA5A, an enzyme that is responsible for the PLP mediated amination that converts L-serine to 2,3-diaminopropionate. It has also been shown that orf5, orf7, orf4 and orf6 participate in the biosynthesis of aminomalonyl-ACP and orf3, orf2 and orf1 synthesize hydroxymalonyl-ACP.&lt;ref name=&quot;Related Genes&quot;&gt;{{cite journal |author=Zhao C, Luo Y, Song C, ''et al.'' |title=Identification of three Zwittermicin A biosynthesis-related genes from Bacillus thuringiensis subsp. kurstaki strain YBT-1520 |journal=Arch. Microbiol. |volume=187 |issue=4 |pages=313–9 |date=April 2007 |pmid=17225146 |doi=10.1007/s00203-006-0196-3 |url=}}&lt;/ref&gt;

[[Image:Zwabreakdown.png|400px|left|thumb|Units used in Zwittermicin A Production]]
[[Image:Diaminosynthesis.png|400px|right|thumb|Biosynthesis of L-2,3 Diaminopropionate]]&lt;br /&gt;
[[Image:Zwagenes.png|800px|center|Gene organization of the Zwittermicin A biosynthetic cluster.]]&lt;br /&gt;Gene organization of the Zwittermicin A biosynthetic cluster.&lt;br /&gt;
&lt;br /&gt;Genes encoding for the seven component hybrid synthase responsible for the assembly of the backbone is likely located on the largest gene, orf8. Assembly begins by the activation of a serine residue. This is done by tethering the amino acid to a peptidal carrier protein via a non-ribosomal peptide synthetase. Subsequently elongation of an activated malonyl unit covalently attached to an acyl carrier protein by a ketosynthase occurs giving the five carbon unit. The next two elongation steps proceed in a similar manner using aminomalonyl and hydroxymalonyl units from a second and third ketosynthase. Finally, condensation of 2,3-diaminopropionate with the carried molecule by a second nonribosomalpeptide synthase produces the zwittermicin A backbone.  Attack of ammonia via an amidotransferase enzyme releases the carrier protein. The last step involves a carbomyltransferase enzyme that carbamolates the released molecule giving the final product.&lt;ref name=&quot;Genetics&quot;&gt;{{cite journal |author=Emmert EA, Klimowicz AK, Thomas MG, Handelsman J |title=Genetics of zwittermicin a production by Bacillus cereus |journal=Appl. Environ. Microbiol. |volume=70 |issue=1 |pages=104–13 |date=January 2004 |pmid=14711631 |pmc=321298 |doi= 10.1128/AEM.70.1.104-113.2004|url=http://aem.asm.org/cgi/pmidlookup?view=long&amp;pmid=14711631}}&lt;/ref&gt;&lt;br /&gt;
[[Image:Zwittermicinsynthesis.gif|1000px|center|thumb|Zwittermicin A Biosynthesis]]

==Footnotes==
&lt;references/&gt;

[[Category:Antibiotics]]</text>
      <sha1>rh7zcof2z65gyv895nmtfnqrccf4qyq</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Macbecin</title>
    <ns>0</ns>
    <id>18210009</id>
    <revision>
      <id>592333089</id>
      <parentid>545360569</parentid>
      <timestamp>2014-01-25T15:14:10Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="2896">{{chembox
| verifiedrevid = 424977367
| ImageFile = Macbecin1.png
| ImageSize = 
| IUPACName = (4''E'',6''Z'',8''S'',10''E'',12''R'',13''S'',14''R'',16''S'',17''R'')-13,14,17-trimethoxy-4,8,10,12,16-pentamethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate
| OtherNames = Macbecin I
| Section1 = {{Chembox Identifiers
|  CASNo_Ref = {{cascite|correct|??}}
| CASNo=73341-72-7
|  PubChem=5458728
|  SMILES=CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C=C(C1OC)C2=O)C)C)OC(=O)N)C)C)OC)OC
  }}
| Section2 = {{Chembox Properties
| C=30 | H = 42 | N=2 | O= 8
|  MolarMass=558.66308
  }}
}}
{{chembox
| ImageFile = Macbecin2.png
| ImageSize = 
| IUPACName = (4''E'',6''Z'',8''S'',10''E'',12''R'',13''S'',14''R'',16''S'',17''R'')-20,22-dihydroxy-13,14,17-trimethoxy-4,8,10,12,16-pentamethyl-3-oxo-2-azabicyclo[16.3.1]docosa-1(22),4,6,10,18,20-hexaen-9-yl carbamate
| OtherNames = Macbecin II
| Section1 = {{Chembox Identifiers
|  CASNo=73341-73-8
|  PubChem=5458729
|  SMILES=CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=C(C(=CC(=C2)O)C1OC)O)C)C)OC(=O)N)C)C)OC)OC
  }}
| Section2 = {{Chembox Properties
| C=30 | H = 44 | N=2 | O= 8
|  MolarMass=560.67896
 }}
}}

'''Macbecin''' belongs to the [[ansamycin]] family of [[antibiotic]]s and was first isolated from [[actinomycete]] bacteria.&lt;ref name=&quot;pmid7380729&quot;&gt;{{cite journal | author = Tanida S, Hasegawa T, Higashide E | title = Macbecins I and II, new antitumor antibiotics. I. Producing organism, fermentation and antimicrobial activities | journal = J. Antibiot. | volume = 33 | issue = 2 | pages = 199–204 |date=February 1980 | pmid = 7380729 | doi = | url =  }}&lt;/ref&gt;&lt;ref name=&quot;pmid7380730&quot;&gt;{{cite journal | author = Muroi M, Izawa M, Kosai Y, Asai M | title = Macbecins I and II, new antitumor antibiotics. II. Isolation and characterization | journal = J. Antibiot. | volume = 33 | issue = 2 | pages = 205–12 |date=February 1980 | pmid = 7380730 | doi = | url =  }}&lt;/ref&gt; Macbecin possesses potent [[chemotherapy|antitumor]] properties.

==Structure==
Macbecin has an unusual [[macrocycle|macrocyclic]] [[lactam]] structure.  There are two variants Macbecin I and II which correspond to the oxidized [[1,4-benzoquinone]] and reduced [[hydroquinone]] respectively.

==Mechanism of action==
Macbecins mechanism of action is in part due to [[heat shock protein]] [[Hsp90]] protein inhibition.&lt;ref name=&quot;pmid9584173&quot;&gt;{{cite journal | author = Bohen SP | title = Genetic and Biochemical Analysis of p23 and Ansamycin Antibiotics in the Function of Hsp90-Dependent Signaling Proteins | journal = Mol. Cell. Biol. | volume = 18 | issue = 6 | pages = 3330–9 |date=June 1998 | pmid = 9584173 | pmc = 108914 | doi = | url =  }}&lt;/ref&gt;

==References==
{{Reflist|2}}

==External links==
* {{MeshName|Macbecin+I}}
* {{MeshName|Macbecin+II}}

[[Category:Antibiotics]]
[[Category:Carbamates]]
[[Category:Quinones]]


{{antibiotic-stub}}</text>
      <sha1>tdxmkbd7ksx12ac6ocfzk8hhpi2wj1z</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Ramoplanin</title>
    <ns>0</ns>
    <id>18067520</id>
    <revision>
      <id>606242668</id>
      <parentid>601582259</parentid>
      <timestamp>2014-04-28T22:02:29Z</timestamp>
      <contributor>
        <username>CheMoBot</username>
        <id>7377957</id>
      </contributor>
      <comment>Updating {{drugbox}} (changes to verified and watched fields) per [[WP:CHEMVALID|Chem/Drugbox validation]] (report [[Wikipedia talk:WikiProject_Pharmacology|errors]] or [[user talk:CheMoBot|bugs]])</comment>
      <text xml:space="preserve" bytes="3038">{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 307712718
| IUPAC_name =  
| image = Ramoplanin A2.svg

&lt;!--Clinical data--&gt;
| tradename =  
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category =  
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, or Class A, B, C --&gt;
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = Oral

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 76168-82-6
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 16132338
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 0WX9996O2G
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1095892

&lt;!--Chemical data--&gt;
| chemical_formula =  
| C=119 | H=154 | Cl=1 | N=21 | O=40 
| molecular_weight = 2554.07 g/mol
}}

'''Ramoplanin''' ([[International Nonproprietary Name|INN]]) is a glycolipodepsipeptide [[antibiotic]] drug derived from strain ATCC 33076 of ''[[Actinoplanes]]''.&lt;ref&gt;Farver DK, Hedge DD, Lee SC. Ramoplanin: a lipoglycodepsipeptide antibiotic. ''Annals of Pharmacotherapy''. 2005 May;39(5):863-8. PMID 15784805&lt;/ref&gt; 

== Mechanism ==
It exerts its bacteriocidal effect by inhibiting [[cell wall]] biosynthesis, acting by inhibiting the transglycosylation step of [[peptidoglycan]] synthesis.&lt;ref&gt;Fang X, Tiyanont K, Zhang Y, Wanner J, Boger D, Walker S. The mechanism of action of ramoplanin and enduracidin. ''Molecular Biosystems''. 2006 Jan;2(1):69-76. PMID 16880924&lt;/ref&gt; 

== Uses ==
Its development has been fast-tracked by the [[U.S. Food and Drug Administration]] as a treatment for multiantibiotic-resistant ''[[Clostridium difficile]]'' infection of the [[gastrointestinal tract]],&lt;ref&gt;Fulco P, Wenzel RP. Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. ''Expert Review of Anti Infective Therapy''. 2006 Dec;4(6):939-45. PMID 17181409&lt;/ref&gt; although it is unstable in the bloodstream and so can be taken only orally against GI tract infections.&lt;ref&gt;Scheinfeld N. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus. ''Journal of Drugs in Dermatology''. 2007 Jan;6(1):97-103. PMID 17373167&lt;/ref&gt;&lt;ref&gt;Balagopal A, Sears CL. Clostridium difficile: new therapeutic options. ''Current Opinion in Pharmacology''. 2007 Oct;7(5):455-8. PMID 17644040&lt;/ref&gt;&lt;ref&gt;Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. ''Clinical Infectious Diseases''. 2008 Jan 15;46 Suppl 1:S32-42. PMID 18177219&lt;/ref&gt; 

== References ==
{{reflist|2}}

{{Cell wall disruptive antibiotics}}

[[Category:Antibiotics]]

{{antibiotic-stub}}</text>
      <sha1>lk9pkrem4fumbtdlufo1dobnnf8na53</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Isoniazid</title>
    <ns>0</ns>
    <id>599463</id>
    <revision>
      <id>608436581</id>
      <parentid>608418431</parentid>
      <timestamp>2014-05-13T19:54:09Z</timestamp>
      <contributor>
        <username>AnomieBOT</username>
        <id>7611264</id>
      </contributor>
      <minor/>
      <comment>Dating maintenance tags: {{Refimprove section}} {{Cn}}</comment>
      <text xml:space="preserve" bytes="14482">'''{{Drugbox
 | verifiedrevid = 459455986
 | IUPAC_name = isonicotinohydrazide
 | image = Isoniazid skeletal.svg
 | width = 160
 | image2 = Isoniazid 3d.png
 | width2 = 220
&lt;!--Clinical data--&gt;
 | tradename =  
 | Drugs.com = {{drugs.com|monograph|isoniazid}}
 | MedlinePlus = a682401
 | pregnancy_category = C
 | legal_status = prescription only (US)
 | routes_of_administration = oral, intramuscular, intravenous

&lt;!--Pharmacokinetic data--&gt;
 | protein_bound = Very low (0-10%)
 | metabolism = liver; CYP450: 2C19, 3A4 inhibitor
 | elimination_half-life = 0.5-1.6h (fast acetylators), 2-5h (slow acetylators)
 | excretion = urine (primarily), feces

&lt;!--Identifiers--&gt;
 | CASNo_Ref = {{cascite|correbct|CAS}}
 | CAS_number_Ref = {{cascite|correct|??}}
 | CAS_number = 54-85-3
 | ATC_prefix = J04
 | ATC_suffix = AC01
 | PubChem = 3767
 | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00951
 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
 | ChemSpiderID = 3635
 | UNII_Ref = {{fdacite|correct|FDA}}
 | UNII = V83O1VOZ8L
 | KEGG_Ref = {{keggcite|correct|kegg}}
 | KEGG = D00346
 | ChEBI_Ref = {{ebicite|correct|EBI}}
 | ChEBI = 6030
 | ChEMBL_Ref = {{ebicite|correct|EBI}}
 | ChEMBL = 64
 | NIAID_ChemDB = 007657

&lt;!--Chemical data--&gt;
 | C=6 | H=7 | N=3 | O=1
 | molecular_weight = 137.139 g/mol
 | smiles = O=C(NN)c1ccncc1
 | InChI = 1/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)
 | InChIKey = QRXWMOHMRWLFEY-UHFFFAOYAD
 | StdInChI_Ref = {{stdinchicite|correct|chemspider}}
 | StdInChI = 1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)
 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
 | StdInChIKey = QRXWMOHMRWLFEY-UHFFFAOYSA-N
}}

'''Isoniazid''' ('''Laniazid''', '''Nydrazid'''), also known as '''isonicotinylhydrazine''' ('''INH'''), is an [[organic compound]] that is the first-line medication in prevention and treatment of [[tuberculosis]]. The compound was first synthesized in the early 20th century,&lt;ref&gt;{{Cite journal|author=Meyer H, Mally J|title=On hydrazine derivatives of pyridine carbonic acids|journal=Monatshefte Chemie verwandte Teile anderer Wissenschaften|volume=33|pages=393&amp;ndash;414|doi = 10.1007/BF01517946|language=German|year=1912 | url = http://springerlink.metapress.com/content/p7145p063227623j/fulltext.pdf|issue=4 }}&lt;/ref&gt; but its activity against tuberculosis was first reported in the early 1950s, and three pharmaceutical companies attempted unsuccessfully to simultaneously patent the drug,&lt;ref&gt;{{Cite journal|journal=Lancet|volume=373|issue=9670|pages=1148&amp;ndash;1149|year=2009
|doi=10.1016/S0140-6736(09)60559-6|title=Fourth-generation fluoroquinolones in tuberculosis|author=Hans L Riede|pmid=19345815}}&lt;/ref&gt; the most prominent one being Roche, which launched its version, Rimifon, in 1952.&lt;ref&gt;[http://www.rocheusa.com/about/history.html Roche USA]&lt;/ref&gt; The drug was first tested at [[Many Farms, Arizona|Many Farms]], a [[Navajo Nation|Navajo]] community, due to the Navajo reservation's dire tuberculosis problem and the fact that the population was [[Naïveté|naïve]] with respect to [[streptomycin]], the main tuberculosis treatment at the time.&lt;ref&gt;{{cite journal|last=Jones|first=David|title=The Health Care Experiments at Many Farms: The Navajo, Tuberculosis, and the Limits of Modern Medicine, 1952-1962|journal=Bulletin of the History of Medicine|year=2002|volume=76|issue=4|pages=749–790|doi=10.1353/bhm.2002.0186|pmid=12446978}}&lt;/ref&gt; With the introduction of isoniazid, a cure for tuberculosis was first considered reasonable.

Isoniazid is available in tablet, syrup, and injectable forms (given intramuscularly or intravenously). It is available worldwide, is inexpensive and is generally well tolerated. It is manufactured from [[isonicotinic acid]], which is produced from [[4-Methylpyridine|4-methylpyridine]].&lt;ref&gt;{{Cite book|author=Shinkichi Shimizu, Nanao Watanabe, Toshiaki Kataoka, Takayuki Shoji, Nobuyuki Abe, Sinji Morishita, Hisao Ichimura|chapter=Pyridine and Pyridine Derivatives|title=Ullmann's Encyclopedia of Industrial Chemistry|year=2007|publisher=John Wiley &amp;amp; Sons|location=New York | doi = 10.1002/14356007.a22_399}}{{Page needed|date=September 2010}}&lt;/ref&gt;

==Preparation==
Isoniazid may be prepared by the base hydrolysis of 4-cyanopyridine to give the [[Isonicotinamide|amide]], followed by displacement of ammonia by [[hydrazine]]:&lt;ref&gt;{{Cite journal| journal = [[Pharmaceutical Chemistry Journal]] | volume= 6 | issue = 11 | year = 1972 | doi = 10.1007/BF00771896 | pages = 696–698 | title = Synthesis of isoniazid from 4-cyanopyridine | author = T. P. Sycheva, T. N. Pavlova and M. N. Shchukina}}&lt;/ref&gt;{{Failed verification|date=May 2012}}

:[[File:Preparation of isoniazid.png|400px]]

==Mechanism of action==
Isoniazid is a [[prodrug]] and must be activated by a bacterial catalase-peroxidase enzyme that in ''M. tuberculosis'' is called KatG.&lt;ref&gt;{{Cite journal|author=Suarez J, Ranguelova K, Jarzecki AA, ''et al.'' |title=An oxyferrous heme/protein-based radical intermediate is catalytically competent in the catalase reaction of Mycobacterium tuberculosis catalase-peroxidase (KatG) |journal=The Journal of Biological Chemistry |volume=284 |issue=11 |pages=7017–29 |date=March 2009 |pmid=19139099 |doi=10.1074/jbc.M808106200 |pmc=2652337}}&lt;/ref&gt;  KatG couples the isonicotinic acyl with [[NADH]] to form isonicotinic acyl-NADH complex. This complex binds tightly to the [[enoyl-acyl carrier protein reductase]] known as InhA, thereby blocking the natural enoyl-AcpM substrate and the action of [[fatty acid synthase]]. This process inhibits the synthesis of [[mycolic acid]], required for the [[mycobacterium|mycobacterial]] cell wall. A range of radicals are produced by KatG activation of isoniazid, including [[nitric oxide]],&lt;ref&gt;{{Cite journal|author=Timmins GS, Master S, Rusnak F, Deretic V |title=Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis |journal=Antimicrobial Agents and Chemotherapy |volume=48 |issue=8 |pages=3006–9 |date=August 2004 |pmid=15273113 |pmc=478481 |doi=10.1128/AAC.48.8.3006-3009.2004}}&lt;/ref&gt; which has also been shown to be important in the action of another antimycobacterial prodrug [[PA-824]].&lt;ref&gt;{{Cite journal|author=Singh R, Manjunatha U, Boshoff HI, ''et al.'' |title=PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release |journal=Science |volume=322 |issue=5906 |pages=1392–5 |date=November 2008 |pmid=19039139 |doi=10.1126/science.1164571 |pmc=2723733}}&lt;/ref&gt;

Isoniazid is [[bactericidal]] to rapidly dividing [[mycobacterium|mycobacteria]], but is [[bacteriostatic]] if the mycobacteria are slow-growing.&lt;ref&gt;{{cite pmid|19686043}}&lt;/ref&gt;

Isoniazid inhibits the [[P450 system]].&lt;ref&gt;{{Cite book|title=Pharmacology | author = Harvey | edition = 4th |date=November 2009}}&lt;/ref&gt;

==Metabolism==
Isoniazid reaches therapeutic concentrations in serum, [[cerebrospinal fluid]], and within [[caseous necrosis|caseous granulomas]]. It is metabolized in the liver via [[acetylation]]. Two forms of the enzyme are responsible for acetylation, so some patients metabolize the drug more quickly than others.  Hence, the [[half-life]] is [[Bimodal distribution|bimodal]], with peaks at one and three hours in the US population. The metabolites are excreted in the urine.  Doses do not usually have to be adjusted in case of [[renal failure]].

==Dosing==
The standard dose of isoniazid in adults is 5&amp;nbsp;mg/kg/day (max 300&amp;nbsp;mg daily) for 6 months.&lt;ref&gt;http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf?ua=1&lt;/ref&gt; The CDC and the WHO differ in their recommendation of intermittent dosing.  The CDC recommends 15&amp;nbsp;mg/kg/day twice weekly (900&amp;nbsp;mg max dose), and the WHO recommends 10&amp;nbsp;mg/kg/day three times weekly (900&amp;nbsp;mg max dose) for either 6 or 9 months.&lt;ref&gt;http://www.cdc.gov/tb/publications/ltbi/treatment.htm&lt;/ref&gt;&lt;ref&gt;http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf?ua=1&lt;/ref&gt;  When prescribed intermittently (twice or thrice weekly), the dose is 10–15&amp;nbsp;mg/kg (max 900&amp;nbsp;mg daily), depending on the regimen chosen. Patients with slow clearance of the drug (via acetylation as described above) may require reduced dosages to avoid [[toxicity]].  The American Academy of Pediatrics recommends dosing for children of either 10–15&amp;nbsp;mg/kg/day for a daily regimen or 20–30&amp;nbsp;mg/kg/day for a twice weekly regimen.  The recommended duration of treatment is 9 months in children.&lt;ref&gt;http://pediatrics.aappublications.org/content/114/Supplement_4/1175.full.pdf&lt;/ref&gt;

==Side effects==
{{refimprove section|date=May 2014}}
Adverse reactions include [[rash]], abnormal [[liver function tests]], [[hepatitis]], [[sideroblastic anemia]], [[high anion gap metabolic acidosis]], [[peripheral neuropathy]], mild [[central nervous system]] (CNS) effects, [[drug interaction]]s resulting in increased [[phenytoin]] (Dilantin) or [[disulfiram]] (Antabuse) levels, intractable seizures ([[status epilepticus]]) and [[drug-induced lupus erythematosus]].{{cn|date=May 2014}}

[[Peripheral neuropathy]] and CNS effects are associated with the use of isoniazid and are due to [[pyridoxine]] (vitamin B&lt;sub&gt;6&lt;/sub&gt;) depletion, but are uncommon at doses of 5&amp;nbsp;mg/kg.{{cn|date=May 2014}} Persons with conditions in which neuropathy is common (e.g., [[diabetes]], [[uremia]], [[alcoholism]], [[malnutrition]], and [[HIV]] infection), as well as [[pregnant]] women and persons with a [[seizure]] disorder, may be given [[pyridoxine]] (vitamin B&lt;sub&gt;6&lt;/sub&gt;) (10–50&amp;nbsp;mg/day) with isoniazid.

Isoniazid may cause severe and sometimes fatal liver damage.{{cn|date=May 2014}} Hepatotoxicity can be avoided with close clinical monitoring of the patient, to be specific, nausea, vomiting, abdominal pain, and loss of appetite. Isoniazid is metabolized by the liver mainly by [[acetylation]] and dehydrazination. The N-acetylhydrazine metabolite is believed to be responsible for the hepatotoxic effects seen in patients treated with isoniazid. The rate of acetylation is genetically determined. Approximately 50% of blacks and Caucasians are slow inactivators; the majority of Inuit and Asians are rapid inactivators. The half-life in fast acetylators is one to two hours, while in slow acetylators, it is two to five hours. Elimination is largely independent of renal function, but the half-life may be prolonged in liver disease. The rate of acetylation has not been shown to significantly alter the effectiveness of isoniazid. However, slow acetylation may lead to higher blood concentrations with chronic administration of the drug, with an increased risk of toxicity. Fast acetylation leads to higher blood levels of the toxic metabolite acetylisoniazid and thus to an increase in toxic reactions - hepatitis which is 250 times more common than in slow acetylators. Isoniazid and its metabolites are excreted in the urine with 75 to 95% of the dose excreted in 24 hours. Small amounts are also excreted in saliva, sputum, and feces. Isoniazid is removed by hemodialysis and peritoneal dialysis.&lt;ref&gt;http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20I)/ISONIAZID.html&lt;/ref&gt;

Headache, poor concentration, weight gain, poor memory, insomnia and depression have all been associated with isoniazid use.{{cn|date=May 2014}} All patients and healthcare workers should be aware of these serious adverse effects, especially if suicidal thinking or behavior are suspected.&lt;ref&gt;{{Cite journal|author=Alao AO, Yolles JC |title=Isoniazid-induced psychosis |journal=The Annals of Pharmacotherapy |volume=32 |issue=9 |pages=889–91 |date=September 1998 |pmid=9762376 |doi=10.1345/aph.17377}}&lt;/ref&gt;&lt;ref&gt;{{cite journal | pmid = 11862134 | year = 2002 | last1 = Iannaccone | first1 = R | last2 = Sue | first2 = YJ | last3 = Avner | first3 = JR | title = Suicidal psychosis secondary to isoniazid | volume = 18 | issue = 1 | pages = 25–7 | journal = Pediatric emergency care | doi=10.1097/00006565-200202000-00008}}&lt;/ref&gt;&lt;ref&gt;{{Cite journal|author=Pallone KA, Goldman MP, Fuller MA |title=Isoniazid-associated psychosis: case report and review of the literature |journal=The Annals of Pharmacotherapy |volume=27 |issue=2 |pages=167–70 |date=February 1993 |pmid=8439690}}&lt;/ref&gt;

INH is known to reduce cytochrome P450 and in theory promotes the efficacy of contraceptives.{{cn|date=May 2014}} Therapy is often combined with [[rifampin]]. Rifampin increases the P450 enzyme and also can reduce the efficacy of contraceptives. Alternative means of birth control should be used when taking these medications.

As previously mentioned, isoniazid is associated with pyridoxine deficiency. Pyridoxyl phosphate (derivative of pyridoxine, i.e. Vitamin B6) is required for d-aminolevulinic acid synthase, the enzyme responsible for the rate-limiting step in heme synthesis. As such, isoniazid-induced pyridoxine-deficiency leads to insufficient heme formation in early red blood cells, leading to [[sideroblastic anemia]].

==Synonyms and abbreviations==
* Isonicotinyl hydrazine
* Isonicotinic acid hydrazide
* INH
* H (for &quot;hydrazide&quot;, and also the [[World Health Organisation|WHO]] standard abbreviation)

==See also==
*[[Iproniazid]]
*[[Tuberculosis treatment]]
*[[Tuberculosis]]
*''[[Mycobacterium tuberculosis]]''

==References==
{{Reflist|2}}

==External links==
:*[http://www.cdc.gov/tb/pubs/corecurr/default.htm Core Curriculum on Tuberculosis (2000)] Division of Tuberculosis Elimination, Centers for Disease Control and Prevention
::See Chapter 6, Treatment of LTBI Regimens - [http://www.cdc.gov/tb/pubs/corecurr/Chapter6/Chapter_6_Regimens.htm Isoniazid]::&lt;br&gt;See Chapter 7 - Treatment of TB Disease Monitoring - [http://www.cdc.gov/tb/pubs/corecurr/Chapter7/Chapter_7_Monitoring.htm Adverse Reactions to First-Line TB Drugs - Isoniazid]::&lt;br&gt;See Table 5 [http://www.cdc.gov/tb/pubs/corecurr/tables/table5.htm First-Line Anti-TB Medications]

:*[http://www.aafp.org/afp/980215ap/romero.html Isoniazid Overdose: Recognition and Management] American Family Physician 1998 Feb 15

{{Antimycobacterials}}
{{Cell wall disruptive antibiotics}}
{{Hydrazines}}

[[Category:Antibiotics]]
[[Category:Prodrugs]]
[[Category:Isonicotinamides]]
[[Category:Tuberculosis]]
[[Category:World Health Organization essential medicines]]
[[Category:Hydrazides]]
[[Category:Antidepressants]]</text>
      <sha1>9rwayyg6lz4eclswh200e84xt1qzvck</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Lipopeptide</title>
    <ns>0</ns>
    <id>15499714</id>
    <revision>
      <id>549255612</id>
      <parentid>545125679</parentid>
      <timestamp>2013-04-08T02:15:35Z</timestamp>
      <contributor>
        <username>My very best wishes</username>
        <id>10071161</id>
      </contributor>
      <text xml:space="preserve" bytes="1781">{{Infobox protein family
| Symbol = 
| Name = Cyclic lipopeptide antibiotics
| image = 
| width = 
| caption = 
| Pfam = 
| Pfam_clan =  
| InterPro = 
| SMART = 
| PROSITE = 
| MEROPS = 
| SCOP = 
| TCDB = 1.D.15
| OPM family = 172
| OPM protein = 1t5n
| CAZy = 
| CDD = 
}}

A '''lipopeptide''' is a [[molecule]] consisting of a [[lipid]] connected to a [[peptide]]. [[Bacteria]] express these molecules. They are bound by [[TLR 1]], and other, [[Toll-like receptors]].
&lt;br /&gt;
Certain lipopeptides are used as [[antibiotics]].&lt;ref&gt;[http://www.google.com/patents/US6911525 US Patent 6911525 - Lipopeptides as antibacterial agents]&lt;/ref&gt;&lt;ref&gt;[http://jac.oxfordjournals.org/cgi/content/full/55/3/283 Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections ], Judith N. Steenbergen*, Jeff Alder, Grace M. Thorne and Francis P. Tally , [[Journal of Antimicrobial Chemotherapy]] 2005 55(3):283-288; {{doi|10.1093/jac/dkh546}}&lt;/ref&gt;

==Examples==
*[[Surfactin]]
*[[Daptomycin]]
*[[Echinocandins]] (e.g., [[caspofungin]])

== See also ==
* [[pepducin]]s, lipopeptides aimed at [[GPCR]]s.

==References==
{{reflist}}

== Further reading ==
{{refbegin | 2}}
*{{cite journal  | author=Giuliani A, Pirri G, Nicoletto S |title=Antimicrobial peptides: an overview of a promising class of therapeutics  |journal=Cent. Eur. J. Biol. |volume=2 |issue= 1 |pages= 1–33 |year= 2007 |doi=10.2478/s11535-007-0010-5  }}
*{{cite journal  | author=Pirri G, Giuliani A, Nicoletto S, Pizutto L, Rinaldi A |title=Lipopeptides as anti-infectives: a practical perspective |journal=Cent. Eur. J. Biol. |volume=4 |issue= 3 |pages= 258–273 |year= 2009 |doi=10.2478/s11535-009-0031-3  }}
{{refend}}

[[Category:Antibiotics]]
[[Category:Lipopeptides]]


{{biochemistry-stub}}</text>
      <sha1>4l5darx7844ck0iedq79h7ow0qnfzsd</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>List of antibiotics</title>
    <ns>0</ns>
    <id>18605046</id>
    <revision>
      <id>609138119</id>
      <parentid>609137812</parentid>
      <timestamp>2014-05-18T20:08:26Z</timestamp>
      <contributor>
        <ip>151.0.60.233</ip>
      </contributor>
      <text xml:space="preserve" bytes="20151">The following is a list of [[antibiotics]], sorted by class. The highest division is between [[bactericidal]] antibiotics and [[bacteriostatic]] antibiotics. Bactericidals kill [[bacteria]] directly, whereas bacteriostatics prevent them from dividing. However, these classifications are based on laboratory behavior. In practice, both can prevent a bacterial infection.&lt;ref&gt;Pelczar, M.J., Chan, E.C.S. and Krieg, N.R. (1999) “Host-Parasite Interaction; Nonspecific Host Resistance”, In: Microbiology Conceptsand Applications, 6th ed., McGraw-Hill Inc., New York, U.S.A. pp. 478-479.&lt;/ref&gt;

''See also [[Pathogenic bacteria#Clinical characteristics|pathogenic bacteria]] for a list of antibiotics sorted by target bacteria.''

{| class=&quot;wikitable&quot;
|+ Antibiotics by class
|-
! Generic name !! Brand names !! Common uses&lt;ref name=&quot;merck&quot;&gt;For common Uses and possible side effects reference is: Robert Berkow (ed.) ''[[Merck Manual|The Merck Manual of Medical Information - Home Edition]]''. Pocket (September 1999), ISBN 0-671-02727-1.&lt;/ref&gt; !! Possible side effects&lt;ref name=&quot;merck&quot; /&gt; !! Mechanism of action
|-
! colspan=&quot;5&quot; | [[Aminoglycoside|Aminoglycosides]]
|-
| [[Amikacin]] || [[Amikin]] || rowspan=&quot;7&quot; | Infections caused by [[Gram-negative bacteria]], such as ''[[Escherichia coli]]'' and ''[[Klebsiella]]'' particularly ''[[Pseudomonas aeruginosa]]''. Effective against Aerobic bacteria (not obligate/facultative anaerobes) and [[tularemia]].
| rowspan=&quot;8&quot; |
* [[Ototoxicity|Hearing loss]]
* [[Vertigo (medical)|Vertigo]]
* [[Nephrotoxicity|Kidney damage]]
| rowspan=&quot;8&quot;| Binding to the bacterial [[30S]] [[ribosome|ribosomal]] subunit (some work by binding to the [[50S]] subunit), inhibiting the translocation of the peptidyl-tRNA from the A-site to the P-site and also causing misreading of mRNA, leaving the bacterium unable to synthesize proteins vital to its growth.
|-
|[[Gentamicin]] || [[Garamycin]]
|-
|[[Kanamycin]] || [[Kantrex]]
|-
|[[Neomycin]]|| Neo-Fradin&lt;ref name=&quot;Up to date&quot;&gt;{{cite web |url=http://www.uptodate.com/contents/neomycin-drug-information?source=search_result&amp;search=neomycin&amp;selectedTitle=1~135 |title=Neomycin Drug Information |publisher=uptodate |accessdate=2/11/2012}}{{subscription required}}&lt;/ref&gt;
|-
|[[Netilmicin]] || [[Netromycin]]
|-
|[[Tobramycin]] || [[Nebcin]]
|-
|[[Paromomycin]] || [[Humatin]] ||
|-
|[[Streptomycin]] || ||[[Tuberculosis]]
|-
|[[Spectinomycin]] || Trobicin || [[Gonorrhea]] ||
|-
! colspan=&quot;5&quot; | [[Ansamycin|Ansamycins]]
|-
|[[Geldanamycin]] || || rowspan=&quot;2&quot; | Experimental, as [[antineoplastic|antitumor antibiotics]]
| rowspan=&quot;2&quot; |
| rowspan=&quot;2&quot; |
|-
|[[Herbimycin]] ||
|-
|[[Rifaximin]] || Xifaxan || [[Traveler's diarrhea]] caused by ''[[E. coli]]'' || ||
|-
|-
!colspan=&quot;5&quot; | [[Carbacephem]]
|-
|[[Loracarbef]] || [[Lorabid]] || Discontinued || || prevents bacterial cell division by inhibiting cell wall synthesis.
|-
!colspan=&quot;5&quot; | [[Carbapenem|Carbapenems]]
|-
|[[Ertapenem]] || [[Invanz]] || rowspan=&quot;4&quot; | Bactericidal for both Gram-positive and Gram-negative organisms and therefore useful for empiric broad-spectrum antibacterial coverage. (Note MRSA resistance to this class.)
| rowspan=&quot;4&quot; |
* Gastrointestinal upset and diarrhea
* Nausea
* Seizures
* Headache
* Rash and allergic reactions
| rowspan=&quot;4&quot; | Inhibition of cell wall synthesis
|-
|[[Doripenem]] || [[Doribax]]
|-
|[[Imipenem]]/[[Cilastatin]] || [[Primaxin]]
|-
|[[Meropenem]] || [[Merrem]]
|-
! colspan=&quot;5&quot; | [[Cephalosporin|Cephalosporins]] ([[Cephalosporins#First generation|First generation]])
|-
|[[Cefadroxil]] || [[Duricef]] || rowspan=&quot;4&quot; | Good coverage against Gram-positive infections.
| rowspan=&quot;4&quot; |
* Gastrointestinal upset and diarrhea
* Nausea (if alcohol taken concurrently)
* Allergic reactions
| rowspan=&quot;4&quot; | Same mode of action as other [[beta-lactam antibiotic]]s: disrupt the synthesis of the [[peptidoglycan]] layer of bacterial [[cell wall]]s.
|-
|[[Cefazolin]] || [[Ancef]]
|-
|[[Cefalotin]] or [[Cefalothin]] || [[Keflin]] (discontinued)
|-
|[[Cefalexin]] || [[Keflex]]
|-
! colspan=&quot;5&quot; | [[Cephalosporin|Cephalosporins]] ([[Cephalosporins#Second generation|Second generation]])
|-
|[[Cefaclor]] || [[Distaclor]] || rowspan=&quot;5&quot; | Less Gram-positive cover, improved Gram-negative cover. || rowspan=&quot;5&quot; |
* Gastrointestinal upset and diarrhea
* Nausea (if alcohol taken concurrently)
* Allergic reactions
| rowspan=&quot;5&quot; | Same mode of action as other [[beta-lactam antibiotic]]s: disrupt the synthesis of the [[peptidoglycan]] layer of bacterial [[cell wall]]s.
|-
|[[Cefamandole]] || [[Mandol]] (discontinued)
|-
|[[Cefoxitin]] || [[Mefoxin]] (discontinued)
|-
|[[Cefprozil]] || [[Cefzil]]
|-
|[[Cefuroxime]] || [[Ceftin]], [[Zinnat]] (UK)
|-
! colspan=&quot;5&quot; | [[Cephalosporin|Cephalosporins]] ([[Cephalosporins#Third generation|Third generation]])
|-
|[[Cefixime]] || [[Suprax]] || rowspan=&quot;10&quot; | Improved coverage of Gram-negative organisms, except ''[[Pseudomonas]]''. Reduced Gram-positive cover. || rowspan=&quot;10&quot; |
* Gastrointestinal upset and diarrhea
* Nausea (if alcohol taken concurrently)
* Allergic reactions
| rowspan=&quot;10&quot; | Same mode of action as other [[beta-lactam antibiotic]]s: disrupt the synthesis of the [[peptidoglycan]] layer of bacterial [[cell wall]]s.
|-
|[[Cefdinir]] || [[Omnicef]], Cefdiel
|-
|[[Cefditoren]] || [[Spectracef]], Meiact
|-
|[[Cefoperazone]] || [[Cefobid]] (discontinued)
|-
|[[Cefotaxime]] || [[Claforan]]
|-
|[[Cefpodoxime]] || [[Vantin]]
|-
|[[Ceftazidime]] [Unlike most third-generation agents, ceftazidime is active against ''Pseudomonas aeruginosa'']
 || [[Fortaz]]
|-
|[[Ceftibuten]] || [[Cedax]]
|-
|[[Ceftizoxime]] || Cefizox (discontinued)
|-
|[[Ceftriaxone]] || [[Rocephin]]
|-
! colspan=&quot;5&quot; | [[Cephalosporin|Cephalosporins]] ([[Cephalosporins#Fourth generation|Fourth generation]])
|-
|[[Cefepime]] || [[Maxipime]]
||
Covers pseudomonal infections.
||
* Gastrointestinal upset and diarrhea
* Nausea (if alcohol taken concurrently)
* Allergic reactions
| Same mode of action as other [[beta-lactam antibiotic]]s: disrupt the synthesis of the [[peptidoglycan]] layer of bacterial [[cell wall]]s.
|-
! colspan=&quot;5&quot; | [[Cephalosporin|Cephalosporins]] ([[Cephalosporins#Fifth generation|Fifth generation]])
|-
|[[Ceftaroline fosamil]] || [[Teflaro]] || Used to treat [[Methicillin-resistant Staphylococcus aureus|MRSA]] ||
* Gastrointestinal upset and diarrhea
* Allergic reaction
| Same mode of action as other [[beta-lactam antibiotic]]s: disrupt the synthesis of the [[peptidoglycan]] layer of bacterial [[cell wall]]s.
|-
|[[Ceftobiprole]] || [[Zeftera]] || Used to treat [[Methicillin-resistant Staphylococcus aureus|MRSA]] ||
* Gastrointestinal upset and diarrhea
* Nausea (if alcohol taken concurrently)
* Allergic reactions
| Same mode of action as other [[beta-lactam antibiotic]]s: disrupt the synthesis of the [[peptidoglycan]] layer of bacterial [[cell wall]]s.
|-
!colspan=&quot;5&quot; | [[Glycopeptide antibiotic|Glycopeptides]]
|-
|[[Teicoplanin]] || Targocid (UK) || rowspan=&quot;3&quot; | Active against aerobic and anaerobic Gram-positive bacteria including MRSA; Vancomycin is used orally for the treatment of ''[[Clostridium difficile|C. difficile]]'' || rowspan=&quot;3&quot; | || rowspan=&quot;3&quot; | inhibiting [[peptidoglycan]] synthesis
|-
|[[Vancomycin]] || [[Vancocin]]
|-
|[[Telavancin]] || [[Vibativ]]
|-
!colspan=&quot;5&quot; | [[Lincosamides]]
|-
|[[Clindamycin]] || [[Cleocin]] || rowspan=&quot;2&quot; | Serious staph-, pneumo-, and streptococcal infections in penicillin-allergic patients, also anaerobic infections; clindamycin topically for [[acne]] || rowspan=&quot;2&quot; | Possible ''[[Clostridium difficile|C. difficile]]''-related [[pseudomembranous enterocolitis]]|| rowspan=&quot;2&quot; | Bind to 50S subunit of bacterial ribosomal [[RNA]] thereby inhibiting protein synthesis
|-
|[[Lincomycin]] || Lincocin
|-
!colspan=&quot;5&quot; | [[Lipopeptide]]
|-
|[[Daptomycin]] || [[Cubicin]] || [[Gram-positive]] organisms || || Bind to the membrane and cause rapid depolarization, resulting in a loss of membrane potential leading to inhibition of protein, DNA and RNA synthesis
|-
!colspan=&quot;5&quot; | [[Macrolide|Macrolides]]
|-
|[[Azithromycin]] || [[Zithromax]], [[Sumamed]], [[Xithrone]] || rowspan=&quot;6&quot; | [[Streptococcal infection|Streptococcal infections]], [[syphilis]], [[upper respiratory tract infection]]s, [[lower respiratory tract infection]]s, [[mycoplasmal infection]]s, [[Lyme disease]] || rowspan=&quot;6&quot; |
* Nausea, vomiting, and diarrhea (especially at higher doses)
* Prolonged cardiac [[QT interval]] (especially erythromycin)
* [[Jaundice]]
| rowspan=&quot;8&quot; |[[enzyme inhibitor|inhibition]] of bacterial [[protein biosynthesis]] by binding reversibly to the subunit [[50S]] of the bacterial [[ribosome]], thereby inhibiting translocation of peptidyl [[Transfer RNA|tRNA]].
|-
|[[Clarithromycin]] || [[Biaxin]]
|-
|[[Dirithromycin]] || [[Dynabac]] (discontinued)
|-
|[[Erythromycin]] || [[Erythocin]], [[Erythroped]]
|-
|[[Roxithromycin]] ||
|-
|[[Troleandomycin]] || Tao (discontinued)
|-
|[[Telithromycin]] || [[Ketek]] || [[Pneumonia]] || Visual Disturbance, Liver Toxicity.&lt;ref&gt;{{cite journal
|last= Splete
|first= Heidi
|coauthors= Kerri Wachter
|date=March 2006
|title= Liver toxicity reported with Ketek
|journal= Internal Medicine News}}
&lt;/ref&gt;
|-
|[[Spiramycin]] || Rovamycine|| [[Mouth infections]] ||
|-
!colspan=&quot;5&quot; | [[Monobactams]]
|-
|[[Aztreonam]] || [[Azactam]] || Gram-negative bacteria || || Same mode of action as other [[beta-lactam antibiotic]]s: disrupt the synthesis of the [[peptidoglycan]] layer of bacterial [[cell wall]]s.
|-
!colspan=&quot;5&quot; | [[Nitrofurans]]
|-
||[[Furazolidone]] || Furoxone || Bacterial or [[protozoal]] [[diarrhea]] or [[enteritis]] || ||
|-
|[[Nitrofurantoin]] || [[Macrodantin]], [[Macrobid]] || [[Urinary tract infections]] || ||
|-
!colspan=&quot;5&quot; | [[2-Oxazolidone|Oxazolidonones]]
|-
|[[Linezolid]] || [[Zyvox]] || [[Vancomycin-resistant Staphylococcus aureus|VRSA]] ||
*[[Thrombocytopenia]]
*[[Peripheral neuropathy]] 
| rowspan=&quot;4&quot; | [[Protein synthesis inhibitor]]; prevents the initiation step
|-
|[[Posizolid]] || Phase II clinical trials || ||
|-
|[[Radezolid]] || Phase II clinical trials || ||
|-
|[[Torezolid]] || Phase II clinical trials || ||
|-
!colspan=&quot;5&quot; | [[Penicillin|Penicillins]]
|-
|[[Amoxicillin]] || [[Novamox]], [[Amoxil]] || rowspan=&quot;16&quot; | Wide range of infections; penicillin used for [[streptococcal infection]]s, [[syphilis]], and [[Lyme disease]] || rowspan=&quot;16&quot; |
* Gastrointestinal upset and diarrhea
* Allergy with serious [[anaphylactic reaction]]s
* Brain and kidney damage (rare)
| rowspan=&quot;16&quot; | Same mode of action as other [[beta-lactam antibiotic]]s: disrupt the synthesis of the [[peptidoglycan]] layer of bacterial [[cell wall]]s.
|-
|[[Ampicillin]] || Principen (discontinued)
|-
|[[Azlocillin]] ||
|-
|[[Carbenicillin]] || Geocillin (discontinued)
|-
|[[Cloxacillin]] || Tegopen (discontinued)
|-
|[[Dicloxacillin]] || Dynapen (discontinued)
|-
|[[Flucloxacillin]] || [[Floxapen]] (Sold to European generics Actavis Group)
|-
|[[Mezlocillin]] || Mezlin (discontinued)
|-
|[[Methicillin]] || Staphcillin (discontinued)
|-
|[[Nafcillin]] || Unipen (discontinued)
|-
|[[Oxacillin]] || Prostaphlin (discontinued)
|-
|[[Penicillin G]] || Pentids (discontinued)
|-
|[[Penicillin V]] || Veetids (Pen-Vee-K) (discontinued)
|-
|[[Piperacillin]] || Pipracil (discontinued)
|-
|[[Penicillin G]] || Pfizerpen
|-
|[[Temocillin]] || Negaban (UK) (discontinued)
|-
|[[Ticarcillin]] || Ticar (discontinued)
|-
! colspan=&quot;5&quot; | Penicillin combinations
|-
|[[co-amoxiclav|Amoxicillin/clavulanate]] || Augmentin || rowspan=&quot;4&quot; | || rowspan=&quot;4&quot; | || rowspan=&quot;4&quot; | The second component prevents bacterial [[antibiotic resistance|resistance]] to the first component
|-
|[[Ampicillin/sulbactam]] || Unasyn
|-
|[[Piperacillin/tazobactam]] || Zosyn
|-
|[[Ticarcillin/clavulanate]] || Timentin
|-
!colspan=&quot;5&quot; | [[Polypeptide antibiotics|Polypeptides]]
|-
|[[Bacitracin]] || || rowspan=&quot;3&quot; | Eye, ear or bladder infections; usually applied directly to the eye or inhaled into the lungs; rarely given by injection, although the use of intravenous colistin is experiencing a resurgence due to the emergence of [[multi drug resistant]] organisms. || rowspan=&quot;3&quot; | Kidney and nerve damage (when given by injection)
| Inhibits [[isoprenyl pyrophosphate]], a molecule that carries the building blocks of the [[peptidoglycan]] bacterial [[cell wall]] outside of the inner membrane&lt;ref&gt;[http://www.pnas.org/cgi/content/abstract/68/12/3223 Mechanism of Action of Bacitracin: Complexation with Metal Ion and C55-Isoprenyl Pyrophosphate] K. John Stone and Jack L. Strominger&lt;/ref&gt;
|-
|[[Colistin]] || Coly-Mycin-S || rowspan=&quot;2&quot; | Interact with the Gram-negative [[bacterial outer membrane]] and [[cytoplasmic membrane]], displacing bacterial counterions, which destabilizes the outer membrane. Act like a detergent against the cytoplasmic membrane, which alters its permeability. Polymyxin B and E are bactericidal even in an isosmotic solution.
|-
|[[Polymyxin B]] ||
|-
!colspan=&quot;5&quot; | [[Quinolone|Quinolones]]/Fluoroquinolone
|-
|[[Ciprofloxacin]] || [[Cipro]], [[Ciproxin]], Ciprobay || rowspan=&quot;9&quot; | Urinary tract infections, [[bacterial prostatitis]], community-acquired [[pneumonia]], [[bacterial diarrhea]], [[mycoplasmal infection]]s, [[gonorrhea]] || rowspan=&quot;13&quot; | Nausea (rare), irreversible damage to [[central nervous system]] (uncommon), tendinosis (rare)
| rowspan=&quot;13&quot; |inhibit the bacterial [[DNA gyrase]] or the [[topoisomerase]] IV enzyme, thereby inhibiting [[DNA]] replication and transcription.
|-
|[[Enoxacin]] || Penetrex
|-
|[[Gatifloxacin]] || [[Tequin]]
|-
|[[Gemifloxacin]] || [[Factive]]&lt;ref&gt;{{cite web |url=http://www.emedexpert.com/lists/antibiotics.shtml |title=List of Antibiotics |accessdate=February 7, 2014}}&lt;/ref&gt;
|-
|[[Levofloxacin]] || [[Levaquin]]
|-
|[[Lomefloxacin]] || Maxaquin
|-
|[[Moxifloxacin]] || [[Avelox]]
|-
|[[Nalidixic acid]] || NegGram
|-
|[[Norfloxacin]] || Noroxin
|-
|[[Ofloxacin]] || [[Floxin]], Ocuflox
|-
|[[Trovafloxacin]] || [[Trovan]] || Withdrawn
|-
|[[Grepafloxacin]] || [[Raxar]] || Withdrawn
|-
|[[Sparfloxacin]] || [[Zagam]] || Withdrawn
|-
|[[Temafloxacin]] || [[Omniflox]] || Withdrawn
|-
!colspan=&quot;5&quot; | [[Sulfonamide (medicine)|Sulfonamides]]
|-
|[[Mafenide]] || Sulfamylon || rowspan=&quot;11&quot; | [[Urinary tract infection|Urinary tract infections]] (except sulfacetamide, used for [[Conjunctivitis#Bacterial|eye infections]], and mafenide and silver sulfadiazine, used topically for [[burn]]s) || rowspan=&quot;11&quot; |
* Nausea, vomiting, and diarrhea
* [[Allergy]] (including skin rashes)
* Crystals in urine
* [[Renal failure|Kidney failure]]
* Decrease in [[white blood cell]] count
* Sensitivity to sunlight
| rowspan=&quot;11&quot; | [[Folate synthesis]] inhibition. They are [[competitive inhibitor]]s of the enzyme [[dihydropteroate synthetase]], DHPS. DHPS catalyses the conversion of PABA ([[para-Aminobenzoic acid|''para''-aminobenzoate]]) to [[dihydropteroic acid|dihydropteroate]], a key step in [[folate]] synthesis. Folate is necessary for the cell to synthesize [[nucleic acid]]s (nucleic acids are essential building blocks of [[DNA]] and [[RNA]]), and in its absence cells cannot divide.

|-
|[[Sulfacetamide]] || Sulamyd, Bleph-10
|-
|[[Sulfadiazine]] || Micro-Sulfon
|-
|[[Silver sulfadiazine]] || Silvadene
|-
|[[Sulfadimethoxine]]  || Di-Methox, Albon
|-
|[[Sulfamethizole]] || Thiosulfil Forte
|-
|[[Sulfamethoxazole]] || Gantanol
|-
|[[Sulfanilimide]] (archaic) ||
|-
|[[Sulfasalazine]] || Azulfidine
|-
|[[Sulfisoxazole]] || Gantrisin
|-
|[[Trimethoprim]]-[[Sulfamethoxazole]] ([[Co-trimoxazole]]) ([[TMP-SMX]]) || [[Bactrim]], Septra
|-
|[[Prontosil|Sulfonamidochrysoidine]] (archaic) || [[Prontosil]]
|-
!colspan=&quot;5&quot; | [[Tetracycline antibiotics|Tetracyclines]]
|-
|[[Demeclocycline]] || Declomycin || rowspan=&quot;5&quot; | [[Syphilis]], [[Chlamydia infection|chlamydial]] infections, [[Lyme disease]], [[mycoplasmal infection]]s, acne [[rickettsia]]l infections, *[[malaria]] *Note: Malaria is caused by a [[protist]] and not a bacterium. || rowspan=&quot;5&quot; |
* Gastrointestinal upset
* Sensitivity to sunlight
* Potential toxicity to mother and fetus during pregnancy
* Enamel hypoplasia (staining of teeth; potentially permanent)
* transient depression of bone growth
| rowspan=&quot;5&quot; |inhibiting the binding of [[aminoacyl-tRNA]] to the [[mRNA-ribosome]] complex. They do so mainly by binding to the [[30S ribosomal subunit]] in the [[mRNA translation]] complex.
|-
|[[Doxycycline]] || [[Vibramycin]]
|-
|[[Minocycline]] || [[Minocin]]
|-
|[[Oxytetracycline]] || [[Terramycin]]
|-
|[[Tetracycline]] || [[Sumycin]], [[Achromycin V]], [[Steclin]]
|-
! colspan=&quot;5&quot; | Drugs against [[mycobacteria]]
|-
|[[Clofazimine]] || Lamprene || [[Leprostatic agent|Antileprotic]]|| ||
|-
|[[Dapsone]] ||Avlosulfon ||[[Leprostatic agent|Antileprotic]]|| ||
|-
|[[Capreomycin]] || Capastat || [[Antituberculosis]] || ||
|-
|[[Cycloserine]] || Seromycin || [[Antituberculosis]], [[urinary tract infections]] || ||
|-
|[[Ethambutol]] || Myambutol || [[Antituberculosis]] || ||
|-
|[[Ethionamide]] || Trecator || [[Antituberculosis]] || || Inhibits peptide synthesis
|-
|[[Isoniazid]] || I.N.H. || [[Antituberculosis]] || ||
|-
|[[Pyrazinamide]] || Aldinamide || [[Antituberculosis]] || ||
|-
|[[Rifampicin]] (Rifampin in US) || Rifadin, Rimactane || mostly [[Gram-positive]] and [[mycobacteria]] ||Reddish-orange sweat, tears, and urine || Binds to the β subunit of [[RNA polymerase]] to inhibit transcription
|-
|[[Rifabutin]] || Mycobutin || [[Mycobacterium avium complex|''Mycobacterium avium'' complex]] || Rash, discolored urine, GI symptoms ||
|-
|[[Rifapentine]] || Priftin || [[Antituberculosis]] || ||
|-
|[[Streptomycin]] || ||[[Antituberculosis]] ||[[Neurotoxicity]], [[ototoxicity]] || As other [[aminoglycosides]]
|-
! colspan=&quot;5&quot; | Others
|-
|[[Arsphenamine]] || [[Salvarsan]] ||[[Spirochaete|Spirochaetal]] infections (obsolete) || ||
|-
|[[Chloramphenicol]] || [[Chloromycetin]] || [[Meningitis]], [[Methicillin-resistant Staphylococcus aureus|MRSA]], topical use, or for low-cost internal treatment. Historic: [[typhus]], [[cholera]]. [[Gram-negative]], [[Gram-positive]], [[anaerobe]]s || Rarely: [[aplastic anemia]]. || Inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome
|-
|[[Fosfomycin]] || Monurol || Acute [[cystitis]] in women || || Inactivates [[enolpyruvyl transferase]], thereby blocking [[cell wall]] synthesis
|-
|[[Fusidic acid]] || [[Fucidin]] || || ||
|-
|[[Metronidazole]] || [[Flagyl]] || Infections caused by [[anaerobic bacteria]]; also [[amoebiasis]], [[trichomoniasis]], [[giardiasis]] ||Discolored urine, [[headache]], [[Dysgeusia|metallic taste]], [[nausea]]; [[alcohol]] is contraindicated || Produces toxic [[free radicals]] that disrupt DNA and proteins. This non-specific mechanism is responsible for its activity against a variety of bacteria, amoebae, and protozoa.
|-
|[[Mupirocin]] || [[Bactroban]] ||[[Ointment]] for [[impetigo]], [[Cream (pharmaceutical)|cream]] for infected cuts || ||Inhibits isoleucine t-RNA synthetase (IleRS) causing inhibition of protein synthesis
|-
|[[Platensimycin]] || || || ||
|-
|[[Quinupristin/Dalfopristin]] || [[Synercid]] || || ||
|-
|[[Thiamphenicol]] || || [[Gram-negative]], [[Gram-positive]], [[anaerobe]]s. Widely used in veterinary medicine. || Rash. Lacks known anemic side-effects. || A chloramphenicol analog. May inhibit bacterial protein synthesis by binding to the 50S subunit of the ribosome
|-
|[[Tigecycline]] || Tigacyl || Indicated for complicated skin/skin structure infections and complicated intra-abdominal infections. || Teeth discoloration ||
|-
|[[Tinidazole]] || Tindamax Fasigyn || Protozoal infections || Upset stomach, bitter taste, and itchiness ||
|-
|[[Trimethoprim]] || Proloprim, Trimpex ||Urinary tract infections||||
|-

! Generic Name !! Brand Names !! Common Uses&lt;ref name=&quot;merck&quot; /&gt; !! Possible Side Effects&lt;ref name=&quot;merck&quot; /&gt; !! Mechanism of action
|}

==References==
{{reflist}}

==See also==
* [[Timeline of antibiotics]], listed by year of introduction
* [[Pathogenic bacteria]]

[[Category:Antibiotics]]</text>
      <sha1>qjqg94vtm8j08ixubf838pejlsrdkne</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Thiocarlide</title>
    <ns>0</ns>
    <id>12819509</id>
    <revision>
      <id>593180496</id>
      <parentid>527561148</parentid>
      <timestamp>2014-01-30T21:39:41Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="3584">{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470606991
| IUPAC_name = 1,3-bis[4-(3-methylbutoxy)phenyl]thiourea
| image = Tiocarlide.png

&lt;!--Clinical data--&gt;
| tradename =  
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category =  
| legal_AU = &lt;!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --&gt;
| legal_CA = &lt;!--             / Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL         / P       / POM / CD / Class A, B, C --&gt;
| legal_US = &lt;!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V --&gt;
| legal_status =  
| routes_of_administration =  

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 910-86-1
| ATC_prefix = J04
| ATC_suffix = AD02
| PubChem = 3001386
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2272774
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 43M23X81Y2
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 214920

&lt;!--Chemical data--&gt;
| C=23 | H=32 | N=2 | O=2 | S=1 
| molecular_weight = 400.578 g/mol
| smiles = S=C(Nc1ccc(OCCC(C)C)cc1)Nc2ccc(OCCC(C)C)cc2
| InChI = 1/C23H32N2O2S/c1-17(2)13-15-26-21-9-5-19(6-10-21)24-23(28)25-20-7-11-22(12-8-20)27-16-14-18(3)4/h5-12,17-18H,13-16H2,1-4H3,(H2,24,25,28)
| InChIKey = BWBONKHPVHMQHE-UHFFFAOYAL
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C23H32N2O2S/c1-17(2)13-15-26-21-9-5-19(6-10-21)24-23(28)25-20-7-11-22(12-8-20)27-16-14-18(3)4/h5-12,17-18H,13-16H2,1-4H3,(H2,24,25,28)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BWBONKHPVHMQHE-UHFFFAOYSA-N
}}

'''Thiocarlide''' (or '''tiocarlide''' or '''isoxyl''') is a [[thiourea]] drug used in the treatment of [[tuberculosis]], inhibiting synthesis of [[oleic acid]] and [[tuberculostearic acid]].&lt;ref&gt;{{cite journal |author=Phetsuksiri B, Jackson M, Scherman H, ''et al'' |title=Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis |journal=J. Biol. Chem. |volume=278 |issue=52 |pages=53123–30 |date=December 2003 |pmid=14559907 |doi=10.1074/jbc.M311209200 |url=http://www.jbc.org/cgi/content/full/278/52/53123}}&lt;/ref&gt;

Thiocarlide has considerable anti[[mycobacteria]]l activity ''in vitro'' and is effective against multi-drug resistant strains of ''Mycobacterium tuberculosis''.&lt;ref&gt;{{cite journal |author=Phetsuksiri B, Baulard AR, Cooper AM, ''et al'' |title=Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis |journal=Antimicrob. Agents Chemother. |volume=43 |issue=5 |pages=1042–51 |date=May 1999 |pmid=10223912 |pmc=89109 |doi= |url=http://aac.asm.org/cgi/pmidlookup?view=long&amp;pmid=10223912}}&lt;/ref&gt; Isoxyl inhibits ''M. bovis'' with six hours of exposure, which is similar to [[isoniazid]] and [[ethionamide]], two other prominent anti-TB drugs.  Unlike these two drugs, however, isoxyl also partially inhibits the synthesis of fatty acids.

Thiocarlide was developed by a [[Belgium|Belgian]] company, [[Continental Pharma]] S.A. Belgo-Canadienne in [[Brussels]], Belgium. The head researcher was Professor [[N. P. Buu-Hoi]], head of Continental Pharma's Research Division.

==References==
{{reflist}}

{{Antimycobacterials}}

[[Category:Antibiotics]]
[[Category:Thioureas]]
[[Category:Phenol ethers]]


{{antiinfective-drug-stub}}</text>
      <sha1>jkr1nu94q2dqzsujvpizyhfni5r3qpd</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Enviomycin</title>
    <ns>0</ns>
    <id>18634286</id>
    <revision>
      <id>517281474</id>
      <parentid>451723731</parentid>
      <timestamp>2012-10-11T22:28:52Z</timestamp>
      <contributor>
        <username>The chemistds</username>
        <id>13073709</id>
      </contributor>
      <comment>added CSID, (Std)InChI &amp; (Std)InChIKey</comment>
      <text xml:space="preserve" bytes="3212">{{Drugbox
| Watchedfields = changed
| verifiedrevid = 443977985
| IUPAC_name = 3,6-diamino-''N''-[(3''R'',6''Z'')-3-(2-amino-3,4,5,6-tetrahydropyrimidin-4-yl)-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohexadec-15-yl]-4-hydroxyhexanamide
| image = Enviomycin.svg

&lt;!--Clinical data--&gt;
| tradename =  
| Drugs.com = {{drugs.com|international|enviomycin}}
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category =  
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, or Class A, B, C --&gt;
| legal_US = &lt;!-- OTC / Rx-only / Schedule I, II, III, IV, V --&gt;
| legal_status = Rx-only
| routes_of_administration = IM

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

&lt;!--Identifiers--&gt;
| CAS_number = 33103-22-9
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 3032903
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = XU299C23A2
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07897
|  ChemSpiderID = 16736480
|  InChI = 1/C25H43N13O10/c26-3-1-16(41)10(27)5-17(42)33-12-6-31-23(47)18(11-2-4-30-24(28)37-11)38-20(44)13(7-32-25(29)48)34-21(45)14(8-39)36-22(46)15(9-40)35-19(12)43/h7,10-12,14-16,18,39-41H,1-6,8-9,26-27H2,(H,31,47)(H,33,42)(H,34,45)(H,35,43)(H,36,46)(H,38,44)(H3,28,30,37)(H3,29,32,48)/b13-7-/t10-,11-,12+,14+,15+,16-,18+/m1/s1
|  InChIKey = HPWIIERXAFODPP-GHBBWTPBBK
|  StdInChI = 1S/C25H43N13O10/c26-3-1-16(41)10(27)5-17(42)33-12-6-31-23(47)18(11-2-4-30-24(28)37-11)38-20(44)13(7-32-25(29)48)34-21(45)14(8-39)36-22(46)15(9-40)35-19(12)43/h7,10-12,14-16,18,39-41H,1-6,8-9,26-27H2,(H,31,47)(H,33,42)(H,34,45)(H,35,43)(H,36,46)(H,38,44)(H3,28,30,37)(H3,29,32,48)/b13-7-/t10-,11-,12+,14+,15+,16-,18+/m1/s1
|  StdInChIKey = HPWIIERXAFODPP-GHBBWTPBSA-N

&lt;!--Chemical data--&gt;
| chemical_formula =  
| C=25 | H=43 | N=13 | O=10 
| molecular_weight = 685.69 g/mol
| smiles = C1CN=C(NC1C2C(=O)NCC(C(=O)NC(C(=O)NC(C(=O)NC(=CNC(=O)N)C(=O)N2)CO)CO)NC
}}

'''Enviomycin''' ([[International Nonproprietary Name|INN]], also called '''tuberactinomycin N''') is an [[antibiotic]] drug, isolated from ''Streptomyces griseoverticillatus'' var. ''tuberacticus''.&lt;ref&gt;[http://www.google.com/patents?id=FWMvAAAAEBAJ&amp;dq=3892732 Jinnosuke Abe et al. Antibiotic Tuberactinomycin-N and process for production thereof. US patent 3892732]&lt;/ref&gt; It is used in the treatment of [[tuberculosis]].&lt;ref&gt;{{cite journal | last1 = Selvakumar | first1 = N | last2 = Kumar | first2 = V | last3 = Acharyulu | first3 = GS | last4 = Rehman | first4 = F | last5 = Paramasivan | first5 = CN | last6 = Prabhakar | first6 = R | title = Susceptibility of south Indian strains of Mycobacterium tuberculosis to tuberactinomycin | journal = The Indian journal of medical research | volume = 95 | pages = 101–4 | year = 1992 | pmid = 1506058 }}&lt;/ref&gt; 

==References==
&lt;references/&gt;

[[Category:Antibiotics]]


{{antiinfective-drug-stub}}</text>
      <sha1>6ulp38p7dyjk4i97ekjl7tu8w9anh1a</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Netropsin</title>
    <ns>0</ns>
    <id>18841083</id>
    <revision>
      <id>594965815</id>
      <parentid>585765906</parentid>
      <timestamp>2014-02-11T11:56:56Z</timestamp>
      <contributor>
        <ip>2.223.192.154</ip>
      </contributor>
      <comment>Netropsin is not an oligopeptide</comment>
      <text xml:space="preserve" bytes="3554">{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 416422024
| ImageFile =Netropsin.png
| OtherNames = Nt, congocidin, sinanomycin
| Section1 = {{Chembox Identifiers
|   CASNo_Ref = {{cascite|correct|??}}
| CASNo =  1438-30-8
| PubChem = 4461
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 553984
  }}
| Section2 = {{Chembox Properties
|   Formula = C&lt;sub&gt;18&lt;/sub&gt;H&lt;sub&gt;26&lt;/sub&gt;N&lt;sub&gt;10&lt;/sub&gt;O&lt;sub&gt;3&lt;/sub&gt; · 2HCl
|   MolarMass = 503.39 g/mol
|   Appearance = White powder
  }}
}}
'''Netropsin''' is a polyamide with [[antibiotic]] and [[Antiviral drug|antiviral]] activity. 

Netropsin was discovered by Finlay ''et al.'' and first isolated from the [[Actinobacteria|actinobacterium]] ''Streptomyces netropsis''.&lt;ref&gt;A.C. Finlay, F. A. Hochstein, B. A. Sobin, and F. X. Murphy, ''J. Am. Chem Soc.'' '''73''' 341-343 (1951)&lt;/ref&gt; It belongs to the class of pyrrole-amidine [[antibiotics]]. Synonyms for the compound are '''congocidine''' and '''sinanomycin'''.&lt;ref&gt;http://www.sigmaaldrich.com/catalog/search/ProductDetail/SIGMA/N9653&lt;/ref&gt;

== DNA binding properties ==
Netropsin binds to the [[minor groove]] of AT-rich sequences of double stranded [[DNA]].&lt;ref&gt;C. Zimmer and U. Wähnert, ''Prog. Biophys. Molec. Biol.'' '''47''' 31-112 (1986)&lt;/ref&gt; 
In contrast, Netropsin does not bind single stranded DNA or double stranded RNA. 
Crystallographic structures of DNA-bound Netropsin have been obtained and elucidate details of how the drug binds in the minor groove.&lt;ref&gt;M. L. Kopka, C. Yoon, D. Goodsell, P. Pjura, and R.E. Dickerson, ''J. Mol. Biol.'' '''183''' 553-563 (1985)&lt;/ref&gt;&lt;ref&gt;M. L. Kopka, C. Yoon, D. Goodsell, P. Pjura, and R.E. Dickerson, ''Proc. Natl. Acad. Sci. USA'' '''82''' 1376-1380 (1985)&lt;/ref&gt;
In the bound structure, the drug makes hydrogen bonding interactions with four subsequent base pairs of the DNA duplex,
locally displacing the water molecules of the spine of hydration.

[[Image:Netropsin DNA bound.gif|thumb|right|150px|Netropsin (shown in space-filling representation) bound to DNA (shown as bonds). Image was created from the crystallographic structure (Protein Data Bank accession code 101D) using the software VMD ([[Visual Molecular Dynamics]]).]]

Using gel mobility and analytical ultracentrifugation, 
it was shown that Netropsin binding to DNA increases the twist per base by similar to 9˚ per molecule bound.&lt;ref&gt;G. Snounou and A. D. B. Malcolm, ''J. Mol. Biol.'' '''167''' 211-216 (1983)&lt;/ref&gt;&lt;ref&gt;H. Triebel, H. Bär, R. Geuther, and G. Burckhardt, ''Progr. Colloid. Polym. Sci.'' '''99''' 45-54 (1995)&lt;/ref&gt;
Therefore, it removes supercoils when interacting with positively supercoiled DNA and introduces 
(additional) negative supercoils when binding to relaxed or negatively supercoiled DNA.
Netropsin's effect on supercoiled DNA was observed in detail at the single-molecule level using a magnetic tweezers.&lt;ref&gt;J. Lipfert, S. Klijnhout, and Nynke H. Dekker, &quot;Nucleic Acids Res.&quot; &quot;38&quot; 7122-32 (2010)&lt;/ref&gt;

== Antibiotic properties ==
It has been shown that Netropsin is active both against [[Gram-positive bacteria]] and [[Gram-negative bacteria]]
.&lt;ref&gt;C. Zimmer and U. Wähnert, ''Prog. Biophys. Molec. Biol.'' '''47''' 31-112 (1986)&lt;/ref&gt;

== See also ==
* [[Lexitropsin]]
* [[Hoechst 33258]]
* [[DNA-binding protein]]
* [[Single-strand binding protein]]
* [[List of nucleic acid simulation software|Nucleic acid simulations]]

== References ==
{{Reflist}}

[[Category:Peptides]]
[[Category:Antibiotics]]
[[Category:DNA-binding substances]]
[[Category:Imidazoles]]</text>
      <sha1>4alca47rwbkjay8uycnsuzg3l73580c</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Myxopyronin</title>
    <ns>0</ns>
    <id>19885739</id>
    <revision>
      <id>592608669</id>
      <parentid>581523129</parentid>
      <timestamp>2014-01-27T08:59:28Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>/* References */Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="5631">'''Myxopyronin''' ('''Myx''') is an alpha-[[pyrone]] [[antibiotic]], the first in a new class of inhibitors of bacterial [[RNA polymerase]] (RNAP) that target switch 1 and switch 2 of the RNAP &quot;switch region.&quot; [[Rifamycin]] antibacterial agents, which are first-line treatments for [[tuberculosis]], and [[lipiarmycin]] (fidaxomicin, Dificid) also target RNAP, but target different sites in RNAP. Myxopyronin does not have [[cross-resistance]] with rifamycins and lipiarmycin.  Myxopyronin may be useful to address the growing problem of [[drug resistance]] in tuberculosis. It also may be useful in treatment of [[methicillin-resistant Staphylococcus aureus]] (MRSA). It is in [[pre-clinical development]] and has not yet started [[clinical trial]]s.  

Myxopyronin was first isolated in 1983 from a soil bacterium by Rolf Jansen and Herbert Irschik. A total synthesis of myxopyronin was first reported in 1998 by James S. Panek and co-workers. The target, the mechanism of action, and the structure of the complex of RNAP with myxopyronin were first reported in 2008 by [[Richard H. Ebright]] and co-workers. Novel analogs of myxopyronin have been synthesized at Anadys Pharmaceuticals (San Diego, CA) and at Rutgers University (Piscataway, NJ).  Terence I. Moy and co-workers at Cubist Pharmaceuticals (Lexington, MA) have stated that, based on high resistance rate and high serum protein binding (comparable to rifamycins and lipiarmycin), the unmodified natural product myxopyronin B is not a viable starting point for antibiotic development. 

==References==

*{{Citation
  | last = Irschik
  | first = Herbert
| title = The myxopyronins, new inhibitors of bacterial RNA synthesis from Myxococcus fulvus (Myxobacterales)
| year = 1983
  | url = http://www.journalarchive.jst.go.jp/jnlpdf.php?cdjournal=antibiotics1968&amp;cdvol=36&amp;noissue=12&amp;startpage=1651&amp;lang=en&amp;from=jnlabstract
| volume = 36
| issue = 12
| pages = 1651–1658
| doi = 10.7164/antibiotics.36.1651
  | last2 = Gerth
  | first2 = K.
  | last3 = Höfle
  | first3 = G.
  | last4 = Kohl
  | first4 = W.
  | last5 = Reichenbach
  | first5 = H.
  | journal = The Journal of Antibiotics
  | pmid = 6420386}}

*{{Citation
  | last = Panek
  | first = James
  | title = Total Synthesis and Preliminary Antibacterial Evaluation of the RNA Polymerase Inhibitors (±)-Myxopyronin A and B
  | year = 1998
  | last2 = Schaus
  | first2 = Jennifer V.
  | last3 = Lam
  | first3 = Kelvin
  | last4 = Palfreyman
  | first4 = Michael G.
  | last5 = Wuonola
  | first5 = Mark
  | last6 = Gustafson
  | first6 = Gary
  | last7 = Panek
  | first7 = James S.
  | journal = The Journal of Organic Chemistry
  | volume = 63
  | issue = 7
  | pages = 2401–6
  | doi = 10.1021/jo9721610 }}

*{{Citation
  | last = Doundoulakis et al.
  | first = 
  | title = 
  | newspaper = Bioorganic &amp; Medicinal Chemistry Letters Volume 14, Issue 22, 15 November 2004, Pages 5667-5672
  | year = 2004}}

*{{Citation
  | last = Lira et al.
  | first = 
  | title = 
  | newspaper = Bioorganic &amp; Medicinal Chemistry Letters Volume 17, Issue 24, 15 December 2007, Pages 6797-6800
  | year = 2007}}

*{{Citation
  | last = Blue
  | first = Laura
  | title = A New Class of Antibiotics Could Offer Hope Against TB
  | newspaper = Time
  | date = 17 October 2008
  | url = http://www.time.com/time/health/article/0,8599,1851375,00.html}}

*{{Citation
 | author = Jayanta Mukhopadhyay, Kalyan Das, Sajida Ismail, David Koppstein, Minyoung Jang, Brian Hudson, Stefan Sarafianos, Steven Tuske, Jay Patel, Rolf Jansen, Herbert Irschik, Eddy Arnold &amp; Richard H. Ebright
 | title = The RNA polymerase &quot;switch region&quot; is a target for inhibitors
 | journal = Cell
 | volume = 135
 | issue = 2
 | pages = 295–307
 |date=October 2008
 | doi = 10.1016/j.cell.2008.09.033
 | pmid = 18957204
 | pmc = 2580802 }}

*{{Citation
  | last = Belogurov
  | first = G
  | authorlink = 
  | coauthors = et al.
  | title = Transcription inactivation through local refolding of the RNA polymerase structure
  | journal = Nature
  | volume = 457
  | issue = 7227
  | pages = 332–5
  | publisher = 
  | location = 
  | quote = advance online publication 22 October 2008
  | url = 
  | doi = 10.1038/nature07510
  | id = 
  | pmid = 18946472
  | pmc = 2628454}}

*{{Citation
 | author = Mary X. Ho, Brian P. Hudson, Kalyan Das, Eddy Arnold &amp; Richard H. Ebright
 | title = Structures of RNA polymerase-antibiotic complexes
 | journal = Current opinion in structural biology
 | volume = 19
 | issue = 6
 | pages = 715–723
 |date=December 2009
 | doi = 10.1016/j.sbi.2009.10.010
 | pmid = 19926275
 | pmc = 2950656 }}

*{{Citation
 |author=Srivastava A, Talaue M, Liu S, Degen D, Ebright RY, Sineva E, Chakraborty A, Druzhinin SY, Chatterjee S, Mukhopadhyay J, Ebright YW, Zozula A, Shen J, Sengupta S, Niedfeldt RR, Xin C, Kaneko T, Irschik H, Jansen R, Donadio S, Connell N, Ebright RH
 |title=New target for inhibition of bacterial RNA polymerase: 'switch region'
 |journal=Curr Opin Microbiol
 |volume=14
 |issue=5
 |pages=532–43
 |date=August 2011
 |pmid=21862392
 |doi=10.1016/j.mib.2011.07.030
 |pmc=3196380}}

*{{Citation
 | author = Terence I. Moy, Anu Daniel, Crystal Hardy, Andrew Jackson, Owen Rehrauer, You Seok Hwang, Dong Zou, Kien Nguyen, Jared A. Silverman,Qingyi Li, Christopher Murphy
 | title = Evaluating the activity of the RNA polymerase inhibitor myxopyronin B against Staphylococcus aureus
 | journal = FEMS Microbiology Letters
 | volume = 319
 | issue = 2
 | pages = 176–179
 | year = 2011
 | doi = 10.1111/j.1574-6968.2011.02282.x
 | pmid = 21477256 }}


[[Category:Antibiotics]]


{{med-stub}}</text>
      <sha1>juas7ht1okzlwkcatat3014psprzhss</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Clorobiocin</title>
    <ns>0</ns>
    <id>20008186</id>
    <revision>
      <id>490414337</id>
      <parentid>490279789</parentid>
      <timestamp>2012-05-03T04:38:12Z</timestamp>
      <contributor>
        <username>CheMoBot</username>
        <id>7377957</id>
      </contributor>
      <comment>Updating {{drugbox}} (changes to verified and watched fields - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per [[WP:CHEMVALID|Chem/Drugbox validation]] (report [[Wikipedia talk:WikiProject_Ph...</comment>
      <text xml:space="preserve" bytes="2588">{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 387418010
| IUPAC_name = (3S,4R,5R,6S)-6-[(8-chloro-4-hydroxy-3-{[4-hydroxy-3-(3-methylbut-2-en-1-yl)benzene]amido}-2-oxo-2H-chromen-7-yl)oxy]-5-hydroxy-3-methoxy-2,2-dimethyloxan-4-yl 5-methylpyrrole-2-carboxylate &lt;ref name=&quot;drugbank&quot;&gt;[http://www.drugbank.ca/drugs/DB03966], http://www.drugbank.ca/drugs/DB03966. &lt;/ref&gt;
| image=Clorobiocin.png

&lt;!--Clinical data--&gt;
| tradename =  
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category =  
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, or Class A, B, C --&gt;
| legal_US = &lt;!-- OTC / Rx-only / Schedule I, II, III, IV, V --&gt;
| legal_status =  
| routes_of_administration =  

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 39868-96-7
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 73622
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 303984
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 66286
|  InChI = 1/C35H37ClN2O11/c1-16(2)7-9-18-15-19(10-13-22(18)39)31(42)38-25-26(40)20-11-14-23(24(36)28(20)47-33(25)44)46-34-27(41)29(30(45-6)35(4,5)49-34)48-32(43)21-12-8-17(3)37-21/h7-8,10-15,27,29-30,34,37,39,41,44H,9H2,1-6H3,(H,38,42)/t27-,29+,30-,34-/m1/s1
|  InChIKey = NOLDNICYUPLDOY-LFLQOBSNBG
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C35H37ClN2O11/c1-16(2)7-9-18-15-19(10-13-22(18)39)31(42)38-25-26(40)20-11-14-23(24(36)28(20)47-33(25)44)46-34-27(41)29(30(45-6)35(4,5)49-34)48-32(43)21-12-8-17(3)37-21/h7-8,10-15,27,29-30,34,37,39,41,44H,9H2,1-6H3,(H,38,42)/t27-,29+,30-,34-/m1/s1
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = NOLDNICYUPLDOY-LFLQOBSNSA-N

&lt;!--Chemical data--&gt;
| C=35 | H=37 | Cl=1 | N=2 | O=11 
| molecular_weight = 697.13 g/mol
| smiles = CC1=CC=C(N1)C(=O)O[C@H]2[C@H]([C@@H](OC([C@@H]2OC)(C)C)OC3=C(C4=C(C=C3)C(=O)C(=C(O4)O)NC(=O)C5=CC(=C(C=C5)O)CC=C(C)C)Cl)O
| synonyms = Chlorobiocin
}}

'''Clorobiocin''' is an [[aminocoumarin]].&lt;ref&gt;{{cite pmid|12618544}}&lt;/ref&gt;&lt;ref&gt;{{cite pmid|19463934}}&lt;/ref&gt;

==References==
{{reflist}}

{{antibiotic-stub}}
{{Nucleic acid inhibitors}}
[[Category:Antibiotics]]
[[Category:Imidazoles]]</text>
      <sha1>ixjy3sbgrobxhy914zq4l85lht5apir</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Coumermycin A1</title>
    <ns>0</ns>
    <id>20008204</id>
    <revision>
      <id>515005991</id>
      <parentid>456833578</parentid>
      <timestamp>2012-09-28T14:16:17Z</timestamp>
      <contributor>
        <username>Mllyjn</username>
        <id>16472234</id>
      </contributor>
      <comment>Added see also section.</comment>
      <text xml:space="preserve" bytes="1981">{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 387419821
| IUPAC_name = [(3''R'',4''S'',5''R'')-5-Hydroxy-6-[2-hydroxy-3-&lt;nowiki&gt;[[&lt;/nowiki&gt;4-&lt;nowiki&gt;[[&lt;/nowiki&gt;2-hydroxy-7-[(3''R'',4''S'',5''R'')-3-hydroxy-5-methoxy-6,6-dimethyl-4-(5-methyl-1''H''-pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-8-methyl-4-oxochromen-3-yl]carbamoyl]-3-methyl-1''H''-pyrrole-2-carbonyl]amino]-8-methyl-4-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] 5-methyl-1''H''-pyrrole-2-carboxylate
| image = Coumermycin A1.png

&lt;!--Clinical data--&gt;
| tradename =  
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category =  
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, or Class A, B, C --&gt;
| legal_US = &lt;!-- OTC / Rx-only / Schedule I, II, III, IV, V --&gt;
| legal_status =  
| routes_of_administration =  

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 4434-05-3
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 451651
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 555830

&lt;!--Chemical data--&gt;
| C=55 | H=59 | N=5 | O=20 
| molecular_weight = 1110.08 g/mol
| smiles = CC1=CC=C(N1)C(=O)O[C@H]2[C@H](C(OC([C@@H]2OC)(C)C)OC3=C(C4=C(C=C3)C(=O)C(=C(O4)O)NC(=O)C5=CNC(=C5C)C(=O)NC6=C(OC7=C(C6=O)C=CC(=C7C)OC8[C@@H]([C@@H]([C@H](C(O8)(C)C)OC)OC(=O)C9=CC=C(N9)C)O)O)C)O
| synonyms = Coumamycin
}}

'''Coumermycin A1''' is an [[aminocoumarin]].&lt;ref&gt;{{cite pmid|19463934}}&lt;/ref&gt;&lt;ref&gt;{{cite pmid|18473891}}&lt;/ref&gt;
==See also==
[[Chemically induced dimerization]]

==References==
{{reflist}}

{{antibiotic-stub}}
{{Nucleic acid inhibitors}}
[[Category:Antibiotics]]
[[Category:Imidazoles]]</text>
      <sha1>t7tsi4df4orranhvw2k251f6kattril</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Dalfopristin</title>
    <ns>0</ns>
    <id>5223019</id>
    <revision>
      <id>603269433</id>
      <parentid>601172299</parentid>
      <timestamp>2014-04-08T07:19:47Z</timestamp>
      <contributor>
        <username>CheMoBot</username>
        <id>7377957</id>
      </contributor>
      <comment>Updating {{drugbox}} (changes to verified and watched fields - updated 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per [[WP:CHEMVALID|Chem/Drugbox validation]] (report [[Wikipedia talk:WikiProject_Pharmacology|errors]] or [[user talk:CheMoBo...</comment>
      <text xml:space="preserve" bytes="9762">{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 375046138
| IUPAC_name = (3''R'',4''R'',5''E'',10''E'',12''E'',14''S'',26''R'',26a''S'')-26-&lt;nowiki&gt;[[&lt;/nowiki&gt;2-(diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a- octahydro-14-hydroxy-3-isopropyl-4,12-dimethyl-3''H''-21,18-nitrilo-1''H'',22''H''-pyrrolo[2,1-''c''][1,8,4,19]-dioxadiazacyclotetracosine-1,7,16,22(4''H'',17''H'')-tetrone
| image = Dalfopristin.png

&lt;!--Clinical data--&gt;
| tradename =  
| Drugs.com = {{drugs.com|international|dalfopristin}}
| MedlinePlus = a603007
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category =  
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, or Class A, B, C --&gt;
| legal_US =  Rx-only
| legal_status =  
| routes_of_administration =

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life = 1 hour
| excretion =

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 112362-50-2
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 6435782
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB01764
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = R9M4FJE48E
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D00853
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200937
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 16736919

&lt;!--Chemical data--&gt;
| C=34 | H=50 | N=4 | O=9 | S=1 
| molecular_weight = 690.85 g/mol
| smiles            = CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@@H]([C@@H](/C=C/C(=O)NC/C=C/C(=C/[C@H](CC(=O)CC3=NC(=CO3)C2=O)O)/C)C)C(C)C
| InChI             = 1/C34H50N4O9S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b10-9+,12-11+,23-18+/t24-,25-,28-,31-,32-/m1/s1
| InChIKey          = SUYRLXYYZQTJHF-VMBLUXKRBB
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C34H50N4O9S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b10-9+,12-11+,23-18+/t24-,25-,28-,31-,32-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = SUYRLXYYZQTJHF-VMBLUXKRSA-N
}}

'''Dalfopristin''' is a semi-synthetic [[streptogramin]] [[antibiotic]] analogue of ostreogyrcin A ([[Virginiamycin|virginiamycin M]], [[pristinamycin|pristinamycin IIA]], [[streptogramin A]]).&lt;ref name=scbt&gt;[http://www.scbt.com/datasheet-362728.html Dalfopristin (as mesylate) (CAS 112362-50-2)]&lt;/ref&gt;  The combination [[quinupristin/dalfopristin]] (marketed under the trade name [[Quinupristin/dalfopristin|Synercid]]) was brought to the market by [[Rhône-Poulenc|Rhone-Poulenc Rorer Pharmaceuticals]] in 1999.&lt;ref name=fda&gt;http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid.cfm&lt;/ref&gt; [[Synercid]] (weight-to-weight ratio of 30% [[quinupristin]] to 70% dalfopristin) is used to treat [[infection]]s by [[staphylococcus|staphylococci]] and by [[vancomycin]]-resistant ''[[Enterococcus|Enterococcus faecium]]''.&lt;ref&gt;{{cite journal | doi = 10.1016/S0149-2918(01)80028-X | author = Allington DR, Rivey MP | title = Quinupristin/dalfopristin: a therapeutic review | journal = Clin Ther | year = 2001 | volume = 23 | issue = 1 | pages = 24–44 | pmid = 11219478}}&lt;/ref&gt;

==Synthesis==
Through the [[addition]] of diethylaminoethylthiol to the 2-[[pyrroline]] group and [[oxidation]] of the [[sulfate]] of ostreogrycin A, a structurally more [[hydrophobic]] compound is formed. This [[hydrophobic]] compound contains a readily [[ionizable]] group that is available for salt formation.&lt;ref name=scbt /&gt;

==Large Scale Preparation==
Dalfopristin is synthesized from [[Pristinamycine|pristinamycine IIa]] through achieving a stereoselective [[Michael addition|Michael-type addition]] of 2-diethylaminoethanethiol on the conjugated double bond of the dehydroproline ring &lt;ref name=recentdevelopments&gt;{{cite journal |last=Barriere |first=J.C. |last2=Berthaud |first2=N. |last3=Beyer |first3=D. |last4=Dutka-Malen |first4=S. |last5=Paris |first5=J.M. |last6=Desnottes |first6=J.F. |date=April 1998 |title=Recent Developments in Streptogramin Research |url=http://www.ncbi.nlm.nih.gov/pubmed/10197038 |journal=Current Pharmaceutical Design |publisher= |volume=4 |issue=2 |pages=155–190 |doi= |accessdate=24 November 2013 |PMID=10197038}}&lt;/ref&gt;
. The first method found was using [[sodium periodate]] associated with [[ruthenium dioxide]] to directly oxidize the sulfur derivative into a [[sulfone]]. However, using [[hydrogen peroxide]] with [[sodium tungstate]] in a 2-phase medium produces an improved yield, and is therefore the method of choice for large scale production.

The production of the dalfopristin portion of [[quinupristin/dalfopristin]] is achieved through purifying cocrystallization of the quinupristin and dalfopristin from [[acetone]] solutions.&lt;ref name=recentdevelopments /&gt;

==Physical Characteristics (as mesylate salt)==
{| class=&quot;wikitable&quot;
|-
| '''Appearance''' || White to yellow solid
|-
| '''[[State of matter|Physical State]]''' || Solid
|-
| '''[[Solubility]]''' || Soluble in ethanol, methanol, DMSO, DMF, and water (0.072&amp;nbsp;mg/ml)
|-
| '''Storage''' || -20°C
|-
| '''[[Boiling Point]]''' || 940.5°C at 760 mmHg
|-
| '''[[Melting Point]]''' || 150°C
|-
| '''[[Density]]''' || 1.27 g/cm^3
|-
| '''[[Refractive Index]]''' || n20D 1.58
|-
| '''[[PKa|pK Values]]''' || pKa: 13.18 (Predicted), pKb: 8.97 (Predicted)
|}

==Antimicrobial Activity==
Alone, both dalfopristin and [[quinupristin]] have modest [[in vitro]] [[bacteriostatic]] activity. However, 8-16 times higher in vitro [[bactericidal]] activity is seen against many [[gram-positive bacteria]] when the two [[streptogramins]] are combined &lt;ref name=therapeuticreview&gt;{{cite journal |last=Allington |first=Douglas R. |last2=Rivey |first2=Michael P. |date=January 2001 |title=Quinupristin/Dalfopristin: A Therapeutic Review |url= |journal=Clinical Therapeutics |volume=23 |issue=1 |pages=1–21 |PMID=11219478  |accessdate=24 November 2013 |doi=10.1016/S0149-2918(01)80028-X}}&lt;/ref&gt;
. While [[quinupristin/dalfopristin]] is effective against [[staphylococcus|staphylococci]] and [[Vancomycin-resistant Enterococcus|vancomycin-resistant Enterococcus faecium]], in vitro studies have not demonstrated bactericidal activity against all strains and species of common gram-positive bacteria.

==Mechanism of Action==
Both dalfopristin and quinupristin bind to sites located on the 50S subunit of the [[ribosome]]. Initial dalfopristin binding results in a conformational change of the ribosome, allowing for increased binding by quinupristin.&lt;ref name=therapeuticreview /&gt; A stable drug-ribosome complex is created when the two drugs are used together. This complex inhibits [[protein synthesis]] through prevention of peptide-chain formation and blocking the extrusion of newly formed peptide chains. In many cases, this leads to bacterial cell death.

==Mechanism of Resistance==
Streptogramin resistance is mediated through enzymatic drug inactivation, efflux or active transport of drug out of the cell, and most commonly, conformational alterations in ribosomal target binding sites.&lt;ref name=therapeuticreview /&gt; Enzymatic drug inactivation may occur in [[staphylococcal]] and [[enterococcal]] species through production of dalfopristin-inactivating acetyltransferase or quinupristin-inactivating hydrolase. Efflux or active transport of the drug may occur in coagulase-negative staphylococci and [[Enterococcus faecium]]. Constitutive ribosome modification has been seen in staphylococci with resistance seen in quinupristin only.

While resistance to dalfopristin may be conferred via a single point of mutation, [[quinupristin/dalfopristin]] offers the benefit of requiring multiple points of mutation targeting both dalfopristin and quinupristin components to confer drug resistance.&lt;ref name=therapeuticreview /&gt; Comparatively, only 2-5% of staphylococcal isolates collected in France show resistance to a related streptogramin, [[pristinamycin]], in over 35 years of use.

==Drug Interactions==
Both dalfopristin and quinupristin are extensively hepatically metabolized, excreted from the feces, and serve as an inhibitor of [[cytochrome P450]] (CYP) 3A4 enzyme pathway.&lt;ref name=therapeuticreview /&gt; Caution should be taken with concommitent use with drugs metabolized by the [[CYP3A4]] pathway. Concomitant use of [[quinupristin/dalfopristin]] with [[cyclosporine]] for 2–5 days has shown to result in a two-fold increase in cyclosporine levels.

No adverse effects have been seen in patients with [[hepatic impairment]] and no recommendations by the manufacturer have been made for dose reduction of [[quinupristin/dalfopristin]] in this patient population.

==Commercialization==
While little information is available regarding the regulatory and commercialization history of Dalfopristin alone, Synercid (quinupristin/dalfopristin), made by Rhone-Poulenc Rorer Pharmaceuticals, was approved in 1999 as an IV injectable for the treatment of vancomycin resistant Enterococcus faecium and complicated skin and skin structure infections.&lt;ref name=fda /&gt; Dalfopristin can be purchased alone on the internet from various chemical manufacturers as a [[mesylate]] salt.

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Oxazoles]]</text>
      <sha1>rqd3qzuakcebroyyi06qn8fnuu9hvlf</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Production of antibiotics</title>
    <ns>0</ns>
    <id>2515404</id>
    <revision>
      <id>601224358</id>
      <parentid>578353494</parentid>
      <timestamp>2014-03-25T17:49:34Z</timestamp>
      <contributor>
        <username>GKFX</username>
        <id>14918984</id>
      </contributor>
      <minor/>
      <comment>/* top */ delink</comment>
      <text xml:space="preserve" bytes="3893">{{no footnotes|date=May 2013}}
The '''production of antibiotics''' has been widespread since the pioneering efforts of [[Howard Walter Florey|Florey]] and [[Ernst Boris Chain|Chain]] in 1938. The importance of [[antibiotics]] to medicine has led to much research into their discovery and production.

== Identifying useful antibiotics ==
[[Image:Klebsiella_pneumoniae_01.png|thumb|An [[agar plate]] streaked with [[microorganism]]s.]]

Despite the wide variety of known antibiotics, less than 1% of antimicrobial agents have medical or commercial [[Value (economics)|value]].  For example, whereas [[penicillin]] has a high [[therapeutic index]] as it does not generally affect human cells, this is not so for many antibiotics. Other antibiotics simply lack advantage over those already in use, or have no other practical applications.

Useful antibiotics are often discovered using a screening process.  To conduct such a screen, isolates of many different [[microorganism]]s are [[Microbiological culture|cultured]] and then tested for production of [[Diffusion|diffusible]] products that inhibit the growth of test organisms. Most antibiotics identified in such a screen are already known and must therefore be disregarded. The remainder must be tested for their selective toxicities and therapeutic activities, and the best candidates can be examined and possibly modified.

A more modern version of this approach is a [[Rational drug design|rational design]] program. This involves screening directed towards finding new natural products that [[Enzyme inhibitor|inhibit]] a specific target, such as an [[enzyme]] only found in the target pathogen, rather than tests to show general inhibition of a culture.

== Industrial production techniques ==
Antibiotics are produced industrially by a process of [[industrial fermentation|fermentation]], where the source microorganism is grown in large containers (100,000–150,000 liters or more) containing a liquid [[growth medium]]. Oxygen concentration, temperature, [[pH]] and [[nutrient]] levels must be optimal, and are closely monitored and adjusted if necessary. As antibiotics are [[secondary metabolite]]s, the population size must be controlled very carefully to ensure that maximum yield is obtained before the cells die. Once the process is complete, the antibiotic must be extracted and purified to a [[crystal]]line product. This is simpler to achieve if the antibiotic is soluble in [[Soluble|organic solvent]]. Otherwise it must first be removed by [[ion exchange]], [[adsorption]] or [[Precipitation (chemistry)|chemical precipitation]].

== Strains used for production ==
Microorganisms used in fermentation are rarely identical to the [[wild type]]. This is because species are often [[Genetically modified organism|genetically modified]] to yield the maximum amounts of antibiotics. [[Mutation]] is often used, and is encouraged by introducing [[mutagen]]s such as ultraviolet radiation, x-rays or certain chemicals. Selection and further [[reproduction]] of the higher yielding strains over many generations can raise yields by 20-fold or more.
Another technique used to increase yields is [[gene]] amplification, where copies of genes coding for enzymes involved in the antibiotic production can be inserted back into a cell, via vectors such as [[plasmid]]s. This process must be closely linked with retesting of antibiotic production.

== References ==
* {{cite book | author=Baron, Samuel | title=Medical Microbiology, 4th ed. | publisher=The University of Texas Medical Branch at Galveston | year=1996 | isbn=0-9631172-1-1 | url=http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View..ShowTOC&amp;rid=mmed.TOC&amp;depth=10 }}
* {{cite book | author=Madigan, Michael; Martinko, John (editors)| title=Brock Biology of Microorganisms (11th ed.)| publisher=Prentice Hall | year=2005 | isbn=0-13-144329-1}}

[[Category:Antibiotics]]</text>
      <sha1>bsoio1qp0uv1lf4hf5hhr77kof6rj3u</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Oxacephem</title>
    <ns>0</ns>
    <id>20885991</id>
    <revision>
      <id>592730052</id>
      <parentid>571722811</parentid>
      <timestamp>2014-01-28T02:00:49Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="1342">[[File:Latamoxef.svg|thumb|[[Latamoxef]] or moxalactam]]
[[File:Flomoxef.png|thumb|[[Flomoxef]]]]
An '''oxacephem''' is a molecule similar to a [[cephem]], but with oxygen substituted for the sulfur. They are synthetically made compounds and have not been discovered in nature.

An example is [[moxalactam]].&lt;ref&gt;{{cite web |url=http://www.medscape.com/viewarticle/464632_2 |title=Medscape.com |format= |work= |accessdate=2008-12-29}}&lt;/ref&gt;

Another example is [[flomoxef]].&lt;ref name=&quot;pmid2621177&quot;&gt;{{cite journal |author=Yazawa K, Mikami Y, Uno J, Otozai K, Arai T |title=In-vitro activity of flomoxef, a new oxacephem group antibiotic, against Nocardia in comparison with other cephalosporins |journal=J. Antimicrob. Chemother. |volume=24 |issue=6 |pages=921–5 |date=December 1989 |pmid=2621177 |doi= 10.1093/jac/24.6.921|url=http://jac.oxfordjournals.org/cgi/pmidlookup?view=long&amp;pmid=2621177}}&lt;/ref&gt;&lt;ref name=&quot;pmid8468113&quot;&gt;{{cite journal |author=Cazzola M, Brancaccio V, De Giglio C, Paternò E, Matera MG, Rossi F |title=Flomoxef, a new oxacephem antibiotic, does not cause hemostatic defects |journal=Int J Clin Pharmacol Ther Toxicol |volume=31 |issue=3 |pages=148–52 |date=March 1993 |pmid=8468113 |doi= |url=}}&lt;/ref&gt;

==References==
{{reflist}}

{{Cell wall disruptive antibiotics}}

[[Category:Antibiotics]]


{{antibiotic-stub}}</text>
      <sha1>r2r8ul7jafc1mtg0gpbvx2avy5e963r</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Streptazolin</title>
    <ns>0</ns>
    <id>18860920</id>
    <revision>
      <id>545394871</id>
      <parentid>543867996</parentid>
      <timestamp>2013-03-19T09:32:11Z</timestamp>
      <contributor>
        <username>Addbot</username>
        <id>6569922</id>
      </contributor>
      <minor/>
      <comment>[[User:Addbot|Bot:]] Migrating 1 interwiki links, now provided by [[Wikipedia:Wikidata|Wikidata]] on [[d:q7623339]]</comment>
      <text xml:space="preserve" bytes="2714">{{chembox
| ImageFile1 = Streptazolin.svg
| ImageFile2 = Streptazolin space fill.png
| IUPACName = (2a&lt;sup&gt;1&lt;/sup&gt;''S'',6''Z'',7''S'',7a''S'')-6-ethyliden-2a&lt;sup&gt;1&lt;/sup&gt;,3,4,6,7,7a-hexahydro-7-hydroxy-1-oxa-2a-azacyclopenta[''cd'']inden-2-one
| OtherNames = 
| Section1 = {{Chembox Identifiers
| CASNo = 
| PubChem = 11769676
| SMILES = C=3CCN1C(=O)OC2C1C=3\C(=C\C)\C2O
| StdInChI = 1S/C11H13NO3/c1-2-6-7-4-3-5-12-8(7)10(9(6)13)15-11(12)14/h2,4,
8-10,13H,3,5H2,1H3/b6-2-/t8-,9-,10-/m0/s1
| StdInChIKey = OJIUACOQFBQCDF-IKXJTIOISA-N
| ChEMBL = 450203
| ChEBI = 542525
}}
| Section2 = {{Chembox Properties
| C = 11 | H = 13 | N = 1 | O = 3
| MolarMass = 
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility = }}
| Section3 = {{Chembox Hazards
| MainHazards = 
| FlashPt = 
| Autoignition = }}
}}
'''Streptazolin''' is an [[antibiotic]] and [[Antifungal medication|antifungal]] substance isolated in 1981 from ''[[Streptomyces]] viridochromogenes''.&lt;ref name=&quot;Drautz&quot;&gt;
{{cite journal
| author = Drautz, H, Zähner, H
| title = Isolation and structure of streptazolin
| journal = Helv. Chim. Act.
| year = 1981
| volume = 64
| issue = 6
| pages = 1752–65
| doi = 10.1002/hlca.19810640605
}}&lt;/ref&gt;&lt;ref name=&quot;Karrer&quot;&gt;
{{cite journal
| author = Karrer, A, Dobler, M
| title = Stoffwechselprodukte von Mikroorganismen 217. Mitteilung Röntgenstrukturanalyse von O-Acetyldihydrostreptazolin 
| journal = Helv. Chim. Act.
| year = 1982
| volume = 65
| issue = 5
| pages = 1432–35
| doi = 10.1002/hlca.19820650516
}}&lt;/ref&gt;

Because of its [[polymerisation]] tendency, it is not suitable for therapeutic use. 1,4-[[reduction (chemistry)|reduction]] of the conjugated [[diene]] gives dihydrostreptazolin which is stable, but has very limited microbial properties.&lt;ref name=&quot; name=&quot;Drautz&quot; /&gt;

The first [[total synthesis]] of ([[racemic]]) streptazolin was achieved in 1985 with the aid of a modified [[Ferrier rearrangement]].&lt;ref name=&quot;Kozikowski1984&quot;&gt;
{{cite journal
| author = Kozikowski, AP, Pyeong-uk Park
| title = Synthesis of 2-substituted .DELTA.3-piperidines: the nitrogen analog of the Ferrier rearrangement. An approach to streptazolin
| journal = J. Org. Chem.
| year = 1984
| volume = 49
| issue = 9
| pages = 1674–1676
| doi =10.1021/jo00183a044
}}&lt;/ref&gt;&lt;ref name=&quot;Kozikowski1985&quot;&gt;
{{cite journal
| author = Kozikowski, AP, Pyeong-uk Park
| title = Total synthesis of streptazolin - an application of the aza-analogue of the ferrier rearrangement
| journal = J. Am. Chem. Soc.
| year = 1985
| volume = 107
| issue = 6
| pages = 1763–65
| doi = 10.1021/ja00292a054 
}}&lt;/ref&gt;

== References ==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Carbamates]]


{{antiinfective-drug-stub}}</text>
      <sha1>88o2xv3vf4bb35cdbru9i44n9ley8gk</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Esperamicin</title>
    <ns>0</ns>
    <id>21032802</id>
    <revision>
      <id>565617295</id>
      <parentid>565614386</parentid>
      <timestamp>2013-07-24T14:00:58Z</timestamp>
      <contributor>
        <username>Legobot</username>
        <id>7304691</id>
      </contributor>
      <minor/>
      <comment>BOT: Dating templates: {{dead link}} (1). Errors? [[User:Legobot/Stop/II 2|stop me]]</comment>
      <text xml:space="preserve" bytes="3349">{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 399920724
|Name = Esperamicin A1
|ImageFile=Esperamicin.png
|ImageSize=200px
|IUPACName=
|OtherNames=
|Section1={{Chembox Identifiers
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4940320
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 449274 
| InChI = 1/C59H80N4O22S4/c1-28(2)60-36-27-77-43(25-39(36)73-8)83-52-50(66)47(63-85-45-24-37(64)53(86-12)31(5)79-45)29(3)80-57(52)82-38-18-16-14-15-17-20-59(71)34(19-21-88-89-87-13)46(38)48(62-58(70)76-11)51(67)54(59)84-44-26-42(49(65)30(4)78-44)81-56(69)33-22-40(74-9)41(75-10)23-35(33)61-55(68)32(6)72-7/h14-15,19,22-23,28-31,36-39,42-45,47,49-50,52-54,57,60,63-66,71H,6,21,24-27H2,1-5,7-13H3,(H,61,68)(H,62,70)/b15-14-,34-19+
| InChIKey = LJQQFQHBKUKHIS-WJHRIEJJBF
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C59H80N4O22S4/c1-28(2)60-36-27-77-43(25-39(36)73-8)83-52-50(66)47(63-85-45-24-37(64)53(86-12)31(5)79-45)29(3)80-57(52)82-38-18-16-14-15-17-20-59(71)34(19-21-88-89-87-13)46(38)48(62-58(70)76-11)51(67)54(59)84-44-26-42(49(65)30(4)78-44)81-56(69)33-22-40(74-9)41(75-10)23-35(33)61-55(68)32(6)72-7/h14-15,19,22-23,28-31,36-39,42-45,47,49-50,52-54,57,60,63-66,71H,6,21,24-27H2,1-5,7-13H3,(H,61,68)(H,62,70)/b15-14-,34-19+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = LJQQFQHBKUKHIS-WJHRIEJJSA-N
| CASNo_Ref = {{cascite|correct|??}}
| CASNo=99674-26-7
|  PubChem = 6435576
|  SMILES = O=C(C(\OC)=C)Nc1cc(OC)c(OC)cc1C(=O)OC2CC(OC(C)C2O)OC7C(=O)C(\NC(=O)OC)=C6/C(=C\CSSSC)C7(O)C#C\C=C/C#CC6OC5OC(C)C(NOC3OC(C)C(SC)C(O)C3)C(O)C5OC4OCC(NC(C)C)C(OC)C4
}}
|Section2={{Chembox Properties
|  C=59|H=80|N=4|O=22|S=4
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3={{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}

The '''esperamicins''' are a class of bacteria-derived [[chromoprotein]] [[enediyne]] [[antibiotic]]s, of which esperamicin A1 is the most well studied.  Esperamcin A1 and the related enediyne [[calicheamicin]] are the two most potent antitumor agents known.&lt;ref&gt;[http://jlstasal.myweb.uga.edu/CaliEsp.htm Calicheamicin and Esperamicin are the two most potent antitumor agents known to man], Univ Of Georgia Chem 4500{{dead link|date=July 2013}}&lt;/ref&gt;  The esperamicins are extremely toxic DNA splicing compounds.

Oxygen and oxygen scavengers have no significant effect on DNA breakage.   The cleavage of DNA by esperamicin is greatly accelerated in the presence of [[thiol]] compounds.  Oxygen and active oxygen-radical scavengers have no significant influence upon DNA strand breakage by esperamicin.  The preferential cutting sites of esperamicin are at [[thymidylate]] residues, and the frequency of [[nucleobase]] attacked (T greater than C greater than A greater than G) is different from that of calicheamicin (C much greater than T greater than A = G), [[neocarzinostatin]] (T greater than A greater than C greater than G), or [[bleomycin]] (C greater than T greater than A greater than G).&lt;ref&gt;[http://www.pnas.org/content/86/20/7672.abstract Nucleotide-specific cleavage and minor-groove interaction of DNA with esperamicin antitumor antibiotics]&lt;/ref&gt;

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Cancer research]]
[[Category:Enediynes]]</text>
      <sha1>bvacxnzt2ledps2ynd9kj4f5fscartp</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Enediyne</title>
    <ns>0</ns>
    <id>21032939</id>
    <revision>
      <id>542859992</id>
      <parentid>505785020</parentid>
      <timestamp>2013-03-08T17:59:45Z</timestamp>
      <contributor>
        <username>Addbot</username>
        <id>6569922</id>
      </contributor>
      <minor/>
      <comment>[[User:Addbot|Bot:]] Migrating 3 interwiki links, now provided by [[Wikipedia:Wikidata|Wikidata]] on [[d:q408335]]</comment>
      <text xml:space="preserve" bytes="1997">[[File:Calicheamicin.png|thumb|right|250px|[[Calicheamicin]]]]
'''Enediynes''' are a class of bacterial [[natural product]]s characterized by either nine- and ten-membered rings containing two [[triple bond]]s separated by a [[double bond]].&lt;ref&gt;{{cite journal | doi = 10.1073/pnas.90.13.5881 | journal = PNAS |year= 1993 |volume = 90|issue = 13  | pages = 5881–5888 | title =  Chemistry and biology of natural and designed enediynes| author = K. C. Nicolaou; A. L. Smith; E. W. Yue | pmid = 8327459 | pmc = 46830|bibcode = 1993PNAS...90.5881N }}&lt;/ref&gt; Many of these compounds are capable of undergoing [[Bergman cyclization]]. The resulting [[Radical (chemistry)|diradical]], a [[1,4-dehydrobenzene]] derivative, is capable of abstracting hydrogen atoms from the sugar backbone of DNA which results in strand scission.&lt;ref&gt;{{cite journal | author = S. Walker; R. Landovitz; W.D. Ding; G.A. Ellestad; D. Kahne | title = Cleavage behavior of calicheamicin gamma 1 and calicheamicin T | journal = Proc Natl Acad Sci U.S.A. | year = 1992| volume = 89 | issue = 10 | pages = 4608–12 | pmc=49132 |pmid=1584797 | doi = 10.1073/pnas.89.10.4608|bibcode = 1992PNAS...89.4608W }}&lt;/ref&gt; This high reactivity with DNA makes the substances toxic. They are being researched as antitumor agents.  Several of the naturally occurring enediynes have entered clinical trials against cancer&lt;ref&gt;[http://www.ingentaconnect.com/content/ben/fmc/2004/00000001/00000001/art00011 Designed Enediyne Antitumor Agents]&lt;/ref&gt; &lt;ref&gt;[http://www.chem.uga.edu/vpopik/Enediynes.html Development of Photoswitchable Enediyne Antibiotics]&lt;/ref&gt; and in Japan [[neocarzinostatin]] is used clinically.

Three classes of enediynes exist: 
* [[Calicheamicin]]/[[esperamicin]]
* [[Dynemicin A|Dynemicin ]]
* [[Chromoprotein]] types

The enediyne group in those compounds is often called a warhead. 

==References==
{{Reflist}}

[[Category:Antibiotics]]
[[Category:Cancer research]]
[[Category:Enediynes| ]]
[[Category:Functional groups]]</text>
      <sha1>409qdxypgxwyabqg7pvkf8u3dhxos26</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Lasalocid</title>
    <ns>0</ns>
    <id>21103827</id>
    <revision>
      <id>543128952</id>
      <parentid>462228407</parentid>
      <timestamp>2013-03-10T02:08:30Z</timestamp>
      <contributor>
        <username>Addbot</username>
        <id>6569922</id>
      </contributor>
      <minor/>
      <comment>[[User:Addbot|Bot:]] Migrating 2 interwiki links, now provided by [[Wikipedia:Wikidata|Wikidata]] on [[d:q3827314]]</comment>
      <text xml:space="preserve" bytes="3316">{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 462089190
| IUPAC_name = 6-[(3''R'',4''S'',5''S'',7''R'')-7-[(2''S'',3''S'',5''S'')-5-ethyl-5-[(2''R'',5''R'',6''S'')-
| image = Lasalocid structure.png

&lt;!--Clinical data--&gt;
| tradename =  
| Drugs.com = {{drugs.com|international|lasalocid}}
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category =  
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, or Class A, B, C --&gt;
| legal_US = &lt;!-- OTC / Rx-only / Schedule I, II, III, IV, V --&gt;
| legal_status =  
| routes_of_administration =  

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 25999-31-9
| ATCvet = yes
| ATC_prefix = P51
| ATC_suffix = AH02
| PubChem = 5360807
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4514598
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = W7V2ZZ2FWB
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04671
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 145347

&lt;!--Chemical data--&gt;
| chemical_formula =  
| C=34 | H=54 | O=8 
| molecular_weight = 590.79 g/mol
| smiles = O=C(O)c1c(O)c(ccc1CC[C@@H](C)[C@H](O)[C@@H](C(=O)[C@@H]([C@H]3O[C@@]([C@@H]2O[C@H]([C@](O)(CC2)CC)C)(CC)C[C@@H]3C)CC)C)C
| InChI = 1/C34H54O8/c1-9-25(31-21(6)18-34(11-3,42-31)26-16-17-33(40,10-2)23(8)41-26)30(37)22(7)28(35)19(4)12-14-24-15-13-20(5)29(36)27(24)32(38)39/h13,15,19,21-23,25-26,28,31,35-36,40H,9-12,14,16-18H2,1-8H3,(H,38,39)/t19-,21+,22+,23+,25+,26-,28+,31+,33-,34+/m1/s1
| InChIKey = BBMULGJBVDDDNI-OWKLGTHSBL
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C34H54O8/c1-9-25(31-21(6)18-34(11-3,42-31)26-16-17-33(40,10-2)23(8)41-26)30(37)22(7)28(35)19(4)12-14-24-15-13-20(5)29(36)27(24)32(38)39/h13,15,19,21-23,25-26,28,31,35-36,40H,9-12,14,16-18H2,1-8H3,(H,38,39)/t19-,21+,22+,23+,25+,26-,28+,31+,33-,34+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BBMULGJBVDDDNI-OWKLGTHSSA-N
}}

'''Lasalocid''' is an antibacterial agent and a [[coccidiostat]], which is produced by strains of ''[[Streptomyces]] lasaliensis''. It is the drug in the feed additive called '''Bovatec'''.&lt;ref&gt;[http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm064879.pdf  FOIA Drug Summaries.]&lt;/ref&gt;

Lasalocid is able to make neutral complexes with monovalent and divalent cations and transport them through apolar phase (including lipid bilayer membranes). It can transport also big organic cations like dopamine.

Horses and dogs&lt;ref&gt;[http://veterinaryrecord.bmj.com/content/155/6/174.abstract  BMJ Veterinary Record]&lt;/ref&gt; are very susceptible to the toxic effects of Lasalocid, and it should not be administered.


==References==
{{Reflist}}

[[Category:Antibiotics]]
[[Category:Antiparasitic agents]]
[[Category:Alcohols]]
[[Category:Ketones]]
[[Category:Tetrahydropyrans]]
[[Category:Tetrahydrofurans]]
[[Category:Salicylic acids]]


{{antiinfective-drug-stub}}</text>
      <sha1>rla5po2jn28gpnnlzpsjgxlmxcy511i</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Narasin</title>
    <ns>0</ns>
    <id>21103831</id>
    <revision>
      <id>587790395</id>
      <parentid>568169254</parentid>
      <timestamp>2013-12-26T19:42:20Z</timestamp>
      <contributor>
        <username>Anypodetos</username>
        <id>7442243</id>
      </contributor>
      <comment>Refs; rephrase unclear sentence; drugbox additions</comment>
      <text xml:space="preserve" bytes="2647">{{Drugbox
| verifiedrevid = 444434623
| IUPAC_name = (2''R'')-2-[(2''R'',3''S'',5''S'',6''R'')-6-[(1''S'',2''S'',3''S'',5''R'')-5- [(2''S'',5''S'',7''R'',9''S'',10''S'',12''R'',15''R'')-2-[(2''R'',5''R'',6''S'')-5-ethyl-5-hydroxy-6-methyl-2-tetrahydropyranyl]-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.5&lt;sup&gt;7&lt;/sup&gt;.3&lt;sup&gt;5&lt;/sup&gt;]pentadec-13-en-9-yl]-2-hydroxy-1,3-dimethyl-4-oxoheptyl]-3,5-dimethyl-2-tetrahydropyranyl]butanoic acid
| image = narasin.png

&lt;!--Clinical data--&gt;
| tradename =  
| Drugs.com = {{drugs.com|international|narasin}}
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category =  
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, or Class A, B, C --&gt;
| legal_US = &lt;!-- OTC / Rx-only / Schedule I, II, III, IV, V --&gt;
| legal_status =  
| routes_of_administration =  

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 55134-13-9
| ATCvet = yes
| ATC_prefix = P51
| ATC_suffix = AH04
| PubChem = 65452
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| ChemSpiderID = 58911
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = DZY9VU539P
| synonyms = (4''S'')-4-methyl-salinomycin

&lt;!--Chemical data--&gt;
| chemical_formula =  
| C=43 | H=72 | O=11 
| molecular_weight = 765.03 g/mol
| smiles = O=C([C@@H](C)[C@@H](O)[C@H](C)[C@]5([H])O[C@]([C@@H](CC)C(O)=O)([H])[C@@H](C)C[C@@H]5C)[C@H](CC)[C@@]1([H])O[C@@]2(O[C@@]3(CC[C@]([C@]4([H])O[C@@H](C)[C@@](O)(CC)CC4)(C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C
| StdInChI=1S/C43H72O11/c1-12-30(35(46)27(8)34(45)28(9)36-23(4)21-24(5)37(51-36)31(13-2)39(47)48)38-25(6)22-26(7)42(52-38)18-15-32(44)43(54-42)20-19-40(11,53-43)33-16-17-41(49,14-3)29(10)50-33/h15,18,23-34,36-38,44-45,49H,12-14,16-17,19-22H2,1-11H3,(H,47,48)/t23-,24-,25-,26+,27-,28-,29-,30-,31+,32+,33+,34+,36+,37+,38-,40-,41+,42-,43-/m0/s1
| StdInChIKey = VHKXXVVRRDYCIK-CWCPJSEDSA-N
}}

'''Narasin''' is a [[coccidiostat]] and antibacterial agent.&lt;ref&gt;{{pmid|21500637}}&lt;/ref&gt;&lt;ref&gt;{{pmid|2774323}}&lt;/ref&gt; It is a derivative of [[salinomycin]] with an additional [[methyl group]].

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Antiparasitic agents]]
[[Category:Carboxylic acids]]
[[Category:Alcohols]]
[[Category:Ketones]]
[[Category:Tetrahydropyrans]]
[[Category:Tetrahydrofurans]]
[[Category:Spiro compounds]]


{{antiinfective-drug-stub}}</text>
      <sha1>5ysl79svq2dng3ew58b96rvjlzqbmyp</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Hydramacin-1</title>
    <ns>0</ns>
    <id>21140350</id>
    <revision>
      <id>548774424</id>
      <parentid>532146092</parentid>
      <timestamp>2013-04-05T03:31:03Z</timestamp>
      <contributor>
        <username>Squids and Chips</username>
        <id>2947772</id>
      </contributor>
      <minor/>
      <comment>[[:en:WP:CLEANER|WPCleaner]] v1.26 - Repaired 1 link to disambiguation page - [[WP:DPL|(You can help)]] - [[Hydroid]]</comment>
      <text xml:space="preserve" bytes="5619">
[[File:Protein structure 2K35.jpg|thumb|right|150px|Structure of hydramacin-1]]
[[File:Hydra001.jpg|thumb|right|150px|A hydra (size: several millimetres)]]
'''Hydramacin-1''' is a type of [[antimicrobial]] [[protein]]. It was first isolated and reproduced in 2008 from cells of the freshwater [[hydroid (zoology)|hydroid]] ''[[Hydra (genus)|Hydra]]''. Only around 60 [[amino acid]]s long, the protein is unique both in amino acid sequence and [[tertiary structure]], prompting its classification in a new family of proteins, the [[macin protein family|macins]]. The protein's unusual structure is most likely a reason for the compound's potent antimicrobial qualities.&lt;ref name=&quot;Jung2009&quot;&gt;{{cite journal|last=Jung|first=Sascha|coauthors=Andrew J. Dingley, René Augustin, Friederike Anton-Erxleben, Mareike Stanisak, Christoph Gelhaus, Thomas Gutsmann, Malte U. Hammer, Rainer Podschun, Alexandre M. J. J. Bonvin, Matthias Leippe, Thomas C. G. Bosch and Joachim Grötzinger|date=2009-01-16|title=Hydramacin-1, Structure and Antibacterial Activity of a Protein from the Basal Metazoan Hydra|journal=Journal of Biological Chemistry|publisher=The American Society for Biochemistry and Molecular Biology|volume=284|issue=3|pages=1896–1905|doi=10.1074/jbc.M804713200|pmid=19019828}}&lt;/ref&gt;

Antimicrobial tests determined that the protein has an antibacterial effect against both [[Gram-positive bacteria|Gram-positive]] and [[gram-negative bacteria|Gram-negative]] bacteria. This potent antibacterial activity extended to known [[antibiotic resistance|multi-resistant]] strains of pathogenic bacteria, such as those of ''[[Klebsiella oxytoca]]''. Functionally, the protein causes bacterial cells to clump together and aggregate, changing the morphology of the bacterial aggregations it creates. This results in a disruption of the structure of the bacterial membrane.&lt;ref name=&quot;Jung2009&quot;/&gt;

Hydramacin-1 was first isolated from [[epithelial]] cells of the [[cnidaria]]n ''[[Hydra (genus)|Hydra]]'', a small (almost-microscopic) freshwater animal related to [[coral]]s, [[sea anemone]]s and [[jellyfish]].&lt;ref name=&quot;ITISHydra&quot;&gt;{{ITIS | id = 50845 | taxon = Hydra | accessdate = 23 January 2009 }}&lt;/ref&gt;&lt;ref name=&quot;ITISScyphozoa&quot;&gt;{{ITIS | id =51483 | taxon = Scyphozoa | accessdate = 23 January 2009 }}&lt;/ref&gt;&lt;ref name=&quot;ITISAnthozoa&quot;&gt;{{ITIS | id =51938 | taxon = Anthozoa | accessdate = 23 January 2009 }}&lt;/ref&gt;&lt;ref name=&quot;ITISCnidaria&quot;&gt;{{ITIS | id =48738 | taxon = Cnidaria | accessdate = 23 January 2009 }}&lt;/ref&gt; Like other members of the [[Phylum]] [[Cnidaria]], ''Hydra'' possesses specialized defensive epithelial cells called [[cnidocyte]]s that shoot [[toxic]] barbs into organisms they come in physical contact with. German researchers managed to isolate the [[gene]] that coded for the production of the protein from the ''Hydra'' genome in 2008. The gene was transferred and cloned in a [[plasmid]] ([[Pet32a]]) which was inserted in the bacteria ''[[Escherichia coli]]'', a standard method of replicating a protein isolated from a much larger organism.&lt;ref name=&quot;Jung2009&quot;/&gt; The three-dimensional structure of the resulting protein was then determined by [[Protein nuclear magnetic resonance spectroscopy|
NMR spectroscopy]] and is now published online by the [[Protein Data Bank]].&lt;ref name=&quot;PDBHydramacin1&quot;&gt;{{cite web|url=http://www.rcsb.org/pdb/explore/explore.do?structureId=2K35|title=Hydramacin-1 (2K35)|publisher=Protein Data Bank|accessdate=2009-01-23}}&lt;/ref&gt; 

Hydramacin-1 is a single-chain protein composed of sixty [[amino acid]]s. It is a unique combination of amino acids on the surface of the molecule that gives the protein its potent antimicrobial qualities. This specialized part of the protein tertiary structure, a positively charged belt in between two [[hydrophobic]] (and ionically inert) regions, has been suggested as the trigger for bacterial aggregation influence by the protein.&lt;ref name=&quot;Jung2009&quot;/&gt;

Hydramacin-1 is different from any other antibacterial currently known, except for two proteins found in [[leech]]es. The researchers propose placing hydramacin-1 and the proteins from the leech in a newly designated protein family called the [[macin protein family|macins]]. The proteins closest in structure to the macins are a [[Superfamily (molecular biology)|superfamily]] of proteins derived from [[scorpion]] [[venom]], dubbed the [[scorpion oxin]]s.&lt;ref name=SD20090117&gt;
{{cite news | title = New Family Of Antibacterial Agents Uncovered | work = Science News | publisher = ScienceDaily | date = 2009-01-17 | url = http://www.sciencedaily.com/releases/2009/01/090115190456.htm | accessdate = 2009-01-17}}&lt;/ref&gt;

==References==
{{reflist}}

==Bibliography==
*{{cite journal|last=Jung|first=Sascha|coauthors=Andrew J. Dingley, René Augustin, Friederike Anton-Erxleben, Mareike Stanisak, Christoph Gelhaus, Thomas Gutsmann, Malte U. Hammer, Rainer Podschun, Alexandre M. J. J. Bonvin, Matthias Leippe, Thomas C. G. Bosch and Joachim Grötzinger|date=2009-01-16|title=Hydramacin-1, Structure and Antibacterial Activity of a Protein from the Basal Metazoan Hydra|journal=Journal of Biological Chemistry|publisher=The American Society for Biochemistry and Molecular Biology|volume=284|issue=3|pages=1896–1905|doi=10.1074/jbc.M804713200|pmid=19019828}}

==External links==
* [http://www.rcsb.org/pdb/explore/explore.do?structureId=2K35 Hydramacin-1 (2K35)] in the [[Protein Data Bank]], including sequence and 3-dimensional structural information.
* [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2K35 Hydramacin-1 (2K35) at the OCA]

[[Category:Antibiotics]]
[[Category:Proteins]]</text>
      <sha1>kjc9k6k1e81ziwva2x71um91baqj0ae</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Salinomycin</title>
    <ns>0</ns>
    <id>21103848</id>
    <revision>
      <id>585777172</id>
      <parentid>546556856</parentid>
      <timestamp>2013-12-12T18:22:59Z</timestamp>
      <contributor>
        <username>Mogism</username>
        <id>16902756</id>
      </contributor>
      <minor/>
      <comment>/* Pre-clinical */Cleanup/[[WP:AWB/T|Typo fixing]], [[WP:AWB/T|typo(s) fixed]]: a anti → an anti using [[Project:AWB|AWB]]</comment>
      <text xml:space="preserve" bytes="6955">{{chembox
| Verifiedfields = changed
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 62UXS86T64
| verifiedrevid = 373936925
|ImageFile=Salinomycin.png
|ImageSize=200px
|IUPACName=(2R)-2-[(5S,6R)-6-[(1S,2S,3S,5R)-5-[(2S,5R,7S,9S,10S,12R,15R)-2-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyl-2-tetrahydropyranyl]-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.5^{7}.3^{5}]pentadec-13-en-9-yl]-2-hydroxy-1,3-dimethyl-4-oxoheptyl]-5-methyl-2-tetrahydropyranyl]butanoic acid
| IUPACName_hidden = yes
|OtherNames=
|Section1={{Chembox Identifiers
|  CASNo_Ref = {{cascite|correct|??}}
| CASNo=53003-10-4
|  PubChem=72370
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1208572
|  ATCvet = yes
|  ATCCode_prefix = P51
|  ATCCode_suffix = AH01
|  SMILES=O=C([C@H]([C@H]([C@@H]([C@]3([H])O[C@]([C@@H](CC)C(O)=O)([H])CC[C@@H]3C)C)O)C)[C@H](CC)[C@@]([C@@H](C)C[C@H]2C)([H])O[C@]12O[C@@]4(CC[C@]([C@]5([H])O[C@@H](C)[C@](CC)(O)CC5)(C)O4)[C@H](O)C=C1  }}
|Section2={{Chembox Properties
|  Formula=C&lt;sub&gt;42&lt;/sub&gt;H&lt;sub&gt;70&lt;/sub&gt;O&lt;sub&gt;11&lt;/sub&gt;
|  MolarMass=751.00 g/mol
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3={{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}

'''Salinomycin''' is an [[antibacterial]] and [[coccidiostat]] [[ionophore]] therapeutic drug.

== Cancer research ==
===Pre-clinical===
Salinomycin has been shown by Piyush Gupta et al. of the [[Massachusetts Institute of Technology]] and the [[Broad Institute]] to kill [[breast cancer]] [[stem cell]]s in mice at least 100 times more effectively than the anti-cancer drug [[paclitaxel]]. The study screened 16,000 different chemical compounds and found that only a small subset, including salinomycin and [[etoposide]], targeted [[cancer stem cells]] responsible for metastasis and relapse.&lt;ref&gt;{{cite news 
|title=Drug shows cancer stem cells not invulnerable 
|publisher=[[New Scientist]] 
|url=http://www.newscientist.com/article/dn17610-drug-shows-cancer-stem-cells-not-invulnerable.html 
|date=2009-08-13}}
&lt;/ref&gt;&lt;ref&gt;
{{cite news 
| url=http://www.broadinstitute.org/news/1305
| title=New method takes aim at aggressive cancer cells
| publisher=[[Broad Institute]]
| work=Broad Communications
| date=2009-08-13
| accessdate=2009-08-13
}}
&lt;/ref&gt;&lt;ref&gt;
{{cite journal
| doi=10.1016/j.cell.2009.06.034
| last=Gupta
| first=P. et al.
| pmid=19682730
| title=Identification of selective inhibitors of cancer stem cells by high-throughput screening
| journal=Cell 
| date=2009-08-13
| last2=Onder
| first2=Tamer T.
| last3=Jiang
| first3=Guozhi
| last4=Tao
| first4=Kai
| last5=Kuperwasser
| first5=Charlotte
| last6=Weinberg
| first6=Robert A.
| last7=Lander
| first7=Eric S.
| volume=138
| issue=4
| pages=645–59
}}
&lt;/ref&gt;&lt;ref&gt;
{{cite journal
| author      = Adam Huczynski
| date        = 
| year        = 2012
| volume      =79
| pages=235–238
| title       = Salinomycin – a New Cancer Drug Candidate
| journal      = Chemical Biology &amp; Drug Design
| doi          = 10.1111/j.1747-0285.2011.01287.x
}}
&lt;/ref&gt;

The [[mechanism of action]] by which salinomycin kills cancer stem cells specifically remains unknown, but is thought to be due to its action as a potassium ionophore due to the detection of [[nigericin]] in the same compound screen. Studies performed in 2011 showed that salinomycin could induce [[apoptosis]] of human cancer cells. Promising results from a few clinical pilote studies reveal that salinomycin is able to effectively eliminate CSCs and to induce partial clinical regression of heavily pretreated and therapy-resistant cancers. The ability of salinomycin to kill both CSCs and therapy-resistant cancer cells may define the compound as a novel and an effective anticancer drug.&lt;ref&gt;C.  Naujokat, R. Steinhart ” Salinomycin as a Drug for Targeting Human Cancer Stem Cells”, ''[[Journal of Biomedicine and Biotechnology]]'', Volume 2012 (2012), Article ID 950658, {{doi| 10.1155/2012/950658}}, [http://downloads.hindawi.com/journals/bmri/2012/950658.pdf open access review article]&lt;/ref&gt;&lt;ref&gt;A. Huczyński, ”Polyether ionophores—promising bioactive molecules for cancer therapy”, ''[[Bioorganic &amp; Medicinal Chemistry Letters]]'', 2012,22, 7002-7010,{{doi|10.1016/j.bmcl.2012.09.046}}, [http://pdn.sciencedirect.com/science?_ob=MiamiImageURL&amp;_cid=271398&amp;_user=10&amp;_pii=S0960894X12011924&amp;_check=y&amp;_origin=article&amp;_zone=toolbar&amp;_coverDate=2012--01&amp;view=c&amp;originContentFamily=serial&amp;wchp=dGLzVlt-zSkzV&amp;md5=84788aa32c6c31005037121056abfe26&amp;pid=1-s2.0-S0960894X12011924-main.pdf  open access review article] &lt;/ref&gt; It has been also shown that Salinomycin and its derivatives exhibit potent antiproliferative activity against the drug-resistant cancer cell lines.&lt;ref&gt; A. Huczyński, J. Janczak, M. Antoszczak, J. Wietrzyk, E. Maj, B. Brzezinski, , ” Antiproliferative activity of salinomycin and its derivatives”, ''[[Bioorganic &amp; Medicinal Chemistry Letters]]'', 2012,22, 7146-7150,{{doi|10.1016/j.bmcl.2012.09.068}},&lt;/ref&gt; Salinomycin is the key compound in the pharmaceutical company Verastem's efforts to produce an anti-cancer-stem-cell drug.

== Use in agriculture ==
Salinomycin is used in chicken fodder as a [[coccidiostat]].

== Biosynthesis ==
A team from the [[University of Cambridge]] has cloned and sequenced the biosynthetic cluster responsible for salinomycin production, from ''Streptomyces albus'' DSM 41398.&lt;ref&gt;{{cite journal
| doi=10.1002/cbic.201100590
| last=Yurkovich
| first=Marie E. et al.
| pmid= 22076845
| title=A Late-Stage Intermediate in Salinomycin Biosynthesis Is Revealed by Specific Mutation in the Biosynthetic Gene Cluster
| journal=ChemBioChem
| date=2011-11-11
| last2=Tyrakis
| first2=Petros A.
| last3=Hong
| first3=Hui
| last4=Sun
| first4=Yuhui
| last5=Samborskyy
| first5=Markiyan 
| last6=Kamiya
| first6=Kohei
| last7=Leadlay
| first7=Peter F.
| volume=13
| issue=1
| pages=66–71
}}&lt;/ref&gt; This has shown that the [[polyketide]] backbone of salinomycin is synthesised on an assembly line of nine [[polyketide synthase]] (PKS) multienzymes. Furthermore, the cluster contains genes involved in oxidative cyclization including ''salC'' (epoxidase) and ''salBI/BII/BIII'' (epoxide hydrolase) genes. The cluster also contains genes suspected to be involved in self-resistance, export, precursor supply and regulation.  Interestingly, the cluster contains a NRPS-like carrier protein, SalX, that is suspected to tether “pre-salinomycin” during oxidative cyclization. By inactivating salC the Cambridge-based team have demonstrated that salinomycin biosynthesis proceeds via a diene intermediate.

==See also==
* [[Narasin]] a derivative of salinomycin which has an additional methyl group.
* [[Targeted therapy]]

==References==

{{Reflist}}

[[Category:Antibiotics]]
[[Category:Antiparasitic agents]]
[[Category:Ionophores]]
[[Category:Carboxylic acids]]
[[Category:Alcohols]]
[[Category:Ketones]]
[[Category:Tetrahydropyrans]]
[[Category:Tetrahydrofurans]]</text>
      <sha1>fj2px844282jr10t5lhr9bb0jjt78ey</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Platensimycin</title>
    <ns>0</ns>
    <id>5192329</id>
    <revision>
      <id>576269608</id>
      <parentid>576268803</parentid>
      <timestamp>2013-10-08T10:45:04Z</timestamp>
      <contributor>
        <username>CheMoBot</username>
        <id>7377957</id>
      </contributor>
      <comment>Updating {{chembox}} (changes to verified fields - updated 'ChEBI_Ref') per [[WP:CHEMVALID|Chem/Drugbox validation]] (report [[Wikipedia_talk:WikiProject_Chemicals|errors]] or [[user talk:CheMoBot|bugs]])</comment>
      <text xml:space="preserve" bytes="12091">{{chembox
| Verifiedfields = changed
| verifiedrevid = 461752648
| ImageFile = Platensimycin.PNG
| ImageFile2 = Platensimycin 2GFX.png
| ImageSize = 350px
| ImageSize2 = 350px
| IUPACName = 3-&lt;nowiki&gt;[&lt;/nowiki&gt;[3-[(1''R'',3''R'',4''R'',5a''R'',9''R'',9a''S'')-1,4,5,8,9,9a-hexahydro-3,9-dimethyl-8-oxo-3''H''-1,4:3,5a-dimethano-2-benzoxepin-9-yl]-1-oxopropyl]amino]-2,4-dihydroxy-benzoic acid
| OtherNames =
| Section1 = {{Chembox Identifiers
|   ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5257055
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 560671
| InChI = 1/C24H27NO7/c1-22(7-6-17(28)25-18-14(26)4-3-13(19(18)29)21(30)31)16(27)5-8-24-10-12-9-15(20(22)24)32-23(12,2)11-24/h3-5,8,12,15,20,26,29H,6-7,9-11H2,1-2H3,(H,25,28)(H,30,31)/t12-,15+,20+,22-,23+,24+/m1/s1
| InChIKey = CSOMAHTTWTVBFL-OFBLZTNGBM
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C24H27NO7/c1-22(7-6-17(28)25-18-14(26)4-3-13(19(18)29)21(30)31)16(27)5-8-24-10-12-9-15(20(22)24)32-23(12,2)11-24/h3-5,8,12,15,20,26,29H,6-7,9-11H2,1-2H3,(H,25,28)(H,30,31)/t12-,15+,20+,22-,23+,24+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = CSOMAHTTWTVBFL-OFBLZTNGSA-N
| CASNo_Ref = {{cascite|changed|??}}
| CASNo = 835876-32-9
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 68236
|   PubChem = 6857724
|   DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB08407
| SMILES = O=C(O)c1c(O)c(c(O)cc1)NC(=O)CC[C@@]5(C(=O)\C=C/[C@@]34C[C@@]2(O[C@@H](C[C@@H]2C3)[C@H]45)C)C
}}
| Section2 = {{Chembox Properties
|   C=24|H=27|N=1|O=7
|   MolarMass = 441.47368 [[Gram|g]]/[[Mole (unit)|mol]]
|   Appearance =
|   Density =
|   MeltingPt =
|   BoilingPt =
|   Solubility =
  }}
| Section3 = {{Chembox Hazards
|   MainHazards =
|   FlashPt =
|   Autoignition =
  }}
}}

'''Platensimycin''', a [[metabolite]] of ''[[Streptomyces]] platensis'', which is an excellent example of a unique structural class of natural [[antibiotic]]s, has been demonstrated to be a breakthrough in recent antibiotic research due to its unique functional pattern and significant antibacterial activity.&lt;ref&gt;J. Wang, S.M. Soisson, K .Young, S.B. Singh etc,''Nature'' '''2006''', ''441'', 358-61.&lt;/ref&gt;&lt;ref&gt;D T. Manallack, I T. Crosby, Y. Khakham and B. Capuano, ''Current Medicinal Chemistry'' '''2008''', ''15'', 705-710.&lt;/ref&gt; This compound is a member of a class of antibiotics which act by blocking [[enzymes]] involved in the [[condensation reaction|condensation]] steps in [[fatty acid]] [[biosynthesis]],&lt;ref&gt;D. Häbich, F. Von Nussbaum, ''ChemMedChem'' '''2006''', ''1'', 951-954.&lt;/ref&gt; which [[Gram-positive bacteria]] need to biosynthesise [[cell membranes]] (β-ketoacyl-(acyl-carrier-protein (ACP)) synthase [[Beta-ketoacyl-acyl-carrier-protein synthase I|I]]/[[Beta-ketoacyl-acyl-carrier-protein synthase II|II]] (FabF/B)). Other enzymes in this pathway have similarly been proven antibiotic targets for example FabI, the [[Enoyl-acyl carrier protein reductase|enoyl-ACP (acyl carrier protein) reductase]], that is inhibited by [[isoniazid]] and related compounds and the [[antiseptic]] agent [[triclosan]].&lt;ref&gt;H T. Wright, and K.A Reynolds, ''Curr Opin Microbiol '' '''2007''', ''10'', 447-53.&lt;/ref&gt;

==History==

Platensimycin was first isolated from a strain of ''Streptomyces platensis'' by the [[Merck &amp; Co.|Merck]] group [1] by using two-plate system where control organisms were compared to cells expressing fabF [[antisense RNA]]. This method uses the combination of target-based whole-cell and biochemical [[assay]]s. The advantage of this method is that the concentrations of compounds in these extracts is sometimes too low to be identified in whole cell assays but are easily found in this two-plate assay system. They tried to find a drug targeting condensing enzymes and can be used clinically. Therefore, they systematically screened 250,000 natural product extracts (83,000 [[strains (biology)|strains]] in three growth conditions) led to the identification of a potent and selective small molecule from a strain of Streptomyces platensis recovered from a [[soil sample]] collected in South Africa. This molecule, platensimycin (C24H27NO7, relative [[molecular mass]] 441.47), comprises two distinct structural elements connected by an [[amide bond]]. They still showed that Platensimycin has potent, [[Broad-spectrum antibiotic|broad-spectrum]] Gram-positive activity ''[[in vitro]]'' (Table below) and exhibits no [[cross-resistance]] to other key [[Antibiotic resistance|antibiotic-resistant]] bacteria including [[Methicillin-resistant Staphylococcus aureus]](MRSA), [[vancomycin]]-intermediate [[Staphylococcus aureus|S. aureus]], [[Vancomycin-resistant Enterococcus|vancomycin-resistant Enterococci]], and [[linezolid]]-resistant and [[macrolide]]-resistant [[pathogen]]s.
[1]
A first [[total synthesis]] of [[Racemic mixture|racemic]] platensimycin has been published.[7] Its structure consists of a 3-amino-[[2,4-Dihydroxybenzoic acid|2,4-dihydroxybenzoic acid]] [[Chemical polarity|polar]] part linked through an amide bond to a [[lipophilic]] [[Polycyclic compound|pentacyclic]] [[ketolide]].&lt;ref&gt;K. C. Nicolaou, A. Li, D. J. Edmonds,  ''Angew. Chem.'' '''2006''', ''118'', 7244-48.&lt;/ref&gt;

==Clinical use==

Platensimycin is an [[Experimental drug|experimental new drug]] in [[Pre-clinical development|preclinical trials]] in an effort to combat MRSA in a [[Animal model|mouse model]].[1] Platensimycin is a very effective antibiotic ''in vivo'' when continuously administered to cells, however this efficacy is reduced when administered by more conventional means.&lt;ref&gt;K B. Herath, A B. Attygalle, and S B. Singh,''JACS'' '''2007''', ''129'', 15422-23.&lt;/ref&gt; Consequently, and in light of the elevated levels of the drug necessary for effectiveness, [[clinical trial]]s have been delayed pending the development of variants of similar chemical form which have more favorable properties.&lt;ref&gt;M J. Smanski, R M. Peterson, S R. Rajski, and B. Shen,''Antimicrobial Agents and Chemotherapy.'' '''2009'''&lt;/ref&gt;
Since the importance of platensimycin, it has been studied to improve the production by [[gene regulation]]&lt;ref&gt;Y. Chen, M.J. Smanski, B. Shen,''Appl Microbiol Biotechnol'' '''2010''', ''86'', 19-25.&lt;/ref&gt; and it is also emphasized recently to investigate the tolerance of modification without affecting activity by chemical modifications,&lt;ref&gt;J. Krauss, V. Knorr, V. Manhardt, S. Scheffels, F. Bracher, ''Arch Pharm (Weinheim)'' '''2008''', ''341'', 386-92.&lt;/ref&gt; which can hopefully create the easier synthetic pathway&lt;ref&gt;Y.Y. Yeung, E.J. Corey,  ''Org Lett '' '''2008''', ''10'', 3877-8.&lt;/ref&gt;&lt;ref&gt;X. Lu, Q. You, ''Curr Med Chem '' '''2010''', ''17'', 1139-55.&lt;/ref&gt; or increase the activity of platensimycin.&lt;ref&gt;D T. Manallack, I T. Crosby, Y. Khakham and B. Capuano, ''Current Medicinal Chemistry'' '''2008''', ''15'', 705-10.&lt;/ref&gt;

==Biosynthesis==

The biosynthesis of plantensimycin has been studied by Singh Group[6] using [[isotope]] incorporation experiments to show that the benzoic ring is produced from [[Pyruvic acid|pyruvate]] and [[acetate]] via the [[TCA cycle]], while the C-17 [[Tetracycline antibiotics|tetracyclic]] [[enone]] [[acid]] core is produced from the [[Non-mevalonate pathway|non-mevalonate]] [[terpenoid]] pathway, the pathway is shown as below.[6]

Singh Group observed tetracyclic enone isotope labeling pattern is consistent with the biosynthesis of the tetracycle via the non-mevalonate terpenoid pathway proposed by Rohmer et al.&lt;ref&gt;S. Smith, A. Witkowski, and A K. Joshi, ''Prog. Lipid Res.'' '''2003''', ''42'', 289-317.&lt;/ref&gt; and Arigoni and co-workers.&lt;ref&gt;S W. White, J. Zheng, Y X M. Zhang, and C O. Rock, ''Annu. Rev. Biochem.'' '''2005''', ''74'', 791-831.&lt;/ref&gt; This pathway involves condensation of a [[thiamine]]-activated [[acetyl]] group arising from the [[decarboxylation]] of pyruvate and [[Glyceraldehyde 3-phosphate|glyceraldehyde-3-phosphate]] followed by a transposition step. Since both pyruvate and glyceraldehyde-3-phosphate (also [[glycerol]]) are part of the [[Glycolysis|glycolytic]] pathway, varying levels of incorporations are expected. Thus, the terpenoid building blocks, [[Dimethylallyl pyrophosphate|dimethylallyl diphosphate]] and [[Isopentenyl pyrophosphate|isopentenyl diphosphate]], synthesized by the non-mevalonate pathway utilizing pyruvate and glyceraldehyde-3-phosphate, condense to form the diterpenoid [[Precursor (chemistry)|precursor]] [[Geranylgeranyl pyrophosphate|geranylgeranyl diphosphate]] that [[Cyclic compound|cyclizes]] to intermediate 3 which is related to (or derived from) ent-kaurene.&lt;ref&gt;W P. Revill, M J. Bibb, A K. Scheu, H J. Kieser, and D A. Hopwood, ''J. Bacteriol,'' '''2001''', ''183'', 3526-30.&lt;/ref&gt; [[Organic redox reaction|Oxidative cleavage]] of the [[double bond]] of intermediate would result in the loss of the terminal three carbons producing the C-17 tetracyclic enone acid unit. An N-acyltransferase reaction of tetracyclic enone and [[aminobenzoic acid]] would lead to platensimycin.
Because of the dissimilarity between plantensimycin's mechanism of action and that of conventional antibiotics, it is believed that the capacity for the development of resistance by bacteria may be substantially decreased.&lt;ref&gt;Potent antibiotic to target MRSA. BBC News. May 18, 2006. http://news.bbc.co.uk/1/hi/health/4992696.stm. Retrieved December 14,'''2009'''&lt;/ref&gt;

==Mechanism of action==

Platensimycin has shown good activity against a panel of Gram positive organisms which included various resistant strains. Platensimycin works by inhibiting beta-ketoacyl synthases I/II (FabF/B) which are key enzymes in the production of fatty acids required for bacterial cell membranes. Here is the possible mechanism of action [2]: Firstly, the [[thiol]] group of FabF Cys163 is activated through the [[dipole]] moment of helix N-alpha-3 which lowers the pKa&lt;ref&gt;A C. Price, C O. Rock, S W. White, ''J. Bacteriol,'' '''2003''', ''185'', 4136-43.&lt;/ref&gt; of this [[functional group]]. The [[Nucleophile|nucleophilicity]] of the [[cysteine]] is facilitated by an [[oxyanion hole]] formed with the [[Backbone chain|backbone]] [[amides]] of Cys163 and Phe400. Interestingly, the [[crystal structure]] complex with platensimycin employed a C163Q [[mutant]] which gave a 50-fold increase in apparent binding [1]. The Gln163 [[Residue (chemistry)|residue]] lies adjacent to the [[carboxylate]] of platensimycin but makes no specific [[hydrogen bond]]. Given the close proximity of the carboxylate of platensimycin (presumed to be an [[anion]]) to the anionic thiol of Cys163 in the [[wild type]] enzyme may suggest the reason behind the increase in binding of the C163Q mutant. The second set of residues worth considering comprises His303 and His340 which play a role in the decarboxylation mechanism of the [[malonate|malonyl]] [[Functional group|moiety]]. In particular, His303 activates a structured [[water]] to attack the carboxylate of the incoming malonyl-ACP.&lt;ref&gt;Y M. Zhang, J. Hurlbert, S W. White, C O. Rock, ''J. Biol. Chem.'' '''2006''', ''281'', 17390-99.&lt;/ref&gt; The crystal structure of FabF also demonstrates that His340 forms a hydrogen bond between the amide [[nitrogen]] of Leu342 and the N-delta- atom of the [[imidazole]] ring meaning that the lone pair must reside on this atom [1,18]. In the platensimycin crystal structure the structured water adjacent to His303 is no longer present which may suggest an alternative electronic state for this residue. A strong possibility exists that His303 would present itself as a cation capable of forming an ionic interaction with the benzoic acid group of platensimycin [1].

==References==
&lt;references/&gt;

== External links ==
*[http://www.smm.org/buzz/buzz_tags/platensimycin Science news stories on Platensimycin]
*[http://www.nature.com/nature/journal/v441/n7091/abs/nature04784.html Abstract in Nature: Platensimycin is a selective FabF inhibitor with potent antibiotic properties]

[[Category:Antibiotics]]
[[Category:Salicylic acids]]
[[Category:Anilides]]</text>
      <sha1>5bm9yartkyc7fjpgf80l1tkv186qapz</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>4-Aminosalicylic acid</title>
    <ns>0</ns>
    <id>2715981</id>
    <revision>
      <id>608243220</id>
      <parentid>607992217</parentid>
      <timestamp>2014-05-12T16:24:01Z</timestamp>
      <contributor>
        <username>BethNaught</username>
        <id>20800274</id>
      </contributor>
      <minor/>
      <comment>clean up, [[WP:CHECKWIKI]] error 61 fix: references before punctuation using [[Project:AWB|AWB]]</comment>
      <text xml:space="preserve" bytes="9339">{{Drugbox
| verifiedrevid = 477221040
| IUPAC_name = 4-amino-2-hydroxy-benzoic acid
| image = P-Aminosalicylic acid.svg
| width = 180
| image2 = 4-Aminosalicylic acid 3d structure vander.png

&lt;!--Clinical data--&gt;
| tradename = Paser
| pregnancy_category = C
| legal_UK = POM
| legal_UK = Rx-only
| routes_of_administration = Oral

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound = 50–60%
| metabolism = [[Liver|Hepatic]]
| elimination_half-life =  
| excretion = [[Kidney|Renal]]

&lt;!--Identifiers--&gt;
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 65-49-6
| CAS_supplemental =  
| ATC_prefix = J04
| ATC_suffix = AA01
| ATC_supplemental =  
| PubChem = 4649
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00233
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4488
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5B2658E0N2
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00162
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 27565
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1169
| NIAID_ChemDB = 020064

&lt;!--Chemical data--&gt;
| C=7 | H=7 | N=1 | O=3 
| molecular_weight = 153.135 g/mol
| smiles = O=C(O)c1ccc(cc1O)N
| InChI = 1/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)
| InChIKey = WUBBRNOQWQTFEX-UHFFFAOYAO
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WUBBRNOQWQTFEX-UHFFFAOYSA-N
| melting_point = 150.5
}}

'''4-aminosalicylic acid''', commonly known as PAS, is an [[antibiotic]] used to treat [[tuberculosis]].&lt;ref name=&quot;long&quot; /&gt; This [[organic compound]] has also been use since the 1940s for the treatment of [[inflammatory bowel disease]]s (IBDs), where it has shown greater potency in [[ulcerative colitis]] and [[Crohn's disease]].&lt;ref name=&quot;xl&quot; /&gt; It is thought to act via [[NF-κB]] (nuclear factor-kappa B) inhibition and free radical scavenging. 5-Aminosalicylic acid, sold under the name [[mesalazine]], is a closely related compound that also has medical uses.

==Medical uses==
The main use for 4-aminosalicyclic acid is for the treatment of tuberculosis infections.

===Tuberculosis===
Aminosalicylic acid was introduced to clinical use in 1948. It was the second antibiotic found to be effective in the treatment of tuberculosis, after [[streptomycin]]. PAS formed part of the standard [[tuberculosis treatment|treatment for tuberculosis]] prior to the introduction of [[rifampicin]] and [[pyrazinamide]].&lt;ref&gt;{{cite journal|author=Mitchison DA|title=Role of individual drugs in the chemotherapy of tuberculosis Role of individual drugs in the chemotherapy of tuberculosis|journal=Int J Tuberc Lung Dis|volume=4|issue=9|pages=796–806|pmid=10985648|year=2000}}&lt;/ref&gt;

Its potency is less than that of the current five first-line drugs ([[isoniazid]], [[rifampicin]], [[ethambutol]], [[pyrazinamide]], and [[streptomycin]]) for treating tuberculosis and its cost is higher, but it is still useful in the treatment of [[multidrug-resistant tuberculosis]].&lt;ref name=&quot;long&quot; /&gt; PAS is always used in combination with other anti-TB drugs.

The dose when treating tuberculosis is 150&amp;nbsp;mg/kg/day divided into two to four daily doses; the usual adult dose is therefore approximately 2 to 4 grams four times a day.  It is sold in the US as &quot;Paser&quot; by Jacobus Pharmaceutical, which comes in the form of 4 g packets of delayed-release granules. The drug should be taken with acid food or drink ([[Orange juice|orange]], [[Apple juice|apple]] or [[tomato juice]]).&lt;ref&gt;{{cite web|title=Paser|publisher=RxList|url=http://www.rxlist.com/cgi/generic/paser.htm|accessdate=2008-10-10| archiveurl= http://web.archive.org/web/20081025031915/http://www.rxlist.com/cgi/generic/paser.htm| archivedate= 25 October 2008 &lt;!--DASHBot--&gt;| deadurl= no}}&lt;/ref&gt; PAS was once available in a combination formula with isoniazid called Pasinah&lt;ref&gt;{{cite journal|title=Lichen scrofulosorum: A report of four cases|author=Smith NP, Ryan TJ, Sanderson KV, Sarkany I|journal=Br J Dermatol|volume=94|issue=3|pages=319–325|doi=10.1111/j.1365-2133.1976.tb04391.x|pmid=1252363|year=1976}}&lt;/ref&gt; or Pycamisan 33.&lt;ref&gt;{{cite journal|title=Two incidents of tuberculous infection by milk from attested herds|author=Black JM|journal=Br Med J|pages=1732–1735|year=1961|pmid=20789163|doi=10.1136/bmj.1.5241.1732|last2=Sutherland|first2=IB|volume=1|issue=5241|pmc=1954350}}&lt;/ref&gt;

The [[European Medicines Agency|European Medicines Agency (EMA)]] has recommended granting a marketing authorization for PAS in multidrug-resistant tuberculosis in adults and children when other treatments cannot &quot;be devised for reasons of resistance or tolerability.&quot;&lt;ref&gt;Drug Discovery &amp; Development. [http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001972.jsp&amp;mid=WC0b01ac058004d5c1 EMA Recommends Two New Tuberculosis Treatments.] November 22, 2013.&lt;/ref&gt;

===Inflammatory bowel disease===
PAS has also been used in the treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease),&lt;ref name=&quot;xl&quot;&gt;{{cite journal|author=Daniel F, Seksik P, Cacheux W, Jian R, Marteau P|title=Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis|journal=Inflamm Bowel Dis|volume=10|issue=3|pages=258–260|pmid=15290921|doi=10.1097/00054725-200405000-00013|year=2004}}&lt;/ref&gt; but has been superseded by other drugs such as [[sulfasalazine]] and [[mesalazine]].

===Others===
PAS has been investigated for the use in [[manganese]] [[chelation therapy]], and a 17-year follow-up study shows that it might be superior to other chelation protocols such as [[EDTA]].&lt;ref&gt;{{cite pmid|16766929}}&lt;/ref&gt;

==Pharmacology==
With [[heat]], aminosalicylic acid is [[decarboxylation|decarboxylated]] to produce [[Carbon dioxide|CO&lt;sub&gt;2&lt;/sub&gt;]] and [[3-Aminophenol|3-aminophenol]].&lt;ref&gt;{{cite pmid|16867404}}&lt;/ref&gt;

The U.S. [[Food and Drug Administration|FDA]] assigned PAS to [[pregnancy category]] C, indicating that it is not known whether it will harm an [[fetus|unborn baby]].

==Side effects==
Gastrointestinal [[adverse drug reaction|side-effects]] (nausea, vomiting, diarrhoea) are common; the delayed-release formulation is meant to help overcome this problem.&lt;ref&gt;{{cite doi|10.1056/NEJM197309062891001}}&lt;/ref&gt; It is also a cause of drug-induced [[hepatitis]].  Patients with [[glucose-6-phosphate dehydrogenase deficiency]] should avoid taking aminosalicylic acid as it causes [[haemolysis]].&lt;ref&gt;{{cite pmid|13436516}}&lt;/ref&gt; Thyroid [[goitre]] is also a side-effect because aminosalicylic acid inhibits the synthesis of [[thyroid hormone]]s.&lt;ref&gt;{{cite pmid|13213079}}&lt;/ref&gt;

Drug interactions include elevated [[phenytoin]] levels. When taken with [[rifampicin]], the levels of [[rifampicin]] in the blood fall by about half.&lt;ref&gt;{{cite journal|author=Boman G|title=Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid|year=1974|volume=7|issue=3|pages=217&amp;ndash;25|doi=10.1007/BF00560384|pmid=4854257|journal=European journal of clinical pharmacology}}&lt;/ref&gt;

== History ==
PAS was discovered by the Swedish chemist [[Jörgen Lehmann]] upon the report that the tuberculosis bacterium avidly metabolized [[salicylic acid]]. Lehmann first tried PAS as an oral TB therapy late in 1944. The first patient made a dramatic recovery.&lt;ref&gt;{{cite pmid|21008766}}&lt;/ref&gt; The drug proved better than [[streptomycin]], which had [[Ototoxicity|nerve toxicity]] and to which TB could easily develop resistance. In the 1948, researchers at Britain's [[Medical Research Council (UK)|Medical Research Council]] demonstrated that combined treatment with streptomycin and PAS was superior to either drug alone.&lt;ref name=&quot;long&quot;&gt;{{cite pmid|10529902}}&lt;/ref&gt;

==Synthesis==
PAS is manufactured by the carboxylation of [[3-Aminophenol|3-aminophenol]].&lt;ref name=Mitchell_Waring&gt;{{cite doi|10.1002/14356007.a02_099}}&lt;/ref&gt;

==Other names==
Like many commercially significant compounds, PAS has many names including  ''para''-aminosalicylic acid, ''p''-aminosalicylic acid, 4-ASA, and simply P.

==Mode of action==
PAS has been shown to be a pro-drug and it is incorporated into the folate pathway by dihydropteroate synthase (DHPS) and dihydrofolate synthase (DHFS) to generate a hydroxyl dihydrofolate antimetabolite, which in turn inhibits DHFR enzymatic activity.&lt;ref&gt;Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, Au M, Jang J, Nam J, Dick T, Walker JR, Pethe K, Camacho LR. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J Biol Chem. 288(32):23447-56.  http://www.jbc.org/content/288/32/23447.long&lt;/ref&gt;

&lt;gallery&gt;
File:4-Aminosalicylic_acid_3d_structure.png
&lt;/gallery&gt;

==External links==
*[http://www.drugs.com/MTM/aminosalicylic_acid.html Drugs.com]
*[http://www.rxlist.com/cgi/generic2/paser.htm RxList]

==References==
{{reflist|2}}

{{Antimycobacterials}}

{{DEFAULTSORT:Aminosalicylic acid, 4-}}
[[Category:Tuberculosis]]
[[Category:Antibiotics]]
[[Category:World Health Organization essential medicines]]
[[Category:Anilines]]
[[Category:Salicylic acids]]</text>
      <sha1>kmwn05w00g863bjdkfeo9wxpvi2ec5p</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>TAN-1057 A</title>
    <ns>0</ns>
    <id>12150996</id>
    <revision>
      <id>525861885</id>
      <parentid>452561034</parentid>
      <timestamp>2012-12-01T14:27:19Z</timestamp>
      <contributor>
        <username>Yobot</username>
        <id>7328338</id>
      </contributor>
      <minor/>
      <comment>/* References */clean up /fixed checkwiki error 18 using [[Project:AWB|AWB]] (8717)</comment>
      <text xml:space="preserve" bytes="2387">{{Chembox
| verifiedrevid = 401616968
| Name=TAN-1057 A &lt;small&gt;(top)&lt;/small&gt; and TAN-1057 B &lt;small&gt;(bottom)&lt;/small&gt;
| ImageFile1 = TAN-1057A.png
| ImageSize1 = 200px
| ImageFile2 = TAN-1057B.png
| ImageSize2 = 200px
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 110872
| InChI = 1/C13H25N9O3/c1-22(8-6-19-13(20-10(8)24)21-12(17)25)9(23)5-7(14)3-2-4-18-11(15)16/h7-8H,2-6,14H2,1H3,(H4,15,16,18)(H4,17,19,20,21,24,25)/t7-,8+/m0/s1
| InChIKey = ZMWBCGMRXBPXEU-JGVFFNPUBF
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C13H25N9O3/c1-22(8-6-19-13(20-10(8)24)21-12(17)25)9(23)5-7(14)3-2-4-18-11(15)16/h7-8H,2-6,14H2,1H3,(H4,15,16,18)(H4,17,19,20,21,24,25)/t7-,8+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZMWBCGMRXBPXEU-JGVFFNPUSA-N
| CASNo = 128126-44-3 
| CASOther = &amp;nbsp;(TAN-1057 A)&lt;br&gt;128126-45-4 (TAN-1057 B)
| PubChem = 124498
| SMILES = O=C1N\C(=N/C[C@H]1N(C(=O)C[C@@H](N)CCC/N=C(\N)N)C)NC(=O)N
}}
| Section2 = {{Chembox Properties
| C=13| H=25| N=9| O=3
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility = }}
| Section3 = {{Chembox Hazards
| MainHazards = 
| FlashPt = 
| Autoignition = }}
}}

'''TAN-1057 A''' and '''TAN-1057 B''' are organic compounds found in the ''[[Flexibacter]] sp.'' PK-74 bacterium.  TAN-1057 A and B are closely related structurally as [[diastereomer]]s.  Also related are [[TAN-1057 C]] and TAN-1057 D, isolated from the same bacteria.  The four compounds have been shown to be an effective [[antibiotic]]s against [[methicillin]]-resistant strains of ''[[Staphylococcus aureus]]'' which act through the inhibition of [[protein]] biosynthesis.&lt;ref name=Katayama&gt;{{cite journal | author=Katayama, N | title=TAN-1057 A-D, new antibiotics with potent antibacterial activity against methicillin-resistant Staphylococcus aureus. Taxonomy, fermentation and biological activity | journal=J. Antibiot. | year=1993 | pages=606–613 | volume=46 | issue=4 | pmid=8501003 | display-authors=1 | last2=Fukusumi | first2=S | last3=Funabashi | first3=Y | last4=Iwahi | first4=T | last5=Ono | first5=H}}&lt;/ref&gt;

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Alkaloids]]
[[Category:Guanidines]]
[[Category:Amides]]
[[Category:Ureas]]
[[Category:Pyrimidones]]


{{antibiotic-stub}}</text>
      <sha1>keqcma3io4q2ipvf0zdy13jiyd1v5h7</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>TAN-1057 C</title>
    <ns>0</ns>
    <id>12151020</id>
    <revision>
      <id>407889498</id>
      <parentid>401617094</parentid>
      <timestamp>2011-01-14T19:32:15Z</timestamp>
      <contributor>
        <username>Edgar181</username>
        <id>491706</id>
      </contributor>
      <comment>removed [[Category:1,4 Diazepines]]; added [[Category:1,4-Diazepines]] using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="2268">{{Chembox
| verifiedrevid = 401615853
| Name=TAN-1057 C &lt;small&gt;(top)&lt;/small&gt; and TAN-1057 D &lt;small&gt;(bottom)&lt;/small&gt;
| ImageFile1 = TAN-1057C.png
| ImageSize1 = 200px
| ImageFile2 = TAN-1057D.png
| ImageSize2 = 200px
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 7851330
| InChI = 1/C13H25N9O3/c1-22-9(6-19-20-7-18-13(16)25)11(24)21-8(5-10(22)23)3-2-4-17-12(14)15/h7-9,19H,2-6H2,1H3,(H,21,24)(H4,14,15,17)(H3,16,18,20,25)/t8-,9+/m0/s1
| InChIKey = PNFFUPQADHHLMN-DTWKUNHWBI
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C13H25N9O3/c1-22-9(6-19-20-7-18-13(16)25)11(24)21-8(5-10(22)23)3-2-4-17-12(14)15/h7-9,19H,2-6H2,1H3,(H,21,24)(H4,14,15,17)(H3,16,18,20,25)/t8-,9+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PNFFUPQADHHLMN-DTWKUNHWSA-N
| CASNo = 128126-46-5 
| CASOther = &amp;nbsp;(TAN-1057 C)&lt;br&gt;128126-47-6 (TAN-1057 D)
| PubChem = 9576889
| SMILES = O=C1N(C)[C@@H](C(=O)N[C@H](C1)CCC/N=C(\N)N)CNN\C=N\C(=O)N
}}
| Section2 = {{Chembox Properties
| C=13| H=25| N=9| O=3
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility = }}
| Section3 = {{Chembox Hazards
| MainHazards = 
| FlashPt = 
| Autoignition = }}
}}

'''TAN-1057 C''' and '''TAN-1057 D''' are organic compounds found in the ''[[Flexibacter]] sp.'' PK-74 bacterium.  TAN-1057 C and D are closely related structurally as [[diastereomer]]s.  Also related are [[TAN-1057 A]] and TAN-1057 B, isolated from the same bacteria.  The four compounds have been shown to be an effective [[antibiotic]]s against [[methicillin]]-resistant strains of ''[[Staphylococcus aureus]]'' which act through the inhibition of [[protein]] biosynthesis.&lt;ref name=Katayama&gt;{{cite journal | author=Katayama, N ''et al.'' | title=TAN-1057 A-D, new antibiotics with potent antibacterial activity against methicillin-resistant Staphylococcus aureus. Taxonomy, fermentation and biological activity | journal=J. Antibiot. | year=1993 | pages=606–613 | volume=46 | issue=4 | pmid=8501003}}&lt;/ref&gt;

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Alkaloids]]
[[Category:Guanidines]]
[[Category:Lactams]]
[[Category:1,4-Diazepines]]


{{antibiotic-stub}}</text>
      <sha1>slwrxd3o2ay2gpremmyt1zsrga5j3xj</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Melafix</title>
    <ns>0</ns>
    <id>22168869</id>
    <revision>
      <id>582963410</id>
      <parentid>582962930</parentid>
      <timestamp>2013-11-23T15:45:59Z</timestamp>
      <contributor>
        <username>MartinPoulter</username>
        <id>545807</id>
      </contributor>
      <comment>Added {{[[Template:unreliable sources|unreliable sources]]}} tag to article ([[WP:TW|TW]])</comment>
      <text xml:space="preserve" bytes="2090">{{unreliable sources|date=November 2013}}
'''Melafix''' (a proprietary name) is an all-natural [[aquarium]] [[antibiotic]] consisting of an [[essential oil]] of the [[Melaleuca]] genus. Contrary to popular opinion it is not made from the common [[Melaleuca|Tea tree]], ''Melaleuca alternifolia'', but from ''[[Melaleuca leucadendra]]'', also known as the '''[[Cajeput Tree]]'''. This is confirmed by the manufacturer's Safety Data Sheet.&lt;ref&gt; [http://cms.marsfishcare.com/files/msds/melafix_111909.pdf]&lt;/ref&gt;

It is a wide-range antibiotic product, and thus is effective for a wide variety of mild gram positive bacterial infections, such as [[fin rot]]. However, it is generally ineffective against aquatic [[parasitism|parasites]] and is typically used for treating the wounds caused by them in order to prevent secondary infection by other microorganisms.&lt;ref&gt;[http://www.ponddoc.com/WhatsUpDoc/ProductProfiles/Melafix.htm Melafix - Helpful Tonic for Bacterial Problems such as Fin Rot on Koi and Goldfish]&lt;/ref&gt;

==Controversy &amp; Dangers==

Some consider there to be real dangers with the use of Melafix in fish aquariums. Being that Melafix is an oil based product, it is said that the oil can make it difficult for fish that breathe air. There are theories for why this happens, but what has been shown is if proper water parameters are maintained, there's generally not an issue. 

Melafix needs to used as directed. Many issues that come from the use of Melafix is the fact that it is being used incorrectly. The medication is a mild antibiotic. It can be used to treat mild infections, but used in other ways than intended, could result in the real problem not being treated correctly and Melafix appearing to be the cause of the issue. Knowing the infection and properly treating is a must.&lt;ref&gt;{{cite web|title=Melafix Dangers; Fish as Pets|url=http://www.fish-as-pets.com/2008/12/melafix-dangers-labyrinth-fish.html}}&lt;/ref&gt;

==References==
{{reflist}}


{{Veterinary-med-stub}}

[[Category:Fish health]]
[[Category:Pharmacology]]
[[Category:Antibiotics]]
[[Category:Antifungals]]</text>
      <sha1>e5ld9gpix5agq66bqpazv8fvc16a8w3</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Lactivicin</title>
    <ns>0</ns>
    <id>22813858</id>
    <revision>
      <id>489425946</id>
      <parentid>417749065</parentid>
      <timestamp>2012-04-27T05:10:30Z</timestamp>
      <contributor>
        <username>Alan Liefting</username>
        <id>36352</id>
      </contributor>
      <minor/>
      <comment>category sorting, replaced: &lt;references/&gt; → {{reflist|2}}, added [[CAT:O|orphan]] tag using [[Project:AWB|AWB]]</comment>
      <text xml:space="preserve" bytes="1355">{{Orphan|date=April 2012}}

'''Lactivicin''' is a non [[beta-lactam]] [[antibiotic]] that is active against a range of Gram-positive and Gram-negative [[bacteria]].&lt;ref name=&quot;Lactivicin&quot;&gt;{{cite journal |author=Nozaki Y, Katayama N, Harada S, Ono H, Okazaki H  |title=Lactivicin, a naturally occurring non-beta-lactam antibiotic having beta-lactam-like action: biological activities and mode of action |journal=J. Antibiot. |volume=53 |issue=10 |pages=84–93 |year=1989 |pmid=2493440 |doi=
  }}&lt;/ref&gt; Lactivicin demonstrates a similar affinity for [[penicillin-binding protein]]s to [[beta-lactam antibiotic]]s and is also susceptible to [[beta-lactamase]] enzymes.&lt;ref name=&quot;Lactivicin discovery&quot;&gt;{{cite journal |author=Harada S, Tsubotani S, Hida T, Ono H, Okazaki H |title=Structure of lactivicin, an antibiotic having a new nucleus and similar biological activities to β-lactam antibiotics |journal=Tetrahedron Letters. |volume=27 |issue=51 |pages=6229–6232 |year=1986 |doi=10.1016/S0040-4039(00)85439-8    
  }}&lt;/ref&gt; 
The structure of lactivicin is [4S1-2-(4-
acetylamino-3-oxo-2-isoxazolidinyl)-5-oxo-tetrahydrofuran-2-carboxylic acid.&lt;ref name=&quot;Lactivicin discovery&quot; /&gt;

==References==
{{reflist|2}}
* [http://pubs.acs.org/cen/news/85/i33/8533news7.html Article about lcativicin with rendered structure] of it and PBP.

[[Category:Antibiotics]]</text>
      <sha1>qrc33c2ej7u1evusug7g3zlczzxjn94</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Kendomycin</title>
    <ns>0</ns>
    <id>23147198</id>
    <revision>
      <id>603146777</id>
      <parentid>603145744</parentid>
      <timestamp>2014-04-07T13:00:31Z</timestamp>
      <contributor>
        <username>CheMoBot</username>
        <id>7377957</id>
      </contributor>
      <comment>Updating {{chembox}} (changes to verified and watched fields - updated 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'Watchedfields') per [[WP:CHEMVALID|Chem/Drugbox validation]] (report [[Wikipedia_talk:WikiProject_Chemicals|errors]] or [[use...</comment>
      <text xml:space="preserve" bytes="5185">{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 387363125
|Reference=&lt;ref&gt;[http://www.alexis-biochemicals.com/Kendomycin.5+M5acc5c8c65d.0.html Kendomycin] at Alexis-Biochemicals&lt;/ref&gt;
|ImageFile=Kendomycin.png
|ImageSize=200px
| IUPACName = (1R,9S,10S,12S,14E,16S,19R,20R,21S,22R)-3,9,21-Trihydroxy-5,10,12,14,16,20,22-heptamethyl-23,24-dioxatetracyclo[17.3.1.1&lt;sup&gt;6,9&lt;/sup&gt;.0&lt;sup&gt;2,7&lt;/sup&gt;]tetracosa-2,5,7,14-tetraen-4-one
| SystematicName = (1R,9S,10S,12S,14E,16S,19R,20R,21S,22R)-3,9,21-Trihydroxy-5,10,12,14,16,20,22-heptamethyl-23,24-dioxatetracyclo[17.3.1.1&lt;sup&gt;6,9&lt;/sup&gt;.0&lt;sup&gt;2,7&lt;/sup&gt;]tetracosa-2,5,7,14-tetraen-4-one
|OtherNames=(-)-TAN 2162
|Section1={{Chembox Identifiers
|  CASNo_Ref = {{cascite|correct|??}}
| CASNo=59785-91-0
|  PubChem=5472093
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 523927
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4582118
|  SMILES = C[C@H]\1CC[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)C3=C(C(=O)C(=C4C3=C[C@@](O4)([C@H](C[C@@H](C/C(=C1)/C)C)C)O)C)O)C)O)C
|  InChI = 1/C29H42O6/c1-14-8-9-22-18(5)24(30)19(6)28(34-22)23-21-13-29(33,17(4)12-16(3)11-15(2)10-14)35-27(21)20(7)25(31)26(23)32/h10,13-14,16-19,22,24,28,30,32-33H,8-9,11-12H2,1-7H3/b15-10+/t14-,16+,17-,18-,19+,22+,24-,28+,29+/m0/s1
|  InChIKey = HKLDUJXJTQJSEJ-OLXNOMCWBE
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C29H42O6/c1-14-8-9-22-18(5)24(30)19(6)28(34-22)23-21-13-29(33,17(4)12-16(3)11-15(2)10-14)35-27(21)20(7)25(31)26(23)32/h10,13-14,16-19,22,24,28,30,32-33H,8-9,11-12H2,1-7H3/b15-10+/t14-,16+,17-,18-,19+,22+,24-,28+,29+/m0/s1
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = HKLDUJXJTQJSEJ-OLXNOMCWSA-N
|  RTECS = 
|  MeSHName = C485395
  }}
|Section2={{Chembox Properties
|  Formula=C&lt;sub&gt;29&lt;/sub&gt;H&lt;sub&gt;42&lt;/sub&gt;O&lt;sub&gt;6&lt;/sub&gt;
|  MolarMass=486.64 g/mol
|  Appearance=Yellow powder
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
| SolubleOther = Soluble
| Solvent = [[Dimethyl sulfoxide|DMSO]], [[methanol]]
  }}
|Section3={{Chembox Hazards
|  MainHazards=Toxic
|  FlashPt=
|  Autoignition=
  }}
}}

'''Kendomycin''' is an antitumor macrolide antibiotic first isolated from the bacteria ''[[Streptomyces|Streptomyces violaceoruber]]''.&lt;ref name = &quot;Bode&quot;&gt;{{cite journal | author = H B Bode and A Zeeck | journal = J. Chem. Soc. Perkin Trans. 1 | year =  2000 | volume = 323 | doi = 10.1039/a908387a | title = Structure and biosynthesis of kendomycin, a carbocyclic ansa-compound from Streptomyces | pages = 323 | issue = 3}}&lt;/ref&gt;  It has potent activity as an [[endothelin receptor]] [[receptor antagonist|antagonist]] and anti-[[osteoporosis]] agent.&lt;ref&gt;[http://www.chem.wisc.edu/~burke/Kendo.htm Burke Research Group] University of Wisconsin&lt;/ref&gt;
It also has strong cytotoxicity against various tumor cell lines.&lt;ref name=&quot;Bode&quot;/&gt;

==Total synthesis==
Because of its potent biological activities, kendomcyin has attracted interest as a target of [[total synthesis]]. The first total synthesis of kendomycin was accomplished by Lee and Yuan in 2004.&lt;ref&gt;{{cite journal | author = Yu Yuan, Hongbin Men, and Chulbom Lee | journal = J. Am. Chem. Soc. | year = 2004 | volume = 126 | pages = 14720–14721 | doi = 10.1021/ja0447154 | title = Total Synthesis of Kendomycin:  A Macro−C−Glycosidation Approach | pmid = 15535687 | issue = 45 | pmc = 1785127}}&lt;/ref&gt; The total number of syntheses stands at 6 &lt;ref&gt;{{cite journal | author = A B Smith III, E F Mesaros and E Meyer | journal = J. Am. Chem. Soc. | year = 2006 | volume = 128 | pages = 5292 | doi = 10.1021/ja060369 | title = Evolution of a Total Synthesis of (−)-Kendomycin Exploiting a Petasis−Ferrier Rearrangement/Ring-Closing Olefin Metathesis Strategy | pmid = 16608366 | issue = 15}}&lt;/ref&gt;&lt;ref&gt;{{cite journal | author = J T Lowe and J S Panek | journal = Org. Lett. | year = 2008 | volume = 10 | pages = 3813 | doi = 10.1021/ol801499s | title = Total Synthesis of (−)-Kendomycin | pmid = 18698784 | issue = 17}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |  author =  K B Bahnck and S D Rychnovsky | journal = J. Am. Chem. Soc. | year = 2008 | volume = 130 |  pmid =  18767844 | issue = 13 |  pmc =  2697922 | pages = 177 | doi=10.1021/ja805187p |  title =  Formal Synthesis of (−)-Kendomycin Featuring a Prins-Cyclization to Construct the Macrocycle}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|doi = 10.1002/anie.200900522|pmid = 19350596|title = Total Synthesis of the Antibiotic Kendomycin by Macrocyclization using Photo-Fries Rearrangement and Ring-Closing Metathesis|year = 2009|last1 = Magauer|first1 = Thomas|last2 = Martin|first2 = Harry J.|last3 = Mulzer|first3 = Johann|journal = Angewandte Chemie International Edition|volume = 48|issue = 33|pages = 6032}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|doi=10.1002/anie.201000227|pmid=20818753|title=In Pursuit of a Competitive Target: Total Synthesis of the Antibiotic Kendomycin|year=2010|last1=Martin|first1=Harry J.|last2=Magauer|first2=Thomas|last3=Mulzer|first3=Johann|journal=Angewandte Chemie International Edition|volume=49|issue=33|pages=n/a}}&lt;/ref&gt;

==References==
{{reflist}}

[[Category:Macrolides]]
[[Category:Antibiotics]]
[[Category:Quinone methides]]</text>
      <sha1>8uot5a30f5dr0q4139o2584qavzzez3</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Echinomycin</title>
    <ns>0</ns>
    <id>23553315</id>
    <revision>
      <id>587306418</id>
      <parentid>578169330</parentid>
      <timestamp>2013-12-23T00:56:27Z</timestamp>
      <contributor>
        <username>BattyBot</username>
        <id>15996738</id>
      </contributor>
      <minor/>
      <comment>/* Biosynthesis */fixed [[:Category:CS1 errors: dates|CS1 errors: dates]] &amp; [[WP:AWB/GF|General fixes]] using [[Project:AWB|AWB]] (9803)</comment>
      <text xml:space="preserve" bytes="3014">{{chembox
| verifiedrevid = 424800009
|ImageFile=Echinomycin.png
|ImageSize=200px
|IUPACName=
|OtherNames=Quinomycin A; Levomycin
|Section1={{Chembox Identifiers
|  CASNo_Ref = {{cascite|correct|??}}
| CASNo=512-64-1
|  PubChem=3197
|  SMILES= CC1C(=O)N(C2CSC(C(C(=O)N(C(C(=O)OCC(C(=O)N1)NC(=O)C3=NC4=CC=CC=C4N=C3)C(C)C)C)N(C(=O)C(NC(=O)C(COC(=O)C(N(C2=O)C)C(C)C)NC(=O)C5=NC6=CC=CC=C6N=C5)C)C)SC)C
  }}
|Section2={{Chembox Properties
|  Formula=C&lt;sub&gt;51&lt;/sub&gt;H&lt;sub&gt;64&lt;/sub&gt;N&lt;sub&gt;12&lt;/sub&gt;O&lt;sub&gt;12&lt;/sub&gt;S&lt;sub&gt;2&lt;/sub&gt;
|  MolarMass=1101.26 g/mol
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3={{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}

'''Echinomycin''' is a [[peptide]] [[antibiotic]]. It intercalates into DNA at two specific sites, thereby blocking the binding of hypoxia inducible factor 1 alpha (HIF1alpha).

== Biosynthesis ==

Echinomycin is a bis-intercalator peptide and is biosynthesized by a unique nonribosomal peptide synthetase (NRPs).&lt;ref name=Watanabe&gt;{{cite journal|last=Watanabe|first=K|coauthors=Oguri, H; Oikawa, H|title=Diversification of echinomycin molecular structure by way of chemoenzymatic synthesis and heterologous expression of the engineered echinomycin biosynthetic pathway.|journal=Current Opinion in Chemical Biology|date=April 2009|volume=13|issue=2|pages=189–96|pmid=19278894|doi=10.1016/j.cbpa.2009.02.012}}&lt;/ref&gt; Echinomycin is isolated from various bacteria such as, ''Streptomyces'' ''lasalienis''.  It belongs to a family of quinoxaline [[antibiotics]]. There is great interest in this group of compounds because they have very potent antibacterial, anticancer, and antiviral activities.&lt;ref name=Watanabe2&gt;{{cite journal|last=Watanabe|first=K et al.|title=Total biosynthesis of antitumor nonribosomal peptides in Escherichia coli.|journal=Nature chemical biology|date=August 2006|volume=2|issue=8|pages=423–8|pmid=16799553|doi=10.1038/nchembio803}}&lt;/ref&gt;

The biosynthesis of Echinomycin starts with molecule QC. [[L-tryptophan]] is the precursor for QC and its biosynthesis parallels the first stage of nikkomycin biosynthesis. After QC is biosynthesized, the adenylation domain-containing Ecm1 activates and transfers QC to FabC using the fatty acid biosynthesis [[acyl carrier protein]] (ACP). The first module, Ecm6 accepts the QC-SFabC as the starter unit. Emc7 contains a terminal [[thioesterase]] domain which allows the peptide to dimerize and then release. This cyclized product then goes on to Ecm17, an oxioreductase, creating a disulfide bond. The last step in this biosynthesis transforms the disulfide bond into a thioacetal bridge. This transformation takes place with Ecm18, which is quite similar to [[S-adenosyl-L-methionine]] (SAM)-dependent [[methyltransferase]].&lt;ref name=Watanabe2 /&gt;

[[File:Structure of Echinomycin Biosynthesis.gif|600px|Structure of Echinomycin biosynthesis]]

== References ==
{{Reflist}}

[[Category:Antibiotics]]
[[Category:Quinoxalines]]


{{antibiotic-stub}}</text>
      <sha1>fq1woa7qnxkh4kkr6sqvfg9run7mr4i</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Pristinamycin IA</title>
    <ns>0</ns>
    <id>23484885</id>
    <revision>
      <id>545668749</id>
      <parentid>487187351</parentid>
      <timestamp>2013-03-20T12:19:02Z</timestamp>
      <contributor>
        <username>Louisajb</username>
        <id>13226235</id>
      </contributor>
      <comment>added chembl id</comment>
      <text xml:space="preserve" bytes="1081">{{chembox
| verifiedrevid = 387460400
|ImageFile=Pristinamycin IA.png
|ImageSize=200px
|IUPACName=
|OtherNames=Mikamycin B; Mikamycin IA; NSC 92554; PA 114B; Pristinamycin P 1; Streptogramin B; Vernamycin B
|Section1={{Chembox Identifiers
|  CASNo=3131-03-1
|  PubChem=14974
| ChEMBL = 1256399
|  SMILES=O=C([C@H](CC2=CC=C(N(C)C)C=C2)N(C)[C@]([C@H]6N(CCC6)C5=O)=O)N1[C@H]([C@](N[C@H](C(O[C@H](C)[C@@H](C(N[C@@H]5CC)=O)NC(C4=NC=CC=C4O)=O)=O)[C@]3=CC=CC=C3)=O)CC(CC1)=O
  }}
|Section2={{Chembox Properties
|  Formula=C&lt;sub&gt;45&lt;/sub&gt;H&lt;sub&gt;54&lt;/sub&gt;N&lt;sub&gt;8&lt;/sub&gt;O&lt;sub&gt;10&lt;/sub&gt;
|  MolarMass=866.96 g/mol
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3={{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}

'''Pristinamycin IA''' ('''Mikamycin B''') is an [[antibiotic]] [[cyclic peptide]].  It is a member of the [[streptogramin B]] group of antibiotics and one component of [[pristinamycin]] (the other being [[pristinamycin IIA]]).

[[Category:Antibiotics]]
[[Category:Peptides]]
[[Category:Isonicotinamides]]


{{antibiotic-stub}}</text>
      <sha1>d64xg06gwrt5hny2cjcxhyww0pkrq2q</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Streptogramin B</title>
    <ns>0</ns>
    <id>23190241</id>
    <revision>
      <id>595108286</id>
      <parentid>551852195</parentid>
      <timestamp>2014-02-12T07:39:07Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="4927">'''Streptogramin B''' is a subgroup of the [[streptogramin]] antibiotics family. These natural products are cyclic hexa- or hepta [[depsipeptides]] produced by various members of the genus of bacteria ''[[Streptomyces]]''. Many of the members of the streptogramins reported in the literature have the same structure and different names; for example, [[pristinamycin IA]] = vernamycin Bα = mikamycin B = osteogrycin B.&lt;ref name=oxazolidinone&gt;{{Cite journal| title = Streptogramins, oxazolidinones, and other inhibitors of bacterial protein synthesis| doi = 10.1021/cr030110z| year = 2005| journal = Chem. Rev| pages = 529�542| volume = 105| issue = 2| last1 = Mukhtar	 | first1 =  T.A.| last2 =  Wright	 | first2 =  G.D.| pmid = 15700955| postscript = .	}}&lt;/ref&gt;

==Biosynthesis==

The biosynthesis of streptogramin B is carried out by large multifunctional enzymes called non-ribosomal peptide synthetases (NRPS). In the NRPS system, each amino acid is activated as an aminoacyladenylate and is linked to the enzyme as a thioester with a phosphopantetheinyl group. An elongation reaction then occurs by transferring the activated carboxyl to the amino group in the next amino acid, thus executing the N-to-C stepwise condensation.

NRPSs contain several modules on a single polypeptide. Each of these modules can catalyze activation, condensation and a modification reaction specific to one kind of amino acid.&lt;ref name=&quot;pmid9511056&quot;&gt;{{cite journal |author=Cocito C, Di Giambattista M, Nyssen E, Vannuffel P |title=Inhibition of protein synthesis by streptogramins and related antibiotics |journal=J. Antimicrob. Chemother. |volume=Suppl A |issue= |pages=7–13 |series=39 |date=May 1997 |pmid=9511056 |doi= |url= |postscript=.}}&lt;/ref&gt; A typical elongation module consists of an adenylation domain (A), a peptidyl carrier protein domain (PCP) and a [[condensation domain]] (C). Some other domains may be present that are responsible for modifications to the residues, such as epimerization domain (E) and N-methyltransferase domain (MT). The domain responsible for the termination is the thioesterase domain (TE) located in the final module.&lt;ref&gt;{{Cite journal|  url = http://linkinghub.elsevier.com/retrieve/pii/S0378111902004249| title = Characterization of virginiamycin S biosynthetic genes from Streptomyces virginiae| year = 2002| journal = Gene| pages = 283�290| volume = 286| issue = 2| doi = 10.1016/S0378-1119(02)00424-9| format = w| last1 = Namwat	 | first1 =  W.| last2 =  Kamioka	 | first2 =  Y.| last3 =  Kinoshita	 | first3 =  H.| last4 =  Yamada	 | first4 =  Y.| last5 =  Nihira	 | first5 =  T.| author = | accessdate = 2009-06-12|  postscript = . | pmid=11943483
}}&lt;/ref&gt;

===Amino Acid Composition===

The general amino acid composition of streptogramin B consists of: 3-hydroxypicolinic acid, L-threonine, D-aminobutyric acid, L-proline, 4-N,N-(dimethylamino)-L-phenylalanine, 4-oxo-L-pipecolic acid and phenylglycine.

[[File:Streptogramin B (aa composition).png]]

===Modular Arrangement===

[[File:Streptogramin B (modules).png]]

[[File:Cyclization Streptogramin B.png]]

==Mechanism of Action==

Streptogramins A and B synergically inhibit cell growth of [[gram positive]], less so [[gram negative bacteria]] by inhibiting protein synthesis, but separately they are bacteriostatic. The molecular target of streptogramins is the 23S rRNA. Both streptogramin A and B bind to the P binding site of the 50S ribosome subunit. The type A streptogramin binding causes a conformational change to the 50S subunit, which increases the activity of the type B streptogramin by a 100-fold. Streptogramin B prevents the elongation of protein chains and causes the release of incomplete peptides.&lt;ref name=oxazolidinone /&gt;

==Clinical use==

The streptogramin antibiotics were identified almost 50 years ago, but have only recently found clinical use as a consequence of the increase in multidrug-resistant bacteria.  They present poor solubility in aqueous solution, and this has limited their clinical use; however, the natural products still find use as feed additives in agriculture.&lt;ref name=&quot;pmid11467949&quot;&gt;{{cite journal |author=Mukhtar TA, Koteva KP, Hughes DW, Wright GD |title=Vgb from Staphylococcus aureus inactivates streptogramin B antibiotics by an elimination mechanism not hydrolysis |journal=Biochemistry |volume=40 |issue=30 |pages=8877–86 |date=July 2001 |pmid=11467949 |doi= 10.1021/bi0106787|url= |postscript=.}}&lt;/ref&gt;

Medicinal chemists at Rhône-Poulenc worked in the preparation of semi-synthetic, water-soluble, derivatives of [[pristinamycin IA]] (B type streptogramin) and [[pristinamycin IIA]] (A type streptogramin) giving rise to [[quinupristin]] and [[dalfopristin]], respectively, which, when administered in a 3:7 ratio, comprise the 1999 FDA approved drug [[Synercid]].&lt;ref name=oxazolidinone /&gt;

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Depsipeptides]]</text>
      <sha1>8cu8exf8x6ql2tosuknsvj2e6g3bw03</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Pyocyanin</title>
    <ns>0</ns>
    <id>20117898</id>
    <revision>
      <id>597486140</id>
      <parentid>597422416</parentid>
      <timestamp>2014-02-28T05:59:43Z</timestamp>
      <contributor>
        <username>Anthony Appleyard</username>
        <id>119438</id>
      </contributor>
      <minor/>
      <comment>Anthony Appleyard moved page [[Pyocyanine]] to [[Pyocyanin]] over redirect: Requested at [[WP:RM]] as uncontroversial ([[Special:Permalink/597483704|permalink]])</comment>
      <text xml:space="preserve" bytes="13172">{{Chembox
| verifiedrevid = 424707501
| Reference = &lt;ref&gt;[http://www.sigmaaldrich.com/catalog/ProductDetail.do?lang=en&amp;N4=P0046|SIGMA&amp;N5=SEARCH_CONCAT_PNO|BRAND_KEY&amp;F=SPEC Pyocyanin] at [[Sigma-Aldrich]]&lt;/ref&gt;
| ImageFile = Pyocyanin.png
| ImageSize = 200px
| IUPACName = 5-Methylphenazin-1-one
| OtherNames = Pyocyanin; Pyrocyanine; 5-Methyl-1(5''H'')-phenazinone; Sanasin; Sanazin
| Section1 = {{Chembox Identifiers
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 85-66-5
| PubChem = 6817
| SMILES = CN1C2=CC=CC=C2N=C3C1=CC=CC3=O
}}
| Section2 = {{Chembox Properties
| C=13|H=10|N=2|O=1
| Appearance = Solid
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility = }}
| Section3 = {{Chembox Hazards
| MainHazards = 
| FlashPt = 
| Autoignition = }}
}}
'''Pyocyanin''' (PCN&lt;sup&gt;-&lt;/sup&gt;) is one of the many toxins produced and secreted by the [[Gram negative bacterium]] ''[[Pseudomonas aeruginosa]]''. Pyocyanin is a blue, secondary metabolite with the ability to oxidise and reduce other molecules&lt;ref&gt;
{{Cite journal | author=Hassan H &amp; Fridovich I | title=Mechanism of the antibiotic action pyocyanine.| journal=[[Journal of Bacteriology]] | volume=141 | year=1980 | pages=156–163 | pmid=6243619 | issue=1 | pmc=293551}}&lt;/ref&gt; and therefore can kill microbes competing against ''P. aeruginosa'' as well as mammalian cells of the lungs which ''P. aeruginosa'' has infected during [[cystic fibrosis]]. Since pyocyanin is a [[zwitterion]] at blood pH, it is easily able to cross the cell membrane. There are three different states in which pyocyanin can exist; oxidized, monovalently reduced or divalently reduced. Mitochondria play a huge role in the cycling of pyocyanin between its redox states. Due to its redox-active properties, pyocyanin generates [[reactive oxygen species]].

== Synthesis ==
In order for pyocyanin to be synthesized by ''P. aeruginosa'', two specific genes must be functional. ''MvfR'' is a gene which produces a [[transcription factor]] which activates ''phnAB'' genes. These genes produce the molecule quinolone which then regulates operons 1 and 2 of ''phzRABCDEFG'' which are key to the synthesis of phenazine.&lt;ref&gt;{{Cite journal | author= Mavrodi D, Bonsall, R, Delaney, S, Soule, M, Phillips G &amp; Thomashow, L. S. | title=Function analysis of genes for biosynthesis of pyocyanin and phenazine -1-carboxamide from ''Pseudomonas aeruginosa'' PAO1| journal=[[Journal of Bacteriology]] | volume=183 | year=2001 | pages=6454–6465| doi=10.1128/JB.183.21.6454-6465.2001 | issue= 21}}&lt;/ref&gt; 
The synthesis of pyocyanin is primarily controlled by the [[quorum sensing]] process. ''P.aeruginosa'' strains which are unable to synthesise PCN can still benefit from its effects if the strain has co- infected the lung with wild type strains which can produce pyocyanin.&lt;ref&gt;{{Cite journal | author=Lau E, Ran H, Kong F, Hassett D, Mavrodi D. | title=''Pseudomonas aeruginosa'' Pyocyanin Is Critical for Lung Infection in Mice | journal=[[Infection and Immunity]] | volume=72 | year=2004 | pages=4275–4278 | doi=10.1128/IAI.72.7.4275-4278.2004 | issue=7 }}&lt;/ref&gt; Biosynthesis can be impaired by disrupting the ''aro'' pathway which is responsible for the synthesis of chorismic acid from shikimate.&lt;ref&gt;{{Cite journal | author= Denning G, Iyer S,Reszka K, O'Malley Y,Rasmussen G &amp; Britigan B | title=Phenazine-1-carboxylic acid, a secondary metabolite of Pseudomonas aeruginosa, alters expression of immunomodulatory proteins by human airway epithelial cells | journal=[[American Journal of Physiology]] | volume=285 | year=2003 | pages=584–L592 | doi=10.1152/ajplung.00086.2003 }}&lt;/ref&gt; Chorismic acid is the precursor of pyocyanin.

:[[shikimic acid]] → [[chorismic acid]] → [[phenazine-1-carboxylic acid]] → [[5-methylphenazine-1-carboxylic acid betaine]] → pyocyanin&lt;ref&gt;
{{Cite journal | author=Lau G, Hassett D, Ran H &amp; Kong F | title=The role of pyocyanin in Pseudomonas aeruginosa infection| journal=[[Trends in Molecular Medicine]] | volume=10 | year=2004 | pages=1–666 | doi=10.1016/j.molmed.2004.10.002 | pmid=15567330 | issue=12}}&lt;/ref&gt;

The complete virulence of ''P. aeruginosa'' can only be experienced when pyocyanin is produced.&lt;ref&gt;{{Cite journal | author=Britigin B, Railsback A, Cox D. | title=The ''Pseudomonas aeruginosa'' secretory product pyocyanin inactivates α1 protease inhibitor: implications for the pathogenesis of cystic fibrosis lung disease | journal=[[Infection and Immunity]] | volume=67 | year=1999 | pages=1207–1212 | doi= }}&lt;/ref&gt;

== Redox warfare ==
Pyocyanin inactivates [[catalase]] by reducing its gene’s transcription as well as directly targeting the enzyme itself. [[Glutathione]], an important antioxidant is modulated by pyocyanin.&lt;ref&gt;{{Cite journal | author=Muller M | title=Pyocyanin inducesoxidative stress in human endothelialcells and modulates the glutathione redox cycle | journal=[[Free Radical Biology and Medicine]] | volume=33 | year=2002 | pages=1527–1533| doi=10.1016/S0891-5849(02)01087-0 | issue=11 }}&lt;/ref&gt; In particular the pool of the reduced form is depleted while the oxidised form is promoted by hydrogen peroxide which is not dismutated by catalase. 
In the cystic fibrosis lung, intracellular pyocyanin converts molecular oxygen to the superoxide free radical by reducing [[NADPH]] to NADP&lt;sup&gt;+&lt;/sup&gt;. This has a doubly negative effect on the lungs. Firstly, the NADPH used by pyocyanin depletes the available substrate for the reaction catalysed by the [[NADPH oxidase]] enzyme. Secondly, the superoxide radical generated can inhibit [[cytokines]] such as IL-4, IL-13 and [[IFN-γ]] which usually upregulate NADPH oxidase. When the lung is confronted with pyocyanin, an increased concentration of catalase and [[superoxide dismutase]] is seen in order to deal with the barrage of radicals being produced.&lt;ref&gt;
{{Cite journal | author=Huimin R, Hassett D &amp; Lau G | title= Human targets of ''Pseudomonas aeruginosa'' pyocyanin| journal=[[PNAS]] | volume=100 | year=2003 | pages=14315–14320| doi=10.1073/pnas.2332354100 |pmid = 14605211 | issue=24 | pmc=283589 }}&lt;/ref&gt;

== Targets ==
Pyocyanin is able to target a wide range of cellular components and pathways. Pathways which are affected by pyocyanin include the [[electron transport chain]], vesicular transport, and cell growth. An enhanced susceptibility to pyocyanin is seen in cells which have mutation in certain proteins or complexes. Mutations in genes affecting [[V-ATPase]] synthesis and assembly,&lt;ref&gt;{{Cite journal | author=Ho M, Hirata R, Umemota N, Ohya Y, Takatsuki A, Stevens T &amp; Anraku Y. | title=VMA13 encodes a 54-kDa vacuolar H(+)ATPase subunit required for activity but not assembly of the enzyme complex in ''Saccharomyces cerevisiae'' | journal=[[The Journal of Biological Chemistry]] | volume=268 | year=1993 | pages=18286–18292 | url=http://www.jbc.org/content/268/24/18286.long | issue=24 | pmid=8349704}}&lt;/ref&gt; vesicle transport machinery, protein sorting machinery all confer an increased sensitivity to pyocyanin which further enhances the effects on cystic fibrosis on the patient. Vacuolar- ATPase in yeast cells is a particularly potent target as it is the main non-mitochondrial producer of ATP but also has numerous other functions such as calcium homeostatic control, the facilitation of receptor-mediated endocytosis and the degradation of proteins. Therefore the inactivation of vacuolar-ATPase by hydrogen peroxide produced by pyocyanin has huge consequences for the lung. Additional to these effects, another target of pyocyanin is caspase 3-like proteases which can then go on to initiate [[apoptosis]] and [[necrosis]]. Mitochondrial electron carrier’s ubiquinone and nicotinic acid are also susceptible to pyocyanin.&lt;ref&gt;{{Cite journal | author=Hassett D, Woodruff W, Wozniak D, Vasil M, Cohen S &amp; Ohman D | title= Cloning and characterization of the ''Pseudomonas aeruginosa'' soda and sodB genes encoding manganese- and iron cofactored SOD: demonstration of increased Mn SOD dismutase activity in alginate-producing bacteria | journal=[[Journal of Bacteriology]] | volume=1 | year=1993 | pages=1–666 | pmc=206923 | pmid=8244935 | issue=23}}&lt;/ref&gt; The cell cycle can be disturbed by the action of pyocyanin as well as hinder the proliferation of [[lymphocytes]].&lt;ref&gt;{{Cite journal | author=Sorensen R &amp;Klinger J | title= Biological effects of Pseudomonas aeruginosa phenazine pigments| journal=[[Journal of antibiotic Chemotherapy]]| volume=39 | year=1987 | pages=113–124 | pmid=3118778 }}
&lt;/ref&gt; This is done by the generation of [[reactive oxygen intermediate]]s such as [[hydrogen peroxide]] and [[superoxide]] which cause oxidative stress by damaging DNA directly or alternatively targeting other constituents of the cell cycle such as DNA recombination and repair machinery. Pyocyanin contributes to the disproportion of protease and antiprotease activity by disabling α&lt;sub&gt;1&lt;/sub&gt;- protease inhibitor.

== Cystic fibrosis ==
Many studies have concluded that pyocyanin has a derogatory effect in cystic fibrosis which enables ''P. aeruginosa'' to persist in the cystic fibrosis lung; it is often detected in the sputum from cystic fibrosis patients. Pyocyanin in vitro has the ability to interfere with functions such as ciliary beating and therefore cause epithelial dysfunction as the ciliary are needed to sweep mucus up the throat.&lt;ref&gt;{{Cite journal | author=Kanthakumar K, Taylor G, Tsang K, Cundell D, Rutman A, Smith S, Jeffery P, Cole P &amp; Wilson R | title=Mechanism of action of ''Pseudomona aeruginosa'' pyocyanin on human ciliary beat in vitro | journal=[[Infection and Immunity]] | volume=61 | year=1993 | pages=2848–2853| doi=}}&lt;/ref&gt; Additionally, [[neutrophil]] apoptosis,&lt;ref&gt;{{Cite journal | author=Usher L, Lawson R, Gaery I, Taylor C, Bingle C, Taylor G, Whyte M. | title=Induction of neutrophil apoptosis by the ''Pseudomonas aeruginosa'' exotoxin pyocyanin: a potential mechanism of persistant infection | journal=[[The Journal of Immunology]] | volume=4 | year=2002 | pages=1861–1868 | doi=}}&lt;/ref&gt; immunoglobulin release from [[B-lymphocytes]] and interleukin release e.g. [[Interleukin 8|IL-8]]&lt;ref&gt;
{{Cite journal | author=Denning G, Wollenweber L, Railsback M, Cox C, Stoll L &amp; Britigan B | title=''Pseudomonas'' pyocyanin increases interleukin-8 expression by human airway epithelial cells| journal=[[Infection and Immunity]] | volume=66 | year=1998 | pages=5777–5784 | pmid= 9826354 | issue=12 | pmc=108730}}&lt;/ref&gt; and [[CCL5]] are all impaired by pyocyanin causing the immune system of the lung to be weakened. In vivo studies have shown that the growth of fungus is inhibited in the presence of pyocyanin.&lt;ref&gt;{{Cite journal | author= Kerr J, Taylor G, Rutman A, Hoiby N, Cole P, Wilson R | title=''Pseudomonas aeruginosa'' pyocyanin and 1-hydroxyphenazine inhbit fungal growth| journal=[[Journal of Clinical Pathology]] | volume=52 | year= 1998 | pages=385–387 | doi=10.1136/jcp.52.5.385 | issue= 5 }}&lt;/ref&gt; The fungicidal mechanism is the activation of NAD(P)H to induce a redox active cascade to produce reactive oxygen intermediates. This allows ''P. aeruginosa'' to have a competitive advantage as it may dominate over other microorganisms in the cystic fibrosis lung. 
The intracellular concentration of [[Adenosine triphosphate|ATP]] is also diminished by pyocyanin causing further damage to [[Cystic fibrosis transmembrane conductance regulator|CFTR]] which are already impaired in cystic fibrosis. CFTR channels rely on ATP for two main purposes. Firstly, the binding and hydrolysis of ATP has to occur at two nucleotide binding domains for the channel to move between its open and closed conformation.&lt;ref&gt;
{{Cite journal | author=Ostedgaard S, Baldursson O, Vermeer D, Welsh M, Robertson A |title=Regulation of the cystic fibrosis transmembrane conductance regulator ClK channel by its R domain| journal=[[Journal of Biological Chemistry]] | volume=276 | year=2001 | pages=7689–7692 | doi = 10.1074/jbc.R100001200 | issue=11 }}&lt;/ref&gt; Secondly, phosphorylation of CFTR by [[Protein kinase A]] II should occur in order for the channel to be operational. PKA II is activated by cAMP which is produced from ATP. Both these processes are impaired when ATP is depleted by pyocyanin.

== Defence against pyocyanin ==
''[[Caenorhabditis elegans]]'' possesses two specific [[ABC transporter]]s called ''pgp-1'' and ''pgp-2'' which are effectively able to extrude intracellular pyocyanin in an energy dependent manner.&lt;ref&gt;
{{Cite journal | author=Mahajan-Miklos S, Tan M, Rahme L, Ausubel F| title=Molecular mechanisms of bacterial virulence elucidated using a ''Pseudomonas aeruginosa''-''Caenorhabditis elegans'' pathogenesis model| journal=[[The Cell]] | volume=96 | year=1999 | pages=47–56 | doi=10.1016/S0092-8674(00)80958-7 | pmid=9989496 | issue=1}}
&lt;/ref&gt;

== See also ==
*''[[Pseudomonas Aeruginosa|Pseudomonas aeruginosa]]''
* [[Cystic fibrosis]]

== References ==
{{Reflist}}

== External links ==
*[http://www.caymanchem.com/app/template/Product.vm/catalog/10009594 Pyocyanin profile]

[[Category:Antibiotics]]
[[Category:Biological pigments]]
[[Category:Phenazines]]
[[Category:Ketones]]</text>
      <sha1>6lfqliycpqqlu6sbnbm5jpsnojv7xv7</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Efflux (microbiology)</title>
    <ns>0</ns>
    <id>5657994</id>
    <revision>
      <id>608910357</id>
      <parentid>594817314</parentid>
      <timestamp>2014-05-17T02:28:52Z</timestamp>
      <contributor>
        <ip>78.149.99.186</ip>
      </contributor>
      <comment>/* Eukaryotes */</comment>
      <text xml:space="preserve" bytes="7911">'''Active efflux''' is a mechanism responsible for the moving of toxic substances and [[antibiotic]]s out of the cell; this is considered to be a vital part of [[xenobiotic metabolism]]. This mechanism is important in medicine as it can contribute to bacterial [[antibiotic resistance]]. 

Efflux systems function via an energy-dependent mechanism ([[Active transport]]) to pump out unwanted toxic substances through specific efflux pumps. Some efflux systems are drug-specific, whereas others may accommodate multiple drugs, and thus contribute to bacterial multidrug resistance (MDR).

==Bacteria==
===Bacterial efflux pumps===
Efflux pumps are [[protein]]aceous transporters localized in the [[cytoplasmic membrane]] of all kinds of cells. They are [[active transport]]ers, meaning that they require a source of chemical energy to perform their function. Some are [[Active transport#Types|primary active transporters]] utilizing [[Adenosine triphosphate]] hydrolysis as a source of energy, whereas others are [[Active transport#Types|secondary active transporters]] ([[uniporter]]s, [[symporter]]s, or [[antiporter]]s) in which transport is coupled to an [[electrochemical potential|electrochemical potential difference]] created by pumping out [[hydrogen]] or [[sodium]] [[ions]] outside the cell.
&lt;br&gt;
Bacterial efflux transporters are  classified into five major superfamilies, based on the [[amino acid]] [[peptide sequence|sequence]]  and the energy source used to export their substrates:
# The [[major facilitator superfamily]] (MFS)
# The [[Adenosine triphosphate|ATP]]-binding cassette superfamily (ABC)
# The small multidrug resistance family (SMR)
# The resistance-nodulation-cell division superfamily (RND)
# The [[Multi antimicrobial extrusion protein]] family (MATE).
Of these, only the ABC superfamily are primary transporters, the rest being [[secondary transporters]] utilizing [[proton]] or sodium [[ion gradient|gradient]] as a source of energy.  Whereas MFS dominates in [[Gram positive bacteria]], the RND family was once thought to be unique to Gram negative bacteria. They have since been found in all major Kingdoms.

===Function===
Although antibiotics are the most clinically important substrates of efflux systems, it is probable that most efflux pumps have other natural physiological functions. Examples include:
* The ''[[Escherichia coli|E. coli]]'' AcrAB  efflux system, which has a physiologic role of pumping out bile acids and fatty acids to lower their toxicity.
* The MFS family Ptr pump in ''[[Streptomyces pristinaespiralis]]'' appears to be an [[autoimmunity]] pump for this organism when it turns on production of pristinamycins I and II.
* The AcrAB–TolC system in ''E. coli'' is suspected to have a role in the transport of the calcium-channel components in the ''E. coli'' membrane.
* The MtrCDE system plays a  protective role by providing resistance to faecal lipids in rectal isolates of ''[[Neisseria gonorrhoeae]]''.
* The AcrAB efflux system of ''[[Erwinia amylovora]]''  is important for this organism's [[virulence]], plant (host) colonization, and resistance to plant toxins.
* The MexXY component of the MexXY-OprM multidrug efflux system of ''P. aeruginosa'' is inducible by antibiotics that target ribosomes via the PA5471 gene product.&lt;ref name=&quot;pmid16484195&quot;&gt;{{cite journal | author = Morita Y, Sobel ML, Poole K | title = Antibiotic inducibility of the MexXY multidrug efflux system of ''Pseudomonas aeruginosa'': involvement of the antibiotic-inducible PA5471 gene product. | journal = Antimicrob. Agents Chemother. | volume = 188 | issue = 5 | pages = 1847–55 |date=March 2006 | pmid = 16484195 |  doi = 10.1128/JB.188.5.1847-1855.2006| url = | issn = | pmc=1426571}}&lt;/ref&gt;

The ability of efflux systems to recognize a large number of compounds  other than their natural substrates is probably because substrate recognition is based on [[physical chemistry|physicochemical]] properties, such as [[hydrophobicity]], [[aromaticity]] and [[ionization|ionizable]] character rather than on defined chemical properties, as in classical [[enzyme]]-[[substrate (biochemistry)|substrate]] or [[ligand (biochemistry)|ligand]]-[[receptor (biochemistry)|receptor]] recognition. Because most antibiotics are [[amphiphilic]] molecules - possessing both hydrophilic and hydrophobic characters - they are easily recognized by many efflux pumps.

===Impact on antimicrobial resistance===
The impact of efflux mechanisms on antimicrobial resistance is large; this is usually attributed to the following:
* The [[gene]]tic elements encoding efflux pumps may be encoded on [[chromosome]]s and/or [[plasmids]], thus contributing to both intrinsic (natural) and acquired resistance respectively. As an intrinsic mechanism of resistance, efflux pump genes can survive a hostile environment ( for example in the presence of antibiotics) which allows for the selection of [[mutant]]s  that over-[[gene expression|express]] these genes. Being located on transportable genetic elements as [[plasmids]] or [[transposon]]s is also advantageous for the microorganisms as it allows for the easy spread of efflux genes between distant species.
* Antibiotics can act as inducers and regulators of the [[gene expression|expression]] of some efflux pumps.&lt;ref name=&quot;pmid16484195&quot;/&gt;
* Expression of several efflux pumps in a given bacterial species may lead to a broad spectrum of resistance when considering the shared substrates of some multi-drug efflux pumps,  where one efflux pump may confer resistance to a wide range of antimicrobials.

==Eukaryotes==

In eukaryotic cells, the existence of efflux pumps has been known since the discovery of [[p-glycoprotei]]n in 1976 by Juliano and Ling. Efflux pumps are one of the major causes of anticancer drug resistance in eukaryotic cells. They include monocarboxylate transporters (MCTs), multiple drug resistance proteins (MDRs)- also referred as p-glycoprotein, multidrug resistance-associated proteins (MRPs), peptide transporters (PEPTs), and Na+ phosphate transporters (NPTs). These transporters are distributed along particular portions of the renal proximal tubule, intestine, liver, blood–brain barrier, and other portions of the brain.

==Efflux inhibitors==
Several trials are currently being conducted to develop drugs that can be co-administered with antibiotics to act as inhibitors for the efflux-mediated extrusion of antibiotics. None of the efflux  inhibitors tested is yet in clinical use. However, some of them are used to determine the efflux prevalence in clinical isolates. Its shown that [[Verapamil]] can inhibit P-glycoprotein mediated efflux which can increase oral absorption of some compounds.
Some chemicals found in plants have potential as reflex pump inhibitors. Chemicals such as Capsanthin and capsorubin, [[carotenoid]]s isolated from [[paprika]]; the flavonoids, [[rotenone]], [[chrysin]], [[phloretin]] and [[sakuranetin]].&lt;ref&gt;Molnár J., Engi H., Hohmann J., Molnár P., Deli J., Wesolowska O., Michalak K., Wang Q. &quot;Reversal of multidrug resistance by natural substances from plants&quot;  ''Current Topics in Medicinal Chemistry'' 2010 10:17 (1757-1768)&lt;/ref&gt; Some chemicals' [[nanoparticle|nanoparticles]] such as [[Zinc oxide|ZnO]] can regulate bacterial pumps. They can inhibit effluxing in some bacteria.&lt;ref&gt;{{cite journal|title =ZnO nanoparticles enhanced antibacterial activity of ciprofloxacin against Staphylococcus aureus and Escherichia coli|author = Banoee, M.; Seif, S.; Nazari, Z. E.; Jafari-Fesharaki, P.; Shahverdi, H. R.; ; Moballegh, A.; Moghaddam, K. M.; Shahverdi, A. R. |journal =J Biomed Mater Res B Appl Biomater|year =2010|volume =93|issue =2|pages =557–61|pmid =20225250|doi =10.1002/jbm.b.31615}}&lt;/ref&gt;

==See also==
* [[Antibiotic resistance]]

==References==
{{reflist}}
{{Refimprove|date=January 2007}}

[[Category:Membrane biology]]
[[Category:Antibiotics]]</text>
      <sha1>loytnrpxfyy1zt5eu81aqcfhoxt7lii</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Ambazone</title>
    <ns>0</ns>
    <id>24912139</id>
    <revision>
      <id>602229942</id>
      <parentid>602081835</parentid>
      <timestamp>2014-04-01T06:38:12Z</timestamp>
      <contributor>
        <username>BG19bot</username>
        <id>14508071</id>
      </contributor>
      <minor/>
      <comment>[[WP:CHECKWIKI]] error fix for #61.  Punctuation goes before References. Do [[Wikipedia:GENFIXES|general fixes]] if a problem exists. - using [[Project:AWB|AWB]] (9991)</comment>
      <text xml:space="preserve" bytes="7473">{{multiple issues|
{{Expert-subject|Pharmacology|date=December 2013}}
{{Medref|date=October 2013}}
}}

{{chembox
| verifiedrevid = 443989497
|Reference=&lt;ref&gt;[http://www.chemblink.com/products/539-21-9.htm Ambazone]&lt;/ref&gt;
|ImageFile=Ambazone.svg
|ImageSize=
|IUPACName=[4-(2-(Diaminomethylidene)hydrazinyl)phenyl]iminothiourea
|OtherNames= 2-[4-[(aminoiminomethyl)hydrazono]-2,5-cyclohexadien-1-ylidene]-Hydrazinecarbothioamide; (4-Oxo-2,5-cyclohexadien-1-ylideneamino)guanidine thiosemicarbazone; 1,4-Benzoquinone amidinohydrazone thiosemicarbazone; Ambazon; Anginon; Benzoquinone guanylhydrazone thiosemicarbazone; Faringosept; Guanothiazon; Inversal; Inversal; Ivertol; N-Guanidino-N'-thioureido-p-benzoquinonediimide; Primal; p-Benzoquinone amidinohydrazone thiosemicarbazone;Faringosept (TN); Ambazone (INN); OAMBAZONE; Ambazonum [INN-Latin]; Ambazona [INN-Spanish]; Ambazone [INN:BAN:DCF]; CCRIS 1926; MLS001240207
|Section1= {{Chembox Identifiers
| InChIKey = MLMFUKWWZIZRHX-UWRPRBHNBF
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C8H11N7S/c9-7(10)14-12-5-1-3-6(4-2-5)13-15-8(11)16/h1-4H,(H4,9,10,14)(H3,11,15,16)/b12-5-,13-6+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MLMFUKWWZIZRHX-UWRPRBHNSA-N
| CASNo_Ref = {{cascite|correct|??}}
| CASNo=539-21-9
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = BYK4592A3Q
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 12232507
| EINECS = 208-713-0
| PubChem= 1549158
| SMILES = NC(=S)N\N=C1\C=C/C(=N\NC(N)=N)/C=C1
| InChI = 1/C8H11N7S/c9-7(10)14-12-5-1-3-6(4-2-5)13-15-8(11)16/h1-4H,(H4,9,10,14)(H3,11,15,16)/b12-5-,13-6+
| ATCvet = ATC
| ATCCode_prefix = R02
| ATCCode_suffix = AA01
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07376
  }}
|Section2= {{Chembox Properties
|  Formula=C&lt;sub&gt;8&lt;/sub&gt;H&lt;sub&gt;11&lt;/sub&gt;N&lt;sub&gt;7&lt;/sub&gt;S
|  MolarMass= 237.28 g/mol
|  Appearance= Dark Brown Powder
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility= 0.2 mg/100 ml water
  }}
|Section3= {{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}

'''Ambazone''' is an oral [[antiseptic]].

Ambazon was patented in 1957 by [[Bayer]] under the trade name '''Iversal''', and briefly used in Germany. It is still used in Russia, countries of the former Soviet Union and Romania. It has not been approved by the [[FDA]].

==Synthesis==
Ambazone can be obtained in a two step synthetic method, reacting 1,4-Benzochinone with Aminoguanidine and Thiosemicarbazide.,&lt;ref&gt;Patent DE965723: Verfahren zur Herstellung von ondensationsprodukten. Angemeldet am 31. Januar 1953, veröffentlicht am 19. Juni 1957, Anmelder: Bayer AG, Erfinder: Siegfried Petersen, Gerhard Domagk.&lt;/ref&gt;&lt;ref&gt;A. Kleemann, J. Engel, B. Kutscher, D. Reichert: Pharmaceutical Substances - Synthesis, Patents, Applications, 4. Auflage (2001) Thieme-Verlag Stuttgart, ISBN 978-1-58890-031-9.&lt;/ref&gt;

[[File:Ambazone synthesis 01.PNG|550px]]

Obtaining a pharmacetical grade material is difficult due to high amounts of byproducts, synthetic intermediates and decomposition products.&lt;ref&gt;[http://patentscope.wipo.int/search/en/detailPdf.jsf?ia=RO2004000016&amp;docIdPdf=id00000001847575%3FparSeparator1=&amp;name=WO2005028431PROCESS+FOR+THE+PURIFICATION+OF+1%2C4-BENZOQUINONE+GUANYLHYDRAZONE+THIOSEMICARBAZONE+%28AMBAZONE%29&amp;parSeparator2=&amp;woNum=WO2005028431&amp;prevRecNum=298&amp;nextRecNum=300&amp;recNum=298&amp;queryString=ABE%2F%22toluene%22&amp;office=&amp;sortOption=&amp;prevFilter=&amp;maxRec=856 Patent WO 2005/028431]&lt;/ref&gt;

==Applications==
[[Bacteriostatic agent|Bacteriostatic]] action on [[Streptococcus|hemolytic streptococcus]], [[streptococcus pneumoniae]] and [[Streptococcus viridans|viridans streptococcus]].

==Physical properties==
Through experimental testing ambazone has shown antiseptic properties, along with anti-tumor properties.  Ambazone has the following physical characteristics.
{| class=&quot;wikitable&quot;
|-
! Table 1. Physical properties
|-
| Dark brown
|-
| Odorless
|-
| Tasteless
|-
| Powder
|-
| Melting Point 192–194&amp;nbsp;°C (decomp.)&lt;ref&gt;Marshall Sittig: Pharmaceutical manufacturing encyclopedia. -- 3rd ed. 2007 p. 215&lt;/ref&gt;
|}
{| class=&quot;wikitable&quot;
|-
! Table 2. Solubility !! per 100 ml
|-
| Water || 0.2&amp;nbsp;mg
|-
| Methanol || 0.5&amp;nbsp;mg
|-
| Chloroform || 0.3&amp;nbsp;mg
|-
| 1-butanol || 6.5&amp;nbsp;mg
|-
| Ethyl acetate || 17&amp;nbsp;mg
|-
| Acetone || 50&amp;nbsp;mg
|-
| Ethanol || 85&amp;nbsp;mg
|-
| Dimethyl formamide || 1.7 g
|-
| sulfoxide || 2.5 g
|}
{| class=&quot;wikitable&quot;
|-
! Table 3. Uv-Vis !! nm
|-
| Water || 403
|-
| Alcohols || 440-445
|-
| Ethyl acetate || 453
|-
| Dimethyl sulfoxide || 467
|}

Ambazone is prepared by way of solid based crystallization or grinding.

==Mode of action==
The mode of action for ambazone has been studied extensively and ambazone has been shown to react via different methods. Ambazone shows low mutagenic activity and no cardiovascular, CNS, metabolic, or gastrointestinal side-effects with I.V. doses up to 10-5&amp;nbsp;mol/kg and oral doses up to 10-3&amp;nbsp;mol/kg.  As stated before ambazone can be administered via oral or I.V. administration, but the problem with oral administration is that one experimental study shows there is only a 35-50% absorption while another study shows 40% in the intestines; These results would tend to lead the reader to think that ambazone would not be the best choice for treatment, because with such a low absorbance, there is going to have to be a greater concentration ingested to gain a positive effect from the drug.  The problem with a greater concentration is that ambazone has a half-life of 6–7 hours.  It was stated above that ambazone possess no CNS side-effects and the reason we know this is, due to the fact, that it will not cross the blood brain barrier.  Although this is the body’s way of protecting unwanted substances from attacking the brain, this also limits the treatment of brain tumors with ambazone.

==Therapeutic uses==
The therapeutic properties of ambazone were studied in lab rats and the therapeutic dose was determined to be 60–125&amp;nbsp;mg/kg of body weight.  As stated above, ambazone possesses anti-septic properties shown by its increased activity against gram-positive cocci.  Along with anti-septic properties, ambazone has also shown its ability to fight forms of leukemia in lab rats.  When administered orally the results showed prolongation of life expectancy and curing of L1210 and P388 leukemia in lab rats.  Scientist used different methods to determine the results, such as; mean survival time (MST), percent increase of life span, survival rates, percent change in body weights and number of peritoneal cells.  The results gathered show tremendous strides towards leukemia treatment.  Although we can see positive results, one might wonder, “Are there side effects?”  The results show different answers depending on the test performed.  When testing ambazone via AMES with no metabolic activation we find there are no mutagenic or carcinogenic properties.  When the same test is performed with metabolic activation or when the C-Test is performed we do see the potential for mutagenicity.  The results show two different paths and until further testing has been performed we cannot determine if the good outweighs the bad when it comes to using ambazone for treatment.

==References==
{{reflist}}

{{Throat preparations}}
{{Stomatological preparations}}

[[Category:Antiseptics]]
[[Category:Antibiotics]]
[[Category:Guanidines]]
[[Category:Thioureas]]</text>
      <sha1>lxu63izgreayvq98zsv7wrf0t0wo2nx</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Endiandric acid C</title>
    <ns>0</ns>
    <id>25429092</id>
    <revision>
      <id>575379197</id>
      <parentid>558869780</parentid>
      <timestamp>2013-10-02T02:22:28Z</timestamp>
      <contributor>
        <username>ArmbrustBot</username>
        <id>18663209</id>
      </contributor>
      <minor/>
      <comment>/* References */removing category per [[Wikipedia:Categories for discussion/Log/2013 September 21]], removed: Category:Chemical compounds found in Lauraceae using [[Project:AWB|AWB]]</comment>
      <text xml:space="preserve" bytes="9163">{{Chembox
| ImageFile = Endiandric acid C.svg
| ImageSize = 200px
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 76060-34-9
|   CASNo_Ref = {{cascite|correct|CAS}}
|  PubChem = 
|  ChemSpiderID = 16736127
|  SMILES = OC(=O)[C@H]5C2\C=C/C3[C@@H]5CC4[C@H](C\C=C\C=C\c1ccccc1)[C@@H]2[C@@H]34
|  InChI = InChI=1S/C23H24O2/c24-23(25)22-17-12-11-16-19(22)13-18-15(20(17)21(16)18)10-6-2-5-9-14-7-3-1-4-8-14/h1-9,11-12,15-22H,10,13H2,(H,24,25)/b6-2+,9-5+/t15-,16?,17?,18?,19-,20-,21-,22-/m0/s1
  }}
| Section2 = {{Chembox Properties
|  C=23|H=24|O=2
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility =
  }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition =
  }}
}}

'''Endiandric acid C''', isolated from the ''[[Endiandra introrsa]]'' tree, is a well characterized [[chemical compound]]. Endiadric acid C is reported to have better [[antibiotic]] activity than [[ampicillin]].

This genus of trees is in the family [[Lauraceae]].  These trees are found in the north-eastern Australian [[rainforest]]s and other [[tropical]] and [[subtropical]] regions.  However, these trees are also found in southern [[Canada]] and in [[Chile]].  Endiandric acid C is also isolated from ''E. xanthocarpa'' species.  Endiandric acids are also found in ''[[Beilschmiedia]]'' trees, which were categorized under the ''Endiandra'' genus, but now forms its own genus as they found in cold, high [[latitude]] areas, and even in [[New Zealand]].  Other endiandric acids are found in the ''B. oligandra'' and ''B. anacardioides'' species, which are found in the Western Province of [[Cameroon]].

== Bioactivity ==

This compound has the best [[antibacterial activity]] of Endiandrianic acid A-G compounds.  Endiandric acid C was tested towards five strains of [[bacteria]], which included ''[[Bacillus subtilis]]'', ''[[Micococcus luteus]]'', ''[[Streptococcus faecalis]]'', ''[[Pseudomonas palida]]'', and ''[[Escherichia coli]]'' through examining zone inhibition and minimum concentration, which was found to range between 0.24&amp;nbsp;µg/mL and 500&amp;nbsp;µg/mL.  Endiandric acid C has also been used to cure [[uterine tumor]]s, [[rubella]], and [[female genital infection]]s, and [[rheumatism]]s.

== Biosynthesis ==
[[Image:Bio synthesis endiandric acid c.pdf]]
[[Image:Non-enzyme catalyzed.pdf]]

Many [[biochemist]]s predicted when examining [[K. C. Nicolaou]]’s [[biomimetic synthesis]] of the endiandric acid cascade that [[enzymes]] aided this [[Chemical reaction|reaction]] in the [[biosythesis]].  The biomimetic series determined that this process took place synthetically through a series of [[Diels-Alder cyclization]] reactions and therefore led researches to believe that [[Diels-Alderase]] assisted the formation of endiandric acid C.  

Although it has been discovered since then that many famous cyclization reactions like that of [[Lovastatin]] do result from the Diels-Alderase they have determine that the endiandric acid cascade does not involve enzymes but rather spontaneously undergoes ring formation from a derivative of [[bisnoryangonin]] '''5''', which results from both the [[shikimic acid|shikimate]] and [[acetic]] pathways.  The [[4-hydroxycinnamoyl-CoA]], compound '''2''', is the precursor that comes from the shikimate pathway.  Two units of [[malonyl CoA]] are then added to through the acetate pathway '''3'''.  Compound '''3''' is then reduced to the di-[[enol]] form that [[tautomerize]]s to give the bisnoryangonin '''5'''.  A small amount of compound '''5''' can be isolated, however [[S-Adenosyl methionine|''S''-Adenosyl methionine]] methylates most of it and gives [[yangonin]] '''6'''.  It has been proposed that a bisnoryangonin derivative '''7''', is then reduced by [[dehydrogenase]] to give the [[polyene]] precursor '''8''', that goes through spontaneous 8π conrotatory, 6π disrotatory, and [4+2] cyclization reactions to form endiandric acid C.  This proposal is supported by the fact that endiandric acids naturally occur as racemic mixtures and not in an enantiomerically pure form, which should happen if enzymes mediate this process.  The Diels-Alder reaction itself is a powerful reaction that can give cyclic compounds with many stereogenic centers.

== Organic synthesis ==

[[Image:Biomimetic synthesis.pdf]]

K. C. Nicolaou’s group successfully synthesized compound '''1''', in 1982 using a series of sterocontrolled [[electrocyclic reaction]]s.  They observe that the product looked like multiple endo-adducts resulting that came from several Diels-Alder reactions.  They attempted to synthesize endiandric acid C from an acyclic symmetric diacetylenic diol precursor '''14''', which they hydrogenated using [[Lindlar catalyst]] to give '''15'''.  Compound '''15''' then goes through intramolecular [4+2] [[cycloaddition]]s, 6π disrotatory, and 8π conrotatory cyclization to give compound '''17''', bicyclic diol.  They then silylated compound  '''17''' and reacted it with [[sodium cyanide]] and [[HMPA]] to give the cyanide intermediate '''20''', which was then [[hydrolyze]]d to the [[aldehyde]] form '''21'''.  [[Condensation]] of '''21'''  gave the methyl [[ester]] compound '''22'''.  They reacted the methyl ester with the same reagent as intermediate '''17''' to give the methyl ester form of compound '''28'''.  They then treated Compound '''28''' with a lithio derivative of diethyl cinnamylphosphonate at -78 degrees Celsius, in [[THF]] for 15 minutes to give endiandric acid C '''1'''.

== References ==
&lt;div class=&quot;references-small&quot;&gt;
* Bandaranayake, W. M.; Banfield, J. E.; Black, D. S. C.; Fallon, G. D.; Gatehouse, B. M. Constituents of Endiandra-Spp 1. Endiandric-Acid a Novel Carboxylic-Acid from Endiandra-Introrsa Lauraceae and a Derived Lactone. ''Aust. J. of Chem''. '''1981''', ''34'', 1655-1667.
* Bandaranayake, W. M.; Banfield, J. E.; Black, D. S. C.; Fallon, G. D.; Gatehouse, B. M. Constituents of Endiandra Species. Iii. 4-[(E,E)-5'-Phenylpenta-2',4'-Dien-1'-Yl]Tetracyclo[5.4.0.02.5.03.9]Undec-10-Ene-8-Carboxylic Acid from Endiandra Introrsa (Lauraceae). ''Aust. J. of Chem''. '''1982''', ''35'', 567-579.
* Banfield, J. E.; Black, D. S. C.; Collins, D. J.; Hyland, B. P. M.; Lee, J. J.; Pranowo, S. R. Constituents of Some Species of Beilschmiedia and Endiandra (Lauraceae): New Endiandric Acid and Benzopyran Derivatives Isolated from B. Oligandra. ''Aust. J. of Chem''. '''1994''', ''47'', 587-607.
* Chouna, J. R.; Nkeng-Efouet, P. A.; Lenta, B. N.; Devkota, K. P.; Neumann, B.; Stammler, H.-G.; Kimbu, S. F.; Sewald, N. Antibacterial Endiandric Acid Derivatives from Beilschmiedia Anacardioides. ''Phytochemistry''. '''2009''', ''70'', 684-688.
* Gravel, E.; Poupon, E. Biogenesis and Biomimetic Chemistry: Can Complex Natural Products Be Assembled Spontaneously? ''Eur. J. Org. Chem''. '''2008''', 27-42.
* Miller, A. K.; Trauner, D. Mapping the Chemistry of Highly Unsaturated Pyrone Polyketides. ''Synlett'' '''2006''', 2295-2316.
* Milne, B. F.; Long, P. F.; Starcevic, A.; Hranueli, D.; Jaspars, M. Spontaneity in the Patellamide Biosynthetic Pathway. ''Org. Biomol. Chem''. '''2006''', ''4'', 631-638.
* Nicolaou, K. C.; Petasis, N. A.; Uenishi, J.; Zipkin, R. E. The Endiandric Acid Cascade. Electrocyclizations in Organic Synthesis. 2. Stepwise, Stereocontrolled Total Synthesis of Endiandric Acids C-G. ''J. Am. Chem. Soc''. '''2002''', ''104'', 5557-5558.
* Nicolaou, K. C.; Petasis, N. A.; Zipkin, R. E. The Endiandric Acid Cascade. Electrocyclizations in Organic Synthesis. 4. Biomimetic Approach to Endiandric Acids a-G. Total Synthesis and Thermal Studies. ''J. Am. Chem. Soc''. '''1982''', ''104'', 5560-5562.
* Nicolaou, K. C.; Petasis, N. A.; Zipkin, R. E.; Uenishi, J. The Endiandric Acid Cascade. Electrocyclizations in Organic Synthesis. I. Stepwise, Stereocontrolled Total Synthesis of Endiandric Acids a and B. ''J. Am. Chem. Soc''. '''1982''', ''104'', 5555-5557.
* Nicolaou, K. C.; Zipkin, R. E.; Petasis, N. A. The Endiandric Acid Cascade. Electrocyclizations in Organic Synthesis. 3. &quot;Biomimetic&quot; Approach to Endiandric Acids a-G. Synthesis of Precursors. ''J. Am. Chem. Soc''. '''2002''', ''104'', 5558-5560.
* Oikawa, H. Involvement of the Diels-Alderases in the Biosynthesis of Natural Products. ''Bull. Chem. Soc. Jpn''. '''2005''', ''78'', 537-554.
* Gravel, E.; Poupon, E. Biogenesis and Biomimetic Chemistry: Can Complex Natural Products Be Assembled Spontaneously? '''Euro. J. O. C.''' '''2008''', 27-42.
* Miller, A. K.; Trauner, D. Mapping the Chemistry of Highly Unsaturated Pyrone Polyketides. ''Synlett'' '''2006''', 2295-2316.
* Milne, B. F.; Long, P. F.; Starcevic, A.; Hranueli, D.; Jaspars, M. Spontaneity in the Patellamide Biosynthetic Pathway. ''Organic &amp; Biomolecular Chemistry'' '''2006''', ''4'', 631-638.
* Nicolaou, K. C.; Petasis, N. A.; Zipkin, R. E. The Endiandric Acid Cascade. Electrocyclizations in Organic Synthesis. 4. Biomimetic Approach to Endiandric Acids a-G. Total Synthesis and Thermal Studies. Journal of the ''American Chemical Society'' '''1982''', ''104'', 5560-5562.
&lt;/div&gt;

[[Category:Antibiotics]]
[[Category:Carboxylic acids]]</text>
      <sha1>nec6xuq736xgvfcytcf4ko2lhxw4qtm</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Amp resistance</title>
    <ns>0</ns>
    <id>3338556</id>
    <revision>
      <id>527020911</id>
      <parentid>385444188</parentid>
      <timestamp>2012-12-08T13:46:29Z</timestamp>
      <contributor>
        <username>BattyBot</username>
        <id>15996738</id>
      </contributor>
      <comment>[[WP:AWB/GF|General fixes]], removed orphan tag using [[Project:AWB|AWB]] (8759)</comment>
      <text xml:space="preserve" bytes="286">{{Unreferenced|date=December 2009}}

'''Amp resistance''' is a term for [[antibiotic resistance|resistance]] to the [[antibiotic]] [[ampicillin]]. It is used as a selectable marker in bacterial transformation.

{{DEFAULTSORT:Amp Resistance}}
[[Category:Antibiotics]]


{{Bacteria-stub}}</text>
      <sha1>j6wgjg36p2s3dszp1tkrjyafg6b5tzh</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Bacteriostatic agent</title>
    <ns>0</ns>
    <id>153831</id>
    <revision>
      <id>604028736</id>
      <parentid>604028732</parentid>
      <timestamp>2014-04-13T16:36:38Z</timestamp>
      <contributor>
        <username>ClueBot NG</username>
        <id>13286072</id>
      </contributor>
      <minor/>
      <comment>Reverting possible vandalism by [[Special:Contributions/183.83.221.0|183.83.221.0]] to version by 151.247.153.201. False positive? [[User:ClueBot NG/FalsePositives|Report it]]. Thanks, [[User:ClueBot NG|ClueBot NG]]. (1791966) (Bot)</comment>
      <text xml:space="preserve" bytes="2754">A '''bacteriostatic agent''' or '''bacteriostat''', abbreviated '''Bstatic''', is a biological or chemical agent that stops [[bacteria]] from reproducing, while not necessarily harming them otherwise. Depending on their application, bacteriostatic [[antibiotic]]s, [[disinfectant]]s, [[antiseptic]]s and [[preservative]]s can be distinguished. Upon removal of the bacteriostat, the bacteria usually start to grow again. This is in contrast to [[bactericide]]s, which kill bacteria.&lt;ref name=&quot;pmid14999632&quot;&gt;{{cite journal | author = Pankey GA, Sabath LD | title = Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections | journal = Clin. Infect. Dis. | volume = 38 | issue = 6 | pages = 864–70 |date=March 2004 | pmid = 14999632 | doi = 10.1086/381972 }}&lt;/ref&gt;

Bacteriostats are often used in [[plastic]]s to prevent growth of bacteria on surfaces. Bacteriostats commonly used in laboratory work include [[sodium azide]] (which is acutely toxic) and [[thiomersal]] (which is a mutagen in mammalian cells).

==Bacteriostatic antibiotics==
Bacteriostatic antibiotics limit the growth of [[bacteria]] by interfering with bacterial [[protein]] production, [[DNA]] replication, or other aspects of bacterial cellular [[metabolism]]. They must work together with the immune system to remove the microorganisms from the body.  However, there is not always a precise distinction between them and bactericidal antibiotics; high concentrations of some bacteriostatic agents are also bactericidal, whereas low concentrations of some [[bacteriocidal]] agents are bacteriostatic.

This group&lt;ref name=&quot;isbn1-4051-3543-3&quot;&gt;{{cite book | editor = Andrews J, Shetty N, Tang JW | author = Shetty N, Aarons E, Andrews J | title = Infectious Disease: Pathogenesis, Prevention and Case Studies | publisher = Wiley-Blackwell | location = | year = 2009 | pages = | isbn = 1-4051-3543-3 | url = http://books.google.com/books?id=jNW-lToR2FgC&amp;lpg=PA141&amp;ots=A1vY7K-Z1J&amp;dq=Bacteriostatic%20antibiotics%20Tetracyclines%20%20sulfonamides&amp;pg=PA141#v=onepage&amp;q=Bacteriostatic%20antibiotics%20Tetracyclines%20%20sulfonamides&amp;f=false | chapter = Chapter 5: General principles of antimicrobial therapy | accessdate = }}&lt;/ref&gt; includes
* [[Tetracyclines]]
* [[Sulfonamide (medicine)|Sulfonamides]]
* [[Spectinomycin]]
* [[Trimethoprim]]
* [[Chloramphenicol]]
* [[Macrolides]]
* [[Lincosamides]]
* [[Clindamycin]]
* [[Ethambutol]]
* [[Nitrofurantoin]]
* [[Novobiocin]]
* [[Tigecycline]]
* [[Oxazolidinone]]

== See also ==
* [[List of antibiotics]]
* [[Oligodynamic effect]]

==References==
{{Reflist}}

{{Pharmacology}}

{{DEFAULTSORT:Bacteriostatic Agent}}
[[Category:Antibiotics]]

{{antiinfective-drug-stub}}</text>
      <sha1>nrdcki75952aikzxqlaq7bbu3xctund</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Actinorhodin</title>
    <ns>0</ns>
    <id>26128602</id>
    <revision>
      <id>606732184</id>
      <parentid>597014714</parentid>
      <timestamp>2014-05-02T06:14:21Z</timestamp>
      <contributor>
        <username>Rjwilmsi</username>
        <id>203434</id>
      </contributor>
      <minor/>
      <comment>Added 2 dois to journal cites using [[Project:AWB|AWB]] (10090)</comment>
      <text xml:space="preserve" bytes="3986">{{chembox
| Verifiedfields = changed
| verifiedrevid = 477241707
| ImageFile = Actinorhodin.svg
| ImageSize = 250 px
| IUPACName = [3'-carboxymethyl-5,5',10,10'-tetrahydroxy-1,1'-dimethyl-6,6',9,9'-tetraoxo-3,3',4,4'6,6'9,9'-octahydro-1H,1'H-8,8'-bi(benzo[g]isochromen)-3-yl]acetic acid&lt;ref name=&quot;ebi&quot;&gt;{{cite web|url=http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2448|title=Actinorhodin (CHEBI:2448)|date=18 February 2008|publisher=EBI Small Molecule Database|accessdate=9 February 2010}}&lt;/ref&gt;

| OtherNames = 
| Section1 = {{Chembox Identifiers
|   ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 16735642
| InChI = 1/C32H26O14/c1-9-21-15(3-11(45-9)5-19(35)36)29(41)23-17(33)7-13(27(39)25(23)31(21)43)14-8-18(34)24-26(28(14)40)32(44)22-10(2)46-12(6-20(37)38)4-16(22)30(24)42/h7-12,33-34,39-40H,3-6H2,1-2H3,(H,35,36)(H,37,38)/t9-,10-,11+,12+/m1/s1
| InChIKey = VTIKDEXOEJDMJP-WYUUTHIRBL
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C32H26O14/c1-9-21-15(3-11(45-9)5-19(35)36)29(41)23-17(33)7-13(27(39)25(23)31(21)43)14-8-18(34)24-26(28(14)40)32(44)22-10(2)46-12(6-20(37)38)4-16(22)30(24)42/h7-12,33-34,39-40H,3-6H2,1-2H3,(H,35,36)(H,37,38)/t9-,10-,11+,12+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VTIKDEXOEJDMJP-WYUUTHIRSA-N
| CASNo_Ref = {{cascite|changed|??}}
| CASNo =  1397-77-9
|   PubChem = 
|   SMILES = OC(=O)C[C@@H]5CC=6C(=O)c4c(O)cc(c3cc(O)c2C(=O)C=1C[C@@H](CC(O)=O)O[C@H](C)C=1C(=O)c2c3O)c(O)c4C(=O)C=6[C@@H](C)O5
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 2448
}}
| Section2 = {{Chembox Properties
|   Formula =  
|   MolarMass = 634.54 g mol&lt;sup&gt;-1&lt;/sup&gt;
|   Appearance = 
|   Density = 
|   MeltingPt =
|   BoilingPt = 
|   Solubility = 
  }}
| Section3 = {{Chembox Hazards
|   MainHazards = 
|   FlashPt = 
|   Autoignition = 
  }}
}}

'''Actinorhodin''' is a benzoisochromanequinone [[polyketide]] [[antibiotic]] produced by ''[[Streptomyces coelicolor]]''.&lt;ref name=&quot;pmid1367312&quot;&gt;{{cite journal |author=Magnolo SK, Leenutaphong DL, DeModena JA, ''et al.'' |title=Actinorhodin production by Streptomyces coelicolor and growth of Streptomyces lividans are improved by the expression of a bacterial hemoglobin |journal=Biotechnology (N.Y.) |volume=9 |issue=5 |pages=473–6 |date=May 1991 |pmid=1367312 |doi= 10.1038/nbt0591-473|url=}}&lt;/ref&gt;&lt;ref name=&quot;pmid8655502&quot;&gt;{{cite journal |author=Brian P, Riggle PJ, Santos RA, Champness WC |title=Global negative regulation of Streptomyces coelicolor antibiotic synthesis mediated by an absA-encoded putative signal transduction system |journal=J. Bacteriol. |volume=178 |issue=11 |pages=3221–31 |date=June 1996 |pmid=8655502 |pmc=178074 |doi= |url=http://jb.asm.org/cgi/pmidlookup?view=long&amp;pmid=8655502}}&lt;/ref&gt; The [[gene cluster]] responsible for actinorhodin production contains the biosynthetic enzymes and genes responsible for export of the antibiotic.&lt;ref name=&quot;Tahlan&quot;&gt;{{cite journal|last=Tahlan|first=K|author2=Ahn SK|author3=Sing A|author4=Bodnaruk TD|author5=Willems AR|author6=Davidson AR|author7= Nodwell JR.|date=February 2007|title=Initiation of actinorhodin export in Streptomyces coelicolor|journal=Molecular Microbiology|volume=63|pages=951–961|pmid=17338074|url=http://www.ncbi.nlm.nih.gov/pubmed/17338074|doi=10.1111/j.1365-2958.2006.05559.x}}&lt;/ref&gt; The antibiotic also has the effect of being a [[pH indicator]] due to its pH-dependent color change.&lt;ref name=&quot;Bystrykh&quot;&gt;{{cite journal|last=Bystrykh|first=LV|author2=Fernández-Moreno MA|author3=Herrema JK|author4=Malpartida F|author5=Hopwood DA|author6= Dijkhuizen L|date=April 1996|title=Production of actinorhodin-related &quot;blue pigments&quot; by Streptomyces coelicolor A3(2)|journal=Journal of Bacteriology|volume=178|pages=2238–44|pmid=8636024|url=http://www.ncbi.nlm.nih.gov/pubmed/8636024}}&lt;/ref&gt;

== References ==
{{reflist}}

[[Category:Natural phenols]]
[[Category:Antibiotics]]
[[Category:Quinones]]
[[Category:Acetic acids]]


{{antibiotic-stub}}</text>
      <sha1>kwwmv3hla6zjtirevvf1qlqly4cgc1x</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Methylenomycin A</title>
    <ns>0</ns>
    <id>26134510</id>
    <revision>
      <id>592480430</id>
      <parentid>586466603</parentid>
      <timestamp>2014-01-26T14:21:07Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="2653">{{chembox
| Watchedfields = changed
| verifiedrevid = 420135968
| ImageFile = Methylenomycin A.svg
| ImageSize = 250 px
| IUPACName =  (1''S'',2''R'',5''S'')-1,5-dimethyl-3-methylidene-4-oxo-6-oxabicyclo[3.1.0]hexane-2-carboxylic acid
| OtherNames =
| Section1 = {{Chembox Identifiers
|   ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 9074545
| InChI = 1/C9H10O4/c1-4-5(7(11)12)8(2)9(3,13-8)6(4)10/h5H,1H2,2-3H3,(H,11,12)/t5-,8-,9+/m0/s1
| InChIKey = HBECYYFDLZZMPL-WLGLDCGKBO
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C9H10O4/c1-4-5(7(11)12)8(2)9(3,13-8)6(4)10/h5H,1H2,2-3H3,(H,11,12)/t5-,8-,9+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HBECYYFDLZZMPL-WLGLDCGKSA-N
| CASNo_Ref = {{cascite|correct|??}}
| CASNo =  52775-76-5
|   PubChem = 10899285
|   SMILES = O=C1C(=C)[C@@H](C(=O)O)[C@@]2(O[C@]12C)C
}}
| Section2 = {{Chembox Properties
|   Formula =  C&lt;sub&gt;9&lt;/sub&gt;H&lt;sub&gt;10&lt;/sub&gt;O&lt;sub&gt;4&lt;/sub&gt;
|   MolarMass =  182.19 g mol&lt;sup&gt;-1&lt;/sup&gt;
|   Appearance = 
|   Density = 
|   MeltingPt =
|   BoilingPt = 341.2&amp;nbsp;°C
|   Solubility = 
  }}
| Section3 = {{Chembox Hazards
|   MainHazards = 
|   FlashPtC = 141.2
|   AutoignitionC = 
  }}
}}
'''Methylenomycin A''' is a cyclopentanoid antibiotic produced by ''[[Streptomyces coelicolor]]'' A3(2) that is effective against both [[Gram-negative]] and [[Gram-positive]] bacteria.&lt;ref name=&quot;pmid8655502&quot;&gt;{{cite journal |author=Brian P, Riggle PJ, Santos RA, Champness WC |title=Global negative regulation of Streptomyces coelicolor antibiotic synthesis mediated by an absA-encoded putative signal transduction system |journal=J. Bacteriol. |volume=178 |issue=11 |pages=3221–31 |date=June 1996 |pmid=8655502 |pmc=178074 |doi= |url=http://jb.asm.org/cgi/pmidlookup?view=long&amp;pmid=8655502}}&lt;/ref&gt;&lt;ref name=&quot;pmid1537793&quot;&gt;{{cite journal |author=Hobbs G, Obanye AI, Petty J, ''et al.'' |title=An integrated approach to studying regulation of production of the antibiotic methylenomycin by Streptomyces coelicolor A3(2) |journal=J. Bacteriol. |volume=174 |issue=5 |pages=1487–94 |date=March 1992 |pmid=1537793 |pmc=206543 |doi= |url=http://jb.asm.org/cgi/pmidlookup?view=long&amp;pmid=1537793}}&lt;/ref&gt; Methylenomycins are naturally produced in two variants: A and B. Methylenomycin A is the only known streptomycete antibiotic in which the biosynthesis genes are [[plasmid]] encoded.&lt;ref name=&quot;pmid1537793&quot;/&gt;

==See also==
*[[Methylenomycin B]]

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Epoxides]]
[[Category:Ketones]]
[[Category:Carboxylic acids]]
[[Category:Oxygen heterocycles]]

{{Antibiotic-stub}}</text>
      <sha1>4jwwsh24i8btebvkxybbxktxo39zavy</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Methylenomycin B</title>
    <ns>0</ns>
    <id>26161564</id>
    <revision>
      <id>592480446</id>
      <parentid>568168852</parentid>
      <timestamp>2014-01-26T14:21:15Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="2507">{{chembox
| verifiedrevid = 426622303
| ImageFile = Methylenomycin B.svg
| ImageSize = 250 px
| IUPACName =  2,3-Dimethyl-5-methylene-2-cyclopenten-1-one&lt;ref name=&quot;dl&quot;&gt;{{cite web|url=http://www.druglead.com/cds/Methylenomycins.html|title=Methylenomycins|date=2009|accessdate=9 February 2010}}&lt;/ref&gt;

| OtherNames =
| Section1 = {{Chembox Identifiers
|   ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2303992
| InChI1 = 1/C8H10O/c1-5-4-6(2)8(9)7(5)3/h2,4H2,1,3H3
| InChIKey1 = YDXIEAHUYZKJOH-UHFFFAOYAN
| CASNo_Ref = {{cascite|correct|??}}
| CASNo =  52775-77-6
|   PubChem = 3040648
|   SMILES = O=C/1\C(=C)CC(=C\1C)\C
|   StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YDXIEAHUYZKJOH-UHFFFAOYSA-N
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2303992
|  SMILES = O=C/1\C(=C)CC(=C\1C)\C
|  StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI=1S/C8H10O/c1-5-4-6(2)8(9)7(5)3/h2,4H2,1,3H3
  }}
| Section2 = {{Chembox Properties
|   Formula =  C&lt;sub&gt;8&lt;/sub&gt;H&lt;sub&gt;10&lt;/sub&gt;O
|   MolarMass =  122.16 g mol&lt;sup&gt;-1&lt;/sup&gt;
|   Appearance = 
|   Density = 
|   MeltingPt =
|   BoilingPt = 
|   Solubility = 
  }}
| Section3 = {{Chembox Hazards
|   MainHazards = 
|   FlashPt = 
|   Autoignition = 
  }}
}}
'''Methylenomycin B''' is a cyclopentanoid antibiotic produced by ''[[Streptomyces coelicolor]]'' A3(2) that is effective against both [[Gram-negative]] and [[Gram-positive]] bacteria.&lt;ref name=&quot;pmid8655502&quot;&gt;{{cite journal |author=Brian P, Riggle PJ, Santos RA, Champness WC |title=Global negative regulation of Streptomyces coelicolor antibiotic synthesis mediated by an absA-encoded putative signal transduction system |journal=J. Bacteriol. |volume=178 |issue=11 |pages=3221–31 |date=June 1996 |pmid=8655502 |pmc=178074 |doi= |url=http://jb.asm.org/cgi/pmidlookup?view=long&amp;pmid=8655502}}&lt;/ref&gt;&lt;ref name=&quot;pmid1537793&quot;&gt;{{cite journal |author=Hobbs G, Obanye AI, Petty J, ''et al.'' |title=An integrated approach to studying regulation of production of the antibiotic methylenomycin by Streptomyces coelicolor A3(2) |journal=J. Bacteriol. |volume=174 |issue=5 |pages=1487–94 |date=March 1992 |pmid=1537793 |pmc=206543 |doi= |url=http://jb.asm.org/cgi/pmidlookup?view=long&amp;pmid=1537793}}&lt;/ref&gt; Methylenomycins are naturally produced in two variants: A and B.

==See also==
* [[Methylenomycin A]]

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Ketones]]
[[Category:Cycloalkenes]]

{{Antibiotic-stub}}</text>
      <sha1>6f19m4rlvrliauxuufnmg5eajr59bxa</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>17-Dimethylaminoethylamino-17-demethoxygeldanamycin</title>
    <ns>0</ns>
    <id>17720606</id>
    <revision>
      <id>545340864</id>
      <parentid>510227059</parentid>
      <timestamp>2013-03-19T03:15:58Z</timestamp>
      <contributor>
        <username>Addbot</username>
        <id>6569922</id>
      </contributor>
      <minor/>
      <comment>[[User:Addbot|Bot:]] Migrating 1 interwiki links, now provided by [[Wikipedia:Wikidata|Wikidata]] on [[d:q4552287]]</comment>
      <text xml:space="preserve" bytes="3463">{{chembox
| Verifiedfields = changed
| verifiedrevid = 477209110
|ImageFile=17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.png
|ImageSize=200px
|IUPACName=[(3''R'',5''S'',6''R'',7''S'',8''E'',10''S'',11''S'',12''Z'',14''E'')-21-(2-dimethylaminoethylamino)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate
|  IUPACName_hidden = yes
|OtherNames=17-DMAG; Alvespimycin
|Section1={{Chembox Identifiers
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 16744073
| InChI = 1/C32H48N4O8/c1-18-14-22-27(34-12-13-36(5)6)24(37)17-23(29(22)39)35-31(40)19(2)10-9-11-25(42-7)30(44-32(33)41)21(4)16-20(3)28(38)26(15-18)43-8/h9-11,16-18,20,25-26,28,30,34,38H,12-15H2,1-8H3,(H2,33,41)(H,35,40)/b11-9-,19-10+,21-16+/t18-,20+,25+,26+,28-,30+/m1/s1
| SMILES1 = C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\C=C(\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCCN(C)C)/C)OC)OC(=O)N)\C)C)O)OC
| SMILES = C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\C=C(\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCCN(C)C)/C)OC)OC(=O)N)\C)C)O)OC
| InChIKey = KUFRQPKVAWMTJO-LMZWQJSEBL
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C32H48N4O8/c1-18-14-22-27(34-12-13-36(5)6)24(37)17-23(29(22)39)35-31(40)19(2)10-9-11-25(42-7)30(44-32(33)41)21(4)16-20(3)28(38)26(15-18)43-8/h9-11,16-18,20,25-26,28,30,34,38H,12-15H2,1-8H3,(H2,33,41)(H,35,40)/b11-9-,19-10+,21-16+/t18-,20+,25+,26+,28-,30+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KUFRQPKVAWMTJO-LMZWQJSESA-N
| CASNo_Ref = {{cascite|changed|??}}
| CASNo=467214-20-6
|  ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 383824
| PubChem=5288674
}}
|Section2={{Chembox Properties
|  C=32|H=48|N=4|O=8
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3={{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}

'''17-Dimethylaminoethylamino-17-demethoxygeldanamycin''' (17-DMAG) is a chemical compound which is a [[semi-synthetic]] derivative of the antibiotic [[geldanamycin]].&lt;ref&gt;{{Ref patent
 | country = WO
 | number = 2002079167
 | status = application
 | title = Preparation of geldanamycin derivatives for the treatment of cancer
 | pubdate = 2002
 | gdate = 
 | fdate = 
 | pridate = 
 | inventor =Snader, Kenneth M.; Vishnuvajjala, B. Rao; Hollingshead, Melinda G.; Sausville, Edward A.
 | invent1 = 
 | invent2 = 
 | assign1 = 
 | assign2 = 
 | class = 
}}&lt;/ref&gt;&lt;ref&gt;{{cite journal | doi = 10.1016/j.bmcl.2005.08.013 | author = Rastelli, Giulio; Tian, Zong-Qiang; Wang, Zhan; Myles, David; Liu, Yaoquan | title = Structure-based design of 7-carbamate analogs of geldanamycin | journal = Bioorganic &amp; Medicinal Chemistry Letters | year = 2005 | volume = 15 | issue = 22 | pages = 5016–5021}}&lt;/ref&gt;  It is being studied for the possibility of treating cancer.&lt;ref&gt;{{cite journal | doi = 10.2174/1568009033481831 | author = Sausville, E. A.; Tomaszewski, J. E.; Ivy, P. | title = Clinical development of 17-allylamino, 17-demethoxygeldanamycin | journal = Curr. Cancer Drug Targets | year = 2003 | volume = 3 | issue = 5 | pages = 377–83 | pmid = 14529389}}&lt;/ref&gt;

==References==
{{reflist}}

{{DEFAULTSORT:Dimethylaminoethylamino-17-demethoxygeldanamycin, 17-}}
[[Category:Antibiotics]]
[[Category:Macrocycles]]
[[Category:Quinones]]
[[Category:Carbamates]]
[[Category:Lactams]]
[[Category:Ethers]]
[[Category:Alcohols]]


{{antibiotic-stub}}</text>
      <sha1>o79h6hpfal01pe51mc3bfbowq1b4boj</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Antibiotic tolerance</title>
    <ns>0</ns>
    <id>26339102</id>
    <redirect title="Multidrug tolerance" />
    <revision>
      <id>349513568</id>
      <parentid>346352236</parentid>
      <timestamp>2010-03-12T23:30:43Z</timestamp>
      <contributor>
        <username>Ckocks71</username>
        <id>11544428</id>
      </contributor>
      <minor/>
      <comment>added Category</comment>
      <text xml:space="preserve" bytes="59">#REDIRECT [[Multidrug tolerance]]

[[Category:Antibiotics]]</text>
      <sha1>t10ifi3zyynaa44rmheuh2aelc9cmau</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Animal Drug Availability Act 1996</title>
    <ns>0</ns>
    <id>26628694</id>
    <revision>
      <id>590913472</id>
      <parentid>513593867</parentid>
      <timestamp>2014-01-16T02:49:03Z</timestamp>
      <contributor>
        <username>Jphill19</username>
        <id>14405583</id>
      </contributor>
      <comment>infobox addition</comment>
      <text xml:space="preserve" bytes="9553">{{Infobox U.S. legislation
| shorttitle        = Animal Drug Availability Act 1996
| othershorttitles  =
| longtitle         = An Act to amend the Federal Food, Drug, and Cosmetic Act to provide for improvements in the process of approving and using animal drugs, and for other purposes. 
| colloquialacronym = ADAA
| nickname          = Animal Drug Availability Act of 1995
| enacted by        = 104th
| effective date    = October 9, 1996
| public law url    = http://www.gpo.gov/fdsys/pkg/STATUTE-110/pdf/STATUTE-110-Pg3151.pdf
| cite public law   = 104-250
| cite statutes at large = {{usstat|110|3151}}
| acts amended    = [[Federal Food, Drug, and Cosmetic Act]]
| acts repealed   = 
| title amended   = [[Title 21 of the United States Code|21 U.S.C.: Food and Drugs]]
| sections created = &lt;!--{{USC}} can be used--&gt;
| sections amended = {{unbulleted list|{{Usc-title-chap|21|9}} § 301 et seq.|{{Usc-title-chap|21|9}} § 321 et seq.|{{Usc-title-chap|21|9}} § 354|{{Usc-title-chap|21|9}} § 360b et seq.}}
| leghisturl      = http://thomas.loc.gov/cgi-bin/bdquery/z?d104:HR02508:@@@R
| introducedin    = House
| introducedbill  = {{USBill|104|H.R.|2508}}
| introducedby    = [[Wayne Allard]] ([[Republican Party (United States)|R]]–[[Colorado|CO]])
| introduceddate  = October 19, 1995
| committees      = [[United States House Committee on Energy and Commerce|House Commerce]]
| passedbody1     = House
| passeddate1     = September 24, 1996
| passedvote1     = agreed voice vote
| passedbody2     = Senate
| passedas2       = &lt;!-- used if the second body changes the name of the legislation --&gt;
| passeddate2     = September 25, 1996
| passedvote2     = passed unanimous consent
| conferencedate  = 
| passedbody3     = 
| passeddate3     = 
| passedvote3     = 
| agreedbody3     = &lt;!-- used when the other body agrees without going into committee --&gt;
| agreeddate3     = &lt;!-- used when the other body agrees without going into committee --&gt;
| agreedvote3     = &lt;!-- used when the other body agrees without going into committee --&gt;
| agreedbody4     = &lt;!-- used if agreedbody3 further amends legislation --&gt;
| agreeddate4     = &lt;!-- used if agreedbody3 further amends legislation --&gt;
| agreedvote4     = &lt;!-- used if agreedbody3 further amends legislation --&gt;
| passedbody4     = 
| passeddate4     = 
| passedvote4     = 
| signedpresident = [[Bill Clinton|William J. Clinton]]
| signeddate      = October 9, 1996
| unsignedpresident = &lt;!-- used when passed without presidential signing --&gt;
| unsigneddate    = &lt;!-- used when passed without presidential signing --&gt;
| vetoedpresident = &lt;!-- used when passed by overriding presidential veto --&gt;
| vetoeddate      = &lt;!-- used when passed by overriding presidential veto --&gt;
| overriddenbody1 = &lt;!-- used when passed by overriding presidential veto --&gt;
| overriddendate1 = &lt;!-- used when passed by overriding presidential veto --&gt;
| overriddenvote1 = &lt;!-- used when passed by overriding presidential veto --&gt;
| overriddenbody2 = &lt;!-- used when passed by overriding presidential veto --&gt;
| overriddendate2 = &lt;!-- used when passed by overriding presidential veto --&gt;
| overriddenvote2 = &lt;!-- used when passed by overriding presidential veto --&gt;
| amendments      = 
| SCOTUS cases    = 
}}
The '''Animal Drug Availability Act 1996''' (ADAA) is a [[United States federal law]]. [[Bill Clinton|President Clinton]] signed the ADAA into law in October 1996. While still obligated to [[public health]] concerns, the act intends more rapid [[drug]] and medicated feed approval to assist the [[animal health]] industry.&lt;ref&gt;1  Board of Agriculture, The Use of Drugs in Food Animals: Benefits and Risks. The National Academies Press. 1999. February 2010. Page 99. &lt;http://www.nap.edu/openbook.php?record_id=5137&amp;page=99&gt;&lt;/ref&gt;

==Overview==
The Animal Drug Availability Act specifies the conditions in which the U.S. Secretary of Health can refuse the application of a new drug. The possibility of an unconsidered hazard is not a permitted ground for refusing an application.

The implications of the act include:
* more relaxed controls on [[Field study|field studies]] unless requested and justified by the [[Center for Veterinary Medicine]];
* a strict demand for proof of efficacy;
* a definition of adequate and well controlled procedures for [[field trial]]s;
* supporting labeling focused on the range of recommended or acceptable [[Dosing|dosages]];
* creating veterinary feed directive drugs as a new category of [[animal drugs]].&lt;ref&gt;Board of Agriculture, The Use of Drugs in Food Animals: Benefits and Risks. The National Academies Press. 1999. February 2010. Page 99. &lt;http://www.nap.edu/openbook.php?record_id=5137&amp;page=99&gt;&lt;/ref&gt;

==Details==
=== Antibiotics in agriculture before ADAA statute ===

[[Antibiotic]] use was once common practice before the ADAA approved the use of [[antibacterial]]s in animal feed. For 1985 the estimated annual antibiotic use in the [[United States|U.S.]] are as follows. [[Cow]]s were given 1 million pounds of antibiotics, .55 million pounds for [[swine]], and .67 million pounds for [[poultry]] as therapeutic use, constituting legitimate [[bacterial infection]] treatment.&lt;ref&gt;2  Prescott, John F., “Antibiotics: Miracle Drugs or Pig Food.” Canadian Veterinary Journal. December1997. Pages 263-266. February 2010. &lt;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1576781/?page=1&gt;&lt;/ref&gt; Quantities for subtherapeutic use specified as; increase the daily [[body weight]] gain, improve the food-to-[[weight gain]] ratio, and increase the voluntary intake of food equals 3.1 million pounds in cows, feeding swine with 11 million pounds, and poultry with 2 million pounds.&lt;ref&gt;2  Prescott, John F., “Antibiotics: Miracle Drugs or Pig Food.” Canadian Veterinary Journal. December1997. Pages 263-266. February 2010. &lt;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1576781/?page=1&gt;&lt;/ref&gt; For each of these [[livestock]] species the subtherapeutic use is substantially higher: this contributes unnecessarily to possible microbial resistance.  Those quantities preceded the ADAA, so approving veterinary feed including antibiotics for market contributed to progressing livestock medication. In 2003 the over 24 million pounds of antibiotics used for subtherapeutic use were distributed as follows: 10.3 million pounds for swine, 10.5 million pounds fed to poultry, and 3.7 million pounds given to cows.&lt;ref&gt;3  State Environmental Resource Center. “Antibiotics In Agriculture: Policy Issues Package.” June 27, 2003. February 2010. &lt;http://www.serconline.org/antibiotics/fact.html&gt;&lt;/ref&gt; 

=== Antibiotic resistant bacteria ===
The Union of Concerned Scientists estimate healthy [[Domestic pig|hog]]s receive 5 million pounds of two [[tetracycline antibiotics]], this is 60% greater than the total volume of antibiotics given to sick humans.&lt;ref&gt;3 State Environmental Resource Center. “Antibiotics In Agriculture: Policy Issues Package.” June 27, 2003. February 2010. &lt;http://www.serconline.org/antibiotics/fact.html&gt;&lt;/ref&gt; Medical doctors advise appropriate use of antibiotics, specifically finishing the full antibiotic regimen with consequence of the strongest survivors recuperating and worsening the [[infection.]] Antibiotics create an environment appropriate for bacteria to evolve [[Antibiotic resistance|resistant]] strains, since when faced with death any survivors have become more appropriately adapted. This is the same principle as [[Darwinian evolution|Darwinian evolution by natural selection]]. The development of resistant [[bacteria strain]]s can be attributed to antibiotic use because resistance to the drugs was previously unobserved. The [[World Health Organization]] states: “Shortly after the licensing and use in livestock of [[fluoroquinolone]], a powerful new class of [[antimicrobial]]s, fluoroquinolone-resistant [[Salmonella]] and [[Campylobacter]] isolations from animals, and humans increased.”.&lt;ref&gt;4  World Health Organization. “Use of antimicrobials outside human medicine and resultant antimicrobial resistance in humans.” Fact Sheet No. 268. January 2002. February 2010. &lt;http://www.who.int/mediacentre/factsheets/fs268/en/&gt;&lt;/ref&gt; Most production for [[fast food]] incorporates antibiotics, but there has been a push by major companies including [[McDonald's]], [[Subway restaurant|Subway]] and [[Carl's Jr.]] to discontinues fluoroquinolone use in associated feedlots.&lt;ref&gt;3  State Environmental Resource Center. “Antibiotics In Agriculture: Policy Issues Package.” June 27, 2003. February 2010. &lt;http://www.serconline.org/antibiotics/fact.html&gt;&lt;/ref&gt; 

=== Vancomycin-resistant enterococcus infection ===

[[Vancomycin-resistant enterococcus|VRE]] infection has been positively correlated to [[avoparcin]] use; around the time of Americas ADAA in 1996 [[Denmark]] banned this specific growth promoter and found the flocks at [[Animal slaughter|slaughter]] had a decreased occurrence of VRE to 12% in 1998 from 82% in 1995.&lt;ref&gt;5 Wegener, Henrik C., et all, Danish Veterinary Laboratory. “Use of Antimicrobial Growth Promoters in Food Animals and Enterococcus faecium Resistance to Therapeutic Antimicrobial Drugs in Europe.” Emerging Infectious Diseases Vol. 5 No. 3 May–June. 1999. Center for Disease Control. February 2010. &lt;http://www.cdc.gov/ncidod/EID/vol5no3/wegener.htm&gt;&lt;/ref&gt;

==References==
&lt;references/&gt;

[[Category:Veterinary medicine]]
[[Category:Antibiotics]]
[[Category:United States federal health legislation]]
[[Category:1996 in law]]
[[Category:1996 in the United States]]</text>
      <sha1>jd4gvyth9lce6kurqce6fz1k2x2qxpl</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Solasulfone</title>
    <ns>0</ns>
    <id>25340335</id>
    <revision>
      <id>545803496</id>
      <parentid>482846458</parentid>
      <timestamp>2013-03-20T22:54:32Z</timestamp>
      <contributor>
        <username>Addbot</username>
        <id>6569922</id>
      </contributor>
      <minor/>
      <comment>[[User:Addbot|Bot:]] Migrating 1 interwiki links, now provided by [[Wikipedia:Wikidata|Wikidata]] on [[d:q7557110]]</comment>
      <text xml:space="preserve" bytes="1369">{{chembox
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = H12JE4313S
| ImageFile = Solasulfone.svg
| ImageSize = 200px
| IUPACName = Tetrasodium 3,3'-[sulfonylbis(benzene-4,1-diylimino)]bis(1-phenylpropane-1,3-disulfonate)
| OtherNames = Solapsone; Sulfetrone
| Section1 = {{Chembox Identifiers
|  CASNo = 133-65-3
|  PubChem = 8626
|  ChemSpiderID = 8305
|  SMILES = [Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)C(c1ccccc1)CC(Nc2ccc(cc2)S(=O)(=O)c4ccc(NC(S([O-])(=O)=O)CC(c3ccccc3)S([O-])(=O)=O)cc4)S([O-])(=O)=O
|  InChI = InChI=1S/C30H32N2O14S5.4Na/c33-47(34,25-15-11-23(12-16-25)31-29(50(41,42)43)19-27(48(35,36)37)21-7-3-1-4-8-21)26-17-13-24(14-18-26)32-30(51(44,45)46)20-28(49(38,39)40)22-9-5-2-6-10-22;;;;/h1-18,27-32H,19-20H2,(H,35,36,37)(H,38,39,40)(H,41,42,43)(H,44,45,46);;;;/q;4*+1/p-4
  }}
| Section2 = {{Chembox Properties
|  C=30|H=28|N=2|Na=4|O=14|S=5
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility =
  }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition =
  }}
}}

'''Solasulfone''' is an [[Antileprotic drugs|antileprotic drug]].&lt;ref&gt;''Chemistry for Pharmacy and the Life Sciences'' (1996, Pearson Education Limited) Thomas, Gareth; ppg. 349-350&lt;/ref&gt;
{{-}}

== References ==
{{reflist}}

{{Antibiotic-stub}}

[[Category:Leprosy]]
[[Category:Antibiotics]]
[[Category:Sulfones]]
[[Category:Sulfonates]]</text>
      <sha1>rwjr0em5ta001v5geqglpmjxg9hqqiv</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Nifurquinazol</title>
    <ns>0</ns>
    <id>26914830</id>
    <revision>
      <id>594865103</id>
      <parentid>456578547</parentid>
      <timestamp>2014-02-10T19:02:07Z</timestamp>
      <contributor>
        <username>Vaccinationist</username>
        <id>18163480</id>
      </contributor>
      <minor/>
      <text xml:space="preserve" bytes="1384">{{Drugbox
| IUPAC_name = 2,2'-{[2-(5-nitrofuran-2-yl)quinazolin-4-yl]imino}diethanol
| image = Nifurquinazol.svg

&lt;!--Clinical data--&gt;
| tradename =  
| pregnancy_category =  
| legal_status = Uncontrolled
| routes_of_administration = ?

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

&lt;!--Identifiers--&gt;
| CAS_number = 5055-20-9
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 21139
| ChemSpiderID = 19878
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 44E5RRL600
| KEGG = D05164

&lt;!--Chemical data--&gt;
| C=16 | H=16 | N=4 | O=5 
| molecular_weight = 344.32 g/mol
| smiles = O=[N+]([O-])c3oc(c1nc(N(CCO)CCO)c2c(n1)cccc2)cc3
}}

'''Nifurquinazol''' ('''NF-1088''') is an [[antibacterial]] [[drug|agent]] of the [[nitrofuran]] class.&lt;ref name=&quot;isbn0-412-54090-8&quot;&gt;{{cite book | author = | title = Dictionary of organic compounds | publisher = Chapman &amp; Hall | location = London | year = 1996 | pages = | isbn = 0-412-54090-8 | oclc = | doi = | url = http://books.google.com/?id=5S_uhYzKWisC&amp;lpg=PA4739&amp;dq=Nifurquinazol&amp;pg=PA4739#v=onepage&amp;q}}&lt;/ref&gt; It was never marketed.&lt;ref name=&quot;isbn0-412-54090-8&quot; /&gt;

== References ==
{{Reflist}}


{{Nucleic acid inhibitors}}
{{Chromalveolate antiparasitics}}

[[Category:Antibiotics]]
[[Category:Quinazolines]]
[[Category:Diols]]
[[Category:Nitrofurans]]


{{antiinfective-drug-stub}}</text>
      <sha1>fxb86y6cuc8f8wgsnq8nl8vai6akrtb</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>SmeT</title>
    <ns>0</ns>
    <id>25583871</id>
    <revision>
      <id>593063937</id>
      <parentid>416802668</parentid>
      <timestamp>2014-01-30T04:07:34Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="1520">'''SmeT''' is a transcriptional repressor protein of 24.6 kDa found in the pathogen bacteria ''[[Stenotrophomonas maltophilia]]''. It is responsible for the regulation of the Multidrug Resistance system (MDR) SmeDEF and can increase or decrease the resistance of the bacteria to several antibiotics such as [[tetracycline]], [[chloramphenicol]], [[quinolones]] or [[erythromycin]] through binding to a specific region of the bacterial chromosome. Structurally SmeT forms 9 helices:α1, α2 and α3  are responsible for the DNA binding, α4, α5, α6 and α7 form the effector binding pocket and α8  and α9 allow the dimerization of the protein.&lt;ref name=&quot;Hernandez &quot;&gt;{{cite journal |author=Hernández A, Maté MJ, Sánchez-Díaz PC, Romero A, Rojo F, Martínez JL |title=Structural and functional analysis of SmeT, the repressor of the Stenotrophomonas maltophilia multidrug efflux pump SmeDEF |journal=J. Biol. Chem. |volume=284 |issue=21 |pages=14428–38 |date=May 2009 |pmid=19324881 |pmc=2682891 |doi=10.1074/jbc.M809221200 |url=http://www.jbc.org/cgi/pmidlookup?view=long&amp;pmid=19324881}}&lt;/ref&gt; SmeT is a member of the [[TetR]] family of Tetracycline repressors and its mechanism of repression is based in the binding of two dimmers to its cognate DNA. 


== References ==
&lt;!--- See [[Wikipedia:Footnotes]] on how to create references using &lt;ref&gt;&lt;/ref&gt; tags which will then appear here automatically --&gt;
{{Reflist}}

== External links ==

{{medicine-stub}}
[[Category:Bacterial proteins]]
[[Category:Antibiotics]]</text>
      <sha1>qut1jf1ck6izbbrgj1mn6srf26txjzk</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>AGG01</title>
    <ns>0</ns>
    <id>4909494</id>
    <revision>
      <id>539783648</id>
      <parentid>539546473</parentid>
      <timestamp>2013-02-22T23:35:04Z</timestamp>
      <contributor>
        <username>Dcirovic</username>
        <id>11795905</id>
      </contributor>
      <text xml:space="preserve" bytes="2403">'''AGG01''' is the tentative name of a new [[peptide]] antibiotic discovered in the breast milk of the [[Tammar wallaby]],&lt;ref&gt;{{cite web | title = Fighting superbugs with milk | url = http://www.newscientist.com/article/mg19025484.300-fighting-superbugs-with-milk.html | work = [http://NewScientist.com NewScientist.com] | date = 2006-04-20 | accessdate = 2006-09-07| archiveurl= http://web.archive.org/web/20060908023007/http://www.newscientist.com/article/mg19025484.300-fighting-superbugs-with-milk.html| archivedate= 8 September 2006 &lt;!--DASHBot--&gt;| deadurl= no}}&lt;/ref&gt;  reportedly one hundred times more powerful than [[penicillin]].&lt;ref name=&quot;times&quot;&gt;{{cite news | date=2006-05-21|title = Wallaby milk gives scientists the jump on deadly superbug | url=http://www.timesonline.co.uk/article/0,,2087-2190319,00.html |publisher = Sunday Times (Britain) | location=London}}&lt;/ref&gt;

This compound was found to be effective against [[Methicillin-resistant Staphylococcus aureus|MRSA]], ''[[E. coli]]'', ''[[Streptococci]]'', ''[[Salmonella]]'', ''[[Bacillus subtilis]]'', ''[[Pseudomonas]]'' spp., ''[[Proteus vulgaris]]'', and ''[[Staphylococcus aureus]]''.

AGG01 is a [[cationic]] [[peptide]], which is a polycationic [[protein]] that is rich in positive residues of the [[amino acids]] [[arginine]] and [[lysine]], and which folds into an [[amphipathic]] structure (one which has both [[hydrophobic]] and [[hydrophilic]] areas). These features mean that it can interact with the [[anionic]] [[lipids]] in the bacterial membrane, such as phosphatidylglycerol. It inserts itself into the membrane, by competing with cross-linking proteins between each membrane layer, and then sets up trans-membrane protein channels which induce ion transport out of the cell. This causes huge leakage via osmosis through these 'pores’ and the general consensus is that the loss of these essential molecules is the mechanism by which bacteria are killed. The bacterial membrane has a different structure from the mammalian plasma membrane, so the protein can only kill pathogenic cells and not human ones.

As of 2007, the compound is undergoing pre-clinical trials.&lt;ref&gt;{{cite news | date=2007-05-09|title = Anti-superbug weapon developed from wallaby milk | url=http://www.cosmosmagazine.com/node/1290 |publisher = COSMOS Magazine}}&lt;/ref&gt;

==References==
{{Reflist}}

[[Category:Antibiotics]]


{{Antibiotic-stub}}</text>
      <sha1>h5fndjiyh8nctzo80v2zhksake4uso1</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>GSK 299423</title>
    <ns>0</ns>
    <id>28367329</id>
    <revision>
      <id>443831253</id>
      <parentid>443830157</parentid>
      <timestamp>2011-08-09T07:53:51Z</timestamp>
      <contributor>
        <username>CheMoBot</username>
        <id>7377957</id>
      </contributor>
      <comment>Updating {{chembox}} (no changed fields - added verified revid - updated 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[Wikipedia:WikiProject Chemicals/Chembox validation|Chem/Drugbox validati</comment>
      <text xml:space="preserve" bytes="2604">{{Chembox
| verifiedrevid = 443830157
| ImageFile = GSK 299423.png
| ImageFile2 = GSK299423 3D 2XCS.png
|  ImageSize = 200px
|  ImageAlt = 
| IUPACName = 4-(2-(4-(([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino)piperidin-1-yl)ethyl)-6-methoxyquinoline-3-carbonitrile
| IUPACName_hidden = yes
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 24751852
|  StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NKXJSCXEAVZSMF-UHFFFAOYSA-N
| SMILES = COc1ccc2c(c1)c(c(cn2)C#N)CCN3CCC(CC3)NCc4cc5c(cn4)OCS5
|  StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C25H27N5O2S/c1-31-20-2-3-23-22(11-20)21(17(12-26)13-29-23)6-9-30-7-4-18(5-8-30)27-14-19-10-25-24(15-28-19)32-16-33-25/h2-3,10-11,13,15,18,27H,4-9,14,16H2,1H3
}}
| Section2 = {{Chembox Properties
|  C=25|H=27|N=5|O=2|S=1
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}
[[File:GSK 299423 with Staphylococcus aureus DNA gyrase PDB 2XCS.png|thumb|3D protein map of GSK 299423 (yellow) in complex with ''[[Staphylococcus aureus]]'' [[DNA gyrase]] (teal) and a DNA fragment (orange). From {{PDB|2xcs}}.]]
'''GSK 299423''' or '''GlaxoSmithKline 299423''' is an [[antibiotic]] chemical compound that has been identified as potentially effective in treating patients infected with bacteria expressing the [[New Delhi metallo-beta-lactamase]]. The antibiotic inhibits the enzyme [[topoisomerase]], which bacteria need to replicate.&lt;ref&gt;Sten Stovall, &quot;[http://online.wsj.com/article/BT-CO-20100804-713606.html Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria],&quot; [[The Wall Street Journal]], August 4, 2010&lt;/ref&gt;&lt;ref&gt;Melly Alazraki, &quot;[http://www.dailyfinance.com/story/glaxosmithkline-finds-compound-fight-superbugs/19582888/ GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs']&quot; Daily Finance, August 6, 2010&lt;/ref&gt;&lt;ref name=Bax2010&gt;{{cite journal |journal=Nature |title=Type IIA topoisomerase inhibition by a new class of antibacterial agents |author=Bax BD ''et al.'' |volume=466 |pages=935–40 |doi=10.1038/nature09197 |date=4 August 2010 |pmid=20686482 |issue=7309}} (primary source)&lt;/ref&gt;

No animal studies have been reported. No application has been made for human clinical trials.

==References==
{{reflist}}

{{Bacteria}}

[[Category:Antibiotics]]
[[Category:Quinolines]]
[[Category:Piperidines]]
[[Category:Nitriles]]
[[Category:Phenol ethers]]


{{antibiotic-stub}}</text>
      <sha1>qv66s9dk1wicqbgpy5rut2l2qe0vitd</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Cell envelope antibiotic</title>
    <ns>0</ns>
    <id>23423630</id>
    <revision>
      <id>423294477</id>
      <parentid>386720660</parentid>
      <timestamp>2011-04-10T07:01:37Z</timestamp>
      <contributor>
        <username>MerlIwBot</username>
        <id>14161758</id>
      </contributor>
      <minor/>
      <comment>robot Removing: [[zh:胞外被膜抗生素]]</comment>
      <text xml:space="preserve" bytes="494">A '''cell envelope antibiotic''' is an antibacterial that acts primarily at the level of the [[cell envelope]].

Examples include [[cycloserine]], [[penicillin]], and [[polymyxin B]].&lt;ref name=&quot;urlAntibiotics that affect the cell envelope&quot;&gt;{{cite web |url=http://pathmicro.med.sc.edu/fox/antibiotics1.htm |title=Antibiotics that affect the cell envelope |work= |accessdate=}}&lt;/ref&gt;

==References==
{{reflist}}

{{Cell wall disruptive antibiotics}}

[[Category:Antibiotics]]

{{antibiotic-stub}}</text>
      <sha1>097uqsln5aypqcmq33g82ka257hbo9d</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Hachimycin</title>
    <ns>0</ns>
    <id>14622190</id>
    <revision>
      <id>586853518</id>
      <parentid>586850423</parentid>
      <timestamp>2013-12-19T22:17:13Z</timestamp>
      <contributor>
        <username>AnomieBOT</username>
        <id>7611264</id>
      </contributor>
      <minor/>
      <comment>Dating maintenance tags: {{Unref}}</comment>
      <text xml:space="preserve" bytes="3188">{{unref|date=December 2013}}
{{Drugbox
| verifiedrevid = 448018348
| IUPAC_name = A: (19''E'',21''E'',23''E'',25''E'',27''E'',29''E'',31''E'')-33-{[(2''R'',3''S'',4''S'',5''S'',6''R'')-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-17-[7-(4-aminophenyl)-5-hydroxy-7-oxoheptan-2-yl]-1,3,5,9,11,37-hexahydroxy-18-methyl-13,15-dioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid&lt;br /&gt;B: (19''E'',21''E'',23''E'',25''E'',27''E'',29''E'',31''E'')-33-{[(2''R'',3''S'',4''S'',5''S'',6''R'')-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-17-[7-(4-aminophenyl)-5-hydroxy-7-oxoheptan-2-yl]-1,5,7,9,11,37-hexahydroxy-18-methyl-13,15-dioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid
| image = Hachimycin.svg
| width = 300

&lt;!--Clinical data--&gt;
| tradename =  
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category =  
| legal_AU = &lt;!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --&gt;
| legal_CA = &lt;!--             / Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL         / P       / POM / CD / Class A, B, C --&gt;
| legal_US = &lt;!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V --&gt;
| legal_status =  
| routes_of_administration =

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number =  
| ATC_prefix = D01
| ATC_suffix = AA03
| ATC_supplemental =  {{ATC|G01|AA06}} {{ATC|J02|AA02}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10153168
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/2C58H84N2O18/c1-35-17-14-12-10-8-6-4-5-7-9-11-13-15-20-46(76-57-54(71)52(60)53(70)37(3)75-57)32-49-51(56(72)73)48(68)34-58(74,78-49)33-45(66)29-44(65)28-43(64)27-40(61)18-16-19-41(62)31-50(69)77-55(35)36(2)21-26-42(63)30-47(67)38-22-24-39(59)25-23-38;1-35-17-14-12-10-8-6-4-5-7-9-11-13-15-20-46(76-57-54(71)52(60)53(70)37(3)75-57)32-49-51(56(72)73)48(68)34-58(74,78-49)33-45(66)28-41(62)19-16-18-40(61)27-43(64)29-44(65)31-50(69)77-55(35)36(2)21-26-42(63)30-47(67)38-22-24-39(59)25-23-38/h4-15,17,20,22-25,35-37,40,42-46,48-49,51-55,57,61,63-66,68,70-71,74H,16,18-19,21,26-34,59-60H2,1-3H3,(H,72,73);4-15,17,20,22-25,35-37,40-43,45-46,48-49,51-55,57,61-64,66,68,70-71,74H,16,18-19,21,26-34,59-60H2,1-3H3,(H,72,73)/b5-4-,8-6-,9-7-,12-10-,13-11-,17-14-,20-15-;5-4+,8-6+,9-7+,12-10+,13-11+,17-14-,20-15+/t35?,36?,37-,40?,42?,43?,44?,45?,46?,48?,49?,51?,52+,53-,54+,55?,57+,58?;35?,36?,37-,40?,41?,42?,43?,45?,46?,48?,49?,51?,52+,53-,54+,55?,57+,58?/m11/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RZWQQZWPVPHLSY-UGMBPVHXSA-N
| PubChem = 11979956
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =

&lt;!--Chemical data--&gt;
| C=58 | H=84 | N=2 | O=18 
| molecular_weight = 1097.2902 g/mol
}}
'''Hachimycin''' is a [[polyene]] [[antibiotic]].

== References ==
{{reflist}}

{{Gynecological anti-infectives and antiseptics}}

[[Category:Antibiotics]]


{{antibiotic-stub}}</text>
      <sha1>48tpw4t0qvbtrqssqf8ohqi3n1guukv</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Persister cell</title>
    <ns>0</ns>
    <id>28821584</id>
    <redirect title="Multidrug tolerance" />
    <revision>
      <id>384793112</id>
      <timestamp>2010-09-14T14:28:35Z</timestamp>
      <contributor>
        <username>Lavarith</username>
        <id>7864336</id>
      </contributor>
      <comment>[[WP:AES|←]]Redirected page to [[Multidrug tolerance]]</comment>
      <text xml:space="preserve" bytes="59">#REDIRECT [[Multidrug tolerance]]

[[Category:Antibiotics]]</text>
      <sha1>t10ifi3zyynaa44rmheuh2aelc9cmau</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Lipoglycopeptide</title>
    <ns>0</ns>
    <id>26217449</id>
    <revision>
      <id>600830351</id>
      <parentid>587718315</parentid>
      <timestamp>2014-03-23T04:24:17Z</timestamp>
      <contributor>
        <username>Citation bot</username>
        <id>7903804</id>
      </contributor>
      <minor/>
      <comment>[Cat543-dev]Add: display-authors, author pars. 10-10. You can [[WP:UCB|use this bot]] yourself. [[WP:DBUG|Report bugs here]].</comment>
      <text xml:space="preserve" bytes="3355">'''Lipoglycopeptide'''s are a class of [[antibiotic]] that have [[lipophilic]] side-chains linked to [[glycopeptide]]s. The class includes [[oritavancin]], [[telavancin]] and [[dalbavancin]].&lt;ref&gt;{{Cite journal| doi = 10.1021/cr030103a| title = Glycopeptide and Lipoglycopeptide Antibiotics| pmid = 15700951| year = 2005| last1 = Kahne| first1 = Dan| last2 = Leimkuhler| first2 = Catherine| last3 = Lu| first3 = Wei| last4 = Walsh| first4 = Christopher| journal = Chemical Reviews| volume = 105| issue = 2| pages = 425–448| postscript = &lt;!--None--&gt;}}&lt;/ref&gt;
&lt;ref name=Brunk2011&gt;{{cite news |url=http://www.internalmedicinenews.com/news/infectious-diseases/single-article/fight-against-antimicrobial-resistance-recruiting-new-agents/e79fc1950e.html |title=Fight Against Antimicrobial Resistance Recruiting New Agents  |date=1 Feb 2011 }}&lt;/ref&gt;

Telavancin is the only one that has FDA approval.

Telavancin is the most potent of the 3 against ''[[Clostridium]] spp.''&lt;ref name=dot&gt;{{cite journal|pmid=20426497 |title=New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin |date=2010-05-07 |doi= 10.2165/11534440-000000000-00000|last1=Zhanel|first1=George G.|last2=Calic|first2=Divna|last3=Schweizer|first3=Frank|last4=Zelenitsky|first4=Sheryl|last5=Adam|first5=Heather|last6=Lagacé-Wiens|first6=Philippe R.S.|last7=Rubinstein|first7=Ethan|last8=Gin|first8=Alfred S.|last9=Hoban|first9=Daryl J.|last10=Karlowsky |first10=James A. |journal=Drugs|volume=70|issue=7|pages=859–886 |display-authors=8 }}&lt;/ref&gt;

==Approvals and clinical trials==
[[Telavancin]] (once daily injection)&lt;ref name=VB2006&gt;{{cite journal |author=Van Bambeke F. |title=Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy, |journal=Curr Opin Investig Drugs. |date=August 2006 |volume=7 |issue=8 |pages=740–9 |pmid=16955686}}&lt;/ref&gt; has completed 4 phase III trials.&lt;ref&gt;http://clinicaltrials.gov/ct2/results?term=telavancin&amp;phase=2&lt;/ref&gt; and gained [[Food and Drug Administration|US FDA]] approval in September 2009 for [[complicated skin and skin structure infection]]s (cSSSI).&lt;ref&gt;{{cite press release
  | title = Theravance and Astellas Announce FDA Approval of Vibativ (telavancin) for the Treatment of Complicated Skin and Skin Structure Infections
  | publisher = Theravance, Inc. and Astellas Pharma US, Inc.
  | date = 2009-09-11
  | url = http://www.drugs.com/newdrugs/theravance-astellas-announce-fda-approval-vibativ-telavancin-complicated-skin-skin-structure-1629.html
  | accessdate = September 16, 2009
}}&lt;/ref&gt;

[[Oritavancin]] (once daily injection)&lt;ref name=VB2006/&gt; has completed a phase II trial.
&lt;ref&gt;http://clinicaltrials.gov/ct2/show/NCT00514527&lt;/ref&gt; {{As of|September 2010}} it doesn't have US or European approval for marketing for clinical use. (In December 2008 the FDA declined to approve it, and an EU application was withdrawn.)

[[Dalbavancin]] (once-weekly injection)&lt;ref name=VB2006/&gt; was undergoing a phase II trial, due to end in 2003.&lt;ref&gt;http://clinicaltrials.gov/ct2/show/NCT00057369&lt;/ref&gt; {{As of|September 2010}} it doesn't have US or European approval for marketing for clinical use.

==See also==
* [[Telavancin#Mechanism of action]]

==References==
{{Reflist}}

[[Category:Antibiotics]]


{{Pharma-stub}}</text>
      <sha1>28zkhw8y41j7nqfhtvg03vm7zqq3ur5</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Streptogramin</title>
    <ns>0</ns>
    <id>12384574</id>
    <revision>
      <id>544875599</id>
      <parentid>530340668</parentid>
      <timestamp>2013-03-17T07:36:49Z</timestamp>
      <contributor>
        <username>Addbot</username>
        <id>6569922</id>
      </contributor>
      <minor/>
      <comment>[[User:Addbot|Bot:]] Migrating 2 interwiki links, now provided by [[Wikipedia:Wikidata|Wikidata]] on [[d:q739867]]</comment>
      <text xml:space="preserve" bytes="1094">'''Streptogramins''' are a class of antibiotics.&lt;ref&gt;[http://www.bmb.leeds.ac.uk/mbiology/ug/ugteach/icu8/antibiotics/protein.html University of Leeds: Antimicrobial Chemotherapy]&lt;/ref&gt;

Streptogramins are effective in the treatment of [[Vancomycin-resistant Staphylococcus aureus|vancomycin-resistant ''Staphylococcus aureus'']] (VRSA) and [[Vancomycin-resistant Enterococcus|vancomycin-resistant ''Enterococcus'']] (VRE), two of the most rapidly growing strains of multidrug-resistant bacteria. They fall into two groups: [[streptogramin A]] and [[streptogramin B]].

Members include:
* [[Quinupristin/dalfopristin]]
* [[Pristinamycin]]
* [[Virginiamycin]]
* [[NXL 103]], an experimental streptogramin in clinical trials for the treatment of respiratory tract infections.&lt;ref&gt;Boucheer HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad Bugs, no drugs: No ESKAPE! An Update from the Infectious Society of America. Clin Infect Dis. 2009;48:1-12.&lt;/ref&gt;

==References==
{{Reflist}}

{{Macrolides, lincosamides and streptogramins}}

[[Category:Antibiotics]]

{{antibiotic-stub}}</text>
      <sha1>am8ypt5hahb8p5erekalv3kzeeo3t2z</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>NXL103</title>
    <ns>0</ns>
    <id>25020610</id>
    <revision>
      <id>457331921</id>
      <parentid>457331448</parentid>
      <timestamp>2011-10-25T15:35:26Z</timestamp>
      <contributor>
        <username>Edgar181</username>
        <id>491706</id>
      </contributor>
      <comment>Linopristin</comment>
      <text xml:space="preserve" bytes="3083">{{Drugbox
| type              = combo
| component1        = Linopristin
| class1            = antibiotic
| component2        = Flopristin
| class2            = antibiotic

&lt;!--Clinical data--&gt;
| tradename         = 
| Drugs.com         = 
| MedlinePlus       = 
| pregnancy_AU      = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US      = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category= 
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --&gt;
| legal_US = &lt;!-- OTC / Rx-only / Schedule I, II, III, IV, V --&gt;
| legal_status      = 
| routes_of_administration = 

&lt;!--Identifiers--&gt;
| synonyms          = NXL103; XRP 2868
| CAS_number        = 642080-29-3
|  CASNo_Ref        = {{cascite|correct|}}
| ATCvet            = 
| ATC_prefix        = &lt;!-- 'none' if uncategorised --&gt;
| ATC_suffix        = 
| PubChem           = 
| DrugBank          = 
}}


'''NXL103''' (formerly XRP 2868) is an experimental drug candidate under [[drug development|development]] by Novexel.  It is an oral [[streptogramin]] [[antibiotic]] that has potent ''in vitro'' activity against certain [[Gram positive bacteria]] including [[Methicillin-resistant Staphylococcus aureus|methicillin resistant ''Staphylococcus aureus'']] (MRSA) as well as the important respiratory pathogens including [[penicillin]]-, [[macrolide]]- and [[quinolone]]-resistant strains.&lt;ref name=&quot;x5884&quot;&gt;[http://www.drugs.com/clinical_trials/novexel-reports-positive-phase-ii-trial-results-nxl103-adult-patients-community-acquired-pneumonia-5884.html Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia], drugs.com&lt;/ref&gt;&lt;ref&gt;{{cite journal | pmid = 17065630 | year = 2006 | last1 = Pankuch | first1 = GA | last2 = Hoellman | first2 = D | last3 = Bryskier | first3 = A | last4 = Lowther | first4 = J | last5 = Appelbaum | first5 = PC | title = Effects of various media on the activity of NXL103 (formerly XRP 2868), a new oral streptogramin, against Haemophilus influenzae | volume = 50 | issue = 11 | pages = 3914–6 | doi = 10.1128/AAC.00587-06 | pmc = 1635171 | journal = Antimicrobial agents and chemotherapy}}&lt;/ref&gt;  It is a combination of [[linopristin]] and [[flopristin]].&lt;ref&gt;[http://www.novexel.com/contenu.php?page=nxl103 NXL103] at Novexel.com&lt;/ref&gt;

==Clinical trials==
Positive results have been reported from a phase II trial comparing it with [[amoxicillin]].&lt;ref name=&quot;x5884&quot;/&gt;
Another phase II trial will be run in 2010 comparing it with [[linezolid]] for treatment of [[Skin and skin structure infection|acute bacterial skin and skin structure infection]]s (ABSSSI).&lt;ref&gt;[http://clinicaltrials.gov/ct2/show/NCT00949130 Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)], clinicaltrials.gov&lt;/ref&gt;

==References==
{{reflist}}

[[Category:Antibiotics]]

{{pharma-stub}}</text>
      <sha1>93gy9jcc7961m34ljfes5kxkojj86ro</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Polyoxins</title>
    <ns>0</ns>
    <id>25513480</id>
    <revision>
      <id>550555783</id>
      <parentid>540282698</parentid>
      <timestamp>2013-04-15T23:18:30Z</timestamp>
      <contributor>
        <username>Bgwhite</username>
        <id>264323</id>
      </contributor>
      <comment>Do [[Wikipedia:GENFIXES|general fixes]] and cleanup. - using [[Project:AWB|AWB]] (9084)</comment>
      <text xml:space="preserve" bytes="482">'''Polyoxins''' are a group of [[nucleoside]] [[antibiotics]] composed of [[heterocyclic]] moieties containing [[nitrogen]]. An example is Polyoxin B.&lt;ref&gt;''Brock Biology of Microrganisms'' (2003, Pearson Education Limited) Madigan (et al); pg.708&lt;/ref&gt;
Polyoxins work by inhibiting the [[biosynthesis]] of [[chitin]].&lt;ref&gt;&quot;Biology of Microorganisms&quot; (2012, Pearson Education Limited) Brock; pg. 777-778&lt;/ref&gt;

==References==
{{Reflist}}

[[Category:Antibiotics]]


{{Biochem-stub}}</text>
      <sha1>0iziga9pn010l7a64usiymgv9wf7z4c</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Taksta</title>
    <ns>0</ns>
    <id>26928537</id>
    <revision>
      <id>608541875</id>
      <parentid>590106190</parentid>
      <timestamp>2014-05-14T13:20:36Z</timestamp>
      <contributor>
        <username>Werieth</username>
        <id>11916996</id>
      </contributor>
      <text xml:space="preserve" bytes="1994">'''Taksta''' (previously '''CEM-102''') is a front-loaded oral dosing regimen of sodium [[fusidate]] under development in the U.S. as an [[antibiotic]] for [[gram-positive]] infections including drug-resistant strains such as [[methicillin-resistant Staphylococcus aureus]] (MRSA).&lt;ref&gt;{{cite web|url=http://www.earthtimes.org/articles/show/cempra-announces-expansion-of-clinical,1234560.shtml |title=Cempra Announces Expansion of Clinical Management Team to Advance Leading Antibacterial Clinical Programs TAKSTA(TM) and CEM-101 }}&lt;/ref&gt;

==Clinical trials==
Jan 2010: Taksta has completed enrollment in a Phase 2 trial (due to run until March 2010) and is preparing for Phase 3 studies in the U.S. for acute bacterial [[Skin and skin structure infection|skin structure infection]]s (being compared with [[Linezolid]]).
&lt;ref&gt;{{cite web|url=http://clinicaltrials.gov/ct2/show/NCT00948142 |title=Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections }}&lt;/ref&gt;

Sep 2010: Taksta demonstrated comparable clinical success rates compared to linezolid in a Phase 2 trial in the U.S. for acute bacterial skin and skin structure infections.&lt;ref&gt;Craft JC, Moriarty SR, Clark K, Scott D, Degenhardt TP, Still JG, Corey GR, Still JG, Das A, Fernandes P (2011). &quot;A randomized, double-blind Phase 2 study comparing the efficacy and safeety of an oral fusidic acid loading-dose regimen to oral linezolid in the treatment of acute bacterial skin and skin structure infections.&quot;  Clinical Infectious Diseases 52(Supplement 7):S520-S226.&lt;/ref&gt;

Jun 2011: Taksta may be effective in the treatment of chronic prosthetic joint infections and osteomyelitis.&lt;ref&gt;Wolfe CR. (2011) &quot;Case report: treatment of chronic osteomyelitis.&quot; Clinical Infectious Diseases 52(Supplement 7):S538-S541.&lt;/ref&gt;
==See also==
* [[Fusidic acid]], licensed for some decades outside the US and is in clinical development in the U.S.

==References==
{{Reflist}}


[[Category:Antibiotics]]


{{Pharma-stub}}</text>
      <sha1>s2nla44i09y2mzhsmmwbvxgzrmdyc7j</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Thymineless death</title>
    <ns>0</ns>
    <id>29264072</id>
    <revision>
      <id>593188492</id>
      <parentid>532452132</parentid>
      <timestamp>2014-01-30T22:34:35Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="2719">'''Thymineless death''' is the phenomenon by which bacteria, yeasts and mammalian cells undergo irreversible cell death when they are starved of [[thymidine triphosphate]] (dTTP), an essential precursor for [[DNA replication]].&lt;ref name=Ahmad&gt;{{cite journal|last=Ahmad|first=S. I.|coauthors=Kirk, S. H.; Eisenstark, A.|title=Thymine Metabolism and Thymineless Death in Prokaryotes and Eukaryotes|journal=Annual Review of Microbiology|date=October 1998|volume=52|pages=591–625|doi= 10.1146/annurev.micro.52.1.591|pmid=9891809|url=http://www.annualreviews.org/doi/full/10.1146/annurev.micro.52.1.591|accessdate=3 October 2011}}&lt;/ref&gt; This phenomenon underlies the mechanism of action of several [[antibacterial]], [[antimalarial]] and [[anticancer]] agents, such as [[Trimethoprim]], [[Sulfamethoxazole]], [[Methotrexate]] and [[Fluorouracil]].&lt;ref name=Ahmad /&gt;&lt;ref&gt;{{Cite pmid|12724731}}&lt;/ref&gt;&lt;ref&gt;{{Cite pmid|373913}}&lt;/ref&gt;

== History ==

The phenomenon was first reported in 1954 by Hazel D. Barner and Seymour S. Cohen in ''[[Escherichia coli]]'' when thymine requiring mutants of the bacterium lost viability when grown in a medium lacking [[thymine]] but containing other essential nutrients.&lt;ref&gt;{{Cite pmid|13183905}}&lt;/ref&gt;&lt;ref name=&quot;scientist&quot;&gt;[http://www.the-scientist.com/news/display/54259/ 50 years ago in cell biology - A virologist recalls his work on cell growth inhibition]&lt;/ref&gt; Subsequently, this discovery led to the development of or explained the mechanism of action of several [[pyrimidine]] analogs that targeted thymine metabolism in bacteria and tumor cells.&lt;ref name=&quot;scientist&quot; /&gt;&lt;ref&gt;{{Cite pmid|16590300}}&lt;/ref&gt; The phenomenon was commonly attributed to &quot;unbalanced growth&quot; wherein cells continued fundamental processes of [[RNA transcription]], [[protein synthesis]] and [[metabolism]] in the absence of DNA replication.&lt;ref&gt;{{Cite pmid|16589586}}&lt;/ref&gt;  However, nutrient starvation generally do not kill cells to the extent as observed in cells that lack thymine.  The molecular mechanism of thymineless death remains unknown;&lt;ref name=Ahmad /&gt; DNA breaks were observed during thymineless death, which could explain the killing.&lt;ref name=&quot;pmid21074501&quot;&gt;{{Cite pmid|21074501}}&lt;/ref&gt;&lt;ref name=&quot;pmid7966286&quot;&gt;{{Cite pmid|7966286}}&lt;/ref&gt;  Possible pathways involved with the killing mechanism include: replication initiation,&lt;ref name=&quot;pmid21074501&quot;/&gt;&lt;ref&gt;{{Cite pmid|20132444}}&lt;/ref&gt; breakage of ongoing replication forks,&lt;ref&gt;{{Cite pmid|20465561}}&lt;/ref&gt; futile DNA repair,&lt;ref name=&quot;pmid7966286&quot;/&gt; and an addiction module.&lt;ref&gt;{{Cite pmid|12618443}}&lt;/ref&gt;

== References ==
{{Reflist}}

== External links ==

[[Category:Antibiotics]]
[[Category:Cell death]]
[[Category:Drug mechanisms]]</text>
      <sha1>gb18kmuyuieh511ilcfhpdp14mfw48h</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Peptaibol</title>
    <ns>0</ns>
    <id>29400626</id>
    <revision>
      <id>569640170</id>
      <parentid>564750104</parentid>
      <timestamp>2013-08-21T22:29:45Z</timestamp>
      <contributor>
        <username>My very best wishes</username>
        <id>10071161</id>
      </contributor>
      <text xml:space="preserve" bytes="2392">{{Infobox protein family
| Symbol = 
| Name = 
| image = 
| width = 
| caption = 
| Pfam = 
| Pfam_clan =  
| InterPro = 
| SMART = 
| PROSITE = 
| MEROPS = 
| SCOP = 
| TCDB = 1.D.5
| OPM family = 76
| OPM protein = 1ob7
| CAZy = 
| CDD = 
}}

'''Peptaibols''' are biologically active [[peptide]]s containing between seven and twenty [[amino acid]] residues, some of which are [[non-proteinogenic amino acid]]s. In particular, they contain [[α-aminoisobutyric acid]] along with other unusual aminoacids such as ethylnorvaline, isovaline and [[hydroxyproline]]; the N-terminus is acetylated, and the C-terminal amino acid is hydroxylated to an acid alcohol. They are named pebtaibols due to them being '''pept'''ides containing [[α-aminoisobutyric acid]] ('''Aib''') and ending in an alcoh'''ol'''.&lt;ref name=chugh&gt;{{cite journal|url=http://www.biochemsoctrans.org/bst/029/0565/bst0290565.htm |title=Peptaibols: models for ion channels|author=J. K. Chugh and B. A. Wallace |journal=Biochemical Society Transactions |issue=29 |pages=565–570 |date=20 February 2001 |accessdate=2010-10-29}}&lt;/ref&gt; They are produced by certain fungi, mainly in the ''[[Trichoderma]]'' genus, as [[secondary metabolite]]s which function as [[antibiotic]]s and antifungal agents.&lt;ref name=chugh/&gt;&lt;ref&gt;{{cite pmid|18008385}}&lt;/ref&gt; Some are referred to as '''trichorzianines'''.&lt;ref&gt;{{cite journal|url=http://aem.asm.org/cgi/reprint/60/12/4364.pdf |title=Parallel Formation and Synergism of Hydrolytic Enzymes and Peptaibol Antibiotics, Molecular Mechanisms Involved in the Antagonistic Action of Trichoderma harzianum against Phytopathogenic Fungi |publisher=Applied and Environmental Microbiology|author=Marion Schirmbock, Matlteo Lorito, Yong-Li Wang, Christopher K. Hayes, Inci Arisan-Atac, Felice Scala, Gary E. Harman and Christian P. Kubicek |date=December 1994 |accessdate=2010-10-29}}&lt;/ref&gt; They are [[amphipathic]] which allows them to form [[voltage-dependent ion channel]]s in [[cell membrane]]s which create holes in the membrane making them leaky and leading to the death of the cells. As of 2001, over 317 peptaibols had been identified.&lt;ref name=chugh/&gt; The most widely known peptaibol is [[alamethicin]].

==References==
{{reflist}}

==External links==
*[http://www.cryst.bbk.ac.uk/peptaibol Petaibol database]

[[Category:Antibiotics]]
[[Category:Trichoderma]]
[[Category:Antimicrobial peptides]]</text>
      <sha1>k88b5m24oep1cbxyrismvkxl0tj8xuh</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Myriocin</title>
    <ns>0</ns>
    <id>8687829</id>
    <revision>
      <id>605427915</id>
      <parentid>605426913</parentid>
      <timestamp>2014-04-23T09:18:25Z</timestamp>
      <contributor>
        <username>CheMoBot</username>
        <id>7377957</id>
      </contributor>
      <comment>Updating {{chembox}} (changes to verified fields - updated 'ChEBI_Ref') per [[WP:CHEMVALID|Chem/Drugbox validation]] (report [[Wikipedia_talk:WikiProject_Chemicals|errors]] or [[user talk:CheMoBot|bugs]])</comment>
      <text xml:space="preserve" bytes="3707">{{Chembox
| Verifiedfields = changed
| verifiedrevid = 462256409
|  ImageFile = Myriocin.png
|   ImageName = Myriocin
|  IUPACName = 2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid
|  Synonyms = Antibiotic ISP-1; Thermozymocidin
| Section1 = {{Chembox Identifiers
|  InChI = 1S/C21H39NO6/c1-2-3-4-10-13-17(24)14-11-8-6-5-7-9-12-15-18(25)19(26)21(22,16-23)20(27)28/h9,12,18-19,23,25-26H,2-8,10-11,13-16,22H2,1H3,(H,27,28)/b12-9+/t18-,19+,21+/m1/s1
| InChIKey1 = ZZIKIHCNFWXKDY-GNTQXERDSA-N
| SMILES1 = O=C(O)[C@@](N)([C@@H](O)[C@H](O)C/C=C/CCCCCCC(=O)CCCCCC)CO
| InChI1 = 1S/C21H39NO6/c1-2-3-4-10-13-17(24)14-11-8-6-5-7-9-12-15-18(25)19(26)21(22,16-23)20(27)28/h9,12,18-19,23,25-26H,2-8,10-11,13-16,22H2,1H3,(H,27,28)/b12-9+/t18-,19+,21+/m1/s1
| CASNo_Ref = {{cascite|changed|??}}
| CASNo = 35891-70-4
|  PubChem = 6438394
|   PubChem_Comment = (6''E'')
| ChEBI_Ref = {{ebicite|changed|EBI}} 
| ChEBI = 582124
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 55076
|   PubChem_Ref = {{Pubchemcite}}
|   PubChem1 = 301119
|   PubChem1_Comment = ()
|   PubChem1_Ref = {{Pubchemcite}}
|  ChemSpiderID = 4942874
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
|  ChemSpiderID_Comment = (2S,3R,4R,6E)
|  ChemSpiderID3 = 21467337
|   ChemSpiderID3_Comment = (3''S'',4''S'',6''E'')
|   ChemSpiderID3_Ref = {{Chemspidercite}}
|   ChemSpiderID1 = 11654743
|   ChemSpiderID1_Comment = (6''E'')
|   ChemSpiderID1_Ref = {{Chemspidercite}}
|   ChemSpiderID2 = 266093
|   ChemSpiderID2_Comment = ()
|   ChemSpiderID2_Ref = {{Chemspidercite}}
|  ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 183131
|  UNNumber = 2811
|  RTECS = JX3890000
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = C19914
|  SMILES = CCCCCCC(=O)CCCCCCC=CCC(O)C(O)C(N)(CO)C(O)=O
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C21H39NO6/c1-2-3-4-10-13-17(24)14-11-8-6-5-7-9-12-15-18(25)19(26)21(22,16-23)20(27)28/h9,12,18-19,23,25-26H,2-8,10-11,13-16,22H2,1H3,(H,27,28)
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = ZZIKIHCNFWXKDY-UHFFFAOYSA-N
|  Beilstein = 5113331}}
| Section2 = {{Chembox Properties
|   Formula = C&lt;sub&gt;21&lt;/sub&gt;H&lt;sub&gt;39&lt;/sub&gt;NO&lt;sub&gt;6&lt;/sub&gt;
|   MolarMass = 401.54 g/mol
  }}
}}

'''Myriocin''', also known as antibiotic ISP-1 and thermozymocidin, is an atypical [[amino acid]] and an [[antibiotic]] derived from certain [[thermophilic]] fungi. Among the producing strains are ''[[Mycelia sterilia]]''&lt;ref name=&quot;strain&quot;&gt;[http://www.fermentek.co.il/myriocin.htm Myriocin] from [[Fermentek]]&lt;/ref&gt; and ''[[Isaria sinclairii]]''.

Myriocin is a very potent inhibitor of [[serine palmitoyltransferase]], the first step in [[sphingosine]] biosynthesis.&lt;ref name=&quot;pmid7794249&quot;&gt;{{cite journal |author=Miyake Y, Kozutsumi Y, Nakamura S, Fujita T, Kawasaki T |title=Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin |journal=Biochem. Biophys. Res. Commun. |volume=211 |issue=2 |pages=396–403 |year=1995 |pmid=7794249 |doi=10.1006/bbrc.1995.1827}}&lt;/ref&gt; Due to this property, it is used in biochemical research as a tool for depleting cells of [[sphingolipid]]s.

Myriocin was shown to inhibit the proliferation of an [[Interleukin 2|IL-2]]-dependent mouse cytotoxic [[T cell]] line.

Myriocin possesses [[immunosuppressant]] activity. It is reported to be 10 to 100 fold more potent than [[ciclosporin]].

The [[multiple sclerosis]] drug [[fingolimod]] was derived from myriocin by using [[structure–activity relationship]] studies to determine the parts of the molecule important to its activity.

== References ==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Amino acids]]
[[Category:Hydroxy acids]]</text>
      <sha1>fy0tr01chyf2y5q06n3gybj7ali8a66</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Category:Cell envelope antibiotics</title>
    <ns>14</ns>
    <id>29906081</id>
    <revision>
      <id>588071848</id>
      <parentid>547243888</parentid>
      <timestamp>2013-12-28T14:29:50Z</timestamp>
      <contributor>
        <username>Diptanshu.D</username>
        <id>6870537</id>
      </contributor>
      <comment>Main article for category</comment>
      <text xml:space="preserve" bytes="63">{{Cat main|Cell envelope antibiotic}}

[[Category:Antibiotics]]</text>
      <sha1>nddxz2ncahvly13zfyij941hws7wuw3</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Category:Protein synthesis inhibitor antibiotics</title>
    <ns>14</ns>
    <id>29906119</id>
    <revision>
      <id>547759627</id>
      <parentid>434235321</parentid>
      <timestamp>2013-03-30T05:29:13Z</timestamp>
      <contributor>
        <username>EmausBot</username>
        <id>11292982</id>
      </contributor>
      <minor/>
      <comment>Bot: Migrating 2 langlinks, now provided by Wikidata on [[d:Q8802917]]</comment>
      <text xml:space="preserve" bytes="24">[[Category:Antibiotics]]</text>
      <sha1>rraph4wfiw2kgcz0fys64beuyih80wx</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Category:Nucleic acid inhibitor antibiotics</title>
    <ns>14</ns>
    <id>29906140</id>
    <revision>
      <id>588071458</id>
      <parentid>547741158</parentid>
      <timestamp>2013-12-28T14:25:24Z</timestamp>
      <contributor>
        <username>Diptanshu.D</username>
        <id>6870537</id>
      </contributor>
      <comment>Main article for category</comment>
      <text xml:space="preserve" bytes="61">{{Cat main|Nucleic acid inhibitor}}

[[Category:Antibiotics]]</text>
      <sha1>b0aym0tjrn2vsul1tswj4r2tdk391df</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Nucleic acid inhibitor</title>
    <ns>0</ns>
    <id>20103749</id>
    <revision>
      <id>590174859</id>
      <parentid>586574194</parentid>
      <timestamp>2014-01-11T04:17:20Z</timestamp>
      <contributor>
        <ip>87.254.94.87</ip>
      </contributor>
      <text xml:space="preserve" bytes="2183">[[File:Molbio-Header.svg|thumb|Image illustrates DNA, RNA, and protein synthesis. The first two are [[nucleic acid]]s.]]
A '''nucleic acid inhibitor''' is a type of [[antibacterial]] that acts by inhibiting the production of [[nucleic acid]]s.  There are two major classes: DNA inhibitors and RNA inhibitors.&lt;ref&gt;http://www.ccsf.edu/Departments/Biology/ctoebe/antibiotics.htm&lt;/ref&gt;  The [[antifungal medication|antifungal]] [[flucytosine]] acts in a similar manner.

==DNA inhibitors==
[[DNA]] inhibitors (such as the [[quinolones]], acting upon [[DNA gyrase]] as a [[topoisomerase inhibitor]])&lt;ref name=&quot;SC&quot;/&gt;

Another group of DNA inhibitors, including [[nitrofurantoin]] and [[metronidazole]], act upon anaerobic bacteria.&lt;ref&gt;{{cite pmid|25874}}&lt;/ref&gt; These act by generating metabolites that are incorporated into DNA strands, which then are more prone to breakage.&lt;ref&gt;{{Cite book  | last1 = P. Denyer | first1 = Stephen | last2 = Hodges | first2 = Norman A. | last3 = P. Gorman | first3 = Sean | title = Hugo and Russell's pharmaceutical microbiology | year = 2004 | publisher = Blackwell Science | location = Oxford  | isbn = 0-632-06467-6 | pages = 215  }}&lt;/ref&gt; These drugs are selectively toxic to anaerobic organisms, but can affect human cells.

==RNA inhibitors==
* [[RNA]] inhibitors (such as [[rifampin]], acting upon [[DNA-dependent RNA polymerase]])&lt;ref name=&quot;SC&quot;&gt;http://pathmicro.med.sc.edu/mayer/antibiot.htm&lt;/ref&gt;

==Antifolates (DNA, RNA, and protein)==
[[Antifolate]]s act primarily as inhibitors of both RNA and DNA, and are often grouped with nucleic acid inhibitors in textbooks. However, they also act indirectly as [[protein synthesis inhibitor]]s (because [[tetrahydrofolate]] is also involved in the synthesis of amino acids [[serine]] and [[methionine]]), so they are sometimes considered as their own category, [[antimetabolite]]s.&lt;ref&gt;http://www.life.umd.edu/classroom/bsci424/Chemotherapy/AntibioticMechanisms.htm&lt;/ref&gt; However, the term &quot;antimetabolite&quot;, when used literally, can apply to many different classes of drugs.

==References==
{{reflist}}

{{Major drug groups}}
{{Nucleic acid inhibitors}}

[[Category:Antibiotics]]


{{antibiotic-stub}}</text>
      <sha1>mjacuj2awf7wbxdlsztukpese3y7ckx</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Extended-spectrum penicillin</title>
    <ns>0</ns>
    <id>24023014</id>
    <revision>
      <id>602947111</id>
      <parentid>602945233</parentid>
      <timestamp>2014-04-06T02:03:24Z</timestamp>
      <contributor>
        <username>AnomieBOT</username>
        <id>7611264</id>
      </contributor>
      <minor/>
      <comment>Dating maintenance tags: {{Fact}}</comment>
      <text xml:space="preserve" bytes="1113">'''Extended-spectrum penicillin''' is a group of [[antibiotic]]s that has the widest antibacterial spectrum of all penicillins.&lt;ref&gt;Comprehensive Pharmacy Review, Leon Shargel, 6th edition, p917&lt;/ref&gt; It is also called '''antipseudomonal penicillins'''.{{Fact|date=April 2014}} This group includes the [[carboxypenicillin]]s and the [[ureidopenicillin]]s. Note that [[aminopenicillin]]s, in contrast, do not have activity against ''[[Pseudomonas]]'' species, as their positively-charged amino group does not hinder degradation by bacterially-produced [[beta-lactamase]]s. &lt;ref&gt;{{cite book|last=Golan|first=David E.|title=Principles of Pharmacology|publisher=Lippincott Williams &amp; Wilkins|isbn=1608312704|page=610|edition=2}}&lt;/ref&gt; 

==Products==
*[[Ureidopenicillin]]s
**[[Azlocillin]]
**[[Mezlocillin]]
**[[Piperacillin]]
*[[Carboxypenicillin]]s
**[[Ticarcillin]] (with [[clavulanate]])
**[[Carbenicillin]]
*[[Mecillinam]]

==See also==
* [[Pseudomonas_aeruginosa#Treatment]]

==References==
{{reflist}}

{{Cell wall disruptive antibiotics}}

{{DEFAULTSORT:Extended-Spectrum Penicillin}}
[[Category:Antibiotics]]</text>
      <sha1>gwhlfi496uftar7e6f40rp9o18k4hhp</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Multidrug tolerance</title>
    <ns>0</ns>
    <id>21115942</id>
    <revision>
      <id>594722489</id>
      <parentid>591538401</parentid>
      <timestamp>2014-02-09T20:56:10Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="7853">{{distinguish|multidrug resistance}}

'''Multidrug tolerance''' or '''antibiotic tolerance''' is the ability of a disease-causing [[microorganism]] to resist killing by [[antibiotic]]s or other [[antimicrobial]]s. It is mechanistically distinct from multidrug resistance:&lt;ref name=Lewis2007&gt;{{cite journal |author=Lewis K |title=Persister cells, dormancy and infectious disease |journal=Nature Reviews Microbiology  |volume=5 |issue=1 |pages=48–56 |year=2007 |url=http://www.nature.com/nrmicro/journal/v5/n1/abs/nrmicro1557.html |doi=10.1038/nrmicro1557 |pmid=17143318}}&lt;/ref&gt;  It is not caused by [[mutant]] microbes, but rather by microbial cells that exist in a transient, [[dormancy|dormant]], non-dividing state.  Microorganisms that display multidrug tolerance can be [[bacteria]], [[pathogenic fungi|fungi]] or [[protozoa|parasites]].

==Relevance to chronic infections==
Multidrug tolerance is caused by a small subpopulation of microbial cells termed persisters.&lt;ref name=Bigger1944&gt;{{cite journal |author=Bigger JW |title=Treatment of staphylococcal infections with penicllin by intermittent sterilization |journal=Lancet |volume=244 |issue=6320 |pages=497–500 |date=14 October 1944 |doi=10.1016/S0140-6736(00)74210-3 |url=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2800%2974210-3/fulltext}}&lt;/ref&gt;  Persisters are not mutants, but rather are dormant cells that can survive the antimicrobial treatments that kill the majority of their genetically identical siblings.  Persister cells have entered a non- or extremely slow-growing physiological state which makes them insensitive (refractory or tolerant) to the action of antimicrobial drugs.  When such persisting microbial cells cannot be eliminated by the immune system, they become a reservoir from which recurrence of [[infection]] will develop.&lt;ref name=Gefen2009&gt;{{cite journal |author=Gefen O, Balaban NQ |title=The importance of being persistent: heterogeneity of bacterial populations under antibiotic stress |journal=FEMS Microbiol. Rev. |volume=33 |issue=4 |pages=704–17 |date=July 2009 |pmid=19207742 |doi=10.1111/j.1574-6976.2008.00156.x |url=http://www.phys.huji.ac.il/bio_physics/nathalie/GefenFEMS2009.pdf}}&lt;/ref&gt;  Indeed, it appears that persister cells are the main cause for relapsing and chronic infections.&lt;ref name=Lewis2007/&gt;  Chronic infections can affect people of any age, health, or immune status.

==Medical importance==
Bacterial multidrug or antibiotic tolerance poses medically important challenges.&lt;ref name=Lewis2007/&gt;  It is largely responsible for the inability to eradicate bacterial infections with antibiotic treatment.  Persister cells are highly enriched in [[biofilm]]s, and it has been suggested that this is the reason that makes biofilm-related diseases so hard to treat.&lt;ref name=Lewis2007/&gt;  Examples are chronic infections of [[implant (medicine)|implanted]] medical devices such as [[catheter]]s and artificial joints, [[urinary tract infection]]s, [[otitis media|middle ear infections]] and fatal lung disease ([[cystic fibrosis]]).

==Distinction from multidrug resistance==
Unlike resistance, multidrug tolerance is a [[wikt:transient|transient]], non-heritable [[phenotype]].&lt;ref name=Lewis2007/&gt;&lt;ref name=Bigger1944/&gt;&lt;ref name=Gefen2009/&gt;  Multidrug tolerant persister cells are not [[antibiotic resistance|antibiotic resistant]] mutants.  Resistance is caused by newly acquired genetic traits (by mutation or [[horizontal gene transfer]]) that are [[heredity|heritable]] and confer the ability to grow at elevated concentrations of antimicrobial drugs.  In contrast, multidrug tolerance is caused by a reversible physiological state in a small subpopulation of genetically identical cells,&lt;ref name=Lewis2007/&gt;&lt;ref name=Bigger1944/&gt;&lt;ref name=Gefen2009/&gt; similar to a differentiated cell type.&lt;ref name=Lopez2009&gt;{{cite journal |author=Lopez D, Vlamakis H, Kolter R |title=Generation of multiple cell types in ''Bacillus subtilis'' |journal=FEMS Microbiol Rev |volume=33 |issue=1 |pages=152–63 |date=January 2009 |url=http://www3.interscience.wiley.com/journal/121529639/abstract |doi=10.1111/j.1574-6976.2008.00148.x |pmid=19054118}}&lt;/ref&gt;  It enables this small subpopulation of microbes to survive the antibiotic killing of their surrounding siblings.  Persisting cells resume growth when the antimicrobial agent is removed, and their [[Offspring|progeny]] is [[antibiotic sensitivity|sensitive]] to antimicrobial agents.&lt;ref name=Lewis2007/&gt;&lt;ref name=Bigger1944/&gt;&lt;ref name=Gefen2009/&gt;

==Molecular mechanisms==
The molecular mechanisms that underlie persister cell formation and multidrug tolerance are largely unknown.&lt;ref name=Lewis2007/&gt;&lt;ref name=Gefen2009/&gt; Persister cells are thought to arise spontaneously in a growing microbial population by a [[stochastic]] genetic switch,&lt;ref name=Gefen2009/&gt;&lt;ref name=Jayaraman2008&gt;{{cite journal |author=Jayaraman R |title=Bacterial persistence: some new insights into an old phenomenon |journal=J Biosci. |volume=33 |issue=5 |pages=795–805 |year=2008 |url=http://www.ias.ac.in/jbiosci/dec2008/795.pdf |doi=10.1007/s12038-008-0099-3 |pmid=19179767}}&lt;/ref&gt; although inducible mechanisms of persister cell formation have been described.&lt;ref name=Gefen2009/&gt;&lt;ref name=Dörr2009&gt;{{cite journal |author=Dörr T, Lewis K, Vulic M |title=SOS Response Induces Persistence to Fluoroquinolones in Escherichia coli |journal=PLoS Genet. |volume=5 |issue=12 |pages=e1000760 |year=2009 |url=http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1000760 |doi=10.1371/journal.pgen.1000760 |pmid=20011100 |pmc=2780357 |editor1-last=Rosenberg |editor1-first=Susan M.}}&lt;/ref&gt; Owing to their transient nature and relatively low abundance, it is hard to isolate persister cells in sufficient numbers for experimental characterization, and only a few relevant genes have been identified to date.&lt;ref name=Lewis2007/&gt;&lt;ref name=Gefen2009/&gt;   The best-understood persistence factor is the ''[[Escherichia coli|E. coli]]'' '''''hi'''''gh '''''p'''''ersistence gene, commonly abbreviated as ''hipA''.&lt;ref name=Moyed1983&gt;{{cite journal |author=Moyed HS, Bertrand KP |title=hipA, a newly recognized gene of Escherichia coli K-12 that affects frequency of persistence after inhibition of murein synthesis |journal=J Bacteriol. |volume=155 |issue=2 |pages=768–75 |year=1983 |pmid=6348026 |url=http://jb.asm.org/cgi/reprint/155/2/768 |pmc=217749}}&lt;/ref&gt;&lt;ref name=Schuhmacher2009&gt;{{cite journal |author=Schumacher MA, Piro KM, Xu W, Hansen S, Lewis K, Brennan RG |title=Molecular Mechanisms of HipA Mediated Multidrug Tolerance and its Neutralization by HipB |journal=Science |volume=323 |issue=5912 |pages=396–401 |year=2009 |pmc=2764309 |doi=10.1126/science.1163806 |pmid=19150849}}&lt;/ref&gt;

==Potential treatment==
In May 2011, it was reported by [[Nature.com]] that [[aminoglycosides]] can help suppress multidrug tolerance in numerous species of bacteria, including ''[[E. coli]]'' and ''[[Staphylococcus aureus|S. aureus]]'', by &quot;the generation of a [[proton]]-motive force which facilitates aminoglycoside uptake&quot;.&lt;ref name=Allison2011&gt;{{cite journal |author=Allison KR, Brynildsen MP, Collins JJ |title=Metabolite-enabled eradication of bacterial persisters by aminoglycosides |journal=Nature |volume=473 |pages=216–220 |year=2011 |doi=10.1038/nature10069 |pmid=21562562}}&lt;/ref&gt;

==See also==
*[[Antibiotic resistance]]
*[[Antibiotic sensitivity]]
*[[Bacteria]]
*[[Biofilm]]
*[[Chronic wound]]
*[[Dormancy]]
*[[Infection]]
*[[Infectious Disease]]
*[[Multidrug resistance]]
*[[Pathogen]]
*[[Relapse]]

==References==
{{reflist|2}}

==External links==
* [http://www.northeastern.edu/adc/persistercells.php Persister cells and mode of action of HipA]

{{DEFAULTSORT:Multidrug Tolerance}}
[[Category:Antibiotics]]
[[Category:Bacteria]]
[[Category:Infectious diseases]]</text>
      <sha1>dcgkmwzpbsz48r7emodjcn5r6cocdzl</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Solithromycin</title>
    <ns>0</ns>
    <id>31036922</id>
    <revision>
      <id>593071834</id>
      <parentid>588436845</parentid>
      <timestamp>2014-01-30T05:27:01Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="7228">{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 417774847
| IUPAC_name = (3a''S'',4''R'',7''S'',9''R'',10''R'',11''R'',13''R'',15''R'',15a''R'')-1-[4-[4-(3-aminophenyl)-1''H''-1,2,3-triazol-1-yl]butyl]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-{[3,4,6-trideoxy-3-(dimethylamino)-β-&lt;small&gt;D&lt;/small&gt;-''xylo''-hexopyranosyl]oxy}-2''H''-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1''H'',7''H'',9''H'')-tetrone
| image = Solithromycin.svg
| width = 250

&lt;!--Clinical data--&gt;
| tradename =  
| legal_status = [[clinical trial|Phase III clinical trials, North America, South America, Europe]]
| routes_of_administration = oral, intravenous

&lt;!--Identifiers--&gt;
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 760981-83-7
| ATC_prefix = none
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 9U1ETH79CK
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1240704
| synonyms = CEM-101; OP-1068

&lt;!--Chemical data--&gt;
| C=43 | H=65 | F=1 | N=6 | O=10 
| molecular_weight = 845.01 g/mol
}}

'''Solithromycin''' (formerly known as '''CEM-101''' and OP-1068) is a novel [[ketolide]] [[antibiotic]] undergoing clinical development for the treatment of [[community-acquired pneumonia]] (CAP)&lt;ref name=&quot;pmid15117934&quot;&gt;{{cite journal
|author=Reinert RR
|title=Clinical efficacy of ketolides in the treatment of respiratory tract infections
|journal=[[The Journal of Antimicrobial Chemotherapy]]
|volume=53
|issue=6
|pages=918–27
|date=June 2004
|pmid=15117934
|doi=10.1093/jac/dkh169
|url=
|issn=
|accessdate=2009-06-21
}}&lt;/ref&gt; and other infections.&lt;ref&gt;http://www.cempra.com/research/antibacterials/&lt;/ref&gt;  It is expected to be the first [[macrolide]] antibiotic available in [[intravenous therapy|intravenous]], oral, and pediatric suspension formulations in over 20 years.

Solithromycin exhibits excellent ''[[in vitro]]'' activity against a broad spectrum of [[Gram-positive bacteria|Gram-positive]] [[respiratory tract infections|respiratory tract]] [[pathogen]]s,&lt;ref name=&quot;pmid2017690&quot;&gt;{{cite journal
|author=Woolsey LN, Castaneira M, Jones RN.
|title=CEM-101 activity against Gram-positive organisms
|journal=[[Antimicrobial Agents and Chemotherapy]]
|volume=54
|issue=5
|pages=2182–2187
|date=May 2010
|pmid=2017690
|doi=10.1128/AAC.01662-09
|url=
|issn=
|accessdate=2011-02-28
}}&lt;/ref&gt;&lt;ref name=&quot;pmid20211548&quot;&gt;{{cite journal
|author=Farrell DJ, Sader HS, Castanheira M, Biedenbach DJ, Rhomberg PR, Jones RN.
|title=Antimicrobial characterization of CEM-101 activity against respiratory tract pathogens including multidrug-resistant pneumococcal serogroup 19A isolates
|journal=International Journal of Antimicrobial Agents
|volume=35
|issue=6
|pages=537–543
|date=June 2010
|pmid=20211548
|doi=10.1016/j.ijantimicag.2010.01.026
|url=
|issn=
|accessdate=2011-02-28
}}&lt;/ref&gt; including macrolide-resistant strains.&lt;ref name=&quot;pmid19884376&quot;&gt;{{cite journal
|author=McGhee P, Clark C, Kosowska-Shick K, Nagai K, Dewasse B, Beachel L, Appelbaum PC.
|title=In Vitro Activity of Solithromycin against ''Streptococcus pneumoniae'' and ''Streptococcus pyogenes'' with Defined Macrolide Resistance Mechanisms
|journal=Antimicrobial Agents and Chemotherapy
|volume=54
|issue=1
|pages=230–238
|date=January 2010
|pmid=19884376
|doi=10.1128/AAC.01123-09
|url=
|issn=
|accessdate=2011-02-28
}}&lt;/ref&gt;  Solithromycin has activity against a wide variety of pathogens,&lt;ref&gt;{{cite journal | doi = 10.1016/j.diagmicrobio.2009.10.013 | author = Putnam, Shannon D.; Castanheira, Mariana; Moet, Gary J.; Farrell, David J.; Jones, Ronald N. | title =  CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria | journal = Diagnostic Microbiology and Infectious Disease  | year = 2010 | volume = 66 | issue = 4 | pages = 393–401 | pmid = 20022192}}&lt;/ref&gt;&lt;ref&gt;{{Cite journal | doi = 10.1016/j.ijantimicag.2010.08.021 | author = Putnam, Shannon D.; Sader, Helio S.; Farrell, David J.; Biedenbach, Douglas J.; Castanheira, Mariana | title =  Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci | journal = International Journal of Antimicrobial Agents  | year = 2011 | volume = 37 | issue = 1 | pages = 39–45 | pmid = 21075602}}&lt;/ref&gt; and further research is being conducted for other [[infection]]s.

*May 2011: Solithromycin is in a Phase 2 clinical trial for serious [[community-acquired bacterial pneumonia]] (CABP) and in a Phase 1 clinical trial with an intravenous formulation.&lt;ref name=May2011&gt;{{cite news |url=http://www.prnewswire.com/news-releases/intravenous-iv-administration-of-cempra-pharmaceuticals-solithromycin-cem-101-demonstrates-excellent-systemic-tolerability-in-a-phase-1-clinical-trial-121433699.html |title=Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial |date=7 May 2011 }}&lt;/ref&gt;

*September 2011 : Encouraging results from the phase 2 clinical trial versus [[levofloxacin]] were reported.&lt;ref&gt;{{cite news |url=http://www.medcitynews.com/2011/09/cempra-antibiotic-compound-as-effective-safer-than-levofloxacin/?edition=pharmaceuticals |title=Cempra antibiotic compound as effective, safer than levofloxacin |date=15 Sep 2011 }}&lt;/ref&gt;

==Structure==
[[X-ray crystallography]] studies have shown solithromycin, the first '''fluoroketolide''' in clinical development, has a third region of interactions with the bacterial ribosome,&lt;ref&gt;{{cite journal | doi = 10.1128/AAC.00860-10 | author = Llano-Sotelo B, Dunkle J, Klepacki D, Zhang W, Fernandes P, Cate JH, Mankin AS. | title =  Binding and Action of CEM-101, a New Fluoroketolide Antibiotic That Inhibits Protein Synthesis| journal = Antimicrobial Agents and Chemotherapy| year = 2010 | volume = 54 | issue = 12 | pages = 4961–4970| pmid = 20855725}}&lt;/ref&gt; as compared with two binding sites for other [[ketolide]]s.

The only currently marketed [[ketolide]], [[telithromycin]], suffers from rare, but serious [[side effect]]s.  Recent studies&lt;ref&gt;{{cite journal | doi = 10.1128/AAC.00840-10| author = Bertrand D, Bertrand S, Neveu E, Fernandes P. | title =  Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors| journal = Antimicrobial Agents and Chemotherapy| year = 2010 | volume = 54 | issue = 12 | pages = 599-5402| pmid = 20855733}}&lt;/ref&gt; have shown this to be likely due to the presence of the [[pyridine]]-[[imidazole]] group of the telithromycin side chain acting as an antagonist towards various [[nicotinic acetylcholine receptor]]s.  Since solithromycin, like [[azithromycin]] and [[clarithromycin]], lacks this chemical moiety, it is not expected to cause the adverse events seen with Ketek (telithromycin).

==References==
{{Reflist}}

==Further reading==
*[http://www.cempra.com/research/antibacterials/ Profile of and Research on Solithromycin]

{{Macrolides, lincosamides and streptogramins}}

[[Category:Ketolide antibiotics]]
[[Category:Antibiotics]]
[[Category:Macrolides]]
[[Category:Macrolide antibiotics]]
[[Category:Triazoles]]


{{antibiotic-stub}}</text>
      <sha1>73mpljyc3nyy6jcav52ibn22yx5yxjt</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Cycloserine</title>
    <ns>0</ns>
    <id>4423825</id>
    <revision>
      <id>608471586</id>
      <parentid>608251156</parentid>
      <timestamp>2014-05-14T00:12:41Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Task 5: Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated coauthor parameter errors]]</comment>
      <text xml:space="preserve" bytes="26811">{{Distinguish|Cyclosarin}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 460111047
| IUPAC_name = (''R'')-4-Amino-1,2-oxazolidin-3-one
| image = Cycloserine.svg
| image2 = Cycloserine ball-and-stick.png
&lt;!--Clinical data--&gt;
| tradename = Seromycin
| Drugs.com = {{drugs.com|monograph|cycloserine}}
| pregnancy_category = C
| legal_status =

&lt;!--Pharmacokinetic data--&gt;
| bioavailability = ~70% to 90%
| protein_bound =  
| metabolism = Hepatic
| elimination_half-life = 10 hrs (normal renal function)
| excretion = Renal

&lt;!--Identifiers--&gt;
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 68-41-7
| ATC_prefix = J04
| ATC_suffix = AB01
| ATC_supplemental =  
| PubChem = 6234
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00260
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5998
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 95IK5KI84Z
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00877
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 40009
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 771
| NIAID_ChemDB = 007654

&lt;!--Chemical data--&gt;
| C=3 | H=6 | N=2 | O=2 
| molecular_weight = 102.092 g/mol
| smiles = O=C1NOC[C@H]1N
| InChI = 1/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1
| InChIKey = DYDCUQKUCUHJBH-UWTATZPHBN
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DYDCUQKUCUHJBH-UWTATZPHSA-N
}}

'''Cycloserine''' ('''4-amino-3-isoxazolidinone''') is a drug sold under the brand name '''Seromycin'''. It is  an [[antibiotic]] effective against ''[[Mycobacterium tuberculosis]]''. Since the discovery that cycloserine is able to penetrate into the central nervous system, numerous studies have been conducted to assess the efficacy of cycloserine for psychiatric disorders. It has been found to be effective in the treatment of some neurological disorders, due to its effect as a selective partial agonist of the [[N-Methyl-D-aspartic acid|''N''-methyl-&lt;small&gt;D&lt;/small&gt;-aspartic acid]] (NMDA) [[glutamatergic]] receptors found in the basolateral nucleus of the [[amygdala]]. Specifically, cycloserine affects the glycine-binding sites which are important for opening these NMDA channels.&lt;ref name=&quot;Nitsche - DCS-bg&quot; /&gt;&lt;ref name=Hoffman-DCS-SAD&gt;{{cite journal|last=Hoffman|first=Stefan|title=Augmentation of Exposure Therapy With D-Cycloserine for [[Social Anxiety Disorder]]|journal=Archives Of General Psychiatry|year=2006|volume=63|issue=3|pages=298–304|PMID= 16520435|doi=10.1001/archpsyc.63.3.298}}&lt;/ref&gt; Cycloserine is stable under basic conditions, with the greatest stability at pH = 11.5.&lt;ref name=Kaushal&gt;{{cite journal|last=Kaushal|first=Gagan|author2=Ronaldo Ramirez |author3=Demelash Alambo |author4=Wacharah Taupradist |author5=Krunal Choksi |author6=Cristian Sirbu |title=Initial characterization of D-cycloserine for future formulation development for anxiety disorders|journal=Drug Discoveries &amp; Therapeutics|date=October 2011|volume=5|issue=5|pages=253–260| PMID= 22466372|doi=10.5582/ddt.2011.v5.5.253}}&lt;/ref&gt;  Under mildly acidic conditions, ite breaks down into [[hydroxylamine]] and [[serine|&lt;small&gt;D&lt;/small&gt;-serine]], whereas under prolonged hydrolysis, it breaks down into hydroxylamine and &lt;small&gt;DL&lt;/small&gt;-serine.&lt;ref name=Kaushal /&gt;&lt;ref name=Silverman-GABA&gt;{{cite journal|last=Silverman|first=Richard|title=An Aromatization Mechanism of Inactivation of γ-Aminobutyric Acid Aminotransferase for the Antibiotic l-Cycloserine|journal=Journal of the American Chemical Society|year=1998|volume=120|issue=10|pages=2256–2267|accessdate=11/04/2013}}&lt;/ref&gt;

The name &quot;cycloserine&quot; is a misnomer because the compound has an extra nitrogen atom compared to [[serine]]. (It also has one fewer oxygen atoms and one fewer hydrogen atoms than serine.)

==Antibiotic uses==

===Indications===
For the treatment of tuberculosis, cycloserine is classified as a second-line drug, i.e. its use is only considered if one or more first-line drugs cannot be used. Hence, cycloserine is restricted for use only against multiple drug-resistant and extensively drug-resistant strains of ''M. tuberculosis.'' Another reason for limited use of this drug is the neurological side effects it causes, since it is able to penetrate into the central nervous system (CNS) and cause headaches, drowsiness, [[depression (mood)|depression]], dizziness, [[vertigo]], confusion, [[paresthesias]], [[dysarthria]], hyperirritability, [[psychosis]], [[convulsions]], and shaking (tremors).&lt;ref name=&quot;Nitsche - DCS-bg&quot;&gt;{{cite journal|last=Nitsche|first=Michael|author2=Jaussi, W. |author3=Liebetanz, D. |author4=Lang, N. |author5=Tergau, F. |author6=Paulus, W. |title=Consolidation of human motor cortical neuroplasticity by D-cycloserine|journal=Neuropsychopharmacology|year=2004|volume=29|issue=8|pages=1573–1578|PMID= 15199378|doi=10.1038/sj.npp.1300517}}&lt;/ref&gt;&lt;ref name=WebMD&gt;{{cite web|url=http://www.medscape.com/druginfo/dosage?cid=med&amp;drugid=3512&amp;drugname=DHEA+Oral&amp;monotype=default|title=DHEA Oral|last=Medscape|year=2010|work=Drug Reference|publisher=WebMD LLC.|accessdate=18 February 2010}}&lt;/ref&gt;&lt;ref name=NIH&gt;{{cite web|title=CYCLOSERINE: Human Health Effects|url=http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+68-41-7|publisher=National Institutes of Health}}&lt;/ref&gt; Overdose of cycloserine may result in [[paresis]], [[seizures]], and [[coma]], while alcohol consumption may increase the risk of seizures.&lt;ref name=NIH /&gt; Coadministration of [[pyridoxine]] can reduce the incidence of some of these CNS side effects (e.g. convulsions) caused by cycloserine.

===Mechanism of antibiotic action===
Cycloserine works as an antibiotic by inhibiting cell-wall [[biosynthesis]] in bacteria.&lt;ref name=Lambert-tuberculosis&gt;{{cite journal|last=Lambert|first=M. P.|title=Mechanism of D-cycloserine action: Alanine racemase from Escherichia coli W|journal=Journal of bacteriology|year=1972|volume=110|issue=3|pages=978–987|PMID= 4555420|pmc=247518}}&lt;/ref&gt;&lt;ref name=Prosser&gt;{{cite journal|last=Prosser|first=Gareth|coauthors=Luiz Pedro S. de Carvalho|title=Kinetic mechanism and inhibition of Mycobacterium tuberculosis d-alanine: D-alanine ligase by the antibiotic d-cycloserine|journal=FEBS Journal|date=February 2013|volume=280|issue=4|pages=1150–1166|PMID= 23286234|doi=10.1111/febs.12108}}&lt;/ref&gt;  As a cyclic analogue of [[alanine|&lt;small&gt;D&lt;/small&gt;-alanine]], cycloserine acts against two crucial enzymes important in the [[cytosolic]] stages of [[peptidoglycan]] synthesis: [[alanine racemase]] (Alr) and [[D-alanine—D-alanine ligase|&lt;small&gt;D&lt;/small&gt;-alanine:&lt;small&gt;D&lt;/small&gt;-alanine ligase]] (Ddl).&lt;ref name=Prosser /&gt; The first [[enzyme]] is a pyridoxal 5'-phosphate-dependent enzyme which converts the &lt;small&gt;L&lt;/small&gt;-alanine to the &lt;small&gt;D&lt;/small&gt;-alanine form.&lt;ref name=Prosser /&gt;  The second enzyme is involved in joining two of these &lt;small&gt;D&lt;/small&gt;-alanine residues together by catalyzing the formation of the [[Adenosine triphosphate|ATP]]-dependant &lt;small&gt;D&lt;/small&gt;-alanine-&lt;small&gt;D&lt;/small&gt;-alanine [[dipeptide bond]] between the resulting &lt;small&gt;D&lt;/small&gt;-alanine molecules.&lt;ref name=Prosser /&gt; If both of these enzymes are inhibited, then &lt;small&gt;D&lt;/small&gt;-alanine residues cannot form and previously formed &lt;small&gt;D&lt;/small&gt;-alanine molecules cannot be joined together.&lt;ref name=Prosser /&gt; This effectively leads to inhibition of peptidoglycan synthesis in [[Gram-positive bacteria]].&lt;ref name=Prosser /&gt;

==Psychiatric uses==

=== &lt;small&gt;D&lt;/small&gt;-Cycloserine===
The dextrorotary form of cycloserine has been investigated in numerous studies focusing on fear extinction and addictions in the human and animal model systems.

==== Implications in fear conditioning, memory consolidation, and extinction ====
[[File:Modèle révolutionnaire.jpg|thumb|left|Stimulus-response relationship]]
&lt;small&gt;D&lt;/small&gt;-Cycloserine, when used in conjunction with exposure-based [[cognitive behavior therapy]], helps with fear extinction in an array of anxiety- and stress-inducing disorders.&lt;ref name=Ren&gt;{{cite journal|last=Ren|first=Jintao|author2=Xiaobai Li  |author3=Xinxin Zhang |author4=Min Li |author5=Yan Wang |author6=Yuchao Ma |title=The effects of intra-hippocampal microinfusion of d-cycloserine on fear extinction, and the expression of NMDA receptor subunit NR2B and neurogenesis in the hippocampus in rats|journal=Progress In Neuro-Psychopharmacology And Biological Psychiatry|date=July 2013|volume=44|pages=257–264|PMID= 23523746|doi=10.1016/j.pnpbp.2013.02.017}}&lt;/ref&gt;&lt;ref name=Baker&gt;{{cite journal|last=Baker|first=Kathryn|author2=Gavan P. McNally |author3=Rick Richardson |title=D-cycloserine does not facilitate fear extinction by reducing conditioned stimulus processing or promoting conditioned inhibition to contextual cues|journal=Learning And Memory|date=October 2012|volume=19|issue=10|pages=461–469|PMID= 22984284|doi=10.1101/lm.026674.112}}&lt;/ref&gt;  These disorders and phobias are a result of and get perpetuated through pathological fear memory.&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt; Pavlovian [[fear conditioning]] is a notable animal model to induce this form of conditioning in the lab and provides an avenue to examine mechanisms of learning and memory.&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt; In this conditioning model, a neutral and nonaversive stimulus such as light or tone (termed as the [[conditioned stimulus]], CS) is paired with an aversive stimulus, such as an electrical shock to the foot (termed as the [[unconditioned stimulus]], US).&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt; After these two stimuli are presented together a few times, the animals quickly learn to associate these stimuli together, and elicit a learned response, such as freezing or sweaty fingers (termed as the [[conditioned response]], CR).&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt;

The process of extinction ([[associative learning]]) entails unlearning this association between the CS and US, and results in a decrease in the frequency of the CR being elicited.&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt; This occurs by repeatedly presenting the CS without the US.&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt;  By repeating this numerous times, the animals learn to not associate the stimuli together, which can be examined by the decrease in frequency of the CR being elicited.&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt; Similar to fear conditioning, extinction can be broken down into several categories, such as acquisition (training), consolidation, and retrieval of extinction memory.&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt; Understanding the circuitry and mechanisms of extinction has strong implications for development of novel therapeutics to be used in conjunction with exposure-based cognitive behavioral therapy for patients suffering from anxiety and stress inducing disorders.&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt; Another reason for development of pharmacological therapeutics is due to the fact that a decrease in exhibition of the CR may not always be permanent since episodes of renewal can also result.&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt; Relapse of CR can also occur gradually with time, in lieu of other aversive events or with reinstatement (re-presentation) of the US.&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt; Likewise, with exposure-based cognitive therapies, an impending limitation is the high rates of relapse.&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt; For all of these reasons, there is considerable interest in the creation of pharmacological treatments to enhance extinction and reduce relapse rates.&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt;

Many studies have shown that the extinction process is dependent upon N-methyl-D-aspartate (NMDA) receptors in the [[basolateral amygdala]] (BLA).&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt; &lt;small&gt;D&lt;/small&gt;-Cycloserine (DCS) is a partial agonist of the NMDA receptor, where it increases excitatory NMDA [[neurotransmission]] by binding to the glycine-binding sites.&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt;  DCS has been shown to enhance extinction retention in rats.&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt; It enhances fear extinction during within-sessions which suggests that DCS facilitates the learning aspect of extinction.&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt; Though DCS has been shown to reduce some occurrences of relapse and reinstatement in humans and rats, it doesn’t seem to prevent renewal.&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt; Nevertheless, there is considerable interest in employing DCS as a treatment for psychiatric disorders, due to its beneficial therapeutic effects in several studies which have employed DCS for anxiety disorders, acrophobia, post-traumatic stress disorder, obsessive-compulsive disorder, and panic disorders.&lt;ref name=Ren /&gt;&lt;ref name=Baker /&gt;

====Interaction with the NMDA receptor====
[[File:NMDA receptor.jpg|thumb|NMDA receptor]][[Glutamate]] is a major excitatory [[neurotransmitter]] in the mammalian central nervous system. One of the [[ionotropic receptor]]s that glutamate activates is the NMDA receptor.&lt;ref name=Dravid&gt;{{cite journal|last=Dravid|first=Shashank|author2=Pieter B. Burger |author3=Anand Prakash |author4=Matthew T. Geballe |author5=Roopali Yadav |author6=Phuong Le |author7=Kimberly Vellano |author8=James P. Snyder |author9=Stephen F. Traynelis |displayauthors=9 |title=Structural determinants of D-cycloserine efficacy at the NR1/ NR2C NMDA receptors|journal=The Journal Of Neuroscience: The Official Journal Of The Society For Neuroscience|date=February 2010|volume=30|issue=7|pages=2741–2754|PMID= 20164358|doi=10.1523/JNEUROSCI.5390-09.2010}}&lt;/ref&gt; NMDA glutamatergic receptors are tetrameric, consisting of two NR1 subunits (which bind glycine) and two NR2 subunits (which bind glutamate).&lt;ref name=Dravid /&gt;  These receptors are important for synaptic plasticity and development processes in the brain.&lt;ref name=Dravid /&gt; &lt;small&gt;D&lt;/small&gt;-Cycloserine acts as a partial agonist at NMDA receptors with NR2A, NR2B, NR2C, or NR2D subunits.&lt;ref name=Dravid /&gt; DCS has lower efficacy than the [[endogenous]] agonists [[glycine]] or [[serine|&lt;small&gt;D&lt;/small&gt;-serine]] at the NR1/NR2A, NR1/NR2B and NR1/NR2D receptors.&lt;ref name=Dravid /&gt; However, at the NR1/NR2C receptors, DCS has higher efficacy than endogenous glycine or &lt;small&gt;D&lt;/small&gt;-serine.&lt;ref name=Dravid /&gt; The efficacy of glycine agonists is hypothesized to entail the differential communication between the NR2 subtypes and the NR1 receptors.&lt;ref name=Dravid /&gt; This is due to the fact that residues of the NR1 domain may interact differently with the NR2 domain subtypes, especially during instances of intra-protein conformational changes at the dimer interface.&lt;ref name=Dravid /&gt;  This differential dimer interface interaction may explain why DCS has a higher relative efficacy than the endogenous agonists glycine or D-serine at NR1/NR2C receptors.&lt;ref name=Dravid /&gt; Likewise, recordings performed with a continuous saturating concentration of the endogenous agonists glycine and glutamate have also shown that DCS decreases efficiency of gating by slowing forward rate constant preceding rapid pore openings.&lt;ref name=Dravid /&gt; These [[psychotropic]] responses are related to &lt;small&gt;D&lt;/small&gt;-cycloserine's action as a partial [[agonist]] of the neuronal [[NMDA receptor]] for [[glutamate]] and have been examined in implications with sensory-related fear [[extinction (psychology)|extinction]] in the [[amygdala]], and [[extinction (psychology)|extinction]] of [[cocaine]] seeking in the [[nucleus accumbens]].&lt;ref name=&quot;Walker 2002&quot;&gt;{{pmid|11896173}}&lt;/ref&gt;&lt;ref&gt;{{pmid|20685995}}&lt;/ref&gt;

====Use for social anxiety disorder====
[[File:Portrait of acute anxiety.JPG|thumb|Anxiety]]
Typically, exposure therapy is employed as a psychotherapy to help patients suffering from social anxiety disorder.&lt;ref name=Hoffman-DCS-SAD /&gt;  Nevertheless, many patients still exude symptoms even after therapy.&lt;ref name=Hoffman-DCS-SAD /&gt;   To help such patients, in 2006, a study found that when 50&amp;nbsp;mg of DCS was administered an hour prior to exposure-based cognitive behavior therapy (CBT) sessions, it resulted in a much higher anxiety reduction as compared to the administration of a placebo with CBT.&lt;ref name=Hoffman-DCS-SAD /&gt;  Additionally, the researchers also found that when DCS was given with exposure-based CBT for social performance situations such as public speaking, this also resulted in reduction of social anxiety.&lt;ref name=Hoffman-DCS-SAD /&gt;

====Use for substance dependence disorder (drug addiction)====
[[File:Cocaine3.jpg|thumb|left|Cocaine powder]]
[[Cocaine]] addictions result in drug-seeking and drug-taking behaviors.&lt;ref name=Dhonnchadha&gt;{{cite journal|last=Dhonnchadha|first=Brid|coauthors=Jonathan J Szalay, Cindy Achat-Mendes, Donna M Platt, Michael W Otto, Roger D Spealman and Kathleen M Kantak|title=D-cycloserine Deters Reacquisition of Cocaine Self-Administration by Augmenting Extinction Learning|journal=Neuropsychopharmacology: Official Publication Of The American College Of Neuropsychopharmacology|date=January 2010|volume=35|issue=2|pages=357–367|pmc= 2928163}}&lt;/ref&gt;  These behaviors can be explained by the ''incentive sensitisation'' theory of addiction, in which constant drug use elicits drug-seeking behaviors due to [[associative learning]] processes which occur through Pavlovian conditioning.&lt;ref name=Kamboj&gt;{{cite journal|last=Kamboj|first=Sanjeev|coauthors=Alyssa Joye &amp; Ravi K. Das &amp; Andrew J. W. Gibson &amp; Celia J. A. Morgan &amp; H. Valerie Curran|title=Cue exposure and response prevention with heavy smokers: A laboratory-based randomised placebo-controlled trial examining the effects of D-cycloserine on cue reactivity and attentional bias|journal=Psychopharmacology|date=May 2012|volume=221|issue=2|pages=273–284|PMID= 22101394|doi=10.1007/s00213-011-2571-2}}&lt;/ref&gt; During this time, drug cues gain 'motivational salience' due to sensitisation of the dopaminergic transmission in the nucleus accumbens/ventral striatal reward pathway.&lt;ref name=Kamboj /&gt; Gradually, this culminates in drug cues taking over attentional processes and results in [[craving (withdrawal)|craving]]s, drug-seeking, and relapse.&lt;ref name=Kamboj /&gt;  A notable instance of this can be seen with cocaine addictions, which arise from pairing cocaine use with the external cues which results in conditioning and [[memory consolidation]]. The conditioned responses are cravings and relapse.&lt;ref name=Dhonnchadha /&gt;  Although cue exposure (extinction) therapy is currently being employed to help patients counter the motivation for drug-seeking and drug-taking behaviors, this therapy is not effective consistently, possibly due to its context-dependency, as well as reliance on sound memory systems for [[extinction learning]] (which are possibly impaired with sustained cocaine use).&lt;ref name=Dhonnchadha /&gt; Plus, no promising pharmaceuticals are available for treating drug addictions in the market currently and since cocaine addiction is a major problem in modern society, it is imperative that better therapeutics be created to reverse this problem.&lt;ref name=Dhonnchadha /&gt; As a result, considerable interest in using DCS exists, which has already been found to help with fear extinction in various animal, as well as human, model systems.&lt;ref name=Dhonnchadha /&gt; Extinction of drug addiction is analogous to extinction of fear, in which active learning processes are involved.&lt;ref name=Dhonnchadha /&gt; In particular, animal studies have shown that NMDA receptors are notably important for acquisition and consolidation of cocaine-cue associations in addition to extinction and reconsolidation.&lt;ref name=Dhonnchadha /&gt;

Studies employing various animal model systems to assess the efficacy of DCS in treatment of cocaine addictions have yielded mixed results. For instance, a study  in 2009 found that DCS administration two hours prior to each extinction session acutely increased cravings and susceptibility to cocaine cues in cocaine-dependant persons by stimulation of glutamatergic systems.&lt;ref name=Price&gt;{{cite journal|last=Price|first=Kimber|coauthors=Aimee L. McRae-Clark, Michael E. Saladin, Megan M. Moran-Santa Maria, Stacia M. DeSantis, Sudie E. Back, and Kathleen T. Brady|title=D-Cycloserine and Cocaine Cue Reactivity: Preliminary Findings|journal=American Journal Of Drug &amp; Alcohol Abuse|date=November 2009|volume=35|issue=6|pages=434–438|PMID= 20014913|doi=10.3109/00952990903384332}}&lt;/ref&gt;   However, in 2010, another study found that taking DCS prior to the extinction training lead to reacquisition of cocaine self-administration in rats and monkeys through augmentation of consolidation of extinction learning.&lt;ref name=Dhonnchadha /&gt; This study also found that DCS was effective only when used administered in conjunction with explicit extinction therapy.&lt;ref name=Dhonnchadha /&gt; More studies will need to be conducted to reconcile and substantiate these findings.

A similar type of discrepancy is also seen in studies examining the efficacy of DCS on facilitating extinction in participants with nicotine addictions in conjunction with cue exposure therapy.&lt;ref name=Santa-Anna&gt;{{cite journal|last=Santa-Anna|first=Elizabeth|author2=Bruce J. Rounsavillea |author3=Tami L. Frankforter |author4=Charla Nich |author5=Theresa Babuscio |author6=James Polinga |author7=Kishorchandra Gonsaia |author8=Kevin P. Hill |author9=Kathleen M. Carroll |displayauthors=9 |title=d-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: A pilot investigation|journal=Drug And Alcohol Dependence|date=October 2009|volume=104|issue=3|pages=220–227|PMID= 19592176|doi=10.1016/j.drugalcdep.2009.04.023}}&lt;/ref&gt; Researchers conducting a study in 2009 hypothesized that when nicotine-dependent persons receive DCS in conjunction with cue exposure therapy, they would exhibit a reduced skin conductance response in comparison to the participants receiving a placebo with cue exposure therapy.&lt;ref name=Santa-Anna /&gt;  Their data suggested that when DCS was administered with cue exposure therapy 1 hour prior to each of the two 4.5 h experimental sessions, the participants indeed had a lower skin conductance response.&lt;ref name=Santa-Anna /&gt;  Participants receiving the DCS also expressed a reduced urge to smoke in that study, although the evidence didn't indicate a change in their smoking behavior.&lt;ref name=Santa-Anna /&gt; However, another study, conducted in 2011 found that administration of DCS reduced nicotine self-administration in rats with lower baselines levels of response but was actually detrimental for rats with higher baseline levels.&lt;ref name=Levin&gt;{{cite journal|last=Levin|first=Edward|author2=Susan Slade |author3=Corinne Wells |author4=Ann Petro |author5=Jed E. Rose |title=D-cycloserine selectively decreases nicotine self-administration in rats with low baseline levels of response|journal=Pharmacology Biochemistry And Behavior|year=2011|volume=98|issue=2|pages=210–214|PMID= 21192967|doi=10.1016/j.pbb.2010.12.023}}&lt;/ref&gt;  They found that chronic administration of DCS  in 40&amp;nbsp;mg/kg was effective in creating these responses, implying that NMDA receptors may potentially be implicated in individuals who are trying to quit smoking.

{{Drugbox
| IUPAC_name        = (4S)-4-Amino-1,2-oxazolidin-3-one
| image             = 
| CAS_number        = 339-72-0
| ATC_prefix        = 
| ATC_suffix        = 
| PubChem           = 449215
| DrugBank          = 
| ChemSpiderID      = 395808
| chemical_formula  = C&lt;sub&gt;3&lt;/sub&gt;H&lt;sub&gt;6&lt;/sub&gt;N&lt;sub&gt;2&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt;
| molecular_weight  = 102.092
| smiles            = C1[C@@H](C(=O)NO1)N
| InChI             = 1/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m0/s1
| InChIKey          = DYDCUQKUCUHJBH-REOHCLBHBD
| StdInChI          = 1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m0/s1
| StdInChIKey       = DYDCUQKUCUHJBH-REOHCLBHSA-N
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| pregnancy_AU      =  &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US      =  &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category=  
| legal_AU =  &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA =  &lt;!-- Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK =  &lt;!-- GSL, P, POM, CD, or Class A, B, C --&gt;
| legal_US =  &lt;!-- OTC / Rx-only / Schedule I, II, III, IV, V --&gt;
| legal_status      = 
| routes_of_administration = 
}}

=== &lt;small&gt;L&lt;/small&gt;-Cycloserine===
The levorotary version of the drug, &lt;small&gt;L&lt;/small&gt;-cycloserine, has been shown to irreversibly inhibit GABA pyridoxal 5′-phosphate-dependent aminitransferase in ''E. coli'', as well in the brains of various animals, such as pigs, cats, and monkeys in a time-dependent manner.&lt;ref name=Silverman-GABA /&gt; This results in increased levels of gamma-aminobutyric acid ([[GABA]]), an inhibitory [[neurotransmitter]] ''in vivo'', since its breakdown is halted by the inhibition of [[GABA transaminase]].&lt;ref name=Silverman-GABA /&gt;&lt;ref name=&quot;Polc 1986&quot;&gt;{{pmid|3012401}}&lt;/ref&gt; Small doses of LCS have been suggested to reduce hyperexcitability in the brain in acutely treated and subchronically treated animals through GABAnergic inhibition.&lt;ref name=Polc&gt;{{cite journal|last=Polc|first=P.|coauthors=L. Pieri, E.P. Bonetti, R. Scherschlicht, H. Moehler, R. Kettler, W. Burkard, and W. Haefely|title=Behavioural and biochemical effects after single and repeated administration to mice, rats and cats|journal=Neuropharmacology|date=April 1986|volume=25|issue=4|PMID= 3012401|pages=411–8|doi=10.1016/0028-3908(86)90236-4}}&lt;/ref&gt;  Furthermore, peak effects of this inhibition can be seen 3-4 hr after a single intraperitoneal injection.&lt;ref name=Polc /&gt;  LCS has also been implicated in moderately increasing alanine levels and slightly decreasing [[aspartate]], [[glutamate]], and [[glycine]] levels in the brain.&lt;ref name=Polc /&gt; Small doses of LCS have been shown to reduce levels of cGMP in rat cerebella, whereas small doses administered to cats attentuated the hypothalamically elicited rage reaction.&lt;ref name=Polc /&gt; Larger doses of LCS impaired performance of mice in various tests, such as the rotarod, chimney, and horizontal wire tests.&lt;ref name=Polc /&gt; In rats, the larger doses resulted in reduction of spontaneous [[Animal locomotion|locomotor]] activity.&lt;ref name=Polc /&gt;

== References ==
{{Reflist|30em}}

{{Antimycobacterials}}
{{Cell wall disruptive antibiotics}}
{{Neurotransmitters}}
{{Glycinergics}}

[[Category:Tuberculosis]]
[[Category:Antibiotics]]
[[Category:World Health Organization essential medicines]]
[[Category:Lactams]]
[[Category:Isoxazolidinones]]
[[Category:NMDA receptor agonists]]</text>
      <sha1>6g1iiex73g2ysgpmsfgaely8y38mip0</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Seraticin</title>
    <ns>0</ns>
    <id>18733028</id>
    <revision>
      <id>593029310</id>
      <parentid>559581445</parentid>
      <timestamp>2014-01-29T22:47:48Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated date parameter errors]]</comment>
      <text xml:space="preserve" bytes="1867">'''Seraticin''' is a novel [[antibiotic]] developed by scientists at [[Swansea University]] able to inhibit 12 different strains of [[Methicillin-resistant Staphylococcus aureus|MRSA]], as well as ''E. coli'' and ''C. difficile''. The research was funded by leading charity [[Action Medical Research]], with support from the [[Rosetrees Trust]]. Seraticin was isolated as a compound of less than 500Da molecular weight from the maggot secretions of the common green bottle fly ([[Lucilia sericata]]).&lt;ref&gt;{{cite news|url=http://www.sciencedaily.com/releases/2008/08/080805155624.htm|title=Multi-Tasking Maggots In Superbug Showdown|work=ScienceDaily|accessdate=8 December 2012|date=11 August 2012}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |author=Bexfield A |title=The antibacterial activity against MRSA strains and other bacteria of a &lt;500Da fraction from maggot excretions/secretions of Lucilia sericata (Diptera: Calliphoridae) |journal=Microbes Infect. |volume=10 |issue=4 |pages=325–33 |date=April 2008 |pmid=18400544 |doi=10.1016/j.micinf.2007.12.011 |url= |author-separator=, |author2=Bond AE |author3=Roberts EC |display-authors=3 |last4=Dudley |first4=Edward |last5=Nigam |first5=Yamni |last6=Thomas |first6=Stephen |last7=Newton |first7=Russell P. |last8=Ratcliffe |first8=Norman A.}}&lt;/ref&gt; It was patented in 2008 and has the empirical formula {{chem|C|10|H|16|N|6|O|9}}.&lt;ref name=patent&gt;{{cite journal|url=http://patentscope.wipo.int/search/en/WO2011042684|title=(WO2011042684)  Antimicrobial Composition and a Method of Controlling Contamination and Infection Using Said Composition|journal=US patent|date=01.10.2010|accessdate=8 December 2012}}&lt;/ref&gt;

==References==
{{reflist}}

==External links==
*[http://www.action.org.uk Action Medical Research]
*[http://www.rosetreestrust.co.uk Rosetrees Trust]


[[Category:Antibiotics]]

{{Antibiotics}}
{{Antibiotic-stub}}</text>
      <sha1>c679f8kgubgrmtzr23pw7mwzz0s0q0z</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Fusidic acid</title>
    <ns>0</ns>
    <id>935328</id>
    <revision>
      <id>604717727</id>
      <parentid>604717663</parentid>
      <timestamp>2014-04-18T10:21:34Z</timestamp>
      <contributor>
        <ip>39.34.153.53</ip>
      </contributor>
      <comment>/* Trade names and preparations */</comment>
      <text xml:space="preserve" bytes="19083">{{Drugbox  
| Verifiedfields = changed
| verifiedrevid = 476993164
| IUPAC_name = 2-[(1''S'',2''S'',5''R'',6''S'',7''S'',10''S'',11''S'',13''S'',14''Z'',15''R'',17''R'')-13-(acetyloxy)-5,17-dihydroxy-2,6,10,11-tetramethyltetracyclo[8.7.0.0&lt;sup&gt;2,7&lt;/sup&gt;.0&lt;sup&gt;11,15&lt;/sup&gt;]heptadecan-14-ylidene]-6-methylhept-5-enoic acid
| image = Fusidic acid structure.svg
| drug_name = Fusidic acid

&lt;!--Clinical data--&gt;
| tradename =  Fucidin, Fucithalmic
| Drugs.com = {{drugs.com|CONS|fusidic-acid-oral-injection}}

&lt;!--Pharmacokinetic data--&gt;
| bioavailability = 91% oral bioavailability
| protein_bound = 97 to 99%
| elimination_half-life = Approximately 5 to 6 hours in adults

&lt;!--Identifiers--&gt;
| synonyms = Sodium fusidate
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 6990-06-3
| ATC_prefix = D06
| ATC_suffix = AX01
| ATC_supplemental = {{ATC|D09|AA02}} (dressing) {{ATC|J01|XC01}} {{ATC|S01|AA13}}
| PubChem = 3000226
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB02703
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2271900
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 59XE10C19C
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D04281
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 29013
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 374975

&lt;!--Chemical data--&gt;
| C=31 | H=48 | O=6 
| molecular_weight = 516.709
| smiles = O=C(O)/C(=C3/[C@@H]2C[C@@H](O)[C@H]1[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@@H]4CC[C@@]1([C@]2(C[C@@H]3OC(=O)C)C)C)CC\C=C(/C)C
| InChI = 1/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1
| InChIKey = IECPWNUMDGFDKC-MZJAQBGEBS
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IECPWNUMDGFDKC-MZJAQBGESA-N
}}
'''Fusidic acid''' is a [[bacteriostatic]] [[antibiotic]] that is often used topically in creams and eyedrops, but may also be given systemically as tablets or injections. The global problem of advancing [[antimicrobial resistance]] has led to a renewed interest in its use recently.&lt;ref&gt;Falagas ME, Grammatikos AP, Michalopoulos A. Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther. 2008; 6(5):593-600 PMID 18847400&lt;/ref&gt;

==Pharmacology==
Fusidic acid acts as a bacterial [[protein synthesis inhibitor]] by preventing the turnover of [[elongation factor]] G ([[EF-G]]) from the [[ribosome]]. Fusidic acid is effective primarily on [[gram-positive]] bacteria such as ''[[Staphylococcus]]'' species, ''[[Streptococcus]]'' species, &lt;ref&gt;Leclercq R, Bismuth, R, Casin, I, Cavallo, JD, Croize, J, Felten, A, Goldstein, F, Monteil, H, Quentin-Noury, C, Reverdy, M, Vergnaud, M, Roiron, R. (2000) In Vitro Activity of Fusidic Acid Against Streptococci isolated form Skin and Soft Tissue Infections.  J. Antimicrob. Chemother. 45(1): 27-29.&lt;/ref&gt; and ''[[Corynebacterium]]'' species.  Fusidic acid inhibits bacterial replication and does not kill the bacteria, and is therefore termed &quot;[[bacteriostatic]]&quot;.

Fusidic acid is a true [[antibiotic]], derived from the fungus ''[[Fusidium]] coccineum'' and was developed by Leo Laboratories in [[Denmark|Ballerup, Denmark]] and released for clinical use in the 1960s.  It has also been isolated from ''[[Mucor]] ramannianus'' and ''[[Isaria]] kogana''. The drug is licensed for use as its [[sodium]] [[salt (chemistry)|salt]] '''sodium fusidate''', and it is approved for use under prescription in South Korea, Japan, UK, Canada, Europe, Australia, New Zealand, Thailand, India and Taiwan.  A different oral dosing regimen, based on the compound's pharmacokinetic/pharmacodynamic (PK-PD) profile is in clinical development in the U.S.&lt;ref name=&quot;Moriarty&quot;&gt;Moriarty SR, Clark K, Scott D, Degenhardt TP, Fernandes P, Craft JC, Corey GR, Still JG and Das A (2010). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract L1-1762&lt;/ref&gt; as [[Taksta]].

==Uses==
Fusidic acid is active ''[[in vitro]]'' against ''[[Staphylococcus aureus]]'', most coagulase-negative staphylococci, Beta-hemolytic streptococci, ''Corynebacterium'' species, and most clostridium species. Fusidic acid has no known useful activity against  enterococci or most Gram-negative bacteria (except [[Neisseria]], [[Moraxella]], ''[[Legionella pneumophila]]'', and ''[[Bacteroides fragilis]]''). Fusidic acid is active ''in vitro'' and clinically against ''[[Mycobacterium leprae]]'' but has only marginal activity against ''[[Mycobacterium tuberculosis]]''.

One important clinical use of fusidic acid is its activity against [[methicillin-resistant Staphylococcus aureus]].&lt;ref&gt;[http://www.guardian.co.uk/society/2007/jan/17/nhs.health/  ''Existing drug will cure hospital superbug MRSA, say scientists'' &amp;ndash; The Guardian, 17 January 2007].Accessed 2008-01-17.&lt;/ref&gt; Many strains of MRSA remain sensitive to fusidic acid, but, because there is a low genetic barrier to [[drug resistance]] (a single point mutation is all that is required), fusidic acid must never be used on its own to treat serious MRSA infection and should be combined with another antimicrobial such as [[rifampicin]] when administering oral or topical dosing regimens approved in Europe, Canada, and elsewhere. However, resistance selection is low when pathogens are challenged at high drug exposure.&lt;ref&gt;O'Neill AJ and Chopra I (2004). Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques. Expert Opin. Investig. Drugs. 13(8):1045-1063&lt;/ref&gt; An orally-administered mono-therapy with a high loading dose is under development in the United States.&lt;ref name=&quot;Moriarty&quot; /&gt;

Topical fusidic acid is occasionally used as a treatment for [[acne vulgaris]].&lt;ref&gt;{{cite journal | pmid=10528787 |title=Fusidic acid in skin and soft tissue infections. |year=1999 |last1=Spelman. |journal=International Journal of Antimicrobial Agents |}}&lt;/ref&gt; As a treatment for acne, fusidic acid is often partially effective at improving acne symptoms.&lt;ref&gt;{{cite web|url=http://scienceofacne.com/fusidic-acid-fucidin/|title=Fusidic Acid and Acne Vulgaris |publisher=ScienceOfAcne.com |date=2011-09-11 |accessdate=2012-08-14}}&lt;/ref&gt; However, research studies have indicated that fusidic acid is not as highly active against ''[[Propionibacterium acnes]]'' as many other antibiotics that are commonly used as acne treatments.&lt;ref&gt;{{cite journal | pmid=9536540 |title=Investigation of the mechanism of action of 2% fusidic acid lotion in the treatment of acne vulgaris. |year=1997 |last1=Sommer, et al. |journal=Clinical Experimental Dermatology |}}&lt;/ref&gt; Fusidic acid is also found in several additional topical skin and eye preparations (e.g. [[Fucibet]]), although its use for these purposes is controversial.&lt;ref name=&quot;Howden2006&quot;&gt;{{cite journal | title=Dumb and dumber&amp;mdash;the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in ''Staphylococcus aureus'' | author=Howden BP, Grayson ML | journal=Clin Infect Dis | volume=42 | issue=3 | pages=394&amp;ndash;400 | doi=10.1086/499365 | year=2006 | pmid=16392088 }}&lt;/ref&gt;

Fusidic acid is being tested for indications beyond skin infections.    There is evidence from compassionate use cases that fusidic acid may be effective in the treatment of patients with [[prosthetic]] joint-related chronic [[osteomyelitis]].&lt;ref&gt;Wolfe, CR (2011) Case report: treatment of chronic osteomyelitis. ''Clinical Infectious Diseases'' 52(Supplement 7): S538-S541&lt;/ref&gt;

==Dose==
Fusidic acid should not be used on its own to treat ''[[Staphylococcus aureus|S. aureus]]'' infections when used at low drug dosages.  However, it may be possible to use fusidic acid as monotherapy when used at higher doses.&lt;ref name=&quot;Moriarty&quot; /&gt;
The use of topical preparations (skin creams and eye ointments) containing fusidic acid is strongly associated with the development of resistance,&lt;ref&gt;{{cite journal | author=Mason BW, Howard AJ, Magee JT | title=Fusidic acid resistance in community isolates of methicillin-susceptible ''Staphylococcus aureus'' and fusidic acid prescribing | year=2003 | journal=J Antimicrob Chemother | volume=51 | pages=300&amp;ndash;3  | doi=10.1093/jac/dkg190 | pmid=12654748 | issue=4}}&lt;/ref&gt; and there are voices agitating against the continued use of fusidic acid monotherapy in the community.&lt;ref name=&quot;Howden2006&quot;/&gt;  Topical preparations used in Europe often contain fusidic acid and [[gentamicin]] in combination, which helps to prevent the development of resistance.

Depending on the reason for which sodium fusidate is prescribed, the adult dose can be 250&amp;nbsp;mg twice a day and or up to 750&amp;nbsp;mg three times a day. (Skin conditions normally need the smaller dose). It is available in tablet and suspension form.&lt;ref&gt;[http://www.medsafe.govt.nz/Profs/Datasheet/f/Fucidintabinjsus.htm/  ''Fucidin'' data sheet archived by New Zealand government. December 2005].Accessed: 2007-09-09.&lt;/ref&gt;  A front-loading oral dosing regimen{{clarification needed|date=July 2013}} is in clinical development in the U.S. based on the pharmacokinetic/pharmacodynamic profile of the compound.  It incorporates a dose of 1,500 mg twice on the first day followed by 600 mg twice-daily.  It has been demonstrated in an ''in vitro'' model to have a low potential for selection of resistant organisms.&lt;ref name=&quot;Moriarty&quot; /&gt;
 
There is an intravenous preparation available, but it is irritant to veins, causing [[phlebitis]]. Most people absorb the drug extremely well after taking it orally, so, if a patient can swallow, there is not much need to administer it intravenously, even if used to treat [[endocarditis]] (infection of the heart chambers).

===Pregnancy caution===

There is inadequate evidence of safety in human pregnancy. Animal studies and many years of clinical experience suggest that fusidic acid is devoid of [[Teratology|teratogenic effects]] (birth defects), but fusidic acid can cross the placental barrier.&lt;ref&gt;[http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=2448#PRODUCTINFO  ''Fucidin)'' UK data sheet archived at the electronic Medicines Compendium. June 1997].Accessed: 2007-09-09.&lt;/ref&gt;

===Side-effects===

*Fucidin Tablets and Suspension occasionally cause liver upsets, which can produce jaundice (yellowing of the skin and the whites of the eyes). This condition will almost always get better after the patient finishes taking Fucidin Tablets or Suspension. Other related side-effects include dark urine and lighter-than-usual feces. These, too, should normalize when the course of treatment is completed.&lt;ref&gt;[http://www.betterhealth.vic.gov.au/bhcv2/bhcmed.nsf/pages/cscfucts/$File/cscfucts.pdf  ''Fucidin patient information leaflet, archived by Government of Victoria, Australia]. Accessed: 2007-09-09.&lt;/ref&gt;
*Patients taking the drug should tell their doctors if they notice that their urine is 'very dark', if their feces are 'very pale', or if their skin or the whites of their eyes become yellow, the Australian data sheet for patients adds.

==Resistance==
Because the drug is not licensed for use in the U.S., there are no Clinical and Laboratory Standards Institute standard definitions of fusidic acid resistance.  However, ''in vitro'' susceptibility studies of U.S. strains of several bacterial species such as ''S. aureus'', including MRSA and coagulase negative ''Staphylococcus'', indicate potent activity against these pathogens&lt;ref&gt;Castanheira M, Watters AA, Bell JM, Turnidge JD and Jones RN (2010).  Fusidic acid resistance rates and prevalence of resistance mechanisms among 'Staphylococcus'' spp. isolated in North America and Australia, 2007-2008.  ''Antimicrobial Agents and Chemotherapy'' 54:3614-3617.&lt;/ref&gt;&lt;ref&gt;Pfaller M, Castaneira M, Sader H and Jones R (2010).  Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada.  ''International Journal of Antimicrobial Agents 35:282-287.&lt;/ref&gt;&lt;ref&gt;Castanheira M, Mendes RE, Rhomberg PR and Jones RN (2010).  Activity of fusidic acid tested against contemporary ''Staphylococcus aureus'' collected from United States hospitals.  Infectious Diseases Society of America, 48th Annual Meeting, Abstract 226.&lt;/ref&gt;

In the UK and Australia, susceptibility is defined as a [[minimum inhibitory concentration]] (MIC) of 0.25&amp;nbsp;mg/l or 0.5&amp;nbsp;mg/l or less.  Resistance is defined as an MIC of 2&amp;nbsp;mg/l or more.  In laboratories using disc diffusion methods, susceptibility for a 2.5&amp;nbsp;µg disc is defined as a zone of 22&amp;nbsp;mm or more, and resistance is defined as a zone of 17&amp;nbsp;mm or less; intermediate values are defined as intermediate resistance.  These susceptibility criteria are based on lower dosing regimens used outside of the U.S.  Clinical trials in the U.S. incorporate a different dosing regimen that results in higher blood levels.  Therefore, the U.S. dosing regimen may warrant different susceptibility criteria.

Mechanisms of resistance have been extensively studied only in ''Staphylococcus aureus''.  The most important mechanism is the development of point mutations in ''fusA'', the chromosomal gene that codes for EF-G.  The mutation alters EF-G so that fusidic acid is no longer able to bind to it.&lt;ref&gt;{{cite journal
|author=Turnidge J, Collignon P
|title=Resistance to fusidic acid
|year=1999
|journal=Int J Antimicrob Agents
|volume=12
|issue=Suppl 2
|pages=S35&amp;ndash;44|doi=10.1016/S0924-8579(98)00072-7
}}&lt;/ref&gt;&lt;ref&gt;{{cite journal
|author=Besier S, Ludwig A, Brade V, Wichelhaus TA
|title=Molecular analysis of fusidic acid resistance in ''Staphylococcus aureus''
|year=2003
|journal=Mol Microbiol
|volume=47
|pages=463&amp;ndash;9|doi=10.1046/j.1365-2958.2003.03307.x
|pmid=12519196
|issue=2
}}&lt;/ref&gt;  Resistance is readily acquired when fusidic acid is used alone and commonly develops during the course of treatment. As with most other antibiotics, resistance to fusidic acid arises less frequently when used in combination with other drugs. For this reason, fusidic acid should not be used on its own to treat serious ''Staph. aureus'' infections. However, at least in Canadian hospitals, data collected between 1999-2005 showed rather low rate of resistance of MSSA and MRSA to fusidic acid, and mupirocin was found to be the more problematic topical antibiotic for the aforementioned conditions.&lt;ref&gt;{{cite journal |author=Rennie RP | title=Susceptibility of Staphylococcus aureus to fusidic acid:Canadian data |year=2006 |journal=J Cutan Med Surg| volume=10| pages=277–280 |pmid=17241597 |issue=6}}&lt;/ref&gt; 

Some bacteria also mediate resistance via the ''fusB'' gene, which is carried on a plasmid; the mechanism by which ''fusB'' causes resistance is unknown.

==Interactions==
Fusidic acid should not be used with quinolones, with which they are antagonistic.  When combined with rifampicin, the action of fusidic acid is additive or [[synergy|synergistic]].&lt;ref&gt;{{cite journal
|author=Collignon P, Turnidge J
|title=Fusidic acid in vitro activity
|journal=Int J Antimicrob
|year=1999
|volume=12
|issue=Suppl 2
|pages=S45&amp;ndash;58
|doi=10.1016/S0924-8579(98)00073-9}}&lt;/ref&gt;&lt;br /&gt;
It has been reported on August 8, 2008, that the Irish Medicines Board is investigating the death of a 59-year-old Irish man who developed [[rhabdomyolysis]] after combining [[Lipitor]] and Fusidic Acid, and three similar cases.&lt;ref&gt;{{cite news| url=http://www.independent.ie/national-news/man-died-after-rare-medical-reaction-to-cholesterol-drug-1449275.html | work=Irish Independent | first=Ralph | last=Riegel | title=Man died after rare medical reaction to cholesterol drug | date=2008-08-08}}&lt;/ref&gt; In August, 2011, the UK's Medicines and Healthcare products Regulatory Agency issued a Drug Safety Update warning that &quot;Systemic fusidic acid (Fucidin) should not be given with [[statins]] because of a risk of serious and potentially fatal [[rhabdomyolysis]]. &quot;&lt;ref&gt;Drug Safety Update Sept 2011, vol 5 issue 2: A1.&lt;/ref&gt;

It is delivered as an [[ointment]], as a [[Cream (pharmaceutical)|cream]], as [[eye drop]]s, or in [[Tablet (pharmacy)|tablet]] form.

==Trade names and preparations==
{{colbegin|2}}
*Usidin cream(in pakistan, Pacific Pharmaceuticals Ltd. )
*Usidin-H cream(in pakistan, Pacific Pharmaceuticals Ltd. )
*Usibet cream(in pakistan, Pacific Pharmaceuticals Ltd. )
*fuskin b cream(in pakistan, pharma health )
*fuskin h cream(in pakistan, pharma health )
*fuskin cream(in pakistan, pharma health )
*Fucidin (of Leo in Canada and the US)
*Fucidin H (topical cream with [[corticosteroid]] - Leo)
*Fucidin (of Leo in UK/ Leo-[[Ranbaxy]]-Croslands in India)
*Fucidine (of Leo in France)
*Fucidin (of Leo in Norway and Israel)
*Fucidin (of Adcock Ingram, licenced from Leo, in South Africa)
*Fucithalmic (of Leo in the UK, the Netherlands, Denmark and Portugal)
*Fucicort (topical mixture with [[hydrocortisone]])
*Fucibet (topical mixture with [[betamethasone]])
*Ezaderm (topical mixture with [[betamethasone]])(of United Pharmaceutical &quot;UPM&quot; in Jordan)
*Fuci (of pharopharm in Egypt)
*Fucizon (topical mixture with hydrocortisone of pharopharm in Egypt)
*Foban (topical cream in New Zealand)
*Betafusin (cream mixture with betamethasone valerate in Greece)
*Fusimax  (of Schwartz in India)
*Fusiderm (topical cream and ointment by indi pharma in India)
*Fusid (in Nepal)
*Fudic (topical cream in India)
*Fucidin ({{lang|ko-kr|후시딘}}, of Dong Wha Pharm in South Korea)
*Stanicid (in [[Serbia]])
*Dermy (Topical cream of W.Woodwards in Pakistan)
*Fugen Cream ({{lang|zh|膚即淨軟膏}} in Taiwan)
*Phudicin Cream (in China; 夫西地酸&lt;ref&gt;http://www.pfb.org.cn/catalog/antimicrobial/20100204085231859.htm&lt;/ref&gt;)
*Dermofucin cream, ointment and gel (in Jordan)
*Optifucin viscous eye drops (of API in Jordan)
*Verutex (of Roche in Brazil)
*[[Taksta|TAKSTA]] (of Cempra in U.S.)
*Futasole (of Julphar in Gulf and north Africa)
*Stanicid (2% ointment of Hemofarm in Serbia)
*Fuzidin (tablets of Biosintez in Russia)
*Fuzimet (ointment with methyluracil of Biosintez in Russia)
*Axcel Fusidic Acid(2% cream and ointment of Kotra Pharma, Malaysia)
{{colend}}

==References==
{{reflist|2}}

==External links==
* [http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=FUA Fusidic acid bound to proteins] in the [[Protein Data Bank|PDB]]

{{Antibiotics and chemotherapeutics for dermatological use}}
{{Medicated dressings}}
{{Protein synthesis inhibitor antibiotics}}
{{Sterols}}

{{DEFAULTSORT:Fusidic Acid}}
{{commonscat|Fusidic acid}}

[[Category:Antibiotics]]
[[Category:Steroids]]
[[Category:Alkenes]]
[[Category:Alcohols]]
[[Category:Acetate esters]]</text>
      <sha1>jo3d0vwtm4cyx2t2c37te9gldpihcrb</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Antibiotic misuse</title>
    <ns>0</ns>
    <id>23640750</id>
    <revision>
      <id>608556513</id>
      <parentid>608408251</parentid>
      <timestamp>2014-05-14T15:24:06Z</timestamp>
      <contributor>
        <username>Bluerasberry</username>
        <id>7830073</id>
      </contributor>
      <comment>/* Instances of antibiotic misuse */ use larger PDF files - I got the feedback that many computers can open PDF files, but few can open djvu files...</comment>
      <text xml:space="preserve" bytes="26045">[[File:CDC Get Smart poster healthy adult.png|thumb|This poster from the U.S. Centers for Disease Control and Prevention &quot;Get Smart&quot; campaign, intended for use in doctors' offices and other healthcare facilities, warns that antibiotics do not work for viral illnesses such as the common cold.]]
{{Use dmy dates|date=July 2013}}
'''Antibiotic misuse''', sometimes called '''antibiotic abuse''' or '''antibiotic overuse''', refers to the misuse or overuse of [[antibiotic]]s, with potentially serious effects on health. It is a contributing factor to the development of [[antibiotic resistance]], including the creation of [[Antibiotic resistance|multidrug-resistant bacteria]], informally called &quot;super bugs&quot;: relatively harmless bacteria can develop resistance to multiple antibiotics and cause life-threatening infections.&lt;ref name=&quot;pmid9643260&quot;&gt;{{cite journal |author=Harrison JW, Svec TA |title=The beginning of the end of the antibiotic era? Part II. Proposed solutions to antibiotic abuse |journal=[[Quintessence International]] |volume=29 |issue=4 |pages=223–9 |date=April 1998 |pmid=9643260}}&lt;/ref&gt;

==Instances of antibiotic misuse==
[[File:Choosing Wisely antibiotics poster small English.pdf|thumb|right|Health advocacy messages such as this one encourage patients to talk with their doctor about safety in using antibiotics.]]
Common situations in which antibiotics are overused include the following:
*Apparent viral [[respiratory illness]] in children should not be treated with antibiotics. If there is a diagnosis of bacterial infection, then antibiotics may be used.&lt;ref name=&quot;AAPfive&quot;&gt;{{Citation |author1 = American Academy of Pediatrics |author1-link = American Academy of Pediatrics |title = Five Things Physicians and Patients Should Question |publisher = American Academy of Pediatrics |work = [[Choosing Wisely]]: an initiative of the [[ABIM Foundation]] |page = |url = http://www.choosingwisely.org/doctor-patient-lists/american-academy-of-pediatrics/ |accessdate = 1 August 2013}}, which cites
*{{Cite journal 
| author1 = American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis 
| doi = 10.1542/peds.2006-2223 | title = Diagnosis and Management of Bronchiolitis | journal = Pediatrics | volume = 118 | issue = 4 | pages = 1774–1793 | year = 2006 | pmid = 17015575 | pmc = }}
*{{Cite journal | last1 = Shulman | first1 = S. T. | last2 = Bisno | first2 = A. L. | last3 = Clegg | first3 = H. W. | last4 = Gerber | first4 = M. A. | last5 = Kaplan | first5 = E. L. | last6 = Lee | first6 = G. | last7 = Martin | first7 = J. M. | last8 = Van Beneden | first8 = C. | doi = 10.1093/cid/cis629 | title = Clinical Practice Guideline for the Diagnosis and Management of Group a Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America | journal = Clinical Infectious Diseases | volume = 55 | issue = 10 | pages = e86–102 | year = 2012 | pmid = 22965026 | pmc = }}&lt;/ref&gt;
*When children with [[Tympanostomy tube|ear tubes]] get ear infections, they should have antibiotic eardrops put into their ears to go to the infection rather than having oral antibiotics which are more likely to have unwanted side effects.&lt;ref name=&quot;AANfive1&quot;&gt;{{Citation |author1 = American Academy of Otolaryngology – Head and Neck Surgery |author1-link = American Academy of Otolaryngology – Head and Neck Surgery |title = Five Things Physicians and Patients Should Question |publisher = [[American Academy of Otolaryngology – Head and Neck Surgery]] |work = [[Choosing Wisely]]: an initiative of the [[ABIM Foundation]] |page = |url = http://www.choosingwisely.org/doctor-patient-lists/american-academy-of-otolaryngology-head-and-neck-surgery-foundation// |accessdate = 1 August 2013}}, which cites
*{{cite journal|last1=Rosenfeld|first1=R. M.|last2=Schwartz|first2=S. R.|last3=Pynnonen|first3=M. A.|last4=Tunkel|first4=D. E.|last5=Hussey|first5=H. M.|last6=Fichera|first6=J. S.|last7=Grimes|first7=A. M.|last8=Hackell|first8=J. M.|last9=Harrison|first9=M. F.|last10=Haskell|first10=H.|last11=Haynes|first11=D. S.|last12=Kim|first12=T. W.|last13=Lafreniere|first13=D. C.|last14=LeBlanc|first14=K.|last15=Mackey|first15=W. L.|last16=Netterville|first16=J. L.|last17=Pipan|first17=M. E.|last18=Raol|first18=N. P.|last19=Schellhase|first19=K. G.|title=Clinical Practice Guideline: Tympanostomy Tubes in Children|journal=Otolaryngology -- Head and Neck Surgery|volume=149|issue=1 Suppl|year=2013|pages=S1–S35|issn=0194-5998|doi=10.1177/0194599813487302|pmid=23818543}}&lt;/ref&gt;
*[[Swimmer's ear]] should be treated with antibiotic eardrops, not oral antibiotics.&lt;ref name=&quot;AANfive2&quot;&gt;{{Citation |author1 = American Academy of Otolaryngology – Head and Neck Surgery |author1-link = American Academy of Otolaryngology – Head and Neck Surgery |date =February 2013 |title = Five Things Physicians and Patients Should Question |publisher = [[American Academy of Otolaryngology – Head and Neck Surgery]] |work = [[Choosing Wisely]]: an initiative of the [[ABIM Foundation]] |page = |url = http://www.choosingwisely.org/doctor-patient-lists/american-academy-of-otolaryngology-head-and-neck-surgery-foundation/ |accessdate = 1 August 2013}}, which cites
*{{Cite journal | last1 = Rosenfeld | first1 = R. | last2 = Brown | first2 = L. 
| last3 = Cannon | first3 = C. | last4 = Dolor | first4 = R. | last5 = Ganiats | first5 = T. 
| last6 = Hannley | first6 = M. | last7 = Kokemueller | first7 = P. | last8 = Marcy | first8 = S. 
| last9 = Roland | first9 = P. | last10 = Shiffman | first10 = R. | last11 = Stinnett | first11 = S. S. | last12 = Witsell | first12 = D. L. | author13 = American Academy of Otolaryngology--Head Neck Surgery Foundation | doi = 10.1016/j.otohns.2006.02.014 | title = Clinical practice guideline: Acute otitis externa | journal = Otolaryngology - Head and Neck Surgery | volume = 134 | issue = 4 | pages = S4–23 | year = 2006 | pmid = 16638473 | pmc = }}&lt;/ref&gt;
*[[Sinusitis]] should not be treated with antibiotics because it is usually caused a virus, and even when it is caused by a bacteria, antibiotics are not indicated except in atypical circumstances as it usually resolves without treatment.&lt;ref&gt;{{Citation | author1 = [[Consumer Reports]] |author2 = [[American Academy of Allergy, Asthma, and Immunology]] |date = July 2012 |title = Treating sinusitis: Don't rush to antibiotics |publisher = [[Consumer Reports]] |work = Choosing Wisely: an initiative of the [[ABIM Foundation]] |page = |url =http://consumerhealthchoices.org/wp-content/uploads/2012/04/ChoosingWiselySinusitusAAAAI.pdf  |accessdate = 14 August 2012}}&lt;/ref&gt;
*Viral [[conjunctivitis]] should not be treated with antibiotics. Antibiotics should only be used with confirmation that a patient has bacterial conjunctivitis.&lt;ref name=&quot;AAOfive&quot;&gt;{{Citation |author1 = American Academy of Ophthalmology |author1-link = American Academy of Ophthalmology |date = September 2013 |title = Five Things Physicians and Patients Should Question |publisher = American Academy of Ophthalmology |work = [[Choosing Wisely]]: an initiative of the [[ABIM Foundation]] |page = |url = http://www.choosingwisely.org/doctor-patient-lists/american-academy-of-ophthalmology/ |accessdate = 6 January 2013}}, which cites
#*{{cite journal |last1=Sheikh |first1=Aziz |last2=Hurwitz |first2=Brian |last3=Sheikh |first3=Aziz |title=Antibiotics versus placebo for acute bacterial conjunctivitis |year=2006 |doi=10.1002/14651858.CD001211.pub2 |pmid=16625540 |issue=2 |pages=CD001211}}&lt;/ref&gt;
*Older persons often have bacteria in their urine which is detected in routine urine tests, but unless the person has the symptoms of a [[urinary tract infection]], antibiotics should not be used in response.&lt;ref name=&quot;AGSfive&quot;&gt;{{Citation |author1 =  American Geriatrics Society |author1-link = American Geriatrics Society |title = Five Things Physicians and Patients Should Question |publisher = American Geriatrics Society |work = [[Choosing Wisely]]: an initiative of the [[ABIM Foundation]] |page = |url = http://www.choosingwisely.org/doctor-patient-lists/american-geriatrics-society/ |accessdate = August 1, 2013}}&lt;/ref&gt;
*[[Eczema]] should not usually be treated with antibiotics. Dry skin can be treated with lotions or other symptom treatments.&lt;ref name=&quot;AADfive&quot;&gt;{{Citation |author1 = American Academy of Dermatology |author1-link = American Academy of Dermatology |date = February 2013 |title = Five Things Physicians and Patients Should Question |publisher = [[American Academy of Dermatology]] |work = [[Choosing Wisely]]: an initiative of the [[ABIM Foundation]] |page = |url = http://www.choosingwisely.org/doctor-patient-lists/american-academy-of-dermatology/ |accessdate = 5 December 2013}}&lt;/ref&gt;
*The use of antibiotics to treat surgical wounds does not reduce infection rates in comparison with non-antibiotic ointment or no ointment at all.&lt;ref name=&quot;AADfive&quot;&gt;{{Citation |author1 = American Academy of Dermatology |author1-link = American Academy of Dermatology |date = February 2013 |title = Five Things Physicians and Patients Should Question |publisher = [[American Academy of Dermatology]] |work = [[Choosing Wisely]]: an initiative of the [[ABIM Foundation]] |page = |url = http://www.choosingwisely.org/doctor-patient-lists/american-academy-of-dermatology/ |accessdate = 5 December 2013}}, which cites
*{{Cite journal | last1 = Sheth | first1 = V. M. | last2 = Weitzul | first2 = S. | title = Postoperative topical antimicrobial use | journal = Dermatitis : contact, atopic, occupational, drug 
| volume = 19 | issue = 4 | pages = 181–189 | year = 2008 | pmid = 18674453}}&lt;/ref&gt;

==Social and economic impact==
Antibiotics can cause severe reactions and add significantly to the cost of care.&lt;ref&gt;{{cite journal |author=Beringer PM, Wong-Beringer A, Rho JP |title=Economic aspects of antibacterial adverse effects |journal=PharmacoEconomics |volume=13 |issue=1 Pt 1 |pages=35–49 |date=January 1998 |pmid=10175984 |doi=10.2165/00019053-199813010-00004}}&lt;/ref&gt;  In the United States, antibiotics and anti-infectives are the leading cause of [[adverse effect]] from drugs.  In a study of 32 States in 2011, antibiotics and anti-infectives accounted for nearly 24 percent of ADEs that were present on admission, and 28 percent of those that occurred during a hospital stay.&lt;ref&gt;Weiss AJ, Elixhauser A. Origin of Adverse Drug Events in U.S. Hospitals, 2011. HCUP Statistical Brief #158. Agency for Healthcare Research and Quality, Rockville, MD. July 2013. [http://hcup-us.ahrq.gov/reports/statbriefs/sb158.jsp]&lt;/ref&gt;

Negative reactions to fluoroquinolones are easily misdiagnosed as a seizure disorder, [[Central nervous system|CNS]] problems, or psychiatric problems.&lt;ref&gt;{{cite journal |author=James R. Roberts |date= October 2008 |title=Adverse Reactions to Fluoroquinolones |journal=Emergency Medicine News |volume=30 |issue=10 |pages=16–18 |publisher=Emergency Medicine News |doi=10.1097/01.EEM.0000338244.41795.9c |url=http://journals.lww.com/em-news/Fulltext/2008/10000/Adverse_Reactions_to_Fluoroquinolones_.23.aspx |doi_brokendate=2010-03-01 }}&lt;/ref&gt; In Italy, doctors report fluoroquinolones among the top three prescribed drugs responsible for adverse neurological and psychiatric effects. The neuropsychiatric effects include [[tremor]], [[confusion]], [[anxiety]], [[insomnia]], agitation, and [[psychosis]] (in severe cases). Among the quinolones, [[moxifloxacin]] is reported as having the highest propensity to cause CNS toxicity.&lt;ref&gt;{{cite journal |author=Galatti L |title=Neuropsychiatric reactions to drugs: an analysis of spontaneous reports from general practitioners in Italy |journal=Pharmacological Research |volume=51 |issue=3 |pages=211–6 |date=March 2005 |pmid=15661570 |doi=10.1016/j.phrs.2004.08.003 |author-separator=, |author2=Giustini SE |author3=Sessa A |display-authors=3 |last4=Polimeni |first4=Giovanni |last5=Salvo |first5=Francesco |last6=Spina |first6=Edoardo |last7=Caputi |first7=Achille P.}}&lt;/ref&gt;

==Antibiotic resistance==
{{main|Antibiotic resistance}}
Though antibiotics are required to treat severe bacterial infections, misuse has contributed to a rise in bacterial resistance. The overuse of fluoroquinolone and other antibiotics fuels antibiotic resistance in bacteria, which can inhibit the treatment antibiotic-resistant infections.&lt;ref name=&quot;Neuhauser-2003&quot;&gt;{{cite journal |author=Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP |title=Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use |journal=JAMA |volume=289 |issue=7 |pages=885–8 |date=February 2003 |pmid=12588273 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&amp;pmid=12588273 |doi=10.1001/jama.289.7.885}}&lt;/ref&gt;&lt;ref&gt;{{cite web |title=Studies examine prescribing of antibiotics for respiratory infections in hospital emergency departments |url=http://www.ahrq.gov/research/nov07/1107RA29.htm |publisher=U.S. Department of Health and Human Services |location=USA |quote = From 1995 to 2002, inappropriate antibiotic prescribing for acute respiratory infections, which are usually caused by viruses and thus are not responsive to antibiotics, declined from 61% to 49%. However, the use of broad-spectrum antibiotics such as the fluoroquinolones, jumped from 41% to 77% from 1995 to 2001. Overuse of these antibiotics will eventually render them useless for treating antibiotic-resistant infections, for which broad-spectrum antibiotics are supposed to be reserved. }}&lt;/ref&gt;&lt;ref&gt;{{Cite web |url=http://www.nyc.gov/html/doh/html/tb/tb4a.shtml |title=Fluoroquinolone Resistance and Tuberculosis Treatment |publisher=The New York City Department of Health and Mental Hygiene |location=USA }}&lt;/ref&gt; Their excessive use in children with [[otitis media]] has given rise to a breed of bacteria resistant to antibiotics entirely.&lt;ref name=&quot;Froom J, Culpepper L, Jacobs M, et al. 1997 98–102&quot;&gt;{{cite journal |author=Froom J |title=Antimicrobials for acute otitis media? A review from the International Primary Care Network |journal=BMJ |volume=315 |issue=7100 |pages=98–102 |date=July 1997 |pmid=9240050 |pmc=2127061 |url=http://bmj.com/cgi/pmidlookup?view=long&amp;pmid=9240050 |doi=10.1136/bmj.315.7100.98 |author-separator=, |author2=Culpepper L |author3=Jacobs M |display-authors=3 |last4=Demelker |first4=R. A |last5=Green |first5=L. A |last6=Van Buchem |first6=L. |last7=Grob |first7=P. |last8=Heeren |first8=T.}}&lt;/ref&gt;

Widespread use of fluoroquinolones as a first-line antibiotic has led to decreased [[antibiotic sensitivity]], with negative implications for serious bacterial infections such as those associated with [[cystic fibrosis]], where quinolones are among the few viable antibiotics.&lt;ref&gt;{{cite web |title=Cipro, Related Antibiotics Over-Prescribed, Fueling Microbe Resistance |url=http://www.universityofcalifornia.edu/news/article/4786 |publisher=University Of California |location=USA |date=1 October 2002 |accessdate=13 August 2009}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |author=K. Bassett |coauthors=B. Mintzes V. Musini T.L. Perry Jr M. Wong J.M. Wright |date=November 2002 |title=Therapeutics Letter |journal=Canadian Family Physician |volume=48 |url=http://www.cfpc.ca/cfp/2002/Nov/_pdf/vol48-nov-critical-2.pdf |format=PDF |quote=Gatifloxacin and moxifloxacin have no proven clinical advantages over other fluoroquinolones, macrolides, or amoxicillin. Based on cost, they are not first-choice drugs for their approved indications.}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |author=Ziganshina LE, Squire SB |editor1-last=Ziganshina |editor1-first=Lilia E |title=Fluoroquinolones for treating tuberculosis |journal=Cochrane Database of Systematic Reviews |volume= |issue=1 |pages=CD004795 |year=2008 |pmid=18254061 |doi=10.1002/14651858.CD004795.pub3}}&lt;/ref&gt;

==Inappropriate use==
Antibiotics have no effect on viral infections such as the common cold. They are also ineffective against sore throats, which are usually viral and self-resolving.&lt;ref&gt;{{cite journal |author=Little P, Gould C, Williamson I, Warner G, Gantley M, Kinmonth AL |title=Reattendance and complications in a randomised trial of prescribing strategies for sore throat: the medicalising effect of prescribing antibiotics |journal=BMJ |volume=315 |issue=7104 |pages=350–2 |date=August 1997 |pmid=9270458 |pmc=2127265 |url=http://bmj.com/cgi/pmidlookup?view=long&amp;pmid=9270458 |doi=10.1136/bmj.315.7104.350}}&lt;/ref&gt; Most cases of bronchitis (90&amp;ndash;95%) are viral as well, passing after a few weeks&amp;mdash;the use of antibiotics such as [[ofloxacin]] against bronchitis is superfluous and can put the patient at risk of suffering adverse reactions.&lt;ref&gt;{{cite journal |author=Hueston WJ |title=Antibiotics: neither cost effective nor 'cough' effective |journal=The Journal of Family Practice |volume=44 |issue=3 |pages=261–5 |date=March 1997 |pmid=9071245}}&lt;/ref&gt;

Official guidelines by the [[American Heart Association]] for [[dental antibiotic prophylaxis]] call for the administration of antibiotics to prevent [[infective endocarditis]]. Though the current (2007) guidelines dictate more restricted antibiotic use, many dentists&lt;ref name=&quot;dental&quot;&gt;{{cite journal |author=Zadik Y |title=Dentists' knowledge and implementation of the 2007 American Heart Association guidelines for the prevention of infective endocarditis |journal=Oral Surg Oral Med Oral Pathol Oral Radiol Endod |volume=106 |issue=6 |pages=e16–9 |date=December 2008 |pmid=19000604 |url=http://www.ooooe.net/article/S1079-2104(08)00597-0/abstract |doi=10.1016/j.tripleo.2008.08.009 |author-separator=, |author2=Findler M |author3=Livne S |display-authors=3 |last4=Levin |first4=Liran |last5=Elad |first5=Sharon |last6=American Heart |first6=Association}}&lt;/ref&gt; and dental patients&lt;ref name=&quot;survey&quot;&gt;{{cite journal |author=Elad S, Binenfeld-Alon E, Zadik Y, Aharoni M, Findler M. |title=Survey of acceptance of the 2007 American Heart Association guidelines for the prevention of infective endocarditis: a pilot study|journal=Quintessence Int |volume=42 |issue=3 |pages=243–51 |date=March 2011 |pmid=21465012 |url=http://www.quintpub.com/journals/qi/abstract.php?iss2_id=919&amp;article_id=10528&amp;article=9&amp;title=Survey of acceptance of the 2007 American Heart Association Guidelines for the prevention of infective endocarditis: A pilot study}}&lt;/ref&gt; follow the 1997 guidelines instead, leading to overuse of antibiotics.&lt;ref&gt;{{cite journal |author=Wilson W |title=Prevention of infective endocarditis: guidelines from the American Heart Association |journal=Circulation |volume=116 |issue=15 |pages=1736–54 |date=October 2007 |pmid=17446442 |doi=10.1161/CIRCULATIONAHA.106.183095 |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&amp;pmid=17446442 |author-separator=, |author2=Taubert KA |author3=Gewitz M |display-authors=3 |last4=Lockhart |first4=P. B. |last5=Baddour |first5=L. M. |last6=Levison |first6=M. |last7=Bolger |first7=A. |last8=Cabell |first8=C. H. |last9=Takahashi |first9=M.}}&lt;/ref&gt;

===Antibiotics in livestock===
{{main|Antibiotic use in livestock}}
There has been massive use of antibiotics in [[animal husbandry]]. The most abundant use of antimicrobials worldwide are in livestock; they are typically distributed in animal feed or water for purposes such as disease prevention and growth.&lt;ref&gt;{{Citation |last1=Silbergeld |first1= E.K. |last2=Graham |first2=J. |last3=Price |first3=L.B. |title=Industrial food animal production, antimicrobial resistance, and human health |journal=Annual review of public health |volume=29 |pages=151–169 |year=2008 |doi=10.1146/annurev.publhealth.29.020907.090904 |pmid=18348709}}&lt;/ref&gt;
Debates have arisen surrounding the extent of the impact of these antibiotics, particularly antimicrobial growth promoters, on human antibiotic resistance. Although some sources believe that there remains a lack of knowledge on which antibiotic use generates the most risk to humans,&lt;ref&gt;{{Citation |last1=Landers |first1=T.F. |last2=Cohen |first2=B. |last3=Wittum |first3=T.E. |last4=Larson |first4=E.L. |title=A review of antibiotic use in food animals: Perspective, policy, and potential |journal=Public health reports |volume=127 |issue=1 |pages=4–22 |year=2012 |doi=10.1093/jac/dkg483}}&lt;/ref&gt; policies and regulations have been placed to limit any harmful effects.

===Fluoroquinolone===
The use of fluoroquinolones as first-line agents is not generally recommended, except for patients who are seriously ill and may soon require hospitalization.&lt;ref&gt;{{cite web |first= |last= |author=Terry K. Babb, Michael Boothe, Heidi Brainerd,Richard E. Brodsky, Kelly C. Conright, Traci Gale, Arthur S. Hansen, R. Duane Hopson, Thomas C. Hunt, Diane Liljegren, Ronald J. Miller, Gregory R. Polston, Richard C. Reem, Janice L. Stables, Alexander H. vonHafften, Trish D. White,Dave Campana, Sandy Kapur, Dr. Jeffrey Demain |title=ALASKA MEDICAID PHARMACY AND THERAPEUTICS COMMITTEE |url=http://www.hss.state.ak.us/dhcs/PDL/minutes_meetings_pdl/minutes_031904_pdl.pdf |publisher= |location=Alaska, USA |format=PDF |date=19 March 2004 |accessdate=12 August 2009| archiveurl= http://web.archive.org/web/20090812223847/http://www.hss.state.ak.us/dhcs/PDL/minutes_meetings_pdl/minutes_031904_pdl.pdf| archivedate= 12 August 2009 &lt;!--DASHBot--&gt;| deadurl= no}}&lt;/ref&gt; However, the use of fluoroquinolones had increased three-fold in emergency rooms in the United States between 1995 and 2002, while the use of safer alternatives such as [[macrolide]]s declined significantly.&lt;ref name=&quot;pmid15745724&quot;&gt;{{cite journal |author=Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS |title=Fluoroquinolone prescribing in the United States: 1995 to 2002 |journal=The American Journal of Medicine |volume=118 |issue=3 |pages=259–68 |date=March 2005 |pmid=15745724 |doi=10.1016/j.amjmed.2004.09.015}}&lt;/ref&gt;&lt;ref&gt;{{Cite web |author=LaTiffany C. Epps |author2=Paul D. Walker |url=http://www.uspharmacist.com/content/d/featured%20articles/c/11538/ |title=Fluoroquinolone Consumption and Emerging Resistance |publisher= |location=USA |date=20 October 2006 }}&lt;/ref&gt;

Patients with [[chronic prostatitis/chronic pelvic pain syndrome|chronic prostatitis]] (category IIIB) are often misdiagnosed as having bacterial forms of [[prostatitis]] and are erroneously treated with fluoroquinolone. Only 5% of patients with prostatitis have bacterial prostatitis, which can alleviated by antibiotics.&lt;ref name=&quot;Campbell&quot;&gt;{{cite book |last1=Wein |first1=Alan J. |last2=Kavoussi |first2= Louis R. |last3=Novick |first3=Andrew C. |last4=Partin |first4=Alan W. |last5=Peters |first5=Craig A. |title=Campbell-Walsh Urology Review Manual |url=http://books.google.com/?id=KGVqAAAAMAAJ |edition=Ninth |date=19 March 2007 |publisher=Saunders |isbn=978-1-4160-3155-0 }}&lt;/ref&gt; A Bulgarian study examined prostatitis patients, all of whom had negative microbiological results. Of the patients given the fluoroquinolone [[ciprofloxacin]], 65% experienced adverse drug reactions (as opposed to 9% of the placebo group). Those given fluoroquinolone also had a lower rate of recovery after six weeks (though not after six months).&lt;ref&gt;{{cite web |author=J. Dimitrakov |author2=J. Tchitalov |author3=T. Zlatanov |author4=D. Dikov  |title=A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Of Antibiotics For The Treatment Of Category Iiib Chronic Pelvic Pain Syndrome In Men |url=http://www.prostatitis.org/a92000.html |publisher=Third International Chronic Prostatitis Network |accessdate=4 September 2009}}&lt;/ref&gt;

A 2003 study concerning the proper use of antibiotics in the emergency room revealed that 99% of instances contained some sort of error. Out of the 100 patients studied, 81 inappropriately received a prescription for [[fluoroquinolone]]. Out of these cases, 43 did not call for fluoroquinolone as a first-line agent, 27 presented no evidence of bacterial infection (based on documented evaluations), and 11 had questionable need for such therapy. Of the 19 cases that both called for and received fluoroquinolone, only one received both the correct dose and duration of therapy.&lt;ref name=&quot;pmid12622607&quot;&gt;{{cite journal |author=Lautenbach E, Larosa LA, Kasbekar N, Peng HP, Maniglia RJ, Fishman NO |title=Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use |journal=Archives of Internal Medicine |volume=163 |issue=5 |pages=601–5 |date=March 2003 |pmid=12622607 |url=http://archinte.ama-assn.org/cgi/pmidlookup?view=long&amp;pmid=12622607 |doi=10.1001/archinte.163.5.601}}&lt;/ref&gt;

In a 1994 study of fluoroquinolone issued in a long-term care setting, 75% of the examined prescriptions were judged to be inappropriate. More than 50% did not call for fluoroquinolone as the first-line agent.&lt;ref name=&quot;Pickering-1994&quot;&gt;{{cite journal |author=Pickering TD, Gurwitz JH, Zaleznik D, Noonan JP, Avorn J |title=The appropriateness of oral fluoroquinolone-prescribing in the long-term care setting |journal=Journal of the American Geriatrics Society |volume=42 |issue=1 |pages=28–32 |date=January 1994 |pmid=8277111}}&lt;/ref&gt;

==See also==
*[[Alliance for the Prudent Use of Antibiotics]]
*[[Natural growth promoter]]

==References==
{{reflist|2}}

==Further reading==
*{{cite book|last=Blaser|first=Martin|title=Missing microbes : how the overuse of antibiotics is fueling our modern plagues|year=2014|publisher=[[Henry Holt and Company]]|isbn=978-0805098105|url=http://us.macmillan.com/missingmicrobes/MartinBlaser}}

==External links==
*[http://www.cdc.gov/getsmart/ Get Smart: Know When Antibiotics Work], provided by the [[Centers for Disease Control and Prevention]]
*[http://www.mayoclinic.org/antibiotics/art-20045720 Antibiotics: Misuse puts you and others at risk] provided by the [[Mayo Clinic]]

{{Unnecessary health care}}

{{DEFAULTSORT:Antibiotic Misuse}}
[[Category:Antibiotics]]
[[Category:Health disasters]]
[[Category:Pharmaceuticals policy]]
[[Category:Veterinary medicine]]
[[Category:Antibiotic resistance]]
[[Category:Unnecessary health care]]</text>
      <sha1>omosb15jmkgbttesmthaw0zii7wepf3</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Reuterin</title>
    <ns>0</ns>
    <id>31296238</id>
    <revision>
      <id>607754647</id>
      <parentid>592930395</parentid>
      <timestamp>2014-05-09T09:57:56Z</timestamp>
      <contributor>
        <username>Rjwilmsi</username>
        <id>203434</id>
      </contributor>
      <minor/>
      <comment>Added 1 doi to a journal cite using [[Project:AWB|AWB]] (10104)</comment>
      <text xml:space="preserve" bytes="4370">'''Reuterin''' is a potent [[antibiotics|antimicrobial]] multi-compound produced by ''[[Lactobacillus reuteri]]'', during the metabolism of [[glycerol]] to [[1,3-propanediol]] catalysed by the [[coenzyme B12]]-dependent diol dehydrase. Reuterin consists of 3-hydroxypropionaldehyde, its hydrate, and its dimer in dynamic equilibrium.&lt;ref&gt;{{cite journal|doi=10.1039/jr9500000490 |author=Hall RH, Stern ES |title=Acid-catalysed hydration of acrylalde. Kinetics of the reaction and isolation of β-hydroxypropionaldehyde |journal=J Chem Soc |pages=490–8 |year=1950 }}&lt;/ref&gt;&lt;ref&gt;{{cite journal |author=Nielsen AT, Moore DW, Schuetze Jr. A |title=&lt;sup&gt;13&lt;/sup&gt;C and &lt;sup&gt;1&lt;/sup&gt;H NMR study of formaldehyde reactions with acetaldehyde and acrolein. Synthesis of 2-(hydroxymethyl)-1,3-propanediol |journal=Pol J Chem |volume=55 |pages=1393–1403 }}&lt;/ref&gt; At concentrations above 1.4[[Molar (concentration)|M]], the HPA dimer is predominant; at concentrations relevant for biological systems, however, HPA hydrate is the most abundant, followed by the aldehyde form.&lt;ref&gt;{{cite journal |author=Vollenweider S, Grassi G, König I, Puhan Z|title=Purification and structural characterization of 3-hydroxypropionaldehyde and its derivatives |journal=J. Agric. Food Chem.|volume=51 |issue=11 |pages=3287–93 |date=May 2003 |pmid=12744656 |doi=10.1021/jf021086d}}&lt;/ref&gt;

Reuterin inhibits the growth of some harmful [[Gram-negative]] and [[Gram-positive]] bacteria, along with [[yeast]]s, [[mold]]s, and [[protozoa]].&lt;ref&gt;{{cite journal |author=Talarico TL, Dobrogosz WJ |title=Chemical characterization of an antimicrobial substance produced by ''Lactobacillus reuteri'' |journal=Antimicrob. Agents Chemother. |volume=33 |issue=5 |pages=674–9|date=May 1989 |pmid=2751282 |pmc=172512 |url=http://aac.asm.org/cgi/pmidlookup?view=long&amp;pmid=2751282 |doi=10.1128/aac.33.5.674}}&lt;/ref&gt; ''L. reuteri'' can secrete sufficient amounts of reuterin to inhibit the growth of harmful gut organisms, without killing beneficial gut bacteria, allowing ''L. reuteri'' to remove gut invaders while keeping normal [[gut flora]] intact.&lt;ref&gt;{{cite journal |author=Casas, Ivan A., [[Walter J. Dobrogosz|Dobrogosz, Walter J.]] |title=Validation of the Probiotic Concept: ''Lactobacillus reuteri'' Confers Broad-spectrum Protection against Disease in Humans and Animals |journal=Microbial Ecology in Health and Disease |volume=12 |issue=4|date=December 1, 2000 |url=http://taylorandfrancis.metapress.com/link.asp?id=th7818k39wgjuwfd}}&lt;/ref&gt;

Reuterin is water soluble, effective in a wide range of [[pH]], resistant to proteolytic and lipolytic enzymes, and has been studied as a [[food preservative]] or auxiliary therapeutic agent.&lt;ref&gt;Vollenweider S, Lacroix C: 3-hydroxypropionaldehyde: applications and perspectives of biotechnological production. Appl Microbiol Biotechnol 2004, 64(1):16-27.&lt;/ref&gt;&lt;ref&gt;Axelsson LT, Chung TC, Dobrogosz WJ, Lindgren SE: Production of a broad spectrum antimicrobial substance by Lactobacillus reuteri. Microb Ecol Health Dis 1989, 2:131-136.&lt;/ref&gt;&lt;ref&gt;El-Ziney MG, van den Tempel T, Debevere J, Jakobsen M: Application of reuterin produced by Lactobacillus reuteri 12002 for meat decontamination and preservation. J Food Prot 1999, 62(3):257-261.&lt;/ref&gt;

==Efficacy against specific pathogenic microorganisms==

Reuterin as an extracted compound has been shown capable of killing [[Escherichia coli O157:H7]] and [[Listeria monocytogenes]], with the addition of lactic acid increasing its [[efficacy]].&lt;ref&gt;{{cite journal|last=El-Ziney|first=MG|coauthors=van den Tempel, T; Debevere, J; Jakobsen, M|title=Application of reuterin produced by Lactobacillus reuteri 12002 for meat decontamination and preservation.|journal=Journal of food protection|date=March 1999|volume=62|issue=3|pages=257–61|pmid=10090245}}&lt;/ref&gt;  It has also been demonstrated to kill [[Escherichia coli O157:H7]] when produced by L. reuteri.&lt;ref&gt;{{cite journal|last=Muthukumarasamy|first=P|coauthors=Han, JH; Holley, RA|title=Bactericidal effects of Lactobacillus reuteri and allyl isothiocyanate on Escherichia coli O157:H7 in refrigerated ground beef.|journal=Journal of food protection|date=November 2003|volume=66|issue=11|pages=2038–44|pmid=14627280}}&lt;/ref&gt;

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Biochemistry]]
[[Category:Bacteriology]]


{{antibiotic-stub}}</text>
      <sha1>f23qle4je0nk4325aio9iythvqjmexe</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Alazopeptin</title>
    <ns>0</ns>
    <id>31360061</id>
    <revision>
      <id>556284242</id>
      <parentid>529688113</parentid>
      <timestamp>2013-05-22T15:54:21Z</timestamp>
      <contributor>
        <username>CheMoBot</username>
        <id>7377957</id>
      </contributor>
      <comment>Updating {{drugbox}} (changes to verified and watched fields - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEBI_Ref', 'KEGG_Ref') per [[WP:CHEMVALID|Chem/Drugbox validation]] (report [[Wikipedia talk:WikiProject_Pharmacology|errors]] or [[user talk:CheMo...</comment>
      <text xml:space="preserve" bytes="2123">{{Orphan|date=December 2012}}

{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457805069
| IUPAC_name = 6-diazo-2-{6-diazo-5-oxo-2-[(prop-2-en-1-yl)amino]hexanamido}-5-oxohexanoic acid
| image = alazopeptin.png
| alt =  

&lt;!--Clinical data--&gt;
| tradename =  
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category =  
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --&gt;
| legal_US = &lt;!-- OTC / Rx-only / Schedule I, II, III, IV, V --&gt;
| legal_status =  
| routes_of_administration =  

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number =  
| ATCvet =  
| ATC_prefix = None
| ATC_suffix =  
| PubChem = 5486654
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 92957
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 16735646

&lt;!--Chemical data--&gt;
| C=15 | H=20 | N=6 | O=5
| molecular_weight = 364.36 g/mol
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C15H20N6O5/c1-2-7-18-12(5-3-10(22)8-19-16)14(24)21-13(15(25)26)6-4-11(23)9-20-17/h2,8-9,12-13,18H,1,3-7H2,(H2-2,21,22,23,24,25,26)/b10-8-,11-9-
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = RCQIFJCPIWRTAF-WGEIWTTOSA-N
| smiles = C=CCNC(CCC(=C[N+]#N)[O-])C(=O)NC(CCC(=C[N+]#N)[O-])C(=O)O
}}

'''Alazopeptin''' is an [[antitumour]] antibiotic, produced by ''[[Streptomyces griseoplanus]]''. It is sourced from soil near WIlliamsburg, Iowa.&lt;ref&gt;{{cite journal | last1 = Patterson | first1 = E.L. | journal = Antimicrob. Agents Chemotherapy | pages = 115 | year = 1965 }}&lt;/ref&gt;

==References==
{{Reflist}}

[[Category:Antibiotics]]


{{antineoplastic-drug-stub}}</text>
      <sha1>q9vqt42p23uwwpdbipmyqzhdkzvw86w</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Vinyldithiin</title>
    <ns>0</ns>
    <id>31922947</id>
    <revision>
      <id>555367944</id>
      <parentid>550924066</parentid>
      <timestamp>2013-05-16T14:03:31Z</timestamp>
      <contributor>
        <ip>169.226.91.11</ip>
      </contributor>
      <text xml:space="preserve" bytes="4926">'''Vinyldithiins''', more precisely named 3-vinyl-4''H''-1,2-dithiin and 2-vinyl-4''H''-1,3-dithiin, are [[organosulfur]] [[phytochemicals]] formed in the breakdown of [[allicin]] from crushed [[garlic]] (''Allium sativum''). Vinyldithiins are [[Diels-Alder]] dimers of thioacrolein, H&lt;sub&gt;2&lt;/sub&gt;C=CHCH=S, formed in turn by decomposition of allicin.&lt;ref name=Block2010/&gt; In garlic supplements, vinyldithiins are only found in garlic oil [[Solvent extraction|macerates]] that are made by incubation of crushed garlic in oil.&lt;ref&gt;Lawson LD. Garlic: a review of its medicinal effects and indicated active compounds. In: Lawson LD, Bauer R, eds. Phytomedicines of Europe: Chemistry and Biological Activity. Washington, D. C.: American Chemical Society; 1998:177-209.&lt;/ref&gt;

==Structure and Occurrence==
When a garlic clove is crushed, the [[enzyme]] [[alliinase]] is released forming allicin from the cysteine sulfoxide [[alliin]].  Allicin breaks down into additional organosulfur compounds.  In the presence of oil or organic solvents, among the compounds formed are the [[isomer]]ic vinyldithiins and [[ajoene]]. As shown in the Scheme, allicin ('''1''') decomposes into 2-propenesulfenic acid ('''2''') and thioacrolein ('''3'''). Compound '''2''' reforms allicin while '''3''' gives Diels-Alder dimers 3-vinyl-4''H''-1,2-dithiin ('''4''') and 2-vinyl-4''H''-1,3-dithiin ('''5''').&lt;ref name=Block2010&gt;{{cite book|author=Block, E|title=Garlic and Other Alliums: The Lore and the Science|url=http://books.google.com/?id=6AB89RHV9ucC&amp;printsec=frontcover|publisher=Royal Society of Chemistry|year=2010|isbn=0-85404-190-7}}&lt;/ref&gt;&lt;ref&gt;http://lpi.oregonstate.edu/infocenter/phytochemicals/garlic/&lt;/ref&gt;  Garlic cloves yield about 2.5-4.5 mg of allicin per gram when crushed. One fresh garlic clove weighs 2-4 g.&lt;ref&gt;Lawson LD. Garlic: a review of its medicinal effects and indicated active compounds. In: Lawson LD, Bauer R, eds. Phytomedicines of Europe: Chemistry and Biological Activity. Washington, D. C.: American Chemical Society; 1998:177-209.&lt;/ref&gt;

[[Image:Formation_of_vinyldithiins_from_allicin.png|600px|center|Formation_of_vinyldithiins_from_allicin]]

==Potential Health Benefits==
Vinyldithiins have been investigated as a preventative for [[cardiovascular disease]] and as [[antioxidant]]s.  In the early 1980s, it was noted that people in the [[Mediterranean]] had lower risk of cardiovascular disease.&lt;ref&gt;Keys A. Wine, garlic, and CHD in seven countries. Lancet. 1980;1(8160):145-146.&lt;/ref&gt; Since garlic is used extensively in the Mediterranean, it is hypothesized that the chemicals in garlic might have cardiovascular effects.  
Studies have been done measuring the use of garlic for controlling serum [[cholesterol]] levels.  Analysis of these studies show that vinyldithiins in garlic have little to no effect on serum [[lipids]].&lt;ref&gt;Gardner CD, Lawson LD, Block E, et al. Effect of raw garlic vs commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: a randomized clinical trial. Arch Intern Med. 2007;167(4):346-353.&lt;/ref&gt;  Vinyldithiins in garlic have been shown to significantly lower the incidence of [[platelet aggregation]].&lt;ref&gt;Rahman K, Billington D. Dietary supplementation with aged garlic extract inhibits ADP-induced platelet aggregation in humans. J Nutr. 2000;130(11):2662-2665.&lt;/ref&gt;  Reduction of platelet aggregation may result in reduction of [[myocardial infarction]] or [[ischemic stroke]].  Ingestion of foods containing vinyldithiins and other organosulfur compounds may decrease the risk of gastric and colon [[cancer]].&lt;ref&gt;Fleischauer AT, Poole C, Arab L. Garlic consumption and cancer prevention: meta-analyses of colorectal and stomach cancers. Am J Clin Nutr. 2000;72(4):1047-1052.&lt;/ref&gt; 2-Vinyl-4''H''-1,2-dithiin was found to exhibit inhibitory activity against [[lipid]] [[hydroperoxide]] (LOOH) formation in human [[low-density lipoprotein]] (LDL).&lt;ref&gt;Nishimura H, Higuchi O, Tateshita K. Antioxidative activity of sulfur-containing compounds in ''Allium'' species for human LDL oxidation in vitro. Biofactors 2004;21(1-4):277-280.&lt;/ref&gt; A [[copolymer]] of 2-vinyl-4''H''-1,2-dithiin and [[N-Vinylpyrrolidone]] has been patented as a biocompatible polymer with antithrombogenic ([[antithrombotic]]) and [[antibiotic]] properties.&lt;ref&gt;Hermes RE. Antithrombogenic and antibiotic composition and methods of preparation thereof. US 4917921, January 1, 1990. http://www.osti.gov/bridge/product.biblio.jsp?osti_id=867345&lt;/ref&gt;

== References ==
{{reflist|2}}

[[Category:Phytochemicals]]
[[Category:Thiosulfinates]]
[[Category:Sulfoxides]]
[[Category:Alkenes]]
[[Category:Anti-inflammatory agents]]
[[Category:Antibiotics]]
[[Category:Dietary antioxidants]]
[[Category:Pungent flavors]]
[[Category:Allioideae]]
[[Category:Allium]]
[[Category:Garlic]]
[[Category:Antifungals]]
[[Category:Articles created via the Article Wizard]]</text>
      <sha1>rvwcneiixra7syhmzsxliy4obs6gzef</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Anthramycin</title>
    <ns>0</ns>
    <id>31950871</id>
    <revision>
      <id>608407881</id>
      <parentid>587837877</parentid>
      <timestamp>2014-05-13T16:43:17Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Task 5: Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated coauthor parameter errors]]</comment>
      <text xml:space="preserve" bytes="1666">{{one source|date=December 2013}}
{{Chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457132162
| ImageFile = Anthramycin.png
|  ImageSize =
|  ImageAlt =
| IUPACName =
| OtherNames =
| Section1 = {{Chembox Identifiers
|  CASNo_Ref = {{cascite|correct|??}}
| CASNo =
|  PubChem = 
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 25056543
|  StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VGQOVCHZGQWAOI-HYUHUPJXSA-N
|  StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI=1S/C16H17N3O4/c1-8-2-4-10-13(14(8)21)18-15(22)11-6-9(3-5-12(17)20)7-19(11)16(10)23/h2-5,7,11,15,18,21-22H,6H2,1H3,(H2,17,20)/b5-3+/t11-,15-/m0/s1
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1230992
|  UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0WZD9Y66WN
| SMILES = Cc1ccc2C(=O)N3C=C(C[C@H]3[C@H](O)Nc2c1O)\C=C\C(=O)N   }}
| Section2 = {{Chembox Properties
|  C=16 |H=17 |N=3 |O=4
|  MolarMass = 315.3 g/mol
|  Appearance =
|  Density =
|  MeltingPt =
|  BoilingPt =
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards =
|  FlashPt =
|  Autoignition = }}
}}

'''Anthramycin''' is a pyrrolobenzodiazepine [[antibiotic]] with [[antitumour]] activity.&lt;ref&gt;{{Cite journal
| doi = 10.1016/j.tet.2004.07.040
| volume = 60
| issue = 43
| pages = 9649–57
| last = Kitamura
| first = Tsuyoshi
|author2=Yoshihiro Sato |author3=Miwako Mori
 | title = Synthetic study of (+)-anthramycin using ring-closing enyne metathesis and cross-metathesis
| journal = Tetrahedron
| year=2004
}}&lt;/ref&gt;

==References==
{{reflist}}
[[Category:Drugs]]
[[Category:Antibiotics]]
[[Category:Antineoplastic drugs]]</text>
      <sha1>2d5eb0hpbqggpq6njb507o87zbtxb0c</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Promin</title>
    <ns>0</ns>
    <id>32526740</id>
    <revision>
      <id>607205034</id>
      <parentid>592859344</parentid>
      <timestamp>2014-05-05T16:57:31Z</timestamp>
      <contributor>
        <username>Rjwilmsi</username>
        <id>203434</id>
      </contributor>
      <minor/>
      <comment>Added 1 dois to journal cites using [[Project:AWB|AWB]] (10094)</comment>
      <text xml:space="preserve" bytes="7416">{{drugbox| verifiedrevid = 441698882
|
|
| IUPAC_name = 2,3,4,5,6-pentahydroxy-1-[4-[4-[(2,3,4,5,6-pentahydroxy-1-sulfohexyl)amino]phenyl]sulfonylanilino]hexane-1-sulfonic acid
| OtherNames = Sodium glucosulfone, Aceprosol, Promanide, Tasmin, Sulfona P
| image = Promin Molecular Structure Skeletal.svg
| image2 = Promin Molecular Structure Spacefill.png
| InChI = 1S/C24H36N2O18S3/c27-9-15(29)17(31)19(33)21(35)23(46(39,40)41)25-11-1-5-13(6-2-11)45(37,38)14-7-3-12(4-8-14)26-24(47(42,43)44)22(36)20(34)18(32)16(30)10-28/h1-8,15-36H,9-10H2,(H,39,40,41)(H,42,43,44)
| InChIKey = SQQCWHCJRWYRLB-UHFFFAOYSA-N
| smiles1 = 
| CAS_number = 
| PubChem = 3481
| C=24|H=36|N=2|O=18|S=3
| molecular_weight = 736.74024 g/mol
| smiles = C1=CC(=CC=C1NC(C(C(C(C(CO)O)O)O)O)S(=O)(=O)O)S(=O)(=O)C2=CC=C(C=C2)NC(C(C(C(C(CO)O)O)O)O)S(=O)(=O)O
}}
'''Promin''', or '''sodium glucosulfone''' is a [[sulfone]] drug that was investigated for the treatment of [[malaria]],&lt;ref name=&quot;isbn0-8135-4438-6&quot;&gt;{{cite book |author=Leo B. Slater |title=War and disease: biomedical research on malaria in the twentieth century |publisher=Rutgers University Press |location=New Brunswick, N.J |year=2009 |pages=102 |isbn=0-8135-4438-6 |oclc= |doi= |accessdate=}}&lt;/ref&gt; [[tuberculosis]]&lt;ref name=&quot;isbn0-8135-5009-2&quot;&gt;{{cite book |author=Dr David Lilienfeld; Prof Dona Schneider |title=Public Health: The Development of a Discipline, Volume 2, Twentieth-Century Challenges, vol. 2 |publisher=Rutgers University Press |location=New Brunswick, N.J |year=2011 |pages=351 |isbn=0-8135-5009-2 |oclc= |doi= |accessdate=}}&lt;/ref&gt; and [[leprosy]].&lt;ref&gt;Faget GH, et al. (1943) The Promin Treatment of Leprosy, Public Health Report 58:1729-1741, (Reprint Int J Lepr 34(3), 298-310, 1966)&lt;/ref&gt;  It is broken down in the body to [[dapsone]], which is the therapeutic form.&lt;ref name=&quot;pmid498567&quot;&gt;{{cite journal |author=McDougall AC |title=Dapsone |journal=Clin. Exp. Dermatol. |volume=4 |issue=2 |pages=139–42 |date=June 1979 |pmid=498567 |doi= 10.1111/j.1365-2230.1979.tb01608.x|url=}}&lt;/ref&gt;

==History==
The first synthesis of Promin is sometimes credited to Edward Tillitson and B.F. Tuller of Parke, Davis, &amp; Co. pharmaceuticals in August 1937. &lt;ref name=&quot;johansen 2003 star reprint&quot;&gt;{{cite article |author=Johansen E.A.|title=Current Data on Promin Therapy; reprinted in The Star October-December 2003|url=http://www.fortyandeight.org/storage/The%20Star%20Oct_Dec_2003.pdf}}&lt;/ref&gt;&lt;ref name=Wozel89&gt;Wozel, Gottfried; The Story of Sulfones in Tropical Medicine and Dermatology; International Journal of Dermatology, Volume 28, Issue 1, pages 17–21, January 1989. Published online as: {{doi|10.1111/j.1365-4362.1989.tb01301.x}} at URL: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-4362.1989.tb01301.x/pdf&lt;/ref&gt; However, although Parke-Davis did in fact synthesize the compound, it seems certain that they were not the first; in cooperation with J. Wittmann, [[Emil Fromm]] synthesised various sulfone compounds in 1908, including both dapsone and some of its derivatives, such as promin. Fromm and Wittmann however were engaged on chemical rather than medical work, and no-one investigated the medical value of such compounds till some decades afterwards.&lt;ref name=Wozel89 /&gt; The medical evaluation of sulfones was inspired by the discovery of the unprecedented value of synthetic compounds such as sulfonamides in treating microbial diseases. Early investigations yielded disappointing results, but subsequently promin and dapsone proved valuable in treating mycobacterial diseases. They were the first treatments to show more than a glimmer of hope of controlling such infections.&lt;ref&gt;Desikan, K. V. ; Multi-drug Regimen in Leprosy and its impact on Prevalence of the Disease ; MJAFI (Medical Journal, Armed Forces India) 2003; 59 : 2-4&lt;/ref&gt;

Initially, Promin appeared to be safer than dapsone, so it was further investigated at the [[Mayo Clinic]] as a treatment for tuberculosis in a [[guinea pig]] model.&lt;ref name=&quot;isbn0-471-89979-8&quot;&gt;{{cite book |author=Sneader, Walter |title=Drug discovery: a history |publisher=Wiley |location=New York |year=2005 |pages= |isbn=0-471-89979-8 |oclc= |doi= |accessdate=}}&lt;/ref&gt;  Because it was already known that leprosy and tuberculosis were both caused by mycobacteria (''[[Mycobacterium leprae]]'' and ''[[Mycobacterium tuberculosis]]'', respectively), [[Guy Henry Faget]] of the [[National Hansen's Disease Museum|National Leprosarium]] in Carville, Louisiana, requested information about the drug from Parke-Davis.  They, in turn, informed him of the work being done on leprosy in rats by Edmund Cowdry at the [[Washington University School of Medicine]].  His successful results, published in 1941, convinced Faget to begin human studies, both with promin and [[sulfoxone]] sodium, a related compound from [[Abbott Laboratories]].  The initial trials were on six volunteers, and were then expanded and replicated in different locations.  Despite severe side effects that caused the initial tests to be suspended temporarily, the drug was shown to be effective.&lt;ref name=&quot;isbn0-471-89979-8&quot; /&gt;&lt;ref&gt;John Tayman (2006), ''[http://books.google.com/books?id=7SXEMMraz0kC&amp;pg=PA252 The Colony]'', Simon and Schuster. Page 252.&lt;/ref&gt;  This breakthrough was reported worldwide, and led to a reduction in the stigma attached to leprosy, and consequent better treatment of patients, at the time still referred to as &quot;inmates&quot;, and forbidden from using public transport.&lt;ref name=time&gt;{{cite news |title=Hope for Lepers |author= |url=http://www.time.com/time/printout/0,8816,934821,00.html |newspaper=Time Magazine |date=30 December 1946 |accessdate=22 July 2011}}&lt;/ref&gt;

==Pharmacology==
Promin is heat-stable and water soluble, and can therefore be heat-sterilized.&lt;ref name=singh2002synthetic&gt;{{cite book |author= Singh, R.  |title= Synthetic Drugs |publisher= Mittal Publications |year= 2002 |pages= 291 |isbn= 978-81-7099-831-0 |url=http://books.google.co.uk/books?id=QkmF7rcBaRIC }}&lt;/ref&gt;  It can be injected intravenously,&lt;ref name=singh2002synthetic /&gt; and is available in ampules.&lt;ref name=&quot;isbn81-8061-283-X&quot;&gt;{{cite book |author= |title=Clinical Leprosy |publisher=Jaypee Brothers Medical Publishers (P) Ltd |location= |year=2004 |pages= |isbn=81-8061-283-X |oclc= |doi= |accessdate=}}&lt;/ref&gt;  

Beyond its solubility, however, promin was later found to have no real advantages over the simpler compound dapsone (which is administered in tablet form).  Promin and other sulfones can also not be used as substitutes for dapsone when intolerance develops, as this is a general reaction to sulfones, and not specific to dapsone.&lt;ref name=2008PharmText&gt;{{cite book |author= |title=Textbook Of Pharmacology |publisher=Elsevier India Pvt. Ltd.  |year=2008 |pages=X-87 |isbn=978-81-312-1158-8 |url=http://books.google.co.uk/books?id=51ozlZRBvQwC }}&lt;/ref&gt;  

Today, the drugs of choice for treating leprosy are dapsone, [[rifampicin]] and [[clofazimine]].&lt;ref name=ravina2011evolution&gt;{{cite book |author=Ravina, E. and Kubinyi, H.  |title=The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs |publisher=John Wiley &amp; Sons |year=2011 |pages=80 |isbn=978-3-527-32669-3 |url=http://books.google.co.uk/books?id=iDNy0XxGqT8C }}&lt;/ref&gt;

==References==
{{reflist}}

[[Category:Anilines]]
[[Category:Sulfones]]
[[Category:Dihydropteroate synthetase inhibitors]]
[[Category:Antibiotics]]
[[Category:Leprosy]]</text>
      <sha1>em1yqokqv27piwqnnmqvn2k6ufd9swu</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Template:Antimycobacterials</title>
    <ns>10</ns>
    <id>6172058</id>
    <revision>
      <id>589285344</id>
      <parentid>553999716</parentid>
      <timestamp>2014-01-05T13:08:55Z</timestamp>
      <contributor>
        <username>Ruslik0</username>
        <id>1130897</id>
      </contributor>
      <comment>+delamanid/metronidazole</comment>
      <text xml:space="preserve" bytes="2299">{{Navbox
| name  = Antimycobacterials
| title = [[Antimycobacterial]]s, including [[tuberculosis treatment]] and [[leprostatic agent]]s ([[ATC code J04|J04]])
| state = {{{state|autocollapse}}}
|listclass = hlist
| groupstyle = background:PowderBlue; 

  | group1 = [[Nucleic acid inhibitor]]
  | list1  = {{Navbox subgroup
| groupstyle = background:PowderBlue; 

| group1 = [[Rifamycin]]s/&lt;BR&gt;[[RNA polymerase]] inhibitor 
| list1  =
* [[Rifampicin]]&lt;sup&gt;#&lt;/sup&gt;
* [[Rifabutin]]
* [[Rifapentine]]

| group2 = [[Antifolate]]s/[[Dihydropteroate synthetase inhibitor|DSI]]
| list2  =
* [[Dapsone]]&lt;sup&gt;#&lt;/sup&gt;
* [[Acedapsone]]
* [[Aldesulfone sodium]]

| group3 = ASA
| list3  =
* ''[[4-Aminosalicylic acid]]''&lt;sup&gt;#&lt;/sup&gt; ([[Calcium aminosalicylate]]
* [[Sodium aminosalicylate]])

}} 


  | group2 = [[Protein synthesis inhibitor]]
  | list2  = {{Navbox subgroup
| groupstyle = background:PowderBlue; 

| group1 = [[Aminoglycoside]]s
| list1  =
* [[Amikacin]]&lt;sup&gt;#&lt;/sup&gt;
* [[Capreomycin]]&lt;sup&gt;#&lt;/sup&gt;
* [[Kanamycin]]&lt;sup&gt;#&lt;/sup&gt;
* [[Streptomycin]]&lt;sup&gt;#&lt;/sup&gt;


| group2 = [[2-Oxazolidone|Oxazolidone]]
| list2  =
* [[Linezolid]]


}} 

  | group3 = [[Cell envelope antibiotic]]
  | list3  = {{Navbox subgroup
  | groupstyle = background-color: PowderBlue

| group1 = [[Peptidoglycan]] layer
| list1  =
* [[Alanine]] analogue: [[Cycloserine]]&lt;sup&gt;#&lt;/sup&gt;

  | group2 = [[Arabinogalactan]] layer
  |  list2 =
* [[Ethylenediamine]]/[[arabinosyltransferase]] inhibitor: [[Ethambutol]]&lt;sup&gt;#&lt;/sup&gt;&lt;BR&gt;

[[SQ109]]&lt;sup&gt;†&lt;/sup&gt;

  | group3 = [[Mycolic acid]] layer
  |  list3 =
* [[Hydrazide]]s/[[mycolic acid]] synth. inhibition: [[Isoniazid]]&lt;sup&gt;#&lt;/sup&gt;&lt;BR&gt;

*[[Thiocarbamide]]s: [[Ethionamide]]&lt;sup&gt;#&lt;/sup&gt;
* [[Prothionamide]]
* [[Thiocarlide]]

}} 

  | group8 = Other/unknown
  |  list8 =
* ''[[Phenazine]]'' ([[Clofazimine]])&lt;sup&gt;#&lt;/sup&gt;
* ''[[Pyrazine]]'' ([[Pyrazinamide]]&lt;sup&gt;#&lt;/sup&gt;, [[Morinamide]])
* ''[[Isoxazole]]'' ([[Terizidone]])
* [[Bedaquiline]]
* ''[[Metronidazole]]'' (''[[delamanid]]'')

  | group9 = Combinations
  |  list9 =
* [[Rifampicin/isoniazid/pyrazinamide]]

| belowstyle = background: transparent; padding: 0px;
| below = {{PharmNavFootnote}}{{Bacteria navs}}

}}&lt;noinclude&gt;
{{collapsible option}}
[[Category:Antibiotics]]
[[Category:Drug_templates by ATC]]
&lt;/noinclude&gt;</text>
      <sha1>pfpsgiw0kg6twzaqqev6bzmfilxe18n</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Raphanin</title>
    <ns>0</ns>
    <id>32895192</id>
    <revision>
      <id>607875975</id>
      <parentid>599067274</parentid>
      <timestamp>2014-05-10T07:02:34Z</timestamp>
      <contributor>
        <username>Rjwilmsi</username>
        <id>203434</id>
      </contributor>
      <minor/>
      <comment>Added 1 doi to a journal cite using [[Project:AWB|AWB]] (10104)</comment>
      <text xml:space="preserve" bytes="5731">{{Chembox
| ImageFile = Raphanin.png
| ImageSize = 200px
| IUPACName = 4-Isothiocyanato-1-(methylsulfinyl)but-1-ene
| OtherNames = Sulforaphen; Sulforaphene; Sativin
| Section1 = {{Chembox Identifiers
|  CASNo = 592-95-0
|   CASNo_Ref = {{cascite|correct|CAS}}
|  PubChem = 6433206
|  ChemSpiderID = 16736047
|  SMILES = S=C=N/CC\C=C\S(=O)C
|  InChI = 1/C6H9NOS2/c1-10(8)5-3-2-4-7-6-9/h3,5H,2,4H2,1H3
|  InChIKey = QKGJFQMGPDVOQE-UHFFFAOYAU
|  StdInChI = 1S/C6H9NOS2/c1-10(8)5-3-2-4-7-6-9/h3,5H,2,4H2,1H3
|  StdInChIKey = QKGJFQMGPDVOQE-UHFFFAOYSA-N
  }}
| Section2 = {{Chembox Properties
|  C=6|H=9|N=1|O=1|S=2
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility =
  }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition =
  }}
}}

'''Raphanin''' is the main sulfur component found in [[radish]] seeds of ''[[Raphanus sativus]]'' and is also found in [[broccoli]] and [[red cabbage]].&lt;ref name=&quot;SinhaHui2010&quot;&gt;{{cite book|last1=Sinha|first1=Nirmal K.|last2=Hui|first2=Y. H.|coauthors=Muhammad Siddiq, Jasim Ahmed|title=Handbook of Vegetables and Vegetable Processing|url=http://books.google.com/books?id=Fz58umYZVK8C&amp;pg=PT156|year=2010|publisher=John Wiley and Sons|isbn=978-0-8138-1541-1|page=156}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|doi=10.1007/s00217-007-0674-0|title=Comparison of glucosinolate levels in commercial broccoli and red cabbage from conventional and ecological farming |journal=European Food Research and Technology|author=Michael Meyer and Sieghard T. Adam|volume=226|issue=6|pages=1429–1437}}&lt;/ref&gt; It was first described by [[G. Ivanovics]] and [[S. Horvath]] in 1947.&lt;ref name=&quot;Baron1950&quot;&gt;{{cite book|last=Baron|first=Abraham Louis|title=Handbook of antibiotics|url=http://books.google.com/books?id=vtbQAAAAMAAJ|year=1950|publisher=Reinhold|page=215}}&lt;/ref&gt;&lt;ref&gt;{{Cite journal
  | last = Ivãnovics, G. &amp; S. Horvãth
  | title = Raphanin, an Antibacterial Principle of the Radish (Raphanus sativus)
  | journal = Nature
  | issue = 4061
  | pages = 297–298
  |year=1947 
  | doi = 10.1038/160297a0 |pmid=20261763
  | volume=160
}}
&lt;/ref&gt; Raphanin inhibits activity of viruses, some fungi and various bacteria including ''[[Staphylococus]]'', ''[[Streptococus]]'', ''[[Streptococcus pneumoniae|Pneumococcus]]'' and ''[[Escherichia coli]]'' (see table). The effect is stronger against [[Gram-positive]] than [[Gram-negative]] bacteria and against [[DNA]] than [[RNA]] viruses; it is suppressed by [[Serum (blood)|serum]] and by sulfur compounds such as [[hydrogen sulfide]], [[mercaptoacetic acid]], [[cystine]] and [[glutathione]].&lt;ref name=&quot;Florey)1949&quot;&gt;{{cite book|last=Florey|first=Howard|title=Antibiotics: a survey of penicillin, streptomycin, and other antimicrobial substances from fungi, actinomycetes, bacteria, and plants|url=http://books.google.com/books?id=iNXwAAAAMAAJ|year=1949|publisher=Oxford University Press|pages=625–6}}&lt;/ref&gt;&lt;ref name=b1/&gt;&lt;ref name=&quot;Baron1950&quot;/&gt;&lt;ref name=&quot;Akadémia1968&quot;&gt;{{cite book|title=Acta microbiologica Academiae Scientiarum Hungaricae|url=http://books.google.com/books?id=5TVMAAAAYAAJ|year=1968|publisher=Magyar Tudományos Akadémia|pages=311–3}}&lt;/ref&gt;&lt;ref name=&quot;Summers2007&quot;&gt;{{cite book|last=Summers|first=Sean|title=World History on Satan's Diet|url=http://books.google.com/books?id=RkSbK0ujZyIC&amp;pg=PA4|year= 2007|publisher=Wheatmark, Inc.|isbn=978-1-58736-806-6|page=4}}&lt;/ref&gt; The antibacterial, antifungal and antiviral effects from consuming radishes were recognized in [[Traditional Chinese medicine]].&lt;ref name=&quot;Hu2005&quot;&gt;{{cite book|last=Hu|first=Shiu-ying|title=Food plants of China|url=http://books.google.com/books?id=2OiYydyrsygC&amp;pg=PA132|year=2005|publisher=Chinese University Press|isbn=978-962-996-229-6|page=132}}&lt;/ref&gt;Given that Raphanin can be chiefly responsible for keeping the production of [[thyroxine]] and [[calcitonin]] in normal balance, in Russia, radishes have long been used for treating both types of thyroid problems.&lt;ref&gt;{{cite web|url=http://www.naturalpedia.com/Radishes-5.html|title=Radishes|publisher=Natural Pedia|accessdate=4 September 2011}}&lt;/ref&gt;However, in the abstract to his 1947 paper, Ivanovics noted that because raphanin is highly toxic, it did not &quot;hold the promise of a useful therapeutic agent&quot;.&lt;ref&gt;{{Cite journal
  | last = Ivànovics, G. and Horvath, S. | title = Isolation and Properties of Raphanin, an Antibacterial Substance from Radish Seed  | journal = Experimental Biology and Medicine 
  | volume = 66 | pages = 625–630|pmid=18900045
  | year = 1947 | issue=3 | doi=10.3181/00379727-66-16177
}}&lt;/ref&gt; 

{|Class=&quot;wikitable&quot; style=&quot;text-align:center&quot;
|+ [[Minimum inhibitory concentration]] of raphanin&lt;ref name=b1&gt;{{cite book|last1=Chang|first1=Hson-Mou|last2=Pui-Hay|first2=Paul|last3=Yao|first3=Sih-Cheng|title=Pharmacology and Applications of Chinese Material Medical|url=http://books.google.com/books?id=SU_ZX6lI1OIC&amp;pg=PA969|year= 2001|publisher=World Scientific|isbn=978-981-02-3694-6|page=969}}&lt;/ref&gt;
!Bacteria !! MIC (mg/mL)
|-
| ''[[Staphylococus]]''||0.04
|-
| ''[[Shigella dysenteriae]]''||0.125
|-
| ''[[Salmonella typhi]]''||0.125
|-
| ''[[Escherichia coli]]''||0.2
|}

== See also ==
* [[Sulforaphane]]

== References ==
{{Reflist}}

== External links ==

*[http://www.freshpatents.com/Poisonless-sulfur-free-of-noxious-ingredients-and-method-for-manufacturing-the-same-dt20070111ptan20070009613.php A patent for: Poisonless sulfur free of noxious ingredients and method for manufacturing the same ], includes discussion of raphanin
*[http://books.google.ca/books?hl=en&amp;lr=&amp;id=cCPkeRdCKqgC&amp;oi=fnd&amp;pg=PR7 Rawsome!: maximizing health, energy, and culinary delight with the raw foods diet]

[[Category:Antibiotics]]
[[Category:Isothiocyanates]]</text>
      <sha1>bovb8v8mvodfxt5ccxrhfy9te0ezkyi</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Linopristin</title>
    <ns>0</ns>
    <id>33527731</id>
    <revision>
      <id>462091989</id>
      <parentid>457344958</parentid>
      <timestamp>2011-11-23T12:00:09Z</timestamp>
      <contributor>
        <username>Beetstra</username>
        <id>855858</id>
      </contributor>
      <comment>Script assisted update of identifiers for the [[WP:WikiProject_Chemicals/Chembox_validation|Chem/Drugbox validation project]] (updated: 'UNII').</comment>
      <text xml:space="preserve" bytes="1777">{{Chembox
| ImageFile =Linopristin.svg
|  ImageSize =200px
|  ImageAlt =
| IUPACName = ''N''-((6''R'',9''S'',10''R'',13''S'',15a''S'',22''S'',24a''S'')-22-(4-(dimethylamino)benzyl)-6-ethyl-10,23-dimethyl-18-(morpholinomethyl)-5,8,12,15,21,24-hexaoxo-13-phenyl-2,3,5,6,7,8,9,10,12,13,14,15,15a,16,19,21,22,23,24,24a-icosahydro-1''H''-pyrido[2,1-f]pyrrolo[2,1-l][1,4,7,10,13,16]oxapentaazacyclononadecin-9-yl)-3-hydroxypicolinamide
| IUPACName_hidden = yes
| OtherNames = RPR 202698; RPR 202868
| Section1 = {{Chembox Identifiers
|  CASNo = 325965-23-9
|   CASNo_Ref = {{cascite|correct|}}
|  UNII = 312V80FR4J
| PubChem =
|  SMILES = O=C([C@H](CC1=CC=C(N(C)C)C=C1)N(C)C([C@H]2N(CCC2)C3=O)=O)N4[C@H](C(N[C@H](C(O[C@H](C)[C@@H](C(N[C@@H]3CC)=O)NC(C5=NC=CC=C5O)=O)=O)C6=CC=CC=C6)=O)CC=C(CN7CCOCC7)C4}}
| Section2 = {{Chembox Properties
|  C=50 | H=63 | N=9 | O=10
|  Appearance =
|  Density =
|  MeltingPt =
|  BoilingPt =
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards =
|  FlashPt =
|  Autoignition = }}
}}

'''Linopristin''' is an [[antibiotic]] of the [[streptogramin B]] class.  It is one of the components of the antibiotic combination [[NXL103]].&lt;ref&gt;{{cite journal | author = Pankuch, Glenn A.; Kelly, Linda M.; Lin, Gengrong; Bryskier, Andre; Couturier, Catherine; Jacobs, Michael R.; Appelbaum, Peter C. | title = Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and Haemophilus species | journal = Antimicrobial Agents and Chemotherapy | year = 2003 | volume = 47 | issue = 10 | pages = 3270–3274 | doi = 10.1128/AAC.47.10.3270-3274.2003 | pmid = 14506040 | pmc = 201162}}&lt;/ref&gt;

==References==
{{reflist}} 


{{antibiotic-stub}}

[[Category:Antibiotics]]
[[Category:Depsipeptides]]</text>
      <sha1>fv5j2aqzmdpdtg13welv3q1y1gidn77</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Subtherapeutic antibiotic use in swine</title>
    <ns>0</ns>
    <id>33532401</id>
    <revision>
      <id>608556754</id>
      <parentid>595436929</parentid>
      <timestamp>2014-05-14T15:25:53Z</timestamp>
      <contributor>
        <username>Rjwilmsi</username>
        <id>203434</id>
      </contributor>
      <minor/>
      <comment>Added 9 dois to journal cites using [[Project:AWB|AWB]] (10159)</comment>
      <text xml:space="preserve" bytes="13193">[[File:CAFO hogs.jpg|thumb|right|commercial swine production]]
[[Antibiotics]] are commonly used in commercial [[swine]] production in the United States and around the world. They are used for disease treatment, disease prevention and control, and growth promotion. When used for growth promoting purposes, antibiotics are given at low concentrations for long periods of time.&lt;ref name=&quot;Cox&quot;&gt;{{cite journal|last=Cox|first=L.A.|coauthors=Popken|title=Assessing Potential Human Health Hazards and Benefits from Subtherapeutic Antibiotics in the United States: Tetracyclines as a Case Study|journal=Risk Analysis|year=2010|volume=30|issue=3|pages=432–458}}&lt;/ref&gt; Low concentration of antibiotics, also referred to as [[wikt:subtherapeutic|subtherapeutic]] (STA), are given as feed and water additives which improve daily weight gain and feed efficiency through alterations in digestion and disease suppression.&lt;ref&gt;{{cite journal|last=MacDonald|first=J.M.|coauthors=McBride|title=The Transformation of U.S. livestock agriculture: Scale, efficiency, and risks.|journal=Economic Information Bulletin|date=January 2009|volume=No. (EIB-43)|url=http://www.ers.usda.gov/Publications/EIB43|accessdate=2011-10-25}}&lt;/ref&gt; Additionally, the use of STA in swine results in healthier animals and reduces the “microbial load” on meat resulting in an assumed decrease in potential [[Foodborne illness]] risk.&lt;ref name=&quot;Hurd&quot;&gt;{{cite journal|last=Hurd|first=H.S.|coauthors=Malladi|title=A stochastic assessment of the public health risks of the use of macrolide antibiotics in food animals|journal=Risk Analysis|year=2008|volume=28|issue=3|pages=695–710|doi=10.1111/j.1539-6924.2008.01054.x}}&lt;/ref&gt;&lt;ref name=&quot;Arsenault&quot;&gt;{{cite journal|last=Arsenault|first=J|coauthors=et al|title=Prevalence and risk factors for Salmonella and Campylobacter spp. carcass contamination in turkeys slaughtered in Quebec|journal=Canada J Food Prot|year=2007|volume=70|issue=6|pages=1350–1359}}&lt;/ref&gt;&lt;ref name=&quot;Singer&quot;&gt;{{cite journal|last=Singer|first=R.S.|coauthors=et al|title=Modeling the relationship between food animal health and human foodborne illness|journal=Prev Vet Med|year=2007|volume=79|issue=2-4|pages=186–203|doi=10.1016/j.prevetmed.2006.12.003}}&lt;/ref&gt; While the benefits of subtherapeutic antibiotic administration are well-documented, there is much concern and debate regarding the development of bacterial antibiotic resistance associated with their use.

This is a specific case of the more general practice of [[antibiotic use in livestock]].

==Amount and types of antibiotics used==
Currently, there appears to be a lack of reliable data associated with the amount of antibiotics used in livestock production.&lt;ref name=&quot;Becker&quot;/&gt; In 2001, the [[Union of Concerned Scientists]] (UCS) published that 24.6 million pounds of antibiotics are used annually for growth promotant purposes. This, they claimed, represented 70% of the antibiotics produced annually in the United States.&lt;ref&gt;{{cite journal|last=Union of Concerned Scientists|title=Hogging It: Estimates of Antimicrobial Abuse in Livestock|date=January 2001}}&lt;/ref&gt; However, groups such as the Animal Health Institute have taken issue with this figure, accusing the UCS of using questionable methods and assumptions.&lt;ref name=&quot;Becker&quot;/&gt; Listed in Table 1 are the specific types of antibiotics used in swine disease treatment, prevention and growth promotion and their importance in human medicine. 
 
{| class=&quot;wikitable&quot;
|-
! Antibiotic !! Use in Swine !! Importance in Human Medicine
|-
| Sulfonamide || &lt;center&gt; Growth &lt;/center&gt; || &lt;center&gt; Not &lt;/center&gt;
|-
| Cephalosporin (3rd gen) || &lt;center&gt; Disease treatment &lt;/center&gt; || &lt;center&gt; Critical &lt;/center&gt;
|-
| Pencillins || &lt;center&gt; Disease treatment, growth &lt;/center&gt; || &lt;center&gt; High &lt;/center&gt;
|-
| Macrolides || &lt;center&gt; Disease treatment, prevention, and growth &lt;/center&gt; || &lt;center&gt; Critical &lt;/center&gt;
|-
| Tetracycline || &lt;center&gt; Disease treatment, prevention, and growth &lt;/center&gt; || &lt;center&gt; High &lt;/center&gt;
|-
| Lincosamide || &lt;center&gt; Disease treatment &lt;/center&gt; || &lt;center&gt; High &lt;/center&gt;
|-
| Pleuromutilin || &lt;center&gt; Growth &lt;/center&gt; || &lt;center&gt; Not &lt;/center&gt;
|-
| Polypeptide || &lt;center&gt; Growth &lt;/center&gt; || &lt;center&gt; Not &lt;/center&gt;
|-
| Carbadox || &lt;center&gt; Growth &lt;/center&gt; || &lt;center&gt; Not &lt;/center&gt;
|}
Table 1- Commonly used antibiotics in swine production and their relative importance in human medicine.   With regard to human medicine importance, FDA ranks antibiotics as “critically important” (“critical” in the above table), “highly important” (“high” in the table), or “important.” The ranking is based on five criteria from the most important (it is used in treating pathogens that cause foodborne disease) to the least important (there is difficulty in transmitting resistance across genera and species).&lt;ref name=&quot;Becker&quot;/&gt;{{rp|4}}

==Antibiotic resistance development==
Bacterial [[antibiotic resistance]] is a process that can occur when bacteria are exposed to STA administration. When a population of bacteria that resides in a hog are exposed to a particular antibiotic for growth promotant purposes, the bacteria that are susceptible to the drug die while the organisms that are resistant will not be affected and will continue to replicate, resulting in a higher proportion of resistant organisms.&lt;ref&gt;{{cite web|last=CDC|title=Antibiotic resistance 101|url=http://www.cdc.gov/narms/get_smart.htm|accessdate=2011-10-25}}&lt;/ref&gt; It has been shown that resistance to antibiotics develops in animals that are fed subtherapeutic doses of antibiotics for growth promoting purposes.&lt;ref&gt;{{cite journal|last=Mathew, A. et al|title=Antibiotic Resistance in Bacteria Associated with Food Animals: A United States Perspective of Livestock Production|journal=Foodborne Pathogens and Disease|year=2007|volume=4|issue=2|pages=115–133|doi=10.1089/fpd.2006.0066}}&lt;/ref&gt; Certain bacteria that have the potential to cause human illness, such as [[Salmonella]], that naturally reside in the swine gastrointestinal tracts are constantly exposed to antibiotics. With time, these bacteria become resistant to that class of antibiotics. There is great concern regarding the probability of subtherapeutic antibiotic use in swine causing treatment failures in human medicine.&lt;ref name=&quot;Becker&quot;&gt;{{cite journal|last=Becker|first=Geoffrey|title=Antibiotic Use in Agriculture: Background and Legislation|journal=Congressional Research Service|url=http://nationalaglawcenter.org/wp-content/uploads/assets/crs/R40739.pdf|date=January 2010|pages=1–15}}&lt;/ref&gt;

==Resistance and the risk of treatment failure==

There is concern that use of antibiotics in swine is leading to an increase in resistant bacteria. The reason for concern is that these resistant bacteria could lead to food-borne illness that is less responsive to treatment. Many proponents of the ban cite the “precautionary principle” of public health, which states if there is evidence of harm, the method in question should be avoided.&lt;ref name=&quot;Marshall&quot;/&gt; Risk assessment studies have explored the possibility of harm more objectively through causal pathways and model building.&lt;ref name=&quot;Cox&quot;/&gt; These studies show a very small risk of failure of medical treatment due to resistant bacteria caused by the feeding of STA to livestock. For example, a [[Stochastic process|stochastic]] risk assessment done in 2008 showed that the risk of consequences from an infection with drug resistant [[Campylobacteriosis]] was approximately 1 in 82 million.&lt;ref name=&quot;Hurd&quot;/&gt;

The general causal pathway depends on a number of variables and probabilities. First, the animal must be harboring resistant bacteria and the bacteria have a probability that they can survive from the animal to the dinner table at infectious doses.&lt;ref&gt;{{cite journal|last=Snary|first=E.L.|coauthors=et al|title=Antimicrobial resistance: a microbial risk assessment perspective|journal=[[Journal of Antimicrobial Chemotherapy]]|year=2004|volume=53|pages=906–917|doi=10.1093/jac/dkh182}}&lt;/ref&gt; Humans must then be exposed to these resistant bacteria by eating undercooked meat or coming into contact with them in the environment. Resistant bacteria and their genetic material that codes for resistance are not only found in food, but also the environment. For example, studies have found that resistant bacteria can leak from hog waste lagoons into ground water, creating an exposure through the public water supply.&lt;ref&gt;{{cite journal|last=Koike, S. et al.|title=Monitoring and Source Tracking of Tetracycline Resistance Genes in Lagoons and Groundwater Adjacent to Swine Production Facilities over a 3-Year Period|journal=Applied and Environmental Microbiology|year=2007|volume=73|issue=15|pages=4813–23|doi=10.1128/aem.00665-07}}&lt;/ref&gt; Upon exposure, an individual must develop illness that is severe enough for them to seek medical attention. Factors such as age and immune system condition may influence disease susceptibility, which could impact the severity of disease. If the individual becomes ill and needs medical attention, a physician may prescribe an antibiotic. This pathway depends on the medical doctor’s ability to identify potential antibiotic resistance before prescribing treatment to a patient affected by food-borne illness.&lt;ref name=&quot;Cox&quot;/&gt;&lt;ref name=&quot;Hurd&quot;/&gt;&lt;ref name=&quot;Arsenault&quot;/&gt;&lt;ref name=&quot;Singer&quot;/&gt; If the bacteria causing the illness is resistant to the drug the physician recommended, then the illness will not be improved by the medication. This could potentially lead to increased morbidity and mortality.&lt;ref&gt;{{cite journal|last=Witte|first=W.|title=Selective pressure by antibiotic use in livestock|journal=International Journal of Antimicrobial Agents|year=2000|volume=16|issue=1|pages=19–24|doi=10.1016/s0924-8579(00)00301-0}}&lt;/ref&gt;

==European ban and legislation in the United States==
In 1999, the [[European Union]] banned the use of subtherapeutic antibiotics in livestock. Data from Europe, particularly from Denmark, shows that the prevalence of bacteria resistant to particular antibiotics has decreased since the ban.&lt;ref&gt;{{cite journal|last=Aarestrup|first=F.M.|coauthors=et al|title=Changes in the use of antimicrobials and the effects on productivity of swine farms in Denmark|journal=Am. J. Vet. Res.|year=2010|volume=71|pages=726–733|doi=10.2460/ajvr.71.7.726}}&lt;/ref&gt; Some opponents of the use of subtherapeutic antibiotics in swine cite data and results from Europe to support a ban in the United States. They argue that since the ban in Europe, antibiotics resistance has decreased while the overall health of swine has remained the same.&lt;ref name=&quot;Marshall&quot;&gt;{{cite journal|last=Marshall|coauthors=Levy|title=Food Animals and Antimicrobials: Impacts on Human Health|journal=Clinical Microbiology Reviews|date=Oct 2011|volume=24|issue=4|pages=718–733|doi=10.1128/cmr.00002-11}}&lt;/ref&gt; 

In 2003, the [[Food and Drug Administration]] released Guidance #152, which makes recommendations on how to best develop new animal drugs with regard to the potential impacts on human health.&lt;ref name=&quot;FDA&quot;&gt;{{cite journal|last=Food and Drug Administration|title=Evaluating the safety of antimicrobial new animal drugs with regard to their microbiological effects on bacteria of human health concern|url=http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm052519.pdf|date=October 2003|volume=Guidance #152}}&lt;/ref&gt; In the summer of 2010, the FDA released Guidance #209, which suggests limited livestock use of antibiotics that are medically important to humans.&lt;ref&gt;{{cite web|last=Food and Drug Administration|title=The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals|url=http://www.fda.gov/downloads/animalveterinary/guidancecomplianceenforcement/guidanceforindustry/ucm216936.pdf|accessdate=2011-11-15}}&lt;/ref&gt; In 2009, Rep. Louise Slaughter introduced HR 1549,otherwise known as The Preservation of Antibiotics for Medical Treatment Act (PAMTA). Under this bill, medically important antibiotics would be phased out in livestock and other restrictions would be placed on antibiotic use in food-producing animals.&lt;ref&gt;{{cite web|last=Slaughter|first=Louise|title=PAMTA|publisher=http://www.louise.house.gov/index.php?option=com_content&amp;view=article&amp;id=1315&amp;Itemid=138#summary|accessdate=2011-11-20}}&lt;/ref&gt; Some scientists argue that withdrawing antibiotic use will result in more diseased animals, which can result in an increased bacterial load on meat and an increased risk of food-borne illness.&lt;ref name=&quot;Cox&quot;/&gt; Opponents of such a ban argue that the economic implications would be devastating in terms of higher food prices. One study found that the price of pork would increase five cents a pound.&lt;ref&gt;{{cite journal|last=Hayes|coauthors=et al|title=Economic impact of a ban on the use of over the counter antibiotics in U.S. swine rations|journal=International Food and Agribusiness Management Review|year=2001|volume=4|pages=81–97|doi=10.1016/s1096-7508(01)00071-4}}&lt;/ref&gt;

==References==
{{reflist|colwidth=30em}}

[[Category:Antibiotics]]
[[Category:Food politics]]
[[Category:Pig farming]]</text>
      <sha1>d49j5m5fmfoq8zej3tz0n4fjdu0san1</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Validamycin</title>
    <ns>0</ns>
    <id>33558783</id>
    <revision>
      <id>578615508</id>
      <parentid>544327832</parentid>
      <timestamp>2013-10-24T22:46:08Z</timestamp>
      <contributor>
        <username>Cydebot</username>
        <id>1215485</id>
      </contributor>
      <minor/>
      <comment>Robot - Removing category Chemical compounds found in Streptomyces species per [[WP:CFD|CFD]] at [[Wikipedia:Categories for discussion/Log/2013 October 8]].</comment>
      <text xml:space="preserve" bytes="1770">{{Chembox
| ImageFile = Validamycin.svg
| ImageSize = 200px
| IUPACName = (1''R'',2''R'',3''S'',4''S'',6''R'')-2,3-dihydroxy-6-(hydroxymethyl)-4-{[(1''S'',4''S'',5''S'',6''S'')-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}cyclohexyl β-&lt;small&gt;D&lt;/small&gt;-glucopyranoside
| OtherNames = Validamycin A; Valimon; Validacin
| Section1 = {{Chembox Identifiers
|  CASNo = 37248-47-8
|   CASNo_Ref = {{cascite|correct|}}
|  PubChem = 
|  ChemSpiderID = 16736085
| ChEMBL = 520780
|  SMILES = OC/C3=C/[C@H](N[C@H]2C[C@H](CO)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@H]3O
|  InChI = 1/C20H35NO13/c22-3-6-1-8(12(26)15(29)11(6)25)21-9-2-7(4-23)19(17(31)13(9)27)34-20-18(32)16(30)14(28)10(5-24)33-20/h1,7-32H,2-5H2/t7-,8+,9+,10-,11+,12+,13+,14-,15+,16+,17-,18-,19-,20+/m1/s1
|  InChIKey = JARYYMUOCXVXNK-IMTORBKUBD
|  StdInChI = 1S/C20H35NO13/c22-3-6-1-8(12(26)15(29)11(6)25)21-9-2-7(4-23)19(17(31)13(9)27)34-20-18(32)16(30)14(28)10(5-24)33-20/h1,7-32H,2-5H2/t7-,8+,9+,10-,11+,12+,13+,14-,15+,16+,17-,18-,19-,20+/m1/s1
|  StdInChIKey = JARYYMUOCXVXNK-IMTORBKUSA-N
  }}
| Section2 = {{Chembox Properties
|  C=20|H=35|N=1|O=13
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility =
  }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition =
  }}
}}

'''Validamycin''' is an [[antibiotic]] and [[fungicide]] produced by ''[[Streptomyces hygroscopicus]]''. It is used as an inhibitor of [[trehalase]].&lt;ref&gt;{{cite pmid | 22036231}}&lt;/ref&gt;  It is used for the control of sheath blight of rice and damping-off  of cucumbers.

== References ==
{{reflist}}

[[Category:Amino sugars]]
[[Category:Oligosaccharides]]
[[Category:Cyclitols]]
[[Category:Antibiotics]]
[[Category:Fungicides]]</text>
      <sha1>6qwn30u6unm52fe21atixwf8b3aa785</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Mercer protocol</title>
    <ns>0</ns>
    <id>33738732</id>
    <revision>
      <id>607612733</id>
      <parentid>493480045</parentid>
      <timestamp>2014-05-08T11:03:05Z</timestamp>
      <contributor>
        <username>Rjwilmsi</username>
        <id>203434</id>
      </contributor>
      <minor/>
      <comment>Added 1 doi to a journal cite using [[Project:AWB|AWB]] (10102)</comment>
      <text xml:space="preserve" bytes="1327">The '''Mercer protocol''' is a common regimen for antibiotic prophylaxis in the context of [[Premature rupture of membranes|preterm premature rupture of membranes]] (PPROM) during [[pregnancy]], when immediate delivery is contraindicated due to known or suspected fetal lung immaturity.  It was first described by Mercer ''et al''. in 1997.&lt;ref&gt;{{cite journal|last=Mercer|first=BM|coauthors=Miodovnik, M, Thurnau, GR, Goldenberg, RL, Das, AF, Ramsey, RD, Rabello, YA, Meis, PJ, Moawad, AH, Iams, JD, Van Dorsten, JP, Paul, RH, Bottoms, SF, Merenstein, G, Thom, EA, Roberts, JM, McNellis, D|title=Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.|journal=JAMA: the Journal of the American Medical Association|date=1997-09-24|volume=278|issue=12|pages=989–95|pmid=9307346|doi=10.1001/jama.278.12.989}}&lt;/ref&gt;

==Regimen==
The protocol consists of two stages.  First, intravenously administer [[ampicillin]] (2 g) and [[erythromycin]] (250&amp;nbsp;mg) every 6 hours for 48 hours.  After 48 hours, administer oral amoxicillin (250&amp;nbsp;mg) and erythromycin (333&amp;nbsp;mg) every 8 hours for 5 days.

==References==

{{Reflist}}



[[Category:Antibiotics]]</text>
      <sha1>dsdliiazckhyacjt335ewqa24xsgaxg</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Quinupristin</title>
    <ns>0</ns>
    <id>2398874</id>
    <revision>
      <id>601173767</id>
      <parentid>585777113</parentid>
      <timestamp>2014-03-25T10:40:41Z</timestamp>
      <contributor>
        <username>The chemistds</username>
        <id>13073709</id>
      </contributor>
      <comment>added CSID and InChIs</comment>
      <text xml:space="preserve" bytes="2888">{{Drugbox
| IUPAC_name        = ''N''-{(6''R'',9''S'',10''R'',13''S'',15a''S'',18''R'',22''S'',24a''S'')-18-
{[(3''S'')-1-azabicyclo[2.2.2]oct-3-ylthio]methyl-22-[4-(dimethylamino)benzyl]-
6-ethyl-10,23-dimethyl-5,8,12,15,17,21,24-heptaoxo-13-phenyldocosahydro-12''H''-
pyrido[2,1-''f'']pyrrolo-[2,1-''l''][1,4,7,10,13,16] oxapentaazacyclononadecin-9-yl}-3-
hydroxypyridine-2-carboxamide
| image             = Quinupristin.png
| CAS_number        = 120138-50-3
| ATC_prefix        = 
| ATC_suffix        = 
| PubChem           = 5388937
| DrugBank          = 
| ChEMBL            = 1200649
| ChemSpiderID      = 4470884
| smiles            = CC[C@@H]1C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)N3C[C@H](C(=O)C[C@H]3C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CS[C@@H]6CN7CCC6CC7)CC8=CC=C(C=C8)N(C)C)C
| InChI             = 1/C53H67N9O10S/c1-6-37-50(68)61-23-11-14-38(61)51(69)59(5)40(26-32-16-18-36(19-17-32)58(3)4)52(70)62-28-35(30-73-43-29-60-24-20-33(43)21-25-60)42(64)27-39(62)47(65)57-45(34-12-8-7-9-13-34)53(71)72-31(2)44(48(66)55-37)56-49(67)46-41(63)15-10-22-54-46/h7-10,12-13,15-19,22,31,33,35,37-40,43-45,63H,6,11,14,20-21,23-30H2,1-5H3,(H,55,66)(H,56,67)(H,57,65)/t31-,35+,37-,38+,39+,40+,43-,44+,45+/m1/s1
| InChIKey          = WTHRRGMBUAHGNI-LCYNINFDBA
| StdInChI          = 1S/C53H67N9O10S/c1-6-37-50(68)61-23-11-14-38(61)51(69)59(5)40(26-32-16-18-36(19-17-32)58(3)4)52(70)62-28-35(30-73-43-29-60-24-20-33(43)21-25-60)42(64)27-39(62)47(65)57-45(34-12-8-7-9-13-34)53(71)72-31(2)44(48(66)55-37)56-49(67)46-41(63)15-10-22-54-46/h7-10,12-13,15-19,22,31,33,35,37-40,43-45,63H,6,11,14,20-21,23-30H2,1-5H3,(H,55,66)(H,56,67)(H,57,65)/t31-,35+,37-,38+,39+,40+,43-,44+,45+/m1/s1
| StdInChIKey       = WTHRRGMBUAHGNI-LCYNINFDSA-N
| C=53|H=67|N=9|O=10|S=1
| molecular_weight  = 1022.24 g/mol
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 3.1 hours
| excretion         = 
| pregnancy_AU      =  &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US      =  &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category=  
| legal_AU =  &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA =  &lt;!-- Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK =  &lt;!-- GSL, P, POM, CD, or Class A, B, C --&gt;
| legal_US =  &lt;!-- OTC / Rx-only / Schedule I, II, III, IV, V --&gt;
| legal_status      = 
| routes_of_administration = 
}}

'''Quinupristin''' is an [[antibiotic]], often used in combination with [[dalfopristin]] under the trade name [[Synercid]]. It is active against Gram-positive bacteria, atypical but not Gram negatives. They inhibit protein synthesis of the cells.'''
Quinupristin &amp; dalfopristin are not active against Enterococcus faecalis and they need to be given in combination with other antibacterials for mixed infections which also involve Gram negative organisms.'''  
[[Category:Antibiotics]]</text>
      <sha1>fhjgomq17ovd3mvfri7x53qy82a4fo6</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Antibiotic resistance</title>
    <ns>0</ns>
    <id>1914</id>
    <revision>
      <id>609093560</id>
      <parentid>609093281</parentid>
      <timestamp>2014-05-18T13:41:05Z</timestamp>
      <contributor>
        <username>IjonTichyIjonTichy</username>
        <id>16635488</id>
      </contributor>
      <comment>/* Development pipeline */ add a citation</comment>
      <text xml:space="preserve" bytes="100304">[[File:Antibiotic sensitvity and resistance.JPG|right|thumb|Antibiotic resistance tests: The bacteria in the culture on the left are susceptible to the antibiotics contained in the white paper discs. The bacteria in the culture on the right are resistant to most of the antibiotics.]]

'''Antibiotic resistance''' is a form of [[drug resistance]] whereby some (or, less commonly, all) sub-populations of a [[microorganism]], usually a bacterial species, are able to survive after exposure to one or more [[antibiotic]]s; pathogens resistant to multiple antibiotics are considered ''[[multidrug resistant]]'' (MDR) or, more colloquially, '''superbugs'''.&lt;ref&gt;name=cdcgetsmart&gt;{{cite web|title=Antibiotic Resistance Questions &amp; Answers|url=http://www.cdc.gov/getsmart/antibiotic-use/antibiotic-resistance-faqs.html#e|work=Get Smart: Know When Antibiotics Work|publisher=Centers for Disease Control and Prevention, USA|accessdate=20 March 2013|date=30 June 2009}}&lt;/ref&gt;

Antibiotic resistance is a serious and growing phenomenon in contemporary medicine and has emerged as one of the pre-eminent public health concerns of the 21st century, in particular as it pertains to pathogenic organisms (the term is especially relevant to organisms that cause disease in humans). A [[World Health Organization]] report released April 30, 2014 states, &quot;this serious threat is no longer a prediction for the future, it is happening right now in every region of the world and has the potential to affect anyone, of any age, in any country. Antibiotic resistance–when bacteria change so antibiotics no longer work in people who need them to treat infections–is now a major threat to public health.&quot;&lt;ref name=&quot;who.int&quot;&gt;[http://www.who.int/mediacentre/news/releases/2014/amr-report/en/ &quot;WHO's first global report on antibiotic resistance reveals serious, worldwide threat to public health&quot;] Retrieved 2014-05-02&lt;/ref&gt;

In the simplest cases, drug-resistant organisms may have acquired resistance to first-line antibiotics, thereby necessitating the use of second-line agents. Typically, a first-line agent is selected on the basis of several factors including safety, availability, and cost; a second-line agent is usually broader in spectrum, has a less favourable risk-benefit profile, and is more expensive or, in dire circumstances, may be locally unavailable. In the case of some MDR pathogens, resistance to second- and even third-line antibiotics is, thus, sequentially acquired, a case quintessentially illustrated by ''[[Staphylococcus aureus]]'' in some [[nosocomial]] settings. Some pathogens, such as ''[[Pseudomonas aeruginosa]]'', also   possess a high level of intrinsic resistance.

It may take the form of a spontaneous or induced genetic [[mutation]], or the acquisition of resistance [[gene]]s from other bacterial species by [[horizontal gene transfer]] via [[bacterial conjugation|conjugation]], [[Transduction (genetics)|transduction]], or [[transformation (genetics)|transformation]]. Many antibiotic resistance genes reside on transmissible [[plasmids]], facilitating their transfer. Exposure to an antibiotic [[natural selection|naturally selects]] for the survival of the organisms with the genes for resistance. In this way, a gene for antibiotic resistance may readily spread through an ecosystem of bacteria. Antibiotic-resistance plasmids frequently contain genes conferring resistance to several different antibiotics. This is not the case for ''[[Mycobacterium tuberculosis]]'', the bacteria that causes [[Tuberculosis]], since evidence is lacking for whether these bacteria have plasmids.&lt;ref name=pmid2115217&gt;{{cite journal |pmid=2115217 |year=1990 |last1=Zainuddin |first1=ZF |last2=Dale |first2=JW |title=Does Mycobacterium tuberculosis have plasmids? |volume=71 |issue=1 |pages=43–9 |journal=Tubercle |doi=10.1016/0041-3879(90)90060-l}}&lt;/ref&gt;  Also ''M. tuberculosis'' lack the opportunity to interact with other bacteria in order to share plasmids.&lt;ref name=pmid2115217/&gt;&lt;ref&gt;{{cite journal |doi=10.1128/AAC.01577-08 |title=A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance |year=2009 |last1=Louw |first1=G. E. |last2=Warren |first2=R. M. |last3=Gey Van Pittius |first3=N. C. |last4=McEvoy |first4=C. R. E. |last5=Van Helden |first5=P. D. |last6=Victor |first6=T. C. |journal=Antimicrobial Agents and Chemotherapy |volume=53 |issue=8 |pages=3181–9 |pmid=19451293 |pmc=2715638}}&lt;/ref&gt;

Genes for resistance to antibiotics, like the antibiotics themselves, are ancient.{{sfn|D'Costa|King|Kalan|Morar|2011|pp=457–461}} However, the increasing prevalence of antibiotic-resistant bacterial infections seen in clinical practice stems from antibiotic use both within human medicine and [[veterinary medicine]]. Any use of antibiotics can increase [[selective pressure]] in a population of bacteria to allow the resistant bacteria to thrive and the susceptible bacteria to die off. As resistance towards antibiotics becomes more common, a greater need for alternative treatments arises. However, despite a push for new antibiotic therapies, there has been a continued decline in the number of newly approved drugs.{{sfn|Donadio|Maffioli|Monciardini|Sosio|2010|pp=423–430}} Antibiotic resistance therefore poses a significant problem.

The growing prevalence and incidence of infections due to MDR pathogens is epitomised by the increasing number of familiar acronyms used to describe the causative agent and sometimes the infection; of these, [[Methicillin-resistant Staphylococcus aureus|MRSA]] is probably the most well-known, but others including VISA (vancomycin-intermediate ''S. aureus''), VRSA (vancomycin-resistant ''S. aureus''), ESBL (Extended spectrum beta-lactamase), VRE (Vancomycin-resistant ''Enterococcus'') and MRAB (Multidrug-resistant ''A. baumannii'') are prominent examples. [[Nosocomial infection]]s overwhelmingly dominate cases where MDR pathogens are implicated, but multidrug-resistant infections are also becoming increasingly common in the community.

Although there were low levels of preexisting antibiotic-resistant bacteria before the widespread use of antibiotics,{{sfn|Caldwell|Lindberg|2011}} {{sfn|Nelson|2009|p=294}} evolutionary pressure from their use has played a role in the development of multidrug-resistant varieties and the spread of resistance between bacterial species.{{sfn|Hawkey|Jones|2009|pp=i3-i10}} In medicine, the major problem of the emergence of resistant bacteria is due to misuse and overuse of antibiotics.&lt;ref&gt;{{cite web |archiveurl=http://web.archive.org/web/20040513120635/http://www.who.int/mediacentre/factsheets/fs268/en/index.html|url=http://www.who.int/mediacentre/factsheets/fs268/en/index.html |title=Use of antimicrobials outside human medicine and resultant antimicrobial resistance in humans |author=WHO |authorlink=World Health Organisation |publisher=World Health Organization |archivedate=13 May 2004 |date=January 2002|ref=harv}}&lt;/ref&gt; In some countries, antibiotics are sold over the counter without a prescription, which also leads to the creation of resistant strains. Other practices contributing to resistance include [[antibiotic use in livestock]] feed to promote faster growth.&lt;ref&gt;{{Cite journal | doi = 10.1126/science.295.5552.27a | journal = Science | date = 4 January 2002 | volume = 295 | issue = 5552 | pages = 27–28 | first = Dan |last=Ferber | pmid = 11778017 | title = Livestock Feed Ban Preserves Drugs' Power |ref=harv}}&lt;/ref&gt;&lt;ref name=&quot;mathew&quot;/&gt; Household use of antibacterials in soaps and other products, although not clearly contributing to resistance, is also discouraged (as not being effective at infection control).&lt;ref&gt;{{cite web| last=CDC|url=http://www.cdc.gov/getsmart/antibiotic-use/anitbiotic-resistance-faqs.html#j |trans_title = Are antibacterial-containing products (soaps, household cleaners, etc.) better for preventing the spread of infection? Does their use add to the problem of resistance?| title=Antibiotic Resistance Questions &amp; Answers |publisher=Centers for Disease Control and Prevention|location=Atlanta, Georgia, USA. |accessdate= November 17, 2009|ref=harv| archiveurl= http://web.archive.org/web/20091108223733/http://cdc.gov/getsmart/antibiotic-use/anitbiotic-resistance-faqs.html| archivedate= 8 November 2009 &lt;!--DASHBot--&gt;| deadurl= no}}&lt;/ref&gt; Unsound practices in the pharmaceutical manufacturing industry can also contribute towards the likelihood of creating antibiotic-resistant strains.&lt;ref&gt;{{Cite journal  | last1 = Larsson | first1 = DG. | last2 = Fick | first2 = J. | title = Transparency throughout the production chain -- a way to reduce pollution from the manufacturing of pharmaceuticals? | journal = [[Regul Toxicol Pharmacol]] |date=Jan 2009 | doi = 10.1016/j.yrtph.2009.01.008 | pmid = 19545507  | volume = 53  | issue = 3  | pages = 161–3 |ref=harv}}&lt;/ref&gt; The procedures and clinical practice during the period of drug treatment are frequently flawed&amp;nbsp;— usually no steps are taken to isolate the patient to prevent re-infection or infection by a new pathogen, negating the goal of complete destruction by the end of the course&lt;ref&gt;Healthcare-associated Infections&lt;/ref&gt; (see [[Healthcare-associated infections]] and [[Infection control]]).

Certain antibiotic classes are highly associated with colonisation with &quot;superbugs&quot; compared to other antibiotic classes. A superbug, also called multiresistant, is a bacterium that carries several resistance genes.&lt;ref&gt;{{cite web|url=http://www.sciencedaily.com/articles/a/antibiotic_resistance.htm |title=Antibiotic resistance |publisher=Sciencedaily.com |accessdate=2013-06-12}}&lt;/ref&gt; The risk for colonisation increases if there is a lack of susceptibility (resistance) of the superbugs to the antibiotic used and high tissue penetration, as well as broad-spectrum activity against &quot;good bacteria&quot;. In the case of [[Methicillin-resistant Staphylococcus aureus|MRSA]], increased rates of MRSA infections are seen with [[glycopeptides]], [[cephalosporin]]s, and especially [[quinolones]].&lt;ref&gt;{{cite journal |last=Tacconelli |first=E|last2= De Angelis |first2=G|last3= Cataldo |first3=MA|last4= Pozzi |first4=E|last5= Cauda |first5=R |title=Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis |journal=J. Antimicrob. Chemother. |volume=61 |issue=1 |pages=26–38 |date=January 2008 |pmid=17986491 |doi=10.1093/jac/dkm416 |ref=harv}}&lt;/ref&gt;&lt;ref&gt;{{Cite journal | last1 = Muto | first1 = CA. | last2 = Jernigan | first2 = JA. | last3 = Ostrowsky | first3 = BE. | last4 = Richet | first4 = HM. | last5 = Jarvis | first5 = WR. | last6 = Boyce | first6 = JM. | last7 = Farr | first7 = BM. | title = SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus | journal = Infect Control Hosp Epidemiol | volume = 24 | issue = 5 | pages = 362–86 |date=May 2003 | doi = 10.1086/502213 | pmid = 12785411 |ref=harv}}&lt;/ref&gt; In the case of colonisation with ''[[Clostridium difficile]]'', the high-risk antibiotics include cephalosporins and in particular quinolones and [[clindamycin]].&lt;ref&gt;{{cite web |first=Dr Ralf-Peter |last=Vonberg |title=Clostridium difficile: a challenge for hospitals |url=http://www.ihe-online.com/feature-articles/clostridium-difficile-a-challenge-for-hospitals/trackback/1/index.html |work=European Center for Disease Prevention and Control |publisher=IHE |location=Institute for Medical Microbiology and Hospital Epidemiology |accessdate=27 July 2009|ref=harv| archiveurl= http://web.archive.org/web/20090611151535/http://www.ihe-online.com/feature-articles/clostridium-difficile-a-challenge-for-hospitals/trackback/1/index.html| archivedate= 11 June 2009 &lt;!--DASHBot--&gt;| deadurl= no}}&lt;/ref&gt;&lt;ref&gt;{{Cite journal  | last = Kuijper | first = EJ | last2 = van Dissel | first2 = J. | last3 = Wilcox | first3 = MH | title = Clostridium difficile: changing epidemiology and new treatment options | journal = Current Opinion in Infectious Diseases | volume = 20 | issue = 4 | pages = 376–83 |date=Aug 2007 | doi = 10.1097/QCO.0b013e32818be71d | pmid = 17609596 |ref=harv}}&lt;/ref&gt;

Of antibiotics used in the United States in 1997, half were used in humans and half in animals; in 2013, 80% were used in animals.&lt;ref&gt;{{cite book|last=editors|first=Ronald Eccles, Olaf Weber, |title=Common cold|year=2009|publisher=Birkhäuser|location=Basel|isbn=978-3-7643-9894-1|url=http://books.google.ca/books?id=rRIdiGE42IEC|edition=Online-Ausg.|page = 240}}&lt;/ref&gt;&lt;ref name=TheRealNews-2014-05-18&gt;{{cite web
|url=http://therealnews.com/t2/index.php?option=com_content&amp;task=view&amp;id=31&amp;Itemid=74&amp;jumival=11872
|title=Why Are Antibiotics Becoming Useless All Over the World? 
|author=[[Martin Khor]]
|date=2014-05-18
|publisher=''[[The Real News]]''
|accessdate=2014-05-18
}}&lt;/ref&gt;

==Natural occurrence==

There is evidence that naturally occurring antibiotic resistance is common.&lt;ref name=Wright10&gt;{{cite journal|last=Wright|first=GD|title=Antibiotic resistance in the environment: a link to the clinic?|journal=Current Opinion in Microbiology|date=October 2010|volume=13|issue=5|pages=589–94|pmid=20850375|doi=10.1016/j.mib.2010.08.005}}&lt;/ref&gt; The [[genes]] that confer this resistance are known as the environmental [[resistome]].&lt;ref name=Wright10/&gt; These genes may be transferred from non-disease-causing bacteria to those that do cause disease, leading to clinically significant antibiotic resistance.&lt;ref name=Wright10/&gt;

In 1952, an experiment conducted by [[Joshua Lederberg|Joshua]] and [[Esther Lederberg]] showed that [[penicillin]]-resistant bacteria existed before penicillin treatment.&lt;ref&gt;{{cite web|url=http://evolution.berkeley.edu/evolibrary/article/mutations_07|title=Mutations are random|publisher =University of California|accessdate=Aug 14, 2011}}&lt;/ref&gt; While experimenting at the [[University of Wisconsin-Madison]], Joshua Lederberg and his graduate student Norton Zinder also demonstrated preexistent bacterial resistance to [[streptomycin]].&lt;ref&gt;Richard William Nelson. ''Darwin, Then and Now: The Most Amazing Story in the History of Science'', iUniverse, 2009, p. 294&lt;/ref&gt; In 1962, the presence of [[penicillinase]] was detected in dormant ''[[Bacillus licheniformis]]'' [[endospores]], revived from dried soil on the roots of plants, preserved since 1689 in the [[British Museum]].&lt;ref&gt;Wayne W. Umbreit, ''Advances in Applied Microbiology'', vol. 11, Academic Press, 1970, p. 80&lt;/ref&gt;&lt;ref&gt;M. R. Pollock. &quot;Origin and Function of Penicillinase: a Problem in Biochemical Evolution&quot;,''[[British Medical Journal]]'', 14 Oct 1967, p. 76&lt;/ref&gt;&lt;ref name=&quot;penicillinase&quot;&gt;''[[New Scientist]]'', Jun 8, 1972, p. 546&lt;/ref&gt; Six [[Strain (biology)|strains]] of ''[[Clostridium]]'', found in the bowels of William Braine and John Hartnell (members of the [[Franklin Expedition]]) showed resistance to [[cefoxitin]] and [[clindamycin]].&lt;ref name=&quot;NS&quot;&gt;''[[New Scientist]]'', Feb 11, 1989, p. 34&lt;/ref&gt; It was suggested that penicillinase may have emerged as a defense mechanism for bacteria in their [[habitat]]s, such as the case of penicillinase-rich ''[[Staphylococcus aureus]]'', living with penicillin-producing ''[[Trichophyton]]'', however this was deemed [[circumstantial evidence|circumstantial]].&lt;ref name=&quot;penicillinase&quot;/&gt; Search for a penicillinase ancestor has focused on the class of [[protein]]s that must be ''a priori'' capable of specific combination with [[penicillin]].&lt;ref&gt;Pollock, p. 77&lt;/ref&gt; The resistance to cefoxitin and clindamycin in turn was attributed to Braine's and Hartnell's contact with microorganisms that naturally produce them or [[random mutation]] in the [[chromosomes]] of ''Clostridium'' strains.&lt;ref name=&quot;NS&quot;/&gt; Nonetheless there is evidence that [[heavy metals]] and some pollutants may select for antibiotic-resistant bacteria, generating a constant source of them in small numbers.&lt;ref&gt;Abigail A. Salyers, Dixie D. Whitt. ''Revenge of the microbes: how bacterial resistance is undermining the antibiotic miracle'', ASM Press, 2005, p. 34&lt;/ref&gt;

==In medicine==

In 1945, in his [[Nobel lecture]] &quot;Penicillin,&quot; [[Alexander Fleming]] warned against the use of sub‐therapeutic doses of antibiotics – &quot;bought by anyone in the shops&quot; without a prescription:

:&quot;The time may come when penicillin can be bought by anyone in the shops. Then there is the danger that the ignorant man may easily underdose himself and by exposing his microbes to non‐lethal quantities of the drug make them resistant. Here is a hypothetical illustration. Mr. X. has a sore throat. He buys some penicillin and gives himself, not enough to kill the streptococci but enough to educate them to resist penicillin. He then infects his wife. Mrs. X gets pneumonia and is treated with penicillin. As the streptococci are now resistant to penicillin the treatment fails. Mrs. X dies. Who is primarily responsible for Mrs. X’s death?&quot;&lt;ref&gt;http://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdf&lt;/ref&gt;

Inappropriate prescribing of antibiotics has been attributed to a number of causes, including people insisting on antibiotics, physicians prescribing them as they feel they do not have time to explain why they are not necessary, and physicians not knowing when to prescribe antibiotics or being overly cautious for medical and/or legal reasons.&lt;ref&gt;{{cite journal |last=Arnold |first=SR |last2=Straus |first2=SE |title=Interventions to improve antibiotic prescribing practices in ambulatory care |journal=Cochrane Database of Systematic Reviews |issue=4 |pages=CD003539 |year=2005 |pmid=16235325 |doi=10.1002/14651858.CD003539.pub2 |editor1-last=Arnold |editor1-first=Sandra R|ref=harv}}&lt;/ref&gt;  For example, a third of people believe that antibiotics are effective for the [[common cold]],&lt;ref&gt;{{cite journal |last=McNulty |first=CA |last2= Boyle |first2=P |last3= Nichols |first3=T |last4=Clappison |first4=P |last5=Davey |first5=P |title=The public's attitudes to and compliance with antibiotics |journal=[[J. Antimicrob. Chemother.]] |volume=60 Suppl 1 |pages=i63–8 |date=August 2007 |pmid=17656386 |doi=10.1093/jac/dkm161 |ref=harv}}&lt;/ref&gt; and the common cold is the most common reason antibiotics are prescribed&lt;ref&gt;{{cite book|last=editors|first=Ronald Eccles, Olaf Weber, |title=Common cold|year=2009|publisher=Birkhäuser|location=Basel|isbn=978-3-7643-9894-1|url=http://books.google.ca/books?id=rRIdiGE42IEC|edition=Online-Ausg.|page = 234}}&lt;/ref&gt; even though antibiotics are completely useless against viruses.

The number of persons inappropriately prescribed antibiotics is a greater factor in the increasing rates of bacterial resistance than non-compliance with antibiotic protocol among those prescribed the drugs, although the non-compliance rate is also high.&lt;ref name=&quot;Pechère JC 2001 S170–3&quot;&gt;{{cite journal |last=Pechère |first=JC |title=Patients' interviews and misuse of antibiotics |journal=Clin. Infect. Dis. |volume=33 Suppl 3 |pages=S170–3 |date=September 2001 |pmid=11524715 |doi=10.1086/321844 |ref=harv}}&lt;/ref&gt; A single regimen of antibiotics even in compliant patients leads to a greater risk of resistant organisms to that antibiotic in the person for a month to possibly a year.&lt;ref&gt;{{cite journal |title=Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis|last=Costelloe |first=Ceire|first2=Chris |last2=Metcalfe| first3= Andrew |last3=Lovering |first4=David |last4=Mant|first5= Alastair D |last5=Hay |volume=340 |page=c2096 |publisher=BMJ |doi= 10.1136/bmj.c2096 |date=May 2010 |ref=harv |journal=BMJ}}&lt;/ref&gt;

Antibiotic resistance has been shown to increase with duration of treatment; therefore, as long as a clinically effective lower limit is observed (that depends upon the organism and antibiotic in question), the use by the medical community of shorter courses of antibiotics is likely to decrease rates of resistance, reduce cost, and have better outcomes due to fewer complications such as [[Clostridium difficile|C. difficile]] infection and diarrhea.&lt;ref&gt;{{cite journal |last=Li |first=JZ |last2= Winston |first2=LG |last3=Moore |first3=DH |last4= Bent |first4=S |title=Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis |journal=Am. J. Med. |volume=120 |issue=9 |pages=783–90 |date=September 2007 |pmid=17765048 |doi=10.1016/j.amjmed.2007.04.023 |ref=harv}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=Bignardi|first=G.E.|title=Risk factors for Clostridium difficile infection|journal=Journal of Hospital Infection|date=31 August 1998|volume=40|issue=1|pages=1–15|doi=10.1016/S0195-6701(98)90019-6|pmid=9777516}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=Runyon|first=BA|author2=McHutchison, JG|author3= Antillon, MR|author4= Akriviadis, EA|author5= Montano, AA|title=Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients|journal=Gastroenterology|date=June 1991|volume=100|issue=6|pages=1737–42|pmid=2019378}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=Singh|first=Nina|coauthors=PAUL ROGERS, CHARLES W. ATWOOD, MARILYN M. WAGENER and VICTOR L. YU|title=Short-course Empiric Antibiotic Therapy for Patients with Pulmonary Infiltrates in the Intensive Care Unit A Proposed Solution for Indiscriminate Antibiotic Prescription|journal=Am. J. Respir. Crit. Care Med.|date=1 August 2000|volume=162|issue=2|pages=505–511 |pmid=10934078|doi=10.1164/ajrccm.162.2.9909095}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=Gleisner|first=Ana L.M|coauthors=Argenta, Rodrigo; Pimentel, Marcelo; Simon, Tatiana K; Jungblut, Carlos F; Petteffi, Leonardo; de Souza, Rafael M; Sauerssig, Mauricio; Kruel, Cleber D.P; Machado, Adão R.L|title=Infective complications according to duration of antibiotic treatment in acute abdomen|journal=International Journal of Infectious Diseases|date=30 April 2004|volume=8|issue=3|pages=155–162|doi=10.1016/j.ijid.2003.06.003|pmid=15109590}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |doi=10.1097/00006454-199707000-00011 |title=Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis |year=1997 |last1=Pichichero |first1=Michael E. |last2=Cohen |first2=Robert |journal=The Pediatric Infectious Disease Journal |volume=16 |issue=7 |pages=680–95 |pmid=9239773}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |doi=10.1001/archsurg.1986.01400010029002 |title=Efficacy of Short-Course Antibiotic Prophylaxis After Penetrating Intestinal Injury |year=1986 |last1=Dellinger |first1=E. Patchen |journal=Archives of Surgery |volume=121 |pages=23–30 |pmid=3942496 |last2=Wertz |first2=MJ |last3=Lennard |first3=ES |last4=Oreskovich |first4=MR |issue=1}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |doi=10.1016/S0924-8579(02)00360-6 |title=Does short-course antibiotic therapy better meet patient expectations? |year=2003 |last1=Perez-Gorricho |first1=B |last2=Ripoll |first2=M |journal=International Journal of Antimicrobial Agents |volume=21 |issue=3 |pages=222–8 |pmid=12636982 |last3=Pace Study |first3=Group}}&lt;/ref&gt; In some situations a short course is inferior to a long course.&lt;ref&gt;{{cite journal |doi=10.1542/peds.109.5.e70 |title=A Meta-analysis of Randomized, Controlled Trials Comparing Short- and Long-Course Antibiotic Therapy for Urinary Tract Infections in Children |year=2002 |last1=Keren |first1=R. |last2=Chan |first2=E. |journal=Pediatrics |volume=109 |issue=5 |pages=E70–0 |pmid=11986476}}&lt;/ref&gt; One pediatric study found that with one antibiotic a short course was more effective, but with a different antibiotic, a longer course was more effective.&lt;ref&gt;{{cite journal |pmid=16220091 |year=2005 |last1=Casey |first1=JR |last2=Pichichero |first2=ME |title=Metaanalysis of short course antibiotic treatment for group a streptococcal tonsillopharyngitis |volume=24 |issue=10 |pages=909–17 |journal=The Pediatric infectious disease journal |doi=10.1097/01.inf.0000180573.21718.36}}&lt;/ref&gt;

A [[World Health Organization|WHO]] report incorporating data from 114 countries recommends people help tackle resistance by using antibiotics only when prescribed by a doctor and completing the full prescription, even if they feel better. Some infections require treatment long after symptoms are gone, and in all cases, an insufficient course of antibiotics may lead to relapse (with an infection that is now more antibiotic resistant).&lt;ref&gt;{{cite web|url=http://hicsigwiki.asid.net.au/images/4/41/Should_you_stop_an_antibiotic_course_early_if_you_feel_better_R._Everts.pdf |title=Should you stop an antibiotic course early? |format=PDF |accessdate=2013-03-12}}&lt;/ref&gt; Some researchers have found however that antibiotics can often be safely stopped 72&amp;nbsp;hours after symptoms resolve.&lt;ref&gt;{{cite journal |doi=10.1136/bmj.d7955 |title=A prescription for improving antibiotic prescribing in primary care |year=2012 |last1=McCormack |first1=J. |last2=Allan |first2=G. M. |journal=BMJ |volume=344 |pages=d7955 |pmid=22302779}}&lt;/ref&gt; Because patients may feel better before the infection is eradicated, doctors must provide instructions to patients so they know when it is safe to stop taking a prescription. Some researchers advocate doctors' using a very short course of antibiotics, reevaluating the patient after a few days, and stopping treatment if there are no longer clinical signs of infection.&lt;ref&gt;Marc Bonten, MD; Eijkman-Winkler Institute for Medical Microbiology, Infectious Diseases, and Inflammation; Utrecht, the Netherland | http://hicsigwiki.asid.net.au/images/4/41/Should_you_stop_an_antibiotic_course_early_if_you_feel_better_R._Everts.pdf&lt;/ref&gt;

A large number of people do not finish a course of antibiotics primarily because they feel better (varying from 10% to 44%, depending on the country).&lt;ref&gt;{{cite journal |last=Pechère |first=JC |last2=Hughes |first2=D |last3= Kardas |first3=P |last4= Cornaglia |first4=G |title=Non-compliance with antibiotic therapy for acute community infections: a global survey |journal=Int. J. Antimicrob. Agents |volume=29 |issue=3 |pages=245–53 |date=March 2007 |pmid=17229552 |doi=10.1016/j.ijantimicag.2006.09.026 |ref=harv}}&lt;/ref&gt; Compliance with once-daily antibiotics is better than with twice-daily antibiotics.&lt;ref&gt;{{cite journal |last=Kardas |first=P |title=Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial |journal=J. Antimicrob. Chemother. |volume=59 |issue=3 |pages=531–6 |date=March 2007 |pmid=17289766 |doi=10.1093/jac/dkl528 |ref=harv}}&lt;/ref&gt;  Patients taking less than the required dosage or failing to take their doses within the prescribed timing results in decreased concentration of antibiotics in the bloodstream and tissues, and, in turn, exposure of bacteria to suboptimal antibiotic concentrations increases the frequency of antibiotic resistant organisms, however factors within the intensive care unit setting such as mechanical ventilation and multiple underlying diseases also appeared to contribute to bacterial resistance.&lt;ref&gt;{{cite journal |last=Thomas |first=JK |last2= Forrest |first2=A |last3= Bhavnani |first3=SM|title=Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy |journal=Antimicrob. Agents Chemother. |volume=42 |issue=3 |pages=521–7 |date=March 1998 |pmid=9517926 |pmc=105492 |ref=harv |last4=Hyatt |first4=JM |last5=Cheng |first5=A |last6=Ballow |first6=CH |last7=Schentag |first7=JJ}}&lt;/ref&gt; These nosocomial pneumonia patients represented a situation where there was relatively little contribution of host defense to outcome, and therefore may not be applicable to otherwise healthy individuals taking antibiotics.

Antibiotic-tolerant states may depend on physiological adaptations without direct connections to antibiotic target activity or to drug uptake, [[efflux (microbiology)|efflux]], or inactivation.

Poor hand hygiene by hospital staff has been associated with the spread of resistant organisms,&lt;ref&gt;{{cite journal |last=Girou |first=E  |last2=Legrand |first2=P |last3=Soing-Altrach |first3=S |title=Association between hand hygiene compliance and methicillin-resistant Staphylococcus aureus prevalence in a French rehabilitation hospital |journal=Infect Control Hosp Epidemiol |volume=27 |issue=10 |pages=1128–30 |date=October 2006 |pmid=17006822 |doi=10.1086/507967 |ref=harv |last4=Lemire |first4=Astrid |last5=Poulain |first5=Celine |last6=Allaire |first6=Alexandra |last7=Tkoub‐Scheirlinck |first7=Latifa |last8=Chai |first8=Steeve Ho Tam |last9=Dupeyron |first9=Catherine |displayauthors=8}}&lt;/ref&gt; and an increase in hand washing compliance results in decreased rates of these organisms.&lt;ref&gt;{{cite journal |last=Swoboda |first=SM |last2=Earsing |first2=K |last3=Strauss |first3=K |last4=Lane |first4=S |last5=Lipsett |first5=PA |title=Electronic monitoring and voice prompts improve hand hygiene and decrease nosocomial infections in an intermediate care unit |journal=Crit. Care Med. |volume=32 |issue=2 |pages=358–63 |date=February 2004 |pmid=14758148 |doi=10.1097/01.CCM.0000108866.48795.0F |ref=harv}}&lt;/ref&gt;

The improper use of antibiotics and therapeutic treatments can often be attributed to the presence of structural violence in particular regions. Socioeconomic factors such as race and poverty affect the accessibility of and adherence to drug therapy. The efficacy of treatment programs for these drug-resistant strains depends on whether or not programmatic improvements take into account the effects of structural violence.&lt;ref&gt;Farmer, Paul E., Bruce Nizeye, Sara Stulac, and Salmaan Keshavjee. 2006. Structural Violence and Clinical Medicine. PLoS Medicine, 1686–1691.&lt;/ref&gt;

==Role of other animals==
{{main|Antibiotic use in livestock}}
The emergence of antibiotic-resistant microorganisms in human medicine is primarily the result of the use of antibiotics in humans, although the use of antibiotics in animals is also partly responsible.&lt;ref&gt;The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment: Workshop Summary. Institute of Medicine (US) Forum on Emerging Infections; Knobler SL, Lemon SM, Najafi M, et al., editors. Washington (DC): National Academies Press (US); 2003.[http://www.ncbi.nlm.nih.gov/books/NBK97126/]&lt;/ref&gt;&lt;ref name=TheRealNews-2014-05-18/&gt;

Antibiotic drugs are used non-therapeutically in animals that are intended for human consumption, such as cattle, pigs, chickens, fish, etc.&lt;ref name=TheRealNews-2014-05-18/&gt; Since the last third of the 20th century, there has been extensive use of antibiotics in [[animal husbandry]]. Some of these drugs are not considered significant for use in humans, because of their lack of either efficacy or purpose in humans (such as the use of [[ionopores]] in ruminants&lt;ref&gt;{{cite web|last=Hersom|first=Matt|title=Application of Ionophores in Cattle Diets|url=http://edis.ifas.ufl.edu/pdffiles/AN/AN28500.pdf|work=AN285 Department of Animal Sciences|publisher=University of Florida IFAS Extension|accessdate=14 March 2013}}&lt;/ref&gt;), or because that drug has mostly gone out of use in humans (such as [[Sulfonamide (medicine)|sulfa drugs]] due to widespread allergic reactions and antibiotic resistance among human pathogens){{citation needed|date=May 2014}}. Others however are used in both animals and humans, including penicillin and some forms of tetracycline.&lt;ref&gt;  The Editorial Board of the ''[[New York Times]]'', May 10, 2014, 
 [http://www.nytimes.com/2014/05/11/opinion/sunday/the-rise-of-antibiotic-resistance.html?ref=opinion&amp;_r=0 The Rise of Antibiotic Resistance]&lt;/ref&gt; Historically, regulation of antibiotic use in food animals has been limited to limiting drug residues in meat, egg, and milk products, rather than by direct concern over the development of antibiotic resistance. This mirrors the primary concerns in human medicine, where, in general, researchers and doctors were more concerned about effective but non-toxic doses of drugs rather than antibiotic resistance.

The resistant bacteria which antibiotic exposure selects in animals can be transmitted to humans via three pathways, those being through the consumption of [[animal product]]s (milk, meat, eggs, etc.), from close or direct contact with animals or other humans, or through the environment.&lt;ref&gt;{{cite web|last=Schneider|first=K|last2=Garrett|first2=L|title=Non-therapeutic Use of Antibiotics in Animal Agriculture, Corresponding Resistance Rates, and What Can be Done About It|url=http://www.cgdev.org/content/article/detail/1422307/|publisher=Center for Global Development|date=June 19, 2009|ref=harv}}&lt;/ref&gt; In the first pathway, [[food preservation]] methods can help eliminate, decrease, or prevent the growth of bacteria in some food classes. Evidence for the transfer of antibiotic- resistant microorganisms from animals to humans has been scant, and most evidence shows that pathogens of concern in human populations originated in humans and are maintained there, with rare cases of transference to humans.&lt;ref&gt;Hurd HS, Doores S, Hayes D, Mathew A, Maurer J, Silley P, Singer RS, Jones RN. “Public health consequences of macrolide use in food animals: a deterministic risk assessment “. J Food Prot. 2004 May;67(5):980-92&lt;/ref&gt;&lt;ref&gt;Hurd HS, Malladi S. “A stochastic assessment of the public health risks of the use of macrolide antibiotics in food animals”. Risk Anal. 2008 Jun;28(3):695-710. doi: 10.1111/j.1539-6924.2008.01054.x&lt;/ref&gt; The use of antibiotics in animals can be classified into different use patterns according to its purpose. The most accepted classification discriminates therapeutic, prophylactic, metaphylactic, and growth promotion uses of antibiotics.&lt;ref&gt;Joint FAO/OIE/WHO Expert Workshop
on Non-Human Antimicrobial Usage and Antimicrobial Resistance: Scientific assessment [http://www.who.int/foodsafety/publications/micro/en/amr.pdf]&lt;/ref&gt;  All four patterns select for bacterial resistance, since antibiotic resistance is a natural evolutionary process, but the non-therapeutic uses expose larger number of animals, and therefore of bacteria, for more extended periods, and at lower doses. They therefore greatly increase the cross-section for the evolution of resistance.

The [[World Health Organization]] concluded that inappropriate use of antibiotics in animal husbandry is an underlying contributor to the emergence and spread of antibiotic-resistant germs, and that the use of antibiotics as growth promoters in animal feeds should be prohibited, in the absence of risk assessments. Regarding this matter, the [[OIE]] has added to the Terrestrial Animal Health Code a series of guidelines with recommendations to its members for the creation and harmonization of national antimicrobial resistance surveillance and monitoring programs,&lt;ref&gt;[http://www.oie.int/index.php?id=169&amp;L=0&amp;htmfile=chapitre_1.6.7.htm OIE, Terrestrial Animal Health Code]&lt;/ref&gt; monitoring of the quantities of antibiotics used in animal husbandry,&lt;ref&gt;[http://www.oie.int/index.php?id=169&amp;L=0&amp;htmfile=chapitre_1.6.8.htm OIE,Terrestrial Animal Health Code]&lt;/ref&gt; and recommendations to ensure the proper and prudent use of antibiotic substances. Another guideline introduced in the terrestrial Animal Health Code is the implementation of methodologies that help to establish risk factors associated with this worldwide concern. The OIE concluded that risk assessments should be performed in order to assess, manage and define the possible health risks of antibiotic resistance in human and animal populations.&lt;ref&gt;[http://www.oie.int/index.php?id=169&amp;L=0&amp;htmfile=chapitre_1.6.9.htm OIE,Terrestrial Animal Health Code]&lt;/ref&gt;

In the world, antibiotics are widely used on animals. As in human medicine, antibiotics can often be bought without prescription and veterinary supervision for use on pets and livestock. Bacteria remaining in these animals are likely to be resistant to the antibiotics used, and may be passed into the environment by the excretion and secretion of materials such as milk, feces, urine, saliva, semen, lochia, etc. The actual impact of these resistant germs depends on their specific type and on the animal or organism they henceforth infect. Some germs, such as tetanus, are toxic regardless of their antibiotic-resistant status. (It is useful to remember that antibiotics are not used in treatment of all diseases caused by bacteria. Tetanus, as an example, is prevented by vaccine and is extremely difficult to treat once symptoms appear.)

In 1998, European Union health ministers voted to ban four antibiotics widely used to promote animal growth (despite their scientific panel's recommendations{{citation needed|date=May 2014}}). Regulation banning the use of antibiotics in European feed, with the exception of two antibiotics in poultry feeds, became effective in 2006.&lt;ref&gt;{{cite journal|last=Castanon|first=J.I.|year=2007|title=History of the use of antibiotic as growth promoters in European poultry feeds|journal=Poult. Sci.|volume=86|issue=11|pages=2466–71|pmid=17954599|doi=10.3382/ps.2007-00249|ref=harv}}&lt;/ref&gt; In Scandinavia, there is evidence that the ban has led to a lower prevalence of antimicrobial resistance in (nonhazardous) animal bacterial populations.&lt;ref&gt;{{cite journal|last=Bengtsson|first=B.|last2=Wierup|first2=M.|year=2006|title= Antimicrobial resistance in Scandinavia after ban of antimicrobial growth promoters|journal=Anim. Biotechnol.|volume=17|issue=2|pages= 147–56|pmid=17127526|doi=10.1080/10495390600956920|ref=harv}}&lt;/ref&gt; However, a corresponding change in antibiotic-resistance cases among humans has not yet been demonstrated.

===In the United States===
In the United States, the [[United States Department of Agriculture]] (USDA) and the [[Food and Drug Administration]] (FDA) collect data on antibiotic use in animals and humans.&lt;ref name=&quot;gao&quot;&gt;{{cite web|url=http://www.gao.gov/assets/330/323097.html|title=GAO-11-801, Antibiotic Resistance: Agencies Have Made Limited Progress Addressing Antibiotic Use in Animals|publisher=gao.gov|accessdate=2014-01-25}}&lt;/ref&gt; In research studies, occasional animal-to-human spread of drug-resistant organisms has been demonstrated. Antibiotics and other drugs are used in U.S. animal feed to promote animal productivity.&lt;ref name=&quot;mathew&quot;&gt;{{cite journal|last=Mathew|first=AG|last2=Cissell|first2=R |last3=Liamthong|first3=S|title=Antibiotic resistance in bacteria associated with food animals: a United States perspective of livestock production|journal=Foodborne Pathog. Dis.|volume=4|issue=2|pages=115–33|year=2007|pmid=17600481|doi=10.1089/fpd.2006.0066|ref=harv}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=Sapkota|first=AR|last2=Lefferts|first2=LY|last3=McKenzie|first3=S|last4=Walker|first4=P|title=What Do We Feed to Food-Production Animals? A Review of Animal Feed Ingredients and Their Potential Impacts on Human Health|journal=Environ. Health Perspect. |volume=115|issue=5|pages=663–70|date=May 2007|pmid=17520050|pmc=1867957|doi=10.1289/ehp.9760|ref=harv}}&lt;/ref&gt; In particular, poultry feed and water is a common route of administration of drugs, due to higher overall costs when drugs are administered by handling animals individually. In general, animals that appear ill are not permitted to be slaughtered for human consumption in the United States.

Growing U.S. consumer concern about using antibiotics in animal feed has led to a niche market of &quot;antibiotic-free&quot; animal products, but this small market is unlikely to change entrenched, industry-wide practices.&lt;ref&gt;{{cite journal|last=Baker|first=R|title=Health management with reduced antibiotic use&amp;nbsp;— the U.S. experience|journal=Anim. Biotechnol.|volume=17|issue=2|pages=195–205|year=2006|pmid=17127530 |doi=10.1080/10495390600962274|ref=harv}}&lt;/ref&gt;

In 2001, the [[Union of Concerned Scientists]] estimated that greater than 70% of the antibiotics used in the U.S. are given to food animals (for example, chickens, pigs, and cattle), in the absence of disease.&lt;ref&gt;{{cite web|url= http://www.ucsusa.org/food_and_environment/antibiotics_and_food/hogging-it-estimates-of-antimicrobial-abuse-in-livestock.html|title= Executive summary from the UCS report &quot;Hogging It: Estimates of Antimicrobial Abuse in Livestock&quot;|publisher=Union of Concerned Scientists|date=January 2001|ref=harv}}&lt;/ref&gt;&lt;ref name=TheRealNews-2014-05-18/&gt; The amounts given are termed &quot;sub-therapeutic&quot;, i.e., insufficient to combat disease. Despite no diagnosis of disease, the administration of these drugs (most of which are not significant to human medicine) results in decreased mortality and morbidity and increased growth in the animals so treated. It is theorized that sub-therapeutic dosages kills some, but not all, of the bacterial organisms in the animal — likely leaving those that are naturally antibiotic-resistant{{citation needed|date=May 2014}}. Studies have shown, however, that, in essence, the overall population levels of bacteria are unchanged; only the mix of bacteria is affected.{{citation needed|date=May 2012}}

The actual mechanism by which sub-therapeutic antibiotic feed additives serve as growth promoters is thus unclear. Some people have speculated that animals and fowl may have sub-clinical infections, which would be cured by low levels of antibiotics in feed, thereby allowing the creatures to thrive. No convincing evidence has been advanced for this theory, and the bacterial load in an animal is essentially unchanged by use of antibiotic feed additives. The mechanism of growth promotion is therefore probably something other than &quot;killing off the bad bugs.&quot;

In 2000, the FDA announced their intention to revoke approval of [[fluoroquinolone]] use in poultry production because of substantial evidence linking it to the emergence of fluoroquinolone-resistant ''[[Campylobacter]]'' infections in humans. Legal challenges from the food animal and pharmaceutical industries delayed the final decision to do so until 2006.&lt;ref name=&quot;Nelson-2007&quot;&gt;{{Cite journal|last1=Nelson|first1=JM.|last2=Chiller|first2=TM.|last3=Powers|first3=JH.|last4=Angulo|first4=FJ.| title=Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story|journal=Clin Infect Dis|volume=44|issue=7|pages=977–80|date=Apr 2007|doi=10.1086/512369|pmid=17342653|ref=harv}}&lt;/ref&gt; Fluroquinolones have been banned from extra-label use in food animals in the USA since 2007. However, they remain widely used in companion and exotic animals.

In 2001, ''National Hog Farmer'' magazine warned U.S. producers that ''C. difficile'' &quot;is sweeping the industry, killing many piglets&quot; (Neutkens D; &quot;New Clostridium Claiming Baby Pigs&quot;). In 2006, a study by the USDA's National Animal Health Monitoring System further investigated the prevalence of ''C. difficile'' in hog farms. The study, which covered hog farms of a size typical of those producing 94% of US swine, found the prevalence of ''C. difficile'' &quot;relatively low (11.4%)&quot; and that there was no difference in region or in size of farm.&lt;ref&gt;{{cite web|last=APHIS|title=Clostridium difficile on U.S. Swine Operations|url=http://www.aphis.usda.gov/animal_health/nahms/swine/downloads/swine2006/Swine2006_is_Cdiff.pdf|accessdate=24 October 2013}}&lt;/ref&gt; Human infection with ''C. difficile'' (either drug-resistant or not) is most commonly associated with the use of strong antibiotics in hospitalized humans, and is not associated with humans in contact with farm animals.

During 2007, two federal bills (S. 549&lt;ref&gt;{{cite web|url=http://www.govtrack.us/congress/bill.xpd?bill=s110-549|title=US Senate Bill S. 549: Preservation of Antibiotics for Medical Treatment Act of 2007|ref=harv}}&lt;/ref&gt; and H.R. 962&lt;ref&gt;{{cite web|url=http://www.govtrack.us/congress/bill.xpd?bill=h110-962 |title=Preservation of Antibiotics for Medical Treatment Act of 2007|ref=harv}}&lt;/ref&gt;) aimed at phasing out &quot;nontherapeutic&quot; antibiotics in U.S. food animal production. The Senate bill, introduced by Sen. [[Ted Kennedy|Edward &quot;Ted&quot; Kennedy]], died. The House bill, introduced by Rep. [[Louise Slaughter]], died after being referred to Committee.

In the United States, the FDA first determined in 1977 that there is evidence of emergence of antibiotic-resistant bacterial strains in livestock. The long-established practice of permitting OTC sales of antibiotics (including penicillin and other drugs) to lay animal owners for administration to their own animals nonetheless continued in all states. In March 2012, the [[United States District Court for the Southern District of New York]], ruling in an action brought by the [[Natural Resources Defense Council]] and others, ordered the FDA to revoke approvals for the use of antibiotics in livestock that violated FDA regulations.&lt;ref name=MPFDA&gt;{{cite news|title=FDA Told to Move on Antibiotic Use in Livestock|url=http://www.medpagetoday.com/PublicHealthPolicy/FDAGeneral/31792|accessdate=March 24, 2012|newspaper=MedPage Today|date=March 23, 2012|author=John Gever}}&lt;/ref&gt; On April 11, 2012 the FDA announced a voluntary program to phase out unsupervised use of drugs as feed additives and convert approved over-the-counter uses for antibiotics to prescription use only, requiring veterinarian supervision of their use and a prescription.&lt;ref name=NYTPrescription&gt;{{cite news|title=U.S. Tightens Rules on Antibiotics Use for Livestock|url=http://www.nytimes.com/2012/04/12/us/antibiotics-for-livestock-will-require-prescription-fda-says.html|accessdate=April 12, 2012|newspaper=The New York Times|date=April 11, 2012|author=Gardiner Harris}}&lt;/ref&gt;&lt;ref name=FDAFAQ&gt;{{cite web|title=FDA's Strategy on Antimicrobial Resistance&amp;nbsp;— Questions and Answers|url=http://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm216939.htm|publisher=U.S. Food and Drug Administration|accessdate=April 12, 2012|date=April 11, 2012|quote=“Judicious use” is using an antimicrobial drug appropriately and only when necessary; Based on a thorough review of the available scientific information, FDA recommends that use of medically important antimicrobial drugs in food-producing animals be limited to situations where the use of these drugs is necessary for ensuring animal health, and their use includes veterinary oversight or consultation. FDA believes that using medically important antimicrobial drugs to increase production in food-producing animals is not a judicious use.}}&lt;/ref&gt; In December 2013, the FDA announced the commencement of these steps to phase out the use of antibiotics for the purposes of promoting livestock growth.&lt;ref&gt;{{cite web|last=Tavernise|first=Sabrina|title=F.D.A. to Phase Out Use of Some Antibiotics in Animals Raised for Meat|url=http://www.nytimes.com/2013/12/12/health/fda-to-phase-out-use-of-some-antibiotics-in-animals-raised-for-meat.html|publisher=[[The New York Times]]|accessdate=11 December 2013}}&lt;/ref&gt;&lt;ref name=TheRealNews-2014-05-18/&gt;

==Environmental impact==
Antibiotics have been polluting the environment since their introduction through human waste (medication, farming), animals, and the pharmaceutical industry.&lt;ref name=&quot;Martinez, J. L. 2012 pp. 151- 171&quot;&gt;Martinez, J. L., &amp; Olivares, J. (2012). Envrironmental Pollution By Antibiotic Resistance Genes. In P. L. Keen, &amp; M. H. Montforts, Antimicrobial Resistance in the Environment (pp. 151- 171). Hoboken, N.J.: John Wiley &amp; Sons.&lt;/ref&gt; Along with antibiotic waste, resistant bacteria follow, thus introducing antibiotic-resistant bacteria into the environment. As bacteria replicate quickly, the resistant bacteria that enter the environment replicate their resistance genes as they continue to divide. In addition, bacteria carrying resistance genes have the ability to spread those genes to other species via horizontal gene transfer. Therefore, even if the specific antibiotic is no longer introduced into the environment, antibiotic-resistance genes will persist through the bacteria that have since replicated without continuous exposure.&lt;ref name=&quot;Martinez, J. L. 2012 pp. 151- 171&quot;/&gt;

A study the [[Poudre River]] ([[Colorado]], [[United States]]) implicated wastewater treatment plants, as well as animal-feeding operations in the dispersal of antibiotic-resistance genes into the environment.&lt;ref&gt;Pruden, A., &amp; Arabi, M. (2012). Quantifying Anthropogenic Impacts on Environmental Reservoirs of Antibiotic Resistance. In P. L. Keen, &amp; M. H. Montforts, Antimicrobial Resistance in the Environment (pp. 173-202). Hoboken, N.J.: John Wiley &amp; Sons.&lt;/ref&gt; This research was done using molecular signatures in order to determine the sources, and the location at the Poudre River was chosen due to lack of other anthropogenic influences upstream. The study indicates that monitoring of antibiotic-resistance genes may be useful in determining not only the point of origin of their release but also how these genes persist in the environment. In addition, studying physical and chemical methods of treatment may alleviate pressure of antibiotic-resistance genes in the environment, and thus their entry back into human contact.

==Mechanisms of antibiotic resistance==
{{see also|Microevolution}}
[[File:Antibiotic resistance.svg|thumb|right|Schematic representation of how antibiotic resistance evolves via natural selection. The top section represents a population of bacteria before exposure to an antibiotic. The middle section shows the population directly after exposure, the phase in which selection took place. The last section shows the distribution of resistance in a new generation of bacteria. The legend indicates the resistance levels of individuals.]]

[[File:mecA Resistance.svg|thumb|right|Diagram depicting antibiotic resistance through alteration of the antibiotic's target site, modeled after MRSA's resistance to penicillin. Beta-lactam antibiotics permanently inactivate [[Penicillin-binding protein|PBP enzymes]], which are essential for bacterial life, by permanently binding to their active sites. [[Methicillin-resistant Staphylococcus aureus|MRSA]], however, expresses a PBP that does not allow the antibiotic into its active site.]]
Antibiotic resistance can be a result of [[horizontal gene transfer]],&lt;ref&gt;{{cite journal|last=Ochiai|first= K.|last2= Yamanaka|first2= T |last3=Kimura |first3=K |last4=Sawada|first4= O |year=1959|title= Inheritance of drug resistance (and its transfer) between Shigella strains and Between Shigella and E.coli strains|journal= Hihon Iji Shimpor, |page= 1861|volume= 34|language= Japanese|ref=harv}}
&lt;/ref&gt; and also of unlinked point mutations in the [[pathogen]] [[genome]] at a rate of about 1 in 10&lt;sup&gt;8&lt;/sup&gt; per chromosomal replication. The antibiotic action against the pathogen can be seen as an environmental pressure. Those bacteria with a mutation that allows them to survive live to reproduce. They then pass this trait to their offspring, which leads to the evolution of a fully resistant colony.

The four main mechanisms by which microorganisms exhibit resistance to antimicrobials are:
#Drug inactivation or modification: for example, enzymatic deactivation of [[Penicillin|''penicillin'' G]] in some penicillin-resistant bacteria through the production of [[Beta-lactamases|β-lactamases]].
#Alteration of target site: for example, alteration of [[Penicillin binding protein|PBP]]—the binding target site of penicillins—in [[Methicillin-resistant Staphylococcus aureus|MRSA]] and other penicillin-resistant bacteria
#Alteration of metabolic pathway: for example, some [[sulfa drugs|sulfonamide]]-resistant bacteria do not require [[para-aminobenzoic acid]] (PABA), an important precursor for the synthesis of [[folic acid]] and [[nucleic acids]] in bacteria inhibited by sulfonamides, instead, like mammalian cells, they turn to using preformed folic acid.
#Reduced drug accumulation: by decreasing drug [[Semipermeable membrane|permeability]] or increasing active [[efflux (microbiology)|efflux]] (pumping out) of the drugs across the cell surface&lt;ref&gt;{{cite journal |last=Li|first= X|last2=Nikadio |first2=H |title = Efflux-Mediated Drug Resistance in Bacteria: an Update| journal = Drug | volume = 69 | issue = 12 | pages = 1555–623| year = 2009 | pmid = 19678712 |  doi = 10.2165/11317030-000000000-00000|pmc= 2847397 |ref=harv}}&lt;/ref&gt;

There are three known mechanisms of [[fluoroquinolone]] resistance. Some types of [[Efflux (microbiology)|efflux]] pumps can act to decrease intracellular [[quinolone]] concentration.&lt;ref&gt;{{cite journal |last = Morita |first=Y|last2=Kodama |first2=K |last3= Shiota |first3=S |last4=Mine |first4=T |last5= Kataoka |first5=A |last6= Mizushima |first6=T |last7= Tsuchiya |first7=T | title = NorM, a Putative Multidrug Efflux Protein, of Vibrio parahaemolyticus and Its Homolog in Escherichia coli | journal = Antimicrob. Agents Chemother. | volume = 42 | issue = 7 | pages = 1778–82 |date=July 1998 | pmid = 9661020 | pmc = 105682 |ref=harv}}&lt;/ref&gt; In Gram-negative bacteria, plasmid-mediated resistance genes produce proteins that can bind to [[DNA gyrase]], protecting it from the action of quinolones. Finally, mutations at key sites in DNA gyrase or [[topoisomerase IV]] can decrease their binding affinity to quinolones, decreasing the drug's effectiveness.&lt;ref&gt;{{cite journal |last=Robicsek |first=A |last2= Jacoby |first2=GA|last3= Hooper |first3=DC |title=The worldwide emergence of plasmid-mediated quinolone resistance |journal=Lancet Infect Dis |volume=6 |issue=10 |pages=629–40 |date=October 2006 |pmid=17008172 |doi=10.1016/S1473-3099(06)70599-0 |ref=harv}}&lt;/ref&gt; Research has shown the bacterial protein [[LexA]] may play a key role in the acquisition of bacterial mutations giving resistance to quinolones and rifampicin.&lt;ref&gt;{{cite journal |last=Cirz |first=RT |last2= Chin |first2=JK |last3= Andes |first3=DR |last4= de Crécy-Lagard |first4=V  |last5=Craig |first5=WA |last6=Romesberg |first6=FE |title=Inhibition of Mutation and Combating the Evolution of Antibiotic Resistance |journal=PLoS Biol. |volume=3 |issue=6 |pages=e176 |year=2005 |pmid=15869329 |doi=10.1371/journal.pbio.0030176 |pmc=1088971|ref=harv}}&lt;/ref&gt;

Antibiotic resistance can also be introduced artificially into a microorganism through laboratory protocols, sometimes used as a [[selectable marker]] to examine the mechanisms of gene transfer or to identify individuals that absorbed a piece of DNA that included the resistance gene and another gene of interest. A recent study demonstrated that the extent of [[horizontal gene transfer]] among ''Staphylococcus'' is much greater than previously expected—and encompasses genes with functions beyond antibiotic resistance and virulence, and beyond genes residing within the [[mobile genetic elements]].&lt;ref&gt;{{cite journal |last=Chan |first=CX |last2=Beiko |first2=RG |last3= Ragan |first3=MA |title=Lateral Transfer of Genes and Gene Fragments in Staphylococcus Extends beyond Mobile Elements |journal=J Bacteriol |volume=193 |issue=15 |pages=3964–3977 |date=August 2011 |pmid=21622749 |doi=10.1128/JB.01524-10 |pmc=3147504|ref=harv}}&lt;/ref&gt;

For a long time, it has been thought that, for a microorganism to become resistant to an antibiotic, it must be in a large population. However, recent findings show that there is no necessity of large populations of bacteria for the appearance of antibiotic resistance. We know now that small populations of E.coli in an antibiotic gradient can become resistant. Any heterogeneous environment with respect to nutrient and antibiotic gradients may facilitate the development of antibiotic resistance in small bacterial populations and this is also true for the human body. Researchers hypothesize that the mechanism of resistance development is based on four SNP mutations in the genome of E.coli produced by the gradient of antibiotic. These mutations confer the bacteria emergence of antibiotic resistance.

A common misconception is that a person can become resistant to certain antibiotics. It is a strain of microorganism that can become resistant, not a person's body.&lt;ref&gt;{{cite web|url=http://www.cdc.gov/getsmart/antibiotic-use/antibiotic-resistance-faqs.html |title=CDC: Get Smart: Know When Antibiotics Work |publisher=Cdc.gov |accessdate=2013-06-12}}&lt;/ref&gt;&lt;ref&gt;{{cite web|url=http://www.tufts.edu/med/apua/about_issue/societal_prob.shtml |title=APUA: General Background: Antibiotic Resistance, A Societal Problem |publisher=Tufts.edu |accessdate=2013-06-12}}&lt;/ref&gt;

==Resistant pathogens==

===''Staphylococcus aureus''===
{{Main|Methicillin-resistant Staphylococcus aureus}}
''[[Staphylococcus aureus]]'' (colloquially known as &quot;Staph aureus&quot; or a &quot;Staph infection&quot;) is one of the major resistant pathogens. Found on the [[mucous membranes]] and the [[human skin]] of around a third of the population, it is extremely adaptable to antibiotic pressure. It was one of the earlier bacteria in which [[penicillin]] resistance was found—in 1947, just four years after the drug started being mass-produced. [[Methicillin]] was then the antibiotic of choice, but has since been replaced by [[oxacillin]] due to significant kidney toxicity. [[Methicillin-resistant Staphylococcus aureus|Methicillin-resistant ''Staphylococcus aureus'']] (MRSA) was first detected in Britain in 1961, and is now &quot;quite common&quot; in hospitals. MRSA was responsible for 37% of fatal cases of [[sepsis]] in the [[United Kingdom|UK]] in 1999, up from 4% in 1991. Half of all ''S. aureus'' infections in the [[United States|US]] are resistant to penicillin, methicillin, [[tetracycline]] and [[erythromycin]].

This left [[vancomycin]] as the only effective agent available at the time. However, strains with intermediate (4-8&amp;nbsp;μg/ml) levels of resistance, termed glycopeptide-intermediate ''Staphylococcus aureus'' (GISA) or vancomycin-intermediate ''Staphylococcus aureus'' (VISA), began appearing in the late 1990s. The first identified case was in Japan in 1996, and strains have since been found in hospitals in England, France and the US. The first documented strain with complete (&gt;16&amp;nbsp;μg/ml) resistance to vancomycin, termed [[Vancomycin-resistant Staphylococcus aureus|vancomycin-resistant ''Staphylococcus aureus'']] (VRSA) appeared in the United States in 2002.&lt;ref&gt;{{Cite pmid|14563898}}&lt;/ref&gt; However, in 2011, a variant of vancomycin has been tested that binds to the lactate variation and also binds well to the original target, thus reinstating potent antimicrobial activity.&lt;ref&gt;{{cite journal |title=A Redesigned Vancomycin Engineered for Dual d-Ala-d-Ala and d-Ala-d-Lac Binding Exhibits Potent Antimicrobial Activity Against Vancomycin-Resistant Bacteria |author=Xie et al. |journal=J. Am. Chem. Soc. 133, |doi=10.1021/ja207142h |year=2011 |pmid=21823662 |volume=133 |issue=35 |pages=13946–9 |last2=Pierce |first2=Joshua G. |last3=James |first3=Robert C. |last4=Okano |first4=Akinori |last5=Boger |first5=Dale L. |pmc=3164945}}&lt;/ref&gt;

A new class of antibiotics, [[Linezolid|oxazolidinones]], became available in the 1990s, and the first commercially available oxazolidinone, [[linezolid]], is comparable to vancomycin in effectiveness against MRSA. Linezolid-resistance in ''S. aureus'' was reported in 2001.&lt;ref&gt;{{cite journal|last=Tsiodras|first=Sotirios|author2=Gold, Howard S|author3=Sakoulas, George|author4=Eliopoulos, George M|author5=Wennersten, Christine|author6=Venkataraman, Lata|author7=Moellering, Robert C|author8= Ferraro, Mary Jane|title=Linezolid resistance in a clinical isolate of Staphylococcus aureus|journal=The Lancet|volume=358|issue=9277|pages=207–208|doi=10.1016/S0140-6736(01)05410-1|pmid=11476839}}&lt;/ref&gt;

Community-acquired MRSA (CA-MRSA) has now emerged as an epidemic that is responsible for rapidly progressive, fatal diseases, including necrotizing pneumonia, severe [[sepsis]], and [[necrotizing fasciitis]].&lt;ref name=&quot;pmid17146447&quot;&gt;{{cite journal |last=Boyle-Vavra |first=S |last2= Daum |first2=RS |title=Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin |journal=Lab. Invest. |volume=87 |issue=1 |pages=3–9 |year=2007 |pmid=17146447 |doi=10.1038/labinvest.3700501|ref=harv}}&lt;/ref&gt; MRSA is the most frequently identified antimicrobial drug-resistant pathogen in US hospitals. The [[epidemiology]] of infections caused by MRSA is rapidly changing. In the past 10&amp;nbsp;years{{when|date=October 2012}}, infections caused by this organism have emerged in the community. The two MRSA clones in the United States most closely associated with community outbreaks, [[USA400]] (MW2 strain, ST1 lineage) and [[USA300]], often contain [[Panton-Valentine leukocidin]] (PVL) genes and, more frequently, have been associated with skin and soft tissue infections. Outbreaks of CA-MRSA infections have been reported in correctional facilities, among athletic teams, among military recruits, in newborn nurseries, and among men that have sex with men. CA-MRSA infections now appear endemic in many urban regions and cause most CA-''S. aureus'' infections.&lt;ref name=&quot;pmid17479885&quot;&gt;{{cite journal |last=Maree |first=CL |last2= Daum |first2=RS |last3= Boyle-Vavra |first3=S |last4= Matayoshi |first4=K  |last5=Miller |first5=LG |title=Community-associated Methicillin-resistant Staphylococcus aureus Isolates and Healthcare-Associated Infections |journal=Emerging Infect. Dis. |volume=13 |issue=2 |pages=236–42 |year=2007 |pmid=17479885 |doi= 10.3201/eid1302.060781 |pmc=2725868|ref=harv}}&lt;/ref&gt;

===''Streptococcus'' and ''Enterococcus''===
''[[Streptococcus pyogenes]]'' (Group A ''Streptococcus'': GAS) infections can usually be treated with many different antibiotics. Early treatment may reduce the risk of death from invasive group A streptococcal disease. However, even the best medical care does not prevent death in every case. For those with very severe illness, supportive care in an intensive-care unit may be needed. For persons with necrotizing fasciitis, surgery often is needed to remove damaged tissue.&lt;ref&gt;{{cite web |author=CDCP |title=Group A Streptococcal (GAS) Disease (strep throat, necrotizing fasciitis, impetigo) -- Frequently Asked Questions |url=http://www.cdc.gov/ncidod/dbmd/diseaseinfo/groupastreptococcal_g.htm |date=2005-10-11 |publisher=Centers for Disease Control and Prevention |accessdate=2007-12-11|ref=harv| archiveurl= http://web.archive.org/web/20071219224215/http://www.cdc.gov/ncidod/dbmd/diseaseinfo/groupastreptococcal_g.htm| archivedate= 19 December 2007 &lt;!--DASHBot--&gt;| deadurl= no}}&lt;/ref&gt; Strains of ''S. pyogenes'' resistant to [[macrolide]] antibiotics have emerged; however, all strains remain uniformly susceptible to [[penicillin]].&lt;ref name=&quot;pmid15109426&quot;&gt;{{cite journal |last=Albrich |first=W |last2=Monnet |first2=DL |last3=Harbarth |first3=S |title=Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes |journal=Emerging Infect. Dis. |volume=10 |issue=3 |pages=514–7 |year=2004 |pmid=15109426 |ref=harv |pmc=3322805 |doi=10.3201/eid1003.030252}}&lt;/ref&gt;

Resistance of ''[[Streptococcus pneumoniae]]'' to penicillin and other beta-lactams is increasing worldwide. The major mechanism of resistance involves the introduction of mutations in genes encoding penicillin-binding proteins. Selective pressure is thought to play an important role, and use of beta-lactam antibiotics has been implicated as a risk factor for infection and colonization. ''S. pneumoniae'' is responsible for [[pneumonia]], [[bacteremia]], [[otitis media]], [[meningitis]], [[sinusitis]], [[peritonitis]] and [[arthritis]].&lt;ref name=&quot;pmid15109426&quot;/&gt;

Multidrug-resistant ''[[Enterococcus faecalis]]'' and ''[[Enterococcus faecium]]'' are associated with [[nosocomial infection]]s.&lt;ref name=&quot;pmid18947320&quot;&gt;{{cite journal |last=Hidron |first=AI|last2= Edwards |first2=JR |last3= Patel |first3=J |title=NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007 |journal=Infect Control Hosp Epidemiol |volume=29 |issue=11 |pages=996–1011 |date=November 2008 |pmid=18947320 |doi=10.1086/591861 |ref=harv |last4=Horan |first4=Teresa C. |last5=Sievert |first5=Dawn M. |last6=Pollock |first6=Daniel A. |last7=Fridkin |first7=Scott K. |author8=National Healthcare Safety Network Team |author9=Participating National Healthcare Safety Network Facilities|displayauthors=9}}&lt;/ref&gt; Among these strains, [[penicillin]]-resistant ''[[Enterococcus]]'' was seen in 1983, [[vancomycin-resistant Enterococcus|vancomycin-resistant ''Enterococcus'']] in 1987, and [[linezolid]]-resistant ''[[Enterococcus]]'' in the late 1990s.{{Citation needed|date=April 2010}}

===''Pseudomonas aeruginosa''===
''[[Pseudomonas aeruginosa]]'' is a highly prevalent [[opportunistic pathogen]]. One of the most worrisome characteristics of ''P. aeruginosa'' is its low antibiotic susceptibility, which is attributable to a concerted action of [[efflux (microbiology)|multidrug efflux pumps]] with chromosomally encoded antibiotic resistance genes (for example, ''mexAB-oprM'', ''mexXY'', etc.) and the low permeability of the bacterial cellular envelopes.&lt;ref name=&quot;Poole2004&quot;&gt;{{cite journal|last=Poole, |first=K. |year=2004|title= Efflux-mediated multiresistance in Gram-negative bacteria|journal= Clinical Microbiology and Infection |volume=10 |issue=1|pages= 12–26 |doi=10.1111/j.1469-0691.2004.00763.x |pmid=14706082|ref=harv}}&lt;/ref&gt;  ''Pseudomonas aeruginosa'' has the ability to produce HAQs and it has been found that HAQs have prooxidant effects, and overexpressing modestly increased susceptibility to antibiotics.
The study experimented with the ''Pseudomonas aeruginosa'' biofilms and found that a disruption of relA and spoT genes produced an inactivation of the Stringent response (SR) in cells with nutrient limitation, which provides cells be more susceptible to antibiotics.&lt;ref&gt;{{cite journal |doi=10.1126/science.1211037 |title=Active Starvation Responses Mediate Antibiotic Tolerance in Biofilms and Nutrient-Limited Bacteria |year=2011 |last1=Nguyen |first1=D. |last2=Joshi-Datar |first2=A. |last3=Lepine |first3=F. |last4=Bauerle |first4=E. |last5=Olakanmi |first5=O. |last6=Beer |first6=K. |last7=McKay |first7=G. |last8=Siehnel |first8=R. |last9=Schafhauser |first9=J. |last10=Wang |first10=Y. |last11=Britigan |first11=B. E. |last12=Singh |first12=P. K. |journal=Science |volume=334 |issue=6058 |pages=982–6 |pmid=22096200}}&lt;/ref&gt;

===''Clostridium difficile''===
''[[Clostridium difficile]]'' is a nosocomial pathogen that causes diarrheal disease in hospitals world wide.&lt;ref&gt;{{cite journal|last=Gerding |first=D.N.|last2= Johnson |first2=S.|last3= Peterson |first3=L.R.|last4= Mulligan |first4=M.E.|last5= Silva |first5=J. Jr. |year=1995|title= Clostridium difficile-associated diarrhea and colitis|journal= Infect. Control. Hosp. Epidemiol. |volume=16|pages=459–477|ref=harv |doi=10.1086/648363|pmid=7594392|issue=8}}&lt;/ref&gt;&lt;ref name=McDonald_2005&gt;{{cite journal |last=McDonald |first=L |title=''Clostridium difficile'': responding to a new threat from an old enemy |journal=Infect. Control. Hosp. Epidemiol. |volume=26 |issue=8 |pages=672–5 |year=2005 | pmid=16156321 |doi=10.1086/502600|ref=harv}}&lt;/ref&gt; [[Clindamycin]]-resistant ''C. difficile'' was reported as the causative agent of large outbreaks of diarrheal disease in hospitals in New York, Arizona, Florida and Massachusetts between 1989 and 1992.&lt;ref name=Johnson1999&gt;{{cite journal |last=Johnson |first=S.|last2= Samore |first2=M.H.|last3= Farrow |first3=K.A |title=Epidemics of diarrhea caused by a clindamycin-resistant strain of ''Clostridium difficile'' in four hospitals |journal=New England Journal of Medicine |volume=341 |issue= 23|pages=1645–1651 |year=1999 |pmid=10572152 |doi=10.1056/NEJM199911253412203 |ref=harv |last4=Killgore |first4=George E. |last5=Tenover |first5=Fred C. |last6=Lyras |first6=Dena |last7=Rood |first7=Julian I. |last8=Degirolami |first8=Paola |last9=Baltch |first9=Aldona L. |first10=Mary Ellen |first11=Suzanne M. |first12=Dale N.|displayauthors=8}}&lt;/ref&gt; Geographically dispersed outbreaks of ''C. difficile'' strains resistant to [[fluoroquinolone]] antibiotics, such as ciprofloxacin and levofloxacin, were also reported in North America in 2005.&lt;ref name=Loo_2005&gt;{{cite journal |last=Loo |first=V|last2= Poirier |first2=L|last3= Miller |first3=M |title=A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality |journal=N Engl J Med |volume=353 |issue=23 |pages=2442–9 |year=2005 |pmid=16322602 |doi=10.1056/NEJMoa051639|ref=harv |last4=Oughton |first4=Matthew |last5=Libman |first5=Michael D. |last6=Michaud |first6=Sophie |last7=Bourgault |first7=Anne-Marie |last8=Nguyen |first8=Tuyen |last9=Frenette |first9=Charles |first10=Mirabelle |first11=Anne |first12=Paul |first13=Susan |first14=Ken |first15=Thomas J. |first16=Ruth |first17=Pierre |first18=Yury |first19=André|displayauthors=8}}&lt;/ref&gt;

===''Salmonella'' and ''E. coli''===
Infection with ''[[Escherichia coli]]'' and ''[[Salmonella]]'' can result from the consumption of contaminated food and water. When both bacteria are spread, serious health conditions arise. Many people are hospitalized each year after becoming infected, with some dying as a result. Since 1993, some strains of  ''E. coli'' have become resistant to multiple types of [[quinolones|fluoroquinolone antibiotics]].{{Citation needed|date=November 2011}}

===''Acinetobacter baumannii''===
On November 5, 2004, the [[Centers for Disease Control and Prevention]] (CDC) reported an increasing number of ''[[Acinetobacter baumannii]]'' bloodstream infections in patients at military medical facilities in which service members injured in the [[Iraq]]/[[Kuwait]] region during [[Iraq war|Operation Iraqi Freedom]] and in [[Afghanistan]] during [[Operation Enduring Freedom]] were treated. Most of these showed [[multidrug resistance]] (MRAB), with a few isolates resistant to all drugs tested.&lt;ref name=&quot;pmid15549020&quot;&gt;{{cite journal |title=Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004 |journal=MMWR Morb. Mortal. Wkly. Rep. |volume=53 |issue=45 |pages=1063–6 |year=2004 |pmid=15549020 |url=http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5345a1.htm |publisher= Centers for Disease Control and Prevention (CDC)|ref=harv |author1=Centers for Disease Control and Prevention (CDC)}}&lt;/ref&gt;&lt;ref&gt;{{cite web|url=http://www.medscape.com/viewarticle/575837 |title=Medscape abstract on Acinetobacter baumannii: Acinetobacter baumannii: An Emerging Multidrug-resistant Threat|ref=harv|quote=membership only website}}&lt;/ref&gt;

===''Klebsiella pneumoniae''===
Klebsiella pneumoniae carbapenemase ([[Beta-lactamase#KPC (K. pneumoniae carbapenemase) (Class A)|KPC]])-producing bacteria are a group of emerging highly drug-resistant Gram-negative bacilli causing infections associated with significant morbidity and mortality whose incidence is rapidly increasing in a variety of clinical settings around the world. [[Carbapenem]] antibiotics (heretofore often the treatment of last resort for resistant infections) are generally not effective against KPC-producing organisms.&lt;ref&gt;{{cite journal |doi=10.1097/SMJ.0b013e3181fd7d5a |title=Emergence of Klebsiella pneumoniae Carbapenemase-Producing Bacteria |year=2011 |last1=Arnold |first1=Ryan S. |last2=Thom |first2=Kerri A. |last3=Sharma |first3=Saarika |last4=Phillips |first4=Michael |last5=Kristie Johnson |first5=J. |last6=Morgan |first6=Daniel J. |journal=Southern Medical Journal |volume=104 |pages=40–5 |pmid=21119555 |issue=1 |pmc=3075864}}&lt;/ref&gt;

===''Mycobacterium tuberculosis''===
[[Tuberculosis]] is increasing across the globe, especially in developing countries, over the past few years. TB resistant to antibiotics is called [[Multi-drug-resistant tuberculosis|MDR TB]] (Multidrug Resistant TB). Globally, MDR TB causes 150,000 deaths annually.&lt;ref&gt;{{cite web |publisher=Agency for Healthcare Research and Quality |url=http://www.innovations.ahrq.gov/content.aspx?id=3762 |title=Antimicrobial Resistance Still Poses a Public Health Threat: A Conversation With Edward J. Septimus, MD, FIDSA, FACP, FSHEA, Clinical Professor of Internal Medicine at Texas A&amp;M Health Science Center |date=2013-04-17 |accessdate=2013-09-26}}&lt;/ref&gt; The rise of the HIV/AIDS epidemic has contributed to this.&lt;ref name=&quot;journals.lww.com&quot;&gt;{{cite journal |doi=10.1097/QCO.0b013e3283229fab |title=Extensively drug-resistant tuberculosis |year=2009 |last1=Lobue |first1=Philip |journal=Current Opinion in Infectious Diseases |volume=22 |issue=2 |pages=167–73 |pmid=19283912}}&lt;/ref&gt;

TB was considered one of the most prevalent diseases, and did not have a cure until the discovery of [[Streptomycin]] by [[Selman Waksman]] in 1943.&lt;ref&gt;{{cite journal |doi=10.1159/000029220 |title=History of Tuberculosis |year=1998 |last1=Herzog |first1=Basel |journal=Respiration |volume=65 |pages=5–15 |pmid=9523361 |issue=1}}&lt;/ref&gt; However, the bacteria soon developed resistance. Since then, drugs such as [[isoniazid]] and [[rifampin]] have been used. M. tuberculosis develops resistance to drugs by spontaneous mutations in its genomes. Resistance to one drug is common, and this is why treatment is usually done with more than one drug. [[Extensively drug-resistant tuberculosis|Extensively Drug-Resistant TB]] (XDR TB) is TB that is also resistant to the second line of drugs.&lt;ref name=&quot;journals.lww.com&quot;/&gt;&lt;ref&gt;{{cite journal |doi=10.1016/j.ddmec.2010.09.006 |title=Transmission of MDR tuberculosis |year=2010 |last1=Gao |first1=Qian |last2=Li |first2=Xia |journal=Drug Discovery Today: Disease Mechanisms |volume=7 |pages=e61}}&lt;/ref&gt;

Resistance of ''[[Mycobacterium tuberculosis]]'' to [[isoniazid]], [[rifampin]], and other common treatments has become an increasingly relevant clinical challenge. (For more on Drug-Resistant TB, visit the [[Multi-drug-resistant tuberculosis]] page.)

===''Neisseria gonorrhoeae''===
{{main|Antibiotic resistance in gonorrhea}}
{{expand section|information from main article|date=November 2013}}
[[Neisseria gonorrhoeae]] is a sexually transmitted pathogen that can cause pelvic pain, pain on urination, penile, and vaginal discharge, as well as systemic symptoms in human infection. The bacteria was first identified in 1879,&lt;ref&gt;{{cite journal|last=Ligon|first=B. Lee|title=Albert Ludwig Sigesmund Neisser: Discoverer of the Cause of Gonorrhea|journal=Seminars in Pediatric Infectious Diseases|date=October 2005|volume=16|issue=4|pages=336–341|accessdate=10 December 2013|doi=10.1053/j.spid.2005.07.001}}&lt;/ref&gt; although some Biblical scholars believe that references to the disease can be found as early as Parshat Metzora of the [[Old Testament]].&lt;ref&gt;{{cite book|last=Rosner|first=Fred|title=Medicine in the Bible and the Talmud : selections from classical Jewish sources|year=1995|publisher=KTAV Pub. House|location=Hoboken, NJ|isbn=0-88125-506-8|edition=Augm. ed.}}&lt;/ref&gt;
Treatment with [[penicillin]] in the 1940s proved helpful, but by the 1970s resistant strains predominated. Resistance to penicillin has developed through two mechanisms: chomasomally mediated resistance (CMRNG) and penicillinase-mediated resistance (PPNG). CMRNG involves stepwise mutation of penA, which codes for the penicilin-binding protein (PBP-2); mtr, which encodes an efflux pump to remove penicilin from the cell; and penB, which encodes the bacterial cell wall porins. PPNG involves the acquisition of a plasmid-borne beta-lactamase.&lt;ref name=&quot;Tapsall 2001&quot;&gt;Tapsall (2001) Antimicrobial resistance in ''Niesseria gonorrhoeae''. World Health Organization.&lt;/ref&gt;
[[quinolones|Fluoroquinolones]] were a useful next-line treatment until resistance was achieved through efflux pumps and mutations to the gyrA gene, which encodes [[DNA gyrase]].&lt;ref name=&quot;Tapsall 2001&quot;/&gt; Third-generation cephalosporins have been used to treat gonorrhoea since 2007, although resistant strains have emerged. Strains of Neisseria gonorrhoea have also been found to be resistant to [[tetracyclines]] and [[aminoglycosides]]. Neisseria gonorrheoea has a high affinity for horizontal gene transfer, and as a result, the existence of any strain resistant to a given drug could spread easily across strains.
Today, injectable ceftriaxone is used, sometimes in combination with azithromycin or doxycycline.&lt;ref name=Japan10&gt;{{cite journal |author=Deguchi T, Nakane K, Yasuda M, Maeda S |title=Emergence and spread of drug resistant Neisseria gonorrhoeae |journal=J. Urol. |volume=184 |issue=3 |pages=851–8; quiz 1235 |date=September 2010 |pmid=20643433 |doi=10.1016/j.juro.2010.04.078 |url=}}&lt;/ref&gt;&lt;ref name=MMWR2012&gt;{{cite journal|last=Centers for Disease Control and Prevention|first=(CDC)|title=Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections.|journal=MMWR. Morbidity and mortality weekly report|date=Aug 10, 2012|volume=61|pages=590–4|pmid=22874837|issue=31}}&lt;/ref&gt;

==Ways to fight antibiotic resistance==

=== World Health Organization recommendations ===

An April 30, 2014, report by the [[World Health Organization|WHO]] makes the following recommendations for how to tackle antibiotic resistance:&lt;ref name=&quot;who.int&quot;/&gt;
* People can help tackle resistance by:
** using antibiotics only when prescribed by a doctor;
** completing the full prescription, even if they feel better;
** never sharing antibiotics with others or using leftover prescriptions.
* Health workers and pharmacists can help tackle resistance by:
** enhancing infection prevention and control;
** only prescribing and dispensing antibiotics when they are truly needed;
** prescribing and dispensing the right antibiotic(s) to treat the illness.
* Policymakers can help tackle resistance by:
** strengthening resistance tracking and laboratory capacity;
** regulating and promoting appropriate use of medicines.
* Policymakers and industry can help tackle resistance by:
** fostering innovation and research and development of new tools;
** promoting cooperation and information sharing among all stakeholders.

===Preventing infections===
Rational use of [[antibiotics]] may reduce the chances of development of opportunistic infection by antibiotic-resistant bacteria due to [[dysbacteriosis]]. Our immune systems will cure minor bacterial infections on their own. If we give it the chance without relying on antibiotics to cure a small infection, it will be less likely to become immune or resistant to the antibiotic. It is also important to note that antibiotics will not cure viral infections such as colds and the flu, and taking an antibiotic unnecessarily to treat a viral infection can lead to the resistance of antibiotics&lt;ref&gt;{{cite web|title=Evolution of Antibiotic Resistance|url=http://www.pbs.org/wgbh/evolution/library/10/4/l_104_03.html|work=PBS.org|publisher=WGBH Educational Foundation and Clear Blue Sky Productions, Inc.|accessdate=11 June 2013}}&lt;/ref&gt; In one study, the use of fluoroquinolones is clearly associated with ''[[Clostridium difficile]]''  infection, which is a leading cause of [[nosocomial]] [[diarrhea]] in the United States,&lt;ref name=&quot;pmid12781017&quot;&gt;{{cite journal |last=McCusker |first=ME|last2= Harris |first2=AD|last3= Perencevich |first3=E|last4= Roghmann |first4=MC |title=Fluoroquinolone Use and Clostridium difficile–Associated Diarrhea |journal=Emerging Infect. Dis. |volume=9 |issue=6 |pages=730–3 |year=2003 |pmid=12781017 |pmc=3000134|ref=harv |doi=10.3201/eid0906.020385}}&lt;/ref&gt; and a major cause of death, worldwide.&lt;ref name=&quot;pmid9866738&quot;&gt;{{cite journal |last=Frost |first=F|last2= Craun |first2=GF|last3= Calderon |first3=RL |title=Increasing hospitalization and death possibly due to Clostridium difficile diarrheal disease |journal=Emerging Infect. Dis. |volume=4 |issue=4 |pages=619–25 |year=1998 |pmid=9866738 |doi= 10.3201/eid0404.980412 |pmc=2640242|ref=harv }}&lt;/ref&gt;

[[Vaccine]]s do not have the problem of resistance because a vaccine enhances the body's natural defenses, whereas an antibiotic operates separately from the body's normal defenses. Nevertheless, new strains that escape immunity induced by vaccines may [[Evolution|evolve]]; for example, an updated [[influenza vaccine]] is needed each year.

While theoretically promising, antistaphylococcal vaccines have shown limited efficacy, because of immunological variation between ''Staphylococcus'' species, and the limited duration of effectiveness of the antibodies produced. Development and testing of more effective vaccines is underway.&lt;ref&gt;{{cite web|url=http://www.homesteadschools.com/nursing/courses/Immunity/Chapter05.html |title=Immunity, Infectious Diseases,and Pandemics—What You Can Do |publisher=HomesteadSchools.com |accessdate=2013-06-12}}&lt;/ref&gt;

The Australian Commonwealth Scientific and Industrial Research Organisation ([[CSIRO]]), realizing the need for the reduction of antibiotic use, has been working on two alternatives. One alternative is to prevent diseases by adding [[cytokine]]s instead of antibiotics to animal feed.&lt;ref name=&quot;blogspot1&quot;&gt;{{cite web|url=http://biotechnolo.blogspot.com/2009_12_01_archive.html |title=Science,Technology,genetics,research on biotechnology: December 2009 |publisher=Biotechnolo.blogspot.com |accessdate=2013-06-12}}&lt;/ref&gt; These proteins are made in the animal body &quot;naturally&quot; after a disease and are not antibiotics, so they do not contribute to the problem of antibiotic resistance. Furthermore, studies on using cytokines have shown they also enhance the growth of animals like the antibiotics now used, but without the drawbacks of nontherapeutic antibiotic use. Cytokines have the potential to achieve the animal growth rates traditionally sought by the use of antibiotics without the contribution of antibiotic resistance associated with the widespread nontherapeutic uses of antibiotics currently used in the food animal production industries. In addition, CSIRO is working on vaccines for diseases.&lt;ref name=&quot;blogspot1&quot;/&gt;

===Phage therapy===
[[Phage therapy]], an approach that has been extensively researched and used as a therapeutic agent for over 60&amp;nbsp;years, especially in the [[Soviet Union]], represents a potentially significant but currently underdeveloped approach to the treatment of bacterial disease.&lt;ref&gt;{{cite doi|10.3389/fmicb.2012.00238}}&lt;/ref&gt; Phage therapy was widely used in the United States until the discovery of antibiotics, in the early 1940s. Bacteriophages or &quot;phages&quot; are viruses that invade bacterial cells and, in the case of lytic phages, disrupt bacterial metabolism and cause the bacterium to [[lysis|lyse]]. Phage therapy is the therapeutic use of lytic [[bacteriophages]] to treat [[pathogenic]] bacterial infections.&lt;ref&gt;{{cite journal| title=Phages and their application against drug-resistant bacteria| journal=J. Chem. Technol. Biotechnol.| year=2001| volume=76| pages=689–699| first=N |last=Chanishvili|first2= T |last2=Chanishvili|first3= M. |last3=Tediashvili|first4= P.A. |last4=Barrow | doi=10.1002/jctb.438| issue=7 |ref=harv}}&lt;/ref&gt;
&lt;ref&gt;{{cite journal| title=The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr90| first=D. |last=Jikia|first2= N. |last2=Chkhaidze |first3=E. |last3=Imedashvili|first4= I. |last4=Mgaloblishvili|first5= G. |last5=Tsitlanadze| journal=Clinical &amp; Experimental Dermatology| year=2005| volume=30| issue=1| pmid=15663496 | doi = 10.1111/j.1365-2230.2004.01600.x| pages=23–6|ref=harv| last6=Katsarava| first6=R.| last7=Glenn Morris| first7=J.| last8=Sulakvelidze| first8=Alexander }}&lt;/ref&gt;
&lt;ref&gt;{{cite journal|last=Weber-Dabrowska |first=B|last2= Mulczyk |first2=M |last3= Górski |first3=A |title=Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man |journal=Transplant. Proc. |volume=35 |issue=4 |pages=1385–6 |date=June 2003 |pmid=12826166 | doi=10.1016/S0041-1345(03)00525-6 |ref=harv}}&lt;/ref&gt;

Bacteriophage therapy is a potentially important alternative to antibiotics in the current era of multidrug-resistant pathogens. A review of studies that dealt with the therapeutic use of phages from 1966 to 1996 and few latest ongoing phage therapy projects via internet showed: Phages were used topically, orally or systemically in Polish and Soviet studies. The success rate found in these studies was 80–95%, with few gastrointestinal or allergic side-effects. British studies also demonstrated significant efficacy of phages against ''[[Escherichia coli]]'', ''[[Acinetobacter]]'' spp., ''[[Pseudomonas]]'' spp., and ''[[Staphylococcus aureus]]''. US studies dealt with improving the bioavailability of phage. Phage therapy may prove as an important alternative to antibiotics for treating multidrug-resistant pathogens.&lt;ref&gt;{{cite journal | title= Bacteriophage therapy: an alternative to conventional antibiotics | last=Mathur |first=MD|last2= Vidhani |first2=S |last3= Mehndiratta|first3= PL| journal=J Assoc Physicians India | year=2003 | volume=51 | pages=593–6 | doi= 10.1258/095646202760159701 | pmid= 12194741 | issue= 8 |ref=harv | last4= Bhalla | first4= P | last5= Reddy | first5= B S N}}&lt;/ref&gt;

Discovery of the structure of the [[viral protein]] [[PlyC]] is allowing researchers to understand the way it kills a significant range of pathogenic bacteria.&lt;ref&gt;[http://www.abc.net.au/news/2012-07-29/australian-scientists-discover-antibiotic-alternative/4161926 Scientists discover possible antibiotics alternative] - Australian Broadcasting Corporation&amp;nbsp;— Retrieved 29 July 2012.&lt;/ref&gt;

==Research==

===Development pipeline===

Since the discovery of antibiotics, [[research and development]] (R&amp;D) efforts have provided new drugs in time to treat bacteria that became resistant to older antibiotics, but in the 2000s there has been concern that development has slowed enough that seriously ill patients may run out of treatment options.&lt;ref&gt;[https://www.wp.dh.gov.uk/publications/files/2013/03/CMO-Annual-Report-Volume-2-20111.pdf CMO Annual Report]&lt;/ref&gt;  Another concern is that doctors may become reluctant to perform routine surgeries due to the increased risk of harmful infection.&lt;ref name=&quot;obama&quot; /&gt; Backup treatments can have serious side-effects; for example, treatment of multi-drug-resistant tuberculosis can cause deafness and insanity.&lt;ref&gt;[http://www.npr.org/2013/06/04/188566805/moldova-grapples-with-whether-to-isolate-tb-patients Moldova Grapples With Whether To Isolate TB Patients : NPR&lt;!-- Bot generated title --&gt;]&lt;/ref&gt;  The potential crisis at hand is the result of a marked decrease in industry R&amp;D.&lt;ref name=&quot;bbc&quot;&gt;{{cite web|last=Walsh |first=Fergus |url=http://www.bbc.co.uk/news/health-21737844 |title=BBC News&amp;nbsp;— Antibiotics resistance 'as big a risk as terrorism' - medical chief |publisher=Bbc.co.uk |accessdate=2013-03-12}}&lt;/ref&gt;  Poor financial investment in antibiotic research has exacerbated the situation.&lt;ref name=&quot;bbc&quot;/&gt;&lt;ref name=TheRealNews-2014-05-18/&gt; In 2011, [[Pfizer]], one of the last major pharmaceutical companies developing new antibiotics, shut down its primary research effort, citing poor shareholder returns relative to drugs for chronic illnesses.&lt;ref name=&quot;medpage&quot;&gt;{{cite web|last= Gever |first=John |url=http://www.medpagetoday.com/InfectiousDisease/GeneralInfectiousDisease/24708 |title=Pfizer Moves May Dim Prospect for New Antibiotics |publisher=MedPage Today |date=2011-02-04 |accessdate=2013-03-12}}&lt;/ref&gt;

In the United States, drug companies and the administration of [[President Barack Obama]] have been proposing changing the standards by which the FDA approves antibiotics targeted at resistant organisms.&lt;ref name=&quot;obama&quot;&gt;[http://www.npr.org/blogs/health/2013/06/04/188380562/obama-administration-seeks-to-loosen-antibiotic-approvals Obama Administration Seeks To Ease Approvals For Antibiotics : Shots - Health News : NPR&lt;!-- Bot generated title --&gt;]&lt;/ref&gt;&lt;ref&gt;{{cite journal |doi=10.1038/492019a |title=FDA under pressure to relax drug rules |year=2012 |last1=Ledford |first1=Heidi |journal=Nature |volume=492 |issue=7427 |pages=19 |pmid=23222585}}&lt;/ref&gt;  On 12 December 2013, the Antibiotic Development to Advance Patient Treatment (ADAPT) Act of 2013 was introduced in the [[U.S. Congress]]. The ADAPT Act aims to fast-track the drug development in order to combat the growing public health threat of 'superbugs'. Under this Act, the FDA can approve antibiotics and antifungals needed for life-threatening infections based on data from smaller clinical trials. The [[Centers for Disease Control and Prevention|CDC]] will reinforce the monitoring of the use of antibiotics that treat serious and life-threatening infections and the emerging resistance, and make the data publicly available. The FDA antibiotics labeling process, 'Susceptibility Test Interpretive Criteria for Microbial Organisms' or 'breakpoints' is also streamlined to allow the most up-to-date and cutting-edge data available to healthcare professionals under the new Act.&lt;ref&gt;{{cite web|url=http://green.house.gov/press-release/green-gingrey-introduce-adapt-act-safeguard-public-health|title=Green, Gingrey Introduce ADAPT Act to Safeguard Public Health|author=Press Release|publisher=U.S. Congress|date=12 December 2013}}&lt;/ref&gt;&lt;ref&gt;{{cite web|url=http://assets.fiercemarkets.net/public/lifesciences/HR3742.pdf|title=Antibiotic Development to Advance Patient Treatment Act of 2013|publisher=U.S. Congress|date=12 December 2013}}&lt;/ref&gt;

The U.S. [[National Institutes of Health]] plans to fund a new research network on the issue up to $62&amp;nbsp;million from 2013 to 2019.&lt;ref&gt;[http://www.nih.gov/news/health/jun2013/niaid-03.htm NIH to fund clinical research network on antibacterial resistance&lt;!-- Bot generated title --&gt;]&lt;/ref&gt;  Using authority created by the [[Pandemic and All Hazards Preparedness Act]] of 2006, the [[Biomedical Advanced Research and Development Authority]] in the U.S. [[Department of Health and Human Services]] announced that it will spend between $40&amp;nbsp;million and $200&amp;nbsp;million in funding for R&amp;D on new antibiotic drugs under development by [[GlaxoSmithKline]].&lt;ref&gt;[http://www.phe.gov/Preparedness/news/Pages/strategic-alliance-130522.aspx PHE&lt;!-- Bot generated title --&gt;]&lt;/ref&gt;

===Mechanism===
In research published on October 17, 2008 in ''[[Cell (journal)|Cell]]'', a team of scientists pinpointed the place on bacteria where the antibiotic [[myxopyronin]] launches its attack, and why that attack is successful. The myxopyronin binds to and inhibits the crucial bacterial enzyme [[RNA polymerase]]. The myxopyronin changes the structure of the switch-2 segment of the enzyme, inhibiting its function of reading and transmitting DNA code. This prevents RNA polymerase from delivering genetic information to the [[ribosomes]], causing the bacteria to die.&lt;ref&gt;{{cite journal |author=Mukhopadhyay, J.; Das, K.; Ismail, S.; Koppstein, D.; Jang, M.; Hudson, B.; Sarafianos, S.; Tuske, S.; Patel, J., Jansen, R., Irschik, H., Arnold, E., [[Richard H. Ebright|Ebright, R.H.]]|year=2008|title=The RNA polymerase &quot;switch region&quot; is a target for inhibitors|doi=10.1016/j.cell.2008.09.033 |journal=Cell |volume=135 |pages=295–307 |pmid=18957204 |issue=2 |pmc=2580802|ref=harv}}&lt;/ref&gt;

In 2012, a team of the University of Leipzig modified a peptide found in honeybees. It is effective against 37 types of bacteria.&lt;ref&gt;{{cite web|url=http://cen.acs.org/articles/90/web/2012/05/Modified-Bee-Peptide-Slays-Deadly.html |title=Modified Bee Peptide Slays Deadly Bacteria &amp;#124; Chemical &amp; Engineering News |publisher=Cen.acs.org |date=2012-05-29 |accessdate=2013-03-12}}&lt;/ref&gt;

One major cause of antibiotic resistance is the increased pumping activity of microbial [[ABC transporters]], which diminishes the effective drug concentration inside the microbial cell. ABC transporter inhibitors that can be used in combination with current antimicrobials are being tested in clinical trials and are available for therapeutic regimens.&lt;ref name= Ponte-SucreA&gt;{{cite book |editor1-last=Ponte-Sucre |editor1-first=A | year=2009 |title=ABC Transporters in Microorganisms | publisher=Caister Academic Press | isbn= 978-1-904455-49-3}}{{page needed|date=November 2013}}&lt;/ref&gt;

===Applications===
Antibiotic resistance is an important tool for [[genetic engineering]]. By constructing a [[plasmid]] that contains an antibiotic-resistance gene as well as the gene being engineered or expressed, a researcher can ensure that, when bacteria replicate, only the copies that carry the plasmid survive. This ensures that the gene being manipulated passes along when the bacteria replicates.

In general, the most commonly used antibiotics in genetic engineering are &quot;older&quot; antibiotics that have largely fallen out of use in clinical practice. These include:
*[[ampicillin]]
*[[kanamycin]]
*[[tetracycline]]
*[[chloramphenicol]]

In industry, the use of antibiotic resistance is disfavored, since maintaining bacterial cultures would require feeding them large quantities of antibiotics. Instead, the use of [[auxotrophic]] bacterial strains (and function-replacement plasmids) is preferred.

==See also==
*[[Alliance for the Prudent Use of Antibiotics]]
*[[Antibacterial soap]]
*[[Beta-lactamase#KPC (K. pneumoniae carbapenemase) (Class A)]] (KPC) antibacterial resistance gene
*[[Broad-spectrum antibiotic]]
*[[Carbapenem resistant enterobacteriaceae]]
*[[Center for Disease Dynamics, Economics &amp; Policy]]
*[[Drug of last resort]]
*[[Index of environmental articles]]
*[[Multidrug tolerance]]
*[[Multidrug-resistant gram-negative bacteria]]
*[[New Delhi metallo-beta-lactamase]] (NDM-1) antibacterial resistance gene
*[[Pesticide resistance]]

==Footnotes==
{{Reflist|30em}}

==References==
;Books
*{{cite web|url=http://evolution.berkeley.edu/evolibrary/article/mutations_07|trans_title = Mutations are random|title=Understanding Evolution|publisher =University of California Museum of Paleontology |editor-first=Roy |editor-last=Caldwell |editor2-first=David |editor2-last=Lindberg|year=2011|accessdate=Aug 14, 2011|ref=harv}}
*{{cite book|first=Richard William |last= Nelson|title=Darwin, Then and Now: The Most Amazing Story in the History of Science|publisher= iUniverse|year=2009|page=294|ref=harv| format=Self Published}}
;Journals
*{{cite journal |last=Arias |first=Cesar A. |year=2009 |title=Antibiotic-Resistant Bugs in the 21st Century&amp;nbsp;— A Clinical Super-Challenge |journal=[[New England Journal of Medicine]] |volume=360 |issue=5 |pages=439–443 |doi=10.1056/NEJMp0804651 |url= |accessdate= |pmid=19179312 |last2=Murray |first2=BE |ref=harv}}
*{{cite journal|journal=Nature|volume=477|pages= 457–461|date=September 2011 | doi=10.1038/nature10388|issue=7365|title=Antibiotic resistance is ancient |last1=D'Costa |first1=Vanessa| last2=King|first2=Christine |last3=Kalan|first3=Lindsay| last4=Morar|first4=Mariya| last5=Sung |first5=Wilson| last6=Schwarz|first6=Carsten| last7=Froese|first7=Duane|last8=Zazula|first8=Grant |last9=Calmels|first9=Fabrice|pmid=21881561|ref=harv|bibcode = 2011Natur.477..457D|last10=Debruyne|first10=Regis|last11=Golding|first11=G. Brian|last12=Poinar|first12=Hendrik N.|last13=Wright|first13=Gerard D. }}
*{{cite journal|journal=The Journal of Antibiotics|volume=63|pages= 423–430|date=August 2010 | doi=10.1038/ja.2010.62|issue=8|title=Antibiotic discovery in the twenty-first century: Current trends and future perspectives |last1=Donadio|first1=Stefano| last2=Maffioli|first2=Sonia|last3=Monciardini |first3=Paolo|last4=Sosio |first4=Margherita|last5=Jabes|first5=Daniela|pmid=20551985|ref=harv}}
*{{cite journal |last=Goossens |first=H|last2= Ferech |first2=M| last3=Vander Stichele |first3=R|last4= Elseviers |first4=M |title=Outpatient antibiotic use in Europe and association with resistance: a cross-national database study |journal=Lancet |volume=365 |issue=9459 |pages=579–87 |year=2005 |pmid=15708101 |doi=10.1016/S0140-6736(05)17907-0 |ref=harv |series= Group Esac Project |last5=Esac Project |first5=Group}}
*{{cite journal|last=Hawkey|first=PM|last2=Jones |first2=AM|title=The changing epidemiology of resistance|journal=The Journal of antimicrobial chemotherapy|date=September 2009 |volume=64 Suppl 1|pages=i3–10|pmid=19675017|doi=10.1093/jac/dkp256|ref=harv}}
*{{cite journal |last=Soulsby |first=EJ |title=Resistance to antimicrobials in humans and animals: Overusing antibiotics is not the only cause and reducing use is not the only solution |journal=BMJ |volume=331 |issue=7527 |pages=1219–20 |year=2005 |pmid=16308360 |doi=10.1136/bmj.331.7527.1219 |pmc=1289307|ref=harv}}
*{{cite journal|url=http://www.csiro.au/solutions/Alternatives-to-antibodies.html |title=Alternatives to Antibiotics Reduce Animal Disease|journal= Commonwealth Scientific and Industrial Research Organization|date=9 Jan 2006|ref=harv}}

==External links==
*[http://pharmaxchange.info/press/2011/02/animation-of-antimicrobial-resistance/ Animation of Antibiotic Resistance]
*[http://www.cdc.gov/ncidod/dhqp/ar_mrsa_spotlight_2006.html CDC Article on Hospital Acquired MRSA]
*[http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca.html CDC Article on Community Acquired MRSA]
*[http://www.cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf CDC Guideline &quot;Management of Multidrug-Resistant Organisms in Healthcare Settings, 2006&quot;]
*[http://www.reactgroup.org/ ReAct Action on Antibiotic Resistance]
*[http://www.apua.org/ Alliance for the Prudent Use of Antibiotics]
*{{cite doi|10.1111/j.1539-6924.2006.00723.x}}
*[http://www.bacteriophagetherapy.info/ Information about phage therapy&amp;nbsp;– a possible alternative to antibiotics in case of resistant infections]
*[http://www.gmo-safety.eu/basic-info/288.once-necessary-undesirable.html Antibiotic-resistance genes as markers] Once necessary, now undesirable
*[https://web.archive.org/web/20071105214608/http://cbs5.com/health/local_story_025195614.html CBS Article on Phage Therapy and Antibiotic Resistance]
*[https://web.archive.org/web/20080610061943/http://knowledge.allianz.com/en/globalissues/safety_security/health_pandemics/hospital_infections_mrsa.html Hospitals: Breeding the Superbug] Article on MRSA infections in hospitals, Allianz Knowledge, by Valdis Wish, May 2008.
*[http://www.eu-burden.info/burden/pages/home.php BURDEN of Resistance and Disease in European Nations - An EU-Project to estimate the financial burden of antibiotic resistance in European Hospitals ]
*[http://www.extendingthecure.org/ Extending the Cure: Policy Research to Extend Antibiotic Effectiveness ]
*[https://web.archive.org/web/20071214142631/http://www.fda.gov/oc/antimicrobial/questions.html 2003 New Guidance for Industry on Antimicrobial Drugs for Food Animals Questions and Answers, U.S. FDA]
*[http://www.scidev.net/en/health/antibiotic-resistance/ SciDev.net Antibiotic Resistance spotlight] The [[Science and Development Network]] is an online science and development network focused on news and information important to the developing world
*[http://www.dobugsneeddrugs.org/ Do Bugs Need Drugs?]
*[http://www.pharmaceutical-int.com/article/combating-drug-resistance.html Combating Drug Resistance] - Tackling drug resistance in bacteria and other pathogens.
*[http://www.technologyreview.com/news/513461/nanoparticle-disguised-as-a-blood-cell-fights-bacterial-infection/?utm_campaign=newsletters&amp;utm_source=newsletter-daily-all&amp;utm_medium=email&amp;utm_content=20130415] Nanoparticles could treat antibiotic resistant infections.

{{Pharmacology}}
{{Portal bar|Molecular and Cellular Biology|Biology|Medicine}}

{{DEFAULTSORT:Antibiotic Resistance}}
[[Category:Antibiotic resistance| ]]
[[Category:Antibiotics]]
[[Category:Evolutionary biology]]
[[Category:Health disasters]]
[[Category:Pharmaceuticals policy]]
[[Category:Veterinary medicine]]

{{Link GA|ar}}</text>
      <sha1>5nofz6c6zuhe0xy9amcrc5i1ay85rw2</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Category:Antibiotic resistance</title>
    <ns>14</ns>
    <id>34370962</id>
    <revision>
      <id>602998637</id>
      <parentid>588138816</parentid>
      <timestamp>2014-04-06T12:40:53Z</timestamp>
      <contributor>
        <username>Sahehco</username>
        <id>8716944</id>
      </contributor>
      <comment>added [[Category:Drug resistance]] using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="196">{{Commons category|Antibiotic resistance}}
[[Category:Antibiotics]]
[[Category:Health disasters]]
[[Category:Biological evolution]]
[[Category:Pharmaceuticals policy]]
[[Category:Drug resistance]]</text>
      <sha1>8qgf6y0sxoozhnsnukt0kq0zztj03d5</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Category:Antibiotic stubs</title>
    <ns>14</ns>
    <id>7288400</id>
    <revision>
      <id>546948377</id>
      <parentid>477850938</parentid>
      <timestamp>2013-03-25T18:43:24Z</timestamp>
      <contributor>
        <username>Addbot</username>
        <id>6569922</id>
      </contributor>
      <minor/>
      <comment>[[User:Addbot|Bot:]] Migrating 1 interwiki links, now provided by [[Wikipedia:Wikidata|Wikidata]] on [[d:q8255978]]</comment>
      <text xml:space="preserve" bytes="258">{{WPSS-cat}}
{{Stub Category|article=[[antibiotic]]s ([[ATC code J01]])|newstub=antibiotic-stub|category=Antibiotics}}

{{see also|Category:Medical treatment stubs|Category:Chemistry stubs|Category:Biochemistry stubs}}

[[Category:Antiinfective agent stubs]]</text>
      <sha1>dgzabo61emw2m5k2k48m82xerqmz8s0</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Furazolidone</title>
    <ns>0</ns>
    <id>1899348</id>
    <revision>
      <id>606972823</id>
      <parentid>606605923</parentid>
      <timestamp>2014-05-04T02:15:06Z</timestamp>
      <contributor>
        <username>Flyer22</username>
        <id>4293477</id>
      </contributor>
      <comment>Reverted 1 [[WP:AGF|good faith]] edit by [[Special:Contributions/125.19.208.122|125.19.208.122]] using [[WP:STiki|STiki]]</comment>
      <text xml:space="preserve" bytes="5793">{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 461105422
| IUPAC_name = 3-{[(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one
| image = Furazolidone.svg
| image2 = Furazolidone ball-and-stick.png

&lt;!--Clinical data--&gt;
| tradename =  
| Drugs.com = {{drugs.com|CONS|furazolidone}}
| pregnancy_category =  
| legal_status =  
| routes_of_administration = Oral-Local

&lt;!--Pharmacokinetic data--&gt;
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

&lt;!--Identifiers--&gt;
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 67-45-8
| ATC_prefix = G01
| ATC_suffix = AX06
| ATC_supplemental = {{ATCvet|J01|XE90}}
| PubChem = 3435
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00614
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3317
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5J9CPU3RE0
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = C07999
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1103

&lt;!--Chemical data--&gt;
| C=8 | H=7 | N=3 | O=5 
| molecular_weight = 225.16
| smiles = [O-][N+](=O)c2oc(C=NN1C(=O)OCC1)cc2
| InChI = 1/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2
| InChIKey = PLHJDBGFXBMTGZ-UHFFFAOYAA
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PLHJDBGFXBMTGZ-UHFFFAOYSA-N
}}

'''Furazolidone''' is a [[nitrofuran]] [[antibacterial]]. It is marketed by [[Roberts Laboratories]] under the brand name '''Furoxone''' and by [[GlaxoSmithKline]] as '''Dependal-M'''.

== Uses ==

Furazolidone has been used in human and veterinary medicine. It has a broad spectrum of activity being active against 

*Gram positive
**''[[Clostridium perfringens]]''
**''[[Corynebacterium pyogenes]]''
**[[Streptococcus|Streptococci]]
**[[Staphylococcus|Staphylococci]] 
*Gram negative
**''[[Escherichia coli]]''
**''[[Salmonella dublin]]''
**''[[Salmonella typhimurium]]''
*Protozoa
**''[[Giardia lamblia]]''
**''[[Eimeria]]'' species
**''[[Histomonas meleagridis]]'' 

=== Use in humans ===

In humans it has used to treat [[diarrhoea]] and [[enteritis]] caused by [[bacteria]] or [[protozoa]]n infections. It has been used to treat traveler's diarrhoea, [[cholera]] and [[salmonella|bacteremic salmonellosis]].
Use in treating ''[[Helicobacter pylori]]'' infections has also been proposed.&lt;ref name=&quot;pmid18372934&quot;&gt;{{cite journal |author=Machado RS, Silva MR, Viriato A |title=Furazolidone, tetracycline and omeprazole: a low-cost alternative for Helicobacter pylori eradication in children |journal=Jornal de pediatria |volume=84 |issue=2 |pages=160–5 |year=2008 |pmid=18372934 |doi=10.2223/JPED.1772}}&lt;/ref&gt;

Furazolidone is also used for [[giardiasis]] (due to ''[[Giardia lamblia]]''), though it is not a first line treatment.&lt;ref name=&quot;pmid15625030&quot;&gt;{{cite journal |author=Petri WA |title=Treatment of Giardiasis |journal=Curr Treat Options Gastroenterol |volume=8 |issue=1 |pages=13–17 |date=February 2005 |pmid=15625030 |doi= 10.1007/s11938-005-0047-3|url=http://www.treatment-options.com/1092-8472/8/13 |format={{dead link|date=May 2010}}}}&lt;/ref&gt;

As for all medicines the most recent local recommendations for its use should be always be followed. The usual dose is:
* Adult: 100 mg 4 times daily. Usual duration: 2-5 days, up to 7 days in some patients or 10 days for giardiasis. 
* Child: 1.25 mg/kg 4 times daily, usually given for 2-5 days or up to 10 days for giardiasis.

===Use in animals===

As a [[veterinary medicine]], furazolidone has been used with some success to treat [[salmon]]ids for ''[[Myxobolus cerebralis]]'' infections. 

It has also been used in [[aquaculture]].&lt;ref name=&quot;pmid10694929&quot;&gt;{{cite journal |author=Meng J, Mangat SS, Grudzinski IP, Law FC |title=Evidence of 14C-furazolidone metabolite binding to the hepatic DNA of trout |journal=Drug Metabol Drug Interact |volume=14 |issue=4 |pages=209–19 |year=1998 |pmid=10694929 |doi= |url=}}&lt;/ref&gt;

Since furazolidone is a nitrofuran antibiotic, its use in food animals is currently prohibited by the FDA under the Animal Medicinal Drug Use Clarification Act, 1994.&lt;ref&gt;{{cite web|last=Bagley|first=Clell|title=Drugs Prohibited from Extralabel Use in Animals|url=http://extension.usu.edu/dairy/files/uploads/htms/drugs.htm|accessdate=14 April 2014}}&lt;/ref&gt;

===Use in laboratory===

It is used to differentiate [[micrococcus|micrococci]] and [[staphylococcus|staphylococci]].

==Mechanism==
It is believed to work by [[crosslinking of DNA]].&lt;ref name=&quot;urlDrugBank: Showing Furazolidone (DB00614)&quot;&gt;{{cite web |url=http://www.drugbank.ca/drugs/DB00614 |title=DrugBank: Showing Furazolidone (DB00614) |format= |work= |accessdate=2008-12-19}}&lt;/ref&gt;

==Side effects==
Furazolidone is no longer available in the US. Though an effective antibiotic when all others fail, against extremely drug resistant infections, it has many side effects, and as with other [[nitrofuran]]s generally, [[minimum inhibitory concentration]]s also produce systemic toxicity (tremors, convulsions, peripheral neuritis, gastrointestinal disturbances, depression of spermatogenesis.) Nitrofurans are recognized by FDA as mutagens/carcinogens, and can no longer be used since 1991.&lt;ref&gt;http://caraga.da.gov.ph/services/banmed-Nitrofurans.htm {{dead link|date=December 2013}}&lt;/ref&gt;

==References==
{{reflist|2}}

{{Gynecological anti-infectives and antiseptics}}
{{Excavata antiparasitics}}
{{Nucleic acid inhibitors}}

[[Category:Antibiotics]]
[[Category:Antiprotozoal agents]]
[[Category:Nitrofurans]]
[[Category:Monoamine oxidase inhibitors]]
[[Category:Oxazolidinones]]
[[Category:Hydrazones]]</text>
      <sha1>pwpo8pgc8xztcm22lxhwzyy6kuz1qn8</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>DB-2073</title>
    <ns>0</ns>
    <id>35666960</id>
    <revision>
      <id>578614827</id>
      <parentid>517823891</parentid>
      <timestamp>2013-10-24T22:40:33Z</timestamp>
      <contributor>
        <username>Cydebot</username>
        <id>1215485</id>
      </contributor>
      <minor/>
      <comment>Robot - Removing category Chemical compounds found in Proteobacteria per [[WP:CFD|CFD]] at [[Wikipedia:Categories for discussion/Log/2013 October 8]].</comment>
      <text xml:space="preserve" bytes="1331">{{Chembox
|  ImageFile = DB-2073.png
|  ImageSize =
|  ImageAlt = Chemical structure of DB-2073
|  IUPACName = 2-hexyl-5-propylbenzene-1,3-diol
|  OtherNames = 2-n-hexyl-5-n-propylresorcinol
| Section1 = {{Chembox Identifiers
|  CASNo = 39341-78-1
|  PubChem = 197183
|  ChemSpiderID = 170764
|  SMILES = Oc1cc(cc(O)c1CCCCCC)CCC
|  InChI = 1/C15H24O2/c1-3-5-6-7-9-13-14(16)10-12(8-4-2)11-15(13)17/h10-11,16-17H,3-9H2,1-2H3
|  InChIKey = VERGPVBZPMTZDY-UHFFFAOYAD
|  StdInChI = 1S/C15H24O2/c1-3-5-6-7-9-13-14(16)10-12(8-4-2)11-15(13)17/h10-11,16-17H,3-9H2,1-2H3
|  StdInChIKey = VERGPVBZPMTZDY-UHFFFAOYSA-N
|  InChI = 1S/C15H24O2/c1-3-5-6-7-9-13-14(16)10-12(8-4-2)11-15(13)17/h10-11,16-17H,3-9H2,1-2H3
  }}
| Section2 = {{Chembox Properties
|  Formula = C&lt;sub&gt;15&lt;/sub&gt;H&lt;sub&gt;24&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt;		
|  MolarMass = 236.35 g/mol
|  ExactMass = 236.17763 u
|  Appearance =
|  Density =
|  MeltingPt =
|  BoilingPt =
|  Solubility = 
  }}
| Section3 = {{Chembox Hazards
|  MainHazards =
|  FlashPt =
|  Autoignition = 
  }}
}}
'''DB-2073''' is an [[alkylresorcinol]] [[antibiotic]] isolated from the broth culture of ''[[Pseudomonas]]'' sp B-9004.&lt;ref&gt;{{Cite PMID|1206006|noedit}}&lt;/ref&gt; &lt;ref&gt;{{Cite PMID|1206007|noedit}}&lt;/ref&gt;

== References ==
{{Reflist}}

[[Category:Alkylresorcinols]]
[[Category:Antibiotics]]

{{Natural phenol-stub}}</text>
      <sha1>03jzdlf7pbjszndea8ssa1h8aazbpam</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Enzybiotics</title>
    <ns>0</ns>
    <id>36074373</id>
    <revision>
      <id>593552529</id>
      <parentid>589100082</parentid>
      <timestamp>2014-02-02T08:07:55Z</timestamp>
      <contributor>
        <username>Rjwilmsi</username>
        <id>203434</id>
      </contributor>
      <minor/>
      <comment>Journal cites,  using [[Project:AWB|AWB]] (9901)</comment>
      <text xml:space="preserve" bytes="2671">'''Enzybiotics''' are an experimental [[antibiotic]] approach employing [[enzymes]] to combat pathogenic bacterial infections.  The name is a combination of the words &quot;enzyme&quot; and &quot;antibiotics&quot; first coined in March 2001 by Nelson et al.&lt;ref&gt;{{cite journal|last=Nelson,|first=D|coauthors=Loomis, L; Fischetti, VA;|title=Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme.|journal=Proceedings of the National Academy of Sciences|date=March 2001|volume=98|issue=7|pages=4107–12|doi=10.1073/pnas.061038398|pmc=31187}}&lt;/ref&gt;  Many of the enzymes used as enzybiotics are [[lysins]], enzymes derived from bacterial viruses (or [[bacteriophages]]) used to release progeny bacteriophage from infected bacteria, though other natural or synthetic enzymes may be used.&lt;ref&gt;{{cite journal|last=Veiga-Crespo|first=P|coauthors=Ageitos, JM; Poza, M; Villa, TG|title=Enzybiotics: a look to the future, recalling the past.|journal=Journal of pharmaceutical sciences|date=August 2007|volume=96|issue=8|pages=1917–24|pmid=17518365|doi=10.1002/jps.20853}}&lt;/ref&gt;&lt;ref&gt;Veiga-Crespo, P. and Villa, T. G. (2009) Phylogeny of Enzybiotics, in Enzybiotics: Antibiotic Enzymes as Drugs and Therapeutics (eds T. G. Villa and P. Veiga-Crespo), John Wiley &amp; Sons, Inc., Hoboken, NJ, USA. {{DOI|10.1002/9780470570548.ch4}}&lt;/ref&gt;

==Phage-derived enzymes==
Enzybiotic approaches have attempted to incorporate bacteriophage-derived [[lysins]] to kill bacterial cells.&lt;ref&gt;{{cite journal|last=Hermoso|first=JA|coauthors=García, JL; García, P|title=Taking aim on bacterial pathogens: from phage therapy to enzybiotics.|journal=Current Opinion in Microbiology|date=October 2007|volume=10|issue=5|pages=461–72|pmid=17904412|doi=10.1016/j.mib.2007.08.002}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=Pastagia|first=M|coauthors=Schuch, R; Fischetti, VA; Huang, D.|title=Lysins: the arrival of pathogen-directed anti-infectives.|journal=Journal of Medical Microbiology|date=October 2013|pages=1506–15|doi =10.1099/jmm.0.061028-0}}&lt;/ref&gt; One particular lysin, isolated from phage P68 of ''[[Staphylococcus aureus]]'', has shown antimicrobial activity against its host species when used along with the antibiotic [[gentamicin]].&lt;ref&gt;{{cite journal|last=Manoharadas|first=S|coauthors=Witte, A; Bläsi, U|title=Antimicrobial activity of a chimeric enzybiotic towards Staphylococcus aureus.|journal=Journal of biotechnology|date=2009-01-01|volume=139|issue=1|pages=118–23|pmid=18940209|doi=10.1016/j.jbiotec.2008.09.003}}&lt;/ref&gt;

==See also==
* [[Phage therapy]]

==References==
{{Reflist}}

[[Category:Antibiotics]]


{{microbiology-stub}}</text>
      <sha1>066oetdqr79fgf9wpydzhowfprmxukn</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Allyl isothiocyanate</title>
    <ns>0</ns>
    <id>1576787</id>
    <revision>
      <id>607468934</id>
      <parentid>607468828</parentid>
      <timestamp>2014-05-07T12:21:15Z</timestamp>
      <contributor>
        <username>Edgar181</username>
        <id>491706</id>
      </contributor>
      <minor/>
      <text xml:space="preserve" bytes="5932">{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477314225
|   Name = Allyl isothiocyanate
|   ImageFile = Allyl-isothiocyanate-2D-skeletal.png
|   ImageSize = 200px
|   ImageName = Allyl isothiocyanate
|   ImageFile1 = Allyl-isothiocyanate-3D-vdW.png
|   ImageSize1 = 150px
|   ImageName1 = Space-filling model of allyl isothiocyanate
|   IUPACName = 3-Isothiocyanato-1-propene
|   OtherNames = synthetic mustard oil
| Section1 = {{Chembox Identifiers
|   UNII_Ref = {{fdacite|correct|FDA}}
| UNII = BN34FX42G3
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 73224
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02818
| InChI = 1/C4H5NS/c1-2-3-5-4-6/h2H,1,3H2
| InChIKey = ZOJBYZNEUISWFT-UHFFFAOYAS
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C4H5NS/c1-2-3-5-4-6/h2H,1,3H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZOJBYZNEUISWFT-UHFFFAOYSA-N
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo = 57-06-7
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 233248
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 21105854
|   SMILES = C=CCN=C=S
| PubChem = 5971
}}
| Section2 = {{Chembox Properties
|   C=4|H=5|N=1|S=1
|   Density = 1.013–1.020 g/cm&lt;sup&gt;3&lt;/sup&gt;
|   MeltingPtC = −102
|   BoilingPtC = 148
|   BoilingPtCH = 154
  }}
}}

'''Allyl isothiocyanate (AITC)''' is the [[organosulfur compound]] with the formula CH&lt;sub&gt;2&lt;/sub&gt;CHCH&lt;sub&gt;2&lt;/sub&gt;NCS. This colorless oil is responsible for the pungent taste of [[mustard (condiment)|mustard]], [[radish]], [[horseradish]], and [[wasabi]]. This pungency and the lachrymatory effect of AITC is mediated through the [[TRPA1]] and [[TRPV1]]  ion channels.&lt;ref&gt;{{cite journal | last1 = Everaerts | first1 = W. | last2 = Gees | first2 = M. | last3 = Alpizar | first3 = Y. A. | last4 = Farre | first4 = R. | last5 = Leten | first5 = C. | last6 = Apetrei | first6 = A. | last7 = Dewachter | first7 = I. | last8 = van Leuven | first8 = F. | last9 = Vennekens | first9 = R. | displayauthors=8| title = The Capsaicin Receptor TRPV1 is a Crucial Mediator of the Noxious Effects of Mustard Oil | journal = Current Biology | year = 2011 | volume = 21 | issue = 4 | pages = 316–321 | pmid = 21315593 | doi = 10.1016/j.cub.2011.01.031 }}&lt;/ref&gt;&lt;ref name=&quot;pmid18501939&quot;&gt;{{cite journal | author = Brône, B.; Peeters, P. J.; Marrannes, R.; Mercken, M.; Nuydens, R.; Meert, T.; Gijsen, H. J. | title = Tear gasses CN, CR, and CS are potent activators of the human TRPA1 receptor | journal = [[Toxicology and Applied Pharmacology]] | year = 2008 | volume = 231 | issue = 2 | pages = 150–156 | pmid = 18501939 | doi = 10.1016/j.taap.2008.04.00 }}&lt;/ref&gt;&lt;ref name=&quot;pmid21741838&quot;&gt;{{cite journal | author = Ryckmans, T.; Aubdool, A. A.; Bodkin, J. V.; Cox, P.; Brain, S. D.; Dupont, T.; Fairman, E.; Hashizume, Y.; Ishii, N. et al. | title = Design and Pharmacological Evaluation of [[PF-4840154]], a Non-Electrophilic Reference Agonist of the TrpA1 Channel | journal = Bioorganic and Medicinal Chemistry Letters | year = 2011 | volume = 21 | issue = 16 | pages = 4857–4859 | pmid = 21741838 | doi = 10.1016/j.bmcl.2011.06.035 }}&lt;/ref&gt; It is slightly soluble in water, but well soluble in most organic solvents.&lt;ref name=Ullmann&gt;{{ Ullmann | author = Romanowski, F.; Klenk, H. | title = Thiocyanates and Isothiocyanates, Organic | doi = 10.1002/14356007.a26_749 }}&lt;/ref&gt;

==Biosynthesis and biological functions==
Allyl isothiocyanate comes from the seeds of black mustard (''[[Brassica nigra]]'') or brown Indian mustard (''[[Brassica juncea]]'').  When these [[mustard seed]]s are broken, the [[enzyme]] [[myrosinase]] is released and acts on a [[glucosinolate]] known as [[sinigrin]] to give allyl isothiocyanate.  

Allyl isothiocyanate serves the plant as a defense against [[herbivore]]s; since it is harmful to the plant itself, it is stored in the harmless form of the glucosinolate, separate from the myrosinase enzyme.  When an animal chews the plant, the allyl isothiocyanate is released, repelling the animal.

==Commercial and other applications==
Allyl isothiocyanate is produced commercially by the reaction of [[allyl chloride]] and [[thiocyanate|potassium thiocyanate]]:&lt;ref name=Ullmann/&gt;

:CH&lt;sub&gt;2&lt;/sub&gt;=CHCH&lt;sub&gt;2&lt;/sub&gt;Cl  +  KSCN  →  CH&lt;sub&gt;2&lt;/sub&gt;=CHCH&lt;sub&gt;2&lt;/sub&gt;NCS  +  KCl

The product obtained in this fashion is sometimes known as ''synthetic mustard oil''.  Allyl isothiocyanate can also be liberated by dry [[distillation]] of the seeds.  The product obtained in this fashion is known as [[mustard oil|volatile oil of mustard]] and is usually around 92% pure.  It is used principally as a [[flavoring]] agent in foods.  Synthetic allyl isothiocyanate is used as an [[insecticide]],&lt;!--as an [[animal repellent]], to [[denatured alcohol|denature alcohol]], and as a [[topical anesthetic]].--&gt; [[antibacterial|bacteriocide]],&lt;ref&gt;{{cite pmid|15246236}}&lt;/ref&gt; and nematocide, and is used in certain cases for crop protection.&lt;ref name=Ullmann/&gt;

Hydrolysis of allyl isothiocyanate gives [[allylamine]].&lt;ref&gt;{{OrgSynth | author = Leffler, M. T. | title = Allylamine | volume = 18 | pages = 5 | collvol = 2 | collvolpages = 24 | year = 1938 | prep = CV2P0024 }}&lt;/ref&gt;

==Safety==
Allyl isothiocyanate has an [[Median lethal dose|LD&lt;sub&gt;50&lt;/sub&gt;]] of 151&amp;nbsp;mg/kg and is a [[lachrymator]].&lt;ref name=Ullmann/&gt;

==Oncology==
Based on ''[[in vitro]]'' experiments and [[animal model]]s, allyl isothiocyanate exhibits many desirable attributes of a cancer chemopreventive agent.&lt;ref&gt;{{cite pmid|19960458}}&lt;/ref&gt;

== References ==
{{reflist}}

== See also ==
*[[Piperine]], the active piquant chemical in [[black pepper]]
*[[Capsaicin]], the active piquant chemical in [[chili pepper]]s
*[[Allicin]], the active piquant flavor chemical in raw [[garlic]]

[[Category:Antibiotics]]
[[Category:Insecticides]]
[[Category:Isothiocyanates]]
[[Category:Pungent flavors]]</text>
      <sha1>jfebcxju50bcuskudp0jgnu3d4265vn</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>(6S)-6-Fluoroshikimic acid</title>
    <ns>0</ns>
    <id>36281234</id>
    <revision>
      <id>578899035</id>
      <parentid>512896961</parentid>
      <timestamp>2013-10-27T01:49:33Z</timestamp>
      <contributor>
        <username>Choess</username>
        <id>245519</id>
      </contributor>
      <comment>added [[Category:Cyclitols]] using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="3724">{{DISPLAYTITLE:(6''S'')-6-Fluoroshikimic acid}}
{{chembox
|   Name =  (6''S'')-6-Fluoroshikimic acid
|   ImageFile = Fluoroshikimic acid.png
|   ImageSize = 150px
|   ImageName = Chemical structure of (6''S'')-6-fluoroshikimic acid
|   IUPACName = (3''R'',4''R'',5''S'',6''S'')-6-fluoro-3,4,5-trihydroxycyclohexene-1-carboxylic acid
| Section1 = {{Chembox Identifiers
|   CASNo_Ref = 
|   CASNo = 
|   ChEBI_Ref = 
|   ChEBI = 
|   ChEMBL_Ref = 
|   ChEMBL = 
|  PubChem = 10219767
|  ChemSpiderID = 8395259
|  SMILES = F[C@H]1C(=C/[C@@H](O)[C@@H](O)[C@@H]1O)\C(=O)O
|  InChI = 1/C7H9FO5/c8-4-2(7(12)13)1-3(9)5(10)6(4)11/h1,3-6,9-11H,(H,12,13)/t3-,4+,5-,6-/m1/s1
|  InChIKey = XFSMSJCDVCOESF-JGWLITMVBO
|  StdInChI = 1S/C7H9FO5/c8-4-2(7(12)13)1-3(9)5(10)6(4)11/h1,3-6,9-11H,(H,12,13)/t3-,4+,5-,6-/m1/s1
|  StdInChIKey = XFSMSJCDVCOESF-JGWLITMVSA-N
|   EINECS = 
|   KEGG_Ref = 
|   KEGG = 
|   PubChem = 10219767
  }}
| Section2 = {{Chembox Properties
|   Formula = C&lt;sub&gt;7&lt;/sub&gt;H&lt;sub&gt;9&lt;/sub&gt;FO&lt;sub&gt;5&lt;/sub&gt;
|   MolarMass = 192.14 g/mol
|   ExactMass = 192.04340159 u
|   MeltingPt = 
  }}
}}

'''(6''S'')-6-Fluoroshikimic acid''' is an antibacterial agent acting on the aromatic biosynthetic pathway.&lt;ref&gt;{{Cite journal | title = (6S)-6-Fluoroshikimic Acid, an Antibacterial Agent Acting on the Aromatic Biosynthetic Pathway | author = Davies GM, Barrett-Bee KJ, Jude DA, Lehan M, Nichols WW, Pinder PE, Thain JL, Watkins WJ, Wilson RG | journal = [[Antimicrobial Agents and Chemotherapy]] | year = 1994 | volume = 38 | issue = 2 | pages = 403–406 | pmid = 8192477 | pmc = 284469 | doi = 10.1128/AAC.38.2.403 | url = http://www.ncbi.nlm.nih.gov/pmc/articles/PMC284469/pdf/aac00368-0245.pdf | format = pdf }}&lt;/ref&gt; It may be used against ''[[Plasmodium falciparum]]'', the causative agent of malaria.&lt;ref&gt;{{Cite journal | author = McConkey GA | title = Targeting the Shikimate Pathway in the Malaria Parasite ''Plasmodium falciparum'' | journal = Antimicrobial Agents and Chemotherapy | year = 1999 | volume = 43 | issue = 1 | pages = 175–177 | pmid = 9869588 | pmc = 89043 | url = http://www.ncbi.nlm.nih.gov/pmc/articles/PMC89043/pdf/ac000175.pdf | format = pdf }}&lt;/ref&gt; The molecule is targeting the enzymes of the [[shikimate pathway]]. This metabolic pathway is not present in mammals. The mechanism of action of the molecule is not through the inhibition of [[chorismate synthase]] but by the inhibition of [[4-aminobenzoic acid]] synthesis.&lt;ref&gt;{{Cite journal | author = Bornemann S, Ramjee MK, Balasubramanian S, Abell C, Coggins JR, Lowe DJ, Thorneley RN | title = ''Escherichia coli'' Chorismate Synthase Catalyzes the Conversion of (6S)-6-Fluoro-5-enolpyruvylshikimate-3-phosphate to 6-Fluorochorismate | journal = [[Journal of Biological Chemistry]] | year = 1995 | volume = 270 | issue = 39 | pages = 22811–22815 | doi = 10.1074/jbc.270.39.22811 | pmid = 7559411 | url = http://www.jbc.org/content/270/39/22811.full.pdf | format = pdf }}&lt;/ref&gt;

The use of the molecule led to resistances in ''[[Escherichia coli]]''.&lt;ref&gt;{{Cite journal | title = Frequency and Mechanism of Resistance to Antibacterial Action of ZM 240401, (6S)-6-Fluoro-Shikimic Acid | author = Ewart CD, Jude DA, Thain JL, Nichols WW | journal = Antimicrobial Agents and Chemotherapy | year = 1995 | volume = 39 | issue = 1 | pages = 87–93 | doi = 10.1128/AAC.39.1.87 | pmid = 7695335 | pmc = 162490 | url = http://www.ncbi.nlm.nih.gov/pmc/articles/PMC162490/pdf/390087.pdf | format = pdf }}&lt;/ref&gt;

== See also ==
* [[Shikimic acid]]

== References ==
{{Reflist}}

{{DEFAULTSORT:Fluoroshikimic acid, (6S)-6-}}
[[Category:Antibiotics]]
[[Category:Organofluorides]]
[[Category:Carboxylic acids]]
[[Category:Cyclitols]]

{{antibiotic-stub}}</text>
      <sha1>9pj1wxwkv8hqtddh2g18u6yw3yvbf0i</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Albomycin</title>
    <ns>0</ns>
    <id>36533310</id>
    <revision>
      <id>503971519</id>
      <parentid>503971143</parentid>
      <timestamp>2012-07-24T16:44:04Z</timestamp>
      <contributor>
        <username>Edgar181</username>
        <id>491706</id>
      </contributor>
      <comment>this ref is for [[aabomycin]]</comment>
      <text xml:space="preserve" bytes="1018">'''Albomycin''' is an antibiotic belonging to the class of [[sideromycin]]s, which are &quot;compounds composed of iron carriers linked to antibiotic moieties&quot;, and is particularly effective against ''[[Streptococcus pneumoniae]]'' and ''[[Piricularia oryzae]]'' strains which are resistant to [[blasticidin]] and [[kasugamycin]].&lt;ref&gt;{{cite web|url=http://www.sciencedirect.com/science/article/pii/S1438422107000392|title=Albomycin is an effective antibiotic, as exemplified with Yersinia enterocolitica and Streptococcus pneumoniae|publisher=''[[International Journal of Medical Microbiology]]''|date=Volume 297, Issue 6, 15 October 2007, Pages 459–469|accessdate=24 July 2012}}&lt;/ref&gt;&lt;ref&gt;{{cite web|url=http://jb.asm.org/content/188/11/3878.short|title=Albomycin Uptake via a Ferric Hydroxamate Transport System of Streptococcus pneumoniae R6 |publisher=''[[Journal of Microbiology]]''|date= June 2006 vol. 188|accessdate=24 July 2012}}&lt;/ref&gt;

==References==
{{reflist}}


{{antibiotic-stub}}

[[Category:Antibiotics]]</text>
      <sha1>jue1fu1rm1krh559agdldku6brn3r2w</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Aspergillic acid</title>
    <ns>0</ns>
    <id>37462331</id>
    <revision>
      <id>590257645</id>
      <parentid>564954192</parentid>
      <timestamp>2014-01-11T19:25:40Z</timestamp>
      <contributor>
        <ip>193.190.253.146</ip>
      </contributor>
      <text xml:space="preserve" bytes="7362">{{Chembox
|  Name =Aspergillic Acid
|  ImageFile =Aspergillic Acid.jpg
|   ImageSize = 150px
|  IUPACName =6-Butan-2-yl-1-hydroxy-3-(2-methylpropyl)pyrazin-2-one
|  IUPACName_hidden = No
|  SystematicName =1-Hydroxy-6-(2-butanyl)-3-isobutyl-2(1''H'')-pyrazinone
|  OtherNames =6-sec-butyl-1-hydroxy-3-isobutyl-2(1''H'')-pyrazinone; 6-sec-butyl-3-isobutylpyrazinol 1-oxide; 2-hydroxy-3-isobutyl-6-(1-methylpropyl)pyrazine 1-oxide; 3-isobutyl-6-sec-butyl-2-hydroxypyrazine 1-oxide&lt;ref&gt;{{cite web|url=http://www.drugfuture.com/chemdata/aspergillic-acid.html |title=Aspergillic Acid |publisher=Drugfuture.com |date= |accessdate=2012-11-26}}&lt;/ref&gt;
| Section1 = {{Chembox Identifiers
|  Abbreviations =
|  CASNo =490-02-8
|  CASNo_Comment =
|  CASNo_Ref =
|  CASNos =
|  CASOther =
|  PubChem =73679
|  PubChem_Comment =
|  PubChem5 =
|  PubChem5_Comment =
|  PubChemOther =
|  ChemSpiderID =46477436 
|  ChemSpiderID_Comment =
|  ChemSpiderID5 =
|  ChemSpiderIDOther =  
|  EINECS =
|  EC-number =
|  EINECSCASNO =
|  UNNumber =
|  DrugBank =
|  KEGG =
|  MeSHName =
|  ChEBI =
|  RTECS =
|  ATCvet =
|  ATCCode_prefix =
|  ATCCode_suffix =
|  ATC_Supplemental =
|  SMILES = CCC(C)C1=CN=C(C(=O)N1O)CC(C)C
|  InChI =InChI=1S/C12H20N2O2/c1-5-9(4)11-7-13-10(6-8(2)3)12(15)14(11)16/h7-9,16H,
5-6H2,1-4H3
|  Beilstein =
|  Gmelin =
|  3DMet =}}
| Section2 = {{Chembox Properties
|  C=12|H=20|N=2|O=2
|  Appearance =Pale yellow needles
|  Density =1.163 g/cm&lt;sup&gt;3&lt;/sup&gt;
|  MeltingPtC =98
|  Melting_notes =
|  BoilingPt =
|  Boiling_notes =
|  SolubleOther = vs bz, eth, EtOH
|  LogP = 1.7
|  VaporPressure = 
|  HenryConstant =
|  AtmosphericOHRateConstant =
|  pKa =
|  pKb =
|  Sheet Resistance =
|  Methacrylate Equiv Wt =
|  Bulk Conductivity = }}
| Section3 = {{Chembox Structure
|  CrystalStruct =
|  Coordination =
|  MolShape = }}
| Section4 = {{Chembox Thermochemistry
| DeltaHf      = 
| DeltaHc      = 
| Entropy      = 
| HeatCapacity = 
}}
| Section5 = {{Chembox Pharmacology
|  AdminRoutes =
|  Bioavail =
|  Metabolism =
|  HalfLife =
|  ProteinBound =
|  Excretion =
|  Legal_status =
|  Legal_US =
|  Legal_UK =
|  Legal_AU =
|  Legal_CA =
|  PregCat =
|  PregCat_AU =
|  PregCat_US = }}
| Section6 = {{Chembox Explosive
|  ShockSens =
|  FrictionSens =
|  ExplosiveV =
|  REFactor = }}
| Section7 = {{Chembox Hazards
|  ExternalMSDS =
|  EUClass =
|  EUIndex =
|  MainHazards =
|  NFPA-H =
|  NFPA-F =
|  NFPA-R =
|  NFPA-O =
|  RPhrases =
|  SPhrases =
|  RSPhrases =
|  FlashPt =
|  Autoignition =
|  ExploLimits =
|  LD50 =
|  PEL = }}
| Section8 = {{Chembox Related
|  OtherAnions =
|  OtherCations =
|  OtherFunctn =
|  Function =
|  OtherCpds = }}
}}

'''Aspergillic acid''' is an [[Organic compound|organic]] [[chemical compound]] with the molecular formula C&lt;sub&gt;12&lt;/sub&gt;H&lt;sub&gt;20&lt;/sub&gt;N&lt;sub&gt;2&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt;. It has a pale yellow [[crystalline]] appearance. Aspergillic acid is most commonly known as an [[antibiotic]] and [[fungicide|antifungal]] agent that is derived from certain strains of the fungus ''[[Aspergillus flavus]]''.&lt;ref&gt;http://www.jbc.org/content/236/2/512.full.pdf&lt;/ref&gt;&lt;ref&gt;{{Cite journal | url = http://books.google.com/?id=caTqdbD7j4AC&amp;pg=PA123&amp;dq=aspergillic+acid#v=onepage&amp;q=aspergillic%20acid&amp;f=false | title = Lewisʼ Dictionary of Toxicology | isbn = 9781566702232 | author1 = Robert a Lewis | first1 = PH.D | year = 1998}}&lt;/ref&gt;

== History ==
In 1940 [[Edwin C. White]] and [[Justina H. Hill]] discovered that a fungal strain of  ''Aspergillus flavus'' growing in a surface culture on a [[tryptone]]-[[salt]] was capable of producing a [[bactericidal]] [[filtrate]]. It has also been shown to be a bactericidal for some Gram-negative as well as Gram-positive bacteria. Over the next few years they worked off this discovery and succeeded to isolate the active material in the crystalline form. In 1943 they managed to isolate this antibiotic compound and called it aspergillic acid primarily because of its origin and [[acidic]] properties. Scientists have since been working with the ''Asperigillus flavus ''strain to produce various types of [[antibacterial]] substances.&lt;ref&gt;http://www.jbc.org/content/171/1/321.full.pdf&lt;/ref&gt;&lt;ref name=&quot;pubs&quot;&gt;http://pubs.acs.org/doi/pdf/10.1021/jo01350a062&lt;/ref&gt;

==Structure==
The structure of aspergillic acid was made by Dutcher and Spring and his co-workers. They suggested that it is a cylic hydroxamic acid related to [[pyridine]]. It can be reduced to a neutral deoxyaspergillic acid, which is a [[racemization]] product found by Newbold, et al. to be identical with 3-isobutyl-6-sec-butyl-2-hydroxypyrazine. Because of this, aspergillic acid has been assigned the corresponding l-oxide or [[tautomeric]] pyridine hydroxamic acid structure show below.&lt;ref name=&quot;pubs&quot; /&gt;

[[File:Aspergillic acid analog.png|Aspergillic acid analog]]

==Toxicity==

The toxicity of aspergillic acid is controlled by the hydroxamic acid functionality, and there is little effect on toxicity observed between the differences in the 3 and 6 position side chain substituents. [[Chelation]] of physiologically important ions, such as [[calcium]] by aspergillic acid appears to be the likely mechanism of its toxic action.&lt;ref&gt;Deshpande, S. S. &quot;Handbook of Food Toxicology.&quot; Google Books. N.p.,&lt;http://books.google.com/books?id=Mk-IdNTTJB0C&gt;.&lt;/ref&gt;

== Synthesis ==
Different ''[[Aspergillus]]'' strains are capable of making various [[hydroxypyrazine]] [[derivative (chemistry)|derivative]]s. ''Aspergillus flavus'' is used to produce an antibiotic substance called [[flavacol]]. Flavacol is then added to cultures of ''[[A. selerotiorum]]'' and is ''N''-hydroxylated into [[neoaspergillic acid]]. It is then [[hydroxylated]] in the side-chain in order to make [[neohydroxyaspergillic acid]] &lt;ref name=&quot;books.google&quot;&gt;{{Cite journal | url = http://books.google.com/?id=tYk1HMEg_SUC&amp;pg=PA252&amp;dq=aspergillic+acid+reactions#v=onepage&amp;q&amp;f=false | title = Biosynthesis: A Review of the Literature Published During 1970 and 1971 | isbn = 9780851865430}}&lt;/ref&gt;

Other studies show that aspergillic acid can also be derived from one molecule of [[leucine|&lt;small&gt;L&lt;/small&gt;-leucine]] and one molecule of [[isoleucine|&lt;small&gt;L&lt;/small&gt;-isoleucine]] in ''Aspergillus flavus''.&lt;ref name=&quot;books.google&quot; /&gt;

==Reactions==
When aspergillic acid reactions with [[iron trichloride]] (FeCl&lt;sub&gt;3&lt;/sub&gt;), there is the formation of green cupric salt. This suggests that aspergillic acid is a hydroxamic acid derivative, which is also confirmed by the formation of deoxyaspergillic acid by [[dry distillation]] with [[copper chromite]] [[catalyst]].

Bromination of aspergillic acid followed by [[Organic redox reaction|reduction]] with [[zinc]] and [[acetic acid]] gives a [[diketopiperazine]]. [[Hydrolysis]] with [[hydrobromic acid|HBr]] yields a mixture of &lt;small&gt;DL&lt;/small&gt;-leucine and &lt;small&gt;DL&lt;/small&gt;-isoleucine. These reaction schemes can be seen below:&lt;ref name=&quot;books.google_a&quot;&gt;{{Cite journal | url = http://books.google.com/?id=YV9yXTDkue4C&amp;pg=PA190&amp;lpg=PA190&amp;dq=Aspergillic+Acid+reactions#v=onepage&amp;q&amp;f=false | title = The Alkaloids | isbn = 9780124695290 | author1 = Brossi | first1 = Arnold | date = 1986-12-01}}&lt;/ref&gt; 

[[File:Aspergillic acid reactions 2.png|Aspergillic acid reactions 2]]&lt;ref name=&quot;books.google_a&quot; /&gt;

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Organic acids]]</text>
      <sha1>3xl4athhyl82zk5yo60ln4i39jirqcr</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Arenicin</title>
    <ns>0</ns>
    <id>37785163</id>
    <revision>
      <id>578849511</id>
      <parentid>527860445</parentid>
      <timestamp>2013-10-26T17:55:13Z</timestamp>
      <contributor>
        <username>ChrisGualtieri</username>
        <id>16333418</id>
      </contributor>
      <minor/>
      <comment>General Fixes, added [[CAT:O|orphan]] tag using [[Project:AWB|AWB]]</comment>
      <text xml:space="preserve" bytes="8264">{{Orphan|date=October 2013}}

'''Arenicin''' is the name used to classify a group of [[antimicrobial peptides]], which have shown promise as a novel drug to combat [[Gram-negative bacteria]].

The Arenicin family consists of three different subjects, each distinct in their structure: Arenicin-1, Arenicin-2, and the most recently discovered, Arencin-3. Arenicin-1 and Arenicin-2 were identified by a Russian research group in 2004, while Arenicin-3 was discovered by a Danish biopharmaceutical company called Adenium Biotech, which once operated within Novozymes A/S.&lt;ref name=&quot;adeniumbiotech&quot;&gt;Neve, S., Raventós, D., et al. [http://adeniumbiotech.com/wp-content/uploads/2011/10/Arenicin-2010-HTS-final2_CAH.pdf &quot;NZ17074 : An Arenicin-3 variant found by HTS screening of yeast libraries&quot;]. Novozymes A/S. Copenhagen: Adenium Biotech, Web. 21 Nov. 2012.&lt;/ref&gt;

Given the growing acquisition of [[multidrug resistance]] among bacterial [[pathogens]], particularly in Gram-negative bacteria, the development of Arenicin as a novel drug treatment has been under way. Arenicin-3 has been of particular interest in the fight against urinary tract infections caused by [[E. coli]] strains. It is also being developed with the intention of treating hospital acquired infections. In both applications, there are two proposed modes of action by which Arenicin-3 interacts with the bacteria.&lt;ref name=&quot;google&quot;&gt;Adenium Biotech Aps. EP2509617A1, 2012, [http://www.google.com/patents/EP2509617A1?cl=en &quot;Arenicin-3 for use in the treatment of urinary tract infections&quot;]&lt;/ref&gt;

Adenium Biotech currently remains in the [[preclinical]] testing period of their product, Arenicin-3. [[Toxicology]], drug efficacy, and other information have yet to be determined with further research completed in clinical settings. However, with Gram-negative bacteria causing 65% of hospital-acquired infections, the commercial market for Arenicin is large.&lt;ref&gt;[http://adeniumbiotech.com/wp-content/uploads/2011/11/Corporate-presentation2.pdf &quot;Adenium Biotech&quot;]. Novozymes A/S. Copenhagen: Adenium Biotech, Web. 21 Nov. 2012.&lt;/ref&gt;

==Background (Discovery and Development)==
The drug Arenicin was discovered by the company Adenium Biotech, which spun off from [[Novozymes]] A/S in 2011 and was given funding support from NovoSeeds and Sunstone Life Science Ventures Fund III.&lt;ref&gt;[http://adeniumbiotech.com/ &quot;Adenium Biotech&quot;]. Novozymes A/S. Copenhagen: Adenium Biotech, Web. 29, Nov. 2012.&lt;/ref&gt;  The compound was initially found in secretions from the [[lugworm]], and is part of its defense against invasive bacteria.&lt;ref&gt;[http://adeniumbiotech.com/arencin &quot;Arenecin&quot;]. Novozymes A/S. Copenhagen: Adenium Biotech, Web. 29, Nov. 2012.&lt;/ref&gt;  Adenium Biotech currently holds patents for Arenicin’s use against [[urinary tract infections]].&lt;ref name=&quot;google&quot; /&gt;  Arenicin is currently in the pre-clinical trial development phase.

==Structure==
Arenicin-1 is composed of 21 [[amino acids]] with a [[beta hairpin]] structure. It contains one [[disulfide bond]] connecting Cys3 and Cys20, which forms its unique 18 amino acid ring.&lt;ref&gt;Lee, Ju-Un, Dong-Il Kang, et al. [http://www.ncbi.nlm.nih.gov/pubmed/17285588 &quot;Solution Structures and Biological Functions of the Antimicrobial Peptide, Arenicin-1, and Its Linear Derivative&quot;]. Peptide Science 88.2 (2007): 208-16. 6 Feb. 2007. Web. 21 Nov. 2012.&lt;/ref&gt;

Arenicin-2 is a 21 amino acid peptide with a beta hairpin structure in aqueous solution. It has one disulfide bond and nine [[hydrogen bonds]], giving it a stable structure.&lt;ref&gt;Ovchnnikova, Tatiana V., Zakhard O. Shankarev, et al. [http://bingprimo.hosted.exlibrisgroup.com &quot;Recombinant Expression, Synthesis, Purification, and Solution Structure of Arenicin&quot;]. Biochemical and Biophysical Research Communications 360.1 (2007): 156-62. Web. 21 Nov. 2012.&lt;/ref&gt;

Arenicin-3 is a 21 amino acid peptide with the sequence GFCWYVCYRNGVRVCYRRCN. It has two disulfide bonds bridging between Cys2, Cys20 and Cys7, Cys16. In aqueous solution Arenicin-3 takes on a beta hairpin structure.  Due to the 4 positive arginines along with nine hydrophobic amino acids, Arenicin-3 is [[amphipathic]].&lt;ref name=&quot;adeniumbiotech&quot; /&gt;

==Mode of Action==
There are currently two proposed [[mode of action]]s, but the exact mechanism is still under active research.

Cationic residues on Arenicin-3 interacts with positively charged [[lipopolysaccharides]] on the outer membrane of Gram-negative bacteria.&lt;ref&gt;Nielsen, A.K., D. Sandvang, et al. [http://adeniumbiotech.com/wp-content/uploads/2011/10/Ppt0000032_CAH.pdf &quot;Transcriptional profiling indicates a dual mode-of-action of Arenicin-3&quot;]. Novozymes A/S. Copenhagen: Adenium Biotech, Web. 21 Nov. 2012.&lt;/ref&gt;  Peptides that were translocated across the outer membrane create pores in the cytoplasmic membrane, thereby disrupting the osmotic balance of the cell. Studies showing the influx of TRITC and efflux of [[Adenosine triphosphate|ATP]] supports this hypothesis.  In addition, Arenicin-3 does not seem to induce [[cell lysis]], which is important in the avoidance of sepsis during infection.&lt;ref name=&quot;Nielsen&quot;&gt;Nielsen.&lt;/ref&gt;

Peptides that were translocated into the cell membrane then exert a secondary effect by inhibiting protein synthesis. It is hypothesized this mode of action is similar to that of Tachyplesin I, which binds to the minor groove of [[DNA]].&lt;ref name=&quot;Nielsen&quot; /&gt;&lt;ref&gt;Yonezawa et al., Biochemistry vol 31, 2998–3004, 1992.&lt;/ref&gt;

The [[bactericidal]] properties of Arenicin-3 are responsible for its efficacy in inducing a 3-log reduction of E. coli bacterial load within 4 hours in a [[murine]] peritonitis model.&lt;ref&gt;andvang, D., Neve, S., et al. [http://adeniumbiotech.com/wp-content/uploads/2011/10/F1_2073.pdf &quot;NZ17074 - Pharmacokinetic and efficacy in mice&quot;]. Novozymes A/S. Copenhagen: Adenium Biotech, Web. 21 Nov. 2012.&lt;/ref&gt;  Further experiments showed no significant inoculum effect on Arenicin-3 in an E.coli survival curve experiment, improving the potential for the compound to be developed into a useful therapeutic.&lt;ref&gt;Sandvang, D., Markvardsen, et al. [http://adeniumbiotech.com/wp-content/uploads/2011/10/F1_2071.pdf “NZ17074 - A Novel antimicrobial peptide showing potent in vitro activity against gram negative multi-resistant clinical isolates”]. Novozymes A/S. Copenhagen: Adenium Biotech, Web. 20 Nov. 2012.&lt;/ref&gt;

The Adenium company reports that the Arenicin-3 compound has a 10-11 spontaneous mutation frequency, a measure of the chances that bacteria can evolve a resistance mechanism to the compound.  Bacterial resistance to Arenicin-3 is thus less likely to occur than resistance to other antibiotics as current antibiotics on the market report a spontaneous [[mutation]] frequency of 10-5.&lt;ref&gt;Dr. Peter Nordkild, CEO Adenium Biotech.&lt;/ref&gt;

==Uses==
The Arenicin family has shown to have bactericidal effects on a broad range of multi-drug resistant Gram-negative and Gram-positive bacteria in both [[in vitro]] and [[in vivo]] studies.&lt;ref&gt;Ovchinnikova el al., FEBS Letters, Vol. 577 (1-2), 209-214, 2004.&lt;/ref&gt;   Arenicin-3 is currently being developed as an antibiotic for hospital-acquired infections caused by Gram-negative bacteria.  Hospital-acquired infections are being targeted due to their susceptibility to multi-drug resistance.  In particular, Arenicin-3 is being tested for [[hospital-acquired pneumonia]] and hospital-acquired urinary tract infections.

==References==
{{reflist}}

&lt;!-- This will add a notice to the bottom of the page and won't blank it! The new template which says that your draft is waiting for a review will appear at the bottom; simply ignore the old (grey) drafted templates and the old (red) decline templates. A bot will update your article submission. Until then, please don't change anything in this text box and press &quot;Save page&quot;. --&gt;

&lt;!-- This will add a notice to the bottom of the page and won't blank it! The new template which says that your draft is waiting for a review will appear at the bottom; simply ignore the old (grey) drafted templates and the old (red) decline templates. A bot will update your article submission. Until then, please don't change anything in this text box and press &quot;Save page&quot;. --&gt;

[[Category:Antibiotics]]</text>
      <sha1>i6gsojebt1ubd6grw9pwzg234k4wai4</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Fosfomycin/tobramycin</title>
    <ns>0</ns>
    <id>34157114</id>
    <revision>
      <id>527941756</id>
      <parentid>500980203</parentid>
      <timestamp>2012-12-14T00:38:56Z</timestamp>
      <contributor>
        <username>BG19bot</username>
        <id>14508071</id>
      </contributor>
      <comment>/* References */[[WP:CHECKWIKI]] error fix for #64.  Do [[Wikipedia:GENFIXES|general fixes]] if a problem exists using [[Project:AWB|AWB]] (8805)</comment>
      <text xml:space="preserve" bytes="2962">{{Drugbox
| type              = combo
| drug_name         = Inhaled Fosfomycin/tobramycin (FTI)
| component1        = Fosfomycin
| class1            = [[Phosphonic acid]]
| component2        = Tobramycin
| class2            = [[Aminoglycoside]]
| component3        = &lt;!-- Drugname, automatically linked --&gt;
| class3            = &lt;!-- Group, manual link using [[..|..]] --&gt;
| component4        = &lt;!-- Drugname, automatically linked --&gt;
| class4            = &lt;!-- Group, manual link using [[..|..]] --&gt;

&lt;!--Clinical data--&gt;
| tradename         = 
| Drugs.com         = 
| MedlinePlus       = 
| licence_EU        = &lt;!-- EMA requires brand name --&gt;
| licence_US        = &lt;!-- FDA may use generic name --&gt;
| DailyMedID        = &lt;!-- preference to licence_US --&gt;
| pregnancy_AU      = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US      = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category= 
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --&gt;
| legal_US = &lt;!-- OTC / Rx-only / Schedule I, II, III, IV, V --&gt;
| legal_status      = 
| dependency_liability = 
| routes_of_administration = 

&lt;!--Identifiers--&gt;
| CAS_number        = 
| CAS_supplemental  = 
| ATCvet            = 
| ATC_prefix        = &lt;!-- 'none' if uncategorised --&gt;
| ATC_suffix        = 
| ATC_supplemental  = 
| PubChem           = 
| PubChemSubstance  = 
| IUPHAR_ligand     = 
| DrugBank          = 
| ChemSpiderID      = 
| UNII              = 
| KEGG              = 
| ChEBI             = 
| ChEMBL            = 
| synonyms          = 
}}
'''Fosfomycin/tobramycin''' is a formulation of [[fosfomycin]] and [[tobramycin]].  [[Fosfomycin]] is a phosphonic acid antibiotic active against gram-positive, gram-negative, and anaerobic bacteria. [[Tobramycin]] is an aminoglycoside with gram-negative activity.  It is an inhaled medication targeting those with [[cystic fibrosis]] and is currently being studied by [[Gilead Sciences]] the United States [[Food and Drug Administration]] and the [[NIH]] General Clinical Research Center.&lt;ref name=&quot;pmid22095545&quot;&gt;{{cite journal| author=Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M et al.| title=Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients with Pseudomonas Airway Infection. | journal=Am J Respir Crit Care Med | year= 2011 | volume=  185| issue=  2| pages=  171–8| pmid=22095545 | doi=10.1164/rccm.201105-0924OC | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=22095545  }}&lt;/ref&gt;

== See also ==
* [[Cystic fibrosis]]

== References ==
&lt;references/&gt;

{{DEFAULTSORT:Fosfomycin tobramycin}}
[[Category:Aminoglycoside antibiotics]]
[[Category:Antibiotics]]
[[Category:Phosphonic acids]]
[[Category:Epoxides]]</text>
      <sha1>l4gsivwlgrp2urqvgpgsvyvdajj6kgn</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Kanamycin</title>
    <ns>0</ns>
    <id>2342749</id>
    <revision>
      <id>600124423</id>
      <parentid>600124420</parentid>
      <timestamp>2014-03-18T07:34:19Z</timestamp>
      <contributor>
        <username>ClueBot NG</username>
        <id>13286072</id>
      </contributor>
      <minor/>
      <comment>Reverting possible vandalism by [[Special:Contributions/Ukusaukes|Ukusaukes]] to version by A2-33. False positive? [[User:ClueBot NG/FalsePositives|Report it]]. Thanks, [[User:ClueBot NG|ClueBot NG]]. (1750461) (Bot)</comment>
      <text xml:space="preserve" bytes="6590">{{Distinguish|kanamycin B}}
{{Drugbox
| verifiedrevid = 461938453
| IUPAC_name = 2-(aminomethyl)- 6-[4,6-diamino-3- [4-amino-3,5-dihydroxy-6-(hydroxymethyl) tetrahydropyran-2-yl]oxy- 2-hydroxy- cyclohexoxy]- tetrahydropyran- 3,4,5-triol
| image = Kanamycin A.svg
| image2 = Kanamycin ball-and-stick.png

&lt;!--Clinical data--&gt;
| tradename =  
| Drugs.com = {{drugs.com|monograph|kanamycin-sulfate}}
| pregnancy_category = D
| legal_status = ?
| routes_of_administration = Oral, [[Intravenous therapy|intravenous]], [[Intramuscular injection|intramuscular]]

&lt;!--Pharmacokinetic data--&gt;
| bioavailability = very low after oral delivery
| metabolism = Unknown
| elimination_half-life = 2 hours 30 minutes
| excretion = Urine (as unchanged drug)

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 59-01-8
| ATC_prefix = A07
| ATC_suffix = AA08
| ATC_supplemental = {{ATC|J01|GB04}} {{ATC|S01|AA24}}
| PubChem = 6032
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB01172
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5810
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = RUC37XUP2P
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 17630
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1384
| PDB_ligand = KAN

&lt;!--Chemical data--&gt;
| C=18 | H=36 | N=4 | O=11
| molecular_weight = 484.499
| smiles = O([C@@H]2[C@@H](O)[C@H](O[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O)[C@@H](N)C[C@H]2N)[C@H]3O[C@@H]([C@@H](O)[C@H](N)[C@H]3O)CO
| InChI = 1/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1
| InChIKey = SBUJHOSQTJFQJX-NOAMYHISBU
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SBUJHOSQTJFQJX-NOAMYHISSA-N
}}
'''Kanamycin''' (also known as '''kanamycin A''') is an [[aminoglycoside]] [[bacteriocidal]] [[antibiotic]], available in [[Wiktionary:oral|oral]], [[intravenous]], and intramuscular forms, and used to treat a wide variety of [[infection]]s. Kanamycin is isolated from the bacterium ''[[Streptomyces kanamyceticus]]''&lt;ref&gt;Garrod, L.P., et al.: &quot;Antibiotic and Chemotherapy&quot;, page 131. Churchill Livingstone, 1981&lt;/ref&gt; and its most commonly used form is kanamycin [[sulfate]].

==Mechanism==

Kanamycin interacts with the [[30S]] subunit of [[prokaryotic]] [[ribosomes]]. It induces substantial amounts of mistranslation and indirectly inhibits translocation during [[protein synthesis]].&lt;ref&gt;Pestka, S.: &quot;The Use of Inhibitors in Studies on Protein Synthesis&quot;, Methods in Enzymology 30, pp.261-282, 1975&lt;/ref&gt;&lt;ref&gt;Misumi, M. &amp; Tanaka, N.: &quot;Mechanism of Inhibition of Translocation by Kanamycin and Viomycin: A Comparative Study with Fusidic Acid, Biochem.Biophys.Res.Commun. 92, pp.647-654, 1980&lt;/ref&gt;

==Side effects==

Serious [[adverse effect (medicine)|side effect]]s include tinnitus or loss of hearing, [[toxicity to kidneys]], and [[allergic]] reactions to the [[medication|drug]].&lt;ref&gt;{{Citation | title = Consumer Drug Information: Kanamycin | date = 2 April 2008 | url = http://www.drugs.com/cdi/kanamycin.html | accessdate = 2008-05-04}}&lt;/ref&gt;

==Use in research: kanamycin resistance==

Kanamycin is used in molecular biology as a selective agent most commonly to isolate [[bacteria]] (e.g., ''[[E. coli]]'') which have taken up genes (e.g., of [[plasmid]]s) coupled to a gene coding for '''kanamycin resistance''' (primarily Neomycin phosphotransferase II ['''NPT II'''/'''Neo''']). Bacteria that have been [[Transformation (genetics)|transformed]] with a plasmid containing the kanamycin resistance gene are plated on kanamycin (50-100&amp;nbsp;ug/ml) containing [[agar]] plates or are grown in media containing kanamycin (50-100&amp;nbsp;ug/ml). Only the bacteria that have successfully taken up the kanamycin resistance gene become resistant and will grow under these conditions. As a powder kanamycin is white to off-white and is soluble in water (50&amp;nbsp;mg/ml).

At least one such gene, ''Atwbc19''&lt;ref&gt;{{cite web|url=http://www.isb.vt.edu/articles/oct0501.htm |title=Horizontal Gene Transfer: Plant vs. Bacterial Genes for Antibiotic Resistance Scenario's—What's the Difference? |publisher=Isb.vt.edu |date= |accessdate=2013-06-24}}&lt;/ref&gt; is native to a plant species, of comparatively large size and its coded protein acts in a manner which decreases the possibility of [[horizontal gene transfer]] from the plant to bacteria; it may be incapable of giving resistance to bacteria even if gene transfer occurs.

==The KanMX marker==
The selection marker kanMX is a hybrid gene consisting of a bacterial aminoglycoside phosphotransferase (kan&lt;sup&gt;r&lt;/sup&gt; from [[transposon]] Tn903) under control of the strong TEF [[Promoter (genetics)|promoter]] from ''[[Ashbya gossypii]]''.&lt;ref name=&quot;Wach1994&quot;&gt;{{Cite pmid| 7747518}}&lt;/ref&gt;&lt;ref name=&quot;Steiner1994&quot;&gt;{{Cite pmid| 8107673}}&lt;/ref&gt;

Mammalian cells, yeast, and other [[eukaryote]]s acquire resistance to geneticin (= [[Geneticin|G418]], an  aminoglycoside antibiotic similar to kanamycin) when transformed with a kanMX marker. In yeast, the kanMX marker avoids the requirement of [[Auxotrophy|auxotrophic]] markers. In addition, the kanMX marker renders ''E. coli'' resistant to kanamycin. In [[shuttle vector]]s the KanMX [[Gene cassette|cassette]] is used with an additional bacterial promoter. Several versions of the kanMX cassette are in use, e.g. kanMX1-kanMX6. They primarily differ by additional restriction sites and other small changes around the actual [[open reading frame]].&lt;ref name=&quot;Wach1994&quot; /&gt;&lt;ref name=&quot;Wach1996&quot;&gt;{{Cite pmid| 8904338}}&lt;/ref&gt;

==References==
{{reflist}}

== External links ==
*From kanamycin-evopure.com: 
** [http://www.kanamycin-evopure.com/Technical.html Technical Information]
** [http://www.kanamycin-evopure.com/product.html Purity Survey]
** [http://www.kanamycin-evopure.com/Technical.html Toxicity Data]
** [http://www.kanamycin-evopure.com/Working.html Working Concentrations]
** [http://www.kanamycin-evopure.com/Kanamycin.html  Kanamycin Impurities]

{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}}
{{AminoglycosideAntiBiotics}}

[[Category:Antibiotics]]
[[Category:Aminoglycoside antibiotics]]
[[Category:World Health Organization essential medicines]]</text>
      <sha1>fd0apdu4098qsuylqb9599y6k22mcdb</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Trimethoprim/polymyxin</title>
    <ns>0</ns>
    <id>30511879</id>
    <revision>
      <id>535477349</id>
      <parentid>451604004</parentid>
      <timestamp>2013-01-29T07:11:23Z</timestamp>
      <contributor>
        <username>Yobot</username>
        <id>7328338</id>
      </contributor>
      <minor/>
      <comment>clean up / fixed sortkey (checkwiki error #37 and #6) using [[Project:AWB|AWB]] (8872)</comment>
      <text xml:space="preserve" bytes="1626">{{Unreferenced|date=February 2011}}

{{Drugbox
| verifiedrevid = 451334370

&lt;!--Combo data--&gt;
| type = combo
| component1 = Trimethoprim
| class1 = [[Nucleic acid inhibitor]] [[antibiotic]]
| component2 = Polymyxin
| class2 = [[Cell envelope antibiotic]]

&lt;!--Clinical data--&gt;
| tradename =  
| licence_EU = &lt;!-- EMEA requires brand name --&gt;
| licence_US =  
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US =  
| pregnancy_category =  
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, or Class A, B, C --&gt;
| legal_US =  
| legal_status =  
| dependency_liability =  
| routes_of_administration = [[Eye drop]]s

&lt;!--Identifiers--&gt;
| ATC_prefix = S01
| ATC_suffix = AA30
| PubChem = 24848162
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG =  

&lt;!--Chemical data--&gt;
}}
The [[pharmaceutical drug|drug]] combination '''[[trimethoprim]]/[[polymyxin]]''' ([[International Nonproprietary Name|INNs]], trade name '''Polytrim''') is an [[antimicrobial]] solution for topical [[Eye drop|ophthalmic]] use in the treatment of [[Acute (medicine)|acute]] [[bacterial]] [[conjunctivitis]] and [[Blepharoconjunctivitis#By extent of involvement|blepharoconjunctivitis]].

{{DEFAULTSORT:Trimethoprim polymyxin}}
[[Category:Combination drugs]]
[[Category:Antibiotics]]
[[Category:Dihydrofolate reductase inhibitors]]
[[Category:Pyrimidines]]
[[Category:Phenol ethers]]
[[Category:Polymyxin antibiotics]]
[[Category:Antimicrobial peptides]]


{{pharma-stub}}</text>
      <sha1>gnbl3g28ae258jokg61z6rkdphbon7s</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Tobramycin/dexamethasone</title>
    <ns>0</ns>
    <id>14442271</id>
    <revision>
      <id>578514530</id>
      <parentid>578513823</parentid>
      <timestamp>2013-10-24T06:56:50Z</timestamp>
      <contributor>
        <username>Faroug shiyab</username>
        <id>17841301</id>
      </contributor>
      <text xml:space="preserve" bytes="4421">{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 477865033

&lt;!--Combo data--&gt;
| type = combo
| component1 = Tobramycin
| class1 = [[Aminoglycoside antibiotic]]
| component2 = Dexamethasone
| class2 = [[Glucocorticoid]]

&lt;!--Clinical data--&gt;
| tradename =  
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = C
| pregnancy_category =  
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, or Class A, B, C --&gt;
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = [[Eye drops|Ophthalmic]]

&lt;!--Identifiers--&gt;
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 32986-56-4
| ATCvet =  
| ATC_prefix = S01
| ATC_suffix = CA01
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 10123949
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C22H29FO5.C18H37N5O9/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24;19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3;5-18,24-28H,1-4,19-23H2/t12-,15+,16+,17+,19+,20+,21+,22+;5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m10/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = DWLNMMCXGSKYEM-VQHMUFKESA-N
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1747
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 28864
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D00063
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00684
}}
'''Tobramycin/dexamethasone''' ([[International Nonproprietary Name|INNs]], trade name '''Tobradex''', '''Tobrason''' in Jordan&lt;ref&gt;http://www.jfda.jo/&lt;/ref&gt;) is a [[prescription medication]] in the form of [[eye drops]] and eye [[ointment]], marketed by [[Alcon]]. The active ingredients are [[tobramycin]] 0.3% (an [[antibiotic]]) and [[dexamethasone]] 0.1% (a [[corticosteroid]]). It is prescribed for a wide spectrum of bacterial [[human eye|eye]] infections. Tobradex can also be used to clear or contract [[stye]]s that are also found in the eye. It is prescribed for the treatment of [[conjunctivitis|pink eye]] in combination with bacterial infections. Because it contains a steroid, careful use with gradual reduction of doses is required.

== Contraindications ==
It is strongly contraindicated with [[Herpetic infection|herpetic]] and other [[viral infection|viral]] eye infections. Other contraindications include [[Mycosis|fungal]] and [[mycobacteria]]l infections because tobramycin is inactive against those, and the corticoid acts as an [[immunosuppressive]] agent, preventing the body's immune system from dealing with the infection. The drops are also contraindicated in patients with [[cornea]]l lesions.&lt;ref name=&quot;AustriaCodex&quot;&gt;{{cite book|title=Austria-Codex|editor=Haberfeld, H|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2009|edition=2009/2010|isbn=3-85200-196-X|language=German}}&lt;/ref&gt;&lt;ref&gt;[http://ecatalog.alcon.com/pi/TobraDexSusp_us_en.pdf Tobradex Prescribing Information]. Alcon.&lt;/ref&gt;

== Side effects ==
Similarly to other corticosteroid eye drops, [[side effect]]s include [[hypersensitivity]] and, especially after long-term use, secondary eye infections, [[cataract]] (clouding of the eye lens) and increased [[intraocular pressure]], leading to [[glaucoma]]. Consequently, the drug should not be applied longer than 24 days.&lt;ref name=&quot;AustriaCodex&quot;/&gt;&lt;ref name=&quot;ÖAZ&quot;&gt;{{cite journal
 | author = Ch. Faschinger
 | date = 3 January 2011
 | journal = Österreichische Apothekerzeitung
 | issue = 1/2011
 | pages = 13
 | language = German
 }}&lt;/ref&gt;&lt;ref name=&quot;Arzneistoff-Profile&quot;&gt;{{cite book|title=Arzneistoff-Profile|editor=Dinnendahl, V, Fricke, U|publisher=Govi Pharmazeutischer Verlag|location=Eschborn, Germany|year=2010|edition=23|volume=2|isbn=978-3-7741-9846-3|language=German}}&lt;/ref&gt;

==Interactions==
[[Anticholinergic]] eye drops potentiate the risk of increased intraocular pressure. Systemic [[aminoglycoside antibiotic]]s increase toxicity for ears, nerves and kidney.&lt;ref name=&quot;AustriaCodex&quot; /&gt;

==References==
{{reflist}}

{{AminoglycosideAntiBiotics}}
{{Corticosteroids}}

{{DEFAULTSORT:Tobramycin dexamethasone}}
[[Category:Antibiotics]]
[[Category:Glucocorticoids]]
[[Category:Combination drugs]]</text>
      <sha1>5eyhh8ca7wm5sfa79xzoy7uchnsfcax</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Acetic acid/hydrocortisone</title>
    <ns>0</ns>
    <id>10391074</id>
    <revision>
      <id>587555308</id>
      <parentid>535534937</parentid>
      <timestamp>2013-12-24T20:29:08Z</timestamp>
      <contributor>
        <username>Anypodetos</username>
        <id>7442243</id>
      </contributor>
      <comment>Drugbox additions, [[Category:Combination drugs]]</comment>
      <text xml:space="preserve" bytes="1429">{{Drugbox
| verifiedrevid = 432350644

&lt;!--Combo data--&gt;
| type = combo
| component1 = Acetic acid
| class1 = [[Antibacterial]], [[Antifungal medication|antifungal]]
| component2 = Hydrocortisone
| class2 = [[Anti-inflammatory]]

&lt;!--Clinical data--&gt;
| tradename = Acetasol
| Drugs.com = {{Drugs.com|MTM|acetasol-otic}}
| pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US = 
| pregnancy_category = N
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --&gt;
| legal_US = Rx-only
| legal_status = 
| routes_of_administration = Ear drops

&lt;!--Identifiers--&gt;
| CAS_number = 
| ATCvet = 
| ATC_prefix = S02
| ATC_suffix = CA03
| PubChem = 
| DrugBank = 

&lt;!--Chemical data--&gt;
}}

'''Acetic acid/hydrocortisone''' is a commonly used to treat infections of the [[outer ear]] and [[ear canal]]. Branded as '''Vosol''' and '''Acetasol''', it combines the [[Antiseptic|antibacterial]] and [[Antifungal medication|antifungal]] action of [[acetic acid]] with the [[anti-inflammatory]] functions of [[hydrocortisone]].

== References ==
*[http://www.acetasol.com/ Acetasol Website]

{{DEFAULTSORT:Acetic acid hydrocortisone}}
[[Category:Antibiotics]]
[[Category:Antifungals]]
[[Category:Combination drugs]]


{{pharm-stub}}</text>
      <sha1>0ot5kn423odaxdhkk3q506dvb44m8x2</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Novobiocin</title>
    <ns>0</ns>
    <id>2952018</id>
    <revision>
      <id>599696876</id>
      <parentid>592674285</parentid>
      <timestamp>2014-03-15T08:59:27Z</timestamp>
      <contributor>
        <username>Fuse809</username>
        <id>15929465</id>
      </contributor>
      <comment>PNG-&gt;SVG.</comment>
      <text xml:space="preserve" bytes="17235">{{distinguish2|the [[siderophore]] antibiotic [[albomycin]] ({{PubChem|3083716}})}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 462263512
| IUPAC_name = 4-Hydroxy-3-[4-hydroxy-3-(3-methylbut-2-enyl)benzamido]-8-methylcoumarin-7-yl 3-''O''-carbamoyl-5,5-di-C-methyl-α-l-lyxofuranoside
| image = Novobiocin2DCSD.svg
| width = 350px

&lt;!--Clinical data--&gt;
| tradename =  
| Drugs.com = {{drugs.com|international|novobiocin}}
| pregnancy_category = 
| legal_status = 
| routes_of_administration = intravenous

&lt;!--Pharmacokinetic data--&gt;
| bioavailability = negligible oral bioavailability
| metabolism = excreted unchanged
| elimination_half-life = 6 hours
| excretion = renal

&lt;!--Identifiers--&gt;
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 303-81-1
| ATCvet = yes
| ATC_prefix = J01
| ATC_suffix = XX95
| PubChem = 9346
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB01051
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10226117
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 17EC19951N
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = C05080
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 36506

&lt;!--Chemical data--&gt;
| C=31 | H=36 | N=2 | O=11 
| molecular_weight = 612.624
| smiles = C[C@@]4(C)O[C@@H](Oc3ccc2C(\O)=C(\NC(=O)c1ccc(O)c(C\C=C(/C)C)c1)C(=O)Oc2c3C)[C@H](O)[C@H](OC(N)=O)[C@H]4OC
| InChI = 1/C31H36N2O11/c1-14(2)7-8-16-13-17(9-11-19(16)34)27(37)33-21-22(35)18-10-12-20(15(3)24(18)42-28(21)38)41-29-23(36)25(43-30(32)39)26(40-6)31(4,5)44-29/h7,9-13,23,25-26,29,34-36H,8H2,1-6H3,(H2,32,39)(H,33,37)/t23-,25+,26-,29-/m1/s1
| InChIKey = YJQPYGGHQPGBLI-KGSXXDOSBH
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C31H36N2O11/c1-14(2)7-8-16-13-17(9-11-19(16)34)27(37)33-21-22(35)18-10-12-20(15(3)24(18)42-28(21)38)41-29-23(36)25(43-30(32)39)26(40-6)31(4,5)44-29/h7,9-13,23,25-26,29,34-36H,8H2,1-6H3,(H2,32,39)(H,33,37)/t23-,25+,26-,29-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YJQPYGGHQPGBLI-KGSXXDOSSA-N
}}

'''Novobiocin''', also known as '''albamycin''' or '''cathomycin''', is an [[aminocoumarin]] antibiotic that is produced by the actinomycete ''[[Streptomyces niveus]]'', which has recently been identified as a subjective synonym for ''S. spheroides''&lt;ref&gt;{{cite journal | author = Lanoot B., Vancanneyt M., Cleenwerck I., Wang L., Li W., Liu Z., Swings J. | year = 2002 | title = The search for synonyms among streptomycetes by with SDS-PAGE of whole-cell proteins. Emendation of the species Streptomyces aurantiacus, Streptomyces cacaoi subsp. cacaoi, Streptomyces caeruleus and Streptomyces violaceus | url = | journal = Int. J. Syst. Evol. Microbiol | volume = 52 | issue = Pt 3| pages = 823–829 | doi = 10.1099/ijs.0.02008-0 | pmid = 12054245 }}&lt;/ref&gt; a member of the order [[Actinobacteria]] . Other aminocoumarin antibiotics include clorobiocin and coumermycin A1.&lt;ref name=E&gt;Alessandra da Silva Eustáquio (2004) Biosynthesis of aminocoumarin antibiotics in Streptomyces: Generation of structural analogues by genetic engineering and insights into the regulation of antibiotic production. DISSERTATION
&lt;/ref&gt; Novobiocin was first reported in the mid-1950s (then called '''streptonivicin''').&lt;ref&gt;{{cite journal | author = Hoeksema H., Johnson J. L., Hinman J. W. | year = 1955 | title = Structural studies on streptonivicin, a new antibiotic | url = | journal = J Am Chem Soc | volume = 77 | issue = | pages = 6710–6711 }}&lt;/ref&gt;&lt;ref&gt;{{cite journal | author = Smith C. G., Dietz A., Sokolski W. T., Savage G. M. | year = 1956 | title = Streptonivicin, a new antibiotic. I. Discovery and biologic studies | url = | journal = Anitbiotics &amp; Chemotherapy | volume = 6 | issue = | pages = 135–142 }}&lt;/ref&gt;

==Clinical use==
It is active against ''[[Staphylococcus epidermidis]]'' and may be used to differentiate it from the other coagulase-negative ''[[Staphylococcus saprophyticus]]'', which is resistant to novobiocin, in culture.

Novobiocin was licenced for clinical use under the tradename Albamycin ([[Pharmacia]] And [[Upjohn]]) in the 1960s. Its [[efficacy#Pharmacology|efficacy]] has been demonstrated in
[[Clinical trial#Pre clinical studies|preclinical]] and [[Clinical trial|clinical]] trials.&lt;ref&gt;{{cite journal | author = Raad I., Darouiche R., Hachem R., Sacilowski M., Bodey G. P. | year = 1995 | title = Antibiotics and prevention of microbial colonization of catheters | url = | journal = Antimicrob Agents Chemother | volume = 39 | issue = 11| pages = 2397–2400 | pmid = 8585715 | pmc = 162954 }}&lt;/ref&gt;&lt;ref&gt;{{cite journal | author = Raad I. I., Hachem R. Y., Abi-Said D., Rolston K. V. I., Whimbey E., Buzaid A.C., Legha S. | year = 1998 | title = A prospective crossover randomized trial of novobiocin and rifampin prophylaxis for the prevention of intravascular catheter infections in cancer patients treated with interleukin-2 | url = | journal = Cancer | volume = 82 | issue = 2| pages = 403–411 | doi = 10.1002/(SICI)1097-0142(19980115)82:2&lt;412::AID-CNCR22&gt;3.0.CO;2-0 | pmid = 9445199 }}&lt;/ref&gt; It has since been withdrawn from the market.&lt;ref&gt;[https://www.federalregister.gov/articles/2011/01/19/2011-1000/determination-that-albamycin-novobiocin-sodium-capsule-250-milligrams-was-withdrawn-from-sale-for&lt;/ref&gt; Novobiocin is effective [[Staphylococcus|antistaphylococcal]] agent used in the treatment of [[Methicillin-resistant Staphylococcus aureus|MRSA]].&lt;ref&gt;{{cite journal | author = Walsh T.J. ''et al.'' | year = 1993 | title = Randomized Double-Blinded Trial of Rifampin with Either Novobiocin or Trimethoprim-Sulfamethoxazole against Methicillin-Resistant Staphylococcus aureus Colonization: Prevention of Antimicrobial Resistance and Effect of Host Factors on Outcome | url = | journal = Antimicrobial agents and chemotherapy | volume = 37 | issue = 6| pages = 1334–1342 | pmid = 8328783 | pmc = 187962 }}&lt;/ref&gt;

== Mechanism of action ==
The molecular basis of action of '''novobiocin''', and other related drugs clorobiocin and coumermycin A1 has been examined.&lt;ref name=E/&gt;&lt;ref name=M&gt;{{cite journal | author = Maxwell A | year = 1993 | title = The interaction between coumarin drugs and DNA gyrase | url = | journal = Mol Microbiol | volume = 9 | issue = 4| pages = 681–686 | doi = 10.1111/j.1365-2958.1993.tb01728.x | pmid = 8231802 }}&lt;/ref&gt;&lt;ref&gt;{{cite journal | author = Maxwell A | year = 1999 | title = DNA gyrase as a drug target | url = | journal = Biochem Soc Trans | volume = 27 | issue = 2| pages = 48–53 | pmid = 10093705 }}&lt;/ref&gt;&lt;ref&gt;{{cite journal | author = Lewis R. J., Tsai F. T. F., Wigley D. B. | year = 1996 | title = Molecular mechanisms of drug inhibition of DNA gyrase | url = | journal = Bioessays | volume = 18 | issue = 8| pages = 661–671 | doi = 10.1002/bies.950180810 | pmid = 8760340 }}&lt;/ref&gt;&lt;ref&gt;{{cite journal | author = Maxwell A., Lawson D. M. | year = 2003 | title = The ATP-binding site of type II topoisomerases as a target for antibacterial drugs | url = | journal = Curr Top Med Chem | volume = 3 | issue = 3| pages = 283–303 | doi = 10.2174/1568026033452500 | pmid = 12570764 }}&lt;/ref&gt; Aminocoumarins are very [[potency (pharmacology)|potent]] inhibitors of bacterial DNA gyrase and work by targeting the GyrB subunit of the enzyme involved in energy transduction. Novobiocin as well as the other [[aminocoumarin]] [[antibiotic]]s act as competitive inhibitors of the [[ATPase]] reaction catalysed by GyrB. The potency of novobiocin is considerably higher than that of the [[fluoroquinolone]]s that also target [[DNA gyrase]], but at a different site on the enzyme. The GyrA subunit is involved in the DNA nicking and ligation activity.

==Structure==
Novobiocin is an aminocoumarin. Novobiocin may be divided up into three entities; a benzoic acid derivative, a coumarin residue, and the sugar novobiose.&lt;ref name=M/&gt; [[X-ray crystallography|X-ray crystallographic studies]] have found that the drug-receptor complex of Novobiocin and DNA Gyrase shows that ATP and Novobiocin have overlapping binding sites on the gyrase molecule.&lt;ref&gt;F.T.F. Tsai, O.M. Singh, T.Skarzynski, A.J. Wonacott, S. Weston, A. Tucker, R.A. Pauptit, A.L. Breeze, J.P. Poyser, R. O'Brien et al., The high-resolution crystal structure of a 24-kDa gyrase B fragment from E. coli complexed with one of the most potent coumarin inhibitors, clorobiocin. ''Proteins'' 28 (1997), pp. 41–52 
&lt;/ref&gt; The overlap of the coumarin and ATP-binding sites is consistent with aminocoumarins being competitive inhibitors of the ATPase activity.&lt;ref name=Flatman2006&gt;{{cite journal | author = Flatman R.H., Eustaquio A., Li S., Heide L., Maxwell A. | year = 2006 | title = Structure-Activity Relationships of Aminocoumarin-Type Gyrase and Topoisomerase IV Inhibitors Obtained by Combinatorial Biosynthesis | url = | journal = Antimicrob Agents Chemother | volume = 50 | issue = 4| pages = 1136–1142 | doi = 10.1128/AAC.50.4.1136-1142.2006 | pmid = 16569821 | pmc = 1426943 }}&lt;/ref&gt;

===Structure–activity relationship===
In [[Structure-activity relationship|structure activity relationship]] experiments it was found that removal of the [[carbamoyl|carbamoyl group]] located on the novobiose sugar lead to a dramatic decrease in inhibitory activity of novobiocin.&lt;ref name=Flatman2006/&gt;

==Biosynthesis==
This [[aminocoumarin]] antibiotic consists of three major substituents. The 3-dimethylallyl-4-hydroxybenzoic acid moiety, known as ring A, is derived from [[prephenate]] and [[dimethylallyl pyrophosphate]]. The aminocoumarin moiety, known as ring B, is derived from L-Tyrosine. The final component of novobiocin is the sugar derivative L-noviose, known as ring C, which is derived from glucose-1-phosphate. The biosynthetic gene cluster for novobiocin was identified by Heide and coworkers in 1999 (published 2000) from Streptomyces spheroides NCIB 11891.&lt;ref name=&quot;pmid10770754&quot;&gt;{{cite journal |author=Steffensky M, Mühlenweg A, Wang ZX, Li SM, Heide L |title=Identification of the novobiocin biosynthetic gene cluster of Streptomyces spheroides NCIB 11891 |journal=Antimicrob. Agents Chemother. |volume=44 |issue=5 |pages=1214–22 |date=May 2000 |pmid=10770754 |pmc=89847 |doi= 10.1128/AAC.44.5.1214-1222.2000|url=http://aac.asm.org/cgi/pmidlookup?view=long&amp;pmid=10770754}}&lt;/ref&gt; They identified 23 putative open reading frames (ORFs) and more than 11 other ORFs that may play a role in novobiocin biosynthesis.

The biosynthesis of ring A (see '''Fig. 1''') begins with prephenate which is a derived from the [[shikimic acid]] biosynthetic pathway. The enzyme NovF catalyzes the decarboxylation of [[prephenate]] while simultaneously reducing nicotinamide adenine dinucleotide phosphate (NADP&lt;sup&gt;+&lt;/sup&gt;) to produce [[NADPH]]. Following this NovQ catalyzes the electrophilic substitution of the phenyl ring with [[dimethylallyl pyrophosphate]] (DMAPP) otherwise known as prenylation.&lt;ref name=&quot;pmid12618544&quot;&gt;{{cite journal |author=Pojer F, Wemakor E, Kammerer B, ''et al.'' |title=CloQ, a prenyltransferase involved in clorobiocin biosynthesis |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=100 |issue=5 |pages=2316–21 |date=March 2003 |pmid=12618544 |pmc=151338 |doi=10.1073/pnas.0337708100 |url=http://www.pnas.org/cgi/pmidlookup?view=long&amp;pmid=12618544 |bibcode=2003PNAS..100.2316P}}&lt;/ref&gt; DMAPP can come from either the mevalonic acid pathway or the deoxyxylulose biosynthetic pathway. Next the 3-dimethylallyl-4-hydroxybenzoate molecule is subjected to two oxidative decarboxylations by NovR and molecular oxygen.&lt;ref name=&quot;pmid12777382&quot;&gt;{{cite journal |author=Pojer F, Kahlich R, Kammerer B, Li SM, Heide L |title=CloR, a bifunctional non-heme iron oxygenase involved in clorobiocin biosynthesis |journal=J. Biol. Chem. |volume=278 |issue=33 |pages=30661–8 |date=August 2003 |pmid=12777382 |doi=10.1074/jbc.M303190200 |url=http://www.jbc.org/cgi/pmidlookup?view=long&amp;pmid=12777382}}&lt;/ref&gt; NovR is a non-heme iron oxygenase with a unique bifunctional catalysis. In the first stage both oxygens are incorporated from the molecular oxygen while in the second step only one is incorporated as determined by isotope labeling studies. This completes the formation of ring A.

[[File:Novobiocin Ring A Synthesis.png|thumb|600px|center|'''Figure 1.''' Biosynthesis of 3-dimethylallyl-4-hydroxybenzoic acid component of novobiocin (ring '''A''')]]

The biosynthesis of ring B (see '''Fig. 2''') begins with the natural amino acid [[L-Tyrosine]]. This is then adenylated and thioesterified onto the peptidyl carrier protein (PCP) of NovH by [[Adenosine triphosphate|ATP]] and NovH itself.&lt;ref name=&quot;pmid11325587&quot;&gt;{{cite journal |author=Chen H, Walsh CT |title=Coumarin formation in novobiocin biosynthesis: β-hydroxylation of the aminoacyl enzyme tyrosyl-S-NovH by a cytochrome P450 NovI |journal=Chem. Biol. |volume=8 |issue=4 |pages=301–12 |date=April 2001 |pmid=11325587 |doi= 10.1016/S1074-5521(01)00009-6|url=http://linkinghub.elsevier.com/retrieve/pii/S1074-5521(01)00009-6}}&lt;/ref&gt; NovI then further modifies this PCP bound molecule by oxidizing the β-position using [[NADPH]] and molecular oxygen. NovJ and NovK form a heterodimer of J2K2 which is the active form of this benzylic oxygenase.&lt;ref name=&quot;pmid16171397&quot;&gt;{{cite journal |author=Pacholec M, Hillson NJ, Walsh CT |title=NovJ/NovK catalyze benzylic oxidation of a β-hydroxyl tyrosyl-S-pantetheinyl enzyme during aminocoumarin ring formation in novobiocin biosynthesis |journal=Biochemistry |volume=44 |issue=38 |pages=12819–26 |date=September 2005 |pmid=16171397 |doi=10.1021/bi051297m}}&lt;/ref&gt; This process uses NADP&lt;sup&gt;+&lt;/sup&gt; as a hydride acceptor in the oxidation of the β-alcohol. This ketone will prefer to exist in its enol tautomer in solution. Next a still unidentified protein catalyzes the selective oxidation of the benzene (as shown in Fig. 2). Upon oxidation this intermediate will spontaneously lactonize to form the aromatic ring B and lose NovH in the process.

[[File:Novobiocin Ring B Synthesis.png|thumb|700px|center|'''Figure 2.''' Biosynthesis of 3-amino-4,7-dihydroxy-2H-chromen-2-one component of novobiocin (ring '''B''')]]

The biosynthesis of L-noviose (ring C) is shown in '''Fig. 3'''. This process starts from glucose-1-phosphate where NovV takes dTTP and replaces the phosphate group with a dTDP group. NovT then oxidizes the 4-hydroxy group using NAD&lt;sup&gt;+&lt;/sup&gt;. NovT also accomplishes a dehydroxylation of the 6 position of the sugar. NovW then epimerizes the 3 position of the sugar.&lt;ref name=&quot;pmid15752721&quot;&gt;{{cite journal |author=Thuy TT, Lee HC, Kim CG, Heide L, Sohng JK |title=Functional characterizations of novWUS involved in novobiocin biosynthesis from Streptomyces spheroides |journal=Arch. Biochem. Biophys. |volume=436 |issue=1 |pages=161–7 |date=April 2005 |pmid=15752721 |doi=10.1016/j.abb.2005.01.012 |url=http://linkinghub.elsevier.com/retrieve/pii/S0003-9861(05)00027-5}}&lt;/ref&gt; The methylation of the 5 position is accomplished by NovU and [[S-adenosyl methionine]] (SAM). Finally NovS reduces the 4 position again to achieve epimerization of that position from the starting glucose-1-phosphate using [[NADH]].

[[File:L-Noviose Biosynthesis.png|thumb|700px|center|'''Figure 3.''' Biosynthesis of L-noviose component of novobiocin (ring '''C''')]]

Rings A, B, and C are coupled together and modified to give the finished novobiocin molecule. Rings A and B are coupled together by the enzyme NovL using [[Adenosine triphosphate|ATP]] to diphosphorylate the carboxylate group of ring A so that the carbonyl can be attacked by the amine group on ring B. The resulting compound is methylated by NovO and SAM prior to glycosylation.&lt;ref name=&quot;pmid16274243&quot;&gt;{{cite journal |author=Pacholec M, Tao J, Walsh CT |title=CouO and NovO: C-methyltransferases for tailoring the aminocoumarin scaffold in coumermycin and novobiocin antibiotic biosynthesis |journal=Biochemistry |volume=44 |issue=45 |pages=14969–76 |date=November 2005 |pmid=16274243 |doi=10.1021/bi051599o}}&lt;/ref&gt; NovM adds ring C (L-noviose) to the hydroxyl group derived from tyrosine with the loss of dTDP. Another methylation is accomplished by NovP and SAM at the 4 position of the L-noviose sugar.&lt;ref name=&quot;pmid14694473&quot;&gt;{{cite journal |author=Freel Meyers CL, Oberthür M, Xu H, Heide L, Kahne D, Walsh CT |title=Characterization of NovP and NovN: completion of novobiocin biosynthesis by sequential tailoring of the noviosyl ring |journal=Angew. Chem. Int. Ed. Engl. |volume=43 |issue=1 |pages=67–70 |date=January 2004 |pmid=14694473 |doi=10.1002/anie.200352626}}&lt;/ref&gt; This methylation allows NovN to carbamylate the 3 position of the sugar as shown in '''Fig. 4''' completing the biosynthesis of novobiocin.

[[File:Novobiocin Final Synthesis.png|thumb|700px|center|'''Figure 4.''' Completed biosynthesis of novobiocin from ring systems '''A''', '''B''', and '''C''']]

== References ==
{{reflist|colwidth=30em}}

== External links ==
* [http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=NOV Novobiocin bound to proteins] in the [[Protein Data Bank|PDB]]

{{Nucleic acid inhibitors}}

[[Category:Antibiotics]]
[[Category:Coumarin drugs]]
[[Category:Benzamides]]
[[Category:Carbamates]]</text>
      <sha1>2mt9qoktgu6dkelp5v1hapw4fjukp1g</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Calicheamicin</title>
    <ns>0</ns>
    <id>7684225</id>
    <revision>
      <id>602613450</id>
      <parentid>590846106</parentid>
      <timestamp>2014-04-03T18:20:02Z</timestamp>
      <contributor>
        <ip>171.64.120.222</ip>
      </contributor>
      <comment>/* Mechanism of toxicity */ improved wording</comment>
      <text xml:space="preserve" bytes="8224">{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 455292024
| Name = Calicheamicin k
| ImageFile = Calicheamicin.png
| ImageSize = 350px
| IUPACName = 
| SystematicName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
| Abbreviations = 
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 108212-75-5
| EINECS = 
| EINECSCASNO = 
| PubChem = 
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 27330302
|  SMILES = CCN[C@H]1CO[C@H](C[C@@H]1OC)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O[C@H]3C#C/C=C\C#C[C@]\4(CC(=O)C(=C3/C4=C\CSSSC)NC(=O)OC)O)C)NO[C@H]5C[C@@H]([C@@H]([C@H](O5)C)SC(=O)c6c(c(c(c(c6OC)OC)O[C@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)C)O)OC)O)I)C)O)O
|  InChI = 1/C55H74IN3O21S4/c1-12-57-30-24-73-35(22-34(30)68-6)78-48-43(63)40(26(3)75-53(48)77-33-17-15-13-14-16-19-55(67)23-32(61)41(58-54(66)72-10)38(33)29(55)18-20-82-84-81-11)59-80-36-21-31(60)50(28(5)74-36)83-51(65)37-25(2)39(56)46(49(71-9)45(37)69-7)79-52-44(64)47(70-8)42(62)27(4)76-52/h13-14,18,26-28,30-31,33-36,40,42-44,47-48,50,52-53,57,59-60,62-64,67H,12,20-24H2,1-11H3,(H,58,66)/b14-13-,29-18+/t26-,27+,28-,30+,31+,33+,34+,35+,36+,40-,42+,43+,44-,47-,48-,50-,52+,53+,55-/m1/s1
|  InChIKey = HXCHCVDVKSCDHU-LULTVBGHBW
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C55H74IN3O21S4/c1-12-57-30-24-73-35(22-34(30)68-6)78-48-43(63)40(26(3)75-53(48)77-33-17-15-13-14-16-19-55(67)23-32(61)41(58-54(66)72-10)38(33)29(55)18-20-82-84-81-11)59-80-36-21-31(60)50(28(5)74-36)83-51(65)37-25(2)39(56)46(49(71-9)45(37)69-7)79-52-44(64)47(70-8)42(62)27(4)76-52/h13-14,18,26-28,30-31,33-36,40,42-44,47-48,50,52-53,57,59-60,62-64,67H,12,20-24H2,1-11H3,(H,58,66)/b14-13-,29-18+/t26-,27+,28-,30+,31+,33+,34+,35+,36+,40-,42+,43+,44-,47-,48-,50-,52+,53+,55-/m1/s1
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = HXCHCVDVKSCDHU-LULTVBGHSA-N 
| RTECS = 
| MeSHName =
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI =
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = 
| ATCCode_prefix = 
| ATCCode_suffix = 
| ATC_Supplemental =}}
| Section2 = {{Chembox Properties
| C=55| H=74| I=1| N=3| O=21| S=4
| Appearance = 
| Density = 
| MeltingPt = 
| Melting_notes = 
| BoilingPt = 
| Boiling_notes = 
| Solubility = 
| SolubleOther = 
| Solvent = 
| LogP = 
| VaporPressure = 
| HenryConstant = 
| AtmosphericOHRateConstant = 
| pKa = 
| pKb = }}
| Section3 = {{Chembox Structure
| CrystalStruct = 
| Coordination = 
| MolShape = }}
| Section4 = {{Chembox Thermochemistry
| DeltaHf = 
| DeltaHc = 
| Entropy = 
| HeatCapacity = }}
| Section5 = {{Chembox Pharmacology
| AdminRoutes = 
| Bioavail = 
| Metabolism = 
| HalfLife = 
| ProteinBound =
| Excretion = 
| Legal_status = 
| Legal_US = 
| Legal_UK = 
| Legal_AU = 
| Legal_CA = 
| PregCat = 
| PregCat_AU = 
| PregCat_US = }}
| Section6 = {{Chembox Explosive
| ShockSens = 
| FrictionSens = 
| ExplosiveV = 
| REFactor = }}
| Section7 = {{Chembox Hazards
| ExternalMSDS = 
| EUClass = 
| EUIndex = 
| MainHazards = 
| NFPA-H = 
| NFPA-F = 
| NFPA-R = 
| NFPA-O = 
| RPhrases = 
| SPhrases = 
| RSPhrases = 
| FlashPt = 
| Autoignition = 
| ExploLimits = 
| LD50 =
| PEL = }}
| Section8 = {{Chembox Related
| OtherAnions = 
| OtherCations = 
| OtherFunctn = 
| Function = 
| OtherCpds = }}
}}

The '''calicheamicins''' are a class of [[enediyne]] [[antibiotic]]s derived from the bacterium ''[[Micromonospora echinospora]]'', with calicheamicin γ1 being the most notable.&lt;ref&gt;{{cite journal | author = Lee, May D.; Manning, Joann K.; Williams, David R.; Kuck, Nydia A.; Testa, Raymond T.; Borders, Donald B. | title = Calichemicins, a novel family of antitumor antibiotics. 3. Isolation, purification and characterization of calichemicins β1Br, γ1Br, α2I, α3I, β1I, γ1I, and Δ1I | journal = Journal of Antibiotics |date=July 1989 | volume = 42 | issue = 7 | pages = 1070–87 | pmid = 2753814}}&lt;/ref&gt; It was isolated originally in the mid-1980s from the chalky soil, or &quot;calichi pits&quot;, located in Kerrville, Texas.  The sample was collected by a scientist working for Lederle Labs.&lt;ref&gt;
[http://www.scripps.edu/newsandviews/e_20010226/nicolaou3.html Total Synthesis and the Creative Process: An Interview with K.C. Nicolaou], Scripps Research Institute&lt;/ref&gt;  It is extremely toxic to all cells and in the year 2000, a CD33 antigen-targeted immunoconjugate N-acetyl dimethyl hydrazide calichiamicin   was developed and marketed as [[targeted therapy]] against the non-solid tumor cancer acute myeloid leukemia (AML).&lt;ref&gt;{{cite journal | author = G.A. Ellestad | title = Structural and Conformational Features Relevant to the Anti-Tumor Activity of Calichemicin γ1I | journal = Chirality | year = 2011 | volume = 23 | pages = 660–671 }}&lt;/ref&gt;   Calicheamicin γ1 and the related enediyne [[esperamicin]] are the two of the most potent antitumor agents known.&lt;ref&gt;[http://jlstasal.myweb.uga.edu/CaliEsp.htm Calicheamicin and Esperamicin are the two most potent antitumor agents known to man], Univ Of Georgia, Chem 4500&lt;/ref&gt;

== Mechanism of toxicity ==
Calicheamicins target DNA and cause strand scission. Calicheamicins bind with DNA in the [[minor groove]], wherein they then undergo a reaction analogous to the [[Bergman cyclization]] to generate a diradical species.  This diradical, [[1,4-didehydrobenzene]], then abstracts hydrogen atoms from the deoxyribose (sugar) backbone of DNA, which ultimately leads to strand scission.&lt;ref&gt;{{cite journal | author = S. Walker; R. Landovitz; W.D. Ding; G.A. Ellestad; D. Kahne | title = Cleavage behavior of calicheamicin gamma 1 and calicheamicin T | journal = Proc Natl Acad Sci U.S.A. | year = 1992| volume = 89 | issue = 10 | pages = 4608–12 | pmc=49132 |pmid=1584797 | doi = 10.1073/pnas.89.10.4608}}&lt;/ref&gt;

==Biosynthesis==
The core metabolic pathway for biosynthesis of this molecule resembles that of other characterized enediyne compounds and occurs via a [[polyketide synthase]] pathway.&lt;ref&gt;{{cite journal| journal=Proc Natl Acad Sci U S A. |date=Jun 22, 2010| volume=107| issue=25|pages=11331–5 | title=Polyketide synthase chemistry does not direct biosynthetic divergence between 9- and 10-membered enediynes|pmid= 20534556| doi=10.1073/pnas.1003442107| last1=Horsman| first1=GP| last2=Chen| first2=Y| last3=Thorson| first3=JS| last4=Shen| first4=B| pmc=2895059}}&lt;/ref&gt; The specificity of binding of calicheamicin to the minor groove of DNA was demonstrated by Crothers et al. (1999) to be due to the aryltetrasaccharide group of the molecule.&lt;ref&gt;{{cite journal| title=Cloning and characterization of CalS7 from Micromonospora echinospora sp. calichensis as a glucose-1-phosphate nucleotidyltransferase|author=Simkhada D, Oh TJ, Kim EM, Yoo JC, Sohng JK| journal=Biotechnol Lett.|date=January 2009|volume=31|issue=1|pages=147–53 |pmid= 18807197| doi=10.1007/s10529-008-9844-9}}&lt;/ref&gt;&lt;ref&gt;{{cite journal| journal=Chem Biol.|date=Aug 25, 2008|volume=15| issue=8|pages=842–53|title=Biochemical and structural insights of the early glycosylation steps in calicheamicin biosynthesis| author=Zhang C, Bitto E, Goff RD, Singh S, Bingman CA, Griffith BR, Albermann C, Phillips GN Jr, Thorson JS|pmid= 18721755| doi=10.1016/j.chembiol.2008.06.011| pmc=2965851}}&lt;/ref&gt;

==History==
It has been proposed that [[Alexander the Great]] was poisoned by drinking the water of the river Styx ([[Mavroneri]]) which happened to be contaminated by this compound.&lt;ref&gt;{{Cite journal|journal=Telegraph | author=Nick Squires | url=http://www.telegraph.co.uk/news/worldnews/europe/greece/7924855/Alexander-the-Great-poisoned-by-the-River-Styx.html|title=Alexander the Great poisoned by the River Styx.html|date=August 4, 2010}}&lt;/ref&gt;&lt;ref&gt;{{Cite journal|journal=Discovery News|url=http://news.discovery.com/history/alexander-the-great-bacteria.html|title=Alexander the Great killed by toxic bacteria|author=Rossella Lorenzi|date=16 Jul 2010}}&lt;/ref&gt;

==See also==
* [[Monoclonal antibodies]] using calicheamicins as cytotoxic agents:
** [[Gemtuzumab ozogamicin]]
** [[Inotuzumab ozogamicin]]

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Cancer research]]
[[Category:Enediynes]]
[[Category:Polyketide antibiotics]]
[[Category:Halogen-containing natural products]]</text>
      <sha1>ote8alc3by69vhtqea93a0q6itywaw9</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Tanespimycin</title>
    <ns>0</ns>
    <id>1300614</id>
    <revision>
      <id>580508797</id>
      <parentid>580507273</parentid>
      <timestamp>2013-11-06T21:31:46Z</timestamp>
      <contributor>
        <username>Edgar181</username>
        <id>491706</id>
      </contributor>
      <comment>/* Clinical trials */ cleanup</comment>
      <text xml:space="preserve" bytes="4412">{{DISPLAYTITLE:17-''N''-Allylamino-17-demethoxygeldanamycin}}
{{chembox
| Verifiedfields = changed
| verifiedrevid = 477209222
|   Name=Tanespimycin
|   ImageFile = 17-N-Allylamino-17-demethoxygeldanamycin.svg
|   ImageSize = 200px
|   IUPACName = [(3''S'',5''S'',6''R'',7''S'',8''E'',10''R'',11''S'',12''E'',14''E'')-21-(allylamino)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate
|   OtherNames = 17-''N''-Allylamino-17-demethoxygeldanamycin&lt;br&gt;17-AAG
| Section1 = {{Chembox Identifiers
|   InChI = 1/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1
| InChIKey = AYUNIORJHRXIBJ-TXHRRWQRBY
| SMILES1 = C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\C=C(\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)/C)OC)OC(=O)N)\C)C)O)OC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = AYUNIORJHRXIBJ-TXHRRWQRSA-N
| CASNo_Ref = {{cascite|changed|??}}
| CASNo = 75747-14-7
|   PubChem = 6440175
|   ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 109480
| ChemSpiderID = 21106220
|   SMILES = NC(=O)O[C@H]1C(/C)=C/[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)C\C2=C(/NCC=C)C(=O)\C=C(\NC(=O)C(\C)=C\C=C/[C@@H]1OC)C2=O
}}
| Section2 = {{Chembox Properties
|   C=31|H=43|N=3|O=8
|   Appearance =
|   Density =
|   MeltingPt =
|   BoilingPt =
|   Solubility =
  }}
| Section7 = {{Chembox Hazards
|   MainHazards =
|   FlashPt =
|   Autoignition =
  }}
}}

'''Tanespimycin''' ('''17-''N''-allylamino-17-demethoxygeldanamycin''', '''17-AAG''') is a derivative of the antibiotic [[geldanamycin]] that is being studied in the treatment of [[cancer]], specific young patients with certain types of [[leukemia]] or solid [[tumors]], especially [[kidney]] [[tumors]].  

It works by [[enzyme inhibition|inhibiting]] [[Hsp90]], which is expressed in those tumors.&lt;ref&gt;{{cite journal | pmid = 21454186 | year = 2011 | last1 = Dimopoulos | first1 = MA | last2 = Mitsiades | first2 = CS | last3 = Anderson | first3 = KC | last4 = Richardson | first4 = PG | title = Tanespimycin as antitumor therapy | volume = 11 | issue = 1 | pages = 17–22 | doi = 10.3816/CLML.2011.n.002 | journal = Clinical lymphoma, myeloma &amp; leukemia}}&lt;/ref&gt; 

It belongs to the family of [[medication|drugs]] called [[antineoplastic|antitumor antibiotic]]s.

==Clinical trials==

Tanespimycin [[Bristol-Myers Squibb]] conducted Phase 1&lt;ref&gt;http://www.clinicaltrials.gov/ct/show/NCT00093821 Phase 1 trial: 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors&lt;/ref&gt;&lt;ref&gt;http://www.clinicaltrials.gov/ct/show/NCT00079404 Phase 1 trial : 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia&lt;/ref&gt; and Phase 2 [[clinical trial]]s.  However, in 2010 the company halted [[drug development|development]] of tanespimycin, during late-stage clinical trials as a potential treatment for multiple myeloma. While no definitive explanation was given, it has been suggested that Bristol-Myers Squibb halted development over concerns of the financial feasibility of tanespimycin development given the 2014 expiry of the patent on this compound, and the relative expense of manufacture.&lt;ref name=&quot;available&quot;&gt;[http://www.myelomabeacon.com/news/2010/07/22/tanespimycin-development-halted/]&lt;/ref&gt;

==References==
&lt;references/&gt;

==External links==
*[http://www.nci.nih.gov/ncicancerbulletin/NCI_Cancer_Bulletin_021505/page6 National Cancer Institutie Bulletin on Phase 2 trials against Von Hippel-Lindau disease]
*[http://www.fermentek.co.il/MSDS/17AAG-MSDS.htm Safety sheet for 17AAG]

[[Category:Antibiotics]]
[[Category:Experimental cancer drugs]]
[[Category:Quinones]]
[[Category:Carbamates]]
[[Category:Lactams]]
[[Category:Ethers]]
[[Category:Alcohols]]</text>
      <sha1>6faf8jv5epz3ukpqbiieceo0ntipxqi</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Erythromycin/sulfafurazole</title>
    <ns>0</ns>
    <id>39250630</id>
    <revision>
      <id>553816867</id>
      <parentid>553816824</parentid>
      <timestamp>2013-05-06T18:23:54Z</timestamp>
      <contributor>
        <username>Edgar181</username>
        <id>491706</id>
      </contributor>
      <minor/>
      <comment>Edgar181 moved page [[Erythromycin/Sulfafurazole]] to [[Erythromycin/sulfafurazole]]: decap. for consistency with other combo drugs</comment>
      <text xml:space="preserve" bytes="1740">{{Drugbox
| type              = combo
| component1        = Erythromycin
| class1            = [[Macrolide|Macrolide antibiotic]]
| component2        = Sulfafurazole
| class2            = [[Sulfonamide (medicine)|Sulfonamide antibiotic]]

&lt;!-- Clinical data --&gt;
| tradename         = 
| Drugs.com         = 
| MedlinePlus       = 
| pregnancy_AU      = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US      = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category= 
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --&gt;
| legal_US = &lt;!-- OTC / Rx-only / Schedule I, II, III, IV, V --&gt;
| legal_status      = 
| routes_of_administration = 

&lt;!-- Identifiers --&gt;
| CAS_number        = 
| ATCvet            = 
| ATC_prefix        = &lt;!-- 'none' if uncategorised --&gt;
| ATC_suffix        = 
| PubChem           = 
| DrugBank          = 
}}

'''Erythromycin/sulfafurazole''' ([[trade name]] '''Pediazole''') is a [[combination drug]] with the [[antibiotic]]s [[erythromycin]] and [[sulfafurazole]] (the latter is also known as sulfisoxazole).

It is indicated in [[acute otitis media]] in children, particularly when ''[[Hemophilus influenzae]]'' is the suspected pathogen.&lt;ref&gt;[http://reference.medscape.com/drug/pediazole-erythromycin-base-sulfisoxazole-342546 erythromycin base/sulfisoxazole] at [[Medscape]]. Retrieved April 29, 2013. Patient handout: [http://reference.medscape.com/drug/pediazole-erythromycin-base-sulfisoxazole-342546#91].&lt;/ref&gt;

==References==
{{reflist}}

[[Category:Combination drugs]]
[[Category:Antibiotics]]</text>
      <sha1>gzafd4d5mcm20vokddvxc1vnaqz1aum</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Archaeocin</title>
    <ns>0</ns>
    <id>16350616</id>
    <revision>
      <id>607011888</id>
      <parentid>603947993</parentid>
      <timestamp>2014-05-04T11:08:28Z</timestamp>
      <contributor>
        <username>Rjwilmsi</username>
        <id>203434</id>
      </contributor>
      <minor/>
      <comment>/* Sulfolobicins */Added 1 dois to journal cites using [[Project:AWB|AWB]] (10094)</comment>
      <text xml:space="preserve" bytes="6817">'''Archaeocin'''  is the name given to a new type of potentially useful [[antibiotic]] that is derived from the [[Archaea]] group of organisms.&lt;ref name=BlumP&gt;{{cite book | author = Blum P (editor). | title = Archaea: New Models for Prokaryotic Biology | publisher = Caister Academic Press | year = 2008 |  isbn =  978-1-904455-27-1 }}&lt;/ref&gt; Eight archaeocins have been partially or fully characterized, but hundreds of archaeocins are believed to exist, especially within the [[haloarchaea]]. Production of these archaeal proteinaceous [[antimicrobial]]s is a nearly universal feature of the rod-shaped haloarchaea.&lt;ref name=&quot;pmid11938468&quot;&gt;{{cite journal
|author=O'Connor EM, Shand RF
|title=Halocins and sulfolobicins: the emerging story of archaeal protein and peptide antibiotics
|journal=J. Ind. Microbiol. Biotechnol.
|volume=28
|issue=1
|pages=23–31
|year=2002
|pmid=11938468
|doi=10.1038/sj/jim/7000190
|url=http://link.springer.de/link/service/journals/10295/bibs/2028001/20280023.htm
}}&lt;/ref&gt;

The prevalence of archaeocins from other members of this domain is unknown simply because no one has looked for them. The discovery of new archaeocins hinges on recovery and cultivation of archaeal organisms from the environment. For example, samples from a novel hypersaline field site, Wilson Hot Springs in the Fish Springs National Wildlife Refuge in eastern [[Utah]],&lt;ref name=&quot;WilsonHotSprings&quot;&gt;{{cite web|title= Wilson Hot Springs - A Desert Hypersaline Salt Marsh Research Site|url= http://www4.nau.edu/wilsonhotsprings/WHSPrelimRpt.doc|author= Pete Polsgrove, Amy Fleishman Littlejohn, Barry Roberts and Richard F. Shand, Northern Arizona University|date= June 4–5, 2005}}&lt;/ref&gt; recovered 350 halophilic organisms; preliminary analysis of 75 isolates showed that 48 were archaeal and 27 were bacterial.&lt;ref name=Shand&gt;{{cite book |author= Shand RF; Leyva KJ |year=2008|chapter=Archaeal Antimicrobials: An Undiscovered Country|title=Archaea: New Models for Prokaryotic Biology|publisher=Caister Academic Press|isbn= 978-1-904455-27-1}}&lt;/ref&gt;

== Halocins ==
{{ Details|Halocin}}
Halocins are classified as either [[peptide]] (≤ 10 [[Atomic mass unit|kDa]]; 'microhalocins') or [[protein]] (&gt; 10 kDa) antibiotics produced by members of the archaeal family [[Halobacteriaceae]]. To date, all of the known halocin genes are encoded on megaplasmids (&gt; 100 [[Base pair|kbp]]) and possess typical haloarcheal TATA and BRE promoter regions. Halocin transcripts are leaderless and the translated preproteins or preproproteins are most likely exported using the twin arginine translocation (Tat) pathway, as the Tat signal motif (two adjacent arginine residues) is present within the [[N-terminal end|amino terminus]]. Halocin genes are almost universally expressed at the transition between exponential and stationary phases of growth; the only exception is halocin H1, which is induced during exponential phase. In contrast, the larger halocin proteins are heat-labile and typically obligately halophilic as they lose their activity (or activity is reduced) when desalted.

=== Microhalocins, peptide halocins ===
Currently, five peptide halocins have been partially or completely characterized at the protein and/or genetic levels: HalS8, HalR1, HalC8, HalH7, and HalU1. These [[antimicrobial peptides]] range from ~3 to 7.4 kDa in [[molecular mass]], consisting of 36 to 76 [[amino acid]] residues. Two of the microhalocins (HalS8 and HalC8) are produced by proteolytic cleavage from a larger preproprotein by an unknown mechanism. Microhalocins are hydrophobic peptides that remain active even if desalted and/or stored at 4&amp;nbsp;°C and are fairly insensitive to heat and organic solvents. The first microhalocin to be characterized was HalS8,&lt;ref name=&quot;pmid10940040&quot;&gt;{{cite journal
|author=Price LB, Shand RF
|title=Halocin S8: a 36-amino-acid microhalocin from the haloarchaeal strain S8a
|journal=J. Bacteriol.
|volume=182
|issue=17
|pages=4951–8
|year=2000
|pmid=10940040
|doi=10.1128/JB.182.17.4951-4958.2000
|url=http://jb.asm.org/cgi/pmidlookup?view=long&amp;pmid=10940040
|pmc=111376
}}&lt;/ref&gt; produced by the uncharacterized haloarchaeon S8a isolated from the Great Salt Lake, UT, USA.&lt;ref name=&quot;Shand&quot; /&gt;

=== Protein halocins ===
Two can be classified as protein halocins: HalH1 and HalH4; the molecular masses of the remaining halocins have yet to be elucidated. Halocin H1 is produced by ''Hfx. mediterranei'' M2a (formerly strain Xia3), isolated from a solar saltern near [[Alicante (province)|Alicante, Spain]]. It is a 31 kDa protein that is heat-labile, loses activity when desalted, and exhibits a broad range of inhibition within the haloarchaea. Halocin H1 has yet to be characterized at the protein and genetic levels. In contrast, HalH4, produced by ''Hfx. mediterranei'' R4 (ATCC 33500), also isolated from a solar saltern near Alicante, Spain was the first halocin discovered.&lt;ref name=&quot;pmid8990311&quot;&gt;{{cite journal
|author=Cheung J, Danna KJ, O'Connor EM, Price LB, Shand RF
|title=Isolation, sequence, and expression of the gene encoding halocin H4, a bacteriocin from the halophilic archaeon Haloferax mediterranei R4
|journal=J. Bacteriol.
|volume=179
|issue=2
|pages=548–51
|year=1997
|pmid=8990311
|doi=
|url=http://jb.asm.org/cgi/pmidlookup?view=long&amp;pmid=8990311
|pmc=178729
}}&lt;/ref&gt; The molecular mass of the mature HalH4 protein is 34.9 kDa (359 amino acids), processed from a preprotein of 39.6 kDa; the mechanism for processing is unknown. Halocin H4 is an archaeolytic halocin and adsorbs to sensitive ''Hbt. salinarum cells'' where it may be disrupting membrane permeability.&lt;ref name=&quot;Shand&quot; /&gt;

==Sulfolobicins==
The archaeocins produced by ''[[Sulfolobus]]'' are entirely different from halocins, since their activity is predominantly associated with the cells and not the supernatant. To date, the spectrum of sulfolobicin activity appears to be restricted to other members of the Sulfolobales: the sulfolobicin inhibited ''S. solfataricus'' P1, ''S. shibatae'' B12, and six nonproducing strains of ''S. islandicus''. Activity appears to be archaeocidal but not archaeolytic.&lt;ref name=&quot;Shand&quot; /&gt; Two genes involved in sulfolobicin production have been identified in S. acidocaldarius and S. tokodaii. The sulfolobicins appear to represent a novel calss of antimicrobial proteins.&lt;ref name=&quot;pmid21725003&quot;&gt;{{cite journal
|author=Ellen AF, Rohulya OV, Fusetti F, Wagner M, Albers SV, Driessen AJ
|title=The sulfolobicin genes of Sulfolobus acidocaldarius encode novel antimicrobial proteins
|journal=J. Bacteriol.
|volume=193
|issue=17
|pages=4380–87
|year=2011
|pmid=21725003
|doi=10.1128/jb.05028-11
|url=http://www.ncbi.nlm.nih.gov/pubmed/21725003}}&lt;/ref&gt;

==See also==
* [[Archaea]]

==References==
{{Reflist|2}}

[[Category:Antibiotics]]
[[Category:Archaea]]</text>
      <sha1>i7fpe1awdaqe2mczqedcwrbetmongdp</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Antibiosis</title>
    <ns>0</ns>
    <id>12017661</id>
    <revision>
      <id>607315535</id>
      <parentid>605896540</parentid>
      <timestamp>2014-05-06T11:57:26Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>/* External links */Task 2: Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated coauthor parameter errors]]</comment>
      <text xml:space="preserve" bytes="2118">{{Refimprove|date=July 2010}}
'''Antibiosis''' is a [[biological interaction]] between two or more [[organism]]s that is detrimental to at least one of them; it can also be an antagonistic association between an organism and the metabolic substances produced by another.&lt;ref&gt;{{cite encyclopedia | title=antibiosis| encyclopedia=The Free Dictionary | url=http://www.thefreedictionary.com/antibiosis}}&lt;/ref&gt; Examples of antibiosis include the relationship between [[antibiotics]] and [[bacteria]] and the relationship between animals and disease-causing [[pathogen]]s.

Antibiosis is commonly found and studied in host [[plant]]s and the [[insect]]s which feed upon them. 

&quot;Antibiosis resistance affects the biology of the insect so pest abundance and subsequent damage is reduced compared to that which would have occurred if the insect was on a susceptible crop variety. Antibiosis resistance often results in increased mortality or reduced longevity and reproduction of the insect.&quot;&lt;ref&gt;{{cite web|last=Teetes|first=George L.|title=Plant Resistance to Insects: A Fundamental Component of IPM|url=http://ipmworld.umn.edu/chapters/teetes.htm|work=Radcliffe's IPM World Textbook|publisher=University of Minnesota|accessdate=2011-11-07}}&lt;/ref&gt;

==See also==
* [[Antibiotic]]
* [[Biological pest control]]
* [[Biotechnology]]
* [[Symbiosis]]

==References==
{{Reflist}}

==External links==
{{Wiktionary}}
*{{cite journal | last=Fravel | first=D R | title=Role of Antibiosis in the Biocontrol of Plant Diseases | journal=Annual Review of Phytopathology | year=1988 | doi=10.1146/annurev.py.26.090188.000451 | volume=26 | issue=1 | pages=75–91}}
*{{cite journal | last=Haggag | first=W. |author2=H. Mohamed | title=Biotechnological Aspects of Microorganisms Used in Plant Biological Control | journal=World Journal of Agricultural Sciences | year=2007 | volume=3 | issue=6 | pages=771–776 | url=http://www.idosi.org/wjas/wjas3%286%29/11.pdf}}

{{modelling ecosystems|expanded=other}}

[[Category:Biological interactions]]
[[Category:Antibiotics]]


{{Ecology-stub}}

[[pt:Relação ecológica#Amensalismo ou antibiose]]</text>
      <sha1>fgumuquujf4y5o0zk59kswydj2nh0j5</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Carbomycin</title>
    <ns>0</ns>
    <id>39235909</id>
    <revision>
      <id>607345201</id>
      <parentid>606651132</parentid>
      <timestamp>2014-05-06T16:02:12Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Task 2: Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated coauthor parameter errors]]</comment>
      <text xml:space="preserve" bytes="9079">{{Chembox
| Name = Carbomycin
| ImageFile = Carbomycin_A_2.png
|  ImageSize = 200
|  IUPACName = (2S,3S,4R,6S)-6-{[(2R,3S,4R,5R,6S)-6-{[(3R,7R,8S,9S,10R,12R,14E)-7-Acetoxy-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy}-4-(dimethylamino)-5-hydr oxy-2-methyltetrahydro-2H-pyran-3-yl]oxy}-4-hydroxy-2,4-dimethyltetrahydro-2H-pyran-3-yl 3-methylbutanoate 
|  SystematicName = 
|  OtherNames = 
| Section1 = {{Chembox Identifiers
|  3DMet = 
|  Abbreviations = 
|  ATCvet = 
|  ATCCode_prefix = 
|  ATCCode_suffix = 
|  ATC_Supplemental = 
|  Beilstein = 
|  CASNo = 4564-87-8
|  CASNo_Ref = 
|  CASNos = 
|  CASOther = 
|  ChEBI = 
| ChEMBL = 1231649
|  ChemSpiderID = 4938568
|  DrugBank = 
|  EC-number = 
|  EINECS = 
|  EINECSCASNO = 
|  Gmelin = 
|  InChI = 
|  KEGG = 
|  MeSHName = 
|  PubChem = 
|  RTECS = 
|  SMILES =
|  UNNumber = 
}}
| Section2 = {{Chembox Properties
|  AtmosphericOHRateConstant = 
|  Appearance = 
|  BoilingPt = 
|  Boiling_notes = 
|  Density = 1.24g/ cm3
|  Formula = 
|  HenryConstant = 
|  LogP = 
|  MolarMass = 841.97848 
|  MeltingPt =214℃ (417.2°F) 
|  Melting_notes = 
|  pKa = 
|  pKb =7.2
|  Solubility = 
|  SolubleOther = 
|  Solvent = 
|  VaporPressure = }}
| Section3 = {{Chembox Structure
|  Coordination = 
|  CrystalStruct = 
|  MolShape = }}
| Section4 = {{Chembox Thermochemistry
|  DeltaHc = 
|  DeltaHf = 
|  Entropy = 
|  HeatCapacity = }}
| Section5 = {{Chembox Pharmacology
|  AdminRoutes = 
|  Bioavail = 
|  Excretion = 
|  HalfLife = 
|  Metabolism = 
|  Legal_status = 
|  Legal_US = 
|  Legal_UK = 
|  Legal_AU = 
|  Legal_CA = 
|  PregCat = 
|  PregCat_AU = 
|  PregCat_US = 
|  ProteinBound = }}
| Section6 = {{Chembox Explosive
|  ExplosiveV = 
|  FrictionSens = 
|  REFactor = 
|  ShockSens = }}
| Section7 = {{Chembox Hazards
|  Autoignition = 
|  EUClass = 
|  EUIndex = 
|  ExploLimits = 
|  ExternalMSDS = 
|  FlashPt = 
|  LD50 = 
|  MainHazards = 
|  NFPA-H = 
|  NFPA-F = 
|  NFPA-R = 
|  NFPA-O = 
|  PEL = 
|  RPhrases = 
|  RSPhrases = 
|  SPhrases = }}
| Section8 = {{Chembox Related
|  Function = 
|  OtherAnions = 
|  OtherCations = 
|  OtherCpds = 
|  OtherFunctn = }}
}}

'''Carbomycin''', also known as '''magnamycin''', is a colorless, optically active crystalline&lt;ref name=&quot;Wagner1953&quot;&gt;{{cite journal|last=Wagner|first=Richard L.|coauthors=F.A Hochstein, Kotaro Murai, N. Messina, Peter P Regna|title=Magnamycin. A new Antibiotic|journal=[[J. Am. Chem. Soc.]]|volume=75|year=1953|pages=4684–87|doi =10.1021/ja01115a019|issue= 19}}&lt;/ref&gt; [[macrolide]] [[antibiotic]] with the molecular formula [[Carbon|C]]&lt;sub&gt;42&lt;/sub&gt;[[Hydrogen|H]]&lt;sub&gt;67&lt;/sub&gt;[[Nitrogen|N]][[Oxygen|O]]&lt;sub&gt;16&lt;/sub&gt;. It is derived from the bacterium ''[[Streptomyces halstedii]]'' and active in inhibiting the growth of [[Gram-positive bacteria]] and &quot;certain [[Mycoplasma]] strains.&quot;&lt;ref name=Ziegler&gt;{{cite journal|author= Ziegler, F. E.; Gilligan, P. J.|title=Synthetic Studies on the Carbomycins (Magnamycins): An Exception to the Enantioselective Synthesis of Beta-Alkyl Carboxylic Acids via Chiral Oxazolines|journal=[[Journal of Organic Chemistry|J. Org. Chem]]|volume=46|year=1981|pages=3874–80|doi =10.1021/jo00332a023|issue= 19}}&lt;/ref&gt; Its structure was first proposed by [[Robert Burns Woodward|Robert Woodward]] in 1957 and was subsequently corrected in 1965.&lt;ref&gt;{{cite journal|author= Woodward, R. B., Weiler, L. S., and Dutta, P. C.|title=The Structure of Magnamycin|journal=[[J. Am. Chem. Soc.]]|volume=87|year=1965|pages=4662–63|doi =10.1021/ja00948a058|issue= 20}}&lt;/ref&gt;

== Synthesis ==

The discovery of carbomycin was first reported by Fred W. Tanner Jr. of [[Pfizer]].&lt;ref&gt;{{cite journal|title=Carbomycin|journal=The British Medical Journal|date=26 December 1953|volume=2|pages=1421–22|jstor=20313504|issue=4851}}&lt;/ref&gt; Carbomycin can be isolated from ''Streptomyces halstedii'' via extraction from a fermentation broth and purified through crystallization from alcohol-water mixtures.&lt;ref name=&quot;Wagner1953&quot; /&gt; Carbomycin can be further purified with the use of preparative [[thin-layer chromatography]]. The most efficient solvent is one consisting of ethanol-hexane-water in 90-10-0.15 volume ratio.&lt;ref name=Biosynth&gt;{{cite journal|last=Baghlaf|first=A.O.|coauthors=A.Z.A Abou-Zeid, A.I. El-Diwzny|title=Biosynthesis of Carbomycin, its Extraction, Purification and Mode of Action on Bacillus subtilis|journal=Journal of Chemical Technology and Biotechnology|year=1981|volume=31|issue=1|pages=241–46|doi=10.1002/jctb.503310133}}&lt;/ref&gt; 

In the biosynthesis of carbomycin by ''Streptomyces halstedii'', when soybean meal is used to ferment the antibiotic, the addition of several substances can increase the yield of carbomycin. When [[blackstrap molasses]], a carbon source, is added, an increased yield is observed. Nitrogen sources [[ammonium chloride]], [[ammonium nitrate]], and [[ammonium dihydrogen phosphate]] have the same effect on the production of carbomycin. The addition of the organic salts [[sodium acetate]] and [[sodium tartrate]] also increases the yield of the antibiotic.&lt;ref name=Factors&gt;{{cite journal|last=Ghonaim|first=S.A.|coauthors=A.M. Khalil, A.A. Abou-Zeid|title=Factors affecting fermentative production of magnamycin by Streptomyces halsted II|journal=Agricultural Wastes|date=1980|year=1980|month=March|volume=2|issue=1|pages=31–36|doi=10.1016/0141-4607(80)90044-X}}&lt;/ref&gt; 

Studies of the chemical degradation of carbomycin and comparison of molar activities of [[propionate]]-labeled carbomycins and their degradation products suggest that the [[biosynthesis]] of carbomycin by ''Streptomyces halstedii'' include the synthesis of the [[lactone]] backbone from eight [[acetate]] units and one propionate unit with the branching [[methyl]] group deriving from [[C-3]]{{dn|date=October 2013}} of propionate.&lt;ref&gt;{{cite journal|last=Srinivasan|first=Dorothy|author2=P.R. Srinivasan|title=Studies on the Biosynthesis of Magnamycin|journal=Biochemistry|year=1967|volume=6|issue=10|pages=3111–18|doi=10.1021/bi00862a019}}&lt;/ref&gt;

==Medical use==

As carbomycin is not a strong antibiotic, it is not used extensively and is considered a minor antibiotic; it is most effective when used in combination with other drugs.&lt;ref&gt;{{cite book|last=Welch|first=Henry|title=The Antibiotic Saga|year=1960|publisher=The University of Michigan|location=New York|page=88, 96|url=http://babel.hathitrust.org/cgi/pt?id=mdp.39015007092722;view=1up;seq=2}}&lt;/ref&gt; The range of activity of carbomycin is similar to that of [[erythromycin]]. In testing the response of 74 strains of bacteria, their susceptibility across carbomycin and [[erythromycin]] was consistent. However, a higher concentration of carbomycin is needed to achieve the same effect as that of erythromycin.&lt;ref name=TBMJ&gt;{{cite journal|journal=The British Medical Journal|year=1953|volume=2|issue=4851|pages=1421–22|doi=10.1038/jid.1954.34|title=The Effect of Washing with Soap and with a Detergent on the 4-Hour Sebaceous Secretion in the Forehead12|last1=Kirk|first1=J E|last2=Effersøe|first2=H}}&lt;/ref&gt; The effectiveness of carbomycin as an antibiotic varies. When used to treat 45 patients with pneumonia, carbomycin was as effective as other antibiotics for six patients. Two developed meningitis, while, for twelve patients, it was necessary that the use of carbomycin in treatment be replaced with [[penicillin]].&lt;ref name=&quot;TBMJ&quot;/&gt; Carbomycin has been successful in treating neither [[staphylococcal]] [[sepsis]] nor [[bacterial endocarditis]].&lt;ref name=&quot;TBMJ&quot;/&gt; In 1954, carbomycin was found to be an effective treatment for [[granuloma inguinale]] by Harry M. Robinson and Morris M. Cohen.&lt;ref&gt;{{cite journal|last=Robinson|first=Harry M.|title=Magnamycin in the Treatment of Granuloma Inguinale|journal=Journal of Investigative Dermatology|year=1954|volume=22|issue=4|pages=263–4|pmid=13152395|url=http://www.nature.com/jid/journal/v22/n4/full/jid195436a.html|doi=10.1038/jid.1954.36|last2=Cohen|first2=MM}}&lt;/ref&gt;  However, complete healing from the condition depends on the severity and duration of the condition. There were no adverse reactions found to be associated with the use of carbomycin.

==Mode of action==
''[[In vivo]]'' studies have demonstrated that carbomycin stimulates the &quot;accumulation of peptidyl-[[tRNA]] in cells at the nonpermissive temperature&quot; of 40˚C in ''[[E. coli]]'' and thereby inhibits [[protein synthesis]]. Carbomycin is able to inhibit protein synthesis by stimulating the dissociation of peptidyl-tRNA from the ribosome, inhibiting the nascent peptide chain from passing through the exit tunnel and out of the [[ribosome]].&lt;ref&gt;{{cite journal|last=Menninger|first=J.R.|author2=D.P. Otto|title=Erythromycin, carbomycin, and spiramycin inhibit protein synthesis by stimulating the dissociation of peptidyl-tRNA from ribosomes|journal=Antimicrobial Agents and Chemotherapy|year=1982|volume=21|issue=5|pages=811–18|pmc=182017|doi=10.1128/AAC.21.5.811}}&lt;/ref&gt;

== References ==
{{Reflist}}

[[Category:Antibiotics]]</text>
      <sha1>f2h2uaxnk1qyej97o1xg4dyc8sf5lyj</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Cruciferous vegetables</title>
    <ns>0</ns>
    <id>4175726</id>
    <revision>
      <id>607256577</id>
      <parentid>602690568</parentid>
      <timestamp>2014-05-06T00:09:31Z</timestamp>
      <contributor>
        <username>Keenan Pepper</username>
        <id>124371</id>
      </contributor>
      <comment>/* List of cruciferous vegetables */ wild arugula</comment>
      <text xml:space="preserve" bytes="15935">{{About|the use of Brassicaceae as food|a botanical description of plants in this family (whether or not used for food)|Brassicaceae}}
[[File:Cabbage.jpg|right|thumb|Cabbage plants]]
'''Cruciferous vegetables''' are [[vegetable]]s of the family [[Brassicaceae]] (also called Cruciferae). These vegetables are widely cultivated, with many genera, species, and cultivars being raised for food production such as [[cauliflower]], [[cabbage]], [[cress]], [[bok choy]], [[broccoli]] and similar green leaf vegetables.  The family takes its alternate name (Cruciferae, [[New Latin]] for &quot;cross-bearing&quot;) from the shape of their flowers, whose four [[petals]] resemble a [[cross]].

Ten of the most common cruciferous vegetables eaten by people, known colloquially as '''cole crops''',&lt;ref&gt;http://www.botgard.ucla.edu/html/botanytextbooks/economicbotany/Brassica/index.html&lt;/ref&gt; are in a single [[species]] (''[[Brassica oleracea|B. oleracea]]''); they are not distinguished from one another [[Taxonomy (biology)|taxonomically]], only by horticultural category of [[cultivar group]]s.  Numerous other [[genus|genera]] and species in the family are also edible.  Cruciferous vegetables are one of the dominant food crops worldwide. They are high in [[vitamin C]] and [[dietary fiber|soluble fiber]] and contain multiple [[nutrient]]s and [[phytochemical]]s.

== List of cruciferous vegetables ==

Extensive [[selective breeding]] has produced a large variety of [[cultivar]]s, especially within the genus ''[[Brassica]]''.  One description of genetic factors involved in the breeding of ''Brassica'' species is the [[Triangle of U]].

{| class=&quot;wikitable&quot;
|+'''The taxonomy of common cruciferous vegetables'''
|-
! common name  || genus || specific epithet || Cultivar Group
|----
|[[horseradish]]||''Armoracia''||''rusticana''||
|----
|[[land cress]]||''Barbarea''||''verna''||
|----
|[[ethiopian mustard]]||''Brassica''||''carinata''||
|----
|[[kale]]||''Brassica''||''oleracea''||Acephala Group
|----
|[[collard greens]]||''Brassica''||''oleracea''||Acephala Group
|----
|Chinese broccoli ([[gai-lan]])||''Brassica''||''oleracea''||Alboglabra Group
|----
|[[cabbage]]||''Brassica''||''oleracea''||Capitata Group
|----
|[[Brussels sprouts]]||''Brassica''||''oleracea''||Gemmifera Group
|----
|[[kohlrabi]]||''Brassica''||''oleracea''||Gongylodes Group
|----
|[[broccoli]]||''Brassica''||''oleracea''||Italica Group
|----
|[[broccoflower]]||''Brassica''||''oleracea''||Italica Group × Botrytis Group
|----
|[[Romanesco broccoli|broccoli romanesco]]||''Brassica''||''oleracea''||Botrytis Group / Italica Group
|----
|[[cauliflower]]||''Brassica''||''oleracea''||Botrytis Group
|----
|[[Brassica oleracea|wild broccoli]]||''Brassica''||''oleracea''||Oleracea Group
|----
|[[Chinese cabbage#Varieties|bok choy]]||''Brassica''||''rapa''||''chinensis''
|----
|[[komatsuna]]||''Brassica''||''rapa''||pervidis or komatsuna
|----
|[[mizuna]]||''Brassica''||''rapa''||''nipposinica''
|----
|[[Rapini]] (broccoli rabe)||''Brassica''||''rapa''||''parachinensis''
|----
|[[flowering cabbage]]||''Brassica''||''rapa''||''parachinensis''
|----
|[[chinese cabbage]], [[Chinese cabbage#Varieties|napa cabbage]]||''Brassica''||''rapa''||''pekinensis''
|----
|[[turnip]] root; greens||''Brassica''||''rapa''||''rapifera''
|----
|[[rutabaga]]||''Brassica''||''napus''||''napobrassica''
|----
|[[siberian kale]]||''Brassica''||''napus''||''pabularia''
|----
|[[canola]]/[[rapeseed]]||''Brassica''||''rapa''/''napus''||''oleifera''
|----
|[[wrapped heart mustard cabbage]]||''Brassica''||''juncea''||''rugosa''
|----
|[[mustard seed]]s, brown; greens||''Brassica''||''juncea''||
|----
|[[White Mustard|mustard seeds, white]]||''Brassica'' (or ''Sinapis'')||''hirta''||
|----
|[[Brassica nigra|mustard seeds, black]]||''Brassica''||''nigra''||
|----
|[[tatsoi]]||''Brassica''||''rosularis''||
|----
|[[Diplotaxis tenuifolia|wild arugula]]||''Diplotaxis''||''tenuifolia''||
|----
|[[Eruca sativa|arugula]] (rocket)||''Eruca''||''vesicaria''||
|----
|[[Lepidium campestre|field pepperweed]]||''Lepidium''||''campestre''||
|----
|[[maca]]||''Lepidium''||''meyenii''||
|----
|[[garden cress]]||''Lepidium''||''sativum''||
|----
|[[watercress]]||''Nasturtium''||''officinale''||
|----
|[[radish]]||''Raphanus''||''sativus''||
|----
|[[daikon]]||''Raphanus''||''sativus''||''longipinnatus''
|----
|[[wasabi]]||''Wasabia''||''japonica''||
|}

== Clinical significance ==

=== Drug and toxin metabolism  ===

Chemicals contained in cruciferous vegetables [[enzyme induction and inhibition|induce]] the expression of the liver enzyme [[CYP1A2]].&lt;ref name=&quot;pmid10837004&quot;/&gt;  Furthermore some drugs such as [[haloperidol]] and [[theophylline]] are metabolized by CYP1A2.  Consequently consumption of cruciferous vegetable may decrease [[bioavailability]] and [[biological half-life|half-life]] of these drugs.&lt;ref name=&quot;pmid18928560&quot;/&gt;

''Brassicaceae'' contain a number of [[hepatoprotective|hepato-protective]] agents.&lt;ref name=&quot;pmid16082211&quot;/&gt; [[Agapanthoideae|Alliaceous]] and cruciferous vegetable consumption induces [[glutathione S-transferase]]s, [[glucuronosyltransferase|uridine diphosphate-glucuronosyl transferases]], and [[NADPH:quinone reductase|quinone reductase]]s&lt;ref name=&quot;pmid11201301&quot;/&gt; all of which participate in [[detoxification]] of [[carcinogen]]s such as [[aflatoxin]].&lt;ref name=&quot;pmid16284385&quot;/&gt;

=== Antimicrobial activity ===

[[Isothiocyanate|Iso-thio-cyanates]] are an important factor in the action of [[wasabi]] against ''[[Helicobacter pylori]]'',.&lt;ref name=&quot;pmid15246236&quot;/&gt;&lt;ref name=&quot;pmid15856408&quot;/&gt;&lt;ref name=&quot;pmid12032331&quot;/&gt; [[Isothiocyanate|ITC]] is not a molecule, but a functional group of many different molecules, [[Sinigrin]] being a notable [[Precursor (chemistry)|precursor]] of [[allylisothiocyanate|allyl-ITC]]. A-ITC is a larger part of Wasabi than of most other Brassicaceae. Sulforaphane demonstrates anti-inflammatory effects on Helicobacter pylori-infected gastric mucosae in mice and human subjects.&lt;ref name=&quot;Yanaka&quot;/&gt;

=== Taste ===

People who can taste [[phenylthiocarbamide]], which is either very bitter or tasteless, are less likely to eat cruciferous vegetables,&lt;ref name=&quot;pmid14997422&quot;/&gt; due to the resemblance between [[isothiocyanate]] (ITC) and PTC.

=== Contraindications ===

==== Goiter ====

Cruciferous vegetables can potentially be [[goitrogen]]ic (inducing goiter formation). They contain enzymes that interfere with the formation of thyroid hormone in people with iodine deficiency.&lt;ref name=&quot;url_Goitrogens&quot;/&gt;&lt;ref name = &quot;McDougall_2005&quot;/&gt;  Cooking for 30 minutes significantly reduces the amount of goitrogens and [[nitrile]]s. At high intake of crucifers, the goitrogens inhibit the incorporation of [[iodine]] into [[thyroid hormone]] and also the transfer of [[iodine]] into milk by the [[mammary gland]].&lt;ref name=&quot;url_westonaprice_crucifers&quot;/&gt;

== References ==
{{Reflist|35em|refs=

&lt;ref name = &quot;McDougall_2005&quot;&gt;{{cite journal | author = McDougall J |date=December 2005 | title = Thyroid Deficiency Strikes One in Six | journal = McDougall Newsletter | volume = 4 | issue = 12  | url = http://www.drmcdougall.com/misc/2005nl/december/thyroid.htm }}&lt;/ref&gt;

&lt;ref name=&quot;pmid16082211&quot;&gt;{{cite journal | author = Aggarwal BB, Ichikawa H | title = Molecular targets and anticancer potential of indole-3-carbinol and its derivatives | journal = Cell Cycle | volume = 4 | issue = 9 | pages = 1201–15 |date=September 2005 | pmid = 16082211 | doi = 10.4161/cc.4.9.1993 }}&lt;/ref&gt;

&lt;ref name=&quot;pmid11201301&quot;&gt;{{cite journal | author = Kensler TW, Curphey TJ, Maxiutenko Y, Roebuck BD | title = Chemoprotection by organosulfur inducers of phase 2 enzymes: dithiolethiones and dithiins | journal = Drug Metabol Drug Interact | volume = 17 | issue = 1-4 | pages = 3–22 | year = 2000 | pmid = 11201301 | doi = 10.1515/DMDI.2000.17.1-4.3 }}&lt;/ref&gt;

&lt;ref name=&quot;pmid10837004&quot;&gt;{{cite journal | author = Lampe JW, King IB, Li S, Grate MT, Barale KV, Chen C, Feng Z, Potter JD | title = Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets | journal = Carcinogenesis | volume = 21 | issue = 6 | pages = 1157–62 |date=June 2000 | pmid = 10837004 | doi = 10.1093/carcin/21.6.1157 }}&lt;/ref&gt;

&lt;ref name=&quot;pmid16284385&quot;&gt;{{cite journal | author = Kensler TW, Chen JG, Egner PA, Fahey JW, Jacobson LP, Stephenson KK, Ye L, Coady JL, Wang JB, Wu Y, Sun Y, Zhang QN, Zhang BC, Zhu YR, Qian GS, Carmella SG, Hecht SS, Benning L, Gange SJ, Groopman JD, Talalay P | title = Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China | journal = Cancer Epidemiol. Biomarkers Prev. | volume = 14 | issue = 11 Pt 1 | pages = 2605–13 |date=November 2005 | pmid = 16284385 | doi = 10.1158/1055-9965.EPI-05-0368 }}&lt;/ref&gt;

&lt;ref name=&quot;pmid18928560&quot;&gt;{{cite journal | author = Bibi Z | title = Role of cytochrome P450 in drug interactions | journal = Nutr Metab (Lond) | volume = 5 | issue = | pages = 27 | year = 2008 | pmid = 18928560 | pmc = 2584094 | doi = 10.1186/1743-7075-5-27 | url = }}&lt;/ref&gt;

&lt;ref name=&quot;pmid12032331&quot;&gt;{{cite journal | author = Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, Talalay P, Lozniewski A | title = Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 99 | issue = 11 | pages = 7610–5 |date=May 2002 | pmid = 12032331 | pmc = 124299 | doi = 10.1073/pnas.112203099 }}&lt;/ref&gt;

&lt;ref name=&quot;pmid14997422&quot;&gt;{{cite journal | author = Wooding S, Kim UK, Bamshad MJ, Larsen J, Jorde LB, Drayna D | title = Natural selection and molecular evolution in PTC, a bitter-taste receptor gene | journal = Am. J. Hum. Genet. | volume = 74 | issue = 4 | pages = 637–46 |date=April 2004 | pmid = 14997422 | pmc = 1181941 | doi = 10.1086/383092 | laysummary = http://unews.utah.edu/news_releases/bitter-truth-humans-chimps-developed-ability-to-taste-toxic-compounds-through-separate-genetic-mutations/ | laysource = Science Blog }}&lt;/ref&gt;

&lt;ref name=&quot;pmid15246236&quot;&gt;{{cite journal | author = Shin IS, Masuda H, Naohide K | title = Bactericidal activity of wasabi (Wasabia japonica) against Helicobacter pylori | journal = Int. J. Food Microbiol. | volume = 94 | issue = 3 | pages = 255–61 |date=August 2004 | pmid = 15246236 | doi = 10.1016/S0168-1605(03)00297-6 }}&lt;/ref&gt;
&lt;ref name=&quot;pmid15856408&quot;&gt;{{cite journal | author = Haristoy X, Fahey JW, Scholtus I, Lozniewski A | title = Evaluation of the antimicrobial effects of several isothiocyanates on Helicobacter pylori | journal = Planta Med. | volume = 71 | issue = 4 | pages = 326–30 |date=April 2005 | pmid = 15856408 | doi = 10.1055/s-2005-864098 }}&lt;/ref&gt;

&lt;!--
&lt;ref name=&quot;pmid22500092&quot;&gt;{{cite journal | author = Scott O, Galicia-Connolly E, Adams D, Surette S, Vohra S, Yager JY | title = The safety of cruciferous plants in humans: a systematic review | journal = J. Biomed. Biotechnol. | volume = 2012 | issue = | pages = 503241 | year = 2012 | pmid = 22500092 | pmc = 3303573 | doi = 10.1155/2012/503241 }}&lt;/ref&gt;--&gt;

&lt;ref name=&quot;url_Goitrogens&quot;&gt;{{cite web | url = http://thyroid.about.com/cs/drugdatabase/f/goitrogen.htm | title = What are Goitrogens and How Do they Affect the Thyroid? | author =Shomon M | date = August 27, 2009 | work = Thyroid Disease | publisher = About.com }}&lt;/ref&gt;

&lt;ref name=&quot;url_westonaprice_crucifers&quot;&gt;{{cite web | url = http://www.westonaprice.org/basics/bearers-of-the-cross#goitrogens | author = Masterjohn C | title = Bearers of the Cross: Crucifers in the Context of Traditional Diets and Modern Science | date = 15 February 2008  | publisher = The Weston A. Price Foundation for Wise Traditions in Food, Farming, and the Healing Arts }}&lt;/ref&gt;

&lt;ref name=&quot;Yanaka&quot;&gt;{{cite journal | author = Yanaka A | title = Sulforaphane enhances protection and repair of gastric mucosa against oxidative stress in vitro, and demonstrates anti-inflammatory effects on Helicobacter pylori-infected gastric mucosae in mice and human subjects | journal = Curr. Pharm. Des. | volume = 17 | issue = 16 | pages = 1532–40 | year = 2011 | pmid = 21548875 | doi =10.2174/138161211796196945  }}&lt;/ref&gt;

}}

== Further reading ==
{{refbegin|35em}}
* {{cite book | author = Wood R | title = The new whole foods encyclopedia: a comprehensive resource for healthy eating | year = 1999 | publisher = Penguin/Arkana | location = New York | isbn = 0-14-025032-8 }}
* {{cite journal | author = Tang L, Zirpoli GR, Jayaprakash V, Reid ME, McCann SE, Nwogu CE, Zhang Y, Ambrosone CB, Moysich KB | title = Cruciferous vegetable intake is inversely associated with lung cancer risk among smokers: a case-control study | journal = BMC Cancer | volume = 10| pages = 162 | year = 2010 | pmid = 20423504 | pmc = 2874783 | doi = 10.1186/1471-2407-10-162 }}
{{refend}}

== External links ==
*[http://www.floridata.com/ref/B/bras_jun.cfm ''Brassica juncea'']
*[http://www.floridata.com/ref/B/bras_nap.cfm ''Brassica napa'']
*[http://www.floridata.com/ref/B/brass_ole.cfm ''Brassica oleracea'']
*[http://www.ahs.cqu.edu.au/info/science/psg/AsianVeg/ChinFlCabb.html Chinese flowering cabbage]
*[http://www.fourmilab.ch/images/Romanesco/ romanesco]
*[http://www.ibiblio.org/pfaf/cgi-bin/find_lat?FAM=Cruciferae&amp;CAN=fam Cruciferae]
*[http://www.ibiblio.org/pfaf/D_search.html edible/useful plants]

&lt;!-- Category Vitamins Omitted for failure to mention SMMC --&gt;

&lt;!-- Welsh. [[gb:cruciferous llysiau]] --&gt;

&lt;!-- [[al:perime cruciferous]] --&gt;

&lt;!-- [[ge:cruciferous ბოსტნეული]] --&gt;
&lt;!-- [[ae:الخضراوات]] --&gt;

&lt;!-- [[ua:хрестоцвітних овочів]] --&gt;
&lt;!-- [[by:крыжакветных гародніны]] --&gt;

&lt;!-- [[rs:крсташица поврће]] --&gt;

&lt;!-- [[cn:十字花科蔬菜]] --&gt;
&lt;!-- [[cz:brukvovité zeleniny]] --&gt;

&lt;!-- [[dk:korsblomstrede grøntsager]] --&gt;

&lt;!-- [[ph:pakrus gulay]] --&gt;
&lt;!-- [[gr:σταυρανθή λαχανικά]] --&gt;
&lt;!-- [[il:ירקות ממשפחת המצליבים]] --&gt;
&lt;!-- [[in:cruciferous सब्जियों]] --&gt;

&lt;!-- [[kh:បន្លែ cruciferous]] --&gt;

&lt;!-- [[jp:アブラナ科の野菜]] --&gt;

&lt;!-- [[ir:سبزیجات چلیپاءی]] --&gt;

&lt;!-- [[lk:தோற்ற காய்கறிகள்]] --&gt;

&lt;!-- [[vn:các loại rau]] --&gt;

{{DEFAULTSORT:Cruciferous Vegetables}}
[[Category:Vegetables]]
[[Category:Brassicaceae]]
[[Category:Antidotes]]
&lt;!-- See Aflatoxin --&gt;
[[Category:Hepatology]]
[[Category:Gastroenterology]]
[[Category:Oncology]]
[[Category:Antibiotics]]
[[Category:Isothiocyanates]]
[[Category:Glucosinolates]]
[[Category:Indoles]]

[[am:Խաչածաղկավոր բանջարեղեն]]
[[az:Turpgillere özgü tərəvəz]]
[[ba:Krstonosan povrće]]
[[bg:Кръстоцветни зеленчуци]]
[[de:Kreuzblütler]]
[[es:Verduras crucíferas]]
[[ee:Ristõielised köögiviljad]]
[[fr:Légumes crucifères]]
[[hr:Križonosan povrće]]
[[id:Sayuran]]
[[ie:Glasraí cruciferous]]
[[is:Krossblómaolíu grænmeti]]
[[it:Verdure crocifere]]
[[kr:십자화과 채소]]
[[ht:Krusifèr legim]]
[[la:ຜັກ cruciferous]]
[[lv:Krustziežus dārzeņi]]
[[lt:Kopūstų]]
[[hu:Keresztes virágú zöldségek]]
[[mk:Мешункаст зеленчук]]
[[mt:Ħxejjex kruċiferi]]
[[my:Sayur-sayuran cruciferous]]
[[nl:Kruisbloemige groenten]]
[[no:Cruciferous grønnsaker]]
[[pl:Warzywa kapustne]]
[[pt:Vegetais crucíferos]]
[[ro:Legume crucifere]]
[[ru:Крестоцветных овощей]]
[[se:Korsblommiga grönsaker]]
[[si:Križnic]]
[[sk:Kapustovité zeleniny]]
[[fi:Cruciferous vihannekset]]
[[th:ผักตระกูลกะหล่ำ]]
[[tr:Sebzelerden]]
[[za:Kruis bloemig groente]]</text>
      <sha1>n7o34v1c3nlip3yyjyrwmyddunqf1oc</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Albert Schatz (scientist)</title>
    <ns>0</ns>
    <id>1990488</id>
    <revision>
      <id>596792557</id>
      <parentid>596792327</parentid>
      <timestamp>2014-02-23T16:55:02Z</timestamp>
      <contributor>
        <username>Anthonyhcole</username>
        <id>1265352</id>
      </contributor>
      <comment>/* Academic career */</comment>
      <text xml:space="preserve" bytes="12459">{{Infobox scientist
| image = Albert Schatz.jpg
| image_size=200px
| caption = Albert Schatz
| birth_name = Albert Israel Schatz
| birth_date = {{birth date|1920|2|2|df=y}}
| birth_place = [[Norwich, Connecticut]]
| death_date = {{death date and age|df=yes|2005|1|17|1920|2|2}}
| death_place = [[Philadelphia]], USA
| residence = USA
| cause_of_death = [[pancreatic cancer]]
| citizenship = USA
| field = [[microbiology]]&lt;br&gt;[[science education]]
| work_institutions = [[Brooklyn College]]&lt;br&gt;National Agricultural College in Doylestown&lt;br&gt;[[University of Chile]]&lt;br&gt;[[Washington University]]&lt;br&gt;[[Temple University]]
| alma_mater = [[Rutgers University]]
| doctoral_advisor = 
| doctoral_students = 
| known_for  = discoverer of [[streptomycin]]
| spouse = Vivian Schatz (née Rosenfeld, married 1945)
| children = Linda Schatz &lt;br&gt; Diane Klein
| prizes =  
| religion = 
| website = http://www.albertschatzphd.com
}}

'''Albert Israel Schatz''' (2 February 1920 – 17 January 2005) was an American [[Microbiology|microbiologist]] and science educator, best known as the discoverer of the antibiotic, [[streptomycin]]. Schatz graduated from [[Rutgers University]] in 1942 with a bachelor's degree in soil microbiology, and received his doctorate from Rutgers in 1945.

In 1943, as a 23-year-old postgraduate research assistant working in the university's soil microbiology laboratory under the direction of [[Selman Waksman]], Schatz volunteered to search for soil-born microorganisms that would kill or inhibit the growth of penicillin-resistant bacteria including [[tubercle bacillus]], the bacterium that causes [[tuberculosis]] (TB). In three and a half months he had isolated two strains of bacterium that stopped the growth of tubercle bacillus and several other penicillin-resistant bacteria in a petri dish.&lt;ref name=NYT2005&gt;{{cite news |title= Albert Schatz, Microbiologist, Dies at 84|author= Margalit Fox |url= http://www.nytimes.com/2005/02/02/obituaries/02schatz.html|newspaper= New York Times |date= 2 February 2005|accessdate=17 August 2013}}&lt;/ref&gt;&lt;ref name=GUA2002&gt;{{cite news |title= Time, and the great healer|author= Veronique Mistiaen |url= http://www.theguardian.com/education/2002/nov/02/research.highereducation |newspaper= The Guardian|date=2 November 2002 |accessdate=17 August 2013}}&lt;/ref&gt;

== Personal life ==
Schatz was born in [[Norwich, Connecticut]], and raised on a poor isolated [[Passaic, New Jersey]] farm by his Jewish Russian émigré father and English mother. His initial interest in soil microbiology stemmed from his intention to become a farmer. Seeing workers being assaulted by the authorities during the [[Great Depression|Depression]] prompted him to lifelong socialism and humanitarianism. He and Vivian Rosenfeld, a student at [[New Jersey College for Women]], were married in March 1945 and they had two daughters, Linda and Diane.&lt;ref name=GUA2002/&gt;&lt;ref name=IND2005&gt;{{cite news |title=  Albert Schatz: Co-discoverer of streptomycin|author= Milton Wainwright|url= http://www.independent.co.uk/news/obituaries/albert-schatz-8050901.html|newspaper= The Independent|date= 4 February 2005|accessdate=17 August 2013}}&lt;/ref&gt; The couple were enthusiastic naturalists and environmentalists and they enjoyed the wilds of Vermont. Schatz was interested in the [[paranormal]] and [[alternative medicine]] ([[therapeutic touch]]). He campaigned against the fluoridation of drinking water,&lt;ref name=IND2005/&gt; argued for a &quot;proteolysis-chelation theory&quot; of tooth decay&lt;ref name=IND2005/&gt;&lt;ref&gt;{{cite journal |author=Schatz A., Martin J. J. |title=The proteolysis-chelation theory of dental caries |journal=J Am Dent Assoc |volume=65 |issue= |pages=368–75 |date=September 1962 |pmid=14498070 |doi= |url=}}&lt;/ref&gt; and proposed a novel theory for the cause of the extinction of the dinosaurs.&lt;ref name=IND2005/&gt;

==Academic career==
A fellow postgraduate student, Doris Ralston, described Schatz as &quot;A poverty-stricken, brilliant student who worked with a burning intensity.&quot; He graduated from [[Rutgers University]] in 1942 and commenced working as a postgraduate assistant under the supervision of [[Selman Waksman]], who led the soil microbiology department at Rutgers college of agriculture. Waksman had been directing a research program searching for new antibiotic compounds generated by microorganisms in ordinary soil since 1937, and his teams were to discover more than ten such chemicals between 1940 and 1952. After five months, Schatz was [[Conscription in the United States|conscripted]], and worked as a bacteriologist at a military hospital in Florida until he was discharged due to back problems.&lt;ref name=GUA2002/&gt;

On his return to Waksman's lab in 1943, Schatz offered to take on the search for an antibiotic effective against [[tubercle bacillus]] (the bacterium that causes TB) and [[Gram-negative bacteria]] responsible for other penicillin-resistant diseases. Within three and a half months he had identified two related strains of bacteria in the phylum [[Actinomycetes]] which stopped the growth of tubercle bacillus and several Gram-negative bacteria. One strain came from a mouth swab from a healthy duck, the other from soil outside his lab. He named the antibiotic derived from these bacteria &quot;[[streptomycin]].&quot;&lt;ref name=GUA2002/&gt;

Toxicity tests, animal trials and early clinical trials, for which Schasz produced the streptomycin, were conducted by Mayo Clinic, and by 1944 large clinical trials conducted by Merck in the UK and USA had proven streptomycin's effectiveness against TB, bubonic plague, cholera, typhoid fever and other penicillin-resistant diseases.&lt;ref name=GUA2002/&gt; 
 
After leaving Rutgers in 1946, Schatz worked at [[Brooklyn College]], and the National Agricultural College in Doylestown, Pennsylvania. He was a professor at the [[University of Chile]] from 1962 to 65, Professor of Education at [[Washington University]] from 1965 to 69, and Professor of Science Education at [[Temple University]] from 1969 to 80. Schatz published three textbooks and over 700 scientific papers.&lt;ref name=NYT2005&gt;{{cite news |title= |author= |url= |newspaper= |date= |accessdate=17 August 2013}}&lt;/ref&gt;&lt;ref name=IND2005/&gt;&lt;ref name=RUT2005&gt;{{cite web |url= http://urwebsrv.rutgers.edu/focus/article/Albert%20Schatz,%20co-discoverer%20of%20streptomycin,%20dies%20at%2084/1504|title=  Albert Schatz, co-discoverer of streptomycin, dies at 84|last1= |first1= |last2= |first2= |date= 21 February 2005|website=Rutgers Focus |publisher= Rutgers University Relations |accessdate=15 August 2013}}&lt;/ref&gt;

== Streptomycin controversy ==
Schatz was lead author, with Waksman, on the paper that first reported the discovery of streptomycin, and the second author, with Waksman, on the streptomycin patent application. At Waksman's request, in 1946, Schatz signed over his right to royalties from the US streptomycin patent to the Rutgers Research and Endowment Foundation, and later signed over his foreign rights. He said he agreed to this so as to make streptomycin available as readily and inexpensively as possible, and he understood that the foundation, also, was to receive no profit from the discovery.&lt;ref name = GUA2002/&gt;

Schatz began to feel that Waksman was playing down his (Schatz's) role in the discovery, and taking all the credit and recognition for their achievement. In 1949 it came out that Waksman, contrary to his public pronouncements, had a private agreement with the foundation giving him 20% of the royalties&amp;nbsp;– which by then had amounted to $350,000&amp;nbsp;– so, in March 1950, Schatz sued Waksman and the foundation for a share of the royalties and recognition of his role in the discovery of streptomycin.&lt;ref name=GUA2002/&gt;

An out-of-court settlement awarded Schatz $120,000 for the foreign patent rights, and 3% of the royalties, representing about $15,000 per annum for several years. Waksman conceded in court that Schatz, &quot;is entitled to credit legally and scientifically as co-discoverer of streptomycin.&quot; Schatz was never again able to get work in a top-level microbiology lab.&lt;ref name=GUA2002/&gt;&lt;ref name=NYT1950&gt;{{cite news |title= Dr. Schatz Wins 3% of Royalty; Named Co-Finder of Streptomycin; Key Figures in Streptomycin Discovery Suit |author= |url= http://select.nytimes.com/gst/abstract.html?res=F70D1EFF3E5D117B93C2AA1789D95F448585F9|newspaper= New York Times|date= 30 December 1950|accessdate=17 August 2013}}&lt;/ref&gt;

In October 1952, it was announced that Waksman would be awarded that year's Nobel prize for physiology or medicine for the discovery of streptomycin. After receiving letters from the vice-president of the agricultural college where Schatz was working at the time, and others, the Nobel committee's wording of the actual award on 12 December 1952 was for, &quot;ingenious, systematic and successful studies of the soil microbes that led to the discovery of streptomycin&quot; rather than, &quot;for the discovery of streptomycin&quot; as the original announcement had said.&lt;ref name=GUA2002/&gt;

When Milton Wainwright from [[Sheffield University]] arrived at Rutgers and interviewed faculty members for his 1990 book on antibiotics, ''Miracle Cure'', asking questions about Schatz, it piqued the curiosity of some professors, who made their own inquiries and spoke with Schatz. Convinced that he had been the victim of an injustice, a group of professors, including [[Karl Maramorosch]] and Douglas Eveleigh, began to lobby for Schatz's rehabilitation, culminating in the 1994 awarding of the Rutgers University Medal, the university's highest honor, to Schatz.&lt;ref name=GUA2002/&gt;

==Awards, honors and tributes==
Schatz received honorary degrees from Brazil, Peru, Chile and the Dominican Republic. On the 50th anniversary of the discovery of streptomycin, In 1994, he was awarded the Rutgers University Medal. The ''New York Times'' placed his and Waksman's 1948 streptomycin patent in the top 10 discoveries of the 20th century. The university has made Schatz's basement lab into a museum documenting his and other antibiotic discoveries made at the college.&lt;ref name=RUT2005/&gt;

==Legacy==
Albert Schatz's archives were donated to the [[Temple University]] Library.
{{botanist|A.Schatz}}

==See also==
*[[Nobel Prize controversies]]

==References==
{{reflist}}

==Further reading==
*{{cite journal |author=Kingston W |title=Streptomycin, Schatz v. Waksman, and the balance of credit for discovery |journal=J Hist Med Allied Sci |volume=59 |issue=3 |pages=441–62 |date=July 2004 |pmid=15270337 |doi= 10.1093/jhmas/jrh091|url=}}
*{{cite journal |author=Wainwright M |title=A Response to William Kingston, &quot;Streptomycin, Schatz versus Waksman, and the balance of credit for discovery&quot; |journal=J Hist Med Allied Sci |volume=60 |issue=2 |pages=218–20; discussion 221 |date=April 2005 |pmid=15737959 |doi=10.1093/jhmas/jri024 |url=}}
*{{cite book|author=Peter Pringle|title=Experiment Eleven: Dark Secrets Behind the Discovery of a Wonder Drug|url=http://books.google.com/books?id=0_uXMgEACAAJ|accessdate=18 August 2013|date=16 July 2013|publisher=Bloomsbury USA|isbn=978-1-62040-198-9}}
*{{cite book|author=Inge Auerbacher|title=Finding Dr. Schatz|url=http://books.google.com/books?id=rLW2zLOrLl4C|accessdate=18 August 2013|date=9 March 2006|publisher=iUniverse|isbn=978-0-595-82368-0}}
*{{cite book|author=Milton Wainwright|title=Miracle Cure: The Story of Penicillin and the Golden Age of Antibiotics|url=http://books.google.com/books?id=dRWLQgAACAAJ|accessdate=18 August 2013|year=1990|publisher=Basil Blackwell|isbn=978-0-631-16492-0}}

{{Authority control}}
{{Persondata
|NAME=Schatz, Albert Israel 
|SHORT DESCRIPTION=[[Microbiologist]]
|DATE OF BIRTH=2 February 1920
|PLACE OF BIRTH=[[Norwich, Connecticut]], USA
|DATE OF DEATH=17 January 2005
|PLACE OF DEATH=[[Philadelphia]], USA
}}
{{DEFAULTSORT:Schatz, Albert}}
[[Category:1922 births]]
[[Category:2005 deaths]]
[[Category:People from Norwich, Connecticut]]
[[Category:American scientists]]
[[Category:Soil scientists]]
[[Category:Microbiologists]]
[[Category:Antibiotics]]
[[Category:Rutgers University alumni]]
[[Category:Temple University faculty]]
[[Category:Brooklyn College faculty]]
[[Category:People from Connecticut]]
[[Category:American people of English descent]]
[[Category:American people of Russian-Jewish descent]]
[[Category:American socialists]]
[[Category:American environmentalists]]
[[Category:Deaths from pancreatic cancer]]
[[Category:Cancer deaths in Pennsylvania]]</text>
      <sha1>qiribdvymkd1bb6mqrwt78oq0wpylh7</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Pyrenocine</title>
    <ns>0</ns>
    <id>40253680</id>
    <revision>
      <id>573375514</id>
      <parentid>569011693</parentid>
      <timestamp>2013-09-17T18:50:32Z</timestamp>
      <contributor>
        <username>Edgar181</username>
        <id>491706</id>
      </contributor>
      <comment>not a medical treatment</comment>
      <text xml:space="preserve" bytes="304">
{{Orphan|date=August 2013}}


[[image:Pyrenocine A-C.png|thumb|Pyrenocines A-C]]

'''Pyrenocines''' are [[antibiotic]] [[mycotoxins]].

==Notes==
[http://www.ncbi.nlm.nih.gov/pubmed/3594310 Antibiotic activity of the pyrenocines]


[[Category:Antibiotics]]
[[Category:Mycotoxins]]



{{antibiotic-stub}}</text>
      <sha1>422burri3dqugvjsckp5zb5s2n6jl8w</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>The Demon under the Microscope</title>
    <ns>0</ns>
    <id>39934192</id>
    <revision>
      <id>606217005</id>
      <parentid>603681230</parentid>
      <timestamp>2014-04-28T18:43:19Z</timestamp>
      <contributor>
        <username>John</username>
        <id>764861</id>
      </contributor>
      <comment>clean up, [[WP:MOSICON|deflag]], [[WP:OVERLINK|overlink]], replaced: [[English language|English]] → English, [[United States|U.S.]] → United States using [[Project:AWB|AWB]]</comment>
      <text xml:space="preserve" bytes="1795">{{Infobox book 
| name = The Demon under the Microscope
| orig title = The Demon Under the Microscope: From Battlefield Hospitals to Nazi Labs, One Doctor's Heroic Search for the World's First Miracle Drug
| translator = 
| image = 
| caption = 
| author = [[Thomas Hager]]
| cover_artist = 
| country = United States
| language = English 
| series = 
| subject = [[History]]/[[History of the United States|U.S. History]]
| genre = [[Non-fiction]]
| publisher = Harmony
| release_date = September 19, 2006
| media_type = 
| pages =  352 pages
| size_weight = 
| isbn = ISBN 978-1400082131
| oclc= 
| preceded_by = 
| followed_by = 
}}
'''''The Demon Under the Microscope: From Battlefield Hospitals to Nazi Labs, One Doctor's Heroic Search for the World's First Miracle Drug''''' is a 2006 nonfiction book about the discovery of [[Prontosil]], the first commercially available antibacterial antibiotic and [[sulfanilamide]], the second commercial [[antibiotic]]. Prontosil was the first commercially available antibacterial [[antibiotic]] (with a relatively broad effect against [[Gram-positive]] [[Coccus|cocci]].  It was developed in the 1930s by a research team at the [[Bayer]] Laboratories of the [[IG Farben]] conglomerate in Germany. The discovery and development of this first [[Sulfonamide (medicine)|sulfonamide]] drug opened a new era in medicine.&lt;ref&gt;Hager, Thomas: ''The Demon Under the Microscope: From Battlefield Hospitals to Nazi Labs, One Doctor's Heroic Search for the World's First Miracle Drug''. Harmony Books 2006. ISBN 1-4000-8214-5&lt;/ref&gt;

== References ==
{{Reflist}}

{{SulfonamideAntiBiotics}}

{{DEFAULTSORT:Demon under the Microscope}}
[[Category:2006 books]]
[[Category:History books about medicine]]
[[Category:Antibiotics]]


{{antibiotic-stub}}
{{med-book-stub}}</text>
      <sha1>06w762ksjw6p9xwdef1n8d6x7eyasf6</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Yaequinolone J1</title>
    <ns>0</ns>
    <id>40403277</id>
    <revision>
      <id>571084209</id>
      <parentid>571063781</parentid>
      <timestamp>2013-09-01T14:44:17Z</timestamp>
      <contributor>
        <username>Derek R Bullamore</username>
        <id>698799</id>
      </contributor>
      <comment>Removed {{clean-up|link rot}} tag</comment>
      <text xml:space="preserve" bytes="3092">{{Chembox
|  Name = 
|  ImageFile = Yaequinolone J1.png
|   ImageSize = 150px
|   ImageAlt = 
|   ImageCaption = 
|  ImageFile1 = 
|   ImageSize1 = 
|   ImageAlt1 = 
|   ImageCaption1 = 
|  ImageFile2 = 
|   ImageSize2 = 
|   ImageAlt2 = 
|   ImageCaption2 = 
|  ImageFile3 = 
|   ImageSize3 = 
|   ImageAlt3 = 
|   ImageCaption3 = 
|  ImageFile4 = 
|   ImageSize4 = 
|   ImageAlt4 = 
|   ImageCaption4 = 
|  ImageFileL1 = 
|   ImageSizeL1 = 
|   ImageAltL1 = 
|   ImageCaptionL1 = 
|  ImageFileR1 = 
|   ImageSizeR1 = 
|   ImageAltR1 = 
|   ImageCaptionR1 = 
|  ImageFileL2 = 
|   ImageSizeL2 = 
|   ImageAltL2 = 
|   ImageCaptionL2 = 
|  ImageFileR2 = 
|   ImageSizeR2 = 
|   ImageAltR2 = 
|   ImageCaptionR2 = 
|  IUPACName = 
|  IUPACName_hidden = yes
|  SystematicName = 
|  OtherNames = 
| Section1 = {{Chembox Identifiers
|  Abbreviations = 
|  CASNo = 
|  CASNo_Comment = 
|  CASNo_Ref = 
|  CASNos = 
|  CASOther = 
|  PubChem = 
|  PubChem_Comment = 
|  PubChem5 = 
|  PubChem5_Comment = 
|  PubChemOther = 
|  ChemSpiderID =  9830053 
|  ChemSpiderID_Comment = 
|  ChemSpiderID5 = 
|  ChemSpiderIDOther = 
|  EINECS = 
|  EC-number = 
|  EINECSCASNO = 
|  UNNumber = 
|  DrugBank = 
|  KEGG = 
|  MeSHName = 
|  ChEBI = 
|  RTECS = 
|  ATCvet = 
|  ATCCode_prefix = 
|  ATCCode_suffix = 
|  ATC_Supplemental = 
|  SMILES = 
|  InChI = 
|  Beilstein = 
|  Gmelin = 
|  3DMet = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  Melting_notes = 
|  BoilingPt = 
|  Boiling_notes = 
|  LogP = 
|  VaporPressure = 
|  HenryConstant = 
|  AtmosphericOHRateConstant = 
|  pKa = 
|  pKb = 
|  Solubility = 
|  SolubleOther = 
|  Solvent = 
|  Sheet Resistance = 
|  Methacrylate Equiv Wt = 
|  Bulk Conductivity = }}
| Section3 = {{Chembox Structure
|  CrystalStruct = 
|  Coordination = 
|  MolShape = }}
| Section4 = {{Chembox Thermochemistry
|  DeltaHc = 
|  DeltaHf = 
|  Entropy = 
|  HeatCapacity = }}
| Section5 = {{Chembox Pharmacology
|  AdminRoutes = 
|  Bioavail = 
|  Metabolism = 
|  HalfLife = 
|  ProteinBound = 
|  Excretion = 
|  Legal_status = 
|  Legal_US = 
|  Legal_UK = 
|  Legal_AU = 
|  Legal_CA = 
|  PregCat = 
|  PregCat_AU = 
|  PregCat_US = }}
| Section6 = {{Chembox Explosive
|  ShockSens = 
|  FrictionSens = 
|  ExplosiveV = 
|  REFactor = }}
| Section7 = {{Chembox Hazards
|  ExternalMSDS = 
|  EUClass = 
|  EUIndex = 
|  MainHazards = 
|  NFPA-H = 
|  NFPA-F = 
|  NFPA-R = 
|  NFPA-O = 
|  RPhrases = 
|  SPhrases = 
|  RSPhrases = 
|  FlashPt = 
|  Autoignition = 
|  ExploLimits = 
|  LD50 = 
|  PEL = }}
| Section8 = {{Chembox Related
|  OtherAnions = 
|  OtherCations = 
|  OtherFunctn = 
|  Function = 
|  OtherCpds = }}
}}

'''Yaequinolone J1''' is an [[antibiotic]] made by ''[[Penicillium]]''.&lt;ref&gt;{{cite web|url=http://www.ncbi.nlm.nih.gov/pubmed/16321026 |title=Yaequinolones J1 and J2, novel insecticidal antibiotics from Penicillium sp. FKI-2140|publisher=Ncbi.nlm.gov|accessdate=2013-09-01}}&lt;/ref&gt;

==References==
{{Reflist}}

[[Category:Antibiotics]]


{{antibiotic-stub}}</text>
      <sha1>n9bpnt9ts6bjmo1ur65z8k15ach7m8r</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Arylomycin A2</title>
    <ns>0</ns>
    <id>40306037</id>
    <revision>
      <id>588627391</id>
      <parentid>587461526</parentid>
      <timestamp>2014-01-01T06:33:41Z</timestamp>
      <contributor>
        <username>Foura</username>
        <id>18934483</id>
      </contributor>
      <text xml:space="preserve" bytes="937">{{Multiple issues|{{refimprove|date=August 2013}}{{orphan|date=August 2013}}

}}

{{Chembox
| ImageFile = Arylomycin A2.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 5287707
|  SMILES = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Arylomycin A2''' is a [[synthetic]] arylomycin [[antibiotic]].

==Notes==
[http://www.ncbi.nlm.nih.gov/pubmed/18052061 Structural and initial biological analysis of synthetic arylomycin A2]

[http://onlinelibrary.wiley.com/doi/10.1002/chem.201000924/abstract Intramolecular Suzuki–Miyaura Reaction for the Total Synthesis of Signal Peptidase Inhibitors, Arylomycins A2 and B2]

[[Category:Antibiotics]]


{{Antibiotic-stub}}</text>
      <sha1>goe25e8dzkdlju3ntxom2v4rmw8mdvc</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>CMV423</title>
    <ns>0</ns>
    <id>40313295</id>
    <revision>
      <id>571065180</id>
      <parentid>570886853</parentid>
      <timestamp>2013-09-01T11:29:37Z</timestamp>
      <contributor>
        <username>Malcolma</username>
        <id>320496</id>
      </contributor>
      <comment>added [[Category:Antibiotics]]; removed {{uncategorized}} using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="757">{{Chembox
| ImageFile = CMV423.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 489128
|  SMILES = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''CMV423''' (2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide) is a lead antibiotic.

==Notes==
[http://www.ncbi.nlm.nih.gov/pubmed/12206879 2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections]



[[Category:Antibiotics]]</text>
      <sha1>nrfx9oai7oxcnmlfurcved6a3zfoprs</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Avibactam</title>
    <ns>0</ns>
    <id>40306772</id>
    <revision>
      <id>577301556</id>
      <parentid>577301514</parentid>
      <timestamp>2013-10-15T16:24:02Z</timestamp>
      <contributor>
        <username>Citation bot</username>
        <id>7903804</id>
      </contributor>
      <minor/>
      <comment>[458]Add: year, last1, first1, last2, first2, last3, first3, last4, first4, last5, first5, last6, first6, last7, first7, last8, first8, last9, first9, last10, first10, last11, first11, last12, first12, last13, first13, title, volume, issue, pages, doi,...</comment>
      <text xml:space="preserve" bytes="1505">{{Chembox
| ImageFile = Avibactam structure.svg
|  ImageSize = 200px
|  ImageAlt = 
| IUPACName = (2''S'',5''R'')-7-Oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 9835049
|  SMILES = C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)N
|  InChI = 1S/C7H11N3O6S/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15/h4-5H,1-3H2,(H2,8,11)(H,13,14,15)/t4-,5+/m1/s1
|  InChIKey = NDCUAPJVLWFHHB-UHNVWZDZSA-N}}
| Section2 = {{Chembox Properties
|  C=7|H=11|N=3|O=6|S=1
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Avibactam''' is a non-[[β-lactam]] [[Β-Lactamase inhibitor|β-lactamase inhibitor]] [[antibiotic]].&lt;ref&gt;{{cite journal|pmid=23913691|year=2013|last1=Ehmann|first1=DE|last2=Jahic|first2=H|last3=Ross|first3=PL|last4=Gu|first4=RF|last5=Hu|first5=J|last6=Durand-Réville|first6=TF|last7=Lahiri|first7=S|last8=Thresher|first8=J|last9=Livchak|first9=S|last10=Gao|first10=N|last11=Palmer|first11=T|last12=Walkup|first12=GK|last13=Fisher|first13=SL|title=Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases|volume=288|issue=39|pages=27960–71|doi=10.1074/jbc.M113.485979|pmc=3784710|journal=The Journal of biological chemistry}}&lt;/ref&gt;

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Beta-lactamase inhibitors]]
[[Category:Organosulfates]]


{{Antibiotic-stub}}</text>
      <sha1>dhd6lzk47he7x0m92j3unc6ehq8z7ur</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Brilacidin</title>
    <ns>0</ns>
    <id>40308088</id>
    <revision>
      <id>603740112</id>
      <parentid>600072519</parentid>
      <timestamp>2014-04-11T13:07:12Z</timestamp>
      <contributor>
        <username>Monkbot</username>
        <id>20483999</id>
      </contributor>
      <minor/>
      <comment>Task 4: Fix [[Help:CS1_errors#deprecated_params|CS1 deprecated coauthor parameter errors]] ([[Wikipedia:Bots/Requests for approval/Monkbot 4|bot trial]])</comment>
      <text xml:space="preserve" bytes="4373">{{Drugbox
| IUPAC_name        = N,N'-bis[3-{[5-(carbamimidoylamino)pentanoyl]amino}-2-[(3R)-pyrrolidin-3-yloxy]-5-(trifluoromethyl)phenyl]pyrimidine-4,6-dicarboxamide&lt;ref name=usan&gt;{{cite document|url=http://www.ama-assn.org/resources/doc/usan/brilacidin.pdf|title=STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL|date=July 25, 2012|publisher=American Medical Association}}&lt;/ref&gt;
| image             = Brilacidin-.png
| width             = 150px
| alt               = 
| image2            = 
| width2            = 
| alt2              = 
| imagename         = &lt;!-- else may use drug_name --&gt;
| drug_name         = &lt;!-- else may use imagename --&gt;
| caption           = 

&lt;!-- Clinical data --&gt;
| tradename         = None as of July 2012&lt;ref name=usan /&gt;
| Drugs.com         = 
| MedlinePlus       = 
| licence_EU        = &lt;!-- EMA requires brand name --&gt;
| licence_US        = &lt;!-- FDA may use generic name --&gt;
| DailyMedID        = &lt;!-- preference to licence_US --&gt;
| pregnancy_AU      = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;
| pregnancy_US      = &lt;!-- A / B            / C / D / X --&gt;
| pregnancy_category= 
| legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;
| legal_CA = &lt;!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --&gt;
| legal_UK = &lt;!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --&gt;
| legal_US = &lt;!-- OTC / Rx-only / Schedule I, II, III, IV, V --&gt;
| legal_status      = 
| dependency_liability = 
| routes_of_administration = 

&lt;!-- Pharmacokinetic data --&gt;
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 

&lt;!-- Identifiers --&gt;
| CAS_number        = 1224095-98-0 
| ATCvet            = 
| ATC_prefix        = none
| ATC_suffix        = 
| ATC_supplemental  = 
| PubChem           = 25023695
| PubChemSubstance  = 
| IUPHAR_ligand     = 
| DrugBank          = 
| ChemSpiderID      = 28651526
| UNII              = 
| KEGG              = 
| ChEBI             = 
| ChEMBL            = 
| synonyms          = 

&lt;!-- Chemical data --&gt;
| C=40 | H=50 | F=6 | N=14 | O=6 
| molecular_weight  = 936.9 g/[[Mole (unit)|mol]]
| smiles            = C1CNC[C@@H]1OC2=C(C=C(C=C2NC(=O)C3=CC(=NC=N3)C(=O)NC4=CC(=CC(=C4O[C@@H]5CCNC5)NC(=O)CCCCNC(=N)N)C(F)(F)F)C(F)(F)F)NC(=O)CCCCNC(=N)N
| InChI             = 1/C40H50F6N14O6/c41-39(42,43)21-13-25(57-31(61)5-1-3-9-53-37(47)48)33(65-23-7-11-51-18-23)27(15-21)59-35(63)29-17-30(56-20-55-29)36(64)60-28-16-22(40(44,45)46)14-26(34(28)66-24-8-12-52-19-24)58-32(62)6-2-4-10-54-38(49)50/h13-17,20,23-24,51-52H,1-12,18-19H2,(H,57,61)(H,58,62)(H,59,63)(H,60,64)(H4,47,48,53)(H4,49,50,54)/t23-,24-/m1/s1
| InChIKey          = QPDYBCZNGUJZDK-DNQXCXABBB
| StdInChI          = 1S/C40H50F6N14O6/c41-39(42,43)21-13-25(57-31(61)5-1-3-9-53-37(47)48)33(65-23-7-11-51-18-23)27(15-21)59-35(63)29-17-30(56-20-55-29)36(64)60-28-16-22(40(44,45)46)14-26(34(28)66-24-8-12-52-19-24)58-32(62)6-2-4-10-54-38(49)50/h13-17,20,23-24,51-52H,1-12,18-19H2,(H,57,61)(H,58,62)(H,59,63)(H,60,64)(H4,47,48,53)(H4,49,50,54)/t23-,24-/m1/s1
| StdInChIKey       = QPDYBCZNGUJZDK-DNQXCXABSA-N
| density           = 
| melting_point     = 
| melting_high      = 
| melting_notes     = 
| boiling_point     = 
| boiling_notes     = 
| solubility        = 
| specific_rotation = 
| sec_combustion    = 
}}

'''Brilacidin''' (formerly '''PMX-30063''') is an [[antibiotic]] that works by disrupting bacterial cell membranes, mimicking [[defensin]]s from [[innate immunity]].&lt;ref&gt;{{cite web|url=http://www.biocentury.com/products/pmx-30063|title=brilacidin (formerly PMX-30063)|work=BioCentury BCIQ|accessdate=2013-09-19|publisher=BioCentury Publications}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=Butler|first=Mark S|author2=Cooper, Matthew A|title=Antibiotics in the clinical pipeline in 2011|journal=The Journal of Antibiotics|date=18 May 2011|volume=64|issue=6|pages=413–425|doi=10.1038/ja.2011.44}}&lt;/ref&gt; 

==Notes==
{{reflist}}

==References==
*{{cite web|title=PolyMedix Receives USAN Approval for Generic Name of Brilacidin for PMX-30063|url=http://globenewswire.com/news-release/2012/06/12/479275/259063/en/PolyMedix-Receives-USAN-Approval-for-Generic-Name-of-Brilacidin-for-PMX-30063.html|accessdate=2013-09-19|date=June 12, 2012|publisher=Globe NewsWire}}

{{Antibiotics}}

[[Category:Antibiotics]]


{{Antibiotic-stub}}</text>
      <sha1>duf2rnljt6rh8xbi7l6j8i9b2ogfzgi</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Caprazamycin</title>
    <ns>0</ns>
    <id>40306212</id>
    <revision>
      <id>571159590</id>
      <parentid>570889954</parentid>
      <timestamp>2013-09-02T01:31:24Z</timestamp>
      <contributor>
        <username>Resoru</username>
        <id>5554679</id>
      </contributor>
      <minor/>
      <comment>clean up, added [[CAT:O|orphan]], [[CAT:UL|underlinked]] tags using [[Project:AWB|AWB]]</comment>
      <text xml:space="preserve" bytes="574">{{multiple issues|
{{Underlinked|date=September 2013}}
{{Orphan|date=September 2013}}
}}

[[image:Caprazamycins.png|thumb|Caprazamycin A, B. C. E, F]]

Caprazamycin antibiotics began with the ''[[Streptomyces]]'' isolate Caprazamycin B.

==Notes==
*[http://www.ncbi.nlm.nih.gov/pubmed/12931868 Caprazamycin B, a novel anti-tuberculosis antibiotic, from Streptomyces sp]
*[http://www.ncbi.nlm.nih.gov/pubmed/23532021 Novel semisynthetic antibiotics from caprazamycins A-G: caprazene derivatives and their antibacterial activity]

{{Antibiotic-stub}}

[[Category:Antibiotics]]</text>
      <sha1>qrcuz7oitfsmsly335al3j7mnlyt3zz</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Delvotest</title>
    <ns>0</ns>
    <id>40111892</id>
    <revision>
      <id>604603951</id>
      <parentid>604603815</parentid>
      <timestamp>2014-04-17T15:06:22Z</timestamp>
      <contributor>
        <ip>87.254.17.90</ip>
      </contributor>
      <text xml:space="preserve" bytes="724">{{multiple issues|
{{unreferenced|date=October 2013}}
{{Orphan|date=September 2013}}
}}

'''Delvotest''' is a widely used testing kit which detects all the most frequently used [[antibiotics]] in [[milk production]]. It is used to ensure milk safety.

The dairy sector has a responsibility to prevent the presence of antibiotics in milk for health reasons, processing and economic reasons and legal responsibility to adhere to the Maximum Risk Level defined in law.

Delvotest is a testing method that is used throughout the value chain of dairy by laboratories, dairy companies and farmers.

The UK distributor for Delvo SP-NT and Delvo BLF is http://www.millwoodproducts.co.uk/ 

[[Category:Antibiotics]]
[[Category:Milk]]</text>
      <sha1>mfbzh43bbnofzk11z6d13ac21xcuc0v</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Eravacycline</title>
    <ns>0</ns>
    <id>40308124</id>
    <revision>
      <id>585442455</id>
      <parentid>573846679</parentid>
      <timestamp>2013-12-10T15:22:39Z</timestamp>
      <contributor>
        <username>The chemistds</username>
        <id>13073709</id>
      </contributor>
      <comment>added CSID and InChIs, name and mol mas</comment>
      <text xml:space="preserve" bytes="1665">{{Chembox
| ImageFile = Eravacycline-.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = (4S,4aS,5aR,12aS)-4-(Dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(1-pyrrolidinylacetyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-2-tetracenecarboxamide
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 1207283-85-9
|  PubChem = 54726192
|  ChemSpiderID = 28495485
|  SMILES = CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=C(C(=C4C(=O)C3=C([C@@]2(C(=O)C(=C1O)C(=O)N)O)O)O)NC(=O)CN5CCCC5)F
|  InChI = 1/C27H31FN4O8/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39/h9,11,13,20,34,36-37,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33)/t11-,13-,20-,27-/m0/s1
|  InChIKey = HLFSMUUOKPBTSM-ISIOAQNYBD
|  StdInChI = 1S/C27H31FN4O8/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39/h9,11,13,20,34,36-37,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33)/t11-,13-,20-,27-/m0/s1
|  StdInChIKey = HLFSMUUOKPBTSM-ISIOAQNYSA-N
  }}
| Section2 = {{Chembox Properties
|  Formula = C&lt;sub&gt;27&lt;/sub&gt;H&lt;sub&gt;31&lt;/sub&gt;FN&lt;sub&gt;4&lt;/sub&gt;O&lt;sub&gt;8&lt;/sub&gt;
|  MolarMass = 558.555
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Eravacycline''' (TP-434) is a synthetic [[fluorocycline]] [[antibiotic]] in development.

==Notes==
[http://pubs.acs.org/doi/abs/10.1021/op4000219?journalCode=oprdfk Process R&amp;D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development]

[[Category:Antibiotics]]


{{Antibiotic-stub}}</text>
      <sha1>arghsrm92180ifvjlvcck1w7ye9fj2g</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Etamycin</title>
    <ns>0</ns>
    <id>40280906</id>
    <revision>
      <id>575607469</id>
      <parentid>575607202</parentid>
      <timestamp>2013-10-03T17:27:02Z</timestamp>
      <contributor>
        <username>Edgar181</username>
        <id>491706</id>
      </contributor>
      <text xml:space="preserve" bytes="967">{{Chembox
| ImageFile = Etamycin.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 
| OtherNames = Viridogrisein I, Etamycin A, Neoviridogrisein IV, Antibiotic K-179, Antibiotic F-1370A
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 196972
|  SMILES =  C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2C[C@@H](C[C@@H]2C(=O)N(CC(=O)N(C(C(=O)N[C@H](C(=O)N([C@H](C(=O)O1)C3=CC=CC=C3)C)C)[C@@H](C)C(C)C)C)C)O)CC(C)C)NC(=O)C4=C(C=CC=N4)O}}
| Section2 = {{Chembox Properties
|  C=44|H=62|N=8|O=11
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Etamycin''' is a [[cyclic peptide]] antibiotic isolate of marine [[actinomycete]].&lt;ref&gt;{{cite journal|doi=10.1038/ja.2010.22 | url = http://www.nature.com/ja/journal/v63/n5/full/ja201022a.html}}&lt;/ref&gt;

==Notes==
{{reflist}}


{{Antibiotic-stub}}

[[Category:Antibiotics]]
[[Category:Cyclic peptides]]</text>
      <sha1>joow328kxxdl9hfaxn30ow2prcy9ax4</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Streptonigrin</title>
    <ns>0</ns>
    <id>40403438</id>
    <revision>
      <id>573674924</id>
      <parentid>571211922</parentid>
      <timestamp>2013-09-19T17:54:52Z</timestamp>
      <contributor>
        <username>Dawynn</username>
        <id>6655086</id>
      </contributor>
      <comment>/* Notes */ Stub-sorting. [[Wikipedia:WikiProject Stub sorting|You can help!]]</comment>
      <text xml:space="preserve" bytes="772">{{linkrot|date=August 2013}}

{{Chembox
| ImageFile = Streptonigrin.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 5351165
|  SMILES = }}
| Section2 = {{Chembox Properties
|  C=25|H=22|N=4|O=8
|  MolarMass = 506.46418
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Streptonigrin''' is an antibiotic with anticancer activity.

==Notes==
[http://www.ncbi.nlm.nih.gov/pubmed/14729099 Antitumor antibiotic streptonigrin and its derivatives as inhibitors of nitric oxide-dependent activation of soluble guanylyl cyclase]



[[Category:Antibiotics]]


{{science-stub}}</text>
      <sha1>5l39yud2jyf3bwlqimmavlyw1idzxlp</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Questiomycin A</title>
    <ns>0</ns>
    <id>40393763</id>
    <revision>
      <id>606311545</id>
      <parentid>576719855</parentid>
      <timestamp>2014-04-29T10:48:48Z</timestamp>
      <contributor>
        <username>WildCation</username>
        <id>21073353</id>
      </contributor>
      <comment>Expanded ChemBox, added molar mass, CSID, ChEBI ChEMBL and Kegg IDs, SMILES, InChIs</comment>
      <text xml:space="preserve" bytes="1264">{{Chembox
| ImageFile = Questiomycin A.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 2-Amino-3H-phenoxazin-3-one
| SystematicName = 2-Amino-3H-phenoxazin-3-one
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 72725
|  ChemSpiderID = 65565
|  SMILES = C1=CC=C2C(=C1)N=C3C=C(C(=O)C=C3O2)N
|  InChI = 1/C12H8N2O2/c13-7-5-9-12(6-10(7)15)16-11-4-2-1-3-8(11)14-9/h1-6H,13H2
|  InChIKey = RDJXPXHQENRCNG-UHFFFAOYAN
|  StdInChI = 1S/C12H8N2O2/c13-7-5-9-12(6-10(7)15)16-11-4-2-1-3-8(11)14-9/h1-6H,13H2
|  StdInChIKey = RDJXPXHQENRCNG-UHFFFAOYSA-N
|  RTECS = 
|  MeSHName = 
|  ChEBI = 17293
|  ChEMBL = 146710
|  KEGG = C02161}}
| Section2 = {{Chembox Properties
|  Formula = |C=12|O=2|N=2|H=8|
|  MolarMass = 212.204
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Questiomycin A''' is an [[antibiotic]] made by the fungus ''[[Penicillium expansum]]''.

==See also==
[[Xantocillin]]

==Notes==
*[http://www.ncbi.nlm.nih.gov/pubmed/15283339 Penicillium expansum, a resident fungal strain of the orbital complex Mir, producing xanthocillin X and questiomycin A]



[[Category:Penicillium]]
[[Category:Antibiotics]]</text>
      <sha1>p68w10ffi1n2o65l5st60b8cd8nyadz</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Halocyamine</title>
    <ns>0</ns>
    <id>40291666</id>
    <revision>
      <id>571366214</id>
      <parentid>570892282</parentid>
      <timestamp>2013-09-03T12:01:15Z</timestamp>
      <contributor>
        <username>Alvin Seville</username>
        <id>8629244</id>
      </contributor>
      <comment>removing and categorizing</comment>
      <text xml:space="preserve" bytes="435">[[image:Halocyamine A&amp;B.png|thumb|Halocyamine A and B]]

Halocyaminess are antibiotic peptides isolated from the [[ascidian]] ''Halocynthia roretzi''.

==Notes==
[http://www.ncbi.nlm.nih.gov/pubmed/2322536 Halocyamines: novel antimicrobial tetrapeptide-like substances isolated from the hemocytes of the solitary ascidian Halocynthia roretzi]

[[Category:Ascidiacea]]
[[Category:Antibiotics]]
[[Category:Peptides]]

{{Antibiotic-stub}}</text>
      <sha1>qsj292b2tca562f65b3isfgfozzdk3p</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Omadacycline</title>
    <ns>0</ns>
    <id>40306838</id>
    <revision>
      <id>571487065</id>
      <parentid>570887721</parentid>
      <timestamp>2013-09-04T09:03:43Z</timestamp>
      <contributor>
        <username>Malcolma</username>
        <id>320496</id>
      </contributor>
      <comment>added [[Category:Antibiotics]]; removed {{uncategorized}} using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="787">{{Chembox
| ImageFile = Omadacycline.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 54697325
|  SMILES = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Omadacycline''' is an antibiotic currently undergoing clinical trials.

==Notes==
[http://www.ncbi.nlm.nih.gov/pubmed/22908151 A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections]



[[Category:Antibiotics]]


{{Antibiotic-stub}}</text>
      <sha1>bxx6smn2gluqn3hmz6mprtm4ecmc7tq</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Nocathiacin I</title>
    <ns>0</ns>
    <id>40306477</id>
    <revision>
      <id>571515723</id>
      <parentid>570966147</parentid>
      <timestamp>2013-09-04T14:18:04Z</timestamp>
      <contributor>
        <username>Malcolma</username>
        <id>320496</id>
      </contributor>
      <comment>added [[Category:Antibiotics]]; removed {{uncategorized}} using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="3064">{{Chembox
|  Name = 
|  ImageFile = Nocathiacin I.png
|   ImageSize = 150px
|   ImageAlt = 
|   ImageCaption = 
|  ImageFile1 = 
|   ImageSize1 = 
|   ImageAlt1 = 
|   ImageCaption1 = 
|  ImageFile2 = 
|   ImageSize2 = 
|   ImageAlt2 = 
|   ImageCaption2 = 
|  ImageFile3 = 
|   ImageSize3 = 
|   ImageAlt3 = 
|   ImageCaption3 = 
|  ImageFile4 = 
|   ImageSize4 = 
|   ImageAlt4 = 
|   ImageCaption4 = 
|  ImageFileL1 = 
|   ImageSizeL1 = 
|   ImageAltL1 = 
|   ImageCaptionL1 = 
|  ImageFileR1 = 
|   ImageSizeR1 = 
|   ImageAltR1 = 
|   ImageCaptionR1 = 
|  ImageFileL2 = 
|   ImageSizeL2 = 
|   ImageAltL2 = 
|   ImageCaptionL2 = 
|  ImageFileR2 = 
|   ImageSizeR2 = 
|   ImageAltR2 = 
|   ImageCaptionR2 = 
|  IUPACName = 
|  IUPACName_hidden = yes
|  SystematicName = 
|  OtherNames = 
| Section1 = {{Chembox Identifiers
|  Abbreviations = 
|  CASNo = 
|  CASNo_Comment = 
|  CASNo_Ref = 
|  CASNos = 
|  CASOther = 
|  PubChem = 
|  PubChem_Comment = 
|  PubChem5 = 
|  PubChem5_Comment = 
|  PubChemOther = 
|  ChemSpiderID = 10190178
|  ChemSpiderID_Comment = 
|  ChemSpiderID5 = 
|  ChemSpiderIDOther = 
|  EINECS = 
|  EC-number = 
|  EINECSCASNO = 
|  UNNumber = 
|  DrugBank = 
|  KEGG = 
|  MeSHName = 
|  ChEBI = 
|  RTECS = 
|  ATCvet = 
|  ATCCode_prefix = 
|  ATCCode_suffix = 
|  ATC_Supplemental = 
|  SMILES = 
|  InChI = 
|  Beilstein = 
|  Gmelin = 
|  3DMet = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  Melting_notes = 
|  BoilingPt = 
|  Boiling_notes = 
|  LogP = 
|  VaporPressure = 
|  HenryConstant = 
|  AtmosphericOHRateConstant = 
|  pKa = 
|  pKb = 
|  Solubility = 
|  SolubleOther = 
|  Solvent = 
|  Sheet Resistance = 
|  Methacrylate Equiv Wt = 
|  Bulk Conductivity = }}
| Section3 = {{Chembox Structure
|  CrystalStruct = 
|  Coordination = 
|  MolShape = }}
| Section4 = {{Chembox Thermochemistry
|  DeltaHc = 
|  DeltaHf = 
|  Entropy = 
|  HeatCapacity = }}
| Section5 = {{Chembox Pharmacology
|  AdminRoutes = 
|  Bioavail = 
|  Metabolism = 
|  HalfLife = 
|  ProteinBound = 
|  Excretion = 
|  Legal_status = 
|  Legal_US = 
|  Legal_UK = 
|  Legal_AU = 
|  Legal_CA = 
|  PregCat = 
|  PregCat_AU = 
|  PregCat_US = }}
| Section6 = {{Chembox Explosive
|  ShockSens = 
|  FrictionSens = 
|  ExplosiveV = 
|  REFactor = }}
| Section7 = {{Chembox Hazards
|  ExternalMSDS = 
|  EUClass = 
|  EUIndex = 
|  MainHazards = 
|  NFPA-H = 
|  NFPA-F = 
|  NFPA-R = 
|  NFPA-O = 
|  RPhrases = 
|  SPhrases = 
|  RSPhrases = 
|  FlashPt = 
|  Autoignition = 
|  ExploLimits = 
|  LD50 = 
|  PEL = }}
| Section8 = {{Chembox Related
|  OtherAnions = 
|  OtherCations = 
|  OtherFunctn = 
|  Function = 
|  OtherCpds = }}
}}

'''Nocathiacin I''' is an antibiotic peptide.

==Notes==
[http://www.ncbi.nlm.nih.gov/pubmed/12467390 Synthesis of novel nocathiacin-class antibiotics. Condensation of glycolaldehyde with primary amides and tandem reductive amination of amadori-rearranged 2-oxoethyl intermediates]



[[Category:Antibiotics]]


{{Antibiotic-stub}}</text>
      <sha1>j8k5vxnzvn2ysx2mstr2bs3g0oogf0k</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Mannopeptimycin glycopeptide</title>
    <ns>0</ns>
    <id>40306097</id>
    <revision>
      <id>571515833</id>
      <parentid>570961029</parentid>
      <timestamp>2013-09-04T14:19:09Z</timestamp>
      <contributor>
        <username>Malcolma</username>
        <id>320496</id>
      </contributor>
      <comment>added [[Category:Antibiotics]]; removed {{uncategorized}} using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="2986">{{Chembox
|  Name = 
|  ImageFile = Mannopeptimycin glycopeptide.png
|   ImageSize = 150px
|   ImageAlt = 
|   ImageCaption = 
|  ImageFile1 = 
|   ImageSize1 = 
|   ImageAlt1 = 
|   ImageCaption1 = 
|  ImageFile2 = 
|   ImageSize2 = 
|   ImageAlt2 = 
|   ImageCaption2 = 
|  ImageFile3 = 
|   ImageSize3 = 
|   ImageAlt3 = 
|   ImageCaption3 = 
|  ImageFile4 = 
|   ImageSize4 = 
|   ImageAlt4 = 
|   ImageCaption4 = 
|  ImageFileL1 = 
|   ImageSizeL1 = 
|   ImageAltL1 = 
|   ImageCaptionL1 = 
|  ImageFileR1 = 
|   ImageSizeR1 = 
|   ImageAltR1 = 
|   ImageCaptionR1 = 
|  ImageFileL2 = 
|   ImageSizeL2 = 
|   ImageAltL2 = 
|   ImageCaptionL2 = 
|  ImageFileR2 = 
|   ImageSizeR2 = 
|   ImageAltR2 = 
|   ImageCaptionR2 = 
|  IUPACName = 
|  IUPACName_hidden = yes
|  SystematicName = 
|  OtherNames = 
| Section1 = {{Chembox Identifiers
|  Abbreviations = 
|  CASNo = 
|  CASNo_Comment = 
|  CASNo_Ref = 
|  CASNos = 
|  CASOther = 
|  PubChem = 
|  PubChem_Comment = 
|  PubChem5 = 
|  PubChem5_Comment = 
|  PubChemOther = 
|  ChemSpiderID = 23114590
|  ChemSpiderID_Comment = 
|  ChemSpiderID5 = 
|  ChemSpiderIDOther = 
|  EINECS = 
|  EC-number = 
|  EINECSCASNO = 
|  UNNumber = 
|  DrugBank = 
|  KEGG = 
|  MeSHName = 
|  ChEBI = 
|  RTECS = 
|  ATCvet = 
|  ATCCode_prefix = 
|  ATCCode_suffix = 
|  ATC_Supplemental = 
|  SMILES = 
|  InChI = 
|  Beilstein = 
|  Gmelin = 
|  3DMet = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  Melting_notes = 
|  BoilingPt = 
|  Boiling_notes = 
|  LogP = 
|  VaporPressure = 
|  HenryConstant = 
|  AtmosphericOHRateConstant = 
|  pKa = 
|  pKb = 
|  Solubility = 
|  SolubleOther = 
|  Solvent = 
|  Sheet Resistance = 
|  Methacrylate Equiv Wt = 
|  Bulk Conductivity = }}
| Section3 = {{Chembox Structure
|  CrystalStruct = 
|  Coordination = 
|  MolShape = }}
| Section4 = {{Chembox Thermochemistry
|  DeltaHc = 
|  DeltaHf = 
|  Entropy = 
|  HeatCapacity = }}
| Section5 = {{Chembox Pharmacology
|  AdminRoutes = 
|  Bioavail = 
|  Metabolism = 
|  HalfLife = 
|  ProteinBound = 
|  Excretion = 
|  Legal_status = 
|  Legal_US = 
|  Legal_UK = 
|  Legal_AU = 
|  Legal_CA = 
|  PregCat = 
|  PregCat_AU = 
|  PregCat_US = }}
| Section6 = {{Chembox Explosive
|  ShockSens = 
|  FrictionSens = 
|  ExplosiveV = 
|  REFactor = }}
| Section7 = {{Chembox Hazards
|  ExternalMSDS = 
|  EUClass = 
|  EUIndex = 
|  MainHazards = 
|  NFPA-H = 
|  NFPA-F = 
|  NFPA-R = 
|  NFPA-O = 
|  RPhrases = 
|  SPhrases = 
|  RSPhrases = 
|  FlashPt = 
|  Autoignition = 
|  ExploLimits = 
|  LD50 = 
|  PEL = }}
| Section8 = {{Chembox Related
|  OtherAnions = 
|  OtherCations = 
|  OtherFunctn = 
|  Function = 
|  OtherCpds = }}
}}

'''Mannopeptimycin glycopeptide''' is a lead antibiotic peptide.

==Notes==
[http://www.ncbi.nlm.nih.gov/pubmed/12643932 Novel ether derivatives of mannopeptimycin glycopeptide antibiotic]



[[Category:Antibiotics]]


{{Antibiotic-stub}}</text>
      <sha1>fjv1u0ck3k68yrmf4sr9a7vpglfwbib</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Tachyplesin</title>
    <ns>0</ns>
    <id>40279875</id>
    <revision>
      <id>605417246</id>
      <parentid>605237768</parentid>
      <timestamp>2014-04-23T07:02:22Z</timestamp>
      <contributor>
        <username>BG19bot</username>
        <id>14508071</id>
      </contributor>
      <minor/>
      <comment>[[WP:CHECKWIKI]] error fix for #61.  Punctuation goes before References. Do [[Wikipedia:GENFIXES|general fixes]] if a problem exists. - using [[Project:AWB|AWB]] (10072)</comment>
      <text xml:space="preserve" bytes="577">{{more footnotes|date=August 2013}}

[[image:Tachyplesins.png|thumb|Tachyplesin I and Tachyplesin II]]

'''Tachyplesin''' is an [[antimicrobial peptides|antimicrobial peptide]] isolated from the [[horseshoe crab]]. It has a molecular weight of 2.36 kDa and the amino acid sequence KWCFRVCYRGICYRRCR.&lt;ref&gt;http://www.ncbi.nlm.nih.gov/pubmed/3141410&lt;/ref&gt;

==Notes==
[http://www.ncbi.nlm.nih.gov/pubmed/1666545 Direct virus inactivation of tachyplesin I and its isopeptides from horseshoe crab hemocytes]

==References==
{{Reflist}}

[[Category:Antibiotics]]


{{Antibiotic-stub}}</text>
      <sha1>m8no1j236h8cvghvk8xfapd4mi6xc8x</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Saquayamycin</title>
    <ns>0</ns>
    <id>40423530</id>
    <revision>
      <id>589105559</id>
      <parentid>573636839</parentid>
      <timestamp>2014-01-04T07:22:16Z</timestamp>
      <contributor>
        <username>EricEnfermero</username>
        <id>15977090</id>
      </contributor>
      <minor/>
      <comment>medicine stub → pharm stub</comment>
      <text xml:space="preserve" bytes="311">[[image:Saquayamycin A and B.png|thumb|Saquayamycin A and B]]

'''Saquayamycins''' are &quot;[[aquayamycin]]-type&quot; antibiotics isolated from ''Streptomyces nodosus''.

==Notes==
[http://www.ncbi.nlm.nih.gov/pubmed/3840796 Saquayamycins, new aquayamycin-group antibiotics]



[[Category:Antibiotics]]

{{pharma-stub}}</text>
      <sha1>mh5a5691pujakzx6sb6kop5s1zjsj16</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Saptomycin</title>
    <ns>0</ns>
    <id>40423572</id>
    <revision>
      <id>572598617</id>
      <parentid>571329080</parentid>
      <timestamp>2013-09-12T09:22:29Z</timestamp>
      <contributor>
        <username>Malcolma</username>
        <id>320496</id>
      </contributor>
      <comment>added [[Category:Antibiotics]]; removed {{uncategorized}} using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="399">[[image:Saptomycins D and E.png|thumb|Saptomycins D and E]]

'''Saptomycins''' are antibiotic-anticancer compounds isolated from ''Streptomyces''.

==External links==
* [http://www.ncbi.nlm.nih.gov/pubmed/8244880 Novel antitumor antibiotics, saptomycins. I. Taxonomy of the producing organism, fermentation, HPLC analysis and biological activities]






{{chemistry-stub}}

[[Category:Antibiotics]]</text>
      <sha1>8pb3lr44kp1ivh94t8k542qg0ki50kk</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Lenapenem</title>
    <ns>0</ns>
    <id>40466683</id>
    <revision>
      <id>573587537</id>
      <parentid>572599439</parentid>
      <timestamp>2013-09-19T03:01:59Z</timestamp>
      <contributor>
        <username>Rpyle731</username>
        <id>46515</id>
      </contributor>
      <minor/>
      <comment>stub sort</comment>
      <text xml:space="preserve" bytes="364">[[image:Lenapenem.png|thumb|Lenapenem]]

'''Lenapenem''' is a [[carbapenem]] antibiotic.

==External links==
*[http://www.chemspider.com/Chemical-Structure.187460.html?rid=bc448bea-8bab-4c15-9e10-d0da3b47be84 ChemSpider - Lenapenem]
*[http://www.ncbi.nlm.nih.gov/pubmed/11922861 Recent developments in carbapenems]



[[Category:Antibiotics]]


{{antibiotic-stub}}</text>
      <sha1>9etc667i3mpm1ow3b29lammmwhz3s4l</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Marinone</title>
    <ns>0</ns>
    <id>40504328</id>
    <revision>
      <id>578344691</id>
      <parentid>572599608</parentid>
      <timestamp>2013-10-23T01:26:20Z</timestamp>
      <contributor>
        <username>ChrisGualtieri</username>
        <id>16333418</id>
      </contributor>
      <minor/>
      <comment>General Fixes, added [[CAT:O|orphan]] tag using [[Project:AWB|AWB]]</comment>
      <text xml:space="preserve" bytes="2985">{{Orphan|date=October 2013}}

{{Chembox
|  Name = 
|  ImageFile = Marinone.png
|   ImageSize = 150px
|   ImageAlt = 
|   ImageCaption = 
|  ImageFile1 = 
|   ImageSize1 = 
|   ImageAlt1 = 
|   ImageCaption1 = 
|  ImageFile2 = 
|   ImageSize2 = 
|   ImageAlt2 = 
|   ImageCaption2 = 
|  ImageFile3 = 
|   ImageSize3 = 
|   ImageAlt3 = 
|   ImageCaption3 = 
|  ImageFile4 = 
|   ImageSize4 = 
|   ImageAlt4 = 
|   ImageCaption4 = 
|  ImageFileL1 = 
|   ImageSizeL1 = 
|   ImageAltL1 = 
|   ImageCaptionL1 = 
|  ImageFileR1 = 
|   ImageSizeR1 = 
|   ImageAltR1 = 
|   ImageCaptionR1 = 
|  ImageFileL2 = 
|   ImageSizeL2 = 
|   ImageAltL2 = 
|   ImageCaptionL2 = 
|  ImageFileR2 = 
|   ImageSizeR2 = 
|   ImageAltR2 = 
|   ImageCaptionR2 = 
|  IUPACName = 
|  IUPACName_hidden = yes
|  SystematicName = 
|  OtherNames = 
| Section1 = {{Chembox Identifiers
|  Abbreviations = 
|  CASNo = 
|  CASNo_Comment = 
|  CASNo_Ref = 
|  CASNos = 
|  CASOther = 
|  PubChem = 
|  PubChem_Comment = 
|  PubChem5 = 
|  PubChem5_Comment = 
|  PubChemOther = 
|  ChemSpiderID = 8633563
|  ChemSpiderID_Comment = 
|  ChemSpiderID5 = 
|  ChemSpiderIDOther = 
|  EINECS = 
|  EC-number = 
|  EINECSCASNO = 
|  UNNumber = 
|  DrugBank = 
|  KEGG = 
|  MeSHName = 
|  ChEBI = 
|  RTECS = 
|  ATCvet = 
|  ATCCode_prefix = 
|  ATCCode_suffix = 
|  ATC_Supplemental = 
|  SMILES = 
|  InChI = 
|  Beilstein = 
|  Gmelin = 
|  3DMet = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  Melting_notes = 
|  BoilingPt = 
|  Boiling_notes = 
|  LogP = 
|  VaporPressure = 
|  HenryConstant = 
|  AtmosphericOHRateConstant = 
|  pKa = 
|  pKb = 
|  Solubility = 
|  SolubleOther = 
|  Solvent = 
|  Sheet Resistance = 
|  Methacrylate Equiv Wt = 
|  Bulk Conductivity = }}
| Section3 = {{Chembox Structure
|  CrystalStruct = 
|  Coordination = 
|  MolShape = }}
| Section4 = {{Chembox Thermochemistry
|  DeltaHc = 
|  DeltaHf = 
|  Entropy = 
|  HeatCapacity = }}
| Section5 = {{Chembox Pharmacology
|  AdminRoutes = 
|  Bioavail = 
|  Metabolism = 
|  HalfLife = 
|  ProteinBound = 
|  Excretion = 
|  Legal_status = 
|  Legal_US = 
|  Legal_UK = 
|  Legal_AU = 
|  Legal_CA = 
|  PregCat = 
|  PregCat_AU = 
|  PregCat_US = }}
| Section6 = {{Chembox Explosive
|  ShockSens = 
|  FrictionSens = 
|  ExplosiveV = 
|  REFactor = }}
| Section7 = {{Chembox Hazards
|  ExternalMSDS = 
|  EUClass = 
|  EUIndex = 
|  MainHazards = 
|  NFPA-H = 
|  NFPA-F = 
|  NFPA-R = 
|  NFPA-O = 
|  RPhrases = 
|  SPhrases = 
|  RSPhrases = 
|  FlashPt = 
|  Autoignition = 
|  ExploLimits = 
|  LD50 = 
|  PEL = }}
| Section8 = {{Chembox Related
|  OtherAnions = 
|  OtherCations = 
|  OtherFunctn = 
|  Function = 
|  OtherCpds = }}
}}

'''Marinone''' is an antibiotic made by marine [[actinomycetes]].

==External links==
* [http://www.ncbi.nlm.nih.gov/pubmed/7710421 Bioactive compounds from marine actinomycetes]

[[Category:Antibiotics]]


{{organic-chem-stub}}</text>
      <sha1>5qjt4jktvtl7bsxwur8erg0wfcxqw6j</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Debromomarinone</title>
    <ns>0</ns>
    <id>40504308</id>
    <revision>
      <id>578344674</id>
      <parentid>572599660</parentid>
      <timestamp>2013-10-23T01:26:14Z</timestamp>
      <contributor>
        <username>ChrisGualtieri</username>
        <id>16333418</id>
      </contributor>
      <minor/>
      <comment>General Fixes, added [[CAT:O|orphan]] tag using [[Project:AWB|AWB]]</comment>
      <text xml:space="preserve" bytes="3000">{{Orphan|date=October 2013}}

{{Chembox
|  Name = 
|  ImageFile = Debromomarinone.png
|   ImageSize = 150px
|   ImageAlt = 
|   ImageCaption = 
|  ImageFile1 = 
|   ImageSize1 = 
|   ImageAlt1 = 
|   ImageCaption1 = 
|  ImageFile2 = 
|   ImageSize2 = 
|   ImageAlt2 = 
|   ImageCaption2 = 
|  ImageFile3 = 
|   ImageSize3 = 
|   ImageAlt3 = 
|   ImageCaption3 = 
|  ImageFile4 = 
|   ImageSize4 = 
|   ImageAlt4 = 
|   ImageCaption4 = 
|  ImageFileL1 = 
|   ImageSizeL1 = 
|   ImageAltL1 = 
|   ImageCaptionL1 = 
|  ImageFileR1 = 
|   ImageSizeR1 = 
|   ImageAltR1 = 
|   ImageCaptionR1 = 
|  ImageFileL2 = 
|   ImageSizeL2 = 
|   ImageAltL2 = 
|   ImageCaptionL2 = 
|  ImageFileR2 = 
|   ImageSizeR2 = 
|   ImageAltR2 = 
|   ImageCaptionR2 = 
|  IUPACName = 
|  IUPACName_hidden = yes
|  SystematicName = 
|  OtherNames = 
| Section1 = {{Chembox Identifiers
|  Abbreviations = 
|  CASNo = 
|  CASNo_Comment = 
|  CASNo_Ref = 
|  CASNos = 
|  CASOther = 
|  PubChem = 
|  PubChem_Comment = 
|  PubChem5 = 
|  PubChem5_Comment = 
|  PubChemOther = 
|  ChemSpiderID = 8584615 
|  ChemSpiderID_Comment = 
|  ChemSpiderID5 = 
|  ChemSpiderIDOther = 
|  EINECS = 
|  EC-number = 
|  EINECSCASNO = 
|  UNNumber = 
|  DrugBank = 
|  KEGG = 
|  MeSHName = 
|  ChEBI = 
|  RTECS = 
|  ATCvet = 
|  ATCCode_prefix = 
|  ATCCode_suffix = 
|  ATC_Supplemental = 
|  SMILES = 
|  InChI = 
|  Beilstein = 
|  Gmelin = 
|  3DMet = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  Melting_notes = 
|  BoilingPt = 
|  Boiling_notes = 
|  LogP = 
|  VaporPressure = 
|  HenryConstant = 
|  AtmosphericOHRateConstant = 
|  pKa = 
|  pKb = 
|  Solubility = 
|  SolubleOther = 
|  Solvent = 
|  Sheet Resistance = 
|  Methacrylate Equiv Wt = 
|  Bulk Conductivity = }}
| Section3 = {{Chembox Structure
|  CrystalStruct = 
|  Coordination = 
|  MolShape = }}
| Section4 = {{Chembox Thermochemistry
|  DeltaHc = 
|  DeltaHf = 
|  Entropy = 
|  HeatCapacity = }}
| Section5 = {{Chembox Pharmacology
|  AdminRoutes = 
|  Bioavail = 
|  Metabolism = 
|  HalfLife = 
|  ProteinBound = 
|  Excretion = 
|  Legal_status = 
|  Legal_US = 
|  Legal_UK = 
|  Legal_AU = 
|  Legal_CA = 
|  PregCat = 
|  PregCat_AU = 
|  PregCat_US = }}
| Section6 = {{Chembox Explosive
|  ShockSens = 
|  FrictionSens = 
|  ExplosiveV = 
|  REFactor = }}
| Section7 = {{Chembox Hazards
|  ExternalMSDS = 
|  EUClass = 
|  EUIndex = 
|  MainHazards = 
|  NFPA-H = 
|  NFPA-F = 
|  NFPA-R = 
|  NFPA-O = 
|  RPhrases = 
|  SPhrases = 
|  RSPhrases = 
|  FlashPt = 
|  Autoignition = 
|  ExploLimits = 
|  LD50 = 
|  PEL = }}
| Section8 = {{Chembox Related
|  OtherAnions = 
|  OtherCations = 
|  OtherFunctn = 
|  Function = 
|  OtherCpds = }}
}}

'''Debromomarinone''' is an antibiotic made by marine [[actinomycetes]].

==External links==
* [http://www.ncbi.nlm.nih.gov/pubmed/7710421 Bioactive compounds from marine actinomycetes]

[[Category:Antibiotics]]


{{organic-chem-stub}}</text>
      <sha1>hzlssasczhv5q5j8pj39u7y3mzn48ig</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>MC21-A</title>
    <ns>0</ns>
    <id>40504268</id>
    <revision>
      <id>595632622</id>
      <parentid>583393912</parentid>
      <timestamp>2014-02-15T20:35:15Z</timestamp>
      <contributor>
        <username>Rjwilmsi</username>
        <id>203434</id>
      </contributor>
      <minor/>
      <comment>Journal cites, added 1 PMID using [[Project:AWB|AWB]] (9944)</comment>
      <text xml:space="preserve" bytes="3464">{{Chembox
|  Name = 
|  ImageFile = MC21-A.png
|   ImageSize = 150px
|   ImageAlt = 
|   ImageCaption = 
|  IUPACName =  2,4-Dibromo-6-(3,5-dibromo-2-hydroxyphenyl)phenol
|  SystematicName = 
|  OtherNames = Bromophene; 2,2'-Dihydroxy-3,3',5,5'-tetrabromobiphenyl; 3,3',5,5'-Tetrabromo-2,2'-biphenyldiol
| Section1 = {{Chembox Identifiers
|  Abbreviations = 
|  CASNo = 21987-62-2
|  CASNo_Comment = 
|  CASNo_Ref = 
|  PubChem = 30891
|  PubChem_Comment = 
|  ChemSpiderID = 28660
|  ChemSpiderID_Comment = 
|  EINECS = 
|  EC-number = 
|  EINECSCASNO = 
|  UNNumber = 
|  DrugBank = 
|  KEGG = 
|  MeSHName = 3,3',5,5'-tetrabromo-2,2'-biphenyldiol
|  ChEBI = 
|  RTECS = DV5185000
|  ATCvet = 
|  ATCCode_prefix = 
|  ATCCode_suffix = 
|  ATC_Supplemental = 
|  SMILES = C1=C(C=C(C(=C1Br)O)C2=CC(=CC(=C2O)Br)Br)Br
|  InChI = 1S/C12H6Br4O2/c13-5-1-7(11(17)9(15)3-5)8-2-6(14)4-10(16)12(8)18/h1-4,17-18H
|  InChIKey = TXODBIOSWNNKJM-UHFFFAOYSA-N
|  Beilstein = 
|  Gmelin = 
|  3DMet = }}
| Section2 = {{Chembox Properties
|  C=12 | H=6 |  Br=4 | O=2
|  Appearance = Cryst. (CHCl&lt;sub&gt;3&lt;/sub&gt;) &lt;!-- Physical Description --&gt;
|  Density = 
|  MeltingPt = 205-207 °C
|  Melting_notes = 
|  BoilingPt = 
|  Boiling_notes = 
|  LogP = 
|  VaporPressure = 
|  HenryConstant = 
|  AtmosphericOHRateConstant = 
|  pKa = 
|  pKb = 
|  Solubility = Sol. MeOH, CHCl&lt;sub&gt;3&lt;/sub&gt;&lt;br/&gt;insol. H&lt;sub&gt;2&lt;/sub&gt;O, hexane
|  SolubleOther = 
|  Solvent = 
|  Sheet Resistance = 
|  Methacrylate Equiv Wt = 
|  Bulk Conductivity = }}
| Section3 = {{Chembox Structure
|  CrystalStruct = 
|  Coordination = 
|  MolShape = }}
| Section4 = {{Chembox Thermochemistry
|  DeltaHc = 
|  DeltaHf = 
|  Entropy = 
|  HeatCapacity = }}
| Section5 = {{Chembox Pharmacology
|  AdminRoutes = 
|  Bioavail = 
|  Metabolism = 
|  HalfLife = 
|  ProteinBound = 
|  Excretion = 
|  Legal_status = 
|  Legal_US = 
|  Legal_UK = 
|  Legal_AU = 
|  Legal_CA = 
|  PregCat = 
|  PregCat_AU = 
|  PregCat_US = }}
| Section6 = {{Chembox Explosive
|  ShockSens = 
|  FrictionSens = 
|  ExplosiveV = 
|  REFactor = }}
| Section7 = {{Chembox Hazards
|  ExternalMSDS = 
|  EUClass = 
|  EUIndex = 
|  MainHazards = 
|  NFPA-H = 
|  NFPA-F = 
|  NFPA-R = 
|  NFPA-O = 
|  RPhrases = 
|  SPhrases = 
|  RSPhrases = 
|  FlashPt = 
|  Autoignition = 
|  ExploLimits = 
|  LD50 = 
|  PEL = }}
| Section8 = {{Chembox Related
|  OtherAnions = 
|  OtherCations = 
|  OtherFunctn = [[MC21-B]]&lt;br&gt;[[Polybrominated biphenyl]]
|  Function = [[biphenyl]]s
|  OtherCpds = }}
}}

'''MC21-A''' ('''bromophene''') is an [[antibiotic]] isolated from the O-BC30 strain of a marine [[bacterium]], ''[[Pseudoalteromonas phenolica]]''.&lt;ref name=&quot;Isnansetyo &amp; Kamei&quot;&gt;{{cite journal |last1=Isnansetyo |first1=Alim |last2=Kamei |first2=Yuto |date=February 2003 |title=MC21-A, a Bactericidal Antibiotic Produced by a New Marine Bacterium, ''Pseudoalteromonas phenolica'' sp. nov. O-BC30T, against Methicillin-Resistant ''Staphylococcus aureus'' |url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC151744/ |journal=[[Antimicrobial Agents and Chemotherapy]] |location=Washington, DC |publisher=[[American Society for Microbiology]] |volume=47 |issue=2 |pages=480–488 |doi=10.1128/AAC.47.2.480-488.2003 |issn=1098-6596 |oclc=678833406 |pmc=151744 |accessdate=2013-11-23 |pmid=12543647}}&lt;/ref&gt;

==References==
{{Reflist}}

[[Category:Antibiotics]]
[[Category:Organobromides]]
[[Category:Polyphenols]]
[[Category:Biphenyls]]


{{organohalide-stub}}</text>
      <sha1>6j0pxm1y2mm37otnn3mq7bdm49zjo16</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Helquinoline</title>
    <ns>0</ns>
    <id>40503730</id>
    <revision>
      <id>572599790</id>
      <parentid>572495442</parentid>
      <timestamp>2013-09-12T09:34:54Z</timestamp>
      <contributor>
        <username>Malcolma</username>
        <id>320496</id>
      </contributor>
      <comment>added [[Category:Antibiotics]] using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="3016">{{Chembox
|  Name = 
|  ImageFile = Helquinoline.png
|   ImageSize = 150px
|   ImageAlt = 
|   ImageCaption = 
|  ImageFile1 = 
|   ImageSize1 = 
|   ImageAlt1 = 
|   ImageCaption1 = 
|  ImageFile2 = 
|   ImageSize2 = 
|   ImageAlt2 = 
|   ImageCaption2 = 
|  ImageFile3 = 
|   ImageSize3 = 
|   ImageAlt3 = 
|   ImageCaption3 = 
|  ImageFile4 = 
|   ImageSize4 = 
|   ImageAlt4 = 
|   ImageCaption4 = 
|  ImageFileL1 = 
|   ImageSizeL1 = 
|   ImageAltL1 = 
|   ImageCaptionL1 = 
|  ImageFileR1 = 
|   ImageSizeR1 = 
|   ImageAltR1 = 
|   ImageCaptionR1 = 
|  ImageFileL2 = 
|   ImageSizeL2 = 
|   ImageAltL2 = 
|   ImageCaptionL2 = 
|  ImageFileR2 = 
|   ImageSizeR2 = 
|   ImageAltR2 = 
|   ImageCaptionR2 = 
|  IUPACName = 
|  IUPACName_hidden = yes
|  SystematicName = 
|  OtherNames = 
| Section1 = {{Chembox Identifiers
|  Abbreviations = 
|  CASNo = 
|  CASNo_Comment = 
|  CASNo_Ref = 
|  CASNos = 
|  CASOther = 
|  PubChem = 
|  PubChem_Comment = 
|  PubChem5 = 
|  PubChem5_Comment = 
|  PubChemOther = 
|  ChemSpiderID = 10480270
|  ChemSpiderID_Comment = 
|  ChemSpiderID5 = 
|  ChemSpiderIDOther = 
|  EINECS = 
|  EC-number = 
|  EINECSCASNO = 
|  UNNumber = 
|  DrugBank = 
|  KEGG = 
|  MeSHName = 
|  ChEBI = 
|  RTECS = 
|  ATCvet = 
|  ATCCode_prefix = 
|  ATCCode_suffix = 
|  ATC_Supplemental = 
|  SMILES = 
|  InChI = 
|  Beilstein = 
|  Gmelin = 
|  3DMet = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  Melting_notes = 
|  BoilingPt = 
|  Boiling_notes = 
|  LogP = 
|  VaporPressure = 
|  HenryConstant = 
|  AtmosphericOHRateConstant = 
|  pKa = 
|  pKb = 
|  Solubility = 
|  SolubleOther = 
|  Solvent = 
|  Sheet Resistance = 
|  Methacrylate Equiv Wt = 
|  Bulk Conductivity = }}
| Section3 = {{Chembox Structure
|  CrystalStruct = 
|  Coordination = 
|  MolShape = }}
| Section4 = {{Chembox Thermochemistry
|  DeltaHc = 
|  DeltaHf = 
|  Entropy = 
|  HeatCapacity = }}
| Section5 = {{Chembox Pharmacology
|  AdminRoutes = 
|  Bioavail = 
|  Metabolism = 
|  HalfLife = 
|  ProteinBound = 
|  Excretion = 
|  Legal_status = 
|  Legal_US = 
|  Legal_UK = 
|  Legal_AU = 
|  Legal_CA = 
|  PregCat = 
|  PregCat_AU = 
|  PregCat_US = }}
| Section6 = {{Chembox Explosive
|  ShockSens = 
|  FrictionSens = 
|  ExplosiveV = 
|  REFactor = }}
| Section7 = {{Chembox Hazards
|  ExternalMSDS = 
|  EUClass = 
|  EUIndex = 
|  MainHazards = 
|  NFPA-H = 
|  NFPA-F = 
|  NFPA-R = 
|  NFPA-O = 
|  RPhrases = 
|  SPhrases = 
|  RSPhrases = 
|  FlashPt = 
|  Autoignition = 
|  ExploLimits = 
|  LD50 = 
|  PEL = }}
| Section8 = {{Chembox Related
|  OtherAnions = 
|  OtherCations = 
|  OtherFunctn = 
|  Function = 
|  OtherCpds = }}
}}

'''Helquinoline''' is a tetrahydroquinoline antibiotic isolated from ''Janibacter''.

==External links==
[http://www.ncbi.nlm.nih.gov/pubmed/15032481 Helquinoline, a new tetrahydroquinoline antibiotic from Janibacter limosus Hel 1+]



[[Category:Antibiotics]]


{{organic-chem-stub}}</text>
      <sha1>cj8ovgont03w3wg3zobuosl8vanfj3o</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Moromycin</title>
    <ns>0</ns>
    <id>40423551</id>
    <revision>
      <id>573768820</id>
      <parentid>572599989</parentid>
      <timestamp>2013-09-20T11:54:54Z</timestamp>
      <contributor>
        <username>Dawynn</username>
        <id>6655086</id>
      </contributor>
      <comment>/* Notes */ Stub-sorting. [[Wikipedia:WikiProject Stub sorting|You can help!]]</comment>
      <text xml:space="preserve" bytes="367">[[image:Moromycin A and B.png|thumb|Moromycin A and B]]

'''Moromycins''' are anticancer antibiotics of the [[angucycline]] class.

==Notes==
[http://pubs.acs.org/doi/abs/10.1021/np800281f Article Moromycins A and B, Isolation and Structure Elucidation of C-Glycosylangucycline-Type Antibiotics from Streptomyces sp. KY002]



[[Category:Antibiotics]]


{{drug-stub}}</text>
      <sha1>j45bkyqbek5brd614yqoo3mtdntw773</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Hedamycin</title>
    <ns>0</ns>
    <id>40423734</id>
    <revision>
      <id>572856795</id>
      <parentid>572648763</parentid>
      <timestamp>2013-09-14T07:44:07Z</timestamp>
      <contributor>
        <username>Christian75</username>
        <id>1306352</id>
      </contributor>
      <comment>→ {{Aromatic-stub}}</comment>
      <text xml:space="preserve" bytes="751">{{Chembox
| ImageFile = Hedamycin.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 98033
|  SMILES = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Hedamycin''' is an [[antibiotic]] with anticancer activity.

==External Links==
[http://www.ncbi.nlm.nih.gov/pubmed/15141015 DNA damage responses triggered by a highly cytotoxic monofunctional DNA alkylator, hedamycin, a pluramycin antitumor antibiotic]

{{DEFAULTSORT:Hedamycin}}



[[Category:Antibiotics]]


{{Aromatic-stub}}</text>
      <sha1>56nx36jli3al14qcjgv5sbq8fmbqkqw</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Kettapeptin</title>
    <ns>0</ns>
    <id>40503696</id>
    <revision>
      <id>588967952</id>
      <parentid>588967926</parentid>
      <timestamp>2014-01-03T12:36:48Z</timestamp>
      <contributor>
        <username>Citation bot</username>
        <id>7903804</id>
      </contributor>
      <minor/>
      <comment>[458]Add: year, last1, first1, last2, first2, last3, first3, last4, first4, last5, first5, last6, first6, title, volume, issue, pages, doi, journal. Tweak: last2, last3, last4, last5, last6. Formatted [[WP:ENDASH|dashes]].  | [[User:Edgar181|Edgar181]]</comment>
      <text xml:space="preserve" bytes="2464">{{Chembox
|  Name = 
|  ImageFile = Kettapeptin.svg
|   ImageSize = 250px
|  SystematicName = 
|  OtherNames = 
| Section1 = {{Chembox Identifiers
|  Abbreviations = 
|  CASNo = 
|  PubChem = 
|  ChemSpiderID = 9796916
|  ChemSpiderID_Comment = 
|  SMILES = O=C1O[C@@H](C(C)C)[C@@H](C(=O)N3NCCC[C@@H]3C(=O)N(O)[C@H](C(=O)N(C)[C@@H](C(=O)N2NCCC[C@@H]2C(=O)N[C@@H]1[C@@H](O)C)C)COC)NC(=O)[C@@](O)([C@]4(O)OC(/C(=C/C(C(=O)/C(=C/C)C)C)C)[C@H](CC4)C)CC
|  InChI=1S/C48H78N8O15/c1-13-26(5)37(58)28(7)23-29(8)39-27(6)19-20-48(67,71-39)47(66,14-2)46(65)52-36-38(25(3)4)70-45(64)35(31(10)57)51-40(59)32-17-15-21-49-54(32)41(60)30(9)53(11)42(61)34(24-69-12)56(68)43(62)33-18-16-22-50-55(33)44(36)63/h13,23,25,27-28,30-36,38-39,49-50,57,66-68H,14-22,24H2,1-12H3,(H,51,59)(H,52,65)/b26-13+,29-23+/t27-,28?,30+,31-,32+,33+,34-,35+,36-,38-,39?,47+,48+/m0/s1
|  InChIKey=GXVLICYFXVVWOH-RKMZHTRFSA-N
}}
| Section2 = {{Chembox Properties
|  C=48|H=78|N=8|O=15
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  Melting_notes = 
|  BoilingPt = 
|  Boiling_notes = 
|  Solubility = 
|  SolubleOther = 
|  Solvent = 
}}
| Section5 = {{Chembox Pharmacology
|  AdminRoutes = 
|  Bioavail = 
|  Metabolism = 
|  HalfLife = 
|  ProteinBound = 
|  Excretion = 
|  Legal_status = 
|  Legal_US = 
|  Legal_UK = 
|  Legal_AU = 
|  Legal_CA = 
|  PregCat = 
|  PregCat_AU = 
|  PregCat_US = }}
| Section6 = {{Chembox Explosive
|  ShockSens = 
|  FrictionSens = 
|  ExplosiveV = 
|  REFactor = }}
| Section7 = {{Chembox Hazards
|  ExternalMSDS = 
|  EUClass = 
|  EUIndex = 
|  MainHazards = 
|  NFPA-H = 
|  NFPA-F = 
|  NFPA-R = 
|  NFPA-O = 
|  RPhrases = 
|  SPhrases = 
|  RSPhrases = 
|  FlashPt = 
|  Autoignition = 
|  ExploLimits = 
|  LD50 = 
|  PEL = }}
| Section8 = {{Chembox Related
|  OtherAnions = 
|  OtherCations = 
|  OtherFunctn = 
|  Function = 
|  OtherCpds = }}
}}

'''Kettapeptin''' is a hexadepsipeptide antibiotic isolated from ''[[Streptomyces]]''.&lt;ref&gt;{{cite journal|pmid=16883782|year=2006|last1=Maskey|first1=RP|last2=Fotso|first2=S|last3=Sevvana|first3=M|last4=Usón|first4=I|last5=Grün-Wollny|first5=I|last6=Laatsch|first6=H|title=Kettapeptin: Isolation, structure elucidation and activity of a new hexadepsipeptide antibiotic from a terrestrial Streptomyces sp|volume=59|issue=5|pages=309–14|doi=10.1038/ja.2006.44|journal=The Journal of antibiotics}}&lt;/ref&gt;

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Depsipeptides]]


{{antibiotic-stub}}</text>
      <sha1>m1e73r8f24eac9l2tr8s0zd86wew7xn</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Aplasmomycin</title>
    <ns>0</ns>
    <id>40501095</id>
    <revision>
      <id>572733565</id>
      <parentid>572453762</parentid>
      <timestamp>2013-09-13T08:42:47Z</timestamp>
      <contributor>
        <username>Malcolma</username>
        <id>320496</id>
      </contributor>
      <comment>+[[Category:Antibiotics]]; +[[Category:Antimalarial agents]] using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="801">{{Chembox
| ImageFile = Aplasmomycin.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 23665592
|  SMILES = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Aplasmomycin''' is an antibiotic with antimalarial activity isolated from ''[[Streptomycete]]''.

==External links==
[http://www.ncbi.nlm.nih.gov/pubmed/994322 Studies on marine microorganisms. V. A new antibiotic, aplasmomycin, produced by a streptomycete isolated from shallow sea mud]



[[Category:Antibiotics]]
[[Category:Antimalarial agents]]


{{organic-chem-stub}}</text>
      <sha1>qw7ntosts7gljrrt129q73071czbigg</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Urauchimycin</title>
    <ns>0</ns>
    <id>40501076</id>
    <revision>
      <id>574071610</id>
      <parentid>572733605</parentid>
      <timestamp>2013-09-22T17:48:52Z</timestamp>
      <contributor>
        <username>Yikrazuul</username>
        <id>5113168</id>
      </contributor>
      <comment>data</comment>
      <text xml:space="preserve" bytes="362">[[File:Urauchimycin A.svg|thumb|Urauchimycin A]]

'''Urauchimycins''' are [[antimycin]] antibiotics isolated from marine [[actinomycete]].

==External links==
[http://www.ncbi.nlm.nih.gov/pubmed/8468237 Novel antimycin antibiotics, urauchimycins A and B, produced by marine actinomycete]



[[Category:Antibiotics]]
{{Commons|Urauchimycins}}

{{antibiotic-stub}}</text>
      <sha1>euem1vy54yjn884spz4kel8thggb2ob</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Kedarcidin</title>
    <ns>0</ns>
    <id>40430775</id>
    <revision>
      <id>609074478</id>
      <parentid>606495486</parentid>
      <timestamp>2014-05-18T10:00:07Z</timestamp>
      <contributor>
        <username>Pjoef</username>
        <id>3804503</id>
      </contributor>
      <comment>Disambiguated: [[Ansa]] → [[bridge (chemical)]], [[apoprotein]] → [[Apolipoprotein]]</comment>
      <text xml:space="preserve" bytes="25170">{{Chembox
| ImageFile = Kedarcidin chromophore 2007 revised 1.png
| ImageFile2 = Kedarcidin 3D structure.png
| Width = 320
|  ImageSize = 300px
|  ImageAlt = 
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 6444256
|  PubChem_Comment = (chromophore)
|  ChemSpiderID = 26286043
|  ChemSpiderID_Comment = (chromophore)
|  SMILES = C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]\2COC(=O)C[C@H](c3ccc(c(n3)Cl)O[C@H]4C=C5C#C/C2=C\C#C[C@H]6[C@]5([C@H]4O[C@H]7C[C@@]([C@H]([C@@H](O7)C)O)(C)O)O6)NC(=O)c8cc9c(cc8O)cc(c(c9OC)OC)OC(C)C)O)N(C)C
|  SMILES_Comment = (chromophore)
|  InChI = 1/C53H60ClN3O16/c1-25(2)67-38-18-29-17-35(58)32(20-31(29)46(64-8)47(38)65-9)51(62)56-34-21-42(60)66-24-40(71-43-22-36(59)45(57(6)7)26(3)68-43)28-11-10-12-41-53(73-41)30(14-13-28)19-39(70-37-16-15-33(34)55-50(37)54)49(53)72-44-23-52(5,63)48(61)27(4)69-44/h11,15-20,25-27,34,36,39-41,43-45,48-49,58-59,61,63H,21-24H2,1-9H3,(H,56,62)/b28-11+/t26-,27-,34+,36-,39-,40+,41-,43-,44-,45+,48-,49-,52+,53+/m0/s1
|  InChI_Comment = (chromophore)
|  InChIKey = RSXFZXJOBQZOOM-WXIIGEIKBJ
|  InChIKey_Comment = (chromophore)
|  StdInChI = 1S/C53H60ClN3O16/c1-25(2)67-38-18-29-17-35(58)32(20-31(29)46(64-8)47(38)65-9)51(62)56-34-21-42(60)66-24-40(71-43-22-36(59)45(57(6)7)26(3)68-43)28-11-10-12-41-53(73-41)30(14-13-28)19-39(70-37-16-15-33(34)55-50(37)54)49(53)72-44-23-52(5,63)48(61)27(4)69-44/h11,15-20,25-27,34,36,39-41,43-45,48-49,58-59,61,63H,21-24H2,1-9H3,(H,56,62)/b28-11+/t26-,27-,34+,36-,39-,40+,41-,43-,44-,45+,48-,49-,52+,53+/m0/s1
|  StdInChI_Comment = (chromophore)
|  StdInChIKey = RSXFZXJOBQZOOM-WXIIGEIKSA-N
|  StdInChIKey_Comment = (chromophore)}}
| Section2 = {{Chembox Properties
|  Formula = C&lt;sub&gt;53&lt;/sub&gt;H&lt;sub&gt;60&lt;/sub&gt;ClN&lt;sub&gt;3&lt;/sub&gt;O&lt;sub&gt;16&lt;/sub&gt;
|  MolarMass = 1030.51
|  Appearance = Buff-colored amorphous solid
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = Cytotoxic, mutagen.
|  FlashPt = 
|  Autoignition = }}
}}

'''Kedarcidin''' is a [[chromoprotein]] antibiotic with anticancer activity first isolated from an [[Actinobacteria|''Actinomycete'']] in 1992, comprising an [[bridge (chemical)|ansa-bridged]] [[enediyne]] chromophore (shown) as well as an [[Apolipoprotein|apoprotein]] that serves to stabilize this potent cytotoxin in the producing organism. Like other members of the enediyne antitumor antibiotic family—so named for the nine- or ten-membered core structure bearing an [[alkene]] directly attached to two [[alkyne|alkynyl]] appendages—kedarcidin was likely evolved to kill bacteria that compete with the producing organism. Because it achieves this by causing DNA damage, however, kedarcidin is capable of harming tumor cells, as well. Kedarcidin is thus the subject of considerable scientific research, both for its structural complexity as well as its powerful anticancer properties.

==Discovery and structure elucidation==

Kedarcidin was first discovered in 1992, when bioassays conducted at [[Bristol-Myers Squibb]] indicated the presence of a DNA-damaging chromoprotein in the fermentation broth of a novel actinomycete strain.  The involvement of a non-peptidic [[chromophore]] was deduced by UV spectroscopy, and reverse-phase chromatography effected the dissociation of this [[Noncovalent bonding|noncovalently]] bound chromophore from its apoprotein host. This isolate—kedarcidin chromophore—decomposed readily in ambient conditions, and was shown to possess considerable cytotoxicity ([[IC50|IC&lt;sub&gt;50&lt;/sub&gt;]] 0.4&amp;nbsp;ng/mL, HCT-116 human colorectal carcinoma cell line).&lt;ref name=&quot;Leet 1993&quot; /&gt;

Subsequent [[NMR]], [[mass spectrometry]], chemical degradation, and derivatization experiments enabled the isolation team to correctly identify all of the key structural features of kedarcidin chromophore, including the enediyne bicyclic core, the ansa-bridging chloropyridyl ring, mycarose and kedarosamine sugars, and naphthoamide appendage. Unfortunately, owing to the unique challenges posed by the unprecedented structure, the initial report had several errors. The bicyclic core proved particularly difficult to deconvolute, as the interpretation of [[Nuclear Overhauser effect|NOE]] correlations led the researchers to misassign the relative stereochemistry of the core stereotetrad. Moreover, as global absolute chemistry was assigned on the basis of NOE correlations between the stereodefined L-mycarose sugar and the [[aglycone]], the errors of the stereotetrad propagated to the other two stereocenters of the aglycone. Connectivity of the naphthoamide group to the ansa bridge was also misjudged in the initial report.

These errors were later corrected by the independent synthetic efforts of researchers at [[Tohoku University]] and [[Harvard University]]. In 1997, en route to the originally reported structure, researchers under the direction of Prof. Hirama discovered that the spectroscopic data of the proposed chloroazatyrosyl (''S'')-[[Alpha-amino acid|α-amino acid]] derivative were not consistent with those of the degradation product characterized by Leet ''et al''. Instead, an (''R'')-[[Beta amino acid|β-amino acid]] derivative was proposed and validated by the Hirama group. This revision led Hirama ''et al''. to invert the other aglycone stereocenters as well, affording a revised structure of kedarcidin chromophore that differed only in the relative stereochemistry of the mycarose-bearing carbon, C10.&lt;ref name=&quot;Hirama 1997&quot; /&gt; Finally, in 2007, Prof. Myers and co-workers synthesized the structure proposed by Hirama ''et al''.; the corresponding NMR spectroscopic data were distinct from that of the natural product, leading the Myers group to revise the stereochemistry of the mycarose-bearing carbon to 10-(''S'').&lt;ref name=&quot;Myers 2007&quot; /&gt;

[[File:Kedarcidin structure series of revisions.png|875x227px|framed|center|Evolution of the proposed structure of kedarcidin chromophore]]

==Mechanism of Action==
Like other enediynes, kedarcidin chromophore comprises a core structure that forms destructive free radicals, as well as appendages that deliver this &quot;warhead&quot; to its intended target, DNA. Thus, the general mechanism by which kedarcidin chromophore damages DNA is known; however, the details of this process—particularly the necessity of nucleophilic activiation—have been disputed. 

[[File:Kedarcidin core Bergman equilibrium.png|700px|center|Equilibrium of kedarcidin chromophore core and Bergman-cycloaromatized biradical.&lt;ref name=&quot;Hirama 1995&quot; /&gt;]]

===Free-Radical DNA Damage===
[[File:DNA damage mechanism.png|575x319px|framed|right|Proposed mechanism of DNA scission by kedarcidin chromophore–induced 4'-H abstraction.]] The unifying mechanism of bioactivity in all enediyne antibiotics is the [[Bergman cyclization]], wherein the enediyne portion undergoes spontaneous cycloaromatization to generate a ''para''-[[benzyne]] biradical activated toward homolytic abstraction of hydrogen from suitable donors, including the [[deoxyribose]] sugars of DNA. This generates a carbon-centered free radical on DNA, which undergoes oxidation by molecular oxygen. The resulting peroxide decomposes to form single- or double-stranded breaks in DNA, ultimately leading to cell death.&lt;ref name=&quot;Bioactivation reviews&quot; /&gt;

With considerable sequence selectivity, kedarcidin chromophore binds and cleaves DNA preferentially at TCCTn-mer sites, producing single-strand breaks. Puzzlingly, while the structure of kedarcidin chromophore is most closely related to that of [[neocarzinostatin|neocarzinostatin chromophore]], the former shares sequence-specificity with the structurally distinct [[calicheamicin]] enediyne antitumor antibiotic. The naphthoic acid substructure has been implicated in DNA binding, likely through [[intercalation (chemistry)|intercalation]]. To this end, kedarcidin chromophore–induced DNA cleavage is diminished by the addition of divalent cations divalent cations such as Ca&lt;sup&gt;2+&lt;/sup&gt; and Mg&lt;sup&gt;2+&lt;/sup&gt;, which [[Chelation|chelatively]] bind the naphthoic acid group of kedarcidin chromophore and thus lessen its affinity for DNA. Competition experiments with [[netropsin]], a known binder of the DNA minor groove, indicate that kedarcidin likely binds the minor groove as well.&lt;ref name=&quot;Zein&quot; /&gt;

[[File:Kedarcidin borohydride reduction.png|550x177px|framed|right|Borohydride-induced tandem epoxide opening–Bergman cycloaromatization of kedarcidin chromophore.&lt;ref name=&quot;Leet 1993&quot; /&gt; Analogous nucleophilic &quot;bioactiviation&quot; was initially implicated in the mechanism of action as well.]]

===Nucleophilic Activation===
''In vivo'' nucelophilic addition of [[thiolate]]s to C12 and consequent opening of the core epoxide has been hypothesized to trigger Bergman cyclization in kedarcidin chromophore. Nucleophilic activiation is thought to diminish the ring strain incurred by formation of the cycloaromatized product, and thus activiate kedarcidin chromophore toward DNA scission.&lt;ref name=&quot;Zein&quot; /&gt; In the isolation and structural characterization studies carried out by Leet ''et al''.,&lt;ref name=&quot;Leet 1993&quot; /&gt; C12-[[sodium borohydride]] reduction of kedarcidin chromophore induced rapid cycloaromatization and so facilitated studies of the otherwise unstable natural product. Consequently, C12-nucleophilic activation is proposed extensively in review literature&lt;ref name=&quot;Bioactivation reviews&quot; /&gt; as a possible means for triggering the cycloaromatization event ''in vivo''.

[[File:Ring strain MM2.png|250px|right|Ring strain associated with the C1-C12 double bond in kedarcidin chromophore core.&lt;ref name=&quot;Hirama 1995&quot; /&gt;]]

Recent evidence suggests that spontaneous cycloaromatization of kedarcidin chromophore is competitive with nucleophilic bioactivation, if not the predominant mechanism ''in vivo''. While [[Force field (chemistry)|MM2]] calculations show that the C1–C12 double bond in the bicyclic core imparts a considerable amount of ring strain (ca. 14 kcal·mol&lt;sup&gt;−1&lt;/sup&gt;) to the [6,5,5] tricycle formed upon Bergman cyclization–reduction, Hirama ''et al.'' note that the 5,9-fused enediyne core is susceptible to cycloaromatization–redution in the absence of both thiol &quot;activating agents&quot; and (non-solvent) hydrogen donors. The kedarcidin chromophore aglycone similarly undergoes reductive cycloaromatization at comparable rates irrespective of the presence of [[2-Mercaptoethanol|β-mercaptoethanol]], a common thiol reductant.&lt;ref name=&quot;Myers 2002&quot; /&gt; In a model system, it was found that the 5,9-bicyclic core of kedarcidin chromophore exists in equilibrium with the corresponding 5,5,6-tricyclic cycloaromatized biradical.&lt;ref name=&quot;Hirama 1995&quot; /&gt; The rate of pseudo-first-order decay of this model enediyne is highly dependent on the solvent hydrogen-donor ability, indicating that the hydrogen abstraction step following biradical formation is kinetically significant in the cycloaromatization of the enediyne, as opposed to acyclic systems, where formation of the biradical itself is known to be the rate-limiting step.&lt;ref name=&quot;Bergman 1972&quot; /&gt; It is noteworthy that of the solvents examined, [[tetrahydrofuran]]—structurally homologous with [[deoxyribose]]—led to comparatively fast decomposition of the 5,9-fused enediyne scaffold (''t''&lt;sub&gt;½&lt;/sub&gt; = 68 min);&lt;ref name=&quot;Hirama 1995&quot; /&gt; Zein ''et al.'' independently remark that deoxyribose 4'-hydrogen abstraction is most likely operative in kedarcidin chromophore bioactivity.&lt;ref name=&quot;Zein&quot; /&gt;

==Synthesis of epi-kedarcidin chromophore==
In 2007, Myers and co-workers at Harvard University reported the synthesis of C10-epi-kedarcidin chromophore, corresponding to the 1997 revised structure advanced by Hirama ''et al''. Critical to the success of this endeavor was [[retrosynthetic analysis]] that focused on the convergent coupling of components with roughly equal chemical complexity. Several of the major challenges of C10-epi-kedarcidin chromophore, as well as the strategies used in addressing these difficulties are discussed below.

[[File:Retrosynthetic approach kedarcidin.png|750x472px|framed|center|Retrosynthetic approach to 10-epi-kedarcidin chromophore employed by Ren, Hogan, Anderson, and Myers (2007).]]

===  Inherent instability of the enediyne core ===
The instability toward [[Bergman cyclization]]–reduction decomposition pathways poses a major threat to any proposed synthesis of [[enediyne]]s. Myers and co-workers addressed this liability by late-stage [[Dehydration reaction|dehydrative]] installation of the olefin. Without this unsaturation linking the two alkynyl bridges, synthetic intermediates are not disposed toward Bergman-type decomposition, and risk of decomposition is mitigated. In this case, dehydration of a [[propargyl]]ic alcohol was induced by treatment with [[Martin sulfurane]].

[[File:Martin sulfurane mechanism.png|620px|center]]

===Epoxide stereochemistry===
In targeting 10-epi-kedarcidin chromophore, Myers ''et al''. sought to install the epoxide functionality syn to the adjacent C10 hydroxyl group. This was accomplished by vanadium-catalyzed epoxidation directed by the C10 hydroxyl group.&lt;ref&gt;Rossiter, B. E.; Verhoeven, T. R.; Sharpless, K. B. ''Tetrahedron Lett.'' '''1979''', ''20'', 4733.&lt;/ref&gt; Had the natural C10-(''S'')-epimer been desired, it is conceivable that [[protecting group|trialkylsilyl protection]] of the C10 hydroxyl would lead to the desired α-face epoxidation product by steric occlusion of the β face of the olefin; however, without a directing group to accelerate the oxidation of a proximal alkene, this hypothetical reaction would likely suffer from poor [[regioselectivity]], as oxidation of other C–C unsaturations in the molecule would compete with the desired reaction.

[[File:Epoxide stereochemistry kedarcidin.png|750px|center]]

===Construction of the bicyclic core===
Myers and co-workers have pioneered the application of transannular anionic cyclization reactions in the synthesis of the 5,9-fused bicyclic core of kedarcidin chromophore and [[Neocarzinostatin|neocarzinostatin chromophore]].  In the first incarnation, hydride delivery to a cyclic tetrayne was guided by aluminum coordination to a proximal alkoxide, thus generating the desired enediyne core in one step via two successive [[Baldwin's rules|5-exo-dig]]–type cyclizations.&lt;ref name=&quot;Myers 1998&quot; /&gt; Later-generation syntheses of the core intercept this cascade cyclization, relying on [[Organolithium reagent|lithium-halogen exchange]] on a cyclic vinyl bromide to generate the vinyl anion precursor to the bicyclic product.&lt;ref name=&quot;Myers 2007&quot; /&gt;&lt;ref name=&quot;Myers 2000&quot; /&gt;

[[File:Transannular cyclization.png|750px|center|Transannular cyclization in the synthesis of the bicyclic core of kedarcidin chromophore.]]

The bicyclic core of C10-epi-kedarcidin chromophore was prepared by the sequential application of three carbon-carbon bond forming reactions, as shown in the retrosynthetic schematic above. First, a [[Sonogashira coupling]] was carried out between a bromovinyl electrophile and alkynyl nucleophile; ring closure to give a cyclic triyne was then accomplished by [[Glaser coupling]] of two terminal alkynes.The 5,9-fused bicyclic core was established by ''in situ'' generation of a vinyllithium species that underwent transannular 5-exo-dig cyclization.

===Ansa-bridging macrolactone===
The ansa-bridging macrolactone was constructed following the first Sonogashira coupling, using Shiina's lactonization conditions.&lt;ref name=&quot;Shiina&quot; /&gt; This protocol, similar to [[Yamaguchi esterification]], employs 2-methyl-6-nitrobenzoic anhydride, [[4-dimethylaminopyridine]], and [[triethylamine]] as a base to promote intramolecular esterification.

[[File:Shiina lactonization mechanism.png|350px|frameless|center]]

==Biosynthesis==
The means by which bacteria construct enediynes like kedarcidin continues to motivate research. Kedarcidin chromophore, beyond the carbocyclic core it shares with other enediynes, presents additional [[biosynthesis|biosynthetic]] puzzles: The relative stereochemistry of the groups appended to the carbocyclic core of kedarcidin chomophore differs from that of closely related enediynes; the (''R'')-2-aza-3-chloro-β-[[tyrosine]] substructure has not been identified in any other known natural product; and despite its seeming simplicity, little literature precedence exists for the biosynthesis of the isopropoxy subsituent of the naphthonate group.

[[File:Kedarcidin biosynthesis.png|900px|center|Proposed component-based biosynthesis of kedarcidin chromophore. Inversion at C11 of the common enediyne core is invoked to explain the relative stereochemistry of the final product, which differs from most other enediynes, including neocarzinostatin chromophore.]]

The biosynthetic gene clusters encoding the biological machinery responsible for producing enediynes have been cloned and characterized for five 9-membered enediynes ([[C-1027]],&lt;ref name=&quot;C-1027&quot; /&gt; [[neocarzinostatin]],&lt;ref name=&quot;NCS&quot;/&gt; [[maduropeptin]],&lt;ref name=&quot;MDP&quot;/&gt; [[sporolides]],&lt;ref name=&quot;SPO&quot;/&gt; and kedarcidin&lt;ref name=&quot;Shen 2013&quot;/&gt;), and three 10-membered enediynes ([[calicheamicin]],&lt;ref name=&quot;CAL&quot;/&gt; [[esperamicin]],&lt;ref name=&quot;ESP&quot;/&gt; and [[Dynemicin A|dynemicin]]&lt;ref name=&quot;DYN&quot;/&gt;). Comparative studies of these biosynthetic apparatus have shown that the enediyne core of these molecules is initiated by a common enzyme, enediyne polyketide synthase (PKS). The polyene product of this enzyme is then divergently elaborated into the 9- or 10-membered cores of the enediynes depending on the specific PKS-associated enzymes present. A convergent biosynthetic strategy is then employed by the producing organisms, whereby the varying peripheral appendages of the enediynes are attached to the core structure to furnish the final product.

In 2013, the successful cloning and characterization of the kedarcidin biosynthetic cluster (&quot;''ked''&quot;) was reported by researchers at the [[Scripps Research Institute]] and the [[University of Wisconsin-Madison]].&lt;ref name=&quot;Shen 2013&quot; /&gt; The identity of this cloned gene cluster was corroborated by ''kedA'', a gene in the cluster that encodes the previously isolated kedarcidin apoprotein, as well as ''kedE'' and ''kedE10'', the co-expression of which in ''E. coli'' led to the formation of a signature heptaene product previously implicated in enediyne core biosynthesis.

[[File:Azatyrosine biosynthesis.png|550px|right|Proposed biosynthesis of the activated aza-β-tyrosine subunit.]]

The 2-aza-β-tyrosine subunit of kedarcidin chromophore is altogether unknown in any other natural product; this lack of precedence frustrates any attempt at ''a priori'' identification of the genes responsible for synthesizing this structure. However, six genes are conserved among the biosynthetic clusters of kedarcidin, [[C-1027]], and [[maduropeptin]]—while these later two enediynes do not contain a 2-aza-β-tyrosine subunit, they do feature similar (&lt;small&gt;L&lt;/small&gt;)-[[tyrosine]]-derived components, leading Shen ''et al.'' to propose a pathway for the synthesis of the corresponding kedarcidin subunit beginning with 2-aza-&lt;small&gt;L&lt;/small&gt;-tyrosine.&lt;ref name=&quot;Shen 2013&quot;/&gt; This α-amino acid is thus believed to be converted to the corresponding β-amino acid by KedY4, an [[Mutase|aminomutase]] encoded in the ''ked'' cluster. The resulting product is believed to be loaded onto the [[Carrier protein|peptidyl carrier protein]] KedY2 and subsequently chlorinated by KedY3, an [[FAD]]-dependent halogenase.&lt;ref name=&quot;Shen 2013&quot;/&gt;

[[File:2-naphthonate biosynthesis.png|500px|right|Proposed biosynthesis of activated 2-naphthonate subunit.]]

Insight into the biosynthesis of the isopropoxy-2-naphthonate appendage was similarly gained by comparative analysis of the ''ked'' cluster to those of [[neocarzinostatin]] and [[maduropeptin]], enediynes with [[naphthoic acid|naphthonate]] or [[benzoate]] substructures, respectively. Five genes, KedN1–N5, bear high sequence homology with the enzymes responsible for naphthonate synthesis in neocarzinostatin—consequently, the intermediacy of 3,6,8-trihydroxy-2-naphthoic acid is proposed in kedarcidin biosynthesis. This compound is believed to be oxygenated to the 3,6,7,8-tetrahydroxy derivative, then triply ''O''-methylated by KedN1, an ''O''-methyltransferase. To furnish the unique isopropoxy substituent, Shen ''et al.'' invoke double ''C''-methylation of the corresponding methoxy group by the [[radical SAM]] [[methyltransferase]] KedN5.&lt;ref name=&quot;Shen 2013&quot;/&gt;

==Conclusion==

Owing to its non-specific cytotoxicity, instability under ambient conditions, and relative expense of isolation and manufacture, kedarcidin chromophore has not been investigated rigorously as a therapeutic candidate. However, the recent scientific advances discussed above have served to diminish this last hurdle, as [[Chemical synthesis|fully synthetic]] and [[Biosynthesis|biosynthetic]] routes toward scalable kedarcidin production are now within reach. Moreover, with the rising popularity of [[antibody-drug conjugate]] therapies, toxicity liabilities may be mitigated through targeted delivery of this potent cytotoxin, potentially enabling efficient therapies that use minimal quantities of this complex material. The recent development of [[inotuzumab ozogamicin]], a calicheamicin-based antibody-drug conjugate for the treatment of non-Hodgkin lymphoma, reinforces the potential of enediynes to find critical use in the treatment of human disease. Thus, the biological potential and complex molecular architecture of kedarcidin may likely inspire further scientific inquiry into this substance, and possibly deliver new ordnance in the war against cancer.

==References==
{{reflist|refs=
&lt;ref name=&quot;Myers 2007&quot;&gt;Ren, F.; Hogan, P. C.; Anderson, A. J.; Myers, A. G. ''J. Am. Chem. Soc.'' '''2007''', ''129'', 5381–5383.&lt;/ref&gt;
&lt;ref name=&quot;Leet 1993&quot;&gt;Leet, J. E.; Schroeder, D. R.; Langley, D. R.; Colson, K. L.; Huang, S.; Klohr, S. E.; Lee, M. S.; Golik, J.; Hofstead, S. J.; Doyle, T. W.; Matson, J. A. ''J. Am. Chem. Soc.'' '''1993''', ''115'', 8432–8443.&lt;/ref&gt;
&lt;ref name=&quot;Hirama 1997&quot;&gt;Kawata, S.; Ashizawa, S.; Hirama, M. ''J. Am. Chem. Soc.'' '''1997''', ''119'', 12012–12013.&lt;/ref&gt;
&lt;ref name=&quot;Myers 1998&quot;&gt;Myers, A. G.; Goldberg, S. D. ''Tetrahedron Lett''. '''1998''', ''39'', 9633–9636.&lt;/ref&gt;
&lt;ref name=&quot;Myers 2000&quot;&gt;Myers, A. G.; Goldberg, S. D. ''Angew. Chem. Int. Ed.'' '''2000''', ''39'', 2732–2735.&lt;/ref&gt;
&lt;ref name=&quot;Shiina&quot;&gt;Shiina, I.; Kubota, M.; Oshiumi, H.; Hashizume, M. ''J. Org. Chem.'', '''2004''', ''69'', 1822–1830&lt;/ref&gt;
&lt;ref name=&quot;Zein&quot;&gt;Zein, N.; Colson, K. L.; Leet, J. E.; Schroeder, D. R.; Solomon, W.; Doyle, T. W.; Casazza, A. M. ''Proc. Nat. Acad. Sci. USA'' '''1993''', ''90'', 2822–2826.&lt;/ref&gt;
&lt;ref name=&quot;Hirama 1995&quot;&gt;Iida, K.-I.; Hirama, M. ''J. Am. Chem. Soc.'' '''1995''', ''117'', 8875–8876.&lt;/ref&gt;
&lt;ref name=&quot;Bergman 1972&quot;&gt;Jones, R. R.; Bergman, R. G. ''J. Am. Chem. Soc.'' '''1972''', ''94'', 660–661.&lt;/ref&gt;
&lt;ref name=&quot;Bioactivation reviews&quot;&gt;(a) Smith, A. L.; Nicolaou, K. C. ''J. Med. Chem.'' '''1996''', ''39'', 2103. (b) Xi, Z.; Goldberg, I. H. ''Comp. Nat. Prod. Chem.'' '''1999''', ''7'', 553. (c) Zein, N.; Schroeder, D. R. ''Adv. DNA Sequence-Specific Agents'', '''1998''', ''3'', 201.&lt;/ref&gt;
&lt;ref name=&quot;Myers 2002&quot;&gt;Myers, A. G.; Hurd, A. R.; Hogan, P. C. ''J. Am. Chem. Soc.'' '''2002''', ''124'', 4583–4585.&lt;/ref&gt;
&lt;ref name=&quot;Shen 2013&quot;&gt;Lohman, J. R.; Huang, S.-X.; Horsman, G. P.; Dilfer, P. E.; Huang, T.; Chen, Y.; Wendt-Pienkowski, E.; Shen, B. ''Mol. BioSyst.'' '''2013''', ''9'', 478–491.&lt;/ref&gt;
&lt;ref name=&quot;C-1027&quot;&gt;Liu, W.; Christenson, S. D.; Standage, S.; Shen, B. ''Science'' '''2002''', ''297'', 1170–1173.&lt;/ref&gt;
&lt;ref name=&quot;NCS&quot;&gt;Liu, W.; Nonaka, K.; Nie, L.; Zhang, J.; Christenson, S. D.; Bae, J.; Van Lanen, S. G.; Zazopoulos, E.; Farnet, C. M.; Yang, C. F.; Shen, B. ''Chem. Biol.'' '''2005''', ''12'', 293–302.&lt;/ref&gt;
&lt;ref name=&quot;MDP&quot;&gt;Van Lanen, S. G.; Oh, T.-J.; Liu, W.; Wendt-Pienkowski, E.; Shen, B. ''J. Am. Chem. Soc.'' '''2007''', ''129'', 13082–13094.&lt;/ref&gt;
&lt;ref name=&quot;SPO&quot;&gt;McGlinchey, R. P.; Nett, M.; Moore, B. S. ''J. Am. Chem. Soc.'' '''2008''', ''130'', 2406–2407.&lt;/ref&gt;
&lt;ref name=&quot;CAL&quot;&gt;Ahlert, J.; Shepard, E.; Lomovskaya, N.; Zazopoulos, E.; Staffa, A.; Bachmann, B. O.; Huang, K, Fonstein, L.; Czisny, A.; Whitwam, R. E.; Farnet, C. M.; Thorson, T. S. ''Science'' '''2002''', ''297'', 1173–1176.&lt;/ref&gt;
&lt;ref name=&quot;ESP&quot;&gt;(a) Zazopoulos, E.; Huang, K.; Staffa, A.; Liu, W.; Bachmann, B. O.; Nonaka, K.; Ahlert, J.; Thorson, J. S.; Shen, B.; Farnet, C. M. ''Nat. Biotechnol.'' '''2003''', ''21'', 187–190. (b) Liu, W.; Ahlert, J.; Gao, Q.; Wendt-Pienkowski, E.; Shen, B.; Thorson, J. S. ''Proc. Natl. Acad. Sci. U. S. A.'' '''2003''', ''100'', 11959–11963.&lt;/ref&gt;
&lt;ref name=&quot;DYN&quot;&gt;Gao, Q.; Thorson, J. S. ''FEMS Microbiol. Lett.'' '''2008''', ''282'', 105–114.&lt;/ref&gt;

}}

==External links==
* [http://www.ncbi.nlm.nih.gov/pubmed/1399845 Kedarcidin, a new chromoprotein antitumor antibiotic. II. Isolation, purification and physico-chemical properties]

[[Category:Antibiotics]]</text>
      <sha1>bhv671uh75nmpvm19qm5rwqg2k333pe</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Neopluramycin</title>
    <ns>0</ns>
    <id>40429821</id>
    <revision>
      <id>573343309</id>
      <parentid>573339447</parentid>
      <timestamp>2013-09-17T15:53:06Z</timestamp>
      <contributor>
        <username>Malcolma</username>
        <id>320496</id>
      </contributor>
      <comment>added [[Category:Antibiotics]]; removed {{uncategorized}} using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="499">[[image:Neopluramycin.png|thumb|Neopluramycin]]

'''Neopluramycin''' is an antibiotic that inhibits [[nucleic acid]] synthesis.

==External links==
*[http://www.chemspider.com/Chemical-Structure.4514107.html ChemSpider - Neopluramycin]
*[http://www.ncbi.nlm.nih.gov/pubmed/5460277 Isolation and characterization of a new antibiotic, neopluramycin]
*[http://www.ncbi.nlm.nih.gov/pubmed/4323924 Neopluramycin, an inhibitor of nucleic acid synthesis]



[[Category:Antibiotics]]


{{organic-chem-stub}}</text>
      <sha1>qsakxk4i7oz58g66yq4wfxoyf3b6kzn</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Neothramycin</title>
    <ns>0</ns>
    <id>40430643</id>
    <revision>
      <id>573347009</id>
      <parentid>573339538</parentid>
      <timestamp>2013-09-17T16:13:53Z</timestamp>
      <contributor>
        <username>Malcolma</username>
        <id>320496</id>
      </contributor>
      <comment>added [[Category:Antibiotics]]; removed {{uncategorized}} using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="293">[[image:Neothramycin A and B.png|thumb|Neothramycin A and B]]

'''Neothramycins''' are antibiotics with anticancer activities.

==External links==
* [http://www.ncbi.nlm.nih.gov/pubmed/3565180 The treatment of bladder cancer by neothramycin]


[[Category:Antibiotics]]



{{organic-chem-stub}}</text>
      <sha1>ezzei3hounw4b8rgs9dcfa51v0xzi62</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Chartreusin</title>
    <ns>0</ns>
    <id>40430465</id>
    <revision>
      <id>573467275</id>
      <parentid>573257594</parentid>
      <timestamp>2013-09-18T08:07:55Z</timestamp>
      <contributor>
        <username>Malcolma</username>
        <id>320496</id>
      </contributor>
      <comment>added [[Category:Antibiotics]]; removed {{uncategorized}} using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="720">{{Chembox
| ImageFile = Chartreusin.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 5281394
|  SMILES = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Chartreusin''' is an antibiotic with anticancer activity. Chartreusin is chemically related to [[elsamitrucin]].

==External links==
* [http://www.ncbi.nlm.nih.gov/pubmed/14529449 Chartreusin, elsamicin A and related anti-cancer antibiotics]



[[Category:Antibiotics]]


{{organic-chem-stub}}</text>
      <sha1>qzumoq215h4wl0hnnudcz1i6sqnnmr0</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Landomycin</title>
    <ns>0</ns>
    <id>40431302</id>
    <revision>
      <id>607880912</id>
      <parentid>573467345</parentid>
      <timestamp>2014-05-10T08:11:58Z</timestamp>
      <contributor>
        <username>Rjwilmsi</username>
        <id>203434</id>
      </contributor>
      <minor/>
      <comment>/* References */Added 1 doi to a journal cite using [[Project:AWB|AWB]] (10104)</comment>
      <text xml:space="preserve" bytes="770">[[image:Landomycin A and B.png|thumb|Landomycin A and B]]

'''Landomycins''' are [[angucycline]] antibiotics isolated from ''Streptomyces''.

==References==
*{{cite journal | last =Henkel | first =T | last2 =Rohr | first2 =J | last3 =Beale | first3 =J. M.  | last4 =Schwenen | first4 =L. | title =Landomycins, new angucycline antibiotics from Streptomyces sp. I. Structural studies on landomycins A-D | journal =The Journal of Antibiotics | volume =43 | issue =5 | pages =492–503 | publisher =Japan Antibiotics Research Association | location =Tokyo | date =May 1990 | url =http://www.ncbi.nlm.nih.gov/pubmed/2358402 | issn =0021-8820 | accessdate = September 8, 2013 | doi=10.7164/antibiotics.43.492}}

{{Reflist}}




[[Category:Antibiotics]]


{{organic-chem-stub}}</text>
      <sha1>mdi3sh3t0g181fzmayw5p1snshim47t</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Xanthomycin A</title>
    <ns>0</ns>
    <id>40431160</id>
    <revision>
      <id>573469559</id>
      <parentid>573258082</parentid>
      <timestamp>2013-09-18T08:36:16Z</timestamp>
      <contributor>
        <username>Malcolma</username>
        <id>320496</id>
      </contributor>
      <comment>added [[Category:Antibiotics]]; removed {{uncategorized}} using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="726">{{Chembox
| ImageFile = Xanthomycin A.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 54686186
|  SMILES = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Xanthomycin A''' is an antibiotic with anticancer activity isolated from ''Streptomyces''.

==External links==
* [http://www.ncbi.nlm.nih.gov/pubmed/7287588 Antitumor activity of an antibiotic identical with or closely related to xanthomycin A]



[[Category:Antibiotics]]


{{organic-chem-stub}}</text>
      <sha1>e86m17utl330t8dkmt8xgzb1a1w7bg3</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Maduropeptin</title>
    <ns>0</ns>
    <id>40430939</id>
    <revision>
      <id>573679145</id>
      <parentid>573331451</parentid>
      <timestamp>2013-09-19T18:28:44Z</timestamp>
      <contributor>
        <username>Malcolma</username>
        <id>320496</id>
      </contributor>
      <comment>added [[Category:Antibiotics]]; removed {{uncategorized}} using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="489">[[image:Maduropeptin.png|thumb|Maduropeptin]]

'''Maduropeptin''' is an antibiotic with anticancer activity isolated from ''Actinomadura madurae''.

==External links==
*[http://www.ncbi.nlm.nih.gov/pubmed/20718468 Enediyne antitumor antibiotic maduropeptin biosynthesis featuring a C-methyltransferase that acts on a CoA-tethered aromatic substrate]
*[http://www.chemspider.com/Chemical-Structure.21805429.html ChemSpider - Maduropeptin]



[[Category:Antibiotics]]


{{organic-chem-stub}}</text>
      <sha1>roeoskhbu7epm1zhyt0q0i8nfhssdzg</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Macromomycin B</title>
    <ns>0</ns>
    <id>40430374</id>
    <revision>
      <id>573776845</id>
      <parentid>573331439</parentid>
      <timestamp>2013-09-20T13:21:17Z</timestamp>
      <contributor>
        <username>Malcolma</username>
        <id>320496</id>
      </contributor>
      <comment>added [[Category:Antibiotics]]; removed {{uncategorized}} using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="714">{{Chembox
| ImageFile = Macromomycin B.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 5748693
|  SMILES = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Macromomycin B''' is an antibiotic with anticancer activity.

==External links==
* [http://www.ncbi.nlm.nih.gov/pubmed/1116151 Antitumor activity of macromomycin B (NSC 170105) against murine leukemias, melanoma, and lung carcinoma]



[[Category:Antibiotics]]


{{organic-chem-stub}}</text>
      <sha1>gbcn3ypupbudhh7lgkayl2t5pj5h81r</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Citromycin</title>
    <ns>0</ns>
    <id>40254316</id>
    <revision>
      <id>597773560</id>
      <parentid>590674256</parentid>
      <timestamp>2014-03-02T06:31:52Z</timestamp>
      <contributor>
        <username>BattyBot</username>
        <id>15996738</id>
      </contributor>
      <comment>[[WP:AWB/GF|General fixes]], removed orphan tag using [[Project:AWB|AWB]] (9959)</comment>
      <text xml:space="preserve" bytes="1385">{{Chembox
| ImageFile = Citromycin.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 8,9-Dihydroxy-2-methyl-5''H''-pyrano[3,2-c]chromen-4-one
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 3084655
|  ChemSpiderID = 2341687
|  SMILES = CC1=CC(=O)C2=C(O1)C3=CC(=C(C=C3OC2)O)O
|  InChI = 1/C13H10O5/c1-6-2-9(14)8-5-17-12-4-11(16)10(15)3-7(12)13(8)18-6/h2-4,15-16H,5H2,1H3
|  InChIKey = QZZUHPUWIRSQPB-UHFFFAOYAO
|  StdInChI = 1S/C13H10O5/c1-6-2-9(14)8-5-17-12-4-11(16)10(15)3-7(12)13(8)18-6/h2-4,15-16H,5H2,1H3
|  StdInChIKey = QZZUHPUWIRSQPB-UHFFFAOYSA-N}}
| Section2 = {{Chembox Properties
|  C=13|H=10|O=5
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Citromycin''' is an [[antibiotic]] produced by ''[[Penicillium]]''.&lt;ref&gt;{{cite journal|pmid=17958395|year=2007|last1=Capon|first1=RJ|last2=Stewart|first2=M|last3=Ratnayake|first3=R|last4=Lacey|first4=E|last5=Gill|first5=JH|title=Citromycetins and bilains A-C: New aromatic polyketides and diketopiperazines from Australian marine-derived and terrestrial Penicillium spp|volume=70|issue=11|pages=1746–52|doi=10.1021/np0702483|journal=Journal of natural products}}&lt;/ref&gt;

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Pyrones]]


{{organic-compound-stub}}</text>
      <sha1>ahm0iz9q9qic6ayje71398ngaob9rp2</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Vulgamycin</title>
    <ns>0</ns>
    <id>40624297</id>
    <revision>
      <id>574517305</id>
      <parentid>574436511</parentid>
      <timestamp>2013-09-25T21:31:26Z</timestamp>
      <contributor>
        <username>Malcolma</username>
        <id>320496</id>
      </contributor>
      <comment>added [[Category:Antibiotics]] using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="678">{{Chembox
| ImageFile = Vulgamycin.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 115182
|  SMILES = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Vulgamycin''' is an antibiotic made by ''[[Streptomyces]]''.

==External links==
[http://onlinelibrary.wiley.com/doi/10.1002/ps.2780330406/abstract Herbicidal activity and mode of action of vulgamycin]



[[Category:Antibiotics]]


{{organic-chem-stub}}</text>
      <sha1>45lhiet8fvubflwzmhm22dy8acn8gr0</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Landomycinone</title>
    <ns>0</ns>
    <id>40431332</id>
    <revision>
      <id>587463949</id>
      <parentid>575966267</parentid>
      <timestamp>2013-12-24T03:35:57Z</timestamp>
      <contributor>
        <username>Magioladitis</username>
        <id>1862829</id>
      </contributor>
      <minor/>
      <comment>Tagging, added [[CAT:UL|underlinked]] tag using [[Project:AWB|AWB]] (9814)</comment>
      <text xml:space="preserve" bytes="1110">{{multiple issues|
{{Underlinked|date=December 2013}}
{{orphan|date=September 2013}}
}}

{{Chembox
| ImageFile = Landomycinone.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 51354812
|  SMILES = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Landomycinone''' is the aglycon of [[landomycin]]s.

==References==
*{{cite journal | last =Bugaut | first =Xavier | last2 =Guinchard | first2 =Xavier | last3 =Roulland | first3 =Emmanuel | title =Synthesis of the landomycinone skeleton | journal =The Journal of Organic Chemistry | volume =75 | issue =23 | pages =8190–8198 | publisher =ACS Publications | date =December 3, 2010 | url =http://www.ncbi.nlm.nih.gov/pubmed/21028772 | doi =10.1021/jo1018377 | accessdate = September 8, 2013}}

{{Reflist}}

[[Category:Antibiotics]]
[[Category:Carbohydrate chemistry]]


{{organic-chem-stub}}</text>
      <sha1>qwnnbv2wskaj6lpg7jekhf8zlortu3e</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Sparassol</title>
    <ns>0</ns>
    <id>40690393</id>
    <revision>
      <id>578958933</id>
      <parentid>575966636</parentid>
      <timestamp>2013-10-27T14:30:16Z</timestamp>
      <contributor>
        <username>Yikrazuul</username>
        <id>5113168</id>
      </contributor>
      <minor/>
      <comment>data</comment>
      <text xml:space="preserve" bytes="905">{{Chembox
| ImageFile = Sparassol.svg
|  ImageSize = 200px
|  ImageAlt = 
| IUPACName = methyl 2-hydroxy-4-methoxy-6-methylbenzoate
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 520-43-4
| PubChem = 596344
|  ChemSpiderID = 518393
|  SMILES = CC1=CC(=CC(=C1C(=O)OC)O)OC}}
| Section2 = {{Chembox Properties
|  Formula =  C&lt;sub&gt;10&lt;/sub&gt;H&lt;sub&gt;12&lt;/sub&gt;O&lt;sub&gt;4&lt;/sub&gt;
|  MolarMass =  196.20 g/mol
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Sparassol''' is an antibiotic/antifungal isolated from ''[[Sparassis crispa]]''.

==External links==
* [http://mic.sgmjournals.org/content/139/1/153.short Two new antifungal metabolites produced by Sparassis crispa in culture and in decayed trees ]



[[Category:Antibiotics]]
[[Category:Antifungals]]


{{organic-chem-stub}}</text>
      <sha1>l27hbv67ony9akeext6jbvj0owyp8sh</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Coprinol</title>
    <ns>0</ns>
    <id>40688240</id>
    <revision>
      <id>603168834</id>
      <parentid>575966679</parentid>
      <timestamp>2014-04-07T16:10:21Z</timestamp>
      <contributor>
        <username>WildCation</username>
        <id>21073353</id>
      </contributor>
      <comment>Added CSID, InChIs, SMILES, ChEMBL ID.</comment>
      <text xml:space="preserve" bytes="1048">{{no footnotes|date=October 2013}}
{{Chembox
| ImageFile = Coprinol.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 42608175
|  ChEMBL = 1075969
|  ChemSpiderID = 24680015
|  SMILES = CC1=C2CC(CC2=C(C(=C1CCO)C)O)(C)C
|  InChI = 1/C15H22O2/c1-9-11(5-6-16)10(2)14(17)13-8-15(3,4)7-12(9)13/h16-17H,5-8H2,1-4H3
|  InChIKey = GCMUHPCLXBXQDH-UHFFFAOYAD
|  StdInChI = 1S/C15H22O2/c1-9-11(5-6-16)10(2)14(17)13-8-15(3,4)7-12(9)13/h16-17H,5-8H2,1-4H3
|  StdInChIKey = GCMUHPCLXBXQDH-UHFFFAOYSA-N}}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Coprinol''' is an antibiotic isolated from ''[[Coprinus]]''.

==External links==
* [http://www.ncbi.nlm.nih.gov/pubmed/11302209 Coprinol, a new antibiotic cuparane from a Coprinus species]



[[Category:Antibiotics]]


{{organic-chem-stub}}</text>
      <sha1>faicw9hn2939cfe5kkhc7dcdima4yz5</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Kidamycin</title>
    <ns>0</ns>
    <id>40423604</id>
    <revision>
      <id>584600159</id>
      <parentid>576587964</parentid>
      <timestamp>2013-12-04T23:11:57Z</timestamp>
      <contributor>
        <username>Yobot</username>
        <id>7328338</id>
      </contributor>
      <minor/>
      <comment>[[WP:CHECKWIKI]] error fixes, added [[CAT:O|orphan]] tag using [[Project:AWB|AWB]] (9773)</comment>
      <text xml:space="preserve" bytes="664">{{Orphan|date=December 2013}}

{{Chembox
| ImageFile = Kidamycin.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 
| OtherNames = Rubiflavin B
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 5359060
|  SMILES = }}
| Section2 = {{Chembox Properties
|  C=39|H=48|N=2|O=9
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Kidamycin''' is an [[antibiotic]] with [[anticancer]] activity.&lt;ref&gt;{{cite journal|pmid=5132247}}&lt;/ref&gt;

==References==
{{reflist}}

[[Category:Amino sugars]]
[[Category:Antibiotics]]


{{antibiotic-stub}}</text>
      <sha1>83mz5yv4cy4ap1q7wnvkyr72nwmw610</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Bambermycin</title>
    <ns>0</ns>
    <id>40851080</id>
    <revision>
      <id>578461431</id>
      <parentid>578102545</parentid>
      <timestamp>2013-10-23T21:36:21Z</timestamp>
      <contributor>
        <username>Northamerica1000</username>
        <id>14730724</id>
      </contributor>
      <comment>wikify</comment>
      <text xml:space="preserve" bytes="1118">'''Bambermycin''' (Flavomycin) is a complex of [[antibiotic]]s obtained from ''[[Streptomyces bambergiensis]]'' used as a food additive for [[poultry]] and [[Domestic pig|swine]].&lt;ref&gt;{{cite web | url = http://www.drugs.com/vet/flavomycin-4.html | title = Flavomycin 4 | publisher = drugs.com}}&lt;/ref&gt;  The complex consists mainly of moenomycins A and C.&lt;ref name=PubChem&gt;{{PubChem| 6433554}}&lt;/ref&gt;

Flavomycin is effective against [[Gram-positive bacteria]], but it does not have significant action against ''[[Lactobacillus]]'', ''[[Bifidobacterium]]'', and other protective bacteria.&lt;ref name=Merck&gt;{{cite document | url = http://www.merck-animal-health-usa.com/binaries/intp1069_FLAVOMYCIN_tcm96-86660.pdf | title = Product Information Sheet: Flavomycin®4 (bambermycins) | publisher = Merck Animal Health }}&lt;/ref&gt;  Its [[mechanism of action]] involves inhibition of [[bacterial wall]] synthesis.&lt;ref name=Merck/&gt;

Synonyms included flavofosfolipol, gainpro, menomycin, and flavophospholipol.&lt;ref name=PubChem/&gt;

==References==
{{reflist}}


{{antibiotic-stub}}

[[Category:Antibiotics]]
[[Category:Food additives]]</text>
      <sha1>1xd0ntcn8y2lo2mf7mtns6vy0hwzikp</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Furonazide</title>
    <ns>0</ns>
    <id>41112592</id>
    <revision>
      <id>601874460</id>
      <parentid>583936066</parentid>
      <timestamp>2014-03-29T21:24:42Z</timestamp>
      <contributor>
        <username>Yobot</username>
        <id>7328338</id>
      </contributor>
      <minor/>
      <comment>[[WP:CHECKWIKI]] error fixes + other fixes using [[Project:AWB|AWB]] (10067)</comment>
      <text xml:space="preserve" bytes="2977">{{Orphan|date=November 2013}}

{{Chembox
| ImageFile = Furonazide.svg
| ImageSize = 200px
| IUPACName = 4-Pyridinecarboxylic acid [1-(2-furanyl)ethylidine]hydrazide
| OtherNames = Furilazone; Clitizina; Menazone; FKI
| Section1 = {{Chembox Identifiers
|  CASNo = 3460-67-1
|  PubChem = 
|  ChemSpiderID = 
|  SMILES = 
|  InChI = 
|  InChIKey = 
|  StdInChI = 
|  StdInChIKey = 
  }}
| Section2 = {{Chembox Properties
|  C = 12 | H = 11 | N = 3 | O = 2
|  Appearance = crystals  
|  MeltingPt = 199-201.5 °C
|  BoilingPt = 
|  Solubility =
  }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition =
  }}
}}

'''Furonazide ''' is a crystalline [[tuberculostatic drug]] substance with a reported melting point of 199-201.5&amp;nbsp;°C.&lt;ref name=Miyatake&gt;Kazuo Miyatake, “Derivatives of isonicotinic acid hydrazide”, Japanese Patent 32,002,484 B4 (1957)&lt;/ref&gt;

== Synthesis ==
Furonazide was prepared in 1955 by Miyatake from [[isoniazid]] and [[2-Acetylfuran]] by refluxing in ethanol, followed by filtration of the crystalline product.&lt;ref name=Miyatake/&gt;&lt;ref&gt;{{cite journal | author = Kazuo Miyatake | title = Syntheses of compounds related to isonicotinic acid hydrazide. III. Antitubercular compounds | journal = Yakugaku Zasshi| volume = 75 | pages =1066–9| year = 1955| last2 = Ichimura | first2 = Shozo |last3 = Nagasaki | first3 = Senkichi | last4 = Hoji | first4 = Kazuhiko}}&lt;/ref&gt;

== Applications ==
Furonazide has shown bacteriostatic action and is tuberculostatic at levels of 10-8 molar.&lt;ref name=Miyatake/&gt; The in vitro antibacterial activity of furonazide against [[Bacillus Calmette-Guerin]] was found to be essentially equal to that of isoniazid on an equimolar basis.&lt;ref&gt;{{cite journal | author = Kiichiro Kakemi | title = Stability of drugs in biological media.  II. Relations between the stability in culture media and antibacterial activity of some isoniazid derivatives| journal = Chemical &amp; Pharmaceutical Bulletin| volume = 17| pages =1623–8| year = 1969| last2 = Sezaki| first2 = Hitoshi|last3 = Iwamoto| first3 = Kikuo| last4 = Sano| first4 = Yukito | doi = 10.1248/cpb.17.1623 | issue = 8}}&lt;/ref&gt; In vivo studies in the guinea pig showed furonazide slightly more active than isoniazid as a tuberculostatic agent.&lt;ref&gt;{{cite journal | author = Giovanni Pacilio| title = Tuberculostatic activity of some isoniazid derivatives administered to guinea pigs at different time intervals| journal = Atti della Societa Italiana delle Scienze Veterinarie| volume = 18 | pages =631–6| year = 1964| last2 = Pagnini| first2 = Pietro|last3 = Genazzani| first3 = Enrico}}&lt;/ref&gt; The drug has relatively low toxicity. The [[median lethal dose]] (LD&lt;sub&gt;50&lt;/sub&gt;, rat oral) was reported as 2,600&amp;nbsp;mg/kg.&lt;ref&gt;&quot;Drugs - Synonyms and Properties&quot; data were obtained from Ashgate Publishing Co. (US)&lt;/ref&gt;

== References ==
{{Reflist}}

[[Category:Furans]]
[[Category:Isonicotinamides]]
[[Category:Hydrazides]]
[[Category:Antibiotics]]</text>
      <sha1>8zi5ivqbzgt9ecspab2xdk2r1md0upg</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>MC21-B</title>
    <ns>0</ns>
    <id>34270640</id>
    <revision>
      <id>583394551</id>
      <parentid>583341879</parentid>
      <timestamp>2013-11-26T15:22:09Z</timestamp>
      <contributor>
        <username>Edgar181</username>
        <id>491706</id>
      </contributor>
      <comment>chembox data; categories, etc.</comment>
      <text xml:space="preserve" bytes="2595">{{Chembox
|  Name =
|  ImageFile =MC21-B.svg
|   ImageSize = 200px
|   ImageAlt =
|   ImageCaption =
|  IUPACName = 2,2′,3-Tribromobiphenyl-4,4′-dicarboxylic acid
|  OtherNames =
| Section1 = {{Chembox Identifiers
|  Abbreviations =
|  CASNo =
|  CASNo_Comment =
|  PubChem =
|  PubChem_Comment =
|  ChemSpiderID =
|  ChemSpiderID_Comment =
|  EINECS =
|  EC-number =
|  EINECSCASNO =
|  UNNumber =
|  DrugBank =
|  KEGG =
|  MeSHName =
|  ChEBI =
|  RTECS =
|  ATCvet =
|  ATCCode_prefix =
|  ATCCode_suffix =
|  ATC_Supplemental =
|  SMILES =
|  InChI = 
|  Beilstein =
|  Gmelin =
|  3DMet = }}
| Section2 = {{Chembox Properties
|  C=14 | H=7 | Br=3 | O=4
|  Appearance = White powder &lt;!-- Physical Description --&gt;
|  Density =
|  MeltingPt =
|  Melting_notes =
|  BoilingPt =
|  Boiling_notes =
|  LogP =
|  VaporPressure =
|  HenryConstant =
|  AtmosphericOHRateConstant =
|  pKa =
|  pKb =
|  Solubility = Sol. MeOH, CHCl&lt;sub&gt;3&lt;/sub&gt;&lt;br/&gt;insol. H&lt;sub&gt;2&lt;/sub&gt;O, hexane
|  SolubleOther =
|  Solvent =
|  Sheet Resistance =
|  Methacrylate Equiv Wt =
|  Bulk Conductivity = }}
| Section3 = {{Chembox Structure
|  CrystalStruct =
|  Coordination =
|  MolShape = }}
| Section4 = {{Chembox Thermochemistry
|  DeltaHc =
|  DeltaHf =
|  Entropy =
|  HeatCapacity = }}
| Section5 = {{Chembox Pharmacology
|  AdminRoutes =
|  Bioavail =
|  Metabolism =
|  HalfLife =
|  ProteinBound =
|  Excretion =
|  Legal_status =
|  Legal_US =
|  Legal_UK =
|  Legal_AU =
|  Legal_CA =
|  PregCat =
|  PregCat_AU =
|  PregCat_US = }}
| Section6 = {{Chembox Explosive
|  ShockSens =
|  FrictionSens =
|  ExplosiveV =
|  REFactor = }}
| Section7 = {{Chembox Hazards
|  ExternalMSDS =
|  EUClass =
|  EUIndex =
|  MainHazards =
|  NFPA-H =
|  NFPA-F =
|  NFPA-R =
|  NFPA-O =
|  RPhrases =
|  SPhrases =
|  RSPhrases =
|  FlashPt =
|  Autoignition =
|  ExploLimits =
|  LD50 =
|  PEL = }}
| Section8 = {{Chembox Related
|  OtherAnions =
|  OtherCations =
|  OtherFunctn =
|  Function =
|  OtherCpds = }}
}}

'''MC21-B''' is an [[antibiotic]] isolated from the O-BC30T strain of a marine [[bacterium]], ''[[Pseudoalteromonas phenolica]]''.&lt;ref name=&quot;Isnansetyo &amp; Kamei on O-BC30T&quot;&gt;{{Cite doi|10.1016/j.ijantimicag.2009.02.009|noedit}}&lt;/ref&gt; MC21-B is [[cytotoxic]] to human [[leukaemia]] cells and human normal [[dermal fibroblasts]].&lt;ref name=&quot;Rahman&quot;&gt;{{Cite doi|10.3390/md8030498|noedit}}&lt;/ref&gt;

==See also==
* [[MC21-A]]

==References==
{{Reflist}}

[[Category:Antibiotics]]
[[Category:Biphenyls]]
[[Category:Dicarboxylic acids]]
[[Category:Benzoic acids]]
[[Category:Organobromides]]


{{organohalide-stub}}</text>
      <sha1>jljv3y9c6zwe05lbrv1mkdb3tsyfmel</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Bottromycin</title>
    <ns>0</ns>
    <id>41183836</id>
    <revision>
      <id>608378844</id>
      <parentid>607195972</parentid>
      <timestamp>2014-05-13T13:30:47Z</timestamp>
      <contributor>
        <username>Edgar181</username>
        <id>491706</id>
      </contributor>
      <comment>-[[Category:Organic compounds]]; -[[Category:Nitrogen compounds]]; -[[Category:Oxygen compounds]] using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="30564">&lt;!-- EDIT BELOW THIS LINE --&gt;

&lt;!-- Below the chembox.  Notes:
* Parameters work only in their own section.  
* When a parameter is not needed, please leave it empty, when a parameter is wrong, just clear its contents.  
* When a section is really not needed, delete the whole section. 
For more information, see [[template:chembox]]. --&gt;
{{chembox
| ImageFile = Chemical structure of bottromycin A2.png
| ImageSize = 300px
| ImageAlt = 
| IUPACName = 
| OtherNames = Bottromycin A(2); Bottromycic A2 acid, methyl ester
| Section1 = {{Chembox Identifiers
| Abbreviations = 
| CASNo = 15005-62-6
| EC-number = 
| PubChem = 3081434
|  ChemSpiderID = 26365309
|  SMILES = C[C@@H]1CCN2[C@@H]1C(=O)N[C@H](C(=O)N[C@H](/C(=N/[C@H](C(=O)N[C@@H]([C@@H](C)C3=CC=CC=C3)C(=O)N[C@H](CC(=O)OC)C4=NC=CS4)C(C)(C)C)/NCC2=O)C(C)(C)C)C(C)C
|  InChI = 1/C42H62N8O7S/c1-23(2)30-36(53)49-33(41(5,6)7)35(44-22-28(51)50-19-17-24(3)32(50)38(55)46-30)48-34(42(8,9)10)39(56)47-31(25(4)26-15-13-12-14-16-26)37(54)45-27(21-29(52)57-11)40-43-18-20-58-40/h12-16,18,20,23-25,27,30-34H,17,19,21-22H2,1-11H3,(H,44,48)(H,45,54)(H,46,55)(H,47,56)(H,49,53)/t24-,25+,27-,30+,31+,32+,33-,34-/m1/s1
|  InChIKey = KSIZLOPUXFSFNR-XZNJZDOZBX
|  StdInChI = 1S/C42H62N8O7S/c1-23(2)30-36(53)49-33(41(5,6)7)35(44-22-28(51)50-19-17-24(3)32(50)38(55)46-30)48-34(42(8,9)10)39(56)47-31(25(4)26-15-13-12-14-16-26)37(54)45-27(21-29(52)57-11)40-43-18-20-58-40/h12-16,18,20,23-25,27,30-34H,17,19,21-22H2,1-11H3,(H,44,48)(H,45,54)(H,46,55)(H,47,56)(H,49,53)/t24-,25+,27-,30+,31+,32+,33-,34-/m1/s1
| RTECS =
| MeSHName =
| ChEBI =
| KEGG = 
| ATCCode_prefix = 
| ATCCode_suffix = 
| ATC_Supplemental =}}
| Section2 = {{Chembox Properties
| Formula = | C=42 | H=62 | N=8 | O=7 | S=1
| MolarMass = 823.05608 g.mol&lt;sup&gt;-1&lt;/sup&gt;
| Appearance =
| Density = 
| MeltingPt = 
| Melting_notes =
| BoilingPt = 
| Boiling_notes = 
| Solubility = 
| SolubleOther = 
| Solvent = 
| pKa = 
| pKb = }}
}}&lt;!-- Text starts below--&gt;

'''Bottromycin''' is a macrocyclic peptide with antibiotic activity. It was first discovered in 1957 as a natural product isolated from ''Streptomyces bottropensis''.&lt;ref name= Waisvisz&gt;{{cite journal|last=Waisvisz|first=J. M.|title=Bottromycin. I. A New Sulfur-containing Antibiotic|journal=JACS|year=1957|volume=79|pages=4520–4521|url=http://pubs.acs.org/doi/pdf/10.1021/ja01573a072|doi=10.1021/ja01573a072}}&lt;/ref&gt; It has been shown to inhibit methicillin-resistant ''Staphylococcus aureus'' ([[MRSA]]) and vancomycin-resistant Enterococci ([[Vancomycin-resistant Enterococcus|VRE]]) among other [[Gram-positive bacteria]] and [[mycoplasma]].&lt;ref name=Kobayashi&gt;{{cite journal|last=Kobayashi|first=Yutaka|author2=et al.|title=Bottromycin derivatives: Efficient chemical modifications of the ester moiety and evaluation of anti-MRSA and anti-VRE activities|journal=Bioorganic &amp; Medicinal Chemistry Letters|year=2010|volume=20|pages=6116–6120|url=http://dx.doi.org/10.1016/j.bmcl.2010.08.037|doi=10.1016/j.bmcl.2010.08.037}}&lt;/ref&gt; Bottromycin is structurally distinct from both [[vancomycin]], an aminoglycoside antibiotic, and [[methicillin]], a beta-lactam antibiotic.

Bottromycin binds to the A site of the [[ribosome]] and blocks the binding of [[aminoacyl-tRNA|aminoacyl-''t''RNA]], therefore inhibiting bacterial protein synthesis.&lt;ref name= Otaka&gt;{{cite journal|last=Otaka|first=T.|author2=A. Kaji|title=Mode of action of bottromycin A2. Release of aminoacyl- or peptidyl-tRNA from ribosomes.|journal=Journal of Biological Chemistry|year=1976|volume=251|pages=2299–2306|url=http://www.ncbi.nlm.nih.gov/pubmed/770464}}&lt;/ref&gt; Although bottromycin exhibits antibacterial activity ''in vitro'', it has not yet been developed as a clinical antibiotic, potentially due to its poor stability in blood plasma.&lt;ref name=Kobayashi /&gt;  To increase its stability ''in vivo'', some bottromycin derivatives have been explored.&lt;ref name=Kobayashi /&gt;

The structure of bottromycin contains a macrocyclic [[amidine]] as well as a [[thiazole]] ring. The absolute stereochemistry at several chiral centers has been determined as of 2009.&lt;ref name= Shimamura&gt;{{cite journal|last=Shimamura|first=Hiroyuki|author2=et al.|title=Structure Determination and Total Synthesis of Bottromycin A2: A Potent Antibiotic against MRSA and VRE|journal=Angewandte Chemie International Edition|year=2009|volume=48|pages=914–917|doi=10.1002/anie.200804138|url=http://doi.wiley.com/10.1002/anie.200804138}}&lt;/ref&gt; In 2012, a three-dimensional solution structure of bottromycin was published.&lt;ref name=Gouda&gt;{{cite journal|last=Gouda|first=Hiroaki|author2=et al.|title=Three-dimensional solution structure of bottromycin A2: a potent antibiotic active against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci.|journal=Chem. Pharm. Bull.|year=2012|volume=60|pages=169–171|url=http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;id=22293474&amp;retmode=ref&amp;cmd=prlinks|doi=10.1248/cpb.60.169}}&lt;/ref&gt; The solution structure revealed that several methyl groups are on the same face of the structure.

== History ==

Bottromycin was first isolated from ''Streptomyces bottropensis'' in 1957.&lt;ref name=&quot;Waisvisz&quot;/&gt; It has since been identified in at least two other members of the ''[[Streptomyces]]'' genus;&lt;ref name= Crone /&gt;&lt;ref name= Huo /&gt; members of ''Streptomyces'' are known to be prolific producers of secondary metabolites.&lt;ref&gt;{{cite book|last=Madigan|first=M, Martinko J (eds.)|title=Brock Biology of Microorganisms|year=2005|publisher=Prentice Hall|isbn=0-13-144329-1|edition=11th}}&lt;/ref&gt; Bottromycin has a unique structure, consisting of the macrocyclic amidine linkage and four β-methylated amino acids. Bottromycin blocks aminoacyl ''t''RNA binding to the ribosome by binding to the A site of the 50s subunit.&lt;ref name= Otaka /&gt; Although bottromycin was discovered over 50 years ago, there was a lack of research following initial studies on bottromycin until recent years. The lack of research is potentially a result of bottromycin's low stability in blood plasma.&lt;ref name= Kobayashi /&gt; However, the unique structure and mode of action have recently made bottromycin a more target for drug development, especially given the rise of antibiotic resistance.

==Mechanism of Action==

[[File:Bottromycin mechanism of action2.png|200px|thumbnail|right|Schematic of the mechanism of action of bottromycin]]

The mechanism of action of bottromycin was confirmed nearly 20 years following the discovery of bottromycin.&lt;ref name=Otaka /&gt; Bottromycin functions as an antibiotic through inhibition of protein synthesis. It blocks aminoacyl ''t''RNA binding to the ribosome by binding to the A site of the 50s subunit. This results in release of aminoacyl ''t''RNA from the ribosome and premature termination of protein synthesis. A comparison of other antiobiotics known to bind to the A site of the ribosome, including micrococcin, [[tetracycline]], [[streptomycin]], and [[chloramphenicol]], suggested that only bottromycin and chloramphenicol caused release of aminoacyl ''t''RNA from the ribosome. Of those antibiotics, only micrococcin is also a macrocyclic peptide.

== Structure determination ==

Bottromycin is produced naturally as a series of products differing in methylation patterns. All products contain valine and phenylalanine methylation. Bottromycin A2 is singly methylated on proline, bottromycin B lacks methylation on proline, and bottromycin C contains a doubly methylated proline.

A partial structure of bottromycin was reported shortly after the initial discovery of bottromycin. The first structural studies relied on traditional methods of analysis. Its [[peptide]]-like structure, including the presence of glycine and valine, was first suggested by a combination of acidic [[hydrolysis]], [[acetylation]], [[ninhydrin]] staining, and [[paper chromatography]], among other experiments.&lt;ref&gt;{{cite journal|last=Waisvisz|first=J. M.|author2=et al.|title=Bottromycin. II. Preliminary degradation studies|journal=JACS|year=1957|volume=79|pages=4522–4524|url=http://pubs.acs.org/doi/pdf/10.1021/ja01573a073}}&lt;/ref&gt; The presence of a thiazole ring, along with an adjacent β-methylated phenylalanine, was established by ninhydrin staining, [[potassium permanganate]] oxidation, and comparison to synthetic standards.&lt;ref&gt;{{cite journal|last=Waisvisz|first=J. M.|author2=et al.|title=The structure of the sulfur-containing moiety of bottromycin|journal=JACS|year=1957|volume=79|pages=4524–4527|url=http://pubs.acs.org/doi/pdf/10.1021/ja01573a074|doi=10.1021/ja01573a074}}&lt;/ref&gt; A methyl ester substituent was reported in 1958.&lt;ref&gt;{{cite journal|last=Waisvisz|first=J. M.|coauthors=M. G. Van Der Hoeven|title=The Chemistry and Partial Structure of Bottromycin|journal=JACS|year=1958|volume=80|pages=383–385|url=http://pubs.acs.org/doi/pdf/10.1021/ja01535a034}}&lt;/ref&gt; The same study also reported that the Kunz hydrolysis product lacking a methyl ester was biologically inactive. Nakamura and colleagues later reported that bottromycin contained tert-leucine and ''cis''-3-methylproline.&lt;ref&gt;{{cite journal|last=Nakamura|first=S.|author2=et al.|title=Isolation, characterization and structural elucidation of new amino acids from bottromycin A|journal=Chem. Pharm. Bull.|year=1965|volume=13|pages=599–602|pmid=5867718|doi=10.1248/cpb.13.599}}&lt;/ref&gt; They also proposed a linear iminohexapeptide structure.&lt;ref&gt;{{cite journal|last=Nakamura|first=S.|author2=et al.|title=Bottromycin A1, A2 and their structures|journal=Journal of Antibiotics|year=1966|volume=19|pages=10–12|pmid=5952015}}&lt;/ref&gt;

[[File:Bottromycin A2 3D Structure.png|300px|thumbnail|left|The three-dimensional solution structure of bottromycin A2, based on data from Gouda, et al.&lt;ref name=Gouda /&gt; Oxygen, bright blue; nitrogen, red; sulfur, yellow; main chain, green]]

These early structural studies were not followed up until recent years with the renewed interest in bottromycin. The structure was confirmed in the 1980s and 1990s to be a cyclic iminopeptide based on NMR studies, with a linear side chain connected to the macrocycle via an amidine linkage.&lt;ref&gt;{{cite journal|last=Schipper|first=D.|title=The revised structure of bottromycin A2|journal=Journal of Antibiotics|year=1983|volume=36|pages=1076–1077|pmid=6630058|url=https://www.jstage.jst.go.jp/article/antibiotics1968/36/8/36_8_1076/_article|doi=10.7164/antibiotics.36.1076}}&lt;/ref&gt;&lt;ref&gt;{{cite journal|last=Kaneda|first=M.|title=Studies on bottromycins. I. 1H and 13C NMR assignments of bottromycin A2, the main component of the complex|journal=Journal of Antibiotics|year=1992|volume=45|pages=792–796|pmid=1624382|url=https://www.jstage.jst.go.jp/article/antibiotics1968/45/5/45_5_792/_article|doi=10.7164/antibiotics.45.792}}&lt;/ref&gt;

Its absolute stereochemistry, however, was not characterized until 2009.&lt;ref name= Shimamura /&gt; Stereochemistry at carbon 18 and 25 was proposed by comparing predicted conformers obtained using  [[molecular dynamics]] to experimental constraints obtained through NMR experiments. Stereochemistry at carbon 43 was confirmed by comparing &lt;sup&gt;1&lt;/sup&gt;H NMR of authentic hydrolysis product to a chemically synthesized sample of the same fragment. Finally, optical rotation, &lt;sup&gt;1&lt;/sup&gt;H NMR, and HRMS experiments of chemically synthesized bottromycin matched that of biologically produced bottromycin.

The three-dimensional solution structure of bottromycin A2 was solved by NMR in 2012.&lt;ref name=Gouda /&gt; The overall structure was obtained with good resolution (RMSD 0.74±0.59 Å), with a RMSD of 0.09±0.06 Å for the macrocycle. In this study, it was proposed that the methylated proline residue contributed to the restricted conformation of the macrocycle. The methylated proline and β-OMe alanine residues were found to be on the same face of bottroymycin A2 and it was suggested that this characteristic contributed to binding of bottromycin to the ribosomal A site.

== Biosynthesis ==

The production of bottromycin by ''S. bottropensis'' and ''S. scabies'', as well as the production of a bottromycin analog termed bottromycin D, has been studied.&lt;ref name=Crone&gt;{{cite journal|last=Crone|first=W. J. K.|author2=F. J. Leeper|author3=A. W. Truman|title=Identification and characterisation of the gene cluster for the anti-MRSA antibiotic bottromycin: expanding the biosynthetic diversity of ribosomal peptides|journal=Chemical Science|year=2012|volume=3|pages=3516–3521|doi=10.1039/c2sc21190d|url=http://xlink.rsc.org/?DOI=c2sc21190d}}&lt;/ref&gt;&lt;ref name=Huo&gt;{{cite journal|last=Huo|first=Liujie|author2=et al.|title=Synthetic Biotechnology to Study and Engineer Ribosomal Bottromycin Biosynthesis|journal=Chemistry &amp; Biology|year=2012|volume=19|pages=1278–1287|doi=10.1016/j.chembiol.2012.08.013|url=http://dx.doi.org/10.1016/j.chembiol.2012.08.013}}&lt;/ref&gt;&lt;ref name= Gomez-Escribano&gt;{{cite journal|last=Gomez-Escribano|first=Juan|author2=et al.|title=Posttranslational β-methylation and macrolactamidination in the biosynthesis of the bottromycin complex of ribosomal peptide antibiotics|journal=Chemical Science|year=2012|volume=3|pages=3522–3525|doi=10.1039/c2sc21183a|url=http://xlink.rsc.org/?DOI=c2sc21183a}}&lt;/ref&gt;&lt;ref name= Hou&gt;{{cite journal|last=Hou|first=Y.|title=Structure and Biosynthesis of the Antibiotic Bottromycin D|journal=Organic Letters|year=2012|volume=14|pages=5050–5053|url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466018/|doi=10.1021/ol3022758}}&lt;/ref&gt; It was independently confirmed in 2012 by multiple groups that bottromycin is produced as a ribosomal peptide natural product that it subsequently post-translationally modified. Before this, it was unclear whether bottromycin was produced by [[nonribosomal peptide]] synthetase machinery (NRPS). The presence of amino acids other than the 20 proteinogenic amino acids is often a feature of NRPS products because NRPS machinery can directly incorporate other amino acids, among other chemical building blocks. Ribosomal peptide synthesis, which is the same machinery that produces all proteins found in the cell, is limited to the 20 proteinogenic amino acids. However, bottromycin was found to be a highly modified ribosomal peptide by a combination of genome mining and gene deletion studies.&lt;ref name= Crone /&gt;&lt;ref name= Gomez-Escribano /&gt;

In ribosomal peptide synthesis, the final product results from modifications to a linear peptide starting material translated by the ribosome from an mRNA transcript. In ''S. scabies'' the precursor peptide, termed BtmD, is a 44-amino acid peptide.&lt;ref name= Crone /&gt; The precursor peptide is termed BmbC in ''S. bottropensis''.&lt;ref name=Gomez-Escribano&gt;&lt;/ref&gt; The amino acids forming the bottromycin core are residues 2-9 in BtmD: Gly-Pro-Val-Val-Val-Phe-Asp-Cys. In bottromycin D, the sequence is Gly-Pro-Ala-Val-Val-Phe-Asp-Cys, and the precursor peptide is termed BstA.&lt;ref name= Hou /&gt; BstA shares high sequence homology with BtmD in the follower peptide region. Unlike other ribosomal peptide natural products, which are normally synthesized with a leader peptide that is cleaved, bottromycin is synthesized with a follower peptide. The presence of a follower peptide was identified by bioinformatic analysis of the bottromycin biosynthetic cluster.

[[File:S. bottropensis bottromycin biosynthetic cluster2.png|900px|thumbnail|center|Annotated bottromycin biosynthetic gene cluster in ''S. bottropensis''&lt;ref name= Gomez-Escribano /&gt;]]

The complete biosynthetic gene cluster for bottromycin has been identified. It is predicted to contain 13 genes, including the precursor peptide (notation will follow Crone and colleagues;&lt;ref name=Crone /&gt; other studies had similar results). One of the genes in the cluster, ''btmL'', is proposed to be a [[transcriptional regulator]]. Another gene, ''btmA'', is proposed to export bottromycin. The remaining ten genes are expected to modify the precursor peptide ''btmD'' from a linear peptide to the final macrocyclic product.

{| class=&quot;wikitable&quot; style=&quot;margin: 1em auto 1em auto;&quot;
|+ Gene annotation and proposed function in bottromycin producers
|-
! ''S. scabies'' !! ''S. bottropensis'' !! WMMB272 !! Predicted function
|-
| ''btmA'' || ''bmbT'' || ''bstK'' || Major facilitator superfamily/transporter
|-
| ''btmB'' || ''bmbA'' || ''bstB'' || ''o''-Methyltransferase
|-
| ''btmC'' || ''bmbB'' || ''bstC'' || Radical SAM methyltransferase
|-
| ''btmD'' || ''bmbC'' || ''bstA'' || Precursor peptide
|-
| ''btmE'' || ''bmbD'' || ''bstD'' || YcaO-domain
|-
| ''btmF'' || ''bmbE'' || ''bstE'' || YcaO-domain
|-
| ''btmG'' || ''bmbF'' || ''bstF'' || Radical SAM methyltransferase
|-
| 'btmH'' || ''bmbG'' || ''bstG'' || α/β Hydrolase
|-
| ''btmI'' || ''bmbH || ''bstH'' || Metallo-dependent hydrolase
|-
| ''btmJ'' || ''bmbI'' || ''bstI'' || Cytochrome P450
|-
| ''btmK'' || ''bmbJ'' || ''bstJ'' || Radical SAM methyltransferase
|-
| ''btmL'' || ''bmbR'' ||  || Transcriptional regulator
|-
| ''btmM'' || ''bmbK'' ||  || M17 aminopeptidase
|}

A [[biosynthetic pathway]] has been hypothesized based on proposed gene functions (see figure). ''btmM'', with homology to Zn+2 aminopeptidases, is predicted to cleave the N-terminal methionine residue, which is not present in the bottromycin final product. ''btmE'' and ''btmF'' both contain [[YcaO]]-like domains. It is believed that one Although it is unclear which enzyme is responsible for which step, it is hypothesized that one catalyzes macrocyclic amidine formation while the other catalyzes thiazoline formation. ''btmJ'', encoding an enzyme with cytochrome P450 homology, may oxidize the thiazoline to the thiazole. ''btmH'' or ''btmI'' both have homology to hydrolytic enzymes (α/β hydrolase and metallo-dependent hydrolase, respectively) may catalyze follower peptide hydrolysis. An alternative proposed role for ''btmH'' or ''btmI'' is to function as a cyclodehydratase in macrocyclization. Gene deletion studies failed to elucidate the function of other proteins within the cluster.&lt;ref name=Crone /&gt; 
[[File:Proposed bottromycin biosynthetic pathway2.png|thumbnail|center|900px|Bottromycin biosynthetic pathway proposed by Crone, et al.]]
 
===Methyltransferases in the biosynthetic cluster===

Bioinformatic analysis identified four methyltransferases within the cluster. Bioinformatics suggest that ''btmB'', is an [[O-methyltransferase|''O''-methyltransferase]], while the other three, ''btmC'', ''G'' and ''K'', are [[radical SAM|radical ''S''-adenosyl methionine (SAM) methyltransferases]]. The radical SAM methyltransferases are believed to β-methylate amino acid residues within the precursor peptide. ''btmC'' is believed to methylate phenylalanine, ''btmG'' is believed to methylate both valines, and ''btmK'' is believed to methylate proline based on gene deletion studies.&lt;ref name=Crone /&gt;&lt;ref name=Huo /&gt;

The three putative radical SAM methyltransferases encoded within the pathway are interesting for both mechanistic and biosynthetic reasons. Radical SAM methyltransferases are likely to methylate substrates by an unusual mechanism. Biosynthetically, β-methylations of amino acids are highly unusual in natural products. Polytheonamide B, a peptide natural product produced by a marine symbiont, is the only other structurally characterized example of direct β-methylation of a peptide natural product. The proposed methyl transfer from a SAM-utilizing enzyme was supported by earlier feeding studies with labeled methionine; labeled methionine is used because methionine is converted into SAM within cells.&lt;ref name= Kellenberger&gt;{{cite book|last=Kellenberger|first=Johannes Laurenz|title=Zum stereochmischen Verlauf der C-Methylierungsschritte in der Biosynthese von Bottromycin|year=1997|publisher=PhD Thesis|location=ETH Zurich|url=http://e-collection.library.ethz.ch/view/eth:40556}}&lt;/ref&gt; Even further, this study used stereospecifically labeled methionine ([methyl-(&lt;sup&gt;2&lt;/sup&gt;H-&lt;sup&gt;3&lt;/sup&gt;H)]-(2''S'', methyl-''R'')-methionine) to show that methylation occurred with a net retention of stereochemistry at the methyl group. The author speculated that net retention indicated a radical mechanism with a B12 intermediate.&lt;ref name= Kellenberger /&gt; Radical transfer with a cobalmin B12 cofactor and SAM has been shown with the few characterized radical SAM methyltransferases. Although the evidence points to radical β-methylation during bottromycin biosynthesis, it remains to be seen whether bioinformatic hypothesis and feeding studies will be supported by ''in vitro'' activity assays.

It is interesting to note that the Val3Ala substitution in bottromycin D does not change the β-methylation pattern between bottromycin A2 and D because Val3 is the only valine ''not'' methylated in bottromycin A2. As such, there are still three predicted radical SAM dependent enzymes in the bottromycin D biosynthetic cluster: ''bstC'', ''bstF'', and ''bstJ''.&lt;ref name= Hou /&gt;

As of 2013, all published biosynthetic studies have been bioinformatic or cell-based. No biochemical assays directly demonstrating protein function have yet been published. It is likely that ''in vitro'' mechanistic studies to better elucidate the biosynthetic pathway will be forthcoming.

== Total synthesis ==

[[File:Key steps in bottromycin total synthesis2.png|thumbnail|left|450px|Selected key steps in the total synthesis of bottromycin reported by Shimamura et al.]]

The total synthesis of bottromycin was accomplished in 2009.&lt;ref name= Shimamura /&gt; The synthesis was achieved in 17 steps. Although bottromycin is a peptide-based natural product, it contains an unusual macrocycle and thiazole heterocycle, so that the total synthesis could not be accomplished using traditional [[solid phase peptide synthesis|solid-phase peptide synthesis]]. The synthesis was accomplished using a combination of peptide coupling and other methods. To obtain the primary thia-β-Ala-OMe intermediate, a sequence of condensation, [[Mannich reaction]], and palladium-catalyzed decarboxylation steps were performed. This intermediate was prepared stereoselectively. To obtain the amidine linkage, a tripeptide intermediate was coupled to a phthaloyl-protected thioamide via mercury-mediated condensation using mercury (II) trifluoromethanesulfonate (Hg(OTf)&lt;sub&gt;2&lt;/sub&gt;) to yield a branched amidine intermediate. To obtain the final product macrocycle, macrolactamization of the amidine-containing intermediate was required. Macrolactamization was performed with [[1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide]] (EDCI) and  iPr&lt;sup&gt;2&lt;/sup&gt;NEt yielded the final product, bottromycin A2. To confirm that the synthesized bottromycin A2 had the same stereochemistry as natural bottromycin A2, the product was studied by [[optical rotation]], &lt;sup&gt;1&lt;/sup&gt;H and &lt;sup&gt;13&lt;/sup&gt;C NMR, IR, and HRMS. The data was found to match that of isolated bottromycin A2. Further, the synthetic sample of bottromycin was also found to have antibacterial activity against both MRSA and VRE, although quantitative data was not reported. A full rendering of the synthetic scheme may be seen under the collapsed synthetic scheme link.

{{Collapse|1=[[File:Bottromycin Total Synthesis Part 1.png|thumbnail|center|900px|First part of the bottromycin total synthesis as reported by Shimamura et al.]][[File:Bottromycin Total Synthesis Part 2_2.png|thumbnail|center|900px|The second part of the bottromycin total synthesis as described by Shimamura et al.]]|2=Bottromycin synthetic scheme as described by Shimamura et al.}}

[[File:Key steps in alternative macrocycle synthesis.png|thumbnail|right|400px|The key steps in the alternative macrocycle synthesis reported by Ackermann et al.]]

In 2012, an alternative synthesis of the bottromycin macrocyclic ring system and amidine linkage was reported.&lt;ref&gt;{{cite journal|last=Ackermann|first=Stefanie|author2=et al.|title=Synthetic studies towards bottromycin|journal=Beilstein Journal of Organic Chemistry|year=2012|volume=8|pages=1652–1656|url=http://www.beilstein-journals.org/bjoc/content/8/1/189|doi=10.3762/bjoc.8.189}}&lt;/ref&gt;  The synthesis was achieved in 10 steps. Unlike the previous synthesis, Ackerman and colleagues synthesized a linear peptide and achieved intramolecular amidine formation using an ''S''-methylated endothiopeptide. The endothiopeptide was obtained by a [[Ugi reaction|thio-Ugi reaction]]. The resulting macrocycle was obtained as a racemic mixture at the amidine linkage. The full synthetic scheme may be viewed under the collapsed synthetic scheme link.

{{Collapse|1=[[File:Bottromycin Alternative Ring Synthesis described by Ackermann, et al.png|thumbnail|center|900px|Alternative bottromycin macrocycle synthesis reported by Ackermann et al.]]|2=Synthetic scheme for alternative bottromycin macrocycle synthesis reported by Ackermann et al.}}

== Derivatives of Bottromycin ==

[[File:Bottromycin derivatives2.png|250px|thumbnail|left|A comparison of bottromycin A2 to the synthetic propyl ketone derivative&lt;ref name= Kobayashi /&gt; and to bottromycin D.&lt;ref name= Hou /&gt;]]

Following the total synthesis of bottromycin, Kobayashi and colleagues synthesized a series of bottromycin derivatives and evaluated their anti-MRSA and anti-VRE activity.&lt;ref name=Kobayashi /&gt; Only derivatives of the methyl ester moiety were explored, as they found that the methyl ester was both important for antibacterial activity and unstable in blood plasma. A series of seventeen derivatives were synthesized, with derivatives falling into three general categories: [[amide]] derivatives, [[urea]] derivatives, and [[ketone]] derivatives. All analogs except the carboxylic acid and hydrazide analogs were derivatized from isolated bottromycin A2 using an activated azide ester. The derivatives were tested against six Gram-positive bacterial strains: ''[[Staphylococcus aureus]]'' FDA209P, ''S. aureus'' Smith, MRSA HH-1, MRSA 92-1191, ''[[Enterococcus faecalis]]'' NCTC12201, and ''E. faecalis'' NCTC12203 (both VRE).

Bottromycin A2 had low micromolar activity against all the strains tested, ranging from an MIC of 0.5 μg/mL in ''E. faecalis'' NCTC12203 to 2 μg/mL in MRSA HH-1. The amide and urea derivative families were found to have weaker antibacterial activity than bottromycin A2 against ''S. aureus'', MRSA, and VRE. The MIC values for the amide and urea derivatives were generally four times greater than those for bottromycin A2. They were, however, significantly more stable in mouse plasma than bottromycin A2. Bottromycin A2 completely degraded in mouse plasma after 10 minutes and exhibited 0% residual activity after exposure to rat serum. Only one derivative had lower than 50% residual activity. In contrast, many derivatives retained a significant percentage of residual anti-MRSA activity following exposure to serum. Thioester intermediates to the ketone derivatives were found to be unstable, exhibiting 0% residual activity, although they had improved antibacterial activity, exhibiting sub-micromolar MIC values. The propyl ketone was found to be the most promising derivative of all the analogs obtained, both exhibiting antibacterial activity against the bacterial strains tested and stability in plasma, retaining 100% residual activity. The MIC values obtained for the propyl derivative were the same as those found for bottromycin A2 except in the case of NCTC12201, which had an MIC of 2 μg/mL for the derivative and an MIC of 1 μg/mL for bottromycin A2. A summary of MIC values for tested bacterial strains is shown below. 

Even the least active bottromycin derivatives exhibited greater anti-VRE activity than vancomycin, which was used as a control antibiotic in this study. The propyl derivative and bottromycin A2 had similar antimicrobial activity to [[linezolid]], a synthetic antibiotic active against Gram-positive bacteria including MRSA and VRE, across all the bacterial strains studied.  Overall, the results of this study suggested that further modifications of bottromycin may lead to a more stable, effective antibiotic.  


{| class=&quot;wikitable&quot;
|-
! Compound !! ''S. aureus'' FDA209P (μg/mL) !! ''S. aureus Smith'' (μg/mL) !! MRSA HH-1 (μg/mL) !! MRSA 92-1191 (μg/mL) !! VRE NCTC12201 (μg/mL) !! VRE NCTC12203 (μg/mL) !! Residual anti-MRSA activity (%)
|-
| Bottromycin A2 || 1 || 1 || 1 || 2 || 1 || 0.5 || 0
|-
| Hydrolyzed bottromycin A2 (carboxylic acid) || 64 || 64 || 64 || 128 || 128 || 32 || -
|-
| Propyl derivative || 1 || 1 || 1 || 2 || 2 || 0.5 || 100
|-
| Vancomycin || 1 || 1 || 0.5 || 1 || &gt;128 || &gt;128 || -
|-
| Linezolid || 2 || 2 || 2 || 2 || 2 || 2 || -
|}


A natural derivative of bottromycin, bottromycin D, has also been identified.&lt;ref name= Hou /&gt; It is produced in a marine ''Streptomyces'' species, strain WMMB272. Although the methyl ester is still present in bottromycin D, one of the macrocyclic valines is mutated to an alanine. The [[minimum inhibitory concentration]] (MIC) for bottromycin D was determined and found to be only slightly less active than bottromycin A2 (2 μg/mL for bottromycin D vs. 1 μg/mL for bottromycin A2). The authors postulated that greater conformational flexibility of bottromycin D may be responsible for its lower activity.

No further antibacterial studies of synthetic or biosynthetic bottromycin derivatives have been reported in the literature as of 2013. The search for efficacious analogs will be enabled by bottromycin’s status as a ribosomal peptide. Analogs may be explored biosynthetically by changing the sequence of the precursor peptide; a change in amino acid sequence will lead directly to a modified bottromycin structure.

==Clinical Potential==
As of 2013, bottromycin has not been approved for any clinical applications, nor has it been tested in humans. The ''in vivo'' stability of bottromycin must be improved before it can be considered as a drug candidate. Work by Kobayashi and colleagues has already begun to address this issue, but more work may be in progress.  The need to find new antibiotics to combat antibiotic resistance means that biologic and synthetic interest in bottromycin will likely continue. A combination of biologic and synthetic techniques may yield both an efficacious and stable bottromycin analog for development as a potential drug candidate.

==See also==

*[[Antibacterial|Antibiotic]]
*''[[Streptomyces]]''
*[[Secondary metabolite]]
*[[Peptide]]
*[[MRSA]]
*[[Vancomycin-resistant Enterococcus]]

==References==
{{Reflist}}



[[Category:Peptides]]
[[Category:Antibiotics]]
[[Category:Streptomyces]]
[[Category:Thiazoles]]</text>
      <sha1>adq2b2md4r2y1x8fku09kuwv7d793by</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Pluramycin A</title>
    <ns>0</ns>
    <id>40654416</id>
    <revision>
      <id>585424928</id>
      <parentid>578345832</parentid>
      <timestamp>2013-12-10T12:35:42Z</timestamp>
      <contributor>
        <username>Alvin Seville</username>
        <id>8629244</id>
      </contributor>
      <comment>removing and categorizing</comment>
      <text xml:space="preserve" bytes="811">{{Orphan|date=October 2013}}

{{Chembox
| ImageFile = Pluramycin A.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 5906990
|  SMILES = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Pluramycin A''' is an antibiotic/anticancer compound that inhibits [[nucleic acid]] biosynthesis.

==External links==
* [http://www.ncbi.nlm.nih.gov/pubmed/4869973 Inhibition by pluramycin A of nucleic acid biosynthesis]

[[Category:Antibiotics]]
[[Category:Biosynthesis]]
[[Category:Cancer treatments]]
[[Category:Nucleic acids]]

{{organic-chem-stub}}</text>
      <sha1>7c8j9h775q0zra977hc5vjvzi0laywc</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Styelin A</title>
    <ns>0</ns>
    <id>40291583</id>
    <revision>
      <id>585889132</id>
      <parentid>582881214</parentid>
      <timestamp>2013-12-13T10:54:33Z</timestamp>
      <contributor>
        <username>Malcolma</username>
        <id>320496</id>
      </contributor>
      <comment>added [[Category:Antibiotics]]; removed {{uncategorized}} using [[WP:HC|HotCat]]</comment>
      <text xml:space="preserve" bytes="606">{{Chembox
| ImageFile = Styelin A.png
|  ImageSize = 250px
|  ImageAlt = 
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 49777289
|  SMILES = }}
| Section2 = {{Chembox Properties
|  C=95|H=145|N=29|O=23
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Styelin A''' is an antibiotic peptide isolated from ''[[Styela clava]]''.&lt;ref&gt;{{cite journal|pmid=9467865}}&lt;/ref&gt;

==Notes==
{{reflist}}


[[Category:Antibiotics]]



{{Antibiotic-stub}}</text>
      <sha1>8g1cn1qklr6j061nrrpwwf8up92n888</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Surotomycin</title>
    <ns>0</ns>
    <id>41356740</id>
    <revision>
      <id>591480993</id>
      <parentid>585956849</parentid>
      <timestamp>2014-01-19T23:18:32Z</timestamp>
      <contributor>
        <username>Ground Zero</username>
        <id>232133</id>
      </contributor>
      <minor/>
      <comment>redundant: the present tense indicates the current condition</comment>
      <text xml:space="preserve" bytes="1529">{{Chembox
| ImageFile = Surotomycin.svg
|  ImageSize = 250px
|  ImageAlt = 
| IUPACName = (3S)-3-{[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonaazacyclohentriacontan-30-yl]carbamoyl}-3-[(2R)-3-carbamoyl-2-[(2R)-3-(1H-indol-3-yl)-2-[(2E)-3-(4-pentylphenyl)but-2-enamido]propanamido]propanamido]propanoic acid
| IUPACName_hidden = yes
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 
| ChEMBL = 2375161
|  SMILES = CCCCCC1=CC=C(C=C1)C(\C)=C\C(=O)N[C@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O }}
| Section2 = {{Chembox Properties
|  C=77|H=101|N=17|O=26
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Surotomycin''' is an investigational oral [[antibiotic]]. This antibiotic is under investigation for the treatment of life-threatening [[Diarrhea]], commonly caused by the [[bacteria]] ''[[Clostridium difficile]]''.&lt;ref&gt;http://www.cubist.com/downloads/Surotomycin-Fact-Sheet-13013.pdf&lt;/ref&gt;

==References==
{{reflist}}

{{antibiotic-stub}}

[[Category:Antibiotics]]</text>
      <sha1>f4q3ps852jxrat8s1bea0jd7i5l2dod</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Naphthomycin A</title>
    <ns>0</ns>
    <id>36073704</id>
    <revision>
      <id>589469285</id>
      <parentid>583710783</parentid>
      <timestamp>2014-01-06T17:48:20Z</timestamp>
      <contributor>
        <username>Edgar181</username>
        <id>491706</id>
      </contributor>
      <comment>chembox and data added</comment>
      <text xml:space="preserve" bytes="2971">{{Chembox
| ImageFile = Naphthomycin A.svg
|  ImageSize = 250px
|  ImageAlt = 
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 10101379
|  ChemSpiderID= 8276911
|  SMILES = O=C1c2c3C(=O)/C(=C1/Cl)NC(=O)/C(=C\C=C\C=C/[C@H](C)[C@@H](O)CC(=O)\C(=C/C[C@H](O)\C=C/[C@H](C)[C@H](O)[C@H](\C=C(\C(=O)c2c(O)c(c3)C)C)C)C)C}}
| Section2 = {{Chembox Properties
|  C=40|H=46|Cl=1|N=1|O=9
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Naphthomycin A''' is a type of [[naphthomycin]].  It was isolated as a yellow pigment from ''[[Streptomyces]] collinus'' and it shows antibacterial, antifungal, and antitumor activities.&lt;ref&gt;{{cite journal|last=Kang|first=Q.|coauthors=Y. Shenb, L. Bai|journal=Nat. Prod. Rep.|year=2012|volume=29|pages=243–263|doi=10.1039/c2np00019a|title=Biosynthesis of 3,5-AHBA-derived natural products|issue=2|pmid=22193711}}&lt;/ref&gt; Naphthomycins have the longest ansa aliphatic carbon chain of the [[ansamycin]] family.&lt;ref&gt;{{cite journal|last=Balerna|first=M.|coauthors=W. Keller-Schierlein, C. Martius, H. Zahner|journal=Arch. Microbiol.|year=1969|volume=65|pages=303–317|doi=10.1007/BF00412210|title=Stoffwechselprodukte von Mikroorganismen|issue=4}}&lt;/ref&gt; Biosynthetic origins of the carbon skeleton from [[Polyketide_synthase|PKS1]] were investigated by feeding 13C-labeled precursors and subsequent 13C-[[Nuclear magnetic resonance|NMR]] product analysis. Naphthomycin gene clusters have been cloned and sequenced to confirm involvement in biosynthesis via deletion of a 7.2kb region.&lt;ref&gt;{{cite journal|last=Bai|first=L.|coauthors=Y. Wu, Q. Kang, Y. Shen, Z. Deng|journal=Patent|year=2012|volume=CN: 2012-10300294|pages=225}}&lt;/ref&gt;  Thirty-two genes were identified in the 106kb cluster.&lt;ref&gt;{{cite journal|last=August|first=P.R.|coauthors=L. Tang, Y.J. Yoon, S. Ning, R. MuEller, T.W. Yu, M. Taylor, D. Hoffman, C.G. Kim, X. Zahng, C.R. Hutchinson, H.G. Floss|journal=Chem. Biol.|year=1998|volume=5|pages=69–79|doi=10.1016/S1074-5521(98)90141-7|pmid=9512878|title=Biosynthesis of the ansamycin antibiotic rifamycin: Deductions from the molecular analysis of the rif biosynthetic gene cluster of Amycolatopsis mediterranei S699|issue=2}}&lt;/ref&gt;
[[File:Naphthomycin A 2.pdf|thumb|400px|left|The proposed naphthomycin biosynthetic pathway.&lt;ref&gt;{{cite journal|last=Kang|first=Q|coauthors=Y. Shenb, L. Bai|journal=Nat. Prod. Rep.|year=2012|volume=29|pages=243–263|doi=10.1039/c2np00019a|title=Biosynthesis of 3,5-AHBA-derived natural products|issue=2|pmid=22193711}}&lt;/ref&gt;  A, adenylation; KS, ketosynthase; AT, acyltransferase; T, acyl carrier protein or peptidyl carrier protein; DH, dehydratase; KR, ketoreductase; (*) redundant domain.]]{{clear-left}}

== References ==
{{reflist}}

{{antibiotic-stub}}

[[Category:Pigments]]
[[Category:Antibiotics]]
[[Category:Naphthoquinones]]</text>
      <sha1>4e9fs4uqln5s8khwi7fol2v2sxvsy0m</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Actaplanin</title>
    <ns>0</ns>
    <id>41579756</id>
    <revision>
      <id>601890819</id>
      <parentid>601883113</parentid>
      <timestamp>2014-03-29T23:48:32Z</timestamp>
      <contributor>
        <username>Marvinthefish</username>
        <id>16997053</id>
      </contributor>
      <comment>Link to patent</comment>
      <text xml:space="preserve" bytes="1639">{{no footnotes|date=January 2014}}
{{Chembox
| ImageFile = Actaplanin 1.png
|  ImageSize = 150px
|  ImageAlt = 
| IUPACName = 
| OtherNames = 
| Section1 = {{Chembox Identifiers
|  CASNo = 
|  PubChem = 16132360
|  SMILES = }}
| Section2 = {{Chembox Properties
|  Formula = 
|  MolarMass = 
|  Appearance = 
|  Density = 
|  MeltingPt = 
|  BoilingPt = 
|  Solubility = }}
| Section3 = {{Chembox Hazards
|  MainHazards = 
|  FlashPt = 
|  Autoignition = }}
}}

'''Actaplanin''' is a complex of broad spectrum antibiotics made by [[Actinoplanes]] bacteria. Research carried out by a group in Eli Lilly and Co. in 1984 meant several actaplanins were identified using [[high-performance liquid chromatography]]. Actaplanins A, B&lt;sub&gt;1&lt;/sub&gt;, B&lt;sub&gt;2&lt;/sub&gt;, B&lt;sub&gt;3&lt;/sub&gt;, C&lt;sub&gt;1&lt;/sub&gt; and G were shown to be composed of the same peptide core, an [[amino sugar]] and varying amounts of [[glucose]], [[mannose]] and [[rhamnose]].

==External links==
* [https://www.jstage.jst.go.jp/article/antibiotics1968/37/2/37_2_85/_article/-char/ja/ The Journal of Antibiotics Vol. 37 (1984) No. 2 p85-95]
* [http://www.ncbi.nlm.nih.gov/pubmed/6706856 PubMed link: Actaplanin, new glycopeptide antibiotics produced by Actinoplanes missouriensis. The isolation and preliminary chemical characterization of actaplanin]
* {{ cite patent
 | country = US
 | number = 4115552
 | status = 
 | title = Factor A and B of antibiotic A-4696
 | pubdate = 
 | gdate = 
 | fdate = 
 | pridate = 
 | inventor =
 | invent1 = 
 | invent2 = 
 | assign1 = 
 | assign2 = 
 | class = 
}}



{{organic-chem-stub}}

[[Category:Antibiotics]]
[[Category:Glycopeptide antibiotics]]</text>
      <sha1>7o6js4ullddh498ml9p38jvmblttt0a</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Friulimicin</title>
    <ns>0</ns>
    <id>42270760</id>
    <revision>
      <id>606527300</id>
      <parentid>600890271</parentid>
      <timestamp>2014-04-30T20:22:26Z</timestamp>
      <contributor>
        <username>LilHelpa</username>
        <id>8024439</id>
      </contributor>
      <minor/>
      <comment>[[WP:AWB/T|Typo fixing]] using [[Project:AWB|AWB]]</comment>
      <text xml:space="preserve" bytes="1781">{{Drugbox

| IUPAC_name = 
| image = Friulimicin.svg
| width = 300px

&lt;!--Clinical data--&gt;
| tradename =  	FRIULIMICIN B
| Drugs.com = 
| pregnancy_US = 
| legal_US =
| routes_of_administration =

&lt;!--Pharmacokinetic data--&gt;
| bioavailability = n/a
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

&lt;!--Identifiers--&gt;
| CASNo_Ref = 
| CAS_number_Ref = 
| CAS_number = 239802-15-4
| PubChem = 56842195
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = 
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1688547

&lt;!--Chemical data--&gt;
| C=59 | H=94 | N=14 | O=19
| molecular_weight = 1303.46006 g/mol
&lt;!-- | InChI = 1S/C59H94N14O19/c1-30(2)19-14-12-10-8-9-11-13-15-22-41(75)65-35(25-40(61)74)52(84)71-49-34(7)64-53(85)39-21-18-24-73(39)57(89)46(31(3)4)69-56(88)48(33(6)60)68-43(77)29-63-50(82)36(26-44(78)79)66-42(76)28-62-51(83)37(27-45(80)81)67-55(87)47(32(5)59(91)92)70-54(86)38-20-16-17-23-72(38)58(49)90/h13,15,30-39,46-49H,8-12,14,16-29,60H2,1-7H3,(H2,61,74)(H,62,83)(H,63,82)(H,64,85)(H,65,75)(H,66,76)(H,67,87)(H,68,77)(H,69,88)(H,70,86)(H,71,84)(H,78,79)(H,80,81)(H,91,92)/b15-13-/t32-,33+,34-,35-,36-,37-,38+,39-,46-,47-,48+,49-/m0/s1
 --&gt;
| InChIKey =  
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HVYFVLAUKMGKHL-USKUEUQVSA-N
}}
'''Friulimicin''' is a [[lipopeptide]] antibiotic produced by ''Actinoplanes friuliensis''. It includes the unusual amino acid [[L-threo-3-methylaspartate|methylaspartate]].&lt;ref&gt;{{cite doi|10.1128/AAC.47.2.447-457.2003}}&lt;/ref&gt;

==References==
{{reflist}}

[[Category:Antibiotics]]
[[Category:Lipopeptides]]
[[Category:Cyclic peptides]]</text>
      <sha1>j26brpqycuuyt9cj0gd2j5rlcipqg7g</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Streptomyces isolates</title>
    <ns>0</ns>
    <id>42099953</id>
    <revision>
      <id>607767914</id>
      <parentid>607765594</parentid>
      <timestamp>2014-05-09T12:42:15Z</timestamp>
      <contributor>
        <username>Jatlas</username>
        <id>9102079</id>
      </contributor>
      <comment>/* See also */</comment>
      <text xml:space="preserve" bytes="13154">''Streptomyces'' isolates have yielded the majority of human, animal, and agricultural antibiotics, as well as a number of fundamental chemotherapy medicines. ''[[Streptomyces]]'' is the largest [[antibiotic]]-producing genus of [[actinobacteria]], producing chemotherapy, antibacterial, [[antifungal drug|antifungal]], antiparasitic drugs, and [[Immunosuppressive drug|immunosuppressants]].&lt;ref name=&quot;pmid11702082&quot;&gt;{{cite journal |author=Watve MG, Tickoo R, Jog MM, Bhole BD |title=How many antibiotics are produced by the genus Streptomyces? |journal=Arch. Microbiol. |volume=176 |issue=5 |pages=386–90 |date=November 2001 |pmid=11702082 |doi=10.1007/s002030100345 |url=}}&lt;/ref&gt; ''Streptomyces'' isolates are typically initiated with the aerial [[hyphal]] formation from the [[mycelium]].

== Anticancer medicines ==
[[Image:Doxorubicin–DNA complex 1D12.png|thumb|Doxorubicin [[Intercalation (chemistry)|intercalating DNA]].]]

''[[Streptomyces peucetius]]'', yielded the medicines [[doxorubicin]] ('''Doxil''') and [[daunorubicin]] ('''DaunoXome'''). Doxorubicin is the precursor to [[valrubicin]] ('''Valstar'''), [[myocet]], and [[pirarubicin]]. Daunorubicin is the precursor to [[idarubicin]] ('''Idamycin'''), [[epirubicin]] ('''Ellence'''), and [[zorubicin]]. 

''Streptomyces'' is the original source of [[dactinomycin]] ('''Cosmegen'''), [[bleomycin]] ('''Blenoxane'''), [[pingyangmycin]] ('''Bleomycin A&lt;sub&gt;5&lt;/sub&gt;'''), [[mitomycin C]] ('''Mutamycin'''), [[rebeccamycin]], [[staurosporine]] (precursor to [[stauprimide]] and [[midostaurin]]), [[neothramycin]], [[aclarubicin]], tomaymycin, sibiromycin, and mazethramycin.

== Antibiotics ==
Most clinical antibiotics were found during the &quot;golden age of antibiotics&quot; (1940s–1960s). [[Actinomycin]] was the first antibiotic isolated from ''Streptomyces'' in 1940, followed by [[streptomycin]] three years later. ''Streptomycetes'' isolates (including various [[aminoglycoside]]s) would go on to comprise over two-thirds of all marketed antibiotics.

''Streptomyces'' antibiotics include:
{{columns-list|2|
* [[Chloramphenicol]] (''[[Streptomyces venezuelae]]'')&lt;ref&gt;{{cite journal|doi=10.1099/00221287-90-2-336|title=A Plasmid Involved in Chloramphenicol Production in Streptomyces venezuelae: Evidence from Genetic Mapping|year=1975|last1=Akagawa|first1=H.|last2=Okanishi|first2=M.|last3=Umezawa|first3=H.|journal=Journal of General Microbiology|volume=90|issue=2|pages=336–46|pmid=1194895}}&lt;/ref&gt;
* [[Daptomycin]] (''[[Streptomyces roseosporus]]'')&lt;ref&gt;{{cite journal|doi=10.1099/mic.0.27757-0|title=Daptomycin biosynthesis in Streptomyces roseosporus: Cloning and analysis of the gene cluster and revision of peptide stereochemistry|year=2005|last1=Miao|first1=V.|journal=Microbiology|volume=151|issue=5|pages=1507}}&lt;/ref&gt;
* [[Fosfomycin]] (''[[Streptomyces fradiae]]'')&lt;ref name=&quot;pmid17113999&quot;&gt;{{cite journal |author=Woodyer RD, Shao Z, Thomas PM, ''et al'' |title=Heterologous production of fosfomycin and identification of the minimal biosynthetic gene cluster |journal=Chemistry &amp; biology |volume=13 |issue=11 |pages=1171–82 |date=November 2006 |pmid=17113999 |doi=10.1016/j.chembiol.2006.09.007 |url=http://linkinghub.elsevier.com/retrieve/pii/S1074-5521(06)00340-1}}&lt;/ref&gt;
* [[Lincomycin]] (''[[Streptomyces lincolnensis]]'')&lt;ref&gt;{{cite journal|doi=10.1111/j.1365-2958.1995.tb02338.x|title=Molecular characterization of the lincomycin-production gene cluster of Streptomyces lincolnensis 78-11|year=1995|last1=Peschke|first1=Ursula|last2=Schmidt|first2=Heike|last3=Zhang|first3=Hui-Zhan|last4=Piepersberg|first4=Wolfgang|journal=Molecular Microbiology|volume=16|issue=6|pages=1137–56|pmid=8577249}}&lt;/ref&gt;
* [[Neomycin]] (''[[Streptomyces fradiae]]'')&lt;ref&gt;{{cite journal|author=Howard T. Dulmage |title=The Production of Neomycin by Streptomyces fradiae in Synthetic Media |journal=Applied Microbiology |volume=1 |issue=2 |date=March 1953 |pages=103–106 |pmc=1056872 |pmid=13031516}}&lt;/ref&gt;
* [[Platensimycin]] (''Streptomyces platensis'')
* [[Puromycin]] (''[[Streptomyces alboniger]]'')&lt;ref&gt;{{cite journal|author=L. Sankaran and Burton M. Pogell |url=http://aac.asm.org/content/8/6/721.abstract |title=Biosynthesis of Puromycin in Streptomyces alboniger: Regulation and Properties of O-Demethylpuromycin O-Methyltransferase |journal=Antimicrobial Agents and Chemotherapy |volume=8 |issue=6 |date=1975-12-01 |accessdate=2012-01-19|pmid=1211926|doi=10.1128/AAC.8.6.721|pages=721–32|pmc=429454}}&lt;/ref&gt;
* [[Streptomycin]] (''[[Streptomyces griseus]]'')&lt;ref&gt;{{cite journal|doi=10.1093/nar/15.19.8041|title=Gene cluster for streptomycin biosynthesis inStreptomyces griseus: Nucleotide sequence of three genes and analysis of transcriptional activity|year=1987|last1=Distler|first1=Jürgen|last2=Ebert|first2=Andrea|last3=Mansouri|first3=Kambiz|last4=Pissowotzki|first4=Klaus|last5=Stockmann|first5=Michael|last6=Piepersberg|first6=Wolfgang|journal=Nucleic Acids Research|volume=15|issue=19|pages=8041–56|pmid=3118332|pmc=306325}}&lt;/ref&gt;
* [[Tetracycline]] (''[[Streptomyces rimosus]]'' and ''[[Streptomyces aureofaciens]]'')&lt;ref name=&quot;NelsonGreenwald2001&quot;&gt;{{cite book|author1=Dr. Mark Nelson|author2=Robert A. Greenwald|author3=Wolfgang Hillen|coauthors=Mark L. Nelson|title=Tetracyclines in biology, chemistry and medicine|url=http://books.google.com/books?id=kHNW4tFhZD4C&amp;pg=PA8|accessdate=17 January 2012|year=2001|publisher=Birkhäuser|isbn=978-3-7643-6282-9|pages=8–}}&lt;/ref&gt;
}}

[[Clavulanic acid]] (''[[Streptomyces clavuligerus]]'') is used in combination with some antibiotics (like [[amoxicillin]]) to weaken bacterial-resistance. Novel antiinfectives being developed include [[Guadinomine]] (''Streptomyces'' sp. K01-0509),&lt;ref name=&quot;Holmes2012&quot;&gt;{{Cite journal|pmid= 23030602|year= 2012|last1= Holmes|first1= TC|last2= May|first2= AE|last3= Zaleta-Rivera|first3= K|last4= Ruby|first4= JG|last5= Skewes-Cox|first5= P|last6= Fischbach|first6= MA|last7= Derisi|first7= JL|last8= Iwatsuki|first8= M|last9= Ōmura|first9= S|last10= Khosla|first10= C|title= Molecular insights into the biosynthesis of guadinomine: A type III secretion system inhibitor|volume= 134|issue= 42|pages= 17797–806|doi= 10.1021/ja308622d|pmc= 3483642|journal= Journal of the American Chemical Society}}&lt;/ref&gt; an inhibitor of the [[type III secretion system]].

Non-''Streptomyces'' [[actinomycetes]], filamentous [[fungi]], and non-filamentous [[bacteria]], have also yielded important antibiotics.

== Antifungals ==

[[Nystatin]] (''[[Streptomyces noursei]]''), [[amphotericin B]] (''[[Streptomyces nodosus]]''), and [[natamycin]] (''[[Streptomyces natalensis]]'') are antifungals isolated from ''Streptomyces''.

== Immunosuppressants ==
[[Sirolimus]] ('''Rapamycin'''), [[ascomycin]], and [[tacrolimus]] were isolated from ''Streptomyces''.  [[Pimecrolimus]] is a derivative of ascomycin. [[Ubenimex]] is derived from ''S. olivoreticuli''.&lt;ref&gt;{{cite journal|last=Bauvois|first=B|coauthors=Dauzonne, D|title=Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: Chemistry, biological evaluations, and therapeutic prospects|journal=Medicinal Research Reviews|volume=26|issue=1|pages=88–130|doi=10.1002/med.20044|pmid=16216010|date=January 2006}}&lt;/ref&gt;

== Antiparasitics ==
''[[Streptomyces avermitilis]]'' synthesizes the antiparasitic [[ivermectin]] ('''Stromectol'''). Other antiparasitics made by ''Streptomyces'' include, [[milbemycin oxime]], [[moxidectin]], and [[milbemycin]].

== Biotechnology ==
[[File:Domain_organization_of_PKS_of_rapamycin_and_biosynthetic_intermediates.svg|thumb|Biosynthesis of [[sirolimus]]]]
{{double image|right|Anthracycline aglycone biosyn1.png|97|E-rhod to doxorubicin biosynthesis222.png|100|[[Biosynthesis of doxorubicin]]||}}
''Streptomyces'' is utilized in [[biotechnology]]. Traditionally, ''[[Escherichia coli]]'' was the bacteria of choice to express [[Eukaryote|eukaryotic]] genes, being it was well understood and easy to work with.&lt;ref name=Brawner_1991&gt;{{cite journal |author=Brawner M, Poste G, Rosenberg M, Westpheling J |title=''Streptomyces'': a host for heterologous gene expression |journal=Curr Opin Biotechnol |volume=2 |issue=5 |pages=674–81 |year=1991 |pmid=1367716 |doi=10.1016/0958-1669(91)90033-2}}&lt;/ref&gt;&lt;ref name=Payne_1990&gt;{{cite journal |author=Payne G, DelaCruz N, Coppella S |title=Improved production of heterologous protein from ''Streptomyces lividans'' |journal=Appl Microbiol Biotechnol |volume=33 |issue=4 |pages=395–400 |year=1990 |pmid=1369282 |doi=10.1007/BF00176653}}&lt;/ref&gt; However, use of ''E. coli'' has limitations including misfolding of eukaryotic proteins, insolubility issues, deposition in [[inclusion bodies]],
&lt;ref name=Binnie_1997&gt;{{cite journal |author=Binnie C, Cossar J, Stewart D |title=Heterologous biopharmaceutical protein expression in ''Streptomyces'' |journal=Trends Biotechnol |volume=15 |issue=8 |pages=315–20 |year=1997 |pmid=9263479 |doi=10.1016/S0167-7799(97)01062-7}}&lt;/ref&gt; low secretion efficiency, secretion to [[periplasmic space]]. 

Advantages of using ''Streptomyces'' include, superior secretion mechanisms, higher yields, and a simpler end-product purification process. These properties, among others, make ''Streptomyces'' an attractive alternative to ''E. coli'' and ''[[Bacillus subtilis]]''.&lt;ref name=&quot;Binnie_1997&quot;/&gt;

''[[Streptomyces coelicolor]]'', ''[[Streptomyces avermitilis]]'', ''[[Streptomyces griseus]]'', and ''[[Saccharopolyspora erythraea]]'', are capable of secondary metabolite production. ''[[Streptomyces coelicolor]]'' has shown useful for the [[heterologous expression]] of proteins. Methods like &quot;ribosome engineering&quot; have been used to achieve 180-fold higher yields with ''S. coelicolor''.&lt;ref name=&quot;pmid18310410&quot;&gt;{{cite journal| author=Wang G, Hosaka T, Ochi K| title=Dramatic activation of antibiotic production in Streptomyces coelicolor by cumulative drug resistance mutations. | journal=Appl Environ Microbiol | year= 2008 | volume= 74 | issue= 9 | pages= 2834-40 | pmid=18310410 | doi=10.1128/AEM.02800-07 | pmc=2394871 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=18310410  }} &lt;/ref&gt;

== Other ==
StreptomeDB, a directory of ''Streptomyces'' isolates, contains over 2400 compounds isolated from more than 1900 strains.&lt;ref name=&quot;pmid23193280&quot;&gt;{{cite journal| author=Lucas X, Senger C, Erxleben A, Grüning BA, Döring K, Mosch J et al.| title=StreptomeDB: a resource for natural compounds isolated from Streptomyces species. | journal=Nucleic Acids Res | year= 2013 | volume= 41 | issue= Database issue | pages= D1130-6 | pmid=23193280 | doi=10.1093/nar/gks1253 | pmc=3531085 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=23193280  }} &lt;/ref&gt;[http://www.pharmaceutical-bioinformatics.de/streptomedb/compound_list/], ''[[Streptomyces hygroscopicus]]'' and ''[[Streptomyces viridochromeogenes]]'' produce the herbicide [[bialaphos]]. [[Migrastatin]] (''Streptomycetes platensis''), and its derivative [[isomigrastatin]], are being researched for anticancer activity. Increased efforts of ''Streptomyces'' screenings have included [[endophytes]], [[extremophiles]], and [[Marine biology|marine]] varieties.

A recent screening of [[Traditional Chinese medicine|TCM]] extracts revealed a ''Streptomyces'' that produces a number of antitubercular [[pluramycin A|pluramycin]]s.&lt;ref name=&quot;pmid24190497&quot;&gt;{{cite journal| author=Liu M, Abdel-Mageed WM, Ren B, He W, Huang P, Li X et al.| title=Endophytic Streptomyces sp. Y3111 from traditional Chinese medicine produced antitubercular pluramycins. | journal=Appl Microbiol Biotechnol | year= 2014 | volume= 98 | issue= 3 | pages= 1077-85 | pmid=24190497 | doi=10.1007/s00253-013-5335-6 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=24190497  }} &lt;/ref&gt;

==See also==
{{wikispecies|Streptomyces}}
{{Portal|Biology}}
{{columns-list|2|
*[[Bacillus isolates]]
*''[[Bacillus subtilis]]'' a culinary/industrial bacteria used to produce a number of [[List of fermented soy products|fermented soy products]]
*[[Biotechnology in pharmaceutical manufacturing]]
*''[[Corynebacterium|Corynebacterium glutamicum]]'' the industrial/pharmaceutical bacteria responsible for manufacturing a number of [[amino acid]]s
*''[[Erwinia chrysanthemi]]'' a bacteria used to produce the chemotherapy medicine [[asparaginase]] 
*[[Fungal isolates]]
*[[Medicinal molds]]
*[[Polyene antimycotics]]
*[[Sponge isolates]]
}}

==External links==
*[http://www.pharmaceutical-bioinformatics.de/streptomedb/compound_list/ StreptomeDB]
*[https://uqu.edu.sa/files2/tiny_mce/plugins/filemanager/files/4180164/streptomyces-antibio-future.pdf Antibiotics and Streptomyces : the future of antibiotic discovery]

==References==
{{reflist|2}}

[[Category:Streptomyces]]
[[Category:Biotechnology]]
[[Category:Medicine]]
[[Category:Bacteria]]
[[Category:Chemotherapy]]
[[Category:Cancer]]
[[Category:Antibiotics]]
[[Category:Immunosuppressants]]
[[Category:Antifungals]]
[[Category:Antiparasitic agents]]</text>
      <sha1>98lmfpefz96xzac1bhbmiaujsxdtyq7</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Medicinal molds</title>
    <ns>0</ns>
    <id>30744798</id>
    <revision>
      <id>607765085</id>
      <parentid>607615002</parentid>
      <timestamp>2014-05-09T12:11:38Z</timestamp>
      <contributor>
        <username>Jatlas</username>
        <id>9102079</id>
      </contributor>
      <comment>/* See also */</comment>
      <text xml:space="preserve" bytes="13362">[[image:Aspergillus nidulans.cropped.jpg|thumb|Aspergillus.gif|133|''Aspergillus'']]
'''Medicinal molds''' are fungi used for biotechnology or [[drug discovery]]. Because molds typically exist as thin mycelial [[monolayer]]s, with no protective shell, [[immune system]], or much mobility, they rely on an ability to synthesize a variety of unusual compounds for survival. Researchers have discovered important medicines from molds, like [[penicillin]] and [[lovastatin]]. The biotechnological potential of molds is clearly illustrated with ''Penicillium raistrickii''-derived [[paclitaxel]].

==Anticancer compounds==
[[File:Taxol (Paclitaxel) containing plants hazel nut, taxus, Cardiospermum halicacabum.jpg|thumb|Medicinal molds that synthesize [[paclitaxel]], were discovered in ''[[Taxus]]'' (left), ''[[Corylus]]''&lt;ref name=&quot;pmid22847380&quot;&gt;{{cite journal| author=Bemani E, Ghanati F, Rezaei A, Jamshidi M| title=Effect of phenylalanine on Taxol production and antioxidant activity of extracts of suspension-cultured hazel (Corylus avellana L.) cells. | journal=J Nat Med | year= 2013 | volume= 67 | issue= 3 | pages= 446-51 | pmid=22847380 | doi=10.1007/s11418-012-0696-1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=22847380  }} &lt;/ref&gt; (center), and ''[[Cardiospermum halicacabum]]''&lt;ref name=&quot;pmid18998547&quot;&gt;{{cite journal| author=Gangadevi V, Murugan M, Muthumary J| title=Taxol determination from Pestalotiopsis pauciseta, a fungal endophyte of a medicinal plant. | journal=Sheng Wu Gong Cheng Xue Bao | year= 2008 | volume= 24 | issue= 8 | pages= 1433-8 | pmid=18998547 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=18998547  }} &lt;/ref&gt; (right)]]

[[Bristol-Myers Squibb]] manufactures paclitaxel using ''Penicillium raistrickii'' and plant cell fermentation (PCF). Fungi can synthesize other [[mitotic inhibitor]]s including [[vinblastine]], [[vincristine]], [[podophyllotoxin]], [[griseofulvin]], [[aurantiamine]], [[oxaline]], and [[neoxaline]].&lt;ref&gt;http://www.globalsciencebooks.info/JournalsSup/images/0806/IJBPS_2%281%291-23o.pdf&lt;/ref&gt; 

11,11'-[[Dideoxyverticillin A]], an isolate of marine ''Penicillium'', was used to create dozens of semi-synthetic anticancer compounds.&lt;ref&gt;{{cite web|url=http://web.mit.edu/newsoffice/2013/chemists-find-help-from-nature-in-fighting-cancer-0227.html |title=Research update: Chemists find help from nature in fighting cancer - MIT News Office |publisher=Web.mit.edu |date=2013-02-27 |accessdate=2013-12-17}}&lt;/ref&gt; 11,11'-Dideoxyverticillin A, [[andrastin A]], [[barceloneic acid A]], and [[barceloneic acid B]], are [[farnesyl transferase inhibitor]]s that can be made by ''Penicillium''.&lt;ref name=&quot;pmid16279417&quot;&gt;{{cite journal| author=Overy DP, Larsen TO, Dalsgaard PW, Frydenvang K, Phipps R, Munro MH et al.| title=Andrastin A and barceloneic acid metabolites, protein farnesyl transferase inhibitors from Penicillium albocoremium: chemotaxonomic significance and pathological implications. | journal=Mycol Res | year= 2005 | volume= 109 | issue= Pt 11 | pages= 1243-9 | pmid=16279417 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=16279417  }} &lt;/ref&gt; [[3-O-Methylfunicone]], [[anicequol]], [[duclauxin]], and [[rubratoxin B]], are anticancer/cytotoxic metabolites of ''Penicillium''.

''Penicillium'' is a potential source of the leukemia medicine [[asparaginase]] ('''Erwinaze''').&lt;ref name=&quot;pmid23030468&quot;&gt;{{cite journal| author=Shrivastava A, Khan AA, Shrivastav A, Jain SK, Singhal PK| title=Kinetic studies of L-asparaginase from Penicillium digitatum. | journal=Prep Biochem Biotechnol | year= 2012 | volume= 42 | issue= 6 | pages= 574-81 | pmid=23030468 | doi=10.1080/10826068.2012.672943 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=23030468  }} &lt;/ref&gt;

==Antibiotics==
[[image:Sliced_tempeh_(cropped).jpg|thumb|''[[Rhizopus oligosporus]]'' produces [[tempeh]], as well as a cystine rich antibiotic&lt;ref name=&quot;pmid1368137&quot;&gt;{{cite journal| author=Kobayasi S, Okazaki N, Koseki T| title=Purification and characterization of an antibiotic substance produced from Rhizopus oligosporus IFO 8631. | journal=Biosci Biotechnol Biochem | year= 1992 | volume= 56 | issue= 1 | pages= 94-8 | pmid=1368137 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=1368137  }} &lt;/ref&gt;]]
[[Alexander Fleming]] led the way to the [[beta-lactam antibiotics]] with the ''Penicillium'' mold and [[penicillin]]. [[Cephalosporin]], [[fusafungine]], [[fumagillin]], [[alamethicin]], [[fusidic acid]], [[aphidicolin]], [[cerulenin]], [[brefeldin A]], [[verrucarin A]], [[itaconic acid]], [[aphidicolin]], [[nigrosporin B]], [[eupenifeldin]], [[vermiculine]], [[citromycin]], [[MT81]], and [[citric acid]], can be synthesized by molds.

==Cholesterol biosynthesis inhibitors==
[[File:Red yeast rice.jpg|thumb|''[[Monascus purpureus]]'' produces [[red yeast rice]], as well as three different types of [[statin]]s]]
[[Akira Endo (biochemist)|Akira Endo]] led the way to the [[statin]] medications isolating the [[pravastatin]] precursor [[mevastatin]] from ''Penicillium''. [[Lovastatin]], the first commercial statin, was found in the ''Aspergillus'' mold. ''Aspergillus'' is capable of producing 70mg lovastatin per kilogram of substrate.&lt;ref name=&quot;pmid23118499&quot;&gt;{{cite journal| author=Jahromi MF, Liang JB, Ho YW, Mohamad R, Goh YM, Shokryazdan P| title=Lovastatin production by Aspergillus terreus using agro-biomass as substrate in solid state fermentation. | journal=J Biomed Biotechnol | year= 2012 | volume= 2012 | issue=  | pages= 196264 | pmid=23118499 | doi=10.1155/2012/196264 | pmc=3478940 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=23118499  }} &lt;/ref&gt;

The [[red yeast rice]] mold, ''[[Monascus purpureus]]'', creates lovastatin, mevastatin, and the [[simvastatin]] precursor [[monacolin J]]. [[Zaragozic acid]]s were isolated from [[ascomycota]]. [[Nicotinamide riboside]], a cholesterol biosynthesis inhibitor, is made by ''Saccharomyces cerevisiae''.

==Antifungals==
[[Griseofulvin]], [[caspofungin]], [[strobilurin]], [[azoxystrobin]], [[micafungin]], and [[echinocandins]], were discovered in molds. [[Anidulafungin]] is a derivative of an ''Aspergillus'' metabolite.

==Immunosuppressants==
[[Ciclosporin]], was discovered in ''[[Tolypocladium inflatum]]''. [[Bredinin]]  was discovered in ''Eupenicillium brefeldianum''. [[Mycophenolic acid]] was discovered in ''Penicillium stoloniferum''. Thermophilic molds were the source of the [[fingolimod]] precursor [[myriocin]]. ''Aspergillus'' synthesizes immunosuppressants [[gliotoxin]] and [[:File:Endocrocin.svg|endocrocin]].

==Antimalarials==
Fungal isolates [[codinaeopsin]], [[efrapeptin]]s, zervamicins, and [[antiamoebin]], inhibit malaria protozoa.

==Antidiabetic compounds==
[[Aspergillusol A]] is an [[alpha-glucosidase inhibitor]] made by ''Aspergillus''. 
[[Sclerotiorin]] is an [[aldose reductase inhibitor]] made by ''Penicillium''.

==Ergoloids==
''Aspergillus'' and ''Penicillium'' are potential sources of [[ergot alkaloid]] precursors to psychotropic medicines, [[hydergine]] ([[dihydroergocristine]], [[dihydroergocornine]], [[alpha-dihydroergocryptine|α-]], and [[beta-dihydroergocryptine|β-dihydroergocryptine]]), [[cafergot]], [[dihydroergotamine]], [[methysergide]], [[methylergometrine]], [[nicergoline]], [[lisuride]], [[bromocriptine]], [[cabergoline]], [[pergolide]], as well as bio-active ergolines [[ergine]], [[ergometrine]], [[lysergic acid]], [[lysergic acid hydroxyethylamide]], [[lysergic acid diethylamide]].

==Biotechnology==
[[Fermentek]] produces [[apicidin]], [[beauvericin]], [[cytochalasin E]], [[radicicol]], [[K252a]], [[wortmannin]], and other pharmaceutical compounds using ''Penicillium'', ''Aspergillus'', and ''Fusarium''. Endophytic fungi are currently used to manufacture [[paclitaxel]].

Endophytic fungi are potential sources of the paclitaxel precursor [[baccatin III]], the [[docetaxel]] precursor [[10-deacetylbaccatin]], [[vinblastine]], [[vincristine]], [[huperzine A]], [[hypericin]], [[vincamine]], [[:file:Amarogentin gentiopicrin.png|gentiopicrin]], [[chlorogenic acid]], [[diosgenin]], and [[ginkgolide|ginkgolide B]]. Endophytic fungi are potential sources of [[podophyllotoxin]] and [[camptothecin]], precursors to [[etoposide]], [[teniposide]], [[topotecan]], and [[irinotecan]].

Mycelium can be used to biosynthesize gold [[nanoparticles]] and be used as a [[Mycofiltration|mycofiltrate]] to recover gold from electronic waste.&lt;ref name=&quot;pmid22312264&quot;&gt;{{cite journal| author=Li G, He D, Qian Y, Guan B, Gao S, Cui Y et al.| title=Fungus-Mediated Green Synthesis of Silver Nanoparticles Using Aspergillus terreus. | journal=Int J Mol Sci | year= 2012 | volume= 13 | issue= 1 | pages= 466-76 | pmid=22312264 | doi=10.3390/ijms13010466 | pmc=3269698 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=22312264  }} &lt;/ref&gt;&lt;ref name=&quot;pmid23400423&quot;&gt;{{cite journal| author=Gupta S, Bector S| title=Biosynthesis of extracellular and intracellular gold nanoparticles by Aspergillus fumigatus and A. flavus. | journal=Antonie Van Leeuwenhoek | year= 2013 | volume= 103 | issue= 5 | pages= 1113-23 | pmid=23400423 | doi=10.1007/s10482-013-9892-6 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=23400423  }} &lt;/ref&gt;[http://www.vtt.fi/news/2014/10042014_kannykkaromu.jsp?lang=en] ''Aspergillus'' can metabolize [[piceid]] to [[resveratrol]].&lt;ref name=&quot;pmid17333175&quot;&gt;{{cite journal| author=Wang H, Liu L, Guo YX, Dong YS, Zhang DJ, Xiu ZL| title=Biotransformation of piceid in Polygonum cuspidatum to resveratrol by Aspergillus oryzae. | journal=Appl Microbiol Biotechnol | year= 2007 | volume= 75 | issue= 4 | pages= 763-8 | pmid=17333175 | doi=10.1007/s00253-007-0874-3 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=17333175  }} &lt;/ref&gt; The introduction and expression of the fungal gene responsible for synthesizing [[baccatin III]], to the mushroom ''Flammulina velutipes'' was recently reported.&lt;ref name=&quot;pmid24403190&quot;&gt;{{cite journal| author=Han F, Kang LZ, Zeng XL, Ye ZW, Guo LQ, Lin JF| title=Bioproduction of baccatin III, an advanced precursor of paclitaxol with transgenic Flammulina velutipes expressing 10-Deacetylbaccatin III-10-O-acetyl transferase gene. | journal=J Sci Food Agric | year= 2014 | volume=  | issue=  | pages=  | pmid=24403190 | doi=10.1002/jsfa.6562 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=24403190  }} &lt;/ref&gt; 

==Yeasts==
[[Transgenic]] yeast are used to produce [[artemisinin]], as well as a number of [[insulin analog]]s.&lt;ref&gt;{{cite web|author=Mark Peplow |url=http://www.rsc.org/chemistryworld/2013/04/sanofi-launches-malaria-drug-production |title=Sanofi launches malaria drug production &amp;#124; Chemistry World |publisher=Rsc.org |date= |accessdate=2013-12-17}}&lt;/ref&gt; The first &quot;synthetic [[chromosome]]&quot; produced by yeast was reported in 2014.[http://www.bbc.com/news/science-environment-26768445]

==See also==
{{Portal|Fungi}}
{{columns-list|2|
*''[[Aspergillus oryzae]]'' (koji) the fungus used to produce soy sauce, miso, rice wines, rice beers, and rice vinegars
*[[Bacillus isolates]]
*[[Fungal isolates]]
*[[List of microorganisms used in food and beverage preparation]]
*[[Medicinal mushrooms]]
*[[Mycoremediation]] fungi-based bioremediation
*[[Mycorrhiza]] (''[[Arbuscular mycorrhiza|arbuscular]]'', ''[[Ectomycorrhiza|ecto]]'', ''[[Ericoid mycorrhiza|ericoid]]'') medicinal fungi of the plant kingdom
*''[[Physarum polycephalum]]'' a semi-intelligent slime mold
*''[[Saccharomyces boulardii]]'' a medicinal yeast
*''[[Saccharomyces cerevisiae]]''  (baker's/brewer's yeast) extracts [[Vegemite]], [[Marmite]], [[Cenovis]], [[Guinness Yeast Extract]], [[EpiCor]], [[mannan oligosaccharide-based nutritional supplements|MOS]], [[baker's yeast]], [[yeast extract]], [[PGG-glucan|pgg-glucan]], [[nutritional yeast]], [[nicotinamide riboside]], [[zymosan]]
*[[Streptomyces isolates]] comprise a number of fundamental chemotherapy medicines, as well as more than two thirds of all marketed antibiotics
}}

== References ==
&lt;references /&gt;

==External links==
*[http://www.globalsciencebooks.info/JournalsSup/images/0806/IJBPS_2%281%291-23o.pdf Antitumor Extrolites Produced by ''Penicillium'' Species]
*[http://www.formatex.info/microbiology2/567-576.pdf Endophytic fungi for producing bioactive compounds originally from their host plants ]

{{DEFAULTSORT:Medicinal Molds}}
[[Category:Biotechnology]]
[[Category:Medicinal fungi]]
[[Category:Medicine]]
[[Category:Chemotherapy]]
[[Category:Cancer]]
[[Category:Antibiotics]]
[[Category:Immunosuppressants]]
[[Category:Antifungals]]
[[Category:Antiparasitic agents]]</text>
      <sha1>5gjkpu0mtaerlpaluuk033e7mb78jao</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Medicinal mushroom</title>
    <ns>0</ns>
    <id>22666912</id>
    <revision>
      <id>607765187</id>
      <parentid>606885852</parentid>
      <timestamp>2014-05-09T12:12:40Z</timestamp>
      <contributor>
        <username>Jatlas</username>
        <id>9102079</id>
      </contributor>
      <comment>/* See also */</comment>
      <text xml:space="preserve" bytes="68643">{{medref|date=April 2014}}
{{primary|date=April 2014}}
[[File:Lepista nuda sb777.jpg|thumb|right|''Clitocybe nuda'']]
'''Medicinal mushrooms''' are mushrooms used in medicine or medical research.

==Folk medicine==
{{double image|right|Mushroom.art.3.jpg|141|Psilocybe Mushrooms statues.jpg|80|Mushroom artwork by [[Chen Hongshou]], [[Hiroshige II]], [[Giuseppe Castiglione (Jesuit)|Lang Shining]], [[Korean Bell of Friendship]] (left) Mesoamerican mushroom stones (right)||}}
{{double image|right|Hokkaido Reishi'S Ganoderma Amboinense (reishi) before harvest.JPG|126|Caterpillar Fungus Store, Central Lhasa - ERIK TORNER.jpg|100|''Ganoderma'' cultivation (left, [[Hokkaido]]) ''Cordyceps'' store (right, [[Lhasa]])||}}

[[Mushrooms]], fermentation [[molds]], [[mycelia]], [[sclerotium]], and [[lichens]], have a history of medicinal use spanning millennia. The mushroom with the longest record of medicinal use ''Ganoderma lucidum'', is known in Chinese as líng zhī (&quot;spirit plant&quot;), and in Japanese as mannentake (&quot;10,000 year mushroom&quot;). In ancient Japan, ''Grifola frondosa'' was worth its weight in silver.&lt;ref name=acs-maitake&gt;{{cite web |url=http://www.cancer.org/Treatment/TreatmentsandSideEffects/ComplementaryandAlternativeMedicine/DietandNutrition/maitake-mushrooms |publisher=American Cancer Society |title=Maitake Mushroom |work=Complementary and Alternative Medicine : Diet and Nutrition |year=2008 |accessdate=2011-03-08 }}&lt;/ref&gt;

A [[Hadith]] states, &quot;[[Terfeziaceae|Truffles]] are manna which Allah sent to the people of Israel through Moses, and its juice is a medicine for the eyes.&quot;&lt;ref&gt;{{cite book |chapterurl=http://sahihmuslim.com/sps/smm/sahihmuslim.cfm?scn=dspchaptersfull&amp;BookID=23&amp;ChapterID=863 |pages=5084–9 |publisher=Sahih Muslim |chapter=Book 23, Chapter 27 |title=[[Hadith]] |author=Muhammad |isbn=0-7045-0303-4}}&lt;/ref&gt; [[Ötzi the Iceman]] was found carrying ''Fomes fomentarius'' and ''Piptoporus betulinus''.&lt;ref name=&quot;Peintner U, Pöder R, Pümpel T 1153–62&quot;&gt;{{cite journal |last1=Peintner |first1=U |last2=Poder |first2=R |last3=Pumpel |first3=T |title=The iceman's fungi |journal=Mycological Research |volume=102 |pages=1153–62 |year=1998 |doi=10.1017/S0953756298006546 |issue=10}}&lt;/ref&gt; ''Inonotus obliquus'' was used in Russia as early as the 16th century, and it featured in [[Alexandr Solzhenitsyn]]'s 1967 novel ''[[Cancer Ward]]''.&lt;ref name=&quot;pmid20532760&quot;&gt;{{cite journal |last1=Zheng |first1=Weifa |last2=Miao |first2=Kangjie |last3=Liu |first3=Yubing |last4=Zhao |first4=Yanxia |last5=Zhang |first5=Meimei |last6=Pan |first6=Shenyuan |last7=Dai |first7=Yucheng |title=Chemical diversity of biologically active metabolites in the sclerotia of Inonotus obliquus and submerged culture strategies for up-regulating their production |journal=Applied Microbiology and Biotechnology |volume=87 |issue=4 |pages=1237–54 |year=2010 |pmid=20532760 |doi=10.1007/s00253-010-2682-4}}&lt;/ref&gt; Ancient Egyptians considered mushrooms food for royalty.

==Drugs derived from mushrooms==

Fungi that do not produce mushrooms, have made large contributions to medicine being the source of immunosuppressants [[ciclosporin]], [[mycophenolic acid]], [[mizoribine]], antibiotics [[penicillin]], [[cephalosporin]]s, [[fusafungine]], [[usnic acid]], [[fusidic acid]], [[fumagillin]], [[brefeldin A]], [[verrucarin A]], [[alamethicin]], antifungals [[griseofulvin]], [[echinocandin]]s, [[strobilurin]], [[azoxystrobin]], [[caspofungin]], [[micafungin]].{{cn|date=April 2014}}

The [[statins]] are an important class of cholesterol-lowering drugs; the [[Discovery and development of statins|first generation of statins were derived]] from non-mushroom forming fungi.&lt;ref name=Tolbert&gt;Jonathan A. Tobert  [http://www.nature.com/nrd/journal/v2/n7/full/nrd1112.html Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors] Nature Reviews Drug Discovery 2, 517-526 (July 2003) PMID 12815379&lt;/ref&gt; 

*[[Lovastatin]], which was discovered in a fermentation broth of ''[[Aspergillus terreus]]'' by scientists at [[Merck &amp; Co.]] in 1978, and the first statin approved as a drug&lt;ref name=Tolbert/&gt;
*[[Simvastatin]], a semisynthetic derivative of [[Lovastatin]]&lt;ref name=Tolbert/&gt;
*[[Pravastatin]], derived from compactin, the first statin-like compound, which was discovered in a fermentation broth of ''[[Penicillium citrinum]]'' by scientists at [[Daiichi Sankyo|Sankyo]] in the 1970s&lt;ref name=Tolbert/&gt;

==Medical applications and research==

===Antimicrobial isolates and derivatives===
[[File:Ling Zhi-8.png|thumb|Ling Zhi-8, an immunomodulatory protein isolated from ''Ganoderma lucidum'']]
Antibiotics [[retapamulin]], [[tiamulin]], and [[valnemulin]] are derivatives of the mushroom isolate [[pleuromutilin]]. [[Plectasin]], [[austrocortilutein]], [[austrocortirubin]], [[coprinol]], [[oudemansin A]], [[strobilurin]], [[illudin]], [[pterulone]], and [[sparassol]], are antibiotics isolated from mushrooms. Researchers have isolated a number of antifungal, antiviral, and antiprotozoan, isolates from mushrooms.&lt;ref name=&quot;pmid9705612&quot;&gt;{{cite journal| author=Engler M, Anke T, Sterner O| title=Production of antibiotics by Collybia nivalis, Omphalotus olearis, a Favolaschia and a Pterula species on natural substrates. | journal=Z Naturforsch C | year= 1998 | volume= 53 | issue= 5-6 | pages= 318–24 | pmid=9705612 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=9705612  }}&lt;/ref&gt;

===Anticancer research===
Some countries have approved [[Beta-glucan]] mushroom extracts [[lentinan]], [[polysaccharide-K]], and [[polysaccharide peptide]] as [[immunologic adjuvant]]s.&lt;ref name=&quot;pmid23092289&quot;&gt;{{cite journal|pmid=23092289|year=2013|last1=Ina|first1=K|last2=Kataoka|first2=T|last3=Ando|first3=T|title=The use of lentinan for treating gastric cancer|volume=13|issue=5|pages=681–8|pmc=3664515|journal=Anti-cancer agents in medicinal chemistry|doi=10.2174/1871520611313050002}}&lt;/ref&gt; There is some evidence of this use having effectiveness in prolonging and improving the quality of life for patients with certain cancers, although the [[Memorial Sloan-Kettering Cancer Center]] observes that &quot;well designed, large scale studies are needed to establish the role of lentinan as a useful adjunct to cancer treatment&quot;.&lt;ref name=msk-lentian&gt;{{cite web
|url=http://www.mskcc.org/cancer-care/herb/lentinan
|publisher=[[Memorial Sloan-Kettering Cancer Center]]
|date=27 February 2013
|accessdate=August 2013
|title=Lentinan}}&lt;/ref&gt; According to [[Cancer Research UK]], &quot;there is currently no evidence that any type of mushroom or mushroom extract can prevent or cure cancer&quot;.&lt;ref name=cruk&gt;{{cite web
|url=http://www.cancerresearchuk.org/cancer-help/about-cancer/cancer-questions/mushrooms-in-cancer-treatment
|title=Mushrooms and cancer
|publisher=[[Cancer Research UK]]
|accessdate=August 2013}}&lt;/ref&gt;

===Mushroom enzyme inhibitors===
{| class=&quot;wikitable&quot; style=&quot;text-align:center&quot;; border=&quot;1&quot;	
! Mushroom !! Isolate/extract/metabolite !! Enzyme inhibited 
|-
|''[[Pleurotus ostreatus]]''|| [[lovastatin]] || [[HMG-CoA reductase]]
|-
|''[[Hypholoma sublateritium]]''|| [[clavaric acid]] || [[farnesyltransferase]]
|-
|''[[Polyozellus multiplex]]''|| [[polyozellin]], [[thelephoric acid]], [[kynapcin]]s || [[prolyl endopeptidase]]
|-
|''[[Lentinula edodes]]''|| [[eritadenine]] || [[S-adenosyl-L-homocysteine hydrolase]]
|-
|''[[Coprinopsis atramentaria]]''|| 1-aminocyclopropanol || [[acetaldehyde dehydrogenase]]
|-
|''[[Inonotus obliquus]]''|| extract || [[dipeptidyl peptidase-4]]
|-
|''[[Grifola frondosa]]''|| extract || [[alpha glucosidase]]
|-
|''[[Trametes versicolor]]''|| extract || [[alpha amylase]]
|-
|''[[Pholiota squarrosa]]'', ''[[Daedalea quercina]]'' || extract (''Pholiota squarrosa''), [[quercinol]] (''Daedalea quercina'') || [[xanthine oxidase]]
|-
|''[[Phellinus linteus]]''|| [[phellinstatin]] || [[enoyl-ACP reductase]]
|-
|''[[Phellinus linteus]]''|| [[hispidin]] and [[hypholomine B]] || [[neuraminidase]]
|-
|Various|| extract || [[5-alpha reductase]]
|-
|Various|| extract || [[aromatase]]
|-
|Various|| peptides || [[angiotensin-converting enzyme]]
|-
|''[[Daedalea quercina]]''|| [[quercinol]] || [[cyclooxygenase 2]] &amp; [[horseradish peroxidase]]
|-
|}

===Antidiabetic research===
	
Many mushroom isolates act as [[DPP-4 inhibitors]], [[alpha-glucosidase inhibitor]]s, and [[alpha amylase inhibitor]]s ''in vitro''. [[Ternatin]] is a mushroom isolate that suppresses hyperglycemia.&lt;ref&gt;{{cite journal|pmid=22324407|year=2011|last1=Lo|first1=HC|last2=Wasser|first2=SP|title=Medicinal mushrooms for glycemic control in diabetes mellitus: History, current status, future perspectives, and unsolved problems (review)|volume=13|issue=5|pages=401–26|journal=International journal of medicinal mushrooms|doi=10.1615/intjmedmushr.v13.i5.10}}&lt;/ref&gt;

===Psychotropic research===

Psychotropic medicines created from [[ergot alkaloids]] include [[cafergot]], [[dihydroergotamine]], [[methysergide]], [[methylergometrine]], [[hydergine]], [[nicergoline]], [[lisuride]], [[bromocriptine]], [[cabergoline]], [[pergolide]]. ''[[Polyozellus multiplex]]'' synthesizes [[prolyl endopeptidase]] inhibitors [[polyozellin]], [[thelephoric acid]], [[kynapcin]]s, while ''[[Hericium erinaceus]]'' isolates [[erinacine]] and [[hericenone]] promote [[nerve growth factor]] synthesis and [[myelination]] ''in vitro''.  [[Neurotrophic]] mushroom isolates include [[L-theanine]], [[tricholomalide]]s, [[scabronine]]s, [[termitomycesphin]]s. Many mushrooms synthesize the partial, non-selective, [[serotonin receptor agonist]]/analog [[psilocin]].

===Nutrients and phytochemicals===
[[image:Vitamin D biosynthesis in fungi and animals.jpg|thumb|The [[photochemistry]] of Vitamin D biosynthesis]]
Only fungi and animals can synthesize [[vitamin D]]. Mushrooms have been verified creating D&lt;sub&gt;2&lt;/sub&gt; ([[ergocalciferol]]), D&lt;sub&gt;4&lt;/sub&gt; ([[22-dihydroergocalciferol]]), and vitamin D&lt;sub&gt;1&lt;/sub&gt; ([[Lumisterol]]+D&lt;sub&gt;2&lt;/sub&gt;).&lt;ref&gt;{{cite journal|title=Photobiology of vitamin D in mushrooms and its bioavailability in humans|authors=Keegan RJ, Lu Z, Bogusz JM, Williams JE, Holick MF|journal=Dermatoendocrinol.|date=Jan 1, 2013|volume=5|issue=1|pages=165–76|doi=10.4161/derm.23321|pmid=24494050}}{{primary-inline|date=February 2014}}&lt;/ref&gt; Mushrooms are a rare source of [[ergothioneine]],&lt;ref&gt;{{cite journal|title=The bioavailability of ergothioneine from mushrooms (Agaricus bisporus) and the acute effects on antioxidant capacity and biomarkers of inflammation|authors=Weigand-Heller AJ, Kris-Etherton PM, Beelman RB|journal=Prev Med. |date=May 2012|volume=54 |issue=Suppl|pages=S75-8|doi=10.1016/j.ypmed.2011.12.028|pmid=22230474}}{{primary-inline|date=February 2014}}&lt;/ref&gt; contain [[ACE inhibitor]] peptides, and are a source of [[Prebiotic (nutrition)|prebiotic]] [[dietary fiber]]. Mushrooms also contain a variety of chemicals like [[lovastatin]], [[cordycepin]], [[inotilone]], [[quercinol]], [[antcin B]], [[antrodioxolanone]], and benzocamphorin F having preliminary research evidence for [[anti-inflammatory]] activity. Mushroom mycelia can be used to enhance the concentrations of [[γ-aminobutyric acid]], [[ergothioneine]], and other antioxidants in bread.&lt;ref name=&quot;pmid24552201&quot;&gt;{{cite journal| author=Postemsky P, Curvetto N| title=Enhancement of Wheat Grain Antioxidant Activity by Solid State Fermentation with Grifola spp. | journal=J Med Food | year= 2014 | volume= | issue= | pages= | pmid=24552201 | doi=10.1089/jmf.2013.0108 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=24552201 }}&lt;/ref&gt;&lt;ref name=&quot;pmid23265457&quot;&gt;{{cite journal| author=Ulziijargal E, Yang JH, Lin LY, Chen CP, Mau JL| title=Quality of bread supplemented with mushroom mycelia. | journal=Food Chem | year= 2013 | volume= 138 | issue= 1 | pages= 70–6 | pmid=23265457 | doi=10.1016/j.foodchem.2012.10.051 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=23265457 }}&lt;/ref&gt;

Mushrooms are a rare source of [[ergothioneine]].&lt;ref&gt;{{cite journal|title=The bioavailability of ergothioneine from mushrooms (Agaricus bisporus) and the acute effects on antioxidant capacity and biomarkers of inflammation|authors=Weigand-Heller AJ, Kris-Etherton PM, Beelman RB|journal=Prev Med. |date=May 2012|volume=54 
|issue=Suppl|pages=S75-8|doi=10.1016/j.ypmed.2011.12.028|pmid=22230474}}{{primary-inline|date=February 2014}}&lt;/ref&gt; Mushrooms also contain a variety of [[phytochemicals]] such as [[cordycepin]], [[inotilone]], [[quercinol]], [[antcin B]], [[antrodioxolanone]], and benzocamphorin F having preliminary research evidence for [[anti-inflammatory]] activity.{{cn|date=April 2014}} Mushroom mycelia can be used to enhance the concentrations of [[γ-aminobutyric acid]], [[ergothioneine]], and other antioxidants in bread.&lt;ref name=&quot;pmid24552201&quot;&gt;{{cite journal| author=Postemsky P, Curvetto N| title=Enhancement of Wheat Grain Antioxidant Activity by Solid State Fermentation with Grifola spp. | journal=J Med Food | year= 2014 | volume= | issue= | pages= | pmid=24552201 | doi=10.1089/jmf.2013.0108 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=24552201 }}&lt;/ref&gt;&lt;ref name=&quot;pmid23265457&quot;&gt;{{cite journal| author=Ulziijargal E, Yang JH, Lin LY, Chen CP, Mau JL| title=Quality of bread supplemented with mushroom mycelia. | journal=Food Chem | year= 2013 | volume= 138 | issue= 1 | pages= 70–6 | pmid=23265457 | doi=10.1016/j.foodchem.2012.10.051 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=23265457 }}&lt;/ref&gt;

==Edible species==	
'''''Agaricus bisporus'' (Portobello, cremini, white button, champignon)'''
	 	
{{triple image|right|Champignons Agaricus.jpg|100|Agaricus subrufescens2.jpg|120|Agrocybe aegerita888.jpg|86|''Agaricus bisporus'' (left) ''Agaricus subrufescens'' (center) ''Agrocybe aegerita'' (right)|||}}
	 	
''[[Agaricus bisporus]]'' extracts have immunomodulatory activities ''in vivo'',&lt;ref name=&quot;WB&quot;&gt;{{cite journal |last1=Ren |first1=Z |last2=Guo |first2=Z |last3=Meydani |first3=SN |last4=Wu |first4=Dayong |title=White button mushroom enhances maturation of bone marrow-derived dendritic cells and their antigen presenting function in mice |journal=The Journal of nutrition |volume=138 |issue=3 |pages=544–50 |year=2008 |pmid=18287364 |url=http://jn.nutrition.org/cgi/pmidlookup?view=long&amp;pmid=18287364}}{{Unreliable medical source|primary source|date=March 2011}}&lt;/ref&gt;&lt;ref name=&quot;WB2&quot;&gt;{{cite journal |last1=Wu |first1=Dayong |last2=Pae |first2=Munkyong |last3=Ren |first3=Zhihong |last4=Guo |first4=Zhuyan |last5=Smith |first5=Donald |last6=Meydani |first6=Simin Nikbin |title=Dietary supplementation with white button mushroom enhances natural killer cell activity in C57BL/6 mice |journal=The Journal of nutrition |volume=137 |issue=6 |pages=1472–7 |year=2007 |pmid=17513409 |url=http://jn.nutrition.org/cgi/pmidlookup?view=long&amp;pmid=17513409}}{{Unreliable medical source|primary source|date=March 2011}}&lt;/ref&gt; and activity against several cancer cell lines.&lt;ref name=&quot;pmid8402638&quot;&gt;{{cite journal |last1=Yu |first1=Lugang |last2=Fernig |first2=David G. |last3=Smith |first3=John A. |last4=Milton |first4=Jeremy D. |last5=Rhodes |first5=Jonathan M. |title=Reversible inhibition of proliferation of epithelial cell lines by Agaricus bisporus (edible mushroom) lectin |journal=Cancer Research |volume=53 |issue=19 |pages=4627–32 |year=1993 |pmid=8402638 |url=http://cancerres.aacrjournals.org/content/53/19/4627.short}}{{Unreliable medical source|primary source|date=March 2011}}&lt;/ref&gt;
	 	
'''''Agaricus subrufescens'' (''Agaricus blazei/brasiliensis'', almond mushroom)'''
	 	
''[[Agaricus subrufescens]]'' is a medicinal mushroom associated with Brazil and Japan.&lt;ref name=&quot;pmid11340091&quot;&gt;{{cite journal |first1=Takeshi |last1=Takaku |first2=Yoshiyuki |last2=Kimura |first3=Hiromichi |last3=Okuda |title=Isolation of an antitumor compound from Agaricus blazei Murill and its mechanism of action |journal=The Journal of Nutrition |volume=131 |issue=5 |pages=1409–13 |date=May 2001 |pmid=11340091 |url=http://jn.nutrition.org/cgi/pmidlookup?view=long&amp;pmid=11340091}}&lt;/ref&gt;&lt;ref name=&quot;pmid15728227&quot;&gt;{{cite journal |last1=Hyodo |first1=I. |last2=Amano |first2=N |last3=Eguchi |first3=K |last4=Narabayashi |first4=M |last5=Imanishi |first5=J |last6=Hirai |first6=M |last7=Nakano |first7=T |last8=Takashima |first8=S |title=Nationwide Survey on Complementary and Alternative Medicine in Cancer Patients in Japan |journal=Journal of Clinical Oncology |volume=23 |issue=12 |pages=2645–54 |year=2004 |pmid=15728227 |doi=10.1200/JCO.2005.04.126}}&lt;/ref&gt; Research and small clinical studies demonstrated ''Agaricus subrufescens'' extracts have antihyperglycemic and anticancer activities.&lt;ref name=&quot;pmid = 18997106&quot;&gt;{{cite journal |last1=Fortes |first1=RC |last2=Novaes |first2=MRCG |last3=Recova |first3=VL |last4=Melo |first4=AL |title=Immunological, hematological, and glycemia effects of dietary supplementation with Agaricus sylvaticus on patients' colorectal cancer |journal=Experimental Biology and Medicine |volume=234 |issue=1 |pages=53–62 |year=2009 |pmid=18997106 |doi=10.3181/0806-RM-193}}{{Unreliable medical source|primary source|date=March 2011}}&lt;/ref&gt;&lt;ref name=&quot;Ahn_2004&quot;&gt;{{cite journal |last1=Ahn |first1=W.-S. |last2=Kim |first2=D.-J. |last3=Chae |first3=G.-T. |last4=Lee |first4=J.-M. |last5=Bae |first5=S.-M. |last6=Sin |first6=J.-I. |last7=Kim |first7=Y.-W. |last8=Namkoong |first8=S.-E. |last9=Lee |first9=I. P. |displayauthors=9 |title=Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy |journal=International Journal of Gynecological Cancer |volume=14 |issue=4 |pages=589–94 |year=2004 |pmid=15304151 |doi=10.1111/j.1048-891X.2004.14403.x}}{{Unreliable medical source|primary source|date=March 2011}}&lt;/ref&gt;&lt;ref&gt;{{cite web |url=http://www.mskcc.org/mskcc/html/69112.cfm |title=Agaricus |work=About Herbs, Botanicals &amp; Other Products |publisher=Memorial Sloan-Kettering Cancer Center |accessdate=2010-01-18}}&lt;/ref&gt;&lt;ref name=&quot;pmid18782264&quot;&gt;{{cite journal |last1=Hetland |first1=G. |last2=Johnson |first2=E. |last3=Lyberg |first3=T. |last4=Bernardshaw |first4=S. |last5=Tryggestad |first5=A. M. A. |last6=Grinde |first6=B. |title=Effects of the Medicinal Mushroom ''Agaricus blazei'' Murill on Immunity, Infection and Cancer |journal=Scandinavian Journal of Immunology |volume=68 |issue=4 |pages=363–70 |year=2008 |pmid=18782264 |doi=10.1111/j.1365-3083.2008.02156.x}}&lt;/ref&gt; [[Brefeldin A]] and [[blazein]] were isolated from ''Agaricus subrufescens''.
	 	
'''''Agrocybe aegerita'' (Pioppino, chestnut mushroom)'''
	 	
An ''[[Agrocybe aegerita]]'' extract demonstrated anticancer and immunomodulatory activities ''in vivo''.&lt;ref name=&quot;pmid22947091&quot;&gt;{{cite journal| author=Ji Y, Zheng MF, Ye SG, Wu XB, Chen JY| title=Agrocybe aegerita polysaccharide combined with chemotherapy improves tumor necrosis factor-α and interferon-γ levels in rat esophageal carcinoma. | journal=Dis Esophagus | year= 2012 | volume= | issue= | pages= | pmid=22947091 | doi=10.1111/j.1442-2050.2012.01397.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=22947091 }}&lt;/ref&gt;
	 
'''''Auricularia auricula'' (Wood ear, kikurage)'''
	 	
{{double image|right|Auricularia auricula-judae (xndr).2.jpg|115|Auricularia polytricha redux2.jpg|119|''Auricularia auricula'' (left) ''Auricularia polytricha'' (right)||''''}}
	 	
''[[Auricularia auricula]]'' extracts have antihyperglycemic ''in vivo'', and anticancer, anticoagulant, and anticholesterol activities ''in vitro''.&lt;ref&gt;{{cite journal |pmid=15527075 |year=2004 |last1=Takeujchi |first1=H |last2=He |first2=P |last3=Mooi |first3=LY |title=Reductive effect of hot-water extracts from woody ear (Auricularia auricula-judae Quel.) on food intake and blood glucose concentration in genetically diabetic KK-Ay mice |volume=50 |issue=4 |pages=300–4 |journal=Journal of nutritional science and vitaminology}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |pmid=7196285 |year=1981 |last1=Misaki |first1=A |last2=Kakuta |first2=M |last3=Sasaki |first3=T |last4=Tanaka |first4=M |last5=Miyaji |first5=H |title=Studies on interrelation of structure and antitumor effects of polysaccharides: Antitumor action of periodate-modified, branched (1 goes to 3)-beta-D-glucan of Auricularia auricula-judae, and other polysaccharides containing (1 goes to 3)-glycosidic linkages |volume=92 |issue=1 |pages=115–29 |journal=Carbohydrate research |doi=10.1016/S0008-6215(00)85986-8}}&lt;/ref&gt;
	 	
'''''Auricularia polytricha'' (Cloud ear)'''
	 	
An ''[[Auricularia polytricha]]'' isolate inhibited sarcoma ''in vivo''.&lt;ref name=&quot;pmid20719324&quot;&gt;{{cite journal| author=Song G, Du Q| title=Isolation of a polysaccharide with anticancer activity from Auricularia polytricha using high-speed countercurrent chromatography with an aqueous two-phase system. | journal=J Chromatogr A | year= 2010 | volume= 1217 | issue= 38 | pages= 5930–4 | pmid=20719324 | doi=10.1016/j.chroma.2010.07.036 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=20719324 }}&lt;/ref&gt;
	 	
'''''Boletus badius'''''
	 	
[[Theanine]] can be derived from this mushroom.&lt;ref name=&quot;theanine7&quot;&gt;{{cite web |url=http://www.drugs.com/npc/l-theanine.html |title=l-theanine |work=drugs.com}}&lt;/ref&gt;
	 	
'''''Boletus edulis'' (Porcini, cep, borovik, steinpilz)'''
	 	
{{triple image|right|Boletus edulis 2008 edit2.jpg|113|Coprin-chevelu-888.jpg|65|Cordyceps sinensis.edit.jpg|180|''Boletus edulis'' (left) ''Coprinus comatus'' (center) ''Cordyceps'' attached to a caterpillar (right)|||}}
	 	
A lectin isolated from the [[mycorrhizal]] mushroom ''[[Boletus edulis]]'' has anticancer activity.&lt;ref&gt;{{cite journal |last1=Bovi |first1=Michele |last2=Carrizo |first2=Maria E. |last3=Capaldi |first3=Stefano |last4=Perduca |first4=Massimiliano |last5=Chiarelli |first5=Laurent R. |last6=Galliano |first6=Monica |last7=Monaco |first7=Hugo L. |title=Structure of a lectin with antitumoral properties in king bolete (''Boletus edulis'') mushrooms |journal=Glycobiology |year=2011 |pmid=21303815 |doi=10.1093/glycob/cwr012 |volume=21 |issue=8 |pages=1000–9}}&lt;/ref&gt;
	 	
'''''Cordyceps sinensis'' (Caterpillar fungus, yartsa gunbu, dong chong xia cao)'''
	 	
''[[Ophiocordyceps sinensis|Cordyceps sinensis]]'' is an [[entomopathogenic fungi|entomopathogenic mushroom]] collected on the Tibetan Plateau. The immunosuppressant [[ciclosporin]] was originally isolated from ''Cordyceps subsessilis''. The [[adenosine]] analog [[cordycepin]] was originally isolated from ''Cordyceps''. Other ''Cordyceps'' isolates include, cordymin, cordycepsidone, and cordyheptapeptide.&lt;ref&gt;{{cite journal |last1=Khan |first1=Md.Asaduzzaman |last2=Tania |first2=Mousumi |last3=Zhang |first3=Dian-Zheng |last4=Chen |first4=Han-Chun |title=Cordyceps Mushroom: A Potent Anticancer Nutraceutical |journal=The Open Nutraceuticals Journal |volume=3 |pages=179–83 |year=2010 |doi=10.2174/1876396001003010179}}&lt;/ref&gt; CS-4 is a commercial strain of ''Cordyceps sinensis''.
		
'''''Flammulina velutipes'' (Enokitake)'''
		
{{double image|right|Flammulina velutipes2.jpg|60|Flammulina velutipes (Enokitake, winter mushroom).jpg|70|''Flammulina velutipes'' (left) cultivated ''Flammulina velutipes'' (right)|||}}
	 	
[[Animal testing]] of ''[[Flammulina velutipes]]'' has indicated possible applications in the development of [[vaccine]]s and [[cancer immunotherapy]].
	 	
'''''Grifola frondosa'' (Maitake)'''
	 	
{{triple image|right|Grifola frondosa 888.jpg|142|Hypsizygus marmoreus Shimeji.jpg|157|Shiitakegrowing22.jpg|80|''Grifola frondosa'' (left) ''Hypsizygus tessellatus'' (center) ''Lentinula edodes'' (right)|||''''}}
	 	
''[[Grifola frondosa]]'' studies indicate potential anticancer and antihyperglycemic activities. D-fraction, MD-fraction, SX-fraction, and grifolan, are researched isolates of ''Grifola frondosa''.
	  	
'''''Hypsizygus tessellatus'' (''Hypsizygus marmoreus'', shimeji)'''
	 	
Studies have isolated antiatherosclerotic, antifungal, and immunomodulatory compounds from ''[[Hypsizygus tessellatus]]''.
	 	
'''''Lentinula edodes'' (Shiitake)'''
	 	
[[Lentinan]], [[Active Hexose Correlated Compound|AHCC]], and [[eritadenine]], are isolates of ''[[Lentinula edodes]]''. In 1985 Japan approved lentinan as an adjuvant for gastric cancer. Studies there indicate prolonged survival and improved quality of life when gastric cancer patients with unresectable or recurrent diseases are treated with lentinan in combination with other chemotherapies.
	 	
&lt;ref name=&quot;pmid23092289&quot;&gt;{{cite journal| author=Ina K, Ando T| title=The use of Lentinan for Treating Gastric Cancer. | journal=Anticancer Agents Med Chem | year= 2012 | volume= | issue= | pages= | pmid=23092289 | doi= 10.2174/1871520611313050002| pmc= 3664515| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=23092289 }}&lt;/ref&gt;
	 	
'''''Lignosus rhinocerus'' (Tiger milk mushroom)'''
	 	
''[[Lignosus]] rhinocerus'' is a medicinal mushroom associated with Malaysia.&lt;ref name=&quot;pmid21930194&quot;&gt;{{cite journal| author=Lee SS, Tan NH, Fung SY, Pailoor J, Sim SM| title=Evaluation of the sub-acute toxicity of the sclerotium of Lignosus rhinocerus (Cooke), the Tiger Milk mushroom. | journal=J Ethnopharmacol | year= 2011 | volume= 138 | issue= 1 | pages= 192–200 | pmid=21930194 | doi=10.1016/j.jep.2011.09.004 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=21930194 }}&lt;/ref&gt;
		
'''''Morchella esculenta'' (Morel)'''
	 	
{{double image|right|Morchella esculenta remix.jpg|62|Phallus indusiatus from Kerala, India - remix.jpg|100|''Morchella esculenta'' (left) ''Phallus indusiatus'' (right)||''''}}
	 	
A ''[[Morchella esculenta]]'' isolate has immunomodulatory activity ''in vitro''.&lt;ref name=&quot;pmid12236698&quot;&gt;{{cite journal |last1=Duncan |first1=Christine J. G. |last2=Pugh |first2=Nirmal |last3=Pasco |first3=David S. |last4=Ross |first4=Samir A. |title=Isolation of a Galactomannan That Enhances Macrophage Activation from the Edible FungusMorchella esculenta |journal=Journal of Agricultural and Food Chemistry |volume=50 |issue=20 |pages=5683–5 |year=2002 |pmid=12236698 |doi=10.1021/jf020267c}}&lt;/ref&gt;
	 	
'''''Phallus impudicus'''''
	 	
''[[Phallus impudicus]]'' extracts have been clinically researched in relation to venous thrombosis.&lt;ref&gt;{{cite journal |author=Kuznecova G, Jegina K, Kuznecovs S, Kuznecovs I |year=2007 |title= ''Phallus impudicus'' in thromboprophylaxis in breast cancer patients undergoing chemotherapy and hormonal treatment |journal=The Breast |volume=16 |issue=S1 |page=S56 |doi=10.1016/s0960-9776(07)70211-4}}{{Relevance-inline|reason=what is claimed by the study and why does it matter?|date=March 2012}}&lt;/ref&gt;
	 	
'''''Phallus indusiatus'' (''Dictyophora indusiata'', bamboo mushroom)'''
		
Medicinal use of ''[[Phallus indusiatus]]'' was first noted during the [[Tang Dynasty]]. ''Phallus indusiatus'' extracts promote NGF-synthesis and have anti-inflammatory activity ''in vitro''. ''Phallus indusiatus'' isolates include 5-(hydroxymethyl)-2-furfural, the antibiotic albaflavenone, dictyophorines, and dictyoquinazols.
	 	
'''''Pholiota nameko'' (Nameko)'''	
{{triple image|right|Nameko caps by frankenstoen.edit.jpg|126|Pleurotus citrinopileatus at Chatama's home.jpg|70|Pleurotus djamor crop.jpg|120|''Pholiota nameko'' (left) ''Pleurotus citrinopileatus'' (center) ''Pleurotus djamor'' (right)||||}}
	 	
''[[Pholiota nameko]]'' creates compounds with antiinflammatory, immunomodulatory, and hypolipidemic activities.&lt;ref name=&quot;pmid19815391&quot;&gt;{{cite journal| author=Li H, Zhang M, Ma G| title=Hypolipidemic effect of the polysaccharide from Pholiota nameko. | journal=Nutrition | year= 2010 | volume= 26 | issue= 5 | pages= 556–62 | pmid=19815391 | doi=10.1016/j.nut.2009.06.009 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=19815391 }}&lt;/ref&gt;&lt;ref name=&quot;pmid18620532&quot;&gt;{{cite journal| author=Li H, Lu X, Zhang S, Lu M, Liu H| title=Anti-inflammatory activity of polysaccharide from Pholiota nameko. | journal=Biochemistry (Mosc) | year= 2008 | volume= 73 | issue= 6 | pages= 669–75 | pmid=18620532 | doi= 10.1134/s0006297908060060| pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=18620532 }}&lt;/ref&gt;&lt;ref name=&quot;pmid22044749&quot;&gt;{{cite journal| author=Li H, Liu X, Li Y, Hua Y, Zhi D, Pang G| title=Effects of the polysaccharide from Pholiota nameko on human cytokine network in serum. | journal=Int J Biol Macromol | year= 2012 | volume= 50 | issue= 1 | pages= 164–70 | pmid=22044749 | doi=10.1016/j.ijbiomac.2011.10.015 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=22044749 }}&lt;/ref&gt;
	 	
'''''Pleurotus citrinopileatus'' (Golden oyster mushroom)'''
	
''[[Pleurotus citrinopileatus]]'' extracts have antihyperglycemic activity ''in vivo''.
	 
'''''Pleurotus djamor'' (Pink oyster mushroom)'''
	 	
A ''[[Pleurotus djamor]]'' isolate has anticancer activity ''in vitro''.&lt;ref name=&quot;pmid20647680&quot;&gt;{{cite journal |pages=231–9 |doi=10.2323/jgam.56.231 |title=Isolation and characterization of a novel ribonuclease from the pink oyster mushroom Pleurotus djamor |year=2010 |last1=Wu |first1=Xiangli |last2=Zheng |first2=Suyue |last3=Cui |first3=Li |last4=Wang |first4=Hexiang |last5=Ng |first5=Tzi Bun |journal=The Journal of General and Applied Microbiology |volume=56 |issue=3 |pmid=20647680 }}&lt;/ref&gt;
	 	
'''''Pleurotus eryngii'' (King oyster mushroom, eringi)'''
	
{{triple image|right|Kräuter-SeitlingPleurotus eryngii.jpg|102|Pleurotus ostreatus 605.jpg|122|Krause-Glucke405.jpg|100|''Pleurotus eryngii'' (left) ''Pleurotus ostreatus'' (center) ''Sparassis crispa'' (right)|||}}
	
''[[Pleurotus eryngii]]'' extracts have immunomodulatory activities ''in vitro''.&lt;ref name=&quot;pmid18577373&quot;&gt;{{cite journal |last1=Nozaki |first1=Hirofumi |last2=Itonori |first2=Saki |last3=Sugita |first3=Mutsumi |last4=Nakamura |first4=Kimihide |last5=Ohba |first5=Kiyoshi |last6=Suzuki |first6=Akemi |last7=Kushi |first7=Yasunori |title=Mushroom acidic glycosphingolipid induction of cytokine secretion from murine T cells and proliferation of NK1.1 α/β TCR-double positive cells in vitro |journal=Biochemical and Biophysical Research Communications |volume=373 |issue=3 |pages=435–9 |year=2008 |pmid=18577373 |doi=10.1016/j.bbrc.2008.06.047}}&lt;/ref&gt; Pleurone, erylysin A and B, eryngase, ubiquinone-9, eryngeolysin, a 14 kDa phytase, eryngin, eryngiolide A, and pleureryn, are researched ''Pleurotus eryngii'' isolates.
	 	
'''''Pleurotus ostreatus'' (Oyster mushroom, hiratake)'''
	
''[[Pleurotus ostreatus]]'' creates [[lovastatin]], [[chrysin]], [[pleuran]], and ACE inhibitor peptides.&lt;ref&gt;{{cite journal |last1=Gunde-Cimerman |first1=N |last2=Cimerman |first2=A |title=Pleurotus Fruiting Bodies Contain the Inhibitor of 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase—Lovastatin |journal=Experimental Mycology |volume=19 |issue=1 |pages=1–6 |year=1995 |pmid=7614366 |doi=10.1006/emyc.1995.1001}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |last1=Alarcón |first1=J |last2=Aguila |first2=S |title=Lovastatin production by Pleurotus ostreatus: effects of the C:N ratio |journal=Zeitschrift fur Naturforschung. C, Journal of biosciences |volume=61 |issue=1–2 |pages=95–8 |year=2006 |pmid=16610224}}&lt;/ref&gt; ''Pleurotus ostreatus'' extracts may inhibit cholesterol biosynthesis, as well as having potential anticancer and immunomodulatory activities.&lt;ref name=&quot;pmid19020765&quot;&gt;{{cite journal |last1=Sliva |title=Pleurotus ostreatus inhibits proliferation of human breast and colon cancer cells through p53-dependent as well as p53-independent pathway |journal=International Journal of Oncology |pages=1307–13 |year=1992 |doi=10.3892/ijo_00000122}}&lt;/ref&gt;&lt;ref name=&quot;pmid11575739&quot;&gt;{{cite journal |last1=Bobek |first1=P |last2=Galbavy |first2=S |title=Effect of pleuran (beta-glucan from Pleurotus ostreatus) on the antioxidant status of the organism and on dimethylhydrazine-induced precancerous lesions in rat colon |journal=British journal of biomedical science |volume=58 |issue=3 |pages=164–8 |year=2001 |pmid=11575739}}&lt;/ref&gt;&lt;ref name=&quot;pmid9216672&quot;&gt;{{cite journal |last1=Zusman |first1=I |last2=Reifen |first2=R |last3=Livni |first3=O |last4=Smirnoff |first4=P |last5=Gurevich |first5=P |last6=Sandler |first6=B |last7=Nyska |first7=A |last8=Gal |first8=R |last9=Tendler |first9=Y |displayauthors=9 |title=Role of apoptosis, proliferating cell nuclear antigen and p53 protein in chemically induced colon cancer in rats fed corncob fiber treated with the fungus Pleurotus ostreatus |journal=Anticancer research |volume=17 |issue=3C |pages=2105–13 |year=1997 |pmid=9216672}}&lt;/ref&gt;
	 	
'''''Sparassis crispa'' (Cauliflower mushroom)'''
	
''[[Sparassis crispa]]'' has anticancer and immunomodulating activity ''in vivo''.&lt;ref name=&quot;pmid10919368&quot;&gt;{{cite journal |last1=Ohno |first1=N |last2=Miura |first2=NN |last3=Nakajima |first3=M |last4=Yadomae |first4=T |title=Antitumor 1,3-beta-glucan from cultured fruit body of Sparassis crispa |journal=Biological &amp; Pharmaceutical Bulletin |volume=23 |issue=7 |pages=866–72 |year=2000 |pmid=10919368 |doi=10.1248/bpb.23.866}}&lt;/ref&gt;&lt;ref name=&quot;pmid12132673&quot;&gt;{{cite journal |last1=Harada |first1=Toshie |last2=Miura |first2=Noriko |last3=Adachi |first3=Yoshiyuki |last4=Nakajima |first4=Mitsuhiro |last5=Yadomae |first5=Toshiro |last6=Ohno |first6=Naohito |title=Effect of SCG, 1,3-β-D-Glucan from Sparassis crispa on the Hematopoietic Response in Cyclophosphamide Induced Leukopenic Mice |journal=Biological &amp; Pharmaceutical Bulletin |volume=25 |issue=7 |pages=931–9 |year=2002 |pmid=12132673 |doi=10.1248/bpb.25.931}}&lt;/ref&gt;&lt;ref name=&quot;pmid19180796&quot;&gt;{{cite journal |last1=Nameda |first1=Sachiko |last2=Harada |first2=Toshie |last3=Miura |first3=Noriko N. |last4=Adachi |first4=Yoshiyuki |last5=Yadomae |first5=Toshiro |last6=Nakajima |first6=Mitsuhiro |last7=Ohno |first7=Naohito |title=Enhanced Cytokine Synthesis of Leukocytes by a β‐Glucan Preparation, SCG, Extracted from a Medicinal Mushroom,Sparassis crispa |journal=Immunopharmacology and Immunotoxicology |volume=25 |issue=3 |pages=321–35 |year=2003 |pmid=19180796 |doi=10.1081/IPH-120024500}}&lt;/ref&gt;&lt;ref name=&quot;pmid12581496 &quot;&gt;{{cite journal |last1=Harada |first1=Toshie |last2=Miura |first2=Noriko N. |last3=Adachi |first3=Yoshiyuki |last4=Nakajima |first4=Mitsuhiro |last5=Yadomae |first5=Toshiro |last6=Ohno |first6=Naohito |title=IFN-γInduction by SCG, 1,3-β-D-Glucan fromSparassis crispa, in DBA/2 MiceIn Vitro |journal=Journal of Interferon &amp; Cytokine Research |volume=22 |pages=1227–39 |year=2002 |doi=10.1089/10799900260475759 |issue=12}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |last1=Kim |first1=Hyung Sook |last2=Kim |first2=Jee Youn |last3=Ryu |first3=Hwa Sun |last4=Park |first4=Hyuk-Gu |last5=Kim |first5=Yong Ook |last6=Kang |first6=Jong Soon |last7=Kim |first7=Hwan Mook |last8=Hong |first8=Jin Tae |last9=Kim |first9=Youngsoo |displayauthors=9|title=Induction of dendritic cell maturation by β-glucan isolated from Sparassis crispa |journal=International Immunopharmacology |volume=10 |issue=10 |pages=1284–94 |year=2010 |pmid=20699131 |doi=10.1016/j.intimp.2010.07.012}}&lt;/ref&gt;
	 	
'''''Tremella fuciformis'' (White jelly fungus)'''
	 	
{{double image|right|2011-11-18 Tremella fuciformis Berk.jpg|124|Tremella mesenterica 888.jpg|96|''Tremella fuciformis'' (left) ''Tremella mesenterica'' (right)||''''}}
	
A ''[[Tremella fuciformis]]'' isolate protected against effects of radiation ''in vivo''.
	 	
'''''Tremella mesenterica'' (Golden jelly fungus)'''
	 	
''[[Tremella mesenterica]]'' has potential anticancer and immunomodulating activities.&lt;ref name=&quot;pmid15178391&quot;&gt;{{cite journal |last1=Vinogradov |first1=Evgeny |last2=Petersen |first2=Bent O |last3=Duus |first3=Jens Ø |last4=Wasser |first4=Solomon |title=The structure of the glucuronoxylomannan produced by culinary-medicinal yellow brain mushroom (Tremella mesenterica Ritz.:Fr., Heterobasidiomycetes) grown as one cell biomass in submerged culture |journal=Carbohydrate Research |volume=339 |issue=8 |pages=1483–9 |year=2004 |pmid=15178391 |doi=10.1016/j.carres.2004.04.001}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |first1=Vladimir |last1=Elisashvili |first2=Solomon P. |last2=Wasser |first3=Kok-Kheng |last3=Tan |year=2002 |title=Hypoglycemic, Interferonogenous, and Immunomodulatory Activity of Tremellastin from the Submerged Culture of Tremella mesenterica Retz.: Fr. (Heterobasidiomycetes) |journal=International Journal for Medicinal Mushrooms |volume=4 |issue=3 |url=http://www.begellhouse.com/journals/708ae68d64b17c52,7a31e55f2119a143,68c568f834abaf77.html}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |last1=Vinogradov |first1=Evgeny |last2=Petersen |first2=Bent O. |last3=Duus |first3=Jens O. |last4=Wasser |first4=Solomon P. |title=The Isolation, Structure, and Applications of the Exocellular Heteropolysaccharide Glucuronoxylomannan Produced by Yellow Brain Mushroom Tremella mesenterica Ritz.:Fr. (Heterobasidiomycetes) |journal=International Journal of Medicinal Mushrooms |volume=6 |pages=335 |year=2004 |doi=10.1615/IntJMedMushr.v6.i4.40 |issue=4}}&lt;/ref&gt;
	 	
'''''Tricholoma matsutake'' (Matsutake, pine mushroom)'''
	 	
{{triple image|right|Matsutake2.jpg|93|Maisbeulenbrand Ustilago maydis.jpg|65|StrawMushroom.jpg|79|''Tricholoma matsutake'' (left) ''Ustilago maydis'' (center) ''Volvariella volvacea'' (right)|||''''}}
	
Isolates from the [[mycorrhizal]] mushroom, ''[[Tricholoma matsutake]]'', have anticancer and immunomodulating activities.
	
&lt;ref name=&quot;pmid12775334&quot;&gt;{{cite journal |last1=Ishihara |first1=Yoko |last2=Iijima |first2=Hiroko |last3=Yagi |first3=Yoko |last4=Matsunaga |first4=Kenichi |title=Enhanced Recovery of NK Cell Activity in Mice under Restraint Stress by the Administration of a Biological Response Modifier Derived from the Mycelia of the Basidiomycete ''Tricholoma matsutake'' |journal=Stress |volume=6 |issue=2 |pages=141–8 |year=2003 |pmid=12775334 |doi=10.1080/1025389031000116479}}&lt;/ref&gt;&lt;ref name=&quot;pmid14557678&quot;&gt;{{cite journal |last1=Ishihara |first1=Yoko |last2=Iijima |first2=Hiroko |last3=Yagi |first3=Yoko |last4=Hoshi |first4=Hirotaka |last5=Matsunaga |first5=Kenichi |title=Inhibition of Decrease in Natural Killer Cell Activity in Repeatedly Restraint-Stressed Mice by a Biological Response Modifier Derived from Cultured Mycelia of the Basidiomycete ''Tricholoma matsutake'' |journal=Neuroimmunomodulation |volume=11 |issue=1 |pages=41–8 |year=2004 |pmid=14557678 |doi=10.1159/000072968}}&lt;/ref&gt;&lt;ref name=&quot;pmid14619462&quot;&gt;{{cite journal |last1=Ebina |first1=T |title=Activation of antitumor immunity by intratumor injection of biological preparations |trans_title=Activation of antitumor immunity by intratumor injection of biological preparations |language=Japanese |journal=Gan to kagaku ryoho |volume=30 |issue=11 |pages=1555–8 |year=2003 |pmid=14619462}}&lt;/ref&gt;&lt;ref name=&quot;pmid16277387&quot;&gt;{{cite journal |last1=Hoshi |first1=Hirotaka |last2=Yagi |first2=Yoko |last3=Iijima |first3=Hiroko |last4=Matsunaga |first4=Kenichi |last5=Ishihara |first5=Yoko |last6=Yasuhara |first6=Tadashi |title=Isolation and Characterization of a Novel Immunomodulatory α-Glucan−Protein Complex from the Mycelium ofTricholoma matsutakein Basidiomycetes |journal=Journal of Agricultural and Food Chemistry |volume=53 |issue=23 |pages=8948–56 |year=2005 |pmid=16277387 |doi=10.1021/jf0510743}}&lt;/ref&gt;&lt;ref name=&quot;pmid18680305&quot;&gt;{{cite journal |last1=Hoshi |first1=Hirotaka |last2=Iijima |first2=Hiroko |last3=Ishihara |first3=Yoko |last4=Yasuhara |first4=Tadashi |last5=Matsunaga |first5=Kenichi |title=Absorption and Tissue Distribution of an Immunomodulatory α-d-Glucan after Oral Administration of Tricholoma matsutake |journal=Journal of Agricultural and Food Chemistry |volume=56 |issue=17 |pages=7715–20 |year=2008 |pmid=18680305 |doi=10.1021/jf801123k}}&lt;/ref&gt;&lt;ref name=&quot;pmid20091269&quot;&gt;{{cite journal |last1=Byeon |first1=Se Eun |last2=Lee |first2=Jaehwi |last3=Lee |first3=Eunji |last4=Lee |first4=Song Yi |last5=Hong |first5=Eock Kee |last6=Kim |first6=Young Eon |last7=Cho |first7=Jae Youl |title=Functional activation of macrophages, monocytes and splenic lymphocytes by polysaccharide fraction from Tricholoma matsutake |journal=Archives of Pharmacal Research |volume=32 |issue=11 |pages=1565–72 |year=2009 |pmid=20091269 |doi=10.1007/s12272-009-2108-y}}&lt;/ref&gt;&lt;ref name=&quot;pmid16315899&quot;&gt;{{cite journal |last1=Ebina |first1=T |title=各種担子菌製剤の局所投与による抗腫瘍効果の差異 |trans_title=Antitumor effects of intratumoral injection of Basidiomycetes preparations |language=Japanese |journal=Gan to kagaku ryoho |volume=32 |issue=11 |pages=1654–6 |year=2005 |pmid=16315899 |url=http://www.pieronline.jp/openurl?issn=0385-0684&amp;volume=32&amp;issue=11&amp;spage=1654}}&lt;/ref&gt;
	 	
'''''Ustilago maydis'' (Mexican truffle, huitlacoche, corn fungus)'''
	
''[[Ustilago maydis]]'' creates ustilagine and ustilagic acid.&lt;ref name=&quot;pmid21352944&quot;&gt;{{cite journal| author=Juárez-Montiel M, Ruiloba de León S, Chávez-Camarillo G, Hernández-Rodríguez C, Villa-Tanaca L| title=Huitlacoche (corn smut), caused by the phytopathogenic fungus Ustilago maydis, as a functional food. | journal=Rev Iberoam Micol | year= 2011 | volume= 28 | issue= 2 | pages= 69–73 | pmid=21352944 | doi=10.1016/j.riam.2011.01.001 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=21352944 }}&lt;/ref&gt;
	 	
'''''Volvariella volvacea'' (Straw mushroom)'''
	
''[[Volvariella volvacea]]'', a mushroom associated with [[Southeast Asia]], has anticancer activity ''in vitro''.&lt;ref&gt;{{cite journal |pmid=21792367 |year=2011 |last1=Wu |first1=JY |last2=Chen |first2=CH |last3=Chang |first3=WH |last4=Chung |first4=KT |last5=Liu |first5=YW |last6=Lu |first6=FJ |last7=Chen |first7=CH |title=Anti-Cancer Effects of Protein Extracts from Calvatia lilacina, Pleurotus ostreatus and Volvariella volvacea |volume=2011 |pages=982368 |doi=10.1093/ecam/neq057 |pmc=3139501 |journal=Evidence-based complementary and alternative medicine}}{{Unreliable medical source|date=March 2012}}&lt;/ref&gt;	

==Extractable species==
'''''Astraeus hygrometricus'' (Earthstar)'''	
{{triple image|right|Astraeus hygrometricus 0012.jpg|106|Fomes fomentarius, SW Finland405.jpg|80|Jreishi888.jpg|124|''Astraeus hygrometricus'' (left) ''Fomes fomentarius'' (center) ''Ganoderma lucidum'' (right)|||}}
	 	
''[[Astraeus hygrometricus]]'', a mushroom associated with India and China, has anticancer activity ''in vivo''.&lt;ref name=&quot;pmid20472019&quot;&gt;{{cite journal |pages=2115–21 |doi=10.1016/j.fct.2010.05.013 |title=Antitumor properties of a heteroglucan isolated from Astraeus hygrometricus on Dalton's lymphoma bearing mouse |year=2010 |last1=Mallick |first1=S.K. |last2=Maiti |first2=S. |last3=Bhutia |first3=S.K. |last4=Maiti |first4=T.K. |journal=[[Food and Chemical Toxicology]] |volume=48 |issue=8–9 |pmid=20472019}}{{Unreliable medical source|date=March 2012}}&lt;/ref&gt;&lt;ref name=&quot;pmid20521989&quot;&gt;{{cite journal |pages=665–72 |doi=10.1089/jmf.2009.1300 |title=Immunostimulatory Properties of a Polysaccharide Isolated fromAstraeus hygrometricus |year=2010 |last1=Mallick |first1=Sanjaya K. |last2=Maiti |first2=Swatilekha |last3=Bhutia |first3=Sujit K. |last4=Maiti |first4=Tapas K. |journal=Journal of Medicinal Food |volume=13 |issue=3 |pmid=20521989}}{{Unreliable medical source|date=March 2012}}&lt;/ref&gt;
	 	
'''''Cyathus stercoreus'''''
	 
− 		 
− 	
''[[Cyathus stercoreus]]'' creates [[polyketide]] antioxidants, cyathusals, cyathuscavins, and pulvinatal.&lt;ref name=&quot;Kang2008&quot;&gt;{{cite journal|pmid=18565749|author=Kang HS, Kim KR, Jun EM, Park SH, Lee TS, Suh JW, Kim JP. |year=2008 |title=Cyathuscavins A, B, and C, new free radical scavengers with DNA protection activity from the Basidiomycete ''Cyathus stercoreus'' |journal=Bioorganic &amp; Medicinal Chemistry Letters |volume=18 |pages=4047–50|doi=10.1016/j.bmcl.2008.05.110|issue=14}}&lt;/ref&gt;&lt;ref name=&quot;Kang2007&quot;&gt;{{cite journal|pmid=17511503|author=Kang HS, Jun EM, Park SH, Heo SJ, Lee TS, Yoo ID, Kim JP. |year=2007 |title=Cyathusals A, B, and C, antioxidants from the fermented mushroom ''Cyathus stercoreus'' |journal=Journal of Natural Products |volume=70 |pages=1043–45|doi=10.1021/np060637h|issue=6}}&lt;/ref&gt;
	 	
'''''Cyathus striatus'''''
	 	
''[[Cyathus striatus]]'' creates cyathins, striatins, and antimicrobial compounds.&lt;ref name=&quot;pmid5111071&quot;&gt;{{cite journal| author=Johri BN, Brodie HJ| title=Extracellular production of indolics by the fungus Cyathus. | journal=Mycologia | year= 1971 | volume= 63 | issue= 4 | pages= 736–44 | pmid=5111071 | doi= 10.2307/3758043| pmc= | url= }}&lt;/ref&gt;&lt;ref name=&quot;pmid5156938&quot;&gt;{{cite journal| author=Allbutt AD, Ayer WA, Brodie HJ, Johri BN, Taube H| title=Cyathin, a new antibiotic complex produced by Cyathus helenae. | journal=Can J Microbiol | year= 1971 | volume= 17 | issue= 11 | pages= 1401–7 | pmid=5156938 | doi= 10.1139/m71-223| pmc= | url= }}&lt;/ref&gt;&lt;ref name=&quot;pmid863783&quot;&gt;{{cite journal| author=Anke T, Oberwinkler F| title=The striatins--new antibiotics from the basidiomycete Cyathus striatus (Huds. ex Pers.) Willd. | journal=J Antibiot (Tokyo) | year= 1977 | volume= 30 | issue= 3 | pages= 221–5 | pmid=863783 | doi= 10.7164/antibiotics.30.221| pmc= | url= }}&lt;/ref&gt;
	 
	
'''''Fomes fomentarius'' (Amadou, tinder conk)'''
	 	
''[[Fomes fomentarius]]'' extracts have immunomodulatory activity ''in vivo'', and anticancer activity ''in vitro''.&lt;ref name=&quot;pmid19304524&quot;&gt;{{cite journal |pmid=19304524 |year=2009 |last1=Gao |first1=HL |last2=Lei |first2=LS |last3=Yu |first3=CL |last4=Zhu |first4=ZG |last5=Chen |first5=NN |last6=Wu |first6=SG |title=木蹄层孔菌多糖对小鼠免疫功能的影响 |trans_title=Immunomodulatory effects of Fomes fomentarius polysaccharides: An experimental study in mice |language=Chinese |volume=29 |issue=3 |pages=458–61 |journal=Nan fang yi ke da xue xue bao = Journal of Southern Medical University |url=http://www.j-smu.com/pdf2/200903/200903458.pdf}}{{Unreliable medical source|date=March 2012}}&lt;/ref&gt;&lt;ref name=&quot;pmid17624770&quot;&gt;{{cite journal |pages=3187–94 |doi=10.1016/j.biortech.2007.05.049 |title=Optimization for the production of exopolysaccharide from Fomes fomentarius in submerged culture and its antitumor effect in vitro |year=2008 |last1=Chen |first1=Wei |last2=Zhao |first2=Zhao |last3=Chen |first3=Shi-Fei |last4=Li |first4=Yong-Quan |journal=Bioresource Technology |volume=99 |issue=8 |pmid=17624770}}{{Unreliable medical source|date=March 2012}}&lt;/ref&gt;
	
'''''Ganoderma lucidum'' (Ling zhi, mannentake, reishi)'''
	 	
''[[Ganoderma lucidum]]'' is the mushroom with the longest record of medicinal use. ''Ganoderma lucidum'' is thought to be useful against a variety of ailments. ''Ganoderma lucidum'' contains [[p-hydroxybenzoic acid]], [[cinnamic acid]], and [[lanostane]]-type [[triterpenoids]] like [[ganoderic acid]]s.&lt;ref name=&quot;pmid22567134&quot;&gt;{{cite journal| author=Liu D, Gong J, Dai W, Kang X, Huang Z, Zhang HM et al.| title=The genome of Ganoderma lucidum provides insights into triterpenes biosynthesis and wood degradation [corrected]. | journal=PLoS ONE | year= 2012 | volume= 7 | issue= 5 | pages= e36146 | pmid=22567134 | doi=10.1371/journal.pone.0036146 | pmc=3342255 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=22567134 }}&lt;/ref&gt;
	 	
'''''Hydnellum peckii'''''
	 	
{{triple image|right|Hydnellum peckii101remix.jpg|119|Inonotus obliquus2.jpg|100|Peziza vesiculosa888.jpg|115|''Hydnellum peckii'' (left) ''Inonotus obliquus'' (center) ''Peziza vesiculosa'' (right)|||''''}}
	
[[Atromentin]] is an anticoagulant isolated from the [[mycorrhizal]] mushroom ''[[Hydnellum peckii]]''.&lt;ref name=&quot;pmid5862512&quot;&gt;{{cite journal |pages=1016–20 |doi=10.1002/jps.2600540714 |title=Atromentin. Anticoagulant from ''Hydnellum diabolus'' |year=1965 |last1=Khanna |first1=Jatinder M. |last2=Malone |first2=Marvin H. |last3=Euler |first3=Kenneth L. |last4=Brady |first4=Lynn R. |journal=Journal of Pharmaceutical Sciences |volume=54 |issue=7 |pmid=5862512}}&lt;/ref&gt;&lt;ref name=&quot;pmid17323650&quot;&gt;{{cite journal |pages=808–12 |doi=10.1038/ja.2006.108 |title=Atromentin and Leucomelone, the First Inhibitors Specific to Enoyl-ACP Reductase (FabK) of ''Streptococcus pneumoniae'' |year=2006 |last1=Zheng |first1=Chang-Ji |last2=Sohn |first2=Mi-Jin |last3=Kim |first3=Won-Gon |journal=The Journal of Antibiotics |volume=59 |issue=12 |pmid=17323650}}&lt;/ref&gt;
	 	
'''''Inonotus obliquus'' (Chaga)'''
		
''[[Inonotus obliquus]]'' has been used for centuries in Russia and Eastern Europe. [[Inotodiol]], [[melanin]], [[trametenolic acid]], and the [[betulinic acid]] precursor [[betulin]] are researched ''Inonotus obliquus'' isolates.&lt;ref name=&quot;pmid20352924&quot;&gt;{{cite journal |last1=Gao |first1=Y |last2=Xu |first2=H |last3=Lu |first3=Z |last4=Xu |first4=Z |title=Quantitative determination of steroids in the fruiting bodies and submerged-cultured mycelia of Inonotus obliquus |journal=Se pu |volume=27 |issue=6 |pages=745–9 |year=2009 |pmid=20352924}}&lt;/ref&gt; An ''in vivo'' study showed an ''Inonotus obliquus'' extract increased the melanoma survival rate 4-fold. Additional research indicates potential anticancer activity.&lt;ref name=&quot;mizuno&quot;&gt;{{cite journal |author=Mizuno T, Zhuang C, Abe K, Okamoto H, Kiho T, Ukai S, Leclerc S, Meijer L |title=Antitumor and hypoglycemic activities of polysaccharides from the sclerotia and mycelia of Inonotus obliquus |journal=International Journal of Medicinal Mushrooms |volume=1 |issue=1 |pages=301–16 |year=1999 |issn=1521-9437 |oclc=39977461}}&lt;/ref&gt;&lt;ref name=&quot;pmid16458328&quot;&gt;{{cite journal |last1=Kim |first1=Yong Ook |last2=Park |first2=Hae Woong |last3=Kim |first3=Jong Hoon |last4=Lee |first4=Jae Young |last5=Moon |first5=Seong Hoon |last6=Shin |first6=Chul Soo |title=Anti-cancer effect and structural characterization of endo-polysaccharide from cultivated mycelia of Inonotus obliquus |journal=Life Sciences |volume=79 |issue=1 |pages=72–80 |year=2006 |pmid=16458328 |doi=10.1016/j.lfs.2005.12.047}}&lt;/ref&gt;&lt;ref name=&quot;10.1007/s11094-006-0194-4&quot;&gt;{{cite journal |last1=Shashkina |first1=M. Ya. |last2=Shashkin |first2=P. N. |last3=Sergeev |first3=A. V. |title=Chemical and medicobiological properties of chaga (review) |journal=Pharmaceutical Chemistry Journal |volume=40 |pages=560–8 |year=2006 |doi=10.1007/s11094-006-0194-4 |issue=10}}&lt;/ref&gt;&lt;ref name=&quot;pmid18387711&quot;&gt;{{cite journal |last1=Taji |first1=Sayaka |last2=Yamada |first2=Takeshi |last3=Wada |first3=Shun-Ichi |last4=Tokuda |first4=Harukuni |last5=Sakuma |first5=Kazuo |last6=Tanaka |first6=Reiko |title=Lanostane-type triterpenoids from the sclerotia of Inonotus obliquus possessing anti-tumor promoting activity |journal=European Journal of Medicinal Chemistry |volume=43 |issue=11 |pages=2373–9 |year=2008 |pmid=18387711 |doi=10.1016/j.ejmech.2008.01.037}}&lt;/ref&gt;&lt;ref name=&quot;pmid17049251&quot;&gt;{{cite journal |last1=Nakata |first1=Tomoko |last2=Yamada |first2=Takeshi |last3=Taji |first3=Sayaka |last4=Ohishi |first4=Hirofumi |last5=Wada |first5=Shun-Ichi |last6=Tokuda |first6=Harukuni |last7=Sakuma |first7=Kazuo |last8=Tanaka |first8=Reiko |title=Structure determination of inonotsuoxides A and B and in vivo anti-tumor promoting activity of inotodiol from the sclerotia of Inonotus obliquus |journal=Bioorganic &amp; Medicinal Chemistry |volume=15 |pages=257–64 |year=2007 |doi=10.1016/j.bmc.2006.09.064}}&lt;/ref&gt;&lt;ref name=&quot;pmid15970296&quot;&gt;{{cite journal |last1=Kim |first1=Y |last2=Han |first2=S |last3=Lee |first3=H |last4=Ahn |first4=H |last5=Yoon |first5=Y |last6=Jung |first6=J |last7=Kim |first7=H |last8=Shin |first8=C |title=Immuno-stimulating effect of the endo-polysaccharide produced by submerged culture of |journal=Life Sciences |volume=77 |issue=19 |pages=2438–56 |year=2005 |pmid=15970296 |doi=10.1016/j.lfs.2005.02.023}}&lt;/ref&gt;&lt;ref name=&quot;pmid9595828&quot;&gt;{{cite journal |last1=Rzymowska |first1=J |title=The effect of aqueous extracts from Inonotus obliquus on the mitotic index and enzyme activities |journal=Bollettino chimico farmaceutico |volume=137 |issue=1 |pages=13–5 |year=1998 |pmid=9595828}}&lt;/ref&gt; Befungin is a commercial Russian extract of ''Inonotus obliquus''.&lt;ref name=&quot;pmid11852571&quot;&gt;{{cite journal |last1=Kukulianskaia |first1=TA |last2=Kurchenko |first2=NV |last3=Kurchenko |first3=VP |last4=Babitskaia |first4=VG |title=Physicochemical properties of melanins produced by Inonotus obliquus(&quot;chagi&quot;) in the nature and the cultivated fungus |trans_title=Physicochemical properties of melanins produced by Inonotus obliquus(&quot;chagi&quot;) in the nature and the cultivated fungus |language=Russian |journal=Prikladnaia biokhimiia i mikrobiologiia |volume=38 |issue=1 |pages=68–72 |year=2002 |pmid=11852571}}&lt;/ref&gt;
	 	
'''''Peziza vesiculosa'''''
	 	
''[[Peziza vesiculosa]]'' creates vesiculogen, and has been researched for anticancer activity.&lt;ref name=&quot;pmid3830434&quot;&gt;{{cite journal |last1=Mimura |first1=H |last2=Ohno |first2=N |last3=Suzuki |first3=I |last4=Yadomae |first4=T |title=Purification, antitumor activity, and structural characterization of beta-1,3-glucan from Peziza vesiculosa |journal=Chemical &amp; pharmaceutical bulletin |volume=33 |issue=11 |pages=5096–9 |year=1985 |pmid=3830434 |doi=10.1248/cpb.33.5096}}&lt;/ref&gt;&lt;ref name=&quot;pmid3906079&quot;&gt;{{cite journal |last1=Suzuki |first1=I |last2=Yonekubo |first2=H |last3=Ohno |first3=N |last4=Miyazaki |first4=T |last5=Yadomae |first5=T |title=Effect of a B cell mitogen extracted from a fungus Peziza vesiculosa on antibody production in mice |journal=Journal of pharmacobio-dynamics |volume=8 |issue=7 |pages=494–502 |year=1985 |pmid=3906079 |doi=10.1248/bpb1978.8.494}}&lt;/ref&gt;&lt;ref name=&quot;pmid4064214&quot;&gt;{{cite journal |last1=Ohno |first1=N |last2=Mimura |first2=H |last3=Suzuki |first3=I |last4=Yadomae |first4=T |title=Antitumor activity and structural characterization of polysaccharide fractions extracted with cold alkali from a fungus, Peziza vesiculosa |journal=Chemical &amp; pharmaceutical bulletin |volume=33 |issue=6 |pages=2564–8 |year=1985 |pmid=4064214 |doi=10.1248/cpb.33.2564}}&lt;/ref&gt;&lt;ref name=&quot;pmid7094166&quot;&gt;{{cite journal |last1=Suzuki |first1=I |last2=Yadomae |first2=T |last3=Yonekubo |first3=H |last4=Nishijima |first4=M |last5=Miyazaki |first5=T |title=Antitumor activity of an immunomodulating material extracted from a fungus, Peziza vesiculosa |journal=Chemical &amp; pharmaceutical bulletin |volume=30 |issue=3 |pages=1066–8 |year=1982 |pmid=7094166 |doi=10.1248/cpb.30.1066}}&lt;/ref&gt;&lt;ref name=&quot;pmid316098&quot;&gt;{{cite journal |last1=Yadomae |first1=T |last2=Suzuki |first2=I |last3=Kumazawa |first3=Y |last4=Miyazaki |first4=T |title=A B lymphocyte mitogen extracted from a fungus Peziza vesiculosa |journal=Microbiology and immunology |volume=23 |issue=10 |pages=997–1008 |year=1979 |pmid=316098 |doi=10.1111/j.1348-0421.1979.tb00530.x}}&lt;/ref&gt;
	
'''''Phellinus linteus'' (Meshimakobu, sanghwang)'''
		
{{double image|right|Phellinus igniarius Oak 2009 G12.jpg|107|Piptoporus betulinus 888.jpg|110|''Phellinus igniarius'' (left) ''Piptoporus betulinus'' (right)||''''}}
		
''[[Phellinus linteus]]'' is a mushroom associated with Korea. ''Phellinus linteus'' isolates include [[hispidin]], [[inotilone]], [[hispolon]], [[phellinin]]s, [[phellinstatin]], [[interfungin]]s, and [[hypholomine B]].&lt;ref&gt;{{cite journal |pmid=18827365 |year=2008 |last1=Lee |first1=YS |last2=Kang |first2=YH |last3=Jung |first3=JY |last4=Lee |first4=S |last5=Ohuchi |first5=K |last6=Shin |first6=KH |last7=Kang |first7=IJ |last8=Park |first8=JH |last9=Shin |first9=HK |displayauthors=9 |title=Protein glycation inhibitors from the fruiting body of Phellinus linteus |volume=31 |issue=10 |pages=1968–72 |journal=Biological &amp; Pharmaceutical Bulletin |doi=10.1248/bpb.31.1968}}&lt;/ref&gt; Researchers have also studied the related species ''[[Phellinus igniarius|P. igniarius]]'' and ''P. rimosus''.
	
'''''Piptoporus betulinus'' (Birch polypore)'''	
A hydroquinone isolated from ''[[Piptoporus betulinus]]'' inhibited a [[matrix metalloproteinase]].&lt;ref name=&quot;pmid12596882&quot;&gt;{{cite journal |last1=Kawagishi |first1=Hirokazu |last2=Hamajima |first2=Keiko |last3=Inoue |first3=Yoshimasa |title=Novel Hydroquinone as a Matrix Metallo-proteinase Inhibitor from the Mushroom, Piptoporus betulinus |journal=Bioscience, Biotechnology, and Biochemistry |volume=66 |issue=12 |pages=2748–50 |year=2002 |pmid=12596882 |doi=10.1271/bbb.66.2748}}{{Unreliable medical source|primary, physical chemistry|date=March 2011}}&lt;/ref&gt;
		
'''''Polyporus umbellatus'''''	
{{double image|right|Polyporus umbellatus2.jpg|113|Spaltblättlinge244.jpg|137|''Polyporus umbellatus'' (left) ''Schizophyllum commune'' (right)||''''}}
	 	
''[[Polyporus umbellatus]]'' extracts have anti-inflammatory, anticancer, and immunomodulating activities, ''in vitro''.&lt;ref name=&quot;pmid20673883&quot;&gt;{{cite journal |last1=Li |first1=Xinqun |last2=Xu |first2=Wen |last3=Chen |first3=Jun |title=Polysaccharide purified from Polyporus umbellatus (Per) Fr induces the activation and maturation of murine bone-derived dendritic cells via toll-like receptor 4 |journal=Cellular Immunology |volume=265 |issue=1 |pages=50–6 |year=2010 |pmid=20673883 |doi=10.1016/j.cellimm.2010.07.002}}&lt;/ref&gt;&lt;ref name=&quot;pmid20458671&quot;&gt;{{cite journal |last1=Zhao |first1=Ying-Yong |last2=Chao |first2=Xu |last3=Zhang |first3=Yongmin |last4=Lin |first4=Rui-Chao |last5=Sun |first5=Wen-Ji |title=Cytotoxic Steroids from ''Polyporus umbellatus'' |journal=Planta Medica |volume=76 |issue=15 |pages=1755–8 |year=2010 |pmid=20458671 |doi=10.1055/s-0030-1249926}}&lt;/ref&gt;&lt;ref name=&quot;pmid18439824&quot;&gt;{{cite journal |last1=Sun |first1=Yi |last2=Yasukawa |first2=Ken |title=New anti-inflammatory ergostane-type ecdysteroids from the sclerotium of Polyporus umbellatus |journal=Bioorganic &amp; Medicinal Chemistry Letters |volume=18 |pages=3417–20 |year=2008 |doi=10.1016/j.bmcl.2008.04.008 |pmid=18439824 |issue=11}}&lt;/ref&gt;&lt;ref name=&quot;pmid17666835&quot;&gt;{{cite journal |last1=Zhou |first1=Wei-Wei |last2=Lin |first2=Wen-Han |last3=Guo |first3=Shun-Xing |title=Two New Polyporusterones Isolated from the Sclerotia of Polyporus umbellatus |journal=Chemical &amp; Pharmaceutical Bulletin |volume=55 |issue=8 |pages=1148–50 |year=2007 |pmid=17666835 |doi=10.1248/cpb.55.1148}}&lt;/ref&gt;&lt;ref name=&quot;pmid8030616&quot;&gt;{{cite journal |last1=You |first1=Jyh-sheng |last2=Hau |first2=Dou-mong |last3=Chen |first3=Kung-tung |last4=Huang |first4=Hui-feng |title=Combined Effects of Chuling (''Polyporus umbellatus'') Extract and Mitomycin C on Experimental Liver Cancer |journal=The American Journal of Chinese Medicine |volume=22 |issue=1 |pages=19–28 |year=1994 |pmid=8030616 |doi=10.1142/S0192415X94000048}}&lt;/ref&gt;&lt;ref name=&quot;pmid1576664&quot;&gt;{{cite journal |last1=Ohsawa |first1=T |last2=Yukawa |first2=M |last3=Takao |first3=C |last4=Murayama |first4=M |last5=Bando |first5=H |title=Studies on constituents of fruit body of Polyporus umbellatus and their cytotoxic activity |journal=Chemical &amp; pharmaceutical bulletin |volume=40 |issue=1 |pages=143–7 |year=1992 |pmid=1576664 |doi=10.1248/cpb.40.143}}&lt;/ref&gt;&lt;ref name=&quot;pmid1773459&quot;&gt;{{cite journal |last1=Zhang |first1=YH |last2=Liu |first2=YL |last3=Yan |first3=SC |title=Effect of Polyporus umbellatus polysaccharide on function of macrophages in the peritoneal cavities of mice with liver lesions |journal=Zhong xi yi jie he za zhi |volume=11 |issue=4 |pages=225–6, 198 |year=1991 |pmid=1773459}}&lt;/ref&gt;&lt;ref name=&quot;pmid3195347&quot;&gt;{{cite journal |last1=Lin |first1=YF |last2=Wu |first2=GL |title=Protective effect of Polyporus umbellatus polysaccharide on toxic hepatitis in mice |journal=Zhongguo yao li xue bao |volume=9 |issue=4 |pages=345–8 |year=1988 |pmid=3195347}}&lt;/ref&gt;

'''''Poria cocos'''''
	 	
''[[Poria cocos]]'' is a medicinal fungus associated with China.&lt;ref name=&quot;pmid19631158&quot;&gt;{{cite journal |last1=Esteban |first1=Carlos Illana |title=Interés medicinal de Poria cocos (= Wolfiporia extensa) |trans_title=Medicinal interest of Poria cocos (= Wolfiporia extensa) |language=Spanish |journal=Revista Iberoamericana de Micología |volume=26 |issue=2 |pages=103–7 |year=2009 |pmid=19631158 |doi=10.1016/S1130-1406(09)70019-1}}&lt;/ref&gt;
	 	
'''''Schizophyllum commune'' (Split gill)'''
	 
[[Schizophyllan]] (SPG, sizofiran, sonifilan), an isolate of ''[[Schizophyllum commune]]'', has been researched clinically for anticancer activity.&lt;ref name=&quot;pmid21533366&quot;&gt;{{cite journal| author=Mantovani G, Bianchi A, Curreli L, Ghiani M, Astara G, Lampis B et al.| title=Clinical and immunological evaluation of schizophyllan (SPG) in combination with standard chemotherapy in patients with head and neck squamous cell carcinoma. | journal=Int J Oncol | year= 1997 | volume= 10 | issue= 1 | pages= 213–21 | pmid=21533366 | doi= 10.3892/ijo.10.1.213| pmc= | url= }}&lt;/ref&gt; [[Hydrophobins]] were originally isolated from ''Schizophyllum commune''. A chemically analogous polysaccharide, scleroglucan, is an isolate of ''[[Sclerotium rolfsii]]''.
	 	
'''''Taiwanofungus camphoratus'' (''Antrodia camphorata/cinnamomea'', niuchangchih)'''
	 	
[[Antcin B]], [[antrodioxolanone]], antroquinonol, [[antrocamphin B]], [[zhankuic acid]]s, and antcins are researched ''[[Taiwanofungus camphoratus]]'' isolates.
	 	
'''''Trametes gibbosa'' (''Daedalea gibbosa'')'''
	 	
{{triple image|right|Trametes gibbosa JPG1244.jpg|126|Stumpfungus.crop.jpg|98|Xylaria hypoxylon 03.crop.jpg|109|''Trametes gibbosa'' (left) ''Trametes versicolor'' (center) ''Xylaria hypoxylon'' (right)|||''''}}
	 	
A ''[[Trametes gibbosa]]'' extract inhibited leukemia ''in vivo''.&lt;ref name=&quot;pmid21273596&quot;&gt;{{cite journal |pmid=21273596 |year=2011 |last1=Khamaisie |first1=H |last2=Sussan |first2=S |last3=Tal |first3=M |last4=Najajreh |first4=Y |last5=Ruthardt |first5=M |last6=Mahajna |first6=J |title=Oleic acid is the active component in the mushroom Daedalea gibbosa inhibiting Bcr-Abl kinase autophosphorylation activity |volume=31 |issue=1 |pages=177–83 |journal=Anticancer research}}&lt;/ref&gt;
	 	
'''''Trametes versicolor'' (''Coriolus versicolor'', yun zhi, kawaratake, turkey tail)'''
	 	
Medicinal use of ''[[Trametes versicolor]]'' was first noted during the [[Ming Dynasty]]. [[Polysaccharide-K|PSK]] (Krestin, polysaccharide-K) and [[Polysaccharide Peptide|PSP]] (polysaccharopeptide) are protein-bound polysaccharides isolated from different ''Trametes versicolor'' mycelia strains. In Japan, PSK is a gastric cancer adjuvant. Japan began using PSK in 1977, while China began using PSP in 1987.
		
'''''Xylaria hypoxylon'' (Candlestick fungus)'''
	 
''[[Xylaria hypoxylon]]'' extracts have hemagglutinating, antiproliferative, and antimitogenic activities.&lt;ref&gt;{{cite journal | author = Gu W, Ding H | year = 2008 | title = Two new tetralone derivatives from the culture of ''Xylaria hypoxylon'' AT-028 | url = | journal = Chinese Chemical Letters | volume = 19 | issue = 11| pages = 1323–26 | doi=10.1016/j.cclet.2008.09.006}}&lt;/ref&gt;&lt;ref name=&quot;pmid17542480&quot;&gt;{{cite journal |author=Schüffler A, Sterner O, Anke H |title=Cytotoxic alpha-pyrones from ''Xylaria hypoxylon'' |journal=Z. Naturforsch., C, J. Biosci. |volume=62 |issue=3-4 |pages=169–72 |year=2007 |pmid=17542480 |doi= |url= |accessdate=2009-01-27}}&lt;/ref&gt;&lt;ref&gt;{{cite journal | author = Espada A, Rivera Sagredo A, de la Fuente JM, Hueso Rodriguez JA, Elson SW | year = 1997 | title = New cytochalasins from the fungus ''Xylaria hypoxylon'' | url = | journal = Tetrahedron | volume = 53 | issue = 18| pages = 6485–92 | doi=10.1016/s0040-4020(97)00305-0}}&lt;/ref&gt;&lt;ref name=&quot;pmid16952421&quot;&gt;{{cite journal |author=Liu Q, Wang H, Ng TB |title=First report of a xylose-specific lectin with potent hemagglutinating, antiproliferative and anti-mitogenic activities from a wild ascomycete mushroom |journal=Biochim. Biophys. Acta |volume=1760 |issue=12 |pages=1914–9 |date=December 2006 |pmid=16952421 |doi=10.1016/j.bbagen.2006.07.010 |url= |accessdate=2009-01-27}}&lt;/ref&gt;

==Contamination hazards==
Mushrooms can accumulate, even hyper-accumulate, particular [[heavy metals]] and [[radionuclides]]; in the future they could be used in a cost-effective way to clean liquids contaminated with radioactivity.&lt;ref&gt;[http://www.mycobiology.or.kr/search.php?where=aview&amp;id=10.4489%2FMYCO.2004.32.3.110&amp;code=0184MB&amp;vmode=FULL Uptake of Radionuclides by Some Fungi (www.mycobiology.or.kr)]&lt;/ref&gt;

==See also==
{{Portal|Fungi}}
{{columns-list|2|
*''[[Aspergillus oryzae]]'' (koji) used to produce soy sauce, miso, rice wine, rice beer, and rice vinegar 
* [[Chitin]] and [[chitosan]]
*[[Medicinal molds]] 
*[[Mycelium]] a network of [[hyphae]], and the source of all mushrooms
*[[Mycorrhiza]] (''[[Arbuscular mycorrhiza|arbuscular]]'', ''[[Ectomycorrhiza|ecto]]'', ''[[Ericoid mycorrhiza|ericoid]]'') medicinal fungi of the plant kingdom
*[[Quorn]] a commercial [[mycoprotein]] 
*''[[Saccharomyces boulardii]]'' and ''[[Saccharomyces cerevisiae]]'' (baker's/brewer's yeast) extracts [[Vegemite]], [[Marmite]], [[Cenovis]], [[Promite]], [[Guinness Yeast Extract]],  [[PGG-glucan]], [[EpiCor]], [[mannan oligosaccharide-based nutritional supplements|MOS]], [[nutritional yeast]], [[yeast extract]], [[nicotinamide riboside]], [[zymosan]]
*[[Streptomyces isolates]] comprise a number of fundamental chemotherapy medicines, as well as more than two thirds of all marketed antibiotics
}}

== References ==
{{Reflist|30em}}

==External links==
* MD Anderson Cancer Center '''''Detailed Scientific Review of Trametes versicolor and PSK'''''
* Cancer Research UK ''[http://kcl.academia.edu/RichardSullivan/Books/259287/Medicinal_Mushrooms_Their_therapeutic_properties_and_current_medical_usage_with_special_emphasis_on_cancer_treatments Medicinal Mushrooms: Their therapeutic properties and current medical usage with special emphasis on cancer treatments]''
* Memorial Sloan-Kettering [http://www.mskcc.org/mskcc/html/69112.cfm Agaricus subrufescens], [http://www.mskcc.org/mskcc/html/101134.cfm Phellinus linteus], [http://www.mskcc.org/mskcc/html/69353.cfm Ganoderma lucidum], [http://www.mskcc.org/mskcc/html/69194.cfm Trametes versicolor and PSK], [http://www.mskcc.org/mskcc/html/69294.cfm Grifola frondosa], [http://www.mskcc.org/mskcc/html/97957.cfm Inonotus obliquus], [http://www.mskcc.org/mskcc/html/69318.cfm Pleurotus ostreatus], [http://www.mskcc.org/mskcc/html/69193.cfm Cordyceps], [http://www.mskcc.org/mskcc/html/69377.cfm Shiitake], [http://www.mskcc.org/mskcc/html/69279.cfm Lentinan], [http://www.mskcc.org/mskcc/html/69113.cfm AHCC].
* American Cancer Society [http://www.cancer.org/docroot/eto/content/eto_5_3x_coriolous_versicolor.asp Trametes versicolor and PSK], [http://www.cancer.org/docroot/eto/content/eto_5_3x_maitake_mushroom.asp Grifola frondosa], [http://www.cancer.org/docroot/eto/content/eto_5_3x_shiitake_mushroom.asp?sitearea=eto Shiitake].
* Drugs.com [http://www.drugs.com/npp/turkey-tail.html Trametes versicolor and PSK], [http://www.drugs.com/npp/maitake.html Grifola frondosa], [http://www.drugs.com/npp/reishi-mushroom.html Ganoderma lucidum], [http://www.drugs.com/npp/cordyceps.html Cordyceps], [http://www.drugs.com/npp/lentinan.html Lentinan], [http://www.drugs.com/npp/ahcc.html AHCC], [http://www.drugs.com/pdr/sen-sei-ro-liquid-gold.html Agaricus subrufescens extract], [http://www.drugs.com/drp/abpc-agaricus-blazei-practical-compound.html ABPC].
* National Cancer Institute [http://www.cancer.gov/dictionary?cdrid=285741 Shiitake], [http://www.cancer.gov/dictionary?CdrID=44157 Lentinan], [http://www.cancer.gov/dictionary?CdrID=45536  Cordycepin]

{{DEFAULTSORT:Medicinal Mushrooms}}
[[Category:Experimental medical treatments]]
[[Category:Experimental cancer treatments]]
[[Category:Medicinal fungi]]
[[Category:Chemotherapy]]
[[Category:Cancer]]
[[Category:Antibiotics]]
[[Category:Biotechnology]]</text>
      <sha1>du8edi3skhhdsvcos0a7282hai23jpx</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>Antibiotics</title>
    <ns>0</ns>
    <id>1805</id>
    <revision>
      <id>609245174</id>
      <parentid>609244415</parentid>
      <timestamp>2014-05-19T14:49:10Z</timestamp>
      <contributor>
        <username>Iztwoz</username>
        <id>18174831</id>
      </contributor>
      <minor/>
      <comment>/* Resistance */ ce</comment>
      <text xml:space="preserve" bytes="65887">{{Use dmy dates|date=December 2013}}
[[File:Staphylococcus aureus (AB Test).jpg|right|thumb|200px|Testing the susceptibility of ''[[Staphylococcus aureus]]'' to antibiotics by the [[Kirby-Bauer antibiotic testing|Kirby-Bauer disk diffusion method]] - antibiotics diffuse from antibiotic-containing disks and inhibit growth of ''S. aureus'', resulting in a zone of inhibition.]]

An '''antibiotic''' is an agent that either kills or inhibits the growth of a [[microorganism]].&lt;ref name=&quot;urlDorlands Medical Dictionary:antibacterial&quot;/&gt;&lt;ref name=&quot;urlDorlands Medical Dictionary:antibiotic&quot;/&gt;

The term ''antibiotic'' was first used in 1942 by [[Selman Waksman]] and his collaborators in journal articles to describe any substance produced by a microorganism that is [[wikt:antagonism|antagonistic]] to the growth of other microorganisms in high dilution.&lt;ref name=&quot;Wakeman1947&quot;/&gt; This definition excluded substances that kill bacteria but that are not produced by microorganisms (such as [[gastric juices]] and [[hydrogen peroxide]]). It also excluded [[chemical synthesis|synthetic]] antibacterial compounds such as the [[Sulfonamide (medicine)|sulfonamides]]. Many antibacterial compounds are relatively [[small molecule]]s with a [[molecular weight]] of less than 2000 [[atomic mass unit]]s.

With advances in [[medicinal chemistry]], most modern antibacterials are [[semisynthetic]] modifications of various natural compounds.&lt;ref&gt;{{cite journal |author=von Nussbaum F. ''et al.'' |title=Medicinal Chemistry of Antibacterial Natural Products – Exodus or Revival?|journal=Angew. Chem. Int. Ed. |volume=45 |issue=31 |pages=5072–5129 |year=2006 |pmid= 16881035 |doi=10.1002/anie.200600350 |last2=Brands |first2=Michael |last3=Hinzen |first3=Berthold |last4=Weigand |first4=Stefan |last5=Häbich |first5=Dieter}}&lt;/ref&gt; These include, for example, the [[beta-lactam antibiotics]], which include the [[penicillin]]s (produced by fungi in the genus ''[[Penicillium]]''), the [[cephalosporin]]s, and the [[carbapenem]]s. Compounds that are still isolated from living organisms are the [[aminoglycoside]]s, whereas other antibacterials—for example, the [[Sulfonamide (medicine)|sulfonamides]], the [[quinolone]]s, and the [[oxazolidinone]]s—are produced solely by chemical synthesis. In accordance with this, many antibacterial compounds are classified on the basis of chemical/[[biosynthesis|biosynthetic]] origin into natural, semisynthetic, and synthetic. Another classification system is based on biological activity; in this classification, antibacterials are divided into two broad groups according to their biological effect on microorganisms: [[Bactericide|Bactericidal]] agents kill bacteria, and [[bacteriostatic agent]]s slow down or stall bacterial growth.

==History==
{{See also|Timeline of antibiotics}}

[[File:Penicillin core.svg|thumb|170px|[[Penicillin]], the first natural antibiotic discovered by [[Alexander Fleming]] in 1928]]
Before the early 20th century, treatments for infections were based primarily on [[folk medicine|medicinal folklore]]. Mixtures with antimicrobial properties that were used in treatments of infections were described over 2000 years ago.&lt;ref name=&quot;Considerations for Determining if a Natural Product Is an Effective Wound-Healing Agent&quot;/&gt; Many ancient cultures, including the [[Ancient Egyptian medicine|ancient Egyptians]] and [[Ancient Greek medicine|ancient Greeks]], used specially selected [[mold]] and plant materials and extracts to treat [[infection]]s.&lt;ref name=&quot;Early history of wound treatment&quot;/&gt;&lt;ref name=&quot;Moulds in ancient and more recent medicine&quot;/&gt; More recent observations made in the laboratory of antibiosis between micro-organisms led to the discovery of natural antibacterials produced by microorganisms. [[Louis Pasteur]] observed, &quot;if we could intervene in the antagonism observed between some bacteria, it would offer perhaps the greatest hopes for therapeutics&quot;.&lt;ref name=&quot;Kingston2008&quot;/&gt;
The term 'antibiosis', meaning &quot;against life,&quot; was introduced by the French bacteriologist [[Jean Paul Vuillemin]] as a descriptive name of the phenomenon exhibited by these early antibacterial drugs.&lt;ref name=&quot;CALDERIN2007&quot;/&gt;&lt;ref name=&quot;Early descriptions of antibiosis&quot;&gt;{{cite journal |author=Foster W, Raoult A |title=Early descriptions of antibiosis |journal=J R Coll Gen Pract |volume=24 |issue=149 |pages=889–94 |date=December 1974 |pmid=4618289 |pmc=2157443 |doi= |url=}}&lt;/ref&gt; Antibiosis was first described in 1877 in bacteria when [[Louis Pasteur]] and [[Robert Koch]] observed that an airborne bacillus could inhibit the growth of ''[[Bacillus anthracis]]''.&lt;ref&gt;{{cite journal |author=H. Landsberg |title=Prelude to the discovery of [[penicillin]] |journal=Isis |volume=40 |issue=3 |pages=225–227. |year=1949|doi=10.1086/349043}}&lt;/ref&gt; These drugs were later renamed antibiotics by [[Selman Waksman]], an American microbiologist, in 1942.&lt;ref name=&quot;Wakeman1947&quot;/&gt;&lt;ref name=&quot;CALDERIN2007&quot;/&gt; Synthetic antibiotic chemotherapy as a science and development of antibacterials began in Germany with [[Paul Ehrlich]] in the late 1880s.&lt;ref name=&quot;CALDERIN2007&quot;/&gt; Ehrlich noted that certain dyes would color human, animal, or bacterial cells, whereas others did not. He then proposed the idea that it might be possible to create chemicals that would act as a selective drug that would bind to and kill bacteria without harming the human host. After screening hundreds of dyes against various organisms, he discovered a medicinally useful drug, the synthetic antibacterial [[Salvarsan]]&lt;ref name=&quot;CALDERIN2007&quot;/&gt;&lt;ref name=&quot;Limbird2004&quot;/&gt;&lt;ref name=&quot;Bosch2008&quot;/&gt; now called arsphenamine.

The effects of some types of mold on infection had been noticed many times over the course of history (see: [[History of penicillin]]). In 1928 [[Alexander Fleming]] noticed the same effect in a [[petri dish]] where a number of disease-causing bacteria were killed by a fungus of the genus ''Penicillium.'' Fleming postulated that the effect is mediated by an antibacterial compound he named [[penicillin]], and that its antibacterial properties could be exploited for chemotherapy. He initially characterized some of its biological properties, and attempted to use a crude preparation to treat some infections, but he was unable to pursue its further development without the aid of trained chemists.&lt;ref name=&quot;Fleming1929&quot;/&gt;&lt;ref name=&quot;Sykes2001&quot;/&gt;
[[File:Alexander Fleming.jpg|thumb|left|Alexander Fleming]]
The first [[Sulfonamide (medicine)|sulfonamide]] and first commercially available antibacterial, [[Prontosil]], was developed by a research team led by [[Gerhard Domagk]] in 1932 at the [[Bayer]] Laboratories of the [[IG Farben]] conglomerate in Germany.&lt;ref name=&quot;Bosch2008&quot;/&gt; Domagk received the 1939 [[Nobel Prize in Physiology or Medicine|Nobel Prize for Medicine]] for his efforts. Prontosil had a relatively broad effect against [[Gram-positive]] [[Coccus|cocci]], but not against [[Enterobacteriaceae|enterobacteria]]. Research was stimulated apace by its success. The discovery and development of this sulfonamide [[drug]] opened the era of antibacterials.

In 1939, coinciding with the start of World War II, [[Rene Dubos]] reported the discovery of the first naturally derived antibiotic, [[tyrothricin]], a compound of 20% [[gramicidin]] and 80% [[tyrocidine]], from ''B. brevis.'' It was one of the first commercially manufactured antibiotics universally and was very effective in treating wounds and ulcers during World War II.&lt;ref name=&quot;Epps2006&quot;/&gt; Gramicidin, however, could not be used systemically because of toxicity. Tyrocidine also proved too toxic for systemic usage. Research results obtained during that period were not shared between the Axis and the Allied powers during the war.

Florey and Chain succeeded in purifying the first penicillin, [[penicillin G]], in 1942, but it did not become widely available outside the Allied military before 1945. The chemical structure of penicillin was determined by [[Dorothy Crowfoot Hodgkin]] in 1945. Purified penicillin displayed potent antibacterial activity against a wide range of bacteria and had low toxicity in humans. Furthermore, its activity was not inhibited by biological constituents such as pus, unlike the synthetic sulfonamides. The discovery of such a powerful antibiotic was unprecedented, and the development of penicillin led to renewed interest in the search for antibiotic compounds with similar efficacy and safety.&lt;ref name=&quot;Use of Micro-organisms for therapeutic purposes&quot;/&gt; For their successful development of penicillin, which Fleming had accidentally discovered but could not develop himself, as a therapeutic drug, [[Ernst Chain]] and [[Howard Florey]] shared the 1945 [[Nobel Prize in Medicine]] with Fleming. Florey credited Dubos with pioneering the approach of deliberately and systematically searching for antibacterial compounds, which had led to the discovery of gramicidin and had revived Florey's research in penicillin.&lt;ref name=Epps2006/&gt;

===Etymology===
The term &quot;antibiotic&quot; derives from ''anti'' + βιωτικός (''biōtikos''), &quot;fit for life, lively&quot;,&lt;ref&gt;[http://www.perseus.tufts.edu/hopper/text?doc=Perseus%3Atext%3A1999.04.0057%3Aentry%3Dbiwtiko%2Fsβιωτικός], Henry George Liddell, Robert Scott, ''A Greek-English Lexicon'', on Perseus&lt;/ref&gt; which comes from βίωσις (''biōsis''), &quot;way of life&quot;,&lt;ref&gt;[http://www.perseus.tufts.edu/hopper/text?doc=Perseus%3Atext%3A1999.04.0057%3Aentry%3Dbi%2Fwsis βίωσις], Henry George Liddell, Robert Scott, ''A Greek-English Lexicon'', on Perseus&lt;/ref&gt; and that from βίος (''bios''), &quot;life&quot;.&lt;ref&gt;[http://www.perseus.tufts.edu/hopper/text?doc=Perseus%3Atext%3A1999.04.0057%3Aentry%3Dbi%2Fos1 βίος], Henry George Liddell, Robert Scott, ''A Greek-English Lexicon'', on Perseus&lt;/ref&gt;
&lt;ref name=&quot;Antibiotics FAQ&quot; /&gt;

The term &quot;antibacterial&quot; derives from [[Greek language|Greek]] ἀντί (''anti''), &quot;against&quot;&lt;ref&gt;[http://www.perseus.tufts.edu/hopper/text?doc=Perseus%3Atext%3A1999.04.0057%3Aentry%3Da%29nti%2F ἀντί], Henry George Liddell, Robert Scott, ''A Greek-English Lexicon'', on Perseus&lt;/ref&gt; + βακτήριον (''baktērion''), diminutive of βακτηρία (''baktēria''), &quot;staff, cane&quot;,&lt;ref&gt;[http://www.perseus.tufts.edu/hopper/text?doc=Perseus%3Atext%3A1999.04.0057%3Aentry%3Dbakthri%2Fa βακτηρία], Henry George Liddell, Robert Scott, ''A Greek-English Lexicon'', on Perseus&lt;/ref&gt; because the first ones to be discovered were rod-shaped.&lt;ref&gt;[http://oxforddictionaries.com/definition/bacterium?q=bacterial#bacterium__2 bacterial], on Oxford Dictionaries&lt;/ref&gt;

==Medical uses==
* Treatment
** [[Bacterial infection]]
** [[Protozoan infection]], e.g., [[metronidazole]] is effective against several [[parasitic diseases|parasitics]]
** [[Immunomodulation]], e.g., [[tetracycline]], which is effective in [[periodontitis|periodontal inflammation]], and [[dapsone]], which is effective in [[autoimmune|autoimmune diseases]] such as [[Mouth|oral]] mucous membrane [[pemphigoid]]&lt;ref name=&quot;pmid7037880&quot;&gt;{{cite journal |author=Rogers RS, Seehafer JR, Perry HO |title=Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone |journal=J. Am. Acad. Dermatol. |volume=6 |issue=2 |pages=215–23 |date=February 1982 |pmid=7037880 |doi= 10.1016/S0190-9622(82)70014-3|url=}}&lt;/ref&gt;
* [[Preventive medicine|Prevention]] of infection
** [[Surgical wound]]
** [[Dental antibiotic prophylaxis]]&lt;ref&gt;{{cite journal |author=Wilson W, Taubert KA, Gewitz M, ''et al.'' |title=Prevention of infective endocarditis: guidelines from the American Heart Association |journal=Circulation |volume=116 |issue=15 |pages=1736–54 |date=October 2007 |pmid=17446442 |doi=10.1161/CIRCULATIONAHA.106.183095 |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&amp;pmid=17446442 |quote=American Heart Association Rheumatic Fever}}&lt;/ref&gt;&lt;ref name=&quot;dental&quot;&gt;{{cite journal |author=Zadik Y, Findler M, Livne S, ''et al.'' |title=Dentists' knowledge and implementation of the 2007 American Heart Association guidelines for prevention of infective endocarditis |journal=Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology |volume=106 |issue=6 |pages=e16–9 |date=December 2008 |pmid=19000604 |url=http://www.ooooe.net/article/S1079-2104(08)00597-0/abstract |doi=10.1016/j.tripleo.2008.08.009}}&lt;/ref&gt;
** Conditions of [[neutropenia]], e.g. [[cancer]]-related

==Pharmacodynamics==
{{Main|Antimicrobial pharmacodynamics}}
The successful outcome of antimicrobial therapy with antibacterial compounds depends on several factors. These include [[Immune system|host defense mechanisms]], the location of infection, and the pharmacokinetic and pharmacodynamic properties of the antibacterial.&lt;ref name=&quot;Pankey2004&quot;/&gt; A bactericidal activity of antibacterials may depend on the bacterial growth phase, and it often requires ongoing metabolic activity and division of bacterial cells.&lt;ref name=&quot;Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells&quot;/&gt; These findings are based on laboratory studies, and in clinical settings have also been shown to eliminate bacterial infection.&lt;ref name=&quot;Pankey2004&quot;/&gt;&lt;ref&gt;Pelczar, M.J., Chan, E.C.S. and Krieg, N.R. (1999) &quot;Host-Parasite Interaction; Nonspecific Host Resistance&quot;, In: Microbiology Concepts and Applications, 6th ed., McGraw-Hill Inc., New York, U.S.A. pp.&amp;nbsp;478–479.&lt;/ref&gt; Since the activity of antibacterials depends frequently on its concentration,&lt;ref name=&quot;Rhee2004&quot;/&gt; ''in vitro'' characterization of antibacterial activity commonly includes the determination of the [[minimum inhibitory concentration]] and minimum bactericidal concentration of an antibacterial.&lt;ref name=&quot;Pankey2004&quot;/&gt;&lt;ref name=&quot;Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC)of antimicrobial substances&quot;/&gt;
To predict clinical outcome, the antimicrobial activity of an antibacterial is usually combined with its [[Pharmacokinetics|pharmacokinetic]] profile, and several pharmacological parameters are used as markers of drug efficacy.&lt;ref name=&quot;Antibiotic therapy for severe bacterial infections: correlation between the inhibitory quotient and outcome&quot;/&gt;&lt;ref name=&quot;Sharma2002&quot;/&gt;

==Classes==
{{Main|List of antibiotics}}
[[File:Antibiotics action.png|right|thumb|150px|Molecular targets of antibiotics on the bacteria cell]]

Antibacterial antibiotics are commonly classified based on their mechanism of action, chemical structure, or spectrum of activity. Most target bacterial functions or growth processes.&lt;ref name=&quot;CALDERIN2007&quot;/&gt; Those that target the bacterial cell wall ([[penicillin]]s and [[cephalosporin]]s) or the cell membrane ([[polymyxins]]), or interfere with essential bacterial enzymes ([[rifamycin]]s, [[lipiarmycin]]s, [[quinolone]]s, and [[Sulfonamide (medicine)|sulfonamides]]) have [[bactericidal]] activities. Those that target protein synthesis ([[macrolide]]s, [[lincosamides]] and [[tetracycline]]s) are usually [[bacteriostatic]] (with the exception of bactericidal [[aminoglycoside]]s).&lt;ref name=&quot;The importance of bactericidal drugs: future directions in infectious disease&quot;/&gt; Further categorization is based on their target specificity. &quot;Narrow-spectrum&quot; antibacterial antibiotics target specific types of bacteria, such as [[Gram-negative]] or [[Gram-positive]] bacteria, whereas broad-spectrum antibiotics affect a wide range of bacteria. Following a 40-year hiatus in discovering new classes of antibacterial compounds, four new classes of antibacterial antibiotics have been brought into clinical use: cyclic [[lipopeptides]] (such as [[daptomycin]]), [[glycylcyclines]] (such as [[tigecycline]]), [[oxazolidinone]]s (such as [[linezolid]]), and [[lipiarmycin]]s (such as [[fidaxomicin]]).&lt;ref&gt;Cunha BA. Antibiotic Essentials 2009. Jones &amp; Bartlett Learning, ISBN 978-0-7637-7219-2 p. 180, for example.&lt;/ref&gt;&lt;ref&gt;{{cite journal |doi=10.1016/j.mib.2011.07.030 |title=New target for inhibition of bacterial RNA polymerase: 'switch region' |year=2011 |last1=Srivastava |first1=Aashish |last2=Talaue |first2=Meliza |last3=Liu |first3=Shuang |last4=Degen |first4=David |last5=Ebright |first5=Richard Y |last6=Sineva |first6=Elena |last7=Chakraborty |first7=Anirban |last8=Druzhinin |first8=Sergey Y |last9=Chatterjee |first9=Sujoy |last10=Mukhopadhyay |first10=Jayanta |last11=Ebright |first11=Yon W |last12=Zozula |first12=Alex |last13=Shen |first13=Juan |last14=Sengupta |first14=Sonali |last15=Niedfeldt |first15=Rui Rong |last16=Xin |first16=Cai |last17=Kaneko |first17=Takushi |last18=Irschik |first18=Herbert |last19=Jansen |first19=Rolf |last20=Donadio |first20=Stefano |last21=Connell |first21=Nancy |last22=[[Richard H. Ebright|Ebright]] |first22=Richard H |journal=Current Opinion in Microbiology |volume=14 |issue=5 |pages=532–43 |pmid=21862392 |pmc=3196380}}&lt;/ref&gt;

==Production==
{{Main|Production of antibiotics}}

Since the first pioneering efforts of [[Howard Florey, Baron Florey|Florey]] and [[Ernst Boris Chain|Chain]] in 1939, the importance of antibiotics, including antibacterials, to [[medicine]] has led to intense research into producing antibacterials at large scales. Following screening of antibacterials against a wide range of bacteria, production of the active compounds is carried out using [[Industrial fermentation|fermentation]], usually in strongly aerobic conditions.&lt;ref&gt;{{cite book|title= Pharmaceutical Manufacturing Encyclopedia|page=305|author=William Andrew Publishing|publisher=Elsevier Science |year=2013}}&lt;/ref&gt;

==Administration==
Oral antibioticss are taken by mouth, whereas [[intravenous]] administration may be used in more serious cases, {{Citation needed|date=July 2012}} such as deep-seated [[systemic infection]]s. Antibiotics may also sometimes be administered [[topical]]ly, as with [[eye drop]]s or [[ointment]]s.

==Side-effects==
[[File:Choosing Wisely antibiotics poster small English.pdf|thumb|right|Health advocacy messages such as this one encourage patients to talk with their doctor about safety in using antibiotics]]
Antibiotics are screened for any negative effects on humans or other mammals before approval for clinical use, and are usually considered safe and most are well-tolerated. However, some antibiotics have been associated with a range of adverse [[side effects]].&lt;ref name=&quot;pmid15993671&quot;/&gt;
Side-effects range from mild to very serious depending on the antibiotics used, the microbial organisms targeted, and the individual patient.{{Citation needed|date=January 2011}} Safety profiles of newer drugs are often not as well-established as for those that have a long history of use.&lt;ref name=&quot;pmid15993671&quot;/&gt; Adverse effects range from fever and nausea to major allergic reactions, including [[photodermatitis]] and anaphylaxis.{{Citation needed|date=April 2007}} Common side-effects include [[diarrhea]], resulting from disruption of the species composition in the [[intestinal flora]], resulting, for example, in overgrowth of pathogenic bacteria, such as ''[[Clostridium difficile]]''.&lt;ref&gt;University of Michigan Health System: [http://www.med.umich.edu/1libr/aha/aha_aadiarrh_crs.htm Antibiotic-Associated Diarrhea], 26 November 2006 {{dead link|date=November 2010}}&lt;/ref&gt; Antibacterials can also affect the [[vaginal flora]], and may lead to overgrowth of yeast species of the genus ''[[Candida (genus)|Candida]]'' in the vulvo-vaginal area.&lt;ref name=&quot;Pirotta and Garland&quot;/&gt; Additional side-effects can result from interaction with other drugs, such as elevated risk of [[tendon]] damage from administration of a [[Quinolones|quinolone]] antibiotic with a systemic [[corticosteroid]]. Some scientists have hypothesized that the indiscriminate use of antibiotics alter the host microbiota and this has been associated with [[chronic disease]].&lt;ref&gt;{{cite journal |doi=10.4236/oji.2012.22007 |title=The law of unintended consequences and antibiotics |year=2012 |last1=Thacker |first1=James D. |journal=Open Journal of Immunology |volume=02 |issue=2 |pages=59}}&lt;/ref&gt;&lt;ref&gt;{{cite web|title=Antibiotics and Chronic Liver Diseases|url=http://www.sinomedresearch.org/hcv/articles/c17_ABX.htm}}&lt;/ref&gt;

==Drug-drug interactions==

===Birth control pills===
The majority of studies indicate antibiotics do not interfere with [[contraceptive pill]]s,&lt;ref name=&quot;Weaver1999&quot;/&gt; such as clinical studies that suggest the failure rate of contraceptive pills caused by antibiotics is very low (about 1%).&lt;ref name=&quot;pmid10384856&quot;/&gt; In cases where antibacterials have been suggested to affect the efficiency of birth control pills, such as for the broad-spectrum antibacterial [[rifampicin]], these cases may be due to an increase in the activities of hepatic liver enzymes' causing increased breakdown of the pill's active ingredients.&lt;ref name=&quot;Weaver1999&quot;/&gt; Effects on the intestinal flora, which might result in reduced absorption of estrogens in the colon, have also been suggested, but such suggestions have been inconclusive and controversial.&lt;ref name=&quot;pmid3155374&quot;/&gt;&lt;ref name=&quot;pmid2256523&quot;/&gt; Clinicians have recommended that extra contraceptive measures be applied during therapies using antibacterials that are suspected to interact with oral contraceptives.&lt;ref name=&quot;Weaver1999&quot;/&gt;

===Alcohol===
Interactions between alcohol and certain antibiotics may occur and may cause side-effects and decreased effectiveness of antibiotic therapy.&lt;ref name=&quot;bmj&quot;/&gt;&lt;ref name=&quot;antibiotics-and-alcohol&quot;/&gt;
:&quot;It is sensible to avoid drinking alcohol when taking medication. However, it is unlikely that drinking alcohol in moderation will cause problems if you are taking most common antibiotics. However, there are specific types of antibiotics with which alcohol should be avoided completely, because of serious side-effects.&quot;&lt;ref name=&quot;NHS&quot; /&gt;
Therefore, potential risks of side-effects and effectiveness depend on the type of antibiotic administered. Despite the lack of a categorical counterindication, the belief that alcohol and antibiotics should never be mixed is widespread.

Antibiotics such as [[metronidazole]], [[tinidazole]], [[cephamandole]], [[latamoxef]], [[cefoperazone]], [[cefmenoxime]], and [[furazolidone]], cause a [[disulfiram]]-like chemical reaction with alcohol by inhibiting its breakdown by [[acetaldehyde dehydrogenase]], which may result in vomiting, nausea, and shortness of breath.&lt;ref name=&quot;NHS&quot;/&gt;

Other effects of alcohol on antibiotic activity include altered activity of the liver enzymes that break down the antibiotic compound.&lt;ref name=&quot;Antibiotics FAQ&quot;/&gt; In addition, serum levels of doxycycline and [[erythromycin]] succinate{{Clarify|Why do these serum levels matter?|date=February 2010}} two bacteriostatic antibiotics (see above) may be reduced by alcohol consumption, resulting in reduced efficacy and diminished pharmacotherapeutic effect.&lt;ref&gt;Stockley, IH (2002), Stockley's Drug Interactions. 6th ed. London: Pharmaceutical Press.{{page needed|date=December 2013}}&lt;/ref&gt;

==Resistance==
{{Main|Antibiotic resistance}}

[[File:MRSA7820.jpg|right|thumb|200px|[[Scanning electron micrograph|SEM]] depicting [[methicillin-resistant Staphylococcus aureus|methicillin-resistant ''Staphylococcus aureus'']] bacteria]]

The emergence of resistance of bacteria to antibiotics is a common phenomenon. Emergence of resistance often reflects [[evolution]]ary processes that take place during antibiotic therapy. The antibiotic treatment may [[Natural selection|select]] for bacterial strains with physiologically or genetically enhanced capacity to survive high doses of antibiotics. Under certain conditions, it may result in preferential growth of resistant bacteria, while growth of susceptible bacteria is inhibited by the drug.&lt;ref name=&quot;Balancing the drug-resistance equation&quot;/&gt; For example, antibacterial selection for strains having previously acquired antibacterial-resistance genes was demonstrated in 1943 by the [[Luria–Delbrück experiment]].&lt;ref name=&quot;Mutations of Bacteria from Virus Sensitivity to Virus Resistance&quot;/&gt; Antibiotics such as penicillin and erythromycin, which used to have a high efficacy against many bacterial species and strains, have become less effective, due to the increased resistance of many bacterial strains.&lt;ref name=&quot;voanews.com&quot;/&gt;

Resistance may take the form of biodegredation of pharmaceuticals, such as sulfamethazine-degrading soil bacteria introduced to sulfamethazine through medicated pig feces.&lt;ref&gt;{{cite journal |url=http://www.agr.gc.ca/eng/abstract/?id=27587000000610 |title=Accelerated Biodegradation of Veterinary Antibiotics in Agricultural Soil following Long-Term Exposure, and Isolation of a Sulfamethazine-degrading Microbacterium sp |journal=Journal of Environmental Quality |volume=42|pages=173–178 |doi=10.2134/jeq2012.0162 |pmid=23673752 |year=2013 |last1=Topp |first1=E |last2=Chapman |first2=R |last3=Devers-Lamrani |first3=M |last4=Hartmann |first4=A |last5=Marti |first5=R |last6=Martin-Laurent |first6=F |last7=Sabourin |first7=L |last8=Scott |first8=A |last9=Sumarah |first9=M |displayauthors=9 |issue=1}}&lt;/ref&gt;
The survival of bacteria often results from an inheritable resistance,&lt;ref name=&quot;Witte2004&quot;/&gt; but the growth of resistance to antibacterials also occurs through [[horizontal gene transfer]]. Horizontal transfer is more likely to happen in locations of frequent antibiotic use.&lt;ref name=&quot;A Field Guide To Bacteria, The World Of Bacteria&quot;&gt;{{cite book|last=Dyer|first=Betsey Dexter|title=A Field Guide To Bacteria|year=2003|publisher=Cornell University Press|isbn=978-0-8014-8854-2|chapter=Chapter 9, Pathogens|url=http://www.audible.com/pd/ref=sr_1_1?asin=B002VA8L4Y&amp;qid=1305345229&amp;sr=1-1}}&lt;/ref&gt;

Antibacterial resistance may impose a biological cost, thereby reducing [[biological fitness|fitness]] of resistant strains, which can limit the spread of antibacterial-resistant bacteria, for example, in the absence of antibacterial compounds. Additional mutations, however, may compensate for this fitness cost and can aid the survival of these bacteria.&lt;ref name=&quot;The biological cost of mutational antibiotic resistance: any practical conclusions?&quot;/&gt;

Paleontological data show that both antibiotics and antibiotic resistance are ancient compounds and mechanisms.&lt;ref name=&quot;D'Costa2011&quot;/&gt; Useful antibiotic targets are those for which mutations negatively impact bacterial reproduction or viability.&lt;ref name=&quot;Gladki2013&quot;/&gt;

Several molecular mechanisms of antibacterial resistance exist. Intrinsic antibacterial resistance may be part of the genetic makeup of bacterial strains.&lt;ref name=&quot;Alekshun2007&quot;/&gt; For example, an antibiotic target may be absent from the bacterial [[genome]]. Acquired resistance results from a mutation in the bacterial chromosome or the acquisition of extra-chromosomal DNA.&lt;ref name=&quot;Alekshun2007&quot;/&gt; Antibacterial-producing bacteria have evolved resistance mechanisms that have been shown to be similar to, and may have been transferred to, antibacterial-resistant strains.&lt;ref name=&quot;Glycopeptide antibiotic resistance genes in glycopeptide-producing organisms&quot;/&gt;&lt;ref name=&quot;Multidrug Resistance in Bacteria&quot;/&gt; The spread of antibacterial resistance often occurs through vertical transmission of mutations during growth and by genetic recombination of DNA by [[Horizontal gene transfer|horizontal genetic exchange]].&lt;ref name=&quot;Witte2004&quot;/&gt; For instance, antibacterial resistance genes can be exchanged between different bacterial strains or species via [[plasmids]] that carry these resistance genes.&lt;ref name=&quot;Witte2004&quot;/&gt;&lt;ref name=&quot;Baker2006&quot;/&gt; Plasmids that carry several different resistance genes can confer resistance to multiple antibacterials.&lt;ref name=&quot;Baker2006&quot;/&gt; Cross-resistance to several antibacterials may also occur when a resistance mechanism encoded by a single gene conveys resistance to more than one antibacterial compound.&lt;ref name=&quot;Baker2006&quot;/&gt;

Antibacterial-resistant strains and species, sometimes referred to as &quot;superbugs&quot;, now contribute to the emergence of diseases that were for a while well-controlled. For example, emergent bacterial strains causing [[tuberculosis]] (TB) that are resistant to previously effective antibacterial treatments pose many therapeutic challenges. Every year, nearly half a million new cases of [[multidrug-resistant tuberculosis]] (MDR-TB) are estimated to occur worldwide.&lt;ref&gt;&quot;[http://www.who.int/mediacentre/news/releases/2009/tuberculosis_drug_resistant_20090402/en/index.html Health ministers to accelerate efforts against drug-resistant TB]&quot;. ''World Health Organization (WHO).''&lt;/ref&gt; For example, [[NDM-1]] is a newly identified enzyme conveying bacterial resistance to a broad range of [[beta-lactam]] antibacterials.&lt;ref name=&quot;Are you ready for a world without antibiotics?&quot;/&gt; The United Kingdom's [[Health Protection Agency]] has stated that &quot;most isolates with NDM-1 enzyme are resistant to all standard intravenous antibiotics for treatment of severe infections.&quot;&lt;ref name=&quot;Health Protection Report&quot;/&gt;

===Misuse===
[[File:CDC Get Smart poster healthy adult.png|thumb|This poster from the U.S. Centers for Disease Control and Prevention &quot;Get Smart&quot; campaign, intended for use in doctors' offices and other healthcare facilities, warns that antibiotics do not work for viral illnesses such as the common cold.]]

{{main|Antibiotic misuse}}

Per the ''The ICU Book'' &quot;The first rule of antibiotics is try not to use them, and the second rule is try not to use too many of them.&quot;&lt;ref name=&quot;Marino&quot;/&gt;

Inappropriate antibiotic treatment and overuse of antibiotics have contributed to the emergence of antibiotic-resistant bacteria. [[Self-prescribing|Self prescription]] of antibiotics is an example of misuse.&lt;ref name=&quot;Larson2007&quot;/&gt; Many antibiotics are frequently prescribed to treat symptoms or diseases that do not respond to antibiotics or that are likely to resolve without treatment. Also incorrect or suboptimal antibiotics are prescribed for certain bacterial infections.&lt;ref name=&quot;pmid15993671&quot;/&gt;&lt;ref name=&quot;Larson2007&quot;/&gt; The overuse of antibiotics, like penicillin and erythromycin, have been associated with emerging antibiotic resistance since the 1950s.&lt;ref name=&quot;voanews.com&quot;/&gt;&lt;ref name=&quot;Hawkey2008&quot;/&gt; Widespread usage of antibiotics in hospitals has also been associated with increases in bacterial strains and species that no longer respond to treatment with the most common antibiotics.&lt;ref name=&quot;Hawkey2008&quot;/&gt;

Common forms of antibiotic misuse include excessive use of [[prophylaxis|prophylactic]] antibiotics in travelers and failure of medical professionals to prescribe the correct dosage of antibiotics on the basis of the patient's weight and history of prior use. Other forms of misuse include failure to take the entire prescribed course of the antibiotic, incorrect dosage and administration, or failure to rest for sufficient recovery. Inappropriate antibiotic treatment, for example, is their prescription to treat viral infections such as the [[common cold]]. One study on [[respiratory tract infection]]s found &quot;physicians were more likely to prescribe antibiotics to patients who appeared to expect them&quot;.&lt;ref name=&quot;pmid17467120&quot;/&gt; Multifactorial interventions aimed at both physicians and patients can reduce inappropriate prescription of antibiotics.&lt;ref name=&quot;pmid17509729&quot;/&gt;

Several organizations concerned with antimicrobial resistance are lobbying to eliminate the unnecessary use of antibiotics.&lt;ref name=&quot;Larson2007&quot;/&gt; The issues of misuse and overuse of antibiotics have been addressed by the formation of the U.S. Interagency Task Force on Antimicrobial Resistance. This task force aims to actively address antimicrobial resistance, and is coordinated by the US [[Centers for Disease Control and Prevention]], the [[Food and Drug Administration]] (FDA), and the [[National Institutes of Health]] (NIH), as well as other US agencies.&lt;ref name=&quot;pharmguide&quot;/&gt; An NGO campaign group is ''Keep Antibiotics Working''.&lt;ref name=&quot;Keep Antibiotics Working&quot;/&gt; In France, an &quot;Antibiotics are not automatic&quot; government campaign started in 2002 and led to a marked reduction of unnecessary antibiotic prescriptions, especially in children.&lt;ref&gt;{{cite journal |author= Sabuncu E, David J, Bernède-Bauduin C ''et al.'' |editor1-last= Klugman |editor1-first= Keith P. |title= Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002–2007 |year=2009 |journal= PLoS Med |volume=6 |issue=6 |pages=e1000084 |doi=10.1371/journal.pmed.1000084 |url=http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1000084 |pmid= 19492093 |pmc= 2683932|archiveurl = http://www.webcitation.org/5uJyYYA93 |archivedate = 17 November 2010|deadurl=no}}&lt;/ref&gt;

The emergence of antibiotic resistance has prompted restrictions on their use in the UK in 1970 (Swann report 1969), and the EU has banned the use of antibiotics as growth-promotional agents since 2003.&lt;ref&gt;[http://www.legaltext.ee/text/en/T80294.htm (accessed 12 November 2008)]&lt;/ref&gt; Moreover, several organizations (e.g., The American Society for Microbiology (ASM), American Public Health Association (APHA) and the American Medical Association (AMA)) have called for restrictions on antibiotic use in food animal production and an end to all nontherapeutic uses. {{Citation needed|date=May 2007}} However, commonly there are delays in regulatory and legislative actions to limit the use of antibiotics, attributable partly to resistance against such regulation by industries using or selling antibiotics, and to the time required for research to test causal links between their use and resistance to them. Two federal bills (S.742&lt;ref name=&quot;USbill1&quot;/&gt; and H.R. 2562&lt;ref name=&quot;USbill2&quot;/&gt;) aimed at phasing out nontherapeutic use of antibiotics in US food animals were proposed, but have not passed.&lt;ref name=&quot;USbill1&quot;/&gt;&lt;ref name=&quot;USbill2&quot;/&gt; These bills were endorsed by public health and medical organizations, including the American Holistic Nurses' Association, the American Medical Association, and the American Public Health Association (APHA).&lt;ref&gt;[http://www.acpm.org/2003051H.pdf (accessed 12 November 2008)]&lt;/ref&gt;

There has been extensive use of antibiotics in animal husbandry. In the United States, the question of emergence of antibiotic-resistant bacterial strains due to [[Antibiotic use in livestock|use of antibiotics in livestock]] was raised by the U.S. [[Food and Drug Administration]] (FDA) in 1977. In March 2012, the United States District Court for the Southern District of New York, ruling in an action brought by the [[Natural Resources Defense Council]] and others, ordered the FDA to revoke approvals for the use of antibiotics in livestock, which violated FDA regulations.&lt;ref name=MPFDA&gt;{{cite news |title=FDA Told to Move on Antibiotic Use in Livestock |url=http://www.medpagetoday.com/PublicHealthPolicy/FDAGeneral/31792 |accessdate=24 March 2012 |newspaper=MedPage Today|date=23 March 2012|author=John Gever}}&lt;/ref&gt;

==Alternatives==
The increase in bacterial strains that are resistant to conventional antibacterial therapies has prompted the development of bacterial disease treatment strategies that are alternatives to conventional antibacterials.

===Resistance-modifying agents===
One strategy to address bacterial drug resistance is the discovery and application of compounds that modify resistance to common antibacterials. For example, some resistance-modifying agents may inhibit multidrug resistance mechanisms, such as [[drug efflux]] from the cell, thus increasing the susceptibility of bacteria to an antibacterial. Targets include:
* The [[Efflux (microbiology)|efflux inhibitor]] Phe-Arg-β-naphthylamide.&lt;ref&gt;{{cite journal |doi=10.1016/j.biochi.2005.04.012 |title=Bacterial efflux systems and efflux pumps inhibitors |year=2005 |last1=Marquez |first1=Béatrice |journal=Biochimie |volume=87 |issue=12 |pages=1137–47 |pmid=15951096}}&lt;/ref&gt;
* Beta-lactamase inhibitors, such as [[clavulanic acid]] and [[sulbactam]].
Metabolic stimuli such as sugar can help eradicate a certain type of antibiotic-tolerant bacteria by keeping their metabolism active.&lt;ref&gt;{{cite journal |doi=10.1038/nature10069 |title=Metabolite-enabled eradication of bacterial persisters by aminoglycosides |year=2011 |last1=Allison |first1=Kyle R. |last2=Brynildsen |first2=Mark P. |last3=Collins |first3=James J. |journal=Nature |volume=473 |issue=7346 |pages=216–20 |pmid=21562562 |pmc=3145328}}&lt;/ref&gt;

===[[Vaccines]]===
[[Vaccine]]s rely on [[immune]] modulation or augmentation. Vaccination either excites or reinforces the immune competency of a host to ward off infection, leading to the activation of [[macrophages]], the production of [[antibody|antibodies]], [[inflammation]], and other classic immune reactions. Antibacterial vaccines have been responsible for a drastic reduction in global bacterial diseases.{{Citation needed|date=February 2011}} Vaccines made from attenuated whole cells or lysates have been replaced largely by less reactogenic, cell-free vaccines consisting of purified components, including capsular polysaccharides and their conjugates, to protein carriers, as well as inactivated toxins (toxoids) and proteins.&lt;ref name=MillerAAMillerPF&gt;{{cite book | author= Miller, AA; Miller, PF (editor) | year=2011 | title=Emerging Trends in Antibacterial Discovery: Answering the Call to Arms | publisher=[[Caister Academic Press]] | isbn= 978-1-904455-89-9}}{{page needed|date=December 2013}}&lt;/ref&gt;

==Status of new antibiotics development ==
In a policy report released by the [[Infectious Disease Society of America]] (IDSA) on April 2013, IDSA expressed grave concern over the weak pipeline of antibiotics to combat the growing ability of bacteria, especially the [[Gram-negative bacilli]] (GNB), to develop resistance to antibiotics. Since 2009, only 2 new antibiotics were approved in United States, and the number of new antibiotics annually approved for marketing continues to decline. The report could identify only seven antibiotics currently in [[Phases of clinical research|phase]] 2 or phase 3 clinical trials to treat the GNB, which includes ''[[Escherichia coli|E. coli]]'', ''[[Salmonella]]'', ''[[Shigella]]'', and the ''[[Enterobacteriaceae]]'' bacteria, and these drugs do not address the entire spectrum of the resistance developed by those bacteria.&lt;ref&gt;{{cite news |title=Drug pipeline for worst superbugs ‘on life support’: report |author=Steenhuysen, Julie |url=http://in.reuters.com/article/2013/04/18/us-antibiotics-superbugs-idINBRE93H05520130418?feedType=RSS&amp;feedName=health&amp;utm_source=dlvr.it&amp;utm_medium=twitter&amp;dlvrit=309303 |agency=Reuters |date=18 April 2013 |accessdate=23 June 2013}}&lt;/ref&gt;&lt;ref name=IDSA2013&gt;{{cite journal |doi=10.1093/cid/cit152 |title=10 x '20 Progress&amp;mdash;Development of New Drugs Active Against Gram-Negative Bacilli: An Update from the Infectious Diseases Society of America |year=2013 |last1=Boucher |first1=H. W. |last2=Talbot |first2=G. H. |last3=Benjamin Jr |first3=D. K. |last4=Bradley |first4=J. |last5=Guidos |first5=R. J. |last6=Jones |first6=R. N. |last7=Murray |first7=B. E. |last8=Bonomo |first8=R. A. |last9=Gilbert |first9=D. |journal=Clinical Infectious Diseases |volume=56 |issue=12 |pages=1685–94 |pmid=23599308 |author10=Infectious Diseases Society of America |pmc=3707426}}&lt;/ref&gt;
Some of these seven new antibiotics are combination of existent antibiotics, including:
*Ceftolozane/[[tazobactam]] (CXA-201; CXA-101/tazobactam): [[Antipseudomonal]] [[cephalosporin]]/[[β-lactamase]] inhibitor combination (cell wall synthesis inhibitor). In phase 3.
*[[Ceftazidime]]/[[avibactam]] (ceftazidime/NXL104): Antipseudomonal cephalosporin/β-lactamase inhibitor combination (cell wall synthesis inhibitor). In phase 3.
*[[Ceftaroline]]/avibactam (CPT-avibactam; ceftaroline/NXL104): Anti-[[MRSA]] cephalosporin/ β-lactamase inhibitor combination (cell wall synthesis inhibitor)
*[[Imipenem]]/MK-7655: [[Carbapenem]]/ β-lactamase inhibitor combination (cell wall synthesis inhibitor). In phase 2.
*[[Plazomicin]] (ACHN-490): [[Aminoglycoside]] (protein synthesis inhibitor). In phase 2.
*[[Eravacycline]] (TP-434): A synthetic [[tetracycline]] derivative / protein synthesis inhibitor targeting the ribosome being developed by Tetraphase. Phase 2 trials complete.&lt;ref&gt;Stynes, T. [http://online.wsj.com/article/BT-CO-20130715-705197.html Tetraphase Pharma's Eravacycline Gets Qualified-Infectious-Disease-Product Status.] Wall Street J. Monday, 15 July 2013.&lt;/ref&gt;
*[[Brilacidin]] (PMX-30063): Peptide defense protein mimetic (cell membrane disruption). In phase 2.
The IDSA’s prognosis for sustainable R&amp;D infrastructure for antibiotics development will depend upon clarification of FDA regulatory clinical trial guidance that would facilitate the speedy approval of new drugs, and the appropriate economic incentives for the pharmaceuticals companies to invest in this endeavor.&lt;ref name=IDSA2013/&gt;  On 12 December 2013, the Antibiotic Development to Advance Patient Treatment (ADAPT) Act of 2013 was introduced in the U.S. Congress. The ADAPT Act aims to fast track the drug development in order to combat the growing public health threat of 'superbugs'. Under this Act, FDA can approve antibiotics and antifungals needed for life-threatening infections based on data from smaller clinical trials. The [[Centers for Disease Control and Prevention|CDC]] will reinforce the monitoring of the use of antibiotics that treat serious and life-threatening infections and the emerging resistance, and make the data publicly available. The FDA antibiotics labeling process, 'Susceptibility Test Interpretive Criteria for Microbial Organisms'’ or 'breakpoints' is also streamlined to allow the most up-to-date and cutting-edge data available to healthcare professionals under the new Act.&lt;ref&gt;{{cite web|url=http://green.house.gov/press-release/green-gingrey-introduce-adapt-act-safeguard-public-health|title=Green, Gingrey Introduce ADAPT Act to Safeguard Public Health|author=Press Release|publisher=U.S .Congress|date=12 December 2013}}&lt;/ref&gt;&lt;ref&gt;{{cite web|url=http://assets.fiercemarkets.net/public/lifesciences/HR3742.pdf|title=Antibiotic Development to Advance Patient Treatment Act of 2013|publisher=U.S. Congress|date=12 December 2013}}&lt;/ref&gt; 

==See also==
*[[Antiviral drug|Antiviral]]

==References==
{{reflist|colwidth=30em|refs=
&lt;ref name=&quot; LjunghWadstrom&quot;&gt;{{cite book |author= Ljungh A, Wadstrom T (editors)| year=2009 |title=Lactobacillus Molecular Biology: From Genomics to Probiotics | publisher=[[Caister Academic Press]] | isbn= 978-1-904455-41-7 }}&lt;/ref&gt;

&lt;ref name=&quot;Abuladze2008&quot;&gt;{{cite journal |author=Abuladze T, Li M, Menetrez MY, Dean T, Senecal A, Sulakvelidze A |title=Bacteriophages reduce experimental contamination of hard surfaces, tomato, spinach, broccoli, and ground beef by Escherichia coli O157:H7 |journal=Appl. Environ. Microbiol. |volume=74 |issue=20 |pages=6230–8 |date=October 2008 |pmid=18723643 |pmc=2570303 |doi=10.1128/AEM.01465-08 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC)of antimicrobial substances&quot;&gt;{{cite journal |author=Wiegand I, Hilpert K, Hancock REW |title=Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC)of antimicrobial substances |journal=Nature Protocols |volume=3 |issue=2 |pages=163–175 |date=January 2008 |pmid=18274517 |doi=10.1038/nprot.2007.521 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Alekshun2007&quot;&gt;{{cite journal |author=Alekshun MN, Levy SB |title=Molecular mechanisms of antibacterial multidrug resistance |journal=Cell |volume=128 |issue=6 |pages=1037–50 |date=March 2007 |pmid=17382878 |doi=10.1016/j.cell.2007.03.004 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Antibiotic therapy for severe bacterial infections: correlation between the inhibitory quotient and outcome&quot;&gt;{{cite journal |author=Spanu T, Santangelo R, Andreotti F, Cascio GL, Velardi G, Fadda G |title=Antibiotic therapy for severe bacterial infections: correlation between the inhibitory quotient and outcome |journal=Int. J. Antimicrob. Agents |volume=23 |issue=2 |pages=120–8 |date=February 2004 |pmid=15013036 |doi=10.1016/j.ijantimicag.2003.06.006 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Antibiotics FAQ&quot;&gt;{{cite web|url=http://www.mcgill.ca/studenthealth/information/generalhealth/antibiotics/ |title=Antibiotics FAQ |accessdate=17 February 2008 |publisher=McGill University, Canada | archiveurl = http://web.archive.org/web/20080216195750/http://www.mcgill.ca/studenthealth/information/generalhealth/antibiotics/| archivedate = 16 February 2008}}&lt;/ref&gt;

&lt;ref name=&quot;Are you ready for a world without antibiotics?&quot;&gt;{{cite news | url = http://www.guardian.co.uk/society/2010/aug/12/the-end-of-antibiotics-health-infections | location=London | work=The Guardian | title=Are you ready for a world without antibiotics? | first=Sarah | last=Boseley | date=12 August 2010|archiveurl = http://www.webcitation.org/5uJyc7g0b |archivedate = 17 November 2010|deadurl=no}}&lt;/ref&gt;

&lt;ref name=&quot;Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells&quot;&gt;{{cite journal |author=Mascio CT, Alder JD, Silverman JA |title=Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells |journal=Antimicrob. Agents Chemother. |volume=51 |issue=12 |pages=4255–60 |date=December 2007 |pmid=17923487 |doi=10.1128/AAC.00824-07 |url= |pmc=2167999}}&lt;/ref&gt;

&lt;ref name=&quot;Bacteriophage Ecology: Population Growth, Evolution and Impact of Bacterial Viruses&quot;&gt;{{cite book |editor=Abedon ST |title=Bacteriophage Ecology: Population Growth, Evolution and Impact of Bacterial Viruses |year=2008 |isbn=978-0-521-85845-8 |publisher=Cambridge University Press |location=Cambridge |author=Stephen T. Abedon (Editor)}}&lt;/ref&gt;

&lt;ref name=&quot;Baker2006&quot;&gt;{{cite journal |author=Baker-Austin C, Wright MS, Stepanauskas R, McArthur JV |title=Co-selection of antibiotic and metal resistance |journal=Trends Microbiol. |volume=14 |issue=4 |pages=176–82 |date=April 2006 |pmid=16537105 |doi=10.1016/j.tim.2006.02.006 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Balancing the drug-resistance equation&quot;&gt;{{cite journal |author=Levy SB |title=Balancing the drug-resistance equation |journal=Trends Microbiol. |volume=2 |issue=10 |pages=341–2 |date=October 1994 |pmid=7850197 |doi= 10.1016/0966-842X(94)90607-6|url=}}&lt;/ref&gt;

&lt;ref name=&quot;Bosch2008&quot;&gt;{{cite journal |author=Bosch F, Rosich L |title=The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize |journal=Pharmacology |volume=82 |issue=3 |pages=171–9 |year=2008 |pmid=18679046 |doi=10.1159/000149583 |url= |pmc=2790789}}&lt;/ref&gt;

&lt;ref name=&quot;CALDERIN2007&quot;&gt;Calderon CB, Sabundayo BP (2007). Antimicrobial Classifications: Drugs for Bugs. In Schwalbe R, Steele-Moore L, Goodwin AC. Antimicrobial Susceptibility Testing Protocols. CRC Press. Taylor &amp; Frances group. ISBN 978-0-8247-4100-6&lt;/ref&gt;

&lt;ref name=&quot;Colicins and microcins: the next generation antimicrobials&quot;&gt;{{cite journal |author=Gillor O, Kirkup BC, Riley MA |title=Colicins and microcins: the next generation antimicrobials |journal=Adv. Appl. Microbiol. |volume=54 |issue= |pages=129–46 |year=2004 |pmid=15251279 |doi=10.1016/S0065-2164(04)54005-4 |series=Advances in Applied Microbiology |isbn=978-0-12-002656-2}}&lt;/ref&gt;

&lt;ref name=&quot;Considerations for Determining if a Natural Product Is an Effective Wound-Healing Agent&quot;&gt;{{cite journal |author=Lindblad WJ |title=Considerations for Determining if a Natural Product Is an Effective Wound-Healing Agent|journal=International Journal of Lower Extremity Wounds |volume=7 |issue=2 |pages=75–81 |year=2008 |pmid= 18483011|doi=10.1177/1534734608316028 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;D'Costa2011&quot;&gt;{{cite journal |author=D'Costa VM, King CE, Kalan L, Morar M, Sung WW, Schwarz C, Froese D, Zazula G, Calmels F, Debruyne R, Golding GB, Poinar HN, Wright GD |title=Antibiotic resistance is ancient |journal=Nature |volume=477 |issue=7365 |pages=457–61 |date=August 2011 |pmid=21881561 |doi=10.1038/nature10388 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Dispersing biofilms with engineered enzymatic bacteriophage&quot;&gt;{{cite journal |author=Lu TK, Collins JJ |title=Dispersing biofilms with engineered enzymatic bacteriophage |journal=Proceedings of the National Academy of Sciences of the United States of America |year=2007 |pmid=17592147 |pmc=1899193 |doi=10.1073/pnas.0704624104 |volume=104 |issue=27 |pages=11197–11202}}&lt;/ref&gt;

&lt;ref name=&quot;Early history of wound treatment&quot;&gt;{{cite journal |author=Forrest RD |title=Early history of wound treatment |journal=J R Soc Med |volume=75 |issue=3 |pages=198–205 |date=March 1982 |pmid=7040656 |pmc=1437561 |doi= |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Effects of iron chelators and iron overload on ''Salmonella'' infection&quot;&gt;{{cite journal |author=Jones RL, Peterson CM, Grady RW, Kumbaraci T, Cerami A, Graziano JH |title=Effects of iron chelators and iron overload on ''Salmonella'' infection |journal=Nature |volume=267 |pages=63–65 |year=1977 |doi=10.1038/267063a0 |pmid=323727 |issue=5606}}&lt;/ref&gt;

&lt;ref name=&quot;Epps2006&quot;&gt;{{cite journal |author=Van Epps HL |title=René Dubos: unearthing antibiotics |journal=J. Exp. Med. |volume=203 |issue=2 |page=259 |year=2006 |pmid=16528813 |doi=10.1084/jem.2032fta |pmc=2118194}}&lt;/ref&gt;

&lt;ref name=&quot;Fleming1929&quot;&gt;{{cite journal |author=Fleming A |title=Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae by Alexander Fleming, Reprinted from the British Journal of Experimental Pathology 10:226-236, 1929 |journal=Rev. Infect. Dis. |volume=2 |issue=1 |pages=129–39 |year=1980 |pmid=6994200 |doi= 10.1093/clinids/2.1.129 }}&lt;/ref&gt;

&lt;ref name=&quot;Gladki2013&quot;&gt;{{cite journal |author=Gladki A, Kaczanowski S, Szczesny P, Zielenkiewicz P |title=The evolutionary rate of antibacterial drug targets |journal=BMC Bioinformatics |volume=14 |pages=36 |date=February 2013 |pmid=23374913 |url= |doi=10.1186/1471-2105-14-36 |pmc=3598507}}&lt;/ref&gt;

&lt;ref name=&quot;Glycopeptide antibiotic resistance genes in glycopeptide-producing organisms&quot;&gt;{{cite journal |author=Marshall CG, Lessard IA, Park I, Wright GD |title=Glycopeptide antibiotic resistance genes in glycopeptide-producing organisms |journal=Antimicrob. Agents Chemother. |volume=42 |issue=9 |pages=2215–20 |date=September 1998 |pmid=9736537 |pmc=105782 |doi= |url=http://aac.asm.org/cgi/pmidlookup?view=long&amp;pmid=9736537|archiveurl = http://www.webcitation.org/5uJyfB3uC |archivedate = 17 November 2010|deadurl=no}}&lt;/ref&gt;

&lt;ref name=&quot;Hawkey2008&quot;&gt;{{cite journal |author=Hawkey PM |title=The growing burden of antimicrobial resistance |journal=[[J. Antimicrob. Chemother.]] |volume=62 Suppl 1 |issue= |pages=i1–9 |date=September 2008 |pmid=18684701 |doi=10.1093/jac/dkn241 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Health Protection Report&quot;&gt;{{cite web |url=http://www.hpa.org.uk/hpr/archives/2009/news2609.htm#ndm1 |title=Health Protection Report |publisher=Health Protection Agency |date=3 July 2009 |archiveurl = http://www.webcitation.org/5uJygHVOj |archivedate = 17 November 2010|deadurl=no}}&lt;/ref&gt;

&lt;ref name=&quot;Keep Antibiotics Working&quot;&gt;{{cite web|url=http://www.keepantibioticsworking.com/new/index.cfm |title=Keep Antibiotics Working |publisher=Keep Antibiotics Working |date= |accessdate=21 May 2010 |archiveurl = http://www.webcitation.org/5uJyhPBKO |archivedate = 17 November 2010|deadurl=no}}&lt;/ref&gt;

&lt;ref name=&quot;Kingston2008&quot;&gt;{{cite journal |author=Kingston W |title=Irish contributions to the origins of antibiotics |journal=Irish journal of medical science |volume=177 |issue=2 |pages=87–92 |date=June 2008 |pmid=18347757 |doi=10.1007/s11845-008-0139-x |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Kutateladze2008&quot;&gt;{{cite journal |author=Kutateladze M, Adamia R |title=Phage therapy experience at the Eliava Institute |journal=Med Mal Infect |volume=38 |issue=8 |pages=426–30 |date=August 2008 |pmid=18687542 |doi=10.1016/j.medmal.2008.06.023 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Larson2007&quot;&gt;{{cite journal |author=Larson E |title=Community factors in the development of antibiotic resistance |journal=Annu Rev Public Health |volume=28 |issue= |pages=435–447 |year=2007 |pmid=17094768 |doi=10.1146/annurev.publhealth.28.021406.144020 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Limbird2004&quot;&gt;{{cite journal |author=Limbird LE |title=The receptor concept: a continuing evolution |journal=Mol. Interv. |volume=4 |issue=6 |pages=326–36 |date=December 2004 |pmid=15616162 |doi=10.1124/mi.4.6.6 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Marino&quot;&gt;{{cite book |author=Marino PL |chapter=Antimicrobial therapy |title=The ICU book |publisher=Lippincott Williams &amp; Wilkins |location=Hagerstown, MD |year=2007 |page=817 |isbn=978-0-7817-4802-5}}&lt;/ref&gt;

&lt;ref name=&quot;Mattey2008&quot;&gt;{{cite journal |author=Mattey M, Spencer J |title=Bacteriophage therapy&amp;mdash;cooked goose or phoenix rising? |journal=Current Opinion in Biotechnology |volume=19 |issue=6 |pages=608–12 |date=December 2008 |pmid=18926909 |doi=10.1016/j.copbio.2008.09.001 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Merril2003&quot;&gt;{{cite journal |author=Merril CR, Scholl D, Adhya SL |title=The prospect for bacteriophage therapy in Western medicine |journal=Nature Reviews Drug Discovery |volume=2 |issue=6 |pages=489–97 |date=June 2003 |pmid=12776223 |doi=10.1038/nrd1111 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Moulds in ancient and more recent medicine&quot;&gt;{{cite journal |doi=10.1016/S0269-915X(89)80010-2 |title=Moulds in ancient and more recent medicine |year=1989 |last1=Wainwright |first1=Milton |journal=Mycologist |volume=3 |pages=21}}&lt;/ref&gt;

&lt;ref name=&quot;Multidrug Resistance in Bacteria&quot;&gt;{{cite journal |author=Nikaido H |title=Multidrug Resistance in Bacteria |journal=Annu. Rev. Biochem. |volume= 78|issue= |date=February 2009 |pmid=19231985 |doi=10.1146/annurev.biochem.78.082907.145923 |url= |pmc=2839888 |pages=119–46}}&lt;/ref&gt;

&lt;ref name=&quot;Mutations of Bacteria from Virus Sensitivity to Virus Resistance&quot;&gt;{{cite journal |author=Luria SE, Delbrück M |title=Mutations of Bacteria from Virus Sensitivity to Virus Resistance |journal=Genetics |volume=28 |issue=6 |pages=491–511 |date=November 1943 |pmid=17247100 |pmc=1209226 |doi= |url=http://www.genetics.org/cgi/pmidlookup?view=long&amp;pmid=17247100|archiveurl = http://www.webcitation.org/5uJyjd3Jp |archivedate = 17 November 2010|deadurl=no}}&lt;/ref&gt;

&lt;ref name=&quot;NHS&quot;&gt;{{cite web|url=http://www.nhs.uk/chq/pages/871.aspx |title=Can I drink alcohol while taking antibiotics? |accessdate=17 February 2008 |publisher=NHS Direct (UK electronic health service) |archiveurl = http://www.webcitation.org/5uJykTRhq |archivedate = 17 November 2010|deadurl=no}}&lt;/ref&gt;

&lt;ref name=&quot;Pankey2004&quot;&gt;{{cite journal |author=Pankey GA, Sabath LD. |title=Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections |journal=Clin Infect Dis. |volume=38 |issue=6 |pages=864–870 |date=March 2004 |pmid=14999632 |doi=10.1086/381972 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Sharma2002&quot;&gt;{{cite journal|doi= |author=Sharma, K.K., Sangraula, H., Mediratta, P.K.|date=December 2002 |title=Some new concepts in antibacterial drug therapy |url=http://medind.nic.in/ibi/t02/i6/ibit02i6p390.pdf |journal=Indian Journal of Pharmacology |volume=34 |issue=6 |pages=390–396 |pmid= |format=PDF |accessdate=13 November 2008}}&lt;/ref&gt;

&lt;ref name=&quot;Parfitt2005&quot;&gt;{{cite journal |author=Parfitt T |title=Georgia: an unlikely stronghold for bacteriophage therapy |journal=Lancet |volume=365 |issue=9478 |pages=2166–7 |year=2005 |pmid=15986542 |doi=10.1016/S0140-6736(05)66759-1 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Phagotrophic protozoa: A new weapon against pathogens?&quot;&gt;{{cite journal |author=Nacar A, Nacar E |title=Phagotrophic protozoa: A new weapon against pathogens? |journal=Medical Hypotheses |volume=70 |pages=141–142 |year=2008 |doi=10.1016/j.mehy.2007.03.037 |pmid=17553625 |issue=1}}&lt;/ref&gt;

&lt;ref name=&quot;Pirotta and Garland&quot;&gt;{{cite journal|author=Pirotta MV, Garland SM|year= 2006|title=Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics|journal=J Clin Microbiol.|volume=44|pages=3213–3217|pmid=16954250|doi=10.1128/JCM.00218-06|issue=9|pmc=1594690}}&lt;/ref&gt;

&lt;ref name=&quot;Retargeting R-type pyocins to generate novel bactericidal protein complexes&quot;&gt;{{cite journal |author=Williams SR, Gebhart D, Martin DW, Scholl D |title=Retargeting R-type pyocins to generate novel bactericidal protein complexes |journal=Applied and Environmental Microbiology |year=2008 |doi=10.1128/AEM.00141-08 |volume=74 |issue=12 |pages=3868–3876 |pmid=18441117 |pmc=2446544}}&lt;/ref&gt;

&lt;ref name=&quot;Rhee2004&quot;&gt;{{cite journal |author=Rhee KY, Gardiner DF |title=Clinical relevance of bacteriostatic versus bactericidal activity in the treatment of gram-positive bacterial infections |journal=Clin. Infect. Dis. |volume=39 |issue=5 |pages=755–6 |date=September 2004 |pmid=15356797 |doi=10.1086/422881 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Sykes2001&quot;&gt;{{cite journal |author=Sykes R |title=Penicillin: from discovery to product |journal=Bull. World Health Organ. |volume=79 |issue=8 |pages=778–9 |year=2001 |pmid=11545336 |pmc=2566502 |doi= |url=}}&lt;/ref&gt;

&lt;ref name=&quot;The Bacteriophages&quot;&gt;{{cite book |editor = Abedon ST, Calendar RL |title=The Bacteriophages |year=2005}}&lt;/ref&gt;

&lt;ref name=&quot;The biological cost of mutational antibiotic resistance: any practical conclusions?&quot;&gt;{{cite journal |author=Andersson DI |title=The biological cost of mutational antibiotic resistance: any practical conclusions? |journal=Current Opinion in Microbiology |volume=9 |issue=5 |pages=461–5 |date=October 2006 |pmid=16890008 |doi=10.1016/j.mib.2006.07.002 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;The effect of synthetic iron chelators on bacterial growth in human serum&quot;&gt;{{cite journal |author=Brock JH, Liceaga J, Kontoghiorghes GJ |title=The effect of synthetic iron chelators on bacterial growth in human serum |journal=FEMS Microbiology Letters |volume=47 |issue=1 |pages=55–60 |year=2006 |doi=10.1111/j.1574-6968.1988.tb02490.x}}&lt;/ref&gt;

&lt;ref name=&quot;The importance of bactericidal drugs: future directions in infectious disease&quot;&gt;{{cite journal |author=Finberg RW, Moellering RC, Tally FP, ''et al.'' |title=The importance of bactericidal drugs: future directions in infectious disease |journal=Clin. Infect. Dis. |volume=39 |issue=9 |pages=1314–20 |date=November 2004 |pmid=15494908 |doi=10.1086/425009 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;Thiel2004&quot;&gt;{{cite journal |author=Thiel K |title=Old dogma, new tricks&amp;mdash;21st Century phage therapy |journal=Nat. Biotechnol. |volume=22 |issue=1 |pages=31–6 |date=January 2004 |pmid=14704699 |doi=10.1038/nbt0104-31 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;USbill1&quot;&gt;GovTrack.us. S. 742&amp;mdash;109th Congress (2005): Preservation of Antibiotics for Medical Treatment Act of 2005, GovTrack.us (database of federal legislation) &lt;http://www.govtrack.us/congress/bill.xpd?bill=s109-742&gt; (accessed 12 November 2008)&lt;/ref&gt;

&lt;ref name=&quot;USbill2&quot;&gt;GovTrack.us. H.R. 2562&amp;mdash;109th Congress (2005): Preservation of Antibiotics for Medical Treatment Act of 2005, GovTrack.us (database of federal legislation) &lt;http://www.govtrack.us/congress/bill.xpd?bill=h109-2562&gt; (accessed 12 November 2008)&lt;/ref&gt;

&lt;ref name=&quot;Use of Micro-organisms for therapeutic purposes&quot;&gt;{{cite journal |author=HW Florey |title=Use of Micro-organisms for therapeutic purposes |journal=Br Med J. |volume=2 |issue=4427 |pages=635–642 |year=1945 |pmid=20786386 |pmc=2060276|doi=10.1136/bmj.2.4427.635}}&lt;/ref&gt;

&lt;ref name=&quot;Wakeman1947&quot;&gt;{{cite journal |author=SA Waksman|title=What Is an Antibiotic or an Antibiotic Substance? |journal=Mycologia |volume=39 |issue=5 |pages=565–569 |year=1947|doi=10.2307/3755196 |pmid=20264541 |jstor=3755196}}&lt;/ref&gt;

&lt;ref name=&quot;Weaver1999&quot;&gt;{{cite journal |author=Weaver K, Glasier A |title=Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review |journal=Contraception |volume=59 |issue=2 |pages=71–8 |date=February 1999 |pmid=10361620 |doi= 10.1016/S0010-7824(99)00009-8}}&lt;/ref&gt;

&lt;ref name=&quot;Witte2004&quot;&gt;{{cite journal |author=Witte W |title=International dissemination of antibiotic resistant strains of bacterial pathogens |journal=Infect. Genet. Evol. |volume=4 |issue=3 |pages=187–91 |date=September 2004 |pmid=15450197 |doi=10.1016/j.meegid.2003.12.005 |url=}}&lt;/ref&gt;

&lt;ref name=&quot;antibiotics-and-alcohol&quot;&gt;{{cite web|url=http://www.mayoclinic.com/health/antibiotics-and-alcohol/AN01802 |title=antibiotics-and-alcohol |archiveurl = http://www.webcitation.org/5uJyqaznD |archivedate = 17 November 2010|deadurl=no}}, [[Mayo Clinic]]&lt;/ref&gt;

&lt;ref name=&quot;bmj&quot;&gt;{{cite journal |doi=10.1136/bmj.a2885 |title=Do antibiotics and alcohol mix? The beliefs of genitourinary clinic attendees |year=2008 |last1=Lwanga |first1=J |last2=Mears |first2=A |last3=Bingham |first3=J S |last4=Bradbeer |first4=C S |journal=BMJ |volume=337 |pages=a2885}}&lt;/ref&gt;

&lt;ref name=&quot;pharmguide&quot;&gt;&quot;[http://www.cdc.gov/drugresistance/actionplan/].&quot; ''[[Centers for Disease Control and Prevention]].'' Retrieved 12 March 2009.&lt;/ref&gt;

&lt;ref name=&quot;pmid10384856&quot;&gt;{{cite journal |author=Weisberg E |title=Interactions between oral contraceptives and antifungals/antibacterials. Is contraceptive failure the result? |journal=Clin Pharmacokinet |volume=36 |issue=5 |pages=309–13 |date=May 1999 |pmid=10384856 |doi= 10.2165/00003088-199936050-00001|url=}}&lt;/ref&gt;

&lt;ref name=&quot;pmid15777256&quot;&gt;{{cite journal |author=Gillor O, Nigro LM, Riley MA |title=Genetically engineered bacteriocins and their potential as the next generation of antimicrobials |journal=[[Curr. Pharm. Des.]] |volume=11 |issue=8 |pages=1067–75 |year=2005 |pmid=15777256 |doi=10.2174/1381612053381666}}&lt;/ref&gt;

&lt;ref name=&quot;pmid15993671&quot;&gt;{{cite journal |author=Slama TG, Amin A, Brunton SA, ''et al.'' |title=A clinician's guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria |journal=Am. J. Med. |volume=118 Suppl 7A |issue= 7|pages=1S–6S |date=July 2005 |pmid=15993671 |doi=10.1016/j.amjmed.2005.05.007 |url= }}&lt;/ref&gt;

&lt;ref name=&quot;pmid17168847&quot;&gt;{{cite journal |author=Kirkup BC |title=Bacteriocins as oral and gastrointestinal antibiotics: theoretical considerations, applied research, and practical applications |journal=[[Curr. Med. Chem.]] |volume=13 |issue=27 |pages=3335–50 |year=2006 |pmid=17168847 |doi=10.2174/092986706778773068}}&lt;/ref&gt;

&lt;ref name=&quot;pmid17467120&quot;&gt;{{cite journal |author=Ong S, Nakase J, Moran GJ, Karras DJ, Kuehnert MJ, Talan DA |title=Antibiotic use for emergency department patients with upper respiratory infections: prescribing practices, patient expectations, and patient satisfaction |journal=Annals of Emergency Medicine |volume=50 |issue=3 |pages=213–20 |year=2007 |pmid=17467120 |doi=10.1016/j.annemergmed.2007.03.026}}&lt;/ref&gt;

&lt;ref name=&quot;pmid17509729&quot;&gt;{{cite journal |author=Metlay JP, Camargo CA, MacKenzie T, ''et al.'' |title=[[Cluster randomised controlled trial|Cluster-randomized trial]] to improve antibiotic use for adults with acute respiratory infections treated in emergency departments |journal=Annals of Emergency Medicine |volume=50 |issue=3 |pages=221–30 |year=2007 |pmid=17509729 |doi=10.1016/j.annemergmed.2007.03.022}}&lt;/ref&gt;

&lt;ref name=&quot;pmid2256523&quot;&gt;{{cite journal |author=Orme ML, Back DJ |title=Factors affecting the enterohepatic circulation of oral contraceptive steroids |journal=Am. J. Obstet. Gynecol. |volume=163 |issue=6 Pt 2 |pages=2146–52 |date=December 1990 |pmid=2256523 |doi= 10.1016/0002-9378(90)90555-L|url=http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+57-63-6|archiveurl = http://www.webcitation.org/5uJyrsZqN |archivedate = 17 November 2010|deadurl=no}}&lt;/ref&gt;

&lt;ref name=&quot;pmid3155374&quot;&gt;{{cite journal |author=Hassan T |title=Pharmacologic considerations for patients taking oral contraceptives |journal=Conn Dent Stud J |volume=7 |issue= |pages=7–8 |date=March 1987 |pmid=3155374 |doi= |url=}}&lt;/ref&gt;

&lt;ref name=&quot;pmid7768775&quot;&gt;{{cite journal |author=Soteriadou K, Papvassiliou P, Voyiatzaki C, Boelaert J |title=Effects of iron chelation on the in-vitro growth of leishmania promastigotes |journal=The Journal of antimicrobial chemotherapy |volume=35 |issue=1 |pages=23–29 |year=1995 |pmid=7768775 |doi=10.1093/jac/35.1.23}}&lt;/ref&gt;

&lt;ref name=&quot;urlDorlands Medical Dictionary:antibacterial&quot;&gt;{{cite web |url=http://www.mercksource.com/pp/us/cns/cns_hl_dorlands_split.jsp?pg=/ppdocs/us/common/dorlands/dorland/one/000005889.htm |title=Dorland's Medical Dictionary:antibacterial |work= |accessdate=29 October 2010|archiveurl = http://www.webcitation.org/5uJysabSO |archivedate = 17 November 2010|deadurl=no}}&lt;/ref&gt;

&lt;ref name=&quot;urlDorlands Medical Dictionary:antibiotic&quot;&gt;{{cite web |url=http://www.mercksource.com/pp/us/cns/cns_hl_dorlands_split.jsp?pg=/ppdocs/us/common/dorlands/dorland/one/000005892.htm |title=Dorland's Medical Dictionary:antibiotic |work= |accessdate=29 October 2010|archiveurl = http://www.webcitation.org/5uJyti0mG |archivedate = 17 November 2010|deadurl=no}}&lt;/ref&gt;

&lt;ref name=&quot;voanews.com&quot;&gt;{{cite news | first=Carol | last=Pearson |authorlink= | title=Antibiotic Resistance Fast-Growing Problem Worldwide | date=28 February 2007 | publisher=Voice Of America | url =http://voanews.com/english/archive/2007-02/2007-02-28-voa33.cfm |accessdate=29 December 2008 |archiveurl= http://web.archive.org/web/20081202191614/http://www.voanews.com/english/archive/2007-02/2007-02-28-voa33.cfm| archivedate= 2 December 2008 &lt;!--DASHBot--&gt;| deadurl= no}} {{dead link|date=November 2010}}&lt;/ref&gt;
}}

==External links==
{{Commons category|Antibiotics}}
* {{Dmoz|Health/Pharmacy/Drugs_and_Medications/Antibiotics/}}

{{Major drug groups}}
{{antibiotics}}
{{Infectious disease}}

[[Category:Antibiotics]]
[[Category:Bactericides]]

{{Link GA|cs}}
{{Link GA|es}}
{{Link FA|es}}</text>
      <sha1>b8blzoqr6o6azuktolobufhjng3sni8</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
  <page>
    <title>User:Harmonslide/sandbox</title>
    <ns>2</ns>
    <id>42804273</id>
    <revision>
      <id>609316901</id>
      <parentid>609301017</parentid>
      <timestamp>2014-05-20T00:53:50Z</timestamp>
      <contributor>
        <username>Harmonslide</username>
        <id>19861207</id>
      </contributor>
      <text xml:space="preserve" bytes="6946">{{User sandbox}}
&lt;!-- EDIT BELOW THIS LINE --&gt;

{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 386192575
|ImageFile=PZN-ACS.png
|ImageSize=400px
|OtherNames=plantazolicin A, PZN
|Section1={{Chembox Identifiers
|  CASNo_Ref =
| CASNo=1354655-37-0
|  PubChem=
| ChEMBL_Ref = 
| ChEMBL = 
|  SMILES=CC[C@H](C)[C@@H](c1nc(co1)c2nc(co2)c3nc(co3)c4nc(co4)C5=N[C@@H](C(O5)C)C(=O)N[C@@H](Cc6ccccc6)C(=O)O)NC(=O)C([C@@H](C)CC)NC(=O)c7c(oc(n7)c8c(oc(n8)c9csc(n9)c1c(oc(n1)c1csc(n1)[C@H](CCCNC(=N)N)N(C)C)C)C)C
  }}
|Section2={{Chembox Properties
|  Formula=C&lt;sub&gt;63&lt;/sub&gt;H&lt;sub&gt;69&lt;/sub&gt;N&lt;sub&gt;17&lt;/sub&gt;O&lt;sub&gt;13&lt;/sub&gt;S&lt;sub&gt;2&lt;/sub&gt;
|  MolarMass=1336.45813 g/mol
|  Appearance=
|  Density= 
|  MeltingPt=
|  BoilingPt=
|  Solubility= 
| SolubleOther = 
| Solvent = 
  }}
|Section3={{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}

'''Plantazolicin''' (PZN) is a natural [[antibiotic]] produced by the [[Gram-positive bacteria|gram-positive]] soil bacterium ''[[Bacillus amyloliquefaciens]]'' FZB42. PZN has specifically been identified as a selective [[bactericide|bactericidal agent]] active against ''[[Bacillus anthracis]]'', the causative agent of [[anthrax]]. This [[natural product]] is a ribosomally synthesized and post-translationally modified [[peptide]] (RiPP); it can be classified further as a thiazole/oxazole-modified microcin (TOMM) or a linear azole-containing peptide (LAP).&lt;ref&gt;Arnison PG, Bibb MJ, Bierbaum G, Bowers AA, Bugni TS, Bulaj G, Camarero JA, Campopiano DJ, Challis GL, Clardy J, Cotter PD, Craik DJ, Dawson M, Dittmann E, Donadio S, Dorrestein PC, Entian KD, Fischbach MA, Garavelli JS, Göransson U, Gruber CW, Haft DH, Hemscheidt TK, Hertweck C, Hill C, Horswill AR, Jaspars M, Kelly WL, Klinman JP, Kuipers OP, Link AJ, Liu W, Marahiel MA, Mitchell DA, Moll GN, Moore BS, Müller R, Nair SK, Nes IF, Norris GE, Olivera BM, Onaka H, Patchett ML, Piel J, Reaney MJ, Rebuffat S, Ross RP, Sahl HG, Schmidt EW, Selsted ME, Severinov K, Shen B, Sivonen K, Smith L, Stein T, Süssmuth RD, Tagg JR, Tang GL, Truman AW, Vederas JC, Walsh CT, Walton JD, Wenzel SC, Willey JM, van der Donk WA (2013). “Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature”, Nat. Prod. Rep. 30 (1): 108-160. doi: 10.1039/c2np20085f. PMID 23165928.&lt;/ref&gt;

The significance of PZN stems from its narrow-spectrum antibiotic activity. Most antibiotics in clinical use are [[broad-spectrum antibiotic|broad-spectrum]], acting against a wide variety of bacteria, and [[antibiotic resistance]] to these drugs is common. In contrast, PZN is antibacterial against only a small number of species, including ''[[Bacillus anthracis]]''. 

== History ==

The [[genes]] for the [[biosynthesis]] of PZN were first reported in 2008.&lt;ref&gt;Lee SW, Mitchell DA, Markley AL, Hensler ME, Gonzalez D, Wohlrab A, Dorrestein PC, Nizet V, Dixon JE (2008).    “Discovery of a Widely Distributed Toxin Biosynthetic Gene Cluster”, Proc. Natl. Acad. Sci. USA 105 (15): 5879-84. doi: 10.1073/pnas.0801338105. PMID 18375757.&lt;/ref&gt; The natural product 
was then isolated in 2011 from ''[[Bacillus amyloliquefaciens]]''.&lt;ref&gt;Scholz R, Molohon KJ, Nachtigall J, Vater J, Markley AL, Sussmuth RD, Mitchell DA, Borriss R (2011). “Plantazolicin, a Novel Microcin B17/Streptolysin S-like Natural Product from  '' Bacillus amyloliquefaciens FZB42 '' ”. J. Bacteriol. 193 (1): 215-224. doi: 10.1128/JB.00784-10. PMID 20971906.&lt;/ref&gt; The structure of PZN was solved later that year by the Suessmuth group, primarily through high-resolution [[mass spectrometry]] 
and [[nuclear magnetic resonance|NMR spectroscopy]], and was confirmed by the Mitchell group.&lt;ref&gt;Kalyon B., Helaly SE, Scholz R, Nachtigall J, Vater J, Borriss R, Süssmuth RD (2001). “Plantazolicin A and B: Structure Elucidation of Ribosomally Synthesized Thiazole/Oxazole Peptides from Bacillus amyloliquefaciens FZB42”. Org. Lett. 13 (12): 2996-2999. doi: 10.1021/ol200809m. PMID 21568297.&lt;/ref&gt;&lt;ref name= &quot;Molohon123&quot; &gt;Molohon KJ, Melby JO, Lee J, Evans BS, Dunbar KL, Bumpus SB, Kelleher NL, Mitchell DA (2011). “Structure Determination and Interception of Biosynthetic Intermediates for the Plantazolicin Class of Highly Discriminating Antibiotics”. ACS Chem. Biol. 6 (12): 1307-1313. doi: 10.1021/cb200339d. PMID 21950656.&lt;/ref&gt; In 2013, the first [[total synthesis]] of PZN was reported by the Suessmuth group via a [[biomimetic synthesis|biomimetic approach]].&lt;ref&gt;Banala S, Ensle P, Süssmuth RD (2013). “Total Synthesis of the Ribosomally Synthesized Linear Azole-Containing Peptide Plantazolicin A from Bacillus amyloliquefaciens”, Angew. Chem. Int. Ed. doi: 10.1002/anie.201302266. PMID 23761292.&lt;/ref&gt;

== Biosynthesis ==

[[File:PZN biosynthesis.jpg|thumb|400px|right|The biosynthesis of plantazolicin (PZN) entails modification of a precursor peptide by several enzymes.]] In bacteria, plantazolicin (PZN) is synthesized first as an unmodified peptide via [[translation (biology)|translation]] at the [[ribosome]]. A series of [[enzymes]] then chemically alter the peptide to install its post-translational modifications, including several [[azole]] [[heterocycle|heterocycles]] and an N-terminal [[amine]] dimethylation. 

Specifically, during the biosynthesis of PZN in ''B. amyloliquefaciens'', a ribosomally-synthesized precursor peptide (BamA) undergoes extensive post-translational modification, including cyclodehydrations and dehydrogenations, catalyzed by the BCD enzyme complex. This process converts [[cysteine]] and [[serine]]/[[threonine]] residues into thiazole and (methyl)oxazole heterocycles &lt;ref name= &quot;Molohon123&quot;/&gt; (as seen to the right). 

The exact mechanism of the association of the BamBCD complex with the N-terminal leader peptide region is not yet understood; however, it is thought that the leader peptide is cleaved from the core peptide putatively by the [[protease|peptidase]] contained in the biosynthetic [[gene cluster]].&lt;ref&gt;Melby JO, Nard NJ, Mitchell DA (2011). “Thiazole/Oxazole-Modified Microcins: Complex Natural Products from Ribosomal Templates”. Curr. Op. Chem. Biol. 15 (3): 369-378. doi: 10.1016/j.cbpa.2011.02.027. PMID 21429787.&lt;/ref&gt; Following leader peptide removal, the newly formed N-terminus undergoes methylation to yield an ''Nα,Nα''-dimethylarginine. This final modification results in mature PZN. 

Other organisms such as ''[[Bacillus pumilus]]'' ATCC 7061, ''[[Clavibacter michiganensis| Clavibacter michiganensis subsp. sepedonicus]]'', ''[[Corynebacterium|Corynebacterium urealyticum ]]'' DSM 7109, and''[[Brevibacterium| Brevibacterium linens ]]'' BL2 have been identified with similar gene clusters that have the potential to produce PZN-like molecules.&lt;ref name= &quot;Molohon123&quot; /&gt;

== References==
{{reflist}}

[[Category:Bactericides]] [[Category:Antibiotics]] [[Category:Peptides]]</text>
      <sha1>0wxw925tvn868od00z2k16h8if7432y</sha1>
      <model>wikitext</model>
      <format>text/x-wiki</format>
    </revision>
  </page>
</mediawiki>
